9 付録

表 8 SMA と診断された乳児における重篤な有害事象の発現率

Incidence of serious adverse events in infants diagnosed with SMA
Page 1 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	5 (29.4)	33 (80.5)	56 (70.0)	72 (72.0)	77 (65.8)
呼吸器、胸郭および縦隔障害	1 (5.9)	26 (63.4)	46 (57.5)	61 (61.0)	62 (53.0)
呼吸窮迫	1 (5.9)	10 (24.4)	19 (23.8)	25 (25.0)	26 (22.2)
呼吸不全	0	14 (34.1)	17 (21.3)	22 (22.0)	22 (18.8)
急性呼吸不全	0	7 (17.1)	11 (13.8)	15 (15.0)	15 (12.8)
無気肺	0	2 (4.9)	11 (13.8)	13 (13.0)	13 (11.1)
誤嚥性肺炎	0	4 (9.8)	6 (7.5)	8 (8.0)	8 (6.8)
無呼吸	0	2 (4.9)	2 (2.5)	4 (4.0)	4 (3.4)
誤嚥	0	0	3 (3.8)	4 (4.0)	4 (3.4)
呼吸困難	0	2 (4.9)	4 (5.0)	4 (4.0)	4 (3.4)
低酸素症	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
呼吸停止	0	4 (9.8)	3 (3.8)	3 (3.0)	3 (2.6)
低換気	0	0	1 (1.3)	2 (2.0)	2 (1.7)
呼吸障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
急性呼吸窮迫症候群	0	0	1 (1.3)	1 (1.0)	1 (0.9)
窒息	0	0	0	1 (1.0)	1 (0.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 8　　SMA と診断された乳児における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in infants diagnosed with SMA
Page 2 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
気管支分泌物貯留	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.9)
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気管支分泌増加	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肺障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気縦隔症	0	0	0	1 (1.0)	1 (0.9)
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
気道うっ血	0	1 (2.4)	0	0	0
感染症および寄生虫症	3 (17.6)	15 (36.6)	40 (50.0)	53 (53.0)	56 (47.9)
肺炎	1 (5.9)	4 (9.8)	14 (17.5)	18 (18.0)	19 (16.2)
ライノウイルス感染	0	2 (4.9)	6 (7.5)	10 (10.0)	10 (8.5)
細気管支炎	0	1 (2.4)	4 (5.0)	7 (7.0)	7 (6.0)
ウイルス性肺炎	0	1 (2.4)	5 (6.3)	7 (7.0)	7 (6.0)
ウイルス感染	0	1 (2.4)	4 (5.0)	6 (6.0)	6 (5.1)
気道感染	0	0	4 (5.0)	5 (5.0)	5 (4.3)
上気道感染	0	0	4 (5.0)	5 (5.0)	5 (4.3)
細菌性肺炎	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 8　　SMA と診断された乳児における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in infants diagnosed with SMA
Page 3 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
ＲＳウイルス細気管支炎	0	3 (7.3)	3 (3.8)	4 (4.0)	4 (3.4)
ウイルス性上気道感染	0	6 (14.6)	3 (3.8)	4 (4.0)	4 (3.4)
気管支炎	1 (5.9)	0	3 (3.8)	3 (3.0)	4 (3.4)
下気道感染	0	0	3 (3.8)	3 (3.0)	3 (2.6)
ウイルス性気管支炎	0	0	2 (2.5)	2 (2.0)	2 (1.7)
ウイルス性下気道感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)
ウイルス性気道感染	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
コロナウイルス感染	0	1 (2.4)	0	1 (1.0)	1 (0.9)
耳感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
エンテロウイルス感染	0	0	0	1 (1.0)	1 (0.9)
ロタウイルス胃腸炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鼻咽頭炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
院内感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
パラインフルエンザウイルス感染	0	0	0	1 (1.0)	1 (0.9)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
モラクセラ菌性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
パラインフルエンザウイルス性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 0.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 8　　SMA と診断された乳児における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in infants diagnosed with SMA
Page 4 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
シュードモナス菌性肺炎	0	1 (2.4)	0	1 (1.0)	1 (0.9)
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ストーマ部膿瘍	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿路感染	1 (5.9)	0	0	0	1 (0.9)
心臓障害	0	5 (12.2)	9 (11.3)	12 (12.0)	12 (10.3)
心肺停止	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.1)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
チアノーゼ	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
徐脈	0	0	0	1 (1.0)	1 (0.9)
心膜気腫	0	0	0	1 (1.0)	1 (0.9)
心室性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.9)
代謝および栄養障害	1 (5.9)	4 (9.8)	7 (8.8)	9 (9.0)	10 (8.5)
体重増加不良	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.6)
乳児および小児期早期の哺育障害	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
栄養補給不耐性	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脱水	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 8　　SMA と診断された乳児における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in infants diagnosed with SMA
Page 5 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
成長障害	1 (5.9)	0	0	1 (1.0)	2 (1.7)
低ナトリウム血症	0	0	0	1 (1.0)	1 (0.9)
胃腸障害	1 (5.9)	3 (7.3)	6 (7.5)	7 (7.0)	8 (6.8)
嘔吐	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
嚥下障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
胃出血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
腹部膨満	1 (5.9)	0	0	0	1 (0.9)
胃腸出血	0	1 (2.4)	0	0	0
流涎過多	0	1 (2.4)	0	0	0
一般・全身障害および投与部位の状態	0	1 (2.4)	4 (5.0)	4 (4.0)	4 (3.4)
発熱	0	0	3 (3.8)	3 (3.0)	3 (2.6)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
傷害、中毒および処置合併症	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.6)
麻酔からの覚醒遅延	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ワクチン接種合併症	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 8　　SMA と診断された乳児における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in infants diagnosed with SMA
Page 6 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
創離開	0	0	1 (1.3)	1 (1.0)	1 (0.9)
大腿骨骨折	0	1 (2.4)	0	0	0
頭部損傷	0	1 (2.4)	0	0	0
神経系障害	0	0	2 (2.5)	3 (3.0)	3 (2.6)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
痙攣発作	0	0	0	1 (1.0)	1 (0.9)
臨床検査	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
医学的観察	0	0	1 (1.3)	1 (1.0)	1 (0.9)
酸素飽和度低下	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0
筋骨格系および結合組織障害	0	0	0	1 (1.0)	1 (0.9)
滑膜炎	0	0	0	1 (1.0)	1 (0.9)
皮膚および皮下組織障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 8　　SMA と診断された乳児における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in infants diagnosed with SMA
Page 7 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
血管障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.9)
精神障害	0	1 (2.4)	0	0	0
激越	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 9　　SMA と診断された被験者における重篤な有害事象の発現率

Incidence of serious adverse events in subjects diagnosed with SMA
Page 1 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	5 (29.4)	72 (72.0)	77 (65.8)	7 (12.5)	84 (48.6)
呼吸器、胸郭および縦隔障害	1 (5.9)	61 (61.0)	62 (53.0)	2 (3.6)	64 (37.0)
呼吸窮迫	1 (5.9)	25 (25.0)	26 (22.2)	0	26 (15.0)
呼吸不全	0	22 (22.0)	22 (18.8)	1 (1.8)	23 (13.3)
急性呼吸不全	0	15 (15.0)	15 (12.8)	1 (1.8)	16 (9.2)
無気肺	0	13 (13.0)	13 (11.1)	0	13 (7.5)
誤嚥性肺炎	0	8 (8.0)	8 (6.8)	0	8 (4.6)
呼吸困難	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)
無呼吸	0	4 (4.0)	4 (3.4)	0	4 (2.3)
誤嚥	0	4 (4.0)	4 (3.4)	0	4 (2.3)
低酸素症	0	4 (4.0)	4 (3.4)	0	4 (2.3)
呼吸停止	0	3 (3.0)	3 (2.6)	0	3 (1.7)
低換気	0	2 (2.0)	2 (1.7)	0	2 (1.2)
呼吸障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
急性呼吸窮迫症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
窒息	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 9　　SMA と診断された被験者における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in subjects diagnosed with SMA
Page 2 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
気管支分泌物貯留	0	1 (1.0)	1 (0.9)	0	1 (0.6)
慢性呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管支分泌増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
感染症および寄生虫症	3 (17.6)	53 (53.0)	56 (47.9)	4 (7.1)	60 (34.7)
肺炎	1 (5.9)	18 (18.0)	19 (16.2)	1 (1.8)	20 (11.6)
ライノウイルス感染	0	10 (10.0)	10 (8.5)	0	10 (5.8)
ウイルス性肺炎	0	7 (7.0)	7 (6.0)	2 (3.6)	9 (5.2)
細気管支炎	0	7 (7.0)	7 (6.0)	0	7 (4.0)
ウイルス感染	0	6 (6.0)	6 (5.1)	0	6 (3.5)
ＲＳウイルス細気管支炎	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)
気道感染	0	5 (5.0)	5 (4.3)	0	5 (2.9)
上気道感染	0	5 (5.0)	5 (4.3)	0	5 (2.9)
気管支炎	1 (5.9)	3 (3.0)	4 (3.4)	0	4 (2.3)
下気道感染	0	3 (3.0)	3 (2.6)	1 (1.8)	4 (2.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 9　　SMA と診断された被験者における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in subjects diagnosed with SMA
Page 3 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
細菌性肺炎	0	4 (4.0)	4 (3.4)	0	4 (2.3)
ウイルス性上気道感染	0	4 (4.0)	4 (3.4)	0	4 (2.3)
ウイルス性気管支炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ウイルス性下気道感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
ウイルス性気道感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
コロナウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
耳感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
エンテロウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胃腸炎	0	0	0	1 (1.8)	1 (0.6)
ロタウイルス胃腸炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
鼻咽頭炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
院内感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
パラインフルエンザウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
インフルエンザ性肺炎	0	1 1.0)	1 (0.9)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 9　　SMA と診断された被験者における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in subjects diagnosed with SMA
Page 4 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
モラクセラ菌性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
パラインフルエンザウイルス性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
シュードモナス菌性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ストーマ部膿瘍	0	1 (1.0)	1 (0.9)	0	1 (0.6)
尿路感染	1 (5.9)	0	1 (0.9)	0	1 (0.6)
心臓障害	0	12 (12.0)	12 (10.3)	0	12 (6.9)
心肺停止	0	6 (6.0)	6 (5.1)	0	6 (3.5)
心停止	0	3 (3.0)	3 (2.6)	0	3 (1.7)
チアノーゼ	0	2 (2.0)	2 (1.7)	0	2 (1.2)
徐脈	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心室性頻脈	0	1 (1.0)	1 (0.9)	0	1 (0.6)
代謝および栄養障害	1 (5.9)	9 (9.0)	10 (8.5)	0	10 (5.8)
体重増加不良	0	3 (3.0)	3 (2.6)	0	3 (1.7)
成長障害	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
乳児および小児期早期の哺育障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 9　　SMA と診断された被験者における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in subjects diagnosed with SMA
Page 5 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
栄養補給不耐性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
脱水	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低ナトリウム血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胃腸障害	1 (5.9)	7 (7.0)	8 (6.8)	0	8 (4.6)
嘔吐	0	4 (4.0)	4 (3.4)	0	4 (2.3)
嚥下障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
腹部膨満	1 (5.9)	0	1 (0.9)	0	1 (0.6)
胃出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
傷害、中毒および処置合併症	0	3 (3.0)	3 (2.6)	2 (3.6)	5 (2.9)
腰椎穿刺後症候群	0	0	0	2 (3.6)	2 (1.2)
麻酔からの覚醒遅延	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ワクチン接種合併症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
創離開	0	1 (1.0)	1 (0.9)	0	1 (0.6)
一般・全身障害および投与部位の状態	0	4 (4.0)	4 (3.4)	0	4 (2.3)
発熱	0	3 (3.0)	3 (2.6)	0	3 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 9　　SMA と診断された被験者における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in subjects diagnosed with SMA
Page 6 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
死亡	0	1 (1.0)	1 (0.9)	0	1 (0.6)
神経系障害	0	3 (3.0)	3 (2.6)	0	3 (1.7)
脳損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
痙攣発作	0	1 (1.0)	1 (0.9)	0	1 (0.6)
臨床検査	0	2 (2.0)	2 (1.7)	0	2 (1.2)
医学的観察	0	1 (1.0)	1 (0.9)	0	1 (0.6)
酸素飽和度低下	0	1 (1.0)	1 (0.9)	0	1 (0.6)
免疫系障害	0	0	0	1 (1.8)	1 (0.6)
薬物過敏症	0	0	0	1 (1.8)	1 (0.6)
筋骨格系および結合組織障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚および皮下組織障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 9　　SMA と診断された被験者における重篤な有害事象の発現率（続き）

Incidence of serious adverse events in subjects diagnosed with SMA
Page 7 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血管障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ショック	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別

Incidence of Adverse Events - Infants diagnosed with SMA
Page 1 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	13 (76.5)	4 (100)	16 (100)	38 (92.7)	72 (90.0)
感染症および寄生虫症	10 (58.8)	3 (75.0)	16 (100)	29 (70.7)	57 (71.3)
上気道感染	6 (35.3)	1 (25.0)	11 (68.8)	9 (22.0)	20 (25.0)
肺炎	1 (5.9)	1 (25.0)	6 (37.5)	6 (14.6)	17 (21.3)
鼻咽頭炎	3 (17.6)	0	6 (37.5)	4 (9.8)	14 (17.5)
ウイルス性上気道感染	0	0	2 (12.5)	8 (19.5)	10 (12.5)
ライノウイルス感染	1 (5.9)	0	6 (37.5)	5 (12.2)	8 (10.0)
細気管支炎	1 (5.9)	0	3 (18.8)	3 (7.3)	8 (10.0)
ウイルス感染	0	0	4 (25.0)	2 (4.9)	7 (8.8)
気道感染	0	2 (50.0)	3 (18.8)	2 (4.9)	7 (8.8)
ウイルス性肺炎	1 (5.9)	1 (25.0)	2 (12.5)	1 (2.4)	6 (7.5)
口腔カンジダ症	0	0	1 (6.3)	3 (7.3)	6 (7.5)
結膜炎	0	0	1 (6.3)	3 (7.3)	5 (6.3)
気管支炎	1 (5.9)	0	0	0	5 (6.3)
耳感染	0	0	1 (6.3)	1 (2.4)	4 (5.0)
ウイルス性気道感染	0	0	1 (6.3)	2 (4.9)	4 (5.0)
下気道感染	0	0	1 (6.3)	1 (2.4)	3 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 2 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ＲＳウイルス細気管支炎	0	0	1 (6.3)	3 (7.3)	3 (3.8)
細菌性肺炎	0	0	1 (6.3)	2 (4.9)	3 (3.8)
尿路感染	1 (5.9)	0	0	0	3 (3.8)
ウイルス性気管支炎	0	0	0	0	3 (3.8)
インフルエンザ	2 (11.8)	0	1 (6.3)	0	2 (2.5)
ウイルス性下気道感染	0	0	1 (6.3)	0	2 (2.5)
皮膚カンジダ	0	0	0	1 (2.4)	2 (2.5)
アデノウイルス感染	0	0	0	0	2 (2.5)
細菌性結膜炎	0	0	0	1 (2.4)	2 (2.5)
ストーマ部膿瘍	0	0	0	0	2 (2.5)
中耳炎	2 (11.8)	1 (25.0)	5 (31.3)	2 (4.9)	1 (1.3)
細菌性気管炎	0	0	2 (12.5)	4 (9.8)	1 (1.3)
鼻炎	1 (5.9)	0	1 (6.3)	3 (7.3)	1 (1.3)
胃腸炎	0	0	1 (6.3)	0	1 (1.3)
皮膚真菌感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
手足口病	0	0	1 (6.3)	0	1 (1.3)
細菌感染	0	0	1 (6.3)	0	1 (1.3)
モラクセラ菌性肺炎	0	0	1 (6.3)	0	1 (1.3)
カンジダ性おむつ皮疹	0	1 (25.0)	0	0	1 (1.3)
ウイルス性胃腸炎	1 (5.9)	0	0	2 (4.9)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 3 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
膿痂疹	1 (5.9)	0	0	1 (2.4)	1 (1.3)
蜂巣炎	0	0	0	1 (2.4)	1 (1.3)
限局性感染	0	0	0	0	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
感染性湿疹	0	0	0	0	1 (1.3)
眼感染	0	0	0	0	1 (1.3)
真菌感染	0	0	0	1 (2.4)	1 (1.3)
ロタウイルス胃腸炎	0	0	0	0	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
院内感染	0	0	0	0	1 (1.3)
口腔ヘルペス	0	0	0	0	1 (1.3)
急性中耳炎	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	1 (2.4)	1 (1.3)
シュードモナス感染	0	0	0	2 (4.9)	1 (1.3)
ばら疹	0	0	0	0	1 (1.3)
敗血症	0	0	0	0	1 (1.3)
ブドウ球菌性敗血症	0	0	0	0	1 (1.3)
ブドウ球菌皮膚感染	0	0	0	0	1 (1.3)
エンテロウイルス感染	0	0	2 (12.5)	0	0
メタニューモウイルス感染	0	0	2 (12.5)	0	0
パラインフルエンザウイルス感染	0	1 (25.0)	1 (6.3)	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 4 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アデノウイルス性上気道感染	0	0	1 (6.3)	0	0
細菌性疾患キャリアー	0	0	1 (6.3)	1 (2.4)	0
コロナウイルス感染	0	0	1 (6.3)	2 (4.9)	0
伝染性紅斑	0	0	1 (6.3)	0	0
ウイルス性胃炎	0	0	1 (6.3)	0	0
ヘモフィルス感染	0	0	1 (6.3)	0	0
モラクセラ感染	0	0	1 (6.3)	0	0
粘膜皮膚カンジダ症	0	0	1 (6.3)	0	0
細菌性気道感染	0	0	1 (6.3)	1 (2.4)	0
ブドウ球菌性菌血症	0	0	1 (6.3)	0	0
ブドウ球菌感染	0	0	1 (6.3)	2 (4.9)	0
気管炎	0	0	1 (6.3)	1 (2.4)	0
レンサ球菌性咽頭炎	1 (5.9)	1 (25.0)	0	0	0
シュードモナス菌性肺炎	0	1 (25.0)	0	1 (2.4)	0
皮膚感染	1 (5.9)	0	0	1 (2.4)	0
ＲＳウイルス感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0
伝染性軟属腫	0	0	0	0	0
腟感染	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 5 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
外陰腟真菌感染	0	0	0	0	0
カンジダ感染	0	0	0	3 (7.3)	0
ブドウ球菌性眼感染	0	0	0	0	0
麦粒腫	0	0	0	1 (2.4)	0
単核細胞症症候群	0	0	0	0	0
咽頭炎	0	0	0	0	0
セラチア感染	0	0	0	1 (2.4)	0
副鼻腔炎	0	0	0	0	0
皮膚細菌感染	0	0	0	0	0
ストーマ部感染	0	0	0	3 (7.3)	0
扁桃炎	0	0	0	0	0
ウイルス性発疹	0	0	0	1 (2.4)	0
呼吸器、胸郭および縦隔障害	5 (29.4)	3 (75.0)	15 (93.8)	34 (82.9)	55 (68.8)
呼吸窮迫	1 (5.9)	1 (25.0)	6 (37.5)	14 (34.1)	19 (23.8)
呼吸不全	0	0	6 (37.5)	14 (34.1)	17 (21.3)
無気肺	0	0	5 (31.3)	9 (22.0)	15 (18.8)
急性呼吸不全	0	1 (25.0)	3 (18.8)	8 (19.5)	11 (13.8)
鼻閉	2 (11.8)	1 (25.0)	6 (37.5)	6 (14.6)	8 (10.0)
誤嚥性肺炎	0	0	3 (18.8)	6 (14.6)	7 (8.8)
呼吸困難	0	1 (25.0)	1 (6.3)	6 (14.6)	7 (8.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 6 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
咳嗽	2 (11.8)	2 (50.0)	4 (25.0)	8 (19.5)	6 (7.5)
低酸素症	0	0	4 (25.0)	2 (4.9)	6 (7.5)
上気道うっ血	1 (5.9)	0	1 (6.3)	1 (2.4)	5 (6.3)
無呼吸	0	0	3 (18.8)	3 (7.3)	4 (5.0)
鼻漏	1 (5.9)	0	2 (12.5)	3 (7.3)	4 (5.0)
誤嚥	0	0	2 (12.5)	1 (2.4)	4 (5.0)
気管支分泌物貯留	0	1 (25.0)	2 (12.5)	4 (9.8)	3 (3.8)
副鼻腔うっ血	0	0	1 (6.3)	0	3 (3.8)
呼吸停止	0	0	1 (6.3)	4 (9.8)	3 (3.8)
上気道分泌増加	0	0	4 (25.0)	1 (2.4)	2 (2.5)
慢性呼吸不全	0	1 (25.0)	3 (18.8)	0	2 (2.5)
低換気	0	0	1 (6.3)	0	2 (2.5)
呼吸障害	0	0	0	0	2 (2.5)
喘鳴	0	0	2 (12.5)	0	1 (1.3)
気胸	0	0	2 (12.5)	0	1 (1.3)
息詰まり	0	0	1 (6.3)	1 (2.4)	1 (1.3)
呼吸補助筋の動員	0	0	1 (6.3)	1 (2.4)	1 (1.3)
アレルギー性鼻炎	0	1 (25.0)	0	0	1 (1.3)
急性呼吸窮迫症候群	0	0	0	0	1 (1.3)
気管支閉塞	0	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	0	0	1 (1.3)
減呼吸	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 7 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気管支分泌増加	0	0	0	1 (2.4)	1 (1.3)
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
胸水	0	0	0	0	1 (1.3)
呼吸性アルカローシス	0	0	0	0	1 (1.3)
気道うっ血	0	0	0	3 (7.3)	1 (1.3)
変色痰	0	0	0	0	1 (1.3)
肺うっ血	0	0	2 (12.5)	0	0
肺水腫	0	0	2 (12.5)	0	0
無呼吸発作	0	0	1 (6.3)	0	0
喉頭肉芽腫	0	0	1 (6.3)	0	0
鼻汁変色	0	0	1 (6.3)	0	0
気縦隔症	0	0	1 (6.3)	0	0
湿性咳嗽	0	0	1 (6.3)	0	0
拘束性肺疾患	0	0	1 (6.3)	0	0
低音性連続性ラ音	0	0	1 (6.3)	0	0
睡眠時無呼吸症候群	0	0	1 (6.3)	4 (9.8)	0
頻呼吸	0	0	1 (6.3)	2 (4.9)	0
気管障害	0	0	1 (6.3)	0	0
窒息	0	1 (25.0)	0	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	0
口腔咽頭痛	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 8 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鼻出血	0	0	0	0	0
扁桃肥大	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0
カタル	0	0	0	1 (2.4)	0
発声障害	0	0	0	0	0
肺臓炎	0	0	0	0	0
上気道の炎症	0	0	0	2 (4.9)	0
胃腸障害	6 (35.3)	4 (100)	14 (87.5)	23 (56.1)	46 (57.5)
便秘	1 (5.9)	1 (25.0)	8 (50.0)	9 (22.0)	24 (30.0)
嘔吐	0	2 (50.0)	6 (37.5)	8 (19.5)	12 (15.0)
生歯	1 (5.9)	2 (50.0)	2 (12.5)	3 (7.3)	11 (13.8)
胃食道逆流性疾患	2 (11.8)	0	6 (37.5)	6 (14.6)	9 (11.3)
嚥下障害	1 (5.9)	0	0	8 (19.5)	9 (11.3)
下痢	0	1 (25.0)	4 (25.0)	7 (17.1)	8 (10.0)
流涎過多	0	0	2 (12.5)	2 (4.9)	3 (3.8)
放屁	2 (11.8)	1 (25.0)	1 (6.3)	1 (2.4)	3 (3.8)
胃炎	0	0	1 (6.3)	1 (2.4)	3 (3.8)
血便排泄	0	0	0	0	2 (2.5)
腹部膨満	2 (11.8)	1 (25.0)	2 (12.5)	0	1 (1.3)
腹部不快感	1 (5.9)	0	0	0	1 (1.3)
アフタ性潰瘍	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 9 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胃出血	0	0	0	0	1 (1.3)
乳児仙痛	0	0	0	0	1 (1.3)
乳児吐出	0	0	0	0	1 (1.3)
上部消化管出血	0	0	0	0	1 (1.3)
口唇のひび割れ	0	0	1 (6.3)	0	0
排便回数増加	0	0	1 (6.3)	0	0
腹痛	0	1 (25.0)	0	0	0
消化管運動低下	0	1 (25.0)	0	0	0
吐血	0	1 (25.0)	0	0	0
悪心	0	0	0	0	0
上腹部痛	0	0	0	2 (4.9)	0
腹部症状	0	0	0	0	0
口腔内痛	0	0	0	0	0
口内炎	0	0	0	1 (2.4)	0
血性下痢	0	0	0	1 (2.4)	0
食中毒	0	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	0	0	1 (2.4)	0
消化管刺激症状	0	0	0	1 (2.4)	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 10 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
一般・全身障害および投与部位の状態	4 (23.5)	3 (75.0)	11 (68.8)	27 (65.9)	44 (55.0)
発熱	3 (17.6)	3 (75.0)	11 (68.8)	22 (53.7)	39 (48.8)
疼痛	0	0	4 (25.0)	2 (4.9)	1 (1.3)
カテーテル留置部位炎症	0	0	0	1 (2.4)	1 (1.3)
泣き	0	0	0	0	1 (1.3)
死亡	0	0	0	1 (2.4)	1 (1.3)
薬物不耐性	0	0	0	0	1 (1.3)
低体温	0	0	0	0	1 (1.3)
ワクチン接種後の易刺激性	0	0	0	0	1 (1.3)
倦怠感	0	0	0	0	1 (1.3)
小結節	0	0	0	0	1 (1.3)
腫脹	0	0	0	0	1 (1.3)
不快感	0	1 (25.0)	1 (6.3)	0	0
末梢性浮腫	0	1 (25.0)	1 (6.3)	0	0
医療機器リーク	0	0	1 (6.3)	0	0
医療機器閉塞	0	0	1 (6.3)	1 (2.4)	0
浮腫	0	0	1 (6.3)	3 (7.3)	0
血管穿刺部位内出血	0	0	1 (6.3)	2 (4.9)	0
末梢腫脹	0	1 (25.0)	0	0	0
適用部位紅斑	1 (5.9)	0	0	0	0
注入部位内出血	1 (5.9)	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 11 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
疲労	0	0	0	1 (2.4)	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
適用部位発疹	0	0	0	1 (2.4)	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0
医療機器機能不良	0	0	0	1 (2.4)	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
注入部位血管外漏出	0	0	0	1 (2.4)	0
注射部位血腫	0	0	0	1 (2.4)	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
血管穿刺部位反応	0	0	0	1 (2.4)	0
皮膚および皮下組織障害	6 (35.3)	4 (100)	10 (62.5)	13 (31.7)	21 (26.3)
発疹	0	1 (25.0)	4 (25.0)	4 (9.8)	8 (10.0)
おむつ皮膚炎	2 (11.8)	2 (50.0)	2 (12.5)	2 (4.9)	6 (7.5)
斑状出血	0	0	1 (6.3)	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 12 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
接触性皮膚炎	0	1 (25.0)	0	2 (4.9)	2 (2.5)
過角化	0	0	0	0	2 (2.5)
汗疹	0	0	0	0	2 (2.5)
湿疹	0	1 (25.0)	2 (12.5)	2 (4.9)	1 (1.3)
皮膚炎	2 (11.8)	0	1 (6.3)	0	1 (1.3)
紅斑	1 (5.9)	0	0	3 (7.3)	1 (1.3)
蕁麻疹	0	0	0	0	1 (1.3)
アレルギー性皮膚炎	0	0	0	0	1 (1.3)
環状肉芽腫	0	0	0	0	1 (1.3)
丘疹性皮疹	0	0	0	0	1 (1.3)
皮膚浮腫	0	0	0	0	1 (1.3)
過剰肉芽組織	0	0	3 (18.8)	0	0
皮膚刺激	0	1 (25.0)	2 (12.5)	0	0
脱毛症	0	0	1 (6.3)	0	0
点状出血	0	0	1 (6.3)	0	0
そう痒症	0	0	1 (6.3)	0	0
皮膚色素脱失	0	0	1 (6.3)	0	0
皮膚潰瘍	0	0	1 (6.3)	0	0
皮下気腫	0	0	1 (6.3)	0	0
皮膚障害	0	1 (25.0)	0	0	0
貨幣状湿疹	1 (5.9)	0	0	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 13 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0
褥瘡性潰瘍	0	0	0	2 (4.9)	0
毛孔性角化症	0	0	0	1 (2.4)	0
皮膚病変	0	0	0	0	0
アトピー性皮膚炎	0	0	0	2 (4.9)	0
皮膚乾燥	0	0	0	1 (2.4)	0
多汗症	0	0	0	1 (2.4)	0
寝汗	0	0	0	0	0
臨床検査	1 (5.9)	1 (25.0)	6 (37.5)	14 (34.1)	17 (21.3)
酸素飽和度低下	0	0	2 (12.5)	9 (22.0)	8 (10.0)
体重減少	0	1 (25.0)	1 (6.3)	1 (2.4)	3 (3.8)
血中カリウム減少	0	0	0	0	2 (2.5)
体温上昇	0	0	0	0	2 (2.5)
Ｃ－反応性蛋白増加	0	0	0	1 (2.4)	2 (2.5)
ヒトライノウイルス検査陽性	0	0	2 (12.5)	0	1 (1.3)
好中球数増加	0	0	2 (12.5)	0	1 (1.3)
心拍数増加	0	0	1 (6.3)	1 (2.4)	1 (1.3)
モラクセラ検査陽性	0	0	1 (6.3)	0	1 (1.3)
シュードモナス検査陽性	0	0	1 (6.3)	0	1 (1.3)
ブドウ球菌検査陽性	0	0	1 (6.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 14 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (1.3)
血中クロール減少	0	0	0	0	1 (1.3)
血中鉄減少	0	0	0	0	1 (1.3)
血中ナトリウム減少	0	0	0	0	1 (1.3)
体温低下	0	0	0	1 (2.4)	1 (1.3)
心電図ＳＴ－Ｔ部分異常	0	0	0	1 (2.4)	1 (1.3)
心拍数不整	0	0	0	0	1 (1.3)
炎症マーカー上昇	0	0	0	0	1 (1.3)
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	1 (1.3)
肝機能検査異常	0	0	0	0	1 (1.3)
医学的観察	0	0	0	0	1 (1.3)
尿量減少	0	0	0	0	1 (1.3)
ビタミンＡ減少	0	0	0	0	1 (1.3)
白血球数増加	0	0	2 (12.5)	0	0
骨密度減少	0	0	1 (6.3)	0	0
呼吸音異常	0	0	1 (6.3)	0	0
心拍数減少	0	0	1 (6.3)	0	0
好中球百分率増加	0	0	1 (6.3)	0	0
セラチア検査陽性	0	0	1 (6.3)	0	0
レンサ球菌検査陽性	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 15 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0
ヘッドラグ異常	0	0	0	1 (2.4)	0
リンパ節触知	0	0	0	1 (2.4)	0
呼吸数増加	0	0	0	1 (2.4)	0
レスピロウイルス検査陽性	0	0	0	1 (2.4)	0
トランスアミナーゼ上昇	0	0	0	1 (2.4)	0
尿検査異常	0	0	0	0	0
ビタミンＤ減少	0	0	0	1 (2.4)	0
心臓障害	2 (11.8)	2 (50.0)	4 (25.0)	11 (26.8)	16 (20.0)
頻脈	2 (11.8)	1 (25.0)	1 (6.3)	5 (12.2)	6 (7.5)
心肺停止	0	0	1 (6.3)	3 (7.3)	5 (6.3)
徐脈	0	1 (25.0)	2 (12.5)	3 (7.3)	4 (5.0)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
チアノーゼ	0	0	1 (6.3)	2 (4.9)	2 (2.5)
心室性頻脈	0	1 (25.0)	0	0	1 (1.3)
左室肥大	0	0	0	0	1 (1.3)
上室性頻脈	0	0	0	0	1 (1.3)
心筋症	0	0	1 (6.3)	0	0
心膜気腫	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 16 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
動悸	0	0	0	0	0
傷害、中毒および処置合併症	3 (17.6)	3 (75.0)	8 (50.0)	10 (24.4)	15 (18.8)
処置による疼痛	0	1 (25.0)	1 (6.3)	0	2 (2.5)
ストーマ部紅斑	0	0	1 (6.3)	2 (4.9)	2 (2.5)
大腿骨骨折	0	0	0	1 (2.4)	2 (2.5)
挫傷	0	0	1 (6.3)	0	1 (1.3)
処置後腫脹	1 (5.9)	0	0	0	1 (1.3)
術後激越	0	0	0	0	1 (1.3)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
擦過傷	0	0	0	1 (2.4)	1 (1.3)
伝染病曝露	0	0	0	0	1 (1.3)
処置合併症	0	0	0	0	1 (1.3)
処置部位反応	0	0	0	0	1 (1.3)
ストーマ合併症	0	0	0	2 (4.9)	1 (1.3)
ワクチン接種合併症	0	0	0	1 (2.4)	1 (1.3)
創離開	0	0	0	0	1 (1.3)
節足動物咬傷	0	1 (25.0)	2 (12.5)	0	0
関節脱臼	0	0	2 (12.5)	0	0
栄養補給チューブ合併症	0	0	2 (12.5)	2 (4.9)	0
皮膚擦過傷	0	0	2 (12.5)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 17 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ダンピング症候群	0	0	1 (6.3)	0	0
耳擦過傷	0	0	1 (6.3)	0	0
口唇損傷	0	0	1 (6.3)	0	0
外傷性気胸	0	0	1 (6.3)	0	0
歯牙損傷	0	0	1 (6.3)	0	0
軟部組織損傷	0	1 (25.0)	0	0	0
サンバーン	0	1 (25.0)	0	0	0
熱傷	0	1 (25.0)	0	0	0
転倒	1 (5.9)	0	0	0	0
処置後合併症	1 (5.9)	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	0
硬膜下血腫	1 (5.9)	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
裂傷	0	0	0	1 (2.4)	0
四肢損傷	0	0	0	0	0
節足動物刺傷	0	0	0	0	0
関節損傷	0	0	0	0	0
靭帯捻挫	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
気管内挿管合併症	0	0	0	1 (2.4)	0
頭部損傷	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 18 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
肉離れ	0	0	0	0	0
処置後挫傷	0	0	0	1 (2.4)	0
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
ストーマ部出血	0	0	0	1 (2.4)	0
ストーマ部炎症	0	0	0	1 (2.4)	0
ストーマ部刺激感	0	0	0	1 (2.4)	0
脛骨骨折	0	0	0	0	0
隆起骨折	0	0	0	0	0
気管損傷	0	0	0	1 (2.4)	0
代謝および栄養障害	2 (11.8)	2 (50.0)	3 (18.8)	10 (24.4)	13 (16.3)
体重増加不良	1 (5.9)	1 (25.0)	0	2 (4.9)	5 (6.3)
乳児および小児期早期の哺育障害	0	0	0	2 (4.9)	3 (3.8)
栄養補給不耐性	0	0	0	0	3 (3.8)
成長障害	1 (5.9)	0	1 (6.3)	0	2 (2.5)
脱水	1 (5.9)	0	0	1 (2.4)	1 (1.3)
鉄欠乏	0	0	0	0	1 (1.3)
低ナトリウム血症	0	0	2 (12.5)	0	0
過小食	0	1 (25.0)	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 19 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
代謝性アルカローシス	0	0	1 (6.3)	0	0
食欲減退	0	0	0	0	0
食欲亢進	0	0	0	0	0
ビタミンD欠乏	0	0	0	1 (2.4)	0
食物不耐性	0	0	0	1 (2.4)	0
高血糖	0	0	0	1 (2.4)	0
低血糖	0	0	0	2 (4.9)	0
低カリウム血症	0	0	0	3 (7.3)	0
筋骨格系および結合組織障害	2 (11.8)	3 (75.0)	11 (68.8)	4 (9.8)	11 (13.8)
側弯症	0	2 (50.0)	5 (31.3)	1 (2.4)	4 (5.0)
関節拘縮	1 (5.9)	3 (75.0)	5 (31.3)	2 (4.9)	3 (3.8)
頭位性斜頭症	1 (5.9)	0	0	1 (2.4)	2 (2.5)
脊柱後弯症	0	2 (50.0)	2 (12.5)	1 (2.4)	1 (1.3)
胸郭変形	0	1 (25.0)	2 (12.5)	0	1 (1.3)
四肢痛	0	0	1 (6.3)	0	1 (1.3)
後側弯症	0	0	1 (6.3)	0	1 (1.3)
背部痛	0	0	0	0	1 (1.3)
泉門閉鎖遅延	0	0	0	0	1 (1.3)
斜頚	1 (5.9)	1 (25.0)	1 (6.3)	0	0
手変形	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 20 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
関節硬直	0	0	1 (6.3)	1 (2.4)	0
脊柱前弯症	0	0	1 (6.3)	0	0
脊柱変形	0	0	1 (6.3)	0	0
滑膜炎	0	0	1 (6.3)	0	0
筋力低下	1 (5.9)	0	0	1 (2.4)	0
体重支持困難	1 (5.9)	0	0	0	0
関節痛	0	0	0	0	0
筋緊張	0	0	0	0	0
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	0	0	1 (2.4)	0
神経系障害	2 (11.8)	2 (50.0)	7 (43.8)	2 (4.9)	8 (10.0)
眼振	0	1 (25.0)	0	1 (2.4)	2 (2.5)
不随意性筋収縮	0	0	3 (18.8)	0	1 (1.3)
よだれ	0	0	1 (6.3)	0	1 (1.3)
痙攣発作	0	0	1 (6.3)	0	1 (1.3)
脳損傷	0	0	0	0	1 (1.3)
間代	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 21 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
傾眠	0	0	0	0	1 (1.3)
失神	0	0	1 (6.3)	0	0
脳梗塞	0	0	1 (6.3)	0	0
脳脊髄液漏	0	0	1 (6.3)	0	0
嗜眠	0	0	1 (6.3)	0	0
頭痛	0	1 (25.0)	0	0	0
反射亢進	1 (5.9)	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	0
失声症	0	0	0	0	0
感覚鈍麻	0	0	0	0	0
片頭痛	0	0	0	0	0
振戦	0	0	0	0	0
味覚異常	0	0	0	0	0
失読症	0	0	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	0	0	1 (2.4)	0
精神障害	0	0	3 (18.8)	5 (12.2)	8 (10.0)
不安	0	0	3 (18.8)	0	2 (2.5)
激越	0	0	0	2 (4.9)	2 (2.5)
易刺激性	0	0	0	1 (2.4)	2 (2.5)
息こらえ	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 22 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気分動揺	0	0	0	0	1 (1.3)
落ち着きのなさ	0	0	0	1 (2.4)	1 (1.3)
睡眠障害	0	0	0	2 (4.9)	1 (1.3)
不眠症	0	0	0	0	0
チック	0	0	0	0	0
注意欠陥多動性障害	0	0	0	0	0
不快気分	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
免疫系障害	1 (5.9)	1 (25.0)	5 (31.3)	4 (9.8)	6 (7.5)
季節性アレルギー	1 (5.9)	1 (25.0)	2 (12.5)	2 (4.9)	2 (2.5)
薬物過敏症	0	0	2 (12.5)	1 (2.4)	2 (2.5)
過敏症	0	0	1 (6.3)	2 (4.9)	1 (1.3)
食物アレルギー	0	0	0	0	1 (1.3)
血管障害	2 (11.8)	1 (25.0)	2 (12.5)	0	4 (5.0)
高血圧	1 (5.9)	0	1 (6.3)	0	1 (1.3)
蒼白	1 (5.9)	0	0	0	1 (1.3)
ショック	0	0	0	0	1 (1.3)
血管炎	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 23 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
毛細血管脆弱	0	0	1 (6.3)	0	0
本態性高血圧症	0	1 (25.0)	0	0	0
低血圧	0	0	0	0	0
眼障害	1 (5.9)	1 (25.0)	1 (6.3)	3 (7.3)	4 (5.0)
霰粒腫	0	0	0	0	1 (1.3)
眼乾燥	0	0	0	1 (2.4)	1 (1.3)
眼運動障害	0	0	0	0	1 (1.3)
近視	0	0	0	0	1 (1.3)
斜視	0	0	0	1 (2.4)	1 (1.3)
眼瞼下垂	0	0	1 (6.3)	0	0
乱視	0	1 (25.0)	0	0	0
後天性涙道狭窄	1 (5.9)	0	0	0	0
遠視	0	0	0	0	0
弱視	0	0	0	1 (2.4)	0
流涙増加	0	0	0	1 (2.4)	0
先天性、家族性および遺伝性障害	0	1 (25.0)	2 (12.5)	4 (9.8)	3 (3.8)
発育性股関節形成不全	0	0	0	1 (2.4)	1 (1.3)
貧血母斑	0	0	0	0	1 (1.3)
鳩胸	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 24 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
斜頭症	0	1 (25.0)	1 (6.3)	0	0
斜指症	0	0	1 (6.3)	0	0
停留精巣	0	0	0	1 (2.4)	0
包茎	0	0	0	1 (2.4)	0
生殖系および乳房障害	0	0	0	0	3 (3.8)
後天性包茎	0	0	0	0	1 (1.3)
卵巣嚢胞	0	0	0	0	1 (1.3)
陰茎障害	0	0	0	0	1 (1.3)
耳および迷路障害	0	1 (25.0)	0	0	2 (2.5)
耳の障害	0	0	0	0	1 (1.3)
耳痛	0	0	0	0	1 (1.3)
耳垢分泌過多	0	1 (25.0)	0	0	0
鼓膜穿孔	0	0	0	0	0
乗物酔い	0	0	0	0	0
腎および尿路障害	0	0	0	1 (2.4)	2 (2.5)
水腎症	0	0	0	0	1 (1.3)
尿閉	0	0	0	0	1 (1.3)
排尿困難	0	0	0	0	0
尿失禁	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 25 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
糖尿	0	0	0	1 (2.4)	0
膀胱尿管逆流	0	0	0	0	0
血液およびリンパ系障害	2 (11.8)	1 (25.0)	4 (25.0)	3 (7.3)	1 (1.3)
貧血	0	0	2 (12.5)	1 (2.4)	1 (1.3)
好中球減少症	1 (5.9)	0	1 (6.3)	0	0
血小板増加症	0	0	1 (6.3)	0	0
リンパ節症	0	1 (25.0)	0	0	0
好酸球増加症	1 (5.9)	0	0	0	0
骨髄障害	0	0	0	1 (2.4)	0
白血球増加症	0	0	0	1 (2.4)	0
肝胆道系障害	0	0	0	0	1 (1.3)
肝腫大	0	0	0	0	1 (1.3)
外科および内科処置	0	0	0	0	1 (1.3)
機械的換気	0	0	0	0	1 (1.3)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.9)	1 (25.0)	1 (6.3)	0	0
アクロコルドン	0	0	1 (6.3)	0	0
血管の良性新生物	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 26 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
脂漏性角化症	1 (5.9)	0	0	0	0
皮膚乳頭腫	0	0	0	0	0
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別

Incidence of Adverse Events - Later-onset
Page 1 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	6 (100)	4 (66.7)	6 (100)	9 (90.0)	8 (100)	7 (87.5)
感染症および寄生虫症	1 (16.7)	1 (16.7)	1 (16.7)	4 (40.0)	6 (75.0)	4 (50.0)
上気道感染	0	1 (16.7)	1 (16.7)	1 (10.0)	2 (25.0)	1 (12.5)
肺炎	0	0	0	0	2 (25.0)	0
鼻咽頭炎	0	0	0	0	0	1 (12.5)
ウイルス性上気道感染	0	0	0	0	0	1 (12.5)
ライノウイルス感染	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
ウイルス感染	1 (16.7)	0	0	0	0	1 (12.5)
気道感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
口腔カンジダ症	0	0	0	0	0	0
結膜炎	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0
耳感染	0	0	0	1 (10.0)	0	0
ウイルス性気道感染	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 2 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	9 (100)	9 (100)	3 (75.0)	13 (92.9)	47 (100)
感染症および寄生虫症	7 (77.8)	5 (55.6)	3 (75.0)	7 (50.0)	36 (76.6)
上気道感染	2 (22.2)	1 (11.1)	1 (25.0)	2 (14.3)	19 (40.4)
肺炎	0	0	0	0	4 (8.5)
鼻咽頭炎	4 (44.4)	3 (33.3)	0	2 (14.3)	7 (14.9)
ウイルス性上気道感染	2 (22.2)	0	0	0	2 (4.3)
ライノウイルス感染	0	0	0	0	0
細気管支炎	0	0	0	0	0
ウイルス感染	1 (11.1)	0	0	0	7 (14.9)
気道感染	0	0	0	0	1 (2.1)
ウイルス性肺炎	0	0	0	0	2 (4.3)
口腔カンジダ症	0	0	0	0	0
結膜炎	0	1 (11.1)	0	0	2 (4.3)
気管支炎	0	0	0	0	0
耳感染	1 (11.1)	0	0	0	2 (4.3)
ウイルス性気道感染	0	0	0	0	1 (2.1)
下気道感染	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 3 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ＲＳウイルス細気管支炎	0	0	0	0	0	0
細菌性肺炎	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
インフルエンザ	0	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
中耳炎	0	0	0	0	2 (25.0)	0
細菌性気管炎	0	0	0	0	0	0
鼻炎	0	0	0	0	1 (12.5)	0
胃腸炎	0	0	0	0	0	0
皮膚真菌感染	0	0	0	0	0	0
手足口病	0	0	0	0	0	0
細菌感染	0	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 4 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ＲＳウイルス細気管支炎	0	0	0	0	1 (2.1)
細菌性肺炎	0	0	0	0	0
尿路感染	1 (11.1)	0	0	1 (7.1)	2 (4.3)
ウイルス性気管支炎	0	0	0	0	0
インフルエンザ	0	1 (11.1)	0	0	2 (4.3)
ウイルス性下気道感染	0	0	0	0	0
皮膚カンジダ	0	0	0	0	2 (4.3)
アデノウイルス感染	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
中耳炎	0	0	1 (25.0)	1 (7.1)	1 (2.1)
細菌性気管炎	0	0	0	0	0
鼻炎	0	0	0	0	0
胃腸炎	0	0	0	1 (7.1)	6 (12.8)
皮膚真菌感染	0	0	0	0	1 (2.1)
手足口病	0	0	0	0	1 (2.1)
細菌感染	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
ウイルス性胃腸炎	1 (11.1)	0	1 (25.0)	0	6 (12.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 5 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
膿痂疹	0	0	0	0	0	0
蜂巣炎	0	0	0	0	0	0
限局性感染	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
感染性湿疹	0	0	0	0	0	0
眼感染	0	0	0	0	0	0
真菌感染	0	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0	0
肺感染	0	0	0	0	0	0
院内感染	0	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0	0
急性中耳炎	0	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
シュードモナス感染	0	0	0	0	0	0
ばら疹	0	0	0	0	0	0
敗血症	0	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 6 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
膿痂疹	0	1 (11.1)	0	0	0
蜂巣炎	0	0	0	0	1 (2.1)
限局性感染	2 (22.2)	0	0	0	1 (2.1)
ＲＳウイルス肺炎	0	0	0	0	1 (2.1)
感染性湿疹	0	0	0	0	0
眼感染	0	0	0	0	0
真菌感染	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
肺感染	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
急性中耳炎	0	0	0	1 (7.1)	0
インフルエンザ性肺炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
ばら疹	0	0	0	0	0
敗血症	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 7 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
アデノウイルス性上気道感染	0	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
伝染性紅斑	0	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0	0
モラクセラ感染	0	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0	0
細菌性気道感染	0	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0	0
気管炎	0	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	2 (20.0)	3 (37.5)	0
シュードモナス菌性肺炎	0	0	0	0	0	0
皮膚感染	0	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	1 (12.5)	0
ウイルス性眼感染	0	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0	0
伝染性軟属腫	0	0	0	0	0	0
腟感染	0	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 8 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
アデノウイルス性上気道感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
細菌性気道感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
気管炎	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	1 (25.0)	0	3 (6.4)
シュードモナス菌性肺炎	0	0	0	0	0
皮膚感染	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	2 (4.3)
ウイルス性眼感染	0	0	0	0	1 (2.1)
ウイルス性消化管感染	1 (11.1)	0	0	0	1 (2.1)
伝染性軟属腫	0	0	0	0	1 (2.1)
腟感染	0	0	0	0	1 (2.1)
ウイルス性扁桃炎	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 9 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
外陰腟真菌感染	0	0	0	0	0	0
カンジダ感染	0	0	0	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0	0
麦粒腫	0	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0	0
咽頭炎	0	0	0	0	0	0
セラチア感染	0	0	0	0	0	0
副鼻腔炎	0	0	0	1 (10.0)	0	1 (12.5)
皮膚細菌感染	0	0	0	0	0	0
ストーマ部感染	0	0	0	0	0	0
扁桃炎	0	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	1 (10.0)	3 (37.5)	1 (12.5)
呼吸窮迫	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
無気肺	0	0	0	0	1 (12.5)	0
急性呼吸不全	0	0	0	0	0	0
鼻閉	0	0	0	0	1 (12.5)	0
誤嚥性肺炎	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 10 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
外陰腟真菌感染	0	0	0	0	1 (2.1)
カンジダ感染	0	0	0	0	0
ブドウ球菌性眼感染	0	1 (11.1)	0	0	0
麦粒腫	0	0	0	0	0
単核細胞症症候群	0	0	1 (25.0)	0	0
咽頭炎	0	0	0	1 (7.1)	0
セラチア感染	0	0	0	0	0
副鼻腔炎	1 (11.1)	0	0	0	0
皮膚細菌感染	0	1 (11.1)	0	0	0
ストーマ部感染	0	0	0	0	0
扁桃炎	0	0	1 (25.0)	0	0
ウイルス性発疹	0	0	0	0	0
呼吸器、胸郭および縦隔障害	3 (33.3)	2 (22.2)	1 (25.0)	3 (21.4)	18 (38.3)
呼吸窮迫	0	0	0	0	0
呼吸不全	0	0	0	0	1 (2.1)
無気肺	0	0	0	0	1 (2.1)
急性呼吸不全	0	0	0	0	1 (2.1)
鼻閉	0	0	0	1 (7.1)	1 (2.1)
誤嚥性肺炎	0	0	0	0	0
呼吸困難	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 11 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
咳嗽	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
上気道うっ血	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
鼻漏	0	0	0	0	1 (12.5)	0
誤嚥	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
副鼻腔うっ血	0	0	0	1 (10.0)	0	0
呼吸停止	0	0	0	0	0	0
上気道分泌増加	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
低換気	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
喘鳴	0	0	0	0	0	1 (12.5)
気胸	0	0	0	0	0	0
息詰まり	0	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0	0
気管支閉塞	0	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0	0
減呼吸	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 12 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
咳嗽	0	1 (11.1)	0	0	5 (10.6)
低酸素症	0	0	0	0	3 (6.4)
上気道うっ血	0	0	0	0	0
無呼吸	0	0	0	0	0
鼻漏	1 (11.1)	1 (11.1)	0	0	3 (6.4)
誤嚥	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	1 (2.1)
呼吸停止	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
低換気	0	0	0	0	0
呼吸障害	0	0	0	0	1 (2.1)
喘鳴	0	0	0	0	1 (2.1)
気胸	0	0	0	0	0
息詰まり	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
気管支閉塞	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 13 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気管支分泌増加	0	0	0	0	0	0
肺障害	0	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0	0
胸水	0	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
変色痰	0	0	0	0	0	0
肺うっ血	0	0	0	0	0	0
肺水腫	0	0	0	0	0	0
無呼吸発作	0	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0	0
鼻汁変色	0	0	0	0	0	0
気縦隔症	0	0	0	0	0	0
湿性咳嗽	0	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0	1 (12.5)
低音性連続性ラ音	0	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0	0
頻呼吸	0	0	0	0	0	0
気管障害	0	0	0	0	0	0
窒息	0	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0	0
口腔咽頭痛	0	0	0	0	1 (12.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 14 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気管支分泌増加	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
変色痰	0	0	0	0	0
肺うっ血	0	0	0	0	1 (2.1)
肺水腫	0	0	0	0	0
無呼吸発作	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
気管障害	0	0	0	0	0
窒息	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
口腔咽頭痛	1 (11.1)	1 (11.1)	0	0	6 (12.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 15 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
鼻出血	0	0	0	0	1 (12.5)	0
扁桃肥大	0	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0	0
カタル	0	0	0	0	0	0
発声障害	0	0	0	0	0	0
肺臓炎	0	0	0	0	0	0
上気道の炎症	0	0	0	0	0	0
胃腸障害	3 (50.0)	3 (50.0)	1 (16.7)	0	2 (25.0)	2 (25.0)
便秘	2 (33.3)	1 (16.7)	0	0	0	0
嘔吐	1 (16.7)	2 (33.3)	0	0	1 (12.5)	1 (12.5)
生歯	0	0	0	0	0	0
胃食道逆流性疾患	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0
下痢	0	0	0	0	1 (12.5)	0
流涎過多	0	0	0	0	0	0
放屁	0	0	0	0	0	0
胃炎	0	0	0	0	0	0
血便排泄	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
腹部不快感	0	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 16 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
鼻出血	1 (11.1)	0	0	0	2 (4.3)
扁桃肥大	0	0	1 (25.0)	1 (7.1)	1 (2.1)
乳幼児突発性危急事態	0	0	0	0	0
カタル	0	0	0	0	0
発声障害	0	0	0	1 (7.1)	0
肺臓炎	0	0	0	1 (7.1)	0
上気道の炎症	0	0	0	0	0
胃腸障害	4 (44.4)	3 (33.3)	0	5 (35.7)	15 (31.9)
便秘	2 (22.2)	2 (22.2)	0	1 (7.1)	1 (2.1)
嘔吐	2 (22.2)	2 (22.2)	0	2 (14.3)	5 (10.6)
生歯	0	0	0	0	0
胃食道逆流性疾患	0	0	0	0	1 (2.1)
嚥下障害	0	0	0	0	0
下痢	0	0	0	0	1 (2.1)
流涎過多	0	0	0	0	0
放屁	0	0	0	0	1 (2.1)
胃炎	0	0	0	0	0
血便排泄	0	0	0	0	0
腹部膨満	0	0	0	0	0
腹部不快感	1 (11.1)	0	0	0	0
アフタ性潰瘍	0	0	0	1 (7.1)	2 (4.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 17 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
胃出血	0	0	0	0	0	0
乳児仙痛	0	0	0	0	0	0
乳児吐出	0	0	0	0	0	0
上部消化管出血	0	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0	0
排便回数増加	0	0	0	0	0	0
腹痛	0	0	0	0	0	0
消化管運動低下	0	0	0	0	0	0
吐血	0	0	0	0	0	0
悪心	1 (16.7)	2 (33.3)	0	0	2 (25.0)	0
上腹部痛	0	0	0	0	0	0
腹部症状	0	0	0	0	0	0
口腔内痛	0	0	0	0	0	1 (12.5)
口内炎	0	0	0	0	0	0
血性下痢	0	0	0	0	0	0
食中毒	0	0	0	0	0	0
胃腸障害	0	0	1 (16.7)	0	0	0
胃腸出血	0	0	0	0	0	0
消化管刺激症状	0	0	0	0	0	0
口の感覚鈍麻	0	0	0	0	0	0
口唇痛	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 18 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
胃出血	0	0	0	0	0
乳児仙痛	0	0	0	0	0
乳児吐出	0	0	0	0	0
上部消化管出血	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
排便回数増加	0	0	0	0	0
腹痛	0	0	0	1 (7.1)	1 (2.1)
消化管運動低下	0	0	0	0	0
吐血	0	0	0	0	0
悪心	2 (22.2)	0	0	1 (7.1)	3 (6.4)
上腹部痛	0	0	0	0	2 (4.3)
腹部症状	0	0	0	0	1 (2.1)
口腔内痛	0	0	0	0	1 (2.1)
口内炎	0	0	0	0	1 (2.1)
血性下痢	0	0	0	0	0
食中毒	1 (11.1)	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
口の感覚鈍麻	1 (11.1)	0	0	0	0
口唇痛	1 (11.1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 19 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
一般・全身障害および投与部位の状態	2 (33.3)	0	1 (16.7)	3 (30.0)	3 (37.5)	4 (50.0)
発熱	1 (16.7)	0	1 (16.7)	2 (20.0)	0	0
疼痛	0	0	0	0	0	1 (12.5)
カテーテル留置部位炎症	0	0	0	0	0	0
泣き	0	0	0	0	0	0
死亡	0	0	0	0	0	0
薬物不耐性	0	0	0	0	0	0
低体温	1 (16.7)	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0	0
倦怠感	0	0	0	0	0	0
小結節	0	0	0	0	0	0
腫脹	0	0	0	0	0	0
不快感	0	0	0	0	0	0
末梢性浮腫	0	0	0	0	0	0
医療機器リーク	0	0	0	0	0	0
医療機器閉塞	0	0	0	0	0	0
浮腫	0	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0	1 (12.5)
末梢腫脹	0	0	0	0	0	0
適用部位紅斑	0	0	0	0	0	0
注入部位内出血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 20 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
一般・全身障害および投与部位の状態	5 (55.6)	5 (55.6)	0	0	15 (31.9)
発熱	0	3 (33.3)	0	0	11 (23.4)
疼痛	0	0	0	0	2 (4.3)
カテーテル留置部位炎症	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
薬物不耐性	0	0	0	0	0
低体温	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
腫脹	0	0	0	0	0
不快感	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
医療機器リーク	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	1 (11.1)	0	0	0	0
適用部位紅斑	0	0	0	0	0
注入部位内出血	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 21 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
疲労	0	0	0	0	1 (12.5)	0
注射部位出血	0	0	0	0	0	0
注射部位疼痛	0	0	0	0	0	0
適用部位発疹	0	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0	1 (12.5)
カテーテル留置部位疼痛	0	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	1 (12.5)	0
胸部不快感	0	0	0	0	1 (12.5)	0
悪寒	0	0	0	0	0	1 (12.5)
医療機器機能不良	0	0	0	0	0	0
冷感	0	0	0	0	0	0
重力性浮腫	0	0	0	0	0	1 (12.5)
注入部位血管外漏出	0	0	0	0	0	0
注射部位血腫	0	0	0	0	0	0
穿刺部位疼痛	1 (16.7)	0	0	1 (10.0)	0	3 (37.5)
穿刺部位反応	1 (16.7)	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0	0
皮膚および皮下組織障害	1 (16.7)	0	1 (16.7)	1 (10.0)	0	0
発疹	0	0	0	1 (10.0)	0	0
おむつ皮膚炎	0	0	0	0	0	0
斑状出血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 22 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
疲労	1 (11.1)	0	0	0	1 (2.1)
注射部位出血	0	0	0	0	1 (2.1)
注射部位疼痛	0	0	0	0	1 (2.1)
適用部位発疹	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	1 (11.1)	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
冷感	1 (11.1)	0	0	0	0
重力性浮腫	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
穿刺部位疼痛	3 (33.3)	2 (22.2)	0	0	0
穿刺部位反応	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0
皮膚および皮下組織障害	1 (11.1)	0	0	0	13 (27.7)
発疹	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	1 (2.1)
斑状出血	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 23 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
接触性皮膚炎	0	0	0	0	0	0
過角化	0	0	0	0	0	0
汗疹	0	0	1 (16.7)	0	0	0
湿疹	1 (16.7)	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
紅斑	0	0	0	0	0	0
蕁麻疹	0	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0	0
環状肉芽腫	0	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0	0
皮膚浮腫	0	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0	0
皮膚刺激	0	0	0	0	0	0
脱毛症	0	0	0	0	0	0
点状出血	0	0	0	0	0	0
そう痒症	0	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0	0
皮下気腫	0	0	0	0	0	0
皮膚障害	0	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 24 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
接触性皮膚炎	0	0	0	0	3 (6.4)
過角化	0	0	0	0	0
汗疹	0	0	0	0	0
湿疹	0	0	0	0	1 (2.1)
皮膚炎	0	0	0	0	1 (2.1)
紅斑	0	0	0	0	1 (2.1)
蕁麻疹	0	0	0	0	1 (2.1)
アレルギー性皮膚炎	0	0	0	0	0
環状肉芽腫	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
皮膚刺激	0	0	0	0	0
脱毛症	0	0	0	0	0
点状出血	0	0	0	0	0
そう痒症	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
皮膚障害	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 25 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ざ瘡	0	0	0	0	0	0
水疱	0	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0	0
毛孔性角化症	0	0	0	0	0	0
皮膚病変	0	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0	0
皮膚乾燥	0	0	0	0	0	0
多汗症	0	0	0	0	0	0
寝汗	0	0	0	0	0	0
臨床検査	0	1 (16.7)	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
体重減少	0	0	0	0	0	0
血中カリウム減少	0	0	0	0	0	0
体温上昇	0	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0	0
好中球数増加	0	0	0	0	0	0
心拍数増加	0	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 26 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ざ瘡	0	0	0	0	1 (2.1)
水疱	0	0	0	0	1 (2.1)
褥瘡性潰瘍	0	0	0	0	1 (2.1)
毛孔性角化症	0	0	0	0	1 (2.1)
皮膚病変	0	0	0	0	1 (2.1)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
多汗症	0	0	0	0	0
寝汗	1 (11.1)	0	0	0	0
臨床検査	2 (22.2)	0	1 (25.0)	0	4 (8.5)
酸素飽和度低下	0	0	0	0	0
体重減少	1 (11.1)	0	0	0	2 (4.3)
血中カリウム減少	0	0	0	0	0
体温上昇	0	0	1 (25.0)	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
好中球数増加	0	0	0	0	0
心拍数増加	0	0	0	0	1 (2.1)
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 27 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0	0
血中クロール減少	0	0	0	0	0	0
血中鉄減少	0	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0	0
体温低下	0	0	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0	0
心拍数不整	0	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0	0
肝機能検査異常	0	0	0	0	0	0
医学的観察	0	0	0	0	0	0
尿量減少	0	0	0	0	0	0
ビタミンＡ減少	0	0	0	0	0	0
白血球数増加	0	0	0	0	0	0
骨密度減少	0	0	0	0	0	0
呼吸音異常	0	0	0	0	0	0
心拍数減少	0	0	0	0	0	0
好中球百分率増加	0	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 28 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
医学的観察	0	0	0	0	0
尿量減少	0	0	0	0	0
ビタミンＡ減少	0	0	0	0	0
白血球数増加	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 29 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
血中テストステロン減少	0	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0	0
リンパ節触知	0	0	0	0	0	0
呼吸数増加	0	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0	0
尿検査異常	0	1 (16.7)	0	0	0	0
ビタミンＤ減少	0	0	0	0	0	0
心臓障害	0	1 (16.7)	0	0	1 (12.5)	0
頻脈	0	0	0	0	0	0
心肺停止	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
心停止	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
左室肥大	0	0	0	0	0	0
上室性頻脈	0	0	0	0	0	0
心筋症	0	0	0	0	0	0
心膜気腫	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 30 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
血中テストステロン減少	0	0	0	0	1 (2.1)
ＣＳＦ白血球数増加	0	0	0	0	1 (2.1)
血中重炭酸塩減少	1 (11.1)	0	0	0	0
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
尿検査異常	0	0	0	0	0
ビタミンＤ減少	0	0	0	0	0
心臓障害	0	0	1 (25.0)	0	1 (2.1)
頻脈	0	0	0	0	1 (2.1)
心肺停止	0	0	0	0	0
徐脈	0	0	0	0	0
心停止	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心室性頻脈	0	0	0	0	0
左室肥大	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
心膜気腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 31 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
動悸	0	1 (16.7)	0	0	1 (12.5)	0
傷害、中毒および処置合併症	2 (33.3)	2 (33.3)	3 (50.0)	1 (10.0)	5 (62.5)	2 (25.0)
処置による疼痛	0	0	0	0	1 (12.5)	1 (12.5)
ストーマ部紅斑	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
挫傷	0	0	0	0	0	0
処置後腫脹	0	0	0	0	0	0
術後激越	0	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0	0
擦過傷	0	0	0	0	0	0
伝染病曝露	0	0	0	0	0	0
処置合併症	0	0	0	0	0	0
処置部位反応	0	0	0	0	0	0
ストーマ合併症	0	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0	0
創離開	0	0	0	0	0	0
節足動物咬傷	0	0	0	0	0	1 (12.5)
関節脱臼	0	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 32 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
動悸	0	0	1 (25.0)	0	0
傷害、中毒および処置合併症	7 (77.8)	7 (77.8)	2 (50.0)	4 (28.6)	22 (46.8)
処置による疼痛	0	0	0	1 (7.1)	4 (8.5)
ストーマ部紅斑	0	0	0	0	0
大腿骨骨折	0	1 (11.1)	0	0	2 (4.3)
挫傷	0	0	0	0	2 (4.3)
処置後腫脹	0	0	0	0	0
術後激越	1 (11.1)	0	0	0	1 (2.1)
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
伝染病曝露	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ストーマ合併症	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	2 (22.2)	0	0	0	1 (2.1)
関節脱臼	0	0	0	0	2 (4.3)
栄養補給チューブ合併症	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 33 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ダンピング症候群	0	0	0	0	0	0
耳擦過傷	0	0	0	0	0	0
口唇損傷	0	0	0	0	0	0
外傷性気胸	0	0	0	0	0	0
歯牙損傷	0	0	0	0	0	0
軟部組織損傷	0	0	0	0	0	0
サンバーン	0	0	0	0	1 (12.5)	0
熱傷	0	0	0	0	0	0
転倒	0	0	0	0	0	0
処置後合併症	0	0	0	0	0	0
処置後不快感	0	0	0	0	0	0
硬膜下血腫	0	0	0	0	0	0
腰椎穿刺後症候群	1 (16.7)	2 (33.3)	2 (33.3)	1 (10.0)	3 (37.5)	1 (12.5)
裂傷	0	0	1 (16.7)	0	1 (12.5)	0
四肢損傷	0	0	0	0	1 (12.5)	0
節足動物刺傷	0	0	0	0	0	0
関節損傷	0	0	0	0	0	0
靭帯捻挫	0	0	0	0	0	0
下肢骨折	0	0	0	0	0	0
半月板損傷	0	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0	0
頭部損傷	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 34 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
歯牙損傷	0	0	0	0	0
軟部組織損傷	0	0	0	0	0
サンバーン	0	1 (11.1)	0	0	0
熱傷	1 (11.1)	0	0	0	0
転倒	0	0	0	0	1 (2.1)
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
腰椎穿刺後症候群	3 (33.3)	6 (66.7)	0	1 (7.1)	10 (21.3)
裂傷	1 (11.1)	1 (11.1)	0	0	3 (6.4)
四肢損傷	0	0	0	0	2 (4.3)
節足動物刺傷	0	0	0	0	1 (2.1)
関節損傷	0	0	1 (25.0)	1 (7.1)	1 (2.1)
靭帯捻挫	0	0	0	0	1 (2.1)
下肢骨折	0	0	0	0	1 (2.1)
半月板損傷	0	0	0	0	1 (2.1)
気管内挿管合併症	0	0	0	0	0
頭部損傷	0	0	0	1 (7.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 35 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
肉離れ	0	0	0	0	0	0
処置後挫傷	0	0	0	0	0	0
術後イレウス	0	0	0	0	1 (12.5)	0
処置による頭痛	0	0	0	0	0	0
処置による悪心	1 (16.7)	0	0	0	0	0
ストーマ部出血	0	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0	0
脛骨骨折	0	0	0	0	0	0
隆起骨折	0	0	0	0	0	1 (12.5)
気管損傷	0	0	0	0	0	0
代謝および栄養障害	0	1 (16.7)	0	0	0	0
体重増加不良	0	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
脱水	0	1 (16.7)	0	0	0	0
鉄欠乏	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0
過小食	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 36 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
肉離れ	0	0	1 (25.0)	0	0
処置後挫傷	0	0	0	0	0
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	1 (7.1)	0
処置による悪心	0	0	0	1 (7.1)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
脛骨骨折	1 (11.1)	0	0	0	0
隆起骨折	1 (11.1)	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	0	1 (11.1)	0	0	3 (6.4)
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0
成長障害	0	0	0	0	0
脱水	0	1 (11.1)	0	0	0
鉄欠乏	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
過小食	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 37 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
代謝性アルカローシス	0	0	0	0	0	0
食欲減退	0	0	0	0	0	0
食欲亢進	0	0	0	0	0	0
ビタミンＤ欠乏	0	0	0	0	0	0
食物不耐性	0	0	0	0	0	0
高血糖	0	0	0	0	0	0
低血糖	0	0	0	0	0	0
低カリウム血症	0	0	0	0	0	0
筋骨格系および結合組織障害	3 (50.0)	2 (33.3)	1 (16.7)	2 (20.0)	1 (12.5)	4 (50.0)
側弯症	0	0	0	1 (10.0)	1 (12.5)	1 (12.5)
関節拘縮	0	0	0	0	0	1 (12.5)
頭位性斜頭症	0	0	0	0	0	0
脊柱後弯症	0	0	0	0	0	0
胸郭変形	0	0	0	0	0	0
四肢痛	0	0	1 (16.7)	0	0	0
後側弯症	0	0	0	0	0	0
背部痛	2 (33.3)	2 (33.3)	0	1 (10.0)	1 (12.5)	2 (25.0)
泉門閉鎖遅延	0	0	0	0	0	0
斜頚	0	0	0	0	0	0
手変形	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 38 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
代謝性アルカローシス	0	0	0	0	0
食欲減退	0	0	0	0	1 (2.1)
食欲亢進	0	0	0	0	1 (2.1)
ビタミンＤ欠乏	0	0	0	0	1 (2.1)
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
筋骨格系および結合組織障害	3 (33.3)	7 (77.8)	2 (50.0)	3 (21.4)	32 (68.1)
側弯症	1 (11.1)	1 (11.1)	1 (25.0)	1 (7.1)	9 (19.1)
関節拘縮	1 (11.1)	1 (11.1)	0	0	7 (14.9)
頭位性斜頭症	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
胸郭変形	0	0	0	0	0
四肢痛	0	1 (11.1)	0	1 (7.1)	3 (6.4)
後側弯症	0	0	0	0	0
背部痛	2 (22.2)	4 (44.4)	1 (25.0)	2 (14.3)	18 (38.3)
泉門閉鎖遅延	0	0	0	0	0
斜頚	0	0	0	0	0
手変形	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 39 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
関節硬直	0	0	0	0	0	0
脊柱前弯症	0	0	0	1 (10.0)	0	0
脊柱変形	0	0	0	0	0	0
滑膜炎	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
体重支持困難	0	0	0	0	0	0
関節痛	0	0	0	0	0	1 (12.5)
筋緊張	0	0	0	0	0	0
筋肉痛	1 (16.7)	0	0	0	0	1 (12.5)
頚部痛	0	0	0	0	0	0
四肢拘縮	0	0	0	0	0	0
骨盤変形	0	0	0	0	0	1 (12.5)
腱障害	0	0	0	0	0	0
神経系障害	4 (66.7)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
眼振	0	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0	0
よだれ	0	0	0	0	0	0
痙攣発作	0	0	0	0	0	0
脳損傷	0	0	0	0	0	0
間代	0	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 40 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
関節硬直	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
筋力低下	0	0	0	0	0
体重支持困難	0	0	0	0	0
関節痛	0	1 (11.1)	0	0	4 (8.5)
筋緊張	0	0	0	0	2 (4.3)
筋肉痛	0	0	0	0	2 (4.3)
頚部痛	0	1 (11.1)	0	0	2 (4.3)
四肢拘縮	0	0	0	0	1 (2.1)
骨盤変形	0	0	0	0	1 (2.1)
腱障害	0	0	0	0	0
神経系障害	2 (22.2)	1 (11.1)	0	3 (21.4)	17 (36.2)
眼振	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0
よだれ	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 41 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
傾眠	0	0	0	0	0	0
失神	0	0	0	0	0	0
脳梗塞	0	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0	0
嗜眠	0	0	0	0	0	0
頭痛	4 (66.7)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
反射亢進	0	0	0	0	0	0
筋緊張低下	0	0	0	0	0	0
失声症	0	0	0	0	0	0
感覚鈍麻	0	0	0	0	0	1 (12.5)
片頭痛	0	0	0	0	0	0
振戦	0	0	0	0	0	0
味覚異常	0	0	0	0	0	0
失読症	0	0	0	0	0	0
錯感覚	1 (16.7)	0	0	0	0	1 (12.5)
失神寸前の状態	0	0	0	0	0	0
精神障害	1 (16.7)	0	0	0	1 (12.5)	0
不安	0	0	0	0	0	0
激越	0	0	0	0	1 (12.5)	0
易刺激性	0	0	0	0	0	0
息こらえ	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 42 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
傾眠	0	0	0	0	0
失神	0	0	0	0	1 (2.1)
脳梗塞	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
嗜眠	0	0	0	0	0
頭痛	1 (11.1)	0	0	3 (21.4)	16 (34.0)
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
失声症	0	0	0	0	1 (2.1)
感覚鈍麻	0	0	0	0	1 (2.1)
片頭痛	0	0	0	0	1 (2.1)
振戦	0	0	0	0	1 (2.1)
味覚異常	1 (11.1)	0	0	0	0
失読症	0	1 (11.1)	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
精神障害	0	2 (22.2)	0	0	1 (2.1)
不安	0	0	0	0	0
激越	0	1 (11.1)	0	0	0
易刺激性	0	0	0	0	0
息こらえ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 43 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気分動揺	0	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0	0
睡眠障害	0	0	0	0	0	0
不眠症	0	0	0	0	0	0
チック	0	0	0	0	0	0
注意欠陥多動性障害	0	0	0	0	0	0
不快気分	0	0	0	0	1 (12.5)	0
睡眠時随伴症	0	0	0	0	0	0
心因性嘔吐	1 (16.7)	0	0	0	0	0
免疫系障害	0	0	0	0	2 (25.0)	0
季節性アレルギー	0	0	0	0	0	0
薬物過敏症	0	0	0	0	1 (12.5)	0
過敏症	0	0	0	0	1 (12.5)	0
食物アレルギー	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
高血圧	0	0	0	0	0	0
蒼白	0	0	0	0	0	0
ショック	0	0	0	0	0	0
血管炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 44 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
不眠症	0	0	0	0	1 (2.1)
チック	0	0	0	0	1 (2.1)
注意欠陥多動性障害	0	1 (11.1)	0	0	0
不快気分	0	0	0	0	0
睡眠時随伴症	0	1 (11.1)	0	0	0
心因性嘔吐	0	0	0	0	0
免疫系障害	0	2 (22.2)	1 (25.0)	0	2 (4.3)
季節性アレルギー	0	1 (11.1)	1 (25.0)	0	1 (2.1)
薬物過敏症	0	0	0	0	0
過敏症	0	1 (11.1)	0	0	1 (2.1)
食物アレルギー	0	0	0	0	0
血管障害	0	0	0	1 (7.1)	0
高血圧	0	0	0	0	0
蒼白	0	0	0	0	0
ショック	0	0	0	0	0
血管炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 45 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
毛細血管脆弱	0	0	0	0	0	0
本態性高血圧症	0	0	0	0	0	0
低血圧	0	0	0	0	0	0
眼障害	0	0	0	0	0	0
霰粒腫	0	0	0	0	0	0
眼乾燥	0	0	0	0	0	0
眼運動障害	0	0	0	0	0	0
近視	0	0	0	0	0	0
斜視	0	0	0	0	0	0
眼瞼下垂	0	0	0	0	0	0
乱視	0	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0	0
遠視	0	0	0	0	0	0
弱視	0	0	0	0	0	0
流涙増加	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0	0
貧血母斑	0	0	0	0	0	0
鳩胸	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 46 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
毛細血管脆弱	0	0	0	0	0
本態性高血圧症	0	0	0	0	0
低血圧	0	0	0	1 (7.1)	0
眼障害	1 (11.1)	0	0	0	1 (2.1)
霰粒腫	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼運動障害	0	0	0	0	0
近視	0	0	0	0	0
斜視	1 (11.1)	0	0	0	0
眼瞼下垂	0	0	0	0	0
乱視	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
遠視	0	0	0	0	1 (2.1)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
鳩胸	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 47 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
斜頭症	0	0	0	0	0	0
斜指症	0	0	0	0	0	0
停留精巣	0	0	0	0	0	0
包茎	0	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0	0
後天性包茎	0	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0	0
陰茎障害	0	0	0	0	0	0
耳および迷路障害	1 (16.7)	0	0	0	1 (12.5)	0
耳の障害	0	0	0	0	0	0
耳痛	0	0	0	0	1 (12.5)	0
耳垢分泌過多	0	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0	0
乗物酔い	1 (16.7)	0	0	0	0	0
腎および尿路障害	0	0	0	0	0	0
水腎症	0	0	0	0	0	0
尿閉	0	0	0	0	0	0
排尿困難	0	0	0	0	0	0
尿失禁	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 48 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
斜頭症	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
包茎	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (2.1)
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0
鼓膜穿孔	0	0	0	0	1 (2.1)
乗物酔い	0	0	0	0	0
腎および尿路障害	0	0	0	1 (7.1)	2 (4.3)
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
排尿困難	0	0	0	0	1 (2.1)
尿失禁	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 49 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
糖尿	0	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0	0
貧血	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
血小板増加症	0	0	0	0	0	0
リンパ節症	0	0	0	0	0	0
好酸球増加症	0	0	0	0	0	0
骨髄障害	0	0	0	0	0	0
白血球増加症	0	0	0	0	0	0
肝胆道系障害	0	0	0	0	0	0
肝腫大	0	0	0	0	0	0
外科および内科処置	0	0	0	0	0	0
機械的換気	0	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	1 (12.5)	0
アクロコルドン	0	0	0	0	0	0
血管の良性新生物	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 50 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
糖尿	0	0	0	0	0
膀胱尿管逆流	0	0	0	1 (7.1)	0
血液およびリンパ系障害	0	0	0	0	1 (2.1)
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	1 (2.1)
血小板増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
好酸球増加症	0	0	0	0	0
骨髄障害	0	0	0	0	0
白血球増加症	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
アクロコルドン	0	0	0	0	0
血管の良性新生物	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 51 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
脂漏性角化症	0	0	0	0	0	0
皮膚乳頭腫	0	0	0	0	1 (12.5)	0
妊娠、産褥および周産期の状態	0	0	0	0	0	0
臍肉芽腫	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 52 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
脂漏性角化症	0	0	0	0	0
皮膚乳頭腫	0	0	0	0	0
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 12　Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 1 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	12 (70.6)	4 (100)	15 (93.8)	36 (87.8)	70 (87.5)
呼吸器、胸郭および縦隔障害	2 (11.8)	2 (50.0)	11 (68.8)	29 (70.7)	46 (57.5)
呼吸不全	0	0	2 (12.5)	8 (19.5)	11 (13.8)
呼吸窮迫	1 (5.9)	1 (25.0)	1 (6.3)	7 (17.1)	9 (11.3)
無気肺	0	0	2 (12.5)	6 (14.6)	8 (10.0)
急性呼吸不全	0	1 (25.0)	1 (6.3)	4 (9.8)	6 (7.5)
鼻閉	1 (5.9)	1 (25.0)	4 (25.0)	5 (12.2)	5 (6.3)
呼吸困難	0	0	0	1 (2.4)	4 (5.0)
無呼吸	0	0	2 (12.5)	2 (4.9)	3 (3.8)
咳嗽	0	0	2 (12.5)	8 (19.5)	3 (3.8)
誤嚥	0	0	1 (6.3)	0	3 (3.8)
低酸素症	0	0	1 (6.3)	1 (2.4)	3 (3.8)
気管支分泌物貯留	0	0	1 (6.3)	3 (7.3)	2 (2.5)
低換気	0	0	1 (6.3)	0	2 (2.5)
慢性呼吸不全	0	0	0	0	2 (2.5)
誤嚥性肺炎	0	0	0	5 (12.2)	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 12　Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA（続き）

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 2 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	13 (100)	4 (100)	15 (100)	26 (100)	59 (100)
Number of subjects with an event	9 (69.2)	4 (100)	15 (100)	25 (96.2)	48 (81.4)
呼吸器、胸郭および縦隔障害	1 (7.7)	2 (50.0)	11 (73.3)	15 (57.7)	21 (35.6)
呼吸不全	0	0	3 (20.0)	7 (26.9)	2 (3.4)
呼吸窮迫	0	0	3 (20.0)	4 (15.4)	8 (13.6)
無気肺	0	0	1 (6.7)	4 (15.4)	6 (10.2)
急性呼吸不全	0	0	1 (6.7)	3 (11.5)	5 (8.5)
鼻閉	1 (7.7)	1 (25.0)	1 (6.7)	0	2 (3.4)
呼吸困難	0	1 (25.0)	1 (6.7)	4 (15.4)	0
無呼吸	0	0	1 (6.7)	1 (3.8)	0
咳嗽	0	0	0	1 (3.8)	1 (1.7)
誤嚥	0	0	1 (6.7)	1 (3.8)	1 (1.7)
低酸素症	0	0	2 (13.3)	1 (3.8)	1 (1.7)
気管支分泌物貯留	0	1 (25.0)	0	1 (3.8)	1 (1.7)
低換気	0	0	0	0	0
慢性呼吸不全	0	0	1 (6.7)	0	0
誤嚥性肺炎	0	0	1 (6.7)	1 (3.8)	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 3 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	10 (100)	4 (100)	13 (100)	18 (100)	41 (100)
Number of subjects with an event	7 (70.0)	4 (100)	11 (84.6)	16 (88.9)	36 (87.8)
呼吸器、胸郭および縦隔障害	1 (10.0)	1 (25.0)	6 (46.2)	11 (61.1)	19 (46.3)
呼吸不全	0	0	0	1 (5.6)	3 (7.3)
呼吸窮迫	0	0	0	5 (27.8)	2 (4.9)
無気肺	0	0	0	0	5 (12.2)
急性呼吸不全	0	0	2 (15.4)	3 (16.7)	7 (17.1)
鼻閉	0	0	0	1 (5.6)	3 (7.3)
呼吸困難	0	0	0	1 (5.6)	2 (4.9)
無呼吸	0	0	0	2 (11.1)	1 (2.4)
咳嗽	1 (10.0)	0	1 (7.7)	0	2 (4.9)
誤嚥	0	0	0	0	0
低酸素症	0	0	1 (7.7)	1 (5.6)	2 (4.9)
気管支分泌物貯留	0	0	0	0	1 (2.4)
低換気	0	0	0	0	0
慢性呼吸不全	0	0	1 (7.7)	0	0
誤嚥性肺炎	0	0	1 (7.7)	0	3 (7.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 4 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	5 (100)	3 (100)	13 (100)	13 (100)	26 (100)
Number of subjects with an event	4 (80.0)	2 (66.7)	10 (76.9)	12 (92.3)	19 (73.1)
呼吸器、胸郭および縦隔障害	1 (20.0)	1 (33.3)	5 (38.5)	4 (30.8)	9 (34.6)
呼吸不全	0	0	1 (7.7)	0	2 (7.7)
呼吸窮迫	0	0	0	1 (7.7)	3 (11.5)
無気肺	0	0	0	0	2 (7.7)
急性呼吸不全	0	0	1 (7.7)	0	1 (3.8)
鼻閉	0	0	1 (7.7)	0	0
呼吸困難	0	0	0	0	1 (3.8)
無呼吸	0	0	0	1 (7.7)	0
咳嗽	1 (20.0)	1 (33.3)	1 (7.7)	0	0
誤嚥	0	0	0	0	0
低酸素症	0	0	0	1 (7.7)	0
気管支分泌物貯留	0	0	0	0	0
低換気	0	0	0	0	0
慢性呼吸不全	0	0	1 (7.7)	0	0
誤嚥性肺炎	0	0	1 (7.7)	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 5 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	1 (100)	2 (100)	13 (100)	9 (100)	19 (100)
Number of subjects with an event	1 (100)	2 (100)	10 (76.9)	3 (33.3)	10 (52.6)
呼吸器、胸郭および縦隔障害	0	0	5 (38.5)	1 (11.1)	1 (5.3)
呼吸不全	0	0	1 (7.7)	0	0
呼吸窮迫	0	0	1 (7.7)	0	0
無気肺	0	0	2 (15.4)	0	0
急性呼吸不全	0	0	0	0	0
鼻閉	0	0	0	0	0
呼吸困難	0	0	0	0	0
無呼吸	0	0	0	0	0
咳嗽	0	0	2 (15.4)	0	0
誤嚥	0	0	0	0	0
低酸素症	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
低換気	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 6 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	13 (100)	0	0
Number of subjects with an event	0	2 (100)	10 (76.9)	0	0
呼吸器、胸郭および縦隔障害	2 (100)	3 (23.1)			
呼吸不全		0	0		
呼吸窮迫		1 (50.0)	1 (7.7)		
無気肺		0	1 (7.7)		
急性呼吸不全		1 (50.0)	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		1 (50.0)	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 7 of 288

	Days 541-630				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	13 (100)	0	0
Number of subjects with an event	0	1 (50.0)	8 (61.5)	0	0
呼吸器、胸郭および縦隔障害	0	4 (30.8)			
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	1 (7.7)		
急性呼吸不全		0	0		
鼻閉		0	1 (7.7)		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	1 (7.7)		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 8 of 288

	Days 631-720				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	9 (100)	0	0
Number of subjects with an event	0	2 (100)	5 (55.6)	0	0
呼吸器、胸郭および縦隔障害	1 (50.0)	2 (22.2)			
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	1 (11.1)		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 9 of 288

	Days 721-810				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	6 (100)	0	0
Number of subjects with an event	0	2 (100)	6 (100)	0	0
呼吸器、胸郭および縦隔障害	1 (50.0)	4 (66.7)			
呼吸不全		0	0		
呼吸窮迫		0	1 (16.7)		
無気肺		0	0		
急性呼吸不全		0	1 (16.7)		
鼻閉		1 (50.0)	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	1 (16.7)		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 10 of 288

	Days 811-900				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	2 (100)	0	0
Number of subjects with an event	0	1 (50.0)	1 (50.0)	0	0
呼吸器、胸郭および縦隔障害	0	0			
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	0		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 11 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	0	0	0
Number of subjects with an event	0	1 (50.0)	0	0	0
呼吸器、胸郭および縦隔障害		1 (50.0)	0		
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	0		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		1 (50.0)	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 12 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	1 (100)	0	0	0
Number of subjects with an event	0	0	0	0	0
呼吸器、胸郭および縦隔障害		0	0		
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	0		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 13 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	0	2 (2.5)
呼吸障害	0	0	0	0	2 (2.5)
鼻漏	0	0	0	1 (2.4)	2 (2.5)
上気道うっ血	0	0	0	1 (2.4)	2 (2.5)
息詰まり	0	0	1 (6.3)	0	1 (1.3)
上気道分泌増加	0	0	1 (6.3)	0	1 (1.3)
気胸	0	0	1 (6.3)	0	1 (1.3)
呼吸補助筋の動員	0	0	1 (6.3)	1 (2.4)	1 (1.3)
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
胸水	0	0	0	0	1 (1.3)
呼吸性アルカローシス	0	0	0	0	1 (1.3)
気道うっ血	0	0	0	3 (7.3)	1 (1.3)
副鼻腔うっ血	0	0	0	0	1 (1.3)
睡眠時無呼吸症候群	0	0	1 (6.3)	3 (7.3)	0
頻呼吸	0	0	1 (6.3)	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 14 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	4 (15.4)	0
呼吸障害	0	0	0	0	0
鼻漏	0	0	1 (6.7)	0	0
上気道うっ血	0	0	0	0	0
息詰まり	0	0	0	0	0
上気道分泌増加	0	0	2 (13.3)	0	1 (1.7)
気胸	0	0	1 (6.7)	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	1 (1.7)
睡眠時無呼吸症候群	0	0	0	1 (3.8)	0
頻呼吸	0	0	0	1 (3.8)	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	1 (6.7)	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 15 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	1 (5.6)	1 (2.4)
呼吸障害	0	0	0	0	0
鼻漏	0	0	1 (7.7)	1 (5.6)	1 (2.4)
上気道うっ血	0	0	0	0	2 (4.9)
息詰まり	0	0	0	1 (5.6)	0
上気道分泌増加	0	0	0	1 (5.6)	1 (2.4)
気胸	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	1 (2.4)
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 16 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	1 (7.7)	0	0
呼吸障害	0	0	0	0	0
鼻漏	1 (20.0)	0	0	0	1 (3.8)
上気道うっ血	1 (20.0)	0	0	0	1 (3.8)
息詰まり	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
気胸	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	2 (15.4)	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	1 (3.8)
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 17 of 288

	Days 361-450				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	0	0
呼吸障害	0	0	0	0	0
鼻漏	0	0	0	1 (11.1)	0
上気道うっ血	0	0	0	0	0
息詰まり	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
気胸	0	0	1 (7.7)	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 18 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	1 (7.7)		
息詰まり		0	0		
上気道分泌増加		0	1 (7.7)		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	1 (7.7)		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 19 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	1 (7.7)		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	1 (7.7)		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 20 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 21 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	1 (16.7)		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 22 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 23 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 24 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 25 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	1 (2.4)	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	1 (2.4)	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	0	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	1 (2.4)	0
喘鳴	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 26 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	1 (1.7)
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	1 (6.7)	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	1 (6.7)	0	0
アレルギー性鼻炎	0	0	0	0	1 (1.7)
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	0	0
喘鳴	0	0	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 27 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	1 (25.0)	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	1 (5.6)	0
高炭酸ガス血症	0	0	0	0	1 (2.4)
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	0	1 (2.4)
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	0	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	1 (5.6)	0
喘鳴	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 28 of 288

Days 271-360

	Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	1 (3.8)
気管支分泌増加	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	0	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	1 (7.7)	0
喘鳴	0	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 29 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	0	0
喉頭肉芽腫	0	0	1 (7.7)	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	1 (7.7)	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	1 (7.7)	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	1 (5.3)
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	0	0
喘鳴	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 30 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	1 (7.7)		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	1 (7.7)		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 31 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	1 (7.7)		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 32 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	1 (11.1)		
拘束性肺疾患		0	0		
アレルギー性鼻炎		1 (50.0)	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 33 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	1 (16.7)		
肺うっ血		0	0		
肺水腫		0	1 (16.7)		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 34 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 35 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 36 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 37 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	7 (41.2)	1 (25.0)	6 (37.5)	21 (51.2)	42 (52.5)
肺炎	1 (5.9)	1 (25.0)	0	4 (9.8)	9 (11.3)
鼻咽頭炎	2 (11.8)	0	1 (6.3)	2 (4.9)	8 (10.0)
ウイルス性上気道感染	0	0	1 (6.3)	4 (9.8)	6 (7.5)
イノウイルス感染	0	0	2 (12.5)	3 (7.3)	5 (6.3)
口腔カンジダ症	0	0	0	2 (4.9)	5 (6.3)
気道感染	0	0	0	1 (2.4)	5 (6.3)
上気道感染	2 (11.8)	0	2 (12.5)	5 (12.2)	4 (5.0)
細気管支炎	0	0	1 (6.3)	3 (7.3)	4 (5.0)
気管支炎	1 (5.9)	0	0	0	4 (5.0)
ウイルス性肺炎	1 (5.9)	0	0	0	3 (3.8)
ウイルス感染	0	0	2 (12.5)	0	2 (2.5)
ウイルス性気道感染	0	0	1 (6.3)	1 (2.4)	2 (2.5)
結膜炎	0	0	0	1 (2.4)	2 (2.5)
モラクセラ菌性肺炎	0	0	1 (6.3)	0	1 (1.3)
カンジダ性おむつ皮疹	0	1 (25.0)	0	0	1 (1.3)
尿路感染	1 (5.9)	0	0	0	1 (1.3)
細菌性気管炎	0	0	0	0	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 38 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	4 (30.8)	3 (75.0)	11 (73.3)	16 (61.5)	34 (57.6)
肺炎	0	1 (25.0)	3 (20.0)	1 (3.8)	4 (6.8)
鼻咽頭炎	2 (15.4)	0	1 (6.7)	0	4 (6.8)
ウイルス性上気道感染	0	0	0	3 (11.5)	6 (10.2)
ライノウイルス感染	0	0	0	3 (11.5)	1 (1.7)
口腔カンジダ症	0	0	0	1 (3.8)	0
気道感染	0	2 (50.0)	1 (6.7)	0	3 (5.1)
上気道感染	0	0	4 (26.7)	1 (3.8)	9 (15.3)
細気管支炎	0	0	1 (6.7)	0	2 (3.4)
気管支炎	0	0	0	0	0
ウイルス性肺炎	0	0	1 (6.7)	0	1 (1.7)
ウイルス感染	0	0	1 (6.7)	0	3 (5.1)
ウイルス性気道感染	0	0	0	0	2 (3.4)
結膜炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	1 (1.7)
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	1 (1.7)
細菌性気管炎	0	0	1 (6.7)	4 (15.4)	0
ウイルス性気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 39 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	5 (50.0)	1 (25.0)	9 (69.2)	12 (66.7)	29 (70.7)
肺炎	0	0	1 (7.7)	0	2 (4.9)
鼻咽頭炎	0	0	2 (15.4)	1 (5.6)	4 (9.8)
ウイルス性上気道感染	0	0	0	2 (11.1)	1 (2.4)
ライノウイルス感染	1 (10.0)	0	2 (15.4)	0	0
口腔カンジダ症	0	0	0	0	1 (2.4)
気道感染	0	0	0	0	4 (9.8)
上気道感染	4 (40.0)	0	2 (15.4)	3 (16.7)	10 (24.4)
細気管支炎	1 (10.0)	0	0	0	1 (2.4)
気管支炎	0	0	0	0	0
ウイルス性肺炎	0	1 (25.0)	0	1 (5.6)	2 (4.9)
ウイルス感染	0	0	0	0	2 (4.9)
ウイルス性気道感染	0	0	0	1 (5.6)	0
結膜炎	0	0	0	1 (5.6)	3 (7.3)
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	0
細菌性気管炎	0	0	0	1 (5.6)	0
ウイルス性気管支炎	0	0	0	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 40 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	2 (40.0)	1 (33.3)	9 (69.2)	8 (61.5)	15 (57.7)
肺炎	0	0	3 (23.1)	1 (7.7)	5 (19.2)
鼻咽頭炎	0	0	3 (23.1)	1 (7.7)	0
ウイルス性上気道感染	0	0	0	0	0
ライノウイルス感染	0	0	2 (15.4)	0	1 (3.8)
口腔カンジダ症	0	0	0	0	1 (3.8)
気道感染	0	1 (33.3)	1 (7.7)	1 (7.7)	1 (3.8)
上気道感染	1 (20.0)	0	2 (15.4)	1 (7.7)	6 (23.1)
細気管支炎	0	0	0	0	1 (3.8)
気管支炎	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0
ウイルス感染	0	0	0	2 (15.4)	1 (3.8)
ウイルス性気道感染	0	0	0	0	1 (3.8)
結膜炎	0	0	0	1 (7.7)	0
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	1 (3.8)
細菌性気管炎	0	0	0	2 (15.4)	0
ウイルス性気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 41 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	1 (100)	1 (50.0)	7 (53.8)	2 (22.2)	4 (21.1)
肺炎	0	0	2 (15.4)	0	0
鼻咽頭炎	0	0	1 (7.7)	0	0
ウイルス性上気道感染	0	0	0	0	0
ライノウイルス感染	0	0	1 (7.7)	0	1 (5.3)
口腔カンジダ症	0	0	0	0	0
気道感染	0	0	0	0	0
上気道感染	0	0	3 (23.1)	0	1 (5.3)
細気管支炎	0	0	1 (7.7)	0	0
気管支炎	0	0	0	0	1 (5.3)
ウイルス性肺炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0
結膜炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	0
細菌性気管炎	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 42 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		2 (100)	7 (53.8)		
肺炎		0	0		
鼻咽頭炎		0	2 (15.4)		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	1 (7.7)		
気道感染		1 (50.0)	2 (15.4)		
上気道感染		0	1 (7.7)		
細気管支炎		0	1 (7.7)		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	1 (7.7)		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 43 of 288

	Days 541-630				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	5 (38.5)		
肺炎		0	0		
鼻咽頭炎		0	1 (7.7)		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	1 (7.7)		
上気道感染		0	2 (15.4)		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	1 (7.7)		
ウイルス性気道感染		0	0		
結膜炎		0	1 (7.7)		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 44 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		1 (50.0)	5 (55.6)		
肺炎		0	1 (11.1)		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		1 (50.0)	0		
上気道感染		0	1 (11.1)		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 45 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	4 (66.7)		
肺炎		0	1 (16.7)		
鼻咽頭炎		0	1 (16.7)		
ウイルス性上気道感染		0	1 (16.7)		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	1 (16.7)		
上気道感染		0	0		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	1 (16.7)		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	1 (16.7)		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 46 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		1 (50.0)	1 (50.0)		
肺炎		0	0		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	0		
上気道感染		1 (50.0)	1 (50.0)		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 47 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	0		
肺炎		0	0		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	0		
上気道感染		0	0		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 48 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	0		
肺炎		0	0		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	0		
上気道感染		0	0		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 49 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	1 (1.3)
耳感染	0	0	0	1 (2.4)	1 (1.3)
感染性湿疹	0	0	0	0	1 (1.3)
真菌感染	0	0	0	0	1 (1.3)
膿痂疹	0	0	0	1 (2.4)	1 (1.3)
限局性感染	0	0	0	0	1 (1.3)
下気道感染	0	0	0	1 (2.4)	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
細菌性肺炎	0	0	0	1 (2.4)	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	0	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
ＲＳウイルス細気管支炎	0	0	0	1 (2.4)	1 (1.3)
鼻炎	0	0	0	1 (2.4)	1 (1.3)
敗血症	0	0	0	0	1 (1.3)
皮膚カンジダ	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
皮膚真菌感染	0	0	1 (6.3)	1 (2.4)	0
ウイルス性胃炎	0	0	1 (6.3)	0	0
メタニューモウイルス感染	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 50 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	0
耳感染	0	0	0	0	2 (3.4)
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	0	0
膿痂疹	1 (7.7)	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	0
肺感染	0	0	0	0	0
細菌性肺炎	0	0	0	1 (3.8)	0
パラインフルエンザウイルス性肺炎	0	0	0	1 (3.8)	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	1 (6.7)	2 (7.7)	1 (1.7)
鼻炎	0	0	0	2 (7.7)	1 (1.7)
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	1 (3.8)	0
ストーマ部膿瘍	0	0	0	0	0
皮膚真菌感染	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 51 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	1 (5.6)	1 (2.4)
耳感染	0	0	1 (7.7)	0	1 (2.4)
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	1 (5.6)	0
膿痂疹	0	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	3 (7.3)
肺感染	0	0	0	0	0
細菌性肺炎	0	0	1 (7.7)	0	1 (2.4)
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	0	0	1 (2.4)
鼻炎	0	0	0	1 (5.6)	0
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	0	1 (2.4)
ストーマ部膿瘍	0	0	0	0	0
皮膚真菌感染	0	0	0	0	1 (2.4)
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 52 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	0
耳感染	0	0	1 (7.7)	0	0
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	0	0
膿痂疹	0	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	1 (3.8)
肺感染	0	0	0	0	0
細菌性肺炎	0	0	0	0	1 (3.8)
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	0	0	0
鼻炎	1 (20.0)	0	0	0	0
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
皮膚真菌感染	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 53 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	0
耳感染	0	0	0	0	0
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	0	0
膿痂疹	0	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	0
肺感染	0	0	0	0	0
細菌性肺炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	0	0	0
鼻炎	0	0	0	0	0
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	1 (5.3)
皮膚真菌感染	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 54 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 55 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	1 (7.7)		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 56 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	1 (11.1)		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 57 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 58 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 59 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 60 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 61 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	1 (25.0)	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	0	0	0
カンジダ感染	0	0	0	2 (4.9)	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	0	1 (2.4)	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	0	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 62 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	1 (3.8)	0
細菌感染	0	0	0	0	0
カンジダ感染	0	0	0	2 (7.7)	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	1 (6.7)	0	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	1 (1.7)
ロタウイルス胃腸炎	0	0	0	0	1 (1.7)
ウイルス性胃腸炎	1 (7.7)	0	0	0	1 (1.7)
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	0	0
インフルエンザ	2 (15.4)	0	0	0	2 (3.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 63 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	2 (4.9)
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	1 (7.7)	0	1 (2.4)
カンジダ感染	0	0	0	0	0
蜂巣炎	0	0	0	1 (5.6)	1 (2.4)
コロナウイルス感染	0	0	0	1 (5.6)	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	1 (2.4)
胃腸炎	0	0	1 (7.7)	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	1 (5.6)	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	1 (2.4)
麦粒腫	0	0	0	0	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 64 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	1 (7.7)	0	0
カンジダ感染	0	0	0	0	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	1 (7.7)	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	1 (7.7)	0
ヘモフィルス感染	0	0	1 (7.7)	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	1 (7.7)	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 65 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	1 (100)	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	0	0	0
カンジダ感染	0	0	0	0	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	1 (7.7)	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	0	0
インフルエンザ	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 66 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 67 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	1 (7.7)		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 68 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	1 (11.1)		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	1 (11.1)		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 69 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	1 (16.7)		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 70 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 71 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 72 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 73 of 288

	Days 1-90				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
中耳炎	0	0	0	1 (2.4)	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	1 (2.4)	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
細菌性気道感染	0	0	0	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	0	0
皮膚感染	0	0	0	1 (2.4)	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	1 (2.4)	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 74 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	1 (6.7)	0	2 (3.4)
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	1 (6.7)	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
中耳炎	0	0	0	0	1 (1.7)
急性中耳炎	0	0	0	0	1 (1.7)
パラインフルエンザウイルス感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	1 (1.7)
シュードモナス菌性肺炎	0	0	0	1 (3.8)	0
シュードモナス感染	0	0	0	1 (3.8)	0
細菌性気道感染	0	0	0	1 (3.8)	0
ばら疹	0	0	0	0	1 (1.7)
セラチア感染	0	0	0	1 (3.8)	0
皮膚感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	1 (6.7)	0	0
ブドウ球菌感染	0	0	0	1 (3.8)	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 75 of 288

	Days 181-270				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	1 (2.4)
口腔ヘルペス	0	0	0	0	0
中耳炎	1 (10.0)	0	3 (23.1)	1 (5.6)	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	1 (2.4)
細菌性気道感染	0	0	0	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	1 (5.6)	0
皮膚感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	1 (2.4)
ブドウ球菌皮膚感染	0	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 76 of 288

	Days 271-360				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	1 (3.8)
中耳炎	1 (20.0)	0	0	0	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
細菌性気道感染	0	0	1 (7.7)	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	0	0
皮膚感染	1 (20.0)	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 77 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
中耳炎	0	1 (50.0)	1 (7.7)	0	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	1 (7.7)	0	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	1 (50.0)	0	0	0
シュードモナス感染	0	0	0	1 (11.1)	0
細菌性気道感染	0	0	0	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	0	0
皮膚感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 78 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	1 (7.7)		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		1 (50.0)	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	1 (7.7)		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 79 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 80 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	1 (11.1)		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 81 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	1 (16.7)		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 82 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 83 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 84 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 85 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	0	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	4 (23.5)	2 (50.0)	10 (62.5)	16 (39.0)	35 (43.8)
便秘	0	0	4 (25.0)	3 (7.3)	13 (16.3)
生歯	0	1 (25.0)	1 (6.3)	3 (7.3)	7 (8.8)
嘔吐	0	0	3 (18.8)	4 (9.8)	6 (7.5)
胃食道逆流性疾患	2 (11.8)	0	4 (25.0)	3 (7.3)	5 (6.3)
嚥下障害	0	0	0	4 (9.8)	4 (5.0)
下痢	0	0	1 (6.3)	5 (12.2)	3 (3.8)
胃炎	0	0	0	0	2 (2.5)
流涎過多	0	0	0	0	2 (2.5)
放屁	2 (11.8)	0	1 (6.3)	1 (2.4)	1 (1.3)
腹部不快感	1 (5.9)	0	0	0	1 (1.3)
アフタ性潰瘍	0	0	0	0	1 (1.3)
胃出血	0	0	0	0	1 (1.3)
血便排泄	0	0	0	0	1 (1.3)
乳児仙痛	0	0	0	0	1 (1.3)
腹痛	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 86 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	2 (7.7)	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	1 (3.8)	0
胃腸障害	1 (7.7)	1 (25.0)	7 (46.7)	12 (46.2)	23 (39.0)
便秘	0	0	2 (13.3)	4 (15.4)	7 (11.9)
生歯	0	0	1 (6.7)	0	3 (5.1)
嘔吐	0	0	3 (20.0)	2 (7.7)	6 (10.2)
胃食道逆流性疾患	0	0	1 (6.7)	1 (3.8)	1 (1.7)
嚥下障害	1 (7.7)	0	0	4 (15.4)	3 (5.1)
下痢	0	0	2 (13.3)	2 (7.7)	2 (3.4)
胃炎	0	0	0	0	0
流涎過多	0	0	0	0	0
放屁	0	1 (25.0)	0	0	1 (1.7)
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	1 (1.7)
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 87 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	1 (5.6)	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	2 (20.0)	1 (25.0)	3 (23.1)	6 (33.3)	14 (34.1)
便秘	1 (10.0)	1 (25.0)	2 (15.4)	0	5 (12.2)
生歯	1 (10.0)	0	0	0	1 (2.4)
嘔吐	0	0	0	0	2 (4.9)
胃食道逆流性疾患	0	0	0	1 (5.6)	1 (2.4)
嚥下障害	0	0	0	2 (11.1)	2 (4.9)
下痢	0	0	1 (7.7)	2 (11.1)	1 (2.4)
胃炎	0	0	0	0	0
流涎過多	0	0	1 (7.7)	0	1 (2.4)
放屁	0	0	0	0	1 (2.4)
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	0
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 88 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	1 (7.7)	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	0	1 (33.3)	3 (23.1)	5 (38.5)	7 (26.9)
便秘	0	0	0	2 (15.4)	1 (3.8)
生歯	0	0	0	0	0
嘔吐	0	1 (33.3)	1 (7.7)	2 (15.4)	1 (3.8)
胃食道逆流性疾患	0	0	0	1 (7.7)	1 (3.8)
嚥下障害	0	0	0	0	0
下痢	0	1 (33.3)	1 (7.7)	1 (7.7)	3 (11.5)
胃炎	0	0	0	1 (7.7)	1 (3.8)
流涎過多	0	0	1 (7.7)	2 (15.4)	0
放屁	0	0	0	0	0
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	0
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 89 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	0	0
気管炎	0	0	1 (7.7)	1 (11.1)	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	0	2 (100)	1 (7.7)	0	4 (21.1)
便秘	0	0	0	0	0
生歯	0	1 (50.0)	0	0	0
嘔吐	0	1 (50.0)	0	0	2 (10.5)
胃食道逆流性疾患	0	0	0	0	1 (5.3)
嚥下障害	0	0	0	0	0
下痢	0	0	1 (7.7)	0	1 (5.3)
胃炎	0	0	0	0	0
流涎過多	0	0	0	0	0
放屁	0	0	0	0	0
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	0
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 90 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	4 (30.8)		
便秘		0	1 (7.7)		
生歯		0	0		
嘔吐		0	1 (7.7)		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	1 (7.7)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 91 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	2 (15.4)		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	1 (7.7)		
胃炎		0	1 (7.7)		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 92 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		1 (50.0)	2 (22.2)		
便秘		0	0		
生歯		0	0		
嘔吐		0	1 (11.1)		
胃食道逆流性疾患		0	1 (11.1)		
嚥下障害		0	0		
下痢		0	1 (11.1)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 93 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	2 (33.3)		
便秘		0	0		
生歯		0	0		
嘔吐		0	1 (16.7)		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	2 (33.3)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 94 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	1 (50.0)		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	1 (50.0)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 95 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	0		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	0		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 96 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	0		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	0		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 97 of 288

	Days 1-90					
		Infantile-onset				
	Study SM201	Study CS3A		Study CS3B		
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg	
腹部膨満	2 (11.8)	0	0	0	0	
上腹部痛	0	0	0	2 (4.9)	0	
口唇のひび割れ	0	0	0	0	0	
血性下痢	0	0	0	0	0	
排便回数増加	0	0	0	0	0	
胃腸出血	0	0	0	0	0	
消化管運動低下	0	0	0	0	0	
消化管刺激症状	0	0	0	0	0	
吐血	0	0	0	0	0	
乳児吐出	0	0	0	0	0	
口内炎	0	0	0	1 (2.4)	0	
上部消化管出血	0	0	0	0	0	
一般・全身障害および投与部位の状態	3 (17.6)	2 (50.0)	9 (56.3)	18 (43.9)	26 (32.5)	General
発熱	2 (11.8)	1 (25.0)	7 (43.8)	11 (26.8)	20 (25.0)	
疼痛	0	0	2 (12.5)	2 (4.9)	1 (1.3)	
泣き	0	0	0	0	1 (1.3)	
死亡	0	0	0	1 (2.4)	1 (1.3)	
低体温	0	0	0	0	1 (1.3)	

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 98 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	1 (6.7)	0	1 (1.7)
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	1 (6.7)	0	0
血性下痢	0	0	0	0	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	1 (3.8)	0
消化管運動低下	0	0	0	0	0
消化管刺激症状	0	0	0	1 (3.8)	0
吐血	0	0	0	0	0
乳児吐出	0	0	0	0	1 (1.7)
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (7.7)	2 (50.0)	5 (33.3)	13 (50.0)	15 (25.4)
発熱	1 (7.7)	2 (50.0)	5 (33.3)	10 (38.5)	14 (23.7)
疼痛	0	0	2 (13.3)	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 99 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	0	0	0
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
血性下痢	0	0	0	1 (5.6)	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動低下	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
吐血	0	0	0	0	0
乳児吐出	0	0	0	0	0
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	1 (2.4)
一般・全身障害および投与部位の状態	2 (20.0)	1 (25.0)	3 (23.1)	4 (22.2)	14 (34.1)
発熱	2 (20.0)	1 (25.0)	3 (23.1)	3 (16.7)	14 (34.1)
疼痛	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 100 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	1 (7.7)	0	0
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
血性下痢	0	0	0	0	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動低下	0	1 (33.3)	0	0	0
消化管刺激症状	0	0	0	0	0
吐血	0	0	0	0	0
乳児吐出	0	0	0	0	0
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (20.0)	1 (33.3)	4 (30.8)	5 (38.5)	11 (42.3)
発熱	1 (20.0)	0	4 (30.8)	3 (23.1)	11 (42.3)
疼痛	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 101 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	0	0	0
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
血性下痢	0	0	0	0	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動低下	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
吐血	0	1 (50.0)	0	0	0
乳児吐出	0	0	0	0	0
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	4 (30.8)	0	4 (21.1)
発熱	0	0	4 (30.8)	0	4 (21.1)
疼痛	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 102 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	1 (7.7)		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	3 (23.1)		
発熱		0	2 (15.4)		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 103 of 288

	Days 541-630				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 104 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		1 (50.0)	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	2 (22.2)		
発熱		0	2 (22.2)		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 105 of 288

	Days 721-810				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		1 (50.0)	2 (33.3)		
発熱		0	2 (33.3)		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 106 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 107 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 108 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 109 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	1 (1.3)
倦怠感	0	0	0	0	1 (1.3)
小結節	0	0	0	0	1 (1.3)
医療機器閉塞	0	0	1 (6.3)	0	0
不快感	0	0	1 (6.3)	0	0
浮腫	0	0	1 (6.3)	2 (4.9)	0
血管穿刺部位内出血	0	0	1 (6.3)	1 (2.4)	0
末梢腫脹	0	1 (25.0)	0	0	0
注入部位内出血	1 (5.9)	0	0	0	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	1 (2.4)	0
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	1 (2.4)	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 110 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	1 (6.7)	0	0
不快感	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	1 (3.8)	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	0	0
医療機器リーク	0	0	1 (6.7)	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	1 (1.7)
疲労	0	0	0	1 (3.8)	0
注入部位血管外漏出	0	0	0	1 (3.8)	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 111 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	0	1 (5.6)	0
不快感	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	0	0
適用部位紅斑	1 (10.0)	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	0	0
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 112 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
不快感	0	1 (33.3)	0	0	0
浮腫	0	0	0	1 (7.7)	0
血管穿刺部位内出血	0	0	0	1 (7.7)	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	0	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	1 (7.7)	0
カテーテル留置部位炎症	0	0	0	0	1 (3.8)
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	1 (7.7)	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	1 (33.3)	0	0	0
腫脹	0	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 113 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
不快感	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	0	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	0	0
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 114 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	1 (7.7)		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 115 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 116 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 117 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		1 (50.0)	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 118 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 119 of 288

	Days 901-990				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 120 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 121 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	1 (2.4)	0
臨床検査	0	0	0	8 (19.5)	13 (16.3)
酸素飽和度低下	0	0	0	5 (12.2)	5 (6.3)
体重減少	0	0	0	1 (2.4)	2 (2.5)
血中鉄減少	0	0	0	0	1 (1.3)
血中カリウム減少	0	0	0	0	1 (1.3)
体温低下	0	0	0	1 (2.4)	1 (1.3)
体温上昇	0	0	0	0	1 (1.3)
電図ＳＴ－Ｔ部分異常	0	0	0	0	1 (1.3)
心拍数不整	0	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	0	0	0	0	1 (1.3)
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	1 (1.3)
医学的観察	0	0	0	0	1 (1.3)
モラクセラ検査陽性	0	0	0	0	1 (1.3)
シュードモナス検査陽性	0	0	0	0	1 (1.3)
ブドウ球菌検査陽性	0	0	0	0	1 (1.3)
尿量減少	0	0	0	0	1 (1.3)
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 122 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	0	0	2 (13.3)	6 (23.1)	5 (8.5)
酸素飽和度低下	0	0	0	4 (15.4)	3 (5.1)
体重減少	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	0
電図ＳＴ－Ｔ部分異常	0	0	0	1 (3.8)	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 123 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	1 (10.0)	0	2 (15.4)	2 (11.1)	5 (12.2)
酸素飽和度低下	0	0	1 (7.7)	2 (11.1)	1 (2.4)
体重減少	0	0	0	0	1 (2.4)
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	1 (2.4)
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	1 (2.4)
電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	1 (10.0)	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 124 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	0	0	2 (15.4)	1 (7.7)	4 (15.4)
酸素飽和度低下	0	0	0	0	0
体重減少	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	1 (3.8)
電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	1 (7.7)	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	1 (7.7)	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 125 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	0	0	1 (7.7)	0	2 (10.5)
酸素飽和度低下	0	0	0	0	1 (5.3)
体重減少	0	0	1 (7.7)	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	0
電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 126 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	1 (7.7)		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	1 (7.7)		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 127 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	2 (15.4)		
酸素飽和度低下		0	1 (7.7)		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	1 (7.7)		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 128 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		1 (50.0)	1 (11.1)		
酸素飽和度低下		0	0		
体重減少		1 (50.0)	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 129 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	1 (16.7)		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	1 (16.7)		
シュードモナス検査陽性		0	1 (16.7)		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 130 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	0		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 131 of 288

	Days 901-990				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	0		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 132 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	0		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 133 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	1 (2.4)	0
ヘッドラグ異常	0	0	0	1 (2.4)	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	1 (2.4)	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	1 (2.4)	0
ビタミンＡ減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 134 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	1 (6.7)	0	0
Ｃ－反応性蛋白増加	0	0	0	0	2 (3.4)
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	1 (6.7)	0	0
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	1 (3.8)	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンＡ減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 135 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	1 (10.0)	0	0	0	1 (2.4)
血中クロール減少	0	0	0	0	1 (2.4)
血中ナトリウム減少	0	0	0	0	1 (2.4)
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	1 (2.4)
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	1 (7.7)	0	0
心拍数増加	0	0	0	1 (5.6)	1 (2.4)
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	1 (7.7)	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンA減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 136 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	1 (3.8)
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	1 (3.8)
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	1 (7.7)	0
好中球数増加	0	0	1 (7.7)	0	1 (3.8)
好中球百分率増加	0	0	1 (7.7)	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンA減少	0	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 137 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	1 (5.3)
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンA減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 138 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	1 (7.7)		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	1 (7.7)		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 139 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	1 (7.7)		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	1 (7.7)		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 140 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	1 (11.1)		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 141 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	1 (16.7)		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 140 of 288
Page 142 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 140 of 288
Page 143 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 144 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 145 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	0	0	0
皮膚および皮下組織障害	4 (23.5)	1 (25.0)	5 (31.3)	8 (19.5)	12 (15.0)
発疹	0	0	1 (6.3)	4 (9.8)	3 (3.8)
おむつ皮膚炎	1 (5.9)	1 (25.0)	0	2 (4.9)	3 (3.8)
接触性皮膚炎	0	0	0	0	2 (2.5)
湿疹	0	0	2 (12.5)	0	1 (1.3)
皮膚炎	2 (11.8)	0	0	0	1 (1.3)
斑状出血	0	0	0	0	1 (1.3)
紅斑	0	0	0	1 (2.4)	1 (1.3)
脱毛症	0	0	1 (6.3)	0	0
過剰肉芽組織	0	0	1 (6.3)	0	0
点状出血	0	0	1 (6.3)	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (2.4)	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	1 (2.4)	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 146 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	1 (3.8)	0
白血球数増加	0	0	0	0	0
皮膚および皮下組織障害	3 (23.1)	2 (50.0)	2 (13.3)	5 (19.2)	7 (11.9)
発疹	0	1 (25.0)	0	0	2 (3.4)
おむつ皮膚炎	1 (7.7)	0	0	0	1 (1.7)
接触性皮膚炎	0	0	0	1 (3.8)	0
湿疹	0	1 (25.0)	0	1 (3.8)	0
皮膚炎	0	0	0	0	1 (1.7)
斑状出血	0	0	0	0	0
紅斑	1 (7.7)	0	0	2 (7.7)	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	1 (6.7)	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (3.8)	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	1 (3.8)	0
皮膚乾燥	0	0	0	1 (3.8)	0
貨幣状湿疹	1 (7.7)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 147 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	1 (7.7)	0	0
皮膚および皮下組織障害	1 (10.0)	1 (25.0)	2 (15.4)	1 (5.6)	5 (12.2)
発疹	0	0	1 (7.7)	0	3 (7.3)
おむつ皮膚炎	0	1 (25.0)	0	0	0
接触性皮膚炎	0	0	0	1 (5.6)	0
湿疹	0	0	0	0	0
皮膚炎	0	0	0	0	0
斑状出血	0	0	0	0	0
紅斑	0	0	0	0	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	1 (2.4)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	1 (10.0)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 148 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	1 (7.7)	0	0
皮膚および皮下組織障害	0	0	1 (7.7)	1 (7.7)	3 (11.5)
発疹	0	0	0	0	0
おむつ皮膚炎	0	0	1 (7.7)	0	1 (3.8)
接触性皮膚炎	0	0	0	0	0
湿疹	0	0	0	1 (7.7)	0
皮膚炎	0	0	0	0	0
斑状出血	0	0	0	0	1 (3.8)
紅斑	0	0	0	0	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 149 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	0	0	0
皮膚および皮下組織障害	0	2 (100)	3 (23.1)	1 (11.1)	1 (5.3)
発疹	0	1 (50.0)	1 (7.7)	0	0
おむつ皮膚炎	0	0	1 (7.7)	0	1 (5.3)
接触性皮膚炎	0	0	0	0	0
湿疹	0	0	0	0	0
皮膚炎	0	0	1 (7.7)	0	0
斑状出血	0	0	0	0	0
紅斑	0	0	0	0	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 150 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	2 (15.4)		
発疹		0	0		
おむつ皮膚炎		1 (50.0)	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	1 (7.7)		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 151 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	1 (7.7)		
発疹		1 (50.0)	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	1 (7.7)		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 152 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	2 (22.2)		
発疹		0	1 (11.1)		
おむつ皮膚炎		0	0		
接触性皮膚炎		1 (50.0)	0		
湿疹		0	0		
皮膚炎		0	1 (11.1)		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 153 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	1 (16.7)		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 154 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		0	0		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 155 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		0	0		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 156 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		0	0		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 157 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	1 (2.4)	0
過角化	0	0	0	0	0
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	0
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	2 (11.8)	0	2 (12.5)	6 (14.6)	11 (13.8)
頻脈	2 (11.8)	0	0	4 (9.8)	4 (5.0)
徐脈	0	0	0	2 (4.9)	3 (3.8)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
心肺停止	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 158 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	1 (1.7)
多汗症	0	0	0	0	0
過角化	0	0	0	0	1 (1.7)
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	2 (3.4)
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	1 (6.7)	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	1 (6.7)	0	0
蕁麻疹	0	0	0	0	1 (1.7)
心臓障害	0	1 (25.0)	2 (13.3)	4 (15.4)	7 (11.9)
頻脈	0	1 (25.0)	1 (6.7)	1 (3.8)	2 (3.4)
徐脈	0	0	1 (6.7)	1 (3.8)	1 (1.7)
心停止	0	0	0	0	0
心肺停止	0	0	0	2 (7.7)	3 (5.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 159 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	0	0
過角化	0	0	0	0	0
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	0
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	1 (2.4)
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	1 (2.4)
皮膚潰瘍	0	0	1 (7.7)	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	0	0	0	3 (16.7)	1 (2.4)
頻脈	0	0	0	1 (5.6)	1 (2.4)
徐脈	0	0	0	1 (5.6)	0
心停止	0	0	0	0	0
心肺停止	0	0	0	1 (5.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 160 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	0	0
過角化	0	0	0	0	1 (3.8)
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	0
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	0	0	0	3 (23.1)	1 (3.8)
頻脈	0	0	0	3 (23.1)	0
徐脈	0	0	0	0	0
心停止	0	0	0	0	0
心肺停止	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 161 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	0	0
過角化	0	0	0	0	0
毛孔性角化症	0	0	0	1 (11.1)	0
汗疹	0	0	0	0	0
そう痒症	0	0	1 (7.7)	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	1 (50.0)	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	0	2 (100)	3 (23.1)	0	1 (5.3)
頻脈	0	0	0	0	1 (5.3)
徐脈	0	1 (50.0)	0	0	0
心停止	0	0	0	0	0
心肺停止	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 162 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	1 (7.7)		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 163 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	1 (7.7)		
頻脈		0	0		
徐脈		0	1 (7.7)		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 164 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 165 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		1 (50.0)	1 (16.7)		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 166 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 167 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 168 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 169 of 288

	Days 1-90				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	1 (6.3)	1 (2.4)	1 (1.3)
上室性頻脈	0	0	0	0	1 (1.3)
心室性頻脈	0	0	0	0	1 (1.3)
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	2 (11.8)	1 (25.0)	4 (25.0)	6 (14.6)	10 (12.5)
処置による疼痛	0	0	1 (6.3)	0	2 (2.5)
ストーマ部紅斑	0	0	0	1 (2.4)	2 (2.5)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
擦過傷	0	0	0	0	1 (1.3)
大腿骨骨折	0	0	0	0	1 (1.3)
処置合併症	0	0	0	0	1 (1.3)
処置部位反応	0	0	0	0	1 (1.3)
ワクチン接種合併症	0	0	0	0	1 (1.3)
創離開	0	0	0	0	1 (1.3)
節足動物咬傷	0	0	1 (6.3)	0	0
栄養補給チューブ合併症	0	0	1 (6.3)	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 170 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	1 (3.8)	1 (1.7)
上室性頻脈	0	0	0	0	0
心室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	1 (7.7)	1 (25.0)	4 (26.7)	2 (7.7)	1 (1.7)
処置による疼痛	0	0	0	0	0
ストーマ部紅斑	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	1 (3.8)	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	0	1 (25.0)	1 (6.7)	0	0
栄養補給チューブ合併症	0	0	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 171 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	0	1 (25.0)	1 (7.7)	4 (22.2)	1 (2.4)
処置による疼痛	0	1 (25.0)	0	0	0
ストーマ部紅斑	0	0	1 (7.7)	1 (5.6)	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	1 (5.6)	0
創離開	0	0	0	0	0
節足動物咬傷	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	1 (5.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 172 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	1 (3.8)
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	1 (20.0)	0	2 (15.4)	3 (23.1)	4 (15.4)
処置による疼痛	0	0	0	0	0
ストーマ部紅斑	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
大腿骨骨折	0	0	0	1 (7.7)	1 (3.8)
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	0	0	1 (7.7)	0	0
栄養補給チューブ合併症	0	0	0	1 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 173 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心室性頻脈	0	1 (50.0)	0	0	0
心筋症	0	0	1 (7.7)	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	1 (7.7)	0	0
傷害、中毒および処置合併症	0	1 (50.0)	2 (15.4)	0	0
処置による疼痛	0	0	0	0	0
ストーマ部紅斑	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	0	1 (50.0)	1 (7.7)	0	0
栄養補給チューブ合併症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 174 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	1 (7.7)		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 175 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	2 (15.4)		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 176 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 177 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		1 (50.0)	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 178 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 179 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 180 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 181 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	1 (6.3)	0	0
サンバーン	0	1 (25.0)	0	0	0
熱傷	0	1 (25.0)	0	0	0
処置後合併症	1 (5.9)	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	0
硬膜下血腫	1 (5.9)	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	1 (2.4)	0
伝染病曝露	0	0	0	0	0
転倒	0	0	0	0	0
頭部損傷	0	0	0	1 (2.4)	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	1 (2.4)	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	1 (2.4)	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 182 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
ダンピング症候群	0	0	1 (6.7)	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	0
転倒	1 (7.7)	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	1 (6.7)	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 183 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	1 (2.4)
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	0
転倒	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 184 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	1 (3.8)
挫傷	0	0	0	0	0
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	1 (3.8)
転倒	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	1 (7.7)	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	1 (20.0)	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 185 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	1 (7.7)	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	0
転倒	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	1 (7.7)	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 186 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	1 (7.7)		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 187 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	1 (7.7)		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	1 (7.7)		
ダンピング症候群		0	0		
耳擦過傷		0	1 (7.7)		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 188 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 189 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 190 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 191 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 192 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 193 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	1 (2.4)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	2 (11.8)	1 (25.0)	1 (6.3)	5 (12.2)	9 (11.3)
体重増加不良	1 (5.9)	0	0	1 (2.4)	4 (5.0)
乳児および小児期早期の哺育障害	0	0	0	2 (4.9)	3 (3.8)
栄養補給不耐性	0	0	0	0	2 (2.5)
脱水	1 (5.9)	0	0	1 (2.4)	1 (1.3)
成長障害	0	0	0	0	1 (1.3)
代謝性アルカローシス	0	0	1 (6.3)	0	0
過小食	0	1 (25.0)	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 194 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	0	1 (1.7)
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	1 (3.8)	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	1 (7.7)	0	1 (6.7)	5 (19.2)	4 (6.8)
体重増加不良	1 (7.7)	0	0	1 (3.8)	2 (3.4)
乳児および小児期早期の哺育障害	0	0	0	0	1 (1.7)
小児期					
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	1 (7.7)	0	1 (6.7)	0	0
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	1 (6.7)	0	0
食物不耐性	0	0	0	1 (3.8)	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 195 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	1 (5.6)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	1 (5.6)	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	1 (5.6)	0
代謝および栄養障害	0	1 (25.0)	2 (15.4)	2 (11.1)	1 (2.4)
体重増加不良	0	1 (25.0)	0	1 (5.6)	0
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	0	0	0	0	1 (2.4)
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 196 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	1 (7.7)	0
ストーマ部出血	0	0	0	1 (7.7)	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	1 (7.7)	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	0	0	0	1 (7.7)	1 (3.8)
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
栄養補給不耐性	0	0	0	0	1 (3.8)
脱水	0	0	0	0	0
成長障害	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	1 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 197 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	0	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	0	0	0	1 (11.1)	0
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	1 (11.1)	0
低血糖	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 198 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
小児期					
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 199 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
小児期					
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 200 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 201 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		1 (50.0)	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		1 (50.0)	0		
体重増加不良		1 (50.0)	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 202 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 203 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 204 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 205 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	1 (6.3)	3 (7.3)	7 (8.8)
激越	0	0	0	1 (2.4)	2 (2.5)
易刺激性	0	0	0	1 (2.4)	2 (2.5)
不安	0	0	1 (6.3)	0	1 (1.3)
息こらえ	0	0	0	0	1 (1.3)
気分動揺	0	0	0	0	1 (1.3)
落ち着きのなさ	0	0	0	1 (2.4)	1 (1.3)
睡眠障害	0	0	0	0	0
筋骨格系および結合組織障害	2 (11.8)	1 (25.0)	1 (6.3)	2 (4.9)	6 (7.5)
関節拘縮	0	1 (25.0)	0	0	2 (2.5)
側弯症	0	0	0	1 (2.4)	2 (2.5)
背部痛	0	0	0	0	1 (1.3)
頭位性斜頭症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 206 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	3 (11.5)	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	1 (1.7)
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	2 (13.3)	2 (7.7)	1 (1.7)
激越	0	0	0	1 (3.8)	0
易刺激性	0	0	0	0	0
不安	0	0	2 (13.3)	0	1 (1.7)
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	1 (3.8)	1 (1.7)
筋骨格系および結合組織障害	1 (7.7)	1 (25.0)	3 (20.0)	0	0
関節拘縮	0	1 (25.0)	2 (13.3)	0	0
側弯症	0	0	1 (6.7)	0	0
背部痛	0	0	0	0	0
頭位性斜頭症	1 (7.7)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 207 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	2 (15.4)	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	1 (5.6)	0
精神障害	0	0	0	0	0
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
筋骨格系および結合組織障害	1 (10.0)	2 (50.0)	1 (7.7)	1 (5.6)	3 (7.3)
関節拘縮	1 (10.0)	1 (25.0)	1 (7.7)	0	0
側弯症	0	1 (25.0)	0	0	2 (4.9)
背部痛	0	0	0	0	0
頭位性斜頭症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 208 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	0	1 (7.7)	0
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	1 (7.7)	0
筋骨格系および結合組織障害	0	1 (33.3)	0	3 (23.1)	2 (7.7)
関節拘縮	0	1 (33.3)	0	2 (15.4)	1 (3.8)
側弯症	0	0	0	0	0
背部痛	0	0	0	0	0
頭位性斜頭症	0	0	0	1 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 209 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	0	0	0
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
筋骨格系および結合組織障害	0	1 (50.0)	4 (30.8)	1 (11.1)	3 (15.8)
関節拘縮	0	1 (50.0)	1 (7.7)	1 (11.1)	1 (5.3)
側弯症	0	0	3 (23.1)	0	1 (5.3)
背部痛	0	0	0	0	0
頭位性斜頭症	0	0	0	0	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 210 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	4 (30.8)		
関節拘縮		0	1 (7.7)		
側弯症		0	1 (7.7)		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 211 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		1 (50.0)	4 (30.8)		
関節拘縮		1 (50.0)	1 (7.7)		
側弯症		1 (50.0)	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 212 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	1 (11.1)		
関節拘縮		0	0		
側弯症		0	1 (11.1)		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 213 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		1 (50.0)	2 (33.3)		
関節拘縮		1 (50.0)	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 214 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		1 (50.0)	0		
関節拘縮		0	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 215 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	0		
関節拘縮		0	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 216 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	0		
関節拘縮		0	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 217 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	1 (6.3)	0	0
手変形	0	0	1 (6.3)	0	0
筋力低下	1 (5.9)	0	0	0	0
斜頚	1 (5.9)	0	0	0	0
体重支持困難	1 (5.9)	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	1 (2.4)	0
神経系障害	2 (11.8)	0	3 (18.8)	0	5 (6.3)
脳損傷	0	0	0	0	1 (1.3)
間代	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
不随意性筋収縮	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 218 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	0	0	0
手変形	0	0	0	0	0
筋力低下	0	0	0	0	0
斜頚	0	0	0	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	1 (6.7)	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	1 (25.0)	3 (20.0)	2 (7.7)	2 (3.4)
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	2 (13.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 219 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	1 (25.0)	0	0	0
手変形	0	0	0	0	0
筋力低下	0	0	0	0	0
斜頚	0	1 (25.0)	0	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	1 (5.6)	0
後側弯症	0	0	0	0	1 (2.4)
脊柱後弯症	0	1 (25.0)	0	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	0	1 (7.7)	1 (5.6)	0
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 220 of 288

	Days 271-360				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	0	0	1 (3.8)
手変形	0	0	0	0	0
筋力低下	0	0	0	1 (7.7)	0
斜頚	0	0	0	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	1 (3.8)
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	0	1 (7.7)	1 (3.8)
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	0	0	0	1 (3.8)
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 221 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	0	0	0
手変形	0	0	0	0	0
筋力低下	0	0	0	0	0
斜頚	0	0	1 (7.7)	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	1 (5.3)
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	0	1 (7.7)	0	0
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 222 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	1 (7.7)		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	1 (7.7)		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		1 (50.0)	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 223 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	1 (7.7)		
後側弯症		0	0		
脊柱後弯症		0	1 (7.7)		
脊柱前弯症		0	0		
四肢痛		0	1 (7.7)		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 224 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	1 (11.1)		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 225 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	1 (16.7)		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	1 (16.7)		
脊柱変形		0	0		
滑膜炎		0	1 (16.7)		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 226 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		1 (50.0)	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 227 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 228 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 229 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	1 (1.3)
痙攣発作	0	0	0	0	1 (1.3)
脳脊髄液漏	0	0	1 (6.3)	0	0
よだれ	0	0	1 (6.3)	0	0
失神	0	0	1 (6.3)	0	0
反射亢進	1 (5.9)	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	3 (3.8)
後天性包茎	0	0	0	0	1 (1.3)
卵巣嚢胞	0	0	0	0	1 (1.3)
陰茎障害	0	0	0	0	1 (1.3)
血管障害	2 (11.8)	0	1 (6.3)	0	2 (2.5)
蒼白	1 (5.9)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 230 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	1 (25.0)	0	1 (3.8)	1 (1.7)
痙攣発作	0	0	1 (6.7)	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	0
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	1 (6.7)	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	1 (3.8)	0
傾眠	0	0	0	0	1 (1.7)
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	0	1 (6.7)	0	0
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 231 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	0
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	1 (7.7)	0	0
失神寸前の状態	0	0	0	1 (5.6)	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	0	0	0	0
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 232 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	1 (3.8)
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	0	0	0	2 (7.7)
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 233 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	0
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	1 (50.0)	0	0	0
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 234 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		1 (50.0)	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 235 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 236 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 237 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 238 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 239 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 240 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 241 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	1 (1.3)
毛細血管脆弱	0	0	1 (6.3)	0	0
高血圧	1 (5.9)	0	0	0	0
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	0
免疫系障害	0	0	0	1 (2.4)	2 (2.5)
薬物過敏症	0	0	0	0	1 (1.3)
過敏症	0	0	0	1 (2.4)	1 (1.3)
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	0	0	0	0
腎および尿路障害	0	0	0	0	2 (2.5)
水腎症	0	0	0	0	1 (1.3)
尿閉	0	0	0	0	1 (1.3)
糖尿	0	0	0	0	0
眼障害	0	1 (25.0)	1 (6.3)	2 (4.9)	1 (1.3)
眼乾燥	0	0	0	1 (2.4)	1 (1.3)
眼瞼下垂	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 242 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	1 (6.7)	0	0
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	0
免疫系障害	0	1 (25.0)	0	2 (7.7)	1 (1.7)
薬物過敏症	0	0	0	0	0
過敏症	0	0	0	0	0
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	1 (25.0)	0	2 (7.7)	1 (1.7)
腎および尿路障害	0	0	0	0	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	0	0
眼障害	1 (7.7)	0	0	0	2 (3.4)
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 243 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	0	0	0
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	0
免疫系障害	1 (10.0)	0	0	0	2 (4.9)
薬物過敏症	0	0	0	0	1 (2.4)
過敏症	0	0	0	0	0
食物アレルギー	0	0	0	0	1 (2.4)
季節性アレルギー	1 (10.0)	0	0	0	0
腎および尿路障害	0	0	0	0	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	0	0
眼障害	0	0	0	1 (5.6)	1 (2.4)
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 244 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	0	0	1 (3.8)
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	1 (3.8)
免疫系障害	0	0	1 (7.7)	2 (15.4)	1 (3.8)
薬物過敏症	0	0	0	1 (7.7)	0
過敏症	0	0	0	1 (7.7)	0
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	0	1 (7.7)	0	1 (3.8)
腎および尿路障害	0	0	0	1 (7.7)	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	1 (7.7)	0
眼障害	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 245 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	0	0	0
本態性高血圧症	0	1 (50.0)	0	0	0
血管炎	0	0	0	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
過敏症	0	0	0	0	0
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	0	0	0	0
腎および尿路障害	0	0	0	0	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	0	0
眼障害	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 246 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	2 (15.4)		
薬物過敏症		0	2 (15.4)		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 247 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	2 (15.4)		
薬物過敏症		0	0		
過敏症		0	1 (7.7)		
食物アレルギー		0	0		
季節性アレルギー		0	1 (7.7)		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 248 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 249 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 250 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 251 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 252 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 253 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	1 (25.0)	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	1 (2.4)	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	1 (5.9)	0	1 (6.3)	1 (2.4)	1 (1.3)
貧血	0	0	0	1 (2.4)	1 (1.3)
好中球減少症	1 (5.9)	0	1 (6.3)	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 254 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	1 (1.7)
後天性涙道狭窄	1 (7.7)	0	0	0	0
眼運動障害	0	0	0	0	1 (1.7)
流涙増加	0	0	0	0	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	0	0	1 (6.7)	1 (3.8)	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	1 (3.8)	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	1 (6.7)	0	0
先天性、家族性および遺伝性障害	0	0	1 (6.7)	2 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 255 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	1 (5.6)	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	0	0
近視	0	0	0	0	1 (2.4)
斜視	0	0	0	1 (5.6)	1 (2.4)
血液およびリンパ系障害	0	1 (25.0)	2 (15.4)	0	0
貧血	0	0	2 (15.4)	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	1 (25.0)	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 256 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	0	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	1 (20.0)	0	0	1 (7.7)	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	1 (7.7)	0
好酸球増加症	1 (20.0)	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	1 (7.7)	2 (7.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 257 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	0	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 258 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 259 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 260 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 261 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 262 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 263 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 264 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 265 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	1 (2.4)	1 (1.3)
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	0	0
斜頭症	0	0	0	0	0
肝胆道系障害	0	0	0	0	1 (1.3)
肝腫大	0	0	0	0	1 (1.3)
外科および内科処置	0	0	0	0	1 (1.3)
機械的換気	0	0	0	0	1 (1.3)
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	1 (5.9)	1 (25.0)	0	0	0
血管の良性新生物	0	1 (25.0)	0	0	0
脂漏性角化症	1 (5.9)	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 266 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	1 (3.8)	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	1 (3.8)	0
斜頭症	0	0	1 (6.7)	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 267 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	0	0
斜頭症	0	1 (25.0)	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 268 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	1 (7.7)	0
発育性股関節形成不全	0	0	0	0	1 (3.8)
貧血母斑	0	0	0	0	1 (3.8)
包茎	0	0	0	0	0
斜頭症	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 269 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	1 (7.7)	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	0	0
斜頭症	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (7.7)	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 270 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 271 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 272 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 273 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 274 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 275 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 276 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 277 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	0
耳および迷路障害	0	0	0	0	0
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 278 of 288

	Days 91-180				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (1.7)
耳の障害	0	0	0	0	1 (1.7)
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 279 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (2.4)
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	1 (2.4)
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 280 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	0	0	0	0
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 281 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	1 (50.0)	0	0	0
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	1 (50.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 282 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 283 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 284 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 285 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 286 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 287 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 288 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 13　Incidence of Adverse Events by severity - Infants diagnosed with SMA

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 1 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	13 (76.5)	4 (100)	16 (100)	33 (80.5)	67 (83.8)
胃腸障害	5 (29.4)	4 (100)	14 (87.5)	19 (46.3)	40 (50.0)
便秘	1 (5.9)	1 (25.0)	7 (43.8)	8 (19.5)	22 (27.5)
嘔吐	0	2 (50.0)	3 (18.8)	6 (14.6)	9 (11.3)
胃食道逆流性疾患	2 (11.8)	0	5 (31.3)	4 (9.8)	7 (8.8)
生歯	0	2 (50.0)	2 (12.5)	2 (4.9)	7 (8.8)
下痢	0	1 (25.0)	2 (12.5)	6 (14.6)	7 (8.8)
放屁	2 (11.8)	1 (25.0)	1 (6.3)	1 (2.4)	3 (3.8)
嚥下障害	1 (5.9)	0	0	2 (4.9)	3 (3.8)
胃炎	0	0	1 (6.3)	1 (2.4)	2 (2.5)
血便排泄	0	0	0	0	2 (2.5)
腹部膨満	2 (11.8)	1 (25.0)	1 (6.3)	0	1 (1.3)
腹部不快感	1 (5.9)	0	0	0	1 (1.3)
アフタ性潰瘍	0	0	0	0	1 (1.3)
乳児仙痛	0	0	0	0	1 (1.3)
乳児吐出	0	0	0	0	1 (1.3)
流涎過多	0	0	0	1 (2.4)	1 (1.3)
上部消化管出血	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 2 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
口唇のひび割れ	0	0	1 (6.3)	0	0
排便回数増加	0	0	1 (6.3)	0	0
腹痛	0	1 (25.0)	0	0	0
消化管運動低下	0	1 (25.0)	0	0	0
吐血	0	1 (25.0)	0	0	0
上腹部痛	0	0	0	2 (4.9)	0
悪心	0	0	0	0	0
口内炎	0	0	0	1 (2.4)	0
血性下痢	0	0	0	1 (2.4)	0
胃腸障害	0	0	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
口腔内痛	0	0	0	0	0
感染症および寄生虫症	7 (41.2)	3 (75.0)	11 (68.8)	20 (48.8)	36 (45.0)
鼻咽頭炎	3 (17.6)	0	2 (12.5)	3 (7.3)	10 (12.5)
上気道感染	4 (23.5)	0	3 (18.8)	4 (9.8)	8 (10.0)
口腔カンジダ症	0	0	1 (6.3)	3 (7.3)	5 (6.3)
結膜炎	0	0	0	3 (7.3)	4 (5.0)
細気管支炎	0	0	0	1 (2.4)	4 (5.0)
気管支炎	0	0	0	0	3 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 3 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性気道感染	0	0	0	0	3 (3.8)
ウイルス感染	0	0	2 (12.5)	1 (2.4)	2 (2.5)
気道感染	0	2 (50.0)	0	1 (2.4)	2 (2.5)
肺炎	0	1 (25.0)	0	1 (2.4)	2 (2.5)
耳感染	0	0	0	1 (2.4)	2 (2.5)
中耳炎	1 (5.9)	1 (25.0)	3 (18.8)	1 (2.4)	1 (1.3)
皮膚真菌感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ウイルス性上気道感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ライノウイルス感染	0	0	1 (6.3)	2 (4.9)	1 (1.3)
カンジダ性おむつ皮疹	0	1 (25.0)	0	0	1 (1.3)
鼻炎	1 (5.9)	0	0	3 (7.3)	1 (1.3)
皮膚カンジダ	0	0	0	1 (2.4)	1 (1.3)
手足口病	0	0	0	0	1 (1.3)
限局性感染	0	0	0	0	1 (1.3)
尿路感染	0	0	0	0	1 (1.3)
細菌感染	0	0	0	0	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)
蜂巣炎	0	0	0	1 (2.4)	1 (1.3)
細菌性結膜炎	0	0	0	1 (2.4)	1 (1.3)
感染性湿疹	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 4 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼感染	0	0	0	0	1 (1.3)
膿痂疹	0	0	0	1 (2.4)	1 (1.3)
口腔ヘルペス	0	0	0	0	1 (1.3)
ばら疹	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
胃腸炎	0	0	1 (6.3)	0	0
細菌性疾患キャリアー	0	0	1 (6.3)	0	0
細菌性気管炎	0	0	1 (6.3)	2 (4.9)	0
エンテロウイルス感染	0	0	1 (6.3)	0	0
伝染性紅斑	0	0	1 (6.3)	0	0
ウイルス性胃炎	0	0	1 (6.3)	0	0
粘膜皮膚カンジダ症	0	0	1 (6.3)	0	0
細菌性気道感染	0	0	1 (6.3)	0	0
ウイルス性肺炎	1 (5.9)	1 (25.0)	0	0	0
シュードモナス菌性肺炎	0	1 (25.0)	0	0	0
ウイルス性胃腸炎	1 (5.9)	0	0	2 (4.9)	0
レンサ球菌性咽頭炎	1 (5.9)	0	0	0	0
皮膚感染	1 (5.9)	0	0	1 (2.4)	0
ウイルス性眼感染	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 5 of 41
Severity: MILD

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
伝染性軟属腫	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0
カンジダ感染	0	0	0	2 (4.9)	0
ブドウ球菌性眼感染	0	0	0	0	0
真菌感染	0	0	0	1 (2.4)	0
麦粒腫	0	0	0	1 (2.4)	0
下気道感染	0	0	0	1 (2.4)	0
単核細胞症症候群	0	0	0	0	0
急性中耳炎	0	0	0	0	0
咽頭炎	0	0	0	0	0
シュードモナス感染	0	0	0	1 (2.4)	0
副鼻腔炎	0	0	0	0	0
皮膚細菌感染	0	0	0	0	0
ブドウ球菌感染	0	0	0	2 (4.9)	0
ストーマ部感染	0	0	0	2 (4.9)	0
扁桃炎	0	0	0	0	0
ウイルス性発疹	0	0	0	1 (2.4)	0
呼吸器、胸郭および縦隔障害	5 (29.4)	2 (50.0)	13 (81.3)	18 (43.9)	28 (35.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 6 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鼻閉	2 (11.8)	1 (25.0)	5 (31.3)	5 (12.2)	8 (10.0)
上気道うっ血	1 (5.9)	0	0	0	5 (6.3)
呼吸困難	0	1 (25.0)	1 (6.3)	1 (2.4)	4 (5.0)
咳嗽	2 (11.8)	2 (50.0)	4 (25.0)	7 (17.1)	3 (3.8)
鼻漏	1 (5.9)	0	2 (12.5)	3 (7.3)	3 (3.8)
副鼻腔うっ血	0	0	0	0	3 (3.8)
無気肺	0	0	2 (12.5)	1 (2.4)	2 (2.5)
上気道分泌増加	0	0	3 (18.8)	1 (2.4)	1 (1.3)
低酸素症	0	0	2 (12.5)	0	1 (1.3)
呼吸窮迫	1 (5.9)	0	1 (6.3)	1 (2.4)	1 (1.3)
息詰まり	0	0	1 (6.3)	0	1 (1.3)
呼吸不全	0	0	1 (6.3)	0	1 (1.3)
呼吸補助筋の動員	0	0	1 (6.3)	1 (2.4)	1 (1.3)
喘鳴	0	0	1 (6.3)	0	1 (1.3)
気管支閉塞	0	0	0	0	1 (1.3)
アレルギー性鼻炎	0	0	0	0	1 (1.3)
肺水腫	0	0	2 (12.5)	0	0
慢性呼吸不全	0	1 (25.0)	1 (6.3)	0	0
肺うっ血	0	0	1 (6.3)	0	0
無呼吸発作	0	0	1 (6.3)	0	0
気管支分泌物貯留	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 7 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鼻汁変色	0	0	1 (6.3)	0	0
誤嚥性肺炎	0	0	1 (6.3)	0	0
湿性咳嗽	0	0	1 (6.3)	0	0
拘束性肺疾患	0	0	1 (6.3)	0	0
低音性連続性ラ音	0	0	1 (6.3)	0	0
睡眠時無呼吸症候群	0	0	1 (6.3)	1 (2.4)	0
頻呼吸	0	0	1 (6.3)	2 (4.9)	0
呼吸性アシドーシス	1 (5.9)	0	0	0	0
口腔咽頭痛	0	0	0	1 (2.4)	0
鼻出血	0	0	0	0	0
扁桃肥大	0	0	0	0	0
誤嚥	0	0	0	1 (2.4)	0
発声障害	0	0	0	0	0
気道うっ血	0	0	0	3 (7.3)	0
上気道の炎症	0	0	0	2 (4.9)	0
一般・全身障害および投与部位の状態	3 (17.6)	3 (75.0)	8 (50.0)	20 (48.8)	24 (30.0)
発熱	1 (5.9)	3 (75.0)	6 (37.5)	15 (36.6)	21 (26.3)
カテーテル留置部位炎症	0	0	0	1 (2.4)	1 (1.3)
泣き	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 8 of 41
Severity: MILD

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
薬物不耐性	0	0	0	0	1 (1.3)
ワクチン接種後の易刺激性	0	0	0	0	1 (1.3)
小結節	0	0	0	0	1 (1.3)
腫脹	0	0	0	0	1 (1.3)
不快感	0	1 (25.0)	1 (6.3)	0	0
末梢性浮腫	0	1 (25.0)	1 (6.3)	0	0
医療機器リーク	0	0	1 (6.3)	0	0
浮腫	0	0	1 (6.3)	1 (2.4)	0
血管穿刺部位内出血	0	0	1 (6.3)	2 (4.9)	0
末梢腫脹	0	1 (25.0)	0	0	0
適用部位紅斑	1 (5.9)	0	0	0	0
注入部位内出血	1 (5.9)	0	0	0	0
疼痛	0	0	0	2 (4.9)	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
適用部位発疹	0	0	0	1 (2.4)	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 9 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
医療機器機能不良	0	0	0	1 (2.4)	0
医療機器閉塞	0	0	0	1 (2.4)	0
疲労	0	0	0	1 (2.4)	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
低体温	0	0	0	0	0
注入部位血管外漏出	0	0	0	1 (2.4)	0
注射部位血腫	0	0	0	1 (2.4)	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
皮膚および皮下組織障害	5 (29.4)	4 (100)	10 (62.5)	13 (31.7)	20 (25.0)
発疹	0	1 (25.0)	4 (25.0)	4 (9.8)	7 (8.8)
おむつ皮膚炎	1 (5.9)	2 (50.0)	2 (12.5)	2 (4.9)	4 (5.0)
斑状出血	0	0	1 (6.3)	0	2 (2.5)
接触性皮膚炎	0	1 (25.0)	0	2 (4.9)	2 (2.5)
過角化	0	0	0	0	2 (2.5)
汗疹	0	0	0	0	2 (2.5)
湿疹	0	1 (25.0)	2 (12.5)	1 (2.4)	1 (1.3)
皮膚炎	2 (11.8)	0	0	0	1 (1.3)
紅斑	1 (5.9)	0	0	3 (7.3)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 10 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
蕁麻疹	0	0	0	0	1 (1.3)
アレルギー性皮膚炎	0	0	0	0	1 (1.3)
環状肉芽腫	0	0	0	0	1 (1.3)
丘疹性皮疹	0	0	0	0	1 (1.3)
皮膚浮腫	0	0	0	0	1 (1.3)
過剰肉芽組織	0	0	3 (18.8)	0	0
皮膚刺激	0	1 (25.0)	2 (12.5)	0	0
脱毛症	0	0	1 (6.3)	0	0
点状出血	0	0	1 (6.3)	0	0
そう痒症	0	0	1 (6.3)	0	0
皮膚色素脱失	0	0	1 (6.3)	0	0
皮膚潰瘍	0	0	1 (6.3)	0	0
皮膚障害	0	1 (25.0)	0	0	0
貨幣状湿疹	1 (5.9)	0	0	0	0
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (2.4)	0
毛孔性角化症	0	0	0	1 (2.4)	0
皮膚病変	0	0	0	0	0
アトピー性皮膚炎	0	0	0	2 (4.9)	0
皮膚乾燥	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 11 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
多汗症	0	0	0	1 (2.4)	0
寝汗	0	0	0	0	0
臨床検査	1 (5.9)	1 (25.0)	5 (31.3)	9 (22.0)	13 (16.3)
体重減少	0	1 (25.0)	1 (6.3)	1 (2.4)	2 (2.5)
体温上昇	0	0	0	0	2 (2.5)
酸素飽和度低下	0	0	2 (12.5)	3 (7.3)	1 (1.3)
心拍数増加	0	0	1 (6.3)	1 (2.4)	1 (1.3)
モラクセラ検査陽性	0	0	1 (6.3)	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (1.3)
血中鉄減少	0	0	0	0	1 (1.3)
血中カリウム減少	0	0	0	0	1 (1.3)
体温低下	0	0	0	1 (2.4)	1 (1.3)
心拍数不整	0	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	0	0	0	0	1 (1.3)
炎症マーカー上昇	0	0	0	0	1 (1.3)
A型インフルエンザウイルス検査陽性	0	0	0	0	1 (1.3)
医学的観察	0	0	0	0	1 (1.3)
シュードモナス検査陽性	0	0	0	0	1 (1.3)
ブドウ球菌検査陽性	0	0	0	0	1 (1.3)
尿量減少	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 12 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンA減少	0	0	0	0	1 (1.3)
骨密度減少	0	0	1 (6.3)	0	0
呼吸音異常	0	0	1 (6.3)	0	0
心拍数減少	0	0	1 (6.3)	0	0
好中球数増加	0	0	1 (6.3)	0	0
セラチア検査陽性	0	0	1 (6.3)	0	0
レンサ球菌検査陽性	0	0	1 (6.3)	0	0
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	0
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	1 (2.4)	0
ヘッドラグ異常	0	0	0	1 (2.4)	0
リンパ節触知	0	0	0	1 (2.4)	0
呼吸数増加	0	0	0	1 (2.4)	0
トランスアミナーゼ上昇	0	0	0	1 (2.4)	0
尿検査異常	0	0	0	0	0
ビタミンD減少	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 13 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
傷害、中毒および処置合併症	3 (17.6)	3 (75.0)	8 (50.0)	10 (24.4)	11 (13.8)
ストーマ部紅斑	0	0	1 (6.3)	2 (4.9)	2 (2.5)
処置による疼痛	0	1 (25.0)	1 (6.3)	0	1 (1.3)
挫傷	0	0	1 (6.3)	0	1 (1.3)
処置後腫脹	1 (5.9)	0	0	0	1 (1.3)
術後激越	0	0	0	0	1 (1.3)
伝染病曝露	0	0	0	0	1 (1.3)
大腿骨骨折	0	0	0	0	1 (1.3)
処置合併症	0	0	0	0	1 (1.3)
処置部位反応	0	0	0	0	1 (1.3)
ストーマ合併症	0	0	0	2 (4.9)	1 (1.3)
ワクチン接種合併症	0	0	0	1 (2.4)	1 (1.3)
栄養補給チューブ合併症	0	0	2 (12.5)	2 (4.9)	0
皮膚擦過傷	0	0	2 (12.5)	0	0
節足動物咬傷	0	1 (25.0)	1 (6.3)	0	0
関節脱臼	0	0	1 (6.3)	0	0
ダンピング症候群	0	0	1 (6.3)	0	0
耳擦過傷	0	0	1 (6.3)	0	0
軟部組織損傷	0	1 (25.0)	0	0	0
サンバーン	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 14 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
熱傷	0	1 (25.0)	0	0	0
転倒	1 (5.9)	0	0	0	0
処置後合併症	1 (5.9)	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
裂傷	0	0	0	1 (2.4)	0
節足動物刺傷	0	0	0	0	0
靭帯捻挫	0	0	0	0	0
四肢損傷	0	0	0	0	0
擦過傷	0	0	0	1 (2.4)	0
頭部損傷	0	0	0	1 (2.4)	0
関節損傷	0	0	0	0	0
肉離れ	0	0	0	0	0
処置後挫傷	0	0	0	1 (2.4)	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
ストーマ部出血	0	0	0	1 (2.4)	0
ストーマ部炎症	0	0	0	1 (2.4)	0
ストーマ部刺激感	0	0	0	1 (2.4)	0
脛骨骨折	0	0	0	0	0
気管損傷	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 15 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
筋骨格系および結合組織障害	2 (11.8)	3 (75.0)	10 (62.5)	3 (7.3)	8 (10.0)
側弯症	0	2 (50.0)	4 (25.0)	1 (2.4)	3 (3.8)
頭位性斜頭症	1 (5.9)	0	0	0	2 (2.5)
関節拘縮	1 (5.9)	2 (50.0)	4 (25.0)	0	1 (1.3)
背部痛	0	0	0	0	1 (1.3)
四肢痛	0	0	0	0	1 (1.3)
泉門閉鎖遅延	0	0	0	0	1 (1.3)
胸郭変形	0	1 (25.0)	2 (12.5)	0	0
脊柱後弯症	0	2 (50.0)	1 (6.3)	1 (2.4)	0
斜頚	0	1 (25.0)	1 (6.3)	0	0
手変形	0	0	1 (6.3)	0	0
関節硬直	0	0	1 (6.3)	1 (2.4)	0
後側弯症	0	0	1 (6.3)	0	0
脊柱前弯症	0	0	1 (6.3)	0	0
脊柱変形	0	0	1 (6.3)	0	0
筋力低下	1 (5.9)	0	0	0	0
体重支持困難	1 (5.9)	0	0	0	0
関節痛	0	0	0	0	0
筋緊張	0	0	0	0	0
筋肉痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 16 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
頚部痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	0	0	1 (2.4)	0
精神障害	0	0	0	2 (4.9)	8 (10.0)
激越	0	0	0	1 (2.4)	2 (2.5)
易刺激性	0	0	0	1 (2.4)	2 (2.5)
不安	0	0	0	0	1 (1.3)
息こらえ	0	0	0	0	1 (1.3)
気分動揺	0	0	0	0	1 (1.3)
落ち着きのなさ	0	0	0	0	1 (1.3)
睡眠障害	0	0	0	1 (2.4)	1 (1.3)
チック	0	0	0	0	0
不快気分	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
代謝および栄養障害	2 (11.8)	0	2 (12.5)	6 (14.6)	7 (8.8)
成長障害	0	0	1 (6.3)	0	2 (2.5)
体重増加不良	1 (5.9)	0	0	1 (2.4)	2 (2.5)
脱水	1 (5.9)	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 17 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
栄養補給不耐性	0	0	0	0	1 (1.3)
鉄欠乏	0	0	0	0	1 (1.3)
過小食	0	0	1 (6.3)	0	0
代謝性アルカローシス	0	0	1 (6.3)	0	0
食欲減退	0	0	0	0	0
食欲亢進	0	0	0	0	0
ビタミンD欠乏	0	0	0	1 (2.4)	0
乳児および小児期早期の哺育障害	0	0	0	1 (2.4)	0
食物不耐性	0	0	0	1 (2.4)	0
高血糖	0	0	0	1 (2.4)	0
低血糖	0	0	0	1 (2.4)	0
神経系障害	2 (11.8)	2 (50.0)	6 (37.5)	1 (2.4)	6 (7.5)
眼振	0	1 (25.0)	0	1 (2.4)	2 (2.5)
不随意性筋収縮	0	0	3 (18.8)	0	1 (1.3)
よだれ	0	0	1 (6.3)	0	1 (1.3)
間代	0	0	0	0	1 (1.3)
傾眠	0	0	0	0	1 (1.3)
失神	0	0	1 (6.3)	0	0
脳脊髄液漏	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 18 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
頭痛	0	1 (25.0)	0	0	0
反射亢進	1 (5.9)	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	0
失声症	0	0	0	0	0
感覚鈍麻	0	0	0	0	0
振戦	0	0	0	0	0
味覚異常	0	0	0	0	0
錯感覚	0	0	0	0	0
心臓障害	2 (11.8)	2 (50.0)	2 (12.5)	5 (12.2)	6 (7.5)
頻脈	2 (11.8)	1 (25.0)	1 (6.3)	4 (9.8)	2 (2.5)
徐脈	0	1 (25.0)	0	1 (2.4)	2 (2.5)
チアノーゼ	0	0	0	0	1 (1.3)
左室肥大	0	0	0	0	1 (1.3)
上室性頻脈	0	0	0	0	1 (1.3)
心筋症	0	0	1 (6.3)	0	0
心室性頻脈	0	1 (25.0)	0	0	0
動悸	0	0	0	0	0
免疫系障害	0	1 (25.0)	5 (31.3)	4 (9.8)	5 (6.3)
季節性アレルギー	0	1 (25.0)	2 (12.5)	2 (4.9)	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 19 of 41
Severity: MILD

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
薬物過敏症	0	0	2 (12.5)	1 (2.4)	1 (1.3)
過敏症	0	0	1 (6.3)	2 (4.9)	1 (1.3)
食物アレルギー	0	0	0	0	1 (1.3)
眼障害	1 (5.9)	1 (25.0)	1 (6.3)	3 (7.3)	4 (5.0)
霰粒腫	0	0	0	0	1 (1.3)
眼乾燥	0	0	0	1 (2.4)	1 (1.3)
眼運動障害	0	0	0	0	1 (1.3)
近視	0	0	0	0	1 (1.3)
斜視	0	0	0	1 (2.4)	1 (1.3)
眼瞼下垂	0	0	1 (6.3)	0	0
乱視	0	1 (25.0)	0	0	0
後天性涙道狭窄	1 (5.9)	0	0	0	0
遠視	0	0	0	0	0
弱視	0	0	0	1 (2.4)	0
流涙増加	0	0	0	1 (2.4)	0
血管障害	1 (5.9)	1 (25.0)	1 (6.3)	0	2 (2.5)
蒼白	1 (5.9)	0	0	0	1 (1.3)
血管炎	0	0	0	0	1 (1.3)
毛細血管脆弱	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 20 of 41
Severity: MILD

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
本態性高血圧症	0	1 (25.0)	0	0	0
先天性、家族性および遺伝性障害	0	1 (25.0)	1 (6.3)	4 (9.8)	2 (2.5)
貧血母斑	0	0	0	0	1 (1.3)
鳩胸	0	0	0	1 (2.4)	1 (1.3)
斜頭症	0	1 (25.0)	1 (6.3)	0	0
停留精巣	0	0	0	1 (2.4)	0
発育性股関節形成不全	0	0	0	1 (2.4)	0
包茎	0	0	0	1 (2.4)	0
生殖系および乳房障害	0	0	0	0	2 (2.5)
卵巣嚢胞	0	0	0	0	1 (1.3)
陰茎障害	0	0	0	0	1 (1.3)
耳および迷路障害	0	1 (25.0)	0	0	1 (1.3)
耳痛	0	0	0	0	1 (1.3)
耳垢分泌過多	0	1 (25.0)	0	0	0
鼓膜穿孔	0	0	0	0	0
乗物酔い	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 21 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腎および尿路障害	0	0	0	1 (2.4)	1 (1.3)
水腎症	0	0	0	0	1 (1.3)
尿失禁	0	0	0	0	0
糖尿	0	0	0	1 (2.4)	0
肝胆道系障害	0	0	0	0	1 (1.3)
肝腫大	0	0	0	0	1 (1.3)
血液およびリンパ系障害	1 (5.9)	1 (25.0)	4 (25.0)	2 (4.9)	0
貧血	0	0	2 (12.5)	1 (2.4)	0
好中球減少症	0	0	1 (6.3)	0	0
血小板増加症	0	0	1 (6.3)	0	0
リンパ節症	0	1 (25.0)	0	0	0
好酸球増加症	1 (5.9)	0	0	0	0
白血球増加症	0	0	0	1 (2.4)	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	1 (5.9)	1 (25.0)	1 (6.3)	0	0
アクロコルドン	0	0	1 (6.3)	0	0
血管の良性新生物	0	1 (25.0)	0	0	0
脂漏性角化症	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 22 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 23 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	9 (52.9)	2 (50.0)	14 (87.5)	25 (61.0)	53 (66.3)
感染症および寄生虫症	6 (35.3)	1 (25.0)	12 (75.0)	12 (29.3)	38 (47.5)
肺炎	1 (5.9)	0	3 (18.8)	1 (2.4)	8 (10.0)
ウイルス性上気道感染	0	0	1 (6.3)	2 (4.9)	8 (10.0)
上気道感染	2 (11.8)	1 (25.0)	8 (50.0)	5 (12.2)	7 (8.8)
ウイルス感染	0	0	2 (12.5)	0	5 (6.3)
ウイルス性肺炎	0	0	1 (6.3)	0	5 (6.3)
ライノウイルス感染	1 (5.9)	0	4 (25.0)	0	4 (5.0)
鼻咽頭炎	0	0	4 (25.0)	1 (2.4)	4 (5.0)
気道感染	0	0	3 (18.8)	1 (2.4)	2 (2.5)
インフルエンザ	2 (11.8)	0	1 (6.3)	0	2 (2.5)
耳感染	0	0	1 (6.3)	0	2 (2.5)
尿路感染	1 (5.9)	0	0	0	2 (2.5)
アデノウイルス感染	0	0	0	0	2 (2.5)
ウイルス性下気道感染	0	0	0	0	2 (2.5)
結膜炎	0	0	1 (6.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 24 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
下気道感染	0	0	1 (6.3)	0	1 (1.3)
細菌性肺炎	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ＲＳウイルス細気管支炎	0	0	1 (6.3)	0	1 (1.3)
気管支炎	1 (5.9)	0	0	0	1 (1.3)
胃腸炎	0	0	0	0	1 (1.3)
ウイルス性胃腸炎	0	0	0	0	1 (1.3)
ウイルス性気道感染	0	0	0	1 (2.4)	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)
細菌性結膜炎	0	0	0	0	1 (1.3)
真菌感染	0	0	0	0	1 (1.3)
ロタウイルス胃腸炎	0	0	0	0	1 (1.3)
口腔カンジダ症	0	0	0	0	1 (1.3)
急性中耳炎	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	0	1 (1.3)
シュードモナス感染	0	0	0	1 (2.4)	1 (1.3)
皮膚カンジダ	0	0	0	0	1 (1.3)
ブドウ球菌皮膚感染	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
細気管支炎	1 (5.9)	0	2 (12.5)	1 (2.4)	0
中耳炎	1 (5.9)	0	2 (12.5)	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 25 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
パラインフルエンザウイルス感染	0	1 (25.0)	1 (6.3)	1 (2.4)	0
アデノウイルス性上気道感染	0	0	1 (6.3)	0	0
細菌感染	0	0	1 (6.3)	0	0
ヘモフィルス感染	0	0	1 (6.3)	0	0
手足口病	0	0	1 (6.3)	0	0
モラクセラ感染	0	0	1 (6.3)	0	0
鼻炎	0	0	1 (6.3)	0	0
ブドウ球菌感染	0	0	1 (6.3)	0	0
気管炎	0	0	1 (6.3)	1 (2.4)	0
レンサ球菌性咽頭炎	0	1 (25.0)	0	0	0
膿痂疹	1 (5.9)	0	0	0	0
ＲＳウイルス感染	0	0	0	0	0
蜂巣炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
腟感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	1 (2.4)	0
細菌性気管炎	0	0	0	1 (2.4)	0
カンジダ感染	0	0	0	1 (2.4)	0
コロナウイルス感染	0	0	0	1 (2.4)	0
細菌性気道感染	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 26 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
セラチア感染	0	0	0	1 (2.4)	0
ストーマ部感染	0	0	0	1 (2.4)	0
呼吸器、胸郭および縦隔障害	0	2 (50.0)	13 (81.3)	17 (41.5)	29 (36.3)
呼吸窮迫	0	1 (25.0)	3 (18.8)	3 (7.3)	7 (8.8)
無気肺	0	0	2 (12.5)	6 (14.6)	7 (8.8)
呼吸不全	0	0	1 (6.3)	1 (2.4)	5 (6.3)
誤嚥性肺炎	0	0	1 (6.3)	5 (12.2)	4 (5.0)
無呼吸	0	0	1 (6.3)	1 (2.4)	3 (3.8)
咳嗽	0	0	0	1 (2.4)	3 (3.8)
気管支分泌物貯留	0	1 (25.0)	1 (6.3)	2 (4.9)	2 (2.5)
誤嚥	0	0	1 (6.3)	0	2 (2.5)
低酸素症	0	0	0	1 (2.4)	2 (2.5)
慢性呼吸不全	0	0	2 (12.5)	0	1 (1.3)
上気道分泌増加	0	0	1 (6.3)	0	1 (1.3)
呼吸停止	0	0	1 (6.3)	1 (2.4)	1 (1.3)
呼吸障害	0	0	0	0	1 (1.3)
急性呼吸窮迫症候群	0	0	0	0	1 (1.3)
呼吸困難	0	0	0	4 (9.8)	1 (1.3)
減呼吸	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 27 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低換気	0	0	0	0	1 (1.3)
気管支分泌増加	0	0	0	1 (2.4)	1 (1.3)
胸水	0	0	0	0	1 (1.3)
呼吸性アルカローシス	0	0	0	0	1 (1.3)
気道うっ血	0	0	0	0	1 (1.3)
鼻漏	0	0	0	0	1 (1.3)
変色痰	0	0	0	0	1 (1.3)
急性呼吸不全	0	0	2 (12.5)	1 (2.4)	0
喘鳴	0	0	1 (6.3)	0	0
喉頭肉芽腫	0	0	1 (6.3)	0	0
鼻閉	0	0	1 (6.3)	1 (2.4)	0
気胸	0	0	1 (6.3)	0	0
肺うっ血	0	0	1 (6.3)	0	0
副鼻腔うっ血	0	0	1 (6.3)	0	0
気管障害	0	0	1 (6.3)	0	0
上気道うっ血	0	0	1 (6.3)	1 (2.4)	0
アレルギー性鼻炎	0	1 (25.0)	0	0	0
カタル	0	0	0	1 (2.4)	0
息詰まり	0	0	0	1 (2.4)	0
鼻出血	0	0	0	0	0
肺臓炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 28 of 41
Severity: MODERATE

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
拘束性肺疾患	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	2 (4.9)	0
一般・全身障害および投与部位の状態	2 (11.8)	0	7 (43.8)	10 (24.4)	19 (23.8)
発熱	2 (11.8)	0	5 (31.3)	7 (17.1)	16 (20.0)
疼痛	0	0	3 (18.8)	0	1 (1.3)
低体温	0	0	0	0	1 (1.3)
倦怠感	0	0	0	0	1 (1.3)
医療機器閉塞	0	0	1 (6.3)	0	0
疲労	0	0	0	0	0
注入部位内出血	0	0	0	1 (2.4)	0
浮腫	0	0	0	2 (4.9)	0
血管穿刺部位反応	0	0	0	1 (2.4)	0
胃腸障害	1 (5.9)	0	6 (37.5)	8 (19.5)	13 (16.3)
生歯	1 (5.9)	0	0	1 (2.4)	4 (5.0)
嘔吐	0	0	2 (12.5)	1 (2.4)	3 (3.8)
流涎過多	0	0	2 (12.5)	0	2 (2.5)
便秘	0	0	1 (6.3)	1 (2.4)	2 (2.5)
胃食道逆流性疾患	0	0	1 (6.3)	2 (4.9)	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 29 of 41
Severity: MODERATE

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
嚥下障害	0	0	0	2 (4.9)	2 (2.5)
下痢	0	0	2 (12.5)	1 (2.4)	1 (1.3)
胃出血	0	0	0	0	1 (1.3)
腹部膨満	0	0	1 (6.3)	0	0
悪心	0	0	0	0	0
腹部症状	0	0	0	0	0
口腔内痛	0	0	0	0	0
腹部不快感	0	0	0	0	0
食中毒	0	0	0	0	0
胃腸出血	0	0	0	1 (2.4)	0
消化管刺激症状	0	0	0	1 (2.4)	0
臨床検査	0	0	4 (25.0)	5 (12.2)	8 (10.0)
酸素飽和度低下	0	0	0	4 (9.8)	6 (7.5)
Ｃ－反応性蛋白増加	0	0	0	1 (2.4)	2 (2.5)
好中球数増加	0	0	1 (6.3)	0	1 (1.3)
体重減少	0	0	0	0	1 (1.3)
アラニンアミノトランスフェラーゼ増加	0	0	0	0	1 (1.3)
血中クロール減少	0	0	0	0	1 (1.3)
血中カリウム減少	0	0	0	0	1 (1.3)
血中ナトリウム減少	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 30 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
心電図ＳＴ－Ｔ部分異常	0	0	0	0	1 (1.3)
肝機能検査異常	0	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	0	0	2 (12.5)	0	0
白血球数増加	0	0	2 (12.5)	0	0
好中球百分率増加	0	0	1 (6.3)	0	0
シュードモナス検査陽性	0	0	1 (6.3)	0	0
ブドウ球菌検査陽性	0	0	1 (6.3)	0	0
心臓障害	0	0	1 (6.3)	4 (9.8)	8 (10.0)
頻脈	0	0	0	1 (2.4)	4 (5.0)
徐脈	0	0	1 (6.3)	2 (4.9)	2 (2.5)
チアノーゼ	0	0	0	1 (2.4)	1 (1.3)
心室性頻脈	0	0	0	0	1 (1.3)
代謝および栄養障害	1 (5.9)	2 (50.0)	1 (6.3)	4 (9.8)	7 (8.8)
乳児および小児期早期の哺育障害	0	0	0	1 (2.4)	3 (3.8)
小児期					
体重増加不良	0	1 (25.0)	0	0	2 (2.5)
栄養補給不耐性	0	0	0	0	2 (2.5)
低ナトリウム血症	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 31 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
過小食	0	1 (25.0)	0	0	0
成長障害	1 (5.9)	0	0	0	0
脱水	0	0	0	0	0
低血糖	0	0	0	1 (2.4)	0
低カリウム血症	0	0	0	3 (7.3)	0
筋骨格系および結合組織障害	1 (5.9)	0	4 (25.0)	3 (7.3)	4 (5.0)
関節拘縮	0	0	1 (6.3)	2 (4.9)	2 (2.5)
側弯症	0	0	1 (6.3)	0	1 (1.3)
脊柱後弯症	0	0	1 (6.3)	0	1 (1.3)
後側弯症	0	0	0	0	1 (1.3)
四肢痛	0	0	1 (6.3)	0	0
滑膜炎	0	0	1 (6.3)	0	0
斜頚	1 (5.9)	0	0	0	0
背部痛	0	0	0	0	0
関節痛	0	0	0	0	0
筋力低下	0	0	0	1 (2.4)	0
頭位性斜頭症	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 32 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
傷害、中毒および処置合併症	1 (5.9)	0	3 (18.8)	1 (2.4)	4 (5.0)
大腿骨骨折	0	0	0	0	1 (1.3)
処置による疼痛	0	0	0	0	1 (1.3)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
擦過傷	0	0	0	0	1 (1.3)
関節脱臼	0	0	1 (6.3)	0	0
節足動物咬傷	0	0	1 (6.3)	0	0
口唇損傷	0	0	1 (6.3)	0	0
外傷性気胸	0	0	1 (6.3)	0	0
歯牙損傷	0	0	1 (6.3)	0	0
硬膜下血腫	1 (5.9)	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
関節損傷	0	0	0	0	0
裂傷	0	0	0	0	0
四肢損傷	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
気管内挿管合併症	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 33 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
頭部損傷	0	0	0	0	0
術後イレウス	0	0	0	0	0
隆起骨折	0	0	0	0	0
皮膚および皮下組織障害	2 (11.8)	0	1 (6.3)	1 (2.4)	2 (2.5)
おむつ皮膚炎	1 (5.9)	0	0	0	1 (1.3)
発疹	0	0	0	0	1 (1.3)
皮膚炎	0	0	1 (6.3)	0	0
皮下気腫	0	0	1 (6.3)	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (2.4)	0
湿疹	0	0	0	1 (2.4)	0
精神障害	0	0	2 (12.5)	3 (7.3)	1 (1.3)
不安	0	0	2 (12.5)	0	1 (1.3)
不眠症	0	0	0	0	0
激越	0	0	0	1 (2.4)	0
注意欠陥多動性障害	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
落ち着きのなさ	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 34 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
睡眠障害	0	0	0	1 (2.4)	0
先天性、家族性および遺伝性障害0	0	1 (6.3)	0	1 (1.3)	
発育性股関節形成不全	0	0	0	0	1 (1.3)
斜指症	0	0	1 (6.3)	0	0
血液およびリンパ系障害	1 (5.9)	0	0	1 (2.4)	1 (1.3)
貧血	0	0	0	0	1 (1.3)
好中球減少症	1 (5.9)	0	0	0	0
骨髄障害	0	0	0	1 (2.4)	0
腎および尿路障害	0	0	0	0	1 (1.3)
尿閉	0	0	0	0	1 (1.3)
排尿困難	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (1.3)
耳の障害	0	0	0	0	1 (1.3)
生殖系および乳房障害	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 35 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
後天性包茎	0	0	0	0	1 (1.3)
神経系障害	0	0	2 (12.5)	1 (2.4)	0
脳梗塞	0	0	1 (6.3)	0	0
嗜眠	0	0	1 (6.3)	0	0
頭痛	0	0	0	0	0
失読症	0	0	0	0	0
失神寸前の状態	0	0	0	1 (2.4)	0
血管障害	1 (5.9)	0	1 (6.3)	0	0
高血圧	1 (5.9)	0	1 (6.3)	0	0
低血圧	0	0	0	0	0
免疫系障害	1 (5.9)	0	0	0	0
季節性アレルギー	1 (5.9)	0	0	0	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	0	0	0	0	
皮膚乳頭腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 36 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	0	2 (50.0)	7 (43.8)	27 (65.9)	44 (55.0)
呼吸器、胸郭および縦隔障害	0	2 (50.0)	7 (43.8)	24 (58.5)	37 (46.3)
呼吸不全	0	0	4 (25.0)	13 (31.7)	11 (13.8)
呼吸窮迫	0	0	2 (12.5)	10 (24.4)	11 (13.8)
急性呼吸不全	0	1 (25.0)	1 (6.3)	7 (17.1)	11 (13.8)
無気肺	0	0	1 (6.3)	2 (4.9)	6 (7.5)
低酸素症	0	0	2 (12.5)	1 (2.4)	3 (3.8)
誤嚥性肺炎	0	0	1 (6.3)	1 (2.4)	3 (3.8)
誤嚥	0	0	1 (6.3)	0	2 (2.5)
呼吸困難	0	0	0	1 (2.4)	2 (2.5)
呼吸停止	0	0	0	3 (7.3)	2 (2.5)
無呼吸	0	0	2 (12.5)	2 (4.9)	1 (1.3)
低換気	0	0	1 (6.3)	0	1 (1.3)
気胸	0	0	1 (6.3)	0	1 (1.3)
気管支分泌物貯留	0	0	0	2 (4.9)	1 (1.3)
慢性呼吸不全	0	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 37 of 41
Severity: SEVERE

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
呼吸障害	0	0	0	0	1 (1.3)
気縦隔症	0	0	1 (6.3)	0	0
窒息	0	1 (25.0)	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0
睡眠時無呼吸症候群	0	0	0	1 (2.4)	0
感染症および寄生虫症	0	0	6 (37.5)	13 (31.7)	25 (31.3)
肺炎	0	0	3 (18.8)	4 (9.8)	7 (8.8)
上気道感染	0	0	0	0	5 (6.3)
細気管支炎	0	0	1 (6.3)	1 (2.4)	4 (5.0)
ライノウイルス感染	0	0	1 (6.3)	3 (7.3)	3 (3.8)
気道感染	0	0	0	0	3 (3.8)
下気道感染	0	0	0	0	2 (2.5)
ＲＳウイルス細気管支炎	0	0	3 (7.3)	2 (2.5)	
細菌性肺炎	0	0	0	1 (2.4)	2 (2.5)
ウイルス性肺炎	0	0	1 (6.3)	1 (2.4)	1 (1.3)
細菌性気管炎	0	0	1 (6.3)	1 (2.4)	1 (1.3)
モラクセラ菌性肺炎	0	0	1 (6.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 38 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気管支炎	0	0	0	0	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
院内感染	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	0	0	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
敗血症	0	0	0	0	1 (1.3)
ブドウ球菌性敗血症	0	0	0	0	1 (1.3)
ウイルス性上気道感染	0	0	0	5 (12.2)	1 (1.3)
メタニューモウイルス感染	0	0	2 (12.5)	0	0
コロナウイルス感染	0	0	1 (6.3)	1 (2.4)	0
エンテロウイルス感染	0	0	1 (6.3)	0	0
ウイルス性下気道感染	0	0	1 (6.3)	0	0
ウイルス性気道感染	0	0	1 (6.3)	1 (2.4)	0
ブドウ球菌性菌血症	0	0	1 (6.3)	0	0
パラインフルエンザウイルス性肺炎	0	0	0	1 (2.4)	0
シュードモナス菌性肺炎	0	0	0	1 (2.4)	0
ウイルス感染	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 39 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
心臓障害	0	0	3 (18.8)	5 (12.2)	7 (8.8)
心肺停止	0	0	1 (6.3)	3 (7.3)	5 (6.3)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
徐脈	0	0	1 (6.3)	0	0
チアノーゼ	0	0	1 (6.3)	1 (2.4)	0
心膜気腫	0	0	1 (6.3)	0	0
胃腸障害	0	0	1 (6.3)	5 (12.2)	5 (6.3)
嚥下障害	0	0	0	4 (9.8)	4 (5.0)
胃炎	0	0	0	0	1 (1.3)
嘔吐	0	0	1 (6.3)	1 (2.4)	0
流涎過多	0	0	0	1 (2.4)	0
一般・全身障害および投与部位の状態	0	0	1 (6.3)	1 (2.4)	3 (3.8)
発熱	0	0	0	0	2 (2.5)
死亡	0	0	0	1 (2.4)	1 (1.3)
疼痛	0	0	1 (6.3)	0	0
穿刺部位疼痛	0	0	0	0	0
神経系障害	0	0	1 (6.3)	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 40 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
痙攣発作	0	0	1 (6.3)	0	1 (1.3)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
片頭痛	0	0	0	0	0
血管障害	0	0	0	0	2 (2.5)
高血圧	0	0	0	0	1 (1.3)
ショック	0	0	0	0	1 (1.3)
代謝および栄養障害	0	0	1 (6.3)	1 (2.4)	1 (1.3)
体重増加不良	0	0	0	1 (2.4)	1 (1.3)
低ナトリウム血症	0	0	1 (6.3)	0	0
筋骨格系および結合組織障害	0	1 (25.0)	0	0	1 (1.3)
胸郭変形	0	0	0	0	1 (1.3)
関節拘縮	0	1 (25.0)	0	0	0
筋肉痛	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 41 of 41
Severity: SEVERE

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
創離開	0	0	0	0	1 (1.3)
腰椎穿刺後症候群	0	0	0	0	0
大腿骨骨折	0	0	0	1 (2.4)	0
免疫系障害	0	0	0	0	1 (1.3)
薬物過敏症	0	0	0	0	1 (1.3)
臨床検査	0	0	0	3 (7.3)	1 (1.3)
酸素飽和度低下	0	0	0	2 (4.9)	1 (1.3)
レスピロウイルス検査陽性	0	0	0	1 (2.4)	0
皮膚および皮下組織障害	0	0	0	0	1 (1.3)
おむつ皮膚炎	0	0	0	0	1 (1.3)
外科および内科処置	0	0	0	0	1 (1.3)
機械的換気	0	0	0	0	1 (1.3)
精神障害	0	0	1 (6.3)	0	0
不安	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 14　Incidence of Adverse Events by severity - Later-onset

Incidence of Adverse Events by severity - Later-onset

Page 1 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	6 (100)	4 (66.7)	6 (100)	8 (80.0)	8 (100)	6 (75.0)
胃腸障害	3 (50.0)	3 (50.0)	1 (16.7)	0	2 (25.0)	2 (25.0)
便秘	2 (33.3)	1 (16.7)	0	0	0	0
嘔吐	1 (16.7)	2 (33.3)	0	0	1 (12.5)	1 (12.5)
胃食道逆流性疾患	0	0	0	0	0	0
生歯	0	0	0	0	0	0
下痢	0	0	0	0	1 (12.5)	0
放屁	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0
胃炎	0	0	0	0	0	0
血便排泄	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
腹部不快感	0	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0	0
乳児仙痛	0	0	0	0	0	0
乳児吐出	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
上部消化管出血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 2 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	9 (100)	9 (100)	3 (75.0)	12 (85.7)	46 (97.9)
胃腸障害	4 (44.4)	3 (33.3)	0	4 (28.6)	13 (27.7)
便秘	1 (11.1)	2 (22.2)	0	0	1 (2.1)
嘔吐	1 (11.1)	2 (22.2)	0	2 (14.3)	4 (8.5)
胃食道逆流性疾患	0	0	0	0	1 (2.1)
生歯	0	0	0	0	0
下痢	0	0	0	0	1 (2.1)
放屁	0	0	0	0	1 (2.1)
嚥下障害	0	0	0	0	0
胃炎	0	0	0	0	0
血便排泄	0	0	0	0	0
腹部膨満	0	0	0	0	0
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	1 (7.1)	2 (4.3)
乳児仙痛	0	0	0	0	0
乳児吐出	0	0	0	0	0
流涎過多	0	0	0	0	0
上部消化管出血	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 3 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
口唇のひび割れ	0	0	0	0	0	0
排便回数増加	0	0	0	0	0	0
腹痛	0	0	0	0	0	0
消化管運動低下	0	0	0	0	0	0
吐血	0	0	0	0	0	0
上腹部痛	0	0	0	0	0	0
悪心	1 (16.7)	2 (33.3)	0	0	2 (25.0)	0
口内炎	0	0	0	0	0	0
血性下痢	0	0	0	0	0	0
胃腸障害	0	0	1 (16.7)	0	0	0
口の感覚鈍麻	0	0	0	0	0	0
口唇痛	0	0	0	0	0	0
口腔内痛	0	0	0	0	0	1 (12.5)
感染症および寄生虫症	1 (16.7)	1 (16.7)	1 (16.7)	3 (30.0)	6 (75.0)	3 (37.5)
鼻咽頭炎	0	0	0	0	0	1 (12.5)
上気道感染	0	1 (16.7)	1 (16.7)	1 (10.0)	2 (25.0)	1 (12.5)
口腔カンジダ症	0	0	0	0	0	0
結膜炎	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 4 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
口唇のひび割れ	0	0	0	0	0
排便回数増加	0	0	0	0	0
腹痛	0	0	0	1 (7.1)	1 (2.1)
消化管運動低下	0	0	0	0	0
吐血	0	0	0	0	0
上腹部痛	0	0	0	0	2 (4.3)
悪心	1 (11.1)	0	0	1 (7.1)	1 (2.1)
口内炎	0	0	0	0	1 (2.1)
血性下痢	0	0	0	0	0
胃腸障害	0	0	0	0	0
口の感覚鈍麻	1 (11.1)	0	0	0	0
口唇痛	1 (11.1)	0	0	0	0
口腔内痛	0	0	0	0	0
感染症および寄生虫症	7 (77.8)	5 (55.6)	3 (75.0)	5 (35.7)	29 (61.7)
鼻咽頭炎	4 (44.4)	2 (22.2)	0	2 (14.3)	5 (10.6)
上気道感染	2 (22.2)	0	1 (25.0)	1 (7.1)	14 (29.8)
口腔カンジダ症	0	0	0	0	0
結膜炎	0	1 (11.1)	0	0	2 (4.3)
細気管支炎	0	0	0	0	0
気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 5 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ウイルス性気道感染	0	0	0	0	0	0
ウイルス感染	1 (16.7)	0	0	0	0	1 (12.5)
気道感染	0	0	0	0	0	0
肺炎	0	0	0	0	0	0
耳感染	0	0	0	1 (10.0)	0	0
中耳炎	0	0	0	0	2 (25.0)	0
皮膚真菌感染	0	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0	0
鼻炎	0	0	0	0	1 (12.5)	0
皮膚カンジダ	0	0	0	0	0	0
手足口病	0	0	0	0	0	0
限局性感染	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0
細菌感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
蜂巣炎	0	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0	0
感染性湿疹	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 6 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ウイルス性気道感染	0	0	0	0	0
ウイルス感染	1 (11.1)	0	0	0	4 (8.5)
気道感染	0	0	0	0	0
肺炎	0	0	0	0	2 (4.3)
耳感染	1 (11.1)	0	0	0	2 (4.3)
中耳炎	0	0	1 (25.0)	1 (7.1)	1 (2.1)
皮膚真菌感染	0	0	0	0	1 (2.1)
ウイルス性上気道感染	2 (22.2)	0	0	0	1 (2.1)
ライノウイルス感染	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
鼻炎	0	0	0	0	0
皮膚カンジダ	0	0	0	0	2 (4.3)
手足口病	0	0	0	0	1 (2.1)
限局性感染	2 (22.2)	0	0	0	1 (2.1)
尿路感染	1 (11.1)	0	0	0	1 (2.1)
細菌感染	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0
蜂巣炎	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0
感染性湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 7 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
眼感染	0	0	0	0	0	0
膿痂疹	0	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0	0
ばら疹	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
胃腸炎	0	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0	0
細菌性気管炎	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
伝染性紅斑	0	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0	0
細菌性気道感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	1 (10.0)	3 (37.5)	0
皮膚感染	0	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0	0
インフルエンザ	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 8 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
眼感染	0	0	0	0	0
膿痂疹	0	1 (11.1)	0	0	0
口腔ヘルペス	0	0	0	0	0
ばら疹	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
胃腸炎	0	0	0	0	2 (4.3)
細菌性疾患キャリアー	0	0	0	0	0
細菌性気管炎	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
細菌性気道感染	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
ウイルス性胃腸炎	1 (11.1)	0	1 (25.0)	0	4 (8.5)
レンサ球菌性咽頭炎	0	0	1 (25.0)	0	1 (2.1)
皮膚感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	1 (2.1)
ウイルス性消化管感染	1 (11.1)	0	0	0	1 (2.1)
インフルエンザ	0	1 (11.1)	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 9 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
伝染性軟属腫	0	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0	0
カンジダ感染	0	0	0	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0	0
真菌感染	0	0	0	0	0	0
麦粒腫	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0	0
急性中耳炎	0	0	0	0	0	0
咽頭炎	0	0	0	0	0	0
シュードモナス感染	0	0	0	0	0	0
副鼻腔炎	0	0	0	1 (10.0)	0	1 (12.5)
皮膚細菌感染	0	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0	0
ストーマ部感染	0	0	0	0	0	0
扁桃炎	0	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	1 (10.0)	2 (25.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 10 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
伝染性軟属腫	0	0	0	0	1 (2.1)
ウイルス性扁桃炎	0	0	0	0	1 (2.1)
外陰腟真菌感染	0	0	0	0	1 (2.1)
カンジダ感染	0	0	0	0	0
ブドウ球菌性眼感染	0	1 (11.1)	0	0	0
真菌感染	0	0	0	0	0
麦粒腫	0	0	0	0	0
下気道感染	0	0	0	0	0
単核細胞症症候群	0	0	1 (25.0)	0	0
急性中耳炎	0	0	0	1 (7.1)	0
咽頭炎	0	0	0	1 (7.1)	0
シュードモナス感染	0	0	0	0	0
副鼻腔炎	1 (11.1)	0	0	0	0
皮膚細菌感染	0	1 (11.1)	0	0	0
ブドウ球菌感染	0	0	0	0	0
ストーマ部感染	0	0	0	0	0
扁桃炎	0	0	1 (25.0)	0	0
ウイルス性発疹	0	0	0	0	0
呼吸器、胸郭および縦隔障害	3 (33.3)	2 (22.2)	1 (25.0)	3 (21.4)	16 (34.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 11 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
鼻閉	0	0	0	0	1 (12.5)	0
上気道うっ血	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
咳嗽	0	0	0	0	0	0
鼻漏	0	0	0	0	1 (12.5)	0
副鼻腔うっ血	0	0	0	1 (10.0)	0	0
無気肺	0	0	0	0	0	0
上気道分泌増加	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
呼吸窮迫	0	0	0	0	0	0
息詰まり	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0	0
喘鳴	0	0	0	0	0	0
気管支閉塞	0	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0	0
肺水腫	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
肺うっ血	0	0	0	0	0	0
無呼吸発作	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 12 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
鼻閉	0	0	0	1 (7.1)	1 (2.1)
上気道うっ血	0	0	0	0	0
呼吸困難	0	0	0	0	0
咳嗽	0	1 (11.1)	0	0	4 (8.5)
鼻漏	1 (11.1)	1 (11.1)	0	0	3 (6.4)
副鼻腔うっ血	0	0	0	0	1 (2.1)
無気肺	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
低酸素症	0	0	0	0	0
呼吸窮迫	0	0	0	0	0
息詰まり	0	0	0	0	0
呼吸不全	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
喘鳴	0	0	0	0	0
気管支閉塞	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
肺水腫	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
肺うっ血	0	0	0	0	1 (2.1)
無呼吸発作	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 13 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
鼻汁変色	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
湿性咳嗽	0	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0	0
頻呼吸	0	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0	0
口腔咽頭痛	0	0	0	0	1 (12.5)	0
鼻出血	0	0	0	0	0	0
扁桃肥大	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
発声障害	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
上気道の炎症	0	0	0	0	0	0
一般・全身障害および投与部位の状態	2 (33.3)	0	1 (16.7)	3 (30.0)	3 (37.5)	3 (37.5)
発熱	1 (16.7)	0	1 (16.7)	2 (20.0)	0	0
カテーテル留置部位炎症	0	0	0	0	0	0
泣き	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 14 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
鼻汁変色	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
口腔咽頭痛	1 (11.1)	1 (11.1)	0	0	6 (12.8)
鼻出血	1 (11.1)	0	0	0	2 (4.3)
扁桃肥大	0	0	1 (25.0)	1 (7.1)	1 (2.1)
誤嚥	0	0	0	0	0
発声障害	0	0	0	1 (7.1)	0
気道うっ血	0	0	0	0	0
上気道の炎症	0	0	0	0	0
一般・全身障害および投与部位の状態	5 (55.6)	5 (55.6)	0	0	11 (23.4)
発熱	0	3 (33.3)	0	0	8 (17.0)
カテーテル留置部位炎症	0	0	0	0	0
泣き	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 15 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
薬物不耐性	0	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0	0
小結節	0	0	0	0	0	0
腫脹	0	0	0	0	0	0
不快感	0	0	0	0	0	0
末梢性浮腫	0	0	0	0	0	0
医療機器リーク	0	0	0	0	0	0
浮腫	0	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0	1 (12.5)
末梢腫脹	0	0	0	0	0	0
適用部位紅斑	0	0	0	0	0	0
注入部位内出血	0	0	0	0	0	0
疼痛	0	0	0	0	0	0
注射部位出血	0	0	0	0	0	0
注射部位疼痛	0	0	0	0	0	0
適用部位発疹	0	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0	1 (12.5)
カテーテル留置部位疼痛	0	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	1 (12.5)	0
胸部不快感	0	0	0	0	1 (12.5)	0
悪寒	0	0	0	0	0	1 (12.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 16 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
薬物不耐性	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0
小結節	0	0	0	0	0
腫脹	0	0	0	0	0
不快感	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
医療機器リーク	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	1 (11.1)	0	0	0	0
適用部位紅斑	0	0	0	0	0
注入部位内出血	0	0	0	0	0
疼痛	0	0	0	0	2 (4.3)
注射部位出血	0	0	0	0	1 (2.1)
注射部位疼痛	0	0	0	0	1 (2.1)
適用部位発疹	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	1 (11.1)	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 17 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
医療機器機能不良	0	0	0	0	0	0
医療機器閉塞	0	0	0	0	0	0
疲労	0	0	0	0	1 (12.5)	0
冷感	0	0	0	0	0	0
重力性浮腫	0	0	0	0	0	1 (12.5)
低体温	1 (16.7)	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0	0
注射部位血腫	0	0	0	0	0	0
穿刺部位疼痛	1 (16.7)	0	0	1 (10.0)	0	2 (25.0)
穿刺部位反応	1 (16.7)	0	0	0	0	0
皮膚および皮下組織障害	1 (16.7)	0	1 (16.7)	1 (10.0)	0	0
発疹	0	0	0	1 (10.0)	0	0
おむつ皮膚炎	0	0	0	0	0	0
斑状出血	0	0	0	0	0	0
接触性皮膚炎	0	0	0	0	0	0
過角化	0	0	0	0	0	0
汗疹	0	0	1 (16.7)	0	0	0
湿疹	1 (16.7)	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
紅斑	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 18 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
医療機器機能不良	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
疲労	1 (11.1)	0	0	0	0
冷感	1 (11.1)	0	0	0	0
重力性浮腫	0	0	0	0	0
低体温	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
穿刺部位疼痛	3 (33.3)	2 (22.2)	0	0	0
穿刺部位反応	0	0	0	0	0
皮膚および皮下組織障害	1 (11.1)	0	0	0	13 (27.7)
発疹	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	1 (2.1)
斑状出血	0	0	0	0	0
接触性皮膚炎	0	0	0	0	3 (6.4)
過角化	0	0	0	0	0
汗疹	0	0	0	0	0
湿疹	0	0	0	0	1 (2.1)
皮膚炎	0	0	0	0	1 (2.1)
紅斑	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 19 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
蕁麻疹	0	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0	0
環状肉芽腫	0	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0	0
皮膚浮腫	0	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0	0
皮膚刺激	0	0	0	0	0	0
脱毛症	0	0	0	0	0	0
点状出血	0	0	0	0	0	0
そう痒症	0	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0	0
皮膚障害	0	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0	0
ざ瘡	0	0	0	0	0	0
水疱	0	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0	0
毛孔性角化症	0	0	0	0	0	0
皮膚病変	0	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0	0
皮膚乾燥	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 20 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
蕁麻疹	0	0	0	0	1 (2.1)
アレルギー性皮膚炎	0	0	0	0	0
環状肉芽腫	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
皮膚刺激	0	0	0	0	0
脱毛症	0	0	0	0	0
点状出血	0	0	0	0	0
そう痒症	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮膚障害	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0
ざ瘡	0	0	0	0	1 (2.1)
水疱	0	0	0	0	1 (2.1)
褥瘡性潰瘍	0	0	0	0	1 (2.1)
毛孔性角化症	0	0	0	0	1 (2.1)
皮膚病変	0	0	0	0	1 (2.1)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 21 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
多汗症	0	0	0	0	0	0
寝汗	0	0	0	0	0	0
臨床検査	0	1 (16.7)	0	0	0	0
体重減少	0	0	0	0	0	0
体温上昇	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
心拍数増加	0	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0	0
血中鉄減少	0	0	0	0	0	0
血中カリウム減少	0	0	0	0	0	0
体温低下	0	0	0	0	0	0
心拍数不整	0	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0	0
A型インフルエンザウイルス検査陽性	0	0	0	0	0	0
医学的観察	0	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0	0
尿量減少	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 22 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
多汗症	0	0	0	0	0
寝汗	1 (11.1)	0	0	0	0
臨床検査	2 (22.2)	0	1 (25.0)	0	3 (6.4)
体重減少	1 (11.1)	0	0	0	1 (2.1)
体温上昇	0	0	1 (25.0)	0	0
酸素飽和度低下	0	0	0	0	0
心拍数増加	0	0	0	0	1 (2.1)
モラクセラ検査陽性	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
A型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 23 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ビタミンA減少	0	0	0	0	0	0
骨密度減少	0	0	0	0	0	0
呼吸音異常	0	0	0	0	0	0
心拍数減少	0	0	0	0	0	0
好中球数増加	0	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
血中テストステロン減少	0	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0	0
心電図ＳＴ－Ｔ部分下降	0	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0	0
リンパ節触知	0	0	0	0	0	0
呼吸数増加	0	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0	0
尿検査異常	0	1 (16.7)	0	0	0	0
ビタミンD減少	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 24 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ビタミンA減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
好中球数増加	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
血中テストステロン減少	0	0	0	0	1 (2.1)
ＣＳＦ白血球数増加	0	0	0	0	1 (2.1)
血中重炭酸塩減少	1 (11.1)	0	0	0	0
心電図ＳＴ－Ｔ部分下降	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
呼吸数増加	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
尿検査異常	0	0	0	0	0
ビタミンD減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 25 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
傷害、中毒および処置合併症	(16.7)	2 (33.3)	3 (50.0)	1 (10.0)	4 (50.0)	1 (12.5)
ストーマ部紅斑	0	0	0	0	0	0
処置による疼痛	0	0	0	0	0	0
挫傷	0	0	0	0	0	0
処置後腫脹	0	0	0	0	0	0
術後激越	0	0	0	0	0	0
伝染病曝露	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
処置合併症	0	0	0	0	0	0
処置部位反応	0	0	0	0	0	0
ストーマ合併症	0	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0	0
節足動物咬傷	0	0	0	0	0	1 (12.5)
関節脱臼	0	0	0	0	0	0
ダンピング症候群	0	0	0	0	0	0
耳擦過傷	0	0	0	0	0	0
軟部組織損傷	0	0	0	0	0	0
サンバーン	0	0	0	0	1 (12.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 26 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
傷害、中毒および処置合併症	5 (55.6)	4 (44.4)	2 (50.0)	3 (21.4)	14 (29.8)
ストーマ部紅斑	0	0	0	0	0
処置による疼痛	0	0	0	1 (7.1)	3 (6.4)
挫傷	0	0	0	0	1 (2.1)
処置後腫脹	0	0	0	0	0
術後激越	1 (11.1)	0	0	0	0
伝染病曝露	0	0	0	0	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ストーマ合併症	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0
節足動物咬傷	2 (22.2)	0	0	0	1 (2.1)
関節脱臼	0	0	0	0	1 (2.1)
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
軟部組織損傷	0	0	0	0	0
サンバーン	0	1 (11.1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 27 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
熱傷	0	0	0	0	0	0
転倒	0	0	0	0	0	0
処置後合併症	0	0	0	0	0	0
処置後不快感	0	0	0	0	0	0
腰椎穿刺後症候群	0	2 (33.3)	2 (33.3)	1 (10.0)	2 (25.0)	0
裂傷	0	0	1 (16.7)	0	1 (12.5)	0
節足動物刺傷	0	0	0	0	0	0
靭帯捻挫	0	0	0	0	0	0
四肢損傷	0	0	0	0	1 (12.5)	0
擦過傷	0	0	0	0	0	0
頭部損傷	0	0	0	0	0	0
関節損傷	0	0	0	0	0	0
肉離れ	0	0	0	0	0	0
処置後挫傷	0	0	0	0	0	0
処置による頭痛	0	0	0	0	0	0
処置による悪心	1 (16.7)	0	0	0	0	0
ストーマ部出血	0	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0	0
脛骨骨折	0	0	0	0	0	0
気管損傷	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 28 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
熱傷	1 (11.1)	0	0	0	0
転倒	0	0	0	0	1 (2.1)
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
腰椎穿刺後症候群	1 (11.1)	4 (44.4)	0	1 (7.1)	7 (14.9)
裂傷	1 (11.1)	1 (11.1)	0	0	2 (4.3)
節足動物刺傷	0	0	0	0	1 (2.1)
靭帯捻挫	0	0	0	0	1 (2.1)
四肢損傷	0	0	0	0	1 (2.1)
擦過傷	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節損傷	0	0	1 (25.0)	0	0
肉離れ	0	0	1 (25.0)	0	0
処置後挫傷	0	0	0	0	0
処置による頭痛	0	0	0	1 (7.1)	0
処置による悪心	0	0	0	1 (7.1)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
脛骨骨折	1 (11.1)	0	0	0	0
気管損傷	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 29 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
筋骨格系および結合組織障害	3 (50.0)	2 (33.3)	0	2 (20.0)	1 (12.5)	3 (37.5)
側弯症	0	0	0	1 (10.0)	0	0
頭位性斜頭症	0	0	0	0	0	0
関節拘縮	0	0	0	0	0	1 (12.5)
背部痛	2 (33.3)	2 (33.3)	0	1 (10.0)	1 (12.5)	1 (12.5)
四肢痛	0	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0	0
胸郭変形	0	0	0	0	0	0
脊柱後弯症	0	0	0	0	0	0
斜頚	0	0	0	0	0	0
手変形	0	0	0	0	0	0
関節硬直	0	0	0	0	0	0
後側弯症	0	0	0	0	0	0
脊柱前弯症	0	0	0	1 (10.0)	0	0
脊柱変形	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
体重支持困難	0	0	0	0	0	0
関節痛	0	0	0	0	0	1 (12.5)
筋緊張	0	0	0	0	0	0
筋肉痛	1 (16.7)	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 30 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
筋骨格系および結合組織障害	1 (11.1)	7 (77.8)	2 (50.0)	2 (14.3)	26 (55.3)
側弯症	1 (11.1)	1 (11.1)	1 (25.0)	1 (7.1)	6 (12.8)
頭位性斜頭症	0	0	0	0	0
関節拘縮	0	1 (11.1)	0	0	7 (14.9)
背部痛	1 (11.1)	4 (44.4)	1 (25.0)	1 (7.1)	12 (25.5)
四肢痛	0	1 (11.1)	0	1 (7.1)	1 (2.1)
泉門閉鎖遅延	0	0	0	0	0
胸郭変形	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
斜頚	0	0	0	0	0
手変形	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
脊柱変形	0	0	0	0	0
筋力低下	0	0	0	0	0
体重支持困難	0	0	0	0	0
関節痛	0	1 (11.1)	0	0	2 (4.3)
筋緊張	0	0	0	0	2 (4.3)
筋肉痛	0	0	0	0	2 (4.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 31 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
頚部痛	0	0	0	0	0	0
四肢拘縮	0	0	0	0	0	0
骨盤変形	0	0	0	0	0	1 (12.5)
腱障害	0	0	0	0	0	0
精神障害	1 (16.7)	0	0	0	1 (12.5)	0
激越	0	0	0	0	1 (12.5)	0
易刺激性	0	0	0	0	0	0
不安	0	0	0	0	0	0
息こらえ	0	0	0	0	0	0
気分動揺	0	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0	0
睡眠障害	0	0	0	0	0	0
チック	0	0	0	0	0	0
不快気分	0	0	0	0	1 (12.5)	0
心因性嘔吐	1 (16.7)	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
脱水	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 32 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
頚部痛	0	1 (11.1)	0	0	2 (4.3)
四肢拘縮	0	0	0	0	1 (2.1)
骨盤変形	0	0	0	0	1 (2.1)
腱障害	0	0	0	0	0
精神障害	0	0	0	0	1 (2.1)
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
チック	0	0	0	0	1 (2.1)
不快気分	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
代謝および栄養障害	0	1 (11.1)	0	0	3 (6.4)
成長障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
脱水	0	1 (11.1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 33 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
栄養補給不耐性	0	0	0	0	0	0
鉄欠乏	0	0	0	0	0	0
過小食	0	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0	0
食欲減退	0	0	0	0	0	0
食欲亢進	0	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
小児期						
食物不耐性	0	0	0	0	0	0
高血糖	0	0	0	0	0	0
低血糖	0	0	0	0	0	0
神経系障害	3 (50.0)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
眼振	0	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0	0
よだれ	0	0	0	0	0	0
間代	0	0	0	0	0	0
傾眠	0	0	0	0	0	0
失神	0	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 34 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
栄養補給不耐性	0	0	0	0	0
鉄欠乏	0	0	0	0	0
過小食	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0
食欲減退	0	0	0	0	1 (2.1)
食欲亢進	0	0	0	0	1 (2.1)
ビタミンD欠乏	0	0	0	0	1 (2.1)
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
神経系障害	2 (22.2)	0	0	3 (21.4)	12 (25.5)
眼振	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0
よだれ	0	0	0	0	0
間代	0	0	0	0	0
傾眠	0	0	0	0	0
失神	0	0	0	0	1 (2.1)
脳脊髄液漏	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 35 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
頭痛	3 (50.0)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
反射亢進	0	0	0	0	0	0
筋緊張低下	0	0	0	0	0	0
失声症	0	0	0	0	0	0
感覚鈍麻	0	0	0	0	0	1 (12.5)
振戦	0	0	0	0	0	0
味覚異常	0	0	0	0	0	0
錯感覚	1 (16.7)	0	0	0	0	1 (12.5)
心臓障害	0	1 (16.7)	0	0	1 (12.5)	0
頻脈	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
左室肥大	0	0	0	0	0	0
上室性頻脈	0	0	0	0	0	0
心筋症	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
動悸	0	1 (16.7)	0	0	1 (12.5)	0
免疫系障害	0	0	0	0	1 (12.5)	0
季節性アレルギー	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 36 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
頭痛	1 (11.1)	0	0	3 (21.4)	9 (19.1)
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
失声症	0	0	0	0	1 (2.1)
感覚鈍麻	0	0	0	0	1 (2.1)
振戦	0	0	0	0	1 (2.1)
味覚異常	1 (11.1)	0	0	0	0
錯感覚	0	0	0	0	0
心臓障害	0	0	1 (25.0)	0	1 (2.1)
頻脈	0	0	0	0	1 (2.1)
徐脈	0	0	0	0	0
チアノーゼ	0	0	0	0	0
左室肥大	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
心室性頻脈	0	0	0	0	0
動悸	0	0	1 (25.0)	0	0
免疫系障害	0	2 (22.2)	1 (25.0)	0	2 (4.3)
季節性アレルギー	0	1 (11.1)	1 (25.0)	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 37 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
薬物過敏症	0	0	0	0	0	0
過敏症	0	0	0	0	1 (12.5)	0
食物アレルギー	0	0	0	0	0	0
眼障害	0	0	0	0	0	0
霰粒腫	0	0	0	0	0	0
眼乾燥	0	0	0	0	0	0
眼運動障害	0	0	0	0	0	0
近視	0	0	0	0	0	0
斜視	0	0	0	0	0	0
眼瞼下垂	0	0	0	0	0	0
乱視	0	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0	0
遠視	0	0	0	0	0	0
弱視	0	0	0	0	0	0
流涙増加	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
蒼白	0	0	0	0	0	0
血管炎	0	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 38 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
薬物過敏症	0	0	0	0	0
過敏症	0	1 (11.1)	0	0	1 (2.1)
食物アレルギー	0	0	0	0	0
眼障害	1 (11.1)	0	0	0	1 (2.1)
霰粒腫	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼運動障害	0	0	0	0	0
近視	0	0	0	0	0
斜視	1 (11.1)	0	0	0	0
眼瞼下垂	0	0	0	0	0
乱視	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
遠視	0	0	0	0	1 (2.1)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0
血管障害	0	0	0	0	0
蒼白	0	0	0	0	0
血管炎	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 39 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
本態性高血圧症	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
貧血母斑	0	0	0	0	0	0
鳩胸	0	0	0	0	0	0
斜頭症	0	0	0	0	0	0
停留精巣	0	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0	0
包茎	0	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0	0
陰茎障害	0	0	0	0	0	0
耳および迷路障害	1 (16.7)	0	0	0	1 (12.5)	0
耳痛	0	0	0	0	1 (12.5)	0
耳垢分泌過多	0	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0	0
乗物酔い	1 (16.7)	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 40 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
本態性高血圧症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0
貧血母斑	0	0	0	0	0
鳩胸	0	0	0	0	0
斜頭症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
包茎	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (2.1)
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0
鼓膜穿孔	0	0	0	0	1 (2.1)
乗物酔い	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 41 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
腎および尿路障害	0	0	0	0	0	0
水腎症	0	0	0	0	0	0
尿失禁	0	0	0	0	0	0
糖尿	0	0	0	0	0	0
肝胆道系障害	0	0	0	0	0	0
肝腫大	0	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0	0
貧血	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
血小板増加症	0	0	0	0	0	0
リンパ節症	0	0	0	0	0	0
好酸球増加症	0	0	0	0	0	0
白血球増加症	0	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0	0
アクロコルドン	0	0	0	0	0	0
血管の良性新生物	0	0	0	0	0	0
脂漏性角化症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 42 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
腎および尿路障害	0	0	0	0	1 (2.1)
水腎症	0	0	0	0	0
尿失禁	0	0	0	0	1 (2.1)
糖尿	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	1 (2.1)
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	1 (2.1)
血小板増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
アクロコルドン	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 43 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
妊娠、産褥および周産期の状態	0	0	0	0	0	0
臍肉芽腫	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 44 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 45 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	2 (33.3)	1 (16.7)	1 (16.7)	1 (10.0)	6 (75.0)	3 (37.5)
感染症および寄生虫症	0	0	0	1 (10.0)	2 (25.0)	1 (12.5)
肺炎	0	0	0	0	1 (12.5)	0
ウイルス性上気道感染	0	0	0	0	0	1 (12.5)
上気道感染	0	0	0	0	0	0
ウイルス感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0	0
鼻咽頭炎	0	0	0	0	0	0
気道感染	0	0	0	0	0	0
インフルエンザ	0	0	0	0	0	0
耳感染	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0	0
結膜炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 46 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	3 (33.3)	4 (44.4)	0	6 (42.9)	29 (61.7)
感染症および寄生虫症	0	2 (22.2)	0	3 (21.4)	18 (38.3)
肺炎	0	0	0	0	1 (2.1)
ウイルス性上気道感染	0	0	0	1 (2.1)	
上気道感染	0	1 (11.1)	0	1 (7.1)	5 (10.6)
ウイルス感染	0	0	0	0	3 (6.4)
ウイルス性肺炎	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0
鼻咽頭炎	0	1 (11.1)	0	0	2 (4.3)
気道感染	0	0	0	0	1 (2.1)
インフルエンザ	0	0	0	0	1 (2.1)
耳感染	0	0	0	0	0
尿路感染	0	0	0	1 (7.1)	1 (2.1)
アデノウイルス感染	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0
結膜炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 47 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
下気道感染	0	0	0	0	0	0
細菌性肺炎	0	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0
胃腸炎	0	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0	0
真菌感染	0	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0	0
口腔カンジダ症	0	0	0	0	0	0
急性中耳炎	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
シュードモナス感染	0	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
中耳炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 48 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
下気道感染	0	0	0	0	0
細菌性肺炎	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0
気管支炎	0	0	0	0	0
胃腸炎	0	0	0	1 (7.1)	4 (8.5)
ウイルス性胃腸炎	0	0	0	0	2 (4.3)
ウイルス性気道感染	0	0	0	0	1 (2.1)
ウイルス性気管支炎	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0
真菌感染	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
口腔カンジダ症	0	0	0	0	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
細気管支炎	0	0	0	0	0
中耳炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 49 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
パラインフルエンザウイルス感染	0	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0	0
感染						
細菌感染	0	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0	0
手足口病	0	0	0	0	0	0
モラクセラ感染	0	0	0	0	0	0
鼻炎	0	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0	0
気管炎	0	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	1 (10.0)	0	0
膿痂疹	0	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	1 (12.5)	0
蜂巣炎	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
腟感染	0	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0	0
細菌性気管炎	0	0	0	0	0	0
カンジダ感染	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
細菌性気道感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 50 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
パラインフルエンザウイルス感染	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
細菌感染	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
鼻炎	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
気管炎	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	0	2 (4.3)
膿痂疹	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	2 (4.3)
蜂巣炎	0	0	0	0	1 (2.1)
ＲＳウイルス肺炎	0	0	0	0	1 (2.1)
腟感染	0	0	0	0	1 (2.1)
細菌性疾患キャリアー	0	0	0	0	0
細菌性気管炎	0	0	0	0	0
カンジダ感染	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
細菌性気道感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 51 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
セラチア感染	0	0	0	0	0	0
ストーマ部感染	0	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	0	1 (12.5)	1 (12.5)
呼吸窮迫	0	0	0	0	0	0
無気肺	0	0	0	0	1 (12.5)	0
呼吸不全	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
咳嗽	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
上気道分泌増加	0	0	0	0	0	0
呼吸停止	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
減呼吸	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 52 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
セラチア感染	0	0	0	0	0
ストーマ部感染	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	1 (7.1)	4 (8.5)
呼吸窮迫	0	0	0	0	0
無気肺	0	0	0	0	0
呼吸不全	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0
無呼吸	0	0	0	0	0
咳嗽	0	0	0	0	1 (2.1)
気管支分泌物貯留	0	0	0	0	0
誤嚥	0	0	0	0	0
低酸素症	0	0	0	0	2 (4.3)
慢性呼吸不全	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
呼吸停止	0	0	0	0	0
呼吸障害	0	0	0	0	1 (2.1)
急性呼吸窮迫症候群	0	0	0	0	0
呼吸困難	0	0	0	0	0
減呼吸	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 53 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
低換気	0	0	0	0	0	0
気管支分泌増加	0	0	0	0	0	0
胸水	0	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
鼻漏	0	0	0	0	0	0
変色痰	0	0	0	0	0	0
急性呼吸不全	0	0	0	0	0	0
喘鳴	0	0	0	0	0	1 (12.5)
喉頭肉芽腫	0	0	0	0	0	0
鼻閉	0	0	0	0	0	0
気胸	0	0	0	0	0	0
肺うっ血	0	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0	0
気管障害	0	0	0	0	0	0
上気道うっ血	0	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0	0
カタル	0	0	0	0	0	0
息詰まり	0	0	0	0	0	0
鼻出血	0	0	0	0	1 (12.5)	0
肺臓炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 54 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
低換気	0	0	0	0	0
気管支分泌増加	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
鼻漏	0	0	0	0	0
変色痰	0	0	0	0	0
急性呼吸不全	0	0	0	0	1 (2.1)
喘鳴	0	0	0	0	1 (2.1)
喉頭肉芽腫	0	0	0	0	0
鼻閉	0	0	0	0	0
気胸	0	0	0	0	0
肺うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0
気管障害	0	0	0	0	0
上気道うっ血	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
カタル	0	0	0	0	0
息詰まり	0	0	0	0	0
鼻出血	0	0	0	0	0
肺臓炎	0	0	0	1 (7.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 55 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
拘束性肺疾患	0	0	0	0	0	1 (12.5)
睡眠時無呼吸症候群	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	1 (12.5)
発熱	0	0	0	0	0	0
疼痛	0	0	0	0	0	1 (12.5)
低体温	0	0	0	0	0	0
倦怠感	0	0	0	0	0	0
医療機器閉塞	0	0	0	0	0	0
疲労	0	0	0	0	0	0
注入部位内出血	0	0	0	0	0	0
浮腫	0	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
生歯	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
便秘	0	0	0	0	0	0
胃食道逆流性疾患	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 56 of 82
Severity: MODERATE

Later-onset SMA

	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
拘束性肺疾患	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	4 (8.5)
発熱	0	0	0	0	3 (6.4)
疼痛	0	0	0	0	0
低体温	0	0	0	0	0
倦怠感	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
疲労	0	0	0	0	1 (2.1)
注入部位内出血	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0
胃腸障害	3 (33.3)	0	0	1 (7.1)	3 (6.4)
生歯	0	0	0	0	0
嘔吐	1 (11.1)	0	0	0	1 (2.1)
流涎過多	0	0	0	0	0
便秘	1 (11.1)	0	0	1 (7.1)	0
胃食道逆流性疾患	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 57 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
嚥下障害	0	0	0	0	0	0
下痢	0	0	0	0	0	0
胃出血	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
悪心	0	0	0	0	0	0
腹部症状	0	0	0	0	0	0
口腔内痛	0	0	0	0	0	0
腹部不快感	0	0	0	0	0	0
食中毒	0	0	0	0	0	0
胃腸出血	0	0	0	0	0	0
消化管刺激症状	0	0	0	0	0	0
臨床検査	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0	0
好中球数増加	0	0	0	0	0	0
体重減少	0	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
血中クロール減少	0	0	0	0	0	0
血中カリウム減少	0	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 58 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
嚥下障害	0	0	0	0	0
下痢	0	0	0	0	0
胃出血	0	0	0	0	0
腹部膨満	0	0	0	0	0
悪心	1 (11.1)	0	0	0	2 (4.3)
腹部症状	0	0	0	0	1 (2.1)
口腔内痛	0	0	0	0	1 (2.1)
腹部不快感	1 (11.1)	0	0	0	0
食中毒	1 (11.1)	0	0	0	0
胃腸出血	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
臨床検査	0	0	0	0	1 (2.1)
酸素飽和度低下	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0
好中球数増加	0	0	0	0	0
体重減少	0	0	0	0	1 (2.1)
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 59 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0	0
肝機能検査異常	0	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0	0
白血球数増加	0	0	0	0	0	0
好中球百分率増加	0	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0	0
心臓障害	0	0	0	0	0	0
頻脈	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
代謝および栄養障害	0	1 (16.7)	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 60 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
白血球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
心臓障害	0	0	0	0	0
頻脈	0	0	0	0	0
徐脈	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心室性頻脈	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 61 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
過小食	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
脱水	0	1 (16.7)	0	0	0	0
低血糖	0	0	0	0	0	0
低カリウム血症	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	1 (16.7)	0	1 (12.5)	2 (25.0)
関節拘縮	0	0	0	0	0	0
側弯症	0	0	0	0	1 (12.5)	1 (12.5)
脊柱後弯症	0	0	0	0	0	0
後側弯症	0	0	0	0	0	0
四肢痛	0	0	1 (16.7)	0	0	0
滑膜炎	0	0	0	0	0	0
斜頚	0	0	0	0	0	0
背部痛	0	0	0	0	0	1 (12.5)
関節痛	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
頭位性斜頭症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 62 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
過小食	0	0	0	0	0
成長障害	0	0	0	0	0
脱水	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
筋骨格系および結合組織障害	2 (22.2)	0	0	1 (7.1)	10 (21.3)
関節拘縮	1 (11.1)	0	0	0	0
側弯症	0	0	0	0	3 (6.4)
脊柱後弯症	0	0	0	0	0
後側弯症	0	0	0	0	0
四肢痛	0	0	0	0	2 (4.3)
滑膜炎	0	0	0	0	0
斜頚	0	0	0	0	0
背部痛	1 (11.1)	0	0	1 (7.1)	6 (12.8)
関節痛	0	0	0	0	2 (4.3)
筋力低下	0	0	0	0	0
頭位性斜頭症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 63 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
傷害、中毒および処置合併症	1 (16.7)	0	0	0	2 (25.0)	1 (12.5)
大腿骨骨折	0	0	0	0	0	0
処置による疼痛	0	0	0	0	1 (12.5)	1 (12.5)
麻酔からの覚醒遅延	0	0	0	0	0	0
擦過傷	0	0	0	0	0	0
関節脱臼	0	0	0	0	0	0
節足動物咬傷	0	0	0	0	0	0
口唇損傷	0	0	0	0	0	0
外傷性気胸	0	0	0	0	0	0
歯牙損傷	0	0	0	0	0	0
硬膜下血腫	0	0	0	0	0	0
腰椎穿刺後症候群	1 (16.7)	0	0	0	1 (12.5)	1 (12.5)
術後激越	0	0	0	0	0	0
挫傷	0	0	0	0	0	0
関節損傷	0	0	0	0	0	0
裂傷	0	0	0	0	0	0
四肢損傷	0	0	0	0	0	0
下肢骨折	0	0	0	0	0	0
半月板損傷	0	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 64 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
傷害、中毒および処置合併症	2 (22.2)	3 (33.3)	0	2 (14.3)	10 (21.3)
大腿骨骨折	0	1 (11.1)	0	0	2 (4.3)
処置による疼痛	0	0	0	0	1 (2.1)
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
関節脱臼	0	0	0	0	1 (2.1)
節足動物咬傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
歯牙損傷	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
腰椎穿刺後症候群	2 (22.2)	2 (22.2)	0	0	2 (4.3)
術後激越	0	0	0	0	1 (2.1)
挫傷	0	0	0	0	1 (2.1)
関節損傷	0	0	0	1 (7.1)	1 (2.1)
裂傷	0	0	0	0	1 (2.1)
四肢損傷	0	0	0	0	1 (2.1)
下肢骨折	0	0	0	0	1 (2.1)
半月板損傷	0	0	0	0	1 (2.1)
気管内挿管合併症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 65 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
頭部損傷	0	0	0	0	0	0
術後イレウス	0	0	0	0	1 (12.5)	0
隆起骨折	0	0	0	0	0	1 (12.5)
皮膚および皮下組織障害	0	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0	0
発疹	0	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
皮下気腫	0	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0	0
湿疹	0	0	0	0	0	0
精神障害	0	0	0	0	0	0
不安	0	0	0	0	0	0
不眠症	0	0	0	0	0	0
激越	0	0	0	0	0	0
注意欠陥多動性障害	0	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 66 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
頭部損傷	0	0	0	1 (7.1)	0
術後イレウス	0	0	0	0	0
隆起骨折	1 (11.1)	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0
発疹	0	0	0	0	0
皮膚炎	0	0	0	0	0
皮下気腫	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
湿疹	0	0	0	0	0
精神障害	0	2 (22.2)	0	0	1 (2.1)
不安	0	0	0	0	0
不眠症	0	0	0	0	1 (2.1)
激越	0	1 (11.1)	0	0	0
注意欠陥多動性障害	0	1 (11.1)	0	0	0
睡眠時随伴症	0	1 (11.1)	0	0	0
落ち着きのなさ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 67 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
睡眠障害	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0	0
斜指症	0	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0	0
貧血	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
骨髄障害	0	0	0	0	0	0
腎および尿路障害	0	0	0	0	0	0
尿閉	0	0	0	0	0	0
排尿困難	0	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0	0
耳および迷路障害	0	0	0	0	0	0
耳の障害	0	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 68 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
睡眠障害	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
斜指症	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
腎および尿路障害	0	0	0	1 (7.1)	1 (2.1)
尿閉	0	0	0	0	0
排尿困難	0	0	0	0	1 (2.1)
膀胱尿管逆流	0	0	0	1 (7.1)	0
耳および迷路障害	0	0	0	0	0
耳の障害	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 69 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
後天性包茎	0	0	0	0	0	0
神経系障害	1 (16.7)	0	0	0	0	0
脳梗塞	0	0	0	0	0	0
嗜眠	0	0	0	0	0	0
頭痛	1 (16.7)	0	0	0	0	0
失読症	0	0	0	0	0	0
失神寸前の状態	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
高血圧	0	0	0	0	0	0
低血圧	0	0	0	0	0	0
免疫系障害	0	0	0	0	0	0
季節性アレルギー	0	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	1 (12.5)	0
皮膚乳頭腫	0	0	0	0	1 (12.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 70 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
後天性包茎	0	0	0	0	0
神経系障害	0	1 (11.1)	0	0	7 (14.9)
脳梗塞	0	0	0	0	0
嗜眠	0	0	0	0	0
頭痛	0	0	0	0	7 (14.9)
失読症	0	1 (11.1)	0	0	0
失神寸前の状態	0	0	0	0	0
血管障害	0	0	0	1 (7.1)	0
高血圧	0	0	0	0	0
低血圧	0	0	0	1 (7.1)	0
免疫系障害	0	0	0	0	0
季節性アレルギー	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む	0	0	0	0	0
皮膚乳頭腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 71 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	0	0	0	0	2 (25.0)	2 (25.0)
呼吸器、胸郭および縦隔障害	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
呼吸窮迫	0	0	0	0	0	0
急性呼吸不全	0	0	0	0	0	0
無気肺	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
呼吸停止	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
低換気	0	0	0	0	0	0
気胸	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 72 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	0	0	0	0	4 (8.5)
呼吸器、胸郭および縦隔障害	0	0	0	0	2 (4.3)
呼吸不全	0	0	0	0	1 (2.1)
呼吸窮迫	0	0	0	0	0
急性呼吸不全	0	0	0	0	0
無気肺	0	0	0	0	1 (2.1)
低酸素症	0	0	0	0	1 (2.1)
誤嚥性肺炎	0	0	0	0	0
誤嚥	0	0	0	0	0
呼吸困難	0	0	0	0	1 (2.1)
呼吸停止	0	0	0	0	0
無呼吸	0	0	0	0	0
低換気	0	0	0	0	0
気胸	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 73 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
肺障害	0	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
気縦隔症	0	0	0	0	0	0
窒息	0	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	1 (12.5)	0
肺炎	0	0	0	0	1 (12.5)	0
上気道感染	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0	0
気道感染	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0	0
細気管支炎						
細菌性肺炎	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
細菌性気管炎	0	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 74 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
呼吸障害	0	0	0	0	0
気縦隔症	0	0	0	0	0
窒息	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	2 (4.3)
肺炎	0	0	0	0	1 (2.1)
上気道感染	0	0	0	0	0
細気管支炎	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0
気道感染	0	0	0	0	0
下気道感染	0	0	0	0	1 (2.1)
ＲＳウイルス細気管支炎	0	0	0	0	1 (2.1)
細菌性肺炎	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	2 (4.3)
細菌性気管炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 75 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気管支炎	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
肺感染	0	0	0	0	0	0
院内感染	0	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
敗血症	0	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0	0
ウイルス感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 76 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気管支炎	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0
肺感染	0	0	0	0	0
院内感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
敗血症	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
下気道感染	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 77 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
心臓障害	0	0	0	0	0	0
心肺停止	0	0	0	0	0	0
心停止	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心膜気腫	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0
胃炎	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	1 (12.5)
発熱	0	0	0	0	0	0
死亡	0	0	0	0	0	0
疼痛	0	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0	1 (12.5)
神経系障害	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 78 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
心臓障害	0	0	0	0	0
心肺停止	0	0	0	0	0
心停止	0	0	0	0	0
徐脈	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心膜気腫	0	0	0	0	0
胃腸障害	0	0	0	0	0
嚥下障害	0	0	0	0	0
胃炎	0	0	0	0	0
嘔吐	0	0	0	0	0
流涎過多	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0
発熱	0	0	0	0	0
死亡	0	0	0	0	0
疼痛	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0
神経系障害	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 79 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
痙攣発作	0	0	0	0	0	0
脳損傷	0	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0	0
片頭痛	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
高血圧	0	0	0	0	0	0
ショック	0	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0	1 (12.5)
胸郭変形	0	0	0	0	0	0
関節拘縮	0	0	0	0	0	0
筋肉痛	0	0	0	0	0	1 (12.5)
傷害、中毒および処置合併症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 80 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
痙攣発作	0	0	0	0	0
脳損傷	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
片頭痛	0	0	0	0	1 (2.1)
血管障害	0	0	0	0	0
高血圧	0	0	0	0	0
ショック	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0
胸郭変形	0	0	0	0	0
関節拘縮	0	0	0	0	0
筋肉痛	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 81 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
創離開	0	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
免疫系障害	0	0	0	0	1 (12.5)	0
薬物過敏症	0	0	0	0	1 (12.5)	0
臨床検査	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0	0
外科および内科処置	0	0	0	0	0	0
機械的換気	0	0	0	0	0	0
精神障害	0	0	0	0	0	0
不安	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 82 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
創離開	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	1 (2.1)
大腿骨骨折	0	0	0	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
臨床検査	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
精神障害	0	0	0	0	0
不安	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 15　Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA
Page 1 of 3

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	3 (17.6)	0	2 (12.5)	6 (14.6)	9 (11.3)
臨床検査	1 (5.9)	0	0	0	2 (2.5)
体温低下	0	0	0	0	1 (1.3)
体温上昇	0	0	0	0	1 (1.3)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
心拍数増加	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (5.9)	0	0	3 (7.3)	2 (2.5)
発熱	1 (5.9)	0	0	2 (4.9)	2 (2.5)
疼痛	0	0	0	1 (2.4)	0
神経系障害	1 (5.9)	0	0	0	1 (1.3)
眼振	0	0	0	0	1 (1.3)
反射亢進	1 (5.9)	0	0	0	0
頭痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA
Page 2 of 3

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
錯感覚	0	0	0	0	0
心臓障害	1 (5.9)	0	0	0	1 (1.3)
頻脈	1 (5.9)	0	0	0	1 (1.3)
動悸	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	1 (1.3)
処置後腫脹	0	0	0	0	1 (1.3)
腰椎穿刺後症候群	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	1 (1.3)
貧血母斑	0	0	0	0	1 (1.3)
感染症および寄生虫症	0	0	0	0	1 (1.3)
蜂巣炎	0	0	0	0	1 (1.3)
血管障害	0	0	0	0	1 (1.3)
血管炎	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA
Page 3 of 3

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血液およびリンパ系障害	0	0	1 (6.3)	0	0
好中球減少症	0	0	1 (6.3)	0	0
胃腸障害	0	0	1 (6.3)	2 (4.9)	0
嘔吐	0	0	1 (6.3)	1 (2.4)	0
下痢	0	0	0	1 (2.4)	0
筋骨格系および結合組織障害	1 (5.9)	0	0	0	0
筋力低下	1 (5.9)	0	0	0	0
体重支持困難	1 (5.9)	0	0	0	0
皮膚および皮下組織障害	0	0	0	1 (2.4)	0
発疹	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 16　Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 1 of 6

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	1 (16.7)	1 (16.7)	0	0	0	0
臨床検査	0	0	0	0	0	0
体温低下	0	0	0	0	0	0
体温上昇	0	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0	0
心拍数増加	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	0
発熱	0	0	0	0	0	0
疼痛	0	0	0	0	0	0
神経系障害	1 (16.7)	0	0	0	0	0
眼振	0	0	0	0	0	0
反射亢進	0	0	0	0	0	0
頭痛	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	0	0	0	0	5 (10.6)
臨床検査	0	0	0	0	2 (4.3)
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	1 (2.1)
心拍数増加	0	0	0	0	1 (2.1)
一般・全身障害および投与部位の状態	0	0	0	0	0
発熱	0	0	0	0	0
疼痛	0	0	0	0	0
神経系障害	0	0	0	0	2 (4.3)
眼振	0	0	0	0	0
反射亢進	0	0	0	0	0
頭痛	0	0	0	0	2 (4.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 3 of 6

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
錯感覚	1 (16.7)	0	0	0	0	0
心臓障害	0	1 (16.7)	0	0	0	0
頻脈	0	0	0	0	0	0
動悸	0	1 (16.7)	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	0	0
処置後腫脹	0	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
貧血母斑	0	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	0	0
蜂巣炎	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
血管炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 4 of 6

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
錯感覚	0	0	0	0	0
心臓障害	0	0	0	0	0
頻脈	0	0	0	0	0
動悸	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	1 (2.1)
処置後腫脹	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	1 (2.1)
先天性、家族性および遺伝性障害	0	0	0	0	0
貧血母斑	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	0
蜂巣炎	0	0	0	0	0
血管障害	0	0	0	0	0
血管炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 5 of 6

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
血液およびリンパ系障害	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
下痢	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
体重支持困難	0	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0	0
発疹	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
血液およびリンパ系障害	0	0	0	0	0
好中球減少症	0	0	0	0	0
胃腸障害	0	0	0	0	0
嘔吐	0	0	0	0	0
下痢	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0
筋力低下	0	0	0	0	0
体重支持困難	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
発疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 17　Incidence of fatal Adverse Events - Infants diagnosed with SMA

Incidence of fatal Adverse Events - Infants diagnosed with SMA
Page 1 of 2

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	0	1 (25.0)	3 (18.8)	13 (31.7)	12 (15.0)
呼吸器、胸郭および縦隔障害	0	1 (25.0)	2 (12.5)	10 (24.4)	7 (8.8)
呼吸不全	0	0	2 (12.5)	7 (17.1)	4 (5.0)
急性呼吸不全	0	0	0	1 (2.4)	1 (1.3)
呼吸停止	0	0	0	0	1 (1.3)
呼吸窮迫	0	0	0	2 (4.9)	1 (1.3)
窒息	0	1 (25.0)	0	0	0
心臓障害	0	0	0	2 (4.9)	2 (2.5)
心肺停止	0	0	0	2 (4.9)	2 (2.5)
神経系障害	0	0	0	0	2 (2.5)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	0	0	0	1 (2.4)	1 (1.3)
死亡	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of fatal Adverse Events - Infants diagnosed with SMA
Page 2 of 2

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	0	0	1 (6.3)	0	0
ウイルス性下気道感染	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 18　Incidence of Serious Adverse Events - Infants diagnosed with SMA

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 1 of 6

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	5 (29.4)	3 (75.0)	13 (81.3)	33 (80.5)	56 (70.0)
呼吸器、胸郭および縦隔障害	1 (5.9)	3 (75.0)	12 (75.0)	26 (63.4)	46 (57.5)
呼吸窮迫	1 (5.9)	1 (25.0)	5 (31.3)	10 (24.4)	19 (23.8)
呼吸不全	0	0	5 (31.3)	14 (34.1)	17 (21.3)
急性呼吸不全	0	1 (25.0)	3 (18.8)	7 (17.1)	11 (13.8)
無気肺	0	0	2 (12.5)	2 (4.9)	11 (13.8)
誤嚥性肺炎	0	0	2 (12.5)	4 (9.8)	6 (7.5)
呼吸困難	0	0	0	2 (4.9)	4 (5.0)
誤嚥	0	0	1 (6.3)	0	3 (3.8)
低酸素症	0	0	1 (6.3)	1 (2.4)	3 (3.8)
呼吸停止	0	0	0	4 (9.8)	3 (3.8)
無呼吸	0	0	2 (12.5)	2 (4.9)	2 (2.5)
呼吸障害	0	0	0	0	2 (2.5)
低換気	0	0	1 (6.3)	0	1 (1.3)
急性呼吸窮迫症候群	0	0	0	0	1 (1.3)
気管支分泌物貯留	0	0	0	2 (4.9)	1 (1.3)
慢性呼吸不全	0	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 2 of 6

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気管支分泌増加	0	0	0	0	1 (1.3)
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
気縦隔症	0	0	1 (6.3)	0	0
窒息	0	1 (25.0)	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0
気道うっ血	0	0	0	1 (2.4)	0
感染症および寄生虫症	3 (17.6)	2 (50.0)	11 (68.8)	15 (36.6)	40 (50.0)
肺炎	1 (5.9)	0	4 (25.0)	4 (9.8)	14 (17.5)
ライノウイルス感染	0	0	4 (25.0)	2 (4.9)	6 (7.5)
ウイルス性肺炎	0	0	2 (12.5)	1 (2.4)	5 (6.3)
細気管支炎	0	0	3 (18.8)	1 (2.4)	4 (5.0)
ウイルス感染	0	0	2 (12.5)	1 (2.4)	4 (5.0)
上気道感染	0	0	1 (6.3)	0	4 (5.0)
気道感染	0	1 (25.0)	0	0	4 (5.0)
ＲＳウイルス細気管支炎	0	0	1 (6.3)	3 (7.3)	3 (3.8)
細菌性肺炎	0	0	1 (6.3)	1 (2.4)	3 (3.8)
ウイルス性上気道感染	0	0	1 (6.3)	6 (14.6)	3 (3.8)
気管支炎	1 (5.9)	0	0	0	3 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 3 of 6

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
下気道感染	0	0	0	0	3 (3.8)
ウイルス性気管支炎	0	0	0	0	2 (2.5)
ウイルス性下気道感染	0	0	1 (6.3)	0	1 (1.3)
ウイルス性気道感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
耳感染	0	0	0	0	1 (1.3)
ロタウイルス胃腸炎	0	0	0	0	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
鼻咽頭炎	0	0	0	0	1 (1.3)
院内感染	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	0	0	1 (1.3)
モラクセラ菌性肺炎	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	1 (2.4)	1 (1.3)
ブドウ球菌性敗血症	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
メタニューモウイルス感染	0	0	2 (12.5)	0	0
コロナウイルス感染	0	0	1 (6.3)	1 (2.4)	0
エンテロウイルス感染	0	0	1 (6.3)	0	0
パラインフルエンザウイルス感染	0	1 (25.0)	0	0	0
シュードモナス菌性肺炎	0	1 (25.0)	0	1 (2.4)	0
尿路感染	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 4 of 6

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胃腸炎	0	0	0	0	0
心臓障害	0	0	3 (18.8)	5 (12.2)	9 (11.3)
心肺停止	0	0	1 (6.3)	3 (7.3)	5 (6.3)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
チアノーゼ	0	0	1 (6.3)	1 (2.4)	1 (1.3)
心室性頻脈	0	0	0	0	1 (1.3)
徐脈	0	0	1 (6.3)	0	0
心膜気腫	0	0	1 (6.3)	0	0
代謝および栄養障害	1 (5.9)	0	2 (12.5)	4 (9.8)	7 (8.8)
体重増加不良	0	0	0	2 (4.9)	3 (3.8)
乳児および小児期早期の哺育障害	0	0	0	2 (4.9)	2 (2.5)
栄養補給不耐性	0	0	0	0	2 (2.5)
脱水	0	0	0	0	1 (1.3)
成長障害	1 (5.9)	0	1 (6.3)	0	0
低ナトリウム血症	0	0	1 (6.3)	0	0
胃腸障害	1 (5.9)	0	1 (6.3)	3 (7.3)	6 (7.5)
嘔吐	0	0	1 (6.3)	1 (2.4)	3 (3.8)
嚥下障害	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 5 of 6

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胃出血	0	0	0	0	1 (1.3)
腹部膨満	1 (5.9)	0	0	0	0
胃腸出血	0	0	0	1 (2.4)	0
流涎過多	0	0	0	1 (2.4)	0
一般・全身障害および投与部位の状態	0	0	0	1 (2.4)	4 (5.0)
発熱	0	0	0	0	3 (3.8)
死亡	0	0	0	1 (2.4)	1 (1.3)
傷害、中毒および処置合併症	0	0	0	2 (4.9)	3 (3.8)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
ワクチン接種合併症	0	0	0	0	1 (1.3)
創離開	0	0	0	0	1 (1.3)
腰椎穿刺後症候群	0	0	0	0	0
大腿骨骨折	0	0	0	1 (2.4)	0
頭部損傷	0	0	0	1 (2.4)	0
神経系障害	0	0	1 (6.3)	0	2 (2.5)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 6 of 6

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
痙攣発作	0	0	1 (6.3)	0	0
臨床検査	0	0	0	2 (4.9)	2 (2.5)
医学的観察	0	0	0	0	1 (1.3)
酸素飽和度低下	0	0	0	1 (2.4)	1 (1.3)
レスピロウイルス検査陽性	0	0	0	1 (2.4)	0
皮膚および皮下組織障害	0	0	0	0	1 (1.3)
皮膚炎	0	0	0	0	1 (1.3)
血管障害	0	0	0	0	1 (1.3)
ショック	0	0	0	0	1 (1.3)
筋骨格系および結合組織障害	0	0	1 (6.3)	0	0
滑膜炎	0	0	1 (6.3)	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
精神障害	0	0	0	1 (2.4)	0
激越	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 19　Table 19: Incidence of Serious Adverse Events - Later-onset

Incidence of Serious Adverse Events - Later-onset
Page 1 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	0	0	0	0	2 (25.0)	0
呼吸器、胸郭および縦隔障害	0	0	0	0	0	0
呼吸窮迫	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
急性呼吸不全	0	0	0	0	0	0
無気肺	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
呼吸停止	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
低換気	0	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 2 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	0	1 (11.1)	0	0	5 (10.6)
呼吸器、胸郭および縦隔障害	0	0	0	0	2 (4.3)
呼吸窮迫	0	0	0	0	0
呼吸不全	0	0	0	0	1 (2.1)
急性呼吸不全	0	0	0	0	1 (2.1)
無気肺	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0
呼吸困難	0	0	0	0	1 (2.1)
誤嚥	0	0	0	0	0
低酸素症	0	0	0	0	0
呼吸停止	0	0	0	0	0
無呼吸	0	0	0	0	0
呼吸障害	0	0	0	0	0
低換気	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 3 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気管支分泌増加	0	0	0	0	0	0
肺障害	0	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0	0
気縦隔症	0	0	0	0	0	0
窒息	0	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	1 (12.5)	0
肺炎	0	0	0	0	1 (12.5)	0
ライノウイルス感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
ウイルス感染	0	0	0	0	0	0
上気道感染	0	0	0	0	0	0
気道感染	0	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0	0
細菌性肺炎	0	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 4 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気管支分泌増加	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
気縦隔症	0	0	0	0	0
窒息	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0
気道うっ血	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	4 (8.5)
肺炎	0	0	0	0	1 (2.1)
ライノウイルス感染	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	2 (4.3)
細気管支炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0
上気道感染	0	0	0	0	0
気道感染	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	1 (2.1)
細菌性肺炎	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0
気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 5 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
下気道感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
耳感染	0	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0	0
肺感染	0	0	0	0	0	0
鼻咽頭炎	0	0	0	0	0	0
院内感染	0	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 6 of 12

Later-onset SMA

	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
下気道感染	0	0	0	0	1 (2.1)
ウイルス性気管支炎	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	1 (2.1)
耳感染	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
肺感染	0	0	0	0	0
鼻咽頭炎	0	0	0	0	0
院内感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
尿路感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 7 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
胃腸炎	0	0	0	0	0	0
心臓障害	0	0	0	0	0	0
心肺停止	0	0	0	0	0	0
心停止	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
心膜気腫	0	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0	0
脱水	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 8 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
胃腸炎	0	0	0	0	1 (2.1)
心臓障害	0	0	0	0	0
心肺停止	0	0	0	0	0
心停止	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心室性頻脈	0	0	0	0	0
徐脈	0	0	0	0	0
心膜気腫	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
胃腸障害	0	0	0	0	0
嘔吐	0	0	0	0	0
嚥下障害	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 9 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
胃出血	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
胃腸出血	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	0
発熱	0	0	0	0	0	0
死亡	0	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0	0
創離開	0	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
頭部損傷	0	0	0	0	0	0
神経系障害	0	0	0	0	0	0
脳損傷	0	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 10 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
胃出血	0	0	0	0	0
腹部膨満	0	0	0	0	0
胃腸出血	0	0	0	0	0
流涎過多	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0
発熱	0	0	0	0	0
死亡	0	0	0	0	0
傷害、中毒および処置合併症	0	1 (11.1)	0	0	1 (2.1)
麻酔からの覚醒遅延	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
腰椎穿刺後症候群	0	1 (11.1)	0	0	1 (2.1)
大腿骨骨折	0	0	0	0	0
頭部損傷	0	0	0	0	0
神経系障害	0	0	0	0	0
脳損傷	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 11 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
痙攣発作	0	0	0	0	0	0
臨床検査	0	0	0	0	0	0
医学的観察	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
ショック	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0	0
滑膜炎	0	0	0	0	0	0
免疫系障害	0	0	0	0	1 (12.5)	0
薬物過敏症	0	0	0	0	1 (12.5)	0
精神障害	0	0	0	0	0	0
激越	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 12 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
痙攣発作	0	0	0	0	0
臨床検査	0	0	0	0	0
医学的観察	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
皮膚炎	0	0	0	0	0
血管障害	0	0	0	0	0
ショック	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0
滑膜炎	0	0	0	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
精神障害	0	0	0	0	0
激越	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 20　Incidence of Adeverse Events leading to study drug discontinuation - Infants diagnosed with SMA

Incidence of Adeverse Events leading to study drug discontinuation - Infants diagnosed with SMA
Page 1 of 2

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	0	0	3 (18.8)	12 (29.3)	12 (15.0)
呼吸器、胸郭および縦隔障害	0	0	2 (12.5)	9 (22.0)	7 (8.8)
呼吸不全	0	0	2 (12.5)	6 (14.6)	4 (5.0)
急性呼吸不全	0	0	0	1 (2.4)	1 (1.3)
呼吸停止	0	0	0	0	1 (1.3)
呼吸窮迫	0	0	0	2 (4.9)	1 (1.3)
心臓障害	0	0	0	2 (4.9)	2 (2.5)
心肺停止	0	0	0	2 (4.9)	2 (2.5)
神経系障害	0	0	0	0	2 (2.5)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	0	0	0	1 (2.4)	1 (1.3)
死亡	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of Adeverse Events leading to study drug discontinuation - Infants diagnosed with SMA
Page 2 of 2

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	0	0	1 (6.3)	0	0
ウイルス性下気道感染	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 21　Demographic Characteristics of Infants Diagnosed With SMA

Demographic characteristics of infants diagnosed with SMA
Page 1 of 5

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies	Presymptomatic and symptomatic
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17	41	80	100	117
Age at first dose/sham procedure					
<30 days (less than 1 month)	14 (82)	0	0	0	14 (12)
>=30 days to <90 days (1 to 3 months)	3 (18)	2 (5)	6 (8)	10 (10)	13 (11)
>=90 days to <180 days (3 to 6 months)	0	14 (34)	43 (54)	51 (51)	51 (44)
>=180 days (6 months or older)	0	25 (61)	31 (39)	39 (39)	39 (33)
>=1 year to <2 years	0	0	0	0	0
>=2 years to <6 years	0	0	0	0	0
>=6 years	0	0	0	0	0
n	17	41	80	100	117
Mean	21.9	180.5	163.4	160.9	140.7
SD	11.19	50.92	49.57	52.23	69.04
Median	19.0	205.0	164.5	164.5	148.0
25th, 75th percentiles	13.0, 27.0	143.0, 215.0	118.0, 208.5	118.0, 210.0	96.0, 200.0
Min, Max	8, 42	30, 262	52, 242	37, 242	8, 242

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 2 of 5

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Gestational age (weeks)					
n	17	41	80	100	117
Mean	39.1	39.3	38.9	39.0	39.0
SD	1.11	1.33	1.30	1.34	1.30
Median	39.0	40.0	39.0	39.0	39.0
25th, 75th percentiles	38.0, 40.0	38.0, 40.0	38.0, 40.0	38.0, 40.0	38.0, 40.0
Min, Max	38, 41	37, 42	36, 41	35, 42	35, 42
Sex					
n	17	41	80	100	117
Male	11 (65)	17 (41)	37 (46)	49 (49)	60 (51)
Female	6 (35)	24 (59)	43 (54)	51 (51)	57 (49)
Ethnicity					
n	17	41	80	100	117
Hispanic or Latino	2 (12)	4 (10)	12 (15)	13 (13)	15 (13)
Not Hispanic or Latino	11 (65)	37 (90)	68 (85)	87 (87)	98 (84)
Not Reported	4 (24)	0	0	0	4 (3)

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 3 of 5

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Race					
n	17	41	80	100	117
Asian	2 (12)	1 (2)	5 (6)	6 (6)	8 (7)
Black	0	0	3 (4)	4 (4)	4 (3)
Native Hawaiian or other Pacific Islander	0	0	0	0	0
White	9 (53)	36 (88)	68 (85)	84 (84)	93 (79)
Other	2 (12)	1 (2)	3 (4)	4 (4)	6 (5)
Multiple	0	2 (5)	1 (1)	2 (2)	2 (2)
Not Reported	4 (24)	1 (2)	0	0	4 (3)

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 4 of 5

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :symptomatic:	Presymptomatic and
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Geographic region					
North America	12 (71)	22 (54)	38 (48)	58 (58)	70 (60)
Europe	3 (18)	17 (41)	30 (38)	30 (30)	33 (28)
Asia-Pacific	2 (12)	2 (5)	12 (15)	12 (12)	14 (12)
Height (cm)					
n	17	41	80	100	117
Mean	52.6	64.2	64.1	64.2	62.5
SD	2.99	3.77	4.53	4.68	6.06
Median	52.3	64.3	64.7	64.8	63.0
25th, 75th percentiles	50.3, 55.0	61.3, 66.0	60.5, 66.5	60.7, 66.5	59.0, 66.2
Min, Max	49, 59	56, 74	55, 75	54, 75	49, 75

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 5 of 5

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Weight (kg)					
n	17	41	80	100	117
Mean	3.9	6.7	6.6	6.6	6.2
SD	0.74	1.01	0.98	1.05	1.38
Median	3.9	6.7	6.5	6.6	6.3
25th, 75th percentiles	3.3, 4.5	6.1, 7.1	5.8, 7.0	5.8, 7.1	5.4, 7.0
Min, Max	3, 5	5, 10	5, 9	5, 9	3, 9
Weight for age percentile					
n	17	41	80	100	117
Mean	44.5	24.4	26.8	29.4	31.6
SD	27.73	26.74	27.82	28.26	28.57
Median	43.4	12.9	16.0	17.5	20.0
25th, 75th percentiles	28.1, 57.9	5.2, 35.3	4.5, 45.3	5.3, 53.0	6.6, 55.0
Min, Max	2, 94	1, 98	1, 94	1, 94	1, 94

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 22　SMA History of Infants Diagnosed With SMA

SMA history of infants diagnosed with SMA
Page 1 of 3

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies	Presymptomatic and symptomatic
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17	41	80	100	117
SMN2 copy number					
1 copy	0	0	0	0	0
2 copies	12 (71)	40 (98)	78 (98)	95 (95)	107 (91)
3 copies	5 (29)	1 (2)	0	2 (2)	7 (6)
4 copies	0	0	0	0	0
5 copies	0	0	0	0	0
Unknown	0	0	2 (3)	3 (3)	3 (3)

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at diagnosis not recorded for presymptomatic infants.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

SMA history of infants diagnosed with SMA
Page 2 of 3

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies	Presymptomatic and symptomatic
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17	41	80	100	117
Age at symptom onset (months)					
<30 days (less than 1 month)	-	5 (12)	20 (25)	27 (27)	27 (23)
>=30 days to <90 days (1 to 3 months)	-	27 (66)	52 (65)	62 (62)	62 (53)
>=90 days to <180 days (3 to 6 months)	-	9 (22)	8 (10)	11 (11)	11 (9)
>=180 days (6 months or older)	-	0	0	0	0
n		41	80	100	100
Mean		2.2	1.8	1.8	1.8
SD		1.07	0.91	0.99	0.99
Median		1.8	1.5	1.6	1.6
25th, 75th percentiles		1.4, 2.8	1.0, 2.5	0.9, 2.5	0.9, 2.5
Min, Max		0, 5	0, 4	0, 5	0, 5

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at diagnosis not recorded for presymptomatic infants.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

SMA history of infants diagnosed with SMA
Page 3 of 3

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :symptomatic:	Presymptomatic and
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17	41	80	100	117
Age at diagnosis (months)					
<30 days (less than 1 month)	-	3 (7)	7 (9)	11 (11)	11 (11)
>=30 days to <90 days (1 to 3 months)	-	9 (22)	44 (55)	52 (52)	52 (52)
>=90 days to <180 days (3 to 6 months)	-	26 (63)	28 (35)	36 (36)	36 (36)
>=180 days (6 months or older)	-	3 (7)	1 (1)	1 (1)	1 (1)
n		41	80	100	100
Mean		4.0	2.9	2.8	2.8
SD		1.72	1.53	1.51	1.51
Median		4.6	2.5	2.5	2.5
25th, 75th percentiles		2.8, 5.1	1.8, 4.1	1.8, 4.0	1.8, 4.0
Min, Max		0, 7	0, 7	0, 7	0, 7

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at diagnosis not recorded for presymptomatic infants.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 23　Demographic Characteristics of Subjects Diagnosed With SMA

Demographic characteristics of subjects diagnosed with SMA
Page 1 of 3

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17	100	117	56	173
Age at first dose/sham procedure					
<30 days (less than 1 month)	14 (82)	0	14 (12)	0	14 (8)
>=30 days to <90 days (1 to 3 months)	3 (18)	10 (10)	13 (11)	0	13 (8)
>=90 days to <180 days (3 to 6 months)	0	51 (51)	51 (44)	0	51 (29)
>=180 days to <365 days (6 months to 1 year)	0	39 (39)	39 (33)	0	39 (23)
>=1 year to <2 years	0	0	0	0	0
>=2 years to <6 years	0	0	0	28 (50)	28 (16)
>=6 years	0	0	0	28 (50)	28 (16)
n	17	100	117	56	173
Mean	21.9	160.9	140.7	7.19	951.8
SD	11.19	52.23	69.04	4.078	1447.19
Median	19.0	164.5	148.0	6.15	199.0
25th, 75th percentiles	13.0, 27.0	118.0, 210.0	96.0, 200.0	4.10, 9.35	118.0, 1501.0
Min, Max	8, 42	37, 242	8, 242	2.0, 15.9	8, 5833

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

Demographic characteristics of subjects diagnosed with SMA
Page 2 of 3

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Sex					
n	17	100	117	56	173
Male	11 (65)	49 (49)	60 (51)	26 (46)	86 (50)
Female	6 (35)	51 (51)	57 (49)	30 (54)	87 (50)
Ethnicity					
n	17	100	117	56	173
Hispanic or Latino	2 (12)	13 (13)	15 (13)	8 (14)	23 (13)
Not Hispanic or Latino	11 (65)	87 (87)	98 (84)	48 (86)	146 (84)
Not Reported	4 (24)	0	4 (3)	0	4 (2)
Race					
n	17	100	117	56	173
Asian	2 (12)	6 (6)	8 (7)	2 (4)	10 (6)
Black	0	4 (4)	4 (3)	3 (5)	7 (4)
Native Hawaiian or other Pacific Islander	0	0	0	0	0
White	9 (53)	84 (84)	93 (79)	49 (88)	142 (82)
Other	2 (12)	4 (4)	6 (5)	1 (2)	7 (4)
Multiple	0	2 (2)	2 (2)	1 (2)	3 (2)
Not Reported	4 (24)	0	4 (3)	0	4 (2)

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Demographic characteristics of subjects diagnosed with SMA
Page 3 of 3

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Geographic region					
North America	12 (71)	58 (58)	70 (60)	56 (100)	126 (73)
Europe	3 (18)	30 (30)	33 (28)	0	33 (19)
Asia-Pacific	2 (12)	12 (12)	14 (12)	0	14 (8)
Height (cm)					
n	17	100	117	33	150
Mean	52.6	64.2	62.5	120.9	75.4
SD	2.99	4.68	6.06	24.97	27.40
Median	52.3	64.8	63.0	120.2	65.1
25th, 75th percentiles	50.3, 55.0	60.7, 66.5	59.0, 66.2	98.9, 144.5	60.4, 73.0
Min, Max	49, 59	54, 75	49, 75	82, 171	49, 171
Weight (kg)					
n	17	100	117	56	173
Mean	3.9	6.6	6.2	26.2	12.7
SD	0.74	1.05	1.38	17.76	13.77
Median	3.9	6.6	6.3	19.1	7.0
25th, 75th percentiles	3.3, 4.5	5.8, 7.1	5.4, 7.0	13.4, 32.8	5.8, 13.3
Min, Max	3, 5	5, 9	3, 9	10, 83	3, 83

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 24　SMA History of Subjects Diagnosed With SMA

SMA history of subjects diagnosed with SMA
Page 1 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17	100	117	56	173
SMN2 copy number					
1 copy	0	0	0	0	0
2 copies	12 (71)	95 (95)	107 (91)	1 (2)	108 (62)
3 copies	5 (29)	2 (2)	7 (6)	46 (82)	53 (31)
4 copies	0	0	0	8 (14)	8 (5)
5 copies	0	0	0	1 (2)	1 (<1)
Unknown	0	3 (3)	3 (3)	0	3 (2)

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at diagnosis not recorded for presymptomatic infants.
3:Ambulatory status at baseline not assessed for infants.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

SMA history of subjects diagnosed with SMA
Page 2 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17	100	117	56	173
Age at symptom onset (months)					
<30 days (less than 1 month)	-	27 (27)	27 (23)	0	27 (16)
>=30 days to <90 days (1 to 3 months)	-	62 (62)	62 (53)	0	62 (36)
>=90 days to <180 days (3 to 6 months)	-	11 (11)	11 (9)	2 (4)	13 (8)
>=180 days to <365 days (6 months to 1 year)	-	0	0	10 (18)	10 (6)
>=1 year to <2 years	-	0	0	36 (64)	36 (21)
>=2 years to <6 years	-	0	0	8 (14)	8 (5)
>=6 years	-	0	0	0	0
n		100	100	56	156
Mean		1.8	1.8	16.4	7.1
SD		0.99	0.99	10.94	9.59
Median		1.6	1.6	14.0	2.8
25th, 75th percentiles		0.9, 2.5	0.9, 2.5	12.0, 18.0	1.4, 12.0
Min, Max		0, 5	0, 5	3, 60	0, 60

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at diagnosis not recorded for presymptomatic infants.
3:Ambulatory status at baseline not assessed for infants.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

SMA history of subjects diagnosed with SMA
Page 3 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17	100	117	56	173
Age at diagnosis (months)					
<30 days (less than 1 month)	-	11 (11)	11 (11)	1 (2)	12 (8)
>=30 days to <90 days (1 to 3 months)	-	52 (52)	52 (52)	0	52 (33)
>=90 days to <180 days (3 to 6 months)	-	36 (36)	36 (36)	0	36 (23)
>=180 days to <365 days (6 months to 1 year)	-	1 (1)	1 (1)	2 (4)	3 (2)
>=1 year to <2 years	-	0	0	28 (50)	28 (18)
>=2 years to <6 years	-	0	0	22 (39)	22 (14)
>=6 years	-	0	0	3 (5)	3 (2)
n		100	100	56	156
Mean		2.8	2.8	27.8	11.8
SD		1.51	1.51	22.98	18.27
Median		2.5	2.5	20.0	4.1
25th, 75th percentiles		1.8, 4.0	1.8, 4.0	15.0, 29.5	2.1, 16.0
Min, Max		0, 7	0, 7	0, 144	0, 144

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at diagnosis not recorded for presymptomatic infants.
3:Ambulatory status at baseline not assessed for infants.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

SMA history of subjects diagnosed with SMA
Page 4 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17	100	117	56	173
Ambulatory status					
n	17 (100)	100 (100)	117 (100)	56 (100)	173 (100)
Ambulant	-	-	-	23 (41)	-
Non-ambulant	-	-	-	33 (59)	-

NOTE 1:Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2:Age at diagnosis not recorded for presymptomatic infants.
3:Ambulatory status at baseline not assessed for infants.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 25　Infants Diagnosed With SMA:Concomitant Medications

Infants diagnosed with SMA: concomitant medications
Page 1 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:symptomatic:	Presymptomatic and
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100)	41 (100)	80 (100)	100 (100)	117 (100)
Number of subjects who received a concomitant medication	15 (88)	41 (100)	80 (100)	100 (100)	115 (98)
PARACETAMOL	11 (65)	31 (76)	57 (71)	77 (77)	88 (75)
POVIDONE-IODINE	3 (18)	27 (66)	53 (66)	61 (61)	64 (55)
EMLA	8 (47)	31 (76)	41 (51)	54 (54)	62 (53)
LIDOCAINE	11 (65)	14 (34)	33 (41)	51 (51)	62 (53)
SALBUTAMOL	2 (12)	21 (51)	42 (53)	59 (59)	61 (52)
PNEUMOCOCCAL VACCINE	5 (29)	14 (34)	41 (51)	51 (51)	56 (48)
SODIUM CHLORIDE	7 (41)	17 (41)	38 (48)	47 (47)	54 (46)
PALIVIZUMAB	1 (6)	15 (37)	35 (44)	51 (51)	52 (44)
IBUPROFEN	2 (12)	21 (51)	30 (38)	43 (43)	45 (38)
INFLUENZA VACCINE	2 (12)	12 (29)	28 (35)	38 (38)	40 (34)
AMOXICILLIN	2 (12)	13 (32)	27 (34)	37 (37)	39 (33)
HAEMOPHILUS INFLUENZA TYPE B VACCINE	7 (41)	11 (27)	20 (25)	29 (29)	36 (31)
RANITIDINE	1 (6)	16 (39)	22 (28)	32 (32)	33 (28)
ROTAVIRUS VACCINE	6 (35)	5 (12)	19 (24)	27 (27)	33 (28)
CEFTRIAXONE	2 (12)	10 (24)	21 (26)	29 (29)	31 (26)
VACCIN IPAD D.T.C.3 (18)	10 (24)	18 (23)	27 (27)	30 (26)	
OXYGEN	0	15 (37)	19 (24)	28 (28)	28 (24)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 2 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
SUCROSE	4 (24)	3 (7)	23 (29)	24 (24)	28 (24)
HEPATITIS B VACCINE	2 (12)	6 (15)	18 (23)	25 (25)	27 (23)
MACROGOL	0	12 (29)	14 (18)	26 (26)	26 (22)
AUGMENTIN	0	7 (17)	18 (23)	25 (25)	25 (21)
MIDAZOLAM	2 (12)	11 (27)	16 (20)	22 (22)	24 (21)
MORPHINE	0	14 (34)	14 (18)	23 (23)	23 (20)
MEASLES MUMPS & RUBELLA LIVE ATTENUATED (FREE	0	5 (12)	16 (20)	22 (22)	22 (19)
CHLORHEXIDINE	0	10 (24)	20 (25)	21 (21)	21 (18)
CLINDAMYCIN	0	7 (17)	13 (16)	21 (21)	21 (18)
DEXTROSE AND SODIUM CHLORIDE INJECTION	1 (6)	9 (22)	15 (19)	20 (20)	21 (18)
FENTANYL	1 (6)	11 (27)	16 (20)	20 (20)	21 (18)
OSMOTAN	1 (6)	6 (15)	10 (13)	19 (19)	20 (17)
POLIO VACCINE	3 (18)	5 (12)	9 (11)	17 (17)	20 (17)
PIP/TAZO	0	5 (12)	13 (16)	19 (19)	19 (16)
COLECALCIFEROL	1 (6)	7 (17)	13 (16)	17 (17)	18 (15)
NYSTATIN	2 (12)	8 (20)	12 (15)	16 (16)	18 (15)
VITAMIN D NOS	6 (35)	7 (17)	12 (15)	12 (12)	18 (15)
BUDESONIDE	3 (18)	5 (12)	12 (15)	14 (14)	17 (15)
DORNASE ALFA	0	2 (5)	11 (14)	17 (17)	17 (15)
GLYCEROL	0	9 (22)	15 (19)	17 (17)	17 (15)
AZITHROMYCIN	1 (6)	3 (7)	10 (13)	15 (15)	16 (14)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 3 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
CEFAZOLIN	0	6 (15)	10 (13)	16 (16)	16 (14)
CETIRIZINE	1 (6)	5 (12)	10 (13)	15 (15)	16 (14)
VARICELLA ZOSTER VACCINE	0	7 (17)	12 (15)	16 (16)	16 (14)
GLYCOPYRRONIUM	0	4 (10)	12 (15)	15 (15)	15 (13)
LORAZEPAM	0	2 (5)	8 (10)	15 (15)	15 (13)
PROPOFOL	3 (18)	7 (17)	9 (11)	12 (12)	15 (13)
BARIUM	0	2 (5)	5 (6)	14 (14)	14 (12)
SIMETICONE	2 (12)	4 (10)	5 (6)	12 (12)	14 (12)
ACETYLCYSTEINE	0	3 (7)	9 (11)	13 (13)	13 (11)
CIPROFLOXACIN	0	4 (10)	9 (11)	13 (13)	13 (11)
HEPATITIS A VACCINE	0	2 (5)	10 (13)	13 (13)	13 (11)
INFANRIX IPV+HIB	1 (6)	2 (5)	12 (15)	12 (12)	13 (11)
DEXMEDETOMIDINE	2 (12)	6 (15)	7 (9)	10 (10)	12 (10)
FLEBOBAG RING LACT	2 (12)	4 (10)	4 (5)	10 (10)	12 (10)
LANSOPRAZOLE	0	4 (10)	8 (10)	12 (12)	12 (10)
NITROUS OXIDE	2 (12)	3 (7)	7 (9)	10 (10)	12 (10)
ATROPINE	0	6 (15)	7 (9)	11 (11)	11 (9)
CEFDINIR	1 (6)	2 (5)	6 (8)	10 (10)	11 (9)
HYDROCORTISONE	2 (12)	5 (12)	7 (9)	9 (9)	11 (9)
IPRATROPIUM	0	3 (7)	9 (11)	11 (11)	11 (9)
OMEPRAZOLE	1 (6)	3 (7)	7 (9)	10 (10)	11 (9)
PEDIARIX	5 (29)	3 (7)	5 (6)	6 (6)	11 (9)
SPEKTRAMOX	0	1 (2)	7 (9)	11 (11)	11 (9)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 4 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
AMOXICILLIN W/CLAVULANATE POTASSIUM	0	3 (7)	10 (13)	10 (10)	10 (9)
INFANRIX HEXA	0	1 (2)	8 (10)	10 (10)	10 (9)
ROCURONIUM	0	7 (17)	7 (9)	10 (10)	10 (9)
SEVOFLURANE	2 (12)	1 (2)	5 (6)	8 (8)	10 (9)
BACTRIM	0	3 (7)	5 (6)	9 (9)	9 (8)
DEXAMETHASONE	0	4 (10)	3 (4)	9 (9)	9 (8)
DIPHENHYDRAMINE	0	2 (5)	4 (5)	9 (9)	9 (8)
FAMOTIDINE	0	6 (15)	6 (8)	9 (9)	9 (8)
FLUTICASONE	0	0	5 (6)	9 (9)	9 (8)
FUROSEMIDE	0	4 (10)	7 (9)	9 (9)	9 (8)
GLYCERIN	0	0	0	9 (9)	9 (8)
HEPARIN	0	3 (7)	4 (5)	9 (9)	9 (8)
HIBISOL	1 (6)	2 (5)	8 (10)	8 (8)	9 (8)
PREDNISOLONE	0	3 (7)	7 (9)	9 (9)	9 (8)
SODIUM BICARBONATE	0	1 (2)	4 (5)	9 (9)	9 (8)
AMOXI-CLAVULANICO	3 (18)	0	5 (6)	5 (5)	8 (7)
CEFUROXIME	2 (12)	2 (5)	4 (5)	6 (6)	8 (7)
IRON	0	1 (2)	5 (6)	8 (8)	8 (7)
LEVOSALBUTAMOL	1 (6)	3 (7)	3 (4)	7 (7)	8 (7)
MULTIVITAMINS	0	2 (5)	7 (9)	8 (8)	8 (7)
MUPIROCIN	1 (6)	4 (10)	4 (5)	7 (7)	8 (7)
CLOTRIMAZOLE	3 (18)	2 (5)	4 (5)	4 (4)	7 (6)
ERYTHROMYCIN	0	4 (10)	7 (9)	7 (7)	7 (6)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 5 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
LACTULOSE	0	3 (7)	6 (8)	7 (7)	7 (6)
OSELTAMIVIR	0	0	6 (8)	7 (7)	7 (6)
POTASSIUM	0	6 (15)	6 (8)	7 (7)	7 (6)
ANESTHETICS, GENERAL	0	0	2 (3)	6 (6)	6 (5)
DOCUSATE	0	5 (12)	4 (5)	6 (6)	6 (5)
EMLAPATCH	0	1 (2)	4 (5)	6 (6)	6 (5)
EPINEPHRINE	0	3 (7)	4 (5)	6 (6)	6 (5)
FATS NOS	0	2 (5)	3 (4)	6 (6)	6 (5)
GLUCOSE	0	4 (10)	5 (6)	6 (6)	6 (5)
KETAMINE	0	4 (10)	4 (5)	6 (6)	6 (5)
KETOROLAC	0	3 (7)	3 (4)	6 (6)	6 (5)
LACTOBACILLUS NOS	0	1 (2)	5 (6)	6 (6)	6 (5)
METHYLPREDNISOLONE	0	2 (5)	3 (4)	6 (6)	6 (5)
PANTOPRAZOLE	0	1 (2)	6 (8)	6 (6)	6 (5)
TOBRAMYCIN	0	2 (5)	5 (6)	6 (6)	6 (5)
VANCOMYCIN	0	8 (20)	3 (4)	6 (6)	6 (5)
VITAMINS NOS	2 (12)	2 (5)	4 (5)	4 (4)	6 (5)
AQUAPHOR	0	2 (5)	4 (5)	5 (5)	5 (4)
BENZOCAINE	0	2 (5)	1 (1)	5 (5)	5 (4)
BISEPTINE	0	2 (5)	5 (6)	5 (5)	5 (4)
CEFOTAXIME	0	1 (2)	4 (5)	5 (5)	5 (4)
DOMPERIDONE	0	2 (5)	2 (3)	5 (5)	5 (4)
ESOMEPRAZOLE	0	3 (7)	5 (6)	5 (5)	5 (4)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 6 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
GENTAMICIN	0	0	5 (6)	5 (5)	5 (4)
IMMUNOGLOBULIN ANTI RESPIRATORY SYNCYTIAL VIR	0	2 (5)	5 (6)	5 (5)	5 (4)
LACTOBACILLUS ACIDOPHILUS	2 (12)	1 (2)	3 (4)	3 (3)	5 (4)
MINERALS NOS W/VITAMINS NOS	0	2 (5)	3 (4)	5 (5)	5 (4)
POLY-VI-SOL WITH IRON	1 (6)	1 (2)	1 (1)	4 (4)	5 (4)
SOLUTIONS FOR PARENTERAL NUTRITION	0	2 (5)	4 (5)	5 (5)	5 (4)
UNACID	0	3 (7)	5 (6)	5 (5)	5 (4)
ACICLOVIR	0	0	3 (4)	4 (4)	4 (3)
BACITRACIN	0	5 (12)	3 (4)	4 (4)	4 (3)
BOTULINUM TOXIN TYPE A	0	0	1 (1)	4 (4)	4 (3)
BUPIVACAINE	0	2 (5)	4 (5)	4 (4)	4 (3)
CEFALEXIN	0	3 (7)	3 (4)	4 (4)	4 (3)
CEFEPIME	0	3 (7)	3 (4)	4 (4)	4 (3)
ETOMIDATE	0	0	3 (4)	4 (4)	4 (3)
FERROUS SULFATE W/VITAMINS NOS	0	1 (2)	4 (5)	4 (4)	4 (3)
I.V.SOLUTIONS	0	0	1 (1)	4 (4)	4 (3)
MENINGOCOCCAL VACCINE	0	2 (5)	3 (4)	4 (4)	4 (3)
MULTIVITAMINS WITH IRON	0	0	2 (3)	4 (4)	4 (3)
ONDANSETRON	0	0	3 (4)	4 (4)	4 (3)
PREDNISONE	0	1 (2)	4 (5)	4 (4)	4 (3)
REHYDRON	0	0	0	4 (4)	4 (3)
SALINE	0	3 (7)	4 (5)	4 (4)	4 (3)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 7 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
TRIAMCINOLONE	0	2 (5)	2 (3)	4 (4)	4 (3)
ZINC	0	2 (5)	1 (1)	4 (4)	4 (3)
ALTEPLASE	0	1 (2)	1 (1)	3 (3)	3 (3)
AMPICILLIN	0	1 (2)	2 (3)	3 (3)	3 (3)
BECLOMETASONE	2 (12)	1 (2)	1 (1)	1 (1)	3 (3)
CEFIXIME	0	0	1 (1)	3 (3)	3 (3)
CEFOXITIN	0	1 (2)	1 (1)	3 (3)	3 (3)
CLARITHROMYCIN	0	1 (2)	2 (3)	3 (3)	3 (3)
COMBIVENT	0	1 (2)	2 (3)	3 (3)	3 (3)
DESONIDE	0	0	1 (1)	3 (3)	3 (3)
ENTONOX	0	1 (2)	3 (4)	3 (3)	3 (3)
ERGOCALCIFEROL	0	4 (10)	0	3 (3)	3 (3)
FLUCONAZOLE	0	1 (2)	1 (1)	3 (3)	3 (3)
FUSIDIC ACID	1 (6)	1 (2)	1 (1)	2 (2)	3 (3)
HEPATITIS VACCINES	0	0	2 (3)	3 (3)	3 (3)
LACTOBACILLUS RHAMNOSUS	0	0	1 (1)	3 (3)	3 (3)
LEVETIRACETAM	0	0	2 (3)	3 (3)	3 (3)
LEVOCARNITINE	1 (6)	0	0	2 (2)	3 (3)
LIDOCAINE W/SODIUM BICARBONATE	3 (18)	1 (2)	0	0	3 (3)
LORATADINE	0	0	3 (4)	3 (3)	3 (3)
MEROPENEM	0	1 (2)	1 (1)	3 (3)	3 (3)
MICONAZOLE	0	2 (5)	3 (4)	3 (3)	3 (3)
OXYCODONE	0	3 (7)	3 (4)	3 (3)	3 (3)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 8 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
POLY-VI-SOL	0	0	0	3 (3)	3 (3)
PROBIOTICS	0	1 (2)	1 (1)	3 (3)	3 (3)
QUADRACEL	0	1 (2)	3 (4)	3 (3)	3 (3)
ROPIVACAINE	0	0	3 (4)	3 (3)	3 (3)
SENNA ALEXANDRINA	0	2 (5)	1 (1)	3 (3)	3 (3)
SILVER NITRATE	2 (12)	2 (5)	0	1 (1)	3 (3)
SULTAMICILLIN	0	3 (7)	3 (4)	3 (3)	3 (3)
TETRACAINE	0	0	3 (4)	3 (3)	3 (3)
VECURONIUM	0	1 (2)	3 (4)	3 (3)	3 (3)
XILONIBSA	0	0	0	3 (3)	3 (3)
ACETAZOLAMIDE	0	0	1 (1)	2 (2)	2 (2)
AMIKACIN	0	1 (2)	1 (1)	2 (2)	2 (2)
AMITRIPTYLINE	0	1 (2)	2 (3)	2 (2)	2 (2)
AMPHOTERICIN B	0	0	2 (3)	2 (2)	2 (2)
ANAESTHETICS	0	1 (2)	2 (3)	2 (2)	2 (2)
ANESTHETICS	0	0	1 (1)	2 (2)	2 (2)
BENZYLPENICILLIN	0	1 (2)	2 (3)	2 (2)	2 (2)
BIFIDOBACTERIUM LACTIS	0	2 (5)	2 (3)	2 (2)	2 (2)
CEFPODOXIME	0	0	2 (3)	2 (2)	2 (2)
CEFTAZIDIME	0	2 (5)	1 (1)	2 (2)	2 (2)
CHLOROTHIAZIDE	0	1 (2)	2 (3)	2 (2)	2 (2)
CLONIDINE	0	1 (2)	2 (3)	2 (2)	2 (2)
DIMETICONE	0	2 (5)	1 (1)	2 (2)	2 (2)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 9 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
DUOCID	0	0	2 (3)	2 (2)	2 (2)
ECONAZOLE	0	0	2 (3)	2 (2)	2 (2)
ELECTROLYTES NOS W/GLUCOSE	1 (6)	5 (12)	1 (1)	1 (1)	2 (2)
EMOLLIENTS AND PROTECTIVES	0	1 (2)	2 (3)	2 (2)	2 (2)
FENOTEROL	2 (12)	0	0	0	2 (2)
FOSPHENYTOIN	0	0	2 (3)	2 (2)	2 (2)
HYOSCINE	0	1 (2)	2 (3)	2 (2)	2 (2)
INSULIN	0	0	2 (3)	2 (2)	2 (2)
IOPAMIDOL	1 (6)	0	1 (1)	1 (1)	2 (2)
ISRADIPINE	0	0	1 (1)	2 (2)	2 (2)
LEVOFLOXACIN	0	2 (5)	2 (3)	2 (2)	2 (2)
MAGNESIUM HYDROXIDE	0	0	0	2 (2)	2 (2)
MELATONIN	0	1 (2)	2 (3)	2 (2)	2 (2)
MENHIBRIX	0	0	2 (3)	2 (2)	2 (2)
METHADONE	0	2 (5)	2 (3)	2 (2)	2 (2)
METHYLROSANILINIUM	0	0	1 (1)	2 (2)	2 (2)
METOCLOPRAMIDE	0	2 (5)	1 (1)	2 (2)	2 (2)
MOVICOL	0	1 (2)	2 (3)	2 (2)	2 (2)
MULTVIT	0	1 (2)	1 (1)	2 (2)	2 (2)
NEOSTIGMINE	0	1 (2)	2 (3)	2 (2)	2 (2)
NEOTRACIN	0	0	1 (1)	2 (2)	2 (2)
NISITA	0	0	2 (3)	2 (2)	2 (2)
OTHER DERMATOLOGICAL PREPARATIONS	0	0	1 (1)	2 (2)	2 (2)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 10 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
OXYMETAZOLINE	1 (6)	1 (2)	1 (1)	1 (1)	2 (2)
PARAFFIN	1 (6)	0	0	1 (1)	2 (2)
PETROLATUM	0	2 (5)	1 (1)	2 (2)	2 (2)
PIPERACILLIN	0	0	1 (1)	2 (2)	2 (2)
PLASMA	0	0	1 (1)	2 (2)	2 (2)
PLASMA LYTE 148	0	0	2 (3)	2 (2)	2 (2)
POLYSPORIN	0	0	0	2 (2)	2 (2)
PROTEIN SUPPLEMENTS	0	0	1 (1)	2 (2)	2 (2)
RACECADOTRIL	0	0	2 (3)	2 (2)	2 (2)
RACEPINEFRINE	0	2 (5)	1 (1)	2 (2)	2 (2)
REMIFENTANIL	0	2 (5)	2 (3)	2 (2)	2 (2)
ROXITHROMYCIN	0	0	2 (3)	2 (2)	2 (2)
SACCHAROMYCES BOULARDII	0	0	2 (3)	2 (2)	2 (2)
SAMBUCUS NIGRA	0	1 (2)	1 (1)	2 (2)	2 (2)
SODIUM FLUORIDE	0	1 (2)	2 (3)	2 (2)	2 (2)
SUCRALFATE	0	0	2 (3)	2 (2)	2 (2)
TPN	0	0	0	2 (2)	2 (2)
UVESTEROL	0	0	2 (3)	2 (2)	2 (2)
XYLOCAINE-EPINEPHRINE	0	1 (2)	1 (1)	2 (2)	2 (2)
XYLOMETAZOLINE	0	1 (2)	2 (3)	2 (2)	2 (2)
ADENOSINE	0	0	1 (1)	1 (1)	1 (<1)
ADIARIL	0	0	1 (1)	1 (1)	1 (<1)
ALBUMIN HUMAN	0	0	1 (1)	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 11 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
ALCLOMETASONE	0	2 (5)	1 (1)	1 (1)	1 (<1)
ALOE VERA	0	0	1 (1)	1 (1)	1 (<1)
AMBROXOL	0	0	1 (1)	1 (1)	1 (<1)
AMINO ACIDS NOS	0	2 (5)	0	1 (1)	1 (<1)
AMINOPHYLLINE	0	0	1 (1)	1 (1)	1 (<1)
AMIODARONE	1 (6)	0	0	0	1 (<1)
ANTIBIOTICS	0	0	0	1 (1)	1 (<1)
ANTIDIARRHEAL MICROORGANISMS	0	0	1 (1)	1 (1)	1 (<1)
ANTIFUNGALS FOR DERMATOLOGICAL USE	0	0	1 (1)	1 (1)	1 (<1)
ASCORBIC ACID W/RETINOL/VITAMIN D NOS	0	2 (5)	1 (1)	1 (1)	1 (<1)
ATRACURIUM	0	0	1 (1)	1 (1)	1 (<1)
AURALGAN	0	0	0	1 (1)	1 (<1)
AUXERGYL D3	0	0	1 (1)	1 (1)	1 (<1)
AVEENO BABY DAILY MOISTURE	0	0	0	1 (1)	1 (<1)
BENZALKONIUM	0	1 (2)	1 (1)	1 (1)	1 (<1)
BETAMETHASONE	1 (6)	4 (10)	0	0	1 (<1)
BETHANECHOL	0	0	1 (1)	1 (1)	1 (<1)
BICITRA	0	0	0	1 (1)	1 (<1)
BISACODYL	0	0	1 (1)	1 (1)	1 (<1)
BLOOD, WHOLE	0	0	1 (1)	1 (1)	1 (<1)
BUDESONIDE W/FORMOTEROL FUMARATE	0	0	1 (1)	1 (1)	1 (<1)
CALCIUM	0	1 (2)	1 (1)	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 12 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
CALCIUM CARBONATE	0	0	0	1 (1)	1 (<1)
CAMPHOR	0	0	1 (1)	1 (1)	1 (<1)
CANESTEN-HC	0	0	1 (1)	1 (1)	1 (<1)
CAPTOPRIL	0	0	1 (1)	1 (1)	1 (<1)
CARBOCISTEINE	0	0	1 (1)	1 (1)	1 (<1)
CARBOHYDRATES NOS W/FATS NOS/MINERA	0	0	1 (1)	1 (1)	1 (<1)
CEFADROXIL	0	0	0	1 (1)	1 (<1)
CEFOTETAN	0	0	1 (1)	1 (1)	1 (<1)
CEFPROZIL	0	1 (2)	0	1 (1)	1 (<1)
CHAMAEMELUM NOBILE	0	0	0	1 (1)	1 (<1)
CHLORAMPHENICOL	0	0	1 (1)	1 (1)	1 (<1)
CLAVULANIC ACID	0	6 (15)	1 (1)	1 (1)	1 (<1)
CONTRAST MEDIA	0	0	1 (1)	1 (1)	1 (<1)
CORTICOSTEROIDS FOR SYSTEMIC USE	0	0	1 (1)	1 (1)	1 (<1)
CROMOGLICIC ACID	0	0	1 (1)	1 (1)	1 (<1)
DEMAZIN	0	0	1 (1)	1 (1)	1 (<1)
DESITIN	0	3 (7)	1 (1)	1 (1)	1 (<1)
DESITIN WITH ZINC OXIDE	0	0	0	1 (1)	1 (<1)
DESLORATADINE	0	0	0	1 (1)	1 (<1)
DEXIBUPROFEN	0	0	1 (1)	1 (1)	1 (<1)
DIAZEPAM	0	1 (2)	1 (1)	1 (1)	1 (<1)
DIGOXIN	0	0	1 (1)	1 (1)	1 (<1)
DIMENHYDRINATE	0	0	0	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 13 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
DIPROBASE	0	0	1 (1)	1 (1)	1 (<1)
DOPAMINE	0	0	1 (1)	1 (1)	1 (<1)
EL-4	0	0	1 (1)	1 (1)	1 (<1)
ETHYL CHLORIDE	0	0	0	1 (1)	1 (<1)
EUCERIN	0	0	1 (1)	1 (1)	1 (<1)
EUPEPTINA	0	0	1 (1)	1 (1)	1 (<1)
EUPHRASIA OFFICINALIS	0	0	1 (1)	1 (1)	1 (<1)
EXCIPIAL	0	0	1 (1)	1 (1)	1 (<1)
FEXOFENADINE	0	0	1 (1)	1 (1)	1 (<1)
FISH OIL	0	0	1 (1)	1 (1)	1 (<1)
FITOSTIMOLINE	1 (6)	0	0	0	1 (<1)
FLUCLOXACILLIN	0	0	1 (1)	1 (1)	1 (<1)
FLUOCINOLONE ACETONIDE	0	0	1 (1)	1 (1)	1 (<1)
FLUOROMETHOLONE	0	0	0	1 (1)	1 (<1)
FRUCTOSE	0	0	0	1 (1)	1 (<1)
GASTROGRAFIN	0	0	1 (1)	1 (1)	1 (<1)
GAVISCON	0	0	1 (1)	1 (1)	1 (<1)
GERBER SOOTHE	1 (6)	0	0	0	1 (<1)
GOLYTELY	0	0	0	1 (1)	1 (<1)
GUAIFENESIN	0	0	0	1 (1)	1 (<1)
HAEMOPHILUS INFLUENZAE	0	0	0	1 (1)	1 (<1)
HEPARIN SODIUM W/SODIUM CHLORIDE	0	2 (5)	1 (1)	1 (1)	1 (<1)
HEPARINOID	0	1 (2)	1 (1)	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 14 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
HERBAL NOS W/MINERALS NOS/VITAMINS NOS	1 (6)	0	0	0	1 (<1)
HOMATROPINE	0	0	1 (1)	1 (1)	1 (<1)
HYDROMORPHONE	0	2 (5)	1 (1)	1 (1)	1 (<1)
HYDROXYQUINOLINE	0	0	1 (1)	1 (1)	1 (<1)
I.V.SOLUTION ADDITIVES	0	0	0	1 (1)	1 (<1)
ICHTHOPASTE	0	0	0	1 (1)	1 (<1)
IMMUNOGLOBULIN ANTIHEPATITIS B	0	0	0	1 (1)	1 (<1)
INTRALIPID	0	0	1 (1)	1 (1)	1 (<1)
IOHEXOL	0	1 (2)	1 (1)	1 (1)	1 (<1)
IOTALAMIC ACID	0	0	1 (1)	1 (1)	1 (<1)
IOXILAN	0	1 (2)	1 (1)	1 (1)	1 (<1)
ISOPROPANOL	0	0	1 (1)	1 (1)	1 (<1)
KETOCONAZOLE	1 (6)	1 (2)	0	0	1 (<1)
LACTINEX	0	0	1 (1)	1 (1)	1 (<1)
LISINOPRIL	0	0	1 (1)	1 (1)	1 (<1)
LOPERAMIDE	0	0	1 (1)	1 (1)	1 (<1)
MAALOX	0	0	0	1 (1)	1 (<1)
MAALOX PLUS	0	0	1 (1)	1 (1)	1 (<1)
MACROGOL 3350	0	0	1 (1)	1 (1)	1 (<1)
MACROGOL 4000	0	1 (2)	1 (1)	1 (1)	1 (<1)
MAGNESIUM	1 (6)	1 (2)	0	0	1 (<1)
MANNITOL	0	0	1 (1)	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 15 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
MARCAIN-ADRENALIN	0	1 (2)	1 (1)	1 (1)	1 (<1)
MEASLES VACCINE	0	1 (2)	1 (1)	1 (1)	1 (<1)
MEDIUM-CHAIN TRIGLYCERIDES	0	1 (2)	1 (1)	1 (1)	1 (<1)
MENADIONE	0	0	1 (1)	1 (1)	1 (<1)
MEROKEN NEW	0	1 (2)	1 (1)	1 (1)	1 (<1)
METAMIZOLE	0	1 (2)	1 (1)	1 (1)	1 (<1)
METANIUM	0	0	1 (1)	1 (1)	1 (<1)
METOPIMAZINE	0	0	1 (1)	1 (1)	1 (<1)
METRONIDAZOLE	0	0	0	1 (1)	1 (<1)
MICAFUNGIN	0	0	1 (1)	1 (1)	1 (<1)
MICROKLIST	0	0	1 (1)	1 (1)	1 (<1)
MONTELUKAST	0	0	1 (1)	1 (1)	1 (<1)
MOXIFLOXACIN	0	0	1 (1)	1 (1)	1 (<1)
MUCOLYTICS	0	0	1 (1)	1 (1)	1 (<1)
MULTIVITAMINS WITH MINERALS	0	0	1 (1)	1 (1)	1 (<1)
NAFCILLIN	0	0	1 (1)	1 (1)	1 (<1)
NEOSPORIN	0	0	1 (1)	1 (1)	1 (<1)
NORMOSOL	0	0	1 (1)	1 (1)	1 (<1)
OLOPATADINE	0	0	1 (1)	1 (1)	1 (<1)
OMEGA-3 FATTY ACIDS	0	0	1 (1)	1 (1)	1 (<1)
OMEGA-6 FATTY ACIDS	0	0	0	1 (1)	1 (<1)
ORAL REHYDRATION SALT FORMULATIONS	0	0	1 (1)	1 (1)	1 (<1)
OSMOSAL	0	1 (2)	0	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 16 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
OTHER ANTISEPTICS AND DISINFECTANTS	0	1 (2)	1 (1)	1 (1)	1 (<1)
OTHER EMOLLIENTS AND PROTECTIVES	1 (6)	0	0	0	1 (<1)
OTHER MINERAL SUPPLEMENTS	0	0	0	1 (1)	1 (<1)
OTHER NUTRIENTS	0	0	1 (1)	1 (1)	1 (<1)
PANCRELIPASE	0	0	0	1 (1)	1 (<1)
PAPAVERINE	0	0	1 (1)	1 (1)	1 (<1)
PIPERACILLIN W/TAZOBACTAM	0	1 (2)	1 (1)	1 (1)	1 (<1)
PIRITRAMIDE	0	0	1 (1)	1 (1)	1 (<1)
POLY VI SOL	0	1 (2)	1 (1)	1 (1)	1 (<1)
POTASSIUM CITRATE	0	0	1 (1)	1 (1)	1 (<1)
POTASSIUM PERMANGANATE	0	0	1 (1)	1 (1)	1 (<1)
POTASSIUM PHOSPHATE MONOBASIC	0	0	0	1 (1)	1 (<1)
PRIORIX TETRA	0	0	0	1 (1)	1 (<1)
PROBIOTICS NOS	0	1 (2)	1 (1)	1 (1)	1 (<1)
PROCATEROL	0	0	1 (1)	1 (1)	1 (<1)
PROCET	0	0	1 (1)	1 (1)	1 (<1)
PROPRANOLOL	1 (6)	0	0	0	1 (<1)
PROTEIN HYDROLYSATE	0	0	1 (1)	1 (1)	1 (<1)
PSEUDOEPHEDRINE	0	0	1 (1)	1 (1)	1 (<1)
RED BLOOD CELLS	0	0	1 (1)	1 (1)	1 (<1)
RESPIRATORY SYSTEM	0	1 (2)	1 (1)	1 (1)	1 (<1)
RETINOL W/VITAMIN D NOS/WOOL FAT	1 (6)	0	0	0	1 (<1)
RIFINAH	0	0	1 (1)	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 17 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
RINGER-LACTATE	0	0	0	1 (1)	1 (<1)
ROCEPHIN IM.0 0	1 (1)	1 (1)	1 (<1)		
SAPROPTERIN	0	0	1 (1)	1 (1)	1 (<1)
SENSORCAINE W/EPINEPHRINE BITARTRATE	1 (6)	0	0	0	1 (<1)
SODIUM	0	0	1 (1)	1 (1)	1 (<1)
SODIUM FLUORIDE W/VITAMINS NOS	0	0	1 (1)	1 (1)	1 (<1)
SODIUM PHOSPHATE	0	0	1 (1)	1 (1)	1 (<1)
SPIRONOLACTONE	1 (6)	0	0	0	1 (<1)
STOMATOLOGICAL PREPARATIONS	0	0	1 (1)	1 (1)	1 (<1)
SULCONAZOLE	0	0	1 (1)	1 (1)	1 (<1)
SUXAMETHONIUM	0	1 (2)	0	1 (1)	1 (<1)
TECHNETIUM TC 99M SULFUR COLLOID	0	0	1 (1)	1 (1)	1 (<1)
TETANUS VACCINE	0	0	1 (1)	1 (1)	1 (<1)
THEOPHYLLINE	0	0	1 (1)	1 (1)	1 (<1)
TIPEPIDINE	0	0	1 (1)	1 (1)	1 (<1)
TRIGLYCERIDES	0	0	1 (1)	1 (1)	1 (<1)
TRIMETHOPRIM	0	0	1 (1)	1 (1)	1 (<1)
TUBERCULOSIS VACCINES	0	0	1 (1)	1 (1)	1 (<1)
TUSSIN DM	0	0	1 (1)	1 (1)	1 (<1)
UNSPECIFIED HERBAL	0	0	0	1 (1)	1 (<1)
UREA HYDROGEN PEROXIDE	0	0	0	1 (1)	1 (<1)
VACCINES	0	0	0	1 (1)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 18 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
VALISONE-G	0	0	1 (1)	1 (1)	1 (<1)
VANICREAM	1 (6)	0	0	0	1 (<1)
VICODIN	0	0	0	1 (1)	1 (<1)
VIKOMINAS	0	0	1 (1)	1 (1)	1 (<1)
VIRAL VACCINES	1 (6)	0	0	0	1 (<1)
VITAMINS, OTHER COMBINATIONS	0	1 (2)	1 (1)	1 (1)	1 (<1)
WATER FOR INJECTION	0	2 (5)	0	1 (1)	1 (<1)
ABSORBABLE GELATIN SPONGE	0	0	0	0	0
ACETYLSALICYLIC ACID	0	0	0	0	0
ADAPALENE	0	0	0	0	0
ALKA-SELTZER PLUS	0	0	0	0	0
AMINO ACIDS NOS W/FATS NOS/MALTODEXTRIN/MINER	0	1 (2)	0	0	0
AMINOCAPROIC ACID	0	0	0	0	0
ANAESTHETICS FOR TOPICAL USE	0	0	0	0	0
ANOVLAR	0	0	0	0	0
ANTISEPTIC SOLUTION	0	0	0	0	0
ANTIVIRALS	0	0	0	0	0
ARGININE	0	0	0	0	0
ARTIFICIAL TEARS	0	0	0	0	0
ASCORBIC ACID	0	1 (2)	0	0	0
ASCORBIC ACID (VITAMIN C), PLAIN	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 19 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
ASCORBIC ACID W/CALCIUM PHOSPHATE/LACTOBACILL	0	0	0	0	0
ASCORBIC ACID W/HERBAL NOS/LEVOGLUTAMIDE/LYSI	0	0	0	0	0
AVENA SATIVA	0	1 (2)	0	0	0
AVOCA	0	1 (2)	0	0	0
BACITRACIN W/POLYMYXIN B	0	1 (2)	0	0	0
BENZACLIN TOPICAL	0	0	0	0	0
BLOOD AND RELATED PRODUCTS	0	0	0	0	0
BLOOD CELLS, PACKED HUMAN	0	0	0	0	0
BROMFED	0	0	0	0	0
CAFFEINE	0	0	0	0	0
CALAMINE	0	1 (2)	0	0	0
CALCIUM D3	0	0	0	0	0
CALCIUM GLUCONATE	0	2 (5)	0	0	0
CARBOHYDRATES NOS W/POTASSIUM CHLORIDE/SODIUM	0	1 (2)	0	0	0
CARBOMER	0	1 (2)	0	0	0
CARNITINE W/PROTEINS NOS/TAURINE	0	0	0	0	0
CEFACLOR	0	1 (2)	0	0	0
CHROMIUM	0	1 (2)	0	0	0
CINNAMOMUM VERUM	0	0	0	0	0
CIPRODAC-DM	0	1 (2)	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 20 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
CISATRACURIUM	0	0	0	0	0
CLONALIN	0	0	0	0	0
CLONAZEPAM	0	0	0	0	0
CLOSTRIDIUM BUTYRICUM	0	1 (2)	0	0	0
CODEINE/PROMETHAZINE	0	0	0	0	0
COLISTIN	0	1 (2)	0	0	0
COLOSTRUM	0	0	0	0	0
COMPOUND SODIUM CHLORIDE	0	0	0	0	0
COTYLENOL	0	0	0	0	0
COUGH AND COLD PREPARATIONS	0	1 (2)	0	0	0
COUGH SYRUP	0	0	0	0	0
CUTASEPT G	0	2 (5)	0	0	0
D-FLUORETTEN	0	1 (2)	0	0	0
DESFLURANE	0	0	0	0	0
DEXMETHYLPHENIDATE	0	0	0	0	0
DEXTROMETHORPHAN	0	0	0	0	0
DEXTROSE IN LACTATED RINGER'S	0	1 (2)	0	0	0
DEXTROSE W/POTASSIUM CHLORIDE	0	1 (2)	0	0	0
DIMETANE DX	0	0	0	0	0
DIMETAPP	0	0	0	0	0
DIMETAPP DM	0	0	0	0	0
DIPHENTANN-D	0	0	0	0	0
DOCOSANOL	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 21 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
DUONASE	0	0	0	0	0
ECHINACEA PURPUREA	0	0	0	0	0
EPHEDRINE	0	0	0	0	0
ETHANOL	0	1 (2)	0	0	0
ETHINYL ESTRADIOL W/NORGESTREL	0	0	0	0	0
ETODOLAC	0	0	0	0	0
EUGYNON	0	0	0	0	0
EXCEDRIN	0	0	0	0	0
FLEET ENEMA	0	0	0	0	0
FLUORIDE	0	0	0	0	0
FOLIC ACID	0	0	0	0	0
GABAPENTIN	0	0	0	0	0
GENERAL NUTRIENTS	0	1 (2)	0	0	0
GLYCERYL TRINITRATE	0	1 (2)	0	0	0
GUAIAZULENE	0	1 (2)	0	0	0
HALIBORANGE	0	1 (2)	0	0	0
HERBAL EXTRACT NOS	0	0	0	0	0
HERBAL PREPARATION	0	1 (2)	0	0	0
HOMEOPATHIC PREPARATION	0	0	0	0	0
HONEY	0	1 (2)	0	0	0
HUMAN PAPILLOMA VACCINE	0	0	0	0	0
HUMAN RED BLOOD CELLS	0	0	0	0	0
HYALURONIDASE	0	1 (2)	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 22 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
HYDROMOL	0	1 (2)	0	0	0
HYDROXYZINE	0	0	0	0	0
HYPERTONIC SOLUTIONS	0	1 (2)	0	0	0
HYPROMELLOSE	0	1 (2)	0	0	0
INFANT FORMULAS	0	2 (5)	0	0	0
ISOFLURANE	0	0	0	0	0
JARRO DOPHILUS	0	1 (2)	0	0	0
JONOSTERIL	0	0	0	0	0
LACTOBACILLUS REUTERI	0	1 (2)	0	0	0
LEKOVIT CA	0	0	0	0	0
LEVOGLUTAMIDE	0	0	0	0	0
LINEZOLID	0	1 (2)	0	0	0
MAGNESIUM SULFATE	0	1 (2)	0	0	0
MANGANESE	0	1 (2)	0	0	0
MARCAINE WITH EPINEPHRINE	0	0	0	0	0
MENTHOL W/METHYL SALICYLATE	0	0	0	0	0
METFORMIN	0	0	0	0	0
METHYLPHENIDATE	0	0	0	0	0
MICROLAX	0	1 (2)	0	0	0
MINERAL OIL EMULSION	0	0	0	0	0
MINERAL SUPPLEMENTS	0	0	0	0	0
MOMETASONE	0	0	0	0	0
MULTI DAY MULTIVITAMIN PLUS IRON	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 23 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
MULTIVITAMIN	0	0	0	0	0
MULTIVITAMINS WITH FLUORIDE	0	0	0	0	0
MULTONIC	0	0	0	0	0
NALBUPHINE	0	1 (2)	0	0	0
NAPROXEN	0	0	0	0	0
NARINE	0	0	0	0	0
NEUTRA-PHOS-K	0	1 (2)	0	0	0
NITROFURANTOIN	0	0	0	0	0
NOREPINEPHRINE	0	1 (2)	0	0	0
OFLOXACIN	0	0	0	0	0
OPIAT	0	1 (2)	0	0	0
ORAL REHYDRATION SALT	0	1 (2)	0	0	0
OTHER MINERAL PRODUCTS	0	1 (2)	0	0	0
OTHER VITAMIN PRODUCTS, COMBINATIONS	0	0	0	0	0
OTOSPORIN	0	1 (2)	0	0	0
PAMIDRONIC ACID	0	0	0	0	0
PANSORAL	0	1 (2)	0	0	0
PARADRYL EXPECT	0	1 (2)	0	0	0
PARAFFIN SOFT	0	0	0	0	0
PARAFFIN, LIQUID	0	0	0	0	0
PEDIACARE COUGH-COLD	0	0	0	0	0
PETHIDINE	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 24 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
PHENOL	0	0	0	0	0
PHENTERMINE	0	0	0	0	0
PHENYLEPHRINE	0	0	0	0	0
PHYSIO 140	0	1 (2)	0	0	0
PIMECROLIMUS	0	1 (2)	0	0	0
PLASMALYTE A	0	1 (2)	0	0	0
POLY-VI-FLOR	0	1 (2)	0	0	0
POLYCARBOPHIL	0	0	0	0	0
POLYMYXIN	0	1 (2)	0	0	0
POLYTRIM	0	0	0	0	0
PROMETHAZINE	0	0	0	0	0
PROTEINS NOS W/VITAMINS NOS	0	0	0	0	0
PSYLLIUM HYDROPHILIC MUCILLOID	0	0	0	0	0
REDUCTO	0	1 (2)	0	0	0
RETINOL W/VITAMIN D NOS	0	1 (2)	0	0	0
RIFAMYCIN	0	1 (2)	0	0	0
SACCHAROMYCES BOULARDIL LYOPHYLIZED	0	0	0	0	0
SALACTOL	0	0	0	0	0
SALICYLIC ACID	0	0	0	0	0
SELENIUM	0	1 (2)	0	0	0
SENNOSIDE A+B	0	0	0	0	0
SILVER	0	0	0	0	0
SODIUM W/POTASSIUM PHOSPHATE	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 25 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
SOLPADEINE	0	0	0	0	0
SULFAMETHOXAZOLE	0	0	0	0	0
SUPRADYN	0	0	0	0	0
SURGICAL DRESSINGS	0	1 (2)	0	0	0
TEETHING #3	0	2 (5)	0	0	0
TETRYZOLINE	0	0	0	0	0
THIOCTIC ACID	0	0	0	0	0
THOMAPYRIN N	0	0	0	0	0
TOCOPHEROL	0	0	0	0	0
TOLTERODINE	0	0	0	0	0
TRAMADOL	0	1 (2)	0	0	0
TRANEXAMIC ACID	0	0	0	0	0
TRETINOIN	0	0	0	0	0
TRI-VI-FLOR	0	1 (2)	0	0	0
TRIAMINIC-DM	0	0	0	0	0
TROPICAMIDE	0	1 (2)	0	0	0
TUMS	0	0	0	0	0
UBIDECARENONE	0	0	0	0	0
VICKS FORMULA 44M	0	0	0	0	0
VITAMIN B COMPLEX	0	0	0	0	0
VITAMIN C WITH ZINC	0	0	0	0	0
VITIS VINIFERA	0	0	0	0	0
ZEASORB	0	1 (2)	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 26 of 26

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
ZINC CHLORIDE	0	1 (2)	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 26　Subjects Diagnosed With SMA:Concomitant Medications

Subjects diagnosed with SMA: concomitant medications
Page 1 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100)	100 (100)	117 (100)	56 (100)	173 (100)
Number of subjects who received a concomitant medication	15 (88)	100 (100)	115 (98)	56 (100)	171 (99)
PARACETAMOL	11 (65)	77 (77)	88 (75)	41 (73)	129 (75)
LIDOCAINE	11 (65)	51 (51)	62 (53)	35 (63)	97 (56)
SODIUM CHLORIDE	7 (41)	47 (47)	54 (46)	38 (68)	92 (53)
POVIDONE-IODINE	3 (18)	61 (61)	64 (55)	18 (32)	82 (47)
IBUPROFEN	2 (12)	43 (43)	45 (38)	36 (64)	81 (47)
EMLA	8 (47)	54 (54)	62 (53)	18 (32)	80 (46)
SALBUTAMOL	2 (12)	59 (59)	61 (52)	12 (21)	73 (42)
MIDAZOLAM	2 (12)	22 (22)	24 (21)	47 (84)	71 (41)
FLEBOBAG RING LACT	2 (12)	10 (10)	12 (10)	52 (93)	64 (37)
INFLUENZA VACCINE	2 (12)	38 (38)	40 (34)	22 (39)	62 (36)
OXYGEN	0	28 (28)	28 (24)	34 (61)	62 (36)
FENTANYL	1 (6)	20 (20)	21 (18)	38 (68)	59 (34)
AMOXICILLIN	2 (12)	37 (37)	39 (33)	18 (32)	57 (33)
PNEUMOCOCCAL VACCINE	5 (29)	51 (51)	56 (48)	1 (2)	57 (33)
PROPOFOL	3 (18)	12 (12)	15 (13)	42 (75)	57 (33)
ONDANSETRON	0	4 (4)	4 (3)	52 (93)	56 (32)
PALIVIZUMAB	1 (6)	51 (51)	52 (44)	1 (2)	53 (31)
NITROUS OXIDE	2 (12)	10 (10)	12 (10)	37 (66)	49 (28)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 2 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
SEVOFLURANE	2 (12)	8 (8)	10 (9)	37 (66)	47 (27)
MACROGOL	0	26 (26)	26 (22)	17 (30)	43 (25)
RANITIDINE	1 (6)	32 (32)	33 (28)	6 (11)	39 (23)
CEFTRIAXONE	2 (12)	29 (29)	31 (26)	5 (9)	36 (21)
HAEMOPHILUS INFLUENZA TYPE B VACCINE	7 (41)	29 (29)	36 (31)	0	36 (21)
AUGMENTIN	0	25 (25)	25 (21)	8 (14)	33 (19)
HIBISOL	1 (6)	8 (8)	9 (8)	24 (43)	33 (19)
MORPHINE	0	23 (23)	23 (20)	10 (18)	33 (19)
ROTAVIRUS VACCINE	6 (35)	27 (27)	33 (28)	0	33 (19)
CHLORHEXIDINE	0	21 (21)	21 (18)	11 (20)	32 (18)
VACCIN IPAD D.T.C.3 (18)	27 (27)	30 (26)	2 (4)	32 (18)	
MULTIVITAMINS	0	8 (8)	8 (7)	22 (39)	30 (17)
DEXAMETHASONE	0	9 (9)	9 (8)	20 (36)	29 (17)
AZITHROMYCIN	1 (6)	15 (15)	16 (14)	12 (21)	28 (16)
HEPATITIS B VACCINE	2 (12)	25 (25)	27 (23)	1 (2)	28 (16)
SUCROSE	4 (24)	24 (24)	28 (24)	0	28 (16)
DEXTROSE AND SODIUM CHLORIDE INJECTION	1 (6)	20 (20)	21 (18)	5 (9)	26 (15)
CETIRIZINE	1 (6)	15 (15)	16 (14)	9 (16)	25 (14)
COLECALCIFEROL	1 (6)	17 (17)	18 (15)	7 (13)	25 (14)
DEXMEDETOMIDINE	2 (12)	10 (10)	12 (10)	12 (21)	24 (14)
KETAMINE	0	6 (6)	6 (5)	18 (32)	24 (14)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 3 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
CEFAZOLIN	0	16 (16)	16 (14)	7 (13)	23 (13)
MEASLES MUMPS & RUBELLA LIVE ATTENUATED (FREE	0	22 (22)	22 (19)	1 (2)	23 (13)
OSMOTAN	1 (6)	19 (19)	20 (17)	3 (5)	23 (13)
BUDESONIDE	3 (18)	14 (14)	17 (15)	5 (9)	22 (13)
CLINDAMYCIN	0	21 (21)	21 (18)	1 (2)	22 (13)
DIPHENHYDRAMINE	0	9 (9)	9 (8)	13 (23)	22 (13)
GLYCEROL	0	17 (17)	17 (15)	5 (9)	22 (13)
KETOROLAC	0	6 (6)	6 (5)	16 (29)	22 (13)
POLIO VACCINE	3 (18)	17 (17)	20 (17)	2 (4)	22 (13)
GLYCOPYRRONIUM	0	15 (15)	15 (13)	6 (11)	21 (12)
REMIFENTANIL	0	2 (2)	2 (2)	19 (34)	21 (12)
CEFDINIR	1 (6)	10 (10)	11 (9)	9 (16)	20 (12)
PIP/TAZO	0	19 (19)	19 (16)	1 (2)	20 (12)
VITAMIN D NOS	6 (35)	12 (12)	18 (15)	1 (2)	19 (11)
HYDROCORTISONE	2 (12)	9 (9)	11 (9)	7 (13)	18 (10)
LORAZEPAM	0	15 (15)	15 (13)	3 (5)	18 (10)
NYSTATIN	2 (12)	16 (16)	18 (15)	0	18 (10)
VARICELLA ZOSTER VACCINE	0	16 (16)	16 (14)	2 (4)	18 (10)
DORNASE ALFA	0	17 (17)	17 (15)	0	17 (10)
MULTIVITAMIN	0	0	0	17 (30)	17 (10)
SIMETICONE	2 (12)	12 (12)	14 (12)	2 (4)	16 (9)
BARIUM	0	14 (14)	14 (12)	1 (2)	15 (9)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 4 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
CIPROFLOXACIN	0	13 (13)	13 (11)	2 (4)	15 (9)
ISOFLURANE	0	0	0	15 (27)	15 (9)
FLUTICASONE	0	9 (9)	9 (8)	5 (9)	14 (8)
HEPATITIS A VACCINE	0	13 (13)	13 (11)	1 (2)	14 (8)
OSELTAMIVIR	0	7 (7)	7 (6)	7 (13)	14 (8)
ACETYLCYSTEINE	0	13 (13)	13 (11)	0	13 (8)
INFANRIX IPV+HIB	1 (6)	12 (12)	13 (11)	0	13 (8)
ROCURONIUM	0	10 (10)	10 (9)	3 (5)	13 (8)
BACTRIM	0	9 (9)	9 (8)	3 (5)	12 (7)
HEPARIN	0	9 (9)	9 (8)	3 (5)	12 (7)
LANSOPRAZOLE	0	12 (12)	12 (10)	0	12 (7)
OMEPRAZOLE	1 (6)	10 (10)	11 (9)	1 (2)	12 (7)
PREDNISOLONE	0	9 (9)	9 (8)	3 (5)	12 (7)
AMOXICILLIN W/CLAVULANATE POTASSIUM	0	10 (10)	10 (9)	1 (2)	11 (6)
ATROPINE	0	11 (11)	11 (9)	0	11 (6)
CEFALEXIN	0	4 (4)	4 (3)	7 (13)	11 (6)
IPRATROPIUM	0	11 (11)	11 (9)	0	11 (6)
LEVOSALBUTAMOL	1 (6)	7 (7)	8 (7)	3 (5)	11 (6)
PEDIARIX	5 (29)	6 (6)	11 (9)	0	11 (6)
SPEKTRAMOX	0	11 (11)	11 (9)	0	11 (6)
AMOXI-CLAVULANICO	3 (18)	5 (5)	8 (7)	2 (4)	10 (6)
BUPIVACAINE	0	4 (4)	4 (3)	6 (11)	10 (6)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 5 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ERGOCALCIFEROL	0	3 (3)	3 (3)	7 (13)	10 (6)
FUROSEMIDE	0	9 (9)	9 (8)	1 (2)	10 (6)
INFANRIX HEXA	0	10 (10)	10 (9)	0	10 (6)
SODIUM BICARBONATE	0	9 (9)	9 (8)	1 (2)	10 (6)
TOBRAMYCIN	0	6 (6)	6 (5)	4 (7)	10 (6)
CLOTRIMAZOLE	3 (18)	4 (4)	7 (6)	2 (4)	9 (5)
DOCUSATE	0	6 (6)	6 (5)	3 (5)	9 (5)
FAMOTIDINE	0	9 (9)	9 (8)	0	9 (5)
GLYCERIN	0	9 (9)	9 (8)	0	9 (5)
IRON	0	8 (8)	8 (7)	1 (2)	9 (5)
MUPIROCIN	1 (6)	7 (7)	8 (7)	1 (2)	9 (5)
OXYCODONE	0	3 (3)	3 (3)	6 (11)	9 (5)
POTASSIUM	0	7 (7)	7 (6)	2 (4)	9 (5)
ANESTHETICS, GENERAL	0	6 (6)	6 (5)	2 (4)	8 (5)
CEFUROXIME	2 (12)	6 (6)	8 (7)	0	8 (5)
ERYTHROMYCIN	0	7 (7)	7 (6)	1 (2)	8 (5)
GLUCOSE	0	6 (6)	6 (5)	2 (4)	8 (5)
GUAIFENESIN	0	1 (1)	1 (<1)	7 (13)	8 (5)
LORATADINE	0	3 (3)	3 (3)	5 (9)	8 (5)
METHYLPREDNISOLONE	0	6 (6)	6 (5)	2 (4)	8 (5)
VANCOMYCIN	0	6 (6)	6 (5)	2 (4)	8 (5)
VITAMINS NOS	2 (12)	4 (4)	6 (5)	2 (4)	8 (5)
CEFOTAXIME	0	5 (5)	5 (4)	2 (4)	7 (4)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 6 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
EPINEPHRINE	0	6 (6)	6 (5)	1 (2)	7 (4)
FISH OIL	0	1 (1)	1 (<1)	6 (11)	7 (4)
LACTULOSE	0	7 (7)	7 (6)	0	7 (4)
BENZOCAINE	0	5 (5)	5 (4)	1 (2)	6 (3)
DIAZEPAM	0	1 (1)	1 (<1)	5 (9)	6 (3)
EMLAPATCH	0	6 (6)	6 (5)	0	6 (3)
ESOMEPRAZOLE	0	5 (5)	5 (4)	1 (2)	6 (3)
FATS NOS	0	6 (6)	6 (5)	0	6 (3)
FERROUS SULFATE W/VITAMINS NOS	0	4 (4)	4 (3)	2 (4)	6 (3)
LACTOBACILLUS ACIDOPHILUS	2 (12)	3 (3)	5 (4)	1 (2)	6 (3)
LACTOBACILLUS NOS	0	6 (6)	6 (5)	0	6 (3)
MINERALS NOS W/VITAMINS NOS	0	5 (5)	5 (4)	1 (2)	6 (3)
NEOTRACIN	0	2 (2)	2 (2)	4 (7)	6 (3)
PANTOPRAZOLE	0	6 (6)	6 (5)	0	6 (3)
PREDNISONE	0	4 (4)	4 (3)	2 (4)	6 (3)
TRIAMCINOLONE	0	4 (4)	4 (3)	2 (4)	6 (3)
UNACID	0	5 (5)	5 (4)	1 (2)	6 (3)
ZINC	0	4 (4)	4 (3)	2 (4)	6 (3)
ACICLOVIR	0	4 (4)	4 (3)	1 (2)	5 (3)
AQUAPHOR	0	5 (5)	5 (4)	0	5 (3)
ASCORBIC ACID	0	0	0	5 (9)	5 (3)
BISEPTINE	0	5 (5)	5 (4)	0	5 (3)
DEXTROMETHORPHAN	0	0	0	5 (9)	5 (3)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 7 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
DOMPERIDONE	0	5 (5)	5 (4)	0	5 (3)
EPHEDRINE	0	0	0	5 (9)	5 (3)
GENTAMICIN	0	5 (5)	5 (4)	0	5 (3)
I.V.SOLUTIONS	0	4 (4)	4 (3)	1 (2)	5 (3)
IMMUNOGLOBULIN ANTI RESPIRATORY SYNCYTIAL VIR	0	5 (5)	5 (4)	0	5 (3)
MELATONIN	0	2 (2)	2 (2)	3 (5)	5 (3)
PHENYLEPHRINE	0	0	0	5 (9)	5 (3)
POLY-VI-SOL WITH IRON	1 (6)	4 (4)	5 (4)	0	5 (3)
PROCET	0	1 (1)	1 (<1)	4 (7)	5 (3)
PSEUDOEPHEDRINE	0	1 (1)	1 (<1)	4 (7)	5 (3)
REHYDRON	0	4 (4)	4 (3)	1 (2)	5 (3)
SALINE	0	4 (4)	4 (3)	1 (2)	5 (3)
SENNA ALEXANDRINA	0	3 (3)	3 (3)	2 (4)	5 (3)
SOLUTIONS FOR PARENTERAL NUTRITION	0	5 (5)	5 (4)	0	5 (3)
XILONIBSA	0	3 (3)	3 (3)	2 (4)	5 (3)
ALBUMIN HUMAN	0	1 (1)	1 (<1)	3 (5)	4 (2)
BACITRACIN	0	4 (4)	4 (3)	0	4 (2)
BIFIDOBACTERIUM LACTIS	0	2 (2)	2 (2)	2 (4)	4 (2)
BISACODYL	0	1 (1)	1 (<1)	3 (5)	4 (2)
BOTULINUM TOXIN TYPE A	0	4 (4)	4 (3)	0	4 (2)
CEFEPIME	0	4 (4)	4 (3)	0	4 (2)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 8 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ETOMIDATE	0	4 (4)	4 (3)	0	4 (2)
FLUCONAZOLE	0	3 (3)	3 (3)	1 (2)	4 (2)
GABAPENTIN	0	0	0	4 (7)	4 (2)
HYOSCINE	0	2 (2)	2 (2)	2 (4)	4 (2)
MAGNESIUM HYDROXIDE	0	2 (2)	2 (2)	2 (4)	4 (2)
MENINGOCOCCAL VACCINE	0	4 (4)	4 (3)	0	4 (2)
MONTELUKAST	0	1 (1)	1 (<1)	3 (5)	4 (2)
MULTIVITAMINS WITH IRON	0	4 (4)	4 (3)	0	4 (2)
NAPROXEN	0	0	0	4 (7)	4 (2)
NEOSTIGMINE	0	2 (2)	2 (2)	2 (4)	4 (2)
OTHER MINERAL SUPPLEMENTS	0	1 (1)	1 (<1)	3 (5)	4 (2)
PROBIOTICS	0	3 (3)	3 (3)	1 (2)	4 (2)
QUADRACEL	0	3 (3)	3 (3)	1 (2)	4 (2)
SAMBUCUS NIGRA	0	2 (2)	2 (2)	2 (4)	4 (2)
SILVER NITRATE	2 (12)	1 (1)	3 (3)	1 (2)	4 (2)
XYLOCAINE-EPINEPHRINE	0	2 (2)	2 (2)	2 (4)	4 (2)
ALTEPLASE	0	3 (3)	3 (3)	0	3 (2)
AMITRIPTYLINE	0	2 (2)	2 (2)	1 (2)	3 (2)
AMPICILLIN	0	3 (3)	3 (3)	0	3 (2)
BECLOMETASONE	2 (12)	1 (1)	3 (3)	0	3 (2)
BENZYLPENICILLIN	0	2 (2)	2 (2)	1 (2)	3 (2)
CALCIUM	0	1 (1)	1 (<1)	2 (4)	3 (2)
CEFIXIME	0	3 (3)	3 (3)	0	3 (2)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 9 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
CEFOXITIN	0	3 (3)	3 (3)	0	3 (2)
CLARITHROMYCIN	0	3 (3)	3 (3)	0	3 (2)
CLONIDINE	0	2 (2)	2 (2)	1 (2)	3 (2)
COMBIVENT	0	3 (3)	3 (3)	0	3 (2)
DESONIDE	0	3 (3)	3 (3)	0	3 (2)
ENTONOX	0	3 (3)	3 (3)	0	3 (2)
FUSIDIC ACID	1 (6)	2 (2)	3 (3)	0	3 (2)
HEPATITIS VACCINES	0	3 (3)	3 (3)	0	3 (2)
HYDROMORPHONE	0	1 (1)	1 (<1)	2 (4)	3 (2)
LACTOBACILLUS RHAMNOSUS	0	3 (3)	3 (3)	0	3 (2)
LEVETIRACETAM	0	3 (3)	3 (3)	0	3 (2)
LEVOCARNITINE	1 (6)	2 (2)	3 (3)	0	3 (2)
LIDOCAINE W/SODIUM BICARBONATE	3 (18)	0	3 (3)	0	3 (2)
MEROPENEM	0	3 (3)	3 (3)	0	3 (2)
METOCLOPRAMIDE	0	2 (2)	2 (2)	1 (2)	3 (2)
MICONAZOLE	0	3 (3)	3 (3)	0	3 (2)
MOMETASONE	0	0	0	3 (5)	3 (2)
MOXIFLOXACIN	0	1 (1)	1 (<1)	2 (4)	3 (2)
MULTVIT	0	2 (2)	2 (2)	1 (2)	3 (2)
NALBUPHINE	0	0	0	3 (5)	3 (2)
OMEGA-3 FATTY ACIDS	0	1 (1)	1 (<1)	2 (4)	3 (2)
OXYMETAZOLINE	1 (6)	1 (1)	2 (2)	1 (2)	3 (2)
PETHIDINE	0	0	0	3 (5)	3 (2)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 10 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
POLY-VI-SOL	0	3 (3)	3 (3)	0	3 (2)
ROPIVACAINE	0	3 (3)	3 (3)	0	3 (2)
SACCHAROMYCES BOULARDII	0	2 (2)	2 (2)	1 (2)	3 (2)
SODIUM FLUORIDE	0	2 (2)	2 (2)	1 (2)	3 (2)
SULTAMICILLIN	0	3 (3)	3 (3)	0	3 (2)
TETRACAINE	0	3 (3)	3 (3)	0	3 (2)
VECURONIUM	0	3 (3)	3 (3)	0	3 (2)
ACETAZOLAMIDE	0	2 (2)	2 (2)	0	2 (1)
AMIKACIN	0	2 (2)	2 (2)	0	2 (1)
AMINO ACIDS NOS	0	1 (1)	1 (<1)	1 (2)	2 (1)
AMPHOTERICIN B	0	2 (2)	2 (2)	0	2 (1)
ANAESTHETICS	0	2 (2)	2 (2)	0	2 (1)
ANESTHETICS	0	2 (2)	2 (2)	0	2 (1)
BENZACLIN TOPICAL	0	0	0	2 (4)	2 (1)
CALCIUM GLUCONATE	0	0	0	2 (4)	2 (1)
CEFPODOXIME	0	2 (2)	2 (2)	0	2 (1)
CEFPROZIL	0	1 (1)	1 (<1)	1 (2)	2 (1)
CEFTAZIDIME	0	2 (2)	2 (2)	0	2 (1)
CHLOROTHIAZIDE	0	2 (2)	2 (2)	0	2 (1)
DEMAZIN	0	1 (1)	1 (<1)	1 (2)	2 (1)
DESFLURANE	0	0	0	2 (4)	2 (1)
DIMETICONE	0	2 (2)	2 (2)	0	2 (1)
DUOCID	0	2 (2)	2 (2)	0	2 (1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 11 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ECONAZOLE	0	2 (2)	2 (2)	0	2 (1)
ELECTROLYTES NOS W/GLUCOSE	1 (6)	1 (1)	2 (2)	0	2 (1)
EMOLLIENTS AND PROTECTIVES	0	2 (2)	2 (2)	0	2 (1)
FENOTEROL	2 (12)	0	2 (2)	0	2 (1)
FEXOFENADINE	0	1 (1)	1 (<1)	1 (2)	2 (1)
FOSPHENYTOIN	0	2 (2)	2 (2)	0	2 (1)
INSULIN	0	2 (2)	2 (2)	0	2 (1)
IOPAMIDOL	1 (6)	1 (1)	2 (2)	0	2 (1)
ISRADIPINE	0	2 (2)	2 (2)	0	2 (1)
LEKOVIT CA	0	0	0	2 (4)	2 (1)
LEVOFLOXACIN	0	2 (2)	2 (2)	0	2 (1)
LEVOGLUTAMIDE	0	0	0	2 (4)	2 (1)
LOPERAMIDE	0	1 (1)	1 (<1)	1 (2)	2 (1)
MAALOX	0	1 (1)	1 (<1)	1 (2)	2 (1)
MENHIBRIX	0	2 (2)	2 (2)	0	2 (1)
METAMIZOLE	0	1 (1)	1 (<1)	1 (2)	2 (1)
METFORMIN	0	0	0	2 (4)	2 (1)
METHADONE	0	2 (2)	2 (2)	0	2 (1)
METHYLROSANILINIUM	0	2 (2)	2 (2)	0	2 (1)
MOVICOL	0	2 (2)	2 (2)	0	2 (1)
NISITA	0	2 (2)	2 (2)	0	2 (1)
OTHER DERMATOLOGICAL PREPARATIONS	0	2 (2)	2 (2)	0	2 (1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 12 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
PARAFFIN	1 (6)	1 (1)	2 (2)	0	2 (1)
PETROLATUM	0	2 (2)	2 (2)	0	2 (1)
PIPERACILLIN	0	2 (2)	2 (2)	0	2 (1)
PLASMA	0	2 (2)	2 (2)	0	2 (1)
PLASMA LYTE 148	0	2 (2)	2 (2)	0	2 (1)
POLYCARBOPHIL	0	0	0	2 (4)	2 (1)
POLYSPORIN	0	2 (2)	2 (2)	0	2 (1)
PROTEIN SUPPLEMENTS	0	2 (2)	2 (2)	0	2 (1)
RACECADOTRIL	0	2 (2)	2 (2)	0	2 (1)
RACEPINEFRINE	0	2 (2)	2 (2)	0	2 (1)
RED BLOOD CELLS	0	1 (1)	1 (<1)	1 (2)	2 (1)
ROXITHROMYCIN	0	2 (2)	2 (2)	0	2 (1)
SENNOSIDE A+B	0	0	0	2 (4)	2 (1)
SODIUM FLUORIDE W/VITAMINS NOS	0	1 (1)	1 (<1)	1 (2)	2 (1)
SODIUM PHOSPHATE	0	1 (1)	1 (<1)	1 (2)	2 (1)
SUCRALFATE	0	2 (2)	2 (2)	0	2 (1)
THOMAPYRIN N	0	0	0	2 (4)	2 (1)
TPN	0	2 (2)	2 (2)	0	2 (1)
TUMS	0	0	0	2 (4)	2 (1)
UBIDECARENONE	0	0	0	2 (4)	2 (1)
UREA HYDROGEN PEROXIDE	0	1 (1)	1 (<1)	1 (2)	2 (1)
UVESTEROL	0	2 (2)	2 (2)	0	2 (1)
XYLOMETAZOLINE	0	2 (2)	2 (2)	0	2 (1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 13 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ABSORBABLE GELATIN SPONGE	0	0	0	1 (2)	1 (<1)
ACETYLSALICYLIC ACID	0	0	0	1 (2)	1 (<1)
ADAPALENE	0	0	0	1 (2)	1 (<1)
ADENOSINE	0	1 (1)	1 (<1)	0	1 (<1)
ADIARIL	0	1 (1)	1 (<1)	0	1 (<1)
ALCLOMETASONE	0	1 (1)	1 (<1)	0	1 (<1)
ALKA-SELTZER PLUS	0	0	0	1 (2)	1 (<1)
ALOE VERA	0	1 (1)	1 (<1)	0	1 (<1)
AMBROXOL	0	1 (1)	1 (<1)	0	1 (<1)
AMINOCAPROIC ACID	0	0	0	1 (2)	1 (<1)
AMINOPHYLLINE	0	1 (1)	1 (<1)	0	1 (<1)
AMIODARONE	1 (6)	0	1 (<1)	0	1 (<1)
ANAESTHETICS FOR TOPICAL USE	0	0	0	1 (2)	1 (<1)
ANOVLAR	0	0	0	1 (2)	1 (<1)
ANTIBIOTICS	0	1 (1)	1 (<1)	0	1 (<1)
ANTIDIARRHEAL MICROORGANISMS	0	1 (1)	1 (<1)	0	1 (<1)
ANTIFUNGALS FOR DERMATOLOGICAL USE	0	1 (1)	1 (<1)	0	1 (<1)
ANTISEPTIC SOLUTION	0	0	0	1 (2)	1 (<1)
ANTIVIRALS	0	0	0	1 (2)	1 (<1)
ARGININE	0	0	0	1 (2)	1 (<1)
ARTIFICIAL TEARS	0	0	0	1 (2)	1 (<1)
ASCORBIC ACID (VITAMIN C), PLAIN	0	0	0	1 (2)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 14 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ASCORBIC ACID W/CALCIUM PHOSPHATE/LACTOBACILL	0	0	0	1 (2)	1 (<1)
ASCORBIC ACID W/HERBAL NOS/LEVOGLUTAMIDE/LYSI	0	0	0	1 (2)	1 (<1)
ASCORBIC ACID W/RETINOL/VITAMIN D NOS	0	1 (1)	1 (<1)	0	1 (<1)
ATRACURIUM	0	1 (1)	1 (<1)	0	1 (<1)
AURALGAN	0	1 (1)	1 (<1)	0	1 (<1)
AUXERGYL D3	0	1 (1)	1 (<1)	0	1 (<1)
AVEENO BABY DAILY MOISTURE	0	1 (1)	1 (<1)	0	1 (<1)
BENZALKONIUM	0	1 (1)	1 (<1)	0	1 (<1)
BETAMETHASONE	1 (6)	0	1 (<1)	0	1 (<1)
BETHANECHOL	0	1 (1)	1 (<1)	0	1 (<1)
BICITRA	0	1 (1)	1 (<1)	0	1 (<1)
BLOOD AND RELATED PRODUCTS	0	0	0	1 (2)	1 (<1)
BLOOD CELLS, PACKED HUMAN	0	0	0	1 (2)	1 (<1)
BLOOD, WHOLE	0	1 (1)	1 (<1)	0	1 (<1)
BROMFED	0	0	0	1 (2)	1 (<1)
BUDESONIDE W/FORMOTEROL FUMARATE	0	1 (1)	1 (<1)	0	1 (<1)
CAFFEINE	0	0	0	1 (2)	1 (<1)
CALCIUM CARBONATE	0	1 (1)	1 (<1)	0	1 (<1)
CALCIUM D3	0	0	0	1 (2)	1 (<1)
CAMPHOR	0	1 (1)	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 15 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
CANESTEN-HC	0	1 (1)	1 (<1)	0	1 (<1)
CAPTOPRIL	0	1 (1)	1 (<1)	0	1 (<1)
CARBOCISTEINE	0	1 (1)	1 (<1)	0	1 (<1)
CARBOHYDRATES NOS W/FATS NOS/MINERA	0	1 (1)	1 (<1)	0	1 (<1)
CARNITINE W/PROTEINS NOS/TAURINE	0	0	0	1 (2)	1 (<1)
CEFADROXIL	0	1 (1)	1 (<1)	0	1 (<1)
CEFOTETAN	0	1 (1)	1 (<1)	0	1 (<1)
CHAMAEMELUM NOBILE	0	1 (1)	1 (<1)	0	1 (<1)
CHLORAMPHENICOL	0	1 (1)	1 (<1)	0	1 (<1)
CINNAMOMUM VERUM	0	0	0	1 (2)	1 (<1)
CISATRACURIUM	0	0	0	1 (2)	1 (<1)
CLAVULANIC ACID	0	1 (1)	1 (<1)	0	1 (<1)
CLONALIN	0	0	0	1 (2)	1 (<1)
CLONAZEPAM	0	0	0	1 (2)	1 (<1)
CODEINE/PROMETHAZINE	0	0	0	1 (2)	1 (<1)
COLOSTRUM	0	0	0	1 (2)	1 (<1)
COMPOUND SODIUM CHLORIDE	0	0	0	1 (2)	1 (<1)
CONTRAST MEDIA	0	1 (1)	1 (<1)	0	1 (<1)
CORTICOSTEROIDS FOR SYSTEMIC USE	0	1 (1)	1 (<1)	0	1 (<1)
COTYLENOL	0	0	0	1 (2)	1 (<1)
COUGH SYRUP	0	0	0	1 (2)	1 (<1)
CROMOGLICIC ACID	0	1 (1)	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 16 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
DESITIN	0	1 (1)	1 (<1)	0	1 (<1)
DESITIN WITH ZINC OXIDE	0	1 (1)	1 (<1)	0	1 (<1)
DESLORATADINE	0	1 (1)	1 (<1)	0	1 (<1)
DEXIBUPROFEN	0	1 (1)	1 (<1)	0	1 (<1)
DEXMETHYLPHENIDATE	0	0	0	1 (2)	1 (<1)
DEXTROSE IN LACTATED RINGER'S	0	0	0	1 (2)	1 (<1)
DEXTROSE W/POTASSIUM CHLORIDE	0	0	0	1 (2)	1 (<1)
DIGOXIN	0	1 (1)	1 (<1)	0	1 (<1)
DIMENHYDRINATE	0	1 (1)	1 (<1)	0	1 (<1)
DIMETANE DX	0	0	0	1 (2)	1 (<1)
DIMETAPP	0	0	0	1 (2)	1 (<1)
DIMETAPP DM	0	0	0	1 (2)	1 (<1)
DIPHENTANN-D	0	0	0	1 (2)	1 (<1)
DIPROBASE	0	1 (1)	1 (<1)	0	1 (<1)
DOCOSANOL	0	0	0	1 (2)	1 (<1)
DOPAMINE	0	1 (1)	1 (<1)	0	1 (<1)
DUONASE	0	0	0	1 (2)	1 (<1)
ECHINACEA PURPUREA	0	0	0	1 (2)	1 (<1)
EL-4	0	1 (1)	1 (<1)	0	1 (<1)
ETHINYL ESTRADIOL W/NORGESTREL	0	0	0	1 (2)	1 (<1)
ETHYL CHLORIDE	0	1 (1)	1 (<1)	0	1 (<1)
ETODOLAC	0	0	0	1 (2)	1 (<1)
EUCERIN	0	1 (1)	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 17 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
EUGYNON	0	0	0	1 (2)	1 (<1)
EUPEPTINA	0	1 (1)	1 (<1)	0	1 (<1)
EUPHRASIA OFFICINALIS	0	1 (1)	1 (<1)	0	1 (<1)
EXCEDRIN	0	0	0	1 (2)	1 (<1)
EXCIPIAL	0	1 (1)	1 (<1)	0	1 (<1)
FITOSTIMOLINE	1 (6)	0	1 (<1)	0	1 (<1)
FLEET ENEMA	0	0	0	1 (2)	1 (<1)
FLUCLOXACILLIN	0	1 (1)	1 (<1)	0	1 (<1)
FLUOCINOLONE ACETONIDE	0	1 (1)	1 (<1)	0	1 (<1)
FLUORIDE	0	0	0	1 (2)	1 (<1)
FLUOROMETHOLONE	0	1 (1)	1 (<1)	0	1 (<1)
FOLIC ACID	0	0	0	1 (2)	1 (<1)
FRUCTOSE	0	1 (1)	1 (<1)	0	1 (<1)
GASTROGRAFIN	0	1 (1)	1 (<1)	0	1 (<1)
GAVISCON	0	1 (1)	1 (<1)	0	1 (<1)
GERBER SOOTHE	1 (6)	0	1 (<1)	0	1 (<1)
GOLYTELY	0	1 (1)	1 (<1)	0	1 (<1)
HAEMOPHILUS INFLUENZAE	0	1 (1)	1 (<1)	0	1 (<1)
HEPARIN SODIUM W/SODIUM CHLORIDE	0	1 (1)	1 (<1)	0	1 (<1)
HEPARINOID	0	1 (1)	1 (<1)	0	1 (<1)
HERBAL EXTRACT NOS	0	0	0	1 (2)	1 (<1)
HERBAL NOS W/MINERALS NOS/VITAMINS NOS	1 (6)	0	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 18 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
HOMATROPINE	0	1 (1)	1 (<1)	0	1 (<1)
HOMEOPATHIC PREPARATION	0	0	0	1 (2)	1 (<1)
HUMAN PAPILLOMA VACCINE	0	0	0	1 (2)	1 (<1)
HUMAN RED BLOOD CELLS	0	0	0	1 (2)	1 (<1)
HYDROXYQUINOLINE	0	1 (1)	1 (<1)	0	1 (<1)
HYDROXYZINE	0	0	0	1 (2)	1 (<1)
I.V.SOLUTION ADDITIVES	0	1 (1)	1 (<1)	0	1 (<1)
ICHTHOPASTE	0	1 (1)	1 (<1)	0	1 (<1)
IMMUNOGLOBULIN ANTIHEPATITIS B	0	1 (1)	1 (<1)	0	1 (<1)
INTRALIPID	0	1 (1)	1 (<1)	0	1 (<1)
IOHEXOL	0	1 (1)	1 (<1)	0	1 (<1)
IOTALAMIC ACID	0	1 (1)	1 (<1)	0	1 (<1)
IOXILAN	0	1 (1)	1 (<1)	0	1 (<1)
ISOPROPANOL	0	1 (1)	1 (<1)	0	1 (<1)
JARRO DOPHILUS	0	0	0	1 (2)	1 (<1)
JONOSTERIL	0	0	0	1 (2)	1 (<1)
KETOCONAZOLE	1 (6)	0	1 (<1)	0	1 (<1)
LACTINEX	0	1 (1)	1 (<1)	0	1 (<1)
LISINOPRIL	0	1 (1)	1 (<1)	0	1 (<1)
MAALOX PLUS	0	1 (1)	1 (<1)	0	1 (<1)
MACROGOL 3350	0	1 (1)	1 (<1)	0	1 (<1)
MACROGOL 4000	0	1 (1)	1 (<1)	0	1 (<1)
MAGNESIUM	1 (6)	0	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 19 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
MAGNESIUM SULFATE	0	0	0	1 (2)	1 (<1)
MANNITOL	0	1 (1)	1 (<1)	0	1 (<1)
MARCAIN-ADRENALIN	0	1 (1)	1 (<1)	0	1 (<1)
MARCAINE WITH EPINEPHRINE	0	0	0	1 (2)	1 (<1)
MEASLES VACCINE	0	1 (1)	1 (<1)	0	1 (<1)
MEDIUM-CHAIN TRIGLYCERIDES	0	1 (1)	1 (<1)	0	1 (<1)
MENADIONE	0	1 (1)	1 (<1)	0	1 (<1)
MENTHOL W/METHYL SALICYLATE	0	0	0	1 (2)	1 (<1)
MEROKEN NEW	0	1 (1)	1 (<1)	0	1 (<1)
METANIUM	0	1 (1)	1 (<1)	0	1 (<1)
METHYLPHENIDATE	0	0	0	1 (2)	1 (<1)
METOPIMAZINE	0	1 (1)	1 (<1)	0	1 (<1)
METRONIDAZOLE	0	1 (1)	1 (<1)	0	1 (<1)
MICAFUNGIN	0	1 (1)	1 (<1)	0	1 (<1)
MICROKLIST	0	1 (1)	1 (<1)	0	1 (<1)
MINERAL OIL EMULSION	0	0	0	1 (2)	1 (<1)
MINERAL SUPPLEMENTS	0	0	0	1 (2)	1 (<1)
MUCOLYTICS	0	1 (1)	1 (<1)	0	1 (<1)
MULTI DAY MULTIVITAMIN PLUS IRON	0	0	0	1 (2)	1 (<1)
MULTIVITAMINS WITH FLUORIDE	0	0	0	1 (2)	1 (<1)
MULTIVITAMINS WITH MINERALS	0	1 (1)	1 (<1)	0	1 (<1)
MULTONIC	0	0	0	1 (2)	1 (<1)
NAFCILLIN	0	1 (1)	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 20 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
NARINE	0	0	0	1 (2)	1 (<1)
NEOSPORIN	0	1 (1)	1 (<1)	0	1 (<1)
NITROFURANTOIN	0	0	0	1 (2)	1 (<1)
NORMOSOL	0	1 (1)	1 (<1)	0	1 (<1)
OFLOXACIN	0	0	0	1 (2)	1 (<1)
OLOPATADINE	0	1 (1)	1 (<1)	0	1 (<1)
OMEGA-6 FATTY ACIDS	0	1 (1)	1 (<1)	0	1 (<1)
ORAL REHYDRATION SALT FORMULATIONS	0	1 (1)	1 (<1)	0	1 (<1)
OSMOSAL	0	1 (1)	1 (<1)	0	1 (<1)
OTHER ANTISEPTICS AND DISINFECTANTS	0	1 (1)	1 (<1)	0	1 (<1)
OTHER EMOLLIENTS AND PROTECTIVES	1 (6)	0	1 (<1)	0	1 (<1)
OTHER NUTRIENTS	0	1 (1)	1 (<1)	0	1 (<1)
OTHER VITAMIN PRODUCTS, COMBINATIONS	0	0	0	1 (2)	1 (<1)
PAMIDRONIC ACID	0	0	0	1 (2)	1 (<1)
PANCRELIPASE	0	1 (1)	1 (<1)	0	1 (<1)
PAPAVERINE	0	1 (1)	1 (<1)	0	1 (<1)
PARAFFIN SOFT	0	0	0	1 (2)	1 (<1)
PARAFFIN, LIQUID	0	0	0	1 (2)	1 (<1)
PEDIACARE COUGH-COLD	0	0	0	1 (2)	1 (<1)
PHENOL	0	0	0	1 (2)	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 21 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
PHENTERMINE	0	0	0	1 (2)	1 (<1)
PIMECROLIMUS	0	0	0	1 (2)	1 (<1)
PIPERACILLIN W/TAZOBACTAM	0	1 (1)	1 (<1)	0	1 (<1)
PIRITRAMIDE	0	1 (1)	1 (<1)	0	1 (<1)
POLY VI SOL	0	1 (1)	1 (<1)	0	1 (<1)
POLYTRIM	0	0	0	1 (2)	1 (<1)
POTASSIUM CITRATE	0	1 (1)	1 (<1)	0	1 (<1)
POTASSIUM PERMANGANATE	0	1 (1)	1 (<1)	0	1 (<1)
POTASSIUM PHOSPHATE MONOBASIC	0	1 (1)	1 (<1)	0	1 (<1)
PRIORIX TETRA	0	1 (1)	1 (<1)	0	1 (<1)
PROBIOTICS NOS	0	1 (1)	1 (<1)	0	1 (<1)
PROCATEROL	0	1 (1)	1 (<1)	0	1 (<1)
PROMETHAZINE	0	0	0	1 (2)	1 (<1)
PROPRANOLOL	1 (6)	0	1 (<1)	0	1 (<1)
PROTEIN HYDROLYSATE	0	1 (1)	1 (<1)	0	1 (<1)
PROTEINS NOS W/VITAMINS NOS	0	0	0	1 (2)	1 (<1)
PSYLLIUM HYDROPHILIC MUCILLOID	0	0	0	1 (2)	1 (<1)
RESPIRATORY SYSTEM	0	1 (1)	1 (<1)	0	1 (<1)
RETINOL W/VITAMIN D NOS/WOOL FAT	1 (6)	0	1 (<1)	0	1 (<1)
RIFINAH	0	1 (1)	1 (<1)	0	1 (<1)
RINGER-LACTATE	0	1 (1)	1 (<1)	0	1 (<1)
ROCEPHIN IM.0	1 (1)	1 (<1)	0	1 (<1)	

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 22 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
SACCHAROMYCES BOULARDIL LYOPHYLIZED	0	0	0	1 (2)	1 (<1)
SALACTOL	0	0	0	1 (2)	1 (<1)
SALICYLIC ACID	0	0	0	1 (2)	1 (<1)
SAPROPTERIN	0	1 (1)	1 (<1)	0	1 (<1)
SENSORCAINE W/EPINEPHRINE BITARTRATE	1 (6)	0	1 (<1)	0	1 (<1)
SILVER	0	0	0	1 (2)	1 (<1)
SODIUM	0	1 (1)	1 (<1)	0	1 (<1)
SODIUM W/POTASSIUM PHOSPHATE	0	0	0	1 (2)	1 (<1)
SOLPADEINE	0	0	0	1 (2)	1 (<1)
SPIRONOLACTONE	1 (6)	0	1 (<1)	0	1 (<1)
STOMATOLOGICAL PREPARATIONS	0	1 (1)	1 (<1)	0	1 (<1)
SULCONAZOLE	0	1 (1)	1 (<1)	0	1 (<1)
SULFAMETHOXAZOLE	0	0	0	1 (2)	1 (<1)
SUPRADYN	0	0	0	1 (2)	1 (<1)
SUXAMETHONIUM	0	1 (1)	1 (<1)	0	1 (<1)
TECHNETIUM TC 99M SULFUR COLLOID	0	1 (1)	1 (<1)	0	1 (<1)
TETANUS VACCINE	0	1 (1)	1 (<1)	0	1 (<1)
TETRYZOLINE	0	0	0	1 (2)	1 (<1)
THEOPHYLLINE	0	1 (1)	1 (<1)	0	1 (<1)
THIOCTIC ACID	0	0	0	1 (2)	1 (<1)
TIPEPIDINE	0	1 (1)	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 23 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
TOCOPHEROL	0	0	0	1 (2)	1 (<1)
TOLTERODINE	0	0	0	1 (2)	1 (<1)
TRANEXAMIC ACID	0	0	0	1 (2)	1 (<1)
TRETINOIN	0	0	0	1 (2)	1 (<1)
TRIAMINIC-DM	0	0	0	1 (2)	1 (<1)
TRIGLYCERIDES	0	1 (1)	1 (<1)	0	1 (<1)
TRIMETHOPRIM	0	1 (1)	1 (<1)	0	1 (<1)
TUBERCULOSIS VACCINES	0	1 (1)	1 (<1)	0	1 (<1)
TUSSIN DM	0	1 (1)	1 (<1)	0	1 (<1)
UNSPECIFIED HERBAL	0	1 (1)	1 (<1)	0	1 (<1)
VACCINES	0	1 (1)	1 (<1)	0	1 (<1)
VALISONE-G	0	1 (1)	1 (<1)	0	1 (<1)
VANICREAM	1 (6)	0	1 (<1)	0	1 (<1)
VICKS FORMULA 44M	0	0	0	1 (2)	1 (<1)
VICODIN	0	1 (1)	1 (<1)	0	1 (<1)
VIKOMINAS	0	1 (1)	1 (<1)	0	1 (<1)
VIRAL VACCINES	1 (6)	0	1 (<1)	0	1 (<1)
VITAMIN B COMPLEX	0	0	0	1 (2)	1 (<1)
VITAMIN C WITH ZINC	0	0	0	1 (2)	1 (<1)
VITAMINS, OTHER COMBINATIONS	0	1 (1)	1 (<1)	0	1 (<1)
VITIS VINIFERA	0	0	0	1 (2)	1 (<1)
WATER FOR INJECTION	0	1 (1)	1 (<1)	0	1 (<1)

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 24 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
AMINO ACIDS NOS W/FATS NOS/MALTODEXTRIN/MINER	0	0	0	0	0
AVENA SATIVA	0	0	0	0	0
AVOCA	0	0	0	0	0
BACITRACIN W/POLYMYXIN B	0	0	0	0	0
CALAMINE	0	0	0	0	0
CARBOHYDRATES NOS W/POTASSIUM CHLORIDE/SODIUM	0	0	0	0	0
CARBOMER	0	0	0	0	0
CEFACLOR	0	0	0	0	0
CHROMIUM	0	0	0	0	0
CIPRODAC-DM	0	0	0	0	0
CLOSTRIDIUM BUTYRICUM	0	0	0	0	0
COLISTIN	0	0	0	0	0
COUGH AND COLD PREPARATIONS	0	0	0	0	0
CUTASEPT G	0	0	0	0	0
D-FLUORETTEN	0	0	0	0	0
ETHANOL	0	0	0	0	0
GENERAL NUTRIENTS	0	0	0	0	0
GLYCERYL TRINITRATE	0	0	0	0	0
GUAIAZULENE	0	0	0	0	0
HALIBORANGE	0	0	0	0	0
HERBAL PREPARATION	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 25 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
HONEY	0	0	0	0	0
HYALURONIDASE	0	0	0	0	0
HYDROMOL	0	0	0	0	0
HYPERTONIC SOLUTIONS	0	0	0	0	0
HYPROMELLOSE	0	0	0	0	0
INFANT FORMULAS	0	0	0	0	0
LACTOBACILLUS REUTERI	0	0	0	0	0
LINEZOLID	0	0	0	0	0
MANGANESE	0	0	0	0	0
MICROLAX	0	0	0	0	0
NEUTRA-PHOS-K	0	0	0	0	0
NOREPINEPHRINE	0	0	0	0	0
OPIAT	0	0	0	0	0
ORAL REHYDRATION SALT	0	0	0	0	0
OTHER MINERAL PRODUCTS	0	0	0	0	0
OTOSPORIN	0	0	0	0	0
PANSORAL	0	0	0	0	0
PARADRYL EXPECT	0	0	0	0	0
PHYSIO 140	0	0	0	0	0
PLASMALYTE A	0	0	0	0	0
POLY-VI-FLOR	0	0	0	0	0
POLYMYXIN	0	0	0	0	0
REDUCTO	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 26 of 26

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
RETINOL W/VITAMIN D NOS	0	0	0	0	0
RIFAMYCIN	0	0	0	0	0
SELENIUM	0	0	0	0	0
SURGICAL DRESSINGS	0	0	0	0	0
TEETHING #3	0	0	0	0	0
TRAMADOL	0	0	0	0	0
TRI-VI-FLOR	0	0	0	0	0
TROPICAMIDE	0	0	0	0	0
ZEASORB	0	0	0	0	0
ZINC CHLORIDE	0	0	0	0	0

NOTE:Numbers in parentheses are percentages.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 27　Incidence of Adverse Events in Subjects With SMA Treated With ISIS 396443

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 1 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	13 (76.5)	92 (92.0)	105 (89.7)	56 (100.0)	161 (93.1)
感染症および寄生虫症	10 (58.8)	76 (76.0)	86 (73.5)	44 (78.6)	130 (75.1)
上気道感染	6 (35.3)	32 (32.0)	38 (32.5)	27 (48.2)	65 (37.6)
鼻咽頭炎	3 (17.6)	20 (20.0)	23 (19.7)	16 (28.6)	39 (22.5)
肺炎	1 (5.9)	24 (24.0)	25 (21.4)	5 (8.9)	30 (17.3)
ウイルス感染	0	11 (11.0)	11 (9.4)	9 (16.1)	20 (11.6)
ウイルス性上気道感染	0	12 (12.0)	12 (10.3)	5 (8.9)	17 (9.8)
ライノウイルス感染	1 (5.9)	14 (14.0)	15 (12.8)	0	15 (8.7)
中耳炎	2 (11.8)	7 (7.0)	9 (7.7)	5 (8.9)	14 (8.1)
気道感染	0	12 (12.0)	12 (10.3)	1 (1.8)	13 (7.5)
細気管支炎	1 (5.9)	11 (11.0)	12 (10.3)	0	12 (6.9)
ウイルス性肺炎	1 (5.9)	9 (9.0)	10 (8.5)	2 (3.6)	12 (6.9)
ウイルス性胃腸炎	1 (5.9)	1 (1.0)	2 (1.7)	8 (14.3)	10 (5.8)
レンサ球菌性咽頭炎	1 (5.9)	1 (1.0)	2 (1.7)	8 (14.3)	10 (5.8)
結膜炎	0	6 (6.0)	6 (5.1)	3 (5.4)	9 (5.2)
耳感染	0	5 (5.0)	5 (4.3)	4 (7.1)	9 (5.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 2 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胃腸炎	0	2 (2.0)	2 (1.7)	7 (12.5)	9 (5.2)
インフルエンザ	2 (11.8)	3 (3.0)	5 (4.3)	3 (5.4)	8 (4.6)
尿路感染	1 (5.9)	3 (3.0)	4 (3.4)	4 (7.1)	8 (4.6)
口腔カンジダ症	0	7 (7.0)	7 (6.0)	0	7 (4.0)
気管支炎	1 (5.9)	5 (5.0)	6 (5.1)	0	6 (3.5)
ウイルス性気道感染	0	5 (5.0)	5 (4.3)	1 (1.8)	6 (3.5)
下気道感染	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)
ＲＳウイルス細気管支炎	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)
限局性感染	0	1 (1.0)	1 (0.9)	3 (5.4)	4 (2.3)
細菌性肺炎	0	4 (4.0)	4 (3.4)	0	4 (2.3)
鼻炎	1 (5.9)	2 (2.0)	3 (2.6)	1 (1.8)	4 (2.3)
皮膚カンジダ	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
細菌性気管炎	0	3 (3.0)	3 (2.6)	0	3 (1.7)
ウイルス性気管支炎	0	3 (3.0)	3 (2.6)	0	3 (1.7)
皮膚真菌感染	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
手足口病	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
膿痂疹	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
ウイルス性下気道感染	0	3 (3.0)	3 (2.6)	0	3 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 3 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ＲＳウイルス感染	0	0	0	3 (5.4)	3 (1.7)
副鼻腔炎	0	0	0	3 (5.4)	3 (1.7)
アデノウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
細菌感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
カンジダ性おむつ皮疹	0	2 (2.0)	2 (1.7)	0	2 (1.2)
蜂巣炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
細菌性結膜炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
エンテロウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ウイルス性消化管感染	0	0	0	2 (3.6)	2 (1.2)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
急性中耳炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
パラインフルエンザウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
モラクセラ菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
ストーマ部膿瘍	0	2 (2.0)	2 (1.7)	0	2 (1.2)
アデノウイルス性上気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
細菌性疾患キャリアー	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 4 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
コロナウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
感染性湿疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
伝染性紅斑	0	1 (1.0)	1 (0.9)	0	1 (0.6)
眼感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌性眼感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性眼感染	0	0	0	1 (1.8)	1 (0.6)
真菌感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性胃炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ロタウイルス胃腸炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ヘモフィルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
伝染性軟属腫	0	0	0	1 (1.8)	1 (0.6)
単核細胞症症候群	0	0	0	1 (1.8)	1 (0.6)
モラクセラ感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
粘膜皮膚カンジダ症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
院内感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
口腔ヘルペス	0	1 (1.0)	1 (0.9)	0	1 (0.6)
咽頭炎	0	0	0	1 (1.8)	1 (0.6)
インフルエンザ性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
パラインフルエンザウイルス性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 5 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
シュードモナス菌性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
シュードモナス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気道感染細菌性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ばら疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
敗血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚細菌感染	0	0	0	1 (1.8)	1 (0.6)
皮膚感染	1 (5.9)	0	1 (0.9)	0	1 (0.6)
ブドウ球菌性菌血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌皮膚感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
扁桃炎	0	0	0	1 (1.8)	1 (0.6)
気管炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
腟感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性扁桃炎	0	0	0	1 (1.8)	1 (0.6)
外陰腟真菌感染	0	0	0	1 (1.8)	1 (0.6)
カンジダ感染	0	0	0	0	0
麦粒腫	0	0	0	0	0
セラチア感染	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 6 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ストーマ部感染	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
呼吸器、胸郭および縦隔障害	5 (29.4)	73 (73.0)	78 (66.7)	25 (44.6)	103 (59.5)
呼吸窮迫	1 (5.9)	26 (26.0)	27 (23.1)	0	27 (15.6)
呼吸不全	0	23 (23.0)	23 (19.7)	1 (1.8)	24 (13.9)
無気肺	0	20 (20.0)	20 (17.1)	1 (1.8)	21 (12.1)
咳嗽	2 (11.8)	12 (12.0)	14 (12.0)	6 (10.7)	20 (11.6)
鼻閉	2 (11.8)	15 (15.0)	17 (14.5)	3 (5.4)	20 (11.6)
急性呼吸不全	0	15 (15.0)	15 (12.8)	1 (1.8)	16 (9.2)
低酸素症	0	10 (10.0)	10 (8.5)	3 (5.4)	13 (7.5)
鼻漏	1 (5.9)	6 (6.0)	7 (6.0)	6 (10.7)	13 (7.5)
呼吸困難	0	9 (9.0)	9 (7.7)	1 (1.8)	10 (5.8)
誤嚥性肺炎	0	10 (10.0)	10 (8.5)	0	10 (5.8)
口腔咽頭痛	0	0	0	8 (14.3)	8 (4.6)
無呼吸	0	7 (7.0)	7 (6.0)	0	7 (4.0)
上気道うっ血	1 (5.9)	6 (6.0)	7 (6.0)	0	7 (4.0)
誤嚥	0	6 (6.0)	6 (5.1)	0	6 (3.5)
気管支分泌物貯留	0	6 (6.0)	6 (5.1)	0	6 (3.5)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 7 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
慢性呼吸不全	0	6 (6.0)	6 (5.1)	0	6 (3.5)
上気道分泌増加	0	6 (6.0)	6 (5.1)	0	6 (3.5)
副鼻腔うっ血	0	4 (4.0)	4 (3.4)	2 (3.6)	6 (3.5)
呼吸停止	0	4 (4.0)	4 (3.4)	0	4 (2.3)
喘鳴	0	3 (3.0)	3 (2.6)	1 (1.8)	4 (2.3)
鼻出血	0	0	0	3 (5.4)	3 (1.7)
低換気	0	3 (3.0)	3 (2.6)	0	3 (1.7)
気胸	0	3 (3.0)	3 (2.6)	0	3 (1.7)
肺うっ血	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
呼吸障害	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
扁桃肥大	0	0	0	3 (5.4)	3 (1.7)
息詰まり	0	2 (2.0)	2 (1.7)	0	2 (1.2)
肺水腫	0	2 (2.0)	2 (1.7)	0	2 (1.2)
拘束性肺疾患	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
アレルギー性鼻炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
呼吸補助筋の動員	0	2 (2.0)	2 (1.7)	0	2 (1.2)
急性呼吸窮迫症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
無呼吸発作	0	1 (1.0)	1 (0.9)	0	1 (0.6)
窒息	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管支閉塞	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 8 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
発声障害	0	0	0	1 (1.8)	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
減呼吸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管支分泌増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
喉頭肉芽腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
鼻汁変色	0	1 (1.0)	1 (0.9)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胸水	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺臓炎	0	0	0	1 (1.8)	1 (0.6)
湿性咳嗽	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸性アシドーシス	1 (5.9)	0	1 (0.9)	0	1 (0.6)
呼吸性アルカローシス	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気道うっ血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低音性連続性ラ音	0	1 (1.0)	1 (0.9)	0	1 (0.6)
睡眠時無呼吸症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
変色痰	0	1 (1.0)	1 (0.9)	0	1 (0.6)
頻呼吸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 9 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
乳幼児突発性危急事態	0	0	0	0	0
カタル	0	0	0	0	0
上気道の炎症	0	0	0	0	0
胃腸障害	6 (35.3)	64 (64.0)	70 (59.8)	26 (46.4)	96 (55.5)
便秘	1 (5.9)	33 (33.0)	34 (29.1)	7 (12.5)	41 (23.7)
嘔吐	0	20 (20.0)	20 (17.1)	12 (21.4)	32 (18.5)
胃食道逆流性疾患	2 (11.8)	15 (15.0)	17 (14.5)	1 (1.8)	18 (10.4)
生歯	1 (5.9)	15 (15.0)	16 (13.7)	0	16 (9.2)
下痢	0	13 (13.0)	13 (11.1)	2 (3.6)	15 (8.7)
嚥下障害	1 (5.9)	9 (9.0)	10 (8.5)	0	10 (5.8)
悪心	0	0	0	10 (17.9)	10 (5.8)
放屁	2 (11.8)	5 (5.0)	7 (6.0)	1 (1.8)	8 (4.6)
腹部膨満	2 (11.8)	4 (4.0)	6 (5.1)	0	6 (3.5)
流涎過多	0	5 (5.0)	5 (4.3)	0	5 (2.9)
アフタ性潰瘍	0	1 (1.0)	1 (0.9)	3 (5.4)	4 (2.3)
胃炎	0	4 (4.0)	4 (3.4)	0	4 (2.3)
腹部不快感	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
腹痛	0	1 (1.0)	1 (0.9)	2 (3.6)	3 (1.7)
上腹部痛	0	0	0	2 (3.6)	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 10 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血便排泄	0	2 (2.0)	2 (1.7)	0	2 (1.2)
口腔内痛	0	0	0	2 (3.6)	2 (1.2)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
口唇のひび割れ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
食中毒	0	0	0	1 (1.8)	1 (0.6)
排便回数増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胃出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胃腸障害	0	0	0	1 (1.8)	1 (0.6)
消化管運動低下	0	1 (1.0)	1 (0.9)	0	1 (0.6)
吐血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
乳児仙痛	0	1 (1.0)	1 (0.9)	0	1 (0.6)
乳児吐出	0	1 (1.0)	1 (0.9)	0	1 (0.6)
口唇痛	0	0	0	1 (1.8)	1 (0.6)
口内炎	0	0	0	1 (1.8)	1 (0.6)
上部消化管出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血性下痢	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管刺激症状	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 11 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
一般・全身障害および投与部位の状態	4 (23.5)	58 (58.0)	62 (53.0)	31 (55.4)	93 (53.8)
発熱	3 (17.6)	53 (53.0)	56 (47.9)	16 (28.6)	72 (41.6)
穿刺部位疼痛	0	0	0	10 (17.9)	10 (5.8)
疼痛	0	5 (5.0)	5 (4.3)	2 (3.6)	7 (4.0)
疲労	0	0	0	3 (5.4)	3 (1.7)
不快感	0	2 (2.0)	2 (1.7)	0	2 (1.2)
低体温	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
末梢性浮腫	0	2 (2.0)	2 (1.7)	0	2 (1.2)
末梢腫脹	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
血管穿刺部位内出血	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
適用部位紅斑	1 (5.9)	0	1 (0.9)	0	1 (0.6)
カテーテル留置部位出血	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位炎症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位関連反応	0	0	0	1 (1.8)	1 (0.6)
胸部不快感	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
泣き	0	1 (1.0)	1 (0.9)	0	1 (0.6)
死亡	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 12 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
医療機器リーク	0	1 (1.0)	1 (0.9)	0	1 (0.6)
医療機器閉塞	0	1 (1.0)	1 (0.9)	0	1 (0.6)
薬物不耐性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
冷感	0	0	0	1 (1.8)	1 (0.6)
重力性浮腫	0	0	0	1 (1.8)	1 (0.6)
注入部位内出血	1 (5.9)	0	1 (0.9)	0	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
ワクチン接種後の易刺激性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
倦怠感	0	1 (1.0)	1 (0.9)	0	1 (0.6)
小結節	0	1 (1.0)	1 (0.9)	0	1 (0.6)
浮腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
穿刺部位反応	0	0	0	1 (1.8)	1 (0.6)
腫脹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
適用部位発疹	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 13 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
傷害、中毒および処置合併症	3 (17.6)	26 (26.0)	29 (24.8)	40 (71.4)	69 (39.9)
腰椎穿刺後症候群	0	0	0	23 (41.1)	23 (13.3)
処置による疼痛	0	4 (4.0)	4 (3.4)	6 (10.7)	10 (5.8)
裂傷	0	0	0	7 (12.5)	7 (4.0)
節足動物咬傷	0	3 (3.0)	3 (2.6)	3 (5.4)	6 (3.5)
大腿骨骨折	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.9)
挫傷	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
関節脱臼	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
四肢損傷	0	0	0	3 (5.4)	3 (1.7)
ストーマ部紅斑	0	3 (3.0)	3 (2.6)	0	3 (1.7)
サンバーン	0	1 (1.0)	1 (0.9)	2 (3.6)	3 (1.7)
術後激越	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
転倒	1 (5.9)	0	1 (0.9)	1 (1.8)	2 (1.2)
栄養補給チューブ合併症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
関節損傷	0	0	0	2 (3.6)	2 (1.2)
処置後腫脹	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
処置による悪心	0	0	0	2 (3.6)	2 (1.2)
皮膚擦過傷	0	2 (2.0)	2 (1.7)	0	2 (1.2)
熱傷	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 14 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
隆起骨折	0	0	0	2 (3.6)	2 (1.2)
節足動物刺傷	0	0	0	1 (1.8)	1 (0.6)
麻酔からの覚醒遅延	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ダンピング症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
耳擦過傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
擦過傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
伝染病曝露	0	1 (1.0)	1 (0.9)	0	1 (0.6)
頭部損傷	0	0	0	1 (1.8)	1 (0.6)
靱帯捻挫	0	0	0	1 (1.8)	1 (0.6)
口唇損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
下肢骨折	0	0	0	1 (1.8)	1 (0.6)
半月板損傷	0	0	0	1 (1.8)	1 (0.6)
肉離れ	0	0	0	1 (1.8)	1 (0.6)
外傷性気胸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
処置後合併症	1 (5.9)	0	1 (0.9)	0	1 (0.6)
処置後不快感	1 (5.9)	0	1 (0.9)	0	1 (0.6)
術後イレウス	0	0	0	1 (1.8)	1 (0.6)
処置合併症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 15 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
軟部組織損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ストーマ合併症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
硬膜下血腫	1 (5.9)	0	1 (0.9)	0	1 (0.6)
脛骨骨折	0	0	0	1 (1.8)	1 (0.6)
歯牙損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ワクチン接種合併症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
創離開	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管内挿管合併症	0	0	0	0	0
処置後挫傷	0	0	0	0	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
気管損傷	0	0	0	0	0
筋骨格系および結合組織障害	2 (11.8)	25 (25.0)	27 (23.1)	41 (73.2)	68 (39.3)
側弯症	0	11 (11.0)	11 (9.4)	15 (26.8)	26 (15.0)
背部痛	0	1 (1.0)	1 (0.9)	23 (41.1)	24 (13.9)
関節拘縮	1 (5.9)	11 (11.0)	12 (10.3)	10 (17.9)	22 (12.7)
四肢痛	0	2 (2.0)	2 (1.7)	5 (8.9)	7 (4.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 16 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
関節痛	0	0	0	5 (8.9)	5 (2.9)
脊柱後弯症	0	5 (5.0)	5 (4.3)	0	5 (2.9)
胸郭変形	0	4 (4.0)	4 (3.4)	0	4 (2.3)
筋肉痛	0	0	0	4 (7.1)	4 (2.3)
頚部痛	0	0	0	3 (5.4)	3 (1.7)
頭位性斜頭症	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
斜頚	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
後側弯症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
脊柱前弯症	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
筋緊張	0	0	0	2 (3.6)	2 (1.2)
骨盤変形	0	0	0	2 (3.6)	2 (1.2)
泉門閉鎖遅延	0	1 (1.0)	1 (0.9)	0	1 (0.6)
四肢拘縮	0	0	0	1 (1.8)	1 (0.6)
手変形	0	1 (1.0)	1 (0.9)	0	1 (0.6)
関節硬直	0	1 (1.0)	1 (0.9)	0	1 (0.6)
筋力低下	1 (5.9)	0	1 (0.9)	0	1 (0.6)
脊柱変形	0	1 (1.0)	1 (0.9)	0	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
体重支持困難	1 (5.9)	0	1 (0.9)	0	1 (0.6)
腱障害	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 17 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
皮膚および皮下組織障害	6 (35.3)	35 (35.0)	41 (35.0)	17 (30.4)	58 (33.5)
発疹	0	13 (13.0)	13 (11.1)	1 (1.8)	14 (8.1)
おむつ皮膚炎	2 (11.8)	10 (10.0)	12 (10.3)	1 (1.8)	13 (7.5)
接触性皮膚炎	0	3 (3.0)	3 (2.6)	3 (5.4)	6 (3.5)
湿疹	0	4 (4.0)	4 (3.4)	2 (3.6)	6 (3.5)
皮膚炎	2 (11.8)	2 (2.0)	4 (3.4)	1 (1.8)	5 (2.9)
斑状出血	0	3 (3.0)	3 (2.6)	0	3 (1.7)
紅斑	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
過剰肉芽組織	0	3 (3.0)	3 (2.6)	0	3 (1.7)
汗疹	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
皮膚刺激	0	3 (3.0)	3 (2.6)	0	3 (1.7)
過角化	0	2 (2.0)	2 (1.7)	0	2 (1.2)
蕁麻疹	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
ざ瘡	0	0	0	1 (1.8)	1 (0.6)
脱毛症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
水疱	0	0	0	1 (1.8)	1 (0.6)
褥瘡性潰瘍	0	0	0	1 (1.8)	1 (0.6)
アレルギー性皮膚炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
貨幣状湿疹	1 (5.9)	0	1 (0.9)	0	1 (0.6)
環状肉芽腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 18 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
毛孔性角化症	0	0	0	1 (1.8)	1 (0.6)
寝汗	0	0	0	1 (1.8)	1 (0.6)
点状出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
そう痒症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脂漏性皮膚炎	1 (5.9)	0	1 (0.9)	0	1 (0.6)
皮膚色素脱失	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚病変	0	0	0	1 (1.8)	1 (0.6)
皮膚浮腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚潰瘍	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮下気腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
多汗症	0	0	0	0	0
神経系障害	2 (11.8)	17 (17.0)	19 (16.2)	30 (53.6)	49 (28.3)
頭痛	0	1 (1.0)	1 (0.9)	28 (50.0)	29 (16.8)
不随意性筋収縮	0	4 (4.0)	4 (3.4)	0	4 (2.3)
眼振	0	3 (3.0)	3 (2.6)	0	3 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 19 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
よだれ	0	2 (2.0)	2 (1.7)	0	2 (1.2)
感覚鈍麻	0	0	0	2 (3.6)	2 (1.2)
痙攣発作	0	2 (2.0)	2 (1.7)	0	2 (1.2)
失神	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
失声症	0	0	0	1 (1.8)	1 (0.6)
脳損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脳梗塞	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脳脊髄液漏	0	1 (1.0)	1 (0.9)	0	1 (0.6)
間代	0	1 (1.0)	1 (0.9)	0	1 (0.6)
味覚異常	0	0	0	1 (1.8)	1 (0.6)
失読症	0	0	0	1 (1.8)	1 (0.6)
反射亢進	1 (5.9)	0	1 (0.9)	0	1 (0.6)
筋緊張低下	1 (5.9)	0	1 (0.9)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
嗜眠	0	1 (1.0)	1 (0.9)	0	1 (0.6)
片頭痛	0	0	0	1 (1.8)	1 (0.6)
錯感覚	0	0	0	1 (1.8)	1 (0.6)
傾眠	0	1 (1.0)	1 (0.9)	0	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)
失神寸前の状態	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 20 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
臨床検査	1 (5.9)	24 (24.0)	25 (21.4)	8 (14.3)	33 (19.1)
酸素飽和度低下	0	10 (10.0)	10 (8.5)	0	10 (5.8)
体重減少	0	5 (5.0)	5 (4.3)	3 (5.4)	8 (4.6)
体温上昇	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
心拍数増加	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ヒトライノウイルス検査陽性	0	3 (3.0)	3 (2.6)	0	3 (1.7)
好中球数増加	0	3 (3.0)	3 (2.6)	0	3 (1.7)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
血中カリウム減少	0	2 (2.0)	2 (1.7)	0	2 (1.2)
Ｃ－反応性蛋白増加	0	2 (2.0)	2 (1.7)	0	2 (1.2)
モラクセラ検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
シュードモナス検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ブドウ球菌検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
白血球数増加	0	2 (2.0)	2 (1.7)	0	2 (1.2)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)
血中クロール減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中鉄減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中テストステロン減少	0	0	0	1 (1.8)	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 21 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
体温低下	0	1 (1.0)	1 (0.9)	0	1 (0.6)
骨密度減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸音異常	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ＣＳＦ白血球数増加	0	0	0	1 (1.8)	1 (0.6)
心電図ＳＴ－Ｔ部分異常	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心拍数減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心拍数不整	0	1 (1.0)	1 (0.9)	0	1 (0.6)
炎症マーカー上昇	0	1 (1.0)	1 (0.9)	0	1 (0.6)
Ａ型インフルエンザウイルス検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肝機能検査異常	0	1 (1.0)	1 (0.9)	0	1 (0.6)
医学的観察	0	1 (1.0)	1 (0.9)	0	1 (0.6)
好中球百分率増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
セラチア検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
レンサ球菌検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)
尿量減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ビタミンＡ減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 22 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンD減少	0	0	0	0	0
心臓障害	2 (11.8)	22 (22.0)	24 (20.5)	3 (5.4)	27 (15.6)
頻脈	2 (11.8)	8 (8.0)	10 (8.5)	1 (1.8)	11 (6.4)
徐脈	0	7 (7.0)	7 (6.0)	0	7 (4.0)
心肺停止	0	6 (6.0)	6 (5.1)	0	6 (3.5)
心停止	0	3 (3.0)	3 (2.6)	0	3 (1.7)
チアノーゼ	0	3 (3.0)	3 (2.6)	0	3 (1.7)
動悸	0	0	0	2 (3.6)	2 (1.2)
心室性頻脈	0	2 (2.0)	2 (1.7)	0	2 (1.2)
心筋症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
左室肥大	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
上室性頻脈	0	1 (1.0)	1 (0.9)	0	1 (0.6)
代謝および栄養障害	2 (11.8)	18 (18.0)	20 (17.1)	5 (8.9)	25 (14.5)
体重増加不良	1 (5.9)	6 (6.0)	7 (6.0)	0	7 (4.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 23 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
脱水	1 (5.9)	1 (1.0)	2 (1.7)	2 (3.6)	4 (2.3)
成長障害	1 (5.9)	3 (3.0)	4 (3.4)	0	4 (2.3)
乳児および小児期早期の哺育障害	0	3 (3.0)	3 (2.6)	0	3 (1.7)
栄養補給不耐性	0	3 (3.0)	3 (2.6)	0	3 (1.7)
低ナトリウム血症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
過小食	0	2 (2.0)	2 (1.7)	0	2 (1.2)
食欲減退	0	0	0	1 (1.8)	1 (0.6)
食欲亢進	0	0	0	1 (1.8)	1 (0.6)
鉄欠乏	0	1 (1.0)	1 (0.9)	0	1 (0.6)
代謝性アルカローシス	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ビタミンD欠乏	0	0	0	1 (1.8)	1 (0.6)
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
免疫系障害	1 (5.9)	12 (12.0)	13 (11.1)	7 (12.5)	20 (11.6)
季節性アレルギー	1 (5.9)	5 (5.0)	6 (5.1)	3 (5.4)	9 (5.2)
薬物過敏症	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 24 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
過敏症	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.9)
食物アレルギー	0	1 (1.0)	1 (0.9)	0	1 (0.6)
精神障害	0	11 (11.0)	11 (9.4)	4 (7.1)	15 (8.7)
不安	0	5 (5.0)	5 (4.3)	0	5 (2.9)
激越	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
易刺激性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
注意欠陥多動性障害	0	0	0	1 (1.8)	1 (0.6)
息こらえ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
不快気分	0	0	0	1 (1.8)	1 (0.6)
不眠症	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.9)	0	1 (0.6)
睡眠時随伴症	0	0	0	1 (1.8)	1 (0.6)
落ち着きのなさ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
睡眠障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
チック	0	0	0	1 (1.8)	1 (0.6)
心因性嘔吐	0	0	0	1 (1.8)	1 (0.6)
血管障害	2 (11.8)	7 (7.0)	9 (7.7)	1 (1.8)	10 (5.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 25 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
高血圧	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
蒼白	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
毛細血管脆弱	0	1 (1.0)	1 (0.9)	0	1 (0.6)
本態性高血圧症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低血圧	0	0	0	1 (1.8)	1 (0.6)
ショック	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血管炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血液およびリンパ系障害	2 (11.8)	6 (6.0)	8 (6.8)	1 (1.8)	9 (5.2)
貧血	0	3 (3.0)	3 (2.6)	0	3 (1.7)
好中球減少症	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
好酸球増加症	1 (5.9)	0	1 (0.9)	0	1 (0.6)
リンパ節症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血小板増加症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
骨髄障害	0	0	0	0	0
白血球増加症	0	0	0	0	0
眼障害	1 (5.9)	6 (6.0)	7 (6.0)	2 (3.6)	9 (5.2)
斜視	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
乱視	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 26 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
霰粒腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
後天性涙道狭窄	1 (5.9)	0	1 (0.9)	0	1 (0.6)
眼乾燥	0	1 (1.0)	1 (0.9)	0	1 (0.6)
眼運動障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.9)	0	1 (0.6)
遠視	0	0	0	1 (1.8)	1 (0.6)
近視	0	1 (1.0)	1 (0.9)	0	1 (0.6)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0
先天性、家族性および遺伝性障害	0	6 (6.0)	6 (5.1)	0	6 (3.5)
斜頭症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
斜指症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
発育性股関節形成不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
貧血母斑	0	1 (1.0)	1 (0.9)	0	1 (0.6)
鳩胸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
停留精巣	0	0	0	0	0
包茎	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 27 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
耳および迷路障害	0	3 (3.0)	3 (2.6)	3 (5.4)	6 (3.5)
耳痛	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
耳の障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
耳垢分泌過多	0	1 (1.0)	1 (0.9)	0	1 (0.6)
乗物酔い	0	0	0	1 (1.8)	1 (0.6)
鼓膜穿孔	0	0	0	1 (1.8)	1 (0.6)
腎および尿路障害	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.9)
排尿困難	0	0	0	1 (1.8)	1 (0.6)
水腎症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.9)	0	1 (0.6)
膀胱尿管逆流	0	0	0	1 (1.8)	1 (0.6)
糖尿	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.9)	2 (2.0)	3 (2.6)	1 (1.8)	4 (2.3)
アクロコルドン	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血管の良性新生物	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脂漏性角化症	1 (5.9)	0	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 28 of 28

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
皮膚乳頭腫	0	0	0	1 (1.8)	1 (0.6)
生殖系および乳房障害	0	3 (3.0)	3 (2.6)	0	3 (1.7)
後天性包茎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
卵巣嚢胞	0	1 (1.0)	1 (0.9)	0	1 (0.6)
陰茎障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肝胆道系障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肝腫大	0	1 (1.0)	1 (0.9)	0	1 (0.6)
妊娠、産褥および周産期の状態	1 (5.9)	0	1 (0.9)	0	1 (0.6)
臍肉芽腫	1 (5.9)	0	1 (0.9)	0	1 (0.6)
外科および内科処置	0	1 (1.0)	1 (0.9)	0	1 (0.6)
機械的換気	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 28　Frequency of Adverse Events in Subjects With SMA Treated With ISIS 396443

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 1 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17	100	117	56	173
Number of events	94 (100.0)	1433 (100.0)	1527 (100.0)	682 (100.0)	2209 (100.0)
感染症および寄生虫症	31 (33.0)	378 (26.4)	409 (26.8)	190 (27.9)	599 (27.1)
上気道感染	9 (9.6)	55 (3.8)	64 (4.2)	53 (7.8)	117 (5.3)
鼻咽頭炎	5 (5.3)	31 (2.2)	36 (2.4)	23 (3.4)	59 (2.7)
肺炎	1 (1.1)	41 (2.9)	42 (2.8)	10 (1.5)	52 (2.4)
気道感染	0	31 (2.2)	31 (2.0)	1 (0.1)	32 (1.4)
ウイルス感染	0	14 (1.0)	14 (0.9)	11 (1.6)	25 (1.1)
ウイルス性上気道感染	0	17 (1.2)	17 (1.1)	5 (0.7)	22 (1.0)
中耳炎	2 (2.1)	9 (0.6)	11 (0.7)	6 (0.9)	17 (0.8)
ライノウイルス感染	1 (1.1)	16 (1.1)	17 (1.1)	0	17 (0.8)
細気管支炎	1 (1.1)	13 (0.9)	14 (0.9)	0	14 (0.6)
耳感染	0	8 (0.6)	8 (0.5)	5 (0.7)	13 (0.6)
レンサ球菌性咽頭炎	1 (1.1)	1 (<0.1)	2 (0.1)	11 (1.6)	13 (0.6)
ウイルス性肺炎	1 (1.1)	9 (0.6)	10 (0.7)	3 (0.4)	13 (0.6)
尿路感染	3 (3.2)	3 (0.2)	6 (0.4)	6 (0.9)	12 (0.5)
結膜炎	0	6 (0.4)	6 (0.4)	4 (0.6)	10 (0.5)
胃腸炎	0	2 (0.1)	2 (0.1)	8 (1.2)	10 (0.5)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 2 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ウイルス性胃腸炎	1 (1.1)	1 (<0.1)	2 (0.1)	8 (1.2)	10 (0.5)
口腔カンジダ症	0	9 (0.6)	9 (0.6)	0	9 (0.4)
インフルエンザ	2 (2.1)	3 (0.2)	5 (0.3)	3 (0.4)	8 (0.4)
ウイルス性気道感染	0	7 (0.5)	7 (0.5)	1 (0.1)	8 (0.4)
下気道感染	0	6 (0.4)	6 (0.4)	1 (0.1)	7 (0.3)
鼻炎	1 (1.1)	5 (0.3)	6 (0.4)	1 (0.1)	7 (0.3)
気管支炎	1 (1.1)	5 (0.3)	6 (0.4)	0	6 (0.3)
ウイルス性気管支炎	0	5 (0.3)	5 (0.3)	0	5 (0.2)
ＲＳウイルス細気管支炎	0	4 (0.3)	4 (0.3)	1 (0.1)	5 (0.2)
細菌性気管炎	0	4 (0.3)	4 (0.3)	0	4 (0.2)
限局性感染	0	1 (<0.1)	1 (<0.1)	3 (0.4)	4 (0.2)
細菌性肺炎	0	4 (0.3)	4 (0.3)	0	4 (0.2)
皮膚カンジダ	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
ストーマ部膿瘍	0	4 (0.3)	4 (0.3)	0	4 (0.2)
細菌感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
エンテロウイルス感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
皮膚真菌感染	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
手足口病	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
膿痂疹	1 (1.1)	1 (<0.1)	2 (0.1)	1 (0.1)	3 (0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 3 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ウイルス性下気道感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
パラインフルエンザウイルス感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
モラクセラ菌性肺炎	0	3 (0.2)	3 (0.2)	0	3 (0.1)
ＲＳウイルス感染	0	0	0	3 (0.4)	3 (0.1)
副鼻腔炎	0	0	0	3 (0.4)	3 (0.1)
アデノウイルス感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
カンジダ性おむつ皮疹	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
蜂巣炎	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
細菌性結膜炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
真菌感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
ウイルス性消化管感染	0	0	0	2 (0.3)	2 (<0.1)
メタニューモウイルス感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
院内感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
急性中耳炎	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
シュードモナス菌性肺炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
ＲＳウイルス肺炎	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
ブドウ球菌皮膚感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 4 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
アデノウイルス性上気道感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
細菌性疾患キャリアー	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
コロナウイルス感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
感染性湿疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
伝染性紅斑	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
眼感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ブドウ球菌性眼感染	0	0	0	1 (0.1)	1 (<0.1)
ウイルス性眼感染	0	0	0	1 (0.1)	1 (<0.1)
ウイルス性胃炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ロタウイルス胃腸炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ヘモフィルス感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肺感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
伝染性軟属腫	0	0	0	1 (0.1)	1 (<0.1)
単核細胞症症候群	0	0	0	1 (0.1)	1 (<0.1)
モラクセラ感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
粘膜皮膚カンジダ症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
口腔ヘルペス	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
咽頭炎	0	0	0	1 (0.1)	1 (<0.1)
インフルエンザ性肺炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
パラインフルエンザウイルス性肺炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 5 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
シュードモナス感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
細菌性気道感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ばら疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
敗血症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚細菌感染	0	0	0	1 (0.1)	1 (<0.1)
皮膚感染	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
ブドウ球菌性菌血症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ブドウ球菌感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ブドウ球菌性敗血症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
扁桃炎	0	0	0	1 (0.1)	1 (<0.1)
気管炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
腟感染	0	0	0	1 (0.1)	1 (<0.1)
ウイルス性扁桃炎	0	0	0	1 (0.1)	1 (<0.1)
外陰腟真菌感染	0	0	0	1 (0.1)	1 (<0.1)
カンジダ感染	0	0	0	0	0
麦粒腫	0	0	0	0	0
セラチア感染	0	0	0	0	0
ストーマ部感染	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 6 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
呼吸器、胸郭および縦隔障害	8 (8.5)	327 (22.8)	335 (21.9)	54 (7.9)	389 (17.6)
無気肺	0	46 (3.2)	46 (3.0)	3 (0.4)	49 (2.2)
呼吸窮迫	1 (1.1)	39 (2.7)	40 (2.6)	0	40 (1.8)
急性呼吸不全	0	35 (2.4)	35 (2.3)	1 (0.1)	36 (1.6)
鼻閉	2 (2.1)	23 (1.6)	25 (1.6)	3 (0.4)	28 (1.3)
咳嗽	2 (2.1)	17 (1.2)	19 (1.2)	7 (1.0)	26 (1.2)
呼吸不全	0	25 (1.7)	25 (1.6)	1 (0.1)	26 (1.2)
低酸素症	0	15 (1.0)	15 (1.0)	3 (0.4)	18 (0.8)
鼻漏	1 (1.1)	7 (0.5)	8 (0.5)	6 (0.9)	14 (0.6)
誤嚥性肺炎	0	13 (0.9)	13 (0.9)	0	13 (0.6)
口腔咽頭痛	0	0	0	11 (1.6)	11 (0.5)
呼吸困難	0	9 (0.6)	9 (0.6)	1 (0.1)	10 (0.5)
上気道分泌増加	0	9 (0.6)	9 (0.6)	0	9 (0.4)
無呼吸	0	8 (0.6)	8 (0.5)	0	8 (0.4)
副鼻腔うっ血	0	6 (0.4)	6 (0.4)	2 (0.3)	8 (0.4)
気管支分泌物貯留	0	7 (0.5)	7 (0.5)	0	7 (0.3)
慢性呼吸不全	0	7 (0.5)	7 (0.5)	0	7 (0.3)
上気道うっ血	1 (1.1)	6 (0.4)	7 (0.5)	0	7 (0.3)
誤嚥	0	6 (0.4)	6 (0.4)	0	6 (0.3)
鼻出血	0	0	0	6 (0.9)	6 (0.3)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 7 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
呼吸停止	0	5 (0.3)	5 (0.3)	0	5 (0.2)
喘鳴	0	3 (0.2)	3 (0.2)	2 (0.3)	5 (0.2)
気胸	0	4 (0.3)	4 (0.3)	0	4 (0.2)
低換気	0	3 (0.2)	3 (0.2)	0	3 (0.1)
肺うっ血	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
呼吸障害	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
扁桃肥大	0	0	0	3 (0.4)	3 (0.1)
息詰まり	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
肺水腫	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
拘束性肺疾患	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
アレルギー性鼻炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
呼吸補助筋の動員	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
急性呼吸窮迫症候群	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
無呼吸発作	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
窒息	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気管支閉塞	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
発声障害	0	0	0	1 (0.1)	1 (<0.1)
高炭酸ガス血症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
減呼吸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気管支分泌増加	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
喉頭肉芽腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 8 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
肺障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
鼻汁変色	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
閉塞性気道障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
胸水	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気縦隔症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肺臓炎	0	0	0	1 (0.1)	1 (<0.1)
湿性咳嗽	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
呼吸性アシドーシス	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
呼吸性アルカローシス	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気道うっ血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
低音性連続性ラ音	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
睡眠時無呼吸症候群	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
変色痰	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
頻呼吸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気管障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
乳幼児突発性危急事態	0	0	0	0	0
カタル	0	0	0	0	0
上気道の炎症	0	0	0	0	0
胃腸障害	10 (10.6)	168 (11.7)	178 (11.7)	60 (8.8)	238 (10.8)
嘔吐	0	34 (2.4)	34 (2.2)	17 (2.5)	51 (2.3)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 9 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
便秘	1 (1.1)	36 (2.5)	37 (2.4)	11 (1.6)	48 (2.2)
下痢	0	24 (1.7)	24 (1.6)	3 (0.4)	27 (1.2)
胃食道逆流性疾患	2 (2.1)	16 (1.1)	18 (1.2)	1 (0.1)	19 (0.9)
生歯	1 (1.1)	15 (1.0)	16 (1.0)	0	16 (0.7)
嚥下障害	1 (1.1)	12 (0.8)	13 (0.9)	0	13 (0.6)
悪心	0	0	0	11 (1.6)	11 (0.5)
放屁	2 (2.1)	5 (0.3)	7 (0.5)	1 (0.1)	8 (0.4)
腹部膨満	2 (2.1)	4 (0.3)	6 (0.4)	0	6 (0.3)
流涎過多	0	5 (0.3)	5 (0.3)	0	5 (0.2)
アフタ性潰瘍	0	1 (<0.1)	1 (<0.1)	3 (0.4)	4 (0.2)
胃炎	0	4 (0.3)	4 (0.3)	0	4 (0.2)
腹部不快感	1 (1.1)	1 (<0.1)	2 (0.1)	1 (0.1)	3 (0.1)
腹痛	0	1 (<0.1)	1 (<0.1)	2 (0.3)	3 (0.1)
上腹部痛	0	0	0	2 (0.3)	2 (<0.1)
血便排泄	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
口腔内痛	0	0	0	2 (0.3)	2 (<0.1)
腹部症状	0	0	0	1 (0.1)	1 (<0.1)
口唇のひび割れ	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
食中毒	0	0	0	1 (0.1)	1 (<0.1)
排便回数増加	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
胃出血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 10 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胃腸障害	0	0	0	1 (0.1)	1 (<0.1)
消化管運動低下	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
吐血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
口の感覚鈍麻	0	0	0	1 (0.1)	1 (<0.1)
乳児仙痛	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
乳児吐出	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
口唇痛	0	0	0	1 (0.1)	1 (<0.1)
口内炎	0	0	0	1 (0.1)	1 (<0.1)
上部消化管出血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血性下痢	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
一般・全身障害および投与部位の状態	9 (9.6)	151 (10.5)	160 (10.5)	55 (8.1)	215 (9.7)
発熱	7 (7.4)	123 (8.6)	130 (8.5)	23 (3.4)	153 (6.9)
穿刺部位疼痛	0	0	0	12 (1.8)	12 (0.5)
疼痛	0	5 (0.3)	5 (0.3)	3 (0.4)	8 (0.4)
低体温	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
末梢性浮腫	0	4 (0.3)	4 (0.3)	0	4 (0.2)
医療機器閉塞	0	3 (0.2)	3 (0.2)	0	3 (0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 11 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
疲労	0	0	0	3 (0.4)	3 (0.1)
不快感	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
末梢腫脹	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
血管穿刺部位内出血	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
適用部位紅斑	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
カテーテル留置部位出血	0	0	0	1 (0.1)	1 (<0.1)
カテーテル留置部位炎症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
カテーテル留置部位疼痛	0	0	0	1 (0.1)	1 (<0.1)
カテーテル留置部位関連反応	0	0	0	1 (0.1)	1 (<0.1)
胸部不快感	0	0	0	1 (0.1)	1 (<0.1)
悪寒	0	0	0	1 (0.1)	1 (<0.1)
泣き	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
死亡	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
医療機器リーク	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
薬物不耐性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
冷感	0	0	0	1 (0.1)	1 (<0.1)
重力性浮腫	0	0	0	1 (0.1)	1 (<0.1)
注入部位内出血	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
注射部位出血	0	0	0	1 (0.1)	1 (<0.1)
注射部位疼痛	0	0	0	1 (0.1)	1 (<0.1)
ワクチン接種後の易刺激性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 12 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
倦怠感	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
小結節	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
浮腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
穿刺部位反応	0	0	0	1 (0.1)	1 (<0.1)
腫脹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
適用部位発疹	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0
筋骨格系および結合組織障害	5 (5.3)	71 (5.0)	76 (5.0)	101 (14.8)	177 (8.0)
背部痛	0	1 (<0.1)	1 (<0.1)	45 (6.6)	46 (2.1)
関節拘縮	1 (1.1)	33 (2.3)	34 (2.2)	11 (1.6)	45 (2.0)
側弯症	0	13 (0.9)	13 (0.9)	17 (2.5)	30 (1.4)
四肢痛	0	3 (0.2)	3 (0.2)	7 (1.0)	10 (0.5)
関節痛	0	0	0	8 (1.2)	8 (0.4)
脊柱後弯症	0	5 (0.3)	5 (0.3)	0	5 (0.2)
胸郭変形	0	4 (0.3)	4 (0.3)	0	4 (0.2)
筋肉痛	0	0	0	4 (0.6)	4 (0.2)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 13 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
頚部痛	0	0	0	3 (0.4)	3 (0.1)
頭位性斜頭症	1 (1.1)	2 (0.1)	3 (0.2)	0	3 (0.1)
斜頚	1 (1.1)	2 (0.1)	3 (0.2)	0	3 (0.1)
後側弯症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
脊柱前弯症	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
筋緊張	0	0	0	2 (0.3)	2 (<0.1)
骨盤変形	0	0	0	2 (0.3)	2 (<0.1)
泉門閉鎖遅延	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
四肢拘縮	0	0	0	1 (0.1)	1 (<0.1)
手変形	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
関節硬直	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
筋力低下	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
脊柱変形	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
滑膜炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
体重支持困難	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
腱障害	0	0	0	0	0
傷害、中毒および処置合併症	5 (5.3)	44 (3.1)	49 (3.2)	88 (12.9)	137 (6.2)
腰椎穿刺後症候群	0	0	0	33 (4.8)	33 (1.5)
処置による疼痛	0	4 (0.3)	4 (0.3)	10 (1.5)	14 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 14 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
節足動物咬傷	0	7 (0.5)	7 (0.5)	4 (0.6)	11 (0.5)
裂傷	0	0	0	7 (1.0)	7 (0.3)
大腿骨骨折	0	2 (0.1)	2 (0.1)	3 (0.4)	5 (0.2)
術後激越	0	1 (<0.1)	1 (<0.1)	3 (0.4)	4 (0.2)
挫傷	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
関節脱臼	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
四肢損傷	0	0	0	4 (0.6)	4 (0.2)
関節損傷	0	0	0	3 (0.4)	3 (0.1)
皮膚擦過傷	0	3 (0.2)	3 (0.2)	0	3 (0.1)
ストーマ部紅斑	0	3 (0.2)	3 (0.2)	0	3 (0.1)
サンバーン	0	1 (<0.1)	1 (<0.1)	2 (0.3)	3 (0.1)
耳擦過傷	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
転倒	1 (1.1)	0	1 (<0.1)	1 (0.1)	2 (<0.1)
栄養補給チューブ合併症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
処置後腫脹	1 (1.1)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
処置による悪心	0	0	0	2 (0.3)	2 (<0.1)
熱傷	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
隆起骨折	0	0	0	2 (0.3)	2 (<0.1)
節足動物刺傷	0	0	0	1 (0.1)	1 (<0.1)
麻酔からの覚醒遅延	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ダンピング症候群	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 15 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
擦過傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
伝染病曝露	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
頭部損傷	0	0	0	1 (0.1)	1 (<0.1)
靭帯捻挫	0	0	0	1 (0.1)	1 (<0.1)
口唇損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
下肢骨折	0	0	0	1 (0.1)	1 (<0.1)
半月板損傷	0	0	0	1 (0.1)	1 (<0.1)
肉離れ	0	0	0	1 (0.1)	1 (<0.1)
外傷性気胸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
処置後合併症	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
処置後不快感	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
術後イレウス	0	0	0	1 (0.1)	1 (<0.1)
処置合併症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
処置による頭痛	0	0	0	1 (0.1)	1 (<0.1)
処置部位反応	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
軟部組織損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ストーマ合併症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
硬膜下血腫	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
脛骨骨折	0	0	0	1 (0.1)	1 (<0.1)
歯牙損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ワクチン接種合併症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 16 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
創離開	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気管内挿管合併症	0	0	0	0	0
処置後挫傷	0	0	0	0	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
気管損傷	0	0	0	0	0
皮膚および皮下組織障害	8 (8.5)	70 (4.9)	78 (5.1)	18 (2.6)	96 (4.3)
発疹	0	20 (1.4)	20 (1.3)	1 (0.1)	21 (1.0)
おむつ皮膚炎	2 (2.1)	11 (0.8)	13 (0.9)	1 (0.1)	14 (0.6)
皮膚炎	2 (2.1)	4 (0.3)	6 (0.4)	1 (0.1)	7 (0.3)
接触性皮膚炎	0	4 (0.3)	4 (0.3)	3 (0.4)	7 (0.3)
湿疹	0	4 (0.3)	4 (0.3)	2 (0.3)	6 (0.3)
斑状出血	0	3 (0.2)	3 (0.2)	0	3 (0.1)
紅斑	1 (1.1)	1 (<0.1)	2 (0.1)	1 (0.1)	3 (0.1)
過剰肉芽組織	0	3 (0.2)	3 (0.2)	0	3 (0.1)
汗疹	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
皮膚刺激	0	3 (0.2)	3 (0.2)	0	3 (0.1)
脱毛症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
水疱	0	0	0	2 (0.3)	2 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 17 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
貨幣状湿疹	2 (2.1)	0	2 (0.1)	0	2 (<0.1)
過角化	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
蕁麻疹	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
ざ瘡	0	0	0	1 (0.1)	1 (<0.1)
褥瘡性潰瘍	0	0	0	1 (0.1)	1 (<0.1)
アレルギー性皮膚炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
環状肉芽腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
毛孔性角化症	0	0	0	1 (0.1)	1 (<0.1)
寝汗	0	0	0	1 (0.1)	1 (<0.1)
点状出血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
そう痒症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
丘疹性皮疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脂漏性皮膚炎	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
皮膚色素脱失	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚病変	0	0	0	1 (0.1)	1 (<0.1)
皮膚浮腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚潰瘍	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮下気腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 18 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
多汗症	0	0	0	0	0
神経系障害	2 (2.1)	21 (1.5)	23 (1.5)	67 (9.8)	90 (4.1)
頭痛	0	1 (<0.1)	1 (<0.1)	54 (7.9)	55 (2.5)
不随意性筋収縮	0	4 (0.3)	4 (0.3)	0	4 (0.2)
片頭痛	0	0	0	3 (0.4)	3 (0.1)
眼振	0	3 (0.2)	3 (0.2)	0	3 (0.1)
錯感覚	0	0	0	3 (0.4)	3 (0.1)
痙攣発作	0	3 (0.2)	3 (0.2)	0	3 (0.1)
よだれ	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
感覚鈍麻	0	0	0	2 (0.3)	2 (<0.1)
失神	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
失声症	0	0	0	1 (0.1)	1 (<0.1)
脳損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脳梗塞	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脳脊髄液漏	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
間代	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
味覚異常	0	0	0	1 (0.1)	1 (<0.1)
失読症	0	0	0	1 (0.1)	1 (<0.1)
反射亢進	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
筋緊張低下	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 19 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
低酸素性虚血性脳症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
嗜眠	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
傾眠	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
振戦	0	0	0	1 (0.1)	1 (<0.1)
失神寸前の状態	0	0	0	0	0
臨床検査	2 (2.1)	71 (5.0)	73 (4.8)	9 (1.3)	82 (3.7)
酸素飽和度低下	0	15 (1.0)	15 (1.0)	0	15 (0.7)
体重減少	0	5 (0.3)	5 (0.3)	3 (0.4)	8 (0.4)
体温上昇	0	4 (0.3)	4 (0.3)	1 (0.1)	5 (0.2)
Ｃ－反応性蛋白増加	0	5 (0.3)	5 (0.3)	0	5 (0.2)
心拍数増加	0	4 (0.3)	4 (0.3)	1 (0.1)	5 (0.2)
好中球数増加	0	4 (0.3)	4 (0.3)	0	4 (0.2)
ヒトライノウイルス検査陽性	0	3 (0.2)	3 (0.2)	0	3 (0.1)
シュードモナス検査陽性	0	3 (0.2)	3 (0.2)	0	3 (0.1)
アラニンアミノトランスフェラーゼ増加	1 (1.1)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.1)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
血中カリウム減少	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
モラクセラ検査陽性	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
ブドウ球菌検査陽性	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
白血球数増加	0	2 (0.1)	2 (0.1)	0	2 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 20 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血中重炭酸塩減少	0	0	0	1 (0.1)	1 (<0.1)
血中クロール減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血中鉄減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血中ナトリウム減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血中テストステロン減少	0	0	0	1 (0.1)	1 (<0.1)
体温低下	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
骨密度減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
呼吸音異常	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ＣＳＦ白血球数増加	0	0	0	1 (0.1)	1 (<0.1)
心電図ＳＴ－Ｔ部分異常	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
心拍数減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
心拍数不整	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
炎症マーカー上昇	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
Ａ型インフルエンザウイルス検査陽性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肝機能検査異常	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
医学的観察	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
好中球百分率増加	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
セラチア検査陽性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
レンサ球菌検査陽性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
尿検査異常	0	0	0	1 (0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 21 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
尿量減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ビタミンA減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンD減少	0	0	0	0	0
心臓障害	2 (2.1)	35 (2.4)	37 (2.4)	4 (0.6)	41 (1.9)
頻脈	2 (2.1)	10 (0.7)	12 (0.8)	1 (0.1)	13 (0.6)
徐脈	0	7 (0.5)	7 (0.5)	0	7 (0.3)
心肺停止	0	6 (0.4)	6 (0.4)	0	6 (0.3)
心停止	0	3 (0.2)	3 (0.2)	0	3 (0.1)
チアノーゼ	0	3 (0.2)	3 (0.2)	0	3 (0.1)
動悸	0	0	0	3 (0.4)	3 (0.1)
心室性頻脈	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
心筋症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
左室肥大	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
心膜気腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
上室性頻脈	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 22 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
代謝および栄養障害	4 (4.3)	30 (2.1)	34 (2.2)	5 (0.7)	39 (1.8)
体重増加不良	2 (2.1)	9 (0.6)	11 (0.7)	0	11 (0.5)
乳児および小児期早期の哺育障害	0	6 (0.4)	6 (0.4)	0	6 (0.3)
脱水	1 (1.1)	1 (<0.1)	2 (0.1)	2 (0.3)	4 (0.2)
成長障害	1 (1.1)	3 (0.2)	4 (0.3)	0	4 (0.2)
栄養補給不耐性	0	4 (0.3)	4 (0.3)	0	4 (0.2)
低ナトリウム血症	0	3 (0.2)	3 (0.2)	0	3 (0.1)
過小食	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
食欲減退	0	0	0	1 (0.1)	1 (<0.1)
食欲亢進	0	0	0	1 (0.1)	1 (<0.1)
鉄欠乏	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
代謝性アルカローシス	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ビタミンD欠乏	0	0	0	1 (0.1)	1 (<0.1)
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
免疫系障害	1 (1.1)	12 (0.8)	13 (0.9)	10 (1.5)	23 (1.0)
季節性アレルギー	1 (1.1)	5 (0.3)	6 (0.4)	4 (0.6)	10 (0.5)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 23 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
過敏症	0	2 (0.1)	2 (0.1)	5 (0.7)	7 (0.3)
薬物過敏症	0	4 (0.3)	4 (0.3)	1 (0.1)	5 (0.2)
食物アレルギー	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
精神障害	0	15 (1.0)	15 (1.0)	8 (1.2)	23 (1.0)
不安	0	5 (0.3)	5 (0.3)	0	5 (0.2)
激越	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
易刺激性	0	3 (0.2)	3 (0.2)	0	3 (0.1)
睡眠障害	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
注意欠陥多動性障害	0	0	0	1 (0.1)	1 (<0.1)
息こらえ	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
不快気分	0	0	0	1 (0.1)	1 (<0.1)
不眠症	0	0	0	1 (0.1)	1 (<0.1)
気分動揺	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
睡眠時随伴症	0	0	0	1 (0.1)	1 (<0.1)
落ち着きのなさ	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
チック	0	0	0	1 (0.1)	1 (<0.1)
心因性嘔吐	0	0	0	1 (0.1)	1 (<0.1)
血管障害	2 (2.1)	8 (0.6)	10 (0.7)	1 (0.1)	11 (0.5)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 24 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
高血圧	1 (1.1)	2 (0.1)	3 (0.2)	0	3 (0.1)
蒼白	1 (1.1)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
血管炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
毛細血管脆弱	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
本態性高血圧症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
低血圧	0	0	0	1 (0.1)	1 (<0.1)
ショック	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
眼障害	1 (1.1)	7 (0.5)	8 (0.5)	2 (0.3)	10 (0.5)
斜視	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
乱視	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
霰粒腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
後天性涙道狭窄	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
眼乾燥	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
眼運動障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
眼瞼下垂	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
遠視	0	0	0	1 (0.1)	1 (<0.1)
近視	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 25 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血液およびリンパ系障害	2 (2.1)	6 (0.4)	8 (0.5)	1 (0.1)	9 (0.4)
貧血	0	3 (0.2)	3 (0.2)	0	3 (0.1)
好中球減少症	1 (1.1)	1 (<0.1)	2 (0.1)	1 (0.1)	3 (0.1)
好酸球増加症	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
リンパ節症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血小板増加症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
骨髄障害	0	0	0	0	0
白血球増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	6 (0.4)	6 (0.4)	0	6 (0.3)
斜頭症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
斜指症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
発育性股関節形成不全	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
貧血母斑	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
鳩胸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
停留精巣	0	0	0	0	0
包茎	0	0	0	0	0
耳および迷路障害	0	3 (0.2)	3 (0.2)	3 (0.4)	6 (0.3)
耳痛	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 26 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
耳の障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
耳垢分泌過多	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
乗物酔い	0	0	0	1 (0.1)	1 (<0.1)
鼓膜穿孔	0	0	0	1 (0.1)	1 (<0.1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.1)	2 (0.1)	3 (0.2)	3 (0.4)	6 (0.3)
皮膚乳頭腫	0	0	0	3 (0.4)	3 (0.1)
アクロコルドン	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血管の良性新生物	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脂漏性角化症	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
腎および尿路障害	0	3 (0.2)	3 (0.2)	3 (0.4)	6 (0.3)
尿閉	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
排尿困難	0	0	0	1 (0.1)	1 (<0.1)
水腎症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
尿失禁	0	0	0	1 (0.1)	1 (<0.1)
膀胱尿管逆流	0	0	0	1 (0.1)	1 (<0.1)
糖尿	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 27 of 27

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
生殖系および乳房障害	0	3 (0.2)	3 (0.2)	0	3 (0.1)
後天性包茎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
卵巣嚢胞	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
陰茎障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肝胆道系障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肝腫大	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
妊娠、産褥および周産期の状態	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
臍肉芽腫	1 (1.1)	0	1 (<0.1)	0	1 (<0.1)
外科および内科処置	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
機械的換気	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 29　Incidence of Adverse Events in Infants Diagnosed With SMA

Incidence of adverse events in infants diagnosed with SMA
Page 1 of 28

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	13 (76.5)	38 (92.7)	72 (90.0)	92 (92.0)	105 (89.7)
感染症および寄生虫症	10 (58.8)	29 (70.7)	57 (71.3)	76 (76.0)	86 (73.5)
上気道感染	6 (35.3)	9 (22.0)	20 (25.0)	32 (32.0)	38 (32.5)
肺炎	1 (5.9)	6 (14.6)	17 (21.3)	24 (24.0)	25 (21.4)
鼻咽頭炎	3 (17.6)	4 (9.8)	14 (17.5)	20 (20.0)	23 (19.7)
ライノウイルス感染	1 (5.9)	5 (12.2)	8 (10.0)	14 (14.0)	15 (12.8)
気道感染	0	2 (4.9)	7 (8.8)	12 (12.0)	12 (10.3)
ウイルス性上気道感染	0	8 (19.5)	10 (12.5)	12 (12.0)	12 (10.3)
細気管支炎	1 (5.9)	3 (7.3)	8 (10.0)	11 (11.0)	12 (10.3)
ウイルス感染	0	2 (4.9)	7 (8.8)	11 (11.0)	11 (9.4)
ウイルス性肺炎	1 (5.9)	1 (2.4)	6 (7.5)	9 (9.0)	10 (8.5)
口腔カンジダ症	0	3 (7.3)	6 (7.5)	7 (7.0)	7 (6.0)
中耳炎	2 (11.8)	2 (4.9)	1 (1.3)	7 (7.0)	9 (7.7)
結膜炎	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.1)
気管支炎	1 (5.9)	0	5 (6.3)	5 (5.0)	6 (5.1)
耳感染	0	1 (2.4)	4 (5.0)	5 (5.0)	5 (4.3)
ウイルス性気道感染	0	2 (4.9)	4 (5.0)	5 (5.0)	5 (4.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 2 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
下気道感染	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
細菌性肺炎	0	2 (4.9)	3 (3.8)	4 (4.0)	4 (3.4)
ＲＳウイルス細気管支炎	0	3 (7.3)	3 (3.8)	4 (4.0)	4 (3.4)
細菌性気管炎	0	4 (9.8)	1 (1.3)	3 (3.0)	3 (2.6)
ウイルス性気管支炎	0	0	3 (3.8)	3 (3.0)	3 (2.6)
インフルエンザ	2 (11.8)	0	2 (2.5)	3 (3.0)	5 (4.3)
ウイルス性下気道感染	0	0	2 (2.5)	3 (3.0)	3 (2.6)
尿路感染	1 (5.9)	0	3 (3.8)	3 (3.0)	4 (3.4)
アデノウイルス感染	0	0	2 (2.5)	2 (2.0)	2 (1.7)
細菌感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
カンジダ性おむつ皮疹	0	0	1 (1.3)	2 (2.0)	2 (1.7)
細菌性結膜炎	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
エンテロウイルス感染	0	0	0	2 (2.0)	2 (1.7)
皮膚真菌感染	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
胃腸炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
手足口病	0	0	1 (1.3)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)
パラインフルエンザウイルス感染	0	1 (2.4)	0	2 (2.0)	2 (1.7)
モラクセラ菌性肺炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 3 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
鼻炎	1 (5.9)	3 (7.3)	1 (1.3)	2 (2.0)	3 (2.6)
皮膚カンジダ	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ストーマ部膿瘍	0	0	2 (2.5)	2 (2.0)	2 (1.7)
アデノウイルス性上気道感染	0	0	0	1 (1.0)	1 (0.9)
細菌性疾患キャリアー	0	1 (2.4)	0	1 (1.0)	1 (0.9)
蜂巣炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
コロナウイルス感染	0	2 (4.9)	0	1 (1.0)	1 (0.9)
感染性湿疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
伝染性紅斑	0	0	0	1 (1.0)	1 (0.9)
眼感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
真菌感染	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性胃炎	0	0	0	1 (1.0)	1 (0.9)
ロタウイルス胃腸炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性胃腸炎	1 (5.9)	2 (4.9)	1 (1.3)	1 (1.0)	2 (1.7)
ヘモフィルス感染	0	0	0	1 (1.0)	1 (0.9)
膿痂疹	1 (5.9)	1 (2.4)	1 (1.3)	1 (1.0)	2 (1.7)
限局性感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
モラクセラ感染	0	0	0	1 (1.0)	1 (0.9)
粘膜皮膚カンジダ症	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 4 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
院内感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
口腔ヘルペス	0	0	1 (1.3)	1 (1.0)	1 (0.9)
急性中耳炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
レンサ球菌性咽頭炎	1 (5.9)	0	0	1 (1.0)	2 (1.7)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
パラインフルエンザウイルス性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
シュードモナス菌性肺炎	0	1 (2.4)	0	1 (1.0)	1 (0.9)
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
シュードモナス感染	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
細菌性気道感染	0	1 (2.4)	0	1 (1.0)	1 (0.9)
ばら疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ブドウ球菌性菌血症	0	0	0	1 (1.0)	1 (0.9)
ブドウ球菌感染	0	2 (4.9)	0	1 (1.0)	1 (0.9)
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ブドウ球菌皮膚感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気管炎	0	1 (2.4)	0	1 (1.0)	1 (0.9)
カンジダ感染	0	3 (7.3)	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 5 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
ウイルス性消化管感染	0	0	0	0	0
麦粒腫	0	1 (2.4)	0	0	0
伝染性軟属腫	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0
咽頭炎	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	0
セラチア感染	0	1 (2.4)	0	0	0
副鼻腔炎	0	0	0	0	0
皮膚細菌感染	0	0	0	0	0
皮膚感染	1 (5.9)	1 (2.4)	0	0	1 (0.9)
ストーマ部感染	0	3 (7.3)	0	0	0
扁桃炎	0	0	0	0	0
腟感染	0	0	0	0	0
ウイルス性発疹	0	1 (2.4)	0	0	0
ウイルス性扁桃炎	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0
呼吸器、胸郭および縦隔障害	5 (29.4)	34 (82.9)	55 (68.8)	73 (73.0)	78 (66.7)
呼吸窮迫	1 (5.9)	14 (34.1)	19 (23.8)	26 (26.0)	27 (23.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 6 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
呼吸不全	0	14 (34.1)	17 (21.3)	23 (23.0)	23 (19.7)
無気肺	0	9 (22.0)	15 (18.8)	20 (20.0)	20 (17.1)
急性呼吸不全	0	8 (19.5)	11 (13.8)	15 (15.0)	15 (12.8)
鼻閉	2 (11.8)	6 (14.6)	8 (10.0)	15 (15.0)	17 (14.5)
咳嗽	2 (11.8)	8 (19.5)	6 (7.5)	12 (12.0)	14 (12.0)
低酸素症	0	2 (4.9)	6 (7.5)	10 (10.0)	10 (8.5)
誤嚥性肺炎	0	6 (14.6)	7 (8.8)	10 (10.0)	10 (8.5)
呼吸困難	0	6 (14.6)	7 (8.8)	9 (9.0)	9 (7.7)
無呼吸	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (6.0)
誤嚥	0	1 (2.4)	4 (5.0)	6 (6.0)	6 (5.1)
気管支分泌物貯留	0	4 (9.8)	3 (3.8)	6 (6.0)	6 (5.1)
慢性呼吸不全	0	0	2 (2.5)	6 (6.0)	6 (5.1)
上気道分泌増加	0	1 (2.4)	2 (2.5)	6 (6.0)	6 (5.1)
鼻漏	1 (5.9)	3 (7.3)	4 (5.0)	6 (6.0)	7 (6.0)
上気道うっ血	1 (5.9)	1 (2.4)	5 (6.3)	6 (6.0)	7 (6.0)
呼吸停止	0	4 (9.8)	3 (3.8)	4 (4.0)	4 (3.4)
副鼻腔うっ血	0	0	3 (3.8)	4 (4.0)	4 (3.4)
低換気	0	0	2 (2.5)	3 (3.0)	3 (2.6)
気胸	0	0	1 (1.3)	3 (3.0)	3 (2.6)
喘鳴	0	0	1 (1.3)	3 (3.0)	3 (2.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 7 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
息詰まり	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
肺うっ血	0	0	0	2 (2.0)	2 (1.7)
肺水腫	0	0	0	2 (2.0)	2 (1.7)
呼吸障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
アレルギー性鼻炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
呼吸補助筋の動員	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
急性呼吸窮迫症候群	0	0	1 (1.3)	1 (1.0)	1 (0.9)
無呼吸発作	0	0	0	1 (1.0)	1 (0.9)
窒息	0	0	0	1 (1.0)	1 (0.9)
気管支閉塞	0	0	1 (1.3)	1 (1.0)	1 (0.9)
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
減呼吸	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気管支分泌増加	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
喉頭肉芽腫	0	0	0	1 (1.0)	1 (0.9)
肺障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鼻汁変色	0	0	0	1 (1.0)	1 (0.9)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
胸水	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気縦隔症	0	0	0	1 (1.0)	1 (0.9)
湿性咳嗽	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 8 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
呼吸性アルカローシス	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気道うっ血	0	3 (7.3)	1 (1.3)	1 (1.0)	1 (0.9)
拘束性肺疾患	0	0	0	1 (1.0)	1 (0.9)
低音性連続性ラ音	0	0	0	1 (1.0)	1 (0.9)
睡眠時無呼吸症候群	0	4 (9.8)	0	1 (1.0)	1 (0.9)
変色痰	0	0	1 (1.3)	1 (1.0)	1 (0.9)
頻呼吸	0	2 (4.9)	0	1 (1.0)	1 (0.9)
気管障害	0	0	0	1 (1.0)	1 (0.9)
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
カタル	0	1 (2.4)	0	0	0
発声障害	0	0	0	0	0
鼻出血	0	0	0	0	0
口腔咽頭痛	0	1 (2.4)	0	0	0
肺臓炎	0	0	0	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	1 (0.9)
扁桃肥大	0	0	0	0	0
上気道の炎症	0	2 (4.9)	0	0	0
胃腸障害	6 (35.3)	23 (56.1)	46 (57.5)	64 (64.0)	70 (59.8)
便秘	1 (5.9)	9 (22.0)	24 (30.0)	33 (33.0)	34 (29.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 9 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
嘔吐	0	8 (19.5)	12 (15.0)	20 (20.0)	20 (17.1)
胃食道逆流性疾患	2 (11.8)	6 (14.6)	9 (11.3)	15 (15.0)	17 (14.5)
生歯	1 (5.9)	3 (7.3)	11 (13.8)	15 (15.0)	16 (13.7)
下痢	0	7 (17.1)	8 (10.0)	13 (13.0)	13 (11.1)
嚥下障害	1 (5.9)	8 (19.5)	9 (11.3)	9 (9.0)	10 (8.5)
放屁	2 (11.8)	1 (2.4)	3 (3.8)	5 (5.0)	7 (6.0)
流涎過多	0	2 (4.9)	3 (3.8)	5 (5.0)	5 (4.3)
腹部膨満	2 (11.8)	0	1 (1.3)	4 (4.0)	6 (5.1)
胃炎	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
血便排泄	0	0	2 (2.5)	2 (2.0)	2 (1.7)
腹部不快感	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
腹痛	0	0	0	1 (1.0)	1 (0.9)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.9)
口唇のひび割れ	0	0	0	1 (1.0)	1 (0.9)
排便回数増加	0	0	0	1 (1.0)	1 (0.9)
胃出血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
消化管運動低下	0	0	0	1 (1.0)	1 (0.9)
吐血	0	0	0	1 (1.0)	1 (0.9)
乳児仙痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
乳児吐出	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 10 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
上部消化管出血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
上腹部痛	0	2 (4.9)	0	0	0
腹部症状	0	0	0	0	0
血性下痢	0	1 (2.4)	0	0	0
食中毒	0	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	1 (2.4)	0	0	0
消化管刺激症状	0	1 (2.4)	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0
口腔内痛	0	0	0	0	0
口内炎	0	1 (2.4)	0	0	0
一般・全身障害および投与状態	4 (23.5)	27 (65.9)	44 (55.0)	58 (58.0)	62 (53.0)
発熱	3 (17.6)	22 (53.7)	39 (48.8)	53 (53.0)	56 (47.9)
疼痛	0	2 (4.9)	1 (1.3)	5 (5.0)	5 (4.3)
不快感	0	0	0	2 (2.0)	2 (1.7)
末梢性浮腫	0	0	0	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 11 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
カテーテル留置部位炎症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.9)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
医療機器リーク	0	0	0	1 (1.0)	1 (0.9)
医療機器閉塞	0	1 (2.4)	0	1 (1.0)	1 (0.9)
薬物不耐性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低体温	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ワクチン接種後の易刺激性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
倦怠感	0	0	1 (1.3)	1 (1.0)	1 (0.9)
小結節	0	0	1 (1.3)	1 (1.0)	1 (0.9)
浮腫	0	3 (7.3)	0	1 (1.0)	1 (0.9)
末梢腫脹	0	0	0	1 (1.0)	1 (0.9)
腫脹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血管穿刺部位内出血	0	2 (4.9)	0	1 (1.0)	1 (0.9)
適用部位紅斑	1 (5.9)	0	0	0	1 (0.9)
適用部位発疹	0	1 (2.4)	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 12 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
悪寒	0	0	0	0	0
医療機器機能不良	0	1 (2.4)	0	0	0
疲労	0	1 (2.4)	0	0	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
注入部位内出血	1 (5.9)	1 (2.4)	0	0	1 (0.9)
注入部位血管外漏出	0	1 (2.4)	0	0	0
注射部位血腫	0	1 (2.4)	0	0	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
血管穿刺部位反応	0	1 (2.4)	0	0	0
皮膚および皮下組織障害	6 (35.3)	13 (31.7)	21 (26.3)	35 (35.0)	41 (35.0)
発疹	0	4 (9.8)	8 (10.0)	13 (13.0)	13 (11.1)
おむつ皮膚炎	2 (11.8)	2 (4.9)	6 (7.5)	10 (10.0)	12 (10.3)
湿疹	0	2 (4.9)	1 (1.3)	4 (4.0)	4 (3.4)
接触性皮膚炎	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
斑状出血	0	0	2 (2.5)	3 (3.0)	3 (2.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 13 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
過剰肉芽組織	0	0	0	3 (3.0)	3 (2.6)
皮膚刺激	0	0	0	3 (3.0)	3 (2.6)
皮膚炎	2 (11.8)	0	1 (1.3)	2 (2.0)	4 (3.4)
過角化	0	0	2 (2.5)	2 (2.0)	2 (1.7)
汗疹	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脱毛症	0	0	0	1 (1.0)	1 (0.9)
アレルギー性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
紅斑	1 (5.9)	3 (7.3)	1 (1.3)	1 (1.0)	2 (1.7)
環状肉芽腫	0	0	1 (1.3)	1 (1.0)	1 (0.9)
点状出血	0	0	0	1 (1.0)	1 (0.9)
そう痒症	0	0	0	1 (1.0)	1 (0.9)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
皮膚色素脱失	0	0	0	1 (1.0)	1 (0.9)
皮膚障害	0	0	0	1 (1.0)	1 (0.9)
皮膚浮腫	0	0	1 (1.3)	1 (1.0)	1 (0.9)
皮膚潰瘍	0	0	0	1 (1.0)	1 (0.9)
皮下気腫	0	0	0	1 (1.0)	1 (0.9)
蕁麻疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 14 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
褥瘡性潰瘍	0	2 (4.9)	0	0	0
アトピー性皮膚炎	0	2 (4.9)	0	0	0
皮膚乾燥	0	1 (2.4)	0	0	0
貨幣状湿疹	1 (5.9)	0	0	0	1 (0.9)
多汗症	0	1 (2.4)	0	0	0
毛孔性角化症	0	1 (2.4)	0	0	0
寝汗	0	0	0	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	1 (0.9)
皮膚病変	0	0	0	0	0
傷害、中毒および処置合併症	3 (17.6)	10 (24.4)	15 (18.8)	26 (26.0)	29 (24.8)
処置による疼痛	0	0	2 (2.5)	4 (4.0)	4 (3.4)
節足動物咬傷	0	0	0	3 (3.0)	3 (2.6)
ストーマ部紅斑	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
挫傷	0	0	1 (1.3)	2 (2.0)	2 (1.7)
栄養補給チューブ合併症	0	2 (4.9)	0	2 (2.0)	2 (1.7)
大腿骨骨折	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
関節脱臼	0	0	0	2 (2.0)	2 (1.7)
皮膚擦過傷	0	0	0	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 15 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.9)
麻酔からの覚醒遅延	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ダンピング症候群	0	0	0	1 (1.0)	1 (0.9)
耳擦過傷	0	0	0	1 (1.0)	1 (0.9)
擦過傷	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
伝染病曝露	0	0	1 (1.3)	1 (1.0)	1 (0.9)
口唇損傷	0	0	0	1 (1.0)	1 (0.9)
外傷性気胸	0	0	0	1 (1.0)	1 (0.9)
処置後腫脹	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置合併症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.9)
軟部組織損傷	0	0	0	1 (1.0)	1 (0.9)
ストーマ合併症	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
サンバーン	0	0	0	1 (1.0)	1 (0.9)
熱傷	0	0	0	1 (1.0)	1 (0.9)
歯牙損傷	0	0	0	1 (1.0)	1 (0.9)
ワクチン接種合併症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
創離開	0	0	1 (1.3)	1 (1.0)	1 (0.9)
節足動物刺傷	0	0	0	0	0
気管内挿管合併症	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 16 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
転倒	1 (5.9)	0	0	0	1 (0.9)
頭部損傷	0	1 (2.4)	0	0	0
関節損傷	0	0	0	0	0
裂傷	0	1 (2.4)	0	0	0
靭帯捻挫	0	0	0	0	0
四肢損傷	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
肉離れ	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
処置後合併症	1 (5.9)	0	0	0	1 (0.9)
処置後挫傷	0	1 (2.4)	0	0	0
処置後不快感	1 (5.9)	0	0	0	1 (0.9)
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
ストーマ部出血	0	1 (2.4)	0	0	0
ストーマ部炎症	0	1 (2.4)	0	0	0
ストーマ部刺激感	0	1 (2.4)	0	0	0
硬膜下血腫	1 (5.9)	0	0	0	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 17 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
脛骨骨折	0	0	0	0	0
隆起骨折	0	0	0	0	0
気管損傷	0	1 (2.4)	0	0	0
筋骨格系および結合組織障害	2 (11.8)	4 (9.8)	11 (13.8)	25 (25.0)	27 (23.1)
関節拘縮	1 (5.9)	2 (4.9)	3 (3.8)	11 (11.0)	12 (10.3)
側弯症	0	1 (2.4)	4 (5.0)	11 (11.0)	11 (9.4)
脊柱後弯症	0	1 (2.4)	1 (1.3)	5 (5.0)	5 (4.3)
胸郭変形	0	0	1 (1.3)	4 (4.0)	4 (3.4)
後側弯症	0	0	1 (1.3)	2 (2.0)	2 (1.7)
四肢痛	0	0	1 (1.3)	2 (2.0)	2 (1.7)
頭位性斜頭症	1 (5.9)	1 (2.4)	2 (2.5)	2 (2.0)	3 (2.6)
斜頚	1 (5.9)	0	0	2 (2.0)	3 (2.6)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
泉門閉鎖遅延	0	0	1 (1.3)	1 (1.0)	1 (0.9)
手変形	0	0	0	1 (1.0)	1 (0.9)
関節硬直	0	1 (2.4)	0	1 (1.0)	1 (0.9)
脊柱前弯症	0	0	0	1 (1.0)	1 (0.9)
脊柱変形	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 18 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
滑膜炎	0	0	0	1 (1.0)	1 (0.9)
関節痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
筋緊張	0	0	0	0	0
筋力低下	1 (5.9)	1 (2.4)	0	0	1 (0.9)
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	1 (2.4)	0	0	0
体重支持困難	1 (5.9)	0	0	0	1 (0.9)
臨床検査	1 (5.9)	14 (34.1)	17 (21.3)	24 (24.0)	25 (21.4)
酸素飽和度低下	0	9 (22.0)	8 (10.0)	10 (10.0)	10 (8.5)
体重減少	0	1 (2.4)	3 (3.8)	5 (5.0)	5 (4.3)
ヒトライノウイルス検査陽性	0	0	1 (1.3)	3 (3.0)	3 (2.6)
好中球数増加	0	0	1 (1.3)	3 (3.0)	3 (2.6)
血中カリウム減少	0	0	2 (2.5)	2 (2.0)	2 (1.7)
体温上昇	0	0	2 (2.5)	2 (2.0)	2 (1.7)
Ｃ－反応性蛋白増加	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
心拍数増加	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 19 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
モラクセラ検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
シュードモナス検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
ブドウ球菌検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
白血球数増加	0	0	0	2 (2.0)	2 (1.7)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中鉄減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
体温低下	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
骨密度減少	0	0	0	1 (1.0)	1 (0.9)
呼吸音異常	0	0	0	1 (1.0)	1 (0.9)
心電図ＳＴ－Ｔ部分異常	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
心拍数減少	0	0	0	1 (1.0)	1 (0.9)
心拍数不整	0	0	1 (1.3)	1 (1.0)	1 (0.9)
炎症マーカー上昇	0	0	1 (1.3)	1 (1.0)	1 (0.9)
Ａ型インフルエンザウイルス検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肝機能検査異常	0	0	1 (1.3)	1 (1.0)	1 (0.9)
医学的観察	0	0	1 (1.3)	1 (1.0)	1 (0.9)
好中球百分率増加	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 20 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
セラチア検査陽性	0	0	0	1 (1.0)	1 (0.9)
レンサ球菌検査陽性	0	0	0	1 (1.0)	1 (0.9)
尿量減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ビタミンA減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中重炭酸塩減少	0	0	0	0	0
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
ヘッドラグ異常	0	1 (2.4)	0	0	0
リンパ節触知	0	1 (2.4)	0	0	0
呼吸数増加	0	1 (2.4)	0	0	0
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0
トランスアミナーゼ上昇	0	1 (2.4)	0	0	0
尿検査異常	0	0	0	0	0
ビタミンD減少	0	1 (2.4)	0	0	0
心臓障害	2 (11.8)	11 (26.8)	16 (20.0)	22 (22.0)	24 (20.5)
頻脈	2 (11.8)	5 (12.2)	6 (7.5)	8 (8.0)	10 (8.5)
徐脈	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (6.0)
心肺停止	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.1)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 21 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
チアノーゼ	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
心室性頻脈	0	0	1 (1.3)	2 (2.0)	2 (1.7)
心筋症	0	0	0	1 (1.0)	1 (0.9)
左室肥大	0	0	1 (1.3)	1 (1.0)	1 (0.9)
心膜気腫	0	0	0	1 (1.0)	1 (0.9)
上室性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.9)
動悸	0	0	0	0	0
代謝および栄養障害	2 (11.8)	10 (24.4)	13 (16.3)	18 (18.0)	20 (17.1)
体重増加不良	1 (5.9)	2 (4.9)	5 (6.3)	6 (6.0)	7 (6.0)
成長障害	1 (5.9)	0	2 (2.5)	3 (3.0)	4 (3.4)
乳児および小児期早期の哺育障害	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.6)
栄養補給不耐性	0	0	3 (3.8)	3 (3.0)	3 (2.6)
低ナトリウム血症	0	0	0	2 (2.0)	2 (1.7)
過小食	0	0	0	2 (2.0)	2 (1.7)
脱水	1 (5.9)	1 (2.4)	1 (1.3)	1 (1.0)	2 (1.7)
鉄欠乏	0	0	1 (1.3)	1 (1.0)	1 (0.9)
代謝性アルカローシス	0	0	0	1 (1.0)	1 (0.9)
食欲減退	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 22 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
食物不耐性	0	1 (2.4)	0	0	0
高血糖	0	1 (2.4)	0	0	0
低血糖	0	2 (4.9)	0	0	0
低カリウム血症	0	3 (7.3)	0	0	0
食欲亢進	0	0	0	0	0
ビタミンD欠乏	0	1 (2.4)	0	0	0
神経系障害	2 (11.8)	2 (4.9)	8 (10.0)	17 (17.0)	19 (16.2)
不随意性筋収縮	0	0	1 (1.3)	4 (4.0)	4 (3.4)
眼振	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.6)
よだれ	0	0	1 (1.3)	2 (2.0)	2 (1.7)
痙攣発作	0	0	1 (1.3)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
脳梗塞	0	0	0	1 (1.0)	1 (0.9)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.9)
間代	0	0	1 (1.3)	1 (1.0)	1 (0.9)
頭痛	0	0	0	1 (1.0)	1 (0.9)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
嗜眠	0	0	0	1 (1.0)	1 (0.9)
傾眠	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 23 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
失神	0	0	0	1 (1.0)	1 (0.9)
失声症	0	0	0	0	0
味覚異常	0	0	0	0	0
失読症	0	0	0	0	0
反射亢進	1 (5.9)	0	0	0	1 (0.9)
感覚鈍麻	0	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	1 (0.9)
片頭痛	0	0	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	1 (2.4)	0	0	0
振戦	0	0	0	0	0
免疫系障害	1 (5.9)	4 (9.8)	6 (7.5)	12 (12.0)	13 (11.1)
季節性アレルギー	1 (5.9)	2 (4.9)	2 (2.5)	5 (5.0)	6 (5.1)
薬物過敏症	0	1 (2.4)	2 (2.5)	4 (4.0)	4 (3.4)
過敏症	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
食物アレルギー	0	0	1 (1.3)	1 (1.0)	1 (0.9)
精神障害	0	5 (12.2)	8 (10.0)	11 (11.0)	11 (9.4)
不安	0	0	2 (2.5)	5 (5.0)	5 (4.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 24 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
激越	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
易刺激性	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
息こらえ	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.9)
落ち着きのなさ	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
睡眠障害	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
注意欠陥多動性障害	0	0	0	0	0
不快気分	0	0	0	0	0
不眠症	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
チック	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
血管障害	2 (11.8)	0	4 (5.0)	7 (7.0)	9 (7.7)
高血圧	1 (5.9)	0	1 (1.3)	2 (2.0)	3 (2.6)
毛細血管脆弱	0	0	0	1 (1.0)	1 (0.9)
本態性高血圧症	0	0	0	1 (1.0)	1 (0.9)
蒼白	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血管炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 25 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
低血圧	0	0	0	0	0
血液およびリンパ系障害	2 (11.8)	3 (7.3)	1 (1.3)	6 (6.0)	8 (6.8)
貧血	0	1 (2.4)	1 (1.3)	3 (3.0)	3 (2.6)
リンパ節症	0	0	0	1 (1.0)	1 (0.9)
好中球減少症	1 (5.9)	0	0	1 (1.0)	2 (1.7)
血小板増加症	0	0	0	1 (1.0)	1 (0.9)
骨髄障害	0	1 (2.4)	0	0	0
好酸球増加症	1 (5.9)	0	0	0	1 (0.9)
白血球増加症	0	1 (2.4)	0	0	0
先天性、家族性および遺伝性障害	0	4 (9.8)	3 (3.8)	6 (6.0)	6 (5.1)
斜頭症	0	0	0	2 (2.0)	2 (1.7)
斜指症	0	0	0	1 (1.0)	1 (0.9)
発育性股関節形成不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
貧血母斑	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鳩胸	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
停留精巣	0	1 (2.4)	0	0	0
包茎	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 26 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
眼障害	1 (5.9)	3 (7.3)	4 (5.0)	6 (6.0)	7 (6.0)
乱視	0	0	0	1 (1.0)	1 (0.9)
霰粒腫	0	0	1 (1.3)	1 (1.0)	1 (0.9)
眼乾燥	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
眼運動障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.9)
近視	0	0	1 (1.3)	1 (1.0)	1 (0.9)
斜視	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
弱視	0	1 (2.4)	0	0	0
後天性涙道狭窄	1 (5.9)	0	0	0	1 (0.9)
遠視	0	0	0	0	0
流涙増加	0	1 (2.4)	0	0	0
耳および迷路障害	0	0	2 (2.5)	3 (3.0)	3 (2.6)
耳の障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
耳痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
耳垢分泌過多	0	0	0	1 (1.0)	1 (0.9)
乗物酔い	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 27 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
生殖系および乳房障害	0	0	3 (3.8)	3 (3.0)	3 (2.6)
後天性包茎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
卵巣嚢胞	0	0	1 (1.3)	1 (1.0)	1 (0.9)
陰茎障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.9)	0	0	2 (2.0)	3 (2.6)
アクロコルドン	0	0	0	1 (1.0)	1 (0.9)
血管の良性新生物	0	0	0	1 (1.0)	1 (0.9)
脂漏性角化症	1 (5.9)	0	0	0	1 (0.9)
皮膚乳頭腫	0	0	0	0	0
腎および尿路障害	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
水腎症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.9)
排尿困難	0	0	0	0	0
糖尿	0	1 (2.4)	0	0	0
尿失禁	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 28 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
肝胆道系障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肝腫大	0	0	1 (1.3)	1 (1.0)	1 (0.9)
外科および内科処置	0	0	1 (1.3)	1 (1.0)	1 (0.9)
機械的換気	0	0	1 (1.3)	1 (1.0)	1 (0.9)
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	1 (0.9)
臍肉芽腫	1 (5.9)	0	0	0	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 30　Frequency of Adverse Events in Infants Diagnosed With SMA

Frequency of adverse events in infants diagnosed with SMA
Page 1 of 28

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17	41	80	100	117
Number of events	94 (100.0)	531 (100.0)	863 (100.0)	1433 (100.0)	1527 (100.0)
感染症および寄生虫症	31 (33.0)	115 (21.7)	237 (27.5)	378 (26.4)	409 (26.8)
上気道感染	9 (9.6)	12 (2.3)	32 (3.7)	55 (3.8)	64 (4.2)
肺炎	1 (1.1)	7 (1.3)	24 (2.8)	41 (2.9)	42 (2.8)
鼻咽頭炎	5 (5.3)	4 (0.8)	18 (2.1)	31 (2.2)	36 (2.4)
気道感染	0	2 (0.4)	16 (1.9)	31 (2.2)	31 (2.0)
ウイルス性上気道感染	0	9 (1.7)	15 (1.7)	17 (1.2)	17 (1.1)
ライノウイルス感染	1 (1.1)	6 (1.1)	9 (1.0)	16 (1.1)	17 (1.1)
ウイルス感染	0	3 (0.6)	9 (1.0)	14 (1.0)	14 (0.9)
細気管支炎	1 (1.1)	3 (0.6)	8 (0.9)	13 (0.9)	14 (0.9)
口腔カンジダ症	0	4 (0.8)	8 (0.9)	9 (0.6)	9 (0.6)
中耳炎	2 (2.1)	2 (0.4)	1 (0.1)	9 (0.6)	11 (0.7)
ウイルス性肺炎	1 (1.1)	1 (0.2)	6 (0.7)	9 (0.6)	10 (0.7)
耳感染	0	1 (0.2)	6 (0.7)	8 (0.6)	8 (0.5)
ウイルス性気道感染	0	3 (0.6)	6 (0.7)	7 (0.5)	7 (0.5)
結膜炎	0	3 (0.6)	5 (0.6)	6 (0.4)	6 (0.4)
下気道感染	0	1 (0.2)	5 (0.6)	6 (0.4)	6 (0.4)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 2 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
気管支炎	1 (1.1)	0	5 (0.6)	5 (0.3)	6 (0.4)
ウイルス性気管支炎	0	0	5 (0.6)	5 (0.3)	5 (0.3)
鼻炎	1 (1.1)	4 (0.8)	4 (0.5)	5 (0.3)	6 (0.4)
細菌性気管炎	0	10 (1.9)	2 (0.2)	4 (0.3)	4 (0.3)
細菌性肺炎	0	2 (0.4)	3 (0.3)	4 (0.3)	4 (0.3)
ＲＳウイルス細気管支炎	0	3 (0.6)	3 (0.3)	4 (0.3)	4 (0.3)
ストーマ部膿瘍	0	0	4 (0.5)	4 (0.3)	4 (0.3)
細菌感染	0	0	1 (0.1)	3 (0.2)	3 (0.2)
エンテロウイルス感染	0	0	0	3 (0.2)	3 (0.2)
インフルエンザ	2 (2.1)	0	2 (0.2)	3 (0.2)	5 (0.3)
ウイルス性下気道感染	0	0	2 (0.2)	3 (0.2)	3 (0.2)
パラインフルエンザウイルス感染	0	1 (0.2)	0	3 (0.2)	3 (0.2)
モラクセラ菌性肺炎	0	0	2 (0.2)	3 (0.2)	3 (0.2)
尿路感染	3 (3.2)	0	3 (0.3)	3 (0.2)	6 (0.4)
アデノウイルス感染	0	0	2 (0.2)	2 (0.1)	2 (0.1)
カンジダ性おむつ皮疹	0	0	1 (0.1)	2 (0.1)	2 (0.1)
細菌性結膜炎	0	1 (0.2)	2 (0.2)	2 (0.1)	2 (0.1)
真菌感染	0	1 (0.2)	2 (0.2)	2 (0.1)	2 (0.1)
皮膚真菌感染	0	1 (0.2)	1 (0.1)	2 (0.1)	2 (0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 3 of 28

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
胃腸炎	0	0	1 (0.1)	2 (0.1)	2 (0.1)
手足口病	0	0	1 (0.1)	2 (0.1)	2 (0.1)
メタニューモウイルス感染	0	0	0	2 (0.1)	2 (0.1)
院内感染	0	0	2 (0.2)	2 (0.1)	2 (0.1)
シュードモナス菌性肺炎	0	1 (0.2)	0	2 (0.1)	2 (0.1)
皮膚カンジダ	0	1 (0.2)	2 (0.2)	2 (0.1)	2 (0.1)
ブドウ球菌皮膚感染	0	0	2 (0.2)	2 (0.1)	2 (0.1)
アデノウイルス性上気道感染	0	0	0	1 (<0.1)	1 (<0.1)
細菌性疾患キャリアー	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
蜂巣炎	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
コロナウイルス感染	0	2 (0.4)	0	1 (<0.1)	1 (<0.1)
感染性湿疹	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
伝染性紅斑	0	0	0	1 (<0.1)	1 (<0.1)
眼感染	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
ウイルス性胃炎	0	0	0	1 (<0.1)	1 (<0.1)
ロタウイルス胃腸炎	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
ウイルス性胃腸炎	1 (1.1)	2 (0.4)	1 (0.1)	1 (<0.1)	2 (0.1)
ヘモフィルス感染	0	0	0	1 (<0.1)	1 (<0.1)
膿痂疹	1 (1.1)	1 (0.2)	1 (0.1)	1 (<0.1)	2 (0.1)
限局性感染	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 4 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
肺感染	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
モラクセラ感染	0	0	0	1 (<0.1)	1 (<0.1)
粘膜皮膚カンジダ症	0	0	0	1 (<0.1)	1 (<0.1)
口腔ヘルペス	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
急性中耳炎	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
レンサ球菌性咽頭炎	1 (1.1)	0	0	1 (<0.1)	2 (0.1)
インフルエンザ性肺炎	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
パラインフルエンザウイルス性肺炎	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
ＲＳウイルス肺炎	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
シュードモナス感染	0	2 (0.4)	1 (0.1)	1 (<0.1)	1 (<0.1)
細菌性気道感染	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
ばら疹	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
敗血症	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
ブドウ球菌性菌血症	0	0	0	1 (<0.1)	1 (<0.1)
ブドウ球菌感染	0	2 (0.4)	0	1 (<0.1)	1 (<0.1)
ブドウ球菌性敗血症	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
気管炎	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
カンジダ感染	0	6 (1.1)	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 5 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
ウイルス性消化管感染	0	0	0	0	0
麦粒腫	0	1 (0.2)	0	0	0
伝染性軟属腫	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0
咽頭炎	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	0
セラチア感染	0	2 (0.4)	0	0	0
副鼻腔炎	0	0	0	0	0
皮膚細菌感染	0	0	0	0	0
皮膚感染	1 (1.1)	1 (0.2)	0	0	1 (<0.1)
ストーマ部感染	0	4 (0.8)	0	0	0
扁桃炎	0	0	0	0	0
腟感染	0	0	0	0	0
ウイルス性発疹	0	1 (0.2)	0	0	0
ウイルス性扁桃炎	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0
呼吸器、胸郭および縦隔障害	8 (8.5)	155 (29.2)	205 (23.8)	327 (22.8)	335 (21.9)
無気肺	0	16 (3.0)	37 (4.3)	46 (3.2)	46 (3.0)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 6 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
呼吸窮迫	1 (1.1)	21 (4.0)	27 (3.1)	39 (2.7)	40 (2.6)
急性呼吸不全	0	11 (2.1)	25 (2.9)	35 (2.4)	35 (2.3)
呼吸不全	0	24 (4.5)	18 (2.1)	25 (1.7)	25 (1.6)
鼻閉	2 (2.1)	7 (1.3)	12 (1.4)	23 (1.6)	25 (1.6)
咳嗽	2 (2.1)	11 (2.1)	7 (0.8)	17 (1.2)	19 (1.2)
低酸素症	0	4 (0.8)	7 (0.8)	15 (1.0)	15 (1.0)
誤嚥性肺炎	0	7 (1.3)	9 (1.0)	13 (0.9)	13 (0.9)
呼吸困難	0	7 (1.3)	7 (0.8)	9 (0.6)	9 (0.6)
上気道分泌増加	0	1 (0.2)	3 (0.3)	9 (0.6)	9 (0.6)
無呼吸	0	10 (1.9)	4 (0.5)	8 (0.6)	8 (0.5)
気管支分泌物貯留	0	5 (0.9)	4 (0.5)	7 (0.5)	7 (0.5)
慢性呼吸不全	0	0	3 (0.3)	7 (0.5)	7 (0.5)
鼻漏	1 (1.1)	3 (0.6)	5 (0.6)	7 (0.5)	8 (0.5)
誤嚥	0	1 (0.2)	4 (0.5)	6 (0.4)	6 (0.4)
副鼻腔うっ血	0	0	4 (0.5)	6 (0.4)	6 (0.4)
上気道うっ血	1 (1.1)	1 (0.2)	5 (0.6)	6 (0.4)	7 (0.5)
呼吸停止	0	5 (0.9)	4 (0.5)	5 (0.3)	5 (0.3)
気胸	0	0	1 (0.1)	4 (0.3)	4 (0.3)
低換気	0	0	2 (0.2)	3 (0.2)	3 (0.2)
喘鳴	0	0	1 (0.1)	3 (0.2)	3 (0.2)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 7 of 28

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
息詰まり	0	2 (0.4)	1 (0.1)	2 (0.1)	2 (0.1)
肺うっ血	0	0	0	2 (0.1)	2 (0.1)
肺水腫	0	0	0	2 (0.1)	2 (0.1)
呼吸障害	0	0	2 (0.2)	2 (0.1)	2 (0.1)
アレルギー性鼻炎	0	0	1 (0.1)	2 (0.1)	2 (0.1)
呼吸補助筋の動員	0	1 (0.2)	1 (0.1)	2 (0.1)	2 (0.1)
急性呼吸窮迫症候群	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
無呼吸発作	0	0	0	1 (<0.1)	1 (<0.1)
窒息	0	0	0	1 (<0.1)	1 (<0.1)
気管支閉塞	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
高炭酸ガス血症	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
減呼吸	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
気管支分泌増加	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
喉頭肉芽腫	0	0	0	1 (<0.1)	1 (<0.1)
肺障害	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
鼻汁変色	0	0	0	1 (<0.1)	1 (<0.1)
閉塞性気道障害	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
胸水	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
気縦隔症	0	0	0	1 (<0.1)	1 (<0.1)
湿性咳嗽	0	0	0	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 8 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
呼吸性アルカローシス	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
気道うっ血	0	3 (0.6)	1 (0.1)	1 (<0.1)	1 (<0.1)
拘束性肺疾患	0	0	0	1 (<0.1)	1 (<0.1)
低音性連続性ラ音	0	0	0	1 (<0.1)	1 (<0.1)
睡眠時無呼吸症候群	0	4 (0.8)	0	1 (<0.1)	1 (<0.1)
変色痰	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
頻呼吸	0	3 (0.6)	0	1 (<0.1)	1 (<0.1)
気管障害	0	0	0	1 (<0.1)	1 (<0.1)
乳幼児突発性危急事態	0	2 (0.4)	0	0	0
カタル	0	1 (0.2)	0	0	0
発声障害	0	0	0	0	0
鼻出血	0	0	0	0	0
口腔咽頭痛	0	1 (0.2)	0	0	0
肺臓炎	0	0	0	0	0
呼吸性アシドーシス	1 (1.1)	0	0	0	1 (<0.1)
扁桃肥大	0	0	0	0	0
上気道の炎症	0	3 (0.6)	0	0	0
胃腸障害	10 (10.6)	58 (10.9)	108 (12.5)	168 (11.7)	178 (11.7)
便秘	1 (1.1)	9 (1.7)	26 (3.0)	36 (2.5)	37 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 9 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
嘔吐	0	8 (1.5)	21 (2.4)	34 (2.4)	34 (2.2)
下痢	0	11 (2.1)	10 (1.2)	24 (1.7)	24 (1.6)
胃食道逆流性疾患	2 (2.1)	6 (1.1)	10 (1.2)	16 (1.1)	18 (1.2)
生歯	1 (1.1)	3 (0.6)	11 (1.3)	15 (1.0)	16 (1.0)
嚥下障害	1 (1.1)	10 (1.9)	12 (1.4)	12 (0.8)	13 (0.9)
放屁	2 (2.1)	1 (0.2)	3 (0.3)	5 (0.3)	7 (0.5)
流涎過多	0	2 (0.4)	3 (0.3)	5 (0.3)	5 (0.3)
腹部膨満	2 (2.1)	0	1 (0.1)	4 (0.3)	6 (0.4)
胃炎	0	1 (0.2)	3 (0.3)	4 (0.3)	4 (0.3)
血便排泄	0	0	2 (0.2)	2 (0.1)	2 (0.1)
腹部不快感	1 (1.1)	0	1 (0.1)	1 (<0.1)	2 (0.1)
腹痛	0	0	0	1 (<0.1)	1 (<0.1)
アフタ性潰瘍	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
口唇のひび割れ	0	0	0	1 (<0.1)	1 (<0.1)
排便回数増加	0	0	0	1 (<0.1)	1 (<0.1)
胃出血	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
消化管運動低下	0	0	0	1 (<0.1)	1 (<0.1)
吐血	0	0	0	1 (<0.1)	1 (<0.1)
乳児仙痛	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
乳児吐出	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 10 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
上部消化管出血	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
上腹部痛	0	2 (0.4)	0	0	0
腹部症状	0	0	0	0	0
血性下痢	0	1 (0.2)	0	0	0
食中毒	0	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	2 (0.4)	0	0	0
消化管刺激症状	0	1 (0.2)	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0
口腔内痛	0	0	0	0	0
口内炎	0	1 (0.2)	0	0	0
一般・全身障害および投与部位の状態	9 (9.6)	54 (10.2)	97 (11.2)	151 (10.5)	160 (10.5)
発熱	7 (7.4)	36 (6.8)	86 (10.0)	123 (8.6)	130 (8.5)
疼痛	0	3 (0.6)	1 (0.1)	5 (0.3)	5 (0.3)
末梢性浮腫	0	0	0	4 (0.3)	4 (0.3)
医療機器閉塞	0	1 (0.2)	0	3 (0.2)	3 (0.2)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 11 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
不快感	0	0	0	2 (0.1)	2 (0.1)
低体温	0	0	2 (0.2)	2 (0.1)	2 (0.1)
カテーテル留置部位炎症	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
泣き	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
死亡	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
医療機器リーク	0	0	0	1 (<0.1)	1 (<0.1)
薬物不耐性	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
ワクチン接種後の易刺激性	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
倦怠感	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
小結節	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
浮腫	0	3 (0.6)	0	1 (<0.1)	1 (<0.1)
末梢腫脹	0	0	0	1 (<0.1)	1 (<0.1)
腫脹	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
血管穿刺部位内出血	0	2 (0.4)	0	1 (<0.1)	1 (<0.1)
適用部位紅斑	1 (1.1)	0	0	0	1 (<0.1)
適用部位発疹	0	1 (0.2)	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 12 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
悪寒	0	0	0	0	0
医療機器機能不良	0	1 (0.2)	0	0	0
疲労	0	1 (0.2)	0	0	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
注入部位内出血	1 (1.1)	1 (0.2)	0	0	1 (<0.1)
注入部位血管外漏出	0	1 (0.2)	0	0	0
注射部位血腫	0	1 (0.2)	0	0	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
血管穿刺部位反応	0	1 (0.2)	0	0	0
臨床検査	2 (2.1)	26 (4.9)	47 (5.4)	71 (5.0)	73 (4.8)
酸素飽和度低下	0	15 (2.8)	13 (1.5)	15 (1.0)	15 (1.0)
Ｃ－反応性蛋白増加	0	1 (0.2)	5 (0.6)	5 (0.3)	5 (0.3)
体重減少	0	1 (0.2)	3 (0.3)	5 (0.3)	5 (0.3)
体温上昇	0	0	4 (0.5)	4 (0.3)	4 (0.3)
心拍数増加	0	1 (0.2)	1 (0.1)	4 (0.3)	4 (0.3)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 13 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
好中球数増加	0	0	1 (0.1)	4 (0.3)	4 (0.3)
ヒトライノウイルス検査陽性	0	0	1 (0.1)	3 (0.2)	3 (0.2)
シュードモナス検査陽性	0	0	1 (0.1)	3 (0.2)	3 (0.2)
血中カリウム減少	0	0	2 (0.2)	2 (0.1)	2 (0.1)
モラクセラ検査陽性	0	0	1 (0.1)	2 (0.1)	2 (0.1)
ブドウ球菌検査陽性	0	0	1 (0.1)	2 (0.1)	2 (0.1)
白血球数増加	0	0	0	2 (0.1)	2 (0.1)
アラニンアミノトランスフェラーゼ増加	1 (1.1)	0	1 (0.1)	1 (<0.1)	2 (0.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.1)	0	1 (0.1)	1 (<0.1)	2 (0.1)
血中クロール減少	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
血中鉄減少	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
血中ナトリウム減少	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
体温低下	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
骨密度減少	0	0	0	1 (<0.1)	1 (<0.1)
呼吸音異常	0	0	0	1 (<0.1)	1 (<0.1)
心電図ＳＴ－Ｔ部分異常	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
心拍数減少	0	0	0	1 (<0.1)	1 (<0.1)
心拍数不整	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
炎症マーカー上昇	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
Ａ型インフルエンザウイルス検査陽性	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 14 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
肝機能検査異常	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
医学的観察	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
好中球百分率増加	0	0	0	1 (<0.1)	1 (<0.1)
セラチア検査陽性	0	0	0	1 (<0.1)	1 (<0.1)
レンサ球菌検査陽性	0	0	0	1 (<0.1)	1 (<0.1)
尿量減少	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
ビタミンＡ減少	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
血中重炭酸塩減少	0	0	0	0	0
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
ヘッドラグ異常	0	1 (0.2)	0	0	0
リンパ節触知	0	1 (0.2)	0	0	0
呼吸数増加	0	1 (0.2)	0	0	0
レスピロウイルス検査陽性	0	1 (0.2)	0	0	0
トランスアミナーゼ上昇	0	1 (0.2)	0	0	0
尿検査異常	0	0	0	0	0
ビタミンＤ減少	0	1 (0.2)	0	0	0
筋骨格系および結合組織障害	5 (5.3)	9 (1.7)	22 (2.5)	71 (5.0)	76 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 15 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
関節拘縮	1 (1.1)	3 (0.6)	9 (1.0)	33 (2.3)	34 (2.2)
側弯症	0	1 (0.2)	5 (0.6)	13 (0.9)	13 (0.9)
脊柱後弯症	0	1 (0.2)	1 (0.1)	5 (0.3)	5 (0.3)
胸郭変形	0	0	1 (0.1)	4 (0.3)	4 (0.3)
四肢痛	0	0	1 (0.1)	3 (0.2)	3 (0.2)
後側弯症	0	0	1 (0.1)	2 (0.1)	2 (0.1)
頭位性斜頭症	1 (1.1)	1 (0.2)	2 (0.2)	2 (0.1)	3 (0.2)
斜頚	1 (1.1)	0	0	2 (0.1)	3 (0.2)
背部痛	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
泉門閉鎖遅延	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
手変形	0	0	0	1 (<0.1)	1 (<0.1)
関節硬直	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
脊柱前弯症	0	0	0	1 (<0.1)	1 (<0.1)
脊柱変形	0	0	0	1 (<0.1)	1 (<0.1)
滑膜炎	0	0	0	1 (<0.1)	1 (<0.1)
関節痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
筋緊張	0	0	0	0	0
筋力低下	1 (1.1)	1 (0.2)	0	0	1 (<0.1)
筋肉痛	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 16 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
頚部痛	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	1 (0.2)	0	0	0
体重支持困難	1 (1.1)	0	0	0	1 (<0.1)
皮膚および皮下組織障害	8 (8.5)	21 (4.0)	34 (3.9)	70 (4.9)	78 (5.1)
発疹	0	5 (0.9)	10 (1.2)	20 (1.4)	20 (1.3)
おむつ皮膚炎	2 (2.1)	2 (0.4)	6 (0.7)	11 (0.8)	13 (0.9)
皮膚炎	2 (2.1)	0	2 (0.2)	4 (0.3)	6 (0.4)
接触性皮膚炎	0	2 (0.4)	3 (0.3)	4 (0.3)	4 (0.3)
湿疹	0	2 (0.4)	1 (0.1)	4 (0.3)	4 (0.3)
斑状出血	0	0	2 (0.2)	3 (0.2)	3 (0.2)
過剰肉芽組織	0	0	0	3 (0.2)	3 (0.2)
皮膚刺激	0	0	0	3 (0.2)	3 (0.2)
脱毛症	0	0	0	2 (0.1)	2 (0.1)
過角化	0	0	2 (0.2)	2 (0.1)	2 (0.1)
汗疹	0	0	2 (0.2)	2 (0.1)	2 (0.1)
アレルギー性皮膚炎	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
紅斑	1 (1.1)	3 (0.6)	1 (0.1)	1 (<0.1)	2 (0.1)
環状肉芽腫	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 17 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
点状出血	0	0	0	1 (<0.1)	1 (<0.1)
そう痒症	0	0	0	1 (<0.1)	1 (<0.1)
丘疹性皮疹	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
皮膚色素脱失	0	0	0	1 (<0.1)	1 (<0.1)
皮膚障害	0	0	0	1 (<0.1)	1 (<0.1)
皮膚浮腫	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
皮膚潰瘍	0	0	0	1 (<0.1)	1 (<0.1)
皮下気腫	0	0	0	1 (<0.1)	1 (<0.1)
蕁麻疹	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0
褥瘡性潰瘍	0	2 (0.4)	0	0	0
アトピー性皮膚炎	0	2 (0.4)	0	0	0
皮膚乾燥	0	1 (0.2)	0	0	0
貨幣状湿疹	2 (2.1)	0	0	0	2 (0.1)
多汗症	0	1 (0.2)	0	0	0
毛孔性角化症	0	1 (0.2)	0	0	0
寝汗	0	0	0	0	0
脂漏性皮膚炎	1 (1.1)	0	0	0	1 (<0.1)
皮膚病変	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 18 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
傷害、中毒および処置合併症	5 (5.3)	21 (4.0)	17 (2.0)	44 (3.1)	49 (3.2)
節足動物咬傷	0	0	0	7 (0.5)	7 (0.5)
処置による疼痛	0	0	2 (0.2)	4 (0.3)	4 (0.3)
皮膚擦過傷	0	0	0	3 (0.2)	3 (0.2)
ストーマ部紅斑	0	2 (0.4)	2 (0.2)	3 (0.2)	3 (0.2)
挫傷	0	0	1 (0.1)	2 (0.1)	2 (0.1)
耳擦過傷	0	0	0	2 (0.1)	2 (0.1)
栄養補給チューブ合併症	0	3 (0.6)	0	2 (0.1)	2 (0.1)
大腿骨骨折	0	2 (0.4)	2 (0.2)	2 (0.1)	2 (0.1)
関節脱臼	0	0	0	2 (0.1)	2 (0.1)
術後激越	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
麻酔からの覚醒遅延	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
ダンピング症候群	0	0	0	1 (<0.1)	1 (<0.1)
擦過傷	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
伝染病曝露	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
口唇損傷	0	0	0	1 (<0.1)	1 (<0.1)
外傷性気胸	0	0	0	1 (<0.1)	1 (<0.1)
処置後腫脹	1 (1.1)	0	1 (0.1)	1 (<0.1)	2 (0.1)
処置合併症	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 19 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
処置部位反応	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
軟部組織損傷	0	0	0	1 (<0.1)	1 (<0.1)
ストーマ合併症	0	3 (0.6)	1 (0.1)	1 (<0.1)	1 (<0.1)
サンバーン	0	0	0	1 (<0.1)	1 (<0.1)
熱傷	0	0	0	1 (<0.1)	1 (<0.1)
歯牙損傷	0	0	0	1 (<0.1)	1 (<0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
創離開	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
節足動物刺傷	0	0	0	0	0
気管内挿管合併症	0	1 (0.2)	0	0	0
転倒	1 (1.1)	0	0	0	1 (<0.1)
頭部損傷	0	1 (0.2)	0	0	0
関節損傷	0	0	0	0	0
裂傷	0	1 (0.2)	0	0	0
靭帯捻挫	0	0	0	0	0
四肢損傷	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
肉離れ	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 20 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
処置後合併症	1 (1.1)	0	0	0	1 (<0.1)
処置後挫傷	0	2 (0.4)	0	0	0
処置後不快感	1 (1.1)	0	0	0	1 (<0.1)
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
ストーマ部出血	0	1 (0.2)	0	0	0
ストーマ部炎症	0	1 (0.2)	0	0	0
ストーマ部刺激感	0	1 (0.2)	0	0	0
硬膜下血腫	1 (1.1)	0	0	0	1 (<0.1)
脛骨骨折	0	0	0	0	0
隆起骨折	0	0	0	0	0
気管損傷	0	1 (0.2)	0	0	0
心臓障害	2 (2.1)	25 (4.7)	24 (2.8)	35 (2.4)	37 (2.4)
頻脈	2 (2.1)	11 (2.1)	8 (0.9)	10 (0.7)	12 (0.8)
徐脈	0	4 (0.8)	4 (0.5)	7 (0.5)	7 (0.5)
心肺停止	0	4 (0.8)	5 (0.6)	6 (0.4)	6 (0.4)
心停止	0	2 (0.4)	2 (0.2)	3 (0.2)	3 (0.2)
チアノーゼ	0	4 (0.8)	2 (0.2)	3 (0.2)	3 (0.2)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 21 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
心室性頻脈	0	0	1 (0.1)	2 (0.1)	2 (0.1)
心筋症	0	0	0	1 (<0.1)	1 (<0.1)
左室肥大	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
心膜気腫	0	0	0	1 (<0.1)	1 (<0.1)
上室性頻脈	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
動悸	0	0	0	0	0
代謝および栄養障害	4 (4.3)	16 (3.0)	21 (2.4)	30 (2.1)	34 (2.2)
体重増加不良	2 (2.1)	4 (0.8)	7 (0.8)	9 (0.6)	11 (0.7)
乳児および小児期早期の哺育障害	0	3 (0.6)	6 (0.7)	6 (0.4)	6 (0.4)
栄養補給不耐性	0	0	4 (0.5)	4 (0.3)	4 (0.3)
成長障害	1 (1.1)	0	2 (0.2)	3 (0.2)	4 (0.3)
低ナトリウム血症	0	0	0	3 (0.2)	3 (0.2)
過小食	0	0	0	2 (0.1)	2 (0.1)
脱水	1 (1.1)	1 (0.2)	1 (0.1)	1 (<0.1)	2 (0.1)
鉄欠乏	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
代謝性アルカローシス	0	0	0	1 (<0.1)	1 (<0.1)
食欲減退	0	0	0	0	0
食物不耐性	0	1 (0.2)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 22 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
高血糖	0	1 (0.2)	0	0	0
低血糖	0	2 (0.4)	0	0	0
低カリウム血症	0	3 (0.6)	0	0	0
食欲亢進	0	0	0	0	0
ビタミンD欠乏	0	1 (0.2)	0	0	0
神経系障害	2 (2.1)	6 (1.1)	9 (1.0)	21 (1.5)	23 (1.5)
不随意性筋収縮	0	0	1 (0.1)	4 (0.3)	4 (0.3)
眼振	0	1 (0.2)	2 (0.2)	3 (0.2)	3 (0.2)
痙攣発作	0	0	1 (0.1)	3 (0.2)	3 (0.2)
よだれ	0	0	1 (0.1)	2 (0.1)	2 (0.1)
脳損傷	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
脳梗塞	0	0	0	1 (<0.1)	1 (<0.1)
脳脊髄液漏	0	0	0	1 (<0.1)	1 (<0.1)
間代	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
頭痛	0	0	0	1 (<0.1)	1 (<0.1)
低酸素性虚血性脳症	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
嗜眠	0	0	0	1 (<0.1)	1 (<0.1)
傾眠	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
失神	0	0	0	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 23 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
失声症	0	0	0	0	0
味覚異常	0	0	0	0	0
失読症	0	0	0	0	0
反射亢進	1 (1.1)	0	0	0	1 (<0.1)
感覚鈍麻	0	0	0	0	0
筋緊張低下	1 (1.1)	0	0	0	1 (<0.1)
片頭痛	0	0	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	5 (0.9)	0	0	0
振戦	0	0	0	0	0
精神障害	0	7 (1.3)	12 (1.4)	15 (1.0)	15 (1.0)
不安	0	0	2 (0.2)	5 (0.3)	5 (0.3)
易刺激性	0	1 (0.2)	3 (0.3)	3 (0.2)	3 (0.2)
激越	0	3 (0.6)	2 (0.2)	2 (0.1)	2 (0.1)
睡眠障害	0	2 (0.4)	2 (0.2)	2 (0.1)	2 (0.1)
息こらえ	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
気分動揺	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
落ち着きのなさ	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
注意欠陥多動性障害	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 24 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
不快気分	0	0	0	0	0
不眠症	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
チック	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
免疫系障害	1 (1.1)	5 (0.9)	6 (0.7)	12 (0.8)	13 (0.9)
季節性アレルギー	1 (1.1)	2 (0.4)	2 (0.2)	5 (0.3)	6 (0.4)
薬物過敏症	0	1 (0.2)	2 (0.2)	4 (0.3)	4 (0.3)
過敏症	0	2 (0.4)	1 (0.1)	2 (0.1)	2 (0.1)
食物アレルギー	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
血管障害	2 (2.1)	0	5 (0.6)	8 (0.6)	10 (0.7)
高血圧	1 (1.1)	0	1 (0.1)	2 (0.1)	3 (0.2)
血管炎	0	0	2 (0.2)	2 (0.1)	2 (0.1)
毛細血管脆弱	0	0	0	1 (<0.1)	1 (<0.1)
本態性高血圧症	0	0	0	1 (<0.1)	1 (<0.1)
蒼白	1 (1.1)	0	1 (0.1)	1 (<0.1)	2 (0.1)
ショック	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
低血圧	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 25 of 28

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
眼障害	1 (1.1)	4 (0.8)	5 (0.6)	7 (0.5)	8 (0.5)
乱視	0	0	0	1 (<0.1)	1 (<0.1)
霰粒腫	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
眼乾燥	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
眼運動障害	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
眼瞼下垂	0	0	0	1 (<0.1)	1 (<0.1)
近視	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
斜視	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
弱視	0	1 (0.2)	0	0	0
後天性涙道狭窄	1 (1.1)	0	0	0	1 (<0.1)
遠視	0	0	0	0	0
流涙増加	0	1 (0.2)	0	0	0
血液およびリンパ系障害	2 (2.1)	4 (0.8)	1 (0.1)	6 (0.4)	8 (0.5)
貧血	0	1 (0.2)	1 (0.1)	3 (0.2)	3 (0.2)
リンパ節症	0	0	0	1 (<0.1)	1 (<0.1)
好中球減少症	1 (1.1)	0	0	1 (<0.1)	2 (0.1)
血小板増加症	0	0	0	1 (<0.1)	1 (<0.1)
骨髄障害	0	1 (0.2)	0	0	0
好酸球増加症	1 (1.1)	0	0	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 26 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
白血球増加症	0	2 (0.4)	0	0	0
先天性、家族性および遺伝性障害	0	4 (0.8)	3 (0.3)	6 (0.4)	6 (0.4)
斜頭症	0	0	0	2 (0.1)	2 (0.1)
斜指症	0	0	0	1 (<0.1)	1 (<0.1)
発育性股関節形成不全	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
貧血母斑	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
鳩胸	0	1 (0.2)	1 (0.1)	1 (<0.1)	1 (<0.1)
停留精巣	0	1 (0.2)	0	0	0
包茎	0	1 (0.2)	0	0	0
耳および迷路障害	0	0	2 (0.2)	3 (0.2)	3 (0.2)
耳の障害	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
耳痛	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
耳垢分泌過多	0	0	0	1 (<0.1)	1 (<0.1)
乗物酔い	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0
腎および尿路障害	0	1 (0.2)	3 (0.3)	3 (0.2)	3 (0.2)
尿閉	0	0	2 (0.2)	2 (0.1)	2 (0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 27 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
水腎症	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
排尿困難	0	0	0	0	0
糖尿	0	1 (0.2)	0	0	0
尿失禁	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0
生殖系および乳房障害	0	0	3 (0.3)	3 (0.2)	3 (0.2)
後天性包茎	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
卵巣嚢胞	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
陰茎障害	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.1)	0	0	2 (0.1)	3 (0.2)
アクロコルドン	0	0	0	1 (<0.1)	1 (<0.1)
血管の良性新生物	0	0	0	1 (<0.1)	1 (<0.1)
脂漏性角化症	1 (1.1)	0	0	0	1 (<0.1)
皮膚乳頭腫	0	0	0	0	0
肝胆道系障害	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
肝腫大	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 28 of 28

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
外科および内科処置	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
機械的換気	0	0	1 (0.1)	1 (<0.1)	1 (<0.1)
妊娠、産褥および周産期の状態	1 (1.1)	0	0	0	1 (<0.1)
臍肉芽腫	1 (1.1)	0	0	0	1 (<0.1)

NOTE 1:Numbers in parentheses are percentages.
2:To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 31　Incidence of Adverse Events by Preferred Term in Infants Diagnosed With SMA

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 1 of 21

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	13 (76.5)	38 (92.7)	72 (90.0)	92 (92.0)	105 (89.7)
発熱	3 (17.6)	22 (53.7)	39 (48.8)	53 (53.0)	56 (47.9)
便秘	1 (5.9)	9 (22.0)	24 (30.0)	33 (33.0)	34 (29.1)
上気道感染	6 (35.3)	9 (22.0)	20 (25.0)	32 (32.0)	38 (32.5)
呼吸窮迫	1 (5.9)	14 (34.1)	19 (23.8)	26 (26.0)	27 (23.1)
肺炎	1 (5.9)	6 (14.6)	17 (21.3)	24 (24.0)	25 (21.4)
呼吸不全	0	14 (34.1)	17 (21.3)	23 (23.0)	23 (19.7)
無気肺	0	9 (22.0)	15 (18.8)	20 (20.0)	20 (17.1)
鼻咽頭炎	3 (17.6)	4 (9.8)	14 (17.5)	20 (20.0)	23 (19.7)
嘔吐	0	8 (19.5)	12 (15.0)	20 (20.0)	20 (17.1)
急性呼吸不全	0	8 (19.5)	11 (13.8)	15 (15.0)	15 (12.8)
胃食道逆流性疾患	2 (11.8)	6 (14.6)	9 (11.3)	15 (15.0)	17 (14.5)
鼻閉	2 (11.8)	6 (14.6)	8 (10.0)	15 (15.0)	17 (14.5)
生歯	1 (5.9)	3 (7.3)	11 (13.8)	15 (15.0)	16 (13.7)
ライノウイルス感染	1 (5.9)	5 (12.2)	8 (10.0)	14 (14.0)	15 (12.8)
下痢	0	7 (17.1)	8 (10.0)	13 (13.0)	13 (11.1)
発疹	0	4 (9.8)	8 (10.0)	13 (13.0)	13 (11.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 2 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
咳嗽	2 (11.8)	8 (19.5)	6 (7.5)	12 (12.0)	14 (12.0)
気道感染	0	2 (4.9)	7 (8.8)	12 (12.0)	12 (10.3)
ウイルス性上気道感染	0	8 (19.5)	10 (12.5)	12 (12.0)	12 (10.3)
細気管支炎	1 (5.9)	3 (7.3)	8 (10.0)	11 (11.0)	12 (10.3)
関節拘縮	1 (5.9)	2 (4.9)	3 (3.8)	11 (11.0)	12 (10.3)
側弯症	0	1 (2.4)	4 (5.0)	11 (11.0)	11 (9.4)
ウイルス感染	0	2 (4.9)	7 (8.8)	11 (11.0)	11 (9.4)
おむつ皮膚炎	2 (11.8)	2 (4.9)	6 (7.5)	10 (10.0)	12 (10.3)
低酸素症	0	2 (4.9)	6 (7.5)	10 (10.0)	10 (8.5)
酸素飽和度低下	0	9 (22.0)	8 (10.0)	10 (10.0)	10 (8.5)
誤嚥性肺炎	0	6 (14.6)	7 (8.8)	10 (10.0)	10 (8.5)
嚥下障害	1 (5.9)	8 (19.5)	9 (11.3)	9 (9.0)	10 (8.5)
呼吸困難	0	6 (14.6)	7 (8.8)	9 (9.0)	9 (7.7)
ウイルス性肺炎	1 (5.9)	1 (2.4)	6 (7.5)	9 (9.0)	10 (8.5)
頻脈	2 (11.8)	5 (12.2)	6 (7.5)	8 (8.0)	10 (8.5)
無呼吸	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (6.0)
徐脈	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (6.0)
口腔カンジダ症	0	3 (7.3)	6 (7.5)	7 (7.0)	7 (6.0)
中耳炎	2 (11.8)	2 (4.9)	1 (1.3)	7 (7.0)	9 (7.7)
誤嚥	0	1 (2.4)	4 (5.0)	6 (6.0)	6 (5.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 3 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
気管支分泌物貯留	0	4 (9.8)	3 (3.8)	6 (6.0)	6 (5.1)
心肺停止	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.1)
慢性呼吸不全	0	0	2 (2.5)	6 (6.0)	6 (5.1)
結膜炎	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.1)
上気道分泌増加	0	1 (2.4)	2 (2.5)	6 (6.0)	6 (5.1)
鼻漏	1 (5.9)	3 (7.3)	4 (5.0)	6 (6.0)	7 (6.0)
上気道うっ血	1 (5.9)	1 (2.4)	5 (6.3)	6 (6.0)	7 (6.0)
体重増加不良	1 (5.9)	2 (4.9)	5 (6.3)	6 (6.0)	7 (6.0)
不安	0	0	2 (2.5)	5 (5.0)	5 (4.3)
気管支炎	1 (5.9)	0	5 (6.3)	5 (5.0)	6 (5.1)
耳感染	0	1 (2.4)	4 (5.0)	5 (5.0)	5 (4.3)
放屁	2 (11.8)	1 (2.4)	3 (3.8)	5 (5.0)	7 (6.0)
脊柱後弯症	0	1 (2.4)	1 (1.3)	5 (5.0)	5 (4.3)
疼痛	0	2 (4.9)	1 (1.3)	5 (5.0)	5 (4.3)
ウイルス性気道感染	0	2 (4.9)	4 (5.0)	5 (5.0)	5 (4.3)
流涎過多	0	2 (4.9)	3 (3.8)	5 (5.0)	5 (4.3)
季節性アレルギー	1 (5.9)	2 (4.9)	2 (2.5)	5 (5.0)	6 (5.1)
体重減少	0	1 (2.4)	3 (3.8)	5 (5.0)	5 (4.3)
腹部膨満	2 (11.8)	0	1 (1.3)	4 (4.0)	6 (5.1)
胸郭変形	0	0	1 (1.3)	4 (4.0)	4 (3.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 4 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
薬物過敏症	0	1 (2.4)	2 (2.5)	4 (4.0)	4 (3.4)
湿疹	0	2 (4.9)	1 (1.3)	4 (4.0)	4 (3.4)
胃炎	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
下気道感染	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
不随意性筋収縮	0	0	1 (1.3)	4 (4.0)	4 (3.4)
細菌性肺炎	0	2 (4.9)	3 (3.8)	4 (4.0)	4 (3.4)
処置による疼痛	0	0	2 (2.5)	4 (4.0)	4 (3.4)
呼吸停止	0	4 (9.8)	3 (3.8)	4 (4.0)	4 (3.4)
ＲＳウイルス細気管支炎	0	3 (7.3)	3 (3.8)	4 (4.0)	4 (3.4)
副鼻腔うっ血	0	0	3 (3.8)	4 (4.0)	4 (3.4)
貧血	0	1 (2.4)	1 (1.3)	3 (3.0)	3 (2.6)
節足動物咬傷	0	0	0	3 (3.0)	3 (2.6)
細菌性気管炎	0	4 (9.8)	1 (1.3)	3 (3.0)	3 (2.6)
ウイルス性気管支炎	0	0	3 (3.8)	3 (3.0)	3 (2.6)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
チアノーゼ	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
接触性皮膚炎	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
斑状出血	0	0	2 (2.5)	3 (3.0)	3 (2.6)
過剰肉芽組織	0	0	0	3 (3.0)	3 (2.6)
成長障害	1 (5.9)	0	2 (2.5)	3 (3.0)	4 (3.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 5 of 21

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
乳児および小児期早期の哺育障害	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.6)
栄養補給不耐性	0	0	3 (3.8)	3 (3.0)	3 (2.6)
ヒトライノウイルス検査陽性	0	0	1 (1.3)	3 (3.0)	3 (2.6)
低換気	0	0	2 (2.5)	3 (3.0)	3 (2.6)
インフルエンザ	2 (11.8)	0	2 (2.5)	3 (3.0)	5 (4.3)
ウイルス性下気道感染	0	0	2 (2.5)	3 (3.0)	3 (2.6)
好中球数増加	0	0	1 (1.3)	3 (3.0)	3 (2.6)
眼振	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.6)
気胸	0	0	1 (1.3)	3 (3.0)	3 (2.6)
皮膚刺激	0	0	0	3 (3.0)	3 (2.6)
ストーマ部紅斑	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
尿路感染	1 (5.9)	0	3 (3.8)	3 (3.0)	4 (3.4)
喘鳴	0	0	1 (1.3)	3 (3.0)	3 (2.6)
アデノウイルス感染	0	0	2 (2.5)	2 (2.0)	2 (1.7)
激越	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
細菌感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
血中カリウム減少	0	0	2 (2.5)	2 (2.0)	2 (1.7)
体温上昇	0	0	2 (2.5)	2 (2.0)	2 (1.7)
Ｃ－反応性蛋白増加	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 6 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
カンジダ性おむつ皮疹	0	0	1 (1.3)	2 (2.0)	2 (1.7)
息詰まり	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
細菌性結膜炎	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
挫傷	0	0	1 (1.3)	2 (2.0)	2 (1.7)
皮膚炎	2 (11.8)	0	1 (1.3)	2 (2.0)	4 (3.4)
不快感	0	0	0	2 (2.0)	2 (1.7)
よだれ	0	0	1 (1.3)	2 (2.0)	2 (1.7)
エンテロウイルス感染	0	0	0	2 (2.0)	2 (1.7)
栄養補給チューブ合併症	0	2 (4.9)	0	2 (2.0)	2 (1.7)
大腿骨骨折	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
皮膚真菌感染	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
胃腸炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
血便排泄	0	0	2 (2.5)	2 (2.0)	2 (1.7)
手足口病	0	0	1 (1.3)	2 (2.0)	2 (1.7)
心拍数増加	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
過角化	0	0	2 (2.5)	2 (2.0)	2 (1.7)
過敏症	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
高血圧	1 (5.9)	0	1 (1.3)	2 (2.0)	3 (2.6)
低ナトリウム血症	0	0	0	2 (2.0)	2 (1.7)
過小食	0	0	0	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 7 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
易刺激性	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
関節脱臼	0	0	0	2 (2.0)	2 (1.7)
後側弯症	0	0	1 (1.3)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)
汗疹	0	0	2 (2.5)	2 (2.0)	2 (1.7)
モラクセラ検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
末梢性浮腫	0	0	0	2 (2.0)	2 (1.7)
四肢痛	0	0	1 (1.3)	2 (2.0)	2 (1.7)
パラインフルエンザウイルス感染	0	1 (2.4)	0	2 (2.0)	2 (1.7)
斜頭症	0	0	0	2 (2.0)	2 (1.7)
モラクセラ菌性肺炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
頭位性斜頭症	1 (5.9)	1 (2.4)	2 (2.5)	2 (2.0)	3 (2.6)
シュードモナス検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
肺うっ血	0	0	0	2 (2.0)	2 (1.7)
肺水腫	0	0	0	2 (2.0)	2 (1.7)
呼吸障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
鼻炎	1 (5.9)	3 (7.3)	1 (1.3)	2 (2.0)	3 (2.6)
アレルギー性鼻炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
痙攣発作	0	0	1 (1.3)	2 (2.0)	2 (1.7)
皮膚擦過傷	0	0	0	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 8 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
皮膚カンジダ	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ブドウ球菌検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
ストーマ部膿瘍	0	0	2 (2.5)	2 (2.0)	2 (1.7)
斜頚	1 (5.9)	0	0	2 (2.0)	3 (2.6)
呼吸補助筋の動員	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
心室性頻脈	0	0	1 (1.3)	2 (2.0)	2 (1.7)
白血球数増加	0	0	0	2 (2.0)	2 (1.7)
腹部不快感	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
腹痛	0	0	0	1 (1.0)	1 (0.9)
後天性包茎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
アクロコルドン	0	0	0	1 (1.0)	1 (0.9)
急性呼吸窮迫症候群	0	0	1 (1.3)	1 (1.0)	1 (0.9)
アデノウイルス性上気道感染	0	0	0	1 (1.0)	1 (0.9)
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.9)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
脱毛症	0	0	0	1 (1.0)	1 (0.9)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.9)
無呼吸発作	0	0	0	1 (1.0)	1 (0.9)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
窒息	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 9 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
乱視	0	0	0	1 (1.0)	1 (0.9)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
細菌性疾患キャリアー	0	1 (2.4)	0	1 (1.0)	1 (0.9)
血管の良性新生物	0	0	0	1 (1.0)	1 (0.9)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中鉄減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
体温低下	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
骨密度減少	0	0	0	1 (1.0)	1 (0.9)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
息こらえ	0	0	1 (1.3)	1 (1.0)	1 (0.9)
呼吸音異常	0	0	0	1 (1.0)	1 (0.9)
気管支閉塞	0	0	1 (1.3)	1 (1.0)	1 (0.9)
毛細血管脆弱	0	0	0	1 (1.0)	1 (0.9)
心筋症	0	0	0	1 (1.0)	1 (0.9)
カテーテル留置部位炎症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
蜂巣炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
脳梗塞	0	0	0	1 (1.0)	1 (0.9)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.9)
霰粒腫	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 10 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
口唇のひび割れ	0	0	0	1 (1.0)	1 (0.9)
斜指症	0	0	0	1 (1.0)	1 (0.9)
間代	0	0	1 (1.3)	1 (1.0)	1 (0.9)
コロナウイルス感染	0	2 (4.9)	0	1 (1.0)	1 (0.9)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.9)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
脱水	1 (5.9)	1 (2.4)	1 (1.3)	1 (1.0)	2 (1.7)
泉門閉鎖遅延	0	0	1 (1.3)	1 (1.0)	1 (0.9)
麻酔からの覚醒遅延	0	0	1 (1.3)	1 (1.0)	1 (0.9)
アレルギー性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
発育性股関節形成不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
医療機器リーク	0	0	0	1 (1.0)	1 (0.9)
医療機器閉塞	0	1 (2.4)	0	1 (1.0)	1 (0.9)
薬物不耐性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
眼乾燥	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
ダンピング症候群	0	0	0	1 (1.0)	1 (0.9)
耳擦過傷	0	0	0	1 (1.0)	1 (0.9)
耳の障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
耳痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
感染性湿疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 11 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
心電図ＳＴ－Ｔ部分異常	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
紅斑	1 (5.9)	3 (7.3)	1 (1.3)	1 (1.0)	2 (1.7)
伝染性紅斑	0	0	0	1 (1.0)	1 (0.9)
本態性高血圧症	0	0	0	1 (1.0)	1 (0.9)
耳垢分泌過多	0	0	0	1 (1.0)	1 (0.9)
擦過傷	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
伝染病曝露	0	0	1 (1.3)	1 (1.0)	1 (0.9)
眼感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
眼運動障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.9)
食物アレルギー	0	0	1 (1.3)	1 (1.0)	1 (0.9)
排便回数増加	0	0	0	1 (1.0)	1 (0.9)
真菌感染	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
胃出血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性胃炎	0	0	0	1 (1.0)	1 (0.9)
ロタウイルス胃腸炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性胃腸炎	1 (5.9)	2 (4.9)	1 (1.3)	1 (1.0)	2 (1.7)
消化管運動低下	0	0	0	1 (1.0)	1 (0.9)
環状肉芽腫	0	0	1 (1.3)	1 (1.0)	1 (0.9)
吐血	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 12 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
ヘモフィルス感染	0	0	0	1 (1.0)	1 (0.9)
手変形	0	0	0	1 (1.0)	1 (0.9)
頭痛	0	0	0	1 (1.0)	1 (0.9)
心拍数減少	0	0	0	1 (1.0)	1 (0.9)
心拍数不整	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肝腫大	0	0	1 (1.3)	1 (1.0)	1 (0.9)
水腎症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
減呼吸	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低体温	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
膿痂疹	1 (5.9)	1 (2.4)	1 (1.3)	1 (1.0)	2 (1.7)
気管支分泌増加	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
乳児仙痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
乳児吐出	0	0	1 (1.3)	1 (1.0)	1 (0.9)
炎症マーカー上昇	0	0	1 (1.3)	1 (1.0)	1 (0.9)
A型インフルエンザウイルス検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鉄欠乏	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ワクチン接種後の易刺激性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
関節硬直	0	1 (2.4)	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 13 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
喉頭肉芽腫	0	0	0	1 (1.0)	1 (0.9)
左室肥大	0	0	1 (1.3)	1 (1.0)	1 (0.9)
嗜眠	0	0	0	1 (1.0)	1 (0.9)
口唇損傷	0	0	0	1 (1.0)	1 (0.9)
肝機能検査異常	0	0	1 (1.3)	1 (1.0)	1 (0.9)
限局性感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
脊柱前弯症	0	0	0	1 (1.0)	1 (0.9)
肺障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
リンパ節症	0	0	0	1 (1.0)	1 (0.9)
倦怠感	0	0	1 (1.3)	1 (1.0)	1 (0.9)
機械的換気	0	0	1 (1.3)	1 (1.0)	1 (0.9)
医学的観察	0	0	1 (1.3)	1 (1.0)	1 (0.9)
代謝性アルカローシス	0	0	0	1 (1.0)	1 (0.9)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.9)
モラクセラ感染	0	0	0	1 (1.0)	1 (0.9)
粘膜皮膚カンジダ症	0	0	0	1 (1.0)	1 (0.9)
近視	0	0	1 (1.3)	1 (1.0)	1 (0.9)
貧血母斑	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鼻汁変色	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 14 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
好中球減少症	1 (5.9)	0	0	1 (1.0)	2 (1.7)
好中球百分率増加	0	0	0	1 (1.0)	1 (0.9)
小結節	0	0	1 (1.3)	1 (1.0)	1 (0.9)
院内感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
浮腫	0	3 (7.3)	0	1 (1.0)	1 (0.9)
口腔ヘルペス	0	0	1 (1.3)	1 (1.0)	1 (0.9)
急性中耳炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
卵巣嚢胞	0	0	1 (1.3)	1 (1.0)	1 (0.9)
蒼白	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
鳩胸	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
陰茎障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
末梢腫脹	0	0	0	1 (1.0)	1 (0.9)
点状出血	0	0	0	1 (1.0)	1 (0.9)
レンサ球菌性咽頭炎	1 (5.9)	0	0	1 (1.0)	2 (1.7)
胸水	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気縦隔症	0	0	0	1 (1.0)	1 (0.9)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
パラインフルエンザウイルス性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
シュードモナス菌性肺炎	0	1 (2.4)	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 15 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
心膜気腫	0	0	0	1 (1.0)	1 (0.9)
外傷性気胸	0	0	0	1 (1.0)	1 (0.9)
処置後腫脹	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置合併症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.9)
湿性咳嗽	0	0	0	1 (1.0)	1 (0.9)
そう痒症	0	0	0	1 (1.0)	1 (0.9)
シュードモナス感染	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
呼吸性アルカローシス	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気道うっ血	0	3 (7.3)	1 (1.3)	1 (1.0)	1 (0.9)
細菌性気道感染	0	1 (2.4)	0	1 (1.0)	1 (0.9)
落ち着きのなさ	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
拘束性肺疾患	0	0	0	1 (1.0)	1 (0.9)
低音性連続性ラ音	0	0	0	1 (1.0)	1 (0.9)
ばら疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
セラチア検査陽性	0	0	0	1 (1.0)	1 (0.9)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 16 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
皮膚色素脱失	0	0	0	1 (1.0)	1 (0.9)
皮膚障害	0	0	0	1 (1.0)	1 (0.9)
皮膚浮腫	0	0	1 (1.3)	1 (1.0)	1 (0.9)
皮膚潰瘍	0	0	0	1 (1.0)	1 (0.9)
睡眠時無呼吸症候群	0	4 (9.8)	0	1 (1.0)	1 (0.9)
睡眠障害	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
軟部組織損傷	0	0	0	1 (1.0)	1 (0.9)
傾眠	0	0	1 (1.3)	1 (1.0)	1 (0.9)
脊柱変形	0	0	0	1 (1.0)	1 (0.9)
変色痰	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ブドウ球菌性菌血症	0	0	0	1 (1.0)	1 (0.9)
ブドウ球菌感染	0	2 (4.9)	0	1 (1.0)	1 (0.9)
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ブドウ球菌皮膚感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ストーマ合併症	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
斜視	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
レンサ球菌検査陽性	0	0	0	1 (1.0)	1 (0.9)
皮下気腫	0	0	0	1 (1.0)	1 (0.9)
サンバーン	0	0	0	1 (1.0)	1 (0.9)
上室性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 17 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
腫脹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
失神	0	0	0	1 (1.0)	1 (0.9)
滑膜炎	0	0	0	1 (1.0)	1 (0.9)
頻呼吸	0	2 (4.9)	0	1 (1.0)	1 (0.9)
熱傷	0	0	0	1 (1.0)	1 (0.9)
血小板増加症	0	0	0	1 (1.0)	1 (0.9)
歯牙損傷	0	0	0	1 (1.0)	1 (0.9)
気管障害	0	0	0	1 (1.0)	1 (0.9)
気管炎	0	1 (2.4)	0	1 (1.0)	1 (0.9)
上部消化管出血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿量減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
蕁麻疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ワクチン接種合併症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
血管炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血管穿刺部位内出血	0	2 (4.9)	0	1 (1.0)	1 (0.9)
ビタミンA減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
創離開	0	0	1 (1.3)	1 (1.0)	1 (0.9)
上腹部痛	0	2 (4.9)	0	0	0
弱視	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 18 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
適用部位紅斑	1 (5.9)	0	0	0	1 (0.9)
適用部位発疹	0	1 (2.4)	0	0	0
骨髄障害	0	1 (2.4)	0	0	0
カンジダ感染	0	3 (7.3)	0	0	0
カタル	0	1 (2.4)	0	0	0
停留精巣	0	1 (2.4)	0	0	0
後天性涙道狭窄	1 (5.9)	0	0	0	1 (0.9)
褥瘡性潰瘍	0	2 (4.9)	0	0	0
アトピー性皮膚炎	0	2 (4.9)	0	0	0
医療機器機能不良	0	1 (2.4)	0	0	0
血性下痢	0	1 (2.4)	0	0	0
皮膚乾燥	0	1 (2.4)	0	0	0
貨幣状湿疹	1 (5.9)	0	0	0	1 (0.9)
気管内挿管合併症	0	1 (2.4)	0	0	0
好酸球増加症	1 (5.9)	0	0	0	1 (0.9)
転倒	1 (5.9)	0	0	0	1 (0.9)
疲労	0	1 (2.4)	0	0	0
食物不耐性	0	1 (2.4)	0	0	0
胃腸出血	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 19 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
消化管刺激症状	0	1 (2.4)	0	0	0
糖尿	0	1 (2.4)	0	0	0
頭部損傷	0	1 (2.4)	0	0	0
ヘッドラグ異常	0	1 (2.4)	0	0	0
麦粒腫	0	1 (2.4)	0	0	0
高血糖	0	1 (2.4)	0	0	0
多汗症	0	1 (2.4)	0	0	0
反射亢進	1 (5.9)	0	0	0	1 (0.9)
低血糖	0	2 (4.9)	0	0	0
低カリウム血症	0	3 (7.3)	0	0	0
筋緊張低下	1 (5.9)	0	0	0	1 (0.9)
注入部位内出血	1 (5.9)	1 (2.4)	0	0	1 (0.9)
注入部位血管外漏出	0	1 (2.4)	0	0	0
注射部位血腫	0	1 (2.4)	0	0	0
毛孔性角化症	0	1 (2.4)	0	0	0
裂傷	0	1 (2.4)	0	0	0
流涙増加	0	1 (2.4)	0	0	0
白血球増加症	0	1 (2.4)	0	0	0
リンパ節触知	0	1 (2.4)	0	0	0
筋力低下	1 (5.9)	1 (2.4)	0	0	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 20 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
口腔咽頭痛	0	1 (2.4)	0	0	0
包茎	0	1 (2.4)	0	0	0
処置後合併症	1 (5.9)	0	0	0	1 (0.9)
処置後挫傷	0	1 (2.4)	0	0	0
処置後不快感	1 (5.9)	0	0	0	1 (0.9)
失神寸前の状態	0	1 (2.4)	0	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	1 (0.9)
呼吸数増加	0	1 (2.4)	0	0	0
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	1 (0.9)
脂漏性角化症	1 (5.9)	0	0	0	1 (0.9)
セラチア感染	0	1 (2.4)	0	0	0
皮膚感染	1 (5.9)	1 (2.4)	0	0	1 (0.9)
ストーマ部出血	0	1 (2.4)	0	0	0
ストーマ部感染	0	3 (7.3)	0	0	0
ストーマ部炎症	0	1 (2.4)	0	0	0
ストーマ部刺激感	0	1 (2.4)	0	0	0
口内炎	0	1 (2.4)	0	0	0
硬膜下血腫	1 (5.9)	0	0	0	1 (0.9)
腱障害	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 21 of 21

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
気管損傷	0	1 (2.4)	0	0	0
トランスアミナーゼ上昇	0	1 (2.4)	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	1 (0.9)
上気道の炎症	0	2 (4.9)	0	0	0
血管穿刺部位反応	0	1 (2.4)	0	0	0
ウイルス性発疹	0	1 (2.4)	0	0	0
ビタミンD減少	0	1 (2.4)	0	0	0
ビタミンD欠乏	0	1 (2.4)	0	0	0
体重支持困難	1 (5.9)	0	0	0	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies:ISIS 396443.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 32　Incidence of Adverse Events by Preferred Term in Subjects With SMA Treated With ISIS 396443

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 1 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	13 (76.5)	92 (92.0)	105 (89.7)	56 (100.0)	161 (93.1)
発熱	3 (17.6)	53 (53.0)	56 (47.9)	16 (28.6)	72 (41.6)
上気道感染	6 (35.3)	32 (32.0)	38 (32.5)	27 (48.2)	65 (37.6)
便秘	1 (5.9)	33 (33.0)	34 (29.1)	7 (12.5)	41 (23.7)
鼻咽頭炎	3 (17.6)	20 (20.0)	23 (19.7)	16 (28.6)	39 (22.5)
嘔吐	0	20 (20.0)	20 (17.1)	12 (21.4)	32 (18.5)
肺炎	1 (5.9)	24 (24.0)	25 (21.4)	5 (8.9)	30 (17.3)
頭痛	0	1 (1.0)	1 (0.9)	28 (50.0)	29 (16.8)
呼吸窮迫	1 (5.9)	26 (26.0)	27 (23.1)	0	27 (15.6)
側弯症	0	11 (11.0)	11 (9.4)	15 (26.8)	26 (15.0)
背部痛	0	1 (1.0)	1 (0.9)	23 (41.1)	24 (13.9)
呼吸不全	0	23 (23.0)	23 (19.7)	1 (1.8)	24 (13.9)
腰椎穿刺後症候群	0	0	0	23 (41.1)	23 (13.3)
関節拘縮	1 (5.9)	11 (11.0)	12 (10.3)	10 (17.9)	22 (12.7)
無気肺	0	20 (20.0)	20 (17.1)	1 (1.8)	21 (12.1)
咳嗽	2 (11.8)	12 (12.0)	14 (12.0)	6 (10.7)	20 (11.6)
鼻閉	2 (11.8)	15 (15.0)	17 (14.5)	3 (5.4)	20 (11.6)
ウイルス感染	0	11 (11.0)	11 (9.4)	9 (16.1)	20 (11.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 2 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胃食道逆流性疾患	2 (11.8)	15 (15.0)	17 (14.5)	1 (1.8)	18 (10.4)
ウイルス性上気道感染	0	12 (12.0)	12 (10.3)	5 (8.9)	17 (9.8)
急性呼吸不全	0	15 (15.0)	15 (12.8)	1 (1.8)	16 (9.2)
生歯	1 (5.9)	15 (15.0)	16 (13.7)	0	16 (9.2)
下痢	0	13 (13.0)	13 (11.1)	2 (3.6)	15 (8.7)
ライノウイルス感染	1 (5.9)	14 (14.0)	15 (12.8)	0	15 (8.7)
中耳炎	2 (11.8)	7 (7.0)	9 (7.7)	5 (8.9)	14 (8.1)
発疹	0	13 (13.0)	13 (11.1)	1 (1.8)	14 (8.1)
おむつ皮膚炎	2 (11.8)	10 (10.0)	12 (10.3)	1 (1.8)	13 (7.5)
低酸素症	0	10 (10.0)	10 (8.5)	3 (5.4)	13 (7.5)
気道感染	0	12 (12.0)	12 (10.3)	1 (1.8)	13 (7.5)
鼻漏	1 (5.9)	6 (6.0)	7 (6.0)	6 (10.7)	13 (7.5)
細気管支炎	1 (5.9)	11 (11.0)	12 (10.3)	0	12 (6.9)
ウイルス性肺炎	1 (5.9)	9 (9.0)	10 (8.5)	2 (3.6)	12 (6.9)
頻脈	2 (11.8)	8 (8.0)	10 (8.5)	1 (1.8)	11 (6.4)
嚥下障害	1 (5.9)	9 (9.0)	10 (8.5)	0	10 (5.8)
呼吸困難	0	9 (9.0)	9 (7.7)	1 (1.8)	10 (5.8)
ウイルス性胃腸炎	1 (5.9)	1 (1.0)	2 (1.7)	8 (14.3)	10 (5.8)
悪心	0	0	0	10 (17.9)	10 (5.8)
酸素飽和度低下	0	10 (10.0)	10 (8.5)	0	10 (5.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 3 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
レンサ球菌性咽頭炎	1 (5.9)	1 (1.0)	2 (1.7)	8 (14.3)	10 (5.8)
誤嚥性肺炎	0	10 (10.0)	10 (8.5)	0	10 (5.8)
処置による疼痛	0	4 (4.0)	4 (3.4)	6 (10.7)	10 (5.8)
穿刺部位疼痛	0	0	0	10 (17.9)	10 (5.8)
結膜炎	0	6 (6.0)	6 (5.1)	3 (5.4)	9 (5.2)
耳感染	0	5 (5.0)	5 (4.3)	4 (7.1)	9 (5.2)
胃腸炎	0	2 (2.0)	2 (1.7)	7 (12.5)	9 (5.2)
季節性アレルギー	1 (5.9)	5 (5.0)	6 (5.1)	3 (5.4)	9 (5.2)
放屁	2 (11.8)	5 (5.0)	7 (6.0)	1 (1.8)	8 (4.6)
インフルエンザ	2 (11.8)	3 (3.0)	5 (4.3)	3 (5.4)	8 (4.6)
口腔咽頭痛	0	0	0	8 (14.3)	8 (4.6)
尿路感染	1 (5.9)	3 (3.0)	4 (3.4)	4 (7.1)	8 (4.6)
体重減少	0	5 (5.0)	5 (4.3)	3 (5.4)	8 (4.6)
無呼吸	0	7 (7.0)	7 (6.0)	0	7 (4.0)
徐脈	0	7 (7.0)	7 (6.0)	0	7 (4.0)
裂傷	0	0	0	7 (12.5)	7 (4.0)
口腔カンジダ症	0	7 (7.0)	7 (6.0)	0	7 (4.0)
疼痛	0	5 (5.0)	5 (4.3)	2 (3.6)	7 (4.0)
四肢痛	0	2 (2.0)	2 (1.7)	5 (8.9)	7 (4.0)
上気道うっ血	1 (5.9)	6 (6.0)	7 (6.0)	0	7 (4.0)
体重増加不良	1 (5.9)	6 (6.0)	7 (6.0)	0	7 (4.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 4 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
腹部膨満	2 (11.8)	4 (4.0)	6 (5.1)	0	6 (3.5)
節足動物咬傷	0	3 (3.0)	3 (2.6)	3 (5.4)	6 (3.5)
誤嚥	0	6 (6.0)	6 (5.1)	0	6 (3.5)
気管支分泌物貯留	0	6 (6.0)	6 (5.1)	0	6 (3.5)
気管支炎	1 (5.9)	5 (5.0)	6 (5.1)	0	6 (3.5)
心肺停止	0	6 (6.0)	6 (5.1)	0	6 (3.5)
慢性呼吸不全	0	6 (6.0)	6 (5.1)	0	6 (3.5)
接触性皮膚炎	0	3 (3.0)	3 (2.6)	3 (5.4)	6 (3.5)
湿疹	0	4 (4.0)	4 (3.4)	2 (3.6)	6 (3.5)
上気道分泌増加	0	6 (6.0)	6 (5.1)	0	6 (3.5)
ウイルス性気道感染	0	5 (5.0)	5 (4.3)	1 (1.8)	6 (3.5)
副鼻腔うっ血	0	4 (4.0)	4 (3.4)	2 (3.6)	6 (3.5)
不安	0	5 (5.0)	5 (4.3)	0	5 (2.9)
関節痛	0	0	0	5 (8.9)	5 (2.9)
皮膚炎	2 (11.8)	2 (2.0)	4 (3.4)	1 (1.8)	5 (2.9)
薬物過敏症	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)
大腿骨骨折	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.9)
過敏症	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.9)
脊柱後弯症	0	5 (5.0)	5 (4.3)	0	5 (2.9)
下気道感染	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 5 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ＲＳウイルス細気管支炎	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)
流涎過多	0	5 (5.0)	5 (4.3)	0	5 (2.9)
激越	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
アフタ性潰瘍	0	1 (1.0)	1 (0.9)	3 (5.4)	4 (2.3)
挫傷	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
胸郭変形	0	4 (4.0)	4 (3.4)	0	4 (2.3)
脱水	1 (5.9)	1 (1.0)	2 (1.7)	2 (3.6)	4 (2.3)
成長障害	1 (5.9)	3 (3.0)	4 (3.4)	0	4 (2.3)
胃炎	0	4 (4.0)	4 (3.4)	0	4 (2.3)
関節脱臼	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
限局性感染	0	1 (1.0)	1 (0.9)	3 (5.4)	4 (2.3)
不随意性筋収縮	0	4 (4.0)	4 (3.4)	0	4 (2.3)
筋肉痛	0	0	0	4 (7.1)	4 (2.3)
細菌性肺炎	0	4 (4.0)	4 (3.4)	0	4 (2.3)
呼吸停止	0	4 (4.0)	4 (3.4)	0	4 (2.3)
鼻炎	1 (5.9)	2 (2.0)	3 (2.6)	1 (1.8)	4 (2.3)
皮膚カンジダ	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
喘鳴	0	3 (3.0)	3 (2.6)	1 (1.8)	4 (2.3)
腹部不快感	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
腹痛	0	1 (1.0)	1 (0.9)	2 (3.6)	3 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 6 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
貧血	0	3 (3.0)	3 (2.6)	0	3 (1.7)
細菌性気管炎	0	3 (3.0)	3 (2.6)	0	3 (1.7)
体温上昇	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ウイルス性気管支炎	0	3 (3.0)	3 (2.6)	0	3 (1.7)
心停止	0	3 (3.0)	3 (2.6)	0	3 (1.7)
チアノーゼ	0	3 (3.0)	3 (2.6)	0	3 (1.7)
斑状出血	0	3 (3.0)	3 (2.6)	0	3 (1.7)
鼻出血	0	0	0	3 (5.4)	3 (1.7)
紅斑	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
過剰肉芽組織	0	3 (3.0)	3 (2.6)	0	3 (1.7)
疲労	0	0	0	3 (5.4)	3 (1.7)
乳児および小児期早期の哺育障害	0	3 (3.0)	3 (2.6)	0	3 (1.7)
栄養補給不耐性	0	3 (3.0)	3 (2.6)	0	3 (1.7)
皮膚真菌感染	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
手足口病	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
心拍数増加	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ヒトライノウイルス検査陽性	0	3 (3.0)	3 (2.6)	0	3 (1.7)
高血圧	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
低換気	0	3 (3.0)	3 (2.6)	0	3 (1.7)
膿痂疹	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 7 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
四肢損傷	0	0	0	3 (5.4)	3 (1.7)
ウイルス性下気道感染	0	3 (3.0)	3 (2.6)	0	3 (1.7)
汗疹	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
頚部痛	0	0	0	3 (5.4)	3 (1.7)
好中球減少症	1 (5.9)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
好中球数増加	0	3 (3.0)	3 (2.6)	0	3 (1.7)
眼振	0	3 (3.0)	3 (2.6)	0	3 (1.7)
気胸	0	3 (3.0)	3 (2.6)	0	3 (1.7)
頭位性斜頭症	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
肺うっ血	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
呼吸障害	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ＲＳウイルス感染	0	0	0	3 (5.4)	3 (1.7)
副鼻腔炎	0	0	0	3 (5.4)	3 (1.7)
皮膚刺激	0	3 (3.0)	3 (2.6)	0	3 (1.7)
ストーマ部紅斑	0	3 (3.0)	3 (2.6)	0	3 (1.7)
サンバーン	0	1 (1.0)	1 (0.9)	2 (3.6)	3 (1.7)
扁桃肥大	0	0	0	3 (5.4)	3 (1.7)
斜頚	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
上腹部痛	0	0	0	2 (3.6)	2 (1.2)
アデノウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 8 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
術後激越	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
細菌感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
血中カリウム減少	0	2 (2.0)	2 (1.7)	0	2 (1.2)
Ｃ－反応性蛋白増加	0	2 (2.0)	2 (1.7)	0	2 (1.2)
カンジダ性おむつ皮疹	0	2 (2.0)	2 (1.7)	0	2 (1.2)
蜂巣炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
息詰まり	0	2 (2.0)	2 (1.7)	0	2 (1.2)
細菌性結膜炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
不快感	0	2 (2.0)	2 (1.7)	0	2 (1.2)
よだれ	0	2 (2.0)	2 (1.7)	0	2 (1.2)
耳痛	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
エンテロウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
転倒	1 (5.9)	0	1 (0.9)	1 (1.8)	2 (1.2)
栄養補給チューブ合併症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ウイルス性消化管感染	0	0	0	2 (3.6)	2 (1.2)
血便排泄	0	2 (2.0)	2 (1.7)	0	2 (1.2)
過角化	0	2 (2.0)	2 (1.7)	0	2 (1.2)
感覚鈍麻	0	0	0	2 (3.6)	2 (1.2)
低ナトリウム血症	0	2 (2.0)	2 (1.7)	0	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 9 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
過小食	0	2 (2.0)	2 (1.7)	0	2 (1.2)
低体温	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
易刺激性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
関節損傷	0	0	0	2 (3.6)	2 (1.2)
後側弯症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
脊柱前弯症	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
モラクセラ検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
筋緊張	0	0	0	2 (3.6)	2 (1.2)
末梢性浮腫	0	2 (2.0)	2 (1.7)	0	2 (1.2)
口腔内痛	0	0	0	2 (3.6)	2 (1.2)
急性中耳炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
蒼白	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
動悸	0	0	0	2 (3.6)	2 (1.2)
パラインフルエンザウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
骨盤変形	0	0	0	2 (3.6)	2 (1.2)
末梢腫脹	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
斜頭症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
モラクセラ菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
処置後腫脹	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 10 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
処置による悪心	0	0	0	2 (3.6)	2 (1.2)
シュードモナス検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
肺水腫	0	2 (2.0)	2 (1.7)	0	2 (1.2)
拘束性肺疾患	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
アレルギー性鼻炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
痙攣発作	0	2 (2.0)	2 (1.7)	0	2 (1.2)
皮膚擦過傷	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ブドウ球菌検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
ストーマ部膿瘍	0	2 (2.0)	2 (1.7)	0	2 (1.2)
斜視	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
失神	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
熱傷	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
隆起骨折	0	0	0	2 (3.6)	2 (1.2)
蕁麻疹	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
呼吸補助筋の動員	0	2 (2.0)	2 (1.7)	0	2 (1.2)
心室性頻脈	0	2 (2.0)	2 (1.7)	0	2 (1.2)
血管穿刺部位内出血	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
白血球数増加	0	2 (2.0)	2 (1.7)	0	2 (1.2)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
ざ瘡	0	0	0	1 (1.8)	1 (0.6)
後天性包茎	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 11 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
アクロコルドン	0	1 (1.0)	1 (0.9)	0	1 (0.6)
急性呼吸窮迫症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
アデノウイルス性上気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脱毛症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
失声症	0	0	0	1 (1.8)	1 (0.6)
無呼吸発作	0	1 (1.0)	1 (0.9)	0	1 (0.6)
適用部位紅斑	1 (5.9)	0	1 (0.9)	0	1 (0.6)
節足動物刺傷	0	0	0	1 (1.8)	1 (0.6)
窒息	0	1 (1.0)	1 (0.9)	0	1 (0.6)
乱視	0	1 (1.0)	1 (0.9)	0	1 (0.6)
注意欠陥多動性障害	0	0	0	1 (1.8)	1 (0.6)
細菌性疾患キャリアー	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血管の良性新生物	0	1 (1.0)	1 (0.9)	0	1 (0.6)
水疱	0	0	0	1 (1.8)	1 (0.6)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)
血中クロール減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中鉄減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中テストステロン減少	0	0	0	1 (1.8)	1 (0.6)
体温低下	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 12 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
骨密度減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脳損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
息こらえ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸音異常	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管支閉塞	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ＣＳＦ白血球数増加	0	0	0	1 (1.8)	1 (0.6)
毛細血管脆弱	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心筋症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
カテーテル留置部位出血	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位炎症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位関連反応	0	0	0	1 (1.8)	1 (0.6)
脳梗塞	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脳脊髄液漏	0	1 (1.0)	1 (0.9)	0	1 (0.6)
霰粒腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
口唇のひび割れ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胸部不快感	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
斜指症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
間代	0	1 (1.0)	1 (0.9)	0	1 (0.6)
コロナウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 13 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
泣き	0	1 (1.0)	1 (0.9)	0	1 (0.6)
後天性涙道狭窄	1 (5.9)	0	1 (0.9)	0	1 (0.6)
死亡	0	1 (1.0)	1 (0.9)	0	1 (0.6)
食欲減退	0	0	0	1 (1.8)	1 (0.6)
褥瘡性潰瘍	0	0	0	1 (1.8)	1 (0.6)
泉門閉鎖遅延	0	1 (1.0)	1 (0.9)	0	1 (0.6)
麻酔からの覚醒遅延	0	1 (1.0)	1 (0.9)	0	1 (0.6)
アレルギー性皮膚炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
発育性股関節形成不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
医療機器リーク	0	1 (1.0)	1 (0.9)	0	1 (0.6)
医療機器閉塞	0	1 (1.0)	1 (0.9)	0	1 (0.6)
薬物不耐性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
眼乾燥	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ダンピング症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
味覚異常	0	0	0	1 (1.8)	1 (0.6)
失読症	0	0	0	1 (1.8)	1 (0.6)
発声障害	0	0	0	1 (1.8)	1 (0.6)
不快気分	0	0	0	1 (1.8)	1 (0.6)
排尿困難	0	0	0	1 (1.8)	1 (0.6)
耳擦過傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
耳の障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 14 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
感染性湿疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
貨幣状湿疹	1 (5.9)	0	1 (0.9)	0	1 (0.6)
心電図ＳＴ－Ｔ部分異常	0	1 (1.0)	1 (0.9)	0	1 (0.6)
好酸球増加症	1 (5.9)	0	1 (0.9)	0	1 (0.6)
伝染性紅斑	0	1 (1.0)	1 (0.9)	0	1 (0.6)
本態性高血圧症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
耳垢分泌過多	0	1 (1.0)	1 (0.9)	0	1 (0.6)
擦過傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
伝染病曝露	0	1 (1.0)	1 (0.9)	0	1 (0.6)
四肢拘縮	0	0	0	1 (1.8)	1 (0.6)
眼感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌性眼感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性眼感染	0	0	0	1 (1.8)	1 (0.6)
眼運動障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.9)	0	1 (0.6)
冷感	0	0	0	1 (1.8)	1 (0.6)
食物アレルギー	0	1 (1.0)	1 (0.9)	0	1 (0.6)
食中毒	0	0	0	1 (1.8)	1 (0.6)
排便回数増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
真菌感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 15 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胃出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性胃炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ロタウイルス胃腸炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胃腸障害	0	0	0	1 (1.8)	1 (0.6)
消化管運動低下	0	1 (1.0)	1 (0.9)	0	1 (0.6)
環状肉芽腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
重力性浮腫	0	0	0	1 (1.8)	1 (0.6)
吐血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ヘモフィルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
手変形	0	1 (1.0)	1 (0.9)	0	1 (0.6)
頭部損傷	0	0	0	1 (1.8)	1 (0.6)
心拍数減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心拍数不整	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肝腫大	0	1 (1.0)	1 (0.9)	0	1 (0.6)
水腎症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
遠視	0	0	0	1 (1.8)	1 (0.6)
反射亢進	1 (5.9)	0	1 (0.9)	0	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
減呼吸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低血圧	0	0	0	1 (1.8)	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 16 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
筋緊張低下	1 (5.9)	0	1 (0.9)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
食欲亢進	0	0	0	1 (1.8)	1 (0.6)
気管支分泌増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
乳児仙痛	0	1 (1.0)	1 (0.9)	0	1 (0.6)
乳児吐出	0	1 (1.0)	1 (0.9)	0	1 (0.6)
炎症マーカー上昇	0	1 (1.0)	1 (0.9)	0	1 (0.6)
A型インフルエンザウイルス検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
注入部位内出血	1 (5.9)	0	1 (0.9)	0	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
不眠症	0	0	0	1 (1.8)	1 (0.6)
鉄欠乏	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ワクチン接種後の易刺激性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
関節硬直	0	1 (1.0)	1 (0.9)	0	1 (0.6)
毛孔性角化症	0	0	0	1 (1.8)	1 (0.6)
喉頭肉芽腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
左室肥大	0	1 (1.0)	1 (0.9)	0	1 (0.6)
嗜眠	0	1 (1.0)	1 (0.9)	0	1 (0.6)
靭帯捻挫	0	0	0	1 (1.8)	1 (0.6)
口唇損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 17 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
口唇痛	0	0	0	1 (1.8)	1 (0.6)
肝機能検査異常	0	1 (1.0)	1 (0.9)	0	1 (0.6)
下肢骨折	0	0	0	1 (1.8)	1 (0.6)
肺障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
リンパ節症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
倦怠感	0	1 (1.0)	1 (0.9)	0	1 (0.6)
機械的換気	0	1 (1.0)	1 (0.9)	0	1 (0.6)
医学的観察	0	1 (1.0)	1 (0.9)	0	1 (0.6)
半月板損傷	0	0	0	1 (1.8)	1 (0.6)
代謝性アルカローシス	0	1 (1.0)	1 (0.9)	0	1 (0.6)
片頭痛	0	0	0	1 (1.8)	1 (0.6)
伝染性軟属腫	0	0	0	1 (1.8)	1 (0.6)
単核細胞症症候群	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.9)	0	1 (0.6)
モラクセラ感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
乗物酔い	0	0	0	1 (1.8)	1 (0.6)
粘膜皮膚カンジダ症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肉離れ	0	0	0	1 (1.8)	1 (0.6)
筋力低下	1 (5.9)	0	1 (0.9)	0	1 (0.6)
近視	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 18 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
貧血母斑	0	1 (1.0)	1 (0.9)	0	1 (0.6)
鼻汁変色	0	1 (1.0)	1 (0.9)	0	1 (0.6)
好中球百分率増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
寝汗	0	0	0	1 (1.8)	1 (0.6)
小結節	0	1 (1.0)	1 (0.9)	0	1 (0.6)
院内感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
浮腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
口腔ヘルペス	0	1 (1.0)	1 (0.9)	0	1 (0.6)
卵巣嚢胞	0	1 (1.0)	1 (0.9)	0	1 (0.6)
錯感覚	0	0	0	1 (1.8)	1 (0.6)
睡眠時随伴症	0	0	0	1 (1.8)	1 (0.6)
鳩胸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
陰茎障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
点状出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
咽頭炎	0	0	0	1 (1.8)	1 (0.6)
胸水	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
インフルエンザ性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
パラインフルエンザウイルス性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
シュードモナス菌性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 19 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
肺臓炎	0	0	0	1 (1.8)	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
外傷性気胸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
処置後合併症	1 (5.9)	0	1 (0.9)	0	1 (0.6)
処置後不快感	1 (5.9)	0	1 (0.9)	0	1 (0.6)
術後イレウス	0	0	0	1 (1.8)	1 (0.6)
処置合併症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.9)	0	1 (0.6)
湿性咳嗽	0	1 (1.0)	1 (0.9)	0	1 (0.6)
そう痒症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
シュードモナス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
穿刺部位反応	0	0	0	1 (1.8)	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸性アシドーシス	1 (5.9)	0	1 (0.9)	0	1 (0.6)
呼吸性アルカローシス	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気道うっ血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
細菌性気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
落ち着きのなさ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低音性連続性ラ音	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ばら疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 20 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
脂漏性皮膚炎	1 (5.9)	0	1 (0.9)	0	1 (0.6)
脂漏性角化症	1 (5.9)	0	1 (0.9)	0	1 (0.6)
敗血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
セラチア検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ショック	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚細菌感染	0	0	0	1 (1.8)	1 (0.6)
皮膚色素脱失	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚感染	1 (5.9)	0	1 (0.9)	0	1 (0.6)
皮膚病変	0	0	0	1 (1.8)	1 (0.6)
皮膚浮腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚乳頭腫	0	0	0	1 (1.8)	1 (0.6)
皮膚潰瘍	0	1 (1.0)	1 (0.9)	0	1 (0.6)
睡眠時無呼吸症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
睡眠障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
軟部組織損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
傾眠	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脊柱変形	0	1 (1.0)	1 (0.9)	0	1 (0.6)
変色痰	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌性菌血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 21 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌皮膚感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ストーマ合併症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
口内炎	0	0	0	1 (1.8)	1 (0.6)
レンサ球菌検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮下気腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
硬膜下血腫	1 (5.9)	0	1 (0.9)	0	1 (0.6)
上室性頻脈	0	1 (1.0)	1 (0.9)	0	1 (0.6)
腫脹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
頻呼吸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血小板増加症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
脛骨骨折	0	0	0	1 (1.8)	1 (0.6)
チック	0	0	0	1 (1.8)	1 (0.6)
扁桃炎	0	0	0	1 (1.8)	1 (0.6)
歯牙損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)
鼓膜穿孔	0	0	0	1 (1.8)	1 (0.6)
臍肉芽腫	1 (5.9)	0	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 22 of 22

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
上部消化管出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.9)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)
尿量減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ワクチン接種合併症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
腟感染	0	0	0	1 (1.8)	1 (0.6)
血管炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
膀胱尿管逆流	0	0	0	1 (1.8)	1 (0.6)
ウイルス性扁桃炎	0	0	0	1 (1.8)	1 (0.6)
ビタミンA減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ビタミンD欠乏	0	0	0	1 (1.8)	1 (0.6)
心因性嘔吐	0	0	0	1 (1.8)	1 (0.6)
外陰腟真菌感染	0	0	0	1 (1.8)	1 (0.6)
体重支持困難	1 (5.9)	0	1 (0.9)	0	1 (0.6)
創離開	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each preferred term.
3:Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE:[redacted] DATE:[redacted]
##[redacted]20[redacted]##

表 33　Infantile-Onset Subjects Treated With ISIS 396443 in Controlled and Uncontrolled Studies:Incidence of Adverse Events by 90-Day Intervals

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 1 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
Number of subjects dosed	100 (100.0)	78 (100.0)	58 (100.0)	42 (100.0)
Number of subjects with an event	89 (89.0)	67 (85.9)	51 (87.9)	31 (73.8)
呼吸器、胸郭および縦隔障害	59 (59.0)	34 (43.6)	26 (44.8)	15 (35.7)
呼吸不全	13 (13.0)	5 (6.4)	3 (5.2)	3 (7.1)
呼吸窮迫	11 (11.0)	11 (14.1)	2 (3.4)	3 (7.1)
無気肺	10 (10.0)	7 (9.0)	5 (8.6)	2 (4.8)
鼻閉	10 (10.0)	4 (5.1)	3 (5.2)	1 (2.4)
急性呼吸不全	8 (8.0)	6 (7.7)	9 (15.5)	2 (4.8)
無呼吸	5 (5.0)	1 (1.3)	1 (1.7)	0
咳嗽	5 (5.0)	1 (1.3)	3 (5.2)	2 (4.8)
誤嚥	4 (4.0)	2 (2.6)	0	0
呼吸困難	4 (4.0)	2 (2.6)	2 (3.4)	1 (2.4)
低酸素症	4 (4.0)	3 (3.8)	3 (5.2)	0
気管支分泌物貯留	3 (3.0)	2 (2.6)	1 (1.7)	0
低換気	3 (3.0)	0	0	0
息詰まり	2 (2.0)	0	0	0
慢性呼吸不全	2 (2.0)	1 (1.3)	1 (1.7)	1 (2.4)
上気道分泌増加	2 (2.0)	3 (3.8)	1 (1.7)	0
誤嚥性肺炎	2 (2.0)	2 (2.6)	4 (6.9)	2 (4.8)
気胸	2 (2.0)	1 (1.3)	0	0
呼吸停止	2 (2.0)	0	1 (1.7)	1 (2.4)
呼吸障害	2 (2.0)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 2 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
Number of subjects dosed	34 (100.0)	15 (100.0)	15 (100.0)	11 (100.0)
Number of subjects with an event	22 (64.7)	12 (80.0)	9 (60.0)	7 (63.6)
呼吸器、胸郭および縦隔障害	6 (17.6)	5 (33.3)	4 (26.7)	3 (27.3)
呼吸不全	1 (2.9)	0	0	0
呼吸窮迫	1 (2.9)	2 (13.3)	0	0
無気肺	2 (5.9)	1 (6.7)	1 (6.7)	1 (9.1)
鼻閉	0	0	1 (6.7)	0
急性呼吸不全	0	1 (6.7)	0	0
無呼吸	0	0	0	0
咳嗽	2 (5.9)	0	1 (6.7)	0
誤嚥	0	0	0	0
呼吸困難	0	0	0	0
低酸素症	0	0	0	0
気管支分泌物貯留	0	0	0	0
低換気	0	0	0	0
息詰まり	0	0	0	0
慢性呼吸不全	0	1 (6.7)	0	0
上気道分泌増加	0	1 (6.7)	1 (6.7)	0
誤嚥性肺炎	0	0	0	0
気胸	1 (2.9)	0	0	0
呼吸停止	0	0	0	0
呼吸障害	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 3 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
Number of subjects dosed	8 (100.0)	4 (100.0)	2 (100.0)	1 (100.0)
Number of subjects with an event	8 (100.0)	2 (50.0)	1 (50.0)	0
呼吸器、胸郭および縦隔障害	5 (62.5)	0	1 (50.0)	0
呼吸不全	0	0	0	0
呼吸窮迫	1 (12.5)	0	0	0
無気肺	0	0	0	0
鼻閉	1 (12.5)	0	0	0
急性呼吸不全	1 (12.5)	0	0	0
無呼吸	0	0	0	0
咳嗽	0	0	1 (50.0)	0
誤嚥	0	0	0	0
呼吸困難	0	0	0	0
低酸素症	0	0	0	0
気管支分泌物貯留	1 (12.5)	0	0	0
低換気	0	0	0	0
息詰まり	0	0	0	0
慢性呼吸不全	0	0	0	0
上気道分泌増加	1 (12.5)	0	0	0
誤嚥性肺炎	0	0	0	0
気胸	0	0	0	0
呼吸停止	0	0	0	0
呼吸障害	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 4 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
鼻漏	2 (2.0)	1 (1.3)	2 (3.4)	1 (2.4)
上気道うっ血	2 (2.0)	0	2 (3.4)	1 (2.4)
呼吸補助筋の動員	2 (2.0)	0	0	0
肺障害	1 (1.0)	0	0	0
閉塞性気道障害	1 (1.0)	0	0	0
胸水	1 (1.0)	0	0	0
呼吸性アルカローシス	1 (1.0)	0	0	0
気道うっ血	1 (1.0)	0	0	0
副鼻腔うっ血	1 (1.0)	1 (1.3)	1 (1.7)	0
睡眠時無呼吸症候群	1 (1.0)	0	0	0
頻呼吸	1 (1.0)	0	0	0
急性呼吸窮迫症候群	0	0	0	1 (2.4)
無呼吸発作	0	1 (1.3)	0	0
窒息	0	0	1 (1.7)	0
気管支閉塞	0	1 (1.3)	0	0
高炭酸ガス血症	0	0	1 (1.7)	0
減呼吸	0	0	0	1 (2.4)
気管支分泌増加	0	0	1 (1.7)	0
喉頭肉芽腫	0	0	0	0
鼻汁変色	0	0	0	0
気縦隔症	0	0	0	0
湿性咳嗽	0	0	0	0
肺うっ血	0	1 (1.3)	0	0
肺水腫	0	0	0	0
拘束性肺疾患	0	1 (1.3)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 5 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
鼻漏	0	0	0	0
上気道うっ血	0	1 (6.7)	0	0
呼吸補助筋の動員	0	0	0	0
肺障害	0	0	0	0
閉塞性気道障害	0	0	0	0
胸水	0	0	0	0
呼吸性アルカローシス	0	0	0	0
気道うっ血	0	0	0	0
副鼻腔うっ血	0	1 (6.7)	1 (6.7)	0
睡眠時無呼吸症候群	0	0	0	0
頻呼吸	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0
無呼吸発作	0	0	0	0
窒息	0	0	0	0
気管支閉塞	0	0	0	0
高炭酸ガス血症	0	0	0	0
減呼吸	0	0	0	0
気管支分泌増加	0	0	0	0
喉頭肉芽腫	1 (2.9)	0	0	0
鼻汁変色	0	1 (6.7)	0	0
気縦隔症	1 (2.9)	0	0	0
湿性咳嗽	0	0	0	0
肺うっ血	1 (2.9)	0	0	0
肺水腫	0	0	0	1 (9.1)
拘束性肺疾患	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 6 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
鼻漏	0	0	0	0
上気道うっ血	0	0	0	0
呼吸補助筋の動員	0	0	0	0
肺障害	0	0	0	0
閉塞性気道障害	0	0	0	0
胸水	0	0	0	0
呼吸性アルカローシス	0	0	0	0
気道うっ血	0	0	0	0
副鼻腔うっ血	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0
頻呼吸	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0
無呼吸発作	0	0	0	0
窒息	0	0	0	0
気管支閉塞	0	0	0	0
高炭酸ガス血症	0	0	0	0
減呼吸	0	0	0	0
気管支分泌増加	0	0	0	0
喉頭肉芽腫	0	0	0	0
鼻汁変色	0	0	0	0
気縦隔症	0	0	0	0
湿性咳嗽	1 (12.5)	0	0	0
肺うっ血	0	0	0	0
肺水腫	1 (12.5)	0	0	0
拘束性肺疾患	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 7 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
アレルギー性鼻炎	0	1 (1.3)	0	0
低音性連続性ラ音	0	0	0	0
変色痰	0	0	0	0
気管障害	0	0	0	0
喘鳴	0	1 (1.3)	1 (1.7)	1 (2.4)
感染症および寄生虫症	49 (49.0)	48 (61.5)	39 (67.2)	25 (59.5)
肺炎	10 (10.0)	8 (10.3)	3 (5.2)	8 (19.0)
鼻咽頭炎	9 (9.0)	5 (6.4)	6 (10.3)	3 (7.1)
ライノウイルス感染	7 (7.0)	1 (1.3)	2 (3.4)	3 (7.1)
ウイルス性上気道感染	7 (7.0)	6 (7.7)	1 (1.7)	0
上気道感染	6 (6.0)	13 (16.7)	12 (20.7)	8 (19.0)
細気管支炎	5 (5.0)	3 (3.8)	1 (1.7)	1 (2.4)
口腔カンジダ症	5 (5.0)	0	1 (1.7)	1 (2.4)
気道感染	5 (5.0)	6 (7.7)	4 (6.9)	3 (7.1)
気管支炎	4 (4.0)	0	0	0
ウイルス感染	4 (4.0)	4 (5.1)	2 (3.4)	1 (2.4)
ウイルス性肺炎	3 (3.0)	2 (2.6)	3 (5.2)	0
ウイルス性気道感染	3 (3.0)	2 (2.6)	0	1 (2.4)
カンジダ性おむつ皮疹	2 (2.0)	0	0	0
結膜炎	2 (2.0)	0	3 (5.2)	0
モラクセラ菌性肺炎	2 (2.0)	1 (1.3)	0	0
細菌性気管炎	1 (1.0)	1 (1.3)	0	0
ウイルス性気管支炎	1 (1.0)	0	2 (3.4)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 8 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
アレルギー性鼻炎	0	0	0	1 (9.1)
低音性連続性ラ音	0	0	1 (6.7)	0
変色痰	1 (2.9)	0	0	0
気管障害	0	1 (6.7)	0	0
喘鳴	0	0	0	0
感染症および寄生虫症	12 (35.3)	9 (60.0)	5 (33.3)	6 (54.5)
肺炎	2 (5.9)	0	0	1 (9.1)
鼻咽頭炎	1 (2.9)	2 (13.3)	1 (6.7)	0
ライノウイルス感染	2 (5.9)	0	0	0
ウイルス性上気道感染	0	0	0	0
上気道感染	4 (11.8)	1 (6.7)	2 (13.3)	1 (9.1)
細気管支炎	1 (2.9)	1 (6.7)	0	0
口腔カンジダ症	0	1 (6.7)	0	0
気道感染	0	3 (20.0)	1 (6.7)	1 (9.1)
気管支炎	1 (2.9)	0	0	0
ウイルス感染	0	1 (6.7)	1 (6.7)	0
ウイルス性肺炎	0	0	0	0
ウイルス性気道感染	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0
結膜炎	0	0	1 (6.7)	0
モラクセラ菌性肺炎	0	0	0	0
細菌性気管炎	0	0	0	0
ウイルス性気管支炎	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 9 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
アレルギー性鼻炎	0	0	0	0
低音性連続性ラ音	0	0	0	0
変色痰	0	0	0	0
気管障害	0	0	0	0
喘鳴	0	0	0	0
感染症および寄生虫症	4 (50.0)	2 (50.0)	0	0
肺炎	1 (12.5)	0	0	0
鼻咽頭炎	1 (12.5)	0	0	0
ライノウイルス感染	0	0	0	0
ウイルス性上気道感染	1 (12.5)	0	0	0
上気道感染	0	2 (50.0)	0	0
細気管支炎	0	0	0	0
口腔カンジダ症	0	0	0	0
気道感染	1 (12.5)	0	0	0
気管支炎	0	0	0	0
ウイルス感染	0	0	0	0
ウイルス性肺炎	1 (12.5)	0	0	0
ウイルス性気道感染	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0
結膜炎	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0
細菌性気管炎	1 (12.5)	0	0	0
ウイルス性気管支炎	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 10 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
細菌性結膜炎	1 (1.0)	0	1 (1.7)	0
耳感染	1 (1.0)	2 (2.6)	2 (3.4)	1 (2.4)
感染性湿疹	1 (1.0)	0	0	0
真菌感染	1 (1.0)	0	0	0
皮膚真菌感染	1 (1.0)	0	1 (1.7)	0
ウイルス性胃炎	1 (1.0)	0	0	0
膿痂疹	1 (1.0)	0	0	0
限局性感染	1 (1.0)	0	0	0
下気道感染	1 (1.0)	0	3 (5.2)	1 (2.4)
肺感染	1 (1.0)	0	0	0
メタニューモウイルス感染	1 (1.0)	1 (1.3)	0	0
レンサ球菌性咽頭炎	1 (1.0)	0	0	0
細菌性肺炎	1 (1.0)	0	2 (3.4)	1 (2.4)
パラインフルエンザウイルス性肺炎	1 (1.0)	0	0	0
ＲＳウイルス肺炎	1 (1.0)	0	0	0
ＲＳウイルス細気管支炎	1 (1.0)	2 (2.6)	1 (1.7)	0
鼻炎	1 (1.0)	1 (1.3)	0	0
敗血症	1 (1.0)	0	0	0
皮膚カンジダ	1 (1.0)	0	1 (1.7)	0
ストーマ部膿瘍	1 (1.0)	0	0	0
尿路感染	1 (1.0)	1 (1.3)	0	1 (2.4)
アデノウイルス性上気道感染	0	0	0	0
アデノウイルス感染	0	0	2 (3.4)	0
細菌性疾患キャリアー	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 11 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
細菌性結膜炎	0	0	0	0
耳感染	0	0	0	0
感染性湿疹	0	0	0	0
真菌感染	0	0	0	0
皮膚真菌感染	0	0	0	0
ウイルス性胃炎	0	0	0	0
膿痂疹	0	0	0	0
限局性感染	0	0	0	0
下気道感染	0	0	0	1 (9.1)
肺感染	0	0	0	0
メタニューモウイルス感染	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	0
細菌性肺炎	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0
ＲＳウイルス感染細気管支炎	0	0	0	0
鼻炎	0	0	1 (6.7)	0
敗血症	0	0	0	0
皮膚カンジダ	0	0	0	0
ストーマ部膿瘍	1 (2.9)	0	0	0
尿路感染	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0
アデノウイルス感染	0	0	0	0
細菌性疾患キャリアー	0	0	0	1 (9.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 12 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
細菌性結膜炎	0	0	0	0
耳感染	0	0	0	0
感染性湿疹	0	0	0	0
真菌感染	0	0	0	0
皮膚真菌感染	0	0	0	0
ウイルス性胃炎	0	0	0	0
膿痂疹	0	0	0	0
限局性感染	0	0	0	0
下気道感染	0	0	0	0
肺感染	0	0	0	0
メタニューモウイルス感染	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	0
細菌性肺炎	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0
ＲＳウイルス感染細気管支炎	0	0	0	0
鼻炎	0	0	0	0
敗血症	0	0	0	0
皮膚カンジダ	0	0	0	0
ストーマ部膿瘍	0	0	0	0
尿路感染	0	0	0	0
アデノウイルス性上気道感染	1 (12.5)	0	0	0
アデノウイルス感染	0	0	0	0
細菌性疾患キャリアー	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 13 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
細菌感染	0	0	2 (3.4)	1 (2.4)
蜂巣炎	0	0	1 (1.7)	0
コロナウイルス感染	0	1 (1.3)	0	0
エンテロウイルス感染	0	0	0	1 (2.4)
伝染性紅斑	0	0	0	0
眼感染	0	0	1 (1.7)	0
胃腸炎	0	1 (1.3)	1 (1.7)	0
ロタウイルス胃腸炎	0	1 (1.3)	0	0
ウイルス性胃腸炎	0	1 (1.3)	0	0
ヘモフィルス感染	0	0	0	1 (2.4)
手足口病	0	0	1 (1.7)	0
インフルエンザ	0	2 (2.6)	0	0
ウイルス性下気道感染	0	3 (3.8)	0	0
モラクセラ感染	0	0	0	0
粘膜皮膚カンジダ症	0	1 (1.3)	0	0
院内感染	0	0	1 (1.7)	0
口腔ヘルペス	0	0	0	1 (2.4)
中耳炎	0	1 (1.3)	3 (5.2)	0
急性中耳炎	0	1 (1.3)	0	0
パラインフルエンザウイルス感染	0	0	0	0
インフルエンザ性肺炎	0	1 (1.3)	0	0
シュードモナス菌性肺炎	0	0	0	0
シュードモナス感染	0	0	1 (1.7)	0
細菌性気道感染	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 14 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
細菌感染	0	0	0	0
蜂巣炎	0	0	0	0
コロナウイルス感染	0	0	0	0
エンテロウイルス感染	1 (2.9)	0	0	0
伝染性紅斑	0	0	0	1 (9.1)
眼感染	0	0	0	0
胃腸炎	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0
ウイルス性胃腸炎	0	0	0	0
ヘモフィルス感染	0	0	0	0
手足口病	0	0	1 (6.7)	0
インフルエンザ	1 (2.9)	0	0	0
下気道感染感染	0	0	0	0
モラクセラ感染	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0
院内感染	0	0	0	0
口腔ヘルペス	0	0	0	0
中耳炎	2 (5.9)	1 (6.7)	0	1 (9.1)
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	1 (2.9)	1 (6.7)	0	0
インフルエンザ性肺炎	0	0	0	0
シュードモナス菌性肺炎	1 (2.9)	0	0	0
シュードモナス感染	0	0	0	0
細菌性気道感染	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 15 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
細菌感染	0	0	0	0
蜂巣炎	0	0	0	0
コロナウイルス感染	0	0	0	0
エンテロウイルス感染	0	0	0	0
伝染性紅斑	0	0	0	0
眼感染	0	0	0	0
胃腸炎	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0
ウイルス性胃腸炎	0	0	0	0
ヘモフィルス感染	0	0	0	0
手足口病	0	0	0	0
インフルエンザ	0	0	0	0
下気道感染感染	0	0	0	0
モラクセラ感染	1 (12.5)	0	0	0
粘膜皮膚カンジダ症	0	0	0	0
院内感染	0	0	0	0
口腔ヘルペス	0	0	0	0
中耳炎	0	0	0	0
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0
インフルエンザ性肺炎	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0
シュードモナス感染	0	0	0	0
細菌性気道感染	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 16 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
ばら疹	0	1 (1.3)	0	0
ブドウ球菌性菌血症	0	1 (1.3)	0	0
ブドウ球菌感染	0	0	0	0
ブドウ球菌性敗血症	0	0	1 (1.7)	0
ブドウ球菌皮膚感染	0	0	1 (1.7)	0
気管炎	0	0	0	0
胃腸障害	47 (47.0)	31 (39.7)	18 (31.0)	11 (26.2)
便秘	17 (17.0)	9 (11.5)	8 (13.8)	1 (2.4)
胃食道逆流性疾患	9 (9.0)	2 (2.6)	1 (1.7)	1 (2.4)
生歯	9 (9.0)	4 (5.1)	1 (1.7)	0
嘔吐	9 (9.0)	9 (11.5)	2 (3.4)	3 (7.1)
下痢	4 (4.0)	4 (5.1)	2 (3.4)	5 (11.9)
嚥下障害	4 (4.0)	3 (3.8)	2 (3.4)	0
放屁	2 (2.0)	2 (2.6)	1 (1.7)	0
胃炎	2 (2.0)	0	0	1 (2.4)
流涎過多	2 (2.0)	0	2 (3.4)	1 (2.4)
腹部不快感	1 (1.0)	0	0	0
腹痛	1 (1.0)	0	0	0
アフタ性潰瘍	1 (1.0)	0	0	0
胃出血	1 (1.0)	0	0	0
血便排泄	1 (1.0)	1 (1.3)	0	0
乳児仙痛	1 (1.0)	0	0	0
腹部膨満	0	2 (2.6)	0	1 (2.4)
口唇のひび割れ	0	1 (1.3)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 17 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
ばら疹	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0
ブドウ球菌感染	0	1 (6.7)	0	0
ブドウ球菌性敗血症	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0
気管炎	1 (2.9)	0	0	0
胃腸障害	7 (20.6)	4 (26.7)	2 (13.3)	3 (27.3)
便秘	0	1 (6.7)	0	0
胃食道逆流性疾患	1 (2.9)	0	0	1 (9.1)
生歯	1 (2.9)	0	0	0
嘔吐	3 (8.8)	1 (6.7)	0	1 (9.1)
下痢	2 (5.9)	1 (6.7)	1 (6.7)	1 (9.1)
嚥下障害	0	0	0	0
放屁	0	0	0	0
胃炎	0	0	1 (6.7)	0
流涎過多	0	0	0	0
腹部不快感	0	0	0	0
腹痛	0	0	0	0
アフタ性潰瘍	0	0	0	0
胃出血	0	0	0	0
血便排泄	0	0	0	0
乳児仙痛	0	0	0	0
腹部膨満	0	0	0	1 (9.1)
口唇のひび割れ	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 18 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
ばら疹	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0
ブドウ球菌感染	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0
気管炎	0	0	0	0
胃腸障害	2 (25.0)	1 (25.0)	0	0
便秘	0	0	0	0
胃食道逆流性疾患	0	0	0	0
生歯	0	0	0	0
嘔吐	1 (12.5)	0	0	0
下痢	2 (25.0)	1 (25.0)	0	0
嚥下障害	0	0	0	0
放屁	0	0	0	0
胃炎	0	0	0	0
流涎過多	0	0	0	0
腹部不快感	0	0	0	0
腹痛	0	0	0	0
アフタ性潰瘍	0	0	0	0
胃出血	0	0	0	0
血便排泄	0	0	0	0
乳児仙痛	0	0	0	0
腹部膨満	0	0	0	0
口唇のひび割れ	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 19 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
排便回数増加	0	0	0	0
消化管運動低下	0	0	0	1 (2.4)
吐血	0	0	0	0
乳児吐出	0	1 (1.3)	0	0
上部消化管出血	0	0	1 (1.7)	0
一般・全身障害および投与部位の状態	37 (37.0)	22 (28.2)	18 (31.0)	16 (38.1)
発熱	28 (28.0)	21 (26.9)	18 (31.0)	15 (35.7)
疼痛	3 (3.0)	2 (2.6)	0	0
泣き	1 (1.0)	0	0	0
死亡	1 (1.0)	0	0	0
医療機器閉塞	1 (1.0)	1 (1.3)	0	0
不快感	1 (1.0)	0	0	1 (2.4)
低体温	1 (1.0)	0	0	0
ワクチン接種後の易刺激性	1 (1.0)	0	0	0
倦怠感	1 (1.0)	0	0	0
小結節	1 (1.0)	0	0	0
浮腫	1 (1.0)	0	0	0
末梢腫脹	1 (1.0)	0	0	0
血管穿刺部位内出血	1 (1.0)	0	0	0
カテーテル留置部位炎症	0	0	0	1 (2.4)
医療機器リーク	0	1 (1.3)	0	0
薬物不耐性	0	1 (1.3)	0	0
末梢性浮腫	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 20 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
排便回数増加	0	1 (6.7)	0	0
消化管運動低下	0	0	0	0
吐血	1 (2.9)	0	0	0
乳児吐出	0	0	0	0
上部消化管出血	0	0	0	0
一般・全身障害および投与部位の状態	8 (23.5)	3 (20.0)	0	2 (18.2)
発熱	8 (23.5)	2 (13.3)	0	2 (18.2)
疼痛	0	0	0	0
泣き	0	0	0	0
死亡	0	0	0	0
医療機器閉塞	0	0	0	0
不快感	0	0	0	0
低体温	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0
倦怠感	0	0	0	0
小結節	0	0	0	0
浮腫	0	0	0	0
末梢腫脹	0	0	0	0
血管穿刺部位内出血	0	0	0	0
カテーテル留置部位炎症	0	0	0	0
医療機器リーク	0	0	0	0
薬物不耐性	0	0	0	0
末梢性浮腫	0	1 (6.7)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 21 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
排便回数増加	0	0	0	0
消化管運動低下	0	0	0	0
吐血	0	0	0	0
乳児吐出	0	0	0	0
上部消化管出血	0	0	0	0
一般・全身障害および投与部位の状態	3 (37.5)	0	0	0
発熱	2 (25.0)	0	0	0
疼痛	0	0	0	0
泣き	0	0	0	0
死亡	0	0	0	0
医療機器閉塞	0	0	0	0
不快感	0	0	0	0
低体温	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0
倦怠感	0	0	0	0
小結節	0	0	0	0
浮腫	0	0	0	0
末梢腫脹	0	0	0	0
血管穿刺部位内出血	0	0	0	0
カテーテル留置部位炎症	0	0	0	0
医療機器リーク	0	0	0	0
薬物不耐性	0	0	0	0
末梢性浮腫	1 (12.5)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 22 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
腫脹	0	0	0	1 (2.4)
皮膚および皮下組織障害	18 (18.0)	11 (14.1)	8 (13.8)	4 (9.5)
おむつ皮膚炎	4 (4.0)	1 (1.3)	1 (1.7)	2 (4.8)
発疹	4 (4.0)	3 (3.8)	4 (6.9)	0
湿疹	3 (3.0)	1 (1.3)	0	0
接触性皮膚炎	2 (2.0)	0	0	0
脱毛症	1 (1.0)	0	0	0
皮膚炎	1 (1.0)	1 (1.3)	0	0
斑状出血	1 (1.0)	0	0	1 (2.4)
紅斑	1 (1.0)	0	0	0
過剰肉芽組織	1 (1.0)	1 (1.3)	0	0
点状出血	1 (1.0)	0	0	0
アレルギー性皮膚炎	0	0	1 (1.7)	0
環状肉芽腫	0	1 (1.3)	0	0
過角化	0	1 (1.3)	0	1 (2.4)
汗疹	0	2 (2.6)	0	0
そう痒症	0	0	0	0
丘疹性皮疹	0	0	1 (1.7)	0
皮膚色素脱失	0	0	0	0
皮膚障害	0	0	0	0
皮膚刺激	0	1 (1.3)	0	0
皮膚浮腫	0	0	1 (1.7)	0
皮膚潰瘍	0	0	1 (1.7)	0
皮下気腫	0	1 (1.3)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 23 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
腫脹	0	0	0	0
皮膚および皮下組織障害	6 (17.6)	3 (20.0)	2 (13.3)	3 (27.3)
おむつ皮膚炎	2 (5.9)	1 (6.7)	0	0
発疹	2 (5.9)	0	1 (6.7)	1 (9.1)
湿疹	0	0	0	0
接触性皮膚炎	0	0	0	1 (9.1)
脱毛症	0	0	0	0
皮膚炎	1 (2.9)	0	0	1 (9.1)
斑状出血	0	0	1 (6.7)	0
紅斑	0	0	0	0
過剰肉芽組織	0	1 (6.7)	0	0
点状出血	0	0	0	0
アレルギー性皮膚炎	0	0	0	0
環状肉芽腫	0	0	0	0
過角化	0	0	0	0
汗疹	0	0	0	0
そう痒症	1 (2.9)	0	0	0
丘疹性皮疹	0	0	0	0
皮膚色素脱失	0	1 (6.7)	0	0
皮膚障害	1 (2.9)	0	0	0
皮膚刺激	0	0	0	0
皮膚浮腫	0	0	0	0
皮膚潰瘍	0	0	0	0
皮下気腫	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 24 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
腫脹	0	0	0	0
皮膚および皮下組織障害	2 (25.0)	0	0	0
おむつ皮膚炎	0	0	0	0
発疹	0	0	0	0
湿疹	0	0	0	0
接触性皮膚炎	0	0	0	0
脱毛症	0	0	0	0
皮膚炎	0	0	0	0
斑状出血	0	0	0	0
紅斑	0	0	0	0
過剰肉芽組織	0	0	0	0
点状出血	0	0	0	0
アレルギー性皮膚炎	0	0	0	0
環状肉芽腫	0	0	0	0
過角化	0	0	0	0
汗疹	0	0	0	0
そう痒症	0	0	0	0
丘疹性皮疹	0	0	0	0
皮膚色素脱失	0	0	0	0
皮膚障害	0	0	0	0
皮膚刺激	2 (25.0)	0	0	0
皮膚浮腫	0	0	0	0
皮膚潰瘍	0	0	0	0
皮下気腫	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 25 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
蕁麻疹	0	1 (1.3)	0	0
傷害、中毒および処置合併症	15 (15.0)	6 (7.7)	3 (5.2)	6 (14.3)
処置による疼痛	3 (3.0)	0	1 (1.7)	0
ストーマ部紅斑	2 (2.0)	0	1 (1.7)	0
節足動物咬傷	1 (1.0)	2 (2.6)	0	1 (2.4)
麻酔からの覚醒遅延	1 (1.0)	0	0	0
擦過傷	1 (1.0)	0	0	0
栄養補給チューブ合併症	1 (1.0)	1 (1.3)	0	0
大腿骨骨折	1 (1.0)	0	0	1 (2.4)
処置合併症	1 (1.0)	0	0	0
処置部位反応	1 (1.0)	0	0	0
皮膚擦過傷	1 (1.0)	0	0	0
サンバーン	1 (1.0)	0	0	0
熱傷	1 (1.0)	0	0	0
ワクチン接種合併症	1 (1.0)	0	0	0
創離開	1 (1.0)	0	0	0
術後激越	0	0	0	1 (2.4)
挫傷	0	0	1 (1.7)	0
ダンピング症候群	0	1 (1.3)	0	0
耳擦過傷	0	0	0	0
伝染病曝露	0	0	0	1 (2.4)
関節脱臼	0	0	0	0
口唇損傷	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 26 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
蕁麻疹	0	0	0	0
傷害、中毒および処置合併症	3 (8.8)	1 (6.7)	2 (13.3)	0
処置による疼痛	0	0	0	0
ストーマ部紅斑	0	0	0	0
節足動物咬傷	2 (5.9)	0	0	0
麻酔からの覚醒遅延	0	0	0	0
擦過傷	0	0	0	0
栄養補給チューブ合併症	0	0	0	0
大腿骨骨折	0	0	0	0
処置合併症	0	0	0	0
処置部位反応	0	0	0	0
皮膚擦過傷	0	0	1 (6.7)	0
サンバーン	0	0	0	0
熱傷	0	0	0	0
ワクチン接種合併症	0	0	0	0
創離開	0	0	0	0
術後激越	0	0	0	0
挫傷	0	0	1 (6.7)	0
ダンピング症候群	0	0	0	0
耳擦過傷	1 (2.9)	0	1 (6.7)	0
伝染病曝露	0	0	0	0
関節脱臼	1 (2.9)	1 (6.7)	0	0
口唇損傷	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 27 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
蕁麻疹	0	0	0	0
傷害、中毒および処置合併症	1 (12.5)	0	0	0
処置による疼痛	0	0	0	0
ストーマ部紅斑	0	0	0	0
節足動物咬傷	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0
擦過傷	0	0	0	0
栄養補給チューブ合併症	0	0	0	0
大腿骨骨折	0	0	0	0
処置合併症	0	0	0	0
処置部位反応	0	0	0	0
皮膚擦過傷	0	0	0	0
サンバーン	0	0	0	0
熱傷	0	0	0	0
ワクチン接種合併症	0	0	0	0
創離開	0	0	0	0
術後激越	0	0	0	0
挫傷	0	0	0	0
ダンピング症候群	0	0	0	0
耳擦過傷	0	0	0	0
伝染病曝露	0	0	0	0
関節脱臼	0	0	0	0
口唇損傷	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 28 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
外傷性気胸	0	1 (1.3)	0	0
処置後腫脹	0	0	0	1 (2.4)
軟部組織損傷	0	0	0	0
ストーマ合併症	0	1 (1.3)	0	0
歯牙損傷	0	0	0	1 (2.4)
心臓障害	13 (13.0)	10 (12.8)	1 (1.7)	1 (2.4)
頻脈	4 (4.0)	4 (5.1)	1 (1.7)	0
徐脈	3 (3.0)	2 (2.6)	0	0
心停止	3 (3.0)	0	0	0
心肺停止	2 (2.0)	3 (3.8)	0	0
チアノーゼ	2 (2.0)	1 (1.3)	0	0
上室性頻脈	1 (1.0)	0	0	0
心室性頻脈	1 (1.0)	0	0	0
心筋症	0	0	0	0
左室肥大	0	0	0	1 (2.4)
心膜気腫	0	0	0	0
臨床検査	13 (13.0)	7 (9.0)	7 (12.1)	6 (14.3)
酸素飽和度低下	5 (5.0)	3 (3.8)	2 (3.4)	0
体重減少	2 (2.0)	0	1 (1.7)	0
血中鉄減少	1 (1.0)	0	0	0
血中カリウム減少	1 (1.0)	0	1 (1.7)	0
体温低下	1 (1.0)	0	0	0
体温上昇	1 (1.0)	0	1 (1.7)	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 29 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
外傷性気胸	0	0	0	0
処置後腫脹	0	0	0	0
軟部組織損傷	0	0	0	0
ストーマ合併症	0	0	0	0
歯牙損傷	0	0	0	0
心臓障害	6 (17.6)	0	1 (6.7)	0
頻脈	1 (2.9)	0	0	0
徐脈	1 (2.9)	0	1 (6.7)	0
心停止	0	0	0	0
心肺停止	1 (2.9)	0	0	0
チアノーゼ	0	0	0	0
上室性頻脈	0	0	0	0
心室性頻脈	1 (2.9)	0	0	0
心筋症	1 (2.9)	0	0	0
左室肥大	0	0	0	0
心膜気腫	1 (2.9)	0	0	0
臨床検査	3 (8.8)	1 (6.7)	2 (13.3)	2 (18.2)
酸素飽和度低下	1 (2.9)	0	1 (6.7)	0
体重減少	1 (2.9)	0	0	1 (9.1)
血中鉄減少	0	0	0	0
血中カリウム減少	0	0	0	0
体温低下	0	0	0	0
体温上昇	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 30 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
外傷性気胸	0	0	0	0
処置後腫脹	0	0	0	0
軟部組織損傷	1 (12.5)	0	0	0
ストーマ合併症	0	0	0	0
歯牙損傷	0	0	0	0
心臓障害	0	0	0	0
頻脈	0	0	0	0
徐脈	0	0	0	0
心停止	0	0	0	0
心肺停止	0	0	0	0
チアノーゼ	0	0	0	0
上室性頻脈	0	0	0	0
心室性頻脈	0	0	0	0
心筋症	0	0	0	0
左室肥大	0	0	0	0
心膜気腫	0	0	0	0
臨床検査	1 (12.5)	0	0	0
酸素飽和度低下	0	0	0	0
体重減少	0	0	0	0
血中鉄減少	0	0	0	0
血中カリウム減少	0	0	0	0
体温低下	0	0	0	0
体温上昇	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 31 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
心電図ＳＴ－Ｔ部分異常	1 (1.0)	0	0	0
心拍数不整	1 (1.0)	0	0	0
ヒトライノウイルス検査陽性	1 (1.0)	0	0	1 (2.4)
Ａ型インフルエンザウイルス検査陽性	1 (1.0)	0	0	0
医学的観察	1 (1.0)	0	0	0
モラクセラ検査陽性	1 (1.0)	0	0	0
シュードモナス検査陽性	1 (1.0)	0	0	0
ブドウ球菌検査陽性	1 (1.0)	0	0	1 (2.4)
尿量減少	1 (1.0)	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	1 (1.7)	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	1 (1.7)	0
血中クロール減少	0	0	1 (1.7)	0
血中ナトリウム減少	0	0	1 (1.7)	0
骨密度減少	0	0	0	0
呼吸音異常	0	1 (1.3)	0	0
Ｃ－反応性蛋白増加	0	2 (2.6)	1 (1.7)	1 (2.4)
心拍数減少	0	0	1 (1.7)	0
心拍数増加	0	1 (1.3)	1 (1.7)	0
炎症マーカー上昇	0	0	0	1 (2.4)
肝機能検査異常	0	0	0	0
好中球数増加	0	0	1 (1.7)	2 (4.8)
好中球百分率増加	0	0	0	1 (2.4)
セラチア検査陽性	0	0	0	0
レンサ球菌検査陽性	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 32 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
心電図ＳＴ－Ｔ部分異常	0	0	0	0
心拍数不整	0	0	0	0
ヒトライノウイルス検査陽性	0	0	1 (6.7)	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0
医学的観察	0	0	0	0
モラクセラ検査陽性	0	0	0	0
シュードモナス検査陽性	0	1 (6.7)	0	0
ブドウ球菌検査陽性	0	0	0	0
尿量減少	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0
血中クロール減少	0	0	0	0
血中ナトリウム減少	0	0	0	0
骨密度減少	0	0	0	1 (9.1)
呼吸音異常	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0
心拍数減少	0	0	0	0
心拍数増加	0	1 (6.7)	1 (6.7)	0
炎症マーカー上昇	0	0	0	0
肝機能検査異常	1 (2.9)	0	0	0
好中球数増加	0	0	1 (6.7)	0
好中球百分率増加	0	0	0	0
セラチア検査陽性	0	0	0	0
レンサ球菌検査陽性	0	1 (6.7)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 33 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
心電図ＳＴ－Ｔ部分異常	0	0	0	0
心拍数不整	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0
医学的観察	0	0	0	0
モラクセラ検査陽性	1 (12.5)	0	0	0
シュードモナス検査陽性	1 (12.5)	0	0	0
ブドウ球菌検査陽性	0	0	0	0
尿量減少	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0
血中クロール減少	0	0	0	0
血中ナトリウム減少	0	0	0	0
骨密度減少	0	0	0	0
呼吸音異常	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0
心拍数減少	0	0	0	0
心拍数増加	0	0	0	0
炎症マーカー上昇	0	0	0	0
肝機能検査異常	0	0	0	0
好中球数増加	0	0	0	0
好中球百分率増加	0	0	0	0
セラチア検査陽性	1 (12.5)	0	0	0
レンサ球菌検査陽性	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 34 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
ビタミンA減少	0	0	0	1 (2.4)
白血球数増加	0	0	1 (1.7)	1 (2.4)
代謝および栄養障害	11 (11.0)	5 (6.4)	4 (6.9)	1 (2.4)
体重増加不良	4 (4.0)	2 (2.6)	1 (1.7)	0
乳児および小児期早期の哺育障害	3 (3.0)	1 (1.3)	0	0
栄養補給不耐性	2 (2.0)	0	0	1 (2.4)
脱水	1 (1.0)	0	0	0
成長障害	1 (1.0)	1 (1.3)	1 (1.7)	0
過小食	1 (1.0)	1 (1.3)	0	0
代謝性アルカローシス	1 (1.0)	0	0	0
低ナトリウム血症	0	0	2 (3.4)	0
鉄欠乏	0	1 (1.3)	0	0
筋骨格系および結合組織障害	8 (8.0)	4 (5.1)	6 (10.3)	3 (7.1)
関節拘縮	3 (3.0)	3 (3.8)	2 (3.4)	2 (4.8)
側弯症	2 (2.0)	1 (1.3)	3 (5.2)	0
背部痛	1 (1.0)	0	0	0
胸郭変形	1 (1.0)	0	1 (1.7)	1 (2.4)
手変形	1 (1.0)	0	0	0
頭位性斜頭症	1 (1.0)	0	0	0
泉門閉鎖遅延	0	0	0	1 (2.4)
関節硬直	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 35 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
ビタミンA減少	0	0	0	0
白血球数増加	0	0	0	0
代謝および栄養障害	0	0	0	0
体重増加不良	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0
栄養補給不耐性	0	0	0	0
脱水	0	0	0	0
成長障害	0	0	0	0
過小食	0	0	0	0
代謝性アルカローシス	0	0	0	0
低ナトリウム血症	0	0	0	0
鉄欠乏	0	0	0	0
筋骨格系および結合組織障害	8 (23.5)	4 (26.7)	5 (33.3)	1 (9.1)
関節拘縮	3 (8.8)	1 (6.7)	2 (13.3)	0
側弯症	4 (11.8)	1 (6.7)	1 (6.7)	1 (9.1)
背部痛	0	0	0	0
胸郭変形	0	1 (6.7)	0	0
手変形	0	0	0	0
頭位性斜頭症	1 (2.9)	0	0	0
泉門閉鎖遅延	0	0	0	0
関節硬直	0	0	1 (6.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 36 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
ビタミンA減少	0	0	0	0
白血球数増加	0	0	0	0
代謝および栄養障害	1 (12.5)	0	0	0
体重増加不良	1 (12.5)	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0
栄養補給不耐性	0	0	0	0
脱水	0	0	0	0
成長障害	0	0	0	0
過小食	0	0	0	0
代謝性アルカローシス	0	0	0	0
低ナトリウム血症	0	0	0	0
鉄欠乏	0	0	0	0
筋骨格系および結合組織障害	3 (37.5)	1 (25.0)	0	0
関節拘縮	1 (12.5)	0	0	0
側弯症	0	0	0	0
背部痛	0	0	0	0
胸郭変形	0	0	0	0
手変形	0	0	0	0
頭位性斜頭症	0	0	0	0
泉門閉鎖遅延	0	0	0	0
関節硬直	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 37 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
後側弯症	0	0	1 (1.7)	0
脊柱後弯症	0	1 (1.3)	1 (1.7)	1 (2.4)
脊柱前弯症	0	0	0	0
四肢痛	0	0	0	0
脊柱変形	0	0	0	0
滑膜炎	0	0	0	0
斜頚	0	0	1 (1.7)	0
神経系障害	8 (8.0)	6 (7.7)	1 (1.7)	1 (2.4)
脳損傷	1 (1.0)	0	0	0
脳脊髄液漏	1 (1.0)	0	0	0
間代	1 (1.0)	0	0	0
よだれ	1 (1.0)	0	0	1 (2.4)
低酸素性虚血性脳症	1 (1.0)	0	0	0
不随意性筋収縮	1 (1.0)	2 (2.6)	0	0
眼振	1 (1.0)	2 (2.6)	0	0
痙攣発作	1 (1.0)	1 (1.3)	0	0
失神	1 (1.0)	0	0	0
脳梗塞	0	1 (1.3)	0	0
頭痛	0	0	0	0
嗜眠	0	0	1 (1.7)	0
傾眠	0	1 (1.3)	0	0
精神障害	8 (8.0)	3 (3.8)	0	0
激越	2 (2.0)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 38 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
後側弯症	0	0	0	0
脊柱後弯症	0	0	1 (6.7)	0
脊柱前弯症	0	0	0	1 (9.1)
四肢痛	1 (2.9)	0	1 (6.7)	0
脊柱変形	0	1 (6.7)	0	0
滑膜炎	0	0	0	0
斜頚	1 (2.9)	0	0	0
神経系障害	1 (2.9)	1 (6.7)	0	0
脳損傷	0	0	0	0
脳脊髄液漏	0	0	0	0
間代	0	0	0	0
よだれ	0	0	0	0
低酸素性虚血性脳症	0	0	0	0
不随意性筋収縮	1 (2.9)	0	0	0
眼振	0	0	0	0
痙攣発作	0	0	0	0
失神	0	0	0	0
脳梗塞	0	0	0	0
頭痛	0	1 (6.7)	0	0
嗜眠	0	0	0	0
傾眠	0	0	0	0
精神障害	0	0	0	0
激越	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 39 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
後側弯症	1 (12.5)	0	0	0
脊柱後弯症	0	1 (25.0)	0	0
脊柱前弯症	0	0	0	0
四肢痛	1 (12.5)	0	0	0
脊柱変形	0	0	0	0
滑膜炎	1 (12.5)	0	0	0
斜頚	0	0	0	0
神経系障害	0	0	0	0
脳損傷	0	0	0	0
脳脊髄液漏	0	0	0	0
間代	0	0	0	0
よだれ	0	0	0	0
低酸素性虚血性脳症	0	0	0	0
不随意性筋収縮	0	0	0	0
眼振	0	0	0	0
痙攣発作	0	0	0	0
失神	0	0	0	0
脳梗塞	0	0	0	0
頭痛	0	0	0	0
嗜眠	0	0	0	0
傾眠	0	0	0	0
精神障害	0	0	0	0
激越	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 40 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
不安	2 (2.0)	3 (3.8)	0	0
易刺激性	2 (2.0)	0	0	0
息こらえ	1 (1.0)	0	0	0
気分動揺	1 (1.0)	0	0	0
落ち着きのなさ	1 (1.0)	0	0	0
睡眠障害	0	1 (1.3)	0	0
眼障害	3 (3.0)	2 (2.6)	1 (1.7)	0
乱視	1 (1.0)	0	0	0
眼乾燥	1 (1.0)	0	0	0
眼瞼下垂	1 (1.0)	0	0	0
霰粒腫	0	1 (1.3)	0	0
眼運動障害	0	1 (1.3)	0	0
近視	0	0	1 (1.7)	0
斜視	0	0	1 (1.7)	0
生殖系および乳房障害	3 (3.0)	0	0	0
後天性包茎	1 (1.0)	0	0	0
卵巣嚢胞	1 (1.0)	0	0	0
陰茎障害	1 (1.0)	0	0	0
血管障害	3 (3.0)	1 (1.3)	0	2 (4.8)
毛細血管脆弱	1 (1.0)	0	0	0
蒼白	1 (1.0)	0	0	0
ショック	1 (1.0)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 41 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
不安	0	0	0	0
易刺激性	0	0	0	0
息こらえ	0	0	0	0
気分動揺	0	0	0	0
落ち着きのなさ	0	0	0	0
睡眠障害	0	0	0	0
眼障害	0	0	0	0
乱視	0	0	0	0
眼乾燥	0	0	0	0
眼瞼下垂	0	0	0	0
霰粒腫	0	0	0	0
眼運動障害	0	0	0	0
近視	0	0	0	0
斜視	0	0	0	0
生殖系および乳房障害	0	0	0	0
後天性包茎	0	0	0	0
卵巣嚢胞	0	0	0	0
陰茎障害	0	0	0	0
血管障害	1 (2.9)	0	0	0
毛細血管脆弱	0	0	0	0
蒼白	0	0	0	0
ショック	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 42 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
不安	0	0	0	0
易刺激性	0	0	0	0
息こらえ	0	0	0	0
気分動揺	0	0	0	0
落ち着きのなさ	0	0	0	0
睡眠障害	0	0	0	0
眼障害	0	0	0	0
乱視	0	0	0	0
眼乾燥	0	0	0	0
眼瞼下垂	0	0	0	0
霰粒腫	0	0	0	0
眼運動障害	0	0	0	0
近視	0	0	0	0
斜視	0	0	0	0
生殖系および乳房障害	0	0	0	0
後天性包茎	0	0	0	0
卵巣嚢胞	0	0	0	0
陰茎障害	0	0	0	0
血管障害	0	0	0	0
毛細血管脆弱	0	0	0	0
蒼白	0	0	0	0
ショック	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 43 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
本態性高血圧症	0	0	0	0
高血圧	0	1 (1.3)	0	1 (2.4)
血管炎	0	0	0	1 (2.4)
血液およびリンパ系障害	2 (2.0)	1 (1.3)	3 (5.2)	0
貧血	1 (1.0)	0	2 (3.4)	0
好中球減少症	1 (1.0)	0	0	0
リンパ節症	0	0	1 (1.7)	0
血小板増加症	0	1 (1.3)	0	0
免疫系障害	2 (2.0)	2 (2.6)	2 (3.4)	2 (4.8)
薬物過敏症	1 (1.0)	0	1 (1.7)	0
過敏症	1 (1.0)	0	0	0
食物アレルギー	0	0	1 (1.7)	0
季節性アレルギー	0	2 (2.6)	0	2 (4.8)
腎および尿路障害	2 (2.0)	0	0	0
水腎症	1 (1.0)	0	0	0
尿閉	1 (1.0)	0	0	0
先天性、家族性および遺伝性障害	1 (1.0)	1 (1.3)	1 (1.7)	2 (4.8)
鳩胸	1 (1.0)	0	0	0
斜指症	0	0	0	0
発育性股関節形成不全	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 44 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
本態性高血圧症	1 (2.9)	0	0	0
高血圧	0	0	0	0
血管炎	0	0	0	0
血液およびリンパ系障害	0	0	0	0
貧血	0	0	0	0
好中球減少症	0	0	0	0
リンパ節症	0	0	0	0
血小板増加症	0	0	0	0
免疫系障害	0	2 (13.3)	2 (13.3)	0
薬物過敏症	0	2 (13.3)	0	0
過敏症	0	0	1 (6.7)	0
食物アレルギー	0	0	0	0
季節性アレルギー	0	0	1 (6.7)	0
腎および尿路障害	0	0	0	0
水腎症	0	0	0	0
尿閉	0	0	0	0
先天性、家族性および遺伝性障害	1 (2.9)	0	0	0
鳩胸	0	0	0	0
斜指症	1 (2.9)	0	0	0
発育性股関節形成不全	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 45 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
本態性高血圧症	0	0	0	0
高血圧	0	0	0	0
血管炎	0	0	0	0
血液およびリンパ系障害	0	0	0	0
貧血	0	0	0	0
好中球減少症	0	0	0	0
リンパ節症	0	0	0	0
血小板増加症	0	0	0	0
免疫系障害	0	0	0	0
薬物過敏症	0	0	0	0
過敏症	0	0	0	0
食物アレルギー	0	0	0	0
季節性アレルギー	0	0	0	0
腎および尿路障害	0	0	0	0
水腎症	0	0	0	0
尿閉	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0
鳩胸	0	0	0	0
斜指症	0	0	0	0
発育性股関節形成不全	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 46 of 48

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
貧血母斑	0	0	0	1 (2.4)
斜頭症	0	1 (1.3)	1 (1.7)	0
肝胆道系障害	1 (1.0)	0	0	0
肝腫大	1 (1.0)	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.0)	0	0	0
血管の良性新生物	1 (1.0)	0	0	0
アクロコルドン	0	0	0	0
外科および内科処置	1 (1.0)	0	0	0
機械的換気	1 (1.0)	0	0	0
耳および迷路障害	0	1 (1.3)	1 (1.7)	0
耳の障害	0	1 (1.3)	0	0
耳痛	0	0	1 (1.7)	0
耳垢分泌過多	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 47 of 48

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
貧血母斑	0	0	0	0
斜頭症	0	0	0	0
肝胆道系障害	0	0	0	0
肝腫大	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (2.9)	0	0	0
血管の良性新生物	0	0	0	0
アクロコルドン	1 (2.9)	0	0	0
外科および内科処置	0	0	0	0
機械的換気	0	0	0	0
耳および迷路障害	1 (2.9)	0	0	0
耳の障害	0	0	0	0
耳痛	0	0	0	0
耳垢分泌過多	1 (2.9)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 48 of 48

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
貧血母斑	0	0	0	0
斜頭症	0	0	0	0
肝胆道系障害	0	0	0	0
肝腫大	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0
血管の良性新生物	0	0	0	0
アクロコルドン	0	0	0	0
外科および内科処置	0	0	0	0
機械的換気	0	0	0	0
耳および迷路障害	0	0	0	0
耳の障害	0	0	0	0
耳痛	0	0	0	0
耳垢分泌過多	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 34　Presymptomatic Infants:Incidence of Adverse Events by 90-Day Intervals

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 1 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
Number of subjects dosed	17 (100.0)	13 (100.0)	10 (100.0)	5 (100.0)	1 (100.0)
Number of subjects with an event	12 (70.6)	9 (69.2)	7 (70.0)	4 (80.0)	1 (100.0)
感染症および寄生虫症	7 (41.2)	4 (30.8)	5 (50.0)	2 (40.0)	1 (100.0)
鼻咽頭炎	2 (11.8)	2 (15.4)	0	0	0
上気道感染	2 (11.8)	0	4 (40.0)	1 (20.0)	0
気管支炎	1 (5.9)	0	0	0	0
肺炎	1 (5.9)	0	0	0	0
ウイルス性肺炎	1 (5.9)	0	0	0	0
尿路感染	1 (5.9)	0	0	0	0
細気管支炎	0	0	1 (10.0)	0	0
ウイルス性胃腸炎	0	1 (7.7)	0	0	0
膿痂疹	0	1 (7.7)	0	0	0
インフルエンザ	0	2 (15.4)	0	0	0
中耳炎	0	0	1 (10.0)	1 (20.0)	0
レンサ球菌性咽頭炎	0	0	0	0	1 (100.0)
鼻炎	0	0	0	1 (20.0)	0
ライノウイルス感染	0	0	1 (10.0)	0	0
皮膚感染	0	0	0	1 (20.0)	0
胃腸障害	4 (23.5)	1 (7.7)	2 (20.0)	0	0
腹部膨満	2 (11.8)	0	0	0	0
放屁	2 (11.8)	0	0	0	0
胃食道逆流性疾患	2 (11.8)	0	0	0	0
腹部不快感	1 (5.9)	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 2 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
便秘	0	0	1 (10.0)	0	0
嚥下障害	0	1 (7.7)	0	0	0
生歯	0	0	1 (10.0)	0	0
皮膚および皮下組織障害	4 (23.5)	3 (23.1)	1 (10.0)	0	0
皮膚炎	2 (11.8)	0	0	0	0
おむつ皮膚炎	1 (5.9)	1 (7.7)	0	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	0
貨幣状湿疹	0	1 (7.7)	1 (10.0)	0	0
紅斑	0	1 (7.7)	0	0	0
一般・全身障害および投与部位の状態	3 (17.6)	1 (7.7)	2 (20.0)	1 (20.0)	0
発熱	2 (11.8)	1 (7.7)	2 (20.0)	1 (20.0)	0
注入部位内出血	1 (5.9)	0	0	0	0
適用部位紅斑	0	0	1 (10.0)	0	0
心臓障害	2 (11.8)	0	0	0	0
頻脈	2 (11.8)	0	0	0	0
傷害、中毒および処置合併症	2 (11.8)	1 (7.7)	0	1 (20.0)	0
処置後合併症	1 (5.9)	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	0
硬膜下血腫	1 (5.9)	0	0	0	0
転倒	0	1 (7.7)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 3 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
処置後腫脹	0	0	0	1 (20.0)	0
代謝および栄養障害	2 (11.8)	1 (7.7)	0	0	0
脱水	1 (5.9)	0	0	0	0
体重増加不良	1 (5.9)	1 (7.7)	0	0	0
成長障害	0	1 (7.7)	0	0	0
筋骨格系および結合組織障害	2 (11.8)	1 (7.7)	1 (10.0)	0	0
筋力低下	1 (5.9)	0	0	0	0
斜頚	1 (5.9)	0	0	0	0
体重支持困難	1 (5.9)	0	0	0	0
関節拘縮	0	0	1 (10.0)	0	0
頭位性斜頭症	0	1 (7.7)	0	0	0
神経系障害	2 (11.8)	0	0	0	0
反射亢進	1 (5.9)	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	0
呼吸器、胸郭および縦隔障害	2 (11.8)	1 (7.7)	1 (10.0)	1 (20.0)	0
鼻閉	1 (5.9)	1 (7.7)	0	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	0
呼吸窮迫	1 (5.9)	0	0	0	0
咳嗽	0	0	1 (10.0)	1 (20.0)	0
鼻漏	0	0	0	1 (20.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 4 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
上気道うっ血	0	0	0	1 (20.0)	0
血管障害	2 (11.8)	0	0	0	0
高血圧	1 (5.9)	0	0	0	0
蒼白	1 (5.9)	0	0	0	0
血液およびリンパ系障害	1 (5.9)	0	0	1 (20.0)	0
好中球減少症	1 (5.9)	0	0	0	0
好酸球増加症	0	0	0	1 (20.0)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.9)	0	0	0	0
脂漏性角化症	1 (5.9)	0	0	0	0
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	0
眼障害	0	1 (7.7)	0	0	0
後天性涙道狭窄	0	1 (7.7)	0	0	0
免疫系障害	0	0	1 (10.0)	0	0
季節性アレルギー	0	0	1 (10.0)	0	0
臨床検査	0	0	1 (10.0)	0	0
アラニンアミノトランスフェラーゼ増加	0	0	1 (10.0)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 5 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
アスパラギン酸アミノトランスフェラーゼ増加	0	0	1 (10.0)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 35　Incidence of Adverse Events in the 24 Hours Following Dosing in Infants Diagnosed With SMA

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 1 of 9

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	8 (47.1)	16 (39.0)	39 (48.8)	48 (48.0)	56 (47.9)
呼吸器、胸郭および縦隔障害	2 (11.8)	3 (7.3)	12 (15.0)	13 (13.0)	15 (12.8)
無気肺	0	0	2 (2.5)	2 (2.0)	2 (1.7)
低酸素症	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
呼吸窮迫	0	0	1 (1.3)	2 (2.0)	2 (1.7)
急性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.9)
息詰まり	0	0	1 (1.3)	1 (1.0)	1 (0.9)
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低換気	0	0	1 (1.3)	1 (1.0)	1 (0.9)
上気道分泌増加	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鼻閉	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
誤嚥性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.9)
上気道うっ血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気管支分泌物貯留	0	1 (2.4)	0	0	0
咳嗽	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 2 of 9

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
鼻出血	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	1 (0.9)
拘束性肺疾患	0	0	0	0	0
胃腸障害	2 (11.8)	3 (7.3)	9 (11.3)	11 (11.0)	13 (11.1)
嘔吐	0	0	3 (3.8)	5 (5.0)	5 (4.3)
便秘	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
嚥下障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
胃食道逆流性疾患	1 (5.9)	1 (2.4)	1 (1.3)	2 (2.0)	3 (2.6)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.9)
生歯	0	0	1 (1.3)	1 (1.0)	1 (0.9)
腹部膨満	1 (5.9)	0	0	0	1 (0.9)
腹痛	0	0	0	0	0
上腹部痛	0	0	0	0	0
腹部症状	0	0	0	0	0
下痢	0	1 (2.4)	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 3 of 9

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
口内炎	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 4 of 9

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
感染症および寄生虫症	1 (5.9)	0	6 (7.5)	8 (8.0)	9 (7.7)
鼻咽頭炎	0	0	3 (3.8)	3 (3.0)	3 (2.6)
膿痂疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
口腔カンジダ症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
中耳炎	0	0	0	1 (1.0)	1 (0.9)
鼻炎	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
ライノウイルス感染	0	0	0	1 (1.0)	1 (0.9)
上気道感染	0	0	0	1 (1.0)	1 (0.9)
胃腸炎	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (5.9)	6 (14.6)	5 (6.3)	7 (7.0)	8 (6.8)
発熱	1 (5.9)	3 (7.3)	4 (5.0)	5 (5.0)	6 (5.1)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血管穿刺部位内出血	0	0	0	1 (1.0)	1 (0.9)
適用部位発疹	0	1 (2.4)	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
悪寒	0	0	0	0	0
疲労	0	0	0	0	0
冷感	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 5 of 9

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
注射部位血腫	0	1 (2.4)	0	0	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
疼痛	0	2 (4.9)	0	0	0
穿刺部位疼痛	0	0	0	0	0
傷害、中毒および処置合併症	1 (5.9)	0	6 (7.5)	7 (7.0)	8 (6.8)
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.9)
節足動物咬傷	0	0	0	1 (1.0)	1 (0.9)
挫傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
大腿骨骨折	0	0	1 (1.3)	1 (1.0)	1 (0.9)
処置後腫脹	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置による疼痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.9)
腰椎穿刺後症候群	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
臨床検査	0	4 (9.8)	6 (7.5)	6 (6.0)	6 (5.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 6 of 9

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
酸素飽和度低下	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中カリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
体温上昇	0	0	1 (1.3)	1 (1.0)	1 (0.9)
Ｃ－反応性蛋白増加	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ブドウ球菌検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中重炭酸塩減少	0	0	0	0	0
呼吸数増加	0	1 (2.4)	0	0	0
尿検査異常	0	0	0	0	0
体重減少	0	1 (2.4)	0	0	0
皮膚および皮下組織障害	2 (11.8)	2 (4.9)	4 (5.0)	5 (5.0)	7 (6.0)
脱毛症	0	0	0	1 (1.0)	1 (0.9)
接触性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
斑状出血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
点状出血	0	0	0	1 (1.0)	1 (0.9)
発疹	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
皮膚炎	2 (11.8)	0	0	0	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 7 of 9

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
多汗症	0	1 (2.4)	0	0	0
汗疹	0	0	0	0	0
精神障害	0	0	4 (5.0)	4 (4.0)	4 (3.4)
易刺激性	0	0	2 (2.5)	2 (2.0)	2 (1.7)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.9)
落ち着きのなさ	0	0	1 (1.3)	1 (1.0)	1 (0.9)
激越	0	0	0	0	0
心臓障害	2 (11.8)	5 (12.2)	3 (3.8)	3 (3.0)	5 (4.3)
頻脈	2 (11.8)	3 (7.3)	3 (3.8)	3 (3.0)	5 (4.3)
徐脈	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
チアノーゼ	0	1 (2.4)	0	0	0
筋骨格系および結合組織障害	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
四肢痛	0	0	0	1 (1.0)	1 (0.9)
側弯症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
滑膜炎	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 8 of 9

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
関節痛	0	0	0	0	0
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	1 (2.4)	0	0	0
神経系障害	1 (5.9)	0	1 (1.3)	3 (3.0)	4 (3.4)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.9)
頭痛	0	0	0	1 (1.0)	1 (0.9)
眼振	0	0	1 (1.3)	1 (1.0)	1 (0.9)
反射亢進	1 (5.9)	0	0	0	1 (0.9)
振戦	0	0	0	0	0
代謝および栄養障害	0	0	1 (1.3)	2 (2.0)	2 (1.7)
過小食	0	0	0	1 (1.0)	1 (0.9)
体重増加不良	0	0	1 (1.3)	1 (1.0)	1 (0.9)
脱水	0	0	0	0	0
眼障害	0	0	0	1 (1.0)	1 (0.9)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 9 of 9

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
腎および尿路障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿失禁	0	0	0	0	0
血液およびリンパ系障害	1 (5.9)	0	0	0	1 (0.9)
好中球減少症	1 (5.9)	0	0	0	1 (0.9)
免疫系障害	0	1 (2.4)	0	0	0
薬物過敏症	0	0	0	0	0
過敏症	0	1 (2.4)	0	0	0
季節性アレルギー	0	0	0	0	0
血管障害	1 (5.9)	0	0	0	1 (0.9)
低血圧	0	0	0	0	0
蒼白	1 (5.9)	0	0	0	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 36　Incidence of Adverse Events in the 72 Hours Following Dosing in Infants Diagnosed With SMA

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 1 of 10

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	9 (52.9)	23 (56.1)	45 (56.3)	61 (61.0)	70 (59.8)
呼吸器、胸郭および縦隔障害	2 (11.8)	9 (22.0)	16 (20.0)	19 (19.0)	21 (17.9)
急性呼吸不全	0	0	3 (3.8)	4 (4.0)	4 (3.4)
無気肺	0	0	4 (5.0)	4 (4.0)	4 (3.4)
呼吸不全	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.6)
低酸素症	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
呼吸窮迫	1 (5.9)	0	1 (1.3)	2 (2.0)	3 (2.6)
無呼吸	0	1 (2.4)	0	1 (1.0)	1 (0.9)
息詰まり	0	0	1 (1.3)	1 (1.0)	1 (0.9)
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.9)
咳嗽	0	4 (9.8)	0	1 (1.0)	1 (0.9)
低換気	0	0	1 (1.3)	1 (1.0)	1 (0.9)
上気道分泌増加	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鼻閉	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
誤嚥性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
上気道うっ血	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 2 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
乳幼児突発性危急事態	0	1 (2.4)	0	0	0
気管支分泌物貯留	0	2 (4.9)	0	0	0
鼻出血	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	1 (0.9)
拘束性肺疾患	0	0	0	0	0
鼻漏	0	1 (2.4)	0	0	0
睡眠時無呼吸症候群	0	1 (2.4)	0	0	0
感染症および寄生虫症	1 (5.9)	4 (9.8)	14 (17.5)	18 (18.0)	19 (16.2)
鼻咽頭炎	0	0	3 (3.8)	4 (4.0)	4 (3.4)
上気道感染	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.6)
口腔カンジダ症	0	0	2 (2.5)	2 (2.0)	2 (1.7)
肺炎	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ウイルス性気管支炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
結膜炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性胃炎	0	0	0	1 (1.0)	1 (0.9)
膿痂疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
中耳炎	0	1 (2.4)	0	1 (1.0)	1 (0.9)
気道感染	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 3 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
ウイルス性気道感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
鼻炎	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
ライノウイルス感染	0	0	0	1 (1.0)	1 (0.9)
ウイルス性上気道感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
細菌性気管炎	0	1 (2.4)	0	0	0
胃腸炎	0	0	0	0	0
副鼻腔炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0
胃腸障害	2 (11.8)	5 (12.2)	13 (16.3)	17 (17.0)	19 (16.2)
嘔吐	0	0	4 (5.0)	6 (6.0)	6 (5.1)
便秘	0	1 (2.4)	5 (6.3)	5 (5.0)	5 (4.3)
胃食道逆流性疾患	1 (5.9)	2 (4.9)	2 (2.5)	3 (3.0)	4 (3.4)
嚥下障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
生歯	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
腹痛	0	0	0	1 (1.0)	1 (0.9)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.9)
腹部膨満	2 (11.8)	0	0	0	2 (1.7)
上腹部痛	0	0	0	0	0
腹部症状	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 4 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
下痢	0	1 (2.4)	0	0	0
食中毒	0	0	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0
口内炎	0	1 (2.4)	0	0	0
一般・全身障害および投与部位の状態	1 (5.9)	9 (22.0)	8 (10.0)	11 (11.0)	12 (10.3)
発熱	1 (5.9)	4 (9.8)	6 (7.5)	8 (8.0)	9 (7.7)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.9)
小結節	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血管穿刺部位内出血	0	1 (2.4)	0	1 (1.0)	1 (0.9)
適用部位発疹	0	1 (2.4)	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
悪寒	0	0	0	0	0
死亡	0	1 (2.4)	0	0	0
疲労	0	0	0	0	0
冷感	0	0	0	0	0
注射部位血腫	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 5 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
疼痛	0	2 (4.9)	0	0	0
穿刺部位疼痛	0	0	0	0	0
傷害、中毒および処置合併症	2 (11.8)	2 (4.9)	6 (7.5)	9 (9.0)	11 (9.4)
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.9)
節足動物咬傷	0	0	0	1 (1.0)	1 (0.9)
挫傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ダンピング症候群	0	0	0	1 (1.0)	1 (0.9)
大腿骨骨折	0	0	1 (1.3)	1 (1.0)	1 (0.9)
処置後腫脹	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置による疼痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.9)
サンバーン	0	0	0	1 (1.0)	1 (0.9)
栄養補給チューブ合併症	0	1 (2.4)	0	0	0
頭部損傷	0	1 (2.4)	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 6 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
臨床検査	0	4 (9.8)	7 (8.8)	8 (8.0)	8 (6.8)
酸素飽和度低下	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中カリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.9)
体温低下	0	0	1 (1.3)	1 (1.0)	1 (0.9)
体温上昇	0	0	1 (1.3)	1 (1.0)	1 (0.9)
Ｃ－反応性蛋白増加	0	0	1 (1.3)	1 (1.0)	1 (0.9)
心拍数増加	0	0	0	1 (1.0)	1 (0.9)
ブドウ球菌検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血中重炭酸塩減少	0	0	0	0	0
呼吸数増加	0	1 (2.4)	0	0	0
尿検査異常	0	0	0	0	0
体重減少	0	1 (2.4)	0	0	0
皮膚および皮下組織障害	3 (17.6)	2 (4.9)	5 (6.3)	7 (7.0)	10 (8.5)
脱毛症	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 7 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
接触性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
おむつ皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
斑状出血	0	0	1 (1.3)	1 (1.0)	1 (0.9)
湿疹	0	0	0	1 (1.0)	1 (0.9)
点状出血	0	0	0	1 (1.0)	1 (0.9)
発疹	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
皮膚炎	2 (11.8)	0	0	0	2 (1.7)
貨幣状湿疹	1 (5.9)	0	0	0	1 (0.9)
多汗症	0	1 (2.4)	0	0	0
汗疹	0	0	0	0	0
寝汗	0	0	0	0	0
心臓障害	2 (11.8)	5 (12.2)	4 (5.0)	4 (4.0)	6 (5.1)
頻脈	2 (11.8)	3 (7.3)	3 (3.8)	3 (3.0)	5 (4.3)
徐脈	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
チアノーゼ	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
代謝および栄養障害	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 8 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
乳児および小児期早期の哺育障害	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
栄養補給不耐性	0	0	1 (1.3)	1 (1.0)	1 (0.9)
過小食	0	0	0	1 (1.0)	1 (0.9)
体重増加不良	0	0	1 (1.3)	1 (1.0)	1 (0.9)
食欲減退	0	0	0	0	0
脱水	0	0	0	0	0
精神障害	0	0	4 (5.0)	4 (4.0)	4 (3.4)
易刺激性	0	0	2 (2.5)	2 (2.0)	2 (1.7)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.9)
落ち着きのなさ	0	0	1 (1.3)	1 (1.0)	1 (0.9)
激越	0	0	0	0	0
不眠症	0	0	0	0	0
筋骨格系および結合組織障害	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.9)
四肢痛	0	0	0	1 (1.0)	1 (0.9)
側弯症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 9 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
滑膜炎	0	0	0	1 (1.0)	1 (0.9)
関節痛	0	0	0	0	0
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	1 (2.4)	0	0	0
神経系障害	1 (5.9)	0	1 (1.3)	3 (3.0)	4 (3.4)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.9)
頭痛	0	0	0	1 (1.0)	1 (0.9)
眼振	0	0	1 (1.3)	1 (1.0)	1 (0.9)
失声症	0	0	0	0	0
反射亢進	1 (5.9)	0	0	0	1 (0.9)
錯感覚	0	0	0	0	0
振戦	0	0	0	0	0
眼障害	0	0	1 (1.3)	2 (2.0)	2 (1.7)
眼乾燥	0	0	1 (1.3)	1 (1.0)	1 (0.9)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 10 of 10

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
腎および尿路障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.9)
尿失禁	0	0	0	0	0
血液およびリンパ系障害	1 (5.9)	0	0	0	1 (0.9)
好中球減少症	1 (5.9)	0	0	0	1 (0.9)
免疫系障害	0	1 (2.4)	0	0	0
薬物過敏症	0	0	0	0	0
過敏症	0	1 (2.4)	0	0	0
季節性アレルギー	0	0	0	0	0
血管障害	1 (5.9)	0	0	0	1 (0.9)
低血圧	0	0	0	0	0
蒼白	1 (5.9)	0	0	0	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 37　Incidence of Adverse Events in the 24 Hours Following Dosing in Subjects With SMA

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 1 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	8 (47.1)	48 (48.0)	56 (47.9)	41 (73.2)	97 (56.1)
筋骨格系および結合組織障害	0	3 (3.0)	3 (2.6)	22 (39.3)	25 (14.5)
背部痛	0	1 (1.0)	1 (0.9)	16 (28.6)	17 (9.8)
側弯症	0	1 (1.0)	1 (0.9)	2 (3.6)	3 (1.7)
筋肉痛	0	0	0	2 (3.6)	2 (1.2)
関節痛	0	0	0	1 (1.8)	1 (0.6)
頚部痛	0	0	0	1 (1.8)	1 (0.6)
四肢痛	0	1 (1.0)	1 (0.9)	0	1 (0.6)
骨盤変形	0	0	0	1 (1.8)	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
腱障害	0	0	0	0	0
傷害、中毒および処置合併症	1 (5.9)	7 (7.0)	8 (6.8)	16 (28.6)	24 (13.9)
腰椎穿刺後症候群	0	0	0	12 (21.4)	12 (6.9)
術後激越	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 2 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
処置後腫脹	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
処置による悪心	0	0	0	2 (3.6)	2 (1.2)
処置による疼痛	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
節足動物咬傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
挫傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
大腿骨骨折	0	1 (1.0)	1 (0.9)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 3 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胃腸障害	2 (11.8)	11 (11.0)	13 (11.1)	10 (17.9)	23 (13.3)
嘔吐	0	5 (5.0)	5 (4.3)	4 (7.1)	9 (5.2)
便秘	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
胃食道逆流性疾患	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
アフタ性潰瘍	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
嚥下障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
悪心	0	0	0	2 (3.6)	2 (1.2)
腹部膨満	1 (5.9)	0	1 (0.9)	0	1 (0.6)
腹痛	0	0	0	1 (1.8)	1 (0.6)
上腹部痛	0	0	0	1 (1.8)	1 (0.6)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
口唇痛	0	0	0	1 (1.8)	1 (0.6)
生歯	0	1 (1.0)	1 (0.9)	0	1 (0.6)
下痢	0	0	0	0	0
口内炎	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (5.9)	7 (7.0)	8 (6.8)	12 (21.4)	20 (11.6)
発熱	1 (5.9)	5 (5.0)	6 (5.1)	3 (5.4)	9 (5.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 4 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
穿刺部位疼痛	0	0	0	7 (12.5)	7 (4.0)
血管穿刺部位内出血	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
泣き	0	1 (1.0)	1 (0.9)	0	1 (0.6)
疲労	0	0	0	1 (1.8)	1 (0.6)
冷感	0	0	0	1 (1.8)	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
適用部位発疹	0	0	0	0	0
注射部位血腫	0	0	0	0	0
疼痛	0	0	0	0	0
呼吸器、胸郭および縦隔障害	2 (11.8)	13 (13.0)	15 (12.8)	5 (8.9)	20 (11.6)
口腔咽頭痛	0	0	0	3 (5.4)	3 (1.7)
無気肺	0	2 (2.0)	2 (1.7)	0	2 (1.2)
低酸素症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
鼻閉	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
呼吸窮迫	0	2 (2.0)	2 (1.7)	0	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 5 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
急性呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
息詰まり	0	1 (1.0)	1 (0.9)	0	1 (0.6)
慢性呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
鼻出血	0	0	0	1 (1.8)	1 (0.6)
低換気	0	1 (1.0)	1 (0.9)	0	1 (0.6)
上気道分泌増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
誤嚥性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸性アシドーシス	1 (5.9)	0	1 (0.9)	0	1 (0.6)
呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
拘束性肺疾患	0	0	0	1 (1.8)	1 (0.6)
上気道うっ血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管支分泌物貯留	0	0	0	0	0
咳嗽	0	0	0	0	0
神経系障害	1 (5.9)	3 (3.0)	4 (3.4)	13 (23.2)	17 (9.8)
頭痛	0	1 (1.0)	1 (0.9)	12 (21.4)	13 (7.5)
脳脊髄液漏	0	1 (1.0)	1 (0.9)	0	1 (0.6)
反射亢進	1 (5.9)	0	1 (0.9)	0	1 (0.6)
眼振	0	1 (1.0)	1 (0.9)	0	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 6 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
感染症および寄生虫症	1 (5.9)	8 (8.0)	9 (7.7)	1 (1.8)	10 (5.8)
鼻咽頭炎	0	3 (3.0)	3 (2.6)	0	3 (1.7)
鼻炎	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
胃腸炎	0	0	0	1 (1.8)	1 (0.6)
膿痂疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
口腔カンジダ症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
中耳炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ライノウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
上気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
臨床検査	0	6 (6.0)	6 (5.1)	3 (5.4)	9 (5.2)
体温上昇	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
酸素飽和度低下	0	2 (2.0)	2 (1.7)	0	2 (1.2)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)
血中クロール減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中カリウム減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
Ｃ－反応性蛋白増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 7 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
呼吸数増加	0	0	0	0	0
体重減少	0	0	0	0	0
皮膚および皮下組織障害	2 (11.8)	5 (5.0)	7 (6.0)	1 (1.8)	8 (4.6)
皮膚炎	2 (11.8)	0	2 (1.7)	0	2 (1.2)
脱毛症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
接触性皮膚炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
斑状出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
汗疹	0	0	0	1 (1.8)	1 (0.6)
点状出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
発疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
多汗症	0	0	0	0	0
心臓障害	2 (11.8)	3 (3.0)	5 (4.3)	1 (1.8)	6 (3.5)
頻脈	2 (11.8)	3 (3.0)	5 (4.3)	1 (1.8)	6 (3.5)
徐脈	0	1 (1.0)	1 (0.9)	0	1 (0.6)
チアノーゼ	0	0	0	0	0
精神障害	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 8 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
易刺激性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
激越	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.9)	0	1 (0.6)
落ち着きのなさ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
免疫系障害	0	0	0	3 (5.4)	3 (1.7)
薬物過敏症	0	0	0	1 (1.8)	1 (0.6)
過敏症	0	0	0	1 (1.8)	1 (0.6)
季節性アレルギー	0	0	0	1 (1.8)	1 (0.6)
代謝および栄養障害	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
脱水	0	0	0	1 (1.8)	1 (0.6)
過小食	0	1 (1.0)	1 (0.9)	0	1 (0.6)
体重増加不良	0	1 (1.0)	1 (0.9)	0	1 (0.6)
腎および尿路障害	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血管障害	1 (5.9)	0	1 (0.9)	1 (1.8)	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 9 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
低血圧	0	0	0	1 (1.8)	1 (0.6)
蒼白	1 (5.9)	0	1 (0.9)	0	1 (0.6)
血液およびリンパ系障害	1 (5.9)	0	1 (0.9)	0	1 (0.6)
好中球減少症	1 (5.9)	0	1 (0.9)	0	1 (0.6)
眼障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 38　Incidence of Adverse Events in the 72 Hours Following Dosing in Subjects With SMA

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 1 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	9 (52.9)	61 (61.0)	70 (59.8)	46 (82.1)	116 (67.1)
傷害、中毒および処置合併症	2 (11.8)	9 (9.0)	11 (9.4)	23 (41.1)	34 (19.7)
腰椎穿刺後症候群	0	0	0	19 (33.9)	19 (11.0)
処置による疼痛	0	1 (1.0)	1 (0.9)	2 (3.6)	3 (1.7)
術後激越	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
処置後腫脹	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
処置による悪心	0	0	0	2 (3.6)	2 (1.2)
節足動物咬傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
挫傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ダンピング症候群	0	1 (1.0)	1 (0.9)	0	1 (0.6)
大腿骨骨折	0	1 (1.0)	1 (0.9)	0	1 (0.6)
処置後不快感	1 (5.9)	0	1 (0.9)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.9)	0	1 (0.6)
サンバーン	0	1 (1.0)	1 (0.9)	0	1 (0.6)
栄養補給チューブ合併症	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 2 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
頭部損傷	0	0	0	0	0
胃腸障害	2 (11.8)	17 (17.0)	19 (16.2)	14 (25.0)	33 (19.1)
嘔吐	0	6 (6.0)	6 (5.1)	9 (16.1)	15 (8.7)
便秘	0	5 (5.0)	5 (4.3)	2 (3.6)	7 (4.0)
悪心	0	0	0	6 (10.7)	6 (3.5)
胃食道逆流性疾患	1 (5.9)	3 (3.0)	4 (3.4)	0	4 (2.3)
腹部膨満	2 (11.8)	0	2 (1.7)	0	2 (1.2)
腹痛	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
アフタ性潰瘍	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
嚥下障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
生歯	0	2 (2.0)	2 (1.7)	0	2 (1.2)
上腹部痛	0	0	0	1 (1.8)	1 (0.6)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
食中毒	0	0	0	1 (1.8)	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
口唇痛	0	0	0	1 (1.8)	1 (0.6)
下痢	0	0	0	0	0
口内炎	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 3 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
一般・全身障害および投与部位の状態	1 (5.9)	11 (11.0)	12 (10.3)	15 (26.8)	27 (15.6)
発熱	1 (5.9)	8 (8.0)	9 (7.7)	3 (5.4)	12 (6.9)
穿刺部位疼痛	0	0	0	9 (16.1)	9 (5.2)
疲労	0	0	0	2 (3.6)	2 (1.2)
血管穿刺部位内出血	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
泣き	0	1 (1.0)	1 (0.9)	0	1 (0.6)
冷感	0	0	0	1 (1.8)	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
小結節	0	1 (1.0)	1 (0.9)	0	1 (0.6)
疼痛	0	0	0	1 (1.8)	1 (0.6)
適用部位発疹	0	0	0	0	0
死亡	0	0	0	0	0
注射部位血腫	0	0	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 4 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
筋骨格系および結合組織障害	0	3 (3.0)	3 (2.6)	24 (42.9)	27 (15.6)
背部痛	0	1 (1.0)	1 (0.9)	19 (33.9)	20 (11.6)
側弯症	0	1 (1.0)	1 (0.9)	2 (3.6)	3 (1.7)
筋肉痛	0	0	0	2 (3.6)	2 (1.2)
頚部痛	0	0	0	2 (3.6)	2 (1.2)
関節痛	0	0	0	1 (1.8)	1 (0.6)
四肢痛	0	1 (1.0)	1 (0.9)	0	1 (0.6)
骨盤変形	0	0	0	1 (1.8)	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
腱障害	0	0	0	0	0
呼吸器、胸郭および縦隔障害	2 (11.8)	19 (19.0)	21 (17.9)	5 (8.9)	26 (15.0)
急性呼吸不全	0	4 (4.0)	4 (3.4)	0	4 (2.3)
無気肺	0	4 (4.0)	4 (3.4)	0	4 (2.3)
口腔咽頭痛	0	0	0	3 (5.4)	3 (1.7)
呼吸窮迫	1 (5.9)	2 (2.0)	3 (2.6)	0	3 (1.7)
呼吸不全	0	3 (3.0)	3 (2.6)	0	3 (1.7)
咳嗽	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 5 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
低酸素症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
鼻閉	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
無呼吸	0	1 (1.0)	1 (0.9)	0	1 (0.6)
息詰まり	0	1 (1.0)	1 (0.9)	0	1 (0.6)
慢性呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
鼻出血	0	0	0	1 (1.8)	1 (0.6)
低換気	0	1 (1.0)	1 (0.9)	0	1 (0.6)
上気道分泌増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
誤嚥性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸性アシドーシス	1 (5.9)	0	1 (0.9)	0	1 (0.6)
拘束性肺疾患	0	0	0	1 (1.8)	1 (0.6)
上気道うっ血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
乳幼児突発性危急事態	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
鼻漏	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
感染症および寄生虫症	1 (5.9)	18 (18.0)	19 (16.2)	4 (7.1)	23 (13.3)
鼻咽頭炎	0	4 (4.0)	4 (3.4)	0	4 (2.3)
上気道感染	0	3 (3.0)	3 (2.6)	1 (1.8)	4 (2.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 6 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
口腔カンジダ症	0	2 (2.0)	2 (1.7)	0	2 (1.2)
肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
鼻炎	1 (5.9)	1 (1.0)	2 (1.7)	0	2 (1.2)
ウイルス性気管支炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
結膜炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性胃炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胃腸炎	0	0	0	1 (1.8)	1 (0.6)
膿痂疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
中耳炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ライノウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
副鼻腔炎	0	0	0	1 (1.8)	1 (0.6)
ウイルス感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性上気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
細菌性気管炎	0	0	0	0	0
神経系障害	1 (5.9)	3 (3.0)	4 (3.4)	18 (32.1)	22 (12.7)
頭痛	0	1 (1.0)	1 (0.9)	17 (30.4)	18 (10.4)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 7 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
失声症	0	0	0	1 (1.8)	1 (0.6)
脳脊髄液漏	0	1 (1.0)	1 (0.9)	0	1 (0.6)
反射亢進	1 (5.9)	0	1 (0.9)	0	1 (0.6)
眼振	0	1 (1.0)	1 (0.9)	0	1 (0.6)
錯感覚	0	0	0	1 (1.8)	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)
皮膚および皮下組織障害	3 (17.6)	7 (7.0)	10 (8.5)	3 (5.4)	13 (7.5)
皮膚炎	2 (11.8)	0	2 (1.7)	0	2 (1.2)
接触性皮膚炎	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
脱毛症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
おむつ皮膚炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
斑状出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
湿疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
貨幣状湿疹	1 (5.9)	0	1 (0.9)	0	1 (0.6)
汗疹	0	0	0	1 (1.8)	1 (0.6)
寝汗	0	0	0	1 (1.8)	1 (0.6)
点状出血	0	1 (1.0)	1 (0.9)	0	1 (0.6)
発疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 8 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
多汗症	0	0	0	0	0
臨床検査	0	8 (8.0)	8 (6.8)	4 (7.1)	12 (6.9)
体温上昇	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
心拍数増加	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
酸素飽和度低下	0	2 (2.0)	2 (1.7)	0	2 (1.2)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)
血中クロール減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中カリウム減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.9)	0	1 (0.6)
体温低下	0	1 (1.0)	1 (0.9)	0	1 (0.6)
Ｃ－反応性蛋白増加	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌検査陽性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)
呼吸数増加	0	0	0	0	0
体重減少	0	0	0	0	0
心臓障害	2 (11.8)	4 (4.0)	6 (5.1)	1 (1.8)	7 (4.0)
頻脈	2 (11.8)	3 (3.0)	5 (4.3)	1 (1.8)	6 (3.5)
徐脈	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 9 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
チアノーゼ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
代謝および栄養障害	0	4 (4.0)	4 (3.4)	2 (3.6)	6 (3.5)
食欲減退	0	0	0	1 (1.8)	1 (0.6)
脱水	0	0	0	1 (1.8)	1 (0.6)
乳児および小児期早期の哺育障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
栄養補給不耐性	0	1 (1.0)	1 (0.9)	0	1 (0.6)
過小食	0	1 (1.0)	1 (0.9)	0	1 (0.6)
体重増加不良	0	1 (1.0)	1 (0.9)	0	1 (0.6)
精神障害	0	4 (4.0)	4 (3.4)	2 (3.6)	6 (3.5)
易刺激性	0	2 (2.0)	2 (1.7)	0	2 (1.2)
激越	0	0	0	1 (1.8)	1 (0.6)
不眠症	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.9)	0	1 (0.6)
落ち着きのなさ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
免疫系障害	0	0	0	3 (5.4)	3 (1.7)
薬物過敏症	0	0	0	1 (1.8)	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 10 of 10

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
過敏症	0	0	0	1 (1.8)	1 (0.6)
季節性アレルギー	0	0	0	1 (1.8)	1 (0.6)
眼障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
眼乾燥	0	1 (1.0)	1 (0.9)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.9)	0	1 (0.6)
腎および尿路障害	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血管障害	1 (5.9)	0	1 (0.9)	1 (1.8)	2 (1.2)
低血圧	0	0	0	1 (1.8)	1 (0.6)
蒼白	1 (5.9)	0	1 (0.9)	0	1 (0.6)
血液およびリンパ系障害	1 (5.9)	0	1 (0.9)	0	1 (0.6)
好中球減少症	1 (5.9)	0	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 39　Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B:Incidence of Adverse Events by Severity - Treatment Group:ISIS 396443

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 1 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					80 (100.0)
Number of subjects with an event	10 (12.5)	18 (22.5)	44 (55.0)	0	72 (90.0)
感染症および寄生虫症	9 (11.3)	23 (28.8)	25 (31.3)	0	57 (71.3)
上気道感染	8 (10.0)	7 (8.8)	5 (6.3)	0	20 (25.0)
肺炎	2 (2.5)	8 (10.0)	7 (8.8)	0	17 (21.3)
鼻咽頭炎	10 (12.5)	4 (5.0)	0	0	14 (17.5)
ウイルス性上気道感染	1 (1.3)	8 (10.0)	1 (1.3)	0	10 (12.5)
細気管支炎	4 (5.0)	0	4 (5.0)	0	8 (10.0)
ライノウイルス感染	1 (1.3)	4 (5.0)	3 (3.8)	0	8 (10.0)
気道感染	2 (2.5)	2 (2.5)	3 (3.8)	0	7 (8.8)
ウイルス感染	2 (2.5)	5 (6.3)	0	0	7 (8.8)
口腔カンジダ症	5 (6.3)	1 (1.3)	0	0	6 (7.5)
ウイルス性肺炎	0	5 (6.3)	1 (1.3)	0	6 (7.5)
気管支炎	3 (3.8)	1 (1.3)	1 (1.3)	0	5 (6.3)
結膜炎	4 (5.0)	1 (1.3)	0	0	5 (6.3)
耳感染	2 (2.5)	2 (2.5)	0	0	4 (5.0)
ウイルス性気道感染	3 (3.8)	1 (1.3)	0	0	4 (5.0)
ウイルス性気管支炎	1 (1.3)	1 (1.3)	1 (1.3)	0	3 (3.8)
下気道感染	0	1 (1.3)	2 (2.5)	0	3 (3.8)
細菌性肺炎	0	1 (1.3)	2 (2.5)	0	3 (3.8)
ＲＳウイルス細気管支炎	0	1 (1.3)	2 (2.5)	0	3 (3.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 2 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
尿路感染	1 (1.3)	2 (2.5)	0	0	3 (3.8)
アデノウイルス感染	0	2 (2.5)	0	0	2 (2.5)
細菌性結膜炎	1 (1.3)	1 (1.3)	0	0	2 (2.5)
インフルエンザ	0	2 (2.5)	0	0	2 (2.5)
ウイルス性下気道感染	0	2 (2.5)	0	0	2 (2.5)
皮膚カンジダ	1 (1.3)	1 (1.3)	0	0	2 (2.5)
ストーマ部膿瘍	1 (1.3)	1 (1.3)	0	0	2 (2.5)
細菌感染	1 (1.3)	0	0	0	1 (1.3)
細菌性気管炎	0	0	1 (1.3)	0	1 (1.3)
カンジダ性おむつ皮疹	1 (1.3)	0	0	0	1 (1.3)
蜂巣炎	1 (1.3)	0	0	0	1 (1.3)
感染性湿疹	1 (1.3)	0	0	0	1 (1.3)
眼感染	1 (1.3)	0	0	0	1 (1.3)
真菌感染	0	1 (1.3)	0	0	1 (1.3)
皮膚真菌感染	1 (1.3)	0	0	0	1 (1.3)
胃腸炎	0	1 (1.3)	0	0	1 (1.3)
ロタウイルス胃腸炎	0	1 (1.3)	0	0	1 (1.3)
ウイルス性胃腸炎	0	1 (1.3)	0	0	1 (1.3)
手足口病	1 (1.3)	0	0	0	1 (1.3)
膿痂疹	1 (1.3)	0	0	0	1 (1.3)
限局性感染	1 (1.3)	0	0	0	1 (1.3)
肺感染	0	0	1 (1.3)	0	1 (1.3)
院内感染	0	0	1 (1.3)	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 3 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
口腔ヘルペス	1 (1.3)	0	0	0	1 (1.3)
中耳炎	1 (1.3)	0	0	0	1 (1.3)
急性中耳炎	0	1 (1.3)	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	1 (1.3)	0	1 (1.3)
モラクセラ菌性肺炎	0	0	1 (1.3)	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	1 (1.3)	0	0	1 (1.3)
ＲＳウイルス肺炎	0	0	1 (1.3)	0	1 (1.3)
シュードモナス感染	0	1 (1.3)	0	0	1 (1.3)
鼻炎	1 (1.3)	0	0	0	1 (1.3)
ばら疹	1 (1.3)	0	0	0	1 (1.3)
敗血症	0	0	1 (1.3)	0	1 (1.3)
ブドウ球菌性敗血症	0	0	1 (1.3)	0	1 (1.3)
ブドウ球菌皮膚感染	0	1 (1.3)	0	0	1 (1.3)
呼吸器、胸郭および縦隔障害	7 (8.8)	11 (13.8)	37 (46.3)	0	55 (68.8)
呼吸窮迫	1 (1.3)	7 (8.8)	11 (13.8)	0	19 (23.8)
呼吸不全	1 (1.3)	5 (6.3)	11 (13.8)	0	17 (21.3)
無気肺	2 (2.5)	7 (8.8)	6 (7.5)	0	15 (18.8)
急性呼吸不全	0	0	11 (13.8)	0	11 (13.8)
鼻閉	8 (10.0)	0	0	0	8 (10.0)
呼吸困難	4 (5.0)	1 (1.3)	2 (2.5)	0	7 (8.8)
誤嚥性肺炎	0	4 (5.0)	3 (3.8)	0	7 (8.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 4 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
咳嗽	3 (3.8)	3 (3.8)	0	0	6 (7.5)
低酸素症	1 (1.3)	2 (2.5)	3 (3.8)	0	6 (7.5)
上気道うっ血	5 (6.3)	0	0	0	5 (6.3)
無呼吸	0	3 (3.8)	1 (1.3)	0	4 (5.0)
誤嚥	0	2 (2.5)	2 (2.5)	0	4 (5.0)
鼻漏	3 (3.8)	1 (1.3)	0	0	4 (5.0)
気管支分泌物貯留	0	2 (2.5)	1 (1.3)	0	3 (3.8)
呼吸停止	0	1 (1.3)	2 (2.5)	0	3 (3.8)
副鼻腔うっ血	3 (3.8)	0	0	0	3 (3.8)
慢性呼吸不全	0	1 (1.3)	1 (1.3)	0	2 (2.5)
低換気	0	1 (1.3)	1 (1.3)	0	2 (2.5)
上気道分泌増加	1 (1.3)	1 (1.3)	0	0	2 (2.5)
呼吸障害	0	1 (1.3)	1 (1.3)	0	2 (2.5)
急性呼吸窮迫症候群	0	1 (1.3)	0	0	1 (1.3)
気管支閉塞	1 (1.3)	0	0	0	1 (1.3)
息詰まり	1 (1.3)	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	1 (1.3)	0	1 (1.3)
減呼吸	0	1 (1.3)	0	0	1 (1.3)
気管支分泌増加	0	1 (1.3)	0	0	1 (1.3)
肺障害	0	0	1 (1.3)	0	1 (1.3)
閉塞性気道障害	0	0	1 (1.3)	0	1 (1.3)
胸水	0	1 (1.3)	0	0	1 (1.3)
気胸	0	0	1 (1.3)	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 5 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
呼吸性アルカローシス	0	1 (1.3)	0	0	1 (1.3)
気道うっ血	0	1 (1.3)	0	0	1 (1.3)
アレルギー性鼻炎	1 (1.3)	0	0	0	1 (1.3)
変色痰	0	1 (1.3)	0	0	1 (1.3)
呼吸補助筋の動員	1 (1.3)	0	0	0	1 (1.3)
喘鳴	1 (1.3)	0	0	0	1 (1.3)
胃腸障害	31 (38.8)	10 (12.5)	5 (6.3)	0	46 (57.5)
便秘	22 (27.5)	2 (2.5)	0	0	24 (30.0)
嘔吐	9 (11.3)	3 (3.8)	0	0	12 (15.0)
生歯	7 (8.8)	4 (5.0)	0	0	11 (13.8)
嚥下障害	3 (3.8)	2 (2.5)	4 (5.0)	0	9 (11.3)
胃食道逆流性疾患	7 (8.8)	2 (2.5)	0	0	9 (11.3)
下痢	7 (8.8)	1 (1.3)	0	0	8 (10.0)
放屁	3 (3.8)	0	0	0	3 (3.8)
胃炎	2 (2.5)	0	1 (1.3)	0	3 (3.8)
流涎過多	1 (1.3)	2 (2.5)	0	0	3 (3.8)
血便排泄	2 (2.5)	0	0	0	2 (2.5)
腹部不快感	1 (1.3)	0	0	0	1 (1.3)
腹部膨満	1 (1.3)	0	0	0	1 (1.3)
アフタ性潰瘍	1 (1.3)	0	0	0	1 (1.3)
胃出血	0	1 (1.3)	0	0	1 (1.3)
乳児仙痛	1 (1.3)	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 6 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
乳児吐血	1 (1.3)	0	0	0	1 (1.3)
上部消化管出血	1 (1.3)	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	22 (27.5)	19 (23.8)	3 (3.8)	0	44 (55.0)
発熱	21 (26.3)	16 (20.0)	2 (2.5)	0	39 (48.8)
カテーテル留置部位炎症	1 (1.3)	0	0	0	1 (1.3)
泣き	1 (1.3)	0	0	0	1 (1.3)
死亡	0	0	1 (1.3)	0	1 (1.3)
薬物不耐性	1 (1.3)	0	0	0	1 (1.3)
低体温	0	1 (1.3)	0	0	1 (1.3)
ワクチン接種後の易刺激性	1 (1.3)	0	0	0	1 (1.3)
倦怠感	0	1 (1.3)	0	0	1 (1.3)
小結節	1 (1.3)	0	0	0	1 (1.3)
疼痛	0	1 (1.3)	0	0	1 (1.3)
腫脹	1 (1.3)	0	0	0	1 (1.3)
皮膚および皮下組織障害	18 (22.5)	2 (2.5)	1 (1.3)	0	21 (26.3)
発疹	7 (8.8)	1 (1.3)	0	0	8 (10.0)
おむつ皮膚炎	4 (5.0)	1 (1.3)	1 (1.3)	0	6 (7.5)
接触性皮膚炎	2 (2.5)	0	0	0	2 (2.5)
斑状出血	2 (2.5)	0	0	0	2 (2.5)
過角化	2 (2.5)	0	0	0	2 (2.5)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 7 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
汗疹	2 (2.5)	0	0	0	2 (2.5)
皮膚炎	1 (1.3)	0	0	0	1 (1.3)
アレルギー性皮膚炎	1 (1.3)	0	0	0	1 (1.3)
湿疹	1 (1.3)	0	0	0	1 (1.3)
紅斑	1 (1.3)	0	0	0	1 (1.3)
環状肉芽腫	1 (1.3)	0	0	0	1 (1.3)
丘疹性皮疹	1 (1.3)	0	0	0	1 (1.3)
皮膚浮腫	1 (1.3)	0	0	0	1 (1.3)
蕁麻疹	1 (1.3)	0	0	0	1 (1.3)
臨床検査	8 (10.0)	8 (10.0)	1 (1.3)	0	17 (21.3)
酸素飽和度低下	1 (1.3)	6 (7.5)	1 (1.3)	0	8 (10.0)
体重減少	2 (2.5)	1 (1.3)	0	0	3 (3.8)
血中カリウム減少	1 (1.3)	1 (1.3)	0	0	2 (2.5)
体温上昇	2 (2.5)	0	0	0	2 (2.5)
Ｃ－反応性蛋白増加	0	2 (2.5)	0	0	2 (2.5)
アラニンアミノトランスフェラーゼ増加	0	1 (1.3)	0	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.3)	0	0	0	1 (1.3)
血中クロール減少	0	1 (1.3)	0	0	1 (1.3)
血中鉄減少	1 (1.3)	0	0	0	1 (1.3)
血中ナトリウム減少	0	1 (1.3)	0	0	1 (1.3)
体温低下	1 (1.3)	0	0	0	1 (1.3)
心電図ＳＴ－Ｔ部分異常	0	1 (1.3)	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 8 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
心拍数増加	1 (1.3)	0	0	0	1 (1.3)
心拍数不整	1 (1.3)	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	1 (1.3)	0	0	0	1 (1.3)
炎症マーカー上昇	1 (1.3)	0	0	0	1 (1.3)
A型インフルエンザウイルス検査陽性	1 (1.3)	0	0	0	1 (1.3)
肝機能検査異常	0	1 (1.3)	0	0	1 (1.3)
医学的観察	1 (1.3)	0	0	0	1 (1.3)
モラクセラ検査陽性	1 (1.3)	0	0	0	1 (1.3)
好中球数増加	0	1 (1.3)	0	0	1 (1.3)
シュードモナス検査陽性	1 (1.3)	0	0	0	1 (1.3)
ブドウ球菌検査陽性	1 (1.3)	0	0	0	1 (1.3)
尿量減少	1 (1.3)	0	0	0	1 (1.3)
ビタミンA減少	1 (1.3)	0	0	0	1 (1.3)
心臓障害	3 (3.8)	6 (7.5)	7 (8.8)	0	16 (20.0)
頻脈	2 (2.5)	4 (5.0)	0	0	6 (7.5)
心肺停止	0	0	5 (6.3)	0	5 (6.3)
徐脈	2 (2.5)	2 (2.5)	0	0	4 (5.0)
心停止	0	0	2 (2.5)	0	2 (2.5)
チアノーゼ	1 (1.3)	1 (1.3)	0	0	2 (2.5)
左室肥大	1 (1.3)	0	0	0	1 (1.3)
上室性頻脈	1 (1.3)	0	0	0	1 (1.3)
心室性頻脈	0	1 (1.3)	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 9 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
傷害、中毒および処置合併症	10 (12.5)	4 (5.0)	1 (1.3)	0	15 (18.8)
大腿骨骨折	1 (1.3)	1 (1.3)	0	0	2 (2.5)
処置による疼痛	1 (1.3)	1 (1.3)	0	0	2 (2.5)
ストーマ部紅斑	2 (2.5)	0	0	0	2 (2.5)
術後激越	1 (1.3)	0	0	0	1 (1.3)
挫傷	1 (1.3)	0	0	0	1 (1.3)
麻酔からの覚醒遅延	0	1 (1.3)	0	0	1 (1.3)
擦過傷	0	1 (1.3)	0	0	1 (1.3)
伝染病曝露	1 (1.3)	0	0	0	1 (1.3)
処置後腫脹	1 (1.3)	0	0	0	1 (1.3)
処置合併症	1 (1.3)	0	0	0	1 (1.3)
処置部位反応	1 (1.3)	0	0	0	1 (1.3)
ストーマ合併症	1 (1.3)	0	0	0	1 (1.3)
ワクチン接種合併症	1 (1.3)	0	0	0	1 (1.3)
創離開	0	0	1 (1.3)	0	1 (1.3)
代謝および栄養障害	5 (6.3)	7 (8.8)	1 (1.3)	0	13 (16.3)
体重増加不良	2 (2.5)	2 (2.5)	1 (1.3)	0	5 (6.3)
乳児および小児期早期の哺育障害	0	3 (3.8)	0	0	3 (3.8)
栄養補給不耐性	1 (1.3)	2 (2.5)	0	0	3 (3.8)
成長障害	2 (2.5)	0	0	0	2 (2.5)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 10 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
脱水	1 (1.3)	0	0	0	1 (1.3)
鉄欠乏	1 (1.3)	0	0	0	1 (1.3)
筋骨格系および結合組織障害	7 (8.8)	3 (3.8)	1 (1.3)	0	11 (13.8)
側弯症	3 (3.8)	1 (1.3)	0	0	4 (5.0)
関節拘縮	1 (1.3)	2 (2.5)	0	0	3 (3.8)
頭位性斜頭症	2 (2.5)	0	0	0	2 (2.5)
背部痛	1 (1.3)	0	0	0	1 (1.3)
胸郭変形	0	0	1 (1.3)	0	1 (1.3)
泉門閉鎖遅延	1 (1.3)	0	0	0	1 (1.3)
後側弯症	0	1 (1.3)	0	0	1 (1.3)
脊柱後弯症	0	1 (1.3)	0	0	1 (1.3)
四肢痛	1 (1.3)	0	0	0	1 (1.3)
神経系障害	6 (7.5)	0	2 (2.5)	0	8 (10.0)
眼振	2 (2.5)	0	0	0	2 (2.5)
脳損傷	0	0	1 (1.3)	0	1 (1.3)
間代	1 (1.3)	0	0	0	1 (1.3)
よだれ	1 (1.3)	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	1 (1.3)	0	1 (1.3)
不随意性筋収縮	1 (1.3)	0	0	0	1 (1.3)
痙攣発作	0	0	1 (1.3)	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 11 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
傾眠	1 (1.3)	0	0	0	1 (1.3)
精神障害	7 (8.8)	1 (1.3)	0	0	8 (10.0)
激越	2 (2.5)	0	0	0	2 (2.5)
不安	1 (1.3)	1 (1.3)	0	0	2 (2.5)
易刺激性	2 (2.5)	0	0	0	2 (2.5)
息こらえ	1 (1.3)	0	0	0	1 (1.3)
気分動揺	1 (1.3)	0	0	0	1 (1.3)
落ち着きのなさ	1 (1.3)	0	0	0	1 (1.3)
睡眠障害	1 (1.3)	0	0	0	1 (1.3)
免疫系障害	5 (6.3)	0	1 (1.3)	0	6 (7.5)
薬物過敏症	1 (1.3)	0	1 (1.3)	0	2 (2.5)
季節性アレルギー	2 (2.5)	0	0	0	2 (2.5)
食物アレルギー	1 (1.3)	0	0	0	1 (1.3)
過敏症	1 (1.3)	0	0	0	1 (1.3)
眼障害	4 (5.0)	0	0	0	4 (5.0)
霰粒腫	1 (1.3)	0	0	0	1 (1.3)
眼乾燥	1 (1.3)	0	0	0	1 (1.3)
眼運動障害	1 (1.3)	0	0	0	1 (1.3)
近視	1 (1.3)	0	0	0	1 (1.3)
斜視	1 (1.3)	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 12 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
血管障害	2 (2.5)	0	2 (2.5)	0	4 (5.0)
高血圧	0	0	1 (1.3)	0	1 (1.3)
蒼白	1 (1.3)	0	0	0	1 (1.3)
ショック	0	0	1 (1.3)	0	1 (1.3)
血管炎	1 (1.3)	0	0	0	1 (1.3)
先天性、家族性および遺伝性障害	2 (2.5)	1 (1.3)	0	0	3 (3.8)
発育性股関節形成不全	0	1 (1.3)	0	0	1 (1.3)
貧血母斑	1 (1.3)	0	0	0	1 (1.3)
鳩胸	1 (1.3)	0	0	0	1 (1.3)
生殖系および乳房障害	2 (2.5)	1 (1.3)	0	0	3 (3.8)
後天性包茎	0	1 (1.3)	0	0	1 (1.3)
卵巣嚢胞	1 (1.3)	0	0	0	1 (1.3)
陰茎障害	1 (1.3)	0	0	0	1 (1.3)
耳および迷路障害	1 (1.3)	1 (1.3)	0	0	2 (2.5)
耳の障害	0	1 (1.3)	0	0	1 (1.3)
耳痛	1 (1.3)	0	0	0	1 (1.3)
腎および尿路障害	1 (1.3)	1 (1.3)	0	0	2 (2.5)
水腎症	1 (1.3)	0	0	0	1 (1.3)
尿閉	0	1 (1.3)	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:ISIS 396443
Page 13 of 13

	Severity				Total
	Mild	Moderate	Severe	Unknown	
血液およびリンパ系障害	0	1 (1.3)	0	0	1 (1.3)
貧血	0	1 (1.3)	0	0	1 (1.3)
肝胆道系障害	1 (1.3)	0	0	0	1 (1.3)
肝腫大	1 (1.3)	0	0	0	1 (1.3)
外科および内科処置	0	0	1 (1.3)	0	1 (1.3)
機械的換気	0	0	1 (1.3)	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 40　Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B:Incidence of Adverse Events by Severity - Treatment Group:Control

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 1 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					41 (100.0)
Number of subjects with an event	3 (7.3)	8 (19.5)	27 (65.9)	0	38 (92.7)
呼吸器、胸郭および縦隔障害	5 (12.2)	5 (12.2)	24 (58.5)	0	34 (82.9)
呼吸窮迫	1 (2.4)	3 (7.3)	10 (24.4)	0	14 (34.1)
呼吸不全	0	1 (2.4)	13 (31.7)	0	14 (34.1)
無気肺	1 (2.4)	6 (14.6)	2 (4.9)	0	9 (22.0)
急性呼吸不全	0	1 (2.4)	7 (17.1)	0	8 (19.5)
咳嗽	7 (17.1)	1 (2.4)	0	0	8 (19.5)
呼吸困難	1 (2.4)	4 (9.8)	1 (2.4)	0	6 (14.6)
鼻閉	5 (12.2)	1 (2.4)	0	0	6 (14.6)
誤嚥性肺炎	0	5 (12.2)	1 (2.4)	0	6 (14.6)
気管支分泌物貯留	0	2 (4.9)	2 (4.9)	0	4 (9.8)
呼吸停止	0	1 (2.4)	3 (7.3)	0	4 (9.8)
睡眠時無呼吸症候群	1 (2.4)	2 (4.9)	1 (2.4)	0	4 (9.8)
無呼吸	0	1 (2.4)	2 (4.9)	0	3 (7.3)
気道うっ血	3 (7.3)	0	0	0	3 (7.3)
鼻漏	3 (7.3)	0	0	0	3 (7.3)
乳幼児突発性危急事態	0	0	2 (4.9)	0	2 (4.9)
低酸素症	0	1 (2.4)	1 (2.4)	0	2 (4.9)
頻呼吸	2 (4.9)	0	0	0	2 (4.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 2 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
上気道の炎症	2 (4.9)	0	0	0	2 (4.9)
誤嚥	1 (2.4)	0	0	0	1 (2.4)
カタル	0	1 (2.4)	0	0	1 (2.4)
息詰まり	0	1 (2.4)	0	0	1 (2.4)
気管支分泌増加	0	1 (2.4)	0	0	1 (2.4)
上気道分泌増加	1 (2.4)	0	0	0	1 (2.4)
口腔咽頭痛	1 (2.4)	0	0	0	1 (2.4)
上気道うっ血	0	1 (2.4)	0	0	1 (2.4)
呼吸補助筋の動員	1 (2.4)	0	0	0	1 (2.4)
感染症および寄生虫症	10 (24.4)	6 (14.6)	13 (31.7)	0	29 (70.7)
上気道感染	4 (9.8)	5 (12.2)	0	0	9 (22.0)
ウイルス性上気道感染	1 (2.4)	2 (4.9)	5 (12.2)	0	8 (19.5)
肺炎	1 (2.4)	1 (2.4)	4 (9.8)	0	6 (14.6)
ライノウイルス感染	2 (4.9)	0	3 (7.3)	0	5 (12.2)
細菌性気管炎	2 (4.9)	1 (2.4)	1 (2.4)	0	4 (9.8)
鼻咽頭炎	3 (7.3)	1 (2.4)	0	0	4 (9.8)
細気管支炎	1 (2.4)	1 (2.4)	1 (2.4)	0	3 (7.3)
カンジダ感染	2 (4.9)	1 (2.4)	0	0	3 (7.3)
結膜炎	3 (7.3)	0	0	0	3 (7.3)
口腔カンジダ症	3 (7.3)	0	0	0	3 (7.3)
ＲＳウイルス細気管支炎	0	0	3 (7.3)	0	3 (7.3)
鼻炎	3 (7.3)	0	0	0	3 (7.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 3 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
ストーマ部感染	2 (4.9)	1 (2.4)	0	0	3 (7.3)
コロナウイルス感染	0	1 (2.4)	1 (2.4)	0	2 (4.9)
ウイルス性胃腸炎	2 (4.9)	0	0	0	2 (4.9)
中耳炎	1 (2.4)	1 (2.4)	0	0	2 (4.9)
細菌性肺炎	0	1 (2.4)	1 (2.4)	0	2 (4.9)
シュードモナス感染	1 (2.4)	1 (2.4)	0	0	2 (4.9)
気道感染	1 (2.4)	1 (2.4)	0	0	2 (4.9)
ウイルス性気道感染	0	1 (2.4)	1 (2.4)	0	2 (4.9)
ブドウ球菌感染	2 (4.9)	0	0	0	2 (4.9)
ウイルス感染	1 (2.4)	0	1 (2.4)	0	2 (4.9)
細菌性疾患キャリアー	0	1 (2.4)	0	0	1 (2.4)
蜂巣炎	1 (2.4)	0	0	0	1 (2.4)
細菌性結膜炎	1 (2.4)	0	0	0	1 (2.4)
耳感染	1 (2.4)	0	0	0	1 (2.4)
真菌感染	1 (2.4)	0	0	0	1 (2.4)
皮膚真菌感染	1 (2.4)	0	0	0	1 (2.4)
麦粒腫	1 (2.4)	0	0	0	1 (2.4)
膿痂疹	1 (2.4)	0	0	0	1 (2.4)
下気道感染	1 (2.4)	0	0	0	1 (2.4)
パラインフルエンザウイルス感染	0	1 (2.4)	0	0	1 (2.4)
パラインフルエンザウイルス性肺炎	0	0	1 (2.4)	0	1 (2.4)
シュードモナス菌性肺炎	0	0	1 (2.4)	0	1 (2.4)
ウイルス性肺炎	0	0	1 (2.4)	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 4 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
細菌性気道感染	0	1 (2.4)	0	0	1 (2.4)
セラチア感染	0	1 (2.4)	0	0	1 (2.4)
皮膚カンジダ	1 (2.4)	0	0	0	1 (2.4)
皮膚感染	1 (2.4)	0	0	0	1 (2.4)
気管炎	0	1 (2.4)	0	0	1 (2.4)
ウイルス性発疹	1 (2.4)	0	0	0	1 (2.4)
一般・全身障害および投与部位の状態	16 (39.0)	10 (24.4)	1 (2.4)	0	27 (65.9)
発熱	15 (36.6)	7 (17.1)	0	0	22 (53.7)
浮腫	1 (2.4)	2 (4.9)	0	0	3 (7.3)
疼痛	2 (4.9)	0	0	0	2 (4.9)
血管穿刺部位内出血	2 (4.9)	0	0	0	2 (4.9)
適用部位発疹	1 (2.4)	0	0	0	1 (2.4)
カテーテル留置部位炎症	1 (2.4)	0	0	0	1 (2.4)
死亡	0	0	1 (2.4)	0	1 (2.4)
医療機器機能不良	1 (2.4)	0	0	0	1 (2.4)
医療機器閉塞	1 (2.4)	0	0	0	1 (2.4)
疲労	1 (2.4)	0	0	0	1 (2.4)
注入部位内出血	0	1 (2.4)	0	0	1 (2.4)
注入部位血管外漏出	1 (2.4)	0	0	0	1 (2.4)
注射部位血腫	1 (2.4)	0	0	0	1 (2.4)
血管穿刺部位反応	0	1 (2.4)	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 5 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
胃腸障害	13 (31.7)	5 (12.2)	5 (12.2)	0	23 (56.1)
便秘	8 (19.5)	1 (2.4)	0	0	9 (22.0)
嚥下障害	2 (4.9)	2 (4.9)	4 (9.8)	0	8 (19.5)
嘔吐	6 (14.6)	1 (2.4)	1 (2.4)	0	8 (19.5)
下痢	6 (14.6)	1 (2.4)	0	0	7 (17.1)
胃食道逆流性疾患	4 (9.8)	2 (4.9)	0	0	6 (14.6)
生歯	2 (4.9)	1 (2.4)	0	0	3 (7.3)
上腹部痛	2 (4.9)	0	0	0	2 (4.9)
流涎過多	1 (2.4)	0	1 (2.4)	0	2 (4.9)
血性下痢	1 (2.4)	0	0	0	1 (2.4)
放屁	1 (2.4)	0	0	0	1 (2.4)
胃炎	1 (2.4)	0	0	0	1 (2.4)
胃腸出血	0	1 (2.4)	0	0	1 (2.4)
消化管刺激症状	0	1 (2.4)	0	0	1 (2.4)
口内炎	1 (2.4)	0	0	0	1 (2.4)
臨床検査	6 (14.6)	5 (12.2)	3 (7.3)	0	14 (34.1)
酸素飽和度低下	3 (7.3)	4 (9.8)	2 (4.9)	0	9 (22.0)
体温低下	1 (2.4)	0	0	0	1 (2.4)
Ｃ－反応性蛋白増加	0	1 (2.4)	0	0	1 (2.4)
心電図ＳＴ－Ｔ部分異常	1 (2.4)	0	0	0	1 (2.4)
ヘッドラグ異常	1 (2.4)	0	0	0	1 (2.4)
心拍数増加	1 (2.4)	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 6 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
リンパ節触知	1 (2.4)	0	0	0	1 (2.4)
呼吸数増加	1 (2.4)	0	0	0	1 (2.4)
レスピロウイルス検査陽性	0	0	1 (2.4)	0	1 (2.4)
トランスアミナーゼ上昇	1 (2.4)	0	0	0	1 (2.4)
ビタミンD減少	1 (2.4)	0	0	0	1 (2.4)
体重減少	1 (2.4)	0	0	0	1 (2.4)
皮膚および皮下組織障害	12 (29.3)	1 (2.4)	0	0	13 (31.7)
発疹	4 (9.8)	0	0	0	4 (9.8)
紅斑	3 (7.3)	0	0	0	3 (7.3)
褥瘡性潰瘍	1 (2.4)	1 (2.4)	0	0	2 (4.9)
アトピー性皮膚炎	2 (4.9)	0	0	0	2 (4.9)
接触性皮膚炎	2 (4.9)	0	0	0	2 (4.9)
おむつ皮膚炎	2 (4.9)	0	0	0	2 (4.9)
湿疹	1 (2.4)	1 (2.4)	0	0	2 (4.9)
皮膚乾燥	1 (2.4)	0	0	0	1 (2.4)
多汗症	1 (2.4)	0	0	0	1 (2.4)
毛孔性角化症	1 (2.4)	0	0	0	1 (2.4)
心臓障害	4 (9.8)	2 (4.9)	5 (12.2)	0	11 (26.8)
頻脈	4 (9.8)	1 (2.4)	0	0	5 (12.2)
徐脈	1 (2.4)	2 (4.9)	0	0	3 (7.3)
心肺停止	0	0	3 (7.3)	0	3 (7.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 7 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
心停止	0	0	2 (4.9)	0	2 (4.9)
チアノーゼ	0	1 (2.4)	1 (2.4)	0	2 (4.9)
傷害、中毒および処置合併症	8 (19.5)	1 (2.4)	1 (2.4)	0	10 (24.4)
栄養補給チューブ合併症	2 (4.9)	0	0	0	2 (4.9)
ストーマ合併症	2 (4.9)	0	0	0	2 (4.9)
ストーマ部紅斑	2 (4.9)	0	0	0	2 (4.9)
気管内挿管合併症	0	1 (2.4)	0	0	1 (2.4)
擦過傷	1 (2.4)	0	0	0	1 (2.4)
大腿骨骨折	0	0	1 (2.4)	0	1 (2.4)
頭部損傷	1 (2.4)	0	0	0	1 (2.4)
裂傷	1 (2.4)	0	0	0	1 (2.4)
処置後挫傷	1 (2.4)	0	0	0	1 (2.4)
ストーマ部出血	1 (2.4)	0	0	0	1 (2.4)
ストーマ部炎症	1 (2.4)	0	0	0	1 (2.4)
ストーマ部刺激感	1 (2.4)	0	0	0	1 (2.4)
気管損傷	1 (2.4)	0	0	0	1 (2.4)
ワクチン接種合併症	1 (2.4)	0	0	0	1 (2.4)
代謝および栄養障害	5 (12.2)	4 (9.8)	1 (2.4)	0	10 (24.4)
低カリウム血症	0	3 (7.3)	0	0	3 (7.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 8 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
乳児および小児期早期の哺育障害	1 (2.4)	1 (2.4)	0	0	2 (4.9)
低血糖	1 (2.4)	1 (2.4)	0	0	2 (4.9)
体重増加不良	1 (2.4)	0	1 (2.4)	0	2 (4.9)
脱水	1 (2.4)	0	0	0	1 (2.4)
食物不耐性	1 (2.4)	0	0	0	1 (2.4)
高血糖	1 (2.4)	0	0	0	1 (2.4)
ビタミンD欠乏	1 (2.4)	0	0	0	1 (2.4)
精神障害	2 (4.9)	3 (7.3)	0	0	5 (12.2)
激越	1 (2.4)	1 (2.4)	0	0	2 (4.9)
睡眠障害	1 (2.4)	1 (2.4)	0	0	2 (4.9)
易刺激性	1 (2.4)	0	0	0	1 (2.4)
落ち着きのなさ	0	1 (2.4)	0	0	1 (2.4)
先天性、家族性および遺伝性障害	4 (9.8)	0	0	0	4 (9.8)
停留精巣	1 (2.4)	0	0	0	1 (2.4)
発育性股関節形成不全	1 (2.4)	0	0	0	1 (2.4)
鳩胸	1 (2.4)	0	0	0	1 (2.4)
包茎	1 (2.4)	0	0	0	1 (2.4)
免疫系障害	4 (9.8)	0	0	0	4 (9.8)
過敏症	2 (4.9)	0	0	0	2 (4.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 9 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
季節性アレルギー	2 (4.9)	0	0	0	2 (4.9)
薬物過敏症	1 (2.4)	0	0	0	1 (2.4)
筋骨格系および結合組織障害	1 (2.4)	3 (7.3)	0	0	4 (9.8)
関節拘縮	0	2 (4.9)	0	0	2 (4.9)
関節硬直	1 (2.4)	0	0	0	1 (2.4)
脊柱後弯症	1 (2.4)	0	0	0	1 (2.4)
筋力低下	0	1 (2.4)	0	0	1 (2.4)
頭位性斜頭症	0	1 (2.4)	0	0	1 (2.4)
側弯症	1 (2.4)	0	0	0	1 (2.4)
腱障害	1 (2.4)	0	0	0	1 (2.4)
血液およびリンパ系障害	2 (4.9)	1 (2.4)	0	0	3 (7.3)
貧血	1 (2.4)	0	0	0	1 (2.4)
骨髄障害	0	1 (2.4)	0	0	1 (2.4)
白血球増加症	1 (2.4)	0	0	0	1 (2.4)
眼障害	3 (7.3)	0	0	0	3 (7.3)
弱視	1 (2.4)	0	0	0	1 (2.4)
眼乾燥	1 (2.4)	0	0	0	1 (2.4)
流涙増加	1 (2.4)	0	0	0	1 (2.4)
斜視	1 (2.4)	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group:Control
Page 10 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
神経系障害	1 (2.4)	1 (2.4)	0	0	2 (4.9)
眼振	1 (2.4)	0	0	0	1 (2.4)
失神寸前の状態	0	1 (2.4)	0	0	1 (2.4)
腎および尿路障害	1 (2.4)	0	0	0	1 (2.4)
糖尿	1 (2.4)	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 41　Presymptomatic Infants Diagnosed With SMA:Incidence of Adverse Events by Severity

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 1 of 5

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					17 (100.0)
Number of subjects with an event	4 (23.5)	9 (52.9)	0	0	13 (76.5)
感染症および寄生虫症	4 (23.5)	6 (35.3)	0	0	10 (58.8)
上気道感染	4 (23.5)	2 (11.8)	0	0	6 (35.3)
鼻咽頭炎	3 (17.6)	0	0	0	3 (17.6)
インフルエンザ	0	2 (11.8)	0	0	2 (11.8)
中耳炎	1 (5.9)	1 (5.9)	0	0	2 (11.8)
細気管支炎	0	1 (5.9)	0	0	1 (5.9)
気管支炎	0	1 (5.9)	0	0	1 (5.9)
ウイルス性胃腸炎	1 (5.9)	0	0	0	1 (5.9)
膿痂疹	0	1 (5.9)	0	0	1 (5.9)
レンサ球菌性咽頭炎	1 (5.9)	0	0	0	1 (5.9)
肺炎	0	1 (5.9)	0	0	1 (5.9)
ウイルス性肺炎	1 (5.9)	0	0	0	1 (5.9)
鼻炎	1 (5.9)	0	0	0	1 (5.9)
ライノウイルス感染	0	1 (5.9)	0	0	1 (5.9)
皮膚感染	1 (5.9)	0	0	0	1 (5.9)
尿路感染	0	1 (5.9)	0	0	1 (5.9)
胃腸障害	5 (29.4)	1 (5.9)	0	0	6 (35.3)
腹部膨満	2 (11.8)	0	0	0	2 (11.8)
放屁	2 (11.8)	0	0	0	2 (11.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 2 of 5

	Severity				Total
	Mild	Moderate	Severe	Unknown	
胃食道逆流性疾患	2 (11.8)	0	0	0	2 (11.8)
腹部不快感	1 (5.9)	0	0	0	1 (5.9)
便秘	1 (5.9)	0	0	0	1 (5.9)
嚥下障害	1 (5.9)	0	0	0	1 (5.9)
生歯	0	1 (5.9)	0	0	1 (5.9)
皮膚および皮下組織障害	4 (23.5)	2 (11.8)	0	0	6 (35.3)
皮膚炎	2 (11.8)	0	0	0	2 (11.8)
おむつ皮膚炎	1 (5.9)	1 (5.9)	0	0	2 (11.8)
貨幣状湿疹	1 (5.9)	0	0	0	1 (5.9)
紅斑	1 (5.9)	0	0	0	1 (5.9)
脂漏性皮膚炎	0	1 (5.9)	0	0	1 (5.9)
呼吸器、胸郭および縦隔障害	5 (29.4)	0	0	0	5 (29.4)
咳嗽	2 (11.8)	0	0	0	2 (11.8)
鼻閉	2 (11.8)	0	0	0	2 (11.8)
呼吸性アシドーシス	1 (5.9)	0	0	0	1 (5.9)
呼吸窮迫	1 (5.9)	0	0	0	1 (5.9)
鼻漏	1 (5.9)	0	0	0	1 (5.9)
上気道うっ血	1 (5.9)	0	0	0	1 (5.9)
一般・全身障害および投与部位の状態	2 (11.8)	2 (11.8)	0	0	4 (23.5)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 3 of 5

	Severity				Total
	Mild	Moderate	Severe	Unknown	
発熱	1 (5.9)	2 (11.8)	0	0	3 (17.6)
適用部位紅斑	1 (5.9)	0	0	0	1 (5.9)
注入部位内出血	1 (5.9)	0	0	0	1 (5.9)
傷害、中毒および処置合併症	2 (11.8)	1 (5.9)	0	0	3 (17.6)
転倒	1 (5.9)	0	0	0	1 (5.9)
処置後合併症	1 (5.9)	0	0	0	1 (5.9)
処置後不快感	1 (5.9)	0	0	0	1 (5.9)
処置後腫脹	1 (5.9)	0	0	0	1 (5.9)
硬膜下血腫	0	1 (5.9)	0	0	1 (5.9)
血液およびリンパ系障害	1 (5.9)	1 (5.9)	0	0	2 (11.8)
好酸球増加症	1 (5.9)	0	0	0	1 (5.9)
好中球減少症	0	1 (5.9)	0	0	1 (5.9)
心臓障害	2 (11.8)	0	0	0	2 (11.8)
頻脈	2 (11.8)	0	0	0	2 (11.8)
代謝および栄養障害	1 (5.9)	1 (5.9)	0	0	2 (11.8)
脱水	1 (5.9)	0	0	0	1 (5.9)
成長障害	0	1 (5.9)	0	0	1 (5.9)
体重増加不良	1 (5.9)	0	0	0	1 (5.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 4 of 5

	Severity				Total
	Mild	Moderate	Severe	Unknown	
筋骨格系および結合組織障害	1 (5.9)	1 (5.9)	0	0	2 (11.8)
関節拘縮	1 (5.9)	0	0	0	1 (5.9)
筋力低下	1 (5.9)	0	0	0	1 (5.9)
頭位性斜頭症	1 (5.9)	0	0	0	1 (5.9)
斜頚	0	1 (5.9)	0	0	1 (5.9)
体重支持困難	1 (5.9)	0	0	0	1 (5.9)
神経系障害	2 (11.8)	0	0	0	2 (11.8)
反射亢進	1 (5.9)	0	0	0	1 (5.9)
筋緊張低下	1 (5.9)	0	0	0	1 (5.9)
血管障害	1 (5.9)	1 (5.9)	0	0	2 (11.8)
高血圧	0	1 (5.9)	0	0	1 (5.9)
蒼白	1 (5.9)	0	0	0	1 (5.9)
眼障害	1 (5.9)	0	0	0	1 (5.9)
後天性涙道狭窄	1 (5.9)	0	0	0	1 (5.9)
免疫系障害	0	1 (5.9)	0	0	1 (5.9)
季節性アレルギー	0	1 (5.9)	0	0	1 (5.9)
臨床検査	1 (5.9)	0	0	0	1 (5.9)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (5.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 5 of 5

	Severity				Total
	Mild	Moderate	Severe	Unknown	
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (5.9)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.9)	0	0	0	1 (5.9)
脂漏性角化症	1 (5.9)	0	0	0	1 (5.9)
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	1 (5.9)
臍肉芽腫	1 (5.9)	0	0	0	1 (5.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 42　Later-Onset Subjects:Incidence of Adverse Events by Severity

Later-onset subjects: incidence of adverse events by severity
Page 1 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					56 (100.0)
Number of subjects with an event	15 (26.8)	35 (62.5)	6 (10.7)	0	56 (100.0)
感染症および寄生虫症	20 (35.7)	22 (39.3)	2 (3.6)	0	44 (78.6)
上気道感染	20 (35.7)	7 (12.5)	0	0	27 (48.2)
鼻咽頭炎	13 (23.2)	3 (5.4)	0	0	16 (28.6)
ウイルス感染	6 (10.7)	3 (5.4)	0	0	9 (16.1)
ウイルス性胃腸炎	6 (10.7)	2 (3.6)	0	0	8 (14.3)
レンサ球菌性咽頭炎	5 (8.9)	3 (5.4)	0	0	8 (14.3)
胃腸炎	2 (3.6)	5 (8.9)	0	0	7 (12.5)
中耳炎	5 (8.9)	0	0	0	5 (8.9)
肺炎	2 (3.6)	2 (3.6)	1 (1.8)	0	5 (8.9)
ウイルス性上気道感染	3 (5.4)	2 (3.6)	0	0	5 (8.9)
耳感染	4 (7.1)	0	0	0	4 (7.1)
尿路感染	2 (3.6)	2 (3.6)	0	0	4 (7.1)
結膜炎	3 (5.4)	0	0	0	3 (5.4)
インフルエンザ	2 (3.6)	1 (1.8)	0	0	3 (5.4)
限局性感染	3 (5.4)	0	0	0	3 (5.4)
ＲＳウイルス感染	0	3 (5.4)	0	0	3 (5.4)
副鼻腔炎	3 (5.4)	0	0	0	3 (5.4)
ウイルス性消化管感染	2 (3.6)	0	0	0	2 (3.6)
ウイルス性肺炎	0	0	2 (3.6)	0	2 (3.6)
皮膚カンジダ	2 (3.6)	0	0	0	2 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 2 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
蜂巣炎	0	1 (1.8)	0	0	1 (1.8)
ブドウ球菌性眼感染	1 (1.8)	0	0	0	1 (1.8)
ウイルス性眼感染	1 (1.8)	0	0	0	1 (1.8)
皮膚真菌感染	1 (1.8)	0	0	0	1 (1.8)
手足口病	1 (1.8)	0	0	0	1 (1.8)
膿痂疹	1 (1.8)	0	0	0	1 (1.8)
下気道感染	0	0	1 (1.8)	0	1 (1.8)
伝染性軟属腫	1 (1.8)	0	0	0	1 (1.8)
単核細胞症症候群	1 (1.8)	0	0	0	1 (1.8)
急性中耳炎	1 (1.8)	0	0	0	1 (1.8)
咽頭炎	1 (1.8)	0	0	0	1 (1.8)
ＲＳウイルス肺炎	0	1 (1.8)	0	0	1 (1.8)
ＲＳウイルス細気管支炎	0	0	1 (1.8)	0	1 (1.8)
気道感染	0	1 (1.8)	0	0	1 (1.8)
ウイルス性気道感染	0	1 (1.8)	0	0	1 (1.8)
鼻炎	1 (1.8)	0	0	0	1 (1.8)
皮膚細菌感染	1 (1.8)	0	0	0	1 (1.8)
扁桃炎	1 (1.8)	0	0	0	1 (1.8)
膣感染	0	1 (1.8)	0	0	1 (1.8)
ウイルス性扁桃炎	1 (1.8)	0	0	0	1 (1.8)
外陰膣真菌感染	1 (1.8)	0	0	0	1 (1.8)
筋骨格系および結合組織障害	26 (46.4)	14 (25.0)	1 (1.8)	0	41 (73.2)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 3 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
背部痛	15 (26.8)	8 (14.3)	0	0	23 (41.1)
側弯症	10 (17.9)	5 (8.9)	0	0	15 (26.8)
関節拘縮	9 (16.1)	1 (1.8)	0	0	10 (17.9)
関節痛	3 (5.4)	2 (3.6)	0	0	5 (8.9)
四肢痛	2 (3.6)	3 (5.4)	0	0	5 (8.9)
筋肉痛	3 (5.4)	0	1 (1.8)	0	4 (7.1)
頚部痛	3 (5.4)	0	0	0	3 (5.4)
筋緊張	2 (3.6)	0	0	0	2 (3.6)
骨盤変形	2 (3.6)	0	0	0	2 (3.6)
四肢拘縮	1 (1.8)	0	0	0	1 (1.8)
脊柱前弯症	1 (1.8)	0	0	0	1 (1.8)
傷害、中毒および処置合併症	22 (39.3)	17 (30.4)	1 (1.8)	0	40 (71.4)
腰椎穿刺後症候群	15 (26.8)	7 (12.5)	1 (1.8)	0	23 (41.1)
裂傷	6 (10.7)	1 (1.8)	0	0	7 (12.5)
処置による疼痛	3 (5.4)	3 (5.4)	0	0	6 (10.7)
節足動物咬傷	3 (5.4)	0	0	0	3 (5.4)
大腿骨骨折	0	3 (5.4)	0	0	3 (5.4)
四肢損傷	2 (3.6)	1 (1.8)	0	0	3 (5.4)
挫傷	1 (1.8)	1 (1.8)	0	0	2 (3.6)
関節脱臼	1 (1.8)	1 (1.8)	0	0	2 (3.6)
関節損傷	1 (1.8)	1 (1.8)	0	0	2 (3.6)
処置による悪心	2 (3.6)	0	0	0	2 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 4 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
サンバーン	2 (3.6)	0	0	0	2 (3.6)
隆起骨折	0	2 (3.6)	0	0	2 (3.6)
術後激越	0	1 (1.8)	0	0	1 (1.8)
節足動物刺傷	1 (1.8)	0	0	0	1 (1.8)
転倒	1 (1.8)	0	0	0	1 (1.8)
頭部損傷	0	1 (1.8)	0	0	1 (1.8)
靭帯捻挫	1 (1.8)	0	0	0	1 (1.8)
下肢骨折	0	1 (1.8)	0	0	1 (1.8)
半月板損傷	0	1 (1.8)	0	0	1 (1.8)
肉離れ	1 (1.8)	0	0	0	1 (1.8)
術後イレウス	0	1 (1.8)	0	0	1 (1.8)
処置による頭痛	1 (1.8)	0	0	0	1 (1.8)
熱傷	1 (1.8)	0	0	0	1 (1.8)
脛骨骨折	1 (1.8)	0	0	0	1 (1.8)
一般・全身障害および投与部位の状態	25 (44.6)	5 (8.9)	1 (1.8)	0	31 (55.4)
発熱	13 (23.2)	3 (5.4)	0	0	16 (28.6)
穿刺部位疼痛	9 (16.1)	0	1 (1.8)	0	10 (17.9)
疲労	2 (3.6)	1 (1.8)	0	0	3 (5.4)
疼痛	1 (1.8)	1 (1.8)	0	0	2 (3.6)
カテーテル留置部位出血	1 (1.8)	0	0	0	1 (1.8)
カテーテル留置部位疼痛	1 (1.8)	0	0	0	1 (1.8)
カテーテル留置部位関連反応	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 5 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
胸部不快感	1 (1.8)	0	0	0	1 (1.8)
悪寒	1 (1.8)	0	0	0	1 (1.8)
冷感	1 (1.8)	0	0	0	1 (1.8)
重力性浮腫	1 (1.8)	0	0	0	1 (1.8)
低体温	1 (1.8)	0	0	0	1 (1.8)
注射部位出血	1 (1.8)	0	0	0	1 (1.8)
注射部位疼痛	1 (1.8)	0	0	0	1 (1.8)
末梢腫脹	1 (1.8)	0	0	0	1 (1.8)
穿刺部位反応	1 (1.8)	0	0	0	1 (1.8)
血管穿刺部位内出血	1 (1.8)	0	0	0	1 (1.8)
神経系障害	20 (35.7)	9 (16.1)	1 (1.8)	0	30 (53.6)
頭痛	20 (35.7)	8 (14.3)	0	0	28 (50.0)
感覚鈍麻	2 (3.6)	0	0	0	2 (3.6)
失声症	1 (1.8)	0	0	0	1 (1.8)
味覚異常	1 (1.8)	0	0	0	1 (1.8)
失読症	0	1 (1.8)	0	0	1 (1.8)
片頭痛	0	0	1 (1.8)	0	1 (1.8)
錯感覚	1 (1.8)	0	0	0	1 (1.8)
失神	1 (1.8)	0	0	0	1 (1.8)
振戦	1 (1.8)	0	0	0	1 (1.8)
胃腸障害	20 (35.7)	6 (10.7)	0	0	26 (46.4)
嘔吐	11 (19.6)	1 (1.8)	0	0	12 (21.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 6 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
悪心	8 (14.3)	2 (3.6)	0	0	10 (17.9)
便秘	5 (8.9)	2 (3.6)	0	0	7 (12.5)
アフタ性潰瘍	3 (5.4)	0	0	0	3 (5.4)
腹痛	2 (3.6)	0	0	0	2 (3.6)
上腹部痛	2 (3.6)	0	0	0	2 (3.6)
下痢	2 (3.6)	0	0	0	2 (3.6)
口腔内痛	1 (1.8)	1 (1.8)	0	0	2 (3.6)
腹部不快感	0	1 (1.8)	0	0	1 (1.8)
腹部症状	0	1 (1.8)	0	0	1 (1.8)
放屁	1 (1.8)	0	0	0	1 (1.8)
食中毒	0	1 (1.8)	0	0	1 (1.8)
胃腸障害	1 (1.8)	0	0	0	1 (1.8)
胃食道逆流性疾患	1 (1.8)	0	0	0	1 (1.8)
口の感覚鈍麻	1 (1.8)	0	0	0	1 (1.8)
口唇痛	1 (1.8)	0	0	0	1 (1.8)
口内炎	1 (1.8)	0	0	0	1 (1.8)
呼吸器、胸郭および縦隔障害	20 (35.7)	3 (5.4)	2 (3.6)	0	25 (44.6)
口腔咽頭痛	8 (14.3)	0	0	0	8 (14.3)
咳嗽	5 (8.9)	1 (1.8)	0	0	6 (10.7)
鼻漏	6 (10.7)	0	0	0	6 (10.7)
鼻出血	2 (3.6)	1 (1.8)	0	0	3 (5.4)
低酸素症	0	2 (3.6)	1 (1.8)	0	3 (5.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 7 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
鼻閉	3 (5.4)	0	0	0	3 (5.4)
扁桃肥大	3 (5.4)	0	0	0	3 (5.4)
副鼻腔うっ血	2 (3.6)	0	0	0	2 (3.6)
急性呼吸不全	0	1 (1.8)	0	0	1 (1.8)
無気肺	0	0	1 (1.8)	0	1 (1.8)
発声障害	1 (1.8)	0	0	0	1 (1.8)
呼吸困難	0	0	1 (1.8)	0	1 (1.8)
肺臓炎	0	1 (1.8)	0	0	1 (1.8)
肺うっ血	1 (1.8)	0	0	0	1 (1.8)
呼吸障害	0	1 (1.8)	0	0	1 (1.8)
呼吸不全	0	0	1 (1.8)	0	1 (1.8)
拘束性肺疾患	0	1 (1.8)	0	0	1 (1.8)
喘鳴	0	1 (1.8)	0	0	1 (1.8)
皮膚および皮下組織障害	17 (30.4)	0	0	0	17 (30.4)
接触性皮膚炎	3 (5.4)	0	0	0	3 (5.4)
湿疹	2 (3.6)	0	0	0	2 (3.6)
ざ瘡	1 (1.8)	0	0	0	1 (1.8)
水疱	1 (1.8)	0	0	0	1 (1.8)
褥瘡性潰瘍	1 (1.8)	0	0	0	1 (1.8)
皮膚炎	1 (1.8)	0	0	0	1 (1.8)
おむつ皮膚炎	1 (1.8)	0	0	0	1 (1.8)
紅斑	1 (1.8)	0	0	0	1 (1.8)
毛孔性角化症	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 8 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
汗疹	1 (1.8)	0	0	0	1 (1.8)
寝汗	1 (1.8)	0	0	0	1 (1.8)
発疹	1 (1.8)	0	0	0	1 (1.8)
皮膚病変	1 (1.8)	0	0	0	1 (1.8)
蕁麻疹	1 (1.8)	0	0	0	1 (1.8)
臨床検査	7 (12.5)	1 (1.8)	0	0	8 (14.3)
体重減少	2 (3.6)	1 (1.8)	0	0	3 (5.4)
血中重炭酸塩減少	1 (1.8)	0	0	0	1 (1.8)
血中テストステロン減少	1 (1.8)	0	0	0	1 (1.8)
体温上昇	1 (1.8)	0	0	0	1 (1.8)
ＣＳＦ白血球数増加	1 (1.8)	0	0	0	1 (1.8)
心拍数増加	1 (1.8)	0	0	0	1 (1.8)
尿検査異常	1 (1.8)	0	0	0	1 (1.8)
免疫系障害	6 (10.7)	0	1 (1.8)	0	7 (12.5)
過敏症	3 (5.4)	0	0	0	3 (5.4)
季節性アレルギー	3 (5.4)	0	0	0	3 (5.4)
薬物過敏症	0	0	1 (1.8)	0	1 (1.8)
代謝および栄養障害	4 (7.1)	1 (1.8)	0	0	5 (8.9)
脱水	1 (1.8)	1 (1.8)	0	0	2 (3.6)
食欲減退	1 (1.8)	0	0	0	1 (1.8)
食欲亢進	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 9 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
ビタミンD欠乏	1 (1.8)	0	0	0	1 (1.8)
精神障害	2 (3.6)	2 (3.6)	0	0	4 (7.1)
激越	1 (1.8)	1 (1.8)	0	0	2 (3.6)
注意欠陥多動性障害	0	1 (1.8)	0	0	1 (1.8)
不快気分	1 (1.8)	0	0	0	1 (1.8)
不眠症	0	1 (1.8)	0	0	1 (1.8)
睡眠時随伴症	0	1 (1.8)	0	0	1 (1.8)
チック	1 (1.8)	0	0	0	1 (1.8)
心因性嘔吐	1 (1.8)	0	0	0	1 (1.8)
心臓障害	3 (5.4)	0	0	0	3 (5.4)
動悸	2 (3.6)	0	0	0	2 (3.6)
頻脈	1 (1.8)	0	0	0	1 (1.8)
耳および迷路障害	3 (5.4)	0	0	0	3 (5.4)
耳痛	1 (1.8)	0	0	0	1 (1.8)
乗物酔い	1 (1.8)	0	0	0	1 (1.8)
鼓膜穿孔	1 (1.8)	0	0	0	1 (1.8)
腎および尿路障害	1 (1.8)	2 (3.6)	0	0	3 (5.4)
排尿困難	0	1 (1.8)	0	0	1 (1.8)
尿失禁	1 (1.8)	0	0	0	1 (1.8)
膀胱尿管逆流	0	1 (1.8)	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 10 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
眼障害	2 (3.6)	0	0	0	2 (3.6)
遠視	1 (1.8)	0	0	0	1 (1.8)
斜視	1 (1.8)	0	0	0	1 (1.8)
血液およびリンパ系障害	1 (1.8)	0	0	0	1 (1.8)
好中球減少症	1 (1.8)	0	0	0	1 (1.8)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	1 (1.8)	0	0	1 (1.8)
皮膚乳頭腫	0	1 (1.8)	0	0	1 (1.8)
血管障害	0	1 (1.8)	0	0	1 (1.8)
低血圧	0	1 (1.8)	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 43　Incidence of Severe Adverse Events in Infants Diagnosed With SMA

Incidence of severe adverse events in infants diagnosed with SMA
Page 1 of 6

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	0	27 (65.9)	44 (55.0)	53 (53.0)	53 (45.3)
呼吸器、胸郭および縦隔障害	0	24 (58.5)	37 (46.3)	46 (46.0)	46 (39.3)
呼吸不全	0	13 (31.7)	11 (13.8)	15 (15.0)	15 (12.8)
急性呼吸不全	0	7 (17.1)	11 (13.8)	13 (13.0)	13 (11.1)
呼吸窮迫	0	10 (24.4)	11 (13.8)	13 (13.0)	13 (11.1)
無気肺	0	2 (4.9)	6 (7.5)	7 (7.0)	7 (6.0)
低酸素症	0	1 (2.4)	3 (3.8)	5 (5.0)	5 (4.3)
誤嚥性肺炎	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
無呼吸	0	2 (4.9)	1 (1.3)	3 (3.0)	3 (2.6)
誤嚥	0	0	2 (2.5)	3 (3.0)	3 (2.6)
呼吸困難	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
低換気	0	0	1 (1.3)	2 (2.0)	2 (1.7)
気胸	0	0	1 (1.3)	2 (2.0)	2 (1.7)
呼吸停止	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
窒息	0	0	0	1 (1.0)	1 (0.9)
気管支分泌物貯留	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 2 of 6

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.9)
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
肺障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
気縦隔症	0	0	0	1 (1.0)	1 (0.9)
呼吸障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
睡眠時無呼吸症候群	0	1 (2.4)	0	0	0
感染症および寄生虫症	0	13 (31.7)	25 (31.3)	31 (31.0)	31 (26.5)
肺炎	0	4 (9.8)	7 (8.8)	10 (10.0)	10 (8.5)
細気管支炎	0	1 (2.4)	4 (5.0)	5 (5.0)	5 (4.3)
上気道感染	0	0	5 (6.3)	5 (5.0)	5 (4.3)
ライノウイルス感染	0	3 (7.3)	3 (3.8)	4 (4.0)	4 (3.4)
気道感染	0	0	3 (3.8)	3 (3.0)	3 (2.6)
細菌性気管炎	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
下気道感染	0	0	2 (2.5)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)
細菌性肺炎	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
モラクセラ菌性肺炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 3 of 6

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ウイルス性肺炎	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
ＲＳウイルス細気管支炎	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
気管支炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性気管支炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
コロナウイルス感染	0	1 (2.4)	0	1 (1.0)	1 (0.9)
エンテロウイルス感染	0	0	0	1 (1.0)	1 (0.9)
ウイルス性下気道感染	0	0	0	1 (1.0)	1 (0.9)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
院内感染	0	0	1 (1.3)	1 (1.0)	1 (0.9)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性気道感染	0	1 (2.4)	0	1 (1.0)	1 (0.9)
敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ブドウ球菌性菌血症	0	0	0	1 (1.0)	1 (0.9)
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ウイルス性上気道感染	0	5 (12.2)	1 (1.3)	1 (1.0)	1 (0.9)
パラインフルエンザウイルス性肺炎	0	1 (2.4)	0	0	0
シュードモナス菌性肺炎	0	1 (2.4)	0	0	0
ウイルス感染	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 4 of 6

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
心臓障害	0	5 (12.2)	7 (8.8)	10 (10.0)	10 (8.5)
心肺停止	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.1)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.6)
徐脈	0	0	0	1 (1.0)	1 (0.9)
チアノーゼ	0	1 (2.4)	0	1 (1.0)	1 (0.9)
心膜気腫	0	0	0	1 (1.0)	1 (0.9)
胃腸障害	0	5 (12.2)	5 (6.3)	6 (6.0)	6 (5.1)
嚥下障害	0	4 (9.8)	4 (5.0)	4 (4.0)	4 (3.4)
胃炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
嘔吐	0	1 (2.4)	0	1 (1.0)	1 (0.9)
流涎過多	0	1 (2.4)	0	0	0
一般・全身障害および投与部位の状態	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.4)
発熱	0	0	2 (2.5)	2 (2.0)	2 (1.7)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
疼痛	0	0	0	1 (1.0)	1 (0.9)
神経系障害	0	0	2 (2.5)	3 (3.0)	3 (2.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 5 of 6

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
痙攣発作	0	0	1 (1.3)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
代謝および栄養障害	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
低ナトリウム血症	0	0	0	1 (1.0)	1 (0.9)
体重増加不良	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
筋骨格系および結合組織障害	0	0	1 (1.3)	2 (2.0)	2 (1.7)
胸郭変形	0	0	1 (1.3)	1 (1.0)	1 (0.9)
関節拘縮	0	0	0	1 (1.0)	1 (0.9)
血管障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
高血圧	0	0	1 (1.3)	1 (1.0)	1 (0.9)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.9)
免疫系障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
薬物過敏症	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 6 of 6

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
傷害、中毒および処置合併症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
創離開	0	0	1 (1.3)	1 (1.0)	1 (0.9)
大腿骨骨折	0	1 (2.4)	0	0	0
臨床検査	0	3 (7.3)	1 (1.3)	1 (1.0)	1 (0.9)
酸素飽和度低下	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0
精神障害	0	0	0	1 (1.0)	1 (0.9)
不安	0	0	0	1 (1.0)	1 (0.9)
皮膚および皮下組織障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
おむつ皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
外科および内科処置	0	0	1 (1.3)	1 (1.0)	1 (0.9)
機械的換気	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 44　Incidence of Severe Adverse Events in Subjects With SMA Treated With ISIS 396443

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 1 of 6

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	0	53 (53.0)	53 (45.3)	6 (10.7)	59 (34.1)
呼吸器、胸郭および縦隔障害	0	46 (46.0)	46 (39.3)	2 (3.6)	48 (27.7)
呼吸不全	0	15 (15.0)	15 (12.8)	1 (1.8)	16 (9.2)
急性呼吸不全	0	13 (13.0)	13 (11.1)	0	13 (7.5)
呼吸窮迫	0	13 (13.0)	13 (11.1)	0	13 (7.5)
無気肺	0	7 (7.0)	7 (6.0)	1 (1.8)	8 (4.6)
低酸素症	0	5 (5.0)	5 (4.3)	1 (1.8)	6 (3.5)
誤嚥性肺炎	0	4 (4.0)	4 (3.4)	0	4 (2.3)
無呼吸	0	3 (3.0)	3 (2.6)	0	3 (1.7)
誤嚥	0	3 (3.0)	3 (2.6)	0	3 (1.7)
呼吸困難	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
低換気	0	2 (2.0)	2 (1.7)	0	2 (1.2)
気胸	0	2 (2.0)	2 (1.7)	0	2 (1.2)
呼吸停止	0	2 (2.0)	2 (1.7)	0	2 (1.2)
窒息	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気管支分泌物貯留	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 2 of 6

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
慢性呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
感染症および寄生虫症	0	31 (31.0)	31 (26.5)	2 (3.6)	33 (19.1)
肺炎	0	10 (10.0)	10 (8.5)	1 (1.8)	11 (6.4)
細気管支炎	0	5 (5.0)	5 (4.3)	0	5 (2.9)
上気道感染	0	5 (5.0)	5 (4.3)	0	5 (2.9)
ウイルス性肺炎	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
ライノウイルス感染	0	4 (4.0)	4 (3.4)	0	4 (2.3)
下気道感染	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ＲＳウイルス細気管支炎	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
気道感染	0	3 (3.0)	3 (2.6)	0	3 (1.7)
細菌性気管炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.2)
細菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 3 of 6

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
モラクセラ菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.2)
気管支炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性気管支炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
コロナウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
エンテロウイルス感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性下気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
院内感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
インフルエンザ性肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
敗血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌性菌血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性上気道感染	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心臓障害	0	10 (10.0)	10 (8.5)	0	10 (5.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 4 of 6

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
心肺停止	0	6 (6.0)	6 (5.1)	0	6 (3.5)
心停止	0	3 (3.0)	3 (2.6)	0	3 (1.7)
徐脈	0	1 (1.0)	1 (0.9)	0	1 (0.6)
チアノーゼ	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
胃腸障害	0	6 (6.0)	6 (5.1)	0	6 (3.5)
嚥下障害	0	4 (4.0)	4 (3.4)	0	4 (2.3)
胃炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
嘔吐	0	1 (1.0)	1 (0.9)	0	1 (0.6)
一般・全身障害および投与部位の状態	0	4 (4.0)	4 (3.4)	1 (1.8)	5 (2.9)
発熱	0	2 (2.0)	2 (1.7)	0	2 (1.2)
死亡	0	1 (1.0)	1 (0.9)	0	1 (0.6)
疼痛	0	1 (1.0)	1 (0.9)	0	1 (0.6)
穿刺部位疼痛	0	0	0	1 (1.8)	1 (0.6)
神経系障害	0	3 (3.0)	3 (2.6)	1 (1.8)	4 (2.3)
痙攣発作	0	2 (2.0)	2 (1.7)	0	2 (1.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 5 of 6

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
脳損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
片頭痛	0	0	0	1 (1.8)	1 (0.6)
筋骨格系および結合組織障害	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
胸郭変形	0	1 (1.0)	1 (0.9)	0	1 (0.6)
関節拘縮	0	1 (1.0)	1 (0.9)	0	1 (0.6)
筋肉痛	0	0	0	1 (1.8)	1 (0.6)
免疫系障害	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
薬物過敏症	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
傷害、中毒および処置合併症	0	1 (1.0)	1 (0.9)	1 (1.8)	2 (1.2)
腰椎穿刺後症候群	0	0	0	1 (1.8)	1 (0.6)
創離開	0	1 (1.0)	1 (0.9)	0	1 (0.6)
代謝および栄養障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
低ナトリウム血症	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 6 of 6

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
体重増加不良	0	1 (1.0)	1 (0.9)	0	1 (0.6)
血管障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
高血圧	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ショック	0	1 (1.0)	1 (0.9)	0	1 (0.6)
臨床検査	0	1 (1.0)	1 (0.9)	0	1 (0.6)
酸素飽和度低下	0	1 (1.0)	1 (0.9)	0	1 (0.6)
精神障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
不安	0	1 (1.0)	1 (0.9)	0	1 (0.6)
皮膚および皮下組織障害	0	1 (1.0)	1 (0.9)	0	1 (0.6)
おむつ皮膚炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)
外科および内科処置	0	1 (1.0)	1 (0.9)	0	1 (0.6)
機械的換気	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 45　Incidence of Potentially Drug-Related Adverse Events in Infants Diagnosed With SMA

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 1 of 3

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	3 (17.6)	6 (14.6)	9 (11.3)	11 (11.0)	14 (12.0)
一般・全身障害および投与部位の状態	1 (5.9)	3 (7.3)	2 (2.5)	2 (2.0)	3 (2.6)
発熱	1 (5.9)	2 (4.9)	2 (2.5)	2 (2.0)	3 (2.6)
疼痛	0	1 (2.4)	0	0	0
臨床検査	1 (5.9)	0	2 (2.5)	2 (2.0)	3 (2.6)
体温低下	0	0	1 (1.3)	1 (1.0)	1 (0.9)
体温上昇	0	0	1 (1.3)	1 (1.0)	1 (0.9)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (0.9)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (0.9)
ＣＳＦ白血球数増加	0	0	0	0	0
心拍数増加	0	0	0	0	0
血液およびリンパ系障害	0	0	0	1 (1.0)	1 (0.9)
好中球減少症	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 2 of 3

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
心臓障害	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
頻脈	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)
動悸	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
貧血母斑	0	0	1 (1.3)	1 (1.0)	1 (0.9)
胃腸障害	0	2 (4.9)	0	1 (1.0)	1 (0.9)
嘔吐	0	1 (2.4)	0	1 (1.0)	1 (0.9)
下痢	0	1 (2.4)	0	0	0
感染症および寄生虫症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
蜂巣炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
傷害、中毒および処置合併症	0	0	1 (1.3)	1 (1.0)	1 (0.9)
処置後腫脹	0	0	1 (1.3)	1 (1.0)	1 (0.9)
腰椎穿刺後症候群	0	0	0	0	0
神経系障害	1 (5.9)	0	1 (1.3)	1 (1.0)	2 (1.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 3 of 3

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
眼振	0	0	1 (1.3)	1 (1.0)	1 (0.9)
頭痛	0	0	0	0	0
反射亢進	1 (5.9)	0	0	0	1 (0.9)
錯感覚	0	0	0	0	0
血管障害	0	0	1 (1.3)	1 (1.0)	1 (0.9)
血管炎	0	0	1 (1.3)	1 (1.0)	1 (0.9)
筋骨格系および結合組織障害	1 (5.9)	0	0	0	1 (0.9)
筋力低下	1 (5.9)	0	0	0	1 (0.9)
体重支持困難	1 (5.9)	0	0	0	1 (0.9)
皮膚および皮下組織障害	0	1 (2.4)	0	0	0
発疹	0	1 (2.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 46　Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B:Incidence of Adverse Events by Relationship to Study Drug - Treatment Group:ISIS 396443

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 1 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
Number of subjects dosed						80 (100.0)
Number of subjects with an event	42 (52.5)	21 (26.3)	9 (11.3)	0	0	72 (90.0)
感染症および寄生虫症	48 (60.0)	8 (10.0)	1 (1.3)	0	0	57 (71.3)
上気道感染	18 (22.5)	2 (2.5)	0	0	0	20 (25.0)
肺炎	17 (21.3)	0	0	0	0	17 (21.3)
鼻咽頭炎	13 (16.3)	1 (1.3)	0	0	0	14 (17.5)
ウイルス性上気道感染	10 (12.5)	0	0	0	0	10 (12.5)
細気管支炎	8 (10.0)	0	0	0	0	8 (10.0)
ライノウイルス感染	8 (10.0)	0	0	0	0	8 (10.0)
気道感染	7 (8.8)	0	0	0	0	7 (8.8)
ウイルス感染	6 (7.5)	1 (1.3)	0	0	0	7 (8.8)
口腔カンジダ症	6 (7.5)	0	0	0	0	6 (7.5)
ウイルス性肺炎	6 (7.5)	0	0	0	0	6 (7.5)
気管支炎	5 (6.3)	0	0	0	0	5 (6.3)
結膜炎	4 (5.0)	1 (1.3)	0	0	0	5 (6.3)
耳感染	4 (5.0)	0	0	0	0	4 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 2 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
気道感染肺炎	4 (5.0)	0	0	0	0	4 (5.0)
ウイルス性気管支炎	3 (3.8)	0	0	0	0	3 (3.8)
下気道感染	3 (3.8)	0	0	0	0	3 (3.8)
細菌性肺炎	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
ＲＳウイルス細気管支炎	3 (3.8)	0	0	0	0	3 (3.8)
尿路感染	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
アデノウイルス感染	2 (2.5)	0	0	0	0	2 (2.5)
細菌性結膜炎	2 (2.5)	0	0	0	0	2 (2.5)
インフルエンザ	2 (2.5)	0	0	0	0	2 (2.5)
ウイルス性下気道感染	2 (2.5)	0	0	0	0	2 (2.5)
皮膚カンジダ	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
ストーマ部膿瘍	2 (2.5)	0	0	0	0	2 (2.5)
細菌感染	1 (1.3)	0	0	0	0	1 (1.3)
細菌性気管炎	1 (1.3)	0	0	0	0	1 (1.3)
カンジダ性おむつ皮疹	1 (1.3)	0	0	0	0	1 (1.3)
蜂巣炎	0	0	1 (1.3)	0	0	1 (1.3)
感染性湿疹	0	1 (1.3)	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 3 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
眼感染	1 (1.3)	0	0	0	0	1 (1.3)
真菌感染	0	1 (1.3)	0	0	0	1 (1.3)
皮膚真菌感染	1 (1.3)	0	0	0	0	1 (1.3)
胃腸炎	1 (1.3)	0	0	0	0	1 (1.3)
ロタウイルス胃腸炎	1 (1.3)	0	0	0	0	1 (1.3)
ウイルス性胃腸炎	1 (1.3)	0	0	0	0	1 (1.3)
手足口病	1 (1.3)	0	0	0	0	1 (1.3)
膿痂疹	1 (1.3)	0	0	0	0	1 (1.3)
限局性感染	1 (1.3)	0	0	0	0	1 (1.3)
肺感染	0	1 (1.3)	0	0	0	1 (1.3)
院内感染	1 (1.3)	0	0	0	0	1 (1.3)
口腔ヘルペス	1 (1.3)	0	0	0	0	1 (1.3)
中耳炎	1 (1.3)	0	0	0	0	1 (1.3)
急性中耳炎	1 (1.3)	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	1 (1.3)	0	0	0	0	1 (1.3)
モラクセラ菌性肺炎	1 (1.3)	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	1 (1.3)	0	0	0	1 (1.3)
ＲＳウイルス肺炎	1 (1.3)	0	0	0	0	1 (1.3)
シュードモナス感染	1 (1.3)	0	0	0	0	1 (1.3)
鼻炎	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 4 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
ばら疹	1 (1.3)	0	0	0	0	1 (1.3)
敗血症	1 (1.3)	0	0	0	0	1 (1.3)
ブドウ球菌性敗血症	1 (1.3)	0	0	0	0	1 (1.3)
ブドウ球菌皮膚感染	1 (1.3)	0	0	0	0	1 (1.3)
呼吸器、胸郭および縦隔障害	46 (57.5)	9 (11.3)	0	0	0	55 (68.8)
呼吸窮迫	18 (22.5)	1 (1.3)	0	0	0	19 (23.8)
呼吸不全	15 (18.8)	2 (2.5)	0	0	0	17 (21.3)
無気肺	13 (16.3)	2 (2.5)	0	0	0	15 (18.8)
急性呼吸不全	9 (11.3)	2 (2.5)	0	0	0	11 (13.8)
鼻閉	7 (8.8)	1 (1.3)	0	0	0	8 (10.0)
呼吸困難	6 (7.5)	1 (1.3)	0	0	0	7 (8.8)
誤嚥性肺炎	6 (7.5)	1 (1.3)	0	0	0	7 (8.8)
咳嗽	5 (6.3)	1 (1.3)	0	0	0	6 (7.5)
低酸素症	5 (6.3)	1 (1.3)	0	0	0	6 (7.5)
上気道うっ血	5 (6.3)	0	0	0	0	5 (6.3)
無呼吸	4 (5.0)	0	0	0	0	4 (5.0)
誤嚥	4 (5.0)	0	0	0	0	4 (5.0)
鼻漏	4 (5.0)	0	0	0	0	4 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 5 of 15

	Relationship to study drug					
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	Total
気管支分泌物貯留	3 (3.8)	0	0	0	0	3 (3.8)
呼吸停止	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
副鼻腔うっ血	3 (3.8)	0	0	0	0	3 (3.8)
慢性呼吸不全	2 (2.5)	0	0	0	0	2 (2.5)
低換気	2 (2.5)	0	0	0	0	2 (2.5)
上気道分泌増加	2 (2.5)	0	0	0	0	2 (2.5)
呼吸障害	2 (2.5)	0	0	0	0	2 (2.5)
急性呼吸窮迫症候群	1 (1.3)	0	0	0	0	1 (1.3)
気管支閉塞	1 (1.3)	0	0	0	0	1 (1.3)
息詰まり	1 (1.3)	0	0	0	0	1 (1.3)
高炭酸ガス血症	1 (1.3)	0	0	0	0	1 (1.3)
減呼吸	1 (1.3)	0	0	0	0	1 (1.3)
気管支分泌増加	1 (1.3)	0	0	0	0	1 (1.3)
肺障害	1 (1.3)	0	0	0	0	1 (1.3)
閉塞性気道障害	1 (1.3)	0	0	0	0	1 (1.3)
胸水	1 (1.3)	0	0	0	0	1 (1.3)
気胸	1 (1.3)	0	0	0	0	1 (1.3)
呼吸性アルカローシス	1 (1.3)	0	0	0	0	1 (1.3)
気道うっ血	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 6 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
アレルギー性鼻炎	1 (1.3)	0	0	0	0	1 (1.3)
変色痰	1 (1.3)	0	0	0	0	1 (1.3)
呼吸補助筋の動員	1 (1.3)	0	0	0	0	1 (1.3)
喘鳴	1 (1.3)	0	0	0	0	1 (1.3)
胃腸障害	39 (48.8)	7 (8.8)	0	0	0	46 (57.5)
便秘	23 (28.8)	1 (1.3)	0	0	0	24 (30.0)
嘔吐	12 (15.0)	0	0	0	0	12 (15.0)
生歯	11 (13.8)	0	0	0	0	11 (13.8)
嚥下障害	7 (8.8)	2 (2.5)	0	0	0	9 (11.3)
胃食道逆流性疾患	8 (10.0)	1 (1.3)	0	0	0	9 (11.3)
下痢	8 (10.0)	0	0	0	0	8 (10.0)
放屁	3 (3.8)	0	0	0	0	3 (3.8)
胃炎	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
流涎過多	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
血便排泄	2 (2.5)	0	0	0	0	2 (2.5)
腹部不快感	1 (1.3)	0	0	0	0	1 (1.3)
腹部膨満	0	1 (1.3)	0	0	0	1 (1.3)
アフタ性潰瘍	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 7 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
胃出血	1 (1.3)	0	0	0	0	1 (1.3)
乳児仙痛	1 (1.3)	0	0	0	0	1 (1.3)
乳児吐血	1 (1.3)	0	0	0	0	1 (1.3)
上部消化管出血	1 (1.3)	0	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	38 (47.5)	4 (5.0)	2 (2.5)	0	0	44 (55.0)
発熱	34 (42.5)	3 (3.8)	2 (2.5)	0	0	39 (48.8)
カテーテル留置部位炎症	1 (1.3)	0	0	0	0	1 (1.3)
泣き	0	1 (1.3)	0	0	0	1 (1.3)
死亡	1 (1.3)	0	0	0	0	1 (1.3)
薬物不耐性	1 (1.3)	0	0	0	0	1 (1.3)
低体温	1 (1.3)	0	0	0	0	1 (1.3)
ワクチン接種後の易刺激性	1 (1.3)	0	0	0	0	1 (1.3)
倦怠感	1 (1.3)	0	0	0	0	1 (1.3)
小結節	1 (1.3)	0	0	0	0	1 (1.3)
疼痛	1 (1.3)	0	0	0	0	1 (1.3)
腫脹	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 8 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
皮膚および皮下組織障害	16 (20.0)	5 (6.3)	0	0	0	21 (26.3)
発疹	5 (6.3)	3 (3.8)	0	0	0	8 (10.0)
おむつ皮膚炎	6 (7.5)	0	0	0	0	6 (7.5)
接触性皮膚炎	2 (2.5)	0	0	0	0	2 (2.5)
斑状出血	2 (2.5)	0	0	0	0	2 (2.5)
過角化	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
汗疹	2 (2.5)	0	0	0	0	2 (2.5)
皮膚炎	1 (1.3)	0	0	0	0	1 (1.3)
アレルギー性皮膚炎	1 (1.3)	0	0	0	0	1 (1.3)
湿疹	0	1 (1.3)	0	0	0	1 (1.3)
紅斑	0	1 (1.3)	0	0	0	1 (1.3)
環状肉芽腫	1 (1.3)	0	0	0	0	1 (1.3)
丘疹性皮疹	1 (1.3)	0	0	0	0	1 (1.3)
皮膚浮腫	0	1 (1.3)	0	0	0	1 (1.3)
蕁麻疹	1 (1.3)	0	0	0	0	1 (1.3)
臨床検査	10 (12.5)	5 (6.3)	2 (2.5)	0	0	17 (21.3)
酸素飽和度低下	5 (6.3)	3 (3.8)	0	0	0	8 (10.0)
体重減少	3 (3.8)	0	0	0	0	3 (3.8)
血中カリウム減少	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 9 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
体温上昇	1 (1.3)	0	1 (1.3)	0	0	2 (2.5)
Ｃ－反応性蛋白増加	2 (2.5)	0	0	0	0	2 (2.5)
アラニンアミノトランスフェラーゼ増加	1 (1.3)	0	0	0	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.3)	0	0	0	0	1 (1.3)
血中クロール減少	1 (1.3)	0	0	0	0	1 (1.3)
血中鉄減少	1 (1.3)	0	0	0	0	1 (1.3)
血中ナトリウム減少	1 (1.3)	0	0	0	0	1 (1.3)
体温低下	0	0	1 (1.3)	0	0	1 (1.3)
心電図ＳＴ－Ｔ部分異常	1 (1.3)	0	0	0	0	1 (1.3)
心拍数増加	1 (1.3)	0	0	0	0	1 (1.3)
心拍数不整	0	1 (1.3)	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
炎症マーカー上昇	1 (1.3)	0	0	0	0	1 (1.3)
Ａ型インフルエンザウイルス検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
肝機能検査異常	1 (1.3)	0	0	0	0	1 (1.3)
医学的観察	1 (1.3)	0	0	0	0	1 (1.3)
モラクセラ検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
好中球数増加	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 10 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
シュードモナス検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
ブドウ球菌検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
尿量減少	0	1 (1.3)	0	0	0	1 (1.3)
ビタミンA減少	1 (1.3)	0	0	0	0	1 (1.3)
心臓障害	12 (15.0)	3 (3.8)	1 (1.3)	0	0	16 (20.0)
頻脈	4 (5.0)	1 (1.3)	1 (1.3)	0	0	6 (7.5)
心肺停止	4 (5.0)	1 (1.3)	0	0	0	5 (6.3)
徐脈	3 (3.8)	1 (1.3)	0	0	0	4 (5.0)
心停止	2 (2.5)	0	0	0	0	2 (2.5)
チアノーゼ	2 (2.5)	0	0	0	0	2 (2.5)
左室肥大	1 (1.3)	0	0	0	0	1 (1.3)
上室性頻脈	0	1 (1.3)	0	0	0	1 (1.3)
心室性頻脈	0	1 (1.3)	0	0	0	1 (1.3)
傷害、中毒および処置合併症	12 (15.0)	2 (2.5)	1 (1.3)	0	0	15 (18.8)
大腿骨骨折	2 (2.5)	0	0	0	0	2 (2.5)
処置による疼痛	2 (2.5)	0	0	0	0	2 (2.5)
ストーマ部紅斑	2 (2.5)	0	0	0	0	2 (2.5)
術後激越	0	1 (1.3)	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 11 of 15

	Relationship to study drug					
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	Total
挫傷	0	1 (1.3)	0	0	0	1 (1.3)
麻酔からの覚醒遅延	1 (1.3)	0	0	0	0	1 (1.3)
擦過傷	1 (1.3)	0	0	0	0	1 (1.3)
伝染病曝露	1 (1.3)	0	0	0	0	1 (1.3)
処置後腫脹	0	0	1 (1.3)	0	0	1 (1.3)
処置合併症	1 (1.3)	0	0	0	0	1 (1.3)
処置部位反応	1 (1.3)	0	0	0	0	1 (1.3)
ストーマ合併症	1 (1.3)	0	0	0	0	1 (1.3)
ワクチン接種合併症	1 (1.3)	0	0	0	0	1 (1.3)
創離開	1 (1.3)	0	0	0	0	1 (1.3)
代謝および栄養障害	11 (13.8)	2 (2.5)	0	0	0	13 (16.3)
体重増加不良	4 (5.0)	1 (1.3)	0	0	0	5 (6.3)
乳児および小児期早期の哺育障害	3 (3.8)	0	0	0	0	3 (3.8)
栄養補給不耐性	3 (3.8)	0	0	0	0	3 (3.8)
成長障害	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
脱水	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 12 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
鉄欠乏	1 (1.3)	0	0	0	0	1 (1.3)
筋骨格系および結合組織障害	11 (13.8)	0	0	0	0	11 (13.8)
側弯症	4 (5.0)	0	0	0	0	4 (5.0)
関節拘縮	3 (3.8)	0	0	0	0	3 (3.8)
頭位性斜頭症	2 (2.5)	0	0	0	0	2 (2.5)
背部痛	1 (1.3)	0	0	0	0	1 (1.3)
胸郭変形	1 (1.3)	0	0	0	0	1 (1.3)
泉門閉鎖遅延	1 (1.3)	0	0	0	0	1 (1.3)
後側弯症	1 (1.3)	0	0	0	0	1 (1.3)
脊柱後弯症	1 (1.3)	0	0	0	0	1 (1.3)
四肢痛	1 (1.3)	0	0	0	0	1 (1.3)
神経系障害	6 (7.5)	1 (1.3)	1 (1.3)	0	0	8 (10.0)
眼振	1 (1.3)	0	1 (1.3)	0	0	2 (2.5)
脳損傷	1 (1.3)	0	0	0	0	1 (1.3)
間代	0	1 (1.3)	0	0	0	1 (1.3)
よだれ	1 (1.3)	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 13 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
不随意性筋収縮	1 (1.3)	0	0	0	0	1 (1.3)
痙攣発作	1 (1.3)	0	0	0	0	1 (1.3)
傾眠	1 (1.3)	0	0	0	0	1 (1.3)
精神障害	5 (6.3)	3 (3.8)	0	0	0	8 (10.0)
激越	0	2 (2.5)	0	0	0	2 (2.5)
不安	2 (2.5)	0	0	0	0	2 (2.5)
易刺激性	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
息こらえ	1 (1.3)	0	0	0	0	1 (1.3)
気分動揺	1 (1.3)	0	0	0	0	1 (1.3)
落ち着きのなさ	1 (1.3)	0	0	0	0	1 (1.3)
睡眠障害	1 (1.3)	0	0	0	0	1 (1.3)
免疫系障害	6 (7.5)	0	0	0	0	6 (7.5)
薬物過敏症	2 (2.5)	0	0	0	0	2 (2.5)
季節性アレルギー	2 (2.5)	0	0	0	0	2 (2.5)
食物アレルギー	1 (1.3)	0	0	0	0	1 (1.3)
過敏症	1 (1.3)	0	0	0	0	1 (1.3)
眼障害	4 (5.0)	0	0	0	0	4 (5.0)
霰粒腫	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 14 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
眼乾燥	1 (1.3)	0	0	0	0	1 (1.3)
眼運動障害	1 (1.3)	0	0	0	0	1 (1.3)
近視	1 (1.3)	0	0	0	0	1 (1.3)
斜視	1 (1.3)	0	0	0	0	1 (1.3)
血管障害	2 (2.5)	1 (1.3)	1 (1.3)	0	0	4 (5.0)
高血圧	0	1 (1.3)	0	0	0	1 (1.3)
蒼白	1 (1.3)	0	0	0	0	1 (1.3)
ショック	1 (1.3)	0	0	0	0	1 (1.3)
血管炎	0	0	1 (1.3)	0	0	1 (1.3)
先天性、家族性および遺伝性障害	1 (1.3)	1 (1.3)	1 (1.3)	0	0	3 (3.8)
発育性股関節形成不全	0	1 (1.3)	0	0	0	1 (1.3)
貧血母斑	0	0	1 (1.3)	0	0	1 (1.3)
鳩胸	1 (1.3)	0	0	0	0	1 (1.3)
生殖系および乳房障害	3 (3.8)	0	0	0	0	3 (3.8)
後天性包茎	1 (1.3)	0	0	0	0	1 (1.3)
卵巣嚢胞	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:ISIS 396443
Page 15 of 15

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
陰茎障害	1 (1.3)	0	0	0	0	1 (1.3)
耳および迷路障害	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
耳の障害	0	1 (1.3)	0	0	0	1 (1.3)
耳痛	1 (1.3)	0	0	0	0	1 (1.3)
腎および尿路障害	2 (2.5)	0	0	0	0	2 (2.5)
水腎症	1 (1.3)	0	0	0	0	1 (1.3)
尿閉	1 (1.3)	0	0	0	0	1 (1.3)
血液およびリンパ系障害障害	1 (1.3)	0	0	0	0	1 (1.3)
貧血	1 (1.3)	0	0	0	0	1 (1.3)
肝胆道系障害	1 (1.3)	0	0	0	0	1 (1.3)
肝腫大	1 (1.3)	0	0	0	0	1 (1.3)
外科および内科処置	1 (1.3)	0	0	0	0	1 (1.3)
機械的換気	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]
##[redacted]20[redacted]##

表 47　Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B:Incidence of Adverse Events by Relationship to Study Drug - Treatment Group:Control

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 1 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
Number of subjects dosed						41 (100.0)
Number of subjects with an event	23 (56.1)	9 (22.0)	6 (14.6)	0	0	38 (92.7)
呼吸器、胸郭および縦隔障害	27 (65.9)	7 (17.1)	0	0	0	34 (82.9)
呼吸窮迫	13 (31.7)	1 (2.4)	0	0	0	14 (34.1)
呼吸不全	12 (29.3)	2 (4.9)	0	0	0	14 (34.1)
無気肺	9 (22.0)	0	0	0	0	9 (22.0)
急性呼吸不全	7 (17.1)	1 (2.4)	0	0	0	8 (19.5)
咳嗽	7 (17.1)	1 (2.4)	0	0	0	8 (19.5)
呼吸困難	4 (9.8)	2 (4.9)	0	0	0	6 (14.6)
鼻閉	6 (14.6)	0	0	0	0	6 (14.6)
誤嚥性肺炎	6 (14.6)	0	0	0	0	6 (14.6)
気管支分泌物貯留	3 (7.3)	1 (2.4)	0	0	0	4 (9.8)
呼吸停止	2 (4.9)	2 (4.9)	0	0	0	4 (9.8)
睡眠時無呼吸症候群	4 (9.8)	0	0	0	0	4 (9.8)
無呼吸	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
気道うっ血	3 (7.3)	0	0	0	0	3 (7.3)
鼻漏	3 (7.3)	0	0	0	0	3 (7.3)
乳幼児突発性危急事態	2 (4.9)	0	0	0	0	2 (4.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 2 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
低酸素症	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
頻呼吸	2 (4.9)	0	0	0	0	2 (4.9)
上気道炎症	2 (4.9)	0	0	0	0	2 (4.9)
誤嚥	1 (2.4)	0	0	0	0	1 (2.4)
カタル	0	1 (2.4)	0	0	0	1 (2.4)
息詰まり	1 (2.4)	0	0	0	0	1 (2.4)
気管支分泌増加	1 (2.4)	0	0	0	0	1 (2.4)
上気道分泌増加	1 (2.4)	0	0	0	0	1 (2.4)
口腔咽頭痛	1 (2.4)	0	0	0	0	1 (2.4)
上気道うっ血	1 (2.4)	0	0	0	0	1 (2.4)
呼吸補助筋の動員	0	1 (2.4)	0	0	0	1 (2.4)
感染症および寄生虫症	24 (58.5)	5 (12.2)	0	0	0	29 (70.7)
上気道感染	8 (19.5)	1 (2.4)	0	0	0	9 (22.0)
ウイルス性上気道感染	8 (19.5)	0	0	0	0	8 (19.5)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 3 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
肺炎	5 (12.2)	1 (2.4)	0	0	0	6 (14.6)
ライノウイルス感染	5 (12.2)	0	0	0	0	5 (12.2)
細菌性気管炎	4 (9.8)	0	0	0	0	4 (9.8)
鼻咽頭炎	3 (7.3)	1 (2.4)	0	0	0	4 (9.8)
細気管支炎	3 (7.3)	0	0	0	0	3 (7.3)
カンジダ感染	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
結膜炎	3 (7.3)	0	0	0	0	3 (7.3)
口腔カンジダ症	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
ＲＳウイルス細気管支炎	3 (7.3)	0	0	0	0	3 (7.3)
鼻炎	3 (7.3)	0	0	0	0	3 (7.3)
ストーマ部感染	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
コロナウイルス感染	2 (4.9)	0	0	0	0	2 (4.9)
ウイルス性胃腸炎	2 (4.9)	0	0	0	0	2 (4.9)
中耳炎	2 (4.9)	0	0	0	0	2 (4.9)
細菌性肺炎	2 (4.9)	0	0	0	0	2 (4.9)
シュードモナス感染	2 (4.9)	0	0	0	0	2 (4.9)
気道感染	2 (4.9)	0	0	0	0	2 (4.9)
ウイルス性気道感染	2 (4.9)	0	0	0	0	2 (4.9)
ブドウ球菌感染	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 4 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
ウイルス感染	2 (4.9)	0	0	0	0	2 (4.9)
細菌性疾患キャリアー	1 (2.4)	0	0	0	0	1 (2.4)
蜂巣炎	1 (2.4)	0	0	0	0	1 (2.4)
細菌性結膜炎	1 (2.4)	0	0	0	0	1 (2.4)
耳感染	1 (2.4)	0	0	0	0	1 (2.4)
真菌感染	1 (2.4)	0	0	0	0	1 (2.4)
皮膚真菌感染	1 (2.4)	0	0	0	0	1 (2.4)
麦粒腫	1 (2.4)	0	0	0	0	1 (2.4)
膿痂疹	1 (2.4)	0	0	0	0	1 (2.4)
下気道感染	1 (2.4)	0	0	0	0	1 (2.4)
パラインフルエンザウイルス感染	1 (2.4)	0	0	0	0	1 (2.4)
パラインフルエンザウイルス性肺炎	1 (2.4)	0	0	0	0	1 (2.4)
シュードモナス菌性肺炎	1 (2.4)	0	0	0	0	1 (2.4)
ウイルス性肺炎	1 (2.4)	0	0	0	0	1 (2.4)
ウイルス性気道感染	1 (2.4)	0	0	0	0	1 (2.4)
セラチア感染	1 (2.4)	0	0	0	0	1 (2.4)
皮膚カンジダ	0	1 (2.4)	0	0	0	1 (2.4)
皮膚感染	0	1 (2.4)	0	0	0	1 (2.4)
気管炎	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 5 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
ウイルス性発疹	1 (2.4)	0	0	0	0	1 (2.4)
一般・全身障害および投与部位の状態	19 (46.3)	5 (12.2)	3 (7.3)	0	0	27 (65.9)
発熱	16 (39.0)	4 (9.8)	2 (4.9)	0	0	22 (53.7)
浮腫	3 (7.3)	0	0	0	0	3 (7.3)
疼痛	1 (2.4)	0	1 (2.4)	0	0	2 (4.9)
血管穿刺部位内出血	2 (4.9)	0	0	0	0	2 (4.9)
適用部位発疹	1 (2.4)	0	0	0	0	1 (2.4)
カテーテル留置部位炎症	1 (2.4)	0	0	0	0	1 (2.4)
死亡	1 (2.4)	0	0	0	0	1 (2.4)
医療機器機能不良	1 (2.4)	0	0	0	0	1 (2.4)
医療機器閉塞	1 (2.4)	0	0	0	0	1 (2.4)
疲労	0	1 (2.4)	0	0	0	1 (2.4)
注入部位内出血	1 (2.4)	0	0	0	0	1 (2.4)
注入部位血管外漏出	1 (2.4)	0	0	0	0	1 (2.4)
注射部位血腫	1 (2.4)	0	0	0	0	1 (2.4)
血管穿刺部位反応	0	1 (2.4)	0	0	0	1 (2.4)
胃腸障害	18 (43.9)	3 (7.3)	2 (4.9)	0	0	23 (56.1)
便秘	8 (19.5)	1 (2.4)	0	0	0	9 (22.0)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 6 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
嚥下障害	7 (17.1)	1 (2.4)	0	0	0	8 (19.5)
嘔吐	6 (14.6)	1 (2.4)	1 (2.4)	0	0	8 (19.5)
下痢	6 (14.6)	0	1 (2.4)	0	0	7 (17.1)
胃食道逆流性曝露	6 (14.6)	0	0	0	0	6 (14.6)
生歯	3 (7.3)	0	0	0	0	3 (7.3)
上腹部痛	2 (4.9)	0	0	0	0	2 (4.9)
流涎過多	2 (4.9)	0	0	0	0	2 (4.9)
血性下痢	1 (2.4)	0	0	0	0	1 (2.4)
放屁	0	1 (2.4)	0	0	0	1 (2.4)
胃炎	1 (2.4)	0	0	0	0	1 (2.4)
胃腸出血	0	1 (2.4)	0	0	0	1 (2.4)
消化管刺激症状	0	1 (2.4)	0	0	0	1 (2.4)
口内炎	1 (2.4)	0	0	0	0	1 (2.4)
臨床検査	12 (29.3)	2 (4.9)	0	0	0	14 (34.1)
酸素飽和度低下	8 (19.5)	1 (2.4)	0	0	0	9 (22.0)
体温低下	1 (2.4)	0	0	0	0	1 (2.4)
Ｃ－反応性蛋白増加	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 7 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
心電図ＳＴ－Ｔ部分異常	1 (2.4)	0	0	0	0	1 (2.4)
ヘッドラグ異常	1 (2.4)	0	0	0	0	1 (2.4)
心拍数増加	1 (2.4)	0	0	0	0	1 (2.4)
リンパ節触知	1 (2.4)	0	0	0	0	1 (2.4)
呼吸数増加	0	1 (2.4)	0	0	0	1 (2.4)
レスピロウイルス検査陽性	1 (2.4)	0	0	0	0	1 (2.4)
トランスアミナーゼ上昇	1 (2.4)	0	0	0	0	1 (2.4)
ビタミンD減少	1 (2.4)	0	0	0	0	1 (2.4)
体重減少	1 (2.4)	0	0	0	0	1 (2.4)
皮膚および皮下組織障害	11 (26.8)	1 (2.4)	1 (2.4)	0	0	13 (31.7)
発疹	3 (7.3)	0	1 (2.4)	0	0	4 (9.8)
紅斑	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
褥瘡性潰瘍	2 (4.9)	0	0	0	0	2 (4.9)
アトピー性皮膚炎	2 (4.9)	0	0	0	0	2 (4.9)
接触性皮膚炎	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
おむつ皮膚炎	2 (4.9)	0	0	0	0	2 (4.9)
湿疹	2 (4.9)	0	0	0	0	2 (4.9)
皮膚乾燥	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 8 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
多汗症	1 (2.4)	0	0	0	0	1 (2.4)
毛孔性角化症	1 (2.4)	0	0	0	0	1 (2.4)
心臓障害	8 (19.5)	3 (7.3)	0	0	0	11 (26.8)
頻脈	5 (12.2)	0	0	0	0	5 (12.2)
徐脈	3 (7.3)	0	0	0	0	3 (7.3)
心肺停止	1 (2.4)	2 (4.9)	0	0	0	3 (7.3)
心停止	2 (4.9)	0	0	0	0	2 (4.9)
チアノーゼ	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
傷害、中毒および処置合併症	9 (22.0)	1 (2.4)	0	0	0	10 (24.4)
栄養補給チューブ合併症	2 (4.9)	0	0	0	0	2 (4.9)
ストーマ合併症	2 (4.9)	0	0	0	0	2 (4.9)
ストーマ部紅斑	2 (4.9)	0	0	0	0	2 (4.9)
気管内挿管合併症	1 (2.4)	0	0	0	0	1 (2.4)
擦過傷	0	1 (2.4)	0	0	0	1 (2.4)
大腿骨骨折	1 (2.4)	0	0	0	0	1 (2.4)
頭部損傷	1 (2.4)	0	0	0	0	1 (2.4)
裂傷	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 9 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
処置後挫傷	1 (2.4)	0	0	0	0	1 (2.4)
ストーマ部出血	1 (2.4)	0	0	0	0	1 (2.4)
ストーマ部炎症	1 (2.4)	0	0	0	0	1 (2.4)
ストーマ部刺激感	1 (2.4)	0	0	0	0	1 (2.4)
気管損傷	1 (2.4)	0	0	0	0	1 (2.4)
ワクチン接種合併症	1 (2.4)	0	0	0	0	1 (2.4)
代謝および栄養障害	8 (19.5)	2 (4.9)	0	0	0	10 (24.4)
低カリウム血症	3 (7.3)	0	0	0	0	3 (7.3)
乳児および小児期早期の哺育障害	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
低血糖	2 (4.9)	0	0	0	0	2 (4.9)
体重増加不良	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
脱水	1 (2.4)	0	0	0	0	1 (2.4)
食物不耐性	0	1 (2.4)	0	0	0	1 (2.4)
高血糖	1 (2.4)	0	0	0	0	1 (2.4)
ビタミンＤ欠乏	1 (2.4)	0	0	0	0	1 (2.4)
精神障害	4 (9.8)	1 (2.4)	0	0	0	5 (12.2)
激越	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 10 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
睡眠障害	2 (4.9)	0	0	0	0	2 (4.9)
易刺激性	1 (2.4)	0	0	0	0	1 (2.4)
落ち着きのなさ	1 (2.4)	0	0	0	0	1 (2.4)
先天性、家族性および遺伝性障害	4 (9.8)	0	0	0	0	4 (9.8)
停留精巣	1 (2.4)	0	0	0	0	1 (2.4)
発育性股関節形成不全	1 (2.4)	0	0	0	0	1 (2.4)
鳩胸	1 (2.4)	0	0	0	0	1 (2.4)
包茎	1 (2.4)	0	0	0	0	1 (2.4)
免疫系障害	4 (9.8)	0	0	0	0	4 (9.8)
過敏症	2 (4.9)	0	0	0	0	2 (4.9)
季節性アレルギー	2 (4.9)	0	0	0	0	2 (4.9)
薬物過敏症	1 (2.4)	0	0	0	0	1 (2.4)
筋骨格系および結合組織障害	4 (9.8)	0	0	0	0	4 (9.8)
関節拘縮	2 (4.9)	0	0	0	0	2 (4.9)
関節硬直	1 (2.4)	0	0	0	0	1 (2.4)
脊柱後弯症	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 11 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
筋力低下	1 (2.4)	0	0	0	0	1 (2.4)
頭位性斜頭症	1 (2.4)	0	0	0	0	1 (2.4)
側弯症	1 (2.4)	0	0	0	0	1 (2.4)
腱障害	1 (2.4)	0	0	0	0	1 (2.4)
血液およびリンパ系障害障害	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
貧血	1 (2.4)	0	0	0	0	1 (2.4)
骨髄障害	1 (2.4)	0	0	0	0	1 (2.4)
白血球増加症	0	1 (2.4)	0	0	0	1 (2.4)
眼障害	1 (2.4)	2 (4.9)	0	0	0	3 (7.3)
弱視	1 (2.4)	0	0	0	0	1 (2.4)
眼乾燥	0	1 (2.4)	0	0	0	1 (2.4)
流涙増加	1 (2.4)	0	0	0	0	1 (2.4)
斜視	0	1 (2.4)	0	0	0	1 (2.4)
神経系障害	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
眼振	1 (2.4)	0	0	0	0	1 (2.4)
失神寸前の状態	0	1 (2.4)	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group:Control
Page 12 of 12

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
腎および尿路障害	1 (2.4)	0	0	0	0	1 (2.4)
糖尿	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 48　Presymptomatic Infants Diagnosed With SMA:Incidence of Adverse Events by Relationship to Study Drug

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 1 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
Number of subjects dosed						17 (100.0)
Number of subjects with an event	7 (41.2)	3 (17.6)	3 (17.6)	0	0	13 (76.5)
感染症および寄生虫症	8 (47.1)	2 (11.8)	0	0	0	10 (58.8)
上気道感染	6 (35.3)	0	0	0	0	6 (35.3)
鼻咽頭炎	3 (17.6)	0	0	0	0	3 (17.6)
インフルエンザ	2 (11.8)	0	0	0	0	2 (11.8)
中耳炎	2 (11.8)	0	0	0	0	2 (11.8)
細気管支炎	1 (5.9)	0	0	0	0	1 (5.9)
気管支炎	1 (5.9)	0	0	0	0	1 (5.9)
ウイルス性胃腸炎	1 (5.9)	0	0	0	0	1 (5.9)
膿痂疹	1 (5.9)	0	0	0	0	1 (5.9)
レンサ球菌性咽頭炎	1 (5.9)	0	0	0	0	1 (5.9)
肺炎	1 (5.9)	0	0	0	0	1 (5.9)
ウイルス性肺炎	0	1 (5.9)	0	0	0	1 (5.9)
鼻炎	1 (5.9)	0	0	0	0	1 (5.9)
ライノウイルス感染	1 (5.9)	0	0	0	0	1 (5.9)
皮膚感染	1 (5.9)	0	0	0	0	1 (5.9)
尿路感染	0	1 (5.9)	0	0	0	1 (5.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 2 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
胃腸障害	6 (35.3)	0	0	0	0	6 (35.3)
腹部膨満	2 (11.8)	0	0	0	0	2 (11.8)
放屁	2 (11.8)	0	0	0	0	2 (11.8)
胃食道逆流性疾患	2 (11.8)	0	0	0	0	2 (11.8)
腹部不快感	1 (5.9)	0	0	0	0	1 (5.9)
便秘	1 (5.9)	0	0	0	0	1 (5.9)
嚥下障害	1 (5.9)	0	0	0	0	1 (5.9)
生歯	1 (5.9)	0	0	0	0	1 (5.9)
皮膚および皮下組織障害	6 (35.3)	0	0	0	0	6 (35.3)
皮膚炎	2 (11.8)	0	0	0	0	2 (11.8)
おむつ皮膚炎	2 (11.8)	0	0	0	0	2 (11.8)
貨幣状湿疹	1 (5.9)	0	0	0	0	1 (5.9)
紅斑	1 (5.9)	0	0	0	0	1 (5.9)
脂漏性皮膚炎	1 (5.9)	0	0	0	0	1 (5.9)
呼吸器、胸郭および縦隔障害	5 (29.4)	0	0	0	0	5 (29.4)
咳嗽	2 (11.8)	0	0	0	0	2 (11.8)
鼻閉	2 (11.8)	0	0	0	0	2 (11.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 3 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
呼吸性アシドーシス	1 (5.9)	0	0	0	0	1 (5.9)
呼吸窮迫	1 (5.9)	0	0	0	0	1 (5.9)
鼻漏	1 (5.9)	0	0	0	0	1 (5.9)
上気道うっ血	1 (5.9)	0	0	0	0	1 (5.9)
一般・全身障害および投与部位の状態	3 (17.6)	0	1 (5.9)	0	0	4 (23.5)
発熱	2 (11.8)	0	1 (5.9)	0	0	3 (17.6)
適用部位紅斑	1 (5.9)	0	0	0	0	1 (5.9)
注入部位内出血	1 (5.9)	0	0	0	0	1 (5.9)
傷害、中毒および処置合併症	2 (11.8)	1 (5.9)	0	0	0	3 (17.6)
転倒	1 (5.9)	0	0	0	0	1 (5.9)
処置後合併症	1 (5.9)	0	0	0	0	1 (5.9)
処置後不快感	0	1 (5.9)	0	0	0	1 (5.9)
処置後腫脹	1 (5.9)	0	0	0	0	1 (5.9)
硬膜下血腫	1 (5.9)	0	0	0	0	1 (5.9)
血液およびリンパ系障害障害	1 (5.9)	1 (5.9)	0	0	0	2 (11.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 4 of 6

	Relationship to study drug					
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	Total
好酸球増加症	0	1 (5.9)	0	0	0	1 (5.9)
好中球減少症	1 (5.9)	0	0	0	0	1 (5.9)
心臓障害	0	1 (5.9)	1 (5.9)	0	0	2 (11.8)
頻脈	0	1 (5.9)	1 (5.9)	0	0	2 (11.8)
代謝および栄養障害	2 (11.8)	0	0	0	0	2 (11.8)
脱水	1 (5.9)	0	0	0	0	1 (5.9)
成長障害	1 (5.9)	0	0	0	0	1 (5.9)
体重増加不良	1 (5.9)	0	0	0	0	1 (5.9)
筋骨格系および結合組織障害	1 (5.9)	0	1 (5.9)	0	0	2 (11.8)
関節拘縮	1 (5.9)	0	0	0	0	1 (5.9)
筋力低下	0	0	1 (5.9)	0	0	1 (5.9)
頭位性斜頭症	1 (5.9)	0	0	0	0	1 (5.9)
斜頚	1 (5.9)	0	0	0	0	1 (5.9)
体重支持困難	0	0	1 (5.9)	0	0	1 (5.9)
神経系障害	0	1 (5.9)	1 (5.9)	0	0	2 (11.8)
反射亢進	0	0	1 (5.9)	0	0	1 (5.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 5 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
筋緊張低下	0	1 (5.9)	0	0	0	1 (5.9)
血管障害	2 (11.8)	0	0	0	0	2 (11.8)
高血圧	1 (5.9)	0	0	0	0	1 (5.9)
蒼白	1 (5.9)	0	0	0	0	1 (5.9)
眼障害	1 (5.9)	0	0	0	0	1 (5.9)
後天性涙道狭窄	1 (5.9)	0	0	0	0	1 (5.9)
免疫系障害	1 (5.9)	0	0	0	0	1 (5.9)
季節性アレルギー	1 (5.9)	0	0	0	0	1 (5.9)
臨床検査	0	0	1 (5.9)	0	0	1 (5.9)
アラニンアミノトランスフェラーゼ増加	0	0	1 (5.9)	0	0	1 (5.9)
アスパラギン酸アミノトランスフェラーゼ増加	0	0	1 (5.9)	0	0	1 (5.9)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.9)	0	0	0	0	1 (5.9)
脂漏性角化症	1 (5.9)	0	0	0	0	1 (5.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 6 of 6

	Relationship to study drug					
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	Total
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0	1 (5.9)
臍肉芽腫	1 (5.9)	0	0	0	0	1 (5.9)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]
##i[redacted]20[redacted]##

表 49　Later-Onset Subjects:Incidence of Adverse Events by Relationship to Study Drug

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 1 of 11

	Relationship to study drug					
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	Total
Number of subjects dosed						56 (100.0)
Number of subjects with an event	20 (35.7)	30 (53.6)	6 (10.7)	0	0	56 (100.0)
感染症および寄生虫症	39 (69.6)	5 (8.9)	0	0	0	44 (78.6)
上気道感染	25 (44.6)	2 (3.6)	0	0	0	27 (48.2)
鼻咽頭炎	14 (25.0)	2 (3.6)	0	0	0	16 (28.6)
ウイルス感染	9 (16.1)	0	0	0	0	9 (16.1)
ウイルス性胃腸炎	8 (14.3)	0	0	0	0	8 (14.3)
レンサ球菌性咽頭炎	8 (14.3)	0	0	0	0	8 (14.3)
胃腸炎	6 (10.7)	1 (1.8)	0	0	0	7 (12.5)
中耳炎	5 (8.9)	0	0	0	0	5 (8.9)
肺炎	5 (8.9)	0	0	0	0	5 (8.9)
ウイルス性上気道感染	5 (8.9)	0	0	0	0	5 (8.9)
耳感染	3 (5.4)	1 (1.8)	0	0	0	4 (7.1)
尿路感染	4 (7.1)	0	0	0	0	4 (7.1)
結膜炎	3 (5.4)	0	0	0	0	3 (5.4)
インフルエンザ	3 (5.4)	0	0	0	0	3 (5.4)
限局性感染	3 (5.4)	0	0	0	0	3 (5.4)
ＲＳウイルス感染	3 (5.4)	0	0	0	0	3 (5.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 2 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
副鼻腔炎	3 (5.4)	0	0	0	0	3 (5.4)
ウイルス性消化管感染	2 (3.6)	0	0	0	0	2 (3.6)
ウイルス性肺炎	2 (3.6)	0	0	0	0	2 (3.6)
皮膚カンジダ	2 (3.6)	0	0	0	0	2 (3.6)
蜂巣炎	1 (1.8)	0	0	0	0	1 (1.8)
ブドウ球菌性眼感染	1 (1.8)	0	0	0	0	1 (1.8)
ウイルス性眼感染	1 (1.8)	0	0	0	0	1 (1.8)
皮膚真菌感染	1 (1.8)	0	0	0	0	1 (1.8)
手足口病	1 (1.8)	0	0	0	0	1 (1.8)
膿痂疹	1 (1.8)	0	0	0	0	1 (1.8)
下気道感染	1 (1.8)	0	0	0	0	1 (1.8)
伝染性軟属腫	1 (1.8)	0	0	0	0	1 (1.8)
単核細胞症症候群	1 (1.8)	0	0	0	0	1 (1.8)
急性中耳炎	1 (1.8)	0	0	0	0	1 (1.8)
咽頭炎	1 (1.8)	0	0	0	0	1 (1.8)
ＲＳウイルス肺炎	1 (1.8)	0	0	0	0	1 (1.8)
ＲＳウイルス細気管支炎	1 (1.8)	0	0	0	0	1 (1.8)
気道感染	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 3 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
ウイルス性気道感染	1 (1.8)	0	0	0	0	1 (1.8)
鼻炎	1 (1.8)	0	0	0	0	1 (1.8)
皮膚細菌感染	1 (1.8)	0	0	0	0	1 (1.8)
扁桃炎	1 (1.8)	0	0	0	0	1 (1.8)
膣感染	1 (1.8)	0	0	0	0	1 (1.8)
ウイルス性扁桃炎	1 (1.8)	0	0	0	0	1 (1.8)
外陰膣真菌感染	1 (1.8)	0	0	0	0	1 (1.8)
筋骨格系および結合組織障害	32 (57.1)	9 (16.1)	0	0	0	41 (73.2)
背部痛	15 (26.8)	8 (14.3)	0	0	0	23 (41.1)
側弯症	15 (26.8)	0	0	0	0	15 (26.8)
関節拘縮	10 (17.9)	0	0	0	0	10 (17.9)
関節痛	4 (7.1)	1 (1.8)	0	0	0	5 (8.9)
四肢痛	5 (8.9)	0	0	0	0	5 (8.9)
筋肉痛	3 (5.4)	1 (1.8)	0	0	0	4 (7.1)
頚部痛	3 (5.4)	0	0	0	0	3 (5.4)
筋緊張	2 (3.6)	0	0	0	0	2 (3.6)
骨盤変形	2 (3.6)	0	0	0	0	2 (3.6)
四肢拘縮	1 (1.8)	0	0	0	0	1 (1.8)
脊柱前弯症	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 4 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
傷害、中毒および処置合併症	28 (50.0)	11 (19.6)	1 (1.8)	0	0	40 (71.4)
腰椎穿刺後症候群	12 (21.4)	10 (17.9)	1 (1.8)	0	0	23 (41.1)
裂傷	7 (12.5)	0	0	0	0	7 (12.5)
処置による疼痛	6 (10.7)	0	0	0	0	6 (10.7)
節足動物咬傷	3 (5.4)	0	0	0	0	3 (5.4)
大腿骨骨折	3 (5.4)	0	0	0	0	3 (5.4)
四肢損傷	3 (5.4)	0	0	0	0	3 (5.4)
挫傷	2 (3.6)	0	0	0	0	2 (3.6)
関節脱臼	2 (3.6)	0	0	0	0	2 (3.6)
関節損傷	2 (3.6)	0	0	0	0	2 (3.6)
処置による悪心	2 (3.6)	0	0	0	0	2 (3.6)
サンバーン	2 (3.6)	0	0	0	0	2 (3.6)
隆起骨折	2 (3.6)	0	0	0	0	2 (3.6)
術後激越	0	1 (1.8)	0	0	0	1 (1.8)
節足動物刺傷	1 (1.8)	0	0	0	0	1 (1.8)
転倒	1 (1.8)	0	0	0	0	1 (1.8)
頭部損傷	1 (1.8)	0	0	0	0	1 (1.8)
靭帯捻挫	1 (1.8)	0	0	0	0	1 (1.8)
下肢骨折	1 (1.8)	0	0	0	0	1 (1.8)
半月板損傷	1 (1.8)	0	0	0	0	1 (1.8)
肉離れ	1 (1.8)	0	0	0	0	1 (1.8)
術後イレウス	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 5 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
処置による頭痛	1 (1.8)	0	0	0	0	1 (1.8)
熱傷	1 (1.8)	0	0	0	0	1 (1.8)
脛骨骨折	1 (1.8)	0	0	0	0	1 (1.8)
一般・全身障害および投与部位の状態	21 (37.5)	10 (17.9)	0	0	0	31 (55.4)
発熱	11 (19.6)	5 (8.9)	0	0	0	16 (28.6)
穿刺部位疼痛	7 (12.5)	3 (5.4)	0	0	0	10 (17.9)
疲労	1 (1.8)	2 (3.6)	0	0	0	3 (5.4)
疼痛	2 (3.6)	0	0	0	0	2 (3.6)
カテーテル留置部位出血	1 (1.8)	0	0	0	0	1 (1.8)
カテーテル留置部位疼痛	1 (1.8)	0	0	0	0	1 (1.8)
カテーテル留置部位関連反応	1 (1.8)	0	0	0	0	1 (1.8)
胸部不快感	1 (1.8)	0	0	0	0	1 (1.8)
悪寒	0	1 (1.8)	0	0	0	1 (1.8)
冷感	0	1 (1.8)	0	0	0	1 (1.8)
重力性浮腫	1 (1.8)	0	0	0	0	1 (1.8)
低体温	0	1 (1.8)	0	0	0	1 (1.8)
注射部位出血	1 (1.8)	0	0	0	0	1 (1.8)
注射部位疼痛	1 (1.8)	0	0	0	0	1 (1.8)
末梢腫脹	1 (1.8)	0	0	0	0	1 (1.8)
穿刺部位反応	1 (1.8)	0	0	0	0	1 (1.8)
血管穿刺部位内出血	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 6 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
神経系障害	18 (32.1)	10 (17.9)	2 (3.6)	0	0	30 (53.6)
頭痛	16 (28.6)	10 (17.9)	2 (3.6)	0	0	28 (50.0)
感覚鈍麻	1 (1.8)	1 (1.8)	0	0	0	2 (3.6)
失声症	1 (1.8)	0	0	0	0	1 (1.8)
味覚異常	0	1 (1.8)	0	0	0	1 (1.8)
失読症	1 (1.8)	0	0	0	0	1 (1.8)
片頭痛	1 (1.8)	0	0	0	0	1 (1.8)
錯感覚	0	0	1 (1.8)	0	0	1 (1.8)
失神	1 (1.8)	0	0	0	0	1 (1.8)
振戦	1 (1.8)	0	0	0	0	1 (1.8)
胃腸障害	19 (33.9)	7 (12.5)	0	0	0	26 (46.4)
嘔吐	7 (12.5)	5 (8.9)	0	0	0	12 (21.4)
悪心	7 (12.5)	3 (5.4)	0	0	0	10 (17.9)
便秘	7 (12.5)	0	0	0	0	7 (12.5)
アフタ性潰瘍	3 (5.4)	0	0	0	0	3 (5.4)
腹痛	2 (3.6)	0	0	0	0	2 (3.6)
上腹部痛	2 (3.6)	0	0	0	0	2 (3.6)
下痢	2 (3.6)	0	0	0	0	2 (3.6)
口腔内痛	2 (3.6)	0	0	0	0	2 (3.6)
腹部不快感	1 (1.8)	0	0	0	0	1 (1.8)
腹部症状	1 (1.8)	0	0	0	0	1 (1.8)
放屁	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 7 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
食中毒	1 (1.8)	0	0	0	0	1 (1.8)
胃腸障害	1 (1.8)	0	0	0	0	1 (1.8)
胃食道逆流性疾患	1 (1.8)	0	0	0	0	1 (1.8)
口の感覚鈍麻	0	1 (1.8)	0	0	0	1 (1.8)
口唇痛	1 (1.8)	0	0	0	0	1 (1.8)
口内炎	0	1 (1.8)	0	0	0	1 (1.8)
呼吸器、胸郭および縦隔障害	23 (41.1)	2 (3.6)	0	0	0	25 (44.6)
口腔咽頭痛	7 (12.5)	1 (1.8)	0	0	0	8 (14.3)
咳嗽	6 (10.7)	0	0	0	0	6 (10.7)
鼻漏	6 (10.7)	0	0	0	0	6 (10.7)
鼻出血	2 (3.6)	1 (1.8)	0	0	0	3 (5.4)
低酸素症	3 (5.4)	0	0	0	0	3 (5.4)
鼻閉	3 (5.4)	0	0	0	0	3 (5.4)
扁桃肥大	3 (5.4)	0	0	0	0	3 (5.4)
副鼻腔うっ血	2 (3.6)	0	0	0	0	2 (3.6)
急性呼吸不全	1 (1.8)	0	0	0	0	1 (1.8)
無気肺	1 (1.8)	0	0	0	0	1 (1.8)
発声障害	1 (1.8)	0	0	0	0	1 (1.8)
呼吸困難	1 (1.8)	0	0	0	0	1 (1.8)
肺臓炎	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 8 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
肺うっ血	1 (1.8)	0	0	0	0	1 (1.8)
呼吸障害	1 (1.8)	0	0	0	0	1 (1.8)
呼吸不全	1 (1.8)	0	0	0	0	1 (1.8)
拘束性肺疾患	1 (1.8)	0	0	0	0	1 (1.8)
喘鳴	1 (1.8)	0	0	0	0	1 (1.8)
皮膚および皮下組織障害	14 (25.0)	3 (5.4)	0	0	0	17 (30.4)
接触性皮膚炎	3 (5.4)	0	0	0	0	3 (5.4)
湿疹	2 (3.6)	0	0	0	0	2 (3.6)
ざ瘡	1 (1.8)	0	0	0	0	1 (1.8)
水疱	1 (1.8)	0	0	0	0	1 (1.8)
褥瘡性潰瘍	1 (1.8)	0	0	0	0	1 (1.8)
皮膚炎	1 (1.8)	0	0	0	0	1 (1.8)
おむつ皮膚炎	1 (1.8)	0	0	0	0	1 (1.8)
紅斑	1 (1.8)	0	0	0	0	1 (1.8)
毛孔性角化症	1 (1.8)	0	0	0	0	1 (1.8)
汗疹	1 (1.8)	0	0	0	0	1 (1.8)
寝汗	0	1 (1.8)	0	0	0	1 (1.8)
発疹	1 (1.8)	0	0	0	0	1 (1.8)
皮膚病変	0	1 (1.8)	0	0	0	1 (1.8)
蕁麻疹	0	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 9 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
臨床検査	2 (3.6)	4 (7.1)	2 (3.6)	0	0	8 (14.3)
体重減少	1 (1.8)	2 (3.6)	0	0	0	3 (5.4)
血中重炭酸塩減少	1 (1.8)	0	0	0	0	1 (1.8)
血中テストステロン減少	1 (1.8)	0	0	0	0	1 (1.8)
体温上昇	0	1 (1.8)	0	0	0	1 (1.8)
ＣＳＦ白血球数増加	0	0	1 (1.8)	0	0	1 (1.8)
心拍数増加	0	0	1 (1.8)	0	0	1 (1.8)
尿検査異常	0	1 (1.8)	0	0	0	1 (1.8)
免疫系障害	6 (10.7)	1 (1.8)	0	0	0	7 (12.5)
過敏症	3 (5.4)	0	0	0	0	3 (5.4)
季節性アレルギー	3 (5.4)	0	0	0	0	3 (5.4)
薬物過敏症	0	1 (1.8)	0	0	0	1 (1.8)
代謝および栄養障害	2 (3.6)	3 (5.4)	0	0	0	5 (8.9)
脱水	1 (1.8)	1 (1.8)	0	0	0	2 (3.6)
食欲減退	0	1 (1.8)	0	0	0	1 (1.8)
食欲亢進	1 (1.8)	0	0	0	0	1 (1.8)
ビタミンＤ欠乏	0	1 (1.8)	0	0	0	1 (1.8)
精神障害	1 (1.8)	3 (5.4)	0	0	0	4 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 10 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
激越	1 (1.8)	1 (1.8)	0	0	0	2 (3.6)
注意欠陥多動性障害	1 (1.8)	0	0	0	0	1 (1.8)
不快気分	1 (1.8)	0	0	0	0	1 (1.8)
不眠症	0	1 (1.8)	0	0	0	1 (1.8)
睡眠時随伴症	0	1 (1.8)	0	0	0	1 (1.8)
チック	1 (1.8)	0	0	0	0	1 (1.8)
心因性嘔吐	1 (1.8)	0	0	0	0	1 (1.8)
心臓障害	2 (3.6)	0	1 (1.8)	0	0	3 (5.4)
動悸	1 (1.8)	0	1 (1.8)	0	0	2 (3.6)
頻脈	1 (1.8)	0	0	0	0	1 (1.8)
耳および迷路障害	3 (5.4)	0	0	0	0	3 (5.4)
耳痛	1 (1.8)	0	0	0	0	1 (1.8)
乗物酔い	1 (1.8)	0	0	0	0	1 (1.8)
鼓膜穿孔	1 (1.8)	0	0	0	0	1 (1.8)
腎および尿路障害	2 (3.6)	1 (1.8)	0	0	0	3 (5.4)
排尿困難	1 (1.8)	0	0	0	0	1 (1.8)
尿失禁	0	1 (1.8)	0	0	0	1 (1.8)
膀胱尿管逆流	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 11 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
眼障害	2 (3.6)	0	0	0	0	2 (3.6)
遠視	1 (1.8)	0	0	0	0	1 (1.8)
斜視	1 (1.8)	0	0	0	0	1 (1.8)
血液およびリンパ系障害障害	1 (1.8)	0	0	0	0	1 (1.8)
好中球減少症	1 (1.8)	0	0	0	0	1 (1.8)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.8)	0	0	0	0	1 (1.8)
皮膚乳頭腫	1 (1.8)	0	0	0	0	1 (1.8)
血管障害	0	1 (1.8)	0	0	0	1 (1.8)
低血圧	0	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 50　Incidence of Events With a Fatal Outcome in Infants Diagnosed With SMA

Incidence of events with a fatal outcome in infants diagnosed with SMA
Page 1 of 2

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	0	13 (31.7)	12 (15.0)	16 (16.0)	16 (13.7)
呼吸器、胸郭および縦隔障害	0	10 (24.4)	7 (8.8)	10 (10.0)	10 (8.5)
呼吸不全	0	7 (17.1)	4 (5.0)	6 (6.0)	6 (5.1)
急性呼吸不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
窒息	0	0	0	1 (1.0)	1 (0.9)
呼吸停止	0	0	1 (1.3)	1 (1.0)	1 (0.9)
呼吸窮迫	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
心臓障害	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
心肺停止	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
神経系障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of events with a fatal outcome in infants diagnosed with SMA
Page 2 of 2

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
一般・全身障害および投与部位の状態	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
感染症および寄生虫症	0	0	0	1 (1.0)	1 (0.9)
ウイルス性下気道感染	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 51　Incidence of Events With a Fatal Outcome in Subjects With SMA

Incidence of events with a fatal outcome in subjects with SMA
Page 1 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	0	16 (16.0)	16 (13.7)	0	16 (9.2)
呼吸器、胸郭および縦隔障害	0	10 (10.0)	10 (8.5)	0	10 (5.8)
呼吸不全	0	6 (6.0)	6 (5.1)	0	6 (3.5)
急性呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
窒息	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸停止	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸窮迫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心臓障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
心肺停止	0	2 (2.0)	2 (1.7)	0	2 (1.2)
神経系障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
脳損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of events with a fatal outcome in subjects with SMA
Page 2 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
一般・全身障害および投与部位の状態	0	1 (1.0)	1 (0.9)	0	1 (0.6)
死亡	0	1 (1.0)	1 (0.9)	0	1 (0.6)
感染症および寄生虫症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性下気道肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]
##[redacted]20[redacted]##

表 52　　Incidence of Potentially Drug-Related Serious Adverse Events in Infants Diagnosed With SMA

Incidence of potentially drug-related serious adverse events in infants diagnosed with SMA

No Potentially Drug-Related Serious Adverse Events Reported

SOURCE:[redacted]　　DATE:[redacted]
##[redacted]20[redacted]##

表 53　Incidence of Adverse Events That Led to Discontinuation of Study Drug in Infants Diagnosed With SMA

Incidence of adverse events that led to discontinuation of study drug in infants diagnosed with SMA
Page 1 of 2

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	17 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	117 (100.0)
Number of subjects with an event	0	12 (29.3)	12 (15.0)	15 (15.0)	15 (12.8)
呼吸器、胸郭および縦隔障害	0	9 (22.0)	7 (8.8)	9 (9.0)	9 (7.7)
呼吸不全	0	6 (14.6)	4 (5.0)	6 (6.0)	6 (5.1)
急性呼吸不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
呼吸停止	0	0	1 (1.3)	1 (1.0)	1 (0.9)
呼吸窮迫	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.9)
心臓障害	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
心肺停止	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
神経系障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.9)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events that led to discontinuation of study drug in infants diagnosed with SMA
Page 2 of 2

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
一般・全身障害および投与部位の状態	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.9)
感染症および寄生虫症	0	0	0	1 (1.0)	1 (0.9)
ウイルス性下気道感染	0	0	0	1 (1.0)	1 (0.9)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies:ISIS 396443

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 54　Incidence of Adverse Events That Led to Discontinuation of Study Drug in Subjects With SMA

Incidence of adverse events that led to discontinuation of study drug in subjects with SMA
Page 1 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	17 (100.0)	100 (100.0)	117 (100.0)	56 (100.0)	173 (100.0)
Number of subjects with an event	0	15 (15.0)	15 (12.8)	0	15 (8.7)
呼吸器、胸郭および縦隔障害	0	9 (9.0)	9 (7.7)	0	9 (5.2)
呼吸不全	0	6 (6.0)	6 (5.1)	0	6 (3.5)
急性呼吸不全	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸停止	0	1 (1.0)	1 (0.9)	0	1 (0.6)
呼吸窮迫	0	1 (1.0)	1 (0.9)	0	1 (0.6)
心臓障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
心肺停止	0	2 (2.0)	2 (1.7)	0	2 (1.2)
神経系障害	0	2 (2.0)	2 (1.7)	0	2 (1.2)
脳損傷	0	1 (1.0)	1 (0.9)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Incidence of adverse events that led to discontinuation of study drug in subjects with SMA
Page 2 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
一般・全身障害および投与部位の状態	0	1 (1.0)	1 (0.9)	0	1 (0.6)
死亡	0	1 (1.0)	1 (0.9)	0	1 (0.6)
感染症および寄生虫症	0	1 (1.0)	1 (0.9)	0	1 (0.6)
ウイルス性下気道肺炎	0	1 (1.0)	1 (0.9)	0	1 (0.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE:[redacted] DATE:[redacted]
##[redacted]20[redacted]##

表 55　Infantile-Onset Subjects Treated With ISIS 396443 in Controlled and Uncontrolled Studies:Shifts From Baseline to Maximum Post-Baseline Urinalysis Laboratory Values

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 1 of 12
URINALYSIS:Specific Gravity

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	62	1	23
High/positive	0	0	0
Unknown	2	0	2

SOURCE:[redacted]20[redacted]　DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 2 of 12
URINALYSIS:pH

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	68	4	23
High/positive	1	0	0
Unknown	2	0	2

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 3 of 12
URINALYSIS:Protein

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	49	19	19
High/positive	2	3	4
Unknown	2	0	2

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 4 of 12
URINALYSIS:Glucose

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	71	1	23
High/positive	0	1	0
Unknown	2	0	2

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 5 of 12
URINALYSIS:Ketones

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	60	11	21
High/positive	0	2	2
Unknown	2	0	2

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 6 of 12
URINALYSIS:Bilirubin

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	68	0	23
High/positive	0	0	0
Unknown	7	0	2

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 7 of 12
URINALYSIS:Occult Blood

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	62	3	24
High/positive	4	1	0
Unknown	2	1	3

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 8 of 12
URINALYSIS:Erythrocytes (/HPF)

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	15	2	11
High/positive	0	2	0
Unknown	22	1	47

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 9 of 12
URINALYSIS:Leukocytes

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	24	7	23
High/positive	3	4	2
Unknown	20	4	13

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 10 of 12
URINALYSIS:Epithelial Cells (/HPF)

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	4	1	2
High/positive	2	3	0
Unknown	1	1	86

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 11 of 12
URINALYSIS:Bacteria

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	4	4	13
High/positive	0	6	0
Unknown	13	4	56

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
shifts from baseline to maximum post-baseline urinalysis laboratory values
Page 12 of 12
URINALYSIS:Casts

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	3	0	2
High/positive	0	0	0
Unknown	5	1	89

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 56　Summary of Shifts From Baseline for Hematology in Infants Diagnosed With SMA

Summary of shifts from baseline for hematology in infants diagnosed with SMA
Page 1 of 3

		Presymptomatic:	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Leukocytes (10^9/L)	Low	1/ 13 (8)	2/ 27 (7)	3/ 55 (5)	5/ 74 (7)	6/ 87 (7)
	High	1/ 14 (7)	5/ 28 (18)	12/ 54 (22)	20/ 71 (28)	21/ 85 (25)
Neutrophils (10^9/L)	Low	2/ 2 (100)	2/ 25 (8)	5/ 55 (9)	8/ 68 (12)	10/ 70 (14)
	High	0/ 2	2/ 26 (8)	6/ 56 (11)	14/ 75 (19)	14/ 77 (18)
Neutrophils/Leukocytes (%)	Low	3/ 3 (100)	4/ 6 (67)	8/ 10 (80)	15/ 21 (71)	18/ 24 (75)
	High	0/ 3	1/ 28 (4)	2/ 57 (4)	6/ 71 (8)	6/ 74 (8)
Lymphocytes (10^9/L)	Low	0/ 15	0/ 27	2/ 57 (4)	6/ 77 (8)	6/ 92 (7)
	High	3/ 15 (20)	8/ 24 (33)	22/ 55 (40)	26/ 69 (38)	29/ 84 (35)
Lymphocytes/Leukocytes (%)	Low	0/ 15	1/ 28 (4)	2/ 57 (4)	4/ 70 (6)	4/ 85 (5)
	High	5/ 5 (100)	4/ 6 (67)	8/ 9 (89)	16/ 20 (80)	21/ 25 (84)
Monocytes (10^9/L)	Low	8/ 15 (53)	3/ 20 (15)	8/ 33 (24)	9/ 53 (17)	17/ 68 (25)
	High	1/ 14 (7)	0/ 27	2/ 57 (4)	9/ 67 (13)	10/ 81 (12)

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value.
Numbers in parentheses are percentages based on the number at risk.
a) Shift to low includes normal to low, high to low, and unknown to low.
b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

Summary of shifts from baseline for hematology in infants diagnosed with SMA
Page 2 of 3

		Presymptomatic:	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Monocytes/Leukocytes (%)	Low	7/ 14 (50)	4/ 23 (17)	7/ 44 (16)	8/ 58 (14)	15/ 72 (21)
	High	1/ 13 (8)	2/ 26 (8)	4/ 57 (7)	10/ 68 (15)	11/ 81 (14)
Eosinophils (10^9/L)	Low	0/ 15	0/ 27	1/ 57 (2)	6/ 77 (8)	6/ 92 (7)
	High	10/ 11 (91)	10/ 15 (67)	12/ 21 (57)	17/ 30 (57)	27/ 41 (66)
Eosinophils/Leukocytes (%)	Low	0/ 15	0/ 28	1/ 57 (2)	6/ 70 (9)	6/ 85 (7)
	High	6/ 9 (67)	9/ 21 (43)	18/ 31 (58)	21/ 43 (49)	27/ 52 (52)
Basophils (10^9/L)	Low	0/ 15	1/ 27 (4)	0/ 57	4/ 72 (6)	4/ 87 (5)
	High	1/ 15 (7)	1/ 27 (4)	2/ 56 (4)	6/ 71 (8)	7/ 86 (8)
Basophils/Leukocytes (%)	Low	0/ 15	1/ 27 (4)	0/ 56	4/ 65 (6)	4/ 80 (5)
	High	3/ 15 (20)	3/ 27 (11)	7/ 56 (13)	8/ 69 (12)	11/ 84 (13)
Erythrocytes (10^12/L)	Low	1/ 14 (7)	2/ 28 (7)	1/ 56 (2)	3/ 76 (4)	4/ 90 (4)
	High	5/ 14 (36)	1/ 21 (5)	8/ 41 (20)	15/ 61 (25)	20/ 75 (27)

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
a) Shift to low includes normal to low, high to low, and unknown to low.
b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Summary of shifts from baseline for hematology in infants diagnosed with SMA
Page 3 of 3

		Presymptomatic:	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Ery.Mean Corpuscular Volume (fL)	Low	1/ 3 (33)	1/ 5 (20)	1/ 8 (13)	3/ 24 (13)	4/ 27 (15)
	High	0/ 3	0/ 5	0/ 8	3/ 28 (11)	3/ 31 (10)
Ery.Mean Corpuscular Hemoglobin (pg/cell)	Low	1/ 3 (33)	1/ 5 (20)	1/ 7 (14)	5/ 23 (22)	6/ 26 (23)
	High	0/ 3	0/ 5	2/ 8 (25)	2/ 27 (7)	2/ 30 (7)
Ery.Mean Corpuscular HGB Concentration (g/L)	Low	0/ 3	1/ 5 (20)	0/ 7	9/ 25 (36)	9/ 28 (32)
	High	0/ 3	0/ 5	0/ 8	2/ 26 (8)	2/ 29 (7)
Hemoglobin (g/L)	Low	2/ 13 (15)	4/ 28 (14)	8/ 55 (15)	14/ 73 (19)	16/ 86 (19)
	High	0/ 14	4/ 28 (14)	6/ 56 (11)	14/ 76 (18)	14/ 90 (16)
Hematocrit (%)	Low	3/ 12 (25)	5/ 27 (19)	9/ 53 (17)	13/ 71 (18)	16/ 83 (19)
	High	0/ 14	4/ 28 (14)	4/ 56 (7)	14/ 76 (18)	14/ 90 (16)
Platelets (10^9/L)	Low	2/ 15 (13)	0/ 28	6/ 55 (11)	8/ 75 (11)	10/ 90 (11)
	High	10/ 13 (77)	3/ 13 (23)	8/ 30 (27)	15/ 45 (33)	25/ 58 (43)

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
a) Shift to low includes normal to low, high to low, and unknown to low.
b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 57　Summary of Shifts From Baseline for Blood Chemistry in Infants Diagnosed With SMA

Summary of shifts from baseline for blood chemistry in infants diagnosed with SMA
Page 1 of 3

		Presymptomatic:	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Liver function						
Aspartate Aminotransferase (U/L)	High	2/ 14 (14)	1/ 25 (4)	3/ 56 (5)	5/ 72 (7)	7/ 86 (8)
Alanine Aminotransferase (U/L)	High	3/ 13 (23)	4/ 25 (16)	6/ 55 (11)	8/ 73 (11)	11/ 86 (13)
Alkaline Phosphatase (U/L)	High	1/ 15 (7)	0/ 26	1/ 58 (2)	2/ 74 (3)	3/ 89 (3)
Direct Bilirubin (umol/L)	High	0/ 15	0/ 24	0/ 50	5/ 63 (8)	5/ 78 (6)
Indirect Bilirubin (umol/L)	High	1/ 10 (10)	0/ 23	0/ 50	0/ 57	1/ 67 (1)
Kidney function						
Blood Urea Nitrogen (mmol/L)	High	0/ 16	0/ 28	1/ 58 (2)	1/ 77 (1)	1/ 93 (1)
Creatinine (umol/L)	High	0/ 15	0/ 28	0/ 59	0/ 79	0/ 94
Cystatin C (mg/L)	High	0/ 1	1/ 28 (4)	0/ 60	0/ 63	0/ 64

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value.
Numbers in parentheses are percentages based on the number at risk.
a) Shift to low includes normal to low, high to low, and unknown to low.
b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]

Summary of shifts from baseline for blood chemistry in infants diagnosed with SMA
Page 2 of 3

		Presymptomatic:	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Electrolytes						
Sodium (mmol/L)	Low	0/ 14	0/ 28	1/ 59 (2)	5/ 76 (7)	5/ 90 (6)
	High	0/ 16	0/ 28	0/ 59	2/ 79 (3)	2/ 95 (2)
Potassium (mmol/L)	Low	0/ 15	4/ 28 (14)	3/ 57 (5)	6/ 77 (8)	6/ 92 (7)
	High	2/ 11 (18)	1/ 28 (4)	4/ 56 (7)	8/ 76 (11)	10/ 87 (11)
Chloride (mmol/L)	Low	0/ 16	1/ 28 (4)	3/ 59 (5)	6/ 79 (8)	6/ 95 (6)
	High	0/ 16	0/ 28	1/ 58 (2)	3/ 77 (4)	3/ 93 (3)
Bicarbonate (mmol/L)	Low	0/ 0	0/ 1	2/ 3 (67)	7/ 22 (32)	7/ 22 (32)
	High	0/ 0	0/ 1	0/ 3	2/ 23 (9)	2/ 23 (9)
Other						
Protein (g/L)	Low	5/ 12 (42)	0/ 26	2/ 55 (4)	3/ 71 (4)	8/ 83 (10)
	High	0/ 16	2/ 28 (7)	9/ 57 (16)	16/ 77 (21)	16/ 93 (17)
Albumin (g/L)	Low	0/ 15	0/ 28	0/ 59	1/ 79 (1)	1/ 94 (1)
	High	3/ 14 (21)	1/ 28 (4)	0/ 57	4/ 77 (5)	7/ 91 (8)
Calcium (mmol/L)	Low	1/ 15 (7)	0/ 28	4/ 58 (7)	4/ 78 (5)	5/ 93 (5)
	High	2/ 11 (18)	1/ 24 (4)	4/ 51 (8)	12/ 67 (18)	14/ 78 (18)
Phosphate (mmol/L)	Low	0/ 15	0/ 27	0/ 59	0/ 79	0/ 94
	High	0/ 15	1/ 27 (4)	2/ 59 (3)	4/ 75 (5)	4/ 90 (4)

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.

a) Shift to low includes normal to low, high to low, and unknown to low.

b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Summary of shifts from baseline for blood chemistry in infants diagnosed with SMA
Page 3 of 3

		Presymptomatic:	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Continued..						
Glucose (mmol/L)	Low	0/ 15	2/ 27 (7)	2/ 58 (3)	4/ 78 (5)	4/ 93 (4)
	High	4/ 14 (29)	9/ 23 (39)	13/ 42 (31)	15/ 60 (25)	19/ 74 (26)
Creatine Kinase (U/L)	Low	0/ 15	0/ 27	0/ 57	2/ 77 (3)	2/ 92 (2)
	High	7/ 11 (64)	4/ 14 (29)	10/ 26 (38)	13/ 36 (36)	20/ 47 (43)

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
a) Shift to low includes normal to low, high to low, and unknown to low.
b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 58　Summary of Shifts From Baseline for CSF Safety Parameters in Subjects With Later-Onset SMA

Summary of shifts from baseline for CSF safety parameters in subjects with later-onset SMA

		Later-onset SMA
Erythrocytes (/cubic mm)	Low	0/ 43
	High	17/ 33 (52)
Leukocytes (/cubic mm)	Low	0/ 52
	High	9/ 51 (18)
Glucose (mmol/L)	Low	7/ 43 (16)
	High	2/ 51 (4)
Protein (g/L)	Low	4/ 40 (10)
	High	9/ 53 (17)

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
a) Shift to low includes normal to low, high to low, and unknown to low.
b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted]　DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 59　Summary of Shifts in ECG Results in Infantile-Onset SMA

Summary of shifts in ECG results in infantile-onset SMA

	Controlled study (CS3B)		Controlled and uncontrolled studies:
	Control	ISIS 396443	ISIS 396443
Number of subjects dosed	41	80	100
Shift to abnormal, not clinically significant (a)	4/34 (12)	12/65 (18)	16/81 (20)
Shift to abnormal, clinically significant (b)	0/34	5/65 (8)	7/81 (9)

NOTE:Entries are number with a shift/number at risk (percentage).Number at risk is the number of subjects whose baseline value was not abnormal and who had at least one post-baseline value.
(a) Shift to 'abnormal, not clinically significant' includes 'unknown' or 'normal' to 'abnormal, not clinically significant'.
(b) Shift to 'abnormal, clinically significant' includes 'unknown' or 'normal' to 'abnormal, clinically significant'.

SOURCE:[redacted]20[redacted]　DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 60　Summary of Shifts in ECG Results in Later-Onset SMA

Summary of shifts in ECG results in later-onset SMA

	Later-onset SMA
Number of subjects dosed	56
Shift to abnormal, not clinically significant (a)	30/45 (67)
Shift to abnormal, clinically significant (b)	0/45

NOTE:Entries are number with a shift/number at risk (percentage).Number at risk is the number of subjects whose baseline value was not abnormal and who had at least one post-baseline value.
(a) Shift to 'abnormal, not clinically significant' includes 'unknown' or 'normal' to 'abnormal, not clinically significant'.
(b) Shift to 'abnormal, clinically significant' includes 'unknown' or 'normal' to 'abnormal, clinically significant'.

SOURCE:[redacted]
DATE:[redacted]

表 61　Incidence of Outliers in ECGs Based on Fridericia Corrected QT Interval

Incidence of outliers in ECGs based on Fridericia corrected QT interval

	Infantile-onset SMA				
	Controlled study (CS3B)		Controlled and uncontrolled studies:Later-onset subjects		All treated
	Control	ISIS 396443	ISIS 396443	SMA	with SMA
Number of subjects dosed	41	80	100	56	173
Number of subjects with:					
(i) any post-baseline ECG	41 (100)	80 (100)	100 (100)	56 (100)	156 (100)
Post-baseline corrected QTcF (msec)					
>450	13 (32)	20 (25)	28 (28)	20 (36)	48 (31)
>480	2 (5)	8 (10)	10 (10)	2 (4)	12 (8)
>500	0	5 (6)	5 (5)	2 (4)	7 (4)
(ii) a baseline and any post-baseline ECG	41 (100)	80 (100)	100 (100)	55 (100)	155 (100)
Increase from baseline in QTcF (msec)					
>30	10 (24)	14 (18)	21 (21)	18 (33)	39 (25)
>60	3 (7)	5 (6)	6 (6)	0	6 (4)
>500 msec post-baseline and >60 msec increase from baseline	0	4 (5)	4 (4)	0	4 (3)

Abbreviation:QTcF=Fridericia-corrected QT interval

SOURCE:[redacted]20[redacted]　　DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 62　Subject Listing of Neurological Tests Performed That Were Not Secondary to SMA With Their Findings

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 1 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1775-3003	CRANIAL NERVES - VISION	-15	Screening	01MAY2012	ABNORMAL	Corrective lenses for astigmatism
396443-CS1 /1775-3004	GENERAL - SPEECH/LANGUAGE	467	Day 8-10	13SEP2013	ABNORMAL	IMMATURE ARTICULATION
	SENSATION - DIP REGION - DISTAL INTERPHALANGEAL JOINT OF THE HAND - LEFT - TEMPERATURE SENSATION	548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT
	SENSATION - DIP REGION - DISTAL INTERPHALANGEAL JOINT OF THE HAND - RIGHT - TEMPERATURE SENSATION	548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT
	SENSATION - FIRST METATARSAL BONE - FOOT DIGIT 1 - LEFT - TEMPERATURE SENSATION	443	Screening-10	20AUG2013	ABSENT	UNKNOWN
		460	Day 1-10/ PRE-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 4 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 6 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT

SOURCE: [redacted]20[redacted]　　DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 2 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1775-3004	SENSATION - FIRST METATARSAL BONE - FOOT DIGIT 1 - RIGHT - TEMPERATURE SENSATION	443	Screening-10	20AUG2013	ABSENT	UNKNOWN
		460	Day 1-10/ PRE-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 4 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 6 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT
	SENSATION - FOOT DIGIT 1 - LEFT - TEMPERATURE SENSATION	29	Day 29	02JUL2012	ABSENT	Maybe lost interest
	SENSATION - FOOT DIGIT 1 - RIGHT - TEMPERATURE SENSATION	29	Day 29	02JUL2012	ABSENT	Maybe lost interest
396443-CS1 /1775-4002	CRANIAL NERVES - FACIAL MOTION	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015	ABNORMAL	MINIMAL EYE CLOSURE WEAKNESS BILATERALLY.
	GENERAL - APPEARANCE/FACIAL/MOTOR EXPR	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015		MINIMAL EYE CLOSURE WEAKNESS BILATERALLY.
	GENERAL - MENTAL STATUS	400	Day 1-10/ 4 HOUR POST-DOSE	14AUG2013	ABNORMAL	DUE TO SEDATION

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 3 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1775-4002	GENERAL - SPEECH/LANGUAGE	400	Day 1-10/ 4 HOUR POST-DOSE	14AUG2013	ABNORMAL	DUE TO SEDATION
	REFLEXES - ANKLE - LEFT - REFLEX	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015	0	
	REFLEXES - ANKLE - RIGHT - REFLEX	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015	0	
		1017	Day 351-12/ 6 HOUR POST-DOSE	23APR2015	0	
396443-CS1 /1776-1004	GENERAL - MENTAL STATUS	1275	Day 533-12	20JUL2015	ABNORMAL	ANXIOUS PER PROCEDURE
396443-CS1 /1776-2002	CRANIAL NERVES - HEARING	726	Screening-12	07MAR2014	ABNORMAL	MILDLY DECREASED BILATERAL TO TUNING FORK
	GENERAL - MENTAL STATUS	1464	Day 715-12	14MAR2016	ABNORMAL	SAD AND TEARFUL
396443-CS1 /1778-4009	PLANTAR RESPONSE - TOE - LEFT - REFLEX	-6	Screening	10AUG2012	ABNORMAL	extensor plantar response
		1	Day 1/ PRE-DOSE	16AUG2012	ABNORMAL	extensor plantar response
		1	Day 1/ 4 HOUR POST-DOSE	16AUG2012	ABNORMAL	extensor plantar response

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 4 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1778-4009	PLANTAR RESPONSE - TOE - LEFT - REFLEX	1	Day 1/ 6 HOUR POST-DOSE	16AUG2012	ABNORMAL	extensor plantar response
		2	Day 2	17AUG2012	ABNORMAL	Babinski
		9	Day 8	24AUG2012	ABNORMAL	extensor plantar response
		29	Day 29	13SEP2012	ABNORMAL	extensor plantar response
		85	Day 85	08NOV2012	ABNORMAL	Extensor plantar response
396443-CS1 /1780-1003	MOTOR SYSTEM - DORSIFLEXION - FOOT - RIGHT - MUSCLE TONE	328	Day 36-2	10DEC2012	ABNORMAL	SPLINTING DUE TO PLANTAR WART
396443-CS1 /1780-1005	GENERAL - SPEECH/LANGUAGE	-2	Screening	23JAN2012	ABNORMAL	Some articulation problems and speech delay, NCS (See medical history item #2)
		1	Day 1/ PRE-DOSE	25JAN2012	ABNORMAL	articulation/ speech abnormal, NCS, no change from baseline
		1	Day 1/ 4 HOUR POST-DOSE	25JAN2012	ABNORMAL	NCS, no change from baseline- articulation dificulties
		1	Day 1/ 6 HOUR POST-DOSE	25JAN2012	ABNORMAL	No change from baseline
		2	Day 2	26JAN2012	ABNORMAL	No change from baseline
		8	Day 8	01FEB2012	ABNORMAL	No change from baseline
		29	Day 29	22FEB2012	ABNORMAL	articulation disorder, NCS, no change from baseline
		422	Screening-2	21MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 5 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1780-1005	GENERAL - SPEECH/LANGUAGE	427	Day 1-2/ PRE-DOSE	26MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		427	Day 1-2/ 4 HOUR POST-DOSE	26MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		427	Day 1-2/ 6 HOUR POST-DOSE	26MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		428	Day 2-2	27MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		434	Day 8-2	02APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		455	Day 29-2/ PRE-DOSE	23APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		455	Day 29-2/ 4 HOUR POST-DOSE	23APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		455	Day 29-2/ 6 HOUR POST-DOSE	23APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		461	Day 36-2	29APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		511	Day 85-2/ PRE-DOSE	18JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		511	Day 85-2/ 4 HOUR POST-DOSE	18JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		511	Day 85-2/ 6 HOUR POST-DOSE	18JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		517	Day 92-2	24JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		601	Day 169-2	16SEP2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER: IMPROVED

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 6 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1780-1005	GENERAL - SPEECH/LANGUAGE	680	Day 253-2	04DEC2013	ABNORMAL	ARTICULATION AND LANGUAGE DISORDER UNCHANGED
		812	Screening-12	15APR2014	ABNORMAL	ARTICULATION ABNORMAL-MILD
		818	Day 1-12	21APR2014	ABNORMAL	ARTICULATION ABNORMAL -MILD
		818	Day 1-12/ 4 HOUR POST-DOSE	21APR2014	ABNORMAL	ARTICULATION ABNORMAL-MILD
		818	Day 1-12/ 6 HOUR POST-DOSE	21APR2014	ABNORMAL	ARTICULATION ABNORMAL-MILD
		825	Day 8-12	28APR2014	ABNORMAL	ARTICULATION
		903	Day 85-12	15JUL2014	ABNORMAL	ARTICULATION--MILD.
		987	Day 169-12	07OCT2014	ABNORMAL	ARTICULATIONS ABOUT MILD
		987	Day 169-12/ 4 HOUR POST-DOSE	07OCT2014	ABNORMAL	ARTICULATION ABOUT MILD
		987	Day 169-12/ 6 HOUR POST-DOSE	07OCT2014	ABNORMAL	MILD ARTICULATION
		1084	Day 260-12	12JAN2015	ABNORMAL	ARTICULATIONS ABOUT MILD
		1175	Day 351-12	13APR2015	ABNORMAL	MILD ARTICULATION
		1175	Day 351-12/ 4 HOUR POST-DOSE	13APR2015	ABNORMAL	ARTICULATION ABOUT MILD
		1175	Day 351-12/ 6 HOUR POST-DOSE	13APR2015	ABNORMAL	ARTICULATION ABOUT MILD
		1269	Day 442-12	16JUL2015	ABNORMAL	ARTICULATION
		1344	Day 533-12	29SEP2015	ABNORMAL	MILD ARTICULATION
		1344	Day 533-12/ 4 HOUR POST-DOSE	29SEP2015	ABNORMAL	MILD ARTICULATION
		1344	Day 533-12/ 6 HOUR POST-DOSE	29SEP2015	ABNORMAL	MILD ARTICULATION
		1444	Day 624-12	07JAN2016	ABNORMAL	MILD ARTICULATION
		1533	Day 715-12	05APR2016	ABNORMAL	MILD ARTICULATION

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 7 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1780-4006	REFLEXES - ANKLE - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - ANKLE - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BICEPS - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BICEPS - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BRACHIORADIALIS - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BRACHIORADIALIS - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - KNEE - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - KNEE - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - TRICEPS - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - TRICEPS - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
396443-CS2 /1775-3204	CRANIAL NERVES - EYE MOVEMENT	260	Day 253-2	15JAN2014	ABNORMAL	VERY SLLIGHT STRABISIMUS ON RIGHT OTHERWISE NORMAL

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 8 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2 /1778-1208	CRANIAL NERVES - VISION	-8	Screening-2	27NOV2012	ABNORMAL	MYOPIA, WEARS CONTACT LENSES
		1	Day 1-2/ PRE-DOSE	05DEC2012	ABNORMAL	MYOPIA
		1	Day 1-2/ 4 HOUR POST-DOSE	05DEC2012	ABNORMAL	MYOPIA
		1	Day 1-2/ 6 HOUR POST-DOSE	05DEC2012	ABNORMAL	MYOPIA
		2	Day 2-2	06DEC2012	ABNORMAL	MYOPIA
		8	Day 8-2	12DEC2012	ABNORMAL	MYOPIA - WEARS CONTACT LENSES
		29	Day 29-2/ PRE-DOSE	02JAN2013	ABNORMAL	MYOPIA
		29	Day 29-2/ 4 HOUR POST-DOSE	02JAN2013	ABNORMAL	MYOPIA
		29	Day 29-2/ 6 HOUR POST-DOSE	02JAN2013	ABNORMAL	MYOPIA
		35	Day 36-2	08JAN2013	ABNORMAL	MYOPIA
		86	Day 85-2/ PRE-DOSE	28FEB2013	ABNORMAL	MYOPIA.WEARING GLASSES.
		86	Day 85-2/ 4 HOUR POST-DOSE	28FEB2013	ABNORMAL	MYOPIA, WEARS GLASSES
		86	Day 85-2/ 6 HOUR POST-DOSE	28FEB2013	ABNORMAL	MYOPIA, WEARS GLASSES
		92	Day 92-2	06MAR2013	ABNORMAL	MYOPIA, WEARS GLASSES
		170	Day 169-2	23MAY2013	ABNORMAL	MYOPIA
		251	Day 253-2	12AUG2013	ABNORMAL	MYOPIA

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 9 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2 /1778-2206	PLANTAR RESPONSE - TOE - LEFT - REFLEX	30	Day 29-2/ PRE-DOSE	10APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
		30	Day 29-2/ 4 HOUR POST-DOSE	10APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
		30	Day 29-2/ 6 HOUR POST-DOSE	10APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
		37	Day 36-2	17APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
396443-CS2 /1778-3207	CRANIAL NERVES - VISION	-9	Screening-2	14MAY2013	ABNORMAL	MYOPIA
		1	Day 1-2/ PRE-DOSE	23MAY2013	ABNORMAL	MYOPIA
		1	Day 1-2/ 4 HOUR POST-DOSE	23MAY2013	ABNORMAL	MYOPIA
		1	Day 1-2/ 6 HOUR POST-DOSE	23MAY2013	ABNORMAL	MYOPIA
		2	Day 2-2	24MAY2013	ABNORMAL	MYOPIA
		7	Day 8-2	29MAY2013	ABNORMAL	MYOPIA
		36	Day 36-2	27JUN2013	ABNORMAL	MYOPIA
		79	Day 85-2/ PRE-DOSE	09AUG2013	ABNORMAL	MYOPIA
		79	Day 85-2/ 4 HOUR POST-DOSE	09AUG2013	ABNORMAL	MYOPIA
		79	Day 85-2/ 6 HOUR POST-DOSE	09AUG2013	ABNORMAL	MYOPIA
		85	Day 92-2	15AUG2013	ABNORMAL	MYOPIA
		168	Day 169-2	06NOV2013	ABNORMAL	MYOPIA
		253	Day 253-2	30JAN2014	ABNORMAL	MYOPIA

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 10 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2 /1780-1201	MOTOR SYSTEM - DORSIFLEXION - FOOT - LEFT - MUSCLE TONE	2	Day 2-2	17OCT2012	ABNORMAL	SECONDARY TO IV PLACEMENT AND REMOVAL.ANXIOUS, WOULD NOT COOPERATE.
396443-CS2 /1780-3205	GENERAL - SPEECH/LANGUAGE	-5	Screening-2	08MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		1	Day 1-2/ PRE-DOSE	13MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		1	Day 1-2/ 4 HOUR POST-DOSE	13MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		1	Day 1-2/ 6 HOUR POST-DOSE	13MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		2	Day 2-2	14MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		9	Day 8-2	21MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		37	Day 36-2	18JUN2013	ABNORMAL	ARTICULATION ABNORMALITIES
		86	Day 85-2/ PRE-DOSE	06AUG2013	ABNORMAL	ARTICULATION ABNORMALITIES
		86	Day 85-2/ 4 HOUR POST-DOSE	06AUG2013	ABNORMAL	ARTICULATION ABNORMALITIES
		86	Day 85-2/ 6 HOUR POST-DOSE	06AUG2013	ABNORMAL	ARTICULATION ABNORMALITIES
		92	Day 92-2	12AUG2013	ABNORMAL	IMPROVED SPEECH ARTICULATION FROM BASELINE
		166	Day 169-2	25OCT2013	ABNORMAL	ARTICULATION ABNORMALITIES
		256	Day 253-2	23JAN2014	ABNORMAL	ARTICULATION ABNORMALITIES
		337	Screening-12	14APR2014	ABNORMAL	ARTICULATION
		341	Day 1-12	18APR2014	ABNORMAL	ARTICULATION

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 11 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2	GENERAL - SPEECH/LANGUAGE /1780-3205	341	Day 1-12/ 4 HOUR POST-DOSE	18APR2014	ABNORMAL	ARTICULATION
		341	Day 1-12/ 6 HOUR POST-DOSE	18APR2014	ABNORMAL	ARTICULATION
		347	Day 8-12	24APR2014	ABNORMAL	ARTICULATION
		428	Day 85-12	14JUL2014	ABNORMAL	ARTICULATION
		690	Day 351-12	02APR2015	ABNORMAL	ARTICULATION
		690	Day 351-12/ 4 HOUR POST-DOSE	02APR2015	ABNORMAL	ARTICULATION
		690	Day 351-12/ 6 HOUR POST-DOSE	02APR2015	ABNORMAL	ARTICULATION
		787	Day 442-12	08JUL2015	ABNORMAL	ARTICULATION
		877	Day 533-12	06OCT2015	ABNORMAL	ARTICULATION
		877	Day 533-12/ 4 HOUR POST-DOSE	06OCT2015	ABNORMAL	ARTICULATION
		877	Day 533-12/ 6 HOUR POST-DOSE	06OCT2015	ABNORMAL	ARTICULATION
		968	Day 624-12	05JAN2016	ABNORMAL	ARTICULATION
		1059	Day 715-12	05APR2016	ABNORMAL	ARTICULATION

SOURCE: [redacted] DATE: [redacted]
[redacted]

表 63　Infantile-Onset Subjects Treated With ISIS 396443 in Controlled and Uncontrolled Studies:Incidence of Adverse Events by Age at First Dose

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 1 of 16

	<90 days of age	>=90 days of age
Number of subjects dosed	10 (100.0)	90 (100.0)
Number of subjects with an event	9 (90.0)	83 (92.2)
感染症および寄生虫症	7 (70.0)	69 (76.7)
上気道感染	2 (20.0)	30 (33.3)
肺炎	2 (20.0)	22 (24.4)
鼻咽頭炎	3 (30.0)	17 (18.9)
ライノウイルス感染	1 (10.0)	13 (14.4)
ウイルス性上気道感染	0	12 (13.3)
細気管支炎	1 (10.0)	10 (11.1)
気道感染	2 (20.0)	10 (11.1)
ウイルス感染	1 (10.0)	10 (11.1)
ウイルス性肺炎	1 (10.0)	8 (8.9)
口腔カンジダ症	0	7 (7.8)
気管支炎	0	5 (5.6)
結膜炎	1 (10.0)	5 (5.6)
中耳炎	2 (20.0)	5 (5.6)
ウイルス性気道感染	0	5 (5.6)
耳感染	1 (10.0)	4 (4.4)
細菌性肺炎	0	4 (4.4)
ＲＳウイルス細気管支炎	0	4 (4.4)
インフルエンザ	0	3 (3.3)
下気道感染	1 (10.0)	3 (3.3)
尿路感染	0	3 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 2 of 16

	<90 days of age	>=90 days of age
アデノウイルス感染	0	2 (2.2)
細菌感染	0	2 (2.2)
細菌性気管炎	1 (10.0)	2 (2.2)
ウイルス性気管支炎	1 (10.0)	2 (2.2)
カンジダ性おむつ皮疹	0	2 (2.2)
細菌性結膜炎	0	2 (2.2)
エンテロウイルス感染	0	2 (2.2)
皮膚真菌感染	0	2 (2.2)
胃腸炎	0	2 (2.2)
ウイルス性下気道感染	1 (10.0)	2 (2.2)
メタニューモウイルス感染	0	2 (2.2)
パラインフルエンザウイルス感染	0	2 (2.2)
モラクセラ菌性肺炎	0	2 (2.2)
皮膚カンジダ	0	2 (2.2)
ストーマ部膿瘍	0	2 (2.2)
細菌性疾患キャリアー	0	1 (1.1)
蜂巣炎	0	1 (1.1)
感染性湿疹	0	1 (1.1)
伝染性紅斑	0	1 (1.1)
眼感染	0	1 (1.1)
真菌感染	0	1 (1.1)
ウイルス性胃炎	0	1 (1.1)
ロタウイルス胃腸炎	0	1 (1.1)
ウイルス性胃腸炎	0	1 (1.1)
ヘモフィルス感染	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 3 of 16

	<90 days of age	>=90 days of age
手足口病	1 (10.0)	1 (1.1)
膿痂疹	0	1 (1.1)
限局性感染	0	1 (1.1)
肺感染	0	1 (1.1)
粘膜皮膚カンジダ症	0	1 (1.1)
院内感染	0	1 (1.1)
口腔ヘルペス	0	1 (1.1)
急性中耳炎	0	1 (1.1)
レンサ球菌性咽頭炎	0	1 (1.1)
インフルエンザ性肺炎	0	1 (1.1)
パラインフルエンザウイルス性肺炎	0	1 (1.1)
シュードモナス菌性肺炎	0	1 (1.1)
ＲＳウイルス肺炎	0	1 (1.1)
シュードモナス感染	0	1 (1.1)
細菌性気道感染	0	1 (1.1)
鼻炎	1 (10.0)	1 (1.1)
ばら疹	0	1 (1.1)
敗血症	0	1 (1.1)
ブドウ球菌感染	0	1 (1.1)
ブドウ球菌性敗血症	0	1 (1.1)
ブドウ球菌皮膚感染	0	1 (1.1)
気管炎	0	1 (1.1)
アデノウイルス性上気道感染	1 (10.0)	0
コロナウイルス感染	1 (10.0)	0
モラクセラ感染	1 (10.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 4 of 16

	<90 days of age	>=90 days of age
ブドウ球菌性菌血症	1 (10.0)	0
呼吸器、胸郭および縦隔障害	6 (60.0)	67 (74.4)
呼吸窮迫	2 (20.0)	24 (26.7)
呼吸不全	3 (30.0)	20 (22.2)
無気肺	1 (10.0)	19 (21.1)
急性呼吸不全	1 (10.0)	14 (15.6)
鼻閉	2 (20.0)	13 (14.4)
咳嗽	1 (10.0)	11 (12.2)
誤嚥性肺炎	0	10 (11.1)
呼吸困難	0	9 (10.0)
低酸素症	1 (10.0)	9 (10.0)
気管支分泌物貯留	0	6 (6.7)
鼻漏	0	6 (6.7)
上気道うっ血	0	6 (6.7)
無呼吸	2 (20.0)	5 (5.6)
慢性呼吸不全	1 (10.0)	5 (5.6)
上気道分泌増加	1 (10.0)	5 (5.6)
誤嚥	2 (20.0)	4 (4.4)
呼吸停止	0	4 (4.4)
低換気	0	3 (3.3)
気胸	0	3 (3.3)
副鼻腔うっ血	1 (10.0)	3 (3.3)
息詰まり	0	2 (2.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 5 of 16

	<90 days of age	>=90 days of age
肺うっ血	0	2 (2.2)
呼吸障害	0	2 (2.2)
アレルギー性鼻炎	0	2 (2.2)
喘鳴	1 (10.0)	2 (2.2)
急性呼吸窮迫症候群	0	1 (1.1)
無呼吸発作	0	1 (1.1)
窒息	0	1 (1.1)
気管支閉塞	0	1 (1.1)
高炭酸ガス血症	0	1 (1.1)
減呼吸	0	1 (1.1)
気管支分泌増加	0	1 (1.1)
喉頭肉芽腫	0	1 (1.1)
肺障害	0	1 (1.1)
鼻汁変色	0	1 (1.1)
閉塞性気道障害	0	1 (1.1)
胸水	0	1 (1.1)
湿性咳嗽	0	1 (1.1)
肺水腫	1 (10.0)	1 (1.1)
呼吸性アルカローシス	0	1 (1.1)
気道うっ血	0	1 (1.1)
拘束性肺疾患	0	1 (1.1)
睡眠時無呼吸症候群	0	1 (1.1)
変色痰	0	1 (1.1)
頻呼吸	0	1 (1.1)
気管障害	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 6 of 16

	<90 days of age	>=90 days of age
呼吸補助筋の動員	1 (10.0)	1 (1.1)
気縦隔症	1 (10.0)	0
低音性連続性ラ音	1 (10.0)	0
胃腸障害	6 (60.0)	58 (64.4)
便秘	4 (40.0)	29 (32.2)
嘔吐	3 (30.0)	17 (18.9)
生歯	1 (10.0)	14 (15.6)
胃食道逆流性疾患	2 (20.0)	13 (14.4)
下痢	1 (10.0)	12 (13.3)
嚥下障害	1 (10.0)	8 (8.9)
腹部膨満	0	4 (4.4)
放屁	1 (10.0)	4 (4.4)
胃炎	0	4 (4.4)
流涎過多	1 (10.0)	4 (4.4)
腹部不快感	0	1 (1.1)
アフタ性潰瘍	0	1 (1.1)
口唇のひび割れ	0	1 (1.1)
排便回数増加	0	1 (1.1)
胃出血	0	1 (1.1)
消化管運動低下	0	1 (1.1)
吐血	0	1 (1.1)
血便排泄	1 (10.0)	1 (1.1)
乳児仙痛	0	1 (1.1)
乳児吐血	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 7 of 16

	<90 days of age	>=90 days of age
上部消化管出血	0	1 (1.1)
腹痛	1 (10.0)	0
一般・全身障害および投与部位の状態	5 (50.0)	53 (58.9)
発熱	5 (50.0)	48 (53.3)
疼痛	1 (10.0)	4 (4.4)
末梢性浮腫	0	2 (2.2)
カテーテル留置部位炎症	0	1 (1.1)
泣き	0	1 (1.1)
死亡	0	1 (1.1)
不快感	1 (10.0)	1 (1.1)
薬物不耐性	0	1 (1.1)
低体温	0	1 (1.1)
ワクチン接種後の易刺激性	0	1 (1.1)
倦怠感	0	1 (1.1)
小結節	0	1 (1.1)
浮腫	0	1 (1.1)
末梢腫脹	0	1 (1.1)
腫脹	0	1 (1.1)
医療機器リーク	1 (10.0)	0
医療機器閉塞	1 (10.0)	0
血管穿刺部位内出血	1 (10.0)	0
皮膚および皮下組織障害	5 (50.0)	30 (33.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 8 of 16

	<90 days of age	>=90 days of age
発疹	2 (20.0)	11 (12.2)
おむつ皮膚炎	2 (20.0)	8 (8.9)
湿疹	1 (10.0)	3 (3.3)
皮膚刺激	0	3 (3.3)
接触性皮膚炎	1 (10.0)	2 (2.2)
斑状出血	1 (10.0)	2 (2.2)
過剰肉芽組織	1 (10.0)	2 (2.2)
過角化	0	2 (2.2)
汗疹	0	2 (2.2)
脱毛症	0	1 (1.1)
皮膚炎	1 (10.0)	1 (1.1)
アレルギー性皮膚炎	0	1 (1.1)
紅斑	0	1 (1.1)
環状肉芽腫	0	1 (1.1)
点状出血	0	1 (1.1)
そう痒症	0	1 (1.1)
丘疹性皮疹	0	1 (1.1)
皮膚色素脱失	0	1 (1.1)
皮膚障害	0	1 (1.1)
皮膚浮腫	0	1 (1.1)
皮膚潰瘍	0	1 (1.1)
蕁麻疹	0	1 (1.1)
皮下気腫	1 (10.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 9 of 16

	<90 days of age	>=90 days of age
傷害、中毒および処置合併症	3 (30.0)	23 (25.6)
処置による疼痛	0	4 (4.4)
節足動物咬傷	0	3 (3.3)
ストーマ部紅斑	0	3 (3.3)
挫傷	0	2 (2.2)
大腿骨骨折	0	2 (2.2)
術後激越	0	1 (1.1)
麻酔からの覚醒遅延	0	1 (1.1)
ダンピング症候群	0	1 (1.1)
伝染病曝露	0	1 (1.1)
栄養補給チューブ合併症	1 (10.0)	1 (1.1)
関節脱臼	1 (10.0)	1 (1.1)
口唇損傷	0	1 (1.1)
処置後腫脹	0	1 (1.1)
処置合併症	0	1 (1.1)
皮膚擦過傷	1 (10.0)	1 (1.1)
軟部組織損傷	0	1 (1.1)
ストーマ合併症	0	1 (1.1)
サンバーン	0	1 (1.1)
熱傷	0	1 (1.1)
歯牙損傷	0	1 (1.1)
ワクチン接種合併症	0	1 (1.1)
創離開	0	1 (1.1)
耳擦過傷	1 (10.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 10 of 16

	<90 days of age	>=90 days of age
擦過傷	1 (10.0)	0
外傷性気胸	1 (10.0)	0
処置部位反応	1 (10.0)	0
臨床検査	1 (10.0)	23 (25.6)
酸素飽和度低下	0	10 (11.1)
体重減少	0	5 (5.6)
ヒトライノウイルス検査陽性	0	3 (3.3)
血中カリウム減少	0	2 (2.2)
体温上昇	0	2 (2.2)
Ｃ－反応性蛋白増加	0	2 (2.2)
心拍数増加	0	2 (2.2)
モラクセラ検査陽性	0	2 (2.2)
好中球数増加	1 (10.0)	2 (2.2)
シュードモナス検査陽性	0	2 (2.2)
ブドウ球菌検査陽性	0	2 (2.2)
アラニンアミノトランスフェラーゼ increased	0	1 (1.1)
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (1.1)
血中クロール減少	0	1 (1.1)
血中鉄減少	0	1 (1.1)
血中ナトリウム減少	0	1 (1.1)
体温低下	0	1 (1.1)
呼吸音異常	0	1 (1.1)
心電図ＳＴ－Ｔ部分異常	0	1 (1.1)
心拍数減少	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 11 of 16

	<90 days of age	>=90 days of age
心拍数不整	0	1 (1.1)
炎症マーカー上昇	0	1 (1.1)
A型インフルエンザウイルス検査陽性	0	1 (1.1)
肝機能検査異常	0	1 (1.1)
医学的観察	0	1 (1.1)
好中球百分率増加	0	1 (1.1)
セラチア検査陽性	0	1 (1.1)
レンサ球菌検査陽性	0	1 (1.1)
尿量減少	0	1 (1.1)
ビタミンA減少	0	1 (1.1)
白血球数増加	1 (10.0)	1 (1.1)
骨密度減少	1 (10.0)	0
筋骨格系および結合組織障害	4 (40.0)	21 (23.3)
側弯症	1 (10.0)	10 (11.1)
関節拘縮	2 (20.0)	9 (10.0)
脊柱後弯症	1 (10.0)	4 (4.4)
胸郭変形	1 (10.0)	3 (3.3)
後側弯症	0	2 (2.2)
頭位性斜頭症	0	2 (2.2)
斜頚	0	2 (2.2)
背部痛	0	1 (1.1)
泉門閉鎖遅延	0	1 (1.1)
手変形	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 12 of 16

	<90 days of age	>=90 days of age
関節硬直	0	1 (1.1)
四肢痛	1 (10.0)	1 (1.1)
脊柱変形	0	1 (1.1)
滑膜炎	0	1 (1.1)
脊柱前弯症	1 (10.0)	0
心臓障害	2 (20.0)	20 (22.2)
頻脈	0	8 (8.9)
徐脈	1 (10.0)	6 (6.7)
心肺停止	0	6 (6.7)
心停止	0	3 (3.3)
チアノーゼ	0	3 (3.3)
心室性頻脈	0	2 (2.2)
左室肥大	0	1 (1.1)
上室性頻脈	0	1 (1.1)
心筋症	1 (10.0)	0
心膜気腫	1 (10.0)	0
代謝および栄養障害	1 (10.0)	17 (18.9)
体重増加不良	0	6 (6.7)
成長障害	0	3 (3.3)
乳児および小児期早期の哺育障害	0	3 (3.3)
栄養補給不耐性	0	3 (3.3)
過小食	0	2 (2.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 13 of 16

	<90 days of age	>=90 days of age
脱水	0	1 (1.1)
低ナトリウム血症	1 (10.0)	1 (1.1)
鉄欠乏	0	1 (1.1)
代謝性アルカローシス	0	1 (1.1)
神経系障害	4 (40.0)	13 (14.4)
眼振	0	3 (3.3)
よだれ	0	2 (2.2)
不随意性筋収縮	2 (20.0)	2 (2.2)
脳損傷	0	1 (1.1)
脳脊髄液漏	0	1 (1.1)
間代	0	1 (1.1)
頭痛	0	1 (1.1)
嗜眠	0	1 (1.1)
痙攣発作	1 (10.0)	1 (1.1)
傾眠	0	1 (1.1)
失神	0	1 (1.1)
脳梗塞	1 (10.0)	0
低酸素性虚血性脳症	1 (10.0)	0
精神障害	1 (10.0)	10 (11.1)
不安	1 (10.0)	4 (4.4)
激越	0	2 (2.2)
易刺激性	0	2 (2.2)
息こらえ	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 14 of 16

	<90 days of age	>=90 days of age
気分動揺	0	1 (1.1)
落ち着きのなさ	0	1 (1.1)
睡眠障害	0	1 (1.1)
免疫系障害	3 (30.0)	9 (10.0)
季節性アレルギー	1 (10.0)	4 (4.4)
薬物過敏症	1 (10.0)	3 (3.3)
過敏症	0	2 (2.2)
食物アレルギー	1 (10.0)	0
眼障害	0	6 (6.7)
乱視	0	1 (1.1)
霰粒腫	0	1 (1.1)
眼乾燥	0	1 (1.1)
眼運動障害	0	1 (1.1)
眼瞼下垂	0	1 (1.1)
近視	0	1 (1.1)
斜視	0	1 (1.1)
血管障害	1 (10.0)	6 (6.7)
毛細血管脆弱	0	1 (1.1)
本態性高血圧症	0	1 (1.1)
高血圧	1 (10.0)	1 (1.1)
蒼白	0	1 (1.1)
ショック	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 15 of 16

	<90 days of age	>=90 days of age
血管炎	0	1 (1.1)
血液およびリンパ系障害	2 (20.0)	4 (4.4)
貧血	0	3 (3.3)
リンパ節症	0	1 (1.1)
好中球減少症	1 (10.0)	0
血小板増加症	1 (10.0)	0
先天性、家族性および遺伝性障害	2 (20.0)	4 (4.4)
発育性股関節形成不全	0	1 (1.1)
貧血母斑	0	1 (1.1)
鳩胸	0	1 (1.1)
斜頭症	1 (10.0)	1 (1.1)
斜指症	1 (10.0)	0
耳および迷路障害	0	3 (3.3)
耳の障害	0	1 (1.1)
耳痛	0	1 (1.1)
耳垢分泌過多	0	1 (1.1)
生殖系および乳房障害	0	3 (3.3)
後天性包茎	0	1 (1.1)
卵巣嚢胞	0	1 (1.1)
陰茎障害	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 16 of 16

	<90 days of age	>=90 days of age
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	2 (2.2)
アクロコルドン	0	1 (1.1)
血管の良性新生物	0	1 (1.1)
腎および尿路障害	1 (10.0)	1 (1.1)
尿閉	0	1 (1.1)
水腎症	1 (10.0)	0
外科および内科処置	0	1 (1.1)
機械的換気	0	1 (1.1)
肝胆道系障害	1 (10.0)	0
肝腫大	1 (10.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 64　Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443:Incidence of Adverse Events by Age at First Dose

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 1 of 17

	<90 days of age	>=90 days of age
Number of subjects dosed	27 (100.0)	90 (100.0)
Number of subjects with an event	22 (81.5)	83 (92.2)
感染症および寄生虫症	17 (63.0)	69 (76.7)
上気道感染	8 (29.6)	30 (33.3)
肺炎	3 (11.1)	22 (24.4)
鼻咽頭炎	6 (22.2)	17 (18.9)
ライノウイルス感染	2 (7.4)	13 (14.4)
ウイルス性上気道感染	0	12 (13.3)
細気管支炎	2 (7.4)	10 (11.1)
気道感染	2 (7.4)	10 (11.1)
ウイルス感染	1 (3.7)	10 (11.1)
ウイルス性肺炎	2 (7.4)	8 (8.9)
口腔カンジダ症	0	7 (7.8)
気管支炎	1 (3.7)	5 (5.6)
結膜炎	1 (3.7)	5 (5.6)
中耳炎	4 (14.8)	5 (5.6)
ウイルス性気道感染	0	5 (5.6)
耳感染	1 (3.7)	4 (4.4)
細菌性肺炎	0	4 (4.4)
ＲＳウイルス細気管支炎	0	4 (4.4)
インフルエンザ	2 (7.4)	3 (3.3)
下気道感染	1 (3.7)	3 (3.3)
尿路感染	1 (3.7)	3 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 2 of 17

	<90 days of age	>=90 days of age
アデノウイルス感染	0	2 (2.2)
細菌感染	0	2 (2.2)
細菌性気管炎	1 (3.7)	2 (2.2)
ウイルス性気管支炎	1 (3.7)	2 (2.2)
カンジダ性おむつ皮疹	0	2 (2.2)
細菌性結膜炎	0	2 (2.2)
エンテロウイルス感染	0	2 (2.2)
皮膚真菌感染	0	2 (2.2)
胃腸炎	0	2 (2.2)
ウイルス性下気道感染	1 (3.7)	2 (2.2)
メタニューモウイルス感染	0	2 (2.2)
パラインフルエンザウイルス感染	0	2 (2.2)
モラクセラ菌性肺炎	0	2 (2.2)
皮膚カンジダ	0	2 (2.2)
ストーマ部膿瘍	0	2 (2.2)
細菌性疾患キャリアー	0	1 (1.1)
蜂巣炎	0	1 (1.1)
感染性湿疹	0	1 (1.1)
伝染性紅斑	0	1 (1.1)
眼感染	0	1 (1.1)
真菌感染	0	1 (1.1)
ウイルス性胃炎	0	1 (1.1)
ロタウイルス胃腸炎	0	1 (1.1)
ウイルス性胃腸炎	1 (3.7)	1 (1.1)
ヘモフィルス感染	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 3 of 17

	<90 days of age	>=90 days of age
手足口病	1 (3.7)	1 (1.1)
膿痂疹	1 (3.7)	1 (1.1)
限局性感染	0	1 (1.1)
肺感染	0	1 (1.1)
粘膜皮膚カンジダ症	0	1 (1.1)
院内感染	0	1 (1.1)
口腔ヘルペス	0	1 (1.1)
急性中耳炎	0	1 (1.1)
レンサ球菌性咽頭炎	1 (3.7)	1 (1.1)
インフルエンザ性肺炎	0	1 (1.1)
パラインフルエンザウイルス性肺炎	0	1 (1.1)
シュードモナス菌性肺炎	0	1 (1.1)
ＲＳウイルス肺炎	0	1 (1.1)
シュードモナス感染	0	1 (1.1)
細菌性気道感染	0	1 (1.1)
鼻炎	2 (7.4)	1 (1.1)
ばら疹	0	1 (1.1)
敗血症	0	1 (1.1)
ブドウ球菌感染	0	1 (1.1)
ブドウ球菌性敗血症	0	1 (1.1)
ブドウ球菌皮膚感染	0	1 (1.1)
気管炎	0	1 (1.1)
アデノウイルス性上気道感染	1 (3.7)	0
コロナウイルス感染	1 (3.7)	0
モラクセラ感染	1 (3.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 4 of 17

	<90 days of age	>=90 days of age
皮膚感染	1 (3.7)	0
ブドウ球菌性菌血症	1 (3.7)	0
呼吸器、胸郭および縦隔障害	11 (40.7)	67 (74.4)
呼吸窮迫	3 (11.1)	24 (26.7)
呼吸不全	3 (11.1)	20 (22.2)
無気肺	1 (3.7)	19 (21.1)
急性呼吸不全	1 (3.7)	14 (15.6)
鼻閉	4 (14.8)	13 (14.4)
咳嗽	3 (11.1)	11 (12.2)
誤嚥性肺炎	0	10 (11.1)
呼吸困難	0	9 (10.0)
低酸素症	1 (3.7)	9 (10.0)
気管支分泌物貯留	0	6 (6.7)
鼻漏	1 (3.7)	6 (6.7)
上気道うっ血	1 (3.7)	6 (6.7)
無呼吸	2 (7.4)	5 (5.6)
慢性呼吸不全	1 (3.7)	5 (5.6)
上気道分泌増加	1 (3.7)	5 (5.6)
誤嚥	2 (7.4)	4 (4.4)
呼吸停止	0	4 (4.4)
低換気	0	3 (3.3)
気胸	0	3 (3.3)
副鼻腔うっ血	1 (3.7)	3 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 5 of 17

	<90 days of age	>=90 days of age
息詰まり	0	2 (2.2)
肺うっ血	0	2 (2.2)
呼吸障害	0	2 (2.2)
アレルギー性鼻炎	0	2 (2.2)
喘鳴	1 (3.7)	2 (2.2)
急性呼吸窮迫症候群	0	1 (1.1)
無呼吸発作	0	1 (1.1)
窒息	0	1 (1.1)
気管支閉塞	0	1 (1.1)
高炭酸ガス血症	0	1 (1.1)
減呼吸	0	1 (1.1)
気管支分泌増加	0	1 (1.1)
喉頭肉芽腫	0	1 (1.1)
肺障害	0	1 (1.1)
鼻汁変色	0	1 (1.1)
閉塞性気道障害	0	1 (1.1)
胸水	0	1 (1.1)
湿性咳嗽	0	1 (1.1)
肺水腫	1 (3.7)	1 (1.1)
呼吸性アルカローシス	0	1 (1.1)
気道うっ血	0	1 (1.1)
拘束性肺疾患	0	1 (1.1)
睡眠時無呼吸症候群	0	1 (1.1)
変色痰	0	1 (1.1)
頻呼吸	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 6 of 17

	<90 days of age	>=90 days of age
気管障害	0	1 (1.1)
呼吸補助筋の動員	1 (3.7)	1 (1.1)
気縦隔症	1 (3.7)	0
呼吸性アシドーシス	1 (3.7)	0
低音性連続性ラ音	1 (3.7)	0
胃腸障害	12 (44.4)	58 (64.4)
便秘	5 (18.5)	29 (32.2)
嘔吐	3 (11.1)	17 (18.9)
生歯	2 (7.4)	14 (15.6)
胃食道逆流性疾患	4 (14.8)	13 (14.4)
下痢	1 (3.7)	12 (13.3)
嚥下障害	2 (7.4)	8 (8.9)
腹部膨満	2 (7.4)	4 (4.4)
放屁	3 (11.1)	4 (4.4)
胃炎	0	4 (4.4)
流涎過多	1 (3.7)	4 (4.4)
腹部不快感	1 (3.7)	1 (1.1)
アフタ性潰瘍	0	1 (1.1)
口唇のひび割れ	0	1 (1.1)
排便回数増加	0	1 (1.1)
胃出血	0	1 (1.1)
消化管運動低下	0	1 (1.1)
吐血	0	1 (1.1)
血便排泄	1 (3.7)	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 7 of 17

	<90 days of age	>=90 days of age
乳児仙痛	0	1 (1.1)
乳児吐血	0	1 (1.1)
上部消化管出血	0	1 (1.1)
腹痛	1 (3.7)	0
一般・全身障害および投与部位の状態	9 (33.3)	53 (58.9)
発熱	8 (29.6)	48 (53.3)
疼痛	1 (3.7)	4 (4.4)
末梢性浮腫	0	2 (2.2)
カテーテル留置部位炎症	0	1 (1.1)
泣き	0	1 (1.1)
死亡	0	1 (1.1)
不快感	1 (3.7)	1 (1.1)
薬物不耐性	0	1 (1.1)
低体温	0	1 (1.1)
ワクチン接種後の易刺激性	0	1 (1.1)
倦怠感	0	1 (1.1)
小結節	0	1 (1.1)
浮腫	0	1 (1.1)
末梢腫脹	0	1 (1.1)
腫脹	0	1 (1.1)
適用部位紅斑	1 (3.7)	0
医療機器リーク	1 (3.7)	0
医療機器閉塞	1 (3.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 8 of 17

	<90 days of age	>=90 days of age
注入部位内出血	1 (3.7)	0
血管穿刺部位内出血	1 (3.7)	0
皮膚および皮下組織障害	11 (40.7)	30 (33.3)
発疹	2 (7.4)	11 (12.2)
おむつ皮膚炎	4 (14.8)	8 (8.9)
湿疹	1 (3.7)	3 (3.3)
皮膚刺激	0	3 (3.3)
接触性皮膚炎	1 (3.7)	2 (2.2)
斑状出血	1 (3.7)	2 (2.2)
過剰肉芽組織	1 (3.7)	2 (2.2)
過角化	0	2 (2.2)
汗疹	0	2 (2.2)
脱毛症	0	1 (1.1)
皮膚炎	3 (11.1)	1 (1.1)
アレルギー性皮膚炎	0	1 (1.1)
紅斑	1 (3.7)	1 (1.1)
環状肉芽腫	0	1 (1.1)
点状出血	0	1 (1.1)
そう痒症	0	1 (1.1)
丘疹性皮疹	0	1 (1.1)
皮膚色素脱失	0	1 (1.1)
皮膚障害	0	1 (1.1)
皮膚浮腫	0	1 (1.1)
皮膚潰瘍	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 9 of 17

	<90 days of age	>=90 days of age
蕁麻疹	0	1 (1.1)
貨幣状湿疹	1 (3.7)	0
脂漏性皮膚炎	1 (3.7)	0
皮下気腫	1 (3.7)	0
傷害、中毒および処置合併症	6 (22.2)	23 (25.6)
処置による疼痛	0	4 (4.4)
節足動物咬傷	0	3 (3.3)
ストーマ部紅斑	0	3 (3.3)
挫傷	0	2 (2.2)
大腿骨骨折	0	2 (2.2)
術後激越	0	1 (1.1)
麻酔からの覚醒遅延	0	1 (1.1)
ダンピング症候群	0	1 (1.1)
伝染病曝露	0	1 (1.1)
栄養補給チューブ合併症	1 (3.7)	1 (1.1)
関節脱臼	1 (3.7)	1 (1.1)
口唇損傷	0	1 (1.1)
処置後腫脹	1 (3.7)	1 (1.1)
処置合併症	0	1 (1.1)
皮膚擦過傷	1 (3.7)	1 (1.1)
軟部組織損傷	0	1 (1.1)
ストーマ合併症	0	1 (1.1)
サンバーン	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 10 of 17

	<90 days of age	>=90 days of age
熱傷	0	1 (1.1)
歯牙損傷	0	1 (1.1)
ワクチン接種合併症	0	1 (1.1)
創離開	0	1 (1.1)
耳擦過傷	1 (3.7)	0
擦過傷	1 (3.7)	0
転倒	1 (3.7)	0
外傷性気胸	1 (3.7)	0
処置後合併症	1 (3.7)	0
処置後不快感	1 (3.7)	0
処置部位反応	1 (3.7)	0
硬膜下血腫	1 (3.7)	0
臨床検査	2 (7.4)	23 (25.6)
酸素飽和度低下	0	10 (11.1)
体重減少	0	5 (5.6)
ヒトライノウイルス検査陽性	0	3 (3.3)
血中カリウム減少	0	2 (2.2)
体温上昇	0	2 (2.2)
Ｃ－反応性蛋白増加	0	2 (2.2)
心拍数増加	0	2 (2.2)
モラクセラ検査陽性	0	2 (2.2)
好中球数増加	1 (3.7)	2 (2.2)
シュードモナス検査陽性	0	2 (2.2)
ブドウ球菌検査陽性	0	2 (2.2)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 11 of 17

	<90 days of age	>=90 days of age
アラニンアミノトランスフェラーゼ増加	1 (3.7)	1 (1.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (3.7)	1 (1.1)
血中クロール減少	0	1 (1.1)
血中鉄減少	0	1 (1.1)
血中ナトリウム減少	0	1 (1.1)
体温低下	0	1 (1.1)
呼吸音異常	0	1 (1.1)
心電図ＳＴ－Ｔ部分異常	0	1 (1.1)
心拍数減少	0	1 (1.1)
心拍数不整	0	1 (1.1)
炎症マーカー上昇	0	1 (1.1)
Ａ型インフルエンザウイルス検査陽性	0	1 (1.1)
肝機能検査異常	0	1 (1.1)
医学的観察	0	1 (1.1)
好中球百分率増加	0	1 (1.1)
セラチア検査陽性	0	1 (1.1)
レンサ球菌検査陽性	0	1 (1.1)
尿量減少	0	1 (1.1)
ビタミンＡ減少	0	1 (1.1)
白血球数増加	1 (3.7)	1 (1.1)
骨密度減少	1 (3.7)	0
筋骨格系および結合組織障害	6 (22.2)	21 (23.3)
側弯症	1 (3.7)	10 (11.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 12 of 17

	<90 days of age	>=90 days of age
関節拘縮	3 (11.1)	9 (10.0)
脊柱後弯症	1 (3.7)	4 (4.4)
胸郭変形	1 (3.7)	3 (3.3)
後側弯症	0	2 (2.2)
頭位性斜頭症	1 (3.7)	2 (2.2)
斜頚	1 (3.7)	2 (2.2)
背部痛	0	1 (1.1)
泉門閉鎖遅延	0	1 (1.1)
手変形	0	1 (1.1)
関節硬直	0	1 (1.1)
四肢痛	1 (3.7)	1 (1.1)
脊柱変形	0	1 (1.1)
滑膜炎	0	1 (1.1)
脊柱前弯症	1 (3.7)	0
筋力低下	1 (3.7)	0
体重支持困難	1 (3.7)	0
心臓障害	4 (14.8)	20 (22.2)
頻脈	2 (7.4)	8 (8.9)
徐脈	1 (3.7)	6 (6.7)
心肺停止	0	6 (6.7)
心停止	0	3 (3.3)
チアノーゼ	0	3 (3.3)
心室性頻脈	0	2 (2.2)
左室肥大	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 13 of 17

	<90 days of age	>=90 days of age
上室性頻脈	0	1 (1.1)
心筋症	1 (3.7)	0
心膜気腫	1 (3.7)	0
代謝および栄養障害	3 (11.1)	17 (18.9)
体重増加不良	1 (3.7)	6 (6.7)
成長障害	1 (3.7)	3 (3.3)
乳児および小児期早期の哺育障害	0	3 (3.3)
栄養補給不耐性	0	3 (3.3)
過小食	0	2 (2.2)
脱水	1 (3.7)	1 (1.1)
低ナトリウム血症	1 (3.7)	1 (1.1)
鉄欠乏	0	1 (1.1)
代謝性アルカローシス	0	1 (1.1)
神経系障害	6 (22.2)	13 (14.4)
眼振	0	3 (3.3)
よだれ	0	2 (2.2)
不随意性筋収縮	2 (7.4)	2 (2.2)
脳損傷	0	1 (1.1)
脳脊髄液漏	0	1 (1.1)
間代	0	1 (1.1)
頭痛	0	1 (1.1)
嗜眠	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 14 of 17

	<90 days of age	>=90 days of age
痙攣発作	1 (3.7)	1 (1.1)
傾眠	0	1 (1.1)
失神	0	1 (1.1)
脳梗塞	1 (3.7)	0
反射亢進	1 (3.7)	0
筋緊張低下	1 (3.7)	0
低酸素性虚血性脳症	1 (3.7)	0
精神障害	1 (3.7)	10 (11.1)
不安	1 (3.7)	4 (4.4)
激越	0	2 (2.2)
易刺激性	0	2 (2.2)
息こらえ	0	1 (1.1)
気分動揺	0	1 (1.1)
落ち着きのなさ	0	1 (1.1)
睡眠障害	0	1 (1.1)
免疫系障害	4 (14.8)	9 (10.0)
季節性アレルギー	2 (7.4)	4 (4.4)
薬物過敏症	1 (3.7)	3 (3.3)
過敏症	0	2 (2.2)
食物アレルギー	1 (3.7)	0
眼障害	1 (3.7)	6 (6.7)
乱視	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 15 of 17

	<90 days of age	>=90 days of age
霰粒腫	0	1 (1.1)
眼乾燥	0	1 (1.1)
眼運動障害	0	1 (1.1)
眼瞼下垂	0	1 (1.1)
近視	0	1 (1.1)
斜視	0	1 (1.1)
後天性涙道狭窄	1 (3.7)	0
血管障害	3 (11.1)	6 (6.7)
毛細血管脆弱	0	1 (1.1)
本態性高血圧症	0	1 (1.1)
高血圧	2 (7.4)	1 (1.1)
蒼白	1 (3.7)	1 (1.1)
ショック	0	1 (1.1)
血管炎	0	1 (1.1)
血液およびリンパ系障害	4 (14.8)	4 (4.4)
貧血	0	3 (3.3)
リンパ節症	0	1 (1.1)
好酸球増加症	1 (3.7)	0
好中球減少症	2 (7.4)	0
血小板増加症	1 (3.7)	0
先天性、家族性および遺伝性障害	2 (7.4)	4 (4.4)
発育性股関節形成不全	0	1 (1.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 16 of 17

	<90 days of age	>=90 days of age
貧血母斑	0	1 (1.1)
鳩胸	0	1 (1.1)
斜頭症	1 (3.7)	1 (1.1)
斜指症	1 (3.7)	0
耳および迷路障害	0	3 (3.3)
耳の障害	0	1 (1.1)
耳痛	0	1 (1.1)
耳垢分泌過多	0	1 (1.1)
生殖系および乳房障害	0	3 (3.3)
後天性包茎	0	1 (1.1)
卵巣嚢胞	0	1 (1.1)
陰茎障害	0	1 (1.1)
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	1 (3.7)	2 (2.2)
アクロコルドン	0	1 (1.1)
血管の良性新生物	0	1 (1.1)
脂漏性角化症	1 (3.7)	0
腎および尿路障害	1 (3.7)	1 (1.1)
尿閉	0	1 (1.1)
水腎症	1 (3.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 17 of 17

	<90 days of age	>=90 days of age
外科および内科処置	0	1 (1.1)
機械的換気	0	1 (1.1)
肝胆道系障害	1 (3.7)	0
肝腫大	1 (3.7)	0
妊娠、産褥および周産期の状態	1 (3.7)	0
臍肉芽腫	1 (3.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 65　Later-Onset Subjects:Incidence of Adverse Events by Age at First Dose

Later-onset subjects: incidence of adverse events by age at first dose
Page 1 of 9

	<6 years of age	>=6 years of age
Number of subjects dosed	28 (100.0)	28 (100.0)
Number of subjects with an event	28 (100.0)	28 (100.0)
傷害、中毒および処置合併症	18 (64.3)	22 (78.6)
腰椎穿刺後症候群	6 (21.4)	17 (60.7)
処置による疼痛	1 (3.6)	5 (17.9)
裂傷	5 (17.9)	2 (7.1)
節足動物咬傷	2 (7.1)	1 (3.6)
節足動物刺傷	0	1 (3.6)
挫傷	1 (3.6)	1 (3.6)
大腿骨骨折	2 (7.1)	1 (3.6)
頭部損傷	0	1 (3.6)
関節損傷	1 (3.6)	1 (3.6)
靭帯捻挫	0	1 (3.6)
四肢損傷	2 (7.1)	1 (3.6)
半月板損傷	0	1 (3.6)
肉離れ	0	1 (3.6)
術後イレウス	0	1 (3.6)
処置による頭痛	0	1 (3.6)
処置による悪心	1 (3.6)	1 (3.6)
サンバーン	1 (3.6)	1 (3.6)
脛骨骨折	0	1 (3.6)
隆起骨折	1 (3.6)	1 (3.6)
術後激越	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 2 of 9

	<6 years of age	>=6 years of age
転倒	1 (3.6)	0
関節脱臼	2 (7.1)	0
下肢骨折	1 (3.6)	0
熱傷	1 (3.6)	0
感染症および寄生虫症	23 (82.1)	21 (75.0)
上気道感染	14 (50.0)	13 (46.4)
鼻咽頭炎	7 (25.0)	9 (32.1)
胃腸炎	2 (7.1)	5 (17.9)
レンサ球菌性咽頭炎	3 (10.7)	5 (17.9)
限局性感染	0	3 (10.7)
副鼻腔炎	0	3 (10.7)
尿路感染	1 (3.6)	3 (10.7)
ウイルス性胃腸炎	6 (21.4)	2 (7.1)
インフルエンザ	1 (3.6)	2 (7.1)
中耳炎	3 (10.7)	2 (7.1)
肺炎	3 (10.7)	2 (7.1)
ウイルス感染	7 (25.0)	2 (7.1)
ウイルス性上気道感染	3 (10.7)	2 (7.1)
蜂巣炎	0	1 (3.6)
結膜炎	2 (7.1)	1 (3.6)
ブドウ球菌性眼感染	0	1 (3.6)
皮膚真菌感染	0	1 (3.6)
ウイルス性消化管感染	1 (3.6)	1 (3.6)
膿痂疹	0	1 (3.6)
急性中耳炎	0	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 3 of 9

	<6 years of age	>=6 years of age
ＲＳウイルス感染	2 (7.1)	1 (3.6)
皮膚カンジダ	1 (3.6)	1 (3.6)
扁桃炎	0	1 (3.6)
外陰膣真菌感染	0	1 (3.6)
耳感染	4 (14.3)	0
ウイルス性眼感染	1 (3.6)	0
手足口病	1 (3.6)	0
下気道感染	1 (3.6)	0
伝染性軟属腫	1 (3.6)	0
単核細胞症症候群	1 (3.6)	0
咽頭炎	1 (3.6)	0
ＲＳウイルス肺炎	1 (3.6)	0
ウイルス性肺炎	2 (7.1)	0
ＲＳウイルス細気管支炎	1 (3.6)	0
気道感染	1 (3.6)	0
ウイルス性気道感染	1 (3.6)	0
鼻炎	1 (3.6)	0
皮膚細菌感染	1 (3.6)	0
膣感染	1 (3.6)	0
ウイルス性扁桃炎	1 (3.6)	0
筋骨格系および結合組織障害	21 (75.0)	20 (71.4)
背部痛	8 (28.6)	15 (53.6)
側弯症	6 (21.4)	9 (32.1)
四肢痛	2 (7.1)	3 (10.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 4 of 9

	<6 years of age	>=6 years of age
関節痛	3 (10.7)	2 (7.1)
関節拘縮	8 (28.6)	2 (7.1)
頚部痛	1 (3.6)	2 (7.1)
脊柱前弯症	0	1 (3.6)
筋肉痛	3 (10.7)	1 (3.6)
骨盤変形	1 (3.6)	1 (3.6)
四肢拘縮	1 (3.6)	0
筋緊張	2 (7.1)	0
神経系障害	10 (35.7)	20 (71.4)
頭痛	9 (32.1)	19 (67.9)
感覚鈍麻	0	2 (7.1)
失声症	0	1 (3.6)
失読症	0	1 (3.6)
片頭痛	0	1 (3.6)
錯感覚	0	1 (3.6)
失神	0	1 (3.6)
味覚異常	1 (3.6)	0
振戦	1 (3.6)	0
一般・全身障害および投与部位の状態	16 (57.1)	15 (53.6)
穿刺部位疼痛	3 (10.7)	7 (25.0)
発熱	12 (42.9)	4 (14.3)
疲労	1 (3.6)	2 (7.1)
疼痛	0	2 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 5 of 9

	<6 years of age	>=6 years of age
カテーテル留置部位出血	0	1 (3.6)
カテーテル留置部位疼痛	0	1 (3.6)
胸部不快感	0	1 (3.6)
悪寒	0	1 (3.6)
重力性浮腫	0	1 (3.6)
注射部位疼痛	0	1 (3.6)
末梢腫脹	0	1 (3.6)
穿刺部位反応	0	1 (3.6)
血管穿刺部位内出血	0	1 (3.6)
カテーテル留置部位関連反応	1 (3.6)	0
冷感	1 (3.6)	0
低体温	1 (3.6)	0
注射部位出血	1 (3.6)	0
胃腸障害	15 (53.6)	11 (39.3)
悪心	6 (21.4)	4 (14.3)
嘔吐	8 (28.6)	4 (14.3)
腹痛	0	2 (7.1)
アフタ性潰瘍	1 (3.6)	2 (7.1)
口腔内痛	0	2 (7.1)
腹部不快感	0	1 (3.6)
腹部症状	0	1 (3.6)
食中毒	0	1 (3.6)
胃腸障害	0	1 (3.6)
胃食道逆流性疾患	0	1 (3.6)
口の感覚鈍麻	0	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 6 of 9

	<6 years of age	>=6 years of age
上腹部痛	2 (7.1)	0
便秘	7 (25.0)	0
下痢	2 (7.1)	0
放屁	1 (3.6)	0
口唇痛	1 (3.6)	0
口内炎	1 (3.6)	0
呼吸器、胸郭および縦隔障害	14 (50.0)	11 (39.3)
口腔咽頭痛	2 (7.1)	6 (21.4)
咳嗽	3 (10.7)	3 (10.7)
副鼻腔うっ血	0	2 (7.1)
鼻出血	2 (7.1)	1 (3.6)
鼻閉	2 (7.1)	1 (3.6)
肺うっ血	0	1 (3.6)
鼻漏	5 (17.9)	1 (3.6)
扁桃肥大	2 (7.1)	1 (3.6)
急性呼吸不全	1 (3.6)	0
無気肺	1 (3.6)	0
発声障害	1 (3.6)	0
呼吸困難	1 (3.6)	0
低酸素症	3 (10.7)	0
肺臓炎	1 (3.6)	0
呼吸障害	1 (3.6)	0
呼吸不全	1 (3.6)	0
拘束性肺疾患	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 7 of 9

	<6 years of age	>=6 years of age
喘鳴	1 (3.6)	0
皮膚および皮下組織障害	11 (39.3)	6 (21.4)
湿疹	0	2 (7.1)
ざ瘡	0	1 (3.6)
皮膚炎	0	1 (3.6)
接触性皮膚炎	2 (7.1)	1 (3.6)
毛孔性角化症	0	1 (3.6)
水疱	1 (3.6)	0
褥瘡性潰瘍	1 (3.6)	0
おむつ皮膚炎	1 (3.6)	0
紅斑	1 (3.6)	0
汗疹	1 (3.6)	0
寝汗	1 (3.6)	0
発疹	1 (3.6)	0
皮膚病変	1 (3.6)	0
蕁麻疹	1 (3.6)	0
免疫系障害	2 (7.1)	5 (17.9)
過敏症	0	3 (10.7)
薬物過敏症	0	1 (3.6)
季節性アレルギー	2 (7.1)	1 (3.6)
臨床検査	3 (10.7)	5 (17.9)
体重減少	1 (3.6)	2 (7.1)
血中重炭酸塩減少	0	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 8 of 9

	<6 years of age	>=6 years of age
血中テストステロン減少	0	1 (3.6)
ＣＳＦ白血球数増加	0	1 (3.6)
心拍数増加	0	1 (3.6)
体温上昇	1 (3.6)	0
尿検査異常	1 (3.6)	0
精神障害	0	4 (14.3)
激越	0	2 (7.1)
注意欠陥多動性障害	0	1 (3.6)
不快気分	0	1 (3.6)
不眠症	0	1 (3.6)
睡眠時随伴症	0	1 (3.6)
チック	0	1 (3.6)
心因性嘔吐	0	1 (3.6)
代謝および栄養障害	3 (10.7)	2 (7.1)
食欲減退	0	1 (3.6)
ビタミンＤ欠乏	0	1 (3.6)
脱水	2 (7.1)	0
食欲亢進	1 (3.6)	0
血液およびリンパ系障害	0	1 (3.6)
好中球減少症	0	1 (3.6)
心臓障害	2 (7.1)	1 (3.6)
動悸	1 (3.6)	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 9 of 9

	<6 years of age	>=6 years of age
頻脈	1 (3.6)	0
眼障害	1 (3.6)	1 (3.6)
遠視	0	1 (3.6)
斜視	1 (3.6)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	1 (3.6)
皮膚乳頭腫	0	1 (3.6)
腎および尿路障害	2 (7.1)	1 (3.6)
膀胱尿管逆流	0	1 (3.6)
排尿困難	1 (3.6)	0
尿失禁	1 (3.6)	0
耳および迷路障害	3 (10.7)	0
耳痛	1 (3.6)	0
乗物酔い	1 (3.6)	0
鼓膜穿孔	1 (3.6)	0
血管障害	1 (3.6)	0
低血圧	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
#[redacted]20[redacted]##

表 66　Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443:Incidence of Adverse Events by Sex

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 1 of 17

	Male	Female
Number of subjects dosed	60 (100.0)	57 (100.0)
Number of subjects with an event	53 (88.3)	52 (91.2)
感染症および寄生虫症	44 (73.3)	42 (73.7)
上気道感染	18 (30.0)	20 (35.1)
鼻咽頭炎	13 (21.7)	10 (17.5)
肺炎	11 (18.3)	14 (24.6)
ライノウイルス感染	10 (16.7)	5 (8.8)
細気管支炎	7 (11.7)	5 (8.8)
中耳炎	7 (11.7)	2 (3.5)
気道感染	6 (10.0)	6 (10.5)
ウイルス感染	6 (10.0)	5 (8.8)
ウイルス性上気道感染	6 (10.0)	6 (10.5)
ウイルス性肺炎	5 (8.3)	5 (8.8)
気管支炎	3 (5.0)	3 (5.3)
口腔カンジダ症	3 (5.0)	4 (7.0)
ウイルス性気道感染	3 (5.0)	2 (3.5)
細菌性気管炎	2 (3.3)	1 (1.8)
ウイルス性気管支炎	2 (3.3)	1 (1.8)
結膜炎	2 (3.3)	4 (7.0)
耳感染	2 (3.3)	3 (5.3)
下気道感染	2 (3.3)	2 (3.5)
ウイルス性下気道感染	2 (3.3)	1 (1.8)
レンサ球菌性咽頭炎	2 (3.3)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 2 of 17

	Male	Female
鼻炎	2 (3.3)	1 (1.8)
皮膚カンジダ	2 (3.3)	0
尿路感染	2 (3.3)	2 (3.5)
アデノウイルス性上気道感染	1 (1.7)	0
アデノウイルス感染	1 (1.7)	1 (1.8)
カンジダ性おむつ皮疹	1 (1.7)	1 (1.8)
コロナウイルス感染	1 (1.7)	0
感染性湿疹	1 (1.7)	0
眼感染	1 (1.7)	0
真菌感染	1 (1.7)	0
ウイルス性胃炎	1 (1.7)	0
ウイルス性胃腸炎	1 (1.7)	1 (1.8)
手足口病	1 (1.7)	1 (1.8)
膿痂疹	1 (1.7)	1 (1.8)
インフルエンザ	1 (1.7)	4 (7.0)
限局性感染	1 (1.7)	0
メタニューモウイルス感染	1 (1.7)	1 (1.8)
モラクセラ感染	1 (1.7)	0
口腔ヘルペス	1 (1.7)	0
急性中耳炎	1 (1.7)	0
パラインフルエンザウイルス感染	1 (1.7)	1 (1.8)
細菌性肺炎	1 (1.7)	3 (5.3)
モラクセラ菌性肺炎	1 (1.7)	1 (1.8)
ＲＳウイルス肺炎	1 (1.7)	0
シュードモナス感染	1 (1.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 3 of 17

	Male	Female
ＲＳウイルス細気管支炎	1 (1.7)	3 (5.3)
細菌性気道感染	1 (1.7)	0
ばら疹	1 (1.7)	0
敗血症	1 (1.7)	0
皮膚感染	1 (1.7)	0
ブドウ球菌性菌血症	1 (1.7)	0
ブドウ球菌皮膚感染	1 (1.7)	0
細菌性疾患キャリアー	0	1 (1.8)
細菌感染	0	2 (3.5)
蜂巣炎	0	1 (1.8)
細菌性結膜炎	0	2 (3.5)
エンテロウイルス感染	0	2 (3.5)
伝染性紅斑	0	1 (1.8)
皮膚真菌感染	0	2 (3.5)
胃腸炎	0	2 (3.5)
ロタウイルス胃腸炎	0	1 (1.8)
ヘモフィルス感染	0	1 (1.8)
肺感染	0	1 (1.8)
粘膜皮膚カンジダ症	0	1 (1.8)
院内感染	0	1 (1.8)
インフルエンザ性肺炎	0	1 (1.8)
パラインフルエンザウイルス性肺炎	0	1 (1.8)
シュードモナス菌性肺炎	0	1 (1.8)
ブドウ球菌感染	0	1 (1.8)
ブドウ球菌性敗血症	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 4 of 17

	Male	Female
ストーマ部膿瘍	0	2 (3.5)
気管炎	0	1 (1.8)
呼吸器、胸郭および縦隔障害	40 (66.7)	38 (66.7)
呼吸窮迫	13 (21.7)	14 (24.6)
呼吸不全	12 (20.0)	11 (19.3)
急性呼吸不全	8 (13.3)	7 (12.3)
咳嗽	8 (13.3)	6 (10.5)
鼻閉	7 (11.7)	10 (17.5)
無気肺	6 (10.0)	14 (24.6)
低酸素症	6 (10.0)	4 (7.0)
無呼吸	5 (8.3)	2 (3.5)
呼吸困難	5 (8.3)	4 (7.0)
上気道うっ血	4 (6.7)	3 (5.3)
気管支分泌物貯留	3 (5.0)	3 (5.3)
上気道分泌増加	3 (5.0)	3 (5.3)
鼻漏	3 (5.0)	4 (7.0)
誤嚥	2 (3.3)	4 (7.0)
慢性呼吸不全	2 (3.3)	4 (7.0)
低換気	2 (3.3)	1 (1.8)
呼吸停止	2 (3.3)	2 (3.5)
副鼻腔うっ血	2 (3.3)	2 (3.5)
無呼吸発作	1 (1.7)	0
窒息	1 (1.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 5 of 17

	Male	Female
鼻汁変色	1 (1.7)	0
閉塞性気道障害	1 (1.7)	0
気縦隔症	1 (1.7)	0
誤嚥性肺炎	1 (1.7)	9 (15.8)
肺うっ血	1 (1.7)	1 (1.8)
肺水腫	1 (1.7)	1 (1.8)
呼吸性アルカローシス	1 (1.7)	0
呼吸障害	1 (1.7)	1 (1.8)
気道うっ血	1 (1.7)	0
アレルギー性鼻炎	1 (1.7)	1 (1.8)
低音性連続性ラ音	1 (1.7)	0
変色痰	1 (1.7)	0
呼吸補助筋の動員	1 (1.7)	1 (1.8)
喘鳴	1 (1.7)	2 (3.5)
急性呼吸窮迫症候群	0	1 (1.8)
気管支閉塞	0	1 (1.8)
息詰まり	0	2 (3.5)
高炭酸ガス血症	0	1 (1.8)
減呼吸	0	1 (1.8)
気管支分泌増加	0	1 (1.8)
喉頭肉芽腫	0	1 (1.8)
肺障害	0	1 (1.8)
胸水	0	1 (1.8)
気胸	0	3 (5.3)
湿性咳嗽	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 6 of 17

	Male	Female
呼吸性アシドーシス	0	1 (1.8)
拘束性肺疾患	0	1 (1.8)
睡眠時無呼吸症候群	0	1 (1.8)
頻呼吸	0	1 (1.8)
気管障害	0	1 (1.8)
胃腸障害	33 (55.0)	37 (64.9)
便秘	17 (28.3)	17 (29.8)
生歯	9 (15.0)	7 (12.3)
嘔吐	9 (15.0)	11 (19.3)
胃食道逆流性疾患	8 (13.3)	9 (15.8)
下痢	5 (8.3)	8 (14.0)
嚥下障害	5 (8.3)	5 (8.8)
放屁	3 (5.0)	4 (7.0)
流涎過多	3 (5.0)	2 (3.5)
腹部膨満	2 (3.3)	4 (7.0)
腹部不快感	1 (1.7)	1 (1.8)
腹痛	1 (1.7)	0
胃炎	1 (1.7)	3 (5.3)
消化管運動低下	1 (1.7)	0
乳児仙痛	1 (1.7)	0
乳児吐血	1 (1.7)	0
アフタ性潰瘍	0	1 (1.8)
口唇のひび割れ	0	1 (1.8)
排便回数増加	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 7 of 17

	Male	Female
胃出血	0	1 (1.8)
吐血	0	1 (1.8)
血便排泄	0	2 (3.5)
上部消化管出血	0	1 (1.8)
一般・全身障害および投与部位の状態	31 (51.7)	31 (54.4)
発熱	27 (45.0)	29 (50.9)
疼痛	4 (6.7)	1 (1.8)
不快感	2 (3.3)	0
末梢性浮腫	2 (3.3)	0
適用部位紅斑	1 (1.7)	0
医療機器リーク	1 (1.7)	0
医療機器閉塞	1 (1.7)	0
薬物不耐性	1 (1.7)	0
注入部位内出血	1 (1.7)	0
倦怠感	1 (1.7)	0
浮腫	1 (1.7)	0
血管穿刺部位内出血	1 (1.7)	0
カテーテル留置部位炎症	0	1 (1.8)
泣き	0	1 (1.8)
死亡	0	1 (1.8)
低体温	0	1 (1.8)
ワクチン接種後の易刺激性	0	1 (1.8)
小結節	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 8 of 17

	Male	Female
末梢腫脹	0	1 (1.8)
腫脹	0	1 (1.8)
皮膚および皮下組織障害	21 (35.0)	20 (35.1)
おむつ皮膚炎	6 (10.0)	6 (10.5)
発疹	6 (10.0)	7 (12.3)
湿疹	4 (6.7)	0
皮膚炎	3 (5.0)	1 (1.8)
斑状出血	2 (3.3)	1 (1.8)
紅斑	2 (3.3)	0
汗疹	2 (3.3)	0
アレルギー性皮膚炎	1 (1.7)	0
接触性皮膚炎	1 (1.7)	2 (3.5)
過剰肉芽組織	1 (1.7)	2 (3.5)
丘疹性皮疹	1 (1.7)	0
皮膚色素脱失	1 (1.7)	0
皮膚刺激	1 (1.7)	2 (3.5)
皮膚浮腫	1 (1.7)	0
皮下気腫	1 (1.7)	0
脱毛症	0	1 (1.8)
貨幣状湿疹	0	1 (1.8)
環状肉芽腫	0	1 (1.8)
過角化	0	2 (3.5)
点状出血	0	1 (1.8)
そう痒症	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 9 of 17

	Male	Female
脂漏性皮膚炎	0	1 (1.8)
皮膚障害	0	1 (1.8)
皮膚潰瘍	0	1 (1.8)
蕁麻疹	0	1 (1.8)
傷害、中毒および処置合併症	15 (25.0)	14 (24.6)
節足動物咬傷	3 (5.0)	0
関節脱臼	2 (3.3)	0
処置後腫脹	2 (3.3)	0
皮膚擦過傷	2 (3.3)	0
ストーマ部紅斑	2 (3.3)	1 (1.8)
挫傷	1 (1.7)	1 (1.8)
ダンピング症候群	1 (1.7)	0
耳擦過傷	1 (1.7)	0
擦過傷	1 (1.7)	0
伝染病曝露	1 (1.7)	0
転倒	1 (1.7)	0
栄養補給チューブ合併症	1 (1.7)	1 (1.8)
大腿骨骨折	1 (1.7)	1 (1.8)
口唇損傷	1 (1.7)	0
外傷性気胸	1 (1.7)	0
処置後不快感	1 (1.7)	0
処置による疼痛	1 (1.7)	3 (5.3)
処置部位反応	1 (1.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 10 of 17

	Male	Female
硬膜下血腫	1 (1.7)	0
サンバーン	1 (1.7)	0
熱傷	1 (1.7)	0
歯牙損傷	1 (1.7)	0
術後激越	0	1 (1.8)
麻酔からの覚醒遅延	0	1 (1.8)
処置後合併症	0	1 (1.8)
処置合併症	0	1 (1.8)
軟部組織損傷	0	1 (1.8)
ストーマ合併症	0	1 (1.8)
ワクチン接種合併症	0	1 (1.8)
創離開	0	1 (1.8)
心臓障害	13 (21.7)	11 (19.3)
徐脈	5 (8.3)	2 (3.5)
頻脈	5 (8.3)	5 (8.8)
心停止	3 (5.0)	0
心肺停止	2 (3.3)	4 (7.0)
心筋症	1 (1.7)	0
心膜気腫	1 (1.7)	0
チアノーゼ	0	3 (5.3)
左室肥大	0	1 (1.8)
上室性頻脈	0	1 (1.8)
心室性頻脈	0	2 (3.5)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 11 of 17

	Male	Female
筋骨格系および結合組織障害	13 (21.7)	14 (24.6)
関節拘縮	8 (13.3)	4 (7.0)
脊柱後弯症	4 (6.7)	1 (1.8)
側弯症	4 (6.7)	7 (12.3)
斜頚	2 (3.3)	1 (1.8)
胸郭変形	1 (1.7)	3 (5.3)
脊柱前弯症	1 (1.7)	0
筋力低下	1 (1.7)	0
四肢痛	1 (1.7)	1 (1.8)
頭位性斜頭症	1 (1.7)	2 (3.5)
脊柱変形	1 (1.7)	0
滑膜炎	1 (1.7)	0
体重支持困難	1 (1.7)	0
背部痛	0	1 (1.8)
泉門閉鎖遅延	0	1 (1.8)
手変形	0	1 (1.8)
関節硬直	0	1 (1.8)
後側弯症	0	2 (3.5)
臨床検査	12 (20.0)	13 (22.8)
体重減少	4 (6.7)	1 (1.8)
酸素飽和度低下	3 (5.0)	7 (12.3)
アラニンアミノトランスフェラーゼ増加	2 (3.3)	0
アスパラギン酸アミノトランスフェラーゼ増加	2 (3.3)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 12 of 17

	Male	Female
血中カリウム減少	2 (3.3)	0
好中球数増加	2 (3.3)	1 (1.8)
白血球数増加	2 (3.3)	0
血中クロール減少	1 (1.7)	0
血中ナトリウム減少	1 (1.7)	0
体温低下	1 (1.7)	0
体温上昇	1 (1.7)	1 (1.8)
骨密度減少	1 (1.7)	0
Ｃ－反応性蛋白増加	1 (1.7)	1 (1.8)
心電図ＳＴ－Ｔ部分異常	1 (1.7)	0
心拍数増加	1 (1.7)	1 (1.8)
ヒトライノウイルス検査陽性	1 (1.7)	2 (3.5)
Ａ型インフルエンザウイルス検査陽性	1 (1.7)	0
肝機能検査異常	1 (1.7)	0
好中球百分率増加	1 (1.7)	0
シュードモナス検査陽性	1 (1.7)	1 (1.8)
ブドウ球菌検査陽性	1 (1.7)	1 (1.8)
尿量減少	1 (1.7)	0
ビタミンＡ減少	1 (1.7)	0
血中鉄減少	0	1 (1.8)
呼吸音異常	0	1 (1.8)
心拍数減少	0	1 (1.8)
心拍数不整	0	1 (1.8)
炎症マーカー上昇	0	1 (1.8)
医学的観察	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 13 of 17

	Male	Female
モラクセラ検査陽性	0	2 (3.5)
セラチア検査陽性	0	1 (1.8)
レンサ球菌検査陽性	0	1 (1.8)
代謝および栄養障害	9 (15.0)	11 (19.3)
体重増加不良	5 (8.3)	2 (3.5)
成長障害	3 (5.0)	1 (1.8)
乳児および小児期早期の哺育障害	1 (1.7)	2 (3.5)
低ナトリウム血症	1 (1.7)	1 (1.8)
脱水	0	2 (3.5)
栄養補給不耐性	0	3 (5.3)
過小食	0	2 (3.5)
鉄欠乏	0	1 (1.8)
代謝性アルカローシス	0	1 (1.8)
神経系障害	9 (15.0)	10 (17.5)
不随意性筋収縮	2 (3.3)	2 (3.5)
脳梗塞	1 (1.7)	0
間代	1 (1.7)	0
よだれ	1 (1.7)	1 (1.8)
頭痛	1 (1.7)	0
筋緊張低下	1 (1.7)	0
低酸素性虚血性脳症	1 (1.7)	0
眼振	1 (1.7)	2 (3.5)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 14 of 17

	Male	Female
痙攣発作	1 (1.7)	1 (1.8)
脳損傷	0	1 (1.8)
脳脊髄液漏	0	1 (1.8)
反射亢進	0	1 (1.8)
嗜眠	0	1 (1.8)
傾眠	0	1 (1.8)
失神	0	1 (1.8)
血液およびリンパ系障害	5 (8.3)	3 (5.3)
貧血	2 (3.3)	1 (1.8)
リンパ節症	1 (1.7)	0
好中球減少症	1 (1.7)	1 (1.8)
血小板増加症	1 (1.7)	0
好酸球増加症	0	1 (1.8)
精神障害	5 (8.3)	6 (10.5)
不安	4 (6.7)	1 (1.8)
息こらえ	1 (1.7)	0
落ち着きのなさ	1 (1.7)	0
睡眠障害	1 (1.7)	0
激越	0	2 (3.5)
易刺激性	0	2 (3.5)
気分動揺	0	1 (1.8)
先天性、家族性および遺伝性障害	4 (6.7)	2 (3.5)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 15 of 17

	Male	Female
斜指症	1 (1.7)	0
貧血母斑	1 (1.7)	0
鳩胸	1 (1.7)	0
斜頭症	1 (1.7)	1 (1.8)
発育性股関節形成不全	0	1 (1.8)
眼障害	4 (6.7)	3 (5.3)
霰粒腫	1 (1.7)	0
後天性涙道狭窄	1 (1.7)	0
眼乾燥	1 (1.7)	0
眼瞼下垂	1 (1.7)	0
乱視	0	1 (1.8)
眼運動障害	0	1 (1.8)
近視	0	1 (1.8)
斜視	0	1 (1.8)
免疫系障害	4 (6.7)	9 (15.8)
季節性アレルギー	2 (3.3)	4 (7.0)
薬物過敏症	1 (1.7)	3 (5.3)
過敏症	1 (1.7)	1 (1.8)
食物アレルギー	0	1 (1.8)
血管障害	3 (5.0)	6 (10.5)
高血圧	1 (1.7)	2 (3.5)
蒼白	1 (1.7)	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 16 of 17

	Male	Female
血管炎	1 (1.7)	0
毛細血管脆弱	0	1 (1.8)
本態性高血圧症	0	1 (1.8)
ショック	0	1 (1.8)
耳および迷路障害	2 (3.3)	1 (1.8)
耳の障害	1 (1.7)	0
耳痛	1 (1.7)	0
耳垢分泌過多	0	1 (1.8)
腎および尿路障害	2 (3.3)	0
水腎症	1 (1.7)	0
尿閉	1 (1.7)	0
生殖系および乳房障害	2 (3.3)	1 (1.8)
後天性包茎	1 (1.7)	0
陰茎障害	1 (1.7)	0
卵巣嚢胞	0	1 (1.8)
肝胆道系障害	1 (1.7)	0
肝腫大	1 (1.7)	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	1 (1.7)	2 (3.5)
脂漏性角化症	1 (1.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 17 of 17

	Male	Female
アクロコルドン	0	1 (1.8)
血管の良性新生物	0	1 (1.8)
外科および内科処置	1 (1.7)	0
機械的換気	1 (1.7)	0
妊娠、産褥および周産期の状態	0	1 (1.8)
臍肉芽腫	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]
##[redacted]20[redacted]##

表 67　Later-Onset Subjects:Incidence of Adverse Events by Sex

Later-onset subjects: incidence of adverse events by sex
Page 1 of 9

	Male	Female
Number of subjects dosed	26 (100.0)	30 (100.0)
Number of subjects with an event	26 (100.0)	30 (100.0)
感染症および寄生虫症	22 (84.6)	22 (73.3)
上気道感染	11 (42.3)	16 (53.3)
鼻咽頭炎	6 (23.1)	10 (33.3)
レンサ球菌性咽頭炎	5 (19.2)	3 (10.0)
胃腸炎	4 (15.4)	3 (10.0)
耳感染	3 (11.5)	1 (3.3)
ウイルス性胃腸炎	3 (11.5)	5 (16.7)
副鼻腔炎	3 (11.5)	0
結膜炎	2 (7.7)	1 (3.3)
肺炎	2 (7.7)	3 (10.0)
ブドウ球菌性眼感染	1 (3.8)	0
ウイルス性眼感染	1 (3.8)	0
ウイルス性消化管感染	1 (3.8)	1 (3.3)
膿痂疹	1 (3.8)	0
インフルエンザ	1 (3.8)	2 (6.7)
伝染性軟属腫	1 (3.8)	0
中耳炎	1 (3.8)	4 (13.3)
ＲＳウイルス肺炎	1 (3.8)	0
ウイルス性肺炎	1 (3.8)	1 (3.3)
ＲＳウイルス細気管支炎	1 (3.8)	0
皮膚細菌感染	1 (3.8)	0
皮膚カンジダ	1 (3.8)	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 2 of 9

	Male	Female
尿路感染	1 (3.8)	3 (10.0)
ウイルス感染	1 (3.8)	8 (26.7)
ウイルス性上気道感染	1 (3.8)	4 (13.3)
蜂巣炎	0	1 (3.3)
皮膚真菌感染	0	1 (3.3)
手足口病	0	1 (3.3)
限局性感染	0	3 (10.0)
下気道感染	0	1 (3.3)
単核細胞症症候群	0	1 (3.3)
急性中耳炎	0	1 (3.3)
咽頭炎	0	1 (3.3)
ＲＳウイルス感染	0	3 (10.0)
気道感染	0	1 (3.3)
ウイルス性気道感染	0	1 (3.3)
鼻炎	0	1 (3.3)
扁桃炎	0	1 (3.3)
膣感染	0	1 (3.3)
ウイルス性扁桃炎	0	1 (3.3)
外陰膣真菌感染	0	1 (3.3)
傷害、中毒および処置合併症	17 (65.4)	23 (76.7)
腰椎穿刺後症候群	9 (34.6)	14 (46.7)
裂傷	3 (11.5)	4 (13.3)
大腿骨骨折	2 (7.7)	1 (3.3)
処置による疼痛	2 (7.7)	4 (13.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 3 of 9

	Male	Female
節足動物咬傷	1 (3.8)	2 (6.7)
関節損傷	1 (3.8)	1 (3.3)
靭帯捻挫	1 (3.8)	0
下肢骨折	1 (3.8)	0
術後イレウス	1 (3.8)	0
処置による頭痛	1 (3.8)	0
処置による悪心	1 (3.8)	1 (3.3)
熱傷	1 (3.8)	0
隆起骨折	1 (3.8)	1 (3.3)
術後激越	0	1 (3.3)
節足動物刺傷	0	1 (3.3)
挫傷	0	2 (6.7)
転倒	0	1 (3.3)
頭部損傷	0	1 (3.3)
関節脱臼	0	2 (6.7)
四肢損傷	0	3 (10.0)
半月板損傷	0	1 (3.3)
肉離れ	0	1 (3.3)
サンバーン	0	2 (6.7)
脛骨骨折	0	1 (3.3)
筋骨格系および結合組織障害	17 (65.4)	24 (80.0)
背部痛	9 (34.6)	14 (46.7)
側弯症	8 (30.8)	7 (23.3)
関節拘縮	4 (15.4)	6 (20.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 4 of 9

	Male	Female
筋肉痛	2 (7.7)	2 (6.7)
関節痛	1 (3.8)	4 (13.3)
脊柱前弯症	1 (3.8)	0
筋緊張	1 (3.8)	1 (3.3)
四肢拘縮	0	1 (3.3)
頚部痛	0	3 (10.0)
四肢痛	0	5 (16.7)
骨盤変形	0	2 (6.7)
一般・全身障害および投与部位の状態	16 (61.5)	15 (50.0)
発熱	10 (38.5)	6 (20.0)
穿刺部位疼痛	5 (19.2)	5 (16.7)
胸部不快感	1 (3.8)	0
疲労	1 (3.8)	2 (6.7)
冷感	1 (3.8)	0
低体温	1 (3.8)	0
注射部位出血	1 (3.8)	0
注射部位疼痛	1 (3.8)	0
疼痛	1 (3.8)	1 (3.3)
穿刺部位反応	1 (3.8)	0
カテーテル留置部位出血	0	1 (3.3)
カテーテル留置部位疼痛	0	1 (3.3)
カテーテル留置部位関連反応	0	1 (3.3)
悪寒	0	1 (3.3)
重力性浮腫	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 5 of 9

	Male	Female
末梢腫脹	0	1 (3.3)
血管穿刺部位内出血	0	1 (3.3)
神経系障害	16 (61.5)	14 (46.7)
頭痛	15 (57.7)	13 (43.3)
味覚異常	1 (3.8)	0
片頭痛	1 (3.8)	0
失神	1 (3.8)	0
振戦	1 (3.8)	0
失声症	0	1 (3.3)
失読症	0	1 (3.3)
感覚鈍麻	0	2 (6.7)
錯感覚	0	1 (3.3)
呼吸器、胸郭および縦隔障害	12 (46.2)	13 (43.3)
口腔咽頭痛	5 (19.2)	3 (10.0)
咳嗽	3 (11.5)	3 (10.0)
鼻漏	3 (11.5)	3 (10.0)
急性呼吸不全	1 (3.8)	0
無気肺	1 (3.8)	0
呼吸困難	1 (3.8)	0
鼻出血	1 (3.8)	2 (6.7)
低酸素症	1 (3.8)	2 (6.7)
鼻閉	1 (3.8)	2 (6.7)
肺うっ血	1 (3.8)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 6 of 9

	Male	Female
呼吸障害	1 (3.8)	0
呼吸不全	1 (3.8)	0
扁桃肥大	1 (3.8)	2 (6.7)
発声障害	0	1 (3.3)
肺臓炎	0	1 (3.3)
拘束性肺疾患	0	1 (3.3)
副鼻腔うっ血	0	2 (6.7)
喘鳴	0	1 (3.3)
胃腸障害	10 (38.5)	16 (53.3)
便秘	6 (23.1)	1 (3.3)
嘔吐	6 (23.1)	6 (20.0)
悪心	5 (19.2)	5 (16.7)
アフタ性潰瘍	1 (3.8)	2 (6.7)
下痢	1 (3.8)	1 (3.3)
口唇痛	1 (3.8)	0
口内炎	1 (3.8)	0
腹部不快感	0	1 (3.3)
腹痛	0	2 (6.7)
上腹部痛	0	2 (6.7)
腹部症状	0	1 (3.3)
放屁	0	1 (3.3)
食中毒	0	1 (3.3)
胃腸障害	0	1 (3.3)
胃食道逆流性疾患	0	1 (3.3)
口の感覚鈍麻	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 7 of 9

	Male	Female
口腔内痛	0	2 (6.7)
皮膚および皮下組織障害	7 (26.9)	10 (33.3)
皮膚炎	1 (3.8)	0
接触性皮膚炎	1 (3.8)	2 (6.7)
おむつ皮膚炎	1 (3.8)	0
湿疹	1 (3.8)	1 (3.3)
紅斑	1 (3.8)	0
毛孔性角化症	1 (3.8)	0
皮膚病変	1 (3.8)	0
ざ瘡	0	1 (3.3)
水疱	0	1 (3.3)
褥瘡性潰瘍	0	1 (3.3)
汗疹	0	1 (3.3)
寝汗	0	1 (3.3)
発疹	0	1 (3.3)
蕁麻疹	0	1 (3.3)
臨床検査	5 (19.2)	3 (10.0)
体重減少	3 (11.5)	0
血中テストステロン減少	1 (3.8)	0
ＣＳＦ白血球数増加	1 (3.8)	0
心拍数増加	1 (3.8)	0
血中重炭酸塩減少	0	1 (3.3)
体温上昇	0	1 (3.3)
尿検査異常	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 8 of 9

	Male	Female
免疫系障害	4 (15.4)	3 (10.0)
季節性アレルギー	2 (7.7)	1 (3.3)
薬物過敏症	1 (3.8)	0
過敏症	1 (3.8)	2 (6.7)
腎および尿路障害	2 (7.7)	1 (3.3)
尿失禁	1 (3.8)	0
膀胱尿管逆流	1 (3.8)	0
排尿困難	0	1 (3.3)
血液およびリンパ系障害	1 (3.8)	0
好中球減少症	1 (3.8)	0
耳および迷路障害	1 (3.8)	2 (6.7)
乗物酔い	1 (3.8)	0
耳痛	0	1 (3.3)
鼓膜穿孔	0	1 (3.3)
眼障害	1 (3.8)	1 (3.3)
斜視	1 (3.8)	0
遠視	0	1 (3.3)
代謝および栄養障害	1 (3.8)	4 (13.3)
食欲亢進	1 (3.8)	0
食欲減退	0	1 (3.3)
脱水	0	2 (6.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 9 of 9

	Male	Female
ビタミンD欠乏	0	1 (3.3)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (3.8)	0
皮膚乳頭腫	1 (3.8)	0
精神障害	1 (3.8)	3 (10.0)
激越	1 (3.8)	1 (3.3)
睡眠時随伴症	1 (3.8)	0
注意欠陥多動性障害	0	1 (3.3)
不快気分	0	1 (3.3)
不眠症	0	1 (3.3)
チック	0	1 (3.3)
心因性嘔吐	0	1 (3.3)
心臓障害	0	3 (10.0)
動悸	0	2 (6.7)
頻脈	0	1 (3.3)
血管障害	0	1 (3.3)
低血圧	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 68　Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443:Incidence of Adverse Events by Race

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 1 of 17

	White	Non-white
Number of subjects dosed	93 (100.0)	20 (100.0)
Number of subjects with an event	86 (92.5)	16 (80.0)
感染症および寄生虫症	69 (74.2)	14 (70.0)
上気道感染	32 (34.4)	6 (30.0)
肺炎	20 (21.5)	4 (20.0)
鼻咽頭炎	15 (16.1)	7 (35.0)
ライノウイルス感染	12 (12.9)	3 (15.0)
ウイルス性上気道感染	12 (12.9)	0
気道感染	10 (10.8)	2 (10.0)
細気管支炎	9 (9.7)	3 (15.0)
ウイルス感染	8 (8.6)	3 (15.0)
口腔カンジダ症	6 (6.5)	1 (5.0)
中耳炎	6 (6.5)	3 (15.0)
ウイルス性肺炎	6 (6.5)	4 (20.0)
気管支炎	5 (5.4)	0
結膜炎	5 (5.4)	1 (5.0)
細菌性肺炎	4 (4.3)	0
ＲＳウイルス細気管支炎	4 (4.3)	0
尿路感染	4 (4.3)	0
ウイルス性気管支炎	3 (3.2)	0
耳感染	3 (3.2)	2 (10.0)
ウイルス性気道感染	3 (3.2)	2 (10.0)
アデノウイルス感染	2 (2.2)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 2 of 17

	White	Non-white
カンジダ性おむつ皮疹	2 (2.2)	0
細菌性結膜炎	2 (2.2)	0
胃腸炎	2 (2.2)	0
ウイルス性胃腸炎	2 (2.2)	0
手足口病	2 (2.2)	0
膿痂疹	2 (2.2)	0
下気道感染	2 (2.2)	2 (10.0)
ウイルス性下気道感染	2 (2.2)	1 (5.0)
メタニューモウイルス感染	2 (2.2)	0
レンサ球菌性咽頭炎	2 (2.2)	0
モラクセラ菌性肺炎	2 (2.2)	0
鼻炎	2 (2.2)	0
皮膚カンジダ	2 (2.2)	0
ストーマ部膿瘍	2 (2.2)	0
細菌性疾患キャリアー	1 (1.1)	0
細菌感染	1 (1.1)	1 (5.0)
細菌性気管炎	1 (1.1)	2 (10.0)
蜂巣炎	1 (1.1)	0
エンテロウイルス感染	1 (1.1)	1 (5.0)
眼感染	1 (1.1)	0
真菌感染	1 (1.1)	0
皮膚真菌感染	1 (1.1)	1 (5.0)
ウイルス性胃炎	1 (1.1)	0
ロタウイルス胃腸炎	1 (1.1)	0
インフルエンザ	1 (1.1)	2 (10.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 3 of 17

	White	Non-white
肺感染	1 (1.1)	0
粘膜皮膚カンジダ症	1 (1.1)	0
院内感染	1 (1.1)	0
口腔ヘルペス	1 (1.1)	0
急性中耳炎	1 (1.1)	0
パラインフルエンザウイルス感染	1 (1.1)	1 (5.0)
パラインフルエンザウイルス性肺炎	1 (1.1)	0
ＲＳウイルス肺炎	1 (1.1)	0
シュードモナス感染	1 (1.1)	0
細菌性気道感染	1 (1.1)	0
ばら疹	1 (1.1)	0
皮膚感染	1 (1.1)	0
ブドウ球菌感染	1 (1.1)	0
ブドウ球菌性敗血症	1 (1.1)	0
ブドウ球菌皮膚感染	1 (1.1)	0
気管炎	1 (1.1)	0
アデノウイルス性上気道感染	0	1 (5.0)
コロナウイルス感染	0	1 (5.0)
感染性湿疹	0	1 (5.0)
伝染性紅斑	0	1 (5.0)
ヘモフィルス感染	0	1 (5.0)
限局性感染	0	1 (5.0)
モラクセラ感染	0	1 (5.0)
インフルエンザ性肺炎	0	1 (5.0)
シュードモナス菌性肺炎	0	1 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 4 of 17

	White	Non-white
敗血症	0	1 (5.0)
ブドウ球菌性菌血症	0	1 (5.0)
呼吸器、胸郭および縦隔障害	64 (68.8)	12 (60.0)
呼吸窮迫	21 (22.6)	6 (30.0)
呼吸不全	20 (21.5)	3 (15.0)
無気肺	18 (19.4)	2 (10.0)
鼻閉	16 (17.2)	1 (5.0)
急性呼吸不全	13 (14.0)	2 (10.0)
咳嗽	12 (12.9)	1 (5.0)
低酸素症	9 (9.7)	1 (5.0)
誤嚥性肺炎	9 (9.7)	1 (5.0)
上気道うっ血	7 (7.5)	0
無呼吸	6 (6.5)	1 (5.0)
誤嚥	5 (5.4)	1 (5.0)
気管支分泌物貯留	5 (5.4)	1 (5.0)
慢性呼吸不全	5 (5.4)	1 (5.0)
呼吸困難	5 (5.4)	4 (20.0)
上気道分泌増加	5 (5.4)	1 (5.0)
鼻漏	5 (5.4)	2 (10.0)
低換気	3 (3.2)	0
副鼻腔うっ血	3 (3.2)	1 (5.0)
気胸	2 (2.2)	1 (5.0)
肺うっ血	2 (2.2)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 5 of 17

	White	Non-white
呼吸停止	2 (2.2)	2 (10.0)
アレルギー性鼻炎	2 (2.2)	0
呼吸補助筋の動員	2 (2.2)	0
喘鳴	2 (2.2)	1 (5.0)
急性呼吸窮迫症候群	1 (1.1)	0
無呼吸発作	1 (1.1)	0
窒息	1 (1.1)	0
気管支閉塞	1 (1.1)	0
息詰まり	1 (1.1)	1 (5.0)
高炭酸ガス血症	1 (1.1)	0
減呼吸	1 (1.1)	0
喉頭肉芽腫	1 (1.1)	0
肺障害	1 (1.1)	0
鼻汁変色	1 (1.1)	0
閉塞性気道障害	1 (1.1)	0
胸水	1 (1.1)	0
湿性咳嗽	1 (1.1)	0
肺水腫	1 (1.1)	1 (5.0)
呼吸障害	1 (1.1)	1 (5.0)
拘束性肺疾患	1 (1.1)	0
低音性連続性ラ音	1 (1.1)	0
睡眠時無呼吸症候群	1 (1.1)	0
変色痰	1 (1.1)	0
気管障害	1 (1.1)	0
気管支分泌増加	0	1 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 6 of 17

	White	Non-white
気縦隔症	0	1 (5.0)
呼吸性アルカローシス	0	1 (5.0)
気道うっ血	0	1 (5.0)
頻呼吸	0	1 (5.0)
胃腸障害	58 (62.4)	11 (55.0)
便秘	27 (29.0)	6 (30.0)
生歯	15 (16.1)	1 (5.0)
嘔吐	15 (16.1)	5 (25.0)
胃食道逆流性疾患	14 (15.1)	3 (15.0)
下痢	11 (11.8)	2 (10.0)
嚥下障害	9 (9.7)	1 (5.0)
放屁	7 (7.5)	0
流涎過多	5 (5.4)	0
腹部膨満	4 (4.3)	2 (10.0)
胃炎	3 (3.2)	1 (5.0)
腹部不快感	2 (2.2)	0
血便排泄	2 (2.2)	0
腹痛	1 (1.1)	0
アフタ性潰瘍	1 (1.1)	0
口唇のひび割れ	1 (1.1)	0
胃出血	1 (1.1)	0
消化管運動低下	1 (1.1)	0
乳児仙痛	1 (1.1)	0
乳児吐血	1 (1.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 7 of 17

	White	Non-white
上部消化管出血	1 (1.1)	0
排便回数増加	0	1 (5.0)
吐血	0	1 (5.0)
一般・全身障害および投与部位の状態	52 (55.9)	10 (50.0)
発熱	46 (49.5)	10 (50.0)
疼痛	5 (5.4)	0
不快感	2 (2.2)	0
末梢性浮腫	2 (2.2)	0
適用部位紅斑	1 (1.1)	0
カテーテル留置部位炎症	1 (1.1)	0
泣き	1 (1.1)	0
死亡	1 (1.1)	0
薬物不耐性	1 (1.1)	0
低体温	1 (1.1)	0
注入部位内出血	1 (1.1)	0
倦怠感	1 (1.1)	0
小結節	1 (1.1)	0
浮腫	1 (1.1)	0
腫脹	1 (1.1)	0
血管穿刺部位内出血	1 (1.1)	0
医療機器リーク	0	1 (5.0)
医療機器閉塞	0	1 (5.0)
ワクチン接種後の易刺激性	0	1 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 8 of 17

	White	Non-white
末梢腫脹	0	1 (5.0)
皮膚および皮下組織障害	33 (35.5)	6 (30.0)
発疹	12 (12.9)	1 (5.0)
おむつ皮膚炎	11 (11.8)	1 (5.0)
斑状出血	3 (3.2)	0
皮膚刺激	3 (3.2)	0
接触性皮膚炎	2 (2.2)	1 (5.0)
湿疹	2 (2.2)	2 (10.0)
過剰肉芽組織	2 (2.2)	1 (5.0)
過角化	2 (2.2)	0
皮膚炎	1 (1.1)	1 (5.0)
貨幣状湿疹	1 (1.1)	0
紅斑	1 (1.1)	1 (5.0)
環状肉芽腫	1 (1.1)	0
汗疹	1 (1.1)	1 (5.0)
そう痒症	1 (1.1)	0
丘疹性皮疹	1 (1.1)	0
脂漏性皮膚炎	1 (1.1)	0
皮膚色素脱失	1 (1.1)	0
皮膚浮腫	1 (1.1)	0
皮膚潰瘍	1 (1.1)	0
蕁麻疹	1 (1.1)	0
脱毛症	0	1 (5.0)
アレルギー性皮膚炎	0	1 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 9 of 17

	White	Non-white
点状出血	0	1 (5.0)
皮膚障害	0	1 (5.0)
皮下気腫	0	1 (5.0)
筋骨格系および結合組織障害	24 (25.8)	3 (15.0)
関節拘縮	12 (12.9)	0
側弯症	9 (9.7)	2 (10.0)
胸郭変形	4 (4.3)	0
脊柱後弯症	4 (4.3)	1 (5.0)
頭位性斜頭症	3 (3.2)	0
斜頚	3 (3.2)	0
後側弯症	2 (2.2)	0
四肢痛	2 (2.2)	0
背部痛	1 (1.1)	0
泉門閉鎖遅延	1 (1.1)	0
手変形	1 (1.1)	0
筋力低下	1 (1.1)	0
脊柱変形	1 (1.1)	0
滑膜炎	1 (1.1)	0
体重支持困難	1 (1.1)	0
関節硬直	0	1 (5.0)
脊柱前弯症	0	1 (5.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 10 of 17

	White	Non-white
傷害、中毒および処置合併症	23 (24.7)	6 (30.0)
処置による疼痛	4 (4.3)	0
節足動物咬傷	3 (3.2)	0
大腿骨骨折	2 (2.2)	0
処置後腫脹	2 (2.2)	0
皮膚擦過傷	2 (2.2)	0
ストーマ部紅斑	2 (2.2)	1 (5.0)
術後激越	1 (1.1)	0
挫傷	1 (1.1)	1 (5.0)
ダンピング症候群	1 (1.1)	0
耳擦過傷	1 (1.1)	0
擦過傷	1 (1.1)	0
転倒	1 (1.1)	0
栄養補給チューブ合併症	1 (1.1)	1 (5.0)
関節脱臼	1 (1.1)	1 (5.0)
口唇損傷	1 (1.1)	0
処置後合併症	1 (1.1)	0
処置後不快感	1 (1.1)	0
処置合併症	1 (1.1)	0
処置部位反応	1 (1.1)	0
ストーマ合併症	1 (1.1)	0
硬膜下血腫	1 (1.1)	0
サンバーン	1 (1.1)	0
熱傷	1 (1.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 11 of 17

	White	Non-white
歯牙損傷	1 (1.1)	0
ワクチン接種合併症	1 (1.1)	0
創離開	1 (1.1)	0
麻酔からの覚醒遅延	0	1 (5.0)
伝染病曝露	0	1 (5.0)
外傷性気胸	0	1 (5.0)
軟部組織損傷	0	1 (5.0)
心臓障害	22 (23.7)	2 (10.0)
頻脈	9 (9.7)	1 (5.0)
徐脈	6 (6.5)	1 (5.0)
心肺停止	6 (6.5)	0
心停止	3 (3.2)	0
チアノーゼ	3 (3.2)	0
心筋症	1 (1.1)	0
左室肥大	1 (1.1)	0
上室性頻脈	1 (1.1)	0
心室性頻脈	1 (1.1)	1 (5.0)
心膜気腫	0	1 (5.0)
臨床検査	22 (23.7)	3 (15.0)
酸素飽和度低下	8 (8.6)	2 (10.0)
体重減少	5 (5.4)	0
ヒトライノウイルス検査陽性	3 (3.2)	0
好中球数増加	3 (3.2)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 12 of 17

	White	Non-white
アラニンアミノトランスフェラーゼ増加	2 (2.2)	0
アスパラギン酸アミノトランスフェラーゼ増加	2 (2.2)	0
血中カリウム減少	2 (2.2)	0
Ｃ－反応性蛋白増加	2 (2.2)	0
心拍数増加	2 (2.2)	0
モラクセラ検査陽性	2 (2.2)	0
シュードモナス検査陽性	2 (2.2)	0
白血球数増加	2 (2.2)	0
血中クロール減少	1 (1.1)	0
血中鉄減少	1 (1.1)	0
血中ナトリウム減少	1 (1.1)	0
体温低下	1 (1.1)	0
体温上昇	1 (1.1)	1 (5.0)
骨密度減少	1 (1.1)	0
呼吸音異常	1 (1.1)	0
心電図ＳＴ－Ｔ部分異常	1 (1.1)	0
心拍数不整	1 (1.1)	0
炎症マーカー上昇	1 (1.1)	0
Ａ型インフルエンザウイルス検査陽性	1 (1.1)	0
肝機能検査異常	1 (1.1)	0
医学的観察	1 (1.1)	0
好中球百分率増加	1 (1.1)	0
セラチア検査陽性	1 (1.1)	0
ブドウ球菌検査陽性	1 (1.1)	1 (5.0)
レンサ球菌検査陽性	1 (1.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 13 of 17

	White	Non-white
尿量減少	1 (1.1)	0
ビタミンA減少	1 (1.1)	0
心拍数減少	0	1 (5.0)
代謝および栄養障害	16 (17.2)	4 (20.0)
体重増加不良	7 (7.5)	0
成長障害	3 (3.2)	1 (5.0)
乳児および小児期早期の哺育障害	3 (3.2)	0
栄養補給不耐性	3 (3.2)	0
脱水	1 (1.1)	1 (5.0)
低ナトリウム血症	1 (1.1)	1 (5.0)
過小食	1 (1.1)	1 (5.0)
鉄欠乏	1 (1.1)	0
代謝性アルカローシス	1 (1.1)	0
神経系障害	16 (17.2)	3 (15.0)
不随意性筋収縮	4 (4.3)	0
よだれ	2 (2.2)	0
眼振	2 (2.2)	1 (5.0)
脳損傷	1 (1.1)	0
間代	1 (1.1)	0
頭痛	1 (1.1)	0
反射亢進	1 (1.1)	0
筋緊張低下	1 (1.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 14 of 17

	White	Non-white
低酸素性虚血性脳症	1 (1.1)	0
嗜眠	1 (1.1)	0
痙攣発作	1 (1.1)	1 (5.0)
傾眠	1 (1.1)	0
失神	1 (1.1)	0
脳梗塞	0	1 (5.0)
脳脊髄液漏	0	1 (5.0)
免疫系障害	10 (10.8)	3 (15.0)
季節性アレルギー	6 (6.5)	0
薬物過敏症	3 (3.2)	1 (5.0)
食物アレルギー	1 (1.1)	0
過敏症	0	2 (10.0)
精神障害	10 (10.8)	1 (5.0)
不安	5 (5.4)	0
激越	2 (2.2)	0
息こらえ	1 (1.1)	0
易刺激性	1 (1.1)	1 (5.0)
気分動揺	1 (1.1)	0
落ち着きのなさ	1 (1.1)	0
睡眠障害	1 (1.1)	0
眼障害	6 (6.5)	1 (5.0)
霰粒腫	1 (1.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 15 of 17

	White	Non-white
後天性涙道狭窄	1 (1.1)	0
眼乾燥	1 (1.1)	0
眼運動障害	1 (1.1)	0
眼瞼下垂	1 (1.1)	0
近視	1 (1.1)	0
斜視	1 (1.1)	0
乱視	0	1 (5.0)
血管障害	6 (6.5)	2 (10.0)
高血圧	2 (2.2)	1 (5.0)
毛細血管脆弱	1 (1.1)	0
蒼白	1 (1.1)	0
ショック	1 (1.1)	0
血管炎	1 (1.1)	0
本態性高血圧症	0	1 (5.0)
血液およびリンパ系障害	5 (5.4)	2 (10.0)
貧血	2 (2.2)	1 (5.0)
好酸球増加症	1 (1.1)	0
リンパ節症	1 (1.1)	0
好中球減少症	1 (1.1)	0
血小板増加症	0	1 (5.0)
先天性、家族性および遺伝性障害	5 (5.4)	1 (5.0)
斜頭症	2 (2.2)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 16 of 17

	White	Non-white
発育性股関節形成不全	1 (1.1)	0
貧血母斑	1 (1.1)	0
鳩胸	1 (1.1)	0
斜指症	0	1 (5.0)
生殖系および乳房障害	3 (3.2)	0
後天性包茎	1 (1.1)	0
卵巣嚢胞	1 (1.1)	0
陰茎障害	1 (1.1)	0
耳および迷路障害	2 (2.2)	1 (5.0)
耳の障害	1 (1.1)	0
耳痛	1 (1.1)	0
耳垢分泌過多	0	1 (5.0)
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	2 (2.2)	1 (5.0)
アクロコルドン	1 (1.1)	0
脂漏性角化症	1 (1.1)	0
血管の良性新生物	0	1 (5.0)
肝胆道系障害	1 (1.1)	0
肝腫大	1 (1.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 17 of 17

	White	Non-white
妊娠、産褥および周産期の状態	1 (1.1)	0
臍肉芽腫	1 (1.1)	0
腎および尿路障害	1 (1.1)	1 (5.0)
水腎症	1 (1.1)	0
尿閉	0	1 (5.0)
外科および内科処置	1 (1.1)	0
機械的換気	1 (1.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 69　Later-Onset Subjects:Incidence of Adverse Events by Race

Later-onset subjects: incidence of adverse events by race
Page 1 of 9

	White	Non-white
Number of subjects dosed	49 (100.0)	7 (100.0)
Number of subjects with an event	49 (100.0)	7 (100.0)
感染症および寄生虫症	39 (79.6)	5 (71.4)
上気道感染	24 (49.0)	3 (42.9)
鼻咽頭炎	15 (30.6)	1 (14.3)
レンサ球菌性咽頭炎	8 (16.3)	0
ウイルス感染	8 (16.3)	1 (14.3)
ウイルス性胃腸炎	7 (14.3)	1 (14.3)
胃腸炎	6 (12.2)	1 (14.3)
中耳炎	5 (10.2)	0
肺炎	5 (10.2)	0
ウイルス性上気道感染	5 (10.2)	0
耳感染	4 (8.2)	0
結膜炎	3 (6.1)	0
インフルエンザ	3 (6.1)	0
限局性感染	3 (6.1)	0
尿路感染	3 (6.1)	1 (14.3)
ウイルス性消化管感染	2 (4.1)	0
ウイルス性肺炎	2 (4.1)	0
ＲＳウイルス感染	2 (4.1)	1 (14.3)
副鼻腔炎	2 (4.1)	1 (14.3)
皮膚カンジダ	2 (4.1)	0
蜂巣炎	1 (2.0)	0
ブドウ球菌性眼感染	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 2 of 9

	White	Non-white
ウイルス性眼感染	1 (2.0)	0
皮膚真菌感染	1 (2.0)	0
手足口病	1 (2.0)	0
膿痂疹	1 (2.0)	0
下気道感染	1 (2.0)	0
伝染性軟属腫	1 (2.0)	0
単核細胞症症候群	1 (2.0)	0
急性中耳炎	1 (2.0)	0
咽頭炎	1 (2.0)	0
ＲＳウイルス肺炎	1 (2.0)	0
ＲＳウイルス細気管支炎	1 (2.0)	0
気道感染	1 (2.0)	0
ウイルス性気道感染	1 (2.0)	0
鼻炎	1 (2.0)	0
皮膚細菌感染	1 (2.0)	0
扁桃炎	1 (2.0)	0
膣感染	1 (2.0)	0
ウイルス性扁桃炎	1 (2.0)	0
外陰膣真菌感染	1 (2.0)	0
傷害、中毒および処置合併症	37 (75.5)	3 (42.9)
腰椎穿刺後症候群	21 (42.9)	2 (28.6)
裂傷	7 (14.3)	0
処置による疼痛	5 (10.2)	1 (14.3)
大腿骨骨折	3 (6.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 3 of 9

	White	Non-white
四肢損傷	3 (6.1)	0
節足動物咬傷	2 (4.1)	1 (14.3)
関節脱臼	2 (4.1)	0
関節損傷	2 (4.1)	0
処置による悪心	2 (4.1)	0
サンバーン	2 (4.1)	0
術後激越	1 (2.0)	0
節足動物刺傷	1 (2.0)	0
挫傷	1 (2.0)	1 (14.3)
転倒	1 (2.0)	0
靭帯捻挫	1 (2.0)	0
下肢骨折	1 (2.0)	0
半月板損傷	1 (2.0)	0
肉離れ	1 (2.0)	0
術後イレウス	1 (2.0)	0
処置による頭痛	1 (2.0)	0
脛骨骨折	1 (2.0)	0
隆起骨折	1 (2.0)	1 (14.3)
頭部損傷	0	1 (14.3)
熱傷	0	1 (14.3)
筋骨格系および結合組織障害	37 (75.5)	4 (57.1)
背部痛	20 (40.8)	3 (42.9)
側弯症	13 (26.5)	2 (28.6)
関節拘縮	10 (20.4)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 4 of 9

	White	Non-white
四肢痛	5 (10.2)	0
関節痛	4 (8.2)	1 (14.3)
筋肉痛	4 (8.2)	0
頚部痛	3 (6.1)	0
筋緊張	2 (4.1)	0
四肢拘縮	1 (2.0)	0
骨盤変形	1 (2.0)	1 (14.3)
脊柱前弯症	0	1 (14.3)
一般・全身障害および投与部位の状態	27 (55.1)	4 (57.1)
発熱	15 (30.6)	1 (14.3)
穿刺部位疼痛	8 (16.3)	2 (28.6)
疲労	3 (6.1)	0
カテーテル留置部位出血	1 (2.0)	0
カテーテル留置部位疼痛	1 (2.0)	0
カテーテル留置部位関連反応	1 (2.0)	0
胸部不快感	1 (2.0)	0
悪寒	1 (2.0)	0
冷感	1 (2.0)	0
低体温	1 (2.0)	0
注射部位出血	1 (2.0)	0
注射部位疼痛	1 (2.0)	0
疼痛	1 (2.0)	1 (14.3)
末梢腫脹	1 (2.0)	0
穿刺部位反応	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 5 of 9

	White	Non-white
血管穿刺部位内出血	1 (2.0)	0
重力性浮腫	0	1 (14.3)
神経系障害	25 (51.0)	5 (71.4)
頭痛	23 (46.9)	5 (71.4)
味覚異常	1 (2.0)	0
失読症	1 (2.0)	0
感覚鈍麻	1 (2.0)	1 (14.3)
片頭痛	1 (2.0)	0
失神	1 (2.0)	0
振戦	1 (2.0)	0
失声症	0	1 (14.3)
錯感覚	0	1 (14.3)
胃腸障害	24 (49.0)	2 (28.6)
嘔吐	12 (24.5)	0
悪心	9 (18.4)	1 (14.3)
便秘	7 (14.3)	0
腹痛	2 (4.1)	0
上腹部痛	2 (4.1)	0
下痢	2 (4.1)	0
腹部不快感	1 (2.0)	0
腹部症状	1 (2.0)	0
アフタ性潰瘍	1 (2.0)	2 (28.6)
放屁	1 (2.0)	0
食中毒	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 6 of 9

	White	Non-white
胃腸障害	1 (2.0)	0
胃食道逆流性疾患	1 (2.0)	0
口の感覚鈍麻	1 (2.0)	0
口唇痛	1 (2.0)	0
口腔内痛	1 (2.0)	1 (14.3)
口内炎	1 (2.0)	0
呼吸器、胸郭および縦隔障害	21 (42.9)	4 (57.1)
口腔咽頭痛	6 (12.2)	2 (28.6)
鼻漏	6 (12.2)	0
咳嗽	5 (10.2)	1 (14.3)
鼻出血	3 (6.1)	0
低酸素症	3 (6.1)	0
鼻閉	3 (6.1)	0
副鼻腔うっ血	2 (4.1)	0
急性呼吸不全	1 (2.0)	0
無気肺	1 (2.0)	0
発声障害	1 (2.0)	0
呼吸困難	1 (2.0)	0
肺臓炎	1 (2.0)	0
肺うっ血	1 (2.0)	0
呼吸障害	1 (2.0)	0
呼吸不全	1 (2.0)	0
拘束性肺疾患	1 (2.0)	0
扁桃肥大	1 (2.0)	2 (28.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 7 of 9

	White	Non-white
喘鳴	1 (2.0)	0
皮膚および皮下組織障害	15 (30.6)	2 (28.6)
接触性皮膚炎	3 (6.1)	0
湿疹	2 (4.1)	0
水疱	1 (2.0)	0
褥瘡性潰瘍	1 (2.0)	0
皮膚炎	1 (2.0)	0
おむつ皮膚炎	1 (2.0)	0
紅斑	1 (2.0)	0
毛孔性角化症	1 (2.0)	0
汗疹	1 (2.0)	0
寝汗	1 (2.0)	0
発疹	1 (2.0)	0
蕁麻疹	1 (2.0)	0
ざ瘡	0	1 (14.3)
皮膚病変	0	1 (14.3)
免疫系障害	7 (14.3)	0
過敏症	3 (6.1)	0
季節性アレルギー	3 (6.1)	0
薬物過敏症	1 (2.0)	0
臨床検査	7 (14.3)	1 (14.3)
体重減少	2 (4.1)	1 (14.3)
血中重炭酸塩減少	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 8 of 9

	White	Non-white
血中テストステロン減少	1 (2.0)	0
体温上昇	1 (2.0)	0
ＣＳＦ白血球数増加	1 (2.0)	0
心拍数増加	1 (2.0)	0
尿検査異常	1 (2.0)	0
代謝および栄養障害	4 (8.2)	1 (14.3)
脱水	2 (4.1)	0
食欲減退	1 (2.0)	0
食欲亢進	1 (2.0)	0
ビタミンＤ欠乏	0	1 (14.3)
耳および迷路障害	3 (6.1)	0
耳痛	1 (2.0)	0
乗物酔い	1 (2.0)	0
鼓膜穿孔	1 (2.0)	0
精神障害	3 (6.1)	1 (14.3)
激越	2 (4.1)	0
注意欠陥多動性障害	1 (2.0)	0
不快気分	1 (2.0)	0
不眠症	1 (2.0)	0
睡眠時随伴症	1 (2.0)	0
チック	1 (2.0)	0
心因性嘔吐	0	1 (14.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 9 of 9

	White	Non-white
心臓障害	2 (4.1)	1 (14.3)
動悸	2 (4.1)	0
頻脈	0	1 (14.3)
腎および尿路障害	2 (4.1)	1 (14.3)
排尿困難	1 (2.0)	0
尿失禁	1 (2.0)	0
膀胱尿管逆流	0	1 (14.3)
血液およびリンパ系障害	1 (2.0)	0
好中球減少症	1 (2.0)	0
眼障害	1 (2.0)	1 (14.3)
遠視	1 (2.0)	0
斜視	0	1 (14.3)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (2.0)	0
皮膚乳頭腫	1 (2.0)	0
血管障害	1 (2.0)	0
低血圧	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 70　Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443:Incidence of Adverse Events by Weight Quartiles

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 1 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
Number of subjects dosed	29 (100.0)	28 (100.0)	28 (100.0)	32 (100.0)
Number of subjects with an event	24 (82.8)	26 (92.9)	26 (92.9)	29 (90.6)
感染症および寄生虫症	20 (69.0)	20 (71.4)	22 (78.6)	24 (75.0)
上気道感染	9 (31.0)	8 (28.6)	9 (32.1)	12 (37.5)
鼻咽頭炎	4 (13.8)	9 (32.1)	4 (14.3)	6 (18.8)
肺炎	4 (13.8)	7 (25.0)	6 (21.4)	8 (25.0)
ウイルス感染	4 (13.8)	3 (10.7)	2 (7.1)	2 (6.3)
気管支炎	3 (10.3)	0	1 (3.6)	2 (6.3)
細気管支炎	2 (6.9)	3 (10.7)	4 (14.3)	3 (9.4)
インフルエンザ	2 (6.9)	2 (7.1)	1 (3.6)	0
中耳炎	2 (6.9)	2 (7.1)	2 (7.1)	3 (9.4)
気道感染	2 (6.9)	1 (3.6)	5 (17.9)	4 (12.5)
細菌感染	1 (3.4)	1 (3.6)	0	0
ウイルス性気管支炎	1 (3.4)	0	2 (7.1)	0
結膜炎	1 (3.4)	1 (3.6)	2 (7.1)	2 (6.3)
ロタウイルス胃腸炎	1 (3.4)	0	0	0
ウイルス性胃腸炎	1 (3.4)	0	0	1 (3.1)
手足口病	1 (3.4)	1 (3.6)	0	0
膿痂疹	1 (3.4)	1 (3.6)	0	0
ウイルス性下気道感染	1 (3.4)	0	2 (7.1)	0
レンサ球菌性咽頭炎	1 (3.4)	0	0	1 (3.1)
ウイルス性肺炎	1 (3.4)	1 (3.6)	2 (7.1)	6 (18.8)
ＲＳウイルス細気管支炎	1 (3.4)	1 (3.6)	1 (3.6)	1 (3.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 2 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
鼻炎	1 (3.4)	1 (3.6)	0	1 (3.1)
ライノウイルス感染	1 (3.4)	3 (10.7)	8 (28.6)	3 (9.4)
皮膚感染	1 (3.4)	0	0	0
尿路感染	1 (3.4)	1 (3.6)	2 (7.1)	0
ウイルス性上気道感染	1 (3.4)	2 (7.1)	6 (21.4)	3 (9.4)
アデノウイルス性上気道感染	0	1 (3.6)	0	0
アデノウイルス感染	0	0	2 (7.1)	0
細菌性疾患キャリアー	0	0	1 (3.6)	0
細菌性気管炎	0	1 (3.6)	1 (3.6)	1 (3.1)
カンジダ性おむつ皮疹	0	0	1 (3.6)	1 (3.1)
蜂巣炎	0	0	0	1 (3.1)
細菌性結膜炎	0	1 (3.6)	0	1 (3.1)
コロナウイルス感染	0	1 (3.6)	0	0
耳感染	0	2 (7.1)	0	3 (9.4)
感染性湿疹	0	0	1 (3.6)	0
エンテロウイルス感染	0	1 (3.6)	1 (3.6)	0
伝染性紅斑	0	1 (3.6)	0	0
眼感染	0	0	0	1 (3.1)
真菌感染	0	1 (3.6)	0	0
皮膚真菌感染	0	1 (3.6)	0	1 (3.1)
ウイルス性胃炎	0	0	1 (3.6)	0
胃腸炎	0	0	1 (3.6)	1 (3.1)
ヘモフィルス感染	0	1 (3.6)	0	0
限局性感染	0	0	1 (3.6)	0
下気道感染	0	2 (7.1)	1 (3.6)	1 (3.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 3 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
肺感染	0	1 (3.6)	0	0
メタニューモウイルス感染	0	0	1 (3.6)	1 (3.1)
モラクセラ感染	0	1 (3.6)	0	0
粘膜皮膚カンジダ症	0	0	1 (3.6)	0
院内感染	0	0	1 (3.6)	0
口腔カンジダ症	0	2 (7.1)	4 (14.3)	1 (3.1)
口腔ヘルペス	0	1 (3.6)	0	0
急性中耳炎	0	0	0	1 (3.1)
パラインフルエンザウイルス感染	0	1 (3.6)	0	1 (3.1)
細菌性肺炎	0	1 (3.6)	1 (3.6)	2 (6.3)
インフルエンザ性肺炎	0	0	1 (3.6)	0
モラクセラ菌性肺炎	0	0	1 (3.6)	1 (3.1)
パラインフルエンザウイルス性肺炎	0	0	0	1 (3.1)
シュードモナス菌性肺炎	0	0	0	1 (3.1)
ＲＳウイルス肺炎	0	0	0	1 (3.1)
シュードモナス感染	0	0	1 (3.6)	0
細菌性気道感染	0	0	1 (3.6)	0
ウイルス性気道感染	0	2 (7.1)	3 (10.7)	0
ばら疹	0	0	1 (3.6)	0
敗血症	0	0	0	1 (3.1)
皮膚カンジダ	0	0	2 (7.1)	0
ブドウ球菌性菌血症	0	1 (3.6)	0	0
ブドウ球菌感染	0	0	1 (3.6)	0
ブドウ球菌性敗血症	0	0	0	1 (3.1)
ブドウ球菌皮膚感染	0	1 (3.6)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 4 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
ストーマ部膿瘍	0	0	2 (7.1)	0
気管炎	0	0	1 (3.6)	0
胃腸障害	13 (44.8)	15 (53.6)	22 (78.6)	20 (62.5)
便秘	4 (13.8)	9 (32.1)	10 (35.7)	11 (34.4)
嚥下障害	3 (10.3)	1 (3.6)	3 (10.7)	3 (9.4)
放屁	3 (10.3)	1 (3.6)	0	3 (9.4)
胃食道逆流性疾患	3 (10.3)	4 (14.3)	7 (25.0)	3 (9.4)
生歯	3 (10.3)	2 (7.1)	3 (10.7)	8 (25.0)
嘔吐	3 (10.3)	5 (17.9)	8 (28.6)	4 (12.5)
腹部膨満	2 (6.9)	0	1 (3.6)	3 (9.4)
胃炎	2 (6.9)	0	1 (3.6)	1 (3.1)
腹部不快感	1 (3.4)	0	0	1 (3.1)
腹痛	1 (3.4)	0	0	0
下痢	1 (3.4)	4 (14.3)	4 (14.3)	4 (12.5)
血便排泄	1 (3.4)	0	1 (3.6)	0
アフタ性潰瘍	0	0	1 (3.6)	0
口唇のひび割れ	0	0	1 (3.6)	0
排便回数増加	0	1 (3.6)	0	0
胃出血	0	0	1 (3.6)	0
消化管運動低下	0	0	0	1 (3.1)
吐血	0	0	0	1 (3.1)
乳児仙痛	0	0	1 (3.6)	0
乳児吐血	0	0	1 (3.6)	0
流涎過多	0	2 (7.1)	3 (10.7)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 5 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
上部消化管出血	0	0	1 (3.6)	0
呼吸器、胸郭および縦隔障害	12 (41.4)	19 (67.9)	23 (82.1)	24 (75.0)
呼吸窮迫	4 (13.8)	8 (28.6)	10 (35.7)	5 (15.6)
無気肺	3 (10.3)	4 (14.3)	8 (28.6)	5 (15.6)
咳嗽	3 (10.3)	1 (3.6)	4 (14.3)	6 (18.8)
鼻閉	3 (10.3)	3 (10.7)	6 (21.4)	5 (15.6)
呼吸不全	2 (6.9)	3 (10.7)	8 (28.6)	10 (31.3)
鼻漏	2 (6.9)	0	2 (7.1)	3 (9.4)
上気道うっ血	2 (6.9)	2 (7.1)	2 (7.1)	1 (3.1)
急性呼吸不全	1 (3.4)	3 (10.7)	5 (17.9)	6 (18.8)
誤嚥	1 (3.4)	4 (14.3)	1 (3.6)	0
気管支閉塞	1 (3.4)	0	0	0
高炭酸ガス血症	1 (3.4)	0	0	0
低換気	1 (3.4)	0	1 (3.6)	1 (3.1)
低酸素症	1 (3.4)	1 (3.6)	4 (14.3)	4 (12.5)
上気道分泌増加	1 (3.4)	2 (7.1)	3 (10.7)	0
肺障害	1 (3.4)	0	0	0
誤嚥性肺炎	1 (3.4)	2 (7.1)	5 (17.9)	2 (6.3)
呼吸性アシドーシス	1 (3.4)	0	0	0
副鼻腔うっ血	1 (3.4)	1 (3.6)	1 (3.6)	1 (3.1)
呼吸補助筋の動員	1 (3.4)	1 (3.6)	0	0
急性呼吸窮迫症候群	0	0	1 (3.6)	0
無呼吸	0	3 (10.7)	4 (14.3)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 6 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
無呼吸発作	0	0	1 (3.6)	0
窒息	0	1 (3.6)	0	0
気管支分泌物貯留	0	1 (3.6)	3 (10.7)	2 (6.3)
息詰まり	0	1 (3.6)	1 (3.6)	0
慢性呼吸不全	0	1 (3.6)	3 (10.7)	2 (6.3)
呼吸困難	0	2 (7.1)	3 (10.7)	4 (12.5)
減呼吸	0	0	1 (3.6)	0
気管支分泌増加	0	1 (3.6)	0	0
喉頭肉芽腫	0	0	1 (3.6)	0
鼻汁変色	0	0	0	1 (3.1)
閉塞性気道障害	0	0	0	1 (3.1)
胸水	0	0	1 (3.6)	0
気縦隔症	0	1 (3.6)	0	0
気胸	0	2 (7.1)	1 (3.6)	0
湿性咳嗽	0	0	0	1 (3.1)
肺うっ血	0	0	1 (3.6)	1 (3.1)
肺水腫	0	1 (3.6)	1 (3.6)	0
呼吸性アルカローシス	0	0	0	1 (3.1)
呼吸停止	0	1 (3.6)	1 (3.6)	2 (6.3)
呼吸障害	0	0	1 (3.6)	1 (3.1)
気道うっ血	0	0	0	1 (3.1)
拘束性肺疾患	0	0	1 (3.6)	0
アレルギー性鼻炎	0	0	0	2 (6.3)
低音性連続性ラ音	0	1 (3.6)	0	0
睡眠時無呼吸症候群	0	0	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 7 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
変色痰	0	0	1 (3.6)	0
頻呼吸	0	1 (3.6)	0	0
気管障害	0	0	1 (3.6)	0
喘鳴	0	1 (3.6)	2 (7.1)	0
一般・全身障害および投与部位の状態	11 (37.9)	15 (53.6)	16 (57.1)	20 (62.5)
発熱	10 (34.5)	13 (46.4)	14 (50.0)	19 (59.4)
適用部位紅斑	1 (3.4)	0	0	0
不快感	1 (3.4)	0	0	1 (3.1)
注入部位内出血	1 (3.4)	0	0	0
疼痛	1 (3.4)	0	1 (3.6)	3 (9.4)
血管穿刺部位内出血	1 (3.4)	0	0	0
カテーテル留置部位炎症	0	0	1 (3.6)	0
泣き	0	0	0	1 (3.1)
死亡	0	1 (3.6)	0	0
医療機器リーク	0	1 (3.6)	0	0
医療機器閉塞	0	1 (3.6)	0	0
薬物不耐性	0	0	1 (3.6)	0
低体温	0	0	1 (3.6)	0
ワクチン接種後の易刺激性	0	1 (3.6)	0	0
倦怠感	0	1 (3.6)	0	0
小結節	0	0	1 (3.6)	0
浮腫	0	0	0	1 (3.1)
末梢性浮腫	0	0	0	2 (6.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 8 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
末梢腫脹	0	0	0	1 (3.1)
腫脹	0	0	1 (3.6)	0
皮膚および皮下組織障害	11 (37.9)	9 (32.1)	11 (39.3)	10 (31.3)
おむつ皮膚炎	5 (17.2)	1 (3.6)	3 (10.7)	3 (9.4)
皮膚炎	2 (6.9)	1 (3.6)	1 (3.6)	0
接触性皮膚炎	1 (3.4)	0	1 (3.6)	1 (3.1)
貨幣状湿疹	1 (3.4)	0	0	0
紅斑	1 (3.4)	1 (3.6)	0	0
過剰肉芽組織	1 (3.4)	1 (3.6)	1 (3.6)	0
発疹	1 (3.4)	2 (7.1)	3 (10.7)	7 (21.9)
脂漏性皮膚炎	1 (3.4)	0	0	0
脱毛症	0	1 (3.6)	0	0
アレルギー性皮膚炎	0	1 (3.6)	0	0
斑状出血	0	1 (3.6)	1 (3.6)	1 (3.1)
湿疹	0	2 (7.1)	1 (3.6)	1 (3.1)
環状肉芽腫	0	1 (3.6)	0	0
過角化	0	0	1 (3.6)	1 (3.1)
汗疹	0	0	2 (7.1)	0
点状出血	0	1 (3.6)	0	0
そう痒症	0	0	0	1 (3.1)
丘疹性皮疹	0	1 (3.6)	0	0
皮膚色素脱失	0	0	0	1 (3.1)
皮膚障害	0	0	0	1 (3.1)
皮膚刺激	0	0	2 (7.1)	1 (3.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 9 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
皮膚浮腫	0	0	0	1 (3.1)
皮膚潰瘍	0	0	0	1 (3.1)
皮下気腫	0	1 (3.6)	0	0
蕁麻疹	0	0	0	1 (3.1)
傷害、中毒および処置合併症	6 (20.7)	6 (21.4)	8 (28.6)	9 (28.1)
擦過傷	1 (3.4)	0	0	0
転倒	1 (3.4)	0	0	0
処置後合併症	1 (3.4)	0	0	0
処置後不快感	1 (3.4)	0	0	0
処置後腫脹	1 (3.4)	0	0	1 (3.1)
処置合併症	1 (3.4)	0	0	0
処置部位反応	1 (3.4)	0	0	0
硬膜下血腫	1 (3.4)	0	0	0
創離開	1 (3.4)	0	0	0
術後激越	0	0	0	1 (3.1)
節足動物咬傷	0	0	0	3 (9.4)
挫傷	0	0	1 (3.6)	1 (3.1)
麻酔からの覚醒遅延	0	1 (3.6)	0	0
ダンピング症候群	0	0	1 (3.6)	0
耳擦過傷	0	1 (3.6)	0	0
伝染病曝露	0	0	0	1 (3.1)
栄養補給チューブ合併症	0	1 (3.6)	1 (3.6)	0
大腿骨骨折	0	0	2 (7.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 10 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
関節脱臼	0	1 (3.6)	0	1 (3.1)
口唇損傷	0	0	0	1 (3.1)
外傷性気胸	0	1 (3.6)	0	0
処置による疼痛	0	2 (7.1)	2 (7.1)	0
皮膚擦過傷	0	1 (3.6)	0	1 (3.1)
軟部組織損傷	0	0	0	1 (3.1)
ストーマ合併症	0	1 (3.6)	0	0
ストーマ部紅斑	0	1 (3.6)	0	2 (6.3)
サンバーン	0	1 (3.6)	0	0
熱傷	0	1 (3.6)	0	0
歯牙損傷	0	0	0	1 (3.1)
ワクチン接種合併症	0	0	1 (3.6)	0
筋骨格系および結合組織障害	6 (20.7)	7 (25.0)	8 (28.6)	6 (18.8)
胸郭変形	2 (6.9)	0	2 (7.1)	0
関節拘縮	2 (6.9)	3 (10.7)	4 (14.3)	3 (9.4)
頭位性斜頭症	2 (6.9)	0	0	1 (3.1)
側弯症	2 (6.9)	4 (14.3)	3 (10.7)	2 (6.3)
脊柱後弯症	1 (3.4)	3 (10.7)	0	1 (3.1)
筋力低下	1 (3.4)	0	0	0
四肢痛	1 (3.4)	0	0	1 (3.1)
斜頚	1 (3.4)	1 (3.6)	0	1 (3.1)
体重支持困難	1 (3.4)	0	0	0
背部痛	0	0	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 11 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
泉門閉鎖遅延	0	0	1 (3.6)	0
手変形	0	0	1 (3.6)	0
関節硬直	0	1 (3.6)	0	0
後側弯症	0	0	2 (7.1)	0
脊柱前弯症	0	1 (3.6)	0	0
脊柱変形	0	0	0	1 (3.1)
滑膜炎	0	0	0	1 (3.1)
血管障害	5 (17.2)	2 (7.1)	1 (3.6)	1 (3.1)
高血圧	2 (6.9)	1 (3.6)	0	0
蒼白	2 (6.9)	0	0	0
毛細血管脆弱	1 (3.4)	0	0	0
本態性高血圧症	0	0	0	1 (3.1)
ショック	0	0	1 (3.6)	0
血管炎	0	1 (3.6)	0	0
代謝および栄養障害	4 (13.8)	7 (25.0)	7 (25.0)	2 (6.3)
体重増加不良	2 (6.9)	3 (10.7)	1 (3.6)	1 (3.1)
脱水	1 (3.4)	1 (3.6)	0	0
成長障害	1 (3.4)	1 (3.6)	2 (7.1)	0
乳児および小児期早期の哺育障害	1 (3.4)	1 (3.6)	1 (3.6)	0
鉄欠乏	1 (3.4)	0	0	0
栄養補給不耐性	0	1 (3.6)	2 (7.1)	0
低ナトリウム血症	0	1 (3.6)	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 12 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
過小食	0	0	1 (3.6)	1 (3.1)
代謝性アルカローシス	0	0	1 (3.6)	0
神経系障害	4 (13.8)	6 (21.4)	5 (17.9)	4 (12.5)
反射亢進	1 (3.4)	0	0	0
筋緊張低下	1 (3.4)	0	0	0
不随意性筋収縮	1 (3.4)	1 (3.6)	1 (3.6)	1 (3.1)
傾眠	1 (3.4)	0	0	0
脳損傷	0	0	1 (3.6)	0
脳梗塞	0	1 (3.6)	0	0
脳脊髄液漏	0	1 (3.6)	0	0
間代	0	1 (3.6)	0	0
よだれ	0	0	1 (3.6)	1 (3.1)
頭痛	0	0	0	1 (3.1)
低酸素性虚血性脳症	0	1 (3.6)	0	0
嗜眠	0	0	1 (3.6)	0
眼振	0	1 (3.6)	1 (3.6)	1 (3.1)
痙攣発作	0	1 (3.6)	1 (3.6)	0
失神	0	0	1 (3.6)	0
血液およびリンパ系障害	3 (10.3)	1 (3.6)	0	4 (12.5)
好中球減少症	2 (6.9)	0	0	0
好酸球増加症	1 (3.4)	0	0	0
貧血	0	0	0	3 (9.4)
リンパ節症	0	0	0	1 (3.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 13 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
血小板増加症	0	1 (3.6)	0	0
心臓障害	3 (10.3)	8 (28.6)	8 (28.6)	5 (15.6)
頻脈	3 (10.3)	2 (7.1)	2 (7.1)	3 (9.4)
徐脈	0	2 (7.1)	3 (10.7)	2 (6.3)
心停止	0	1 (3.6)	1 (3.6)	1 (3.1)
心肺停止	0	1 (3.6)	5 (17.9)	0
心筋症	0	1 (3.6)	0	0
チアノーゼ	0	1 (3.6)	2 (7.1)	0
左室肥大	0	1 (3.6)	0	0
心膜気腫	0	1 (3.6)	0	0
上室性頻脈	0	1 (3.6)	0	0
心室性頻脈	0	1 (3.6)	0	1 (3.1)
臨床検査	3 (10.3)	7 (25.0)	9 (32.1)	6 (18.8)
アラニンアミノトランスフェラーゼ増加	1 (3.4)	0	0	1 (3.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (3.4)	0	0	1 (3.1)
血中鉄減少	1 (3.4)	0	0	0
Ｃ－反応性蛋白増加	1 (3.4)	0	0	1 (3.1)
ヒトライノウイルス検査陽性	1 (3.4)	0	1 (3.6)	1 (3.1)
モラクセラ検査陽性	1 (3.4)	0	1 (3.6)	0
酸素飽和度低下	1 (3.4)	2 (7.1)	5 (17.9)	2 (6.3)
血中クロール減少	0	0	0	1 (3.1)
血中カリウム減少	0	1 (3.6)	0	1 (3.1)
血中ナトリウム減少	0	0	0	1 (3.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 14 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
体温低下	0	0	1 (3.6)	0
体温上昇	0	2 (7.1)	0	0
骨密度減少	0	1 (3.6)	0	0
呼吸音異常	0	0	1 (3.6)	0
心電図ＳＴ－Ｔ部分異常	0	0	1 (3.6)	0
心拍数減少	0	1 (3.6)	0	0
心拍数増加	0	0	2 (7.1)	0
心拍数不整	0	0	0	1 (3.1)
炎症マーカー上昇	0	0	1 (3.6)	0
Ａ型インフルエンザウイルス検査陽性	0	0	1 (3.6)	0
肝機能検査異常	0	0	1 (3.6)	0
医学的観察	0	0	1 (3.6)	0
好中球数増加	0	1 (3.6)	1 (3.6)	1 (3.1)
好中球百分率増加	0	0	0	1 (3.1)
シュードモナス検査陽性	0	0	1 (3.6)	1 (3.1)
セラチア検査陽性	0	0	1 (3.6)	0
ブドウ球菌検査陽性	0	1 (3.6)	1 (3.6)	0
レンサ球菌検査陽性	0	0	1 (3.6)	0
尿量減少	0	1 (3.6)	0	0
ビタミンＡ減少	0	0	1 (3.6)	0
体重減少	0	1 (3.6)	2 (7.1)	2 (6.3)
白血球数増加	0	1 (3.6)	0	1 (3.1)
眼障害	2 (6.9)	1 (3.6)	1 (3.6)	3 (9.4)
後天性涙道狭窄	1 (3.4)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 15 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
眼運動障害	1 (3.4)	0	0	0
乱視	0	0	0	1 (3.1)
霰粒腫	0	0	1 (3.6)	0
眼乾燥	0	1 (3.6)	0	0
眼瞼下垂	0	0	0	1 (3.1)
近視	0	0	0	1 (3.1)
斜視	0	0	0	1 (3.1)
免疫系障害	2 (6.9)	5 (17.9)	4 (14.3)	2 (6.3)
食物アレルギー	1 (3.4)	0	0	0
季節性アレルギー	1 (3.4)	2 (7.1)	2 (7.1)	1 (3.1)
薬物過敏症	0	2 (7.1)	2 (7.1)	0
過敏症	0	1 (3.6)	0	1 (3.1)
精神障害	2 (6.9)	3 (10.7)	3 (10.7)	3 (9.4)
不安	1 (3.4)	0	2 (7.1)	2 (6.3)
易刺激性	1 (3.4)	1 (3.6)	0	0
激越	0	1 (3.6)	1 (3.6)	0
息こらえ	0	0	0	1 (3.1)
気分動揺	0	1 (3.6)	0	0
落ち着きのなさ	0	0	0	1 (3.1)
睡眠障害	0	0	1 (3.6)	0
先天性、家族性および遺伝性障害	1 (3.4)	2 (7.1)	2 (7.1)	1 (3.1)
斜頭症	1 (3.4)	0	0	1 (3.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 16 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
斜指症	0	1 (3.6)	0	0
発育性股関節形成不全	0	0	1 (3.6)	0
貧血母斑	0	1 (3.6)	0	0
鳩胸	0	0	1 (3.6)	0
肝胆道系障害	1 (3.4)	0	0	0
肝腫大	1 (3.4)	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (3.4)	0	0	2 (6.3)
脂漏性角化症	1 (3.4)	0	0	0
アクロコルドン	0	0	0	1 (3.1)
血管の良性新生物	0	0	0	1 (3.1)
妊娠、産褥および周産期の状態	1 (3.4)	0	0	0
臍肉芽腫	1 (3.4)	0	0	0
腎および尿路障害	1 (3.4)	0	0	1 (3.1)
水腎症	1 (3.4)	0	0	0
尿閉	0	0	0	1 (3.1)
耳および迷路障害	0	1 (3.6)	1 (3.6)	1 (3.1)
耳の障害	0	1 (3.6)	0	0
耳痛	0	0	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 17 of 17

	<5.42 kg	5.42-<6.31 kg	6.31-<7 kg	>=7 kg
耳垢分泌過多	0	0	0	1 (3.1)
生殖系および乳房障害	0	0	2 (7.1)	1 (3.1)
後天性包茎	0	0	1 (3.6)	0
卵巣嚢胞	0	0	1 (3.6)	0
陰茎障害	0	0	0	1 (3.1)
外科および内科処置	0	0	1 (3.6)	0
機械的換気	0	0	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 71　Later-Onset Subjects:Incidence of Adverse Events by Weight Quartiles

Later-onset subjects: incidence of adverse events by weight quartiles
Page 1 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
Number of subjects dosed	14 (100.0)	14 (100.0)	14 (100.0)	14 (100.0)
Number of subjects with an event	14 (100.0)	14 (100.0)	14 (100.0)	14 (100.0)
感染症および寄生虫症	12 (85.7)	12 (85.7)	10 (71.4)	10 (71.4)
上気道感染	8 (57.1)	7 (50.0)	7 (50.0)	5 (35.7)
ウイルス感染	4 (28.6)	3 (21.4)	2 (14.3)	0
ウイルス性胃腸炎	3 (21.4)	2 (14.3)	3 (21.4)	0
鼻咽頭炎	3 (21.4)	4 (28.6)	3 (21.4)	6 (42.9)
耳感染	2 (14.3)	2 (14.3)	0	0
胃腸炎	2 (14.3)	1 (7.1)	2 (14.3)	2 (14.3)
中耳炎	2 (14.3)	1 (7.1)	1 (7.1)	1 (7.1)
レンサ球菌性咽頭炎	2 (14.3)	1 (7.1)	3 (21.4)	2 (14.3)
肺炎	2 (14.3)	1 (7.1)	1 (7.1)	1 (7.1)
ウイルス性肺炎	2 (14.3)	0	0	0
ＲＳウイルス感染	2 (14.3)	0	1 (7.1)	0
ウイルス性上気道感染	2 (14.3)	1 (7.1)	1 (7.1)	1 (7.1)
結膜炎	1 (7.1)	1 (7.1)	1 (7.1)	0
ウイルス性眼感染	1 (7.1)	0	0	0
手足口病	1 (7.1)	0	0	0
インフルエンザ	1 (7.1)	0	2 (14.3)	0
下気道感染	1 (7.1)	0	0	0
単核細胞症症候群	1 (7.1)	0	0	0
ＲＳウイルス肺炎	1 (7.1)	0	0	0
ＲＳウイルス細気管支炎	1 (7.1)	0	0	0
ウイルス性気道感染	1 (7.1)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 2 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
皮膚細菌感染	1 (7.1)	0	0	0
尿路感染	1 (7.1)	1 (7.1)	1 (7.1)	1 (7.1)
膣感染	1 (7.1)	0	0	0
ウイルス性扁桃炎	1 (7.1)	0	0	0
蜂巣炎	0	0	0	1 (7.1)
ブドウ球菌性眼感染	0	0	0	1 (7.1)
皮膚真菌感染	0	0	0	1 (7.1)
ウイルス性消化管感染	0	1 (7.1)	1 (7.1)	0
膿痂疹	0	0	0	1 (7.1)
限局性感染	0	0	1 (7.1)	2 (14.3)
伝染性軟属腫	0	1 (7.1)	0	0
急性中耳炎	0	0	1 (7.1)	0
咽頭炎	0	1 (7.1)	0	0
気道感染	0	1 (7.1)	0	0
鼻炎	0	1 (7.1)	0	0
副鼻腔炎	0	1 (7.1)	0	2 (14.3)
皮膚カンジダ	0	1 (7.1)	1 (7.1)	0
扁桃炎	0	0	1 (7.1)	0
外陰膣真菌感染	0	0	1 (7.1)	0
筋骨格系および結合組織障害	12 (85.7)	9 (64.3)	10 (71.4)	10 (71.4)
側弯症	6 (42.9)	1 (7.1)	5 (35.7)	3 (21.4)
背部痛	4 (28.6)	3 (21.4)	8 (57.1)	8 (57.1)
関節拘縮	4 (28.6)	4 (28.6)	1 (7.1)	1 (7.1)
筋肉痛	2 (14.3)	1 (7.1)	0	1 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 3 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
四肢痛	2 (14.3)	0	3 (21.4)	0
関節痛	1 (7.1)	1 (7.1)	2 (14.3)	1 (7.1)
筋緊張	1 (7.1)	1 (7.1)	0	0
頚部痛	1 (7.1)	0	2 (14.3)	0
四肢拘縮	0	1 (7.1)	0	0
脊柱前弯症	0	1 (7.1)	0	0
骨盤変形	0	1 (7.1)	1 (7.1)	0
呼吸器、胸郭および縦隔障害	10 (71.4)	6 (42.9)	6 (42.9)	3 (21.4)
鼻漏	3 (21.4)	2 (14.3)	1 (7.1)	0
咳嗽	2 (14.3)	1 (7.1)	2 (14.3)	1 (7.1)
鼻出血	2 (14.3)	0	1 (7.1)	0
低酸素症	2 (14.3)	1 (7.1)	0	0
扁桃肥大	2 (14.3)	1 (7.1)	0	0
急性呼吸不全	1 (7.1)	0	0	0
無気肺	1 (7.1)	0	0	0
発声障害	1 (7.1)	0	0	0
呼吸困難	1 (7.1)	0	0	0
鼻閉	1 (7.1)	1 (7.1)	1 (7.1)	0
肺臓炎	1 (7.1)	0	0	0
呼吸障害	1 (7.1)	0	0	0
呼吸不全	1 (7.1)	0	0	0
拘束性肺疾患	1 (7.1)	0	0	0
喘鳴	1 (7.1)	0	0	0
口腔咽頭痛	0	3 (21.4)	3 (21.4)	2 (14.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 4 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
肺うっ血	0	0	1 (7.1)	0
副鼻腔うっ血	0	0	2 (14.3)	0
傷害、中毒および処置合併症	9 (64.3)	8 (57.1)	9 (64.3)	14 (100.0)
裂傷	4 (28.6)	1 (7.1)	0	2 (14.3)
節足動物咬傷	2 (14.3)	0	1 (7.1)	0
大腿骨骨折	2 (14.3)	0	1 (7.1)	0
転倒	1 (7.1)	0	0	0
関節脱臼	1 (7.1)	1 (7.1)	0	0
四肢損傷	1 (7.1)	0	1 (7.1)	1 (7.1)
腰椎穿刺後症候群	1 (7.1)	5 (35.7)	5 (35.7)	12 (85.7)
処置による疼痛	1 (7.1)	0	4 (28.6)	1 (7.1)
熱傷	1 (7.1)	0	0	0
術後激越	0	1 (7.1)	0	0
節足動物刺傷	0	0	1 (7.1)	0
挫傷	0	1 (7.1)	0	1 (7.1)
頭部損傷	0	0	0	1 (7.1)
関節損傷	0	0	1 (7.1)	1 (7.1)
靭帯捻挫	0	0	1 (7.1)	0
下肢骨折	0	1 (7.1)	0	0
半月板損傷	0	0	0	1 (7.1)
肉離れ	0	0	1 (7.1)	0
術後イレウス	0	0	1 (7.1)	0
処置による頭痛	0	0	0	1 (7.1)
処置による悪心	0	1 (7.1)	0	1 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 5 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
サンバーン	0	1 (7.1)	0	1 (7.1)
脛骨骨折	0	0	1 (7.1)	0
隆起骨折	0	1 (7.1)	1 (7.1)	0
一般・全身障害および投与部位の状態	7 (50.0)	10 (71.4)	8 (57.1)	6 (42.9)
発熱	7 (50.0)	6 (42.9)	2 (14.3)	1 (7.1)
低体温	1 (7.1)	0	0	0
注射部位出血	1 (7.1)	0	0	0
カテーテル留置部位出血	0	0	1 (7.1)	0
カテーテル留置部位疼痛	0	0	1 (7.1)	0
カテーテル留置部位関連反応	0	1 (7.1)	0	0
胸部不快感	0	0	1 (7.1)	0
悪寒	0	0	1 (7.1)	0
疲労	0	1 (7.1)	0	2 (14.3)
冷感	0	1 (7.1)	0	0
重力性浮腫	0	0	1 (7.1)	0
注射部位疼痛	0	0	0	1 (7.1)
疼痛	0	0	2 (14.3)	0
末梢腫脹	0	0	1 (7.1)	0
穿刺部位疼痛	0	3 (21.4)	4 (28.6)	3 (21.4)
穿刺部位反応	0	0	1 (7.1)	0
血管穿刺部位内出血	0	0	1 (7.1)	0
胃腸障害	6 (42.9)	9 (64.3)	7 (50.0)	4 (28.6)
便秘	3 (21.4)	4 (28.6)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 6 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
悪心	2 (14.3)	4 (28.6)	1 (7.1)	3 (21.4)
嘔吐	2 (14.3)	6 (42.9)	3 (21.4)	1 (7.1)
上腹部痛	1 (7.1)	0	1 (7.1)	0
下痢	1 (7.1)	1 (7.1)	0	0
腹部不快感	0	0	0	1 (7.1)
腹痛	0	0	2 (14.3)	0
腹部症状	0	0	0	1 (7.1)
アフタ性潰瘍	0	2 (14.3)	1 (7.1)	0
放屁	0	0	1 (7.1)	0
食中毒	0	0	0	1 (7.1)
胃腸障害	0	0	1 (7.1)	0
胃食道逆流性疾患	0	0	0	1 (7.1)
口の感覚鈍麻	0	0	0	1 (7.1)
口唇痛	0	1 (7.1)	0	0
口腔内痛	0	0	1 (7.1)	1 (7.1)
口内炎	0	1 (7.1)	0	0
神経系障害	5 (35.7)	7 (50.0)	8 (57.1)	10 (71.4)
頭痛	4 (28.6)	7 (50.0)	7 (50.0)	10 (71.4)
振戦	1 (7.1)	0	0	0
失声症	0	0	1 (7.1)	0
味覚異常	0	1 (7.1)	0	0
失読症	0	0	1 (7.1)	0
感覚鈍麻	0	0	1 (7.1)	1 (7.1)
片頭痛	0	0	0	1 (7.1)
錯感覚	0	0	1 (7.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 7 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
失神	0	0	0	1 (7.1)
皮膚および皮下組織障害	4 (28.6)	6 (42.9)	2 (14.3)	5 (35.7)
接触性皮膚炎	1 (7.1)	1 (7.1)	0	1 (7.1)
汗疹	1 (7.1)	0	0	0
発疹	1 (7.1)	0	0	0
皮膚病変	1 (7.1)	0	0	0
ざ瘡	0	0	0	1 (7.1)
水疱	0	1 (7.1)	0	0
褥瘡性潰瘍	0	1 (7.1)	0	0
皮膚炎	0	0	1 (7.1)	0
おむつ皮膚炎	0	1 (7.1)	0	0
湿疹	0	0	0	2 (14.3)
紅斑	0	1 (7.1)	0	0
毛孔性角化症	0	0	0	1 (7.1)
寝汗	0	1 (7.1)	0	0
蕁麻疹	0	0	1 (7.1)	0
心臓障害	1 (7.1)	1 (7.1)	1 (7.1)	0
頻脈	1 (7.1)	0	0	0
動悸	0	1 (7.1)	1 (7.1)	0
眼障害	1 (7.1)	0	1 (7.1)	0
斜視	1 (7.1)	0	0	0
遠視	0	0	1 (7.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 8 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
代謝および栄養障害	1 (7.1)	2 (14.3)	1 (7.1)	1 (7.1)
食欲亢進	1 (7.1)	0	0	0
食欲減退	0	0	1 (7.1)	0
脱水	0	2 (14.3)	0	0
ビタミンD欠乏	0	0	0	1 (7.1)
腎および尿路障害	1 (7.1)	2 (14.3)	0	0
排尿困難	1 (7.1)	0	0	0
尿失禁	0	1 (7.1)	0	0
膀胱尿管逆流	0	1 (7.1)	0	0
血管障害	1 (7.1)	0	0	0
低血圧	1 (7.1)	0	0	0
血液およびリンパ系障害	0	0	1 (7.1)	0
好中球減少症	0	0	1 (7.1)	0
耳および迷路障害	0	3 (21.4)	0	0
耳痛	0	1 (7.1)	0	0
乗物酔い	0	1 (7.1)	0	0
鼓膜穿孔	0	1 (7.1)	0	0
免疫系障害	0	1 (7.1)	4 (28.6)	2 (14.3)
薬物過敏症	0	0	1 (7.1)	0
過敏症	0	0	1 (7.1)	2 (14.3)
季節性アレルギー	0	1 (7.1)	2 (14.3)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 9 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
臨床検査	0	3 (21.4)	3 (21.4)	2 (14.3)
血中重炭酸塩減少	0	0	1 (7.1)	0
血中テストステロン減少	0	0	0	1 (7.1)
体温上昇	0	0	1 (7.1)	0
ＣＳＦ白血球数増加	0	0	1 (7.1)	0
心拍数増加	0	0	0	1 (7.1)
尿検査異常	0	1 (7.1)	0	0
体重減少	0	2 (14.3)	0	1 (7.1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (7.1)	0
皮膚乳頭腫	0	0	1 (7.1)	0
精神障害	0	0	3 (21.4)	1 (7.1)
激越	0	0	1 (7.1)	1 (7.1)
注意欠陥多動性障害	0	0	1 (7.1)	0
不快気分	0	0	0	1 (7.1)
不眠症	0	0	1 (7.1)	0
睡眠時随伴症	0	0	1 (7.1)	0
チック	0	0	1 (7.1)	0
心因性嘔吐	0	0	1 (7.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 72　Presymptomatic Infants:Incidence of Adverse Events by Geographic Region

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 1 of 5

	North America	Europe	Asia-Pacific
Number of subjects dosed	12 (100.0)	3 (100.0)	2 (100.0)
Number of subjects with an event	10 (83.3)	3 (100.0)	0
感染症および寄生虫症	7 (58.3)	3 (100.0)	0
上気道感染	6 (50.0)	0	0
鼻咽頭炎	2 (16.7)	1 (33.3)	0
中耳炎	2 (16.7)	0	0
細気管支炎	1 (8.3)	0	0
ウイルス性胃腸炎	1 (8.3)	0	0
膿痂疹	1 (8.3)	0	0
レンサ球菌性咽頭炎	1 (8.3)	0	0
ウイルス性肺炎	1 (8.3)	0	0
ライノウイルス感染	1 (8.3)	0	0
皮膚感染	1 (8.3)	0	0
尿路感染	1 (8.3)	0	0
気管支炎	0	1 (33.3)	0
インフルエンザ	0	2 (66.7)	0
肺炎	0	1 (33.3)	0
鼻炎	0	1 (33.3)	0
胃腸障害	5 (41.7)	1 (33.3)	0
腹部膨満	2 (16.7)	0	0
放屁	2 (16.7)	0	0
胃食道逆流性疾患	2 (16.7)	0	0
腹部不快感	1 (8.3)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 2 of 5

	North America	Europe	Asia-Pacific
嚥下障害	1 (8.3)	0	0
生歯	1 (8.3)	0	0
便秘	0	1 (33.3)	0
一般・全身障害および投与部位の状態	4 (33.3)	0	0
発熱	3 (25.0)	0	0
適用部位紅斑	1 (8.3)	0	0
注入部位内出血	1 (8.3)	0	0
皮膚および皮下組織障害	4 (33.3)	2 (66.7)	0
おむつ皮膚炎	2 (16.7)	0	0
貨幣状湿疹	1 (8.3)	0	0
紅斑	1 (8.3)	0	0
脂漏性皮膚炎	1 (8.3)	0	0
皮膚炎	0	2 (66.7)	0
傷害、中毒および処置合併症	3 (25.0)	0	0
転倒	1 (8.3)	0	0
処置後合併症	1 (8.3)	0	0
処置後不快感	1 (8.3)	0	0
処置後腫脹	1 (8.3)	0	0
硬膜下血腫	1 (8.3)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 3 of 5

	North America	Europe	Asia-Pacific
呼吸器、胸郭および縦隔障害	3 (25.0)	2 (66.7)	0
鼻閉	2 (16.7)	0	0
咳嗽	1 (8.3)	1 (33.3)	0
呼吸窮迫	1 (8.3)	0	0
鼻漏	1 (8.3)	0	0
上気道うっ血	1 (8.3)	0	0
呼吸性アシドーシス	0	1 (33.3)	0
心臓障害	2 (16.7)	0	0
頻脈	2 (16.7)	0	0
代謝および栄養障害	2 (16.7)	0	0
脱水	1 (8.3)	0	0
成長障害	1 (8.3)	0	0
体重増加不良	1 (8.3)	0	0
筋骨格系および結合組織障害	2 (16.7)	0	0
関節拘縮	1 (8.3)	0	0
筋力低下	1 (8.3)	0	0
頭位性斜頭症	1 (8.3)	0	0
斜頚	1 (8.3)	0	0
体重支持困難	1 (8.3)	0	0
神経系障害	2 (16.7)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 4 of 5

	North America	Europe	Asia-Pacific
反射亢進	1 (8.3)	0	0
筋緊張低下	1 (8.3)	0	0
血液およびリンパ系障害	1 (8.3)	1 (33.3)	0
好酸球増加症	1 (8.3)	0	0
好中球減少症	0	1 (33.3)	0
眼障害	1 (8.3)	0	0
後天性涙道狭窄	1 (8.3)	0	0
免疫系障害	1 (8.3)	0	0
季節性アレルギー	1 (8.3)	0	0
臨床検査	1 (8.3)	0	0
アラニンアミノトランスフェラーゼ増加	1 (8.3)	0	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (8.3)	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (8.3)	0	0
脂漏性角化症	1 (8.3)	0	0
妊娠、産褥および周産期の状態	1 (8.3)	0	0
臍肉芽腫	1 (8.3)	0	0
血管障害	1 (8.3)	1 (33.3)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 5 of 5

	North America	Europe	Asia-Pacific
高血圧	1 (8.3)	0	0
蒼白	0	1 (33.3)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 73　Infantile-onset subjects in controlled study ISIS 396443-CS3B

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 1 of 32

	North America	
	Control	ISIS 396443
Number of subjects dosed	22 (100.0)	38 (100.0)
Number of subjects with an event	22 (100.0)	35 (92.1)
感染症および寄生虫症	19 (86.4)	30 (78.9)
上気道感染	5 (22.7)	17 (44.7)
ウイルス性上気道感染	8 (36.4)	10 (26.3)
肺炎	4 (18.2)	8 (21.1)
鼻咽頭炎	4 (18.2)	6 (15.8)
ウイルス性肺炎	1 (4.5)	5 (13.2)
ライノウイルス感染	4 (18.2)	5 (13.2)
細気管支炎	2 (9.1)	4 (10.5)
口腔カンジダ症	1 (4.5)	4 (10.5)
細菌性肺炎	2 (9.1)	3 (7.9)
尿路感染	0	3 (7.9)
アデノウイルス感染	0	2 (5.3)
結膜炎	2 (9.1)	2 (5.3)
細菌性結膜炎	1 (4.5)	2 (5.3)
耳感染	1 (4.5)	2 (5.3)
インフルエンザ	0	2 (5.3)
ＲＳウイルス細気管支炎	3 (13.6)	2 (5.3)
ウイルス性気道感染	1 (4.5)	2 (5.3)
皮膚カンジダ	0	2 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 2 of 32

	North America	
	Control	ISIS 396443
ストーマ部膿瘍	0	2 (5.3)
ウイルス感染	2 (9.1)	2 (5.3)
細菌感染	0	1 (2.6)
細菌性気管炎	4 (18.2)	1 (2.6)
気管支炎	0	1 (2.6)
ウイルス性気管支炎	0	1 (2.6)
蜂巣炎	1 (4.5)	1 (2.6)
眼感染	0	1 (2.6)
皮膚真菌感染	1 (4.5)	1 (2.6)
ウイルス性胃腸炎	2 (9.1)	1 (2.6)
ウイルス性下気道感染	0	1 (2.6)
院内感染	0	1 (2.6)
中耳炎	2 (9.1)	1 (2.6)
急性中耳炎	0	1 (2.6)
インフルエンザ性肺炎	0	1 (2.6)
モラクセラ菌性肺炎	0	1 (2.6)
シュードモナス感染	1 (4.5)	1 (2.6)
気道感染	1 (4.5)	1 (2.6)
敗血症	0	1 (2.6)
ブドウ球菌性敗血症	0	1 (2.6)
細菌性疾患キャリアー	1 (4.5)	0
カンジダ感染	2 (9.1)	0
カンジダ性おむつ皮疹	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 3 of 32

	North America	
	Control	ISIS 396443
コロナウイルス感染	2 (9.1)	0
感染性湿疹	0	0
真菌感染	0	0
胃腸炎	0	0
ロタウイルス胃腸炎	0	0
手足口病	0	0
麦粒腫	1 (4.5)	0
膿痂疹	1 (4.5)	0
限局性感染	0	0
下気道感染	0	0
肺感染	0	0
口腔ヘルペス	0	0
パラインフルエンザウイルス感染	1 (4.5)	0
パラインフルエンザウイルス性肺炎	1 (4.5)	0
シュードモナス菌性肺炎	0	0
ＲＳウイルス肺炎	0	0
細菌性気道感染	1 (4.5)	0
鼻炎	0	0
ばら疹	0	0
セラチア感染	1 (4.5)	0
皮膚感染	1 (4.5)	0
ブドウ球菌感染	1 (4.5)	0
ブドウ球菌皮膚感染	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 4 of 32

	North America	
	Control	ISIS 396443
ストーマ部感染	3 (13.6)	0
気管炎	1 (4.5)	0
ウイルス性発疹	1 (4.5)	0
呼吸器、胸郭および縦隔障害	21 (95.5)	30 (78.9)
急性呼吸不全	7 (31.8)	11 (28.9)
呼吸窮迫	10 (45.5)	11 (28.9)
呼吸不全	7 (31.8)	10 (26.3)
無気肺	8 (36.4)	8 (21.1)
鼻閉	6 (27.3)	8 (21.1)
低酸素症	2 (9.1)	6 (15.8)
誤嚥性肺炎	4 (18.2)	6 (15.8)
誤嚥	1 (4.5)	4 (10.5)
咳嗽	7 (31.8)	4 (10.5)
上気道うっ血	1 (4.5)	4 (10.5)
副鼻腔うっ血	0	3 (7.9)
無呼吸	2 (9.1)	2 (5.3)
気管支分泌物貯留	3 (13.6)	2 (5.3)
慢性呼吸不全	0	2 (5.3)
呼吸困難	5 (22.7)	2 (5.3)
低換気	0	2 (5.3)
上気道分泌増加	1 (4.5)	2 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 5 of 32

	North America	
	Control	ISIS 396443
鼻漏	3 (13.6)	2 (5.3)
急性呼吸窮迫症候群	0	1 (2.6)
高炭酸ガス血症	0	1 (2.6)
減呼吸	0	1 (2.6)
胸水	0	1 (2.6)
気胸	0	1 (2.6)
呼吸性アルカローシス	0	1 (2.6)
呼吸停止	4 (18.2)	1 (2.6)
気道うっ血	2 (9.1)	1 (2.6)
アレルギー性鼻炎	0	1 (2.6)
変色痰	0	1 (2.6)
呼吸補助筋の動員	1 (4.5)	1 (2.6)
喘鳴	0	1 (2.6)
乳幼児突発性危急事態	2 (9.1)	0
気管支閉塞	0	0
カタル	0	0
息詰まり	1 (4.5)	0
気管支分泌増加	1 (4.5)	0
肺障害	0	0
閉塞性気道障害	0	0
口腔咽頭痛	0	0
呼吸障害	0	0
睡眠時無呼吸症候群	4 (18.2)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 6 of 32

	North America	
	Control	ISIS 396443
頻呼吸	2 (9.1)	0
上気道の炎症	0	0
胃腸障害	15 (68.2)	29 (76.3)
便秘	5 (22.7)	16 (42.1)
嚥下障害	7 (31.8)	9 (23.7)
生歯	2 (9.1)	8 (21.1)
嘔吐	6 (27.3)	7 (18.4)
下痢	6 (27.3)	6 (15.8)
胃食道逆流性疾患	3 (13.6)	6 (15.8)
放屁	1 (4.5)	3 (7.9)
流涎過多	0	3 (7.9)
胃炎	1 (4.5)	2 (5.3)
血便排泄	0	2 (5.3)
腹部膨満	0	1 (2.6)
胃出血	0	1 (2.6)
乳児仙痛	0	1 (2.6)
乳児吐出	0	1 (2.6)
上部消化管出血	0	1 (2.6)
腹部不快感	0	0
上腹部痛	1 (4.5)	0
アフタ性潰瘍	0	0
血性下痢	1 (4.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 7 of 32

	North America	
	Control	ISIS 396443
胃腸出血	0	0
消化管刺激症状	0	0
口内炎	0	0
一般・全身障害および投与部位の状態	15 (68.2)	23 (60.5)
発熱	12 (54.5)	20 (52.6)
カテーテル留置部位炎症	1 (4.5)	1 (2.6)
泣き	0	1 (2.6)
薬物不耐性	0	1 (2.6)
低体温	0	1 (2.6)
小結節	0	1 (2.6)
疼痛	0	1 (2.6)
腫脹	0	1 (2.6)
適用部位発疹	1 (4.5)	0
死亡	1 (4.5)	0
医療機器機能不良	1 (4.5)	0
医療機器閉塞	1 (4.5)	0
疲労	0	0
注入部位内出血	1 (4.5)	0
注入部位血管外漏出	1 (4.5)	0
注射部位血腫	0	0
ワクチン接種後の易刺激性	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 8 of 32

	North America	
	Control	ISIS 396443
倦怠感	0	0
浮腫	2 (9.1)	0
血管穿刺部位内出血	2 (9.1)	0
血管穿刺部位反応	0	0
皮膚および皮下組織障害	11 (50.0)	19 (50.0)
発疹	3 (13.6)	7 (18.4)
おむつ皮膚炎	2 (9.1)	5 (13.2)
接触性皮膚炎	2 (9.1)	2 (5.3)
斑状出血	0	2 (5.3)
過角化	0	2 (5.3)
皮膚炎	0	1 (2.6)
アレルギー性皮膚炎	0	1 (2.6)
紅斑	2 (9.1)	1 (2.6)
環状肉芽腫	0	1 (2.6)
汗疹	0	1 (2.6)
丘疹性皮疹	0	1 (2.6)
皮膚浮腫	0	1 (2.6)
蕁麻疹	0	1 (2.6)
褥瘡性潰瘍	2 (9.1)	0
アトピー性皮膚炎	2 (9.1)	0
皮膚乾燥	1 (4.5)	0
湿疹	2 (9.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 9 of 32

	North America	
	Control	ISIS 396443
多汗症	1 (4.5)	0
毛孔性角化症	1 (4.5)	0
傷害、中毒および処置合併症	7 (31.8)	11 (28.9)
大腿骨骨折	1 (4.5)	2 (5.3)
処置による疼痛	0	2 (5.3)
ストーマ部紅斑	1 (4.5)	2 (5.3)
術後激越	0	1 (2.6)
挫傷	0	1 (2.6)
擦過傷	0	1 (2.6)
処置後腫脹	0	1 (2.6)
処置部位反応	0	1 (2.6)
ストーマ合併症	2 (9.1)	1 (2.6)
創離開	0	1 (2.6)
麻酔からの覚醒遅延	0	0
気管内挿管合併症	1 (4.5)	0
伝染病曝露	0	0
栄養補給チューブ合併症	2 (9.1)	0
頭部損傷	0	0
裂傷	1 (4.5)	0
処置後挫傷	1 (4.5)	0
処置合併症	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 10 of 32

	North America	
	Control	ISIS 396443
ストーマ部出血	1 (4.5)	0
ストーマ部炎症	1 (4.5)	0
ストーマ部刺激感	1 (4.5)	0
気管損傷	1 (4.5)	0
ワクチン接種合併症	1 (4.5)	0
心臓障害	10 (45.5)	10 (26.3)
頻脈	4 (18.2)	4 (10.5)
徐脈	3 (13.6)	3 (7.9)
心肺停止	3 (13.6)	3 (7.9)
チアノーゼ	2 (9.1)	2 (5.3)
心停止	2 (9.1)	1 (2.6)
左室肥大	0	1 (2.6)
上室性頻脈	0	1 (2.6)
心室性頻脈	0	0
筋骨格系および結合組織障害	4 (18.2)	9 (23.7)
側弯症	1 (4.5)	3 (7.9)
関節拘縮	2 (9.1)	2 (5.3)
背部痛	0	1 (2.6)
胸郭変形	0	1 (2.6)
泉門閉鎖遅延	0	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 11 of 32

	North America	
	Control	ISIS 396443
後側弯症	0	1 (2.6)
脊柱後弯症	1 (4.5)	1 (2.6)
四肢痛	0	1 (2.6)
頭位性斜頭症	1 (4.5)	1 (2.6)
関節硬直	1 (4.5)	0
筋力低下	1 (4.5)	0
腱障害	1 (4.5)	0
臨床検査	10 (45.5)	7 (18.4)
酸素飽和度低下	7 (31.8)	6 (15.8)
体温低下	1 (4.5)	1 (2.6)
心電図ＳＴ－Ｔ部分異常	1 (4.5)	1 (2.6)
心拍数増加	1 (4.5)	1 (2.6)
心拍数不整	0	1 (2.6)
炎症マーカー上昇	0	1 (2.6)
Ａ型インフルエンザウイルス検査陽性	0	1 (2.6)
肝機能検査異常	0	1 (2.6)
好中球数増加	0	1 (2.6)
ブドウ球菌検査陽性	0	1 (2.6)
ビタミンＡ減少	0	1 (2.6)
アラニンアミノトランスフェラーゼ増加	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0
血中クロール減少	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 12 of 32

	North America	
	Control	ISIS 396443
血中鉄減少	0	0
血中カリウム減少	0	0
血中ナトリウム減少	0	0
体温上昇	0	0
Ｃ－反応性蛋白増加	0	0
ヘッドラグ異常	0	0
ヒトライノウイルス検査陽性	0	0
リンパ節触知	1 (4.5)	0
医学的観察	0	0
モラクセラ検査陽性	0	0
シュードモナス検査陽性	0	0
呼吸数増加	0	0
レスピロウイルス検査陽性	1 (4.5)	0
トランスアミナーゼ上昇	1 (4.5)	0
尿量減少	0	0
ビタミンＤ減少	1 (4.5)	0
体重減少	0	0
代謝および栄養障害	7 (31.8)	7 (18.4)
成長障害	0	2 (5.3)
栄養補給不耐性	0	2 (5.3)
脱水	1 (4.5)	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 13 of 32

	North America	
	Control	ISIS 396443
乳児および小児期早期の哺育障害	0	1 (2.6)
鉄欠乏	0	1 (2.6)
体重増加不良	1 (4.5)	1 (2.6)
食物不耐性	0	0
高血糖	1 (4.5)	0
低血糖	2 (9.1)	0
低カリウム血症	3 (13.6)	0
ビタミンD欠乏	1 (4.5)	0
神経系障害	1 (4.5)	6 (15.8)
眼振	0	2 (5.3)
脳損傷	0	1 (2.6)
よだれ	0	1 (2.6)
低酸素性虚血性脳症	0	1 (2.6)
痙攣発作	0	1 (2.6)
傾眠	0	1 (2.6)
間代	0	0
不随意性筋収縮	0	0
失神寸前の状態	1 (4.5)	0
免疫系障害	4 (18.2)	5 (13.2)
薬物過敏症	1 (4.5)	2 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 14 of 32

	North America	
	Control	ISIS 396443
季節性アレルギー	2 (9.1)	2 (5.3)
食物アレルギー	0	1 (2.6)
過敏症	2 (9.1)	0
精神障害	2 (9.1)	5 (13.2)
激越	1 (4.5)	2 (5.3)
不安	0	1 (2.6)
息こらえ	0	1 (2.6)
易刺激性	1 (4.5)	1 (2.6)
落ち着きのなさ	0	1 (2.6)
気分動揺	0	0
睡眠障害	1 (4.5)	0
眼障害	1 (4.5)	4 (10.5)
霰粒腫	0	1 (2.6)
眼乾燥	0	1 (2.6)
眼運動障害	0	1 (2.6)
近視	0	1 (2.6)
斜視	0	1 (2.6)
弱視	0	0
流涙増加	1 (4.5)	0
先天性、家族性および遺伝性障害	4 (18.2)	2 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 15 of 32

	North America	
	Control	ISIS 396443
発育性股関節形成不全	1 (4.5)	1 (2.6)
鳩胸	1 (4.5)	1 (2.6)
停留精巣	1 (4.5)	0
貧血母斑	0	0
包茎	1 (4.5)	0
耳および迷路障害	0	2 (5.3)
耳の障害	0	1 (2.6)
耳痛	0	1 (2.6)
腎および尿路障害	1 (4.5)	2 (5.3)
水腎症	0	1 (2.6)
尿閉	0	1 (2.6)
糖尿	1 (4.5)	0
生殖系および乳房障害	0	2 (5.3)
後天性包茎	0	1 (2.6)
陰茎障害	0	1 (2.6)
卵巣嚢胞	0	0
血管障害	0	2 (5.3)
高血圧	0	1 (2.6)
ショック	0	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 16 of of 32

	North America	
	Control	ISIS 396443
蒼白	0	0
血管炎	0	0
血液およびリンパ系障害	2 (9.1)	1 (2.6)
貧血	1 (4.5)	1 (2.6)
骨髄障害	0	0
白血球増加症	1 (4.5)	0
肝胆道系障害	0	1 (2.6)
肝腫大	0	1 (2.6)
外科および内科処置	0	1 (2.6)
機械的換気	0	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 17 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
Number of subjects dosed	17 (100.0)	30 (100.0)	2 (100.0)	12 (100.0)
Number of subjects with an event	14 (82.4)	26 (86.7)	2 (100.0)	11 (91.7)
呼吸器、胸郭および縦隔障害	12 (70.6)	22 (73.3)	1 (50.0)	3 (25.0)
呼吸窮迫	4 (23.5)	8 (26.7)	0	0
無気肺	1 (5.9)	7 (23.3)	0	0
呼吸不全	6 (35.3)	7 (23.3)	1 (50.0)	0
無呼吸	1 (5.9)	2 (6.7)	0	0
咳嗽	1 (5.9)	2 (6.7)	0	0
呼吸困難	1 (5.9)	2 (6.7)	0	3 (25.0)
呼吸停止	0	2 (6.7)	0	0
呼吸障害	0	2 (6.7)	0	0
鼻漏	0	2 (6.7)	0	0
気管支閉塞	0	1 (3.3)	0	0
気管支分泌物貯留	1 (5.9)	1 (3.3)	0	0
息詰まり	0	1 (3.3)	0	0
気管支分泌増加	0	1 (3.3)	0	0
肺障害	0	1 (3.3)	0	0
閉塞性気道障害	0	1 (3.3)	0	0
誤嚥性肺炎	2 (11.8)	1 (3.3)	0	0
上気道うっ血	0	1 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 18 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
急性呼吸窮迫症候群	0	0	0	0
急性呼吸不全	1 (5.9)	0	0	0
乳幼児突発性危急事態	0	0	0	0
誤嚥	0	0	0	0
カタル	1 (5.9)	0	0	0
慢性呼吸不全	0	0	0	0
高炭酸ガス血症	0	0	0	0
減呼吸	0	0	0	0
低換気	0	0	0	0
低酸素症	0	0	0	0
上気道分泌増加	0	0	0	0
鼻閉	0	0	0	0
口腔咽頭痛	1 (5.9)	0	0	0
胸水	0	0	0	0
気胸	0	0	0	0
呼吸性アルカローシス	0	0	0	0
気道うっ血	1 (5.9)	0	0	0
アレルギー性鼻炎	0	0	0	0
副鼻腔うっ血	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0
変色痰	0	0	0	0
頻呼吸	0	0	0	0
上気道の炎症	2 (11.8)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 19 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
呼吸補助筋の動員	0	0	0	0
喘鳴	0	0	0	0
感染症および寄生虫症	10 (58.8)	21 (70.0)	0	6 (50.0)
肺炎	2 (11.8)	7 (23.3)	0	2 (16.7)
鼻咽頭炎	0	6 (20.0)	0	2 (16.7)
気道感染	1 (5.9)	6 (20.0)	0	0
ウイルス感染	0	5 (16.7)	0	0
気管支炎	0	4 (13.3)	0	0
ライノウイルス感染	1 (5.9)	3 (10.0)	0	0
細気管支炎	1 (5.9)	2 (6.7)	0	2 (16.7)
ウイルス性気管支炎	0	2 (6.7)	0	0
耳感染	0	2 (6.7)	0	0
下気道感染	1 (5.9)	2 (6.7)	0	1 (8.3)
口腔カンジダ症	2 (11.8)	2 (6.7)	0	0
ウイルス性気道感染	1 (5.9)	2 (6.7)	0	0
カンジダ性おむつ皮疹	0	1 (3.3)	0	0
結膜炎	1 (5.9)	1 (3.3)	0	2 (16.7)
真菌感染	1 (5.9)	1 (3.3)	0	0
ロタウイルス胃腸炎	0	1 (3.3)	0	0
手足口病	0	1 (3.3)	0	0
膿痂疹	0	1 (3.3)	0	0
限局性感染	0	1 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 20 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
ウイルス性下気道感染	0	1 (3.3)	0	0
口腔ヘルペス	0	1 (3.3)	0	0
ＲＳウイルス肺炎	0	1 (3.3)	0	0
ウイルス性肺炎	0	1 (3.3)	0	0
ＲＳウイルス細気管支炎	0	1 (3.3)	0	0
鼻炎	3 (17.6)	1 (3.3)	0	0
ばら疹	0	1 (3.3)	0	0
ブドウ球菌皮膚感染	0	1 (3.3)	0	0
上気道感染	4 (23.5)	1 (3.3)	0	2 (16.7)
アデノウイルス感染	0	0	0	0
細菌性疾患キャリアー	0	0	0	0
細菌感染	0	0	0	0
細菌性気管炎	0	0	0	0
カンジダ感染	1 (5.9)	0	0	0
蜂巣炎	0	0	0	0
細菌性結膜炎	0	0	0	0
コロナウイルス感染	0	0	0	0
感染性湿疹	0	0	0	1 (8.3)
眼感染	0	0	0	0
皮膚真菌感染	0	0	0	0
胃腸炎	0	0	0	1 (8.3)
ウイルス性胃腸炎	0	0	0	0
麦粒腫	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 21 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
インフルエンザ	0	0	0	0
肺感染	0	0	0	1 (8.3)
院内感染	0	0	0	0
中耳炎	0	0	0	0
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0
細菌性肺炎	0	0	0	0
インフルエンザ性肺炎	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	1 (8.3)
シュードモナス菌性肺炎	1 (5.9)	0	0	0
シュードモナス感染	1 (5.9)	0	0	0
細菌性気道感染	0	0	0	0
敗血症	0	0	0	0
セラチア感染	0	0	0	0
皮膚カンジダ	1 (5.9)	0	0	0
皮膚感染	0	0	0	0
ブドウ球菌感染	1 (5.9)	0	0	0
ブドウ球菌性敗血症	0	0	0	0
ストーマ部膿瘍	0	0	0	0
ストーマ部感染	0	0	0	0
気管炎	0	0	0	0
尿路感染	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 22 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
ウイルス性発疹	0	0	0	0
ウイルス性上気道感染	0	0	0	0
一般・全身障害および投与部位の状態	11 (64.7)	18 (60.0)	1 (50.0)	3 (25.0)
発熱	9 (52.9)	16 (53.3)	1 (50.0)	3 (25.0)
死亡	0	1 (3.3)	0	0
ワクチン接種後の易刺激性	0	1 (3.3)	0	0
倦怠感	0	1 (3.3)	0	0
適用部位発疹	0	0	0	0
カテーテル留置部位炎症	0	0	0	0
泣き	0	0	0	0
医療機器機能不良	0	0	0	0
医療機器閉塞	0	0	0	0
薬物不耐性	0	0	0	0
疲労	1 (5.9)	0	0	0
低体温	0	0	0	0
注入部位内出血	0	0	0	0
注入部位血管外漏出	0	0	0	0
注射部位血腫	1 (5.9)	0	0	0
小結節	0	0	0	0
浮腫	0	0	1 (50.0)	0
疼痛	2 (11.8)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 23 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
腫脹	0	0	0	0
血管穿刺部位内出血	0	0	0	0
血管穿刺部位反応	1 (5.9)	0	0	0
胃腸障害	8 (47.1)	12 (40.0)	0	5 (41.7)
便秘	4 (23.5)	6 (20.0)	0	2 (16.7)
嘔吐	2 (11.8)	4 (13.3)	0	1 (8.3)
胃食道逆流性疾患	3 (17.6)	3 (10.0)	0	0
下痢	1 (5.9)	2 (6.7)	0	0
腹部不快感	0	1 (3.3)	0	0
胃炎	0	1 (3.3)	0	0
生歯	1 (5.9)	1 (3.3)	0	2 (16.7)
腹部膨満	0	0	0	0
上腹部痛	1 (5.9)	0	0	0
アフタ性潰瘍	0	0	0	1 (8.3)
血性下痢	0	0	0	0
嚥下障害	1 (5.9)	0	0	0
放屁	0	0	0	0
胃出血	0	0	0	0
胃腸出血	1 (5.9)	0	0	0
消化管刺激症状	1 (5.9)	0	0	0
血便排泄	0	0	0	0
乳児仙痛	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 24 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
乳児吐出	0	0	0	0
流涎過多	2 (11.8)	0	0	0
口内炎	1 (5.9)	0	0	0
上部消化管出血	0	0	0	0
臨床検査	4 (23.5)	9 (30.0)	0	1 (8.3)
体重減少	1 (5.9)	3 (10.0)	0	0
血中カリウム減少	0	2 (6.7)	0	0
体温上昇	0	2 (6.7)	0	0
Ｃ－反応性蛋白増加	1 (5.9)	2 (6.7)	0	0
アラニンアミノトランスフェラーゼ増加	0	1 (3.3)	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (3.3)	0	0
血中クロール減少	0	1 (3.3)	0	0
血中鉄減少	0	1 (3.3)	0	0
血中ナトリウム減少	0	1 (3.3)	0	0
ヒトライノウイルス検査陽性	0	1 (3.3)	0	0
医学的観察	0	1 (3.3)	0	0
モラクセラ検査陽性	0	1 (3.3)	0	0
酸素飽和度低下	2 (11.8)	1 (3.3)	0	1 (8.3)
シュードモナス検査陽性	0	1 (3.3)	0	0
尿量減少	0	1 (3.3)	0	0
体温低下	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 25 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
ヘッドラグ異常	1 (5.9)	0	0	0
心拍数増加	0	0	0	0
心拍数不整	0	0	0	0
炎症マーカー上昇	0	0	0	0
A型インフルエンザウイルス検査陽性	0	0	0	0
肝機能検査異常	0	0	0	0
リンパ節触知	0	0	0	0
好中球数増加	0	0	0	0
呼吸数増加	1 (5.9)	0	0	0
レスピロウイルス検査陽性	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0
ビタミンA減少	0	0	0	0
ビタミンD減少	0	0	0	0
代謝および栄養障害	3 (17.6)	6 (20.0)	0	0
体重増加不良	1 (5.9)	4 (13.3)	0	0
乳児および小児期早期の哺育障害	2 (11.8)	2 (6.7)	0	0
栄養補給不耐性	0	1 (3.3)	0	0
脱水	0	0	0	0
成長障害	0	0	0	0
食物不耐性	1 (5.9)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 26 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
高血糖	0	0	0	0
低血糖	0	0	0	0
低カリウム血症	0	0	0	0
鉄欠乏	0	0	0	0
ビタミンD欠乏	0	0	0	0
心臓障害	1 (5.9)	5 (16.7)	0	1 (8.3)
心肺停止	0	2 (6.7)	0	0
頻脈	1 (5.9)	2 (6.7)	0	0
徐脈	0	1 (3.3)	0	0
心停止	0	1 (3.3)	0	0
チアノーゼ	0	0	0	0
左室肥大	0	0	0	0
上室性頻脈	0	0	0	0
心室性頻脈	0	0	0	1 (8.3)
傷害、中毒および処置合併症	2 (11.8)	4 (13.3)	1 (50.0)	0
麻酔からの覚醒遅延	0	1 (3.3)	0	0
伝染病曝露	0	1 (3.3)	0	0
処置合併症	0	1 (3.3)	0	0
ワクチン接種合併症	0	1 (3.3)	0	0
術後激越	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 27 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
挫傷	0	0	0	0
気管内挿管合併症	0	0	0	0
擦過傷	1 (5.9)	0	0	0
栄養補給チューブ合併症	0	0	0	0
大腿骨骨折	0	0	0	0
頭部損傷	1 (5.9)	0	0	0
裂傷	0	0	0	0
処置後挫傷	0	0	0	0
処置後腫脹	0	0	0	0
処置による疼痛	0	0	0	0
処置部位反応	0	0	0	0
ストーマ合併症	0	0	0	0
ストーマ部紅斑	0	0	1 (50.0)	0
ストーマ部出血	0	0	0	0
ストーマ部炎症	0	0	0	0
ストーマ部刺激感	0	0	0	0
気管損傷	0	0	0	0
創離開	0	0	0	0
筋骨格系および結合組織障害	0	2 (6.7)	0	0
関節拘縮	0	1 (3.3)	0	0
頭位性斜頭症	0	1 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 28 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
側弯症	0	1 (3.3)	0	0
背部痛	0	0	0	0
胸郭変形	0	0	0	0
泉門閉鎖遅延	0	0	0	0
関節硬直	0	0	0	0
後側弯症	0	0	0	0
脊柱後弯症	0	0	0	0
筋力低下	0	0	0	0
四肢痛	0	0	0	0
腱障害	0	0	0	0
神経系障害	0	2 (6.7)	1 (50.0)	0
間代	0	1 (3.3)	0	0
不随意性筋収縮	0	1 (3.3)	0	0
脳損傷	0	0	0	0
よだれ	0	0	0	0
低酸素性虚血性脳症	0	0	0	0
眼振	0	0	1 (50.0)	0
失神寸前の状態	0	0	0	0
痙攣発作	0	0	0	0
傾眠	0	0	0	0
精神障害	3 (17.6)	2 (6.7)	0	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 29 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
不安	0	1 (3.3)	0	0
易刺激性	0	1 (3.3)	0	0
睡眠障害	1 (5.9)	1 (3.3)	0	0
激越	1 (5.9)	0	0	0
息こらえ	0	0	0	0
気分動揺	0	0	0	1 (8.3)
落ち着きのなさ	1 (5.9)	0	0	0
血管障害	0	2 (6.7)	0	0
蒼白	0	1 (3.3)	0	0
血管炎	0	1 (3.3)	0	0
高血圧	0	0	0	0
ショック	0	0	0	0
先天性、家族性および遺伝性障害	0	1 (3.3)	0	0
貧血母斑	0	1 (3.3)	0	0
停留精巣	0	0	0	0
発育性股関節形成不全	0	0	0	0
鳩胸	0	0	0	0
包茎	0	0	0	0
免疫系障害	0	1 (3.3)	0	0
過敏症	0	1 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 30 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
薬物過敏症	0	0	0	0
食物アレルギー	0	0	0	0
季節性アレルギー	0	0	0	0
生殖系および乳房障害	0	1 (3.3)	0	0
卵巣嚢胞	0	1 (3.3)	0	0
後天性包茎	0	0	0	0
陰茎障害	0	0	0	0
皮膚および皮下組織障害	1 (5.9)	1 (3.3)	1 (50.0)	1 (8.3)
おむつ皮膚炎	0	1 (3.3)	0	0
褥瘡性潰瘍	0	0	0	0
皮膚炎	0	0	0	0
アレルギー性皮膚炎	0	0	0	0
アトピー性皮膚炎	0	0	0	0
接触性皮膚炎	0	0	0	0
皮膚乾燥	0	0	0	0
斑状出血	0	0	0	0
湿疹	0	0	0	1 (8.3)
紅斑	0	0	1 (50.0)	0
環状肉芽腫	0	0	0	0
多汗症	0	0	0	0
過角化	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 31 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
毛孔性角化症	0	0	0	0
汗疹	0	0	0	1 (8.3)
発疹	1 (5.9)	0	0	1 (8.3)
丘疹性皮疹	0	0	0	0
皮膚浮腫	0	0	0	0
蕁麻疹	0	0	0	0
血液およびリンパ系障害	1 (5.9)	0	0	0
貧血	0	0	0	0
骨髄障害	1 (5.9)	0	0	0
白血球増加症	0	0	0	0
耳および迷路障害	0	0	0	0
耳の障害	0	0	0	0
耳痛	0	0	0	0
眼障害	1 (5.9)	0	1 (50.0)	0
弱視	0	0	1 (50.0)	0
霰粒腫	0	0	0	0
眼乾燥	1 (5.9)	0	0	0
眼運動障害	0	0	0	0
流涙増加	0	0	0	0
近視	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 32 of 32

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
斜視	0	0	1 (50.0)	0
肝胆道系障害	0	0	0	0
肝腫大	0	0	0	0
腎および尿路障害	0	0	0	0
糖尿	0	0	0	0
水腎症	0	0	0	0
尿閉	0	0	0	0
外科および内科処置	0	0	0	0
機械的換気	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 74　Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 1 of 16

	North America	Europe	Asia-Pacific
Number of subjects dosed	58 (100.0)	30 (100.0)	12 (100.0)
Number of subjects with an event	55 (94.8)	26 (86.7)	11 (91.7)
感染症および寄生虫症	49 (84.5)	21 (70.0)	6 (50.0)
上気道感染	29 (50.0)	1 (3.3)	2 (16.7)
肺炎	15 (25.9)	7 (23.3)	2 (16.7)
鼻咽頭炎	12 (20.7)	6 (20.0)	2 (16.7)
ウイルス性上気道感染	12 (20.7)	0	0
ライノウイルス感染	11 (19.0)	3 (10.0)	0
ウイルス性肺炎	8 (13.8)	1 (3.3)	0
細気管支炎	7 (12.1)	2 (6.7)	2 (16.7)
中耳炎	7 (12.1)	0	0
気道感染	6 (10.3)	6 (20.0)	0
ウイルス感染	6 (10.3)	5 (16.7)	0
口腔カンジダ症	5 (8.6)	2 (6.7)	0
細菌性肺炎	4 (6.9)	0	0
細菌性気管炎	3 (5.2)	0	0
結膜炎	3 (5.2)	1 (3.3)	2 (16.7)
耳感染	3 (5.2)	2 (6.7)	0
インフルエンザ	3 (5.2)	0	0
ＲＳウイルス細気管支炎	3 (5.2)	1 (3.3)	0
ウイルス性気道感染	3 (5.2)	2 (6.7)	0
尿路感染	3 (5.2)	0	0
アデノウイルス感染	2 (3.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 2 of 16

	North America	Europe	Asia-Pacific
細菌感染	2 (3.4)	0	0
細菌性結膜炎	2 (3.4)	0	0
エンテロウイルス感染	2 (3.4)	0	0
皮膚真菌感染	2 (3.4)	0	0
ウイルス性下気道感染	2 (3.4)	1 (3.3)	0
メタニューモウイルス感染	2 (3.4)	0	0
パラインフルエンザウイルス感染	2 (3.4)	0	0
モラクセラ菌性肺炎	2 (3.4)	0	0
皮膚カンジダ	2 (3.4)	0	0
ストーマ部膿瘍	2 (3.4)	0	0
アデノウイルス性上気道感染	1 (1.7)	0	0
細菌性疾患キャリアー	1 (1.7)	0	0
気管支炎	1 (1.7)	4 (13.3)	0
ウイルス性気管支炎	1 (1.7)	2 (6.7)	0
カンジダ性おむつ皮疹	1 (1.7)	1 (3.3)	0
蜂巣炎	1 (1.7)	0	0
コロナウイルス感染	1 (1.7)	0	0
伝染性紅斑	1 (1.7)	0	0
眼感染	1 (1.7)	0	0
ウイルス性胃炎	1 (1.7)	0	0
胃腸炎	1 (1.7)	0	1 (8.3)
ウイルス性胃腸炎	1 (1.7)	0	0
ヘモフィルス感染	1 (1.7)	0	0
手足口病	1 (1.7)	1 (3.3)	0
下気道感染	1 (1.7)	2 (6.7)	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 3 of 16

	North America	Europe	Asia-Pacific
モラクセラ感染	1 (1.7)	0	0
粘膜皮膚カンジダ症	1 (1.7)	0	0
院内感染	1 (1.7)	0	0
急性中耳炎	1 (1.7)	0	0
レンサ球菌性咽頭炎	1 (1.7)	0	0
インフルエンザ性肺炎	1 (1.7)	0	0
シュードモナス菌性肺炎	1 (1.7)	0	0
シュードモナス感染	1 (1.7)	0	0
細菌性気道感染	1 (1.7)	0	0
鼻炎	1 (1.7)	1 (3.3)	0
敗血症	1 (1.7)	0	0
ブドウ球菌性菌血症	1 (1.7)	0	0
ブドウ球菌感染	1 (1.7)	0	0
ブドウ球菌性敗血症	1 (1.7)	0	0
気管炎	1 (1.7)	0	0
感染性湿疹	0	0	1 (8.3)
真菌感染	0	1 (3.3)	0
ロタウイルス胃腸炎	0	1 (3.3)	0
膿痂疹	0	1 (3.3)	0
限局性感染	0	1 (3.3)	0
肺感染	0	0	1 (8.3)
口腔ヘルペス	0	1 (3.3)	0
パラインフルエンザウイルス性肺炎	0	0	1 (8.3)
ＲＳウイルス肺炎	0	1 (3.3)	0
ばら疹	0	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 4 of 16

	North America	Europe	Asia-Pacific
ブドウ球菌皮膚感染	0	1 (3.3)	0
呼吸器、胸郭および縦隔障害	48 (82.8)	22 (73.3)	3 (25.0)
呼吸窮迫	18 (31.0)	8 (26.7)	0
呼吸不全	16 (27.6)	7 (23.3)	0
急性呼吸不全	15 (25.9)	0	0
鼻閉	15 (25.9)	0	0
無気肺	13 (22.4)	7 (23.3)	0
咳嗽	10 (17.2)	2 (6.7)	0
低酸素症	10 (17.2)	0	0
誤嚥性肺炎	9 (15.5)	1 (3.3)	0
誤嚥	6 (10.3)	0	0
慢性呼吸不全	6 (10.3)	0	0
上気道分泌増加	6 (10.3)	0	0
無呼吸	5 (8.6)	2 (6.7)	0
気管支分泌物貯留	5 (8.6)	1 (3.3)	0
上気道うっ血	5 (8.6)	1 (3.3)	0
呼吸困難	4 (6.9)	2 (6.7)	3 (25.0)
鼻漏	4 (6.9)	2 (6.7)	0
副鼻腔うっ血	4 (6.9)	0	0
低換気	3 (5.2)	0	0
気胸	3 (5.2)	0	0
喘鳴	3 (5.2)	0	0
肺うっ血	2 (3.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 5 of 16

	North America	Europe	Asia-Pacific
肺水腫	2 (3.4)	0	0
呼吸停止	2 (3.4)	2 (6.7)	0
アレルギー性鼻炎	2 (3.4)	0	0
呼吸補助筋の動員	2 (3.4)	0	0
急性呼吸窮迫症候群	1 (1.7)	0	0
無呼吸発作	1 (1.7)	0	0
窒息	1 (1.7)	0	0
息詰まり	1 (1.7)	1 (3.3)	0
高炭酸ガス血症	1 (1.7)	0	0
減呼吸	1 (1.7)	0	0
喉頭肉芽腫	1 (1.7)	0	0
鼻汁変色	1 (1.7)	0	0
胸水	1 (1.7)	0	0
気縦隔症	1 (1.7)	0	0
湿性咳嗽	1 (1.7)	0	0
呼吸性アルカローシス	1 (1.7)	0	0
気道うっ血	1 (1.7)	0	0
拘束性肺疾患	1 (1.7)	0	0
低音性連続性ラ音	1 (1.7)	0	0
睡眠時無呼吸症候群	1 (1.7)	0	0
変色痰	1 (1.7)	0	0
頻呼吸	1 (1.7)	0	0
気管障害	1 (1.7)	0	0
気管支閉塞	0	1 (3.3)	0
気管支分泌増加	0	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 6 of 16

	North America	Europe	Asia-Pacific
肺障害	0	1 (3.3)	0
閉塞性気道障害	0	1 (3.3)	0
呼吸障害	0	2 (6.7)	0
胃腸障害	47 (81.0)	12 (40.0)	5 (41.7)
便秘	25 (43.1)	6 (20.0)	2 (16.7)
嘔吐	15 (25.9)	4 (13.3)	1 (8.3)
胃食道逆流性疾患	12 (20.7)	3 (10.0)	0
生歯	12 (20.7)	1 (3.3)	2 (16.7)
下痢	11 (19.0)	2 (6.7)	0
嚥下障害	9 (15.5)	0	0
放屁	5 (8.6)	0	0
流涎過多	5 (8.6)	0	0
腹部膨満	4 (6.9)	0	0
胃炎	3 (5.2)	1 (3.3)	0
血便排泄	2 (3.4)	0	0
腹痛	1 (1.7)	0	0
口唇のひび割れ	1 (1.7)	0	0
排便回数増加	1 (1.7)	0	0
胃出血	1 (1.7)	0	0
消化管運動低下	1 (1.7)	0	0
吐血	1 (1.7)	0	0
乳児仙痛	1 (1.7)	0	0
乳児吐出	1 (1.7)	0	0
上部消化管出血	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 7 of 16

	North America	Europe	Asia-Pacific
腹部不快感	0	1 (3.3)	0
アフタ性潰瘍	0	0	1 (8.3)
一般・全身障害および投与部位の状態	37 (63.8)	18 (60.0)	3 (25.0)
発熱	34 (58.6)	16 (53.3)	3 (25.0)
疼痛	5 (8.6)	0	0
不快感	2 (3.4)	0	0
末梢性浮腫	2 (3.4)	0	0
カテーテル留置部位炎症	1 (1.7)	0	0
泣き	1 (1.7)	0	0
医療機器リーク	1 (1.7)	0	0
医療機器閉塞	1 (1.7)	0	0
薬物不耐性	1 (1.7)	0	0
低体温	1 (1.7)	0	0
小結節	1 (1.7)	0	0
浮腫	1 (1.7)	0	0
末梢腫脹	1 (1.7)	0	0
腫脹	1 (1.7)	0	0
血管穿刺部位内出血	1 (1.7)	0	0
死亡	0	1 (3.3)	0
ワクチン接種後の易刺激性	0	1 (3.3)	0
倦怠感	0	1 (3.3)	0
皮膚および皮下組織障害	33 (56.9)	1 (3.3)	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 8 of 16

	North America	Europe	Asia-Pacific
発疹	12 (20.7)	0	1 (8.3)
おむつ皮膚炎	9 (15.5)	1 (3.3)	0
接触性皮膚炎	3 (5.2)	0	0
斑状出血	3 (5.2)	0	0
湿疹	3 (5.2)	0	1 (8.3)
過剰肉芽組織	3 (5.2)	0	0
皮膚刺激	3 (5.2)	0	0
皮膚炎	2 (3.4)	0	0
過角化	2 (3.4)	0	0
脱毛症	1 (1.7)	0	0
アレルギー性皮膚炎	1 (1.7)	0	0
紅斑	1 (1.7)	0	0
環状肉芽腫	1 (1.7)	0	0
汗疹	1 (1.7)	0	1 (8.3)
点状出血	1 (1.7)	0	0
そう痒症	1 (1.7)	0	0
丘疹性皮疹	1 (1.7)	0	0
皮膚色素脱失	1 (1.7)	0	0
皮膚障害	1 (1.7)	0	0
皮膚浮腫	1 (1.7)	0	0
皮膚潰瘍	1 (1.7)	0	0
皮下気腫	1 (1.7)	0	0
蕁麻疹	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 9 of 16

	North America	Europe	Asia-Pacific
筋骨格系および結合組織障害	23 (39.7)	2 (6.7)	0
関節拘縮	10 (17.2)	1 (3.3)	0
側弯症	10 (17.2)	1 (3.3)	0
脊柱後弯症	5 (8.6)	0	0
胸郭変形	4 (6.9)	0	0
後側弯症	2 (3.4)	0	0
四肢痛	2 (3.4)	0	0
斜頚	2 (3.4)	0	0
背部痛	1 (1.7)	0	0
泉門閉鎖遅延	1 (1.7)	0	0
手変形	1 (1.7)	0	0
関節硬直	1 (1.7)	0	0
脊柱前弯症	1 (1.7)	0	0
頭位性斜頭症	1 (1.7)	1 (3.3)	0
脊柱変形	1 (1.7)	0	0
滑膜炎	1 (1.7)	0	0
傷害、中毒および処置合併症	22 (37.9)	4 (13.3)	0
処置による疼痛	4 (6.9)	0	0
節足動物咬傷	3 (5.2)	0	0
ストーマ部紅斑	3 (5.2)	0	0
挫傷	2 (3.4)	0	0
栄養補給チューブ合併症	2 (3.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 10 of 16

	North America	Europe	Asia-Pacific
大腿骨骨折	2 (3.4)	0	0
関節脱臼	2 (3.4)	0	0
皮膚擦過傷	2 (3.4)	0	0
術後激越	1 (1.7)	0	0
ダンピング症候群	1 (1.7)	0	0
耳擦過傷	1 (1.7)	0	0
擦過傷	1 (1.7)	0	0
口唇損傷	1 (1.7)	0	0
外傷性気胸	1 (1.7)	0	0
処置後腫脹	1 (1.7)	0	0
処置部位反応	1 (1.7)	0	0
軟部組織損傷	1 (1.7)	0	0
ストーマ合併症	1 (1.7)	0	0
サンバーン	1 (1.7)	0	0
熱傷	1 (1.7)	0	0
歯牙損傷	1 (1.7)	0	0
創離開	1 (1.7)	0	0
麻酔からの覚醒遅延	0	1 (3.3)	0
伝染病曝露	0	1 (3.3)	0
処置合併症	0	1 (3.3)	0
ワクチン接種合併症	0	1 (3.3)	0
心臓障害	16 (27.6)	5 (16.7)	1 (8.3)
徐脈	6 (10.3)	1 (3.3)	0
頻脈	6 (10.3)	2 (6.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 11 of 16

	North America	Europe	Asia-Pacific
心肺停止	4 (6.9)	2 (6.7)	0
チアノーゼ	3 (5.2)	0	0
心停止	2 (3.4)	1 (3.3)	0
心筋症	1 (1.7)	0	0
左室肥大	1 (1.7)	0	0
心膜気腫	1 (1.7)	0	0
上室性頻脈	1 (1.7)	0	0
心室性頻脈	1 (1.7)	0	1 (8.3)
神経系障害	15 (25.9)	2 (6.7)	0
不随意性筋収縮	3 (5.2)	1 (3.3)	0
眼振	3 (5.2)	0	0
よだれ	2 (3.4)	0	0
痙攣発作	2 (3.4)	0	0
脳損傷	1 (1.7)	0	0
脳梗塞	1 (1.7)	0	0
脳脊髄液漏	1 (1.7)	0	0
頭痛	1 (1.7)	0	0
低酸素性虚血性脳症	1 (1.7)	0	0
嗜眠	1 (1.7)	0	0
傾眠	1 (1.7)	0	0
失神	1 (1.7)	0	0
間代	0	1 (3.3)	0
臨床検査	14 (24.1)	9 (30.0)	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 12 of 16

	North America	Europe	Asia-Pacific
酸素飽和度低下	8 (13.8)	1 (3.3)	1 (8.3)
好中球数増加	3 (5.2)	0	0
心拍数増加	2 (3.4)	0	0
ヒトライノウイルス検査陽性	2 (3.4)	1 (3.3)	0
ブドウ球菌検査陽性	2 (3.4)	0	0
体重減少	2 (3.4)	3 (10.0)	0
白血球数増加	2 (3.4)	0	0
体温低下	1 (1.7)	0	0
骨密度減少	1 (1.7)	0	0
呼吸音異常	1 (1.7)	0	0
心電図ＳＴ－Ｔ部分異常	1 (1.7)	0	0
心拍数減少	1 (1.7)	0	0
心拍数不整	1 (1.7)	0	0
炎症マーカー上昇	1 (1.7)	0	0
Ａ型インフルエンザウイルス検査陽性	1 (1.7)	0	0
肝機能検査異常	1 (1.7)	0	0
モラクセラ検査陽性	1 (1.7)	1 (3.3)	0
好中球百分率増加	1 (1.7)	0	0
シュードモナス検査陽性	1 (1.7)	1 (3.3)	0
セラチア検査陽性	1 (1.7)	0	0
レンサ球菌検査陽性	1 (1.7)	0	0
ビタミンＡ減少	1 (1.7)	0	0
アラニンアミノトランスフェラーゼ増加	0	1 (3.3)	0
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (3.3)	0
血中クロール減少	0	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 13 of 16

	North America	Europe	Asia-Pacific
血中鉄減少	0	1 (3.3)	0
血中カリウム減少	0	2 (6.7)	0
血中ナトリウム減少	0	1 (3.3)	0
体温上昇	0	2 (6.7)	0
Ｃ－反応性蛋白増加	0	2 (6.7)	0
医学的観察	0	1 (3.3)	0
尿量減少	0	1 (3.3)	0
代謝および栄養障害	12 (20.7)	6 (20.0)	0
成長障害	3 (5.2)	0	0
栄養補給不耐性	2 (3.4)	1 (3.3)	0
低ナトリウム血症	2 (3.4)	0	0
過小食	2 (3.4)	0	0
体重増加不良	2 (3.4)	4 (13.3)	0
脱水	1 (1.7)	0	0
乳児および小児期早期の哺育障害	1 (1.7)	2 (6.7)	0
鉄欠乏	1 (1.7)	0	0
代謝性アルカローシス	1 (1.7)	0	0
免疫系障害	11 (19.0)	1 (3.3)	0
季節性アレルギー	5 (8.6)	0	0
薬物過敏症	4 (6.9)	0	0
食物アレルギー	1 (1.7)	0	0
過敏症	1 (1.7)	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 14 of 16

	North America	Europe	Asia-Pacific
精神障害	8 (13.8)	2 (6.7)	1 (8.3)
不安	4 (6.9)	1 (3.3)	0
激越	2 (3.4)	0	0
息こらえ	1 (1.7)	0	0
易刺激性	1 (1.7)	1 (3.3)	0
落ち着きのなさ	1 (1.7)	0	0
気分動揺	0	0	1 (8.3)
睡眠障害	0	1 (3.3)	0
血液およびリンパ系障害	6 (10.3)	0	0
貧血	3 (5.2)	0	0
リンパ節症	1 (1.7)	0	0
好中球減少症	1 (1.7)	0	0
血小板増加症	1 (1.7)	0	0
眼障害	6 (10.3)	0	0
乱視	1 (1.7)	0	0
霰粒腫	1 (1.7)	0	0
眼乾燥	1 (1.7)	0	0
眼運動障害	1 (1.7)	0	0
眼瞼下垂	1 (1.7)	0	0
近視	1 (1.7)	0	0
斜視	1 (1.7)	0	0
先天性、家族性および遺伝性障害	5 (8.6)	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 15 of 16

	North America	Europe	Asia-Pacific
斜頭症	2 (3.4)	0	0
斜指症	1 (1.7)	0	0
発育性股関節形成不全	1 (1.7)	0	0
鳩胸	1 (1.7)	0	0
貧血母斑	0	1 (3.3)	0
血管障害	5 (8.6)	2 (6.7)	0
高血圧	2 (3.4)	0	0
毛細血管脆弱	1 (1.7)	0	0
本態性高血圧症	1 (1.7)	0	0
ショック	1 (1.7)	0	0
蒼白	0	1 (3.3)	0
血管炎	0	1 (3.3)	0
耳および迷路障害	3 (5.2)	0	0
耳の障害	1 (1.7)	0	0
耳痛	1 (1.7)	0	0
耳垢分泌過多	1 (1.7)	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	2 (3.4)	0	0
アクロコルドン	1 (1.7)	0	0
血管の良性新生物	1 (1.7)	0	0
腎および尿路障害	2 (3.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 16 of 16

	North America	Europe	Asia-Pacific
水腎症	1 (1.7)	0	0
尿閉	1 (1.7)	0	0
生殖系および乳房障害	2 (3.4)	1 (3.3)	0
後天性包茎	1 (1.7)	0	0
陰茎障害	1 (1.7)	0	0
卵巣嚢胞	0	1 (3.3)	0
肝胆道系障害	1 (1.7)	0	0
肝腫大	1 (1.7)	0	0
外科および内科処置	1 (1.7)	0	0
機械的換気	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 75　Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 1 of 17

	North America	Europe	Asia-Pacific
Number of subjects dosed	70 (100.0)	33 (100.0)	14 (100.0)
Number of subjects with an event	65 (92.9)	29 (87.9)	11 (78.6)
感染症および寄生虫症	56 (80.0)	24 (72.7)	6 (42.9)
上気道感染	35 (50.0)	1 (3.0)	2 (14.3)
肺炎	15 (21.4)	8 (24.2)	2 (14.3)
鼻咽頭炎	14 (20.0)	7 (21.2)	2 (14.3)
ライノウイルス感染	12 (17.1)	3 (9.1)	0
ウイルス性上気道感染	12 (17.1)	0	0
中耳炎	9 (12.9)	0	0
ウイルス性肺炎	9 (12.9)	1 (3.0)	0
細気管支炎	8 (11.4)	2 (6.1)	2 (14.3)
気道感染	6 (8.6)	6 (18.2)	0
ウイルス感染	6 (8.6)	5 (15.2)	0
口腔カンジダ症	5 (7.1)	2 (6.1)	0
細菌性肺炎	4 (5.7)	0	0
尿路感染	4 (5.7)	0	0
細菌性気管炎	3 (4.3)	0	0
結膜炎	3 (4.3)	1 (3.0)	2 (14.3)
耳感染	3 (4.3)	2 (6.1)	0
インフルエンザ	3 (4.3)	2 (6.1)	0
ＲＳウイルス細気管支炎	3 (4.3)	1 (3.0)	0
ウイルス性気道感染	3 (4.3)	2 (6.1)	0
アデノウイルス感染	2 (2.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 2 of 17

	North America	Europe	Asia-Pacific
細菌感染	2 (2.9)	0	0
細菌性結膜炎	2 (2.9)	0	0
エンテロウイルス感染	2 (2.9)	0	0
皮膚真菌感染	2 (2.9)	0	0
ウイルス性胃腸炎	2 (2.9)	0	0
ウイルス性下気道感染	2 (2.9)	1 (3.0)	0
メタニューモウイルス感染	2 (2.9)	0	0
パラインフルエンザウイルス感染	2 (2.9)	0	0
レンサ球菌性咽頭炎	2 (2.9)	0	0
モラクセラ菌性肺炎	2 (2.9)	0	0
皮膚カンジダ	2 (2.9)	0	0
ストーマ部膿瘍	2 (2.9)	0	0
アデノウイルス性上気道感染	1 (1.4)	0	0
細菌性疾患キャリアー	1 (1.4)	0	0
気管支炎	1 (1.4)	5 (15.2)	0
ウイルス性気管支炎	1 (1.4)	2 (6.1)	0
カンジダ性おむつ皮疹	1 (1.4)	1 (3.0)	0
蜂巣炎	1 (1.4)	0	0
コロナウイルス感染	1 (1.4)	0	0
伝染性紅斑	1 (1.4)	0	0
眼感染	1 (1.4)	0	0
ウイルス性胃炎	1 (1.4)	0	0
胃腸炎	1 (1.4)	0	1 (7.1)
ヘモフィルス感染	1 (1.4)	0	0
手足口病	1 (1.4)	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 3 of 17

	North America	Europe	Asia-Pacific
膿痂疹	1 (1.4)	1 (3.0)	0
下気道感染	1 (1.4)	2 (6.1)	1 (7.1)
モラクセラ感染	1 (1.4)	0	0
粘膜皮膚カンジダ症	1 (1.4)	0	0
院内感染	1 (1.4)	0	0
急性中耳炎	1 (1.4)	0	0
インフルエンザ性肺炎	1 (1.4)	0	0
シュードモナス菌性肺炎	1 (1.4)	0	0
シュードモナス感染	1 (1.4)	0	0
細菌性気道感染	1 (1.4)	0	0
鼻炎	1 (1.4)	2 (6.1)	0
敗血症	1 (1.4)	0	0
皮膚感染	1 (1.4)	0	0
ブドウ球菌性菌血症	1 (1.4)	0	0
ブドウ球菌感染	1 (1.4)	0	0
ブドウ球菌性敗血症	1 (1.4)	0	0
気管炎	1 (1.4)	0	0
感染性湿疹	0	0	1 (7.1)
真菌感染	0	1 (3.0)	0
ロタウイルス胃腸炎	0	1 (3.0)	0
限局性感染	0	1 (3.0)	0
肺感染	0	0	1 (7.1)
口腔ヘルペス	0	1 (3.0)	0
パラインフルエンザウイルス性肺炎	0	0	1 (7.1)
ＲＳウイルス肺炎	0	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 4 of 17

	North America	Europe	Asia-Pacific
ばら疹	0	1 (3.0)	0
ブドウ球菌皮膚感染	0	1 (3.0)	0
胃腸障害	52 (74.3)	13 (39.4)	5 (35.7)
便秘	25 (35.7)	7 (21.2)	2 (14.3)
嘔吐	15 (21.4)	4 (12.1)	1 (7.1)
胃食道逆流性疾患	14 (20.0)	3 (9.1)	0
生歯	13 (18.6)	1 (3.0)	2 (14.3)
下痢	11 (15.7)	2 (6.1)	0
嚥下障害	10 (14.3)	0	0
放屁	7 (10.0)	0	0
腹部膨満	6 (8.6)	0	0
流涎過多	5 (7.1)	0	0
胃炎	3 (4.3)	1 (3.0)	0
血便排泄	2 (2.9)	0	0
腹部不快感	1 (1.4)	1 (3.0)	0
腹痛	1 (1.4)	0	0
口唇のひび割れ	1 (1.4)	0	0
排便回数増加	1 (1.4)	0	0
胃出血	1 (1.4)	0	0
消化管運動低下	1 (1.4)	0	0
吐血	1 (1.4)	0	0
乳児仙痛	1 (1.4)	0	0
乳児吐出	1 (1.4)	0	0
上部消化管出血	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 5 of 17

	North America	Europe	Asia-Pacific
アフタ性潰瘍	0	0	1 (7.1)
呼吸器、胸郭および縦隔障害	51 (72.9)	24 (72.7)	3 (21.4)
呼吸窮迫	19 (27.1)	8 (24.2)	0
鼻閉	17 (24.3)	0	0
呼吸不全	16 (22.9)	7 (21.2)	0
急性呼吸不全	15 (21.4)	0	0
無気肺	13 (18.6)	7 (21.2)	0
咳嗽	11 (15.7)	3 (9.1)	0
低酸素症	10 (14.3)	0	0
誤嚥性肺炎	9 (12.9)	1 (3.0)	0
誤嚥	6 (8.6)	0	0
慢性呼吸不全	6 (8.6)	0	0
上気道分泌増加	6 (8.6)	0	0
上気道うっ血	6 (8.6)	1 (3.0)	0
無呼吸	5 (7.1)	2 (6.1)	0
気管支分泌物貯留	5 (7.1)	1 (3.0)	0
鼻漏	5 (7.1)	2 (6.1)	0
呼吸困難	4 (5.7)	2 (6.1)	3 (21.4)
副鼻腔うっ血	4 (5.7)	0	0
低換気	3 (4.3)	0	0
気胸	3 (4.3)	0	0
喘鳴	3 (4.3)	0	0
肺うっ血	2 (2.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 6 of 17

	North America	Europe	Asia-Pacific
肺水腫	2 (2.9)	0	0
呼吸停止	2 (2.9)	2 (6.1)	0
アレルギー性鼻炎	2 (2.9)	0	0
呼吸補助筋の動員	2 (2.9)	0	0
急性呼吸窮迫症候群	1 (1.4)	0	0
無呼吸発作	1 (1.4)	0	0
窒息	1 (1.4)	0	0
息詰まり	1 (1.4)	1 (3.0)	0
高炭酸ガス血症	1 (1.4)	0	0
減呼吸	1 (1.4)	0	0
喉頭肉芽腫	1 (1.4)	0	0
鼻汁変色	1 (1.4)	0	0
胸水	1 (1.4)	0	0
気縦隔症	1 (1.4)	0	0
湿性咳嗽	1 (1.4)	0	0
呼吸性アルカローシス	1 (1.4)	0	0
気道うっ血	1 (1.4)	0	0
拘束性肺疾患	1 (1.4)	0	0
低音性連続性ラ音	1 (1.4)	0	0
睡眠時無呼吸症候群	1 (1.4)	0	0
変色痰	1 (1.4)	0	0
頻呼吸	1 (1.4)	0	0
気管障害	1 (1.4)	0	0
気管支閉塞	0	1 (3.0)	0
気管支分泌増加	0	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 7 of 17

	North America	Europe	Asia-Pacific
肺障害	0	1 (3.0)	0
閉塞性気道障害	0	1 (3.0)	0
呼吸性アシドーシス	0	1 (3.0)	0
呼吸障害	0	2 (6.1)	0
一般・全身障害および投与部位の状態	41 (58.6)	18 (54.5)	3 (21.4)
発熱	37 (52.9)	16 (48.5)	3 (21.4)
疼痛	5 (7.1)	0	0
不快感	2 (2.9)	0	0
末梢性浮腫	2 (2.9)	0	0
適用部位紅斑	1 (1.4)	0	0
カテーテル留置部位炎症	1 (1.4)	0	0
泣き	1 (1.4)	0	0
医療機器リーク	1 (1.4)	0	0
医療機器閉塞	1 (1.4)	0	0
薬物不耐性	1 (1.4)	0	0
低体温	1 (1.4)	0	0
注入部位内出血	1 (1.4)	0	0
小結節	1 (1.4)	0	0
浮腫	1 (1.4)	0	0
末梢腫脹	1 (1.4)	0	0
腫脹	1 (1.4)	0	0
血管穿刺部位内出血	1 (1.4)	0	0
死亡	0	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 8 of 17

	North America	Europe	Asia-Pacific
ワクチン接種後の易刺激性	0	1 (3.0)	0
倦怠感	0	1 (3.0)	0
皮膚および皮下組織障害	37 (52.9)	3 (9.1)	1 (7.1)
発疹	12 (17.1)	0	1 (7.1)
おむつ皮膚炎	11 (15.7)	1 (3.0)	0
接触性皮膚炎	3 (4.3)	0	0
斑状出血	3 (4.3)	0	0
湿疹	3 (4.3)	0	1 (7.1)
過剰肉芽組織	3 (4.3)	0	0
皮膚刺激	3 (4.3)	0	0
皮膚炎	2 (2.9)	2 (6.1)	0
紅斑	2 (2.9)	0	0
過角化	2 (2.9)	0	0
脱毛症	1 (1.4)	0	0
アレルギー性皮膚炎	1 (1.4)	0	0
貨幣状湿疹	1 (1.4)	0	0
環状肉芽腫	1 (1.4)	0	0
汗疹	1 (1.4)	0	1 (7.1)
点状出血	1 (1.4)	0	0
そう痒症	1 (1.4)	0	0
丘疹性皮疹	1 (1.4)	0	0
脂漏性皮膚炎	1 (1.4)	0	0
皮膚色素脱失	1 (1.4)	0	0
皮膚障害	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 9 of 17

	North America	Europe	Asia-Pacific
皮膚浮腫	1 (1.4)	0	0
皮膚潰瘍	1 (1.4)	0	0
皮下気腫	1 (1.4)	0	0
蕁麻疹	1 (1.4)	0	0
傷害、中毒および処置合併症	25 (35.7)	4 (12.1)	0
処置による疼痛	4 (5.7)	0	0
節足動物咬傷	3 (4.3)	0	0
ストーマ部紅斑	3 (4.3)	0	0
挫傷	2 (2.9)	0	0
栄養補給チューブ合併症	2 (2.9)	0	0
大腿骨骨折	2 (2.9)	0	0
関節脱臼	2 (2.9)	0	0
処置後腫脹	2 (2.9)	0	0
皮膚擦過傷	2 (2.9)	0	0
術後激越	1 (1.4)	0	0
ダンピング症候群	1 (1.4)	0	0
耳擦過傷	1 (1.4)	0	0
擦過傷	1 (1.4)	0	0
転倒	1 (1.4)	0	0
口唇損傷	1 (1.4)	0	0
外傷性気胸	1 (1.4)	0	0
処置後合併症	1 (1.4)	0	0
処置後不快感	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 10 of 17

	North America	Europe	Asia-Pacific
処置部位反応	1 (1.4)	0	0
軟部組織損傷	1 (1.4)	0	0
ストーマ合併症	1 (1.4)	0	0
硬膜下血腫	1 (1.4)	0	0
サンバーン	1 (1.4)	0	0
熱傷	1 (1.4)	0	0
歯牙損傷	1 (1.4)	0	0
創離開	1 (1.4)	0	0
麻酔からの覚醒遅延	0	1 (3.0)	0
伝染病曝露	0	1 (3.0)	0
処置合併症	0	1 (3.0)	0
ワクチン接種合併症	0	1 (3.0)	0
筋骨格系および結合組織障害	25 (35.7)	2 (6.1)	0
関節拘縮	11 (15.7)	1 (3.0)	0
側弯症	10 (14.3)	1 (3.0)	0
脊柱後弯症	5 (7.1)	0	0
胸郭変形	4 (5.7)	0	0
斜頚	3 (4.3)	0	0
後側弯症	2 (2.9)	0	0
四肢痛	2 (2.9)	0	0
頭位性斜頭症	2 (2.9)	1 (3.0)	0
背部痛	1 (1.4)	0	0
泉門閉鎖遅延	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 11 of 17

	North America	Europe	Asia-Pacific
手変形	1 (1.4)	0	0
関節硬直	1 (1.4)	0	0
脊柱前弯症	1 (1.4)	0	0
筋力低下	1 (1.4)	0	0
脊柱変形	1 (1.4)	0	0
滑膜炎	1 (1.4)	0	0
体重支持困難	1 (1.4)	0	0
心臓障害	18 (25.7)	5 (15.2)	1 (7.1)
頻脈	8 (11.4)	2 (6.1)	0
徐脈	6 (8.6)	1 (3.0)	0
心肺停止	4 (5.7)	2 (6.1)	0
チアノーゼ	3 (4.3)	0	0
心停止	2 (2.9)	1 (3.0)	0
心筋症	1 (1.4)	0	0
左室肥大	1 (1.4)	0	0
心膜気腫	1 (1.4)	0	0
上室性頻脈	1 (1.4)	0	0
心室性頻脈	1 (1.4)	0	1 (7.1)
神経系障害	17 (24.3)	2 (6.1)	0
不随意性筋収縮	3 (4.3)	1 (3.0)	0
眼振	3 (4.3)	0	0
よだれ	2 (2.9)	0	0
痙攣発作	2 (2.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 12 of 17

	North America	Europe	Asia-Pacific
脳損傷	1 (1.4)	0	0
脳梗塞	1 (1.4)	0	0
脳脊髄液漏	1 (1.4)	0	0
頭痛	1 (1.4)	0	0
反射亢進	1 (1.4)	0	0
筋緊張低下	1 (1.4)	0	0
低酸素性虚血性脳症	1 (1.4)	0	0
嗜眠	1 (1.4)	0	0
傾眠	1 (1.4)	0	0
失神	1 (1.4)	0	0
間代	0	1 (3.0)	0
臨床検査	15 (21.4)	9 (27.3)	1 (7.1)
酸素飽和度低下	8 (11.4)	1 (3.0)	1 (7.1)
好中球数増加	3 (4.3)	0	0
心拍数増加	2 (2.9)	0	0
ヒトライノウイルス検査陽性	2 (2.9)	1 (3.0)	0
ブドウ球菌検査陽性	2 (2.9)	0	0
体重減少	2 (2.9)	3 (9.1)	0
白血球数増加	2 (2.9)	0	0
アラニンアミノトランスフェラーゼ増加	1 (1.4)	1 (3.0)	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.4)	1 (3.0)	0
体温低下	1 (1.4)	0	0
骨密度減少	1 (1.4)	0	0
呼吸音異常	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 13 of 17

	North America	Europe	Asia-Pacific
心電図ＳＴ－Ｔ部分異常	1 (1.4)	0	0
心拍数減少	1 (1.4)	0	0
心拍数不整	1 (1.4)	0	0
炎症マーカー上昇	1 (1.4)	0	0
Ａ型インフルエンザウイルス検査陽性	1 (1.4)	0	0
肝機能検査異常	1 (1.4)	0	0
モラクセラ検査陽性	1 (1.4)	1 (3.0)	0
好中球百分率増加	1 (1.4)	0	0
シュードモナス検査陽性	1 (1.4)	1 (3.0)	0
セラチア検査陽性	1 (1.4)	0	0
レンサ球菌検査陽性	1 (1.4)	0	0
ビタミンＡ減少	1 (1.4)	0	0
血中クロール減少	0	1 (3.0)	0
血中鉄減少	0	1 (3.0)	0
血中カリウム減少	0	2 (6.1)	0
血中ナトリウム減少	0	1 (3.0)	0
体温上昇	0	2 (6.1)	0
Ｃ－反応性蛋白増加	0	2 (6.1)	0
医学的観察	0	1 (3.0)	0
尿量減少	0	1 (3.0)	0
代謝および栄養障害	14 (20.0)	6 (18.2)	0
成長障害	4 (5.7)	0	0
体重増加不良	3 (4.3)	4 (12.1)	0
脱水	2 (2.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 14 of 17

	North America	Europe	Asia-Pacific
栄養補給不耐性	2 (2.9)	1 (3.0)	0
低ナトリウム血症	2 (2.9)	0	0
過小食	2 (2.9)	0	0
乳児および小児期早期の哺育障害	1 (1.4)	2 (6.1)	0
鉄欠乏	1 (1.4)	0	0
代謝性アルカローシス	1 (1.4)	0	0
免疫系障害	12 (17.1)	1 (3.0)	0
季節性アレルギー	6 (8.6)	0	0
薬物過敏症	4 (5.7)	0	0
食物アレルギー	1 (1.4)	0	0
過敏症	1 (1.4)	1 (3.0)	0
精神障害	8 (11.4)	2 (6.1)	1 (7.1)
不安	4 (5.7)	1 (3.0)	0
激越	2 (2.9)	0	0
息こらえ	1 (1.4)	0	0
易刺激性	1 (1.4)	1 (3.0)	0
落ち着きのなさ	1 (1.4)	0	0
気分動揺	0	0	1 (7.1)
睡眠障害	0	1 (3.0)	0
血液およびリンパ系障害	7 (10.0)	1 (3.0)	0
貧血	3 (4.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 15 of 17

	North America	Europe	Asia-Pacific
好酸球増加症	1 (1.4)	0	0
リンパ節症	1 (1.4)	0	0
好中球減少症	1 (1.4)	1 (3.0)	0
血小板増加症	1 (1.4)	0	0
眼障害	7 (10.0)	0	0
乱視	1 (1.4)	0	0
霰粒腫	1 (1.4)	0	0
後天性涙道狭窄	1 (1.4)	0	0
眼乾燥	1 (1.4)	0	0
眼運動障害	1 (1.4)	0	0
眼瞼下垂	1 (1.4)	0	0
近視	1 (1.4)	0	0
斜視	1 (1.4)	0	0
血管障害	6 (8.6)	3 (9.1)	0
高血圧	3 (4.3)	0	0
毛細血管脆弱	1 (1.4)	0	0
本態性高血圧症	1 (1.4)	0	0
ショック	1 (1.4)	0	0
蒼白	0	2 (6.1)	0
血管炎	0	1 (3.0)	0
先天性、家族性および遺伝性障害	5 (7.1)	1 (3.0)	0
斜頭症	2 (2.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 16 of 17

	North America	Europe	Asia-Pacific
斜指症	1 (1.4)	0	0
発育性股関節形成不全	1 (1.4)	0	0
鳩胸	1 (1.4)	0	0
貧血母斑	0	1 (3.0)	0
耳および迷路障害	3 (4.3)	0	0
耳の障害	1 (1.4)	0	0
耳痛	1 (1.4)	0	0
耳垢分泌過多	1 (1.4)	0	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	3 (4.3)	0	0
アクロコルドン	1 (1.4)	0	0
血管の良性新生物	1 (1.4)	0	0
脂漏性角化症	1 (1.4)	0	0
腎および尿路障害	2 (2.9)	0	0
水腎症	1 (1.4)	0	0
尿閉	1 (1.4)	0	0
生殖系および乳房障害	2 (2.9)	1 (3.0)	0
後天性包茎	1 (1.4)	0	0
陰茎障害	1 (1.4)	0	0
卵巣嚢胞	0	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 17 of 17

	North America	Europe	Asia-Pacific
肝胆道系障害	1 (1.4)	0	0
肝腫大	1 (1.4)	0	0
妊娠、産褥および周産期の状態	1 (1.4)	0	0
臍肉芽腫	1 (1.4)	0	0
外科および内科処置	1 (1.4)	0	0
機械的換気	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 76　Later-onset subjects: incidence of adverse events by geographic region

Later-onset subjects: incidence of adverse events by geographic region
Page 1 of 9

	North America	Europe	Asia-Pacific
Number of subjects dosed	56 (100.0)	0	0
Number of subjects with an event	56 (100.0)	0	0
感染症および寄生虫症	44 (78.6)	0	0
上気道感染	27 (48.2)	0	0
鼻咽頭炎	16 (28.6)	0	0
ウイルス感染	9 (16.1)	0	0
ウイルス性胃腸炎	8 (14.3)	0	0
レンサ球菌性咽頭炎	8 (14.3)	0	0
胃腸炎	7 (12.5)	0	0
中耳炎	5 (8.9)	0	0
肺炎	5 (8.9)	0	0
ウイルス性上気道感染	5 (8.9)	0	0
耳感染	4 (7.1)	0	0
尿路感染	4 (7.1)	0	0
結膜炎	3 (5.4)	0	0
インフルエンザ	3 (5.4)	0	0
限局性感染	3 (5.4)	0	0
ＲＳウイルス感染	3 (5.4)	0	0
副鼻腔炎	3 (5.4)	0	0
ウイルス性消化管感染	2 (3.6)	0	0
ウイルス性肺炎	2 (3.6)	0	0
皮膚カンジダ	2 (3.6)	0	0
蜂巣炎	1 (1.8)	0	0
ブドウ球菌性眼感染	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 2 of 9

	North America	Europe	Asia-Pacific
ウイルス性眼感染	1 (1.8)	0	0
皮膚真菌感染	1 (1.8)	0	0
手足口病	1 (1.8)	0	0
膿痂疹	1 (1.8)	0	0
下気道感染	1 (1.8)	0	0
伝染性軟属腫	1 (1.8)	0	0
単核細胞症症候群	1 (1.8)	0	0
急性中耳炎	1 (1.8)	0	0
咽頭炎	1 (1.8)	0	0
ＲＳウイルス肺炎	1 (1.8)	0	0
ＲＳウイルス細気管支炎	1 (1.8)	0	0
気道感染	1 (1.8)	0	0
ウイルス性気道感染	1 (1.8)	0	0
鼻炎	1 (1.8)	0	0
皮膚細菌感染	1 (1.8)	0	0
扁桃炎	1 (1.8)	0	0
腟感染	1 (1.8)	0	0
ウイルス性扁桃炎	1 (1.8)	0	0
外陰腟真菌感染	1 (1.8)	0	0
筋骨格系および結合組織障害	41 (73.2)	0	0
背部痛	23 (41.1)	0	0
側弯症	15 (26.8)	0	0
関節拘縮	10 (17.9)	0	0
関節痛	5 (8.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 3 of 9

	North America	Europe	Asia-Pacific
四肢痛	5 (8.9)	0	0
筋肉痛	4 (7.1)	0	0
頚部痛	3 (5.4)	0	0
筋緊張	2 (3.6)	0	0
骨盤変形	2 (3.6)	0	0
四肢拘縮	1 (1.8)	0	0
脊柱前弯症	1 (1.8)	0	0
傷害、中毒および処置合併症	40 (71.4)	0	0
腰椎穿刺後症候群	23 (41.1)	0	0
裂傷	7 (12.5)	0	0
処置による疼痛	6 (10.7)	0	0
節足動物咬傷	3 (5.4)	0	0
大腿骨骨折	3 (5.4)	0	0
四肢損傷	3 (5.4)	0	0
挫傷	2 (3.6)	0	0
関節脱臼	2 (3.6)	0	0
関節損傷	2 (3.6)	0	0
処置による悪心	2 (3.6)	0	0
サンバーン	2 (3.6)	0	0
隆起骨折	2 (3.6)	0	0
術後激越	1 (1.8)	0	0
節足動物刺傷	1 (1.8)	0	0
転倒	1 (1.8)	0	0
頭部損傷	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 4 of 9

	North America	Europe	Asia-Pacific
靭帯捻挫	1 (1.8)	0	0
下肢骨折	1 (1.8)	0	0
半月板損傷	1 (1.8)	0	0
肉離れ	1 (1.8)	0	0
術後イレウス	1 (1.8)	0	0
処置による頭痛	1 (1.8)	0	0
熱傷	1 (1.8)	0	0
脛骨骨折	1 (1.8)	0	0
一般・全身障害および投与部位の状態	31 (55.4)	0	0
発熱	16 (28.6)	0	0
穿刺部位疼痛	10 (17.9)	0	0
疲労	3 (5.4)	0	0
疼痛	2 (3.6)	0	0
カテーテル留置部位出血	1 (1.8)	0	0
カテーテル留置部位疼痛	1 (1.8)	0	0
カテーテル留置部位関連反応	1 (1.8)	0	0
胸部不快感	1 (1.8)	0	0
悪寒	1 (1.8)	0	0
冷感	1 (1.8)	0	0
重力性浮腫	1 (1.8)	0	0
低体温	1 (1.8)	0	0
注射部位出血	1 (1.8)	0	0
注射部位疼痛	1 (1.8)	0	0
末梢腫脹	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 5 of 9

	North America	Europe	Asia-Pacific
穿刺部位反応	1 (1.8)	0	0
血管穿刺部位内出血	1 (1.8)	0	0
神経系障害	30 (53.6)	0	0
頭痛	28 (50.0)	0	0
感覚鈍麻	2 (3.6)	0	0
失声症	1 (1.8)	0	0
味覚異常	1 (1.8)	0	0
失読症	1 (1.8)	0	0
片頭痛	1 (1.8)	0	0
錯感覚	1 (1.8)	0	0
失神	1 (1.8)	0	0
振戦	1 (1.8)	0	0
胃腸障害	26 (46.4)	0	0
嘔吐	12 (21.4)	0	0
悪心	10 (17.9)	0	0
便秘	7 (12.5)	0	0
アフタ性潰瘍	3 (5.4)	0	0
腹痛	2 (3.6)	0	0
上腹部痛	2 (3.6)	0	0
下痢	2 (3.6)	0	0
口腔内痛	2 (3.6)	0	0
腹部不快感	1 (1.8)	0	0
腹部症状	1 (1.8)	0	0
放屁	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 6 of 9

	North America	Europe	Asia-Pacific
食中毒	1 (1.8)	0	0
胃腸障害	1 (1.8)	0	0
胃食道逆流性疾患	1 (1.8)	0	0
口の感覚鈍麻	1 (1.8)	0	0
口唇痛	1 (1.8)	0	0
口内炎	1 (1.8)	0	0
呼吸器、胸郭および縦隔障害	25 (44.6)	0	0
口腔咽頭痛	8 (14.3)	0	0
咳嗽	6 (10.7)	0	0
鼻漏	6 (10.7)	0	0
鼻出血	3 (5.4)	0	0
低酸素症	3 (5.4)	0	0
鼻閉	3 (5.4)	0	0
扁桃肥大	3 (5.4)	0	0
副鼻腔うっ血	2 (3.6)	0	0
急性呼吸不全	1 (1.8)	0	0
無気肺	1 (1.8)	0	0
発声障害	1 (1.8)	0	0
呼吸困難	1 (1.8)	0	0
肺臓炎	1 (1.8)	0	0
肺うっ血	1 (1.8)	0	0
呼吸障害	1 (1.8)	0	0
呼吸不全	1 (1.8)	0	0
拘束性肺疾患	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 7 of 9

	North America	Europe	Asia-Pacific
喘鳴	1 (1.8)	0	0
皮膚および皮下組織障害	17 (30.4)	0	0
接触性皮膚炎	3 (5.4)	0	0
湿疹	2 (3.6)	0	0
ざ瘡	1 (1.8)	0	0
水疱	1 (1.8)	0	0
褥瘡性潰瘍	1 (1.8)	0	0
皮膚炎	1 (1.8)	0	0
おむつ皮膚炎	1 (1.8)	0	0
紅斑	1 (1.8)	0	0
毛孔性角化症	1 (1.8)	0	0
汗疹	1 (1.8)	0	0
寝汗	1 (1.8)	0	0
発疹	1 (1.8)	0	0
皮膚病変	1 (1.8)	0	0
蕁麻疹	1 (1.8)	0	0
臨床検査	8 (14.3)	0	0
体重減少	3 (5.4)	0	0
血中重炭酸塩減少	1 (1.8)	0	0
血中テストステロン減少	1 (1.8)	0	0
体温上昇	1 (1.8)	0	0
ＣＳＦ白血球数増加	1 (1.8)	0	0
心拍数増加	1 (1.8)	0	0
尿検査異常	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 8 of 9

	North America	Europe	Asia-Pacific
免疫系障害	7 (12.5)	0	0
過敏症	3 (5.4)	0	0
季節性アレルギー	3 (5.4)	0	0
薬物過敏症	1 (1.8)	0	0
代謝および栄養障害	5 (8.9)	0	0
脱水	2 (3.6)	0	0
食欲減退	1 (1.8)	0	0
食欲亢進	1 (1.8)	0	0
ビタミンD欠乏	1 (1.8)	0	0
精神障害	4 (7.1)	0	0
激越	2 (3.6)	0	0
注意欠陥多動性障害	1 (1.8)	0	0
不快気分	1 (1.8)	0	0
不眠症	1 (1.8)	0	0
睡眠時随伴症	1 (1.8)	0	0
チック	1 (1.8)	0	0
心因性嘔吐	1 (1.8)	0	0
心臓障害	3 (5.4)	0	0
動悸	2 (3.6)	0	0
頻脈	1 (1.8)	0	0
耳および迷路障害	3 (5.4)	0	0
耳痛	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 9 of 9

	North America	Europe	Asia-Pacific
乗物酔い	1 (1.8)	0	0
鼓膜穿孔	1 (1.8)	0	0
腎および尿路障害	3 (5.4)	0	0
排尿困難	1 (1.8)	0	0
尿失禁	1 (1.8)	0	0
膀胱尿管逆流	1 (1.8)	0	0
眼障害	2 (3.6)	0	0
遠視	1 (1.8)	0	0
斜視	1 (1.8)	0	0
血液およびリンパ系障害	1 (1.8)	0	0
好中球減少症	1 (1.8)	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.8)	0	0
皮膚乳頭腫	1 (1.8)	0	0
血管障害	1 (1.8)	0	0
低血圧	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 77　All Subjects Treated With ISIS 396443:Incidence of Adverse Events by Geographic Region

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 1 of 20

	North America	Europe	Asia-Pacific
Number of subjects dosed	126 (100.0)	33 (100.0)	14 (100.0)
Number of subjects with an event	121 (96.0)	29 (87.9)	11 (78.6)
感染症および寄生虫症	100 (79.4)	24 (72.7)	6 (42.9)
上気道感染	62 (49.2)	1 (3.0)	2 (14.3)
鼻咽頭炎	30 (23.8)	7 (21.2)	2 (14.3)
肺炎	20 (15.9)	8 (24.2)	2 (14.3)
ウイルス性上気道感染	17 (13.5)	0	0
ウイルス感染	15 (11.9)	5 (15.2)	0
中耳炎	14 (11.1)	0	0
ライノウイルス感染	12 (9.5)	3 (9.1)	0
ウイルス性肺炎	11 (8.7)	1 (3.0)	0
ウイルス性胃腸炎	10 (7.9)	0	0
レンサ球菌性咽頭炎	10 (7.9)	0	0
細気管支炎	8 (6.3)	2 (6.1)	2 (14.3)
胃腸炎	8 (6.3)	0	1 (7.1)
尿路感染	8 (6.3)	0	0
耳感染	7 (5.6)	2 (6.1)	0
気道感染	7 (5.6)	6 (18.2)	0
結膜炎	6 (4.8)	1 (3.0)	2 (14.3)
インフルエンザ	6 (4.8)	2 (6.1)	0
口腔カンジダ症	5 (4.0)	2 (6.1)	0
細菌性肺炎	4 (3.2)	0	0
ＲＳウイルス細気管支炎	4 (3.2)	1 (3.0)	0
ウイルス性気道感染	4 (3.2)	2 (6.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 2 of 20

	North America	Europe	Asia-Pacific
皮膚カンジダ	4 (3.2)	0	0
細菌性気管炎	3 (2.4)	0	0
皮膚真菌感染	3 (2.4)	0	0
限局性感染	3 (2.4)	1 (3.0)	0
ＲＳウイルス感染	3 (2.4)	0	0
副鼻腔炎	3 (2.4)	0	0
アデノウイルス感染	2 (1.6)	0	0
細菌感染	2 (1.6)	0	0
蜂巣炎	2 (1.6)	0	0
細菌性結膜炎	2 (1.6)	0	0
エンテロウイルス感染	2 (1.6)	0	0
ウイルス性消化管感染	2 (1.6)	0	0
手足口病	2 (1.6)	1 (3.0)	0
膿痂疹	2 (1.6)	1 (3.0)	0
下気道感染	2 (1.6)	2 (6.1)	1 (7.1)
ウイルス性下気道感染	2 (1.6)	1 (3.0)	0
メタニューモウイルス感染	2 (1.6)	0	0
急性中耳炎	2 (1.6)	0	0
パラインフルエンザウイルス感染	2 (1.6)	0	0
モラクセラ菌性肺炎	2 (1.6)	0	0
鼻炎	2 (1.6)	2 (6.1)	0
ストーマ部膿瘍	2 (1.6)	0	0
アデノウイルス性上気道感染	1 (0.8)	0	0
細菌性疾患キャリアー	1 (0.8)	0	0
気管支炎	1 (0.8)	5 (15.2)	0
ウイルス性気管支炎	1 (0.8)	2 (6.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 3 of 20

	North America	Europe	Asia-Pacific
カンジダ性おむつ皮疹	1 (0.8)	1 (3.0)	0
コロナウイルス感染	1 (0.8)	0	0
伝染性紅斑	1 (0.8)	0	0
眼感染	1 (0.8)	0	0
ブドウ球菌性眼感染	1 (0.8)	0	0
ウイルス性眼感染	1 (0.8)	0	0
ウイルス性胃炎	1 (0.8)	0	0
ヘモフィルス感染	1 (0.8)	0	0
伝染性軟属腫	1 (0.8)	0	0
単核細胞症症候群	1 (0.8)	0	0
モラクセラ感染	1 (0.8)	0	0
粘膜皮膚カンジダ症	1 (0.8)	0	0
院内感染	1 (0.8)	0	0
咽頭炎	1 (0.8)	0	0
インフルエンザ性肺炎	1 (0.8)	0	0
シュードモナス菌性肺炎	1 (0.8)	0	0
ＲＳウイルス肺炎	1 (0.8)	1 (3.0)	0
シュードモナス感染	1 (0.8)	0	0
細菌性気道感染	1 (0.8)	0	0
敗血症	1 (0.8)	0	0
皮膚細菌感染	1 (0.8)	0	0
皮膚感染	1 (0.8)	0	0
ブドウ球菌性菌血症	1 (0.8)	0	0
ブドウ球菌感染	1 (0.8)	0	0
ブドウ球菌性敗血症	1 (0.8)	0	0
扁桃炎	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 4 of 20

	North America	Europe	Asia-Pacific
気管炎	1 (0.8)	0	0
膣感染	1 (0.8)	0	0
ウイルス性扁桃炎	1 (0.8)	0	0
外陰膣真菌感染	1 (0.8)	0	0
感染性湿疹	0	0	1 (7.1)
真菌感染	0	1 (3.0)	0
ロタウイルス胃腸炎	0	1 (3.0)	0
肺感染	0	0	1 (7.1)
口腔ヘルペス	0	1 (3.0)	0
パラインフルエンザウイルス性肺炎	0	0	1 (7.1)
ばら疹	0	1 (3.0)	0
ブドウ球菌皮膚感染	0	1 (3.0)	0
胃腸障害	78 (61.9)	13 (39.4)	5 (35.7)
便秘	32 (25.4)	7 (21.2)	2 (14.3)
嘔吐	27 (21.4)	4 (12.1)	1 (7.1)
胃食道逆流性疾患	15 (11.9)	3 (9.1)	0
下痢	13 (10.3)	2 (6.1)	0
生歯	13 (10.3)	1 (3.0)	2 (14.3)
嚥下障害	10 (7.9)	0	0
悪心	10 (7.9)	0	0
放屁	8 (6.3)	0	0
腹部膨満	6 (4.8)	0	0
流涎過多	5 (4.0)	0	0
腹痛	3 (2.4)	0	0
アフタ性潰瘍	3 (2.4)	0	1 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 5 of 20

	North America	Europe	Asia-Pacific
胃炎	3 (2.4)	1 (3.0)	0
腹部不快感	2 (1.6)	1 (3.0)	0
上腹部痛	2 (1.6)	0	0
血便排泄	2 (1.6)	0	0
口腔内痛	2 (1.6)	0	0
腹部症状	1 (0.8)	0	0
口唇のひび割れ	1 (0.8)	0	0
食中毒	1 (0.8)	0	0
排便回数増加	1 (0.8)	0	0
胃出血	1 (0.8)	0	0
胃腸障害	1 (0.8)	0	0
消化管運動低下	1 (0.8)	0	0
吐血	1 (0.8)	0	0
口の感覚鈍麻	1 (0.8)	0	0
乳児仙痛	1 (0.8)	0	0
乳児吐血	1 (0.8)	0	0
口唇痛	1 (0.8)	0	0
口内炎	1 (0.8)	0	0
上部消化管出血	1 (0.8)	0	0
呼吸器、胸郭および縦隔障害	76 (60.3)	24 (72.7)	3 (21.4)
鼻閉	20 (15.9)	0	0
呼吸窮迫	19 (15.1)	8 (24.2)	0
咳嗽	17 (13.5)	3 (9.1)	0
呼吸不全	17 (13.5)	7 (21.2)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 6 of 20

	North America	Europe	Asia-Pacific
急性呼吸不全	16 (12.7)	0	0
無気肺	14 (11.1)	7 (21.2)	0
低酸素症	13 (10.3)	0	0
鼻漏	11 (8.7)	2 (6.1)	0
誤嚥性肺炎	9 (7.1)	1 (3.0)	0
口腔咽頭痛	8 (6.3)	0	0
誤嚥	6 (4.8)	0	0
慢性呼吸不全	6 (4.8)	0	0
上気道分泌増加	6 (4.8)	0	0
副鼻腔うっ血	6 (4.8)	0	0
上気道うっ血	6 (4.8)	1 (3.0)	0
無呼吸	5 (4.0)	2 (6.1)	0
気管支分泌物貯留	5 (4.0)	1 (3.0)	0
呼吸困難	5 (4.0)	2 (6.1)	3 (21.4)
喘鳴	4 (3.2)	0	0
鼻出血	3 (2.4)	0	0
低換気	3 (2.4)	0	0
気胸	3 (2.4)	0	0
肺うっ血	3 (2.4)	0	0
扁桃肥大	3 (2.4)	0	0
肺水腫	2 (1.6)	0	0
呼吸停止	2 (1.6)	2 (6.1)	0
拘束性肺疾患	2 (1.6)	0	0
アレルギー性鼻炎	2 (1.6)	0	0
呼吸補助筋の動員	2 (1.6)	0	0
急性呼吸窮迫症候群	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 7 of 20

	North America	Europe	Asia-Pacific
無呼吸発作	1 (0.8)	0	0
窒息	1 (0.8)	0	0
息詰まり	1 (0.8)	1 (3.0)	0
発声障害	1 (0.8)	0	0
高炭酸ガス血症	1 (0.8)	0	0
減呼吸	1 (0.8)	0	0
喉頭肉芽腫	1 (0.8)	0	0
鼻汁変色	1 (0.8)	0	0
胸水	1 (0.8)	0	0
気縦隔症	1 (0.8)	0	0
肺臓炎	1 (0.8)	0	0
湿性咳嗽	1 (0.8)	0	0
呼吸性アルカローシス	1 (0.8)	0	0
呼吸障害	1 (0.8)	2 (6.1)	0
気道うっ血	1 (0.8)	0	0
低音性連続性ラ音	1 (0.8)	0	0
睡眠時無呼吸症候群	1 (0.8)	0	0
変色痰	1 (0.8)	0	0
頻呼吸	1 (0.8)	0	0
気管障害	1 (0.8)	0	0
気管支閉塞	0	1 (3.0)	0
気管支分泌増加	0	1 (3.0)	0
肺障害	0	1 (3.0)	0
閉塞性気道障害	0	1 (3.0)	0
呼吸性アシドーシス	0	1 (3.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 8 of 20

	North America	Europe	Asia-Pacific
一般・全身障害および投与部位の状態	72 (57.1)	18 (54.5)	3 (21.4)
発熱	53 (42.1)	16 (48.5)	3 (21.4)
穿刺部位疼痛	10 (7.9)	0	0
疼痛	7 (5.6)	0	0
疲労	3 (2.4)	0	0
不快感	2 (1.6)	0	0
低体温	2 (1.6)	0	0
末梢性浮腫	2 (1.6)	0	0
末梢腫脹	2 (1.6)	0	0
血管穿刺部位内出血	2 (1.6)	0	0
適用部位紅斑	1 (0.8)	0	0
カテーテル留置部位出血	1 (0.8)	0	0
カテーテル留置部位炎症	1 (0.8)	0	0
カテーテル留置部位疼痛	1 (0.8)	0	0
カテーテル留置部位関連反応	1 (0.8)	0	0
胸部不快感	1 (0.8)	0	0
悪寒	1 (0.8)	0	0
泣き	1 (0.8)	0	0
医療機器リーク	1 (0.8)	0	0
医療機器閉塞	1 (0.8)	0	0
薬物不耐性	1 (0.8)	0	0
冷感	1 (0.8)	0	0
重力性浮腫	1 (0.8)	0	0
注入部位内出血	1 (0.8)	0	0
注射部位出血	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 9 of 20

	North America	Europe	Asia-Pacific
注射部位疼痛	1 (0.8)	0	0
小結節	1 (0.8)	0	0
浮腫	1 (0.8)	0	0
穿刺部位反応	1 (0.8)	0	0
腫脹	1 (0.8)	0	0
死亡	0	1 (3.0)	0
ワクチン接種後の易刺激性	0	1 (3.0)	0
倦怠感	0	1 (3.0)	0
筋骨格系および結合組織障害	66 (52.4)	2 (6.1)	0
側弯症	25 (19.8)	1 (3.0)	0
背部痛	24 (19.0)	0	0
関節拘縮	21 (16.7)	1 (3.0)	0
四肢痛	7 (5.6)	0	0
関節痛	5 (4.0)	0	0
脊柱後弯症	5 (4.0)	0	0
胸郭変形	4 (3.2)	0	0
筋肉痛	4 (3.2)	0	0
頚部痛	3 (2.4)	0	0
斜頚	3 (2.4)	0	0
後側弯症	2 (1.6)	0	0
脊柱前弯症	2 (1.6)	0	0
筋緊張	2 (1.6)	0	0
骨盤変形	2 (1.6)	0	0
頭位性斜頭症	2 (1.6)	1 (3.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 10 of 20

	North America	Europe	Asia-Pacific
泉門閉鎖遅延	1 (0.8)	0	0
四肢拘縮	1 (0.8)	0	0
手変形	1 (0.8)	0	0
関節硬直	1 (0.8)	0	0
筋力低下	1 (0.8)	0	0
脊柱変形	1 (0.8)	0	0
滑膜炎	1 (0.8)	0	0
体重支持困難	1 (0.8)	0	0
傷害、中毒および処置合併症	65 (51.6)	4 (12.1)	0
腰椎穿刺後症候群	23 (18.3)	0	0
処置による疼痛	10 (7.9)	0	0
裂傷	7 (5.6)	0	0
節足動物咬傷	6 (4.8)	0	0
大腿骨骨折	5 (4.0)	0	0
挫傷	4 (3.2)	0	0
関節脱臼	4 (3.2)	0	0
四肢損傷	3 (2.4)	0	0
ストーマ部紅斑	3 (2.4)	0	0
サンバーン	3 (2.4)	0	0
術後激越	2 (1.6)	0	0
転倒	2 (1.6)	0	0
栄養補給チューブ合併症	2 (1.6)	0	0
関節損傷	2 (1.6)	0	0
処置後腫脹	2 (1.6)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 11 of 20

	North America	Europe	Asia-Pacific
処置による悪心	2 (1.6)	0	0
皮膚擦過傷	2 (1.6)	0	0
熱傷	2 (1.6)	0	0
隆起骨折	2 (1.6)	0	0
節足動物刺傷	1 (0.8)	0	0
ダンピング症候群	1 (0.8)	0	0
耳擦過傷	1 (0.8)	0	0
擦過傷	1 (0.8)	0	0
頭部損傷	1 (0.8)	0	0
靭帯捻挫	1 (0.8)	0	0
口唇損傷	1 (0.8)	0	0
下肢骨折	1 (0.8)	0	0
半月板損傷	1 (0.8)	0	0
肉離れ	1 (0.8)	0	0
外傷性気胸	1 (0.8)	0	0
処置後合併症	1 (0.8)	0	0
処置後不快感	1 (0.8)	0	0
術後イレウス	1 (0.8)	0	0
処置による頭痛	1 (0.8)	0	0
処置部位反応	1 (0.8)	0	0
軟部組織損傷	1 (0.8)	0	0
ストーマ合併症	1 (0.8)	0	0
硬膜下血腫	1 (0.8)	0	0
脛骨骨折	1 (0.8)	0	0
歯牙損傷	1 (0.8)	0	0
創離開	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 12 of 20

	North America	Europe	Asia-Pacific
麻酔からの覚醒遅延	0	1 (3.0)	0
伝染病曝露	0	1 (3.0)	0
処置合併症	0	1 (3.0)	0
ワクチン接種合併症	0	1 (3.0)	0
皮膚および皮下組織障害	54 (42.9)	3 (9.1)	1 (7.1)
発疹	13 (10.3)	0	1 (7.1)
おむつ皮膚炎	12 (9.5)	1 (3.0)	0
接触性皮膚炎	6 (4.8)	0	0
湿疹	5 (4.0)	0	1 (7.1)
皮膚炎	3 (2.4)	2 (6.1)	0
斑状出血	3 (2.4)	0	0
紅斑	3 (2.4)	0	0
過剰肉芽組織	3 (2.4)	0	0
皮膚刺激	3 (2.4)	0	0
過角化	2 (1.6)	0	0
汗疹	2 (1.6)	0	1 (7.1)
蕁麻疹	2 (1.6)	0	0
ざ瘡	1 (0.8)	0	0
脱毛症	1 (0.8)	0	0
水疱	1 (0.8)	0	0
褥瘡性潰瘍	1 (0.8)	0	0
アレルギー性皮膚炎	1 (0.8)	0	0
貨幣状湿疹	1 (0.8)	0	0
環状肉芽腫	1 (0.8)	0	0
毛孔性角化症	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 13 of 20

	North America	Europe	Asia-Pacific
寝汗	1 (0.8)	0	0
点状出血	1 (0.8)	0	0
そう痒症	1 (0.8)	0	0
丘疹性皮疹	1 (0.8)	0	0
脂漏性皮膚炎	1 (0.8)	0	0
皮膚色素脱失	1 (0.8)	0	0
皮膚障害	1 (0.8)	0	0
皮膚病変	1 (0.8)	0	0
皮膚浮腫	1 (0.8)	0	0
皮膚潰瘍	1 (0.8)	0	0
皮下気腫	1 (0.8)	0	0
神経系障害	47 (37.3)	2 (6.1)	0
頭痛	29 (23.0)	0	0
不随意性筋収縮	3 (2.4)	1 (3.0)	0
眼振	3 (2.4)	0	0
よだれ	2 (1.6)	0	0
感覚鈍麻	2 (1.6)	0	0
痙攣発作	2 (1.6)	0	0
失神	2 (1.6)	0	0
失声症	1 (0.8)	0	0
脳損傷	1 (0.8)	0	0
脳梗塞	1 (0.8)	0	0
脳脊髄液漏	1 (0.8)	0	0
味覚異常	1 (0.8)	0	0
失読症	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 14 of 20

	North America	Europe	Asia-Pacific
反射亢進	1 (0.8)	0	0
筋緊張低下	1 (0.8)	0	0
低酸素性虚血性脳症	1 (0.8)	0	0
嗜眠	1 (0.8)	0	0
片頭痛	1 (0.8)	0	0
錯感覚	1 (0.8)	0	0
傾眠	1 (0.8)	0	0
振戦	1 (0.8)	0	0
間代	0	1 (3.0)	0
臨床検査	23 (18.3)	9 (27.3)	1 (7.1)
酸素飽和度低下	8 (6.3)	1 (3.0)	1 (7.1)
体重減少	5 (4.0)	3 (9.1)	0
心拍数増加	3 (2.4)	0	0
好中球数増加	3 (2.4)	0	0
ヒトライノウイルス検査陽性	2 (1.6)	1 (3.0)	0
ブドウ球菌検査陽性	2 (1.6)	0	0
白血球数増加	2 (1.6)	0	0
アラニンアミノトランスフェラーゼ増加	1 (0.8)	1 (3.0)	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (0.8)	1 (3.0)	0
血中重炭酸塩減少	1 (0.8)	0	0
血中テストステロン減少	1 (0.8)	0	0
体温低下	1 (0.8)	0	0
体温上昇	1 (0.8)	2 (6.1)	0
骨密度減少	1 (0.8)	0	0
呼吸音異常	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 15 of 20

	North America	Europe	Asia-Pacific
ＣＳＦ白血球数増加	1 (0.8)	0	0
心電図ＳＴ－Ｔ部分異常	1 (0.8)	0	0
心拍数減少	1 (0.8)	0	0
心拍数不整	1 (0.8)	0	0
炎症マーカー上昇	1 (0.8)	0	0
Ａ型インフルエンザウイルス検査陽性	1 (0.8)	0	0
肝機能検査異常	1 (0.8)	0	0
モラクセラ検査陽性	1 (0.8)	1 (3.0)	0
好中球百分率増加	1 (0.8)	0	0
シュードモナス検査陽性	1 (0.8)	1 (3.0)	0
セラチア検査陽性	1 (0.8)	0	0
レンサ球菌検査陽性	1 (0.8)	0	0
尿検査異常	1 (0.8)	0	0
ビタミンＡ減少	1 (0.8)	0	0
血中クロール減少	0	1 (3.0)	0
血中鉄減少	0	1 (3.0)	0
血中カリウム減少	0	2 (6.1)	0
血中ナトリウム減少	0	1 (3.0)	0
Ｃ－反応性蛋白増加	0	2 (6.1)	0
医学的観察	0	1 (3.0)	0
尿量減少	0	1 (3.0)	0
心臓障害	21 (16.7)	5 (15.2)	1 (7.1)
頻脈	9 (7.1)	2 (6.1)	0
徐脈	6 (4.8)	1 (3.0)	0
心肺停止	4 (3.2)	2 (6.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 16 of 20

	North America	Europe	Asia-Pacific
チアノーゼ	3 (2.4)	0	0
心停止	2 (1.6)	1 (3.0)	0
動悸	2 (1.6)	0	0
心筋症	1 (0.8)	0	0
左室肥大	1 (0.8)	0	0
心膜気腫	1 (0.8)	0	0
上室性頻脈	1 (0.8)	0	0
心室性頻脈	1 (0.8)	0	1 (7.1)
免疫系障害	19 (15.1)	1 (3.0)	0
季節性アレルギー	9 (7.1)	0	0
薬物過敏症	5 (4.0)	0	0
過敏症	4 (3.2)	1 (3.0)	0
食物アレルギー	1 (0.8)	0	0
代謝および栄養障害	19 (15.1)	6 (18.2)	0
脱水	4 (3.2)	0	0
成長障害	4 (3.2)	0	0
体重増加不良	3 (2.4)	4 (12.1)	0
栄養補給不耐性	2 (1.6)	1 (3.0)	0
低ナトリウム血症	2 (1.6)	0	0
過小食	2 (1.6)	0	0
食欲減退	1 (0.8)	0	0
乳児および小児期早期の哺育障害	1 (0.8)	2 (6.1)	0
食欲亢進	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 17 of 20

	North America	Europe	Asia-Pacific
鉄欠乏	1 (0.8)	0	0
代謝性アルカローシス	1 (0.8)	0	0
ビタミンD欠乏	1 (0.8)	0	0
精神障害	12 (9.5)	2 (6.1)	1 (7.1)
激越	4 (3.2)	0	0
不安	4 (3.2)	1 (3.0)	0
注意欠陥多動性障害	1 (0.8)	0	0
息こらえ	1 (0.8)	0	0
不快気分	1 (0.8)	0	0
不眠症	1 (0.8)	0	0
易刺激性	1 (0.8)	1 (3.0)	0
睡眠時随伴症	1 (0.8)	0	0
落ち着きのなさ	1 (0.8)	0	0
チック	1 (0.8)	0	0
心因性嘔吐	1 (0.8)	0	0
気分動揺	0	0	1 (7.1)
睡眠障害	0	1 (3.0)	0
眼障害	9 (7.1)	0	0
斜視	2 (1.6)	0	0
乱視	1 (0.8)	0	0
霰粒腫	1 (0.8)	0	0
後天性涙道狭窄	1 (0.8)	0	0
眼乾燥	1 (0.8)	0	0
眼運動障害	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 18 of 20

	North America	Europe	Asia-Pacific
眼瞼下垂	1 (0.8)	0	0
遠視	1 (0.8)	0	0
近視	1 (0.8)	0	0
血液およびリンパ系障害	8 (6.3)	1 (3.0)	0
貧血	3 (2.4)	0	0
好中球減少症	2 (1.6)	1 (3.0)	0
好酸球増加症	1 (0.8)	0	0
リンパ節症	1 (0.8)	0	0
血小板増加症	1 (0.8)	0	0
血管障害	7 (5.6)	3 (9.1)	0
高血圧	3 (2.4)	0	0
毛細血管脆弱	1 (0.8)	0	0
本態性高血圧症	1 (0.8)	0	0
低血圧	1 (0.8)	0	0
ショック	1 (0.8)	0	0
蒼白	0	2 (6.1)	0
血管炎	0	1 (3.0)	0
耳および迷路障害	6 (4.8)	0	0
耳痛	2 (1.6)	0	0
耳の障害	1 (0.8)	0	0
耳垢分泌過多	1 (0.8)	0	0
乗物酔い	1 (0.8)	0	0
鼓膜穿孔	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 19 of 20

	North America	Europe	Asia-Pacific
先天性、家族性および遺伝性障害	5 (4.0)	1 (3.0)	0
斜頭症	2 (1.6)	0	0
斜指症	1 (0.8)	0	0
発育性股関節形成不全	1 (0.8)	0	0
鳩胸	1 (0.8)	0	0
貧血母斑	0	1 (3.0)	0
腎および尿路障害	5 (4.0)	0	0
排尿困難	1 (0.8)	0	0
水腎症	1 (0.8)	0	0
尿失禁	1 (0.8)	0	0
尿閉	1 (0.8)	0	0
膀胱尿管逆流	1 (0.8)	0	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	4 (3.2)	0	0
アクロコルドン	1 (0.8)	0	0
血管の良性新生物	1 (0.8)	0	0
脂漏性角化症	1 (0.8)	0	0
皮膚乳頭腫	1 (0.8)	0	0
生殖系および乳房障害	2 (1.6)	1 (3.0)	0
後天性包茎	1 (0.8)	0	0
陰茎障害	1 (0.8)	0	0
卵巣嚢胞	0	1 (3.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 20 of 20

	North America	Europe	Asia-Pacific
肝胆道系障害	1 (0.8)	0	0
肝腫大	1 (0.8)	0	0
妊娠、産褥および周産期の状態	1 (0.8)	0	0
臍肉芽腫	1 (0.8)	0	0
外科および内科処置	1 (0.8)	0	0
機械的換気	1 (0.8)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 78　Later-Onset Subjects:Listing of Serious Adverse Events

Later-onset subjects: listing of serious adverse events
Page 1 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1202	396443-CS2	321	321	PSEUDO ALLERGIC REACTION PRESUMABLY TO OPIOID (FENTANYL)	薬物過敏症	SEVERE	UNLIKELY

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted]　　DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 2 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1204	396443-CS2	533	536	PNEUMONIA	肺炎	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 3 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1407	396443-CS12	817	819	HUMAN METAPNEUMOVIRUS PNEUMONITIS	ウイルス性肺炎	SEVERE	NOT RELATED
	396443-CS12	897	898	RESPIRATORY DISTRESS (SHORTNESS OF BREATH)	呼吸困難	SEVERE	NOT RELATED
	396443-CS12	1018	1043	PNEUMONIA	肺炎	SEVERE	NOT RELATED
	396443-CS12	1018	1043	RESPIRATORY FAILURE	呼吸不全	SEVERE	NOT RELATED
	396443-CS12	1018	1043	RSV BRONCHIOLITIS	ＲＳウイルス細気管支炎	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 4 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1412	396443-CS12	812	813	EARLY GASTROENTERITIS	胃腸炎	MODERATE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 5 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1416	396443-CS12	494	498	POST LP HEADACHE	腰椎穿刺後症候群	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 6 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1417	396443-CS12	1017	1020	LOWER RESPIRATORY TRACT INFECTION	下気道感染	SEVERE	NOT RELATED
	396443-CS12	1017	1020	VIRAL PNEUMONIA	ウイルス性肺炎	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 7 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1445	396443-CS12	664	675	ACUTE RESPIRATORY FAILURE WITH HYPOXIA	急性呼吸不全	MODERATE	NOT RELATED
	396443-CS12	664	675	RSV PNEUMONIA	ＲＳウイルス肺炎	MODERATE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 8 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
4207	396443-CS2	4	7	POST-LUMBAR PUNCTURE HEADACHE	腰椎穿刺後症候群	MODERATE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 79　Later-Onset Subjects:Listing of Adverse Events That Led to Discontinuation of Study Drug

Later-onset subjects: listing of adverse events that led to discontinuation of study drug

No Adverse Events Reported That Led To Discontinuation Of Study Drug

SOURCE:[redacted]　DATE:[redacted]
##[redacted]20[redacted]##

表 80　All Subjects Treated With ISIS 396443:Listing of Adverse Events That Led to Discontinuation of Study Drug

All subjects treated with ISIS 396443: listing of adverse events that led to discontinuation of study drug
Page 1 of 2

Subject number	Day of onset	Day of resolution	Date of last dose	Adverse event		Severity (b)	Relationship to study drug(b)
				Investigator term(a)	Preferred term (MedDRA)		
2302	150	163	18MAR2014	RESPIRATORY FAILURE*	呼吸不全	SEVERE	UNLIKELY
2304	40	62	07JAN2014	RESPIRATORY FAILURE*	呼吸不全	SEVERE	NOT RELATED
2311	113	120	08JUL2014	LOWER RESPIRATORY TRACT INFECTION VIRAL*	ウイルス性下気道感染	SEVERE	NOT RELATED
1776-5041	4	6	04MAY2015	RESPIRATORY FAILURE*	呼吸不全	SEVERE	NOT RELATED
1780-5032	54	60	12FEB2016	HYPOXIC BRAIN INJURY*	脳損傷	SEVERE	NOT RELATED
2000-5109	213	214	31JUL2015	ACUTE ON CHRONIC RESPIRATORY FAILURE*	急性呼吸不全	SEVERE	NOT RELATED
2000-5145	33	35	30NOV2014	HYPOXIC-ISCHEMIC ENCEPHALOPATHY*	低酸素性虚血性脳症	SEVERE	NOT RELATED
2000-5418	113	113	12JAN2015	RESPIRATORY FAILURE*	呼吸不全	SEVERE	NOT RELATED
2003-5363	122	122	25DEC2015	CARDIO RESPIRATORY ARREST*	心肺停止	SEVERE	UNLIKELY
2006-5059	79	80	16APR2016	RESPIRATORY FAILURE FOLLOWING PARTIAL PNEUMONIA*	呼吸不全	SEVERE	NOT RELATED

NOTE:(a) *=Adverse Event was serious
(b) Investigator assessment.

SOURCE:[redacted]　　DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: listing of adverse events that led to discontinuation of study drug
Page 2 of 2

Subject number	Day of onset	Day of resolution	Date of last dose	Adverse event: Investigator term(a)	Adverse event: Preferred term (MedDRA)	Severity (b)	Relationship to study drug(b)
2006-5223	192	192	05DEC2015	RESPIRATORY ARREST DUE TO LOWER RESPIRATORY TRACT INFECTION*	呼吸停止	SEVERE	NOT RELATED
2008-5403	84	84	20MAY2015	CARDIO RESPIRATORY ARREST*	心肺停止	SEVERE	NOT RELATED
2010-5219	36	44	23APR2015	RESPIRATORY INSUFFICIENCY*	呼吸不全	SEVERE	NOT RELATED
2037-5009	142	143	11NOV2015	RESPIRATORY DISNESS*	呼吸窮迫	SEVERE	NOT RELATED
2037-5167	82	82	12SEP2015	DEATH DURING ASLEEP*	死亡	SEVERE	NOT RELATED

NOTE:(a) *=Adverse Event was serious
(b) Investigator assessment.

SOURCE:[redacted] DATE:[redacted]
##[redacted]20[redacted]##

9　付録

表 108 SMA と診断された乳児における重篤な有害事象の発現率

Incidence of serious adverse events in infants diagnosed with SMA
Page 1 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	6 (30.0)	39 (95.1)	61 (76.3)	77 (77.0)	83 (69.2)
呼吸器、胸郭および縦隔障害	2 (10.0)	30 (73.2)	48 (60.0)	63 (63.0)	65 (54.2)
呼吸窮迫	1 (5.0)	8 (19.5)	21 (26.3)	27 (27.0)	28 (23.3)
呼吸不全	0	16 (39.0)	20 (25.0)	25 (25.0)	25 (20.8)
無気肺	0	4 (9.8)	14 (17.5)	16 (16.0)	16 (13.3)
急性呼吸不全	0	9 (22.0)	11 (13.8)	15 (15.0)	15 (12.5)
誤嚥性肺炎	0	5 (12.2)	8 (10.0)	10 (10.0)	10 (8.3)
低酸素症	0	1 (2.4)	4 (5.0)	5 (5.0)	5 (4.2)
呼吸停止	0	4 (9.8)	5 (6.3)	5 (5.0)	5 (4.2)
無呼吸	0	2 (4.9)	2 (2.5)	4 (4.0)	4 (3.3)
誤嚥	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.3)
呼吸困難	0	2 (4.9)	4 (5.0)	4 (4.0)	4 (3.3)
低換気	0	0	1 (1.3)	2 (2.0)	2 (1.7)
呼吸障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
急性呼吸窮迫症候群	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
窒息	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in infants diagnosed with SMA
Page 2 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
気管支分泌物貯留	0	5 (12.2)	1 (1.3)	1 (1.0)	1 (0.8)
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気管支分泌増加	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肺障害	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気縦隔症	0	0	0	1 (1.0)	1 (0.8)
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
息詰まり	1 (5.0)	0	0	0	1 (0.8)
気道うっ血	0	1 (2.4)	0	0	0
感染症および寄生虫症	4 (20.0)	19 (46.3)	47 (58.8)	60 (60.0)	64 (53.3)
肺炎	2 (10.0)	5 (12.2)	19 (23.8)	23 (23.0)	25 (20.8)
ライノウイルス感染	1 (5.0)	2 (4.9)	7 (8.8)	11 (11.0)	12 (10.0)
ウイルス性肺炎	0	2 (4.9)	6 (7.5)	8 (8.0)	8 (6.7)
細気管支炎	0	1 (2.4)	4 (5.0)	7 (7.0)	7 (5.8)
気道感染	0	1 (2.4)	6 (7.5)	7 (7.0)	7 (5.8)
ウイルス感染	0	1 (2.4)	5 (6.3)	7 (7.0)	7 (5.8)
ＲＳウイルス細気管支炎	0	3 (7.3)	4 (5.0)	5 (5.0)	5 (4.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in infants diagnosed with SMA
Page 3 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
上気道感染	0	0	4 (5.0)	5 (5.0)	5 (4.2)
気管支炎	1 (5.0)	0	4 (5.0)	4 (4.0)	5 (4.2)
下気道感染	0	0	4 (5.0)	4 (4.0)	4 (3.3)
細菌性肺炎	0	2 (4.9)	3 (3.8)	4 (4.0)	4 (3.3)
ウイルス性上気道感染	0	6 (14.6)	3 (3.8)	4 (4.0)	4 (3.3)
ウイルス性気管支炎	0	0	3 (3.8)	3 (3.0)	3 (2.5)
尿路感染	1 (5.0)	0	3 (3.8)	3 (3.0)	4 (3.3)
ウイルス性下気道感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)
ウイルス性気道感染	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
コロナウイルス感染	0	1 (2.4)	0	1 (1.0)	1 (0.8)
耳感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
エンテロウイルス感染	0	0	0	1 (1.0)	1 (0.8)
ロタウイルス胃腸炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
モラクセラ感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
鼻咽頭炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
パラインフルエンザウイルス感染	0	0	0	1 (1.0)	1 (0.8)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
モラクセラ菌性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in infants diagnosed with SMA
Page 4 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
パラインフルエンザウイルス性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
肺炎球菌性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
シュードモナス菌性肺炎	0	1 (2.4)	0	1 (1.0)	1 (0.8)
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腎盂腎炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ部膿瘍	0	0	1 (1.3)	1 (1.0)	1 (0.8)
カンジダ性敗血症	0	1 (2.4)	0	0	0
全身性感染	0	1 (2.4)	0	0	0
心臓障害	0	7 (17.1)	9 (11.3)	12 (12.0)	12 (10.0)
心肺停止	0	5 (12.2)	5 (6.3)	6 (6.0)	6 (5.0)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
チアノーゼ	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
徐脈	0	0	0	1 (1.0)	1 (0.8)
心膜気腫	0	0	0	1 (1.0)	1 (0.8)
洞性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.8)
代謝および栄養障害	2 (10.0)	5 (12.2)	8 (10.0)	10 (10.0)	12 (10.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in infants diagnosed with SMA
Page 5 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
体重増加不良	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.5)
成長障害	1 (5.0)	1 (2.4)	1 (1.3)	2 (2.0)	3 (2.5)
乳児および小児期早期の哺育障害	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
栄養補給不耐性	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脱水	1 (5.0)	1 (2.4)	1 (1.3)	1 (1.0)	2 (1.7)
低ナトリウム血症	0	0	0	1 (1.0)	1 (0.8)
胃腸障害	1 (5.0)	5 (12.2)	6 (7.5)	7 (7.0)	8 (6.7)
嘔吐	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.3)
嚥下障害	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
胃出血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腹部膨満	1 (5.0)	0	0	0	1 (0.8)
胃腸出血	0	1 (2.4)	0	0	0
レッチング	0	1 (2.4)	0	0	0
流涎過多	0	1 (2.4)	0	0	0
一般・全身障害および投与部位の状態	1 (5.0)	1 (2.4)	7 (8.8)	7 (7.0)	8 (6.7)
発熱	1 (5.0)	0	4 (5.0)	4 (4.0)	5 (4.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in infants diagnosed with SMA
Page 6 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
全身健康状態低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)
外科手術不成功	0	0	1 (1.3)	1 (1.0)	1 (0.8)
傷害、中毒および処置合併症	0	3 (7.3)	3 (3.8)	3 (3.0)	3 (2.5)
麻酔からの覚醒遅延	0	0	1 (1.3)	1 (1.0)	1 (0.8)
栄養補給チューブ合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ワクチン接種合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
大腿骨骨折	0	1 (2.4)	0	0	0
頭部損傷	0	1 (2.4)	0	0	0
気管出血	0	1 (2.4)	0	0	0
気管閉塞	0	1 (2.4)	0	0	0
臨床検査	0	3 (7.3)	3 (3.8)	3 (3.0)	3 (2.5)
医学的観察	0	0	2 (2.5)	2 (2.0)	2 (1.7)
酸素飽和度低下	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
体温上昇	0	1 (2.4)	0	0	0
心拍数減少	0	1 (2.4)	0	0	0
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in infants diagnosed with SMA
Page 7 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
神経系障害	0	0	2 (2.5)	3 (3.0)	3 (2.5)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
痙攣発作	0	0	0	1 (1.0)	1 (0.8)
血管障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血栓症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
筋骨格系および結合組織障害	0	0	0	1 (1.0)	1 (0.8)
滑膜炎	0	0	0	1 (1.0)	1 (0.8)
皮膚および皮下組織障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
精神障害	0	1 (2.4)	0	0	0
激越	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 109　SMA と診断された被験者における重篤な有害事象の発現率

Incidence of serious adverse events in subjects diagnosed with SMA
Page 1 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	6 (30.0)	77 (77.0)	83 (69.2)	7 (12.5)	90 (51.1)
感染症および寄生虫症	4 (20.0)	60 (60.0)	64 (53.3)	4 (7.1)	68 (38.6)
肺炎	2 (10.0)	23 (23.0)	25 (20.8)	1 (1.8)	26 (14.8)
ライノウイルス感染	1 (5.0)	11 (11.0)	12 (10.0)	0	12 (6.8)
ウイルス性肺炎	0	8 (8.0)	8 (6.7)	2 (3.6)	10 (5.7)
細気管支炎	0	7 (7.0)	7 (5.8)	0	7 (4.0)
気道感染	0	7 (7.0)	7 (5.8)	0	7 (4.0)
ウイルス感染	0	7 (7.0)	7 (5.8)	0	7 (4.0)
ＲＳウイルス細気管支炎	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
気管支炎	1 (5.0)	4 (4.0)	5 (4.2)	0	5 (2.8)
下気道感染	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
上気道感染	0	5 (5.0)	5 (4.2)	0	5 (2.8)
細菌性肺炎	0	4 (4.0)	4 (3.3)	0	4 (2.3)
尿路感染	1 (5.0)	3 (3.0)	4 (3.3)	0	4 (2.3)
ウイルス性上気道感染	0	4 (4.0)	4 (3.3)	0	4 (2.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of serious adverse events in subjects diagnosed with SMA
Page 2 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ウイルス性気管支炎	0	3 (3.0)	3 (2.5)	0	3 (1.7)
ウイルス性下気道感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
ウイルス性気道感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
コロナウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
耳感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
エンテロウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃腸炎	0	0	0	1 (1.8)	1 (0.6)
ロタウイルス胃腸炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
モラクセラ感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
鼻咽頭炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
パラインフルエンザウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
インフルエンザ性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
モラクセラ菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
パラインフルエンザウイルス性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺炎球菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in subjects diagnosed with SMA
Page 3 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
シュードモナス菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腎盂腎炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
敗血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ部膿瘍	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸器、胸郭および縦隔障害	2 (10.0)	63 (63.0)	65 (54.2)	2 (3.6)	67 (38.1)
呼吸窮迫	1 (5.0)	27 (27.0)	28 (23.3)	0	28 (15.9)
呼吸不全	0	25 (25.0)	25 (20.8)	1 (1.8)	26 (14.8)
急性呼吸不全	0	15 (15.0)	15 (12.5)	1 (1.8)	16 (9.1)
無気肺	0	16 (16.0)	16 (13.3)	0	16 (9.1)
誤嚥性肺炎	0	10 (10.0)	10 (8.3)	0	10 (5.7)
呼吸困難	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
低酸素症	0	5 (5.0)	5 (4.2)	0	5 (2.8)
呼吸停止	0	5 (5.0)	5 (4.2)	0	5 (2.8)
無呼吸	0	4 (4.0)	4 (3.3)	0	4 (2.3)
誤嚥	0	4 (4.0)	4 (3.3)	0	4 (2.3)
低換気	0	2 (2.0)	2 (1.7)	0	2 (1.1)
呼吸障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in subjects diagnosed with SMA
Page 4 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
急性呼吸窮迫症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
窒息	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管支分泌物貯留	0	1 (1.0)	1 (0.8)	0	1 (0.6)
息詰まり	1 (5.0)	0	1 (0.8)	0	1 (0.6)
慢性呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管支分泌増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心臓障害	0	12 (12.0)	12 (10.0)	0	12 (6.8)
心肺停止	0	6 (6.0)	6 (5.0)	0	6 (3.4)
心停止	0	3 (3.0)	3 (2.5)	0	3 (1.7)
チアノーゼ	0	2 (2.0)	2 (1.7)	0	2 (1.1)
徐脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
洞性頻脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
代謝および栄養障害	2 (10.0)	10 (10.0)	12 (10.0)	0	12 (6.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in subjects diagnosed with SMA
Page 5 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
成長障害	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
体重増加不良	0	3 (3.0)	3 (2.5)	0	3 (1.7)
脱水	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
乳児および小児期早期の哺育障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
栄養補給不耐性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
低ナトリウム血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃腸障害	1 (5.0)	7 (7.0)	8 (6.7)	0	8 (4.5)
嘔吐	0	4 (4.0)	4 (3.3)	0	4 (2.3)
嚥下障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
腹部膨満	1 (5.0)	0	1 (0.8)	0	1 (0.6)
胃出血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
一般・全身障害および投与部位の状態	1 (5.0)	7 (7.0)	8 (6.7)	0	8 (4.5)
発熱	1 (5.0)	4 (4.0)	5 (4.2)	0	5 (2.8)
死亡	0	1 (1.0)	1 (0.8)	0	1 (0.6)
全身健康状態低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in subjects diagnosed with SMA
Page 6 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
外科手術不成功	0	1 (1.0)	1 (0.8)	0	1 (0.6)
傷害、中毒および処置合併症	0	3 (3.0)	3 (2.5)	2 (3.6)	5 (2.8)
腰椎穿刺後症候群	0	0	0	2 (3.6)	2 (1.1)
麻酔からの覚醒遅延	0	1 (1.0)	1 (0.8)	0	1 (0.6)
栄養補給チューブ合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ワクチン接種合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
臨床検査	0	3 (3.0)	3 (2.5)	0	3 (1.7)
医学的観察	0	2 (2.0)	2 (1.7)	0	2 (1.1)
酸素飽和度低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
神経系障害	0	3 (3.0)	3 (2.5)	0	3 (1.7)
脳損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
痙攣発作	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血管障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ショック	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of serious adverse events in subjects diagnosed with SMA
Page 7 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血栓症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
免疫系障害	0	0	0	1 (1.8)	1 (0.6)
薬物過敏症	0	0	0	1 (1.8)	1 (0.6)
筋骨格系および結合組織障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚および皮下組織障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別

Incidence of Adverse Events - Infants diagnosed with SMA
Page 1 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	13 (76.5)	4 (100)	16 (100)	38 (92.7)	72 (90.0)
感染症および寄生虫症	10 (58.8)	3 (75.0)	16 (100)	29 (70.7)	57 (71.3)
上気道感染	6 (35.3)	1 (25.0)	11 (68.8)	9 (22.0)	20 (25.0)
肺炎	1 (5.9)	1 (25.0)	6 (37.5)	6 (14.6)	17 (21.3)
鼻咽頭炎	3 (17.6)	0	6 (37.5)	4 (9.8)	14 (17.5)
ウイルス性上気道感染	0	0	2 (12.5)	8 (19.5)	10 (12.5)
ライノウイルス感染	1 (5.9)	0	6 (37.5)	5 (12.2)	8 (10.0)
細気管支炎	1 (5.9)	0	3 (18.8)	3 (7.3)	8 (10.0)
ウイルス感染	0	0	4 (25.0)	2 (4.9)	7 (8.8)
気道感染	0	2 (50.0)	3 (18.8)	2 (4.9)	7 (8.8)
ウイルス性肺炎	1 (5.9)	1 (25.0)	2 (12.5)	1 (2.4)	6 (7.5)
口腔カンジダ症	0	0	1 (6.3)	3 (7.3)	6 (7.5)
結膜炎	0	0	1 (6.3)	3 (7.3)	5 (6.3)
気管支炎	1 (5.9)	0	0	0	5 (6.3)
耳感染	0	0	1 (6.3)	1 (2.4)	4 (5.0)
ウイルス性気道感染	0	0	1 (6.3)	2 (4.9)	4 (5.0)
下気道感染	0	0	1 (6.3)	1 (2.4)	3 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 2 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ＲＳウイルス細気管支炎	0	0	1 (6.3)	3 (7.3)	3 (3.8)
細菌性肺炎	0	0	1 (6.3)	2 (4.9)	3 (3.8)
尿路感染	1 (5.9)	0	0	0	3 (3.8)
ウイルス性気管支炎	0	0	0	0	3 (3.8)
インフルエンザ	2 (11.8)	0	1 (6.3)	0	2 (2.5)
ウイルス性下気道感染	0	0	1 (6.3)	0	2 (2.5)
皮膚カンジダ	0	0	0	1 (2.4)	2 (2.5)
アデノウイルス感染	0	0	0	0	2 (2.5)
細菌性結膜炎	0	0	0	1 (2.4)	2 (2.5)
ストーマ部膿瘍	0	0	0	0	2 (2.5)
中耳炎	2 (11.8)	1 (25.0)	5 (31.3)	2 (4.9)	1 (1.3)
細菌性気管炎	0	0	2 (12.5)	4 (9.8)	1 (1.3)
鼻炎	1 (5.9)	0	1 (6.3)	3 (7.3)	1 (1.3)
胃腸炎	0	0	1 (6.3)	0	1 (1.3)
皮膚真菌感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
手足口病	0	0	1 (6.3)	0	1 (1.3)
細菌感染	0	0	1 (6.3)	0	1 (1.3)
モラクセラ菌性肺炎	0	0	1 (6.3)	0	1 (1.3)
カンジダ性おむつ皮疹	0	1 (25.0)	0	0	1 (1.3)
ウイルス性胃腸炎	1 (5.9)	0	0	2 (4.9)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 3 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
膿痂疹	1 (5.9)	0	0	1 (2.4)	1 (1.3)
蜂巣炎	0	0	0	1 (2.4)	1 (1.3)
限局性感染	0	0	0	0	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
感染性湿疹	0	0	0	0	1 (1.3)
眼感染	0	0	0	0	1 (1.3)
真菌感染	0	0	0	1 (2.4)	1 (1.3)
ロタウイルス胃腸炎	0	0	0	0	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
院内感染	0	0	0	0	1 (1.3)
口腔ヘルペス	0	0	0	0	1 (1.3)
急性中耳炎	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	1 (2.4)	1 (1.3)
シュードモナス感染	0	0	0	2 (4.9)	1 (1.3)
ばら疹	0	0	0	0	1 (1.3)
敗血症	0	0	0	0	1 (1.3)
ブドウ球菌性敗血症	0	0	0	0	1 (1.3)
ブドウ球菌皮膚感染	0	0	0	0	1 (1.3)
エンテロウイルス感染	0	0	2 (12.5)	0	0
メタニューモウイルス感染	0	0	2 (12.5)	0	0
パラインフルエンザウイルス感染	0	1 (25.0)	1 (6.3)	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 4 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アデノウイルス性上気道感染	0	0	1 (6.3)	0	0
細菌性疾患キャリアー	0	0	1 (6.3)	1 (2.4)	0
コロナウイルス感染	0	0	1 (6.3)	2 (4.9)	0
伝染性紅斑	0	0	1 (6.3)	0	0
ウイルス性胃炎	0	0	1 (6.3)	0	0
ヘモフィルス感染	0	0	1 (6.3)	0	0
モラクセラ感染	0	0	1 (6.3)	0	0
粘膜皮膚カンジダ症	0	0	1 (6.3)	0	0
細菌性気道感染	0	0	1 (6.3)	1 (2.4)	0
ブドウ球菌性菌血症	0	0	1 (6.3)	0	0
ブドウ球菌感染	0	0	1 (6.3)	2 (4.9)	0
気管炎	0	0	1 (6.3)	1 (2.4)	0
レンサ球菌性咽頭炎	1 (5.9)	1 (25.0)	0	0	0
シュードモナス菌性肺炎	0	1 (25.0)	0	1 (2.4)	0
皮膚感染	1 (5.9)	0	0	1 (2.4)	0
ＲＳウイルス感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0
伝染性軟属腫	0	0	0	0	0
腟感染	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 5 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
外陰腟真菌感染	0	0	0	0	0
カンジダ感染	0	0	0	3 (7.3)	0
ブドウ球菌性眼感染	0	0	0	0	0
麦粒腫	0	0	0	1 (2.4)	0
単核細胞症症候群	0	0	0	0	0
咽頭炎	0	0	0	0	0
セラチア感染	0	0	0	1 (2.4)	0
副鼻腔炎	0	0	0	0	0
皮膚細菌感染	0	0	0	0	0
ストーマ部感染	0	0	0	3 (7.3)	0
扁桃炎	0	0	0	0	0
ウイルス性発疹	0	0	0	1 (2.4)	0
呼吸器、胸郭および縦隔障害	5 (29.4)	3 (75.0)	15 (93.8)	34 (82.9)	55 (68.8)
呼吸窮迫	1 (5.9)	1 (25.0)	6 (37.5)	14 (34.1)	19 (23.8)
呼吸不全	0	0	6 (37.5)	14 (34.1)	17 (21.3)
無気肺	0	0	5 (31.3)	9 (22.0)	15 (18.8)
急性呼吸不全	0	1 (25.0)	3 (18.8)	8 (19.5)	11 (13.8)
鼻閉	2 (11.8)	1 (25.0)	6 (37.5)	6 (14.6)	8 (10.0)
誤嚥性肺炎	0	0	3 (18.8)	6 (14.6)	7 (8.8)
呼吸困難	0	1 (25.0)	1 (6.3)	6 (14.6)	7 (8.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 6 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
咳嗽	2 (11.8)	2 (50.0)	4 (25.0)	8 (19.5)	6 (7.5)
低酸素症	0	0	4 (25.0)	2 (4.9)	6 (7.5)
上気道うっ血	1 (5.9)	0	1 (6.3)	1 (2.4)	5 (6.3)
無呼吸	0	0	3 (18.8)	3 (7.3)	4 (5.0)
鼻漏	1 (5.9)	0	2 (12.5)	3 (7.3)	4 (5.0)
誤嚥	0	0	2 (12.5)	1 (2.4)	4 (5.0)
気管支分泌物貯留	0	1 (25.0)	2 (12.5)	4 (9.8)	3 (3.8)
副鼻腔うっ血	0	0	1 (6.3)	0	3 (3.8)
呼吸停止	0	0	1 (6.3)	4 (9.8)	3 (3.8)
上気道分泌増加	0	0	4 (25.0)	1 (2.4)	2 (2.5)
慢性呼吸不全	0	1 (25.0)	3 (18.8)	0	2 (2.5)
低換気	0	0	1 (6.3)	0	2 (2.5)
呼吸障害	0	0	0	0	2 (2.5)
喘鳴	0	0	2 (12.5)	0	1 (1.3)
気胸	0	0	2 (12.5)	0	1 (1.3)
息詰まり	0	0	1 (6.3)	1 (2.4)	1 (1.3)
呼吸補助筋の動員	0	0	1 (6.3)	1 (2.4)	1 (1.3)
アレルギー性鼻炎	0	1 (25.0)	0	0	1 (1.3)
急性呼吸窮迫症候群	0	0	0	0	1 (1.3)
気管支閉塞	0	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	0	0	1 (1.3)
減呼吸	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 7 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気管支分泌増加	0	0	0	1 (2.4)	1 (1.3)
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
胸水	0	0	0	0	1 (1.3)
呼吸性アルカローシス	0	0	0	0	1 (1.3)
気道うっ血	0	0	0	3 (7.3)	1 (1.3)
変色痰	0	0	0	0	1 (1.3)
肺うっ血	0	0	2 (12.5)	0	0
肺水腫	0	0	2 (12.5)	0	0
無呼吸発作	0	0	1 (6.3)	0	0
喉頭肉芽腫	0	0	1 (6.3)	0	0
鼻汁変色	0	0	1 (6.3)	0	0
気縦隔症	0	0	1 (6.3)	0	0
湿性咳嗽	0	0	1 (6.3)	0	0
拘束性肺疾患	0	0	1 (6.3)	0	0
低音性連続性ラ音	0	0	1 (6.3)	0	0
睡眠時無呼吸症候群	0	0	1 (6.3)	4 (9.8)	0
頻呼吸	0	0	1 (6.3)	2 (4.9)	0
気管障害	0	0	1 (6.3)	0	0
窒息	0	1 (25.0)	0	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	0
口腔咽頭痛	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 8 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鼻出血	0	0	0	0	0
扁桃肥大	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0
カタル	0	0	0	1 (2.4)	0
発声障害	0	0	0	0	0
肺臓炎	0	0	0	0	0
上気道の炎症	0	0	0	2 (4.9)	0
胃腸障害	6 (35.3)	4 (100)	14 (87.5)	23 (56.1)	46 (57.5)
便秘	1 (5.9)	1 (25.0)	8 (50.0)	9 (22.0)	24 (30.0)
嘔吐	0	2 (50.0)	6 (37.5)	8 (19.5)	12 (15.0)
生歯	1 (5.9)	2 (50.0)	2 (12.5)	3 (7.3)	11 (13.8)
胃食道逆流性疾患	2 (11.8)	0	6 (37.5)	6 (14.6)	9 (11.3)
嚥下障害	1 (5.9)	0	0	8 (19.5)	9 (11.3)
下痢	0	1 (25.0)	4 (25.0)	7 (17.1)	8 (10.0)
流涎過多	0	0	2 (12.5)	2 (4.9)	3 (3.8)
放屁	2 (11.8)	1 (25.0)	1 (6.3)	1 (2.4)	3 (3.8)
胃炎	0	0	1 (6.3)	1 (2.4)	3 (3.8)
血便排泄	0	0	0	0	2 (2.5)
腹部膨満	2 (11.8)	1 (25.0)	2 (12.5)	0	1 (1.3)
腹部不快感	1 (5.9)	0	0	0	1 (1.3)
アフタ性潰瘍	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 9 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胃出血	0	0	0	0	1 (1.3)
乳児仙痛	0	0	0	0	1 (1.3)
乳児吐出	0	0	0	0	1 (1.3)
上部消化管出血	0	0	0	0	1 (1.3)
口唇のひび割れ	0	0	1 (6.3)	0	0
排便回数増加	0	0	1 (6.3)	0	0
腹痛	0	1 (25.0)	0	0	0
消化管運動低下	0	1 (25.0)	0	0	0
吐血	0	1 (25.0)	0	0	0
悪心	0	0	0	0	0
上腹部痛	0	0	0	2 (4.9)	0
腹部症状	0	0	0	0	0
口腔内痛	0	0	0	0	0
口内炎	0	0	0	1 (2.4)	0
血性下痢	0	0	0	1 (2.4)	0
食中毒	0	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	0	0	1 (2.4)	0
消化管刺激症状	0	0	0	1 (2.4)	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 10 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
一般・全身障害および投与部位の状態	4 (23.5)	3 (75.0)	11 (68.8)	27 (65.9)	44 (55.0)
発熱	3 (17.6)	3 (75.0)	11 (68.8)	22 (53.7)	39 (48.8)
疼痛	0	0	4 (25.0)	2 (4.9)	1 (1.3)
カテーテル留置部位炎症	0	0	0	1 (2.4)	1 (1.3)
泣き	0	0	0	0	1 (1.3)
死亡	0	0	0	1 (2.4)	1 (1.3)
薬物不耐性	0	0	0	0	1 (1.3)
低体温	0	0	0	0	1 (1.3)
ワクチン接種後の易刺激性	0	0	0	0	1 (1.3)
倦怠感	0	0	0	0	1 (1.3)
小結節	0	0	0	0	1 (1.3)
腫脹	0	0	0	0	1 (1.3)
不快感	0	1 (25.0)	1 (6.3)	0	0
末梢性浮腫	0	1 (25.0)	1 (6.3)	0	0
医療機器リーク	0	0	1 (6.3)	0	0
医療機器閉塞	0	0	1 (6.3)	1 (2.4)	0
浮腫	0	0	1 (6.3)	3 (7.3)	0
血管穿刺部位内出血	0	0	1 (6.3)	2 (4.9)	0
末梢腫脹	0	1 (25.0)	0	0	0
適用部位紅斑	1 (5.9)	0	0	0	0
注入部位内出血	1 (5.9)	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 11 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
疲労	0	0	0	1 (2.4)	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
適用部位発疹	0	0	0	1 (2.4)	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0
医療機器機能不良	0	0	0	1 (2.4)	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
注入部位血管外漏出	0	0	0	1 (2.4)	0
注射部位血腫	0	0	0	1 (2.4)	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
血管穿刺部位反応	0	0	0	1 (2.4)	0
皮膚および皮下組織障害	6 (35.3)	4 (100)	10 (62.5)	13 (31.7)	21 (26.3)
発疹	0	1 (25.0)	4 (25.0)	4 (9.8)	8 (10.0)
おむつ皮膚炎	2 (11.8)	2 (50.0)	2 (12.5)	2 (4.9)	6 (7.5)
斑状出血	0	0	1 (6.3)	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 12 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
接触性皮膚炎	0	1 (25.0)	0	2 (4.9)	2 (2.5)
過角化	0	0	0	0	2 (2.5)
汗疹	0	0	0	0	2 (2.5)
湿疹	0	1 (25.0)	2 (12.5)	2 (4.9)	1 (1.3)
皮膚炎	2 (11.8)	0	1 (6.3)	0	1 (1.3)
紅斑	1 (5.9)	0	0	3 (7.3)	1 (1.3)
蕁麻疹	0	0	0	0	1 (1.3)
アレルギー性皮膚炎	0	0	0	0	1 (1.3)
環状肉芽腫	0	0	0	0	1 (1.3)
丘疹性皮疹	0	0	0	0	1 (1.3)
皮膚浮腫	0	0	0	0	1 (1.3)
過剰肉芽組織	0	0	3 (18.8)	0	0
皮膚刺激	0	1 (25.0)	2 (12.5)	0	0
脱毛症	0	0	1 (6.3)	0	0
点状出血	0	0	1 (6.3)	0	0
そう痒症	0	0	1 (6.3)	0	0
皮膚色素脱失	0	0	1 (6.3)	0	0
皮膚潰瘍	0	0	1 (6.3)	0	0
皮下気腫	0	0	1 (6.3)	0	0
皮膚障害	0	1 (25.0)	0	0	0
貨幣状湿疹	1 (5.9)	0	0	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 13 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0
褥瘡性潰瘍	0	0	0	2 (4.9)	0
毛孔性角化症	0	0	0	1 (2.4)	0
皮膚病変	0	0	0	0	0
アトピー性皮膚炎	0	0	0	2 (4.9)	0
皮膚乾燥	0	0	0	1 (2.4)	0
多汗症	0	0	0	1 (2.4)	0
寝汗	0	0	0	0	0
臨床検査	1 (5.9)	1 (25.0)	6 (37.5)	14 (34.1)	17 (21.3)
酸素飽和度低下	0	0	2 (12.5)	9 (22.0)	8 (10.0)
体重減少	0	1 (25.0)	1 (6.3)	1 (2.4)	3 (3.8)
血中カリウム減少	0	0	0	0	2 (2.5)
体温上昇	0	0	0	0	2 (2.5)
Ｃ－反応性蛋白増加	0	0	0	1 (2.4)	2 (2.5)
ヒトライノウイルス検査陽性	0	0	2 (12.5)	0	1 (1.3)
好中球数増加	0	0	2 (12.5)	0	1 (1.3)
心拍数増加	0	0	1 (6.3)	1 (2.4)	1 (1.3)
モラクセラ検査陽性	0	0	1 (6.3)	0	1 (1.3)
シュードモナス検査陽性	0	0	1 (6.3)	0	1 (1.3)
ブドウ球菌検査陽性	0	0	1 (6.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 14 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (1.3)
血中クロール減少	0	0	0	0	1 (1.3)
血中鉄減少	0	0	0	0	1 (1.3)
血中ナトリウム減少	0	0	0	0	1 (1.3)
体温低下	0	0	0	1 (2.4)	1 (1.3)
心電図ＳＴ－Ｔ部分異常	0	0	0	1 (2.4)	1 (1.3)
心拍数不整	0	0	0	0	1 (1.3)
炎症マーカー上昇	0	0	0	0	1 (1.3)
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	1 (1.3)
肝機能検査異常	0	0	0	0	1 (1.3)
医学的観察	0	0	0	0	1 (1.3)
尿量減少	0	0	0	0	1 (1.3)
ビタミンＡ減少	0	0	0	0	1 (1.3)
白血球数増加	0	0	2 (12.5)	0	0
骨密度減少	0	0	1 (6.3)	0	0
呼吸音異常	0	0	1 (6.3)	0	0
心拍数減少	0	0	1 (6.3)	0	0
好中球百分率増加	0	0	1 (6.3)	0	0
セラチア検査陽性	0	0	1 (6.3)	0	0
レンサ球菌検査陽性	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 15 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0
ヘッドラグ異常	0	0	0	1 (2.4)	0
リンパ節触知	0	0	0	1 (2.4)	0
呼吸数増加	0	0	0	1 (2.4)	0
レスピロウイルス検査陽性	0	0	0	1 (2.4)	0
トランスアミナーゼ上昇	0	0	0	1 (2.4)	0
尿検査異常	0	0	0	0	0
ビタミンＤ減少	0	0	0	1 (2.4)	0
心臓障害	2 (11.8)	2 (50.0)	4 (25.0)	11 (26.8)	16 (20.0)
頻脈	2 (11.8)	1 (25.0)	1 (6.3)	5 (12.2)	6 (7.5)
心肺停止	0	0	1 (6.3)	3 (7.3)	5 (6.3)
徐脈	0	1 (25.0)	2 (12.5)	3 (7.3)	4 (5.0)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
チアノーゼ	0	0	1 (6.3)	2 (4.9)	2 (2.5)
心室性頻脈	0	1 (25.0)	0	0	1 (1.3)
左室肥大	0	0	0	0	1 (1.3)
上室性頻脈	0	0	0	0	1 (1.3)
心筋症	0	0	1 (6.3)	0	0
心膜気腫	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 16 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
動悸	0	0	0	0	0
傷害、中毒および処置合併症	3 (17.6)	3 (75.0)	8 (50.0)	10 (24.4)	15 (18.8)
処置による疼痛	0	1 (25.0)	1 (6.3)	0	2 (2.5)
ストーマ部紅斑	0	0	1 (6.3)	2 (4.9)	2 (2.5)
大腿骨骨折	0	0	0	1 (2.4)	2 (2.5)
挫傷	0	0	1 (6.3)	0	1 (1.3)
処置後腫脹	1 (5.9)	0	0	0	1 (1.3)
術後激越	0	0	0	0	1 (1.3)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
擦過傷	0	0	0	1 (2.4)	1 (1.3)
伝染病曝露	0	0	0	0	1 (1.3)
処置合併症	0	0	0	0	1 (1.3)
処置部位反応	0	0	0	0	1 (1.3)
ストーマ合併症	0	0	0	2 (4.9)	1 (1.3)
ワクチン接種合併症	0	0	0	1 (2.4)	1 (1.3)
創離開	0	0	0	0	1 (1.3)
節足動物咬傷	0	1 (25.0)	2 (12.5)	0	0
関節脱臼	0	0	2 (12.5)	0	0
栄養補給チューブ合併症	0	0	2 (12.5)	2 (4.9)	0
皮膚擦過傷	0	0	2 (12.5)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 17 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ダンピング症候群	0	0	1 (6.3)	0	0
耳擦過傷	0	0	1 (6.3)	0	0
口唇損傷	0	0	1 (6.3)	0	0
外傷性気胸	0	0	1 (6.3)	0	0
歯牙損傷	0	0	1 (6.3)	0	0
軟部組織損傷	0	1 (25.0)	0	0	0
サンバーン	0	1 (25.0)	0	0	0
熱傷	0	1 (25.0)	0	0	0
転倒	1 (5.9)	0	0	0	0
処置後合併症	1 (5.9)	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	0
硬膜下血腫	1 (5.9)	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
裂傷	0	0	0	1 (2.4)	0
四肢損傷	0	0	0	0	0
節足動物刺傷	0	0	0	0	0
関節損傷	0	0	0	0	0
靭帯捻挫	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
気管内挿管合併症	0	0	0	1 (2.4)	0
頭部損傷	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 18 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
肉離れ	0	0	0	0	0
処置後挫傷	0	0	0	1 (2.4)	0
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
ストーマ部出血	0	0	0	1 (2.4)	0
ストーマ部炎症	0	0	0	1 (2.4)	0
ストーマ部刺激感	0	0	0	1 (2.4)	0
脛骨骨折	0	0	0	0	0
隆起骨折	0	0	0	0	0
気管損傷	0	0	0	1 (2.4)	0
代謝および栄養障害	2 (11.8)	2 (50.0)	3 (18.8)	10 (24.4)	13 (16.3)
体重増加不良	1 (5.9)	1 (25.0)	0	2 (4.9)	5 (6.3)
乳児および小児期早期の哺育障害	0	0	0	2 (4.9)	3 (3.8)
栄養補給不耐性	0	0	0	0	3 (3.8)
成長障害	1 (5.9)	0	1 (6.3)	0	2 (2.5)
脱水	1 (5.9)	0	0	1 (2.4)	1 (1.3)
鉄欠乏	0	0	0	0	1 (1.3)
低ナトリウム血症	0	0	2 (12.5)	0	0
過小食	0	1 (25.0)	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 19 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
代謝性アルカローシス	0	0	1 (6.3)	0	0
食欲減退	0	0	0	0	0
食欲亢進	0	0	0	0	0
ビタミンD欠乏	0	0	0	1 (2.4)	0
食物不耐性	0	0	0	1 (2.4)	0
高血糖	0	0	0	1 (2.4)	0
低血糖	0	0	0	2 (4.9)	0
低カリウム血症	0	0	0	3 (7.3)	0
筋骨格系および結合組織障害	2 (11.8)	3 (75.0)	11 (68.8)	4 (9.8)	11 (13.8)
側弯症	0	2 (50.0)	5 (31.3)	1 (2.4)	4 (5.0)
関節拘縮	1 (5.9)	3 (75.0)	5 (31.3)	2 (4.9)	3 (3.8)
頭位性斜頭症	1 (5.9)	0	0	1 (2.4)	2 (2.5)
脊柱後弯症	0	2 (50.0)	2 (12.5)	1 (2.4)	1 (1.3)
胸郭変形	0	1 (25.0)	2 (12.5)	0	1 (1.3)
四肢痛	0	0	1 (6.3)	0	1 (1.3)
後側弯症	0	0	1 (6.3)	0	1 (1.3)
背部痛	0	0	0	0	1 (1.3)
泉門閉鎖遅延	0	0	0	0	1 (1.3)
斜頚	1 (5.9)	1 (25.0)	1 (6.3)	0	0
手変形	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 20 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
関節硬直	0	0	1 (6.3)	1 (2.4)	0
脊柱前弯症	0	0	1 (6.3)	0	0
脊柱変形	0	0	1 (6.3)	0	0
滑膜炎	0	0	1 (6.3)	0	0
筋力低下	1 (5.9)	0	0	1 (2.4)	0
体重支持困難	1 (5.9)	0	0	0	0
関節痛	0	0	0	0	0
筋緊張	0	0	0	0	0
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	0	0	1 (2.4)	0
神経系障害	2 (11.8)	2 (50.0)	7 (43.8)	2 (4.9)	8 (10.0)
眼振	0	1 (25.0)	0	1 (2.4)	2 (2.5)
不随意性筋収縮	0	0	3 (18.8)	0	1 (1.3)
よだれ	0	0	1 (6.3)	0	1 (1.3)
痙攣発作	0	0	1 (6.3)	0	1 (1.3)
脳損傷	0	0	0	0	1 (1.3)
間代	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 21 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
傾眠	0	0	0	0	1 (1.3)
失神	0	0	1 (6.3)	0	0
脳梗塞	0	0	1 (6.3)	0	0
脳脊髄液漏	0	0	1 (6.3)	0	0
嗜眠	0	0	1 (6.3)	0	0
頭痛	0	1 (25.0)	0	0	0
反射亢進	1 (5.9)	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	0
失声症	0	0	0	0	0
感覚鈍麻	0	0	0	0	0
片頭痛	0	0	0	0	0
振戦	0	0	0	0	0
味覚異常	0	0	0	0	0
失読症	0	0	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	0	0	1 (2.4)	0
精神障害	0	0	3 (18.8)	5 (12.2)	8 (10.0)
不安	0	0	3 (18.8)	0	2 (2.5)
激越	0	0	0	2 (4.9)	2 (2.5)
易刺激性	0	0	0	1 (2.4)	2 (2.5)
息こらえ	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 22 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気分動揺	0	0	0	0	1 (1.3)
落ち着きのなさ	0	0	0	1 (2.4)	1 (1.3)
睡眠障害	0	0	0	2 (4.9)	1 (1.3)
不眠症	0	0	0	0	0
チック	0	0	0	0	0
注意欠陥多動性障害	0	0	0	0	0
不快気分	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
免疫系障害	1 (5.9)	1 (25.0)	5 (31.3)	4 (9.8)	6 (7.5)
季節性アレルギー	1 (5.9)	1 (25.0)	2 (12.5)	2 (4.9)	2 (2.5)
薬物過敏症	0	0	2 (12.5)	1 (2.4)	2 (2.5)
過敏症	0	0	1 (6.3)	2 (4.9)	1 (1.3)
食物アレルギー	0	0	0	0	1 (1.3)
血管障害	2 (11.8)	1 (25.0)	2 (12.5)	0	4 (5.0)
高血圧	1 (5.9)	0	1 (6.3)	0	1 (1.3)
蒼白	1 (5.9)	0	0	0	1 (1.3)
ショック	0	0	0	0	1 (1.3)
血管炎	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 23 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
毛細血管脆弱	0	0	1 (6.3)	0	0
本態性高血圧症	0	1 (25.0)	0	0	0
低血圧	0	0	0	0	0
眼障害	1 (5.9)	1 (25.0)	1 (6.3)	3 (7.3)	4 (5.0)
霰粒腫	0	0	0	0	1 (1.3)
眼乾燥	0	0	0	1 (2.4)	1 (1.3)
眼運動障害	0	0	0	0	1 (1.3)
近視	0	0	0	0	1 (1.3)
斜視	0	0	0	1 (2.4)	1 (1.3)
眼瞼下垂	0	0	1 (6.3)	0	0
乱視	0	1 (25.0)	0	0	0
後天性涙道狭窄	1 (5.9)	0	0	0	0
遠視	0	0	0	0	0
弱視	0	0	0	1 (2.4)	0
流涙増加	0	0	0	1 (2.4)	0
先天性、家族性および遺伝性障害	0	1 (25.0)	2 (12.5)	4 (9.8)	3 (3.8)
発育性股関節形成不全	0	0	0	1 (2.4)	1 (1.3)
貧血母斑	0	0	0	0	1 (1.3)
鳩胸	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 24 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
斜頭症	0	1 (25.0)	1 (6.3)	0	0
斜指症	0	0	1 (6.3)	0	0
停留精巣	0	0	0	1 (2.4)	0
包茎	0	0	0	1 (2.4)	0
生殖系および乳房障害	0	0	0	0	3 (3.8)
後天性包茎	0	0	0	0	1 (1.3)
卵巣嚢胞	0	0	0	0	1 (1.3)
陰茎障害	0	0	0	0	1 (1.3)
耳および迷路障害	0	1 (25.0)	0	0	2 (2.5)
耳の障害	0	0	0	0	1 (1.3)
耳痛	0	0	0	0	1 (1.3)
耳垢分泌過多	0	1 (25.0)	0	0	0
鼓膜穿孔	0	0	0	0	0
乗物酔い	0	0	0	0	0
腎および尿路障害	0	0	0	1 (2.4)	2 (2.5)
水腎症	0	0	0	0	1 (1.3)
尿閉	0	0	0	0	1 (1.3)
排尿困難	0	0	0	0	0
尿失禁	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 25 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
糖尿	0	0	0	1 (2.4)	0
膀胱尿管逆流	0	0	0	0	0
血液およびリンパ系障害	2 (11.8)	1 (25.0)	4 (25.0)	3 (7.3)	1 (1.3)
貧血	0	0	2 (12.5)	1 (2.4)	1 (1.3)
好中球減少症	1 (5.9)	0	1 (6.3)	0	0
血小板増加症	0	0	1 (6.3)	0	0
リンパ節症	0	1 (25.0)	0	0	0
好酸球増加症	1 (5.9)	0	0	0	0
骨髄障害	0	0	0	1 (2.4)	0
白血球増加症	0	0	0	1 (2.4)	0
肝胆道系障害	0	0	0	0	1 (1.3)
肝腫大	0	0	0	0	1 (1.3)
外科および内科処置	0	0	0	0	1 (1.3)
機械的換気	0	0	0	0	1 (1.3)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.9)	1 (25.0)	1 (6.3)	0	0
アクロコルドン	0	0	1 (6.3)	0	0
血管の良性新生物	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 10　　SMA と診断された乳児被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Infants diagnosed with SMA
Page 26 of 26

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
脂漏性角化症	1 (5.9)	0	0	0	0
皮膚乳頭腫	0	0	0	0	0
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別

Incidence of Adverse Events - Later-onset
Page 1 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	6 (100)	4 (66.7)	6 (100)	9 (90.0)	8 (100)	7 (87.5)
感染症および寄生虫症	1 (16.7)	1 (16.7)	1 (16.7)	4 (40.0)	6 (75.0)	4 (50.0)
上気道感染	0	1 (16.7)	1 (16.7)	1 (10.0)	2 (25.0)	1 (12.5)
肺炎	0	0	0	0	2 (25.0)	0
鼻咽頭炎	0	0	0	0	0	1 (12.5)
ウイルス性上気道感染	0	0	0	0	0	1 (12.5)
ライノウイルス感染	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
ウイルス感染	1 (16.7)	0	0	0	0	1 (12.5)
気道感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
口腔カンジダ症	0	0	0	0	0	0
結膜炎	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0
耳感染	0	0	0	1 (10.0)	0	0
ウイルス性気道感染	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 2 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	9 (100)	9 (100)	3 (75.0)	13 (92.9)	47 (100)
感染症および寄生虫症	7 (77.8)	5 (55.6)	3 (75.0)	7 (50.0)	36 (76.6)
上気道感染	2 (22.2)	1 (11.1)	1 (25.0)	2 (14.3)	19 (40.4)
肺炎	0	0	0	0	4 (8.5)
鼻咽頭炎	4 (44.4)	3 (33.3)	0	2 (14.3)	7 (14.9)
ウイルス性上気道感染	2 (22.2)	0	0	0	2 (4.3)
ライノウイルス感染	0	0	0	0	0
細気管支炎	0	0	0	0	0
ウイルス感染	1 (11.1)	0	0	0	7 (14.9)
気道感染	0	0	0	0	1 (2.1)
ウイルス性肺炎	0	0	0	0	2 (4.3)
口腔カンジダ症	0	0	0	0	0
結膜炎	0	1 (11.1)	0	0	2 (4.3)
気管支炎	0	0	0	0	0
耳感染	1 (11.1)	0	0	0	2 (4.3)
ウイルス性気道感染	0	0	0	0	1 (2.1)
下気道感染	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 3 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ＲＳウイルス細気管支炎	0	0	0	0	0	0
細菌性肺炎	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
インフルエンザ	0	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
中耳炎	0	0	0	0	2 (25.0)	0
細菌性気管炎	0	0	0	0	0	0
鼻炎	0	0	0	0	1 (12.5)	0
胃腸炎	0	0	0	0	0	0
皮膚真菌感染	0	0	0	0	0	0
手足口病	0	0	0	0	0	0
細菌感染	0	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 4 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ＲＳウイルス細気管支炎	0	0	0	0	1 (2.1)
細菌性肺炎	0	0	0	0	0
尿路感染	1 (11.1)	0	0	1 (7.1)	2 (4.3)
ウイルス性気管支炎	0	0	0	0	0
インフルエンザ	0	1 (11.1)	0	0	2 (4.3)
ウイルス性下気道感染	0	0	0	0	0
皮膚カンジダ	0	0	0	0	2 (4.3)
アデノウイルス感染	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
中耳炎	0	0	1 (25.0)	1 (7.1)	1 (2.1)
細菌性気管炎	0	0	0	0	0
鼻炎	0	0	0	0	0
胃腸炎	0	0	0	1 (7.1)	6 (12.8)
皮膚真菌感染	0	0	0	0	1 (2.1)
手足口病	0	0	0	0	1 (2.1)
細菌感染	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
ウイルス性胃腸炎	1 (11.1)	0	1 (25.0)	0	6 (12.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 5 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
膿痂疹	0	0	0	0	0	0
蜂巣炎	0	0	0	0	0	0
限局性感染	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
感染性湿疹	0	0	0	0	0	0
眼感染	0	0	0	0	0	0
真菌感染	0	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0	0
肺感染	0	0	0	0	0	0
院内感染	0	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0	0
急性中耳炎	0	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
シュードモナス感染	0	0	0	0	0	0
ばら疹	0	0	0	0	0	0
敗血症	0	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 6 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
膿痂疹	0	1 (11.1)	0	0	0
蜂巣炎	0	0	0	0	1 (2.1)
限局性感染	2 (22.2)	0	0	0	1 (2.1)
ＲＳウイルス肺炎	0	0	0	0	1 (2.1)
感染性湿疹	0	0	0	0	0
眼感染	0	0	0	0	0
真菌感染	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
肺感染	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
急性中耳炎	0	0	0	1 (7.1)	0
インフルエンザ性肺炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
ばら疹	0	0	0	0	0
敗血症	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 7 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
アデノウイルス性上気道感染	0	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
伝染性紅斑	0	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0	0
モラクセラ感染	0	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0	0
細菌性気道感染	0	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0	0
気管炎	0	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	2 (20.0)	3 (37.5)	0
シュードモナス菌性肺炎	0	0	0	0	0	0
皮膚感染	0	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	1 (12.5)	0
ウイルス性眼感染	0	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0	0
伝染性軟属腫	0	0	0	0	0	0
腟感染	0	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 8 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
アデノウイルス性上気道感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
細菌性気道感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
気管炎	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	1 (25.0)	0	3 (6.4)
シュードモナス菌性肺炎	0	0	0	0	0
皮膚感染	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	2 (4.3)
ウイルス性眼感染	0	0	0	0	1 (2.1)
ウイルス性消化管感染	1 (11.1)	0	0	0	1 (2.1)
伝染性軟属腫	0	0	0	0	1 (2.1)
腟感染	0	0	0	0	1 (2.1)
ウイルス性扁桃炎	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 9 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
外陰腟真菌感染	0	0	0	0	0	0
カンジダ感染	0	0	0	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0	0
麦粒腫	0	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0	0
咽頭炎	0	0	0	0	0	0
セラチア感染	0	0	0	0	0	0
副鼻腔炎	0	0	0	1 (10.0)	0	1 (12.5)
皮膚細菌感染	0	0	0	0	0	0
ストーマ部感染	0	0	0	0	0	0
扁桃炎	0	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	1 (10.0)	3 (37.5)	1 (12.5)
呼吸窮迫	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
無気肺	0	0	0	0	1 (12.5)	0
急性呼吸不全	0	0	0	0	0	0
鼻閉	0	0	0	0	1 (12.5)	0
誤嚥性肺炎	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 10 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
外陰腟真菌感染	0	0	0	0	1 (2.1)
カンジダ感染	0	0	0	0	0
ブドウ球菌性眼感染	0	1 (11.1)	0	0	0
麦粒腫	0	0	0	0	0
単核細胞症症候群	0	0	1 (25.0)	0	0
咽頭炎	0	0	0	1 (7.1)	0
セラチア感染	0	0	0	0	0
副鼻腔炎	1 (11.1)	0	0	0	0
皮膚細菌感染	0	1 (11.1)	0	0	0
ストーマ部感染	0	0	0	0	0
扁桃炎	0	0	1 (25.0)	0	0
ウイルス性発疹	0	0	0	0	0
呼吸器、胸郭および縦隔障害	3 (33.3)	2 (22.2)	1 (25.0)	3 (21.4)	18 (38.3)
呼吸窮迫	0	0	0	0	0
呼吸不全	0	0	0	0	1 (2.1)
無気肺	0	0	0	0	1 (2.1)
急性呼吸不全	0	0	0	0	1 (2.1)
鼻閉	0	0	0	1 (7.1)	1 (2.1)
誤嚥性肺炎	0	0	0	0	0
呼吸困難	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 11 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
咳嗽	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
上気道うっ血	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
鼻漏	0	0	0	0	1 (12.5)	0
誤嚥	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
副鼻腔うっ血	0	0	0	1 (10.0)	0	0
呼吸停止	0	0	0	0	0	0
上気道分泌増加	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
低換気	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
喘鳴	0	0	0	0	0	1 (12.5)
気胸	0	0	0	0	0	0
息詰まり	0	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0	0
気管支閉塞	0	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0	0
減呼吸	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 12 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
咳嗽	0	1 (11.1)	0	0	5 (10.6)
低酸素症	0	0	0	0	3 (6.4)
上気道うっ血	0	0	0	0	0
無呼吸	0	0	0	0	0
鼻漏	1 (11.1)	1 (11.1)	0	0	3 (6.4)
誤嚥	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	1 (2.1)
呼吸停止	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
低換気	0	0	0	0	0
呼吸障害	0	0	0	0	1 (2.1)
喘鳴	0	0	0	0	1 (2.1)
気胸	0	0	0	0	0
息詰まり	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
気管支閉塞	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 13 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気管支分泌増加	0	0	0	0	0	0
肺障害	0	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0	0
胸水	0	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
変色痰	0	0	0	0	0	0
肺うっ血	0	0	0	0	0	0
肺水腫	0	0	0	0	0	0
無呼吸発作	0	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0	0
鼻汁変色	0	0	0	0	0	0
気縦隔症	0	0	0	0	0	0
湿性咳嗽	0	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0	1 (12.5)
低音性連続性ラ音	0	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0	0
頻呼吸	0	0	0	0	0	0
気管障害	0	0	0	0	0	0
窒息	0	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0	0
口腔咽頭痛	0	0	0	0	1 (12.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 14 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気管支分泌増加	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
変色痰	0	0	0	0	0
肺うっ血	0	0	0	0	1 (2.1)
肺水腫	0	0	0	0	0
無呼吸発作	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
気管障害	0	0	0	0	0
窒息	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
口腔咽頭痛	1 (11.1)	1 (11.1)	0	0	6 (12.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 15 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
鼻出血	0	0	0	0	1 (12.5)	0
扁桃肥大	0	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0	0
カタル	0	0	0	0	0	0
発声障害	0	0	0	0	0	0
肺臓炎	0	0	0	0	0	0
上気道の炎症	0	0	0	0	0	0
胃腸障害	3 (50.0)	3 (50.0)	1 (16.7)	0	2 (25.0)	2 (25.0)
便秘	2 (33.3)	1 (16.7)	0	0	0	0
嘔吐	1 (16.7)	2 (33.3)	0	0	1 (12.5)	1 (12.5)
生歯	0	0	0	0	0	0
胃食道逆流性疾患	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0
下痢	0	0	0	0	1 (12.5)	0
流涎過多	0	0	0	0	0	0
放屁	0	0	0	0	0	0
胃炎	0	0	0	0	0	0
血便排泄	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
腹部不快感	0	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 16 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
鼻出血	1 (11.1)	0	0	0	2 (4.3)
扁桃肥大	0	0	1 (25.0)	1 (7.1)	1 (2.1)
乳幼児突発性危急事態	0	0	0	0	0
カタル	0	0	0	0	0
発声障害	0	0	0	1 (7.1)	0
肺臓炎	0	0	0	1 (7.1)	0
上気道の炎症	0	0	0	0	0
胃腸障害	4 (44.4)	3 (33.3)	0	5 (35.7)	15 (31.9)
便秘	2 (22.2)	2 (22.2)	0	1 (7.1)	1 (2.1)
嘔吐	2 (22.2)	2 (22.2)	0	2 (14.3)	5 (10.6)
生歯	0	0	0	0	0
胃食道逆流性疾患	0	0	0	0	1 (2.1)
嚥下障害	0	0	0	0	0
下痢	0	0	0	0	1 (2.1)
流涎過多	0	0	0	0	0
放屁	0	0	0	0	1 (2.1)
胃炎	0	0	0	0	0
血便排泄	0	0	0	0	0
腹部膨満	0	0	0	0	0
腹部不快感	1 (11.1)	0	0	0	0
アフタ性潰瘍	0	0	0	1 (7.1)	2 (4.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 17 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
胃出血	0	0	0	0	0	0
乳児仙痛	0	0	0	0	0	0
乳児吐出	0	0	0	0	0	0
上部消化管出血	0	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0	0
排便回数増加	0	0	0	0	0	0
腹痛	0	0	0	0	0	0
消化管運動低下	0	0	0	0	0	0
吐血	0	0	0	0	0	0
悪心	1 (16.7)	2 (33.3)	0	0	2 (25.0)	0
上腹部痛	0	0	0	0	0	0
腹部症状	0	0	0	0	0	0
口腔内痛	0	0	0	0	0	1 (12.5)
口内炎	0	0	0	0	0	0
血性下痢	0	0	0	0	0	0
食中毒	0	0	0	0	0	0
胃腸障害	0	0	1 (16.7)	0	0	0
胃腸出血	0	0	0	0	0	0
消化管刺激症状	0	0	0	0	0	0
口の感覚鈍麻	0	0	0	0	0	0
口唇痛	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 18 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
胃出血	0	0	0	0	0
乳児仙痛	0	0	0	0	0
乳児吐出	0	0	0	0	0
上部消化管出血	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
排便回数増加	0	0	0	0	0
腹痛	0	0	0	1 (7.1)	1 (2.1)
消化管運動低下	0	0	0	0	0
吐血	0	0	0	0	0
悪心	2 (22.2)	0	0	1 (7.1)	3 (6.4)
上腹部痛	0	0	0	0	2 (4.3)
腹部症状	0	0	0	0	1 (2.1)
口腔内痛	0	0	0	0	1 (2.1)
口内炎	0	0	0	0	1 (2.1)
血性下痢	0	0	0	0	0
食中毒	1 (11.1)	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
口の感覚鈍麻	1 (11.1)	0	0	0	0
口唇痛	1 (11.1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 19 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
一般・全身障害および投与部位の状態	2 (33.3)	0	1 (16.7)	3 (30.0)	3 (37.5)	4 (50.0)
発熱	1 (16.7)	0	1 (16.7)	2 (20.0)	0	0
疼痛	0	0	0	0	0	1 (12.5)
カテーテル留置部位炎症	0	0	0	0	0	0
泣き	0	0	0	0	0	0
死亡	0	0	0	0	0	0
薬物不耐性	0	0	0	0	0	0
低体温	1 (16.7)	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0	0
倦怠感	0	0	0	0	0	0
小結節	0	0	0	0	0	0
腫脹	0	0	0	0	0	0
不快感	0	0	0	0	0	0
末梢性浮腫	0	0	0	0	0	0
医療機器リーク	0	0	0	0	0	0
医療機器閉塞	0	0	0	0	0	0
浮腫	0	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0	1 (12.5)
末梢腫脹	0	0	0	0	0	0
適用部位紅斑	0	0	0	0	0	0
注入部位内出血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 20 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
一般・全身障害および投与部位の状態	5 (55.6)	5 (55.6)	0	0	15 (31.9)
発熱	0	3 (33.3)	0	0	11 (23.4)
疼痛	0	0	0	0	2 (4.3)
カテーテル留置部位炎症	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
薬物不耐性	0	0	0	0	0
低体温	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
腫脹	0	0	0	0	0
不快感	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
医療機器リーク	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	1 (11.1)	0	0	0	0
適用部位紅斑	0	0	0	0	0
注入部位内出血	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 21 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
疲労	0	0	0	0	1 (12.5)	0
注射部位出血	0	0	0	0	0	0
注射部位疼痛	0	0	0	0	0	0
適用部位発疹	0	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0	1 (12.5)
カテーテル留置部位疼痛	0	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	1 (12.5)	0
胸部不快感	0	0	0	0	1 (12.5)	0
悪寒	0	0	0	0	0	1 (12.5)
医療機器機能不良	0	0	0	0	0	0
冷感	0	0	0	0	0	0
重力性浮腫	0	0	0	0	0	1 (12.5)
注入部位血管外漏出	0	0	0	0	0	0
注射部位血腫	0	0	0	0	0	0
穿刺部位疼痛	1 (16.7)	0	0	1 (10.0)	0	3 (37.5)
穿刺部位反応	1 (16.7)	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0	0
皮膚および皮下組織障害	1 (16.7)	0	1 (16.7)	1 (10.0)	0	0
発疹	0	0	0	1 (10.0)	0	0
おむつ皮膚炎	0	0	0	0	0	0
斑状出血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 22 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
疲労	1 (11.1)	0	0	0	1 (2.1)
注射部位出血	0	0	0	0	1 (2.1)
注射部位疼痛	0	0	0	0	1 (2.1)
適用部位発疹	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	1 (11.1)	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
冷感	1 (11.1)	0	0	0	0
重力性浮腫	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
穿刺部位疼痛	3 (33.3)	2 (22.2)	0	0	0
穿刺部位反応	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0
皮膚および皮下組織障害	1 (11.1)	0	0	0	13 (27.7)
発疹	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	1 (2.1)
斑状出血	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 23 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
接触性皮膚炎	0	0	0	0	0	0
過角化	0	0	0	0	0	0
汗疹	0	0	1 (16.7)	0	0	0
湿疹	1 (16.7)	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
紅斑	0	0	0	0	0	0
蕁麻疹	0	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0	0
環状肉芽腫	0	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0	0
皮膚浮腫	0	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0	0
皮膚刺激	0	0	0	0	0	0
脱毛症	0	0	0	0	0	0
点状出血	0	0	0	0	0	0
そう痒症	0	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0	0
皮下気腫	0	0	0	0	0	0
皮膚障害	0	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 24 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
接触性皮膚炎	0	0	0	0	3 (6.4)
過角化	0	0	0	0	0
汗疹	0	0	0	0	0
湿疹	0	0	0	0	1 (2.1)
皮膚炎	0	0	0	0	1 (2.1)
紅斑	0	0	0	0	1 (2.1)
蕁麻疹	0	0	0	0	1 (2.1)
アレルギー性皮膚炎	0	0	0	0	0
環状肉芽腫	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
皮膚刺激	0	0	0	0	0
脱毛症	0	0	0	0	0
点状出血	0	0	0	0	0
そう痒症	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
皮膚障害	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 25 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ざ瘡	0	0	0	0	0	0
水疱	0	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0	0
毛孔性角化症	0	0	0	0	0	0
皮膚病変	0	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0	0
皮膚乾燥	0	0	0	0	0	0
多汗症	0	0	0	0	0	0
寝汗	0	0	0	0	0	0
臨床検査	0	1 (16.7)	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
体重減少	0	0	0	0	0	0
血中カリウム減少	0	0	0	0	0	0
体温上昇	0	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0	0
好中球数増加	0	0	0	0	0	0
心拍数増加	0	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 26 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ざ瘡	0	0	0	0	1 (2.1)
水疱	0	0	0	0	1 (2.1)
褥瘡性潰瘍	0	0	0	0	1 (2.1)
毛孔性角化症	0	0	0	0	1 (2.1)
皮膚病変	0	0	0	0	1 (2.1)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
多汗症	0	0	0	0	0
寝汗	1 (11.1)	0	0	0	0
臨床検査	2 (22.2)	0	1 (25.0)	0	4 (8.5)
酸素飽和度低下	0	0	0	0	0
体重減少	1 (11.1)	0	0	0	2 (4.3)
血中カリウム減少	0	0	0	0	0
体温上昇	0	0	1 (25.0)	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
好中球数増加	0	0	0	0	0
心拍数増加	0	0	0	0	1 (2.1)
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 27 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0	0
血中クロール減少	0	0	0	0	0	0
血中鉄減少	0	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0	0
体温低下	0	0	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0	0
心拍数不整	0	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0	0
肝機能検査異常	0	0	0	0	0	0
医学的観察	0	0	0	0	0	0
尿量減少	0	0	0	0	0	0
ビタミンＡ減少	0	0	0	0	0	0
白血球数増加	0	0	0	0	0	0
骨密度減少	0	0	0	0	0	0
呼吸音異常	0	0	0	0	0	0
心拍数減少	0	0	0	0	0	0
好中球百分率増加	0	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 28 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
医学的観察	0	0	0	0	0
尿量減少	0	0	0	0	0
ビタミンＡ減少	0	0	0	0	0
白血球数増加	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 29 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
血中テストステロン減少	0	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0	0
リンパ節触知	0	0	0	0	0	0
呼吸数増加	0	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0	0
尿検査異常	0	1 (16.7)	0	0	0	0
ビタミンＤ減少	0	0	0	0	0	0
心臓障害	0	1 (16.7)	0	0	1 (12.5)	0
頻脈	0	0	0	0	0	0
心肺停止	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
心停止	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
左室肥大	0	0	0	0	0	0
上室性頻脈	0	0	0	0	0	0
心筋症	0	0	0	0	0	0
心膜気腫	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 30 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
血中テストステロン減少	0	0	0	0	1 (2.1)
ＣＳＦ白血球数増加	0	0	0	0	1 (2.1)
血中重炭酸塩減少	1 (11.1)	0	0	0	0
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
尿検査異常	0	0	0	0	0
ビタミンＤ減少	0	0	0	0	0
心臓障害	0	0	1 (25.0)	0	1 (2.1)
頻脈	0	0	0	0	1 (2.1)
心肺停止	0	0	0	0	0
徐脈	0	0	0	0	0
心停止	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心室性頻脈	0	0	0	0	0
左室肥大	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
心膜気腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 31 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
動悸	0	1 (16.7)	0	0	1 (12.5)	0
傷害、中毒および処置合併症	2 (33.3)	2 (33.3)	3 (50.0)	1 (10.0)	5 (62.5)	2 (25.0)
処置による疼痛	0	0	0	0	1 (12.5)	1 (12.5)
ストーマ部紅斑	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
挫傷	0	0	0	0	0	0
処置後腫脹	0	0	0	0	0	0
術後激越	0	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0	0
擦過傷	0	0	0	0	0	0
伝染病曝露	0	0	0	0	0	0
処置合併症	0	0	0	0	0	0
処置部位反応	0	0	0	0	0	0
ストーマ合併症	0	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0	0
創離開	0	0	0	0	0	0
節足動物咬傷	0	0	0	0	0	1 (12.5)
関節脱臼	0	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 32 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
動悸	0	0	1 (25.0)	0	0
傷害、中毒および処置合併症	7 (77.8)	7 (77.8)	2 (50.0)	4 (28.6)	22 (46.8)
処置による疼痛	0	0	0	1 (7.1)	4 (8.5)
ストーマ部紅斑	0	0	0	0	0
大腿骨骨折	0	1 (11.1)	0	0	2 (4.3)
挫傷	0	0	0	0	2 (4.3)
処置後腫脹	0	0	0	0	0
術後激越	1 (11.1)	0	0	0	1 (2.1)
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
伝染病曝露	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ストーマ合併症	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	2 (22.2)	0	0	0	1 (2.1)
関節脱臼	0	0	0	0	2 (4.3)
栄養補給チューブ合併症	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 33 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ダンピング症候群	0	0	0	0	0	0
耳擦過傷	0	0	0	0	0	0
口唇損傷	0	0	0	0	0	0
外傷性気胸	0	0	0	0	0	0
歯牙損傷	0	0	0	0	0	0
軟部組織損傷	0	0	0	0	0	0
サンバーン	0	0	0	0	1 (12.5)	0
熱傷	0	0	0	0	0	0
転倒	0	0	0	0	0	0
処置後合併症	0	0	0	0	0	0
処置後不快感	0	0	0	0	0	0
硬膜下血腫	0	0	0	0	0	0
腰椎穿刺後症候群	1 (16.7)	2 (33.3)	2 (33.3)	1 (10.0)	3 (37.5)	1 (12.5)
裂傷	0	0	1 (16.7)	0	1 (12.5)	0
四肢損傷	0	0	0	0	1 (12.5)	0
節足動物刺傷	0	0	0	0	0	0
関節損傷	0	0	0	0	0	0
靭帯捻挫	0	0	0	0	0	0
下肢骨折	0	0	0	0	0	0
半月板損傷	0	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0	0
頭部損傷	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 34 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
歯牙損傷	0	0	0	0	0
軟部組織損傷	0	0	0	0	0
サンバーン	0	1 (11.1)	0	0	0
熱傷	1 (11.1)	0	0	0	0
転倒	0	0	0	0	1 (2.1)
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
腰椎穿刺後症候群	3 (33.3)	6 (66.7)	0	1 (7.1)	10 (21.3)
裂傷	1 (11.1)	1 (11.1)	0	0	3 (6.4)
四肢損傷	0	0	0	0	2 (4.3)
節足動物刺傷	0	0	0	0	1 (2.1)
関節損傷	0	0	1 (25.0)	1 (7.1)	1 (2.1)
靭帯捻挫	0	0	0	0	1 (2.1)
下肢骨折	0	0	0	0	1 (2.1)
半月板損傷	0	0	0	0	1 (2.1)
気管内挿管合併症	0	0	0	0	0
頭部損傷	0	0	0	1 (7.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 35 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
肉離れ	0	0	0	0	0	0
処置後挫傷	0	0	0	0	0	0
術後イレウス	0	0	0	0	1 (12.5)	0
処置による頭痛	0	0	0	0	0	0
処置による悪心	1 (16.7)	0	0	0	0	0
ストーマ部出血	0	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0	0
脛骨骨折	0	0	0	0	0	0
隆起骨折	0	0	0	0	0	1 (12.5)
気管損傷	0	0	0	0	0	0
代謝および栄養障害	0	1 (16.7)	0	0	0	0
体重増加不良	0	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
脱水	0	1 (16.7)	0	0	0	0
鉄欠乏	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0
過小食	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 36 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
肉離れ	0	0	1 (25.0)	0	0
処置後挫傷	0	0	0	0	0
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	1 (7.1)	0
処置による悪心	0	0	0	1 (7.1)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
脛骨骨折	1 (11.1)	0	0	0	0
隆起骨折	1 (11.1)	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	0	1 (11.1)	0	0	3 (6.4)
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0
成長障害	0	0	0	0	0
脱水	0	1 (11.1)	0	0	0
鉄欠乏	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
過小食	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 37 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
代謝性アルカローシス	0	0	0	0	0	0
食欲減退	0	0	0	0	0	0
食欲亢進	0	0	0	0	0	0
ビタミンＤ欠乏	0	0	0	0	0	0
食物不耐性	0	0	0	0	0	0
高血糖	0	0	0	0	0	0
低血糖	0	0	0	0	0	0
低カリウム血症	0	0	0	0	0	0
筋骨格系および結合組織障害	3 (50.0)	2 (33.3)	1 (16.7)	2 (20.0)	1 (12.5)	4 (50.0)
側弯症	0	0	0	1 (10.0)	1 (12.5)	1 (12.5)
関節拘縮	0	0	0	0	0	1 (12.5)
頭位性斜頭症	0	0	0	0	0	0
脊柱後弯症	0	0	0	0	0	0
胸郭変形	0	0	0	0	0	0
四肢痛	0	0	1 (16.7)	0	0	0
後側弯症	0	0	0	0	0	0
背部痛	2 (33.3)	2 (33.3)	0	1 (10.0)	1 (12.5)	2 (25.0)
泉門閉鎖遅延	0	0	0	0	0	0
斜頚	0	0	0	0	0	0
手変形	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 38 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
代謝性アルカローシス	0	0	0	0	0
食欲減退	0	0	0	0	1 (2.1)
食欲亢進	0	0	0	0	1 (2.1)
ビタミンＤ欠乏	0	0	0	0	1 (2.1)
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
筋骨格系および結合組織障害	3 (33.3)	7 (77.8)	2 (50.0)	3 (21.4)	32 (68.1)
側弯症	1 (11.1)	1 (11.1)	1 (25.0)	1 (7.1)	9 (19.1)
関節拘縮	1 (11.1)	1 (11.1)	0	0	7 (14.9)
頭位性斜頭症	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
胸郭変形	0	0	0	0	0
四肢痛	0	1 (11.1)	0	1 (7.1)	3 (6.4)
後側弯症	0	0	0	0	0
背部痛	2 (22.2)	4 (44.4)	1 (25.0)	2 (14.3)	18 (38.3)
泉門閉鎖遅延	0	0	0	0	0
斜頚	0	0	0	0	0
手変形	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 39 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
関節硬直	0	0	0	0	0	0
脊柱前弯症	0	0	0	1 (10.0)	0	0
脊柱変形	0	0	0	0	0	0
滑膜炎	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
体重支持困難	0	0	0	0	0	0
関節痛	0	0	0	0	0	1 (12.5)
筋緊張	0	0	0	0	0	0
筋肉痛	1 (16.7)	0	0	0	0	1 (12.5)
頚部痛	0	0	0	0	0	0
四肢拘縮	0	0	0	0	0	0
骨盤変形	0	0	0	0	0	1 (12.5)
腱障害	0	0	0	0	0	0
神経系障害	4 (66.7)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
眼振	0	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0	0
よだれ	0	0	0	0	0	0
痙攣発作	0	0	0	0	0	0
脳損傷	0	0	0	0	0	0
間代	0	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 40 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
関節硬直	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
筋力低下	0	0	0	0	0
体重支持困難	0	0	0	0	0
関節痛	0	1 (11.1)	0	0	4 (8.5)
筋緊張	0	0	0	0	2 (4.3)
筋肉痛	0	0	0	0	2 (4.3)
頚部痛	0	1 (11.1)	0	0	2 (4.3)
四肢拘縮	0	0	0	0	1 (2.1)
骨盤変形	0	0	0	0	1 (2.1)
腱障害	0	0	0	0	0
神経系障害	2 (22.2)	1 (11.1)	0	3 (21.4)	17 (36.2)
眼振	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0
よだれ	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 41 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
傾眠	0	0	0	0	0	0
失神	0	0	0	0	0	0
脳梗塞	0	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0	0
嗜眠	0	0	0	0	0	0
頭痛	4 (66.7)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
反射亢進	0	0	0	0	0	0
筋緊張低下	0	0	0	0	0	0
失声症	0	0	0	0	0	0
感覚鈍麻	0	0	0	0	0	1 (12.5)
片頭痛	0	0	0	0	0	0
振戦	0	0	0	0	0	0
味覚異常	0	0	0	0	0	0
失読症	0	0	0	0	0	0
錯感覚	1 (16.7)	0	0	0	0	1 (12.5)
失神寸前の状態	0	0	0	0	0	0
精神障害	1 (16.7)	0	0	0	1 (12.5)	0
不安	0	0	0	0	0	0
激越	0	0	0	0	1 (12.5)	0
易刺激性	0	0	0	0	0	0
息こらえ	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 42 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
傾眠	0	0	0	0	0
失神	0	0	0	0	1 (2.1)
脳梗塞	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
嗜眠	0	0	0	0	0
頭痛	1 (11.1)	0	0	3 (21.4)	16 (34.0)
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
失声症	0	0	0	0	1 (2.1)
感覚鈍麻	0	0	0	0	1 (2.1)
片頭痛	0	0	0	0	1 (2.1)
振戦	0	0	0	0	1 (2.1)
味覚異常	1 (11.1)	0	0	0	0
失読症	0	1 (11.1)	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
精神障害	0	2 (22.2)	0	0	1 (2.1)
不安	0	0	0	0	0
激越	0	1 (11.1)	0	0	0
易刺激性	0	0	0	0	0
息こらえ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 43 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気分動揺	0	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0	0
睡眠障害	0	0	0	0	0	0
不眠症	0	0	0	0	0	0
チック	0	0	0	0	0	0
注意欠陥多動性障害	0	0	0	0	0	0
不快気分	0	0	0	0	1 (12.5)	0
睡眠時随伴症	0	0	0	0	0	0
心因性嘔吐	1 (16.7)	0	0	0	0	0
免疫系障害	0	0	0	0	2 (25.0)	0
季節性アレルギー	0	0	0	0	0	0
薬物過敏症	0	0	0	0	1 (12.5)	0
過敏症	0	0	0	0	1 (12.5)	0
食物アレルギー	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
高血圧	0	0	0	0	0	0
蒼白	0	0	0	0	0	0
ショック	0	0	0	0	0	0
血管炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 44 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
不眠症	0	0	0	0	1 (2.1)
チック	0	0	0	0	1 (2.1)
注意欠陥多動性障害	0	1 (11.1)	0	0	0
不快気分	0	0	0	0	0
睡眠時随伴症	0	1 (11.1)	0	0	0
心因性嘔吐	0	0	0	0	0
免疫系障害	0	2 (22.2)	1 (25.0)	0	2 (4.3)
季節性アレルギー	0	1 (11.1)	1 (25.0)	0	1 (2.1)
薬物過敏症	0	0	0	0	0
過敏症	0	1 (11.1)	0	0	1 (2.1)
食物アレルギー	0	0	0	0	0
血管障害	0	0	0	1 (7.1)	0
高血圧	0	0	0	0	0
蒼白	0	0	0	0	0
ショック	0	0	0	0	0
血管炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 45 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
毛細血管脆弱	0	0	0	0	0	0
本態性高血圧症	0	0	0	0	0	0
低血圧	0	0	0	0	0	0
眼障害	0	0	0	0	0	0
霰粒腫	0	0	0	0	0	0
眼乾燥	0	0	0	0	0	0
眼運動障害	0	0	0	0	0	0
近視	0	0	0	0	0	0
斜視	0	0	0	0	0	0
眼瞼下垂	0	0	0	0	0	0
乱視	0	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0	0
遠視	0	0	0	0	0	0
弱視	0	0	0	0	0	0
流涙増加	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0	0
貧血母斑	0	0	0	0	0	0
鳩胸	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 46 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
毛細血管脆弱	0	0	0	0	0
本態性高血圧症	0	0	0	0	0
低血圧	0	0	0	1 (7.1)	0
眼障害	1 (11.1)	0	0	0	1 (2.1)
霰粒腫	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼運動障害	0	0	0	0	0
近視	0	0	0	0	0
斜視	1 (11.1)	0	0	0	0
眼瞼下垂	0	0	0	0	0
乱視	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
遠視	0	0	0	0	1 (2.1)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
鳩胸	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 47 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
斜頭症	0	0	0	0	0	0
斜指症	0	0	0	0	0	0
停留精巣	0	0	0	0	0	0
包茎	0	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0	0
後天性包茎	0	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0	0
陰茎障害	0	0	0	0	0	0
耳および迷路障害	1 (16.7)	0	0	0	1 (12.5)	0
耳の障害	0	0	0	0	0	0
耳痛	0	0	0	0	1 (12.5)	0
耳垢分泌過多	0	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0	0
乗物酔い	1 (16.7)	0	0	0	0	0
腎および尿路障害	0	0	0	0	0	0
水腎症	0	0	0	0	0	0
尿閉	0	0	0	0	0	0
排尿困難	0	0	0	0	0	0
尿失禁	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 48 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
斜頭症	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
包茎	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (2.1)
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0
鼓膜穿孔	0	0	0	0	1 (2.1)
乗物酔い	0	0	0	0	0
腎および尿路障害	0	0	0	1 (7.1)	2 (4.3)
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
排尿困難	0	0	0	0	1 (2.1)
尿失禁	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 49 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
糖尿	0	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0	0
貧血	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
血小板増加症	0	0	0	0	0	0
リンパ節症	0	0	0	0	0	0
好酸球増加症	0	0	0	0	0	0
骨髄障害	0	0	0	0	0	0
白血球増加症	0	0	0	0	0	0
肝胆道系障害	0	0	0	0	0	0
肝腫大	0	0	0	0	0	0
外科および内科処置	0	0	0	0	0	0
機械的換気	0	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	1 (12.5)	0
アクロコルドン	0	0	0	0	0	0
血管の良性新生物	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 50 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
糖尿	0	0	0	0	0
膀胱尿管逆流	0	0	0	1 (7.1)	0
血液およびリンパ系障害	0	0	0	0	1 (2.1)
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	1 (2.1)
血小板増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
好酸球増加症	0	0	0	0	0
骨髄障害	0	0	0	0	0
白血球増加症	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
アクロコルドン	0	0	0	0	0
血管の良性新生物	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 51 of 52

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
脂漏性角化症	0	0	0	0	0	0
皮膚乳頭腫	0	0	0	0	1 (12.5)	0
妊娠、産褥および周産期の状態	0	0	0	0	0	0
臍肉芽腫	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 11　　遅発型 SMA の被験者での AE 発現率；試験別、治療別（続き）

Incidence of Adverse Events - Later-onset
Page 52 of 52

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
脂漏性角化症	0	0	0	0	0
皮膚乳頭腫	0	0	0	0	0
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 12　Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 1 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	12 (70.6)	4 (100)	15 (93.8)	36 (87.8)	70 (87.5)
呼吸器、胸郭および縦隔障害	2 (11.8)	2 (50.0)	11 (68.8)	29 (70.7)	46 (57.5)
呼吸不全	0	0	2 (12.5)	8 (19.5)	11 (13.8)
呼吸窮迫	1 (5.9)	1 (25.0)	1 (6.3)	7 (17.1)	9 (11.3)
無気肺	0	0	2 (12.5)	6 (14.6)	8 (10.0)
急性呼吸不全	0	1 (25.0)	1 (6.3)	4 (9.8)	6 (7.5)
鼻閉	1 (5.9)	1 (25.0)	4 (25.0)	5 (12.2)	5 (6.3)
呼吸困難	0	0	0	1 (2.4)	4 (5.0)
無呼吸	0	0	2 (12.5)	2 (4.9)	3 (3.8)
咳嗽	0	0	2 (12.5)	8 (19.5)	3 (3.8)
誤嚥	0	0	1 (6.3)	0	3 (3.8)
低酸素症	0	0	1 (6.3)	1 (2.4)	3 (3.8)
気管支分泌物貯留	0	0	1 (6.3)	3 (7.3)	2 (2.5)
低換気	0	0	1 (6.3)	0	2 (2.5)
慢性呼吸不全	0	0	0	0	2 (2.5)
誤嚥性肺炎	0	0	0	5 (12.2)	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

表 12　Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA（続き）

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 2 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	13 (100)	4 (100)	15 (100)	26 (100)	59 (100)
Number of subjects with an event	9 (69.2)	4 (100)	15 (100)	25 (96.2)	48 (81.4)
呼吸器、胸郭および縦隔障害	1 (7.7)	2 (50.0)	11 (73.3)	15 (57.7)	21 (35.6)
呼吸不全	0	0	3 (20.0)	7 (26.9)	2 (3.4)
呼吸窮迫	0	0	3 (20.0)	4 (15.4)	8 (13.6)
無気肺	0	0	1 (6.7)	4 (15.4)	6 (10.2)
急性呼吸不全	0	0	1 (6.7)	3 (11.5)	5 (8.5)
鼻閉	1 (7.7)	1 (25.0)	1 (6.7)	0	2 (3.4)
呼吸困難	0	1 (25.0)	1 (6.7)	4 (15.4)	0
無呼吸	0	0	1 (6.7)	1 (3.8)	0
咳嗽	0	0	0	1 (3.8)	1 (1.7)
誤嚥	0	0	1 (6.7)	1 (3.8)	1 (1.7)
低酸素症	0	0	2 (13.3)	1 (3.8)	1 (1.7)
気管支分泌物貯留	0	1 (25.0)	0	1 (3.8)	1 (1.7)
低換気	0	0	0	0	0
慢性呼吸不全	0	0	1 (6.7)	0	0
誤嚥性肺炎	0	0	1 (6.7)	1 (3.8)	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 3 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	10 (100)	4 (100)	13 (100)	18 (100)	41 (100)
Number of subjects with an event	7 (70.0)	4 (100)	11 (84.6)	16 (88.9)	36 (87.8)
呼吸器、胸郭および縦隔障害	1 (10.0)	1 (25.0)	6 (46.2)	11 (61.1)	19 (46.3)
呼吸不全	0	0	0	1 (5.6)	3 (7.3)
呼吸窮迫	0	0	0	5 (27.8)	2 (4.9)
無気肺	0	0	0	0	5 (12.2)
急性呼吸不全	0	0	2 (15.4)	3 (16.7)	7 (17.1)
鼻閉	0	0	0	1 (5.6)	3 (7.3)
呼吸困難	0	0	0	1 (5.6)	2 (4.9)
無呼吸	0	0	0	2 (11.1)	1 (2.4)
咳嗽	1 (10.0)	0	1 (7.7)	0	2 (4.9)
誤嚥	0	0	0	0	0
低酸素症	0	0	1 (7.7)	1 (5.6)	2 (4.9)
気管支分泌物貯留	0	0	0	0	1 (2.4)
低換気	0	0	0	0	0
慢性呼吸不全	0	0	1 (7.7)	0	0
誤嚥性肺炎	0	0	1 (7.7)	0	3 (7.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 4 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	5 (100)	3 (100)	13 (100)	13 (100)	26 (100)
Number of subjects with an event	4 (80.0)	2 (66.7)	10 (76.9)	12 (92.3)	19 (73.1)
呼吸器、胸郭および縦隔障害	1 (20.0)	1 (33.3)	5 (38.5)	4 (30.8)	9 (34.6)
呼吸不全	0	0	1 (7.7)	0	2 (7.7)
呼吸窮迫	0	0	0	1 (7.7)	3 (11.5)
無気肺	0	0	0	0	2 (7.7)
急性呼吸不全	0	0	1 (7.7)	0	1 (3.8)
鼻閉	0	0	1 (7.7)	0	0
呼吸困難	0	0	0	0	1 (3.8)
無呼吸	0	0	0	1 (7.7)	0
咳嗽	1 (20.0)	1 (33.3)	1 (7.7)	0	0
誤嚥	0	0	0	0	0
低酸素症	0	0	0	1 (7.7)	0
気管支分泌物貯留	0	0	0	0	0
低換気	0	0	0	0	0
慢性呼吸不全	0	0	1 (7.7)	0	0
誤嚥性肺炎	0	0	1 (7.7)	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 5 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	1 (100)	2 (100)	13 (100)	9 (100)	19 (100)
Number of subjects with an event	1 (100)	2 (100)	10 (76.9)	3 (33.3)	10 (52.6)
呼吸器、胸郭および縦隔障害	0	0	5 (38.5)	1 (11.1)	1 (5.3)
呼吸不全	0	0	1 (7.7)	0	0
呼吸窮迫	0	0	1 (7.7)	0	0
無気肺	0	0	2 (15.4)	0	0
急性呼吸不全	0	0	0	0	0
鼻閉	0	0	0	0	0
呼吸困難	0	0	0	0	0
無呼吸	0	0	0	0	0
咳嗽	0	0	2 (15.4)	0	0
誤嚥	0	0	0	0	0
低酸素症	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
低換気	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 6 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	13 (100)	0	0
Number of subjects with an event	0	2 (100)	10 (76.9)	0	0
呼吸器、胸郭および縦隔障害	2 (100)	3 (23.1)			
呼吸不全		0	0		
呼吸窮迫		1 (50.0)	1 (7.7)		
無気肺		0	1 (7.7)		
急性呼吸不全		1 (50.0)	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		1 (50.0)	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 7 of 288

	Days 541-630				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	13 (100)	0	0
Number of subjects with an event	0	1 (50.0)	8 (61.5)	0	0
呼吸器、胸郭および縦隔障害	0	4 (30.8)			
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	1 (7.7)		
急性呼吸不全		0	0		
鼻閉		0	1 (7.7)		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	1 (7.7)		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 8 of 288

	Days 631-720				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	9 (100)	0	0
Number of subjects with an event	0	2 (100)	5 (55.6)	0	0
呼吸器、胸郭および縦隔障害	1 (50.0)	2 (22.2)			
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	1 (11.1)		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 9 of 288

	Days 721-810				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	6 (100)	0	0
Number of subjects with an event	0	2 (100)	6 (100)	0	0
呼吸器、胸郭および縦隔障害	1 (50.0)	4 (66.7)			
呼吸不全		0	0		
呼吸窮迫		0	1 (16.7)		
無気肺		0	0		
急性呼吸不全		0	1 (16.7)		
鼻閉		1 (50.0)	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	1 (16.7)		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 10 of 288

	Days 811-900				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	2 (100)	0	0
Number of subjects with an event	0	1 (50.0)	1 (50.0)	0	0
呼吸器、胸郭および縦隔障害	0	0			
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	0		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 11 of 288

	Days 901-990				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	2 (100)	0	0	0
Number of subjects with an event	0	1 (50.0)	0	0	0
呼吸器、胸郭および縦隔障害		1 (50.0)	0		
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	0		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		1 (50.0)	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 12 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	0	1 (100)	0	0	0
Number of subjects with an event	0	0	0	0	0
呼吸器、胸郭および縦隔障害		0	0		
呼吸不全		0	0		
呼吸窮迫		0	0		
無気肺		0	0		
急性呼吸不全		0	0		
鼻閉		0	0		
呼吸困難		0	0		
無呼吸		0	0		
咳嗽		0	0		
誤嚥		0	0		
低酸素症		0	0		
気管支分泌物貯留		0	0		
低換気		0	0		
慢性呼吸不全		0	0		
誤嚥性肺炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 13 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	0	2 (2.5)
呼吸障害	0	0	0	0	2 (2.5)
鼻漏	0	0	0	1 (2.4)	2 (2.5)
上気道うっ血	0	0	0	1 (2.4)	2 (2.5)
息詰まり	0	0	1 (6.3)	0	1 (1.3)
上気道分泌増加	0	0	1 (6.3)	0	1 (1.3)
気胸	0	0	1 (6.3)	0	1 (1.3)
呼吸補助筋の動員	0	0	1 (6.3)	1 (2.4)	1 (1.3)
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
胸水	0	0	0	0	1 (1.3)
呼吸性アルカローシス	0	0	0	0	1 (1.3)
気道うっ血	0	0	0	3 (7.3)	1 (1.3)
副鼻腔うっ血	0	0	0	0	1 (1.3)
睡眠時無呼吸症候群	0	0	1 (6.3)	3 (7.3)	0
頻呼吸	0	0	1 (6.3)	0	0
呼吸性アシドーシス	1 (5.9)	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 14 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	4 (15.4)	0
呼吸障害	0	0	0	0	0
鼻漏	0	0	1 (6.7)	0	0
上気道うっ血	0	0	0	0	0
息詰まり	0	0	0	0	0
上気道分泌増加	0	0	2 (13.3)	0	1 (1.7)
気胸	0	0	1 (6.7)	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	1 (1.7)
睡眠時無呼吸症候群	0	0	0	1 (3.8)	0
頻呼吸	0	0	0	1 (3.8)	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	1 (6.7)	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 15 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	1 (5.6)	1 (2.4)
呼吸障害	0	0	0	0	0
鼻漏	0	0	1 (7.7)	1 (5.6)	1 (2.4)
上気道うっ血	0	0	0	0	2 (4.9)
息詰まり	0	0	0	1 (5.6)	0
上気道分泌増加	0	0	0	1 (5.6)	1 (2.4)
気胸	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	1 (2.4)
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 16 of 288

	Days 271-360				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	1 (7.7)	0	0
呼吸障害	0	0	0	0	0
鼻漏	1 (20.0)	0	0	0	1 (3.8)
上気道うっ血	1 (20.0)	0	0	0	1 (3.8)
息詰まり	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
気胸	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	2 (15.4)	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	1 (3.8)
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 17 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止	0	0	0	0	0
呼吸障害	0	0	0	0	0
鼻漏	0	0	0	1 (11.1)	0
上気道うっ血	0	0	0	0	0
息詰まり	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
気胸	0	0	1 (7.7)	0	0
呼吸補助筋の動員	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
無呼吸発作	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 18 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	1 (7.7)		
息詰まり		0	0		
上気道分泌増加		0	1 (7.7)		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	1 (7.7)		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 19 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	1 (7.7)		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	1 (7.7)		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 20 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 21 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	1 (16.7)		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 22 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 23 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 24 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
呼吸停止		0	0		
呼吸障害		0	0		
鼻漏		0	0		
上気道うっ血		0	0		
息詰まり		0	0		
上気道分泌増加		0	0		
気胸		0	0		
呼吸補助筋の動員		0	0		
肺障害		0	0		
閉塞性気道障害		0	0		
胸水		0	0		
呼吸性アルカローシス		0	0		
気道うっ血		0	0		
副鼻腔うっ血		0	0		
睡眠時無呼吸症候群		0	0		
頻呼吸		0	0		
呼吸性アシドーシス		0	0		
急性呼吸窮迫症候群		0	0		
無呼吸発作		0	0		
乳幼児突発性危急事態		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 25 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	1 (2.4)	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	1 (2.4)	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	0	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	1 (2.4)	0
喘鳴	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 26 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	1 (1.7)
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	1 (6.7)	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	1 (6.7)	0	0
アレルギー性鼻炎	0	0	0	0	1 (1.7)
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	0	0
喘鳴	0	0	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 27 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	1 (25.0)	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	1 (5.6)	0
高炭酸ガス血症	0	0	0	0	1 (2.4)
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	0	1 (2.4)
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	0	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	1 (5.6)	0
喘鳴	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 28 of 288

Days 271-360

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	1 (3.8)
気管支分泌増加	0	0	0	0	0
喉頭肉芽腫	0	0	0	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	0	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	0
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	1 (7.7)	0
喘鳴	0	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 29 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息	0	0	0	0	0
気管支閉塞	0	0	0	0	0
カタル	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0
減呼吸	0	0	0	0	0
気管支分泌増加	0	0	0	0	0
喉頭肉芽腫	0	0	1 (7.7)	0	0
鼻汁変色	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
気縦隔症	0	0	1 (7.7)	0	0
湿性咳嗽	0	0	0	0	0
肺うっ血	0	0	1 (7.7)	0	0
肺水腫	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
変色痰	0	0	0	0	1 (5.3)
気管障害	0	0	0	0	0
上気道の炎症	0	0	0	0	0
喘鳴	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 30 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	1 (7.7)		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	1 (7.7)		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 31 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	1 (7.7)		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 32 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	1 (11.1)		
拘束性肺疾患		0	0		
アレルギー性鼻炎		1 (50.0)	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 33 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	1 (16.7)		
肺うっ血		0	0		
肺水腫		0	1 (16.7)		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 34 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 35 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 36 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
窒息		0	0		
気管支閉塞		0	0		
カタル		0	0		
高炭酸ガス血症		0	0		
減呼吸		0	0		
気管支分泌増加		0	0		
喉頭肉芽腫		0	0		
鼻汁変色		0	0		
口腔咽頭痛		0	0		
気縦隔症		0	0		
湿性咳嗽		0	0		
肺うっ血		0	0		
肺水腫		0	0		
拘束性肺疾患		0	0		
アレルギー性鼻炎		0	0		
低音性連続性ラ音		0	0		
変色痰		0	0		
気管障害		0	0		
上気道の炎症		0	0		
喘鳴		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 37 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	7 (41.2)	1 (25.0)	6 (37.5)	21 (51.2)	42 (52.5)
肺炎	1 (5.9)	1 (25.0)	0	4 (9.8)	9 (11.3)
鼻咽頭炎	2 (11.8)	0	1 (6.3)	2 (4.9)	8 (10.0)
ウイルス性上気道感染	0	0	1 (6.3)	4 (9.8)	6 (7.5)
イノウイルス感染	0	0	2 (12.5)	3 (7.3)	5 (6.3)
口腔カンジダ症	0	0	0	2 (4.9)	5 (6.3)
気道感染	0	0	0	1 (2.4)	5 (6.3)
上気道感染	2 (11.8)	0	2 (12.5)	5 (12.2)	4 (5.0)
細気管支炎	0	0	1 (6.3)	3 (7.3)	4 (5.0)
気管支炎	1 (5.9)	0	0	0	4 (5.0)
ウイルス性肺炎	1 (5.9)	0	0	0	3 (3.8)
ウイルス感染	0	0	2 (12.5)	0	2 (2.5)
ウイルス性気道感染	0	0	1 (6.3)	1 (2.4)	2 (2.5)
結膜炎	0	0	0	1 (2.4)	2 (2.5)
モラクセラ菌性肺炎	0	0	1 (6.3)	0	1 (1.3)
カンジダ性おむつ皮疹	0	1 (25.0)	0	0	1 (1.3)
尿路感染	1 (5.9)	0	0	0	1 (1.3)
細菌性気管炎	0	0	0	0	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 38 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	4 (30.8)	3 (75.0)	11 (73.3)	16 (61.5)	34 (57.6)
肺炎	0	1 (25.0)	3 (20.0)	1 (3.8)	4 (6.8)
鼻咽頭炎	2 (15.4)	0	1 (6.7)	0	4 (6.8)
ウイルス性上気道感染	0	0	0	3 (11.5)	6 (10.2)
ライノウイルス感染	0	0	0	3 (11.5)	1 (1.7)
口腔カンジダ症	0	0	0	1 (3.8)	0
気道感染	0	2 (50.0)	1 (6.7)	0	3 (5.1)
上気道感染	0	0	4 (26.7)	1 (3.8)	9 (15.3)
細気管支炎	0	0	1 (6.7)	0	2 (3.4)
気管支炎	0	0	0	0	0
ウイルス性肺炎	0	0	1 (6.7)	0	1 (1.7)
ウイルス感染	0	0	1 (6.7)	0	3 (5.1)
ウイルス性気道感染	0	0	0	0	2 (3.4)
結膜炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	1 (1.7)
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	1 (1.7)
細菌性気管炎	0	0	1 (6.7)	4 (15.4)	0
ウイルス性気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 39 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	5 (50.0)	1 (25.0)	9 (69.2)	12 (66.7)	29 (70.7)
肺炎	0	0	1 (7.7)	0	2 (4.9)
鼻咽頭炎	0	0	2 (15.4)	1 (5.6)	4 (9.8)
ウイルス性上気道感染	0	0	0	2 (11.1)	1 (2.4)
ライノウイルス感染	1 (10.0)	0	2 (15.4)	0	0
口腔カンジダ症	0	0	0	0	1 (2.4)
気道感染	0	0	0	0	4 (9.8)
上気道感染	4 (40.0)	0	2 (15.4)	3 (16.7)	10 (24.4)
細気管支炎	1 (10.0)	0	0	0	1 (2.4)
気管支炎	0	0	0	0	0
ウイルス性肺炎	0	1 (25.0)	0	1 (5.6)	2 (4.9)
ウイルス感染	0	0	0	0	2 (4.9)
ウイルス性気道感染	0	0	0	1 (5.6)	0
結膜炎	0	0	0	1 (5.6)	3 (7.3)
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	0
細菌性気管炎	0	0	0	1 (5.6)	0
ウイルス性気管支炎	0	0	0	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 40 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	2 (40.0)	1 (33.3)	9 (69.2)	8 (61.5)	15 (57.7)
肺炎	0	0	3 (23.1)	1 (7.7)	5 (19.2)
鼻咽頭炎	0	0	3 (23.1)	1 (7.7)	0
ウイルス性上気道感染	0	0	0	0	0
ライノウイルス感染	0	0	2 (15.4)	0	1 (3.8)
口腔カンジダ症	0	0	0	0	1 (3.8)
気道感染	0	1 (33.3)	1 (7.7)	1 (7.7)	1 (3.8)
上気道感染	1 (20.0)	0	2 (15.4)	1 (7.7)	6 (23.1)
細気管支炎	0	0	0	0	1 (3.8)
気管支炎	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0
ウイルス感染	0	0	0	2 (15.4)	1 (3.8)
ウイルス性気道感染	0	0	0	0	1 (3.8)
結膜炎	0	0	0	1 (7.7)	0
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	1 (3.8)
細菌性気管炎	0	0	0	2 (15.4)	0
ウイルス性気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 41 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	1 (100)	1 (50.0)	7 (53.8)	2 (22.2)	4 (21.1)
肺炎	0	0	2 (15.4)	0	0
鼻咽頭炎	0	0	1 (7.7)	0	0
ウイルス性上気道感染	0	0	0	0	0
ライノウイルス感染	0	0	1 (7.7)	0	1 (5.3)
口腔カンジダ症	0	0	0	0	0
気道感染	0	0	0	0	0
上気道感染	0	0	3 (23.1)	0	1 (5.3)
細気管支炎	0	0	1 (7.7)	0	0
気管支炎	0	0	0	0	1 (5.3)
ウイルス性肺炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0
結膜炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
尿路感染	0	0	0	0	0
細菌性気管炎	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 42 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		2 (100)	7 (53.8)		
肺炎		0	0		
鼻咽頭炎		0	2 (15.4)		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	1 (7.7)		
気道感染		1 (50.0)	2 (15.4)		
上気道感染		0	1 (7.7)		
細気管支炎		0	1 (7.7)		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	1 (7.7)		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 43 of 288

	Days 541-630				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	5 (38.5)		
肺炎		0	0		
鼻咽頭炎		0	1 (7.7)		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	1 (7.7)		
上気道感染		0	2 (15.4)		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	1 (7.7)		
ウイルス性気道感染		0	0		
結膜炎		0	1 (7.7)		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 44 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		1 (50.0)	5 (55.6)		
肺炎		0	1 (11.1)		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		1 (50.0)	0		
上気道感染		0	1 (11.1)		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 45 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	4 (66.7)		
肺炎		0	1 (16.7)		
鼻咽頭炎		0	1 (16.7)		
ウイルス性上気道感染		0	1 (16.7)		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	1 (16.7)		
上気道感染		0	0		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	1 (16.7)		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	1 (16.7)		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 46 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		1 (50.0)	1 (50.0)		
肺炎		0	0		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	0		
上気道感染		1 (50.0)	1 (50.0)		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 47 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	0		
肺炎		0	0		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	0		
上気道感染		0	0		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 48 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症		0	0		
肺炎		0	0		
鼻咽頭炎		0	0		
ウイルス性上気道感染		0	0		
ライノウイルス感染		0	0		
口腔カンジダ症		0	0		
気道感染		0	0		
上気道感染		0	0		
細気管支炎		0	0		
気管支炎		0	0		
ウイルス性肺炎		0	0		
ウイルス感染		0	0		
ウイルス性気道感染		0	0		
結膜炎		0	0		
モラクセラ菌性肺炎		0	0		
カンジダ性おむつ皮疹		0	0		
尿路感染		0	0		
細菌性気管炎		0	0		
ウイルス性気管支炎		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 49 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	1 (1.3)
耳感染	0	0	0	1 (2.4)	1 (1.3)
感染性湿疹	0	0	0	0	1 (1.3)
真菌感染	0	0	0	0	1 (1.3)
膿痂疹	0	0	0	1 (2.4)	1 (1.3)
限局性感染	0	0	0	0	1 (1.3)
下気道感染	0	0	0	1 (2.4)	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
細菌性肺炎	0	0	0	1 (2.4)	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	0	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
ＲＳウイルス細気管支炎	0	0	0	1 (2.4)	1 (1.3)
鼻炎	0	0	0	1 (2.4)	1 (1.3)
敗血症	0	0	0	0	1 (1.3)
皮膚カンジダ	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
皮膚真菌感染	0	0	1 (6.3)	1 (2.4)	0
ウイルス性胃炎	0	0	1 (6.3)	0	0
メタニューモウイルス感染	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 50 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	0
耳感染	0	0	0	0	2 (3.4)
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	0	0
膿痂疹	1 (7.7)	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	0
肺感染	0	0	0	0	0
細菌性肺炎	0	0	0	1 (3.8)	0
パラインフルエンザウイルス性肺炎	0	0	0	1 (3.8)	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	1 (6.7)	2 (7.7)	1 (1.7)
鼻炎	0	0	0	2 (7.7)	1 (1.7)
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	1 (3.8)	0
ストーマ部膿瘍	0	0	0	0	0
皮膚真菌感染	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 51 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	1 (5.6)	1 (2.4)
耳感染	0	0	1 (7.7)	0	1 (2.4)
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	1 (5.6)	0
膿痂疹	0	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	3 (7.3)
肺感染	0	0	0	0	0
細菌性肺炎	0	0	1 (7.7)	0	1 (2.4)
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	0	0	1 (2.4)
鼻炎	0	0	0	1 (5.6)	0
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	0	1 (2.4)
ストーマ部膿瘍	0	0	0	0	0
皮膚真菌感染	0	0	0	0	1 (2.4)
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 52 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	0
耳感染	0	0	1 (7.7)	0	0
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	0	0
膿痂疹	0	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	1 (3.8)
肺感染	0	0	0	0	0
細菌性肺炎	0	0	0	0	1 (3.8)
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	0	0	0
鼻炎	1 (20.0)	0	0	0	0
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
皮膚真菌感染	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 53 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎	0	0	0	0	0
耳感染	0	0	0	0	0
感染性湿疹	0	0	0	0	0
真菌感染	0	0	0	0	0
膿痂疹	0	0	0	0	0
限局性感染	0	0	0	0	0
下気道感染	0	0	0	0	0
肺感染	0	0	0	0	0
細菌性肺炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
Ｓウイルス細気管支炎	0	0	0	0	0
鼻炎	0	0	0	0	0
敗血症	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	1 (5.3)
皮膚真菌感染	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 54 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 55 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	1 (7.7)		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 56 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	1 (11.1)		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 57 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 58 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 59 of 288

	Days 901-990				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 60 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
細菌性結膜炎		0	0		
耳感染		0	0		
感染性湿疹		0	0		
真菌感染		0	0		
膿痂疹		0	0		
限局性感染		0	0		
下気道感染		0	0		
肺感染		0	0		
細菌性肺炎		0	0		
パラインフルエンザウイルス性肺炎		0	0		
ＲＳウイルス肺炎		0	0		
Ｓウイルス細気管支炎		0	0		
鼻炎		0	0		
敗血症		0	0		
皮膚カンジダ		0	0		
ストーマ部膿瘍		0	0		
皮膚真菌感染		0	0		
ウイルス性胃炎		0	0		
メタニューモウイルス感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 61 of 288

	Days 1-90				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	1 (25.0)	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	0	0	0
カンジダ感染	0	0	0	2 (4.9)	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	0	1 (2.4)	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	0	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 62 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	1 (3.8)	0
細菌感染	0	0	0	0	0
カンジダ感染	0	0	0	2 (7.7)	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	1 (6.7)	0	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	1 (1.7)
ロタウイルス胃腸炎	0	0	0	0	1 (1.7)
ウイルス性胃腸炎	1 (7.7)	0	0	0	1 (1.7)
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	0	0
インフルエンザ	2 (15.4)	0	0	0	2 (3.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 63 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	2 (4.9)
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	1 (7.7)	0	1 (2.4)
カンジダ感染	0	0	0	0	0
蜂巣炎	0	0	0	1 (5.6)	1 (2.4)
コロナウイルス感染	0	0	0	1 (5.6)	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	1 (2.4)
胃腸炎	0	0	1 (7.7)	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	1 (5.6)	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	1 (2.4)
麦粒腫	0	0	0	0	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 64 of 288

	Days 271-360				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	1 (7.7)	0	0
カンジダ感染	0	0	0	0	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	1 (7.7)	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	1 (7.7)	0
ヘモフィルス感染	0	0	1 (7.7)	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	1 (7.7)	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 65 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎	1 (100)	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0
細菌感染	0	0	0	0	0
カンジダ感染	0	0	0	0	0
蜂巣炎	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	1 (7.7)	0	0
伝染性紅斑	0	0	0	0	0
眼感染	0	0	0	0	0
胃腸炎	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
麦粒腫	0	0	0	0	0
インフルエンザ	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 66 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 67 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	1 (7.7)		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 68 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	1 (11.1)		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	1 (11.1)		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 69 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	1 (16.7)		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 70 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 71 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 72 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
レンサ球菌性咽頭炎		0	0		
アデノウイルス性上気道感染		0	0		
アデノウイルス感染		0	0		
細菌性疾患キャリアー		0	0		
細菌感染		0	0		
カンジダ感染		0	0		
蜂巣炎		0	0		
コロナウイルス感染		0	0		
エンテロウイルス感染		0	0		
伝染性紅斑		0	0		
眼感染		0	0		
胃腸炎		0	0		
ロタウイルス胃腸炎		0	0		
ウイルス性胃腸炎		0	0		
ヘモフィルス感染		0	0		
手足口病		0	0		
麦粒腫		0	0		
インフルエンザ		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 73 of 288

	Days 1-90				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
中耳炎	0	0	0	1 (2.4)	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	1 (2.4)	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
細菌性気道感染	0	0	0	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	0	0
皮膚感染	0	0	0	1 (2.4)	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	1 (2.4)	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 74 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	1 (6.7)	0	2 (3.4)
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	1 (6.7)	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
中耳炎	0	0	0	0	1 (1.7)
急性中耳炎	0	0	0	0	1 (1.7)
パラインフルエンザウイルス感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	1 (1.7)
シュードモナス菌性肺炎	0	0	0	1 (3.8)	0
シュードモナス感染	0	0	0	1 (3.8)	0
細菌性気道感染	0	0	0	1 (3.8)	0
ばら疹	0	0	0	0	1 (1.7)
セラチア感染	0	0	0	1 (3.8)	0
皮膚感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	1 (6.7)	0	0
ブドウ球菌感染	0	0	0	1 (3.8)	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 75 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	1 (2.4)
口腔ヘルペス	0	0	0	0	0
中耳炎	1 (10.0)	0	3 (23.1)	1 (5.6)	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	1 (2.4)
細菌性気道感染	0	0	0	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	1 (5.6)	0
皮膚感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	1 (2.4)
ブドウ球菌皮膚感染	0	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 76 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	1 (3.8)
中耳炎	1 (20.0)	0	0	0	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
細菌性気道感染	0	0	1 (7.7)	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	0	0
皮膚感染	1 (20.0)	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 77 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
院内感染	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0
中耳炎	0	1 (50.0)	1 (7.7)	0	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	1 (7.7)	0	0
インフルエンザ性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	1 (50.0)	0	0	0
シュードモナス感染	0	0	0	1 (11.1)	0
細菌性気道感染	0	0	0	0	0
ばら疹	0	0	0	0	0
セラチア感染	0	0	0	0	0
皮膚感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 78 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	1 (7.7)		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		1 (50.0)	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	1 (7.7)		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 79 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 80 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	1 (11.1)		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 81 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	1 (16.7)		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 82 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 83 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 84 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性下気道感染		0	0		
モラクセラ感染		0	0		
粘膜皮膚カンジダ症		0	0		
院内感染		0	0		
口腔ヘルペス		0	0		
中耳炎		0	0		
急性中耳炎		0	0		
パラインフルエンザウイルス感染		0	0		
インフルエンザ性肺炎		0	0		
シュードモナス菌性肺炎		0	0		
シュードモナス感染		0	0		
細菌性気道感染		0	0		
ばら疹		0	0		
セラチア感染		0	0		
皮膚感染		0	0		
ブドウ球菌性菌血症		0	0		
ブドウ球菌感染		0	0		
ブドウ球菌性敗血症		0	0		
ブドウ球菌皮膚感染		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 85 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	0	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	4 (23.5)	2 (50.0)	10 (62.5)	16 (39.0)	35 (43.8)
便秘	0	0	4 (25.0)	3 (7.3)	13 (16.3)
生歯	0	1 (25.0)	1 (6.3)	3 (7.3)	7 (8.8)
嘔吐	0	0	3 (18.8)	4 (9.8)	6 (7.5)
胃食道逆流性疾患	2 (11.8)	0	4 (25.0)	3 (7.3)	5 (6.3)
嚥下障害	0	0	0	4 (9.8)	4 (5.0)
下痢	0	0	1 (6.3)	5 (12.2)	3 (3.8)
胃炎	0	0	0	0	2 (2.5)
流涎過多	0	0	0	0	2 (2.5)
放屁	2 (11.8)	0	1 (6.3)	1 (2.4)	1 (1.3)
腹部不快感	1 (5.9)	0	0	0	1 (1.3)
アフタ性潰瘍	0	0	0	0	1 (1.3)
胃出血	0	0	0	0	1 (1.3)
血便排泄	0	0	0	0	1 (1.3)
乳児仙痛	0	0	0	0	1 (1.3)
腹痛	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 86 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	2 (7.7)	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	1 (3.8)	0
胃腸障害	1 (7.7)	1 (25.0)	7 (46.7)	12 (46.2)	23 (39.0)
便秘	0	0	2 (13.3)	4 (15.4)	7 (11.9)
生歯	0	0	1 (6.7)	0	3 (5.1)
嘔吐	0	0	3 (20.0)	2 (7.7)	6 (10.2)
胃食道逆流性疾患	0	0	1 (6.7)	1 (3.8)	1 (1.7)
嚥下障害	1 (7.7)	0	0	4 (15.4)	3 (5.1)
下痢	0	0	2 (13.3)	2 (7.7)	2 (3.4)
胃炎	0	0	0	0	0
流涎過多	0	0	0	0	0
放屁	0	1 (25.0)	0	0	1 (1.7)
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	1 (1.7)
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 87 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	1 (5.6)	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	2 (20.0)	1 (25.0)	3 (23.1)	6 (33.3)	14 (34.1)
便秘	1 (10.0)	1 (25.0)	2 (15.4)	0	5 (12.2)
生歯	1 (10.0)	0	0	0	1 (2.4)
嘔吐	0	0	0	0	2 (4.9)
胃食道逆流性疾患	0	0	0	1 (5.6)	1 (2.4)
嚥下障害	0	0	0	2 (11.1)	2 (4.9)
下痢	0	0	1 (7.7)	2 (11.1)	1 (2.4)
胃炎	0	0	0	0	0
流涎過多	0	0	1 (7.7)	0	1 (2.4)
放屁	0	0	0	0	1 (2.4)
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	0
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 88 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	1 (7.7)	0
気管炎	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	0	1 (33.3)	3 (23.1)	5 (38.5)	7 (26.9)
便秘	0	0	0	2 (15.4)	1 (3.8)
生歯	0	0	0	0	0
嘔吐	0	1 (33.3)	1 (7.7)	2 (15.4)	1 (3.8)
胃食道逆流性疾患	0	0	0	1 (7.7)	1 (3.8)
嚥下障害	0	0	0	0	0
下痢	0	1 (33.3)	1 (7.7)	1 (7.7)	3 (11.5)
胃炎	0	0	0	1 (7.7)	1 (3.8)
流涎過多	0	0	1 (7.7)	2 (15.4)	0
放屁	0	0	0	0	0
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	0
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 89 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染	0	0	0	0	0
気管炎	0	0	1 (7.7)	1 (11.1)	0
ウイルス性発疹	0	0	0	0	0
胃腸障害	0	2 (100)	1 (7.7)	0	4 (21.1)
便秘	0	0	0	0	0
生歯	0	1 (50.0)	0	0	0
嘔吐	0	1 (50.0)	0	0	2 (10.5)
胃食道逆流性疾患	0	0	0	0	1 (5.3)
嚥下障害	0	0	0	0	0
下痢	0	0	1 (7.7)	0	1 (5.3)
胃炎	0	0	0	0	0
流涎過多	0	0	0	0	0
放屁	0	0	0	0	0
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0
胃出血	0	0	0	0	0
血便排泄	0	0	0	0	0
乳児仙痛	0	0	0	0	0
腹痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 90 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	4 (30.8)		
便秘		0	1 (7.7)		
生歯		0	0		
嘔吐		0	1 (7.7)		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	1 (7.7)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 91 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	2 (15.4)		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	1 (7.7)		
胃炎		0	1 (7.7)		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 92 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		1 (50.0)	2 (22.2)		
便秘		0	0		
生歯		0	0		
嘔吐		0	1 (11.1)		
胃食道逆流性疾患		0	1 (11.1)		
嚥下障害		0	0		
下痢		0	1 (11.1)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 93 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	2 (33.3)		
便秘		0	0		
生歯		0	0		
嘔吐		0	1 (16.7)		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	2 (33.3)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 94 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	1 (50.0)		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	1 (50.0)		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 95 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	0		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	0		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 96 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ストーマ部感染		0	0		
気管炎		0	0		
ウイルス性発疹		0	0		
胃腸障害		0	0		
便秘		0	0		
生歯		0	0		
嘔吐		0	0		
胃食道逆流性疾患		0	0		
嚥下障害		0	0		
下痢		0	0		
胃炎		0	0		
流涎過多		0	0		
放屁		0	0		
腹部不快感		0	0		
アフタ性潰瘍		0	0		
胃出血		0	0		
血便排泄		0	0		
乳児仙痛		0	0		
腹痛		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 97 of 288

	Days 1-90					
		Infantile-onset				
	Study SM201	Study CS3A		Study CS3B		
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg	
腹部膨満	2 (11.8)	0	0	0	0	
上腹部痛	0	0	0	2 (4.9)	0	
口唇のひび割れ	0	0	0	0	0	
血性下痢	0	0	0	0	0	
排便回数増加	0	0	0	0	0	
胃腸出血	0	0	0	0	0	
消化管運動低下	0	0	0	0	0	
消化管刺激症状	0	0	0	0	0	
吐血	0	0	0	0	0	
乳児吐出	0	0	0	0	0	
口内炎	0	0	0	1 (2.4)	0	
上部消化管出血	0	0	0	0	0	
一般・全身障害および投与部位の状態	3 (17.6)	2 (50.0)	9 (56.3)	18 (43.9)	26 (32.5)	General
発熱	2 (11.8)	1 (25.0)	7 (43.8)	11 (26.8)	20 (25.0)	
疼痛	0	0	2 (12.5)	2 (4.9)	1 (1.3)	
泣き	0	0	0	0	1 (1.3)	
死亡	0	0	0	1 (2.4)	1 (1.3)	
低体温	0	0	0	0	1 (1.3)	

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 98 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	1 (6.7)	0	1 (1.7)
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	1 (6.7)	0	0
血性下痢	0	0	0	0	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	1 (3.8)	0
消化管運動低下	0	0	0	0	0
消化管刺激症状	0	0	0	1 (3.8)	0
吐血	0	0	0	0	0
乳児吐出	0	0	0	0	1 (1.7)
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (7.7)	2 (50.0)	5 (33.3)	13 (50.0)	15 (25.4)
発熱	1 (7.7)	2 (50.0)	5 (33.3)	10 (38.5)	14 (23.7)
疼痛	0	0	2 (13.3)	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 99 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	0	0	0
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
血性下痢	0	0	0	1 (5.6)	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動低下	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
吐血	0	0	0	0	0
乳児吐出	0	0	0	0	0
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	1 (2.4)
一般・全身障害および投与部位の状態	2 (20.0)	1 (25.0)	3 (23.1)	4 (22.2)	14 (34.1)
発熱	2 (20.0)	1 (25.0)	3 (23.1)	3 (16.7)	14 (34.1)
疼痛	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 100 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	1 (7.7)	0	0
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
血性下痢	0	0	0	0	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動低下	0	1 (33.3)	0	0	0
消化管刺激症状	0	0	0	0	0
吐血	0	0	0	0	0
乳児吐出	0	0	0	0	0
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (20.0)	1 (33.3)	4 (30.8)	5 (38.5)	11 (42.3)
発熱	1 (20.0)	0	4 (30.8)	3 (23.1)	11 (42.3)
疼痛	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 101 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満	0	0	0	0	0
上腹部痛	0	0	0	0	0
口唇のひび割れ	0	0	0	0	0
血性下痢	0	0	0	0	0
排便回数増加	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動低下	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
吐血	0	1 (50.0)	0	0	0
乳児吐出	0	0	0	0	0
口内炎	0	0	0	0	0
上部消化管出血	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	4 (30.8)	0	4 (21.1)
発熱	0	0	4 (30.8)	0	4 (21.1)
疼痛	0	0	0	0	0
泣き	0	0	0	0	0
死亡	0	0	0	0	0
低体温	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 102 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	1 (7.7)		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	3 (23.1)		
発熱		0	2 (15.4)		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 103 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 104 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		1 (50.0)	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	2 (22.2)		
発熱		0	2 (22.2)		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 105 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		1 (50.0)	2 (33.3)		
発熱		0	2 (33.3)		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 106 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 107 of 288

	Days 901-990				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 108 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腹部膨満		0	0		
上腹部痛		0	0		
口唇のひび割れ		0	0		
血性下痢		0	0		
排便回数増加		0	0		
胃腸出血		0	0		
消化管運動低下		0	0		
消化管刺激症状		0	0		
吐血		0	0		
乳児吐出		0	0		
口内炎		0	0		
上部消化管出血		0	0		
一般・全身障害および投与部位の状態		0	0		
発熱		0	0		
疼痛		0	0		
泣き		0	0		
死亡		0	0		
低体温		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 109 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	1 (1.3)
倦怠感	0	0	0	0	1 (1.3)
小結節	0	0	0	0	1 (1.3)
医療機器閉塞	0	0	1 (6.3)	0	0
不快感	0	0	1 (6.3)	0	0
浮腫	0	0	1 (6.3)	2 (4.9)	0
血管穿刺部位内出血	0	0	1 (6.3)	1 (2.4)	0
末梢腫脹	0	1 (25.0)	0	0	0
注入部位内出血	1 (5.9)	0	0	0	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	1 (2.4)	0
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	1 (2.4)	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 110 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	1 (6.7)	0	0
不快感	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	1 (3.8)	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	0	0
医療機器リーク	0	0	1 (6.7)	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	1 (1.7)
疲労	0	0	0	1 (3.8)	0
注入部位血管外漏出	0	0	0	1 (3.8)	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 111 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	0	1 (5.6)	0
不快感	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	0	0
適用部位紅斑	1 (10.0)	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	0	0
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 112 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
不快感	0	1 (33.3)	0	0	0
浮腫	0	0	0	1 (7.7)	0
血管穿刺部位内出血	0	0	0	1 (7.7)	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	0	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	1 (7.7)	0
カテーテル留置部位炎症	0	0	0	0	1 (3.8)
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	1 (7.7)	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	1 (33.3)	0	0	0
腫脹	0	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 113 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性	0	0	0	0	0
倦怠感	0	0	0	0	0
小結節	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
不快感	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	0	0	0	0	0
注入部位内出血	0	0	0	0	0
適用部位紅斑	0	0	0	0	0
適用部位発疹	0	0	0	0	0
カテーテル留置部位炎症	0	0	0	0	0
医療機器リーク	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
薬物不耐性	0	0	0	0	0
疲労	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 114 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	1 (7.7)		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 115 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 116 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 117 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		1 (50.0)	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 118 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 119 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 120 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ワクチン接種後の易刺激性		0	0		
倦怠感		0	0		
小結節		0	0		
医療機器閉塞		0	0		
不快感		0	0		
浮腫		0	0		
血管穿刺部位内出血		0	0		
末梢腫脹		0	0		
注入部位内出血		0	0		
適用部位紅斑		0	0		
適用部位発疹		0	0		
カテーテル留置部位炎症		0	0		
医療機器リーク		0	0		
医療機器機能不良		0	0		
薬物不耐性		0	0		
疲労		0	0		
注入部位血管外漏出		0	0		
注射部位血腫		0	0		
末梢性浮腫		0	0		
腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 121 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	1 (2.4)	0
臨床検査	0	0	0	8 (19.5)	13 (16.3)
酸素飽和度低下	0	0	0	5 (12.2)	5 (6.3)
体重減少	0	0	0	1 (2.4)	2 (2.5)
血中鉄減少	0	0	0	0	1 (1.3)
血中カリウム減少	0	0	0	0	1 (1.3)
体温低下	0	0	0	1 (2.4)	1 (1.3)
体温上昇	0	0	0	0	1 (1.3)
電図ＳＴ－Ｔ部分異常	0	0	0	0	1 (1.3)
心拍数不整	0	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	0	0	0	0	1 (1.3)
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	1 (1.3)
医学的観察	0	0	0	0	1 (1.3)
モラクセラ検査陽性	0	0	0	0	1 (1.3)
シュードモナス検査陽性	0	0	0	0	1 (1.3)
ブドウ球菌検査陽性	0	0	0	0	1 (1.3)
尿量減少	0	0	0	0	1 (1.3)
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 122 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	0	0	2 (13.3)	6 (23.1)	5 (8.5)
酸素飽和度低下	0	0	0	4 (15.4)	3 (5.1)
体重減少	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	0
電図ＳＴ－Ｔ部分異常	0	0	0	1 (3.8)	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 123 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	1 (10.0)	0	2 (15.4)	2 (11.1)	5 (12.2)
酸素飽和度低下	0	0	1 (7.7)	2 (11.1)	1 (2.4)
体重減少	0	0	0	0	1 (2.4)
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	1 (2.4)
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	1 (2.4)
電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	1 (10.0)	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 124 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	0	0	2 (15.4)	1 (7.7)	4 (15.4)
酸素飽和度低下	0	0	0	0	0
体重減少	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	1 (3.8)
電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	1 (7.7)	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	1 (7.7)	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 125 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応	0	0	0	0	0
臨床検査	0	0	1 (7.7)	0	2 (10.5)
酸素飽和度低下	0	0	0	0	1 (5.3)
体重減少	0	0	1 (7.7)	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	0
電図ＳＴ－Ｔ部分異常	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 126 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	1 (7.7)		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	1 (7.7)		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 127 of 288

	Days 541-630				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	2 (15.4)		
酸素飽和度低下		0	1 (7.7)		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	1 (7.7)		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 128 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		1 (50.0)	1 (11.1)		
酸素飽和度低下		0	0		
体重減少		1 (50.0)	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 129 of 288

	Days 721-810				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	1 (16.7)		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	1 (16.7)		
シュードモナス検査陽性		0	1 (16.7)		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 130 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	0		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 131 of 288

	Days 901-990				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	0		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 132 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血管穿刺部位反応		0	0		
臨床検査		0	0		
酸素飽和度低下		0	0		
体重減少		0	0		
血中鉄減少		0	0		
血中カリウム減少		0	0		
体温低下		0	0		
体温上昇		0	0		
電図ＳＴ－Ｔ部分異常		0	0		
心拍数不整		0	0		
ヒトライノウイルス検査陽性		0	0		
Ａ型インフルエンザウイルス検査陽性		0	0		
医学的観察		0	0		
モラクセラ検査陽性		0	0		
シュードモナス検査陽性		0	0		
ブドウ球菌検査陽性		0	0		
尿量減少		0	0		
アラニンアミノトランスフェラーゼ増加		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 133 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	1 (2.4)	0
ヘッドラグ異常	0	0	0	1 (2.4)	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	1 (2.4)	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	1 (2.4)	0
ビタミンＡ減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 134 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	1 (6.7)	0	0
Ｃ－反応性蛋白増加	0	0	0	0	2 (3.4)
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	1 (6.7)	0	0
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	1 (3.8)	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンＡ減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 135 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	1 (10.0)	0	0	0	1 (2.4)
血中クロール減少	0	0	0	0	1 (2.4)
血中ナトリウム減少	0	0	0	0	1 (2.4)
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	1 (2.4)
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	1 (7.7)	0	0
心拍数増加	0	0	0	1 (5.6)	1 (2.4)
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	1 (7.7)	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンA減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 136 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	1 (3.8)
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	1 (3.8)
肝機能検査異常	0	0	0	0	0
リンパ節触知	0	0	0	1 (7.7)	0
好中球数増加	0	0	1 (7.7)	0	1 (3.8)
好中球百分率増加	0	0	1 (7.7)	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンA減少	0	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 137 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
心拍数増加	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
肝機能検査異常	0	0	0	0	1 (5.3)
リンパ節触知	0	0	0	0	0
好中球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンA減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 138 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	1 (7.7)		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	1 (7.7)		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 139 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	1 (7.7)		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	1 (7.7)		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 140 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	1 (11.1)		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 141 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	1 (16.7)		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 140 of 288
Page 142 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 140 of 288
Page 143 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 144 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
アスパラギン酸アミノトランスフェラーゼ増加		0	0		
血中クロール減少		0	0		
血中ナトリウム減少		0	0		
骨密度減少		0	0		
呼吸音異常		0	0		
Ｃ－反応性蛋白増加		0	0		
ヘッドラグ異常		0	0		
心拍数減少		0	0		
心拍数増加		0	0		
炎症マーカー上昇		0	0		
肝機能検査異常		0	0		
リンパ節触知		0	0		
好中球数増加		0	0		
好中球百分率増加		0	0		
呼吸数増加		0	0		
レスピロウイルス検査陽性		0	0		
セラチア検査陽性		0	0		
レンサ球菌検査陽性		0	0		
トランスアミナーゼ上昇		0	0		
ビタミンA減少		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 145 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	0	0	0
皮膚および皮下組織障害	4 (23.5)	1 (25.0)	5 (31.3)	8 (19.5)	12 (15.0)
発疹	0	0	1 (6.3)	4 (9.8)	3 (3.8)
おむつ皮膚炎	1 (5.9)	1 (25.0)	0	2 (4.9)	3 (3.8)
接触性皮膚炎	0	0	0	0	2 (2.5)
湿疹	0	0	2 (12.5)	0	1 (1.3)
皮膚炎	2 (11.8)	0	0	0	1 (1.3)
斑状出血	0	0	0	0	1 (1.3)
紅斑	0	0	0	1 (2.4)	1 (1.3)
脱毛症	0	0	1 (6.3)	0	0
過剰肉芽組織	0	0	1 (6.3)	0	0
点状出血	0	0	1 (6.3)	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (2.4)	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	1 (2.4)	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 146 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	1 (3.8)	0
白血球数増加	0	0	0	0	0
皮膚および皮下組織障害	3 (23.1)	2 (50.0)	2 (13.3)	5 (19.2)	7 (11.9)
発疹	0	1 (25.0)	0	0	2 (3.4)
おむつ皮膚炎	1 (7.7)	0	0	0	1 (1.7)
接触性皮膚炎	0	0	0	1 (3.8)	0
湿疹	0	1 (25.0)	0	1 (3.8)	0
皮膚炎	0	0	0	0	1 (1.7)
斑状出血	0	0	0	0	0
紅斑	1 (7.7)	0	0	2 (7.7)	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	1 (6.7)	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (3.8)	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	1 (3.8)	0
皮膚乾燥	0	0	0	1 (3.8)	0
貨幣状湿疹	1 (7.7)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 147 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	1 (7.7)	0	0
皮膚および皮下組織障害	1 (10.0)	1 (25.0)	2 (15.4)	1 (5.6)	5 (12.2)
発疹	0	0	1 (7.7)	0	3 (7.3)
おむつ皮膚炎	0	1 (25.0)	0	0	0
接触性皮膚炎	0	0	0	1 (5.6)	0
湿疹	0	0	0	0	0
皮膚炎	0	0	0	0	0
斑状出血	0	0	0	0	0
紅斑	0	0	0	0	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	1 (2.4)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	1 (10.0)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 148 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	1 (7.7)	0	0
皮膚および皮下組織障害	0	0	1 (7.7)	1 (7.7)	3 (11.5)
発疹	0	0	0	0	0
おむつ皮膚炎	0	0	1 (7.7)	0	1 (3.8)
接触性皮膚炎	0	0	0	0	0
湿疹	0	0	0	1 (7.7)	0
皮膚炎	0	0	0	0	0
斑状出血	0	0	0	0	1 (3.8)
紅斑	0	0	0	0	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 149 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少	0	0	0	0	0
白血球数増加	0	0	0	0	0
皮膚および皮下組織障害	0	2 (100)	3 (23.1)	1 (11.1)	1 (5.3)
発疹	0	1 (50.0)	1 (7.7)	0	0
おむつ皮膚炎	0	0	1 (7.7)	0	1 (5.3)
接触性皮膚炎	0	0	0	0	0
湿疹	0	0	0	0	0
皮膚炎	0	0	1 (7.7)	0	0
斑状出血	0	0	0	0	0
紅斑	0	0	0	0	0
脱毛症	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
点状出血	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 150 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	2 (15.4)		
発疹		0	0		
おむつ皮膚炎		1 (50.0)	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	1 (7.7)		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 151 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	1 (7.7)		
発疹		1 (50.0)	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	1 (7.7)		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 152 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	2 (22.2)		
発疹		0	1 (11.1)		
おむつ皮膚炎		0	0		
接触性皮膚炎		1 (50.0)	0		
湿疹		0	0		
皮膚炎		0	1 (11.1)		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 153 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		1 (50.0)	1 (16.7)		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 154 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		0	0		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 155 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		0	0		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 156 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンD減少		0	0		
白血球数増加		0	0		
皮膚および皮下組織障害		0	0		
発疹		0	0		
おむつ皮膚炎		0	0		
接触性皮膚炎		0	0		
湿疹		0	0		
皮膚炎		0	0		
斑状出血		0	0		
紅斑		0	0		
脱毛症		0	0		
過剰肉芽組織		0	0		
点状出血		0	0		
脂漏性皮膚炎		0	0		
褥瘡性潰瘍		0	0		
アレルギー性皮膚炎		0	0		
アトピー性皮膚炎		0	0		
皮膚乾燥		0	0		
貨幣状湿疹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 157 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	1 (2.4)	0
過角化	0	0	0	0	0
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	0
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	2 (11.8)	0	2 (12.5)	6 (14.6)	11 (13.8)
頻脈	2 (11.8)	0	0	4 (9.8)	4 (5.0)
徐脈	0	0	0	2 (4.9)	3 (3.8)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
心肺停止	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 158 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	1 (1.7)
多汗症	0	0	0	0	0
過角化	0	0	0	0	1 (1.7)
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	2 (3.4)
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	1 (6.7)	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	1 (6.7)	0	0
蕁麻疹	0	0	0	0	1 (1.7)
心臓障害	0	1 (25.0)	2 (13.3)	4 (15.4)	7 (11.9)
頻脈	0	1 (25.0)	1 (6.7)	1 (3.8)	2 (3.4)
徐脈	0	0	1 (6.7)	1 (3.8)	1 (1.7)
心停止	0	0	0	0	0
心肺停止	0	0	0	2 (7.7)	3 (5.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 159 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	0	0
過角化	0	0	0	0	0
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	0
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	1 (2.4)
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	1 (2.4)
皮膚潰瘍	0	0	1 (7.7)	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	0	0	0	3 (16.7)	1 (2.4)
頻脈	0	0	0	1 (5.6)	1 (2.4)
徐脈	0	0	0	1 (5.6)	0
心停止	0	0	0	0	0
心肺停止	0	0	0	1 (5.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 160 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	0	0
過角化	0	0	0	0	1 (3.8)
毛孔性角化症	0	0	0	0	0
汗疹	0	0	0	0	0
そう痒症	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	0	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	0	0	0	3 (23.1)	1 (3.8)
頻脈	0	0	0	3 (23.1)	0
徐脈	0	0	0	0	0
心停止	0	0	0	0	0
心肺停止	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 161 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫	0	0	0	0	0
多汗症	0	0	0	0	0
過角化	0	0	0	0	0
毛孔性角化症	0	0	0	1 (11.1)	0
汗疹	0	0	0	0	0
そう痒症	0	0	1 (7.7)	0	0
丘疹性皮疹	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚障害	0	1 (50.0)	0	0	0
皮膚刺激	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮下気腫	0	0	0	0	0
蕁麻疹	0	0	0	0	0
心臓障害	0	2 (100)	3 (23.1)	0	1 (5.3)
頻脈	0	0	0	0	1 (5.3)
徐脈	0	1 (50.0)	0	0	0
心停止	0	0	0	0	0
心肺停止	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 162 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	1 (7.7)		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 163 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	1 (7.7)		
頻脈		0	0		
徐脈		0	1 (7.7)		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 164 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 165 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		1 (50.0)	1 (16.7)		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 166 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 167 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 168 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
環状肉芽腫		0	0		
多汗症		0	0		
過角化		0	0		
毛孔性角化症		0	0		
汗疹		0	0		
そう痒症		0	0		
丘疹性皮疹		0	0		
皮膚色素脱失		0	0		
皮膚障害		0	0		
皮膚刺激		0	0		
皮膚浮腫		0	0		
皮膚潰瘍		0	0		
皮下気腫		0	0		
蕁麻疹		0	0		
心臓障害		0	0		
頻脈		0	0		
徐脈		0	0		
心停止		0	0		
心肺停止		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 169 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	1 (6.3)	1 (2.4)	1 (1.3)
上室性頻脈	0	0	0	0	1 (1.3)
心室性頻脈	0	0	0	0	1 (1.3)
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	2 (11.8)	1 (25.0)	4 (25.0)	6 (14.6)	10 (12.5)
処置による疼痛	0	0	1 (6.3)	0	2 (2.5)
ストーマ部紅斑	0	0	0	1 (2.4)	2 (2.5)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
擦過傷	0	0	0	0	1 (1.3)
大腿骨骨折	0	0	0	0	1 (1.3)
処置合併症	0	0	0	0	1 (1.3)
処置部位反応	0	0	0	0	1 (1.3)
ワクチン接種合併症	0	0	0	0	1 (1.3)
創離開	0	0	0	0	1 (1.3)
節足動物咬傷	0	0	1 (6.3)	0	0
栄養補給チューブ合併症	0	0	1 (6.3)	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 170 of 288

	Days 91-180				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	1 (3.8)	1 (1.7)
上室性頻脈	0	0	0	0	0
心室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	1 (7.7)	1 (25.0)	4 (26.7)	2 (7.7)	1 (1.7)
処置による疼痛	0	0	0	0	0
ストーマ部紅斑	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	1 (3.8)	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	0	1 (25.0)	1 (6.7)	0	0
栄養補給チューブ合併症	0	0	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 171 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	0	1 (25.0)	1 (7.7)	4 (22.2)	1 (2.4)
処置による疼痛	0	1 (25.0)	0	0	0
ストーマ部紅斑	0	0	1 (7.7)	1 (5.6)	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	1 (5.6)	0
創離開	0	0	0	0	0
節足動物咬傷	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	1 (5.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 172 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
左室肥大	0	0	0	0	1 (3.8)
心膜気腫	0	0	0	0	0
傷害、中毒および処置合併症	1 (20.0)	0	2 (15.4)	3 (23.1)	4 (15.4)
処置による疼痛	0	0	0	0	0
ストーマ部紅斑	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
大腿骨骨折	0	0	0	1 (7.7)	1 (3.8)
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	0	0	1 (7.7)	0	0
栄養補給チューブ合併症	0	0	0	1 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 173 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心室性頻脈	0	1 (50.0)	0	0	0
心筋症	0	0	1 (7.7)	0	0
左室肥大	0	0	0	0	0
心膜気腫	0	0	1 (7.7)	0	0
傷害、中毒および処置合併症	0	1 (50.0)	2 (15.4)	0	0
処置による疼痛	0	0	0	0	0
ストーマ部紅斑	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
節足動物咬傷	0	1 (50.0)	1 (7.7)	0	0
栄養補給チューブ合併症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 174 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	1 (7.7)		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 175 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	2 (15.4)		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 176 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 177 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		1 (50.0)	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 178 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 179 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 180 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
チアノーゼ		0	0		
上室性頻脈		0	0		
心室性頻脈		0	0		
心筋症		0	0		
左室肥大		0	0		
心膜気腫		0	0		
傷害、中毒および処置合併症		0	0		
処置による疼痛		0	0		
ストーマ部紅斑		0	0		
麻酔からの覚醒遅延		0	0		
擦過傷		0	0		
大腿骨骨折		0	0		
処置合併症		0	0		
処置部位反応		0	0		
ワクチン接種合併症		0	0		
創離開		0	0		
節足動物咬傷		0	0		
栄養補給チューブ合併症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 181 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	1 (6.3)	0	0
サンバーン	0	1 (25.0)	0	0	0
熱傷	0	1 (25.0)	0	0	0
処置後合併症	1 (5.9)	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	0
硬膜下血腫	1 (5.9)	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	1 (2.4)	0
伝染病曝露	0	0	0	0	0
転倒	0	0	0	0	0
頭部損傷	0	0	0	1 (2.4)	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	1 (2.4)	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	1 (2.4)	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 182 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
ダンピング症候群	0	0	1 (6.7)	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	0
転倒	1 (7.7)	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	1 (6.7)	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 183 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	1 (2.4)
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	0
転倒	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 184 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	1 (3.8)
挫傷	0	0	0	0	0
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	1 (3.8)
転倒	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	0	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	1 (7.7)	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	1 (20.0)	0	0	0	1 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 185 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷	0	0	0	0	0
サンバーン	0	0	0	0	0
熱傷	0	0	0	0	0
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	1 (7.7)	0	0
気管内挿管合併症	0	0	0	0	0
伝染病曝露	0	0	0	0	0
転倒	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節脱臼	0	0	1 (7.7)	0	0
裂傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後腫脹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 186 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	1 (7.7)		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 187 of 288

	Days 541-630				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	1 (7.7)		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	1 (7.7)		
ダンピング症候群		0	0		
耳擦過傷		0	1 (7.7)		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 188 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 189 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 190 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 191 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 192 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
皮膚擦過傷		0	0		
サンバーン		0	0		
熱傷		0	0		
処置後合併症		0	0		
処置後不快感		0	0		
硬膜下血腫		0	0		
術後激越		0	0		
挫傷		0	0		
ダンピング症候群		0	0		
耳擦過傷		0	0		
気管内挿管合併症		0	0		
伝染病曝露		0	0		
転倒		0	0		
頭部損傷		0	0		
関節脱臼		0	0		
裂傷		0	0		
口唇損傷		0	0		
外傷性気胸		0	0		
処置後挫傷		0	0		
処置後腫脹		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 193 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	1 (2.4)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	2 (11.8)	1 (25.0)	1 (6.3)	5 (12.2)	9 (11.3)
体重増加不良	1 (5.9)	0	0	1 (2.4)	4 (5.0)
乳児および小児期早期の哺育障害	0	0	0	2 (4.9)	3 (3.8)
栄養補給不耐性	0	0	0	0	2 (2.5)
脱水	1 (5.9)	0	0	1 (2.4)	1 (1.3)
成長障害	0	0	0	0	1 (1.3)
代謝性アルカローシス	0	0	1 (6.3)	0	0
過小食	0	1 (25.0)	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 194 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	0	1 (1.7)
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	1 (3.8)	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	1 (7.7)	0	1 (6.7)	5 (19.2)	4 (6.8)
体重増加不良	1 (7.7)	0	0	1 (3.8)	2 (3.4)
乳児および小児期早期の哺育障害	0	0	0	0	1 (1.7)
小児期					
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	1 (7.7)	0	1 (6.7)	0	0
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	1 (6.7)	0	0
食物不耐性	0	0	0	1 (3.8)	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 195 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	1 (5.6)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	1 (5.6)	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	1 (5.6)	0
代謝および栄養障害	0	1 (25.0)	2 (15.4)	2 (11.1)	1 (2.4)
体重増加不良	0	1 (25.0)	0	1 (5.6)	0
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	0	0	0	0	1 (2.4)
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 196 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	1 (7.7)	0
ストーマ部出血	0	0	0	1 (7.7)	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	1 (7.7)	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	0	0	0	1 (7.7)	1 (3.8)
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
栄養補給不耐性	0	0	0	0	1 (3.8)
脱水	0	0	0	0	0
成長障害	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	1 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 197 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷	0	0	0	0	0
ストーマ合併症	0	0	0	0	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
歯牙損傷	0	0	0	0	0
気管損傷	0	0	0	0	0
代謝および栄養障害	0	0	0	1 (11.1)	0
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0
過小食	0	0	0	0	0
食物不耐性	0	0	0	0	0
高血糖	0	0	0	1 (11.1)	0
低血糖	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 198 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
小児期					
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 199 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
小児期					
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 200 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 201 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		1 (50.0)	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		1 (50.0)	0		
体重増加不良		1 (50.0)	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 202 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 203 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 204 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
軟部組織損傷		0	0		
ストーマ合併症		0	0		
ストーマ部出血		0	0		
ストーマ部炎症		0	0		
ストーマ部刺激感		0	0		
歯牙損傷		0	0		
気管損傷		0	0		
代謝および栄養障害		0	0		
体重増加不良		0	0		
乳児および小児期早期の哺育障害		0	0		
栄養補給不耐性		0	0		
脱水		0	0		
成長障害		0	0		
代謝性アルカローシス		0	0		
過小食		0	0		
食物不耐性		0	0		
高血糖		0	0		
低血糖		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 205 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	1 (6.3)	3 (7.3)	7 (8.8)
激越	0	0	0	1 (2.4)	2 (2.5)
易刺激性	0	0	0	1 (2.4)	2 (2.5)
不安	0	0	1 (6.3)	0	1 (1.3)
息こらえ	0	0	0	0	1 (1.3)
気分動揺	0	0	0	0	1 (1.3)
落ち着きのなさ	0	0	0	1 (2.4)	1 (1.3)
睡眠障害	0	0	0	0	0
筋骨格系および結合組織障害	2 (11.8)	1 (25.0)	1 (6.3)	2 (4.9)	6 (7.5)
関節拘縮	0	1 (25.0)	0	0	2 (2.5)
側弯症	0	0	0	1 (2.4)	2 (2.5)
背部痛	0	0	0	0	1 (1.3)
頭位性斜頭症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 206 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	3 (11.5)	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	1 (1.7)
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	2 (13.3)	2 (7.7)	1 (1.7)
激越	0	0	0	1 (3.8)	0
易刺激性	0	0	0	0	0
不安	0	0	2 (13.3)	0	1 (1.7)
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	1 (3.8)	1 (1.7)
筋骨格系および結合組織障害	1 (7.7)	1 (25.0)	3 (20.0)	0	0
関節拘縮	0	1 (25.0)	2 (13.3)	0	0
側弯症	0	0	1 (6.7)	0	0
背部痛	0	0	0	0	0
頭位性斜頭症	1 (7.7)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 207 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	2 (15.4)	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	1 (5.6)	0
精神障害	0	0	0	0	0
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
筋骨格系および結合組織障害	1 (10.0)	2 (50.0)	1 (7.7)	1 (5.6)	3 (7.3)
関節拘縮	1 (10.0)	1 (25.0)	1 (7.7)	0	0
側弯症	0	1 (25.0)	0	0	2 (4.9)
背部痛	0	0	0	0	0
頭位性斜頭症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 208 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	0	1 (7.7)	0
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	1 (7.7)	0
筋骨格系および結合組織障害	0	1 (33.3)	0	3 (23.1)	2 (7.7)
関節拘縮	0	1 (33.3)	0	2 (15.4)	1 (3.8)
側弯症	0	0	0	0	0
背部痛	0	0	0	0	0
頭位性斜頭症	0	0	0	1 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 209 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
鉄欠乏	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0
精神障害	0	0	0	0	0
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
筋骨格系および結合組織障害	0	1 (50.0)	4 (30.8)	1 (11.1)	3 (15.8)
関節拘縮	0	1 (50.0)	1 (7.7)	1 (11.1)	1 (5.3)
側弯症	0	0	3 (23.1)	0	1 (5.3)
背部痛	0	0	0	0	0
頭位性斜頭症	0	0	0	0	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 210 of 288

	Days 451-540				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	4 (30.8)		
関節拘縮		0	1 (7.7)		
側弯症		0	1 (7.7)		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 211 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		1 (50.0)	4 (30.8)		
関節拘縮		1 (50.0)	1 (7.7)		
側弯症		1 (50.0)	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 212 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	1 (11.1)		
関節拘縮		0	0		
側弯症		0	1 (11.1)		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 213 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		1 (50.0)	2 (33.3)		
関節拘縮		1 (50.0)	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 214 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		1 (50.0)	0		
関節拘縮		0	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 215 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	0		
関節拘縮		0	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 216 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低カリウム血症		0	0		
低ナトリウム血症		0	0		
鉄欠乏		0	0		
ビタミンD欠乏		0	0		
精神障害		0	0		
激越		0	0		
易刺激性		0	0		
不安		0	0		
息こらえ		0	0		
気分動揺		0	0		
落ち着きのなさ		0	0		
睡眠障害		0	0		
筋骨格系および結合組織障害		0	0		
関節拘縮		0	0		
側弯症		0	0		
背部痛		0	0		
頭位性斜頭症		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 217 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	1 (6.3)	0	0
手変形	0	0	1 (6.3)	0	0
筋力低下	1 (5.9)	0	0	0	0
斜頚	1 (5.9)	0	0	0	0
体重支持困難	1 (5.9)	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	1 (2.4)	0
神経系障害	2 (11.8)	0	3 (18.8)	0	5 (6.3)
脳損傷	0	0	0	0	1 (1.3)
間代	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
不随意性筋収縮	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 218 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	0	0	0
手変形	0	0	0	0	0
筋力低下	0	0	0	0	0
斜頚	0	0	0	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	1 (6.7)	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	1 (25.0)	3 (20.0)	2 (7.7)	2 (3.4)
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	2 (13.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 219 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	1 (25.0)	0	0	0
手変形	0	0	0	0	0
筋力低下	0	0	0	0	0
斜頚	0	1 (25.0)	0	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	1 (5.6)	0
後側弯症	0	0	0	0	1 (2.4)
脊柱後弯症	0	1 (25.0)	0	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	0	1 (7.7)	1 (5.6)	0
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 220 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	0	0	1 (3.8)
手変形	0	0	0	0	0
筋力低下	0	0	0	1 (7.7)	0
斜頚	0	0	0	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	1 (3.8)
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	0	1 (7.7)	1 (3.8)
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	0
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	0	0	0	1 (3.8)
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 221 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形	0	0	0	0	0
手変形	0	0	0	0	0
筋力低下	0	0	0	0	0
斜頚	0	0	1 (7.7)	0	0
体重支持困難	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
四肢痛	0	0	0	0	1 (5.3)
脊柱変形	0	0	0	0	0
滑膜炎	0	0	0	0	0
腱障害	0	0	0	0	0
神経系障害	0	0	1 (7.7)	0	0
脳損傷	0	0	0	0	0
間代	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
不随意性筋収縮	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 222 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	1 (7.7)		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	1 (7.7)		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		1 (50.0)	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 223 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	1 (7.7)		
後側弯症		0	0		
脊柱後弯症		0	1 (7.7)		
脊柱前弯症		0	0		
四肢痛		0	1 (7.7)		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 224 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	1 (11.1)		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 225 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	1 (16.7)		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	1 (16.7)		
脊柱変形		0	0		
滑膜炎		0	1 (16.7)		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 226 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		1 (50.0)	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 227 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 228 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胸郭変形		0	0		
手変形		0	0		
筋力低下		0	0		
斜頚		0	0		
体重支持困難		0	0		
泉門閉鎖遅延		0	0		
関節硬直		0	0		
後側弯症		0	0		
脊柱後弯症		0	0		
脊柱前弯症		0	0		
四肢痛		0	0		
脊柱変形		0	0		
滑膜炎		0	0		
腱障害		0	0		
神経系障害		0	0		
脳損傷		0	0		
間代		0	0		
低酸素性虚血性脳症		0	0		
不随意性筋収縮		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 229 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	1 (1.3)
痙攣発作	0	0	0	0	1 (1.3)
脳脊髄液漏	0	0	1 (6.3)	0	0
よだれ	0	0	1 (6.3)	0	0
失神	0	0	1 (6.3)	0	0
反射亢進	1 (5.9)	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	3 (3.8)
後天性包茎	0	0	0	0	1 (1.3)
卵巣嚢胞	0	0	0	0	1 (1.3)
陰茎障害	0	0	0	0	1 (1.3)
血管障害	2 (11.8)	0	1 (6.3)	0	2 (2.5)
蒼白	1 (5.9)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 230 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	1 (25.0)	0	1 (3.8)	1 (1.7)
痙攣発作	0	0	1 (6.7)	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	0
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	1 (6.7)	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	1 (3.8)	0
傾眠	0	0	0	0	1 (1.7)
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	0	1 (6.7)	0	0
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 231 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	0
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	1 (7.7)	0	0
失神寸前の状態	0	0	0	1 (5.6)	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	0	0	0	0
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 232 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	1 (3.8)
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	0	0	0	2 (7.7)
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 233 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振	0	0	0	0	0
痙攣発作	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0
よだれ	0	0	0	0	0
失神	0	0	0	0	0
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
脳梗塞	0	0	0	0	0
頭痛	0	0	0	0	0
嗜眠	0	0	0	0	0
失神寸前の状態	0	0	0	0	0
傾眠	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
後天性包茎	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
血管障害	0	1 (50.0)	0	0	0
蒼白	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 234 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		1 (50.0)	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 235 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 236 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 237 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 238 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 239 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 240 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼振		0	0		
痙攣発作		0	0		
脳脊髄液漏		0	0		
よだれ		0	0		
失神		0	0		
反射亢進		0	0		
筋緊張低下		0	0		
脳梗塞		0	0		
頭痛		0	0		
嗜眠		0	0		
失神寸前の状態		0	0		
傾眠		0	0		
生殖系および乳房障害		0	0		
後天性包茎		0	0		
卵巣嚢胞		0	0		
陰茎障害		0	0		
血管障害		0	0		
蒼白		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 241 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	1 (1.3)
毛細血管脆弱	0	0	1 (6.3)	0	0
高血圧	1 (5.9)	0	0	0	0
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	0
免疫系障害	0	0	0	1 (2.4)	2 (2.5)
薬物過敏症	0	0	0	0	1 (1.3)
過敏症	0	0	0	1 (2.4)	1 (1.3)
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	0	0	0	0
腎および尿路障害	0	0	0	0	2 (2.5)
水腎症	0	0	0	0	1 (1.3)
尿閉	0	0	0	0	1 (1.3)
糖尿	0	0	0	0	0
眼障害	0	1 (25.0)	1 (6.3)	2 (4.9)	1 (1.3)
眼乾燥	0	0	0	1 (2.4)	1 (1.3)
眼瞼下垂	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 242 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	1 (6.7)	0	0
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	0
免疫系障害	0	1 (25.0)	0	2 (7.7)	1 (1.7)
薬物過敏症	0	0	0	0	0
過敏症	0	0	0	0	0
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	1 (25.0)	0	2 (7.7)	1 (1.7)
腎および尿路障害	0	0	0	0	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	0	0
眼障害	1 (7.7)	0	0	0	2 (3.4)
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 243 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	0	0	0
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	0
免疫系障害	1 (10.0)	0	0	0	2 (4.9)
薬物過敏症	0	0	0	0	1 (2.4)
過敏症	0	0	0	0	0
食物アレルギー	0	0	0	0	1 (2.4)
季節性アレルギー	1 (10.0)	0	0	0	0
腎および尿路障害	0	0	0	0	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	0	0
眼障害	0	0	0	1 (5.6)	1 (2.4)
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 244 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	0	0	1 (3.8)
本態性高血圧症	0	0	0	0	0
血管炎	0	0	0	0	1 (3.8)
免疫系障害	0	0	1 (7.7)	2 (15.4)	1 (3.8)
薬物過敏症	0	0	0	1 (7.7)	0
過敏症	0	0	0	1 (7.7)	0
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	0	1 (7.7)	0	1 (3.8)
腎および尿路障害	0	0	0	1 (7.7)	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	1 (7.7)	0
眼障害	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 245 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0
高血圧	0	0	0	0	0
本態性高血圧症	0	1 (50.0)	0	0	0
血管炎	0	0	0	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
過敏症	0	0	0	0	0
食物アレルギー	0	0	0	0	0
季節性アレルギー	0	0	0	0	0
腎および尿路障害	0	0	0	0	0
水腎症	0	0	0	0	0
尿閉	0	0	0	0	0
糖尿	0	0	0	0	0
眼障害	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼瞼下垂	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 246 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	2 (15.4)		
薬物過敏症		0	2 (15.4)		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 247 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	2 (15.4)		
薬物過敏症		0	0		
過敏症		0	1 (7.7)		
食物アレルギー		0	0		
季節性アレルギー		0	1 (7.7)		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 248 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 249 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 250 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 251 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 252 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ショック		0	0		
毛細血管脆弱		0	0		
高血圧		0	0		
本態性高血圧症		0	0		
血管炎		0	0		
免疫系障害		0	0		
薬物過敏症		0	0		
過敏症		0	0		
食物アレルギー		0	0		
季節性アレルギー		0	0		
腎および尿路障害		0	0		
水腎症		0	0		
尿閉		0	0		
糖尿		0	0		
眼障害		0	0		
眼乾燥		0	0		
眼瞼下垂		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 253 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	1 (25.0)	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	1 (2.4)	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	1 (5.9)	0	1 (6.3)	1 (2.4)	1 (1.3)
貧血	0	0	0	1 (2.4)	1 (1.3)
好中球減少症	1 (5.9)	0	1 (6.3)	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 254 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	1 (1.7)
後天性涙道狭窄	1 (7.7)	0	0	0	0
眼運動障害	0	0	0	0	1 (1.7)
流涙増加	0	0	0	0	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	0	0	1 (6.7)	1 (3.8)	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	1 (3.8)	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	1 (6.7)	0	0
先天性、家族性および遺伝性障害	0	0	1 (6.7)	2 (7.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 255 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	1 (5.6)	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	0	0
近視	0	0	0	0	1 (2.4)
斜視	0	0	0	1 (5.6)	1 (2.4)
血液およびリンパ系障害	0	1 (25.0)	2 (15.4)	0	0
貧血	0	0	2 (15.4)	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	1 (25.0)	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 256 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	0	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	1 (20.0)	0	0	1 (7.7)	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	1 (7.7)	0
好酸球増加症	1 (20.0)	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	1 (7.7)	2 (7.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 257 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視	0	0	0	0	0
弱視	0	0	0	0	0
霰粒腫	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
眼運動障害	0	0	0	0	0
流涙増加	0	0	0	0	0
近視	0	0	0	0	0
斜視	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
血小板増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 258 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 259 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 260 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 261 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 262 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 263 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 264 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
乱視		0	0		
弱視		0	0		
霰粒腫		0	0		
後天性涙道狭窄		0	0		
眼運動障害		0	0		
流涙増加		0	0		
近視		0	0		
斜視		0	0		
血液およびリンパ系障害		0	0		
貧血		0	0		
好中球減少症		0	0		
骨髄障害		0	0		
好酸球増加症		0	0		
白血球増加症		0	0		
リンパ節症		0	0		
血小板増加症		0	0		
先天性、家族性および遺伝性障害		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 265 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	1 (2.4)	1 (1.3)
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	0	0
斜頭症	0	0	0	0	0
肝胆道系障害	0	0	0	0	1 (1.3)
肝腫大	0	0	0	0	1 (1.3)
外科および内科処置	0	0	0	0	1 (1.3)
機械的換気	0	0	0	0	1 (1.3)
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	1 (5.9)	1 (25.0)	0	0	0
血管の良性新生物	0	1 (25.0)	0	0	0
脂漏性角化症	1 (5.9)	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 266 of 288

	Days 91-180				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	1 (3.8)	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	1 (3.8)	0
斜頭症	0	0	1 (6.7)	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 267 of 288

	Days 181-270				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	0	0
斜頭症	0	1 (25.0)	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 268 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	0	0	0
停留精巣	0	0	0	1 (7.7)	0
発育性股関節形成不全	0	0	0	0	1 (3.8)
貧血母斑	0	0	0	0	1 (3.8)
包茎	0	0	0	0	0
斜頭症	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 269 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸	0	0	0	0	0
斜指症	0	0	1 (7.7)	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
貧血母斑	0	0	0	0	0
包茎	0	0	0	0	0
斜頭症	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (7.7)	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0
アクロコルドン	0	0	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 270 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 271 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 272 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 273 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 274 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 275 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 276 of 288

	Days 991-1080				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鳩胸		0	0		
斜指症		0	0		
停留精巣		0	0		
発育性股関節形成不全		0	0		
貧血母斑		0	0		
包茎		0	0		
斜頭症		0	0		
肝胆道系障害		0	0		
肝腫大		0	0		
外科および内科処置		0	0		
機械的換気		0	0		
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）		0	0		
血管の良性新生物		0	0		
脂漏性角化症		0	0		
アクロコルドン		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 277 of 288

	Days 1-90				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	0
耳および迷路障害	0	0	0	0	0
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 278 of 288

	Days 91-180				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (1.7)
耳の障害	0	0	0	0	1 (1.7)
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 279 of 288

	Days 181-270				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (2.4)
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	1 (2.4)
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 280 of 288

	Days 271-360				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	0	0	0	0
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 281 of 288

	Days 361-450				
		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0
耳および迷路障害	0	1 (50.0)	0	0	0
耳の障害	0	0	0	0	0
耳痛	0	0	0	0	0
耳垢分泌過多	0	1 (50.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 282 of 288

	Days 451-540				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 283 of 288

	Days 541-630				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 284 of 288

	Days 631-720				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 285 of 288

	Days 721-810				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 286 of 288

	Days 811-900				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 287 of 288

	Days 901-990				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by 90 day interval of study treatment - Infants diagnosed with SMA
Page 288 of 288

	Days 991-1080				
	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態		0	0		
臍肉芽腫		0	0		
耳および迷路障害		0	0		
耳の障害		0	0		
耳痛		0	0		
耳垢分泌過多		0	0		

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 13　Incidence of Adverse Events by severity - Infants diagnosed with SMA

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 1 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	13 (76.5)	4 (100)	16 (100)	33 (80.5)	67 (83.8)
胃腸障害	5 (29.4)	4 (100)	14 (87.5)	19 (46.3)	40 (50.0)
便秘	1 (5.9)	1 (25.0)	7 (43.8)	8 (19.5)	22 (27.5)
嘔吐	0	2 (50.0)	3 (18.8)	6 (14.6)	9 (11.3)
胃食道逆流性疾患	2 (11.8)	0	5 (31.3)	4 (9.8)	7 (8.8)
生歯	0	2 (50.0)	2 (12.5)	2 (4.9)	7 (8.8)
下痢	0	1 (25.0)	2 (12.5)	6 (14.6)	7 (8.8)
放屁	2 (11.8)	1 (25.0)	1 (6.3)	1 (2.4)	3 (3.8)
嚥下障害	1 (5.9)	0	0	2 (4.9)	3 (3.8)
胃炎	0	0	1 (6.3)	1 (2.4)	2 (2.5)
血便排泄	0	0	0	0	2 (2.5)
腹部膨満	2 (11.8)	1 (25.0)	1 (6.3)	0	1 (1.3)
腹部不快感	1 (5.9)	0	0	0	1 (1.3)
アフタ性潰瘍	0	0	0	0	1 (1.3)
乳児仙痛	0	0	0	0	1 (1.3)
乳児吐出	0	0	0	0	1 (1.3)
流涎過多	0	0	0	1 (2.4)	1 (1.3)
上部消化管出血	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 2 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
口唇のひび割れ	0	0	1 (6.3)	0	0
排便回数増加	0	0	1 (6.3)	0	0
腹痛	0	1 (25.0)	0	0	0
消化管運動低下	0	1 (25.0)	0	0	0
吐血	0	1 (25.0)	0	0	0
上腹部痛	0	0	0	2 (4.9)	0
悪心	0	0	0	0	0
口内炎	0	0	0	1 (2.4)	0
血性下痢	0	0	0	1 (2.4)	0
胃腸障害	0	0	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
口腔内痛	0	0	0	0	0
感染症および寄生虫症	7 (41.2)	3 (75.0)	11 (68.8)	20 (48.8)	36 (45.0)
鼻咽頭炎	3 (17.6)	0	2 (12.5)	3 (7.3)	10 (12.5)
上気道感染	4 (23.5)	0	3 (18.8)	4 (9.8)	8 (10.0)
口腔カンジダ症	0	0	1 (6.3)	3 (7.3)	5 (6.3)
結膜炎	0	0	0	3 (7.3)	4 (5.0)
細気管支炎	0	0	0	1 (2.4)	4 (5.0)
気管支炎	0	0	0	0	3 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 3 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ウイルス性気道感染	0	0	0	0	3 (3.8)
ウイルス感染	0	0	2 (12.5)	1 (2.4)	2 (2.5)
気道感染	0	2 (50.0)	0	1 (2.4)	2 (2.5)
肺炎	0	1 (25.0)	0	1 (2.4)	2 (2.5)
耳感染	0	0	0	1 (2.4)	2 (2.5)
中耳炎	1 (5.9)	1 (25.0)	3 (18.8)	1 (2.4)	1 (1.3)
皮膚真菌感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ウイルス性上気道感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ライノウイルス感染	0	0	1 (6.3)	2 (4.9)	1 (1.3)
カンジダ性おむつ皮疹	0	1 (25.0)	0	0	1 (1.3)
鼻炎	1 (5.9)	0	0	3 (7.3)	1 (1.3)
皮膚カンジダ	0	0	0	1 (2.4)	1 (1.3)
手足口病	0	0	0	0	1 (1.3)
限局性感染	0	0	0	0	1 (1.3)
尿路感染	0	0	0	0	1 (1.3)
細菌感染	0	0	0	0	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)
蜂巣炎	0	0	0	1 (2.4)	1 (1.3)
細菌性結膜炎	0	0	0	1 (2.4)	1 (1.3)
感染性湿疹	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 4 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
眼感染	0	0	0	0	1 (1.3)
膿痂疹	0	0	0	1 (2.4)	1 (1.3)
口腔ヘルペス	0	0	0	0	1 (1.3)
ばら疹	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
胃腸炎	0	0	1 (6.3)	0	0
細菌性疾患キャリアー	0	0	1 (6.3)	0	0
細菌性気管炎	0	0	1 (6.3)	2 (4.9)	0
エンテロウイルス感染	0	0	1 (6.3)	0	0
伝染性紅斑	0	0	1 (6.3)	0	0
ウイルス性胃炎	0	0	1 (6.3)	0	0
粘膜皮膚カンジダ症	0	0	1 (6.3)	0	0
細菌性気道感染	0	0	1 (6.3)	0	0
ウイルス性肺炎	1 (5.9)	1 (25.0)	0	0	0
シュードモナス菌性肺炎	0	1 (25.0)	0	0	0
ウイルス性胃腸炎	1 (5.9)	0	0	2 (4.9)	0
レンサ球菌性咽頭炎	1 (5.9)	0	0	0	0
皮膚感染	1 (5.9)	0	0	1 (2.4)	0
ウイルス性眼感染	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0
インフルエンザ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 5 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
伝染性軟属腫	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0
カンジダ感染	0	0	0	2 (4.9)	0
ブドウ球菌性眼感染	0	0	0	0	0
真菌感染	0	0	0	1 (2.4)	0
麦粒腫	0	0	0	1 (2.4)	0
下気道感染	0	0	0	1 (2.4)	0
単核細胞症症候群	0	0	0	0	0
急性中耳炎	0	0	0	0	0
咽頭炎	0	0	0	0	0
シュードモナス感染	0	0	0	1 (2.4)	0
副鼻腔炎	0	0	0	0	0
皮膚細菌感染	0	0	0	0	0
ブドウ球菌感染	0	0	0	2 (4.9)	0
ストーマ部感染	0	0	0	2 (4.9)	0
扁桃炎	0	0	0	0	0
ウイルス性発疹	0	0	0	1 (2.4)	0
呼吸器、胸郭および縦隔障害	5 (29.4)	2 (50.0)	13 (81.3)	18 (43.9)	28 (35.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 6 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鼻閉	2 (11.8)	1 (25.0)	5 (31.3)	5 (12.2)	8 (10.0)
上気道うっ血	1 (5.9)	0	0	0	5 (6.3)
呼吸困難	0	1 (25.0)	1 (6.3)	1 (2.4)	4 (5.0)
咳嗽	2 (11.8)	2 (50.0)	4 (25.0)	7 (17.1)	3 (3.8)
鼻漏	1 (5.9)	0	2 (12.5)	3 (7.3)	3 (3.8)
副鼻腔うっ血	0	0	0	0	3 (3.8)
無気肺	0	0	2 (12.5)	1 (2.4)	2 (2.5)
上気道分泌増加	0	0	3 (18.8)	1 (2.4)	1 (1.3)
低酸素症	0	0	2 (12.5)	0	1 (1.3)
呼吸窮迫	1 (5.9)	0	1 (6.3)	1 (2.4)	1 (1.3)
息詰まり	0	0	1 (6.3)	0	1 (1.3)
呼吸不全	0	0	1 (6.3)	0	1 (1.3)
呼吸補助筋の動員	0	0	1 (6.3)	1 (2.4)	1 (1.3)
喘鳴	0	0	1 (6.3)	0	1 (1.3)
気管支閉塞	0	0	0	0	1 (1.3)
アレルギー性鼻炎	0	0	0	0	1 (1.3)
肺水腫	0	0	2 (12.5)	0	0
慢性呼吸不全	0	1 (25.0)	1 (6.3)	0	0
肺うっ血	0	0	1 (6.3)	0	0
無呼吸発作	0	0	1 (6.3)	0	0
気管支分泌物貯留	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 7 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
鼻汁変色	0	0	1 (6.3)	0	0
誤嚥性肺炎	0	0	1 (6.3)	0	0
湿性咳嗽	0	0	1 (6.3)	0	0
拘束性肺疾患	0	0	1 (6.3)	0	0
低音性連続性ラ音	0	0	1 (6.3)	0	0
睡眠時無呼吸症候群	0	0	1 (6.3)	1 (2.4)	0
頻呼吸	0	0	1 (6.3)	2 (4.9)	0
呼吸性アシドーシス	1 (5.9)	0	0	0	0
口腔咽頭痛	0	0	0	1 (2.4)	0
鼻出血	0	0	0	0	0
扁桃肥大	0	0	0	0	0
誤嚥	0	0	0	1 (2.4)	0
発声障害	0	0	0	0	0
気道うっ血	0	0	0	3 (7.3)	0
上気道の炎症	0	0	0	2 (4.9)	0
一般・全身障害および投与部位の状態	3 (17.6)	3 (75.0)	8 (50.0)	20 (48.8)	24 (30.0)
発熱	1 (5.9)	3 (75.0)	6 (37.5)	15 (36.6)	21 (26.3)
カテーテル留置部位炎症	0	0	0	1 (2.4)	1 (1.3)
泣き	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 8 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
薬物不耐性	0	0	0	0	1 (1.3)
ワクチン接種後の易刺激性	0	0	0	0	1 (1.3)
小結節	0	0	0	0	1 (1.3)
腫脹	0	0	0	0	1 (1.3)
不快感	0	1 (25.0)	1 (6.3)	0	0
末梢性浮腫	0	1 (25.0)	1 (6.3)	0	0
医療機器リーク	0	0	1 (6.3)	0	0
浮腫	0	0	1 (6.3)	1 (2.4)	0
血管穿刺部位内出血	0	0	1 (6.3)	2 (4.9)	0
末梢腫脹	0	1 (25.0)	0	0	0
適用部位紅斑	1 (5.9)	0	0	0	0
注入部位内出血	1 (5.9)	0	0	0	0
疼痛	0	0	0	2 (4.9)	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
適用部位発疹	0	0	0	1 (2.4)	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 9 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
医療機器機能不良	0	0	0	1 (2.4)	0
医療機器閉塞	0	0	0	1 (2.4)	0
疲労	0	0	0	1 (2.4)	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
低体温	0	0	0	0	0
注入部位血管外漏出	0	0	0	1 (2.4)	0
注射部位血腫	0	0	0	1 (2.4)	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
皮膚および皮下組織障害	5 (29.4)	4 (100)	10 (62.5)	13 (31.7)	20 (25.0)
発疹	0	1 (25.0)	4 (25.0)	4 (9.8)	7 (8.8)
おむつ皮膚炎	1 (5.9)	2 (50.0)	2 (12.5)	2 (4.9)	4 (5.0)
斑状出血	0	0	1 (6.3)	0	2 (2.5)
接触性皮膚炎	0	1 (25.0)	0	2 (4.9)	2 (2.5)
過角化	0	0	0	0	2 (2.5)
汗疹	0	0	0	0	2 (2.5)
湿疹	0	1 (25.0)	2 (12.5)	1 (2.4)	1 (1.3)
皮膚炎	2 (11.8)	0	0	0	1 (1.3)
紅斑	1 (5.9)	0	0	3 (7.3)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 10 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
蕁麻疹	0	0	0	0	1 (1.3)
アレルギー性皮膚炎	0	0	0	0	1 (1.3)
環状肉芽腫	0	0	0	0	1 (1.3)
丘疹性皮疹	0	0	0	0	1 (1.3)
皮膚浮腫	0	0	0	0	1 (1.3)
過剰肉芽組織	0	0	3 (18.8)	0	0
皮膚刺激	0	1 (25.0)	2 (12.5)	0	0
脱毛症	0	0	1 (6.3)	0	0
点状出血	0	0	1 (6.3)	0	0
そう痒症	0	0	1 (6.3)	0	0
皮膚色素脱失	0	0	1 (6.3)	0	0
皮膚潰瘍	0	0	1 (6.3)	0	0
皮膚障害	0	1 (25.0)	0	0	0
貨幣状湿疹	1 (5.9)	0	0	0	0
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (2.4)	0
毛孔性角化症	0	0	0	1 (2.4)	0
皮膚病変	0	0	0	0	0
アトピー性皮膚炎	0	0	0	2 (4.9)	0
皮膚乾燥	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 11 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
多汗症	0	0	0	1 (2.4)	0
寝汗	0	0	0	0	0
臨床検査	1 (5.9)	1 (25.0)	5 (31.3)	9 (22.0)	13 (16.3)
体重減少	0	1 (25.0)	1 (6.3)	1 (2.4)	2 (2.5)
体温上昇	0	0	0	0	2 (2.5)
酸素飽和度低下	0	0	2 (12.5)	3 (7.3)	1 (1.3)
心拍数増加	0	0	1 (6.3)	1 (2.4)	1 (1.3)
モラクセラ検査陽性	0	0	1 (6.3)	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	1 (1.3)
血中鉄減少	0	0	0	0	1 (1.3)
血中カリウム減少	0	0	0	0	1 (1.3)
体温低下	0	0	0	1 (2.4)	1 (1.3)
心拍数不整	0	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	0	0	0	0	1 (1.3)
炎症マーカー上昇	0	0	0	0	1 (1.3)
A型インフルエンザウイルス検査陽性	0	0	0	0	1 (1.3)
医学的観察	0	0	0	0	1 (1.3)
シュードモナス検査陽性	0	0	0	0	1 (1.3)
ブドウ球菌検査陽性	0	0	0	0	1 (1.3)
尿量減少	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 12 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
ビタミンA減少	0	0	0	0	1 (1.3)
骨密度減少	0	0	1 (6.3)	0	0
呼吸音異常	0	0	1 (6.3)	0	0
心拍数減少	0	0	1 (6.3)	0	0
好中球数増加	0	0	1 (6.3)	0	0
セラチア検査陽性	0	0	1 (6.3)	0	0
レンサ球菌検査陽性	0	0	1 (6.3)	0	0
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	0
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	1 (2.4)	0
ヘッドラグ異常	0	0	0	1 (2.4)	0
リンパ節触知	0	0	0	1 (2.4)	0
呼吸数増加	0	0	0	1 (2.4)	0
トランスアミナーゼ上昇	0	0	0	1 (2.4)	0
尿検査異常	0	0	0	0	0
ビタミンD減少	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 13 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
傷害、中毒および処置合併症	3 (17.6)	3 (75.0)	8 (50.0)	10 (24.4)	11 (13.8)
ストーマ部紅斑	0	0	1 (6.3)	2 (4.9)	2 (2.5)
処置による疼痛	0	1 (25.0)	1 (6.3)	0	1 (1.3)
挫傷	0	0	1 (6.3)	0	1 (1.3)
処置後腫脹	1 (5.9)	0	0	0	1 (1.3)
術後激越	0	0	0	0	1 (1.3)
伝染病曝露	0	0	0	0	1 (1.3)
大腿骨骨折	0	0	0	0	1 (1.3)
処置合併症	0	0	0	0	1 (1.3)
処置部位反応	0	0	0	0	1 (1.3)
ストーマ合併症	0	0	0	2 (4.9)	1 (1.3)
ワクチン接種合併症	0	0	0	1 (2.4)	1 (1.3)
栄養補給チューブ合併症	0	0	2 (12.5)	2 (4.9)	0
皮膚擦過傷	0	0	2 (12.5)	0	0
節足動物咬傷	0	1 (25.0)	1 (6.3)	0	0
関節脱臼	0	0	1 (6.3)	0	0
ダンピング症候群	0	0	1 (6.3)	0	0
耳擦過傷	0	0	1 (6.3)	0	0
軟部組織損傷	0	1 (25.0)	0	0	0
サンバーン	0	1 (25.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 14 of 41
Severity: MILD

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
熱傷	0	1 (25.0)	0	0	0
転倒	1 (5.9)	0	0	0	0
処置後合併症	1 (5.9)	0	0	0	0
処置後不快感	1 (5.9)	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
裂傷	0	0	0	1 (2.4)	0
節足動物刺傷	0	0	0	0	0
靭帯捻挫	0	0	0	0	0
四肢損傷	0	0	0	0	0
擦過傷	0	0	0	1 (2.4)	0
頭部損傷	0	0	0	1 (2.4)	0
関節損傷	0	0	0	0	0
肉離れ	0	0	0	0	0
処置後挫傷	0	0	0	1 (2.4)	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
ストーマ部出血	0	0	0	1 (2.4)	0
ストーマ部炎症	0	0	0	1 (2.4)	0
ストーマ部刺激感	0	0	0	1 (2.4)	0
脛骨骨折	0	0	0	0	0
気管損傷	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 15 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
筋骨格系および結合組織障害	2 (11.8)	3 (75.0)	10 (62.5)	3 (7.3)	8 (10.0)
側弯症	0	2 (50.0)	4 (25.0)	1 (2.4)	3 (3.8)
頭位性斜頭症	1 (5.9)	0	0	0	2 (2.5)
関節拘縮	1 (5.9)	2 (50.0)	4 (25.0)	0	1 (1.3)
背部痛	0	0	0	0	1 (1.3)
四肢痛	0	0	0	0	1 (1.3)
泉門閉鎖遅延	0	0	0	0	1 (1.3)
胸郭変形	0	1 (25.0)	2 (12.5)	0	0
脊柱後弯症	0	2 (50.0)	1 (6.3)	1 (2.4)	0
斜頚	0	1 (25.0)	1 (6.3)	0	0
手変形	0	0	1 (6.3)	0	0
関節硬直	0	0	1 (6.3)	1 (2.4)	0
後側弯症	0	0	1 (6.3)	0	0
脊柱前弯症	0	0	1 (6.3)	0	0
脊柱変形	0	0	1 (6.3)	0	0
筋力低下	1 (5.9)	0	0	0	0
体重支持困難	1 (5.9)	0	0	0	0
関節痛	0	0	0	0	0
筋緊張	0	0	0	0	0
筋肉痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 16 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
頚部痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
骨盤変形	0	0	0	0	0
腱障害	0	0	0	1 (2.4)	0
精神障害	0	0	0	2 (4.9)	8 (10.0)
激越	0	0	0	1 (2.4)	2 (2.5)
易刺激性	0	0	0	1 (2.4)	2 (2.5)
不安	0	0	0	0	1 (1.3)
息こらえ	0	0	0	0	1 (1.3)
気分動揺	0	0	0	0	1 (1.3)
落ち着きのなさ	0	0	0	0	1 (1.3)
睡眠障害	0	0	0	1 (2.4)	1 (1.3)
チック	0	0	0	0	0
不快気分	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
代謝および栄養障害	2 (11.8)	0	2 (12.5)	6 (14.6)	7 (8.8)
成長障害	0	0	1 (6.3)	0	2 (2.5)
体重増加不良	1 (5.9)	0	0	1 (2.4)	2 (2.5)
脱水	1 (5.9)	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 17 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
栄養補給不耐性	0	0	0	0	1 (1.3)
鉄欠乏	0	0	0	0	1 (1.3)
過小食	0	0	1 (6.3)	0	0
代謝性アルカローシス	0	0	1 (6.3)	0	0
食欲減退	0	0	0	0	0
食欲亢進	0	0	0	0	0
ビタミンD欠乏	0	0	0	1 (2.4)	0
乳児および小児期早期の哺育障害	0	0	0	1 (2.4)	0
食物不耐性	0	0	0	1 (2.4)	0
高血糖	0	0	0	1 (2.4)	0
低血糖	0	0	0	1 (2.4)	0
神経系障害	2 (11.8)	2 (50.0)	6 (37.5)	1 (2.4)	6 (7.5)
眼振	0	1 (25.0)	0	1 (2.4)	2 (2.5)
不随意性筋収縮	0	0	3 (18.8)	0	1 (1.3)
よだれ	0	0	1 (6.3)	0	1 (1.3)
間代	0	0	0	0	1 (1.3)
傾眠	0	0	0	0	1 (1.3)
失神	0	0	1 (6.3)	0	0
脳脊髄液漏	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 18 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
頭痛	0	1 (25.0)	0	0	0
反射亢進	1 (5.9)	0	0	0	0
筋緊張低下	1 (5.9)	0	0	0	0
失声症	0	0	0	0	0
感覚鈍麻	0	0	0	0	0
振戦	0	0	0	0	0
味覚異常	0	0	0	0	0
錯感覚	0	0	0	0	0
心臓障害	2 (11.8)	2 (50.0)	2 (12.5)	5 (12.2)	6 (7.5)
頻脈	2 (11.8)	1 (25.0)	1 (6.3)	4 (9.8)	2 (2.5)
徐脈	0	1 (25.0)	0	1 (2.4)	2 (2.5)
チアノーゼ	0	0	0	0	1 (1.3)
左室肥大	0	0	0	0	1 (1.3)
上室性頻脈	0	0	0	0	1 (1.3)
心筋症	0	0	1 (6.3)	0	0
心室性頻脈	0	1 (25.0)	0	0	0
動悸	0	0	0	0	0
免疫系障害	0	1 (25.0)	5 (31.3)	4 (9.8)	5 (6.3)
季節性アレルギー	0	1 (25.0)	2 (12.5)	2 (4.9)	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 19 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
薬物過敏症	0	0	2 (12.5)	1 (2.4)	1 (1.3)
過敏症	0	0	1 (6.3)	2 (4.9)	1 (1.3)
食物アレルギー	0	0	0	0	1 (1.3)
眼障害	1 (5.9)	1 (25.0)	1 (6.3)	3 (7.3)	4 (5.0)
霰粒腫	0	0	0	0	1 (1.3)
眼乾燥	0	0	0	1 (2.4)	1 (1.3)
眼運動障害	0	0	0	0	1 (1.3)
近視	0	0	0	0	1 (1.3)
斜視	0	0	0	1 (2.4)	1 (1.3)
眼瞼下垂	0	0	1 (6.3)	0	0
乱視	0	1 (25.0)	0	0	0
後天性涙道狭窄	1 (5.9)	0	0	0	0
遠視	0	0	0	0	0
弱視	0	0	0	1 (2.4)	0
流涙増加	0	0	0	1 (2.4)	0
血管障害	1 (5.9)	1 (25.0)	1 (6.3)	0	2 (2.5)
蒼白	1 (5.9)	0	0	0	1 (1.3)
血管炎	0	0	0	0	1 (1.3)
毛細血管脆弱	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 20 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
本態性高血圧症	0	1 (25.0)	0	0	0
先天性、家族性および遺伝性障害	0	1 (25.0)	1 (6.3)	4 (9.8)	2 (2.5)
貧血母斑	0	0	0	0	1 (1.3)
鳩胸	0	0	0	1 (2.4)	1 (1.3)
斜頭症	0	1 (25.0)	1 (6.3)	0	0
停留精巣	0	0	0	1 (2.4)	0
発育性股関節形成不全	0	0	0	1 (2.4)	0
包茎	0	0	0	1 (2.4)	0
生殖系および乳房障害	0	0	0	0	2 (2.5)
卵巣嚢胞	0	0	0	0	1 (1.3)
陰茎障害	0	0	0	0	1 (1.3)
耳および迷路障害	0	1 (25.0)	0	0	1 (1.3)
耳痛	0	0	0	0	1 (1.3)
耳垢分泌過多	0	1 (25.0)	0	0	0
鼓膜穿孔	0	0	0	0	0
乗物酔い	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 21 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
腎および尿路障害	0	0	0	1 (2.4)	1 (1.3)
水腎症	0	0	0	0	1 (1.3)
尿失禁	0	0	0	0	0
糖尿	0	0	0	1 (2.4)	0
肝胆道系障害	0	0	0	0	1 (1.3)
肝腫大	0	0	0	0	1 (1.3)
血液およびリンパ系障害	1 (5.9)	1 (25.0)	4 (25.0)	2 (4.9)	0
貧血	0	0	2 (12.5)	1 (2.4)	0
好中球減少症	0	0	1 (6.3)	0	0
血小板増加症	0	0	1 (6.3)	0	0
リンパ節症	0	1 (25.0)	0	0	0
好酸球増加症	1 (5.9)	0	0	0	0
白血球増加症	0	0	0	1 (2.4)	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	1 (5.9)	1 (25.0)	1 (6.3)	0	0
アクロコルドン	0	0	1 (6.3)	0	0
血管の良性新生物	0	1 (25.0)	0	0	0
脂漏性角化症	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 22 of 41
Severity: MILD

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
妊娠、産褥および周産期の状態	1 (5.9)	0	0	0	0
臍肉芽腫	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 23 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	9 (52.9)	2 (50.0)	14 (87.5)	25 (61.0)	53 (66.3)
感染症および寄生虫症	6 (35.3)	1 (25.0)	12 (75.0)	12 (29.3)	38 (47.5)
肺炎	1 (5.9)	0	3 (18.8)	1 (2.4)	8 (10.0)
ウイルス性上気道感染	0	0	1 (6.3)	2 (4.9)	8 (10.0)
上気道感染	2 (11.8)	1 (25.0)	8 (50.0)	5 (12.2)	7 (8.8)
ウイルス感染	0	0	2 (12.5)	0	5 (6.3)
ウイルス性肺炎	0	0	1 (6.3)	0	5 (6.3)
ライノウイルス感染	1 (5.9)	0	4 (25.0)	0	4 (5.0)
鼻咽頭炎	0	0	4 (25.0)	1 (2.4)	4 (5.0)
気道感染	0	0	3 (18.8)	1 (2.4)	2 (2.5)
インフルエンザ	2 (11.8)	0	1 (6.3)	0	2 (2.5)
耳感染	0	0	1 (6.3)	0	2 (2.5)
尿路感染	1 (5.9)	0	0	0	2 (2.5)
アデノウイルス感染	0	0	0	0	2 (2.5)
ウイルス性下気道感染	0	0	0	0	2 (2.5)
結膜炎	0	0	1 (6.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 24 of 41
Severity: MODERATE

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
下気道感染	0	0	1 (6.3)	0	1 (1.3)
細菌性肺炎	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ＲＳウイルス細気管支炎	0	0	1 (6.3)	0	1 (1.3)
気管支炎	1 (5.9)	0	0	0	1 (1.3)
胃腸炎	0	0	0	0	1 (1.3)
ウイルス性胃腸炎	0	0	0	0	1 (1.3)
ウイルス性気道感染	0	0	0	1 (2.4)	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)
細菌性結膜炎	0	0	0	0	1 (1.3)
真菌感染	0	0	0	0	1 (1.3)
ロタウイルス胃腸炎	0	0	0	0	1 (1.3)
口腔カンジダ症	0	0	0	0	1 (1.3)
急性中耳炎	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	0	1 (1.3)
シュードモナス感染	0	0	0	1 (2.4)	1 (1.3)
皮膚カンジダ	0	0	0	0	1 (1.3)
ブドウ球菌皮膚感染	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
細気管支炎	1 (5.9)	0	2 (12.5)	1 (2.4)	0
中耳炎	1 (5.9)	0	2 (12.5)	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 25 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
パラインフルエンザウイルス感染	0	1 (25.0)	1 (6.3)	1 (2.4)	0
アデノウイルス性上気道感染	0	0	1 (6.3)	0	0
細菌感染	0	0	1 (6.3)	0	0
ヘモフィルス感染	0	0	1 (6.3)	0	0
手足口病	0	0	1 (6.3)	0	0
モラクセラ感染	0	0	1 (6.3)	0	0
鼻炎	0	0	1 (6.3)	0	0
ブドウ球菌感染	0	0	1 (6.3)	0	0
気管炎	0	0	1 (6.3)	1 (2.4)	0
レンサ球菌性咽頭炎	0	1 (25.0)	0	0	0
膿痂疹	1 (5.9)	0	0	0	0
ＲＳウイルス感染	0	0	0	0	0
蜂巣炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
腟感染	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	1 (2.4)	0
細菌性気管炎	0	0	0	1 (2.4)	0
カンジダ感染	0	0	0	1 (2.4)	0
コロナウイルス感染	0	0	0	1 (2.4)	0
細菌性気道感染	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 26 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
セラチア感染	0	0	0	1 (2.4)	0
ストーマ部感染	0	0	0	1 (2.4)	0
呼吸器、胸郭および縦隔障害	0	2 (50.0)	13 (81.3)	17 (41.5)	29 (36.3)
呼吸窮迫	0	1 (25.0)	3 (18.8)	3 (7.3)	7 (8.8)
無気肺	0	0	2 (12.5)	6 (14.6)	7 (8.8)
呼吸不全	0	0	1 (6.3)	1 (2.4)	5 (6.3)
誤嚥性肺炎	0	0	1 (6.3)	5 (12.2)	4 (5.0)
無呼吸	0	0	1 (6.3)	1 (2.4)	3 (3.8)
咳嗽	0	0	0	1 (2.4)	3 (3.8)
気管支分泌物貯留	0	1 (25.0)	1 (6.3)	2 (4.9)	2 (2.5)
誤嚥	0	0	1 (6.3)	0	2 (2.5)
低酸素症	0	0	0	1 (2.4)	2 (2.5)
慢性呼吸不全	0	0	2 (12.5)	0	1 (1.3)
上気道分泌増加	0	0	1 (6.3)	0	1 (1.3)
呼吸停止	0	0	1 (6.3)	1 (2.4)	1 (1.3)
呼吸障害	0	0	0	0	1 (1.3)
急性呼吸窮迫症候群	0	0	0	0	1 (1.3)
呼吸困難	0	0	0	4 (9.8)	1 (1.3)
減呼吸	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 27 of 41
Severity: MODERATE

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
低換気	0	0	0	0	1 (1.3)
気管支分泌増加	0	0	0	1 (2.4)	1 (1.3)
胸水	0	0	0	0	1 (1.3)
呼吸性アルカローシス	0	0	0	0	1 (1.3)
気道うっ血	0	0	0	0	1 (1.3)
鼻漏	0	0	0	0	1 (1.3)
変色痰	0	0	0	0	1 (1.3)
急性呼吸不全	0	0	2 (12.5)	1 (2.4)	0
喘鳴	0	0	1 (6.3)	0	0
喉頭肉芽腫	0	0	1 (6.3)	0	0
鼻閉	0	0	1 (6.3)	1 (2.4)	0
気胸	0	0	1 (6.3)	0	0
肺うっ血	0	0	1 (6.3)	0	0
副鼻腔うっ血	0	0	1 (6.3)	0	0
気管障害	0	0	1 (6.3)	0	0
上気道うっ血	0	0	1 (6.3)	1 (2.4)	0
アレルギー性鼻炎	0	1 (25.0)	0	0	0
カタル	0	0	0	1 (2.4)	0
息詰まり	0	0	0	1 (2.4)	0
鼻出血	0	0	0	0	0
肺臓炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 28 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
拘束性肺疾患	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	2 (4.9)	0
一般・全身障害および投与部位の状態	2 (11.8)	0	7 (43.8)	10 (24.4)	19 (23.8)
発熱	2 (11.8)	0	5 (31.3)	7 (17.1)	16 (20.0)
疼痛	0	0	3 (18.8)	0	1 (1.3)
低体温	0	0	0	0	1 (1.3)
倦怠感	0	0	0	0	1 (1.3)
医療機器閉塞	0	0	1 (6.3)	0	0
疲労	0	0	0	0	0
注入部位内出血	0	0	0	1 (2.4)	0
浮腫	0	0	0	2 (4.9)	0
血管穿刺部位反応	0	0	0	1 (2.4)	0
胃腸障害	1 (5.9)	0	6 (37.5)	8 (19.5)	13 (16.3)
生歯	1 (5.9)	0	0	1 (2.4)	4 (5.0)
嘔吐	0	0	2 (12.5)	1 (2.4)	3 (3.8)
流涎過多	0	0	2 (12.5)	0	2 (2.5)
便秘	0	0	1 (6.3)	1 (2.4)	2 (2.5)
胃食道逆流性疾患	0	0	1 (6.3)	2 (4.9)	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 29 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
嚥下障害	0	0	0	2 (4.9)	2 (2.5)
下痢	0	0	2 (12.5)	1 (2.4)	1 (1.3)
胃出血	0	0	0	0	1 (1.3)
腹部膨満	0	0	1 (6.3)	0	0
悪心	0	0	0	0	0
腹部症状	0	0	0	0	0
口腔内痛	0	0	0	0	0
腹部不快感	0	0	0	0	0
食中毒	0	0	0	0	0
胃腸出血	0	0	0	1 (2.4)	0
消化管刺激症状	0	0	0	1 (2.4)	0
臨床検査	0	0	4 (25.0)	5 (12.2)	8 (10.0)
酸素飽和度低下	0	0	0	4 (9.8)	6 (7.5)
Ｃ－反応性蛋白増加	0	0	0	1 (2.4)	2 (2.5)
好中球数増加	0	0	1 (6.3)	0	1 (1.3)
体重減少	0	0	0	0	1 (1.3)
アラニンアミノトランスフェラーゼ増加	0	0	0	0	1 (1.3)
血中クロール減少	0	0	0	0	1 (1.3)
血中カリウム減少	0	0	0	0	1 (1.3)
血中ナトリウム減少	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 30 of 41
Severity: MODERATE

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
心電図ＳＴ－Ｔ部分異常	0	0	0	0	1 (1.3)
肝機能検査異常	0	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	0	0	2 (12.5)	0	0
白血球数増加	0	0	2 (12.5)	0	0
好中球百分率増加	0	0	1 (6.3)	0	0
シュードモナス検査陽性	0	0	1 (6.3)	0	0
ブドウ球菌検査陽性	0	0	1 (6.3)	0	0
心臓障害	0	0	1 (6.3)	4 (9.8)	8 (10.0)
頻脈	0	0	0	1 (2.4)	4 (5.0)
徐脈	0	0	1 (6.3)	2 (4.9)	2 (2.5)
チアノーゼ	0	0	0	1 (2.4)	1 (1.3)
心室性頻脈	0	0	0	0	1 (1.3)
代謝および栄養障害	1 (5.9)	2 (50.0)	1 (6.3)	4 (9.8)	7 (8.8)
乳児および小児期早期の哺育障害	0	0	0	1 (2.4)	3 (3.8)
小児期					
体重増加不良	0	1 (25.0)	0	0	2 (2.5)
栄養補給不耐性	0	0	0	0	2 (2.5)
低ナトリウム血症	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 31 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
過小食	0	1 (25.0)	0	0	0
成長障害	1 (5.9)	0	0	0	0
脱水	0	0	0	0	0
低血糖	0	0	0	1 (2.4)	0
低カリウム血症	0	0	0	3 (7.3)	0
筋骨格系および結合組織障害	1 (5.9)	0	4 (25.0)	3 (7.3)	4 (5.0)
関節拘縮	0	0	1 (6.3)	2 (4.9)	2 (2.5)
側弯症	0	0	1 (6.3)	0	1 (1.3)
脊柱後弯症	0	0	1 (6.3)	0	1 (1.3)
後側弯症	0	0	0	0	1 (1.3)
四肢痛	0	0	1 (6.3)	0	0
滑膜炎	0	0	1 (6.3)	0	0
斜頚	1 (5.9)	0	0	0	0
背部痛	0	0	0	0	0
関節痛	0	0	0	0	0
筋力低下	0	0	0	1 (2.4)	0
頭位性斜頭症	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 32 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
傷害、中毒および処置合併症	1 (5.9)	0	3 (18.8)	1 (2.4)	4 (5.0)
大腿骨骨折	0	0	0	0	1 (1.3)
処置による疼痛	0	0	0	0	1 (1.3)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
擦過傷	0	0	0	0	1 (1.3)
関節脱臼	0	0	1 (6.3)	0	0
節足動物咬傷	0	0	1 (6.3)	0	0
口唇損傷	0	0	1 (6.3)	0	0
外傷性気胸	0	0	1 (6.3)	0	0
歯牙損傷	0	0	1 (6.3)	0	0
硬膜下血腫	1 (5.9)	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
術後激越	0	0	0	0	0
挫傷	0	0	0	0	0
関節損傷	0	0	0	0	0
裂傷	0	0	0	0	0
四肢損傷	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
気管内挿管合併症	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 33 of 41
Severity: MODERATE

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
頭部損傷	0	0	0	0	0
術後イレウス	0	0	0	0	0
隆起骨折	0	0	0	0	0
皮膚および皮下組織障害	2 (11.8)	0	1 (6.3)	1 (2.4)	2 (2.5)
おむつ皮膚炎	1 (5.9)	0	0	0	1 (1.3)
発疹	0	0	0	0	1 (1.3)
皮膚炎	0	0	1 (6.3)	0	0
皮下気腫	0	0	1 (6.3)	0	0
脂漏性皮膚炎	1 (5.9)	0	0	0	0
褥瘡性潰瘍	0	0	0	1 (2.4)	0
湿疹	0	0	0	1 (2.4)	0
精神障害	0	0	2 (12.5)	3 (7.3)	1 (1.3)
不安	0	0	2 (12.5)	0	1 (1.3)
不眠症	0	0	0	0	0
激越	0	0	0	1 (2.4)	0
注意欠陥多動性障害	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
落ち着きのなさ	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 34 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
睡眠障害	0	0	0	1 (2.4)	0
先天性、家族性および遺伝性障害0	0	1 (6.3)	0	1 (1.3)	
発育性股関節形成不全	0	0	0	0	1 (1.3)
斜指症	0	0	1 (6.3)	0	0
血液およびリンパ系障害	1 (5.9)	0	0	1 (2.4)	1 (1.3)
貧血	0	0	0	0	1 (1.3)
好中球減少症	1 (5.9)	0	0	0	0
骨髄障害	0	0	0	1 (2.4)	0
腎および尿路障害	0	0	0	0	1 (1.3)
尿閉	0	0	0	0	1 (1.3)
排尿困難	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (1.3)
耳の障害	0	0	0	0	1 (1.3)
生殖系および乳房障害	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 35 of 41
Severity: MODERATE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
後天性包茎	0	0	0	0	1 (1.3)
神経系障害	0	0	2 (12.5)	1 (2.4)	0
脳梗塞	0	0	1 (6.3)	0	0
嗜眠	0	0	1 (6.3)	0	0
頭痛	0	0	0	0	0
失読症	0	0	0	0	0
失神寸前の状態	0	0	0	1 (2.4)	0
血管障害	1 (5.9)	0	1 (6.3)	0	0
高血圧	1 (5.9)	0	1 (6.3)	0	0
低血圧	0	0	0	0	0
免疫系障害	1 (5.9)	0	0	0	0
季節性アレルギー	1 (5.9)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	
皮膚乳頭腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]P20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 36 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	0	2 (50.0)	7 (43.8)	27 (65.9)	44 (55.0)
呼吸器、胸郭および縦隔障害	0	2 (50.0)	7 (43.8)	24 (58.5)	37 (46.3)
呼吸不全	0	0	4 (25.0)	13 (31.7)	11 (13.8)
呼吸窮迫	0	0	2 (12.5)	10 (24.4)	11 (13.8)
急性呼吸不全	0	1 (25.0)	1 (6.3)	7 (17.1)	11 (13.8)
無気肺	0	0	1 (6.3)	2 (4.9)	6 (7.5)
低酸素症	0	0	2 (12.5)	1 (2.4)	3 (3.8)
誤嚥性肺炎	0	0	1 (6.3)	1 (2.4)	3 (3.8)
誤嚥	0	0	1 (6.3)	0	2 (2.5)
呼吸困難	0	0	0	1 (2.4)	2 (2.5)
呼吸停止	0	0	0	3 (7.3)	2 (2.5)
無呼吸	0	0	2 (12.5)	2 (4.9)	1 (1.3)
低換気	0	0	1 (6.3)	0	1 (1.3)
気胸	0	0	1 (6.3)	0	1 (1.3)
気管支分泌物貯留	0	0	0	2 (4.9)	1 (1.3)
慢性呼吸不全	0	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 37 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
呼吸障害	0	0	0	0	1 (1.3)
気縦隔症	0	0	1 (6.3)	0	0
窒息	0	1 (25.0)	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0
睡眠時無呼吸症候群	0	0	0	1 (2.4)	0
感染症および寄生虫症	0	0	6 (37.5)	13 (31.7)	25 (31.3)
肺炎	0	0	3 (18.8)	4 (9.8)	7 (8.8)
上気道感染	0	0	0	0	5 (6.3)
細気管支炎	0	0	1 (6.3)	1 (2.4)	4 (5.0)
ライノウイルス感染	0	0	1 (6.3)	3 (7.3)	3 (3.8)
気道感染	0	0	0	0	3 (3.8)
下気道感染	0	0	0	0	2 (2.5)
ＲＳウイルス細気管支炎	0	0	3 (7.3)	2 (2.5)	
細菌性肺炎	0	0	0	1 (2.4)	2 (2.5)
ウイルス性肺炎	0	0	1 (6.3)	1 (2.4)	1 (1.3)
細菌性気管炎	0	0	1 (6.3)	1 (2.4)	1 (1.3)
モラクセラ菌性肺炎	0	0	1 (6.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 38 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気管支炎	0	0	0	0	1 (1.3)
ウイルス性気管支炎	0	0	0	0	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
院内感染	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	0	0	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
敗血症	0	0	0	0	1 (1.3)
ブドウ球菌性敗血症	0	0	0	0	1 (1.3)
ウイルス性上気道感染	0	0	0	5 (12.2)	1 (1.3)
メタニューモウイルス感染	0	0	2 (12.5)	0	0
コロナウイルス感染	0	0	1 (6.3)	1 (2.4)	0
エンテロウイルス感染	0	0	1 (6.3)	0	0
ウイルス性下気道感染	0	0	1 (6.3)	0	0
ウイルス性気道感染	0	0	1 (6.3)	1 (2.4)	0
ブドウ球菌性菌血症	0	0	1 (6.3)	0	0
パラインフルエンザウイルス性肺炎	0	0	0	1 (2.4)	0
シュードモナス菌性肺炎	0	0	0	1 (2.4)	0
ウイルス感染	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 39 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
心臓障害	0	0	3 (18.8)	5 (12.2)	7 (8.8)
心肺停止	0	0	1 (6.3)	3 (7.3)	5 (6.3)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
徐脈	0	0	1 (6.3)	0	0
チアノーゼ	0	0	1 (6.3)	1 (2.4)	0
心膜気腫	0	0	1 (6.3)	0	0
胃腸障害	0	0	1 (6.3)	5 (12.2)	5 (6.3)
嚥下障害	0	0	0	4 (9.8)	4 (5.0)
胃炎	0	0	0	0	1 (1.3)
嘔吐	0	0	1 (6.3)	1 (2.4)	0
流涎過多	0	0	0	1 (2.4)	0
一般・全身障害および投与部位の状態	0	0	1 (6.3)	1 (2.4)	3 (3.8)
発熱	0	0	0	0	2 (2.5)
死亡	0	0	0	1 (2.4)	1 (1.3)
疼痛	0	0	1 (6.3)	0	0
穿刺部位疼痛	0	0	0	0	0
神経系障害	0	0	1 (6.3)	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 40 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
痙攣発作	0	0	1 (6.3)	0	1 (1.3)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
片頭痛	0	0	0	0	0
血管障害	0	0	0	0	2 (2.5)
高血圧	0	0	0	0	1 (1.3)
ショック	0	0	0	0	1 (1.3)
代謝および栄養障害	0	0	1 (6.3)	1 (2.4)	1 (1.3)
体重増加不良	0	0	0	1 (2.4)	1 (1.3)
低ナトリウム血症	0	0	1 (6.3)	0	0
筋骨格系および結合組織障害	0	1 (25.0)	0	0	1 (1.3)
胸郭変形	0	0	0	0	1 (1.3)
関節拘縮	0	1 (25.0)	0	0	0
筋肉痛	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Infants diagnosed with SMA
Page 41 of 41
Severity: SEVERE

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
創離開	0	0	0	0	1 (1.3)
腰椎穿刺後症候群	0	0	0	0	0
大腿骨骨折	0	0	0	1 (2.4)	0
免疫系障害	0	0	0	0	1 (1.3)
薬物過敏症	0	0	0	0	1 (1.3)
臨床検査	0	0	0	3 (7.3)	1 (1.3)
酸素飽和度低下	0	0	0	2 (4.9)	1 (1.3)
レスピロウイルス検査陽性	0	0	0	1 (2.4)	0
皮膚および皮下組織障害	0	0	0	0	1 (1.3)
おむつ皮膚炎	0	0	0	0	1 (1.3)
外科および内科処置	0	0	0	0	1 (1.3)
機械的換気	0	0	0	0	1 (1.3)
精神障害	0	0	1 (6.3)	0	0
不安	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 14　Incidence of Adverse Events by severity - Later-onset

Incidence of Adverse Events by severity - Later-onset

Page 1 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	6 (100)	4 (66.7)	6 (100)	8 (80.0)	8 (100)	6 (75.0)
胃腸障害	3 (50.0)	3 (50.0)	1 (16.7)	0	2 (25.0)	2 (25.0)
便秘	2 (33.3)	1 (16.7)	0	0	0	0
嘔吐	1 (16.7)	2 (33.3)	0	0	1 (12.5)	1 (12.5)
胃食道逆流性疾患	0	0	0	0	0	0
生歯	0	0	0	0	0	0
下痢	0	0	0	0	1 (12.5)	0
放屁	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0
胃炎	0	0	0	0	0	0
血便排泄	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
腹部不快感	0	0	0	0	0	0
アフタ性潰瘍	0	0	0	0	0	0
乳児仙痛	0	0	0	0	0	0
乳児吐出	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
上部消化管出血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 2 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	9 (100)	9 (100)	3 (75.0)	12 (85.7)	46 (97.9)
胃腸障害	4 (44.4)	3 (33.3)	0	4 (28.6)	13 (27.7)
便秘	1 (11.1)	2 (22.2)	0	0	1 (2.1)
嘔吐	1 (11.1)	2 (22.2)	0	2 (14.3)	4 (8.5)
胃食道逆流性疾患	0	0	0	0	1 (2.1)
生歯	0	0	0	0	0
下痢	0	0	0	0	1 (2.1)
放屁	0	0	0	0	1 (2.1)
嚥下障害	0	0	0	0	0
胃炎	0	0	0	0	0
血便排泄	0	0	0	0	0
腹部膨満	0	0	0	0	0
腹部不快感	0	0	0	0	0
アフタ性潰瘍	0	0	0	1 (7.1)	2 (4.3)
乳児仙痛	0	0	0	0	0
乳児吐出	0	0	0	0	0
流涎過多	0	0	0	0	0
上部消化管出血	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 3 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
口唇のひび割れ	0	0	0	0	0	0
排便回数増加	0	0	0	0	0	0
腹痛	0	0	0	0	0	0
消化管運動低下	0	0	0	0	0	0
吐血	0	0	0	0	0	0
上腹部痛	0	0	0	0	0	0
悪心	1 (16.7)	2 (33.3)	0	0	2 (25.0)	0
口内炎	0	0	0	0	0	0
血性下痢	0	0	0	0	0	0
胃腸障害	0	0	1 (16.7)	0	0	0
口の感覚鈍麻	0	0	0	0	0	0
口唇痛	0	0	0	0	0	0
口腔内痛	0	0	0	0	0	1 (12.5)
感染症および寄生虫症	1 (16.7)	1 (16.7)	1 (16.7)	3 (30.0)	6 (75.0)	3 (37.5)
鼻咽頭炎	0	0	0	0	0	1 (12.5)
上気道感染	0	1 (16.7)	1 (16.7)	1 (10.0)	2 (25.0)	1 (12.5)
口腔カンジダ症	0	0	0	0	0	0
結膜炎	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 4 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
口唇のひび割れ	0	0	0	0	0
排便回数増加	0	0	0	0	0
腹痛	0	0	0	1 (7.1)	1 (2.1)
消化管運動低下	0	0	0	0	0
吐血	0	0	0	0	0
上腹部痛	0	0	0	0	2 (4.3)
悪心	1 (11.1)	0	0	1 (7.1)	1 (2.1)
口内炎	0	0	0	0	1 (2.1)
血性下痢	0	0	0	0	0
胃腸障害	0	0	0	0	0
口の感覚鈍麻	1 (11.1)	0	0	0	0
口唇痛	1 (11.1)	0	0	0	0
口腔内痛	0	0	0	0	0
感染症および寄生虫症	7 (77.8)	5 (55.6)	3 (75.0)	5 (35.7)	29 (61.7)
鼻咽頭炎	4 (44.4)	2 (22.2)	0	2 (14.3)	5 (10.6)
上気道感染	2 (22.2)	0	1 (25.0)	1 (7.1)	14 (29.8)
口腔カンジダ症	0	0	0	0	0
結膜炎	0	1 (11.1)	0	0	2 (4.3)
細気管支炎	0	0	0	0	0
気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 5 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ウイルス性気道感染	0	0	0	0	0	0
ウイルス感染	1 (16.7)	0	0	0	0	1 (12.5)
気道感染	0	0	0	0	0	0
肺炎	0	0	0	0	0	0
耳感染	0	0	0	1 (10.0)	0	0
中耳炎	0	0	0	0	2 (25.0)	0
皮膚真菌感染	0	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0	0
鼻炎	0	0	0	0	1 (12.5)	0
皮膚カンジダ	0	0	0	0	0	0
手足口病	0	0	0	0	0	0
限局性感染	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0
細菌感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
蜂巣炎	0	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0	0
感染性湿疹	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 6 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ウイルス性気道感染	0	0	0	0	0
ウイルス感染	1 (11.1)	0	0	0	4 (8.5)
気道感染	0	0	0	0	0
肺炎	0	0	0	0	2 (4.3)
耳感染	1 (11.1)	0	0	0	2 (4.3)
中耳炎	0	0	1 (25.0)	1 (7.1)	1 (2.1)
皮膚真菌感染	0	0	0	0	1 (2.1)
ウイルス性上気道感染	2 (22.2)	0	0	0	1 (2.1)
ライノウイルス感染	0	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0	0
鼻炎	0	0	0	0	0
皮膚カンジダ	0	0	0	0	2 (4.3)
手足口病	0	0	0	0	1 (2.1)
限局性感染	2 (22.2)	0	0	0	1 (2.1)
尿路感染	1 (11.1)	0	0	0	1 (2.1)
細菌感染	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0
蜂巣炎	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0
感染性湿疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 7 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
眼感染	0	0	0	0	0	0
膿痂疹	0	0	0	0	0	0
口腔ヘルペス	0	0	0	0	0	0
ばら疹	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
胃腸炎	0	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0	0
細菌性気管炎	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
伝染性紅斑	0	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0	0
細菌性気道感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	1 (10.0)	3 (37.5)	0
皮膚感染	0	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0	0
インフルエンザ	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 8 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
眼感染	0	0	0	0	0
膿痂疹	0	1 (11.1)	0	0	0
口腔ヘルペス	0	0	0	0	0
ばら疹	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
胃腸炎	0	0	0	0	2 (4.3)
細菌性疾患キャリアー	0	0	0	0	0
細菌性気管炎	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
伝染性紅斑	0	0	0	0	0
ウイルス性胃炎	0	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0	0
細菌性気道感染	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
ウイルス性胃腸炎	1 (11.1)	0	1 (25.0)	0	4 (8.5)
レンサ球菌性咽頭炎	0	0	1 (25.0)	0	1 (2.1)
皮膚感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	1 (2.1)
ウイルス性消化管感染	1 (11.1)	0	0	0	1 (2.1)
インフルエンザ	0	1 (11.1)	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 9 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
伝染性軟属腫	0	0	0	0	0	0
ウイルス性扁桃炎	0	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0	0
カンジダ感染	0	0	0	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0	0
真菌感染	0	0	0	0	0	0
麦粒腫	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0	0
急性中耳炎	0	0	0	0	0	0
咽頭炎	0	0	0	0	0	0
シュードモナス感染	0	0	0	0	0	0
副鼻腔炎	0	0	0	1 (10.0)	0	1 (12.5)
皮膚細菌感染	0	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0	0
ストーマ部感染	0	0	0	0	0	0
扁桃炎	0	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	1 (10.0)	2 (25.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 10 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
伝染性軟属腫	0	0	0	0	1 (2.1)
ウイルス性扁桃炎	0	0	0	0	1 (2.1)
外陰腟真菌感染	0	0	0	0	1 (2.1)
カンジダ感染	0	0	0	0	0
ブドウ球菌性眼感染	0	1 (11.1)	0	0	0
真菌感染	0	0	0	0	0
麦粒腫	0	0	0	0	0
下気道感染	0	0	0	0	0
単核細胞症症候群	0	0	1 (25.0)	0	0
急性中耳炎	0	0	0	1 (7.1)	0
咽頭炎	0	0	0	1 (7.1)	0
シュードモナス感染	0	0	0	0	0
副鼻腔炎	1 (11.1)	0	0	0	0
皮膚細菌感染	0	1 (11.1)	0	0	0
ブドウ球菌感染	0	0	0	0	0
ストーマ部感染	0	0	0	0	0
扁桃炎	0	0	1 (25.0)	0	0
ウイルス性発疹	0	0	0	0	0
呼吸器、胸郭および縦隔障害	3 (33.3)	2 (22.2)	1 (25.0)	3 (21.4)	16 (34.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 11 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
鼻閉	0	0	0	0	1 (12.5)	0
上気道うっ血	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
咳嗽	0	0	0	0	0	0
鼻漏	0	0	0	0	1 (12.5)	0
副鼻腔うっ血	0	0	0	1 (10.0)	0	0
無気肺	0	0	0	0	0	0
上気道分泌増加	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
呼吸窮迫	0	0	0	0	0	0
息詰まり	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0	0
喘鳴	0	0	0	0	0	0
気管支閉塞	0	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0	0
肺水腫	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
肺うっ血	0	0	0	0	0	0
無呼吸発作	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 12 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
鼻閉	0	0	0	1 (7.1)	1 (2.1)
上気道うっ血	0	0	0	0	0
呼吸困難	0	0	0	0	0
咳嗽	0	1 (11.1)	0	0	4 (8.5)
鼻漏	1 (11.1)	1 (11.1)	0	0	3 (6.4)
副鼻腔うっ血	0	0	0	0	1 (2.1)
無気肺	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
低酸素症	0	0	0	0	0
呼吸窮迫	0	0	0	0	0
息詰まり	0	0	0	0	0
呼吸不全	0	0	0	0	0
呼吸補助筋の動員	0	0	0	0	0
喘鳴	0	0	0	0	0
気管支閉塞	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
肺水腫	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
肺うっ血	0	0	0	0	1 (2.1)
無呼吸発作	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 13 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
鼻汁変色	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
湿性咳嗽	0	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0	0
頻呼吸	0	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0	0
口腔咽頭痛	0	0	0	0	1 (12.5)	0
鼻出血	0	0	0	0	0	0
扁桃肥大	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
発声障害	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
上気道の炎症	0	0	0	0	0	0
一般・全身障害および投与部位の状態	2 (33.3)	0	1 (16.7)	3 (30.0)	3 (37.5)	3 (37.5)
発熱	1 (16.7)	0	1 (16.7)	2 (20.0)	0	0
カテーテル留置部位炎症	0	0	0	0	0	0
泣き	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 14 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
鼻汁変色	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0
湿性咳嗽	0	0	0	0	0
拘束性肺疾患	0	0	0	0	0
低音性連続性ラ音	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
頻呼吸	0	0	0	0	0
呼吸性アシドーシス	0	0	0	0	0
口腔咽頭痛	1 (11.1)	1 (11.1)	0	0	6 (12.8)
鼻出血	1 (11.1)	0	0	0	2 (4.3)
扁桃肥大	0	0	1 (25.0)	1 (7.1)	1 (2.1)
誤嚥	0	0	0	0	0
発声障害	0	0	0	1 (7.1)	0
気道うっ血	0	0	0	0	0
上気道の炎症	0	0	0	0	0
一般・全身障害および投与部位の状態	5 (55.6)	5 (55.6)	0	0	11 (23.4)
発熱	0	3 (33.3)	0	0	8 (17.0)
カテーテル留置部位炎症	0	0	0	0	0
泣き	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 15 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
薬物不耐性	0	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0	0
小結節	0	0	0	0	0	0
腫脹	0	0	0	0	0	0
不快感	0	0	0	0	0	0
末梢性浮腫	0	0	0	0	0	0
医療機器リーク	0	0	0	0	0	0
浮腫	0	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0	1 (12.5)
末梢腫脹	0	0	0	0	0	0
適用部位紅斑	0	0	0	0	0	0
注入部位内出血	0	0	0	0	0	0
疼痛	0	0	0	0	0	0
注射部位出血	0	0	0	0	0	0
注射部位疼痛	0	0	0	0	0	0
適用部位発疹	0	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0	1 (12.5)
カテーテル留置部位疼痛	0	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	1 (12.5)	0
胸部不快感	0	0	0	0	1 (12.5)	0
悪寒	0	0	0	0	0	1 (12.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 16 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
薬物不耐性	0	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0	0
小結節	0	0	0	0	0
腫脹	0	0	0	0	0
不快感	0	0	0	0	0
末梢性浮腫	0	0	0	0	0
医療機器リーク	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位内出血	0	0	0	0	0
末梢腫脹	1 (11.1)	0	0	0	0
適用部位紅斑	0	0	0	0	0
注入部位内出血	0	0	0	0	0
疼痛	0	0	0	0	2 (4.3)
注射部位出血	0	0	0	0	1 (2.1)
注射部位疼痛	0	0	0	0	1 (2.1)
適用部位発疹	0	0	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	1 (11.1)	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
悪寒	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 17 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
医療機器機能不良	0	0	0	0	0	0
医療機器閉塞	0	0	0	0	0	0
疲労	0	0	0	0	1 (12.5)	0
冷感	0	0	0	0	0	0
重力性浮腫	0	0	0	0	0	1 (12.5)
低体温	1 (16.7)	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0	0
注射部位血腫	0	0	0	0	0	0
穿刺部位疼痛	1 (16.7)	0	0	1 (10.0)	0	2 (25.0)
穿刺部位反応	1 (16.7)	0	0	0	0	0
皮膚および皮下組織障害	1 (16.7)	0	1 (16.7)	1 (10.0)	0	0
発疹	0	0	0	1 (10.0)	0	0
おむつ皮膚炎	0	0	0	0	0	0
斑状出血	0	0	0	0	0	0
接触性皮膚炎	0	0	0	0	0	0
過角化	0	0	0	0	0	0
汗疹	0	0	1 (16.7)	0	0	0
湿疹	1 (16.7)	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
紅斑	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 18 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
医療機器機能不良	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
疲労	1 (11.1)	0	0	0	0
冷感	1 (11.1)	0	0	0	0
重力性浮腫	0	0	0	0	0
低体温	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
穿刺部位疼痛	3 (33.3)	2 (22.2)	0	0	0
穿刺部位反応	0	0	0	0	0
皮膚および皮下組織障害	1 (11.1)	0	0	0	13 (27.7)
発疹	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	1 (2.1)
斑状出血	0	0	0	0	0
接触性皮膚炎	0	0	0	0	3 (6.4)
過角化	0	0	0	0	0
汗疹	0	0	0	0	0
湿疹	0	0	0	0	1 (2.1)
皮膚炎	0	0	0	0	1 (2.1)
紅斑	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 19 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
蕁麻疹	0	0	0	0	0	0
アレルギー性皮膚炎	0	0	0	0	0	0
環状肉芽腫	0	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0	0
皮膚浮腫	0	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0	0
皮膚刺激	0	0	0	0	0	0
脱毛症	0	0	0	0	0	0
点状出血	0	0	0	0	0	0
そう痒症	0	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0	0
皮膚障害	0	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0	0
ざ瘡	0	0	0	0	0	0
水疱	0	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0	0
毛孔性角化症	0	0	0	0	0	0
皮膚病変	0	0	0	0	0	0
アトピー性皮膚炎	0	0	0	0	0	0
皮膚乾燥	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 20 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
蕁麻疹	0	0	0	0	1 (2.1)
アレルギー性皮膚炎	0	0	0	0	0
環状肉芽腫	0	0	0	0	0
丘疹性皮疹	0	0	0	0	0
皮膚浮腫	0	0	0	0	0
過剰肉芽組織	0	0	0	0	0
皮膚刺激	0	0	0	0	0
脱毛症	0	0	0	0	0
点状出血	0	0	0	0	0
そう痒症	0	0	0	0	0
皮膚色素脱失	0	0	0	0	0
皮膚潰瘍	0	0	0	0	0
皮膚障害	0	0	0	0	0
貨幣状湿疹	0	0	0	0	0
ざ瘡	0	0	0	0	1 (2.1)
水疱	0	0	0	0	1 (2.1)
褥瘡性潰瘍	0	0	0	0	1 (2.1)
毛孔性角化症	0	0	0	0	1 (2.1)
皮膚病変	0	0	0	0	1 (2.1)
アトピー性皮膚炎	0	0	0	0	0
皮膚乾燥	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 21 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
多汗症	0	0	0	0	0	0
寝汗	0	0	0	0	0	0
臨床検査	0	1 (16.7)	0	0	0	0
体重減少	0	0	0	0	0	0
体温上昇	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
心拍数増加	0	0	0	0	0	0
モラクセラ検査陽性	0	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0	0
血中鉄減少	0	0	0	0	0	0
血中カリウム減少	0	0	0	0	0	0
体温低下	0	0	0	0	0	0
心拍数不整	0	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0	0
A型インフルエンザウイルス検査陽性	0	0	0	0	0	0
医学的観察	0	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0	0
尿量減少	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 22 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
多汗症	0	0	0	0	0
寝汗	1 (11.1)	0	0	0	0
臨床検査	2 (22.2)	0	1 (25.0)	0	3 (6.4)
体重減少	1 (11.1)	0	0	0	1 (2.1)
体温上昇	0	0	1 (25.0)	0	0
酸素飽和度低下	0	0	0	0	0
心拍数増加	0	0	0	0	1 (2.1)
モラクセラ検査陽性	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
血中鉄減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
体温低下	0	0	0	0	0
心拍数不整	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
炎症マーカー上昇	0	0	0	0	0
A型インフルエンザウイルス検査陽性	0	0	0	0	0
医学的観察	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
尿量減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 23 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
ビタミンA減少	0	0	0	0	0	0
骨密度減少	0	0	0	0	0	0
呼吸音異常	0	0	0	0	0	0
心拍数減少	0	0	0	0	0	0
好中球数増加	0	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
血中テストステロン減少	0	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0	0
血中重炭酸塩減少	0	0	0	0	0	0
心電図ＳＴ－Ｔ部分下降	0	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0	0
リンパ節触知	0	0	0	0	0	0
呼吸数増加	0	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0	0
尿検査異常	0	1 (16.7)	0	0	0	0
ビタミンD減少	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 24 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
ビタミンA減少	0	0	0	0	0
骨密度減少	0	0	0	0	0
呼吸音異常	0	0	0	0	0
心拍数減少	0	0	0	0	0
好中球数増加	0	0	0	0	0
セラチア検査陽性	0	0	0	0	0
レンサ球菌検査陽性	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
血中テストステロン減少	0	0	0	0	1 (2.1)
ＣＳＦ白血球数増加	0	0	0	0	1 (2.1)
血中重炭酸塩減少	1 (11.1)	0	0	0	0
心電図ＳＴ－Ｔ部分下降	0	0	0	0	0
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
呼吸数増加	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
尿検査異常	0	0	0	0	0
ビタミンD減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 25 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
傷害、中毒および処置合併症	(16.7)	2 (33.3)	3 (50.0)	1 (10.0)	4 (50.0)	1 (12.5)
ストーマ部紅斑	0	0	0	0	0	0
処置による疼痛	0	0	0	0	0	0
挫傷	0	0	0	0	0	0
処置後腫脹	0	0	0	0	0	0
術後激越	0	0	0	0	0	0
伝染病曝露	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
処置合併症	0	0	0	0	0	0
処置部位反応	0	0	0	0	0	0
ストーマ合併症	0	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0	0
節足動物咬傷	0	0	0	0	0	1 (12.5)
関節脱臼	0	0	0	0	0	0
ダンピング症候群	0	0	0	0	0	0
耳擦過傷	0	0	0	0	0	0
軟部組織損傷	0	0	0	0	0	0
サンバーン	0	0	0	0	1 (12.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 26 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
傷害、中毒および処置合併症	5 (55.6)	4 (44.4)	2 (50.0)	3 (21.4)	14 (29.8)
ストーマ部紅斑	0	0	0	0	0
処置による疼痛	0	0	0	1 (7.1)	3 (6.4)
挫傷	0	0	0	0	1 (2.1)
処置後腫脹	0	0	0	0	0
術後激越	1 (11.1)	0	0	0	0
伝染病曝露	0	0	0	0	0
大腿骨骨折	0	0	0	0	0
処置合併症	0	0	0	0	0
処置部位反応	0	0	0	0	0
ストーマ合併症	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
栄養補給チューブ合併症	0	0	0	0	0
皮膚擦過傷	0	0	0	0	0
節足動物咬傷	2 (22.2)	0	0	0	1 (2.1)
関節脱臼	0	0	0	0	1 (2.1)
ダンピング症候群	0	0	0	0	0
耳擦過傷	0	0	0	0	0
軟部組織損傷	0	0	0	0	0
サンバーン	0	1 (11.1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 27 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
熱傷	0	0	0	0	0	0
転倒	0	0	0	0	0	0
処置後合併症	0	0	0	0	0	0
処置後不快感	0	0	0	0	0	0
腰椎穿刺後症候群	0	2 (33.3)	2 (33.3)	1 (10.0)	2 (25.0)	0
裂傷	0	0	1 (16.7)	0	1 (12.5)	0
節足動物刺傷	0	0	0	0	0	0
靭帯捻挫	0	0	0	0	0	0
四肢損傷	0	0	0	0	1 (12.5)	0
擦過傷	0	0	0	0	0	0
頭部損傷	0	0	0	0	0	0
関節損傷	0	0	0	0	0	0
肉離れ	0	0	0	0	0	0
処置後挫傷	0	0	0	0	0	0
処置による頭痛	0	0	0	0	0	0
処置による悪心	1 (16.7)	0	0	0	0	0
ストーマ部出血	0	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0	0
脛骨骨折	0	0	0	0	0	0
気管損傷	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 28 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
熱傷	1 (11.1)	0	0	0	0
転倒	0	0	0	0	1 (2.1)
処置後合併症	0	0	0	0	0
処置後不快感	0	0	0	0	0
腰椎穿刺後症候群	1 (11.1)	4 (44.4)	0	1 (7.1)	7 (14.9)
裂傷	1 (11.1)	1 (11.1)	0	0	2 (4.3)
節足動物刺傷	0	0	0	0	1 (2.1)
靭帯捻挫	0	0	0	0	1 (2.1)
四肢損傷	0	0	0	0	1 (2.1)
擦過傷	0	0	0	0	0
頭部損傷	0	0	0	0	0
関節損傷	0	0	1 (25.0)	0	0
肉離れ	0	0	1 (25.0)	0	0
処置後挫傷	0	0	0	0	0
処置による頭痛	0	0	0	1 (7.1)	0
処置による悪心	0	0	0	1 (7.1)	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
ストーマ部刺激感	0	0	0	0	0
脛骨骨折	1 (11.1)	0	0	0	0
気管損傷	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 29 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
筋骨格系および結合組織障害	3 (50.0)	2 (33.3)	0	2 (20.0)	1 (12.5)	3 (37.5)
側弯症	0	0	0	1 (10.0)	0	0
頭位性斜頭症	0	0	0	0	0	0
関節拘縮	0	0	0	0	0	1 (12.5)
背部痛	2 (33.3)	2 (33.3)	0	1 (10.0)	1 (12.5)	1 (12.5)
四肢痛	0	0	0	0	0	0
泉門閉鎖遅延	0	0	0	0	0	0
胸郭変形	0	0	0	0	0	0
脊柱後弯症	0	0	0	0	0	0
斜頚	0	0	0	0	0	0
手変形	0	0	0	0	0	0
関節硬直	0	0	0	0	0	0
後側弯症	0	0	0	0	0	0
脊柱前弯症	0	0	0	1 (10.0)	0	0
脊柱変形	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
体重支持困難	0	0	0	0	0	0
関節痛	0	0	0	0	0	1 (12.5)
筋緊張	0	0	0	0	0	0
筋肉痛	1 (16.7)	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 30 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
筋骨格系および結合組織障害	1 (11.1)	7 (77.8)	2 (50.0)	2 (14.3)	26 (55.3)
側弯症	1 (11.1)	1 (11.1)	1 (25.0)	1 (7.1)	6 (12.8)
頭位性斜頭症	0	0	0	0	0
関節拘縮	0	1 (11.1)	0	0	7 (14.9)
背部痛	1 (11.1)	4 (44.4)	1 (25.0)	1 (7.1)	12 (25.5)
四肢痛	0	1 (11.1)	0	1 (7.1)	1 (2.1)
泉門閉鎖遅延	0	0	0	0	0
胸郭変形	0	0	0	0	0
脊柱後弯症	0	0	0	0	0
斜頚	0	0	0	0	0
手変形	0	0	0	0	0
関節硬直	0	0	0	0	0
後側弯症	0	0	0	0	0
脊柱前弯症	0	0	0	0	0
脊柱変形	0	0	0	0	0
筋力低下	0	0	0	0	0
体重支持困難	0	0	0	0	0
関節痛	0	1 (11.1)	0	0	2 (4.3)
筋緊張	0	0	0	0	2 (4.3)
筋肉痛	0	0	0	0	2 (4.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 31 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
頚部痛	0	0	0	0	0	0
四肢拘縮	0	0	0	0	0	0
骨盤変形	0	0	0	0	0	1 (12.5)
腱障害	0	0	0	0	0	0
精神障害	1 (16.7)	0	0	0	1 (12.5)	0
激越	0	0	0	0	1 (12.5)	0
易刺激性	0	0	0	0	0	0
不安	0	0	0	0	0	0
息こらえ	0	0	0	0	0	0
気分動揺	0	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0	0
睡眠障害	0	0	0	0	0	0
チック	0	0	0	0	0	0
不快気分	0	0	0	0	1 (12.5)	0
心因性嘔吐	1 (16.7)	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
脱水	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 32 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
頚部痛	0	1 (11.1)	0	0	2 (4.3)
四肢拘縮	0	0	0	0	1 (2.1)
骨盤変形	0	0	0	0	1 (2.1)
腱障害	0	0	0	0	0
精神障害	0	0	0	0	1 (2.1)
激越	0	0	0	0	0
易刺激性	0	0	0	0	0
不安	0	0	0	0	0
息こらえ	0	0	0	0	0
気分動揺	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0
睡眠障害	0	0	0	0	0
チック	0	0	0	0	1 (2.1)
不快気分	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
代謝および栄養障害	0	1 (11.1)	0	0	3 (6.4)
成長障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
脱水	0	1 (11.1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 33 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
栄養補給不耐性	0	0	0	0	0	0
鉄欠乏	0	0	0	0	0	0
過小食	0	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0	0
食欲減退	0	0	0	0	0	0
食欲亢進	0	0	0	0	0	0
ビタミンD欠乏	0	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
小児期						
食物不耐性	0	0	0	0	0	0
高血糖	0	0	0	0	0	0
低血糖	0	0	0	0	0	0
神経系障害	3 (50.0)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
眼振	0	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0	0
よだれ	0	0	0	0	0	0
間代	0	0	0	0	0	0
傾眠	0	0	0	0	0	0
失神	0	0	0	0	0	0
脳脊髄液漏	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 34 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
栄養補給不耐性	0	0	0	0	0
鉄欠乏	0	0	0	0	0
過小食	0	0	0	0	0
代謝性アルカローシス	0	0	0	0	0
食欲減退	0	0	0	0	1 (2.1)
食欲亢進	0	0	0	0	1 (2.1)
ビタミンD欠乏	0	0	0	0	1 (2.1)
乳児および小児期早期の哺育障害	0	0	0	0	0
小児期					
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
神経系障害	2 (22.2)	0	0	3 (21.4)	12 (25.5)
眼振	0	0	0	0	0
不随意性筋収縮	0	0	0	0	0
よだれ	0	0	0	0	0
間代	0	0	0	0	0
傾眠	0	0	0	0	0
失神	0	0	0	0	1 (2.1)
脳脊髄液漏	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 35 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
頭痛	3 (50.0)	0	3 (50.0)	4 (40.0)	4 (50.0)	3 (37.5)
反射亢進	0	0	0	0	0	0
筋緊張低下	0	0	0	0	0	0
失声症	0	0	0	0	0	0
感覚鈍麻	0	0	0	0	0	1 (12.5)
振戦	0	0	0	0	0	0
味覚異常	0	0	0	0	0	0
錯感覚	1 (16.7)	0	0	0	0	1 (12.5)
心臓障害	0	1 (16.7)	0	0	1 (12.5)	0
頻脈	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
左室肥大	0	0	0	0	0	0
上室性頻脈	0	0	0	0	0	0
心筋症	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
動悸	0	1 (16.7)	0	0	1 (12.5)	0
免疫系障害	0	0	0	0	1 (12.5)	0
季節性アレルギー	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 36 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
頭痛	1 (11.1)	0	0	3 (21.4)	9 (19.1)
反射亢進	0	0	0	0	0
筋緊張低下	0	0	0	0	0
失声症	0	0	0	0	1 (2.1)
感覚鈍麻	0	0	0	0	1 (2.1)
振戦	0	0	0	0	1 (2.1)
味覚異常	1 (11.1)	0	0	0	0
錯感覚	0	0	0	0	0
心臓障害	0	0	1 (25.0)	0	1 (2.1)
頻脈	0	0	0	0	1 (2.1)
徐脈	0	0	0	0	0
チアノーゼ	0	0	0	0	0
左室肥大	0	0	0	0	0
上室性頻脈	0	0	0	0	0
心筋症	0	0	0	0	0
心室性頻脈	0	0	0	0	0
動悸	0	0	1 (25.0)	0	0
免疫系障害	0	2 (22.2)	1 (25.0)	0	2 (4.3)
季節性アレルギー	0	1 (11.1)	1 (25.0)	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 37 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
薬物過敏症	0	0	0	0	0	0
過敏症	0	0	0	0	1 (12.5)	0
食物アレルギー	0	0	0	0	0	0
眼障害	0	0	0	0	0	0
霰粒腫	0	0	0	0	0	0
眼乾燥	0	0	0	0	0	0
眼運動障害	0	0	0	0	0	0
近視	0	0	0	0	0	0
斜視	0	0	0	0	0	0
眼瞼下垂	0	0	0	0	0	0
乱視	0	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0	0
遠視	0	0	0	0	0	0
弱視	0	0	0	0	0	0
流涙増加	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
蒼白	0	0	0	0	0	0
血管炎	0	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 38 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
薬物過敏症	0	0	0	0	0
過敏症	0	1 (11.1)	0	0	1 (2.1)
食物アレルギー	0	0	0	0	0
眼障害	1 (11.1)	0	0	0	1 (2.1)
霰粒腫	0	0	0	0	0
眼乾燥	0	0	0	0	0
眼運動障害	0	0	0	0	0
近視	0	0	0	0	0
斜視	1 (11.1)	0	0	0	0
眼瞼下垂	0	0	0	0	0
乱視	0	0	0	0	0
後天性涙道狭窄	0	0	0	0	0
遠視	0	0	0	0	1 (2.1)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0
血管障害	0	0	0	0	0
蒼白	0	0	0	0	0
血管炎	0	0	0	0	0
毛細血管脆弱	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 39 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
本態性高血圧症	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
貧血母斑	0	0	0	0	0	0
鳩胸	0	0	0	0	0	0
斜頭症	0	0	0	0	0	0
停留精巣	0	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0	0
包茎	0	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0	0
陰茎障害	0	0	0	0	0	0
耳および迷路障害	1 (16.7)	0	0	0	1 (12.5)	0
耳痛	0	0	0	0	1 (12.5)	0
耳垢分泌過多	0	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0	0
乗物酔い	1 (16.7)	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 40 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
本態性高血圧症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0
貧血母斑	0	0	0	0	0
鳩胸	0	0	0	0	0
斜頭症	0	0	0	0	0
停留精巣	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
包茎	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0
卵巣嚢胞	0	0	0	0	0
陰茎障害	0	0	0	0	0
耳および迷路障害	0	0	0	0	1 (2.1)
耳痛	0	0	0	0	0
耳垢分泌過多	0	0	0	0	0
鼓膜穿孔	0	0	0	0	1 (2.1)
乗物酔い	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 41 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
腎および尿路障害	0	0	0	0	0	0
水腎症	0	0	0	0	0	0
尿失禁	0	0	0	0	0	0
糖尿	0	0	0	0	0	0
肝胆道系障害	0	0	0	0	0	0
肝腫大	0	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0	0
貧血	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
血小板増加症	0	0	0	0	0	0
リンパ節症	0	0	0	0	0	0
好酸球増加症	0	0	0	0	0	0
白血球増加症	0	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0	0
アクロコルドン	0	0	0	0	0	0
血管の良性新生物	0	0	0	0	0	0
脂漏性角化症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 42 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
腎および尿路障害	0	0	0	0	1 (2.1)
水腎症	0	0	0	0	0
尿失禁	0	0	0	0	1 (2.1)
糖尿	0	0	0	0	0
肝胆道系障害	0	0	0	0	0
肝腫大	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	1 (2.1)
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	1 (2.1)
血小板増加症	0	0	0	0	0
リンパ節症	0	0	0	0	0
好酸球増加症	0	0	0	0	0
白血球増加症	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	0
アクロコルドン	0	0	0	0	0
血管の良性新生物	0	0	0	0	0
脂漏性角化症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 43 of 82
Severity: MILD

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
妊娠、産褥および周産期の状態	0	0	0	0	0	0
臍肉芽腫	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 44 of 82
Severity: MILD

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
妊娠、産褥および周産期の状態	0	0	0	0	0
臍肉芽腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 45 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	2 (33.3)	1 (16.7)	1 (16.7)	1 (10.0)	6 (75.0)	3 (37.5)
感染症および寄生虫症	0	0	0	1 (10.0)	2 (25.0)	1 (12.5)
肺炎	0	0	0	0	1 (12.5)	0
ウイルス性上気道感染	0	0	0	0	0	1 (12.5)
上気道感染	0	0	0	0	0	0
ウイルス感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0	0
鼻咽頭炎	0	0	0	0	0	0
気道感染	0	0	0	0	0	0
インフルエンザ	0	0	0	0	0	0
耳感染	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0
アデノウイルス感染	0	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0	0
結膜炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 46 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	3 (33.3)	4 (44.4)	0	6 (42.9)	29 (61.7)
感染症および寄生虫症	0	2 (22.2)	0	3 (21.4)	18 (38.3)
肺炎	0	0	0	0	1 (2.1)
ウイルス性上気道感染	0	0	0	1 (2.1)	
上気道感染	0	1 (11.1)	0	1 (7.1)	5 (10.6)
ウイルス感染	0	0	0	0	3 (6.4)
ウイルス性肺炎	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0
鼻咽頭炎	0	1 (11.1)	0	0	2 (4.3)
気道感染	0	0	0	0	1 (2.1)
インフルエンザ	0	0	0	0	1 (2.1)
耳感染	0	0	0	0	0
尿路感染	0	0	0	1 (7.1)	1 (2.1)
アデノウイルス感染	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0
結膜炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 47 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
下気道感染	0	0	0	0	0	0
細菌性肺炎	0	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0
胃腸炎	0	0	0	0	0	0
ウイルス性胃腸炎	0	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0	0
真菌感染	0	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0	0
口腔カンジダ症	0	0	0	0	0	0
急性中耳炎	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
シュードモナス感染	0	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
中耳炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 48 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
下気道感染	0	0	0	0	0
細菌性肺炎	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0
気管支炎	0	0	0	0	0
胃腸炎	0	0	0	1 (7.1)	4 (8.5)
ウイルス性胃腸炎	0	0	0	0	2 (4.3)
ウイルス性気道感染	0	0	0	0	1 (2.1)
ウイルス性気管支炎	0	0	0	0	0
細菌性結膜炎	0	0	0	0	0
真菌感染	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
口腔カンジダ症	0	0	0	0	0
急性中耳炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
シュードモナス感染	0	0	0	0	0
皮膚カンジダ	0	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
細気管支炎	0	0	0	0	0
中耳炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 49 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
パラインフルエンザウイルス感染	0	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0	0
感染						
細菌感染	0	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0	0
手足口病	0	0	0	0	0	0
モラクセラ感染	0	0	0	0	0	0
鼻炎	0	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0	0
気管炎	0	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	1 (10.0)	0	0
膿痂疹	0	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	1 (12.5)	0
蜂巣炎	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
腟感染	0	0	0	0	0	0
細菌性疾患キャリアー	0	0	0	0	0	0
細菌性気管炎	0	0	0	0	0	0
カンジダ感染	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
細菌性気道感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 50 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
パラインフルエンザウイルス感染	0	0	0	0	0
アデノウイルス性上気道感染	0	0	0	0	0
細菌感染	0	0	0	0	0
ヘモフィルス感染	0	0	0	0	0
手足口病	0	0	0	0	0
モラクセラ感染	0	0	0	0	0
鼻炎	0	0	0	0	0
ブドウ球菌感染	0	0	0	0	0
気管炎	0	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	0	2 (4.3)
膿痂疹	0	0	0	0	0
ＲＳウイルス感染	0	0	0	0	2 (4.3)
蜂巣炎	0	0	0	0	1 (2.1)
ＲＳウイルス肺炎	0	0	0	0	1 (2.1)
腟感染	0	0	0	0	1 (2.1)
細菌性疾患キャリアー	0	0	0	0	0
細菌性気管炎	0	0	0	0	0
カンジダ感染	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
細菌性気道感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 51 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
セラチア感染	0	0	0	0	0	0
ストーマ部感染	0	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	0	1 (12.5)	1 (12.5)
呼吸窮迫	0	0	0	0	0	0
無気肺	0	0	0	0	1 (12.5)	0
呼吸不全	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
咳嗽	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
上気道分泌増加	0	0	0	0	0	0
呼吸停止	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
減呼吸	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 52 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
セラチア感染	0	0	0	0	0
ストーマ部感染	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	1 (7.1)	4 (8.5)
呼吸窮迫	0	0	0	0	0
無気肺	0	0	0	0	0
呼吸不全	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0
無呼吸	0	0	0	0	0
咳嗽	0	0	0	0	1 (2.1)
気管支分泌物貯留	0	0	0	0	0
誤嚥	0	0	0	0	0
低酸素症	0	0	0	0	2 (4.3)
慢性呼吸不全	0	0	0	0	0
上気道分泌増加	0	0	0	0	0
呼吸停止	0	0	0	0	0
呼吸障害	0	0	0	0	1 (2.1)
急性呼吸窮迫症候群	0	0	0	0	0
呼吸困難	0	0	0	0	0
減呼吸	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 53 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
低換気	0	0	0	0	0	0
気管支分泌増加	0	0	0	0	0	0
胸水	0	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
鼻漏	0	0	0	0	0	0
変色痰	0	0	0	0	0	0
急性呼吸不全	0	0	0	0	0	0
喘鳴	0	0	0	0	0	1 (12.5)
喉頭肉芽腫	0	0	0	0	0	0
鼻閉	0	0	0	0	0	0
気胸	0	0	0	0	0	0
肺うっ血	0	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0	0
気管障害	0	0	0	0	0	0
上気道うっ血	0	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0	0
カタル	0	0	0	0	0	0
息詰まり	0	0	0	0	0	0
鼻出血	0	0	0	0	1 (12.5)	0
肺臓炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 54 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
低換気	0	0	0	0	0
気管支分泌増加	0	0	0	0	0
胸水	0	0	0	0	0
呼吸性アルカローシス	0	0	0	0	0
気道うっ血	0	0	0	0	0
鼻漏	0	0	0	0	0
変色痰	0	0	0	0	0
急性呼吸不全	0	0	0	0	1 (2.1)
喘鳴	0	0	0	0	1 (2.1)
喉頭肉芽腫	0	0	0	0	0
鼻閉	0	0	0	0	0
気胸	0	0	0	0	0
肺うっ血	0	0	0	0	0
副鼻腔うっ血	0	0	0	0	0
気管障害	0	0	0	0	0
上気道うっ血	0	0	0	0	0
アレルギー性鼻炎	0	0	0	0	0
カタル	0	0	0	0	0
息詰まり	0	0	0	0	0
鼻出血	0	0	0	0	0
肺臓炎	0	0	0	1 (7.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 55 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
拘束性肺疾患	0	0	0	0	0	1 (12.5)
睡眠時無呼吸症候群	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	1 (12.5)
発熱	0	0	0	0	0	0
疼痛	0	0	0	0	0	1 (12.5)
低体温	0	0	0	0	0	0
倦怠感	0	0	0	0	0	0
医療機器閉塞	0	0	0	0	0	0
疲労	0	0	0	0	0	0
注入部位内出血	0	0	0	0	0	0
浮腫	0	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
生歯	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
便秘	0	0	0	0	0	0
胃食道逆流性疾患	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 56 of 82
Severity: MODERATE

Later-onset SMA

	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
拘束性肺疾患	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	4 (8.5)
発熱	0	0	0	0	3 (6.4)
疼痛	0	0	0	0	0
低体温	0	0	0	0	0
倦怠感	0	0	0	0	0
医療機器閉塞	0	0	0	0	0
疲労	0	0	0	0	1 (2.1)
注入部位内出血	0	0	0	0	0
浮腫	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0
胃腸障害	3 (33.3)	0	0	1 (7.1)	3 (6.4)
生歯	0	0	0	0	0
嘔吐	1 (11.1)	0	0	0	1 (2.1)
流涎過多	0	0	0	0	0
便秘	1 (11.1)	0	0	1 (7.1)	0
胃食道逆流性疾患	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 57 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
嚥下障害	0	0	0	0	0	0
下痢	0	0	0	0	0	0
胃出血	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
悪心	0	0	0	0	0	0
腹部症状	0	0	0	0	0	0
口腔内痛	0	0	0	0	0	0
腹部不快感	0	0	0	0	0	0
食中毒	0	0	0	0	0	0
胃腸出血	0	0	0	0	0	0
消化管刺激症状	0	0	0	0	0	0
臨床検査	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0	0
好中球数増加	0	0	0	0	0	0
体重減少	0	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
血中クロール減少	0	0	0	0	0	0
血中カリウム減少	0	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 58 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
嚥下障害	0	0	0	0	0
下痢	0	0	0	0	0
胃出血	0	0	0	0	0
腹部膨満	0	0	0	0	0
悪心	1 (11.1)	0	0	0	2 (4.3)
腹部症状	0	0	0	0	1 (2.1)
口腔内痛	0	0	0	0	1 (2.1)
腹部不快感	1 (11.1)	0	0	0	0
食中毒	1 (11.1)	0	0	0	0
胃腸出血	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
臨床検査	0	0	0	0	1 (2.1)
酸素飽和度低下	0	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0	0
好中球数増加	0	0	0	0	0
体重減少	0	0	0	0	1 (2.1)
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
血中クロール減少	0	0	0	0	0
血中カリウム減少	0	0	0	0	0
血中ナトリウム減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 59 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0	0
肝機能検査異常	0	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0	0
白血球数増加	0	0	0	0	0	0
好中球百分率増加	0	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0	0
心臓障害	0	0	0	0	0	0
頻脈	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
代謝および栄養障害	0	1 (16.7)	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 60 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
心電図ＳＴ－Ｔ部分異常	0	0	0	0	0
肝機能検査異常	0	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0	0
白血球数増加	0	0	0	0	0
好中球百分率増加	0	0	0	0	0
シュードモナス検査陽性	0	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0	0
心臓障害	0	0	0	0	0
頻脈	0	0	0	0	0
徐脈	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心室性頻脈	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 61 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
過小食	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
脱水	0	1 (16.7)	0	0	0	0
低血糖	0	0	0	0	0	0
低カリウム血症	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	1 (16.7)	0	1 (12.5)	2 (25.0)
関節拘縮	0	0	0	0	0	0
側弯症	0	0	0	0	1 (12.5)	1 (12.5)
脊柱後弯症	0	0	0	0	0	0
後側弯症	0	0	0	0	0	0
四肢痛	0	0	1 (16.7)	0	0	0
滑膜炎	0	0	0	0	0	0
斜頚	0	0	0	0	0	0
背部痛	0	0	0	0	0	1 (12.5)
関節痛	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
頭位性斜頭症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 62 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
過小食	0	0	0	0	0
成長障害	0	0	0	0	0
脱水	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
筋骨格系および結合組織障害	2 (22.2)	0	0	1 (7.1)	10 (21.3)
関節拘縮	1 (11.1)	0	0	0	0
側弯症	0	0	0	0	3 (6.4)
脊柱後弯症	0	0	0	0	0
後側弯症	0	0	0	0	0
四肢痛	0	0	0	0	2 (4.3)
滑膜炎	0	0	0	0	0
斜頚	0	0	0	0	0
背部痛	1 (11.1)	0	0	1 (7.1)	6 (12.8)
関節痛	0	0	0	0	2 (4.3)
筋力低下	0	0	0	0	0
頭位性斜頭症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 63 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
傷害、中毒および処置合併症	1 (16.7)	0	0	0	2 (25.0)	1 (12.5)
大腿骨骨折	0	0	0	0	0	0
処置による疼痛	0	0	0	0	1 (12.5)	1 (12.5)
麻酔からの覚醒遅延	0	0	0	0	0	0
擦過傷	0	0	0	0	0	0
関節脱臼	0	0	0	0	0	0
節足動物咬傷	0	0	0	0	0	0
口唇損傷	0	0	0	0	0	0
外傷性気胸	0	0	0	0	0	0
歯牙損傷	0	0	0	0	0	0
硬膜下血腫	0	0	0	0	0	0
腰椎穿刺後症候群	1 (16.7)	0	0	0	1 (12.5)	1 (12.5)
術後激越	0	0	0	0	0	0
挫傷	0	0	0	0	0	0
関節損傷	0	0	0	0	0	0
裂傷	0	0	0	0	0	0
四肢損傷	0	0	0	0	0	0
下肢骨折	0	0	0	0	0	0
半月板損傷	0	0	0	0	0	0
気管内挿管合併症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 64 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
傷害、中毒および処置合併症	2 (22.2)	3 (33.3)	0	2 (14.3)	10 (21.3)
大腿骨骨折	0	1 (11.1)	0	0	2 (4.3)
処置による疼痛	0	0	0	0	1 (2.1)
麻酔からの覚醒遅延	0	0	0	0	0
擦過傷	0	0	0	0	0
関節脱臼	0	0	0	0	1 (2.1)
節足動物咬傷	0	0	0	0	0
口唇損傷	0	0	0	0	0
外傷性気胸	0	0	0	0	0
歯牙損傷	0	0	0	0	0
硬膜下血腫	0	0	0	0	0
腰椎穿刺後症候群	2 (22.2)	2 (22.2)	0	0	2 (4.3)
術後激越	0	0	0	0	1 (2.1)
挫傷	0	0	0	0	1 (2.1)
関節損傷	0	0	0	1 (7.1)	1 (2.1)
裂傷	0	0	0	0	1 (2.1)
四肢損傷	0	0	0	0	1 (2.1)
下肢骨折	0	0	0	0	1 (2.1)
半月板損傷	0	0	0	0	1 (2.1)
気管内挿管合併症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 65 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
頭部損傷	0	0	0	0	0	0
術後イレウス	0	0	0	0	1 (12.5)	0
隆起骨折	0	0	0	0	0	1 (12.5)
皮膚および皮下組織障害	0	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0	0
発疹	0	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
皮下気腫	0	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0	0
湿疹	0	0	0	0	0	0
精神障害	0	0	0	0	0	0
不安	0	0	0	0	0	0
不眠症	0	0	0	0	0	0
激越	0	0	0	0	0	0
注意欠陥多動性障害	0	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0	0
落ち着きのなさ	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 66 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
頭部損傷	0	0	0	1 (7.1)	0
術後イレウス	0	0	0	0	0
隆起骨折	1 (11.1)	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0
発疹	0	0	0	0	0
皮膚炎	0	0	0	0	0
皮下気腫	0	0	0	0	0
脂漏性皮膚炎	0	0	0	0	0
褥瘡性潰瘍	0	0	0	0	0
湿疹	0	0	0	0	0
精神障害	0	2 (22.2)	0	0	1 (2.1)
不安	0	0	0	0	0
不眠症	0	0	0	0	1 (2.1)
激越	0	1 (11.1)	0	0	0
注意欠陥多動性障害	0	1 (11.1)	0	0	0
睡眠時随伴症	0	1 (11.1)	0	0	0
落ち着きのなさ	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 67 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
睡眠障害	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0	0
斜指症	0	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0	0
貧血	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
骨髄障害	0	0	0	0	0	0
腎および尿路障害	0	0	0	0	0	0
尿閉	0	0	0	0	0	0
排尿困難	0	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0	0
耳および迷路障害	0	0	0	0	0	0
耳の障害	0	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 68 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
睡眠障害	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0
発育性股関節形成不全	0	0	0	0	0
斜指症	0	0	0	0	0
血液およびリンパ系障害	0	0	0	0	0
貧血	0	0	0	0	0
好中球減少症	0	0	0	0	0
骨髄障害	0	0	0	0	0
腎および尿路障害	0	0	0	1 (7.1)	1 (2.1)
尿閉	0	0	0	0	0
排尿困難	0	0	0	0	1 (2.1)
膀胱尿管逆流	0	0	0	1 (7.1)	0
耳および迷路障害	0	0	0	0	0
耳の障害	0	0	0	0	0
生殖系および乳房障害	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 69 of 82
Severity: MODERATE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
後天性包茎	0	0	0	0	0	0
神経系障害	1 (16.7)	0	0	0	0	0
脳梗塞	0	0	0	0	0	0
嗜眠	0	0	0	0	0	0
頭痛	1 (16.7)	0	0	0	0	0
失読症	0	0	0	0	0	0
失神寸前の状態	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
高血圧	0	0	0	0	0	0
低血圧	0	0	0	0	0	0
免疫系障害	0	0	0	0	0	0
季節性アレルギー	0	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	1 (12.5)	0
皮膚乳頭腫	0	0	0	0	1 (12.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 70 of 82
Severity: MODERATE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
後天性包茎	0	0	0	0	0
神経系障害	0	1 (11.1)	0	0	7 (14.9)
脳梗塞	0	0	0	0	0
嗜眠	0	0	0	0	0
頭痛	0	0	0	0	7 (14.9)
失読症	0	1 (11.1)	0	0	0
失神寸前の状態	0	0	0	0	0
血管障害	0	0	0	1 (7.1)	0
高血圧	0	0	0	0	0
低血圧	0	0	0	1 (7.1)	0
免疫系障害	0	0	0	0	0
季節性アレルギー	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む	0	0	0	0	0
皮膚乳頭腫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 71 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	0	0	0	0	2 (25.0)	2 (25.0)
呼吸器、胸郭および縦隔障害	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
呼吸窮迫	0	0	0	0	0	0
急性呼吸不全	0	0	0	0	0	0
無気肺	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
呼吸停止	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
低換気	0	0	0	0	0	0
気胸	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 72 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	0	0	0	0	4 (8.5)
呼吸器、胸郭および縦隔障害	0	0	0	0	2 (4.3)
呼吸不全	0	0	0	0	1 (2.1)
呼吸窮迫	0	0	0	0	0
急性呼吸不全	0	0	0	0	0
無気肺	0	0	0	0	1 (2.1)
低酸素症	0	0	0	0	1 (2.1)
誤嚥性肺炎	0	0	0	0	0
誤嚥	0	0	0	0	0
呼吸困難	0	0	0	0	1 (2.1)
呼吸停止	0	0	0	0	0
無呼吸	0	0	0	0	0
低換気	0	0	0	0	0
気胸	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 73 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
肺障害	0	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
気縦隔症	0	0	0	0	0	0
窒息	0	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	1 (12.5)	0
肺炎	0	0	0	0	1 (12.5)	0
上気道感染	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0	0
気道感染	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0	0
細気管支炎						
細菌性肺炎	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
細菌性気管炎	0	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 74 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
呼吸障害	0	0	0	0	0
気縦隔症	0	0	0	0	0
窒息	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	2 (4.3)
肺炎	0	0	0	0	1 (2.1)
上気道感染	0	0	0	0	0
細気管支炎	0	0	0	0	0
ライノウイルス感染	0	0	0	0	0
気道感染	0	0	0	0	0
下気道感染	0	0	0	0	1 (2.1)
ＲＳウイルス細気管支炎	0	0	0	0	1 (2.1)
細菌性肺炎	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	2 (4.3)
細菌性気管炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 75 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気管支炎	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
肺感染	0	0	0	0	0	0
院内感染	0	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
敗血症	0	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
下気道感染	0	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0	0
ウイルス感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 76 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気管支炎	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0
肺感染	0	0	0	0	0
院内感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0
敗血症	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
下気道感染	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 77 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
心臓障害	0	0	0	0	0	0
心肺停止	0	0	0	0	0	0
心停止	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心膜気腫	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0
胃炎	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	1 (12.5)
発熱	0	0	0	0	0	0
死亡	0	0	0	0	0	0
疼痛	0	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0	1 (12.5)
神経系障害	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 78 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
心臓障害	0	0	0	0	0
心肺停止	0	0	0	0	0
心停止	0	0	0	0	0
徐脈	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心膜気腫	0	0	0	0	0
胃腸障害	0	0	0	0	0
嚥下障害	0	0	0	0	0
胃炎	0	0	0	0	0
嘔吐	0	0	0	0	0
流涎過多	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0
発熱	0	0	0	0	0
死亡	0	0	0	0	0
疼痛	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0
神経系障害	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 79 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
痙攣発作	0	0	0	0	0	0
脳損傷	0	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0	0
片頭痛	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
高血圧	0	0	0	0	0	0
ショック	0	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0	1 (12.5)
胸郭変形	0	0	0	0	0	0
関節拘縮	0	0	0	0	0	0
筋肉痛	0	0	0	0	0	1 (12.5)
傷害、中毒および処置合併症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 80 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
痙攣発作	0	0	0	0	0
脳損傷	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0
片頭痛	0	0	0	0	1 (2.1)
血管障害	0	0	0	0	0
高血圧	0	0	0	0	0
ショック	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0
胸郭変形	0	0	0	0	0
関節拘縮	0	0	0	0	0
筋肉痛	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	1 (2.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 81 of 82
Severity: SEVERE

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
創離開	0	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
免疫系障害	0	0	0	0	1 (12.5)	0
薬物過敏症	0	0	0	0	1 (12.5)	0
臨床検査	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0	0
外科および内科処置	0	0	0	0	0	0
機械的換気	0	0	0	0	0	0
精神障害	0	0	0	0	0	0
不安	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Adverse Events by severity - Later-onset
Page 82 of 82
Severity: SEVERE

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
創離開	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	1 (2.1)
大腿骨骨折	0	0	0	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
臨床検査	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
おむつ皮膚炎	0	0	0	0	0
外科および内科処置	0	0	0	0	0
機械的換気	0	0	0	0	0
精神障害	0	0	0	0	0
不安	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 15　Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA
Page 1 of 3

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	3 (17.6)	0	2 (12.5)	6 (14.6)	9 (11.3)
臨床検査	1 (5.9)	0	0	0	2 (2.5)
体温低下	0	0	0	0	1 (1.3)
体温上昇	0	0	0	0	1 (1.3)
アラニンアミノトランスフェラーゼ増加	1 (5.9)	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.9)	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
心拍数増加	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (5.9)	0	0	3 (7.3)	2 (2.5)
発熱	1 (5.9)	0	0	2 (4.9)	2 (2.5)
疼痛	0	0	0	1 (2.4)	0
神経系障害	1 (5.9)	0	0	0	1 (1.3)
眼振	0	0	0	0	1 (1.3)
反射亢進	1 (5.9)	0	0	0	0
頭痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA
Page 2 of 3

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
錯感覚	0	0	0	0	0
心臓障害	1 (5.9)	0	0	0	1 (1.3)
頻脈	1 (5.9)	0	0	0	1 (1.3)
動悸	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	1 (1.3)
処置後腫脹	0	0	0	0	1 (1.3)
腰椎穿刺後症候群	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	1 (1.3)
貧血母斑	0	0	0	0	1 (1.3)
感染症および寄生虫症	0	0	0	0	1 (1.3)
蜂巣炎	0	0	0	0	1 (1.3)
血管障害	0	0	0	0	1 (1.3)
血管炎	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Infants diagnosed with SMA
Page 3 of 3

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
血液およびリンパ系障害	0	0	1 (6.3)	0	0
好中球減少症	0	0	1 (6.3)	0	0
胃腸障害	0	0	1 (6.3)	2 (4.9)	0
嘔吐	0	0	1 (6.3)	1 (2.4)	0
下痢	0	0	0	1 (2.4)	0
筋骨格系および結合組織障害	1 (5.9)	0	0	0	0
筋力低下	1 (5.9)	0	0	0	0
体重支持困難	1 (5.9)	0	0	0	0
皮膚および皮下組織障害	0	0	0	1 (2.4)	0
発疹	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 16　Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 1 of 6

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	1 (16.7)	1 (16.7)	0	0	0	0
臨床検査	0	0	0	0	0	0
体温低下	0	0	0	0	0	0
体温上昇	0	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0	0
心拍数増加	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	0
発熱	0	0	0	0	0	0
疼痛	0	0	0	0	0	0
神経系障害	1 (16.7)	0	0	0	0	0
眼振	0	0	0	0	0	0
反射亢進	0	0	0	0	0	0
頭痛	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	0	0	0	0	5 (10.6)
臨床検査	0	0	0	0	2 (4.3)
体温低下	0	0	0	0	0
体温上昇	0	0	0	0	0
アラニンアミノトランスフェラーゼ増加	0	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	1 (2.1)
心拍数増加	0	0	0	0	1 (2.1)
一般・全身障害および投与部位の状態	0	0	0	0	0
発熱	0	0	0	0	0
疼痛	0	0	0	0	0
神経系障害	0	0	0	0	2 (4.3)
眼振	0	0	0	0	0
反射亢進	0	0	0	0	0
頭痛	0	0	0	0	2 (4.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 3 of 6

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
錯感覚	1 (16.7)	0	0	0	0	0
心臓障害	0	1 (16.7)	0	0	0	0
頻脈	0	0	0	0	0	0
動悸	0	1 (16.7)	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	0	0
処置後腫脹	0	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0	0	0
貧血母斑	0	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	0	0
蜂巣炎	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
血管炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
錯感覚	0	0	0	0	0
心臓障害	0	0	0	0	0
頻脈	0	0	0	0	0
動悸	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	1 (2.1)
処置後腫脹	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	1 (2.1)
先天性、家族性および遺伝性障害	0	0	0	0	0
貧血母斑	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	0
蜂巣炎	0	0	0	0	0
血管障害	0	0	0	0	0
血管炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 5 of 6

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
血液およびリンパ系障害	0	0	0	0	0	0
好中球減少症	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
下痢	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0	0
筋力低下	0	0	0	0	0	0
体重支持困難	0	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0	0
発疹	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of treatment-related Adverse Events (per protocol judged by investigator as possibly related or related) - Later-onset
Page 6 of 6

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
血液およびリンパ系障害	0	0	0	0	0
好中球減少症	0	0	0	0	0
胃腸障害	0	0	0	0	0
嘔吐	0	0	0	0	0
下痢	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0
筋力低下	0	0	0	0	0
体重支持困難	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
発疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 17　Incidence of fatal Adverse Events - Infants diagnosed with SMA

Incidence of fatal Adverse Events - Infants diagnosed with SMA
Page 1 of 2

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	0	1 (25.0)	3 (18.8)	13 (31.7)	12 (15.0)
呼吸器、胸郭および縦隔障害	0	1 (25.0)	2 (12.5)	10 (24.4)	7 (8.8)
呼吸不全	0	0	2 (12.5)	7 (17.1)	4 (5.0)
急性呼吸不全	0	0	0	1 (2.4)	1 (1.3)
呼吸停止	0	0	0	0	1 (1.3)
呼吸窮迫	0	0	0	2 (4.9)	1 (1.3)
窒息	0	1 (25.0)	0	0	0
心臓障害	0	0	0	2 (4.9)	2 (2.5)
心肺停止	0	0	0	2 (4.9)	2 (2.5)
神経系障害	0	0	0	0	2 (2.5)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	0	0	0	1 (2.4)	1 (1.3)
死亡	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of fatal Adverse Events - Infants diagnosed with SMA
Page 2 of 2

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	0	0	1 (6.3)	0	0
ウイルス性下気道感染	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 18　Incidence of Serious Adverse Events - Infants diagnosed with SMA

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 1 of 6

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	5 (29.4)	3 (75.0)	13 (81.3)	33 (80.5)	56 (70.0)
呼吸器、胸郭および縦隔障害	1 (5.9)	3 (75.0)	12 (75.0)	26 (63.4)	46 (57.5)
呼吸窮迫	1 (5.9)	1 (25.0)	5 (31.3)	10 (24.4)	19 (23.8)
呼吸不全	0	0	5 (31.3)	14 (34.1)	17 (21.3)
急性呼吸不全	0	1 (25.0)	3 (18.8)	7 (17.1)	11 (13.8)
無気肺	0	0	2 (12.5)	2 (4.9)	11 (13.8)
誤嚥性肺炎	0	0	2 (12.5)	4 (9.8)	6 (7.5)
呼吸困難	0	0	0	2 (4.9)	4 (5.0)
誤嚥	0	0	1 (6.3)	0	3 (3.8)
低酸素症	0	0	1 (6.3)	1 (2.4)	3 (3.8)
呼吸停止	0	0	0	4 (9.8)	3 (3.8)
無呼吸	0	0	2 (12.5)	2 (4.9)	2 (2.5)
呼吸障害	0	0	0	0	2 (2.5)
低換気	0	0	1 (6.3)	0	1 (1.3)
急性呼吸窮迫症候群	0	0	0	0	1 (1.3)
気管支分泌物貯留	0	0	0	2 (4.9)	1 (1.3)
慢性呼吸不全	0	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 2 of 6

	Study SM201	Infantile-onset			
		Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
気管支分泌増加	0	0	0	0	1 (1.3)
肺障害	0	0	0	0	1 (1.3)
閉塞性気道障害	0	0	0	0	1 (1.3)
気縦隔症	0	0	1 (6.3)	0	0
窒息	0	1 (25.0)	0	0	0
乳幼児突発性危急事態	0	0	0	2 (4.9)	0
気道うっ血	0	0	0	1 (2.4)	0
感染症および寄生虫症	3 (17.6)	2 (50.0)	11 (68.8)	15 (36.6)	40 (50.0)
肺炎	1 (5.9)	0	4 (25.0)	4 (9.8)	14 (17.5)
ライノウイルス感染	0	0	4 (25.0)	2 (4.9)	6 (7.5)
ウイルス性肺炎	0	0	2 (12.5)	1 (2.4)	5 (6.3)
細気管支炎	0	0	3 (18.8)	1 (2.4)	4 (5.0)
ウイルス感染	0	0	2 (12.5)	1 (2.4)	4 (5.0)
上気道感染	0	0	1 (6.3)	0	4 (5.0)
気道感染	0	1 (25.0)	0	0	4 (5.0)
ＲＳウイルス細気管支炎	0	0	1 (6.3)	3 (7.3)	3 (3.8)
細菌性肺炎	0	0	1 (6.3)	1 (2.4)	3 (3.8)
ウイルス性上気道感染	0	0	1 (6.3)	6 (14.6)	3 (3.8)
気管支炎	1 (5.9)	0	0	0	3 (3.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 3 of 6

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
下気道感染	0	0	0	0	3 (3.8)
ウイルス性気管支炎	0	0	0	0	2 (2.5)
ウイルス性下気道感染	0	0	1 (6.3)	0	1 (1.3)
ウイルス性気道感染	0	0	1 (6.3)	1 (2.4)	1 (1.3)
ＲＳウイルス肺炎	0	0	0	0	1 (1.3)
耳感染	0	0	0	0	1 (1.3)
ロタウイルス胃腸炎	0	0	0	0	1 (1.3)
肺感染	0	0	0	0	1 (1.3)
鼻咽頭炎	0	0	0	0	1 (1.3)
院内感染	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	0	0	1 (1.3)
モラクセラ菌性肺炎	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	0	0	1 (2.4)	1 (1.3)
ブドウ球菌性敗血症	0	0	0	0	1 (1.3)
ストーマ部膿瘍	0	0	0	0	1 (1.3)
メタニューモウイルス感染	0	0	2 (12.5)	0	0
コロナウイルス感染	0	0	1 (6.3)	1 (2.4)	0
エンテロウイルス感染	0	0	1 (6.3)	0	0
パラインフルエンザウイルス感染	0	1 (25.0)	0	0	0
シュードモナス菌性肺炎	0	1 (25.0)	0	1 (2.4)	0
尿路感染	1 (5.9)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 4 of 6

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胃腸炎	0	0	0	0	0
心臓障害	0	0	3 (18.8)	5 (12.2)	9 (11.3)
心肺停止	0	0	1 (6.3)	3 (7.3)	5 (6.3)
心停止	0	0	1 (6.3)	2 (4.9)	2 (2.5)
チアノーゼ	0	0	1 (6.3)	1 (2.4)	1 (1.3)
心室性頻脈	0	0	0	0	1 (1.3)
徐脈	0	0	1 (6.3)	0	0
心膜気腫	0	0	1 (6.3)	0	0
代謝および栄養障害	1 (5.9)	0	2 (12.5)	4 (9.8)	7 (8.8)
体重増加不良	0	0	0	2 (4.9)	3 (3.8)
乳児および小児期早期の哺育障害	0	0	0	2 (4.9)	2 (2.5)
栄養補給不耐性	0	0	0	0	2 (2.5)
脱水	0	0	0	0	1 (1.3)
成長障害	1 (5.9)	0	1 (6.3)	0	0
低ナトリウム血症	0	0	1 (6.3)	0	0
胃腸障害	1 (5.9)	0	1 (6.3)	3 (7.3)	6 (7.5)
嘔吐	0	0	1 (6.3)	1 (2.4)	3 (3.8)
嚥下障害	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 5 of 6

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
胃出血	0	0	0	0	1 (1.3)
腹部膨満	1 (5.9)	0	0	0	0
胃腸出血	0	0	0	1 (2.4)	0
流涎過多	0	0	0	1 (2.4)	0
一般・全身障害および投与部位の状態	0	0	0	1 (2.4)	4 (5.0)
発熱	0	0	0	0	3 (3.8)
死亡	0	0	0	1 (2.4)	1 (1.3)
傷害、中毒および処置合併症	0	0	0	2 (4.9)	3 (3.8)
麻酔からの覚醒遅延	0	0	0	0	1 (1.3)
ワクチン接種合併症	0	0	0	0	1 (1.3)
創離開	0	0	0	0	1 (1.3)
腰椎穿刺後症候群	0	0	0	0	0
大腿骨骨折	0	0	0	1 (2.4)	0
頭部損傷	0	0	0	1 (2.4)	0
神経系障害	0	0	1 (6.3)	0	2 (2.5)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Infants diagnosed with SMA
Page 6 of 6

	Infantile-onset				
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
痙攣発作	0	0	1 (6.3)	0	0
臨床検査	0	0	0	2 (4.9)	2 (2.5)
医学的観察	0	0	0	0	1 (1.3)
酸素飽和度低下	0	0	0	1 (2.4)	1 (1.3)
レスピロウイルス検査陽性	0	0	0	1 (2.4)	0
皮膚および皮下組織障害	0	0	0	0	1 (1.3)
皮膚炎	0	0	0	0	1 (1.3)
血管障害	0	0	0	0	1 (1.3)
ショック	0	0	0	0	1 (1.3)
筋骨格系および結合組織障害	0	0	1 (6.3)	0	0
滑膜炎	0	0	1 (6.3)	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
精神障害	0	0	0	1 (2.4)	0
激越	0	0	0	1 (2.4)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 19　Table 19: Incidence of Serious Adverse Events - Later-onset

Incidence of Serious Adverse Events - Later-onset
Page 1 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
Number of subjects in safety population	6 (100)	6 (100)	6 (100)	10 (100)	8 (100)	8 (100)
Number of subjects with an event	0	0	0	0	2 (25.0)	0
呼吸器、胸郭および縦隔障害	0	0	0	0	0	0
呼吸窮迫	0	0	0	0	0	0
呼吸不全	0	0	0	0	0	0
急性呼吸不全	0	0	0	0	0	0
無気肺	0	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0	0
呼吸困難	0	0	0	0	0	0
誤嚥	0	0	0	0	0	0
低酸素症	0	0	0	0	0	0
呼吸停止	0	0	0	0	0	0
無呼吸	0	0	0	0	0	0
呼吸障害	0	0	0	0	0	0
低換気	0	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 2 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
Number of subjects in safety population	9 (100)	9 (100)	4 (100)	14 (100)	47 (100)
Number of subjects with an event	0	1 (11.1)	0	0	5 (10.6)
呼吸器、胸郭および縦隔障害	0	0	0	0	2 (4.3)
呼吸窮迫	0	0	0	0	0
呼吸不全	0	0	0	0	1 (2.1)
急性呼吸不全	0	0	0	0	1 (2.1)
無気肺	0	0	0	0	0
誤嚥性肺炎	0	0	0	0	0
呼吸困難	0	0	0	0	1 (2.1)
誤嚥	0	0	0	0	0
低酸素症	0	0	0	0	0
呼吸停止	0	0	0	0	0
無呼吸	0	0	0	0	0
呼吸障害	0	0	0	0	0
低換気	0	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
慢性呼吸不全	0	0	0	0	0
高炭酸ガス血症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 3 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
気管支分泌増加	0	0	0	0	0	0
肺障害	0	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0	0
気縦隔症	0	0	0	0	0	0
窒息	0	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0	0
気道うっ血	0	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	1 (12.5)	0
肺炎	0	0	0	0	1 (12.5)	0
ライノウイルス感染	0	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	0	0
細気管支炎	0	0	0	0	0	0
ウイルス感染	0	0	0	0	0	0
上気道感染	0	0	0	0	0	0
気道感染	0	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	0	0
細菌性肺炎	0	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0	0
気管支炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 4 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
気管支分泌増加	0	0	0	0	0
肺障害	0	0	0	0	0
閉塞性気道障害	0	0	0	0	0
気縦隔症	0	0	0	0	0
窒息	0	0	0	0	0
乳幼児突発性危急事態	0	0	0	0	0
気道うっ血	0	0	0	0	0
感染症および寄生虫症	0	0	0	0	4 (8.5)
肺炎	0	0	0	0	1 (2.1)
ライノウイルス感染	0	0	0	0	0
ウイルス性肺炎	0	0	0	0	2 (4.3)
細気管支炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0
上気道感染	0	0	0	0	0
気道感染	0	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0	1 (2.1)
細菌性肺炎	0	0	0	0	0
ウイルス性上気道感染	0	0	0	0	0
気管支炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 5 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
下気道感染	0	0	0	0	0	0
ウイルス性気管支炎	0	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	0	0
耳感染	0	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0	0
肺感染	0	0	0	0	0	0
鼻咽頭炎	0	0	0	0	0	0
院内感染	0	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0	0
尿路感染	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 6 of 12

Later-onset SMA

	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
下気道感染	0	0	0	0	1 (2.1)
ウイルス性気管支炎	0	0	0	0	0
ウイルス性下気道感染	0	0	0	0	0
ウイルス性気道感染	0	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0	1 (2.1)
耳感染	0	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0	0
肺感染	0	0	0	0	0
鼻咽頭炎	0	0	0	0	0
院内感染	0	0	0	0	0
インフルエンザ性肺炎	0	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0	0
ストーマ部膿瘍	0	0	0	0	0
メタニューモウイルス感染	0	0	0	0	0
コロナウイルス感染	0	0	0	0	0
エンテロウイルス感染	0	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0	0
尿路感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 7 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
胃腸炎	0	0	0	0	0	0
心臓障害	0	0	0	0	0	0
心肺停止	0	0	0	0	0	0
心停止	0	0	0	0	0	0
チアノーゼ	0	0	0	0	0	0
心室性頻脈	0	0	0	0	0	0
徐脈	0	0	0	0	0	0
心膜気腫	0	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0	0
体重増加不良	0	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0	0
脱水	0	0	0	0	0	0
成長障害	0	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0	0
胃腸障害	0	0	0	0	0	0
嘔吐	0	0	0	0	0	0
嚥下障害	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 8 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
胃腸炎	0	0	0	0	1 (2.1)
心臓障害	0	0	0	0	0
心肺停止	0	0	0	0	0
心停止	0	0	0	0	0
チアノーゼ	0	0	0	0	0
心室性頻脈	0	0	0	0	0
徐脈	0	0	0	0	0
心膜気腫	0	0	0	0	0
代謝および栄養障害	0	0	0	0	0
体重増加不良	0	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0	0
栄養補給不耐性	0	0	0	0	0
脱水	0	0	0	0	0
成長障害	0	0	0	0	0
低ナトリウム血症	0	0	0	0	0
胃腸障害	0	0	0	0	0
嘔吐	0	0	0	0	0
嚥下障害	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 9 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
胃出血	0	0	0	0	0	0
腹部膨満	0	0	0	0	0	0
胃腸出血	0	0	0	0	0	0
流涎過多	0	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0	0
発熱	0	0	0	0	0	0
死亡	0	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0	0
創離開	0	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0	0
大腿骨骨折	0	0	0	0	0	0
頭部損傷	0	0	0	0	0	0
神経系障害	0	0	0	0	0	0
脳損傷	0	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 10 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
胃出血	0	0	0	0	0
腹部膨満	0	0	0	0	0
胃腸出血	0	0	0	0	0
流涎過多	0	0	0	0	0
一般・全身障害および投与部位の状態	0	0	0	0	0
発熱	0	0	0	0	0
死亡	0	0	0	0	0
傷害、中毒および処置合併症	0	1 (11.1)	0	0	1 (2.1)
麻酔からの覚醒遅延	0	0	0	0	0
ワクチン接種合併症	0	0	0	0	0
創離開	0	0	0	0	0
腰椎穿刺後症候群	0	1 (11.1)	0	0	1 (2.1)
大腿骨骨折	0	0	0	0	0
頭部損傷	0	0	0	0	0
神経系障害	0	0	0	0	0
脳損傷	0	0	0	0	0
低酸素性虚血性脳症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 11 of 12

	Later-onset SMA					
	Study CS1				Study CS2	
	1 mg x 1	3 mg x 1	6 mg x 1	9 mg x 1	3 mg x 3	6 mg x 3
痙攣発作	0	0	0	0	0	0
臨床検査	0	0	0	0	0	0
医学的観察	0	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0	0
皮膚炎	0	0	0	0	0	0
血管障害	0	0	0	0	0	0
ショック	0	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0	0
滑膜炎	0	0	0	0	0	0
免疫系障害	0	0	0	0	1 (12.5)	0
薬物過敏症	0	0	0	0	1 (12.5)	0
精神障害	0	0	0	0	0	0
激越	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of Serious Adverse Events - Later-onset
Page 12 of 12

	Later-onset SMA				
	Study CS2		Study CS10		Study CS12
	9 mg x 2	12 mg x 3	6 mg x 1	9 mg x 1	12 mg
痙攣発作	0	0	0	0	0
臨床検査	0	0	0	0	0
医学的観察	0	0	0	0	0
酸素飽和度低下	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
皮膚および皮下組織障害	0	0	0	0	0
皮膚炎	0	0	0	0	0
血管障害	0	0	0	0	0
ショック	0	0	0	0	0
筋骨格系および結合組織障害	0	0	0	0	0
滑膜炎	0	0	0	0	0
免疫系障害	0	0	0	0	0
薬物過敏症	0	0	0	0	0
精神障害	0	0	0	0	0
激越	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 20　Incidence of Adeverse Events leading to study drug discontinuation - Infants diagnosed with SMA

Incidence of Adeverse Events leading to study drug discontinuation - Infants diagnosed with SMA
Page 1 of 2

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
Number of subjects in safety population	17 (100)	4 (100)	16 (100)	41 (100)	80 (100)
Number of subjects with an event	0	0	3 (18.8)	12 (29.3)	12 (15.0)
呼吸器、胸郭および縦隔障害	0	0	2 (12.5)	9 (22.0)	7 (8.8)
呼吸不全	0	0	2 (12.5)	6 (14.6)	4 (5.0)
急性呼吸不全	0	0	0	1 (2.4)	1 (1.3)
呼吸停止	0	0	0	0	1 (1.3)
呼吸窮迫	0	0	0	2 (4.9)	1 (1.3)
心臓障害	0	0	0	2 (4.9)	2 (2.5)
心肺停止	0	0	0	2 (4.9)	2 (2.5)
神経系障害	0	0	0	0	2 (2.5)
脳損傷	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	0	0	0	1 (2.4)	1 (1.3)
死亡	0	0	0	1 (2.4)	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of Adeverse Events leading to study drug discontinuation - Infants diagnosed with SMA
Page 2 of 2

		Infantile-onset			
	Study SM201	Study CS3A		Study CS3B	
	12 mg	Cohort 1	Cohort 2	Sham control	12 mg
感染症および寄生虫症	0	0	1 (6.3)	0	0
ウイルス性下気道感染	0	0	1 (6.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: AE coding done using the MedDRA version 18.1 dictionary.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 121 Demographic Characteristics of Infants Diagnosed With SMA

Demographic characteristics of infants diagnosed with SMA
Page 1 of 5

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20	41	80	100	120
Age at first dose/sham procedure					
<30 days (less than 1 month)	17 (85.0)	0	0	0	17 (14.2)
>=30 days to <90 days (1 to 3 months)	3 (15.0)	2 (4.9)	6 (7.5)	10 (10.0)	13 (10.8)
>=90 days to <180 days (3 to 6 months)	0	14 (34.1)	43 (53.8)	51 (51.0)	51 (42.5)
>=180 days (6 months or older)	0	25 (61.0)	31 (38.8)	39 (39.0)	39 (32.5)
>=1 year to <2 years	0	0	0	0	0
>=2 years to <6 years	0	0	0	0	0
>=6 years	0	0	0	0	0
n	20	41	80	100	120
Mean	20.5	180.5	163.4	160.9	137.5
SD	11.41	50.92	49.57	52.23	71.07
Median	19.0	205.0	164.5	164.5	146.5
25th, 75th percentiles	12.0, 26.0	143.0, 215.0	118.0, 208.5	118.0, 210.0	88.5, 199.5
Min, Max	3, 42	30, 262	52, 242	37, 242	3, 242

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 2 of 5

	Presymptomatic:	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Gestational age (weeks)					
n	20	41	80	100	120
Mean	39.1	39.3	38.9	39.0	39.0
SD	1.10	1.33	1.30	1.34	1.30
Median	39.0	40.0	39.0	39.0	39.0
25th, 75th percentiles	38.0, 40.0	38.0, 40.0	38.0, 40.0	38.0, 40.0	38.0, 40.0
Min, Max	38, 41	37, 42	36, 41	35, 42	35, 42
Sex					
n	20	41	80	100	120
Male	11 (55.0)	17 (41.5)	37 (46.3)	49 (49.0)	60 (50.0)
Female	9 (45.0)	24 (58.5)	43 (53.8)	51 (51.0)	60 (50.0)
Ethnicity					
n	20	41	80	100	120
Hispanic or Latino	2 (10.0)	4 (9.8)	12 (15.0)	13 (13.0)	15 (12.5)
Not Hispanic or Latino	11 (55.0)	37 (90.2)	68 (85.0)	87 (87.0)	98 (81.7)
Not Reported	7 (35.0)	0	0	0	7 (5.8)

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 3 of 5

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
Race					
n	20	41	80	100	120
Asian	1 (5.0)	1 (2.4)	5 (6.3)	6 (6.0)	7 (5.8)
Black	0	0	3 (3.8)	4 (4.0)	4 (3.3)
Native Hawaiian or other Pacific Islander	0	0	0	0	0
White	10 (50.0)	36 (87.8)	68 (85.0)	84 (84.0)	94 (78.3)
Other	2 (10.0)	1 (2.4)	3 (3.8)	4 (4.0)	6 (5.0)
Multiple	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
Not Reported	7 (35.0)	1 (2.4)	0	0	7 (5.8)

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 4 of 5

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Geographic region					
North America	13 (65.0)	22 (53.7)	38 (47.5)	58 (58.0)	71 (59.2)
Europe	3 (15.0)	17 (41.5)	30 (37.5)	30 (30.0)	33 (27.5)
Asia-Pacific	4 (20.0)	2 (4.9)	12 (15.0)	12 (12.0)	16 (13.3)
Height (cm)					
n	20	41	80	100	120
Mean	52.2	64.2	64.1	64.2	62.2
SD	2.95	3.77	4.53	4.68	6.31
Median	51.4	64.3	64.7	64.8	62.8
25th, 75th percentiles	49.8, 54.7	61.3, 66.0	60.5, 66.5	60.7, 66.5	58.3, 66.1
Min, Max	49, 59	56, 74	55, 75	54, 75	49, 75

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Demographic characteristics of infants diagnosed with SMA
Page 5 of 5

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			Presymptomatic and symptomatic: ISIS 396443
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	
		Control	ISIS 396443		
Weight (kg)					
n	20	41	80	100	120
Mean	3.9	6.7	6.6	6.6	6.2
SD	0.72	1.01	0.98	1.05	1.44
Median	3.7	6.7	6.5	6.6	6.3
25th, 75th percentiles	3.2, 4.4	6.1, 7.1	5.8, 7.0	5.8, 7.1	5.3, 7.0
Min, Max	3, 5	5, 10	5, 9	5, 9	3, 9
Weight for age percentile					
n	20	41	80	100	120
Mean	42.9	24.4	26.8	29.4	31.7
SD	26.08	26.74	27.82	28.26	28.25
Median	42.6	12.9	16.0	17.5	20.8
25th, 75th percentiles	26.2, 57.2	5.2, 35.3	4.5, 45.3	5.3, 53.0	6.7, 54.4
Min, Max	2, 94	1, 98	1, 94	1, 94	1, 94

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 122　SMA History of Infants Diagnosed With SMA

SMA history of infants diagnosed with SMA
Page 1 of 3

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20	41	80	100	120
SMN2 copy number					
1 copy	0	0	0	0	0
2 copies	12 (60.0)	40 (97.6)	80 (100.0)	97 (97.0)	109 (90.8)
3 copies	7 (35.0)	1 (2.4)	0	2 (2.0)	9 (7.5)
4 copies	0	0	0	0	0
5 copies	0	0	0	0	0
Unknown	1 (5.0)	0	0	1 (1.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at diagnosis not recorded for presymptomatic infants.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

SMA history of infants diagnosed with SMA
Page 2 of 3

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20	41	80	100	120
Age at symptom onset (months)					
<30 days (less than 1 month)	-	5 (12.2)	20 (25.0)	27 (27.0)	27 (22.5)
>=30 days to <90 days (1 to 3 months)	-	27 (65.9)	52 (65.0)	62 (62.0)	62 (51.7)
>=90 days to <180 days (3 to 6 months)	-	9 (22.0)	8 (10.0)	11 (11.0)	11 (9.2)
>=180 days (6 months or older)	-	0	0	0	0
n		41	80	100	100
Mean		2.2	1.8	1.8	1.8
SD		1.07	0.91	0.99	0.99
Median		1.8	1.5	1.6	1.6
25th, 75th percentiles		1.4, 2.8	1.0, 2.5	0.9, 2.5	0.9, 2.5
Min, Max		0, 5	0, 4	0, 5	0, 5

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at diagnosis not recorded for presymptomatic infants.

SOURCE: [redacted] DATE: [redacted]20[redacted]

SMA history of infants diagnosed with SMA
Page 3 of 3

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20	41	80	100	120
Age at diagnosis (months)					
<30 days (less than 1 month)	-	3 (7.3)	7 (8.8)	11 (11.0)	11 (11.0)
>=30 days to <90 days (1 to 3 months)	-	9 (22.0)	44 (55.0)	52 (52.0)	52 (52.0)
>=90 days to <180 days (3 to 6 months)	-	26 (63.4)	28 (35.0)	36 (36.0)	36 (36.0)
>=180 days (6 months or older)	-	3 (7.3)	1 (1.3)	1 (1.0)	1 (1.0)
n		41	80	100	100
Mean		4.0	2.9	2.8	2.8
SD		1.72	1.53	1.51	1.51
Median		4.6	2.5	2.5	2.5
25th, 75th percentiles		2.8, 5.1	1.8, 4.1	1.8, 4.0	1.8, 4.0
Min, Max		0, 7	0, 7	0, 7	0, 7

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at diagnosis not recorded for presymptomatic infants.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 123 Demographic Characteristics of Subjects Diagnosed With SMA

Demographic characteristics of subjects diagnosed with SMA
Page 1 of 3

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20	100	120	56	176
Age at first dose/sham procedure					
<30 days (less than 1 month)	17 (85.0)	0	17 (14.2)	0	17 (9.7)
>=30 days to <90 days (1 to 3 months)	3 (15.0)	10 (10.0)	13 (10.8)	0	13 (7.4)
>=90 days to <180 days (3 to 6 months)	0	51 (51.0)	51 (42.5)	0	51 (29.0)
>=180 days to <365 days (6 months to 1 year)	0	39 (39.0)	39 (32.5)	0	39 (22.2)
>=1 year to <2 years	0	0	0	0	0
>=2 years to <6 years	0	0	0	28 (50.0)	28 (15.9)
>=6 years	0	0	0	28 (50.0)	28 (15.9)
n	20	100	120	56	176
Mean	20.5	160.9	137.5	7.25	935.8
SD	11.41	52.23	71.07	4.076	1439.90
Median	19.0	164.5	146.5	6.21	197.0
25th, 75th percentiles	12.0, 26.0	118.0, 210.0	88.5, 199.5	4.13, 9.36	117.5, 1413.0
Min, Max	3, 42	37, 242	3, 242	2.1, 16.0	3, 5833

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Demographic characteristics of subjects diagnosed with SMA
Page 2 of 3

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Sex					
n	20	100	120	56	176
Male	11 (55.0)	49 (49.0)	60 (50.0)	26 (46.4)	86 (48.9)
Female	9 (45.0)	51 (51.0)	60 (50.0)	30 (53.6)	90 (51.1)
Ethnicity					
n	20	100	120	56	176
Hispanic or Latino	2 (10.0)	13 (13.0)	15 (12.5)	8 (14.3)	23 (13.1)
Not Hispanic or Latino	11 (55.0)	87 (87.0)	98 (81.7)	48 (85.7)	146 (83.0)
Not Reported	7 (35.0)	0	7 (5.8)	0	7 (4.0)
Race					
n	20	100	120	56	176
Asian	1 (5.0)	6 (6.0)	7 (5.8)	2 (3.6)	9 (5.1)
Black	0	4 (4.0)	4 (3.3)	3 (5.4)	7 (4.0)
Native Hawaiian or other Pacific Islander	0	0	0	0	0
White	10 (50.0)	84 (84.0)	94 (78.3)	49 (87.5)	143 (81.3)
Other	2 (10.0)	4 (4.0)	6 (5.0)	1 (1.8)	7 (4.0)
Multiple	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
Not Reported	7 (35.0)	0	7 (5.8)	0	7 (4.0)

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Demographic characteristics of subjects diagnosed with SMA
Page 3 of 3

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Geographic region					
North America	13 (65.0)	58 (58.0)	71 (59.2)	56 (100.0)	127 (72.2)
Europe	3 (15.0)	30 (30.0)	33 (27.5)	0	33 (18.8)
Asia-Pacific	4 (20.0)	12 (12.0)	16 (13.3)	0	16 (9.1)
Height (cm)					
n	20	100	120	33	153
Mean	52.2	64.2	62.2	120.9	74.9
SD	2.95	4.68	6.31	24.97	27.36
Median	51.4	64.8	62.8	120.2	65.0
25th, 75th percentiles	49.8, 54.7	60.7, 66.5	58.3, 66.1	98.9, 144.5	60.1, 72.3
Min, Max	49, 59	54, 75	49, 75	82, 171	49, 171
Weight (kg)					
n	20	100	120	56	176
Mean	3.9	6.6	6.2	26.2	12.5
SD	0.72	1.05	1.44	17.76	13.70
Median	3.7	6.6	6.3	19.1	7.0
25th, 75th percentiles	3.2, 4.4	5.8, 7.1	5.3, 7.0	13.4, 32.8	5.8, 13.2
Min, Max	3, 5	5, 9	3, 9	10, 83	3, 83

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at first dose was calculated in 'years' for Later Onset study and 'days' were used for all other columns.

表 124　SMA History of Subjects Diagnosed With SMA

SMA history of subjects diagnosed with SMA
Page 1 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20	100	120	56	176
SMN2 copy number					
1 copy	0	0	0	0	0
2 copies	12 (60.0)	97 (97.0)	109 (90.8)	1 (1.8)	110 (62.5)
3 copies	7 (35.0)	2 (2.0)	9 (7.5)	46 (82.1)	55 (31.3)
4 copies	0	0	0	8 (14.3)	8 (4.5)
5 copies	0	0	0	1 (1.8)	1 (0.6)
Unknown	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at diagnosis not recorded for presymptomatic infants.
3: Ambulatory status at baseline not assessed for infants.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

SMA history of subjects diagnosed with SMA
Page 2 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20	100	120	56	176
Age at symptom onset (months)					
<30 days (less than 1 month)	-	27 (27.0)	27 (22.5)	0	27 (15.3)
>=30 days to <90 days (1 to 3 months)	-	62 (62.0)	62 (51.7)	0	62 (35.2)
>=90 days to <180 days (3 to 6 months)	-	11 (11.0)	11 (9.2)	2 (3.6)	13 (7.4)
>=180 days to <365 days (6 months to 1 year)	-	0	0	10 (17.9)	10 (5.7)
>=1 year to <2 years	-	0	0	36 (64.3)	36 (20.5)
>=2 years to <6 years	-	0	0	8 (14.3)	8 (4.5)
>=6 years	-	0	0	0	0
n		100	100	56	156
Mean		1.8	1.8	16.4	7.1
SD		0.99	0.99	10.94	9.59
Median		1.6	1.6	14.0	2.8
25th, 75th percentiles		0.9, 2.5	0.9, 2.5	12.0, 18.0	1.4, 12.0
Min, Max		0, 5	0, 5	3, 60	0, 60

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at diagnosis not recorded for presymptomatic infants.
3: Ambulatory status at baseline not assessed for infants.

SOURCE: [redacted] DATE: [redacted]20[redacted]

SMA history of subjects diagnosed with SMA
Page 3 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20	100	120	56	176
Age at diagnosis (months)					
<30 days (less than 1 month)	-	11 (11.0)	11 (11.0)	1 (1.8)	12 (7.7)
>=30 days to <90 days (1 to 3 months)	-	52 (52.0)	52 (52.0)	0	52 (33.3)
>=90 days to <180 days (3 to 6 months)	-	36 (36.0)	36 (36.0)	0	36 (23.1)
>=180 days to <365 days (6 months to 1 year)	-	1 (1.0)	1 (1.0)	2 (3.6)	3 (1.9)
>=1 year to <2 years	-	0	0	28 (50.0)	28 (17.9)
>=2 years to <6 years	-	0	0	22 (39.3)	22 (14.1)
>=6 years	-	0	0	3 (5.4)	3 (1.9)
n		100	100	56	156
Mean		2.8	2.8	27.8	11.8
SD		1.51	1.51	22.98	18.27
Median		2.5	2.5	20.0	4.1
25th, 75th percentiles		1.8, 4.0	1.8, 4.0	15.0, 29.5	2.1, 16.0
Min, Max		0, 7	0, 7	0, 144	0, 144

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
表 108
3: Ambulatory status at baseline not assessed for infants.

SOURCE: [redacted] DATE: [redacted]20[redacted]

SMA history of subjects diagnosed with SMA
Page 4 of 4

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20	100	120	56	176
Ambulatory status					
n	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Ambulant	-	-	-	23 (41.1)	-
Non-ambulant	-	-	-	33 (58.9)	-

NOTE 1: Numbers in parentheses are percentages based on the number of subjects dosed with nonmissing data.
2: Age at diagnosis not recorded for presymptomatic infants.
3: Ambulatory status at baseline not assessed for infants.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 125　Infants Diagnosed With SMA: Concomitant Medications

Infants diagnosed with SMA: concomitant medications
Page 1 of 30

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects who received a concomitant medication	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
PARACETAMOL	12 (60.0)	34 (82.9)	65 (81.3)	85 (85.0)	97 (80.8)
PNEUMOCOCCAL VACCINE	11 (55.0)	17 (41.5)	49 (61.3)	59 (59.0)	70 (58.3)
LIDOCAINE	12 (60.0)	14 (34.1)	36 (45.0)	54 (54.0)	66 (55.0)
SALBUTAMOL	3 (15.0)	25 (61.0)	46 (57.5)	63 (63.0)	66 (55.0)
EMLA	9 (45.0)	30 (73.2)	43 (53.8)	56 (56.0)	65 (54.2)
POVIDONE-IODINE	3 (15.0)	27 (65.9)	53 (66.3)	61 (61.0)	64 (53.3)
IBUPROFEN	5 (25.0)	21 (51.2)	38 (47.5)	51 (51.0)	56 (46.7)
SODIUM CHLORIDE	7 (35.0)	18 (43.9)	40 (50.0)	49 (49.0)	56 (46.7)
PALIVIZUMAB	1 (5.0)	16 (39.0)	36 (45.0)	52 (52.0)	53 (44.2)
AMOXICILLIN	4 (20.0)	16 (39.0)	31 (38.8)	41 (41.0)	45 (37.5)
INFLUENZA VACCINE	4 (20.0)	12 (29.3)	31 (38.8)	41 (41.0)	45 (37.5)
HAEMOPHILUS INFLUENZA TYPE B VACCINE	9 (45.0)	13 (31.7)	21 (26.3)	30 (30.0)	39 (32.5)
ROTAVIRUS VACCINE	10 (50.0)	6 (14.6)	21 (26.3)	29 (29.0)	39 (32.5)
CEFTRIAXONE	2 (10.0)	13 (31.7)	28 (35.0)	36 (36.0)	38 (31.7)
RANITIDINE	2 (10.0)	17 (41.5)	26 (32.5)	36 (36.0)	38 (31.7)
HEPATITIS B VACCINE	5 (25.0)	8 (19.5)	24 (30.0)	31 (31.0)	36 (30.0)
VACCIN IPAD D.T.C.	5 (25.0)	11 (26.8)	20 (25.0)	29 (29.0)	34 (28.3)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 2 of 30

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
OXYGEN	0	18 (43.9)	22 (27.5)	31 (31.0)	31 (25.8)
AUGMENTIN	0	7 (17.1)	22 (27.5)	29 (29.0)	29 (24.2)
MIDAZOLAM	3 (15.0)	13 (31.7)	20 (25.0)	26 (26.0)	29 (24.2)
POLIO VACCINE	5 (25.0)	6 (14.6)	16 (20.0)	24 (24.0)	29 (24.2)
SUCROSE	5 (25.0)	3 (7.3)	23 (28.8)	24 (24.0)	29 (24.2)
MACROGOL	0	12 (29.3)	16 (20.0)	28 (28.0)	28 (23.3)
FENTANYL	1 (5.0)	13 (31.7)	20 (25.0)	24 (24.0)	25 (20.8)
MEASLES MUMPS & RUBELLA LIVE ATTENUATED (FREE	1 (5.0)	7 (17.1)	18 (22.5)	24 (24.0)	25 (20.8)
MORPHINE	0	16 (39.0)	16 (20.0)	25 (25.0)	25 (20.8)
CHLORHEXIDINE	0	10 (24.4)	22 (27.5)	23 (23.0)	23 (19.2)
DEXTROSE AND SODIUM CHLORIDE INJECTION	1 (5.0)	10 (24.4)	17 (21.3)	22 (22.0)	23 (19.2)
NYSTATIN	4 (20.0)	9 (22.0)	15 (18.8)	19 (19.0)	23 (19.2)
PROPOFOL	6 (30.0)	9 (22.0)	14 (17.5)	17 (17.0)	23 (19.2)
AZITHROMYCIN	3 (15.0)	4 (9.8)	14 (17.5)	19 (19.0)	22 (18.3)
CLINDAMYCIN	0	8 (19.5)	14 (17.5)	22 (22.0)	22 (18.3)
OSMOTAN	1 (5.0)	7 (17.1)	12 (15.0)	21 (21.0)	22 (18.3)
BUDESONIDE	3 (15.0)	5 (12.2)	15 (18.8)	17 (17.0)	20 (16.7)
FLEBOBAG RING LACT	6 (30.0)	7 (17.1)	8 (10.0)	14 (14.0)	20 (16.7)
GLYCEROL	1 (5.0)	10 (24.4)	17 (21.3)	19 (19.0)	20 (16.7)
VITAMIN D NOS	8 (40.0)	7 (17.1)	12 (15.0)	12 (12.0)	20 (16.7)
PIP/TAZO	0	7 (17.1)	13 (16.3)	19 (19.0)	19 (15.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 3 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
CEFAZOLIN	0	7 (17.1)	12 (15.0)	18 (18.0)	18 (15.0)
COLECALCIFEROL	1 (5.0)	7 (17.1)	13 (16.3)	17 (17.0)	18 (15.0)
GLYCOPYRRONIUM	0	6 (14.6)	15 (18.8)	18 (18.0)	18 (15.0)
BARIUM	1 (5.0)	4 (9.8)	7 (8.8)	16 (16.0)	17 (14.2)
CETIRIZINE	1 (5.0)	5 (12.2)	11 (13.8)	16 (16.0)	17 (14.2)
DORNASE ALFA	0	2 (4.9)	11 (13.8)	17 (17.0)	17 (14.2)
VARICELLA ZOSTER VACCINE	0	8 (19.5)	13 (16.3)	17 (17.0)	17 (14.2)
ACETYLCYSTEINE	1 (5.0)	3 (7.3)	11 (13.8)	15 (15.0)	16 (13.3)
INFANRIX HEXA	2 (10.0)	1 (2.4)	12 (15.0)	14 (14.0)	16 (13.3)
INFANRIX IPV+HIB	3 (15.0)	3 (7.3)	13 (16.3)	13 (13.0)	16 (13.3)
LORAZEPAM	0	3 (7.3)	8 (10.0)	15 (15.0)	15 (12.5)
NITROUS OXIDE	3 (15.0)	3 (7.3)	9 (11.3)	12 (12.0)	15 (12.5)
SIMETICONE	2 (10.0)	5 (12.2)	6 (7.5)	13 (13.0)	15 (12.5)
SPEKTRAMOX	0	3 (7.3)	11 (13.8)	15 (15.0)	15 (12.5)
BACTRIM	0	5 (12.2)	10 (12.5)	14 (14.0)	14 (11.7)
CIPROFLOXACIN	0	6 (14.6)	10 (12.5)	14 (14.0)	14 (11.7)
HEPATITIS A VACCINE	0	2 (4.9)	11 (13.8)	14 (14.0)	14 (11.7)
IPRATROPIUM	0	4 (9.8)	12 (15.0)	14 (14.0)	14 (11.7)
SEVOFLURANE	4 (20.0)	1 (2.4)	7 (8.8)	10 (10.0)	14 (11.7)
CEFDINIR	1 (5.0)	3 (7.3)	8 (10.0)	12 (12.0)	13 (10.8)
DEXMEDETOMIDINE	3 (15.0)	8 (19.5)	7 (8.8)	10 (10.0)	13 (10.8)
PREDNISOLONE	1 (5.0)	3 (7.3)	10 (12.5)	12 (12.0)	13 (10.8)
ROCURONIUM	0	8 (19.5)	10 (12.5)	13 (13.0)	13 (10.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 4 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
ATROPINE	1 (5.0)	7 (17.1)	7 (8.8)	11 (11.0)	12 (10.0)
FLUTICASONE	0	1 (2.4)	8 (10.0)	12 (12.0)	12 (10.0)
HYDROCORTISONE	3 (15.0)	6 (14.6)	7 (8.8)	9 (9.0)	12 (10.0)
LANSOPRAZOLE	0	4 (9.8)	8 (10.0)	12 (12.0)	12 (10.0)
DIPHENHYDRAMINE	2 (10.0)	2 (4.9)	4 (5.0)	9 (9.0)	11 (9.2)
IRON	2 (10.0)	2 (4.9)	6 (7.5)	9 (9.0)	11 (9.2)
LACTULOSE	1 (5.0)	3 (7.3)	9 (11.3)	10 (10.0)	11 (9.2)
MUPIROCIN	2 (10.0)	4 (9.8)	6 (7.5)	9 (9.0)	11 (9.2)
OMEPRAZOLE	1 (5.0)	4 (9.8)	7 (8.8)	10 (10.0)	11 (9.2)
PEDIARIX	5 (25.0)	4 (9.8)	5 (6.3)	6 (6.0)	11 (9.2)
AMOXICILLIN W/CLAVULANATE POTASSIUM	0	4 (9.8)	10 (12.5)	10 (10.0)	10 (8.3)
CEFUROXIME	2 (10.0)	2 (4.9)	6 (7.5)	8 (8.0)	10 (8.3)
DEXAMETHASONE	0	5 (12.2)	4 (5.0)	10 (10.0)	10 (8.3)
FUROSEMIDE	0	4 (9.8)	8 (10.0)	10 (10.0)	10 (8.3)
LACTOBACILLUS NOS	1 (5.0)	1 (2.4)	8 (10.0)	9 (9.0)	10 (8.3)
SODIUM BICARBONATE	0	1 (2.4)	5 (6.3)	10 (10.0)	10 (8.3)
CLOTRIMAZOLE	4 (20.0)	2 (4.9)	5 (6.3)	5 (5.0)	9 (7.5)
FAMOTIDINE	0	6 (14.6)	6 (7.5)	9 (9.0)	9 (7.5)
GLYCERIN	0	0	0	9 (9.0)	9 (7.5)
HEPARIN	0	3 (7.3)	4 (5.0)	9 (9.0)	9 (7.5)
HIBISOL	1 (5.0)	2 (4.9)	8 (10.0)	8 (8.0)	9 (7.5)
LEVOSALBUTAMOL	1 (5.0)	3 (7.3)	4 (5.0)	8 (8.0)	9 (7.5)
AMOXI-CLAVULANICO	3 (15.0)	0	5 (6.3)	5 (5.0)	8 (6.7)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 5 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
KETOROLAC	0	3 (7.3)	5 (6.3)	8 (8.0)	8 (6.7)
MENINGOCOCCAL VACCINE	1 (5.0)	3 (7.3)	6 (7.5)	7 (7.0)	8 (6.7)
METHYLPREDNISOLONE	0	3 (7.3)	5 (6.3)	8 (8.0)	8 (6.7)
MULTIVITAMINS	0	3 (7.3)	7 (8.8)	8 (8.0)	8 (6.7)
POTASSIUM	0	6 (14.6)	7 (8.8)	8 (8.0)	8 (6.7)
BENZOCAINE	2 (10.0)	2 (4.9)	1 (1.3)	5 (5.0)	7 (5.8)
BUPIVACAINE	0	2 (4.9)	7 (8.8)	7 (7.0)	7 (5.8)
EMLAPATCH	0	1 (2.4)	5 (6.3)	7 (7.0)	7 (5.8)
ERYTHROMYCIN	0	4 (9.8)	7 (8.8)	7 (7.0)	7 (5.8)
KETAMINE	1 (5.0)	5 (12.2)	4 (5.0)	6 (6.0)	7 (5.8)
OSELTAMIVIR	0	0	6 (7.5)	7 (7.0)	7 (5.8)
SULTAMICILLIN	0	3 (7.3)	7 (8.8)	7 (7.0)	7 (5.8)
VITAMINS NOS	3 (15.0)	3 (7.3)	4 (5.0)	4 (4.0)	7 (5.8)
ANESTHETICS, GENERAL	0	0	2 (2.5)	6 (6.0)	6 (5.0)
CEFALEXIN	1 (5.0)	3 (7.3)	4 (5.0)	5 (5.0)	6 (5.0)
CEFOTAXIME	0	2 (4.9)	5 (6.3)	6 (6.0)	6 (5.0)
DOCUSATE	0	5 (12.2)	4 (5.0)	6 (6.0)	6 (5.0)
DOMPERIDONE	0	2 (4.9)	3 (3.8)	6 (6.0)	6 (5.0)
EPINEPHRINE	0	4 (9.8)	4 (5.0)	6 (6.0)	6 (5.0)
ERGOCALCIFEROL	0	4 (9.8)	3 (3.8)	6 (6.0)	6 (5.0)
FATS NOS	0	2 (4.9)	3 (3.8)	6 (6.0)	6 (5.0)
GENTAMICIN	1 (5.0)	0	5 (6.3)	5 (5.0)	6 (5.0)
GLUCOSE	0	6 (14.6)	5 (6.3)	6 (6.0)	6 (5.0)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 6 of 30

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
PANTOPRAZOLE	0	1 (2.4)	6 (7.5)	6 (6.0)	6 (5.0)
TOBRAMYCIN	0	2 (4.9)	5 (6.3)	6 (6.0)	6 (5.0)
UNACID	0	4 (9.8)	6 (7.5)	6 (6.0)	6 (5.0)
VANCOMYCIN	0	10 (24.4)	3 (3.8)	6 (6.0)	6 (5.0)
AMIKACIN	1 (5.0)	1 (2.4)	3 (3.8)	4 (4.0)	5 (4.2)
AMPICILLIN	1 (5.0)	2 (4.9)	3 (3.8)	4 (4.0)	5 (4.2)
AQUAPHOR	0	2 (4.9)	4 (5.0)	5 (5.0)	5 (4.2)
BACITRACIN	0	5 (12.2)	4 (5.0)	5 (5.0)	5 (4.2)
BISEPTINE	0	2 (4.9)	5 (6.3)	5 (5.0)	5 (4.2)
ESOMEPRAZOLE	0	3 (7.3)	5 (6.3)	5 (5.0)	5 (4.2)
IMMUNOGLOBULIN ANTI RESPIRATORY SYNCYTIAL VIR	0	2 (4.9)	5 (6.3)	5 (5.0)	5 (4.2)
LACTOBACILLUS ACIDOPHILUS	2 (10.0)	1 (2.4)	3 (3.8)	3 (3.0)	5 (4.2)
MINERALS NOS W/VITAMINS NOS	0	2 (4.9)	3 (3.8)	5 (5.0)	5 (4.2)
ONDANSETRON	1 (5.0)	0	3 (3.8)	4 (4.0)	5 (4.2)
SALINE	0	4 (9.8)	5 (6.3)	5 (5.0)	5 (4.2)
SOLUTIONS FOR PARENTERAL NUTRITION	0	3 (7.3)	4 (5.0)	5 (5.0)	5 (4.2)
TRIAMCINOLONE	0	2 (4.9)	3 (3.8)	5 (5.0)	5 (4.2)
ZINC	1 (5.0)	2 (4.9)	1 (1.3)	4 (4.0)	5 (4.2)
ACICLOVIR	0	0	3 (3.8)	4 (4.0)	4 (3.3)
BOTULINUM TOXIN TYPE A	0	0	1 (1.3)	4 (4.0)	4 (3.3)
CEFEPIME	0	3 (7.3)	3 (3.8)	4 (4.0)	4 (3.3)
CEFIXIME	0	0	2 (2.5)	4 (4.0)	4 (3.3)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 7 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
CEFOXITIN	0	1 (2.4)	2 (2.5)	4 (4.0)	4 (3.3)
ETOMIDATE	0	0	3 (3.8)	4 (4.0)	4 (3.3)
FERROUS SULFATE W/VITAMINS NOS	0	1 (2.4)	4 (5.0)	4 (4.0)	4 (3.3)
FLUCONAZOLE	0	1 (2.4)	2 (2.5)	4 (4.0)	4 (3.3)
I.V. SOLUTIONS	0	0	1 (1.3)	4 (4.0)	4 (3.3)
MEROPENEM	0	2 (4.9)	2 (2.5)	4 (4.0)	4 (3.3)
MICONAZOLE	0	2 (4.9)	4 (5.0)	4 (4.0)	4 (3.3)
MULTIVITAMINS WITH IRON	0	0	2 (2.5)	4 (4.0)	4 (3.3)
POLY-VI-SOL WITH IRON	0	1 (2.4)	1 (1.3)	4 (4.0)	4 (3.3)
PREDNISONE	0	1 (2.4)	4 (5.0)	4 (4.0)	4 (3.3)
REHYDRON	0	0	0	4 (4.0)	4 (3.3)
ALBUMIN HUMAN	0	0	3 (3.8)	3 (3.0)	3 (2.5)
ALTEPLASE	0	1 (2.4)	1 (1.3)	3 (3.0)	3 (2.5)
BECLOMETASONE	2 (10.0)	1 (2.4)	1 (1.3)	1 (1.0)	3 (2.5)
CLARITHROMYCIN	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.5)
COMBIVENT	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
DESONIDE	0	0	1 (1.3)	3 (3.0)	3 (2.5)
DOPAMINE	0	0	3 (3.8)	3 (3.0)	3 (2.5)
DUOCID	0	0	3 (3.8)	3 (3.0)	3 (2.5)
ENTONOX	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
FUSIDIC ACID	1 (5.0)	1 (2.4)	1 (1.3)	2 (2.0)	3 (2.5)
HEPATITIS VACCINES	0	0	2 (2.5)	3 (3.0)	3 (2.5)
HYOSCINE	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 8 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
IOPAMIDOL	1 (5.0)	0	2 (2.5)	2 (2.0)	3 (2.5)
LACTOBACILLUS RHAMNOSUS	0	0	1 (1.3)	3 (3.0)	3 (2.5)
LEVETIRACETAM	0	0	2 (2.5)	3 (3.0)	3 (2.5)
LEVOCARNITINE	1 (5.0)	0	0	2 (2.0)	3 (2.5)
LEVOFLOXACIN	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.5)
LIDOCAINE W/SODIUM BICARBONATE	3 (15.0)	1 (2.4)	0	0	3 (2.5)
LORATADINE	0	0	3 (3.8)	3 (3.0)	3 (2.5)
MEASLES VACCINE	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
MULTVIT	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.5)
OXYCODONE	0	3 (7.3)	3 (3.8)	3 (3.0)	3 (2.5)
OXYMETAZOLINE	1 (5.0)	2 (4.9)	2 (2.5)	2 (2.0)	3 (2.5)
POLY-VI-SOL	0	0	0	3 (3.0)	3 (2.5)
PROBIOTICS	0	1 (2.4)	1 (1.3)	3 (3.0)	3 (2.5)
QUADRACEL	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
RED BLOOD CELLS	0	0	3 (3.8)	3 (3.0)	3 (2.5)
REMIFENTANIL	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.5)
ROPIVACAINE	0	0	3 (3.8)	3 (3.0)	3 (2.5)
SACCHAROMYCES BOULARDII	1 (5.0)	0	2 (2.5)	2 (2.0)	3 (2.5)
SENNA ALEXANDRINA	0	2 (4.9)	1 (1.3)	3 (3.0)	3 (2.5)
SILVER NITRATE	2 (10.0)	2 (4.9)	0	1 (1.0)	3 (2.5)
TETRACAINE	0	0	3 (3.8)	3 (3.0)	3 (2.5)
VECURONIUM	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
XILONIBSA	0	0	0	3 (3.0)	3 (2.5)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 9 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
ACETAZOLAMIDE	0	0	1 (1.3)	2 (2.0)	2 (1.7)
AMBROXOL	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
AMITRIPTYLINE	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
AMPHOTERICIN B	0	0	2 (2.5)	2 (2.0)	2 (1.7)
ANAESTHETICS	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ANESTHETICS	0	0	1 (1.3)	2 (2.0)	2 (1.7)
BCG VACCINE	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
BENZYLPENICILLIN	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
BETAMETHASONE	1 (5.0)	4 (9.8)	1 (1.3)	1 (1.0)	2 (1.7)
BIFIDOBACTERIUM LACTIS	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
CEFPODOXIME	0	0	2 (2.5)	2 (2.0)	2 (1.7)
CEFTAZIDIME	0	3 (7.3)	1 (1.3)	2 (2.0)	2 (1.7)
CHLOROTHIAZIDE	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
CLONIDINE	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
DESITIN	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
DEXTROSE IN LACTATED RINGER'S	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
DIMETICONE	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
ECONAZOLE	0	0	2 (2.5)	2 (2.0)	2 (1.7)
ELECTROLYTES NOS W/GLUCOSE	1 (5.0)	5 (12.2)	1 (1.3)	1 (1.0)	2 (1.7)
EMOLLIENTS AND PROTECTIVES	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
FENOTEROL	2 (10.0)	0	0	0	2 (1.7)
FOSPHENYTOIN	0	0	2 (2.5)	2 (2.0)	2 (1.7)
HEPARIN SODIUM W/SODIUM CHLORIDE	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 10 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
INSULIN	0	0	2 (2.5)	2 (2.0)	2 (1.7)
IOHEXOL	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ISRADIPINE	0	0	1 (1.3)	2 (2.0)	2 (1.7)
MACROGOL 3350	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
MAGNESIUM HYDROXIDE	0	0	0	2 (2.0)	2 (1.7)
MELATONIN	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
MENHIBRIX	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
METHADONE	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
METHYLROSANILINIUM	0	0	1 (1.3)	2 (2.0)	2 (1.7)
METOCLOPRAMIDE	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
MOVICOL	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
NEOSTIGMINE	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
NEOTRACIN	0	0	1 (1.3)	2 (2.0)	2 (1.7)
NISITA	0	0	2 (2.5)	2 (2.0)	2 (1.7)
OTHER DERMATOLOGICAL PREPARATIONS	0	0	1 (1.3)	2 (2.0)	2 (1.7)
PARAFFIN	1 (5.0)	0	0	1 (1.0)	2 (1.7)
PETROLATUM	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
PIPERACILLIN	0	0	1 (1.3)	2 (2.0)	2 (1.7)
PLASMA	0	0	1 (1.3)	2 (2.0)	2 (1.7)
PLASMA LYTE 148	0	0	2 (2.5)	2 (2.0)	2 (1.7)
POLYSPORIN	0	0	0	2 (2.0)	2 (1.7)
PROBIOTICS NOS	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
PROTEIN SUPPLEMENTS	0	0	1 (1.3)	2 (2.0)	2 (1.7)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 11 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
RACECADOTRIL	0	0	2 (2.5)	2 (2.0)	2 (1.7)
RACEPINEFRINE	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
ROXITHROMYCIN	0	0	2 (2.5)	2 (2.0)	2 (1.7)
SAMBUCUS NIGRA	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
SODIUM FLUORIDE	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
SODIUM PHOSPHATE	0	0	2 (2.5)	2 (2.0)	2 (1.7)
SUCRALFATE	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
TPN	0	0	0	2 (2.0)	2 (1.7)
TRIMETHOPRIM	0	0	2 (2.5)	2 (2.0)	2 (1.7)
UREA HYDROGEN PEROXIDE	0	0	1 (1.3)	2 (2.0)	2 (1.7)
XYLOCAINE-EPINEPHRINE	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
XYLOMETAZOLINE	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ADENOSINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ADIARIL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ALBENDAZOLE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ALCLOMETASONE	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
ALOE VERA	0	0	1 (1.3)	1 (1.0)	1 (0.8)
AMINO ACIDS NOS	0	2 (4.9)	0	1 (1.0)	1 (0.8)
AMINOPHYLLINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
AMIODARONE	1 (5.0)	0	0	0	1 (0.8)
ANTIBIOTICS	0	0	0	1 (1.0)	1 (0.8)
ANTIDIARRHEAL MICROORGANISMS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ANTIFUNGALS FOR DERMATOLOGICAL USE	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 12 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ASCORBIC ACID W/RETINOL/VITAMIN D NOS	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
ATRACURIUM	0	0	1 (1.3)	1 (1.0)	1 (0.8)
AURALGAN	0	0	0	1 (1.0)	1 (0.8)
AUXERGYL D3	0	0	1 (1.3)	1 (1.0)	1 (0.8)
AVEENO BABY DAILY MOISTURE	0	0	0	1 (1.0)	1 (0.8)
BACITRACIN/ NEOMYCIN/ POLYMYXIN B	0	0	1 (1.3)	1 (1.0)	1 (0.8)
BENZALKONIUM	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
BETHANECHOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
BICITRA	0	0	0	1 (1.0)	1 (0.8)
BISACODYL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
BLOOD, WHOLE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
BROMHEXINE	1 (5.0)	0	0	0	1 (0.8)
BUDESONIDE W/FORMOTEROL FUMARATE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CALCIUM	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
CALCIUM CARBONATE	0	0	0	1 (1.0)	1 (0.8)
CALGEL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CAMPHOR	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CANESTEN-HC	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CAPTOPRIL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CARBOCISTEINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CARBOHYDRATES NOS W/FATS NOS/MINERA	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CEFADROXIL	0	0	0	1 (1.0)	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 13 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
CEFOTETAN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CEFPROZIL	0	1 (2.4)	0	1 (1.0)	1 (0.8)
CHAMAEMELUM NOBILE	0	0	0	1 (1.0)	1 (0.8)
CHLORAL HYDRATE	1 (5.0)	0	0	0	1 (0.8)
CHLORAMPHENICOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CHLORPHENAMINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CLAVULANIC ACID	0	6 (14.6)	1 (1.3)	1 (1.0)	1 (0.8)
CLONAZEPAM	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CONTRAST MEDIA	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CORTICOSTEROIDS FOR SYSTEMIC USE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
CROMOGLICIC ACID	0	0	1 (1.3)	1 (1.0)	1 (0.8)
DALTEPARIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
DEMAZIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
DESITIN WITH ZINC OXIDE	0	0	0	1 (1.0)	1 (0.8)
DESLORATADINE	0	0	0	1 (1.0)	1 (0.8)
DEXIBUPROFEN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
DIAZEPAM	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
DIFLUCORTOLONE VALERATE W/ISOCONAZOLE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
DIGOXIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
DIMENHYDRINATE	0	0	0	1 (1.0)	1 (0.8)
DIPROBASE	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
DUOVENT	1 (5.0)	0	0	0	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 14 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
EL-4	0	0	1 (1.3)	1 (1.0)	1 (0.8)
EPHEDRINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
EPIPEVISONE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ERTAPENEM	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ETHYL CHLORIDE	0	0	0	1 (1.0)	1 (0.8)
EUCERIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
EUPEPTINA	0	0	1 (1.3)	1 (1.0)	1 (0.8)
EUPHRASIA OFFICINALIS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
EXCIPIAL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
FEXOFENADINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
FISH OIL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
FITOSTIMOLINE	1 (5.0)	0	0	0	1 (0.8)
FLUCLOXACILLIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
FLUOCINOLONE ACETONIDE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
FLUOROMETHOLONE	0	0	0	1 (1.0)	1 (0.8)
FRUCTOSE	0	0	0	1 (1.0)	1 (0.8)
GASTROGRAFIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
GAVISCON	0	0	1 (1.3)	1 (1.0)	1 (0.8)
GERBER SOOTHE	1 (5.0)	0	0	0	1 (0.8)
GOLYTELY	0	0	0	1 (1.0)	1 (0.8)
GUAIFENESIN	0	1 (2.4)	0	1 (1.0)	1 (0.8)
HAEMOPHILUS INFLUENZAE	0	0	0	1 (1.0)	1 (0.8)
HAMAMELIS VIRGINIANA	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 15 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
HEPARINOID	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
HERBAL NOS W/MINERALS NOS/VITAMINS NOS	1 (5.0)	0	0	0	1 (0.8)
HOMATROPINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
HYDROMORPHONE	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
HYDROXYQUINOLINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
I.V. SOLUTION ADDITIVES	0	0	0	1 (1.0)	1 (0.8)
ICHTHOPASTE	0	0	0	1 (1.0)	1 (0.8)
IMMUNOGLOBULIN ANTIHEPATITIS B	0	0	0	1 (1.0)	1 (0.8)
INTRALIPID	0	0	1 (1.3)	1 (1.0)	1 (0.8)
IOTALAMIC ACID	0	0	1 (1.3)	1 (1.0)	1 (0.8)
IOVERSOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
IOXILAN	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
IPRATROPIUM W/SALBUTAMOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ISOPROPANOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
KETOCONAZOLE	1 (5.0)	1 (2.4)	0	0	1 (0.8)
LACTINEX	0	0	1 (1.3)	1 (1.0)	1 (0.8)
LEVOBUPIVACAINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
LISINOPRIL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
LOPERAMIDE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MAALOX	0	0	0	1 (1.0)	1 (0.8)
MAALOX PLUS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MACROGOL 4000	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 16 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
MAGNESIUM	1 (5.0)	1 (2.4)	0	0	1 (0.8)
MANNITOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MARCAIN-ADRENALIN	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
MEDIUM-CHAIN TRIGLYCERIDES	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
MENADIONE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MEQUITAZINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MEROKEN NEW	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
METAMIZOLE	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
METANIUM	0	0	1 (1.3)	1 (1.0)	1 (0.8)
METOPIMAZINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
METRONIDAZOLE	0	0	0	1 (1.0)	1 (0.8)
MICAFUNGIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MICROKLIST	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MOMETASONE	1 (5.0)	0	0	0	1 (0.8)
MONTELUKAST	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MOXIFLOXACIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MUCOLYTICS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
MULTIVITAMINS WITH MINERALS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
NAFCILLIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
NATURES WAY PRIMADOPHILUS ORIGINAL	1 (5.0)	0	0	0	1 (0.8)
NEOSPORIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
NORFLOXACIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
NORMOSOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 17 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
NUTRIENTS NOS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
OFLOXACIN	1 (5.0)	0	0	0	1 (0.8)
OLOPATADINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
OMEGA-3 FATTY ACIDS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
OMEGA-6 FATTY ACIDS	0	0	0	1 (1.0)	1 (0.8)
ORALPAEDON	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ORNITHINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
OSMOSAL	0	1 (2.4)	0	1 (1.0)	1 (0.8)
OTHER ANTISEPTICS AND DISINFECTANTS	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
OTHER EMOLLIENTS AND PROTECTIVES	1 (5.0)	0	0	0	1 (0.8)
OTHER MINERAL SUPPLEMENTS	0	0	0	1 (1.0)	1 (0.8)
OTHER NUTRIENTS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PANCREATIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PANCRELIPASE	0	0	0	1 (1.0)	1 (0.8)
PAPAVERINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PARA-NOX	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PEDITUS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PIPERACILLIN W/TAZOBACTAM	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
PIRITRAMIDE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
POLY VI SOL	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
POTASSIUM CITRATE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
POTASSIUM PERMANGANATE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
POTASSIUM PHOSPHATE MONOBASIC	0	0	0	1 (1.0)	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 18 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
PRILOCAINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PRIMAXIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PRIORIX TETRA	0	0	0	1 (1.0)	1 (0.8)
PROCATEROL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PROCET	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PROPRANOLOL	1 (5.0)	0	0	0	1 (0.8)
PROTEIN HYDROLYSATE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
PSEUDOEPHEDRINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
RESPIRATORY SYSTEM	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
RETINOL W/VITAMIN D NOS/WOOL FAT	1 (5.0)	0	0	0	1 (0.8)
RIFINAH	0	0	1 (1.3)	1 (1.0)	1 (0.8)
RINGER-LACTATE	0	0	0	1 (1.0)	1 (0.8)
ROCEPHIN IM.	0	0	1 (1.3)	1 (1.0)	1 (0.8)
SAPROPTERIN	0	0	1 (1.3)	1 (1.0)	1 (0.8)
SELENIUM SULFIDE	1 (5.0)	0	0	0	1 (0.8)
SENSORCAINE W/EPINEPHRINE BITARTRATE	1 (5.0)	0	0	0	1 (0.8)
SODIUM	0	0	1 (1.3)	1 (1.0)	1 (0.8)
SODIUM FLUORIDE W/VITAMINS NOS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
SPIRONOLACTONE	1 (5.0)	1 (2.4)	0	0	1 (0.8)
STOMATOLOGICAL PREPARATIONS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
SULCONAZOLE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
SUXAMETHONIUM	0	1 (2.4)	0	1 (1.0)	1 (0.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 19 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
TECHNETIUM TC 99M SULFUR COLLOID	0	0	1 (1.3)	1 (1.0)	1 (0.8)
TERRA-CORTRIL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
TETANUS VACCINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
THEOPHYLLINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
THIAMYLAL	1 (5.0)	0	0	0	1 (0.8)
TIPEPIDINE	0	0	1 (1.3)	1 (1.0)	1 (0.8)
TIXOCORTOL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
TRIGLYCERIDES	0	0	1 (1.3)	1 (1.0)	1 (0.8)
TUBERCULOSIS VACCINES	0	0	1 (1.3)	1 (1.0)	1 (0.8)
TUSSIN DM	0	0	1 (1.3)	1 (1.0)	1 (0.8)
UNSPECIFIED HERBAL	0	0	0	1 (1.0)	1 (0.8)
UVESTEROL	0	0	1 (1.3)	1 (1.0)	1 (0.8)
VACCINES	0	0	0	1 (1.0)	1 (0.8)
VALISONE-G	0	0	1 (1.3)	1 (1.0)	1 (0.8)
VANICREAM	1 (5.0)	0	0	0	1 (0.8)
VICODIN	0	0	0	1 (1.0)	1 (0.8)
VIKOMINAS	0	0	1 (1.3)	1 (1.0)	1 (0.8)
VIRAL VACCINES	1 (5.0)	0	0	0	1 (0.8)
VITAMINS, OTHER COMBINATIONS	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
WATER FOR INJECTION	0	2 (4.9)	0	1 (1.0)	1 (0.8)
ABSORBABLE GELATIN SPONGE	0	0	0	0	0
ACETYLSALICYLIC ACID	0	0	0	0	0
ACITAZANOLAST	0	0	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 20 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ACTIFED	0	0	0	0	0
ADAPALENE	0	0	0	0	0
ALFENTANIL	0	0	0	0	0
ALKA-SELTZER PLUS	0	0	0	0	0
ALLIUM SATIVUM	0	0	0	0	0
AMINO ACIDS NOS W/FATS NOS/MALTODEXTRIN/MINER	0	1 (2.4)	0	0	0
AMINOCAPROIC ACID	0	0	0	0	0
AMPICLOX	0	0	0	0	0
ANAESTHETICS FOR TOPICAL USE	0	0	0	0	0
ANESTHETICS FOR TOPICAL USE	0	1 (2.4)	0	0	0
ANOVLAR	0	0	0	0	0
ANTIBIOTICS-RESISTANT LACTIC ACID BACTERIAE	0	0	0	0	0
ANTISEPTIC SOLUTION	0	0	0	0	0
ANTISEPTICS AND DISINFECTANTS	0	0	0	0	0
ANTIVIRALS	0	0	0	0	0
ARGININE	0	0	0	0	0
ARTIFICIAL TEARS	0	1 (2.4)	0	0	0
ASCORBIC ACID	0	1 (2.4)	0	0	0
ASCORBIC ACID (VITAMIN C), PLAIN	0	0	0	0	0
ASCORBIC ACID W/CALCIUM PHOSPHATE/LACTOBACILL	0	0	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 21 of 30

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
ASCORBIC ACID W/HERBAL NOS/LEVOGLUTAMIDE/LYSI	0	0	0	0	0
AVENA SATIVA	0	1 (2.4)	0	0	0
AVOCA	0	1 (2.4)	0	0	0
BACILLUS LICHENFORMIS	0	0	0	0	0
BACITRACIN W/POLYMYXIN B	0	1 (2.4)	0	0	0
BENZACLIN TOPICAL	0	0	0	0	0
BENZYDAMINE	0	0	0	0	0
BIOFERMIN	0	0	0	0	0
BIOTIN	0	0	0	0	0
BLOOD AND RELATED PRODUCTS	0	0	0	0	0
BLOOD CELLS, PACKED HUMAN	0	0	0	0	0
BROMFED	0	0	0	0	0
BROMPHENIRAMINE	0	0	0	0	0
BRONCHICUM	0	0	0	0	0
CAFFEINE	0	0	0	0	0
CALAMINE	0	1 (2.4)	0	0	0
CALCIFEDIOL	0	0	0	0	0
CALCITRIOL	0	0	0	0	0
CALCIUM CARBONATE W/VITAMIN D NOS	0	0	0	0	0
CALCIUM D3	0	0	0	0	0
CALCIUM GLUCONATE	0	2 (4.9)	0	0	0
CALCIUM VITAMIN D3	0	0	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 22 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
CALCIUM W/VITAMIN D NOS	0	0	0	0	0
CARBOHYDRATES NOS W/POTASSIUM CHLORIDE/SODIUM	0	1 (2.4)	0	0	0
CARBOMER	0	1 (2.4)	0	0	0
CARNITINE W/PROTEINS NOS/TAURINE	0	0	0	0	0
CASPOFUNGIN	0	1 (2.4)	0	0	0
CEFACLOR	0	1 (2.4)	0	0	0
CEFCAPENE	0	0	0	0	0
CEPACOL ANESTHETIC	0	0	0	0	0
CHIBRO-S	0	0	0	0	0
CHROMIUM	0	1 (2.4)	0	0	0
CINNAMOMUM VERUM	0	0	0	0	0
CIPRODAC-DM	0	1 (2.4)	0	0	0
CISATRACURIUM	0	0	0	0	0
CLONALIN	0	0	0	0	0
CLOSTRIDIUM BUTYRICUM	0	1 (2.4)	0	0	0
CODEINE/PROMETHAZINE	0	0	0	0	0
COLISTIN	0	1 (2.4)	0	0	0
COLMIN-A	0	0	0	0	0
COLOSTRUM	0	0	0	0	0
COMBEVIT C	0	0	0	0	0
COMPOUND SODIUM CHLORIDE	0	0	0	0	0
CORTISONE	0	0	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 23 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
COTYLENOL	0	0	0	0	0
COUGH AND COLD PREPARATIONS	0	1 (2.4)	0	0	0
COUGH SYRUP	0	0	0	0	0
CURCUMA LONGA	0	0	0	0	0
CUTASEPT G	0	2 (4.9)	0	0	0
CYPROHEPTADINE	0	0	0	0	0
D-FLUORETTEN	0	1 (2.4)	0	0	0
DESFLURANE	0	0	0	0	0
DEXMETHYLPHENIDATE	0	0	0	0	0
DEXTROMETHORPHAN	0	0	0	0	0
DEXTROSE W/POTASSIUM CHLORIDE	0	1 (2.4)	0	0	0
DIMETANE DX	0	0	0	0	0
DIMETAPP	0	0	0	0	0
DIMETAPP DM	0	0	0	0	0
DIPHENTANN-D	0	0	0	0	0
DIPROPHYLLINE	0	0	0	0	0
DOCOSANOL	0	0	0	0	0
DUONASE	0	0	0	0	0
ECHINACEA PURPUREA	0	0	0	0	0
ECOLICIN	0	0	0	0	0
ELECTROLYTE SOLUTIONS	0	0	0	0	0
ELECTROLYTES NOS	0	0	0	0	0
ENEMAS	0	0	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 24 of 30

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
EPINASTINE	0	0	0	0	0
ETHANOL	0	1 (2.4)	0	0	0
ETHINYL ESTRADIOL W/NORGESTREL	0	0	0	0	0
ETODOLAC	0	0	0	0	0
EUGYNON	0	0	0	0	0
EXCEDRIN	0	0	0	0	0
FISH OIL W/VITAMINS NOS	0	0	0	0	0
FLEET ENEMA	0	0	0	0	0
FLINTSTONES COMPLETE	0	0	0	0	0
FLUMAZENIL	0	0	0	0	0
FLUORIDE	0	0	0	0	0
FOLIC ACID	0	1 (2.4)	0	0	0
GABAPENTIN	0	0	0	0	0
GENERAL NUTRIENTS	0	1 (2.4)	0	0	0
GLYCERYL TRINITRATE	0	1 (2.4)	0	0	0
GUAIAZULENE	0	1 (2.4)	0	0	0
HALIBORANGE	0	1 (2.4)	0	0	0
HEDERA HELIX	0	0	0	0	0
HERBAL EXTRACT NOS	0	0	0	0	0
HERBAL OIL NOS	0	0	0	0	0
HERBAL PREPARATION	0	1 (2.4)	0	0	0
HOMEOPATHIC PREPARATION	0	0	0	0	0
HONEY	0	1 (2.4)	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 25 of 30

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
HUMAN PAPILLOMA VACCINE	0	0	0	0	0
HUMAN RED BLOOD CELLS	0	0	0	0	0
HYALURONIDASE	0	1 (2.4)	0	0	0
HYDROMOL	0	1 (2.4)	0	0	0
HYDROXYZINE	0	0	0	0	0
HYPERTONIC SOLUTIONS	0	1 (2.4)	0	0	0
HYPROMELLOSE	0	1 (2.4)	0	0	0
INFANT FORMULAS	0	2 (4.9)	0	0	0
IODINE	0	0	0	0	0
ISOFLURANE	0	0	0	0	0
ITINEROL B6	0	0	0	0	0
JAPANESE ENCEPHALITIS VACCINE	0	0	0	0	0
JARRO DOPHILUS	0	1 (2.4)	0	0	0
JONOSTERIL	0	0	0	0	0
LACTOBACILLUS REUTERI	0	2 (4.9)	0	0	0
LEKOVIT CA	0	0	0	0	0
LEVOCLOPERASTINE	0	0	0	0	0
LEVODROPROPIZINE	0	0	0	0	0
LEVOGLUTAMIDE	0	0	0	0	0
LINEZOLID	0	1 (2.4)	0	0	0
LIPIDS NOS	0	1 (2.4)	0	0	0
MAGNESIUM CITRATE	0	0	0	0	0
MAGNESIUM SULFATE	0	1 (2.4)	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 26 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
MANGANESE	0	1 (2.4)	0	0	0
MARCAINE WITH EPINEPHRINE	0	0	0	0	0
MAXITROL	0	0	0	0	0
MEDICATED DRESSINGS	0	1 (2.4)	0	0	0
MENAQUINONE	0	0	0	0	0
MENTHOL W/METHYL SALICYLATE	0	0	0	0	0
METFORMIN	0	0	0	0	0
METHYLPHENIDATE	0	0	0	0	0
MICROLAX	0	1 (2.4)	0	0	0
MINERAL OIL EMULSION	0	0	0	0	0
MINERAL SUPPLEMENTS	0	0	0	0	0
MULTI DAY MULTIVITAMIN PLUS IRON	0	0	0	0	0
MULTIVITAMIN	0	0	0	0	0
MULTIVITAMIN AND MINERAL	0	1 (2.4)	0	0	0
MULTIVITAMINS WITH FLUORIDE	0	0	0	0	0
MULTONIC	0	0	0	0	0
MUMPS VACCINE	0	1 (2.4)	0	0	0
NALBUPHINE	0	1 (2.4)	0	0	0
NAPROXEN	0	0	0	0	0
NARINE	0	0	0	0	0
NASEPTIN	0	1 (2.4)	0	0	0
NEOMYCIN	0	1 (2.4)	0	0	0
NEUTRA-PHOS-K	0	1 (2.4)	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 27 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
NITROFURANTOIN	0	0	0	0	0
NOREPINEPHRINE	0	1 (2.4)	0	0	0
OPIAT	0	1 (2.4)	0	0	0
ORAL REHYDRATION SALT	0	2 (4.9)	0	0	0
OTHER MINERAL PRODUCTS	0	1 (2.4)	0	0	0
OTHER RESPIRATORY SYSTEM PRODUCTS	0	1 (2.4)	0	0	0
OTHER VITAMIN PRODUCTS, COMBINATIONS	0	0	0	0	0
OTIX	0	0	0	0	0
OTOSPORIN	0	1 (2.4)	0	0	0
OXYTETRACYCLINE	0	0	0	0	0
PAMIDRONIC ACID	0	0	0	0	0
PANSORAL	0	1 (2.4)	0	0	0
PARADRYL EXPECT	0	1 (2.4)	0	0	0
PARAFFIN SOFT	0	0	0	0	0
PARAFFIN, LIQUID	0	0	0	0	0
PEDIACARE COUGH-COLD	0	0	0	0	0
PEDIALYTE	0	0	0	0	0
PERAMIVIR	0	0	0	0	0
PETHIDINE	0	0	0	0	0
PHENOL	0	0	0	0	0
PHENOXYMETHYLPENICILLIN	0	0	0	0	0
PHENTERMINE	0	0	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 28 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
PHENYLEPHRINE	0	0	0	0	0
PHYSIO 140	0	1 (2.4)	0	0	0
PIMECROLIMUS	0	1 (2.4)	0	0	0
PLASMALYTE A	0	1 (2.4)	0	0	0
POLY-VI-FLOR	0	1 (2.4)	0	0	0
POLYCARBOPHIL	0	0	0	0	0
POLYMYXIN	0	1 (2.4)	0	0	0
POLYMYXIN B	0	1 (2.4)	0	0	0
POLYTRIM	0	0	0	0	0
POTASSIUM ASPARTATE	0	0	0	0	0
PRANLUKAST	0	0	0	0	0
PROMETHAZINE	0	0	0	0	0
PROTEINS NOS W/VITAMINS NOS	0	0	0	0	0
PSYLLIUM HYDROPHILIC MUCILLOID	0	0	0	0	0
REDUCTO	0	1 (2.4)	0	0	0
RETINOL W/VITAMIN D NOS	0	2 (4.9)	0	0	0
RIBONUCLEIC ACID	0	0	0	0	0
RIFAMYCIN	0	1 (2.4)	0	0	0
SACCHAROMYCES BOULARDIL LYOPHYLIZED	0	0	0	0	0
SALACTOL	0	0	0	0	0
SALICYLIC ACID	0	0	0	0	0
SANOSTOL	0	0	0	0	0
SELENIUM	0	1 (2.4)	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 29 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
SENNOSIDE A+B	0	0	0	0	0
SILVER	0	0	0	0	0
SODIUM PICOSULFATE	0	0	0	0	0
SODIUM W/POTASSIUM PHOSPHATE	0	0	0	0	0
SOLPADEINE	0	0	0	0	0
SORBITOL	0	1 (2.4)	0	0	0
SULFAMETHOXAZOLE	0	0	0	0	0
SUPRADYN	0	0	0	0	0
SURGICAL DRESSINGS	0	1 (2.4)	0	0	0
TEETHING #3	0	2 (4.9)	0	0	0
TERBUTALINE	0	0	0	0	0
TETRYZOLINE	0	0	0	0	0
THIOCTIC ACID	0	0	0	0	0
THOMAPYRIN N	0	0	0	0	0
TOCOPHEROL	0	0	0	0	0
TOCOPHERYL NICOTINATE	0	0	0	0	0
TOLTERODINE	0	0	0	0	0
TRAMADOL	0	1 (2.4)	0	0	0
TRANEXAMIC ACID	0	0	0	0	0
TRETINOIN	0	0	0	0	0
TRI-VI-FLOR	0	1 (2.4)	0	0	0
TRIAMINIC-DM	0	0	0	0	0
TROPICAMIDE	0	1 (2.4)	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA: concomitant medications
Page 30 of 30

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
TUMS	0	0	0	0	0
UBIDECARENONE	0	0	0	0	0
UBIQUINOL	0	0	0	0	0
VARIDASE	0	0	0	0	0
VICKS FORMULA 44M	0	0	0	0	0
VITAMEDIN INTRAVENOUS	0	0	0	0	0
VITAMIN B COMPLEX	0	0	0	0	0
VITAMIN B12 NOS	0	1 (2.4)	0	0	0
VITAMIN C WITH ZINC	0	0	0	0	0
VITAMINS WITH MINERALS	0	0	0	0	0
VITIS VINIFERA	0	0	0	0	0
ZEASORB	0	1 (2.4)	0	0	0
ZINC CHLORIDE	0	1 (2.4)	0	0	0

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 126　Subjects Diagnosed With SMA: Concomitant Medications

Subjects diagnosed with SMA: concomitant medications
Page 1 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects who received a concomitant medication	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
PARACETAMOL	12 (60.0)	85 (85.0)	97 (80.8)	41 (73.2)	138 (78.4)
LIDOCAINE	12 (60.0)	54 (54.0)	66 (55.0)	35 (62.5)	101 (57.4)
SODIUM CHLORIDE	7 (35.0)	49 (49.0)	56 (46.7)	38 (67.9)	94 (53.4)
IBUPROFEN	5 (25.0)	51 (51.0)	56 (46.7)	36 (64.3)	92 (52.3)
EMLA	9 (45.0)	56 (56.0)	65 (54.2)	18 (32.1)	83 (47.2)
POVIDONE-IODINE	3 (15.0)	61 (61.0)	64 (53.3)	18 (32.1)	82 (46.6)
SALBUTAMOL	3 (15.0)	63 (63.0)	66 (55.0)	12 (21.4)	78 (44.3)
MIDAZOLAM	3 (15.0)	26 (26.0)	29 (24.2)	47 (83.9)	76 (43.2)
FLEBOBAG RING LACT	6 (30.0)	14 (14.0)	20 (16.7)	52 (92.9)	72 (40.9)
PNEUMOCOCCAL VACCINE	11 (55.0)	59 (59.0)	70 (58.3)	1 (1.8)	71 (40.3)
INFLUENZA VACCINE	4 (20.0)	41 (41.0)	45 (37.5)	22 (39.3)	67 (38.1)
OXYGEN	0	31 (31.0)	31 (25.8)	34 (60.7)	65 (36.9)
PROPOFOL	6 (30.0)	17 (17.0)	23 (19.2)	42 (75.0)	65 (36.9)
AMOXICILLIN	4 (20.0)	41 (41.0)	45 (37.5)	18 (32.1)	63 (35.8)
FENTANYL	1 (5.0)	24 (24.0)	25 (20.8)	38 (67.9)	63 (35.8)
ONDANSETRON	1 (5.0)	4 (4.0)	5 (4.2)	52 (92.9)	57 (32.4)
PALIVIZUMAB	1 (5.0)	52 (52.0)	53 (44.2)	1 (1.8)	54 (30.7)
NITROUS OXIDE	3 (15.0)	12 (12.0)	15 (12.5)	37 (66.1)	52 (29.5)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 2 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
SEVOFLURANE	4 (20.0)	10 (10.0)	14 (11.7)	37 (66.1)	51 (29.0)
MACROGOL	0	28 (28.0)	28 (23.3)	17 (30.4)	45 (25.6)
RANITIDINE	2 (10.0)	36 (36.0)	38 (31.7)	6 (10.7)	44 (25.0)
CEFTRIAXONE	2 (10.0)	36 (36.0)	38 (31.7)	5 (8.9)	43 (24.4)
HAEMOPHILUS INFLUENZA TYPE B VACCINE	9 (45.0)	30 (30.0)	39 (32.5)	0	39 (22.2)
ROTAVIRUS VACCINE	10 (50.0)	29 (29.0)	39 (32.5)	0	39 (22.2)
AUGMENTIN	0	29 (29.0)	29 (24.2)	8 (14.3)	37 (21.0)
HEPATITIS B VACCINE	5 (25.0)	31 (31.0)	36 (30.0)	1 (1.8)	37 (21.0)
VACCIN IPAD D.T.C.	5 (25.0)	29 (29.0)	34 (28.3)	2 (3.6)	36 (20.5)
MORPHINE	0	25 (25.0)	25 (20.8)	10 (17.9)	35 (19.9)
AZITHROMYCIN	3 (15.0)	19 (19.0)	22 (18.3)	12 (21.4)	34 (19.3)
CHLORHEXIDINE	0	23 (23.0)	23 (19.2)	11 (19.6)	34 (19.3)
HIBISOL	1 (5.0)	8 (8.0)	9 (7.5)	24 (42.9)	33 (18.8)
POLIO VACCINE	5 (25.0)	24 (24.0)	29 (24.2)	2 (3.6)	31 (17.6)
DEXAMETHASONE	0	10 (10.0)	10 (8.3)	20 (35.7)	30 (17.0)
MULTIVITAMINS	0	8 (8.0)	8 (6.7)	22 (39.3)	30 (17.0)
SUCROSE	5 (25.0)	24 (24.0)	29 (24.2)	0	29 (16.5)
DEXTROSE AND SODIUM CHLORIDE INJECTION	1 (5.0)	22 (22.0)	23 (19.2)	5 (8.9)	28 (15.9)
CETIRIZINE	1 (5.0)	16 (16.0)	17 (14.2)	9 (16.1)	26 (14.8)
MEASLES MUMPS & RUBELLA LIVE ATTENUATED (FREE	1 (5.0)	24 (24.0)	25 (20.8)	1 (1.8)	26 (14.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 3 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
BUDESONIDE	3 (15.0)	17 (17.0)	20 (16.7)	5 (8.9)	25 (14.2)
CEFAZOLIN	0	18 (18.0)	18 (15.0)	7 (12.5)	25 (14.2)
COLECALCIFEROL	1 (5.0)	17 (17.0)	18 (15.0)	7 (12.5)	25 (14.2)
DEXMEDETOMIDINE	3 (15.0)	10 (10.0)	13 (10.8)	12 (21.4)	25 (14.2)
GLYCEROL	1 (5.0)	19 (19.0)	20 (16.7)	5 (8.9)	25 (14.2)
KETAMINE	1 (5.0)	6 (6.0)	7 (5.8)	18 (32.1)	25 (14.2)
OSMOTAN	1 (5.0)	21 (21.0)	22 (18.3)	3 (5.4)	25 (14.2)
DIPHENHYDRAMINE	2 (10.0)	9 (9.0)	11 (9.2)	13 (23.2)	24 (13.6)
GLYCOPYRRONIUM	0	18 (18.0)	18 (15.0)	6 (10.7)	24 (13.6)
KETOROLAC	0	8 (8.0)	8 (6.7)	16 (28.6)	24 (13.6)
CLINDAMYCIN	0	22 (22.0)	22 (18.3)	1 (1.8)	23 (13.1)
NYSTATIN	4 (20.0)	19 (19.0)	23 (19.2)	0	23 (13.1)
CEFDINIR	1 (5.0)	12 (12.0)	13 (10.8)	9 (16.1)	22 (12.5)
REMIFENTANIL	0	3 (3.0)	3 (2.5)	19 (33.9)	22 (12.5)
VITAMIN D NOS	8 (40.0)	12 (12.0)	20 (16.7)	1 (1.8)	21 (11.9)
PIP/TAZO	0	19 (19.0)	19 (15.8)	1 (1.8)	20 (11.4)
HYDROCORTISONE	3 (15.0)	9 (9.0)	12 (10.0)	7 (12.5)	19 (10.8)
VARICELLA ZOSTER VACCINE	0	17 (17.0)	17 (14.2)	2 (3.6)	19 (10.8)
BARIUM	1 (5.0)	16 (16.0)	17 (14.2)	1 (1.8)	18 (10.2)
LORAZEPAM	0	15 (15.0)	15 (12.5)	3 (5.4)	18 (10.2)
BACTRIM	0	14 (14.0)	14 (11.7)	3 (5.4)	17 (9.7)
DORNASE ALFA	0	17 (17.0)	17 (14.2)	0	17 (9.7)
FLUTICASONE	0	12 (12.0)	12 (10.0)	5 (8.9)	17 (9.7)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 4 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
MULTIVITAMIN	0	0	0	17 (30.4)	17 (9.7)
SIMETICONE	2 (10.0)	13 (13.0)	15 (12.5)	2 (3.6)	17 (9.7)
ACETYLCYSTEINE	1 (5.0)	15 (15.0)	16 (13.3)	0	16 (9.1)
CIPROFLOXACIN	0	14 (14.0)	14 (11.7)	2 (3.6)	16 (9.1)
INFANRIX HEXA	2 (10.0)	14 (14.0)	16 (13.3)	0	16 (9.1)
INFANRIX IPV+HIB	3 (15.0)	13 (13.0)	16 (13.3)	0	16 (9.1)
PREDNISOLONE	1 (5.0)	12 (12.0)	13 (10.8)	3 (5.4)	16 (9.1)
ROCURONIUM	0	13 (13.0)	13 (10.8)	3 (5.4)	16 (9.1)
HEPATITIS A VACCINE	0	14 (14.0)	14 (11.7)	1 (1.8)	15 (8.5)
ISOFLURANE	0	0	0	15 (26.8)	15 (8.5)
SPEKTRAMOX	0	15 (15.0)	15 (12.5)	0	15 (8.5)
IPRATROPIUM	0	14 (14.0)	14 (11.7)	0	14 (8.0)
OSELTAMIVIR	0	7 (7.0)	7 (5.8)	7 (12.5)	14 (8.0)
BUPIVACAINE	0	7 (7.0)	7 (5.8)	6 (10.7)	13 (7.4)
CEFALEXIN	1 (5.0)	5 (5.0)	6 (5.0)	7 (12.5)	13 (7.4)
ERGOCALCIFEROL	0	6 (6.0)	6 (5.0)	7 (12.5)	13 (7.4)
ATROPINE	1 (5.0)	11 (11.0)	12 (10.0)	0	12 (6.8)
HEPARIN	0	9 (9.0)	9 (7.5)	3 (5.4)	12 (6.8)
IRON	2 (10.0)	9 (9.0)	11 (9.2)	1 (1.8)	12 (6.8)
LANSOPRAZOLE	0	12 (12.0)	12 (10.0)	0	12 (6.8)
LEVOSALBUTAMOL	1 (5.0)	8 (8.0)	9 (7.5)	3 (5.4)	12 (6.8)
MUPIROCIN	2 (10.0)	9 (9.0)	11 (9.2)	1 (1.8)	12 (6.8)
OMEPRAZOLE	1 (5.0)	10 (10.0)	11 (9.2)	1 (1.8)	12 (6.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 5 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
AMOXICILLIN W/CLAVULANATE POTASSIUM	0	10 (10.0)	10 (8.3)	1 (1.8)	11 (6.3)
CLOTRIMAZOLE	4 (20.0)	5 (5.0)	9 (7.5)	2 (3.6)	11 (6.3)
FUROSEMIDE	0	10 (10.0)	10 (8.3)	1 (1.8)	11 (6.3)
LACTULOSE	1 (5.0)	10 (10.0)	11 (9.2)	0	11 (6.3)
PEDIARIX	5 (25.0)	6 (6.0)	11 (9.2)	0	11 (6.3)
SODIUM BICARBONATE	0	10 (10.0)	10 (8.3)	1 (1.8)	11 (6.3)
AMOXI-CLAVULANICO	3 (15.0)	5 (5.0)	8 (6.7)	2 (3.6)	10 (5.7)
CEFUROXIME	2 (10.0)	8 (8.0)	10 (8.3)	0	10 (5.7)
LACTOBACILLUS NOS	1 (5.0)	9 (9.0)	10 (8.3)	0	10 (5.7)
METHYLPREDNISOLONE	0	8 (8.0)	8 (6.7)	2 (3.6)	10 (5.7)
POTASSIUM	0	8 (8.0)	8 (6.7)	2 (3.6)	10 (5.7)
TOBRAMYCIN	0	6 (6.0)	6 (5.0)	4 (7.1)	10 (5.7)
DOCUSATE	0	6 (6.0)	6 (5.0)	3 (5.4)	9 (5.1)
FAMOTIDINE	0	9 (9.0)	9 (7.5)	0	9 (5.1)
GLYCERIN	0	9 (9.0)	9 (7.5)	0	9 (5.1)
OXYCODONE	0	3 (3.0)	3 (2.5)	6 (10.7)	9 (5.1)
VITAMINS NOS	3 (15.0)	4 (4.0)	7 (5.8)	2 (3.6)	9 (5.1)
ANESTHETICS, GENERAL	0	6 (6.0)	6 (5.0)	2 (3.6)	8 (4.5)
BENZOCAINE	2 (10.0)	5 (5.0)	7 (5.8)	1 (1.8)	8 (4.5)
CEFOTAXIME	0	6 (6.0)	6 (5.0)	2 (3.6)	8 (4.5)
ERYTHROMYCIN	0	7 (7.0)	7 (5.8)	1 (1.8)	8 (4.5)
GLUCOSE	0	6 (6.0)	6 (5.0)	2 (3.6)	8 (4.5)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 6 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
GUAIFENESIN	0	1 (1.0)	1 (0.8)	7 (12.5)	8 (4.5)
LORATADINE	0	3 (3.0)	3 (2.5)	5 (8.9)	8 (4.5)
MENINGOCOCCAL VACCINE	1 (5.0)	7 (7.0)	8 (6.7)	0	8 (4.5)
VANCOMYCIN	0	6 (6.0)	6 (5.0)	2 (3.6)	8 (4.5)
EMLAPATCH	0	7 (7.0)	7 (5.8)	0	7 (4.0)
EPINEPHRINE	0	6 (6.0)	6 (5.0)	1 (1.8)	7 (4.0)
FISH OIL	0	1 (1.0)	1 (0.8)	6 (10.7)	7 (4.0)
SULTAMICILLIN	0	7 (7.0)	7 (5.8)	0	7 (4.0)
TRIAMCINOLONE	0	5 (5.0)	5 (4.2)	2 (3.6)	7 (4.0)
UNACID	0	6 (6.0)	6 (5.0)	1 (1.8)	7 (4.0)
ZINC	1 (5.0)	4 (4.0)	5 (4.2)	2 (3.6)	7 (4.0)
ALBUMIN HUMAN	0	3 (3.0)	3 (2.5)	3 (5.4)	6 (3.4)
DIAZEPAM	0	1 (1.0)	1 (0.8)	5 (8.9)	6 (3.4)
DOMPERIDONE	0	6 (6.0)	6 (5.0)	0	6 (3.4)
EPHEDRINE	0	1 (1.0)	1 (0.8)	5 (8.9)	6 (3.4)
ESOMEPRAZOLE	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
FATS NOS	0	6 (6.0)	6 (5.0)	0	6 (3.4)
FERROUS SULFATE W/VITAMINS NOS	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
GENTAMICIN	1 (5.0)	5 (5.0)	6 (5.0)	0	6 (3.4)
LACTOBACILLUS ACIDOPHILUS	2 (10.0)	3 (3.0)	5 (4.2)	1 (1.8)	6 (3.4)
MINERALS NOS W/VITAMINS NOS	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
NEOTRACIN	0	2 (2.0)	2 (1.7)	4 (7.1)	6 (3.4)
PANTOPRAZOLE	0	6 (6.0)	6 (5.0)	0	6 (3.4)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 7 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
PREDNISONE	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
SALINE	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
ACICLOVIR	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
AMIKACIN	1 (5.0)	4 (4.0)	5 (4.2)	0	5 (2.8)
AMPICILLIN	1 (5.0)	4 (4.0)	5 (4.2)	0	5 (2.8)
AQUAPHOR	0	5 (5.0)	5 (4.2)	0	5 (2.8)
ASCORBIC ACID	0	0	0	5 (8.9)	5 (2.8)
BACITRACIN	0	5 (5.0)	5 (4.2)	0	5 (2.8)
BISEPTINE	0	5 (5.0)	5 (4.2)	0	5 (2.8)
DEXTROMETHORPHAN	0	0	0	5 (8.9)	5 (2.8)
FLUCONAZOLE	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
HYOSCINE	0	3 (3.0)	3 (2.5)	2 (3.6)	5 (2.8)
I.V. SOLUTIONS	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
IMMUNOGLOBULIN ANTI RESPIRATORY SYNCYTIAL VIR	0	5 (5.0)	5 (4.2)	0	5 (2.8)
MELATONIN	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.8)
PHENYLEPHRINE	0	0	0	5 (8.9)	5 (2.8)
PROCET	0	1 (1.0)	1 (0.8)	4 (7.1)	5 (2.8)
PSEUDOEPHEDRINE	0	1 (1.0)	1 (0.8)	4 (7.1)	5 (2.8)
REHYDRON	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
SENNA ALEXANDRINA	0	3 (3.0)	3 (2.5)	2 (3.6)	5 (2.8)
SOLUTIONS FOR PARENTERAL NUTRITION	0	5 (5.0)	5 (4.2)	0	5 (2.8)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 8 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
XILONIBSA	0	3 (3.0)	3 (2.5)	2 (3.6)	5 (2.8)
BIFIDOBACTERIUM LACTIS	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
BISACODYL	0	1 (1.0)	1 (0.8)	3 (5.4)	4 (2.3)
BOTULINUM TOXIN TYPE A	0	4 (4.0)	4 (3.3)	0	4 (2.3)
CEFEPIME	0	4 (4.0)	4 (3.3)	0	4 (2.3)
CEFIXIME	0	4 (4.0)	4 (3.3)	0	4 (2.3)
CEFOXITIN	0	4 (4.0)	4 (3.3)	0	4 (2.3)
ETOMIDATE	0	4 (4.0)	4 (3.3)	0	4 (2.3)
GABAPENTIN	0	0	0	4 (7.1)	4 (2.3)
MAGNESIUM HYDROXIDE	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
MEROPENEM	0	4 (4.0)	4 (3.3)	0	4 (2.3)
MICONAZOLE	0	4 (4.0)	4 (3.3)	0	4 (2.3)
MOMETASONE	1 (5.0)	0	1 (0.8)	3 (5.4)	4 (2.3)
MONTELUKAST	0	1 (1.0)	1 (0.8)	3 (5.4)	4 (2.3)
MULTIVITAMINS WITH IRON	0	4 (4.0)	4 (3.3)	0	4 (2.3)
MULTVIT	0	3 (3.0)	3 (2.5)	1 (1.8)	4 (2.3)
NAPROXEN	0	0	0	4 (7.1)	4 (2.3)
NEOSTIGMINE	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
OTHER MINERAL SUPPLEMENTS	0	1 (1.0)	1 (0.8)	3 (5.4)	4 (2.3)
OXYMETAZOLINE	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
POLY-VI-SOL WITH IRON	0	4 (4.0)	4 (3.3)	0	4 (2.3)
PROBIOTICS	0	3 (3.0)	3 (2.5)	1 (1.8)	4 (2.3)
QUADRACEL	0	3 (3.0)	3 (2.5)	1 (1.8)	4 (2.3)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted]

DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 9 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
RED BLOOD CELLS	0	3 (3.0)	3 (2.5)	1 (1.8)	4 (2.3)
SACCHAROMYCES BOULARDII	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
SAMBUCUS NIGRA	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
SILVER NITRATE	2 (10.0)	1 (1.0)	3 (2.5)	1 (1.8)	4 (2.3)
XYLOCAINE-EPINEPHRINE	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
ALTEPLASE	0	3 (3.0)	3 (2.5)	0	3 (1.7)
AMITRIPTYLINE	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
BECLOMETASONE	2 (10.0)	1 (1.0)	3 (2.5)	0	3 (1.7)
BENZYLPENICILLIN	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
CALCIUM	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
CLARITHROMYCIN	0	3 (3.0)	3 (2.5)	0	3 (1.7)
CLONIDINE	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
COMBIVENT	0	3 (3.0)	3 (2.5)	0	3 (1.7)
DESONIDE	0	3 (3.0)	3 (2.5)	0	3 (1.7)
DEXTROSE IN LACTATED RINGER'S	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
DOPAMINE	0	3 (3.0)	3 (2.5)	0	3 (1.7)
DUOCID	0	3 (3.0)	3 (2.5)	0	3 (1.7)
ENTONOX	0	3 (3.0)	3 (2.5)	0	3 (1.7)
FUSIDIC ACID	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
HEPATITIS VACCINES	0	3 (3.0)	3 (2.5)	0	3 (1.7)
HYDROMORPHONE	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
IOPAMIDOL	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
LACTOBACILLUS RHAMNOSUS	0	3 (3.0)	3 (2.5)	0	3 (1.7)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 10 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
LEVETIRACETAM	0	3 (3.0)	3 (2.5)	0	3 (1.7)
LEVOCARNITINE	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
LEVOFLOXACIN	0	3 (3.0)	3 (2.5)	0	3 (1.7)
LIDOCAINE W/SODIUM BICARBONATE	3 (15.0)	0	3 (2.5)	0	3 (1.7)
MEASLES VACCINE	0	3 (3.0)	3 (2.5)	0	3 (1.7)
METOCLOPRAMIDE	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
MOXIFLOXACIN	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
NALBUPHINE	0	0	0	3 (5.4)	3 (1.7)
OMEGA-3 FATTY ACIDS	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
PETHIDINE	0	0	0	3 (5.4)	3 (1.7)
POLY-VI-SOL	0	3 (3.0)	3 (2.5)	0	3 (1.7)
ROPIVACAINE	0	3 (3.0)	3 (2.5)	0	3 (1.7)
SODIUM FLUORIDE	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
SODIUM PHOSPHATE	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
TETRACAINE	0	3 (3.0)	3 (2.5)	0	3 (1.7)
UREA HYDROGEN PEROXIDE	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
VECURONIUM	0	3 (3.0)	3 (2.5)	0	3 (1.7)
ACETAZOLAMIDE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
AMBROXOL	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
AMINO ACIDS NOS	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
AMPHOTERICIN B	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ANAESTHETICS	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ANESTHETICS	0	2 (2.0)	2 (1.7)	0	2 (1.1)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 11 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
BCG VACCINE	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
BENZACLIN TOPICAL	0	0	0	2 (3.6)	2 (1.1)
BETAMETHASONE	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
CALCIUM GLUCONATE	0	0	0	2 (3.6)	2 (1.1)
CEFPODOXIME	0	2 (2.0)	2 (1.7)	0	2 (1.1)
CEFPROZIL	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
CEFTAZIDIME	0	2 (2.0)	2 (1.7)	0	2 (1.1)
CHLOROTHIAZIDE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
CLONAZEPAM	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
DEMAZIN	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
DESFLURANE	0	0	0	2 (3.6)	2 (1.1)
DESITIN	0	2 (2.0)	2 (1.7)	0	2 (1.1)
DIMETICONE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ECONAZOLE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ELECTROLYTES NOS W/GLUCOSE	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
EMOLLIENTS AND PROTECTIVES	0	2 (2.0)	2 (1.7)	0	2 (1.1)
FENOTEROL	2 (10.0)	0	2 (1.7)	0	2 (1.1)
FEXOFENADINE	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
FOSPHENYTOIN	0	2 (2.0)	2 (1.7)	0	2 (1.1)
HEPARIN SODIUM W/SODIUM CHLORIDE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
INSULIN	0	2 (2.0)	2 (1.7)	0	2 (1.1)
IOHEXOL	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ISRADIPINE	0	2 (2.0)	2 (1.7)	0	2 (1.1)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 12 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
LEKOVIT CA	0	0	0	2 (3.6)	2 (1.1)
LEVOGLUTAMIDE	0	0	0	2 (3.6)	2 (1.1)
LOPERAMIDE	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
MAALOX	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
MACROGOL 3350	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
MENHIBRIX	0	2 (2.0)	2 (1.7)	0	2 (1.1)
METAMIZOLE	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
METFORMIN	0	0	0	2 (3.6)	2 (1.1)
METHADONE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
METHYLROSANILINIUM	0	2 (2.0)	2 (1.7)	0	2 (1.1)
MOVICOL	0	2 (2.0)	2 (1.7)	0	2 (1.1)
NISITA	0	2 (2.0)	2 (1.7)	0	2 (1.1)
OFLOXACIN	1 (5.0)	0	1 (0.8)	1 (1.8)	2 (1.1)
OTHER DERMATOLOGICAL PREPARATIONS	0	2 (2.0)	2 (1.7)	0	2 (1.1)
PARAFFIN	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
PETROLATUM	0	2 (2.0)	2 (1.7)	0	2 (1.1)
PIPERACILLIN	0	2 (2.0)	2 (1.7)	0	2 (1.1)
PLASMA	0	2 (2.0)	2 (1.7)	0	2 (1.1)
PLASMA LYTE 148	0	2 (2.0)	2 (1.7)	0	2 (1.1)
POLYCARBOPHIL	0	0	0	2 (3.6)	2 (1.1)
POLYSPORIN	0	2 (2.0)	2 (1.7)	0	2 (1.1)
PROBIOTICS NOS	0	2 (2.0)	2 (1.7)	0	2 (1.1)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 13 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
PROTEIN SUPPLEMENTS	0	2 (2.0)	2 (1.7)	0	2 (1.1)
RACECADOTRIL	0	2 (2.0)	2 (1.7)	0	2 (1.1)
RACEPINEFRINE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ROXITHROMYCIN	0	2 (2.0)	2 (1.7)	0	2 (1.1)
SENNOSIDE A+B	0	0	0	2 (3.6)	2 (1.1)
SODIUM FLUORIDE W/VITAMINS NOS	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
SUCRALFATE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
THOMAPYRIN N	0	0	0	2 (3.6)	2 (1.1)
TPN	0	2 (2.0)	2 (1.7)	0	2 (1.1)
TRIMETHOPRIM	0	2 (2.0)	2 (1.7)	0	2 (1.1)
TUMS	0	0	0	2 (3.6)	2 (1.1)
UBIDECARENONE	0	0	0	2 (3.6)	2 (1.1)
XYLOMETAZOLINE	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ABSORBABLE GELATIN SPONGE	0	0	0	1 (1.8)	1 (0.6)
ACETYLSALICYLIC ACID	0	0	0	1 (1.8)	1 (0.6)
ADAPALENE	0	0	0	1 (1.8)	1 (0.6)
ADENOSINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ADIARIL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ALBENDAZOLE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ALCLOMETASONE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ALKA-SELTZER PLUS	0	0	0	1 (1.8)	1 (0.6)
ALOE VERA	0	1 (1.0)	1 (0.8)	0	1 (0.6)
AMINOCAPROIC ACID	0	0	0	1 (1.8)	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 14 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
AMINOPHYLLINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
AMIODARONE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
ANAESTHETICS FOR TOPICAL USE	0	0	0	1 (1.8)	1 (0.6)
ANOVLAR	0	0	0	1 (1.8)	1 (0.6)
ANTIBIOTICS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ANTIDIARRHEAL MICROORGANISMS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ANTIFUNGALS FOR DERMATOLOGICAL USE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ANTISEPTIC SOLUTION	0	0	0	1 (1.8)	1 (0.6)
ANTIVIRALS	0	0	0	1 (1.8)	1 (0.6)
ARGININE	0	0	0	1 (1.8)	1 (0.6)
ARTIFICIAL TEARS	0	0	0	1 (1.8)	1 (0.6)
ASCORBIC ACID (VITAMIN C), PLAIN	0	0	0	1 (1.8)	1 (0.6)
ASCORBIC ACID W/CALCIUM PHOSPHATE/LACTOBACILL	0	0	0	1 (1.8)	1 (0.6)
ASCORBIC ACID W/HERBAL NOS/LEVOGLUTAMIDE/LYSI	0	0	0	1 (1.8)	1 (0.6)
ASCORBIC ACID W/RETINOL/VITAMIN D NOS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ATRACURIUM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
AURALGAN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
AUXERGYL D3	0	1 (1.0)	1 (0.8)	0	1 (0.6)
AVEENO BABY DAILY MOISTURE	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 15 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
BACITRACIN/ NEOMYCIN/ POLYMYXIN B	0	1 (1.0)	1 (0.8)	0	1 (0.6)
BENZALKONIUM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
BETHANECHOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
BICITRA	0	1 (1.0)	1 (0.8)	0	1 (0.6)
BLOOD AND RELATED PRODUCTS	0	0	0	1 (1.8)	1 (0.6)
BLOOD CELLS, PACKED HUMAN	0	0	0	1 (1.8)	1 (0.6)
BLOOD, WHOLE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
BROMFED	0	0	0	1 (1.8)	1 (0.6)
BROMHEXINE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
BUDESONIDE W/FORMOTEROL FUMARATE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CAFFEINE	0	0	0	1 (1.8)	1 (0.6)
CALCIUM CARBONATE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CALCIUM D3	0	0	0	1 (1.8)	1 (0.6)
CALGEL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CAMPHOR	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CANESTEN-HC	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CAPTOPRIL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CARBOCISTEINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CARBOHYDRATES NOS W/FATS NOS/MINERA	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CARNITINE W/PROTEINS NOS/TAURINE	0	0	0	1 (1.8)	1 (0.6)
CEFADROXIL	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 16 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
CEFOTETAN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CHAMAEMELUM NOBILE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CHLORAL HYDRATE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
CHLORAMPHENICOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CHLORPHENAMINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CINNAMOMUM VERUM	0	0	0	1 (1.8)	1 (0.6)
CISATRACURIUM	0	0	0	1 (1.8)	1 (0.6)
CLAVULANIC ACID	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CLONALIN	0	0	0	1 (1.8)	1 (0.6)
CODEINE/PROMETHAZINE	0	0	0	1 (1.8)	1 (0.6)
COLOSTRUM	0	0	0	1 (1.8)	1 (0.6)
COMPOUND SODIUM CHLORIDE	0	0	0	1 (1.8)	1 (0.6)
CONTRAST MEDIA	0	1 (1.0)	1 (0.8)	0	1 (0.6)
CORTICOSTEROIDS FOR SYSTEMIC USE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
COTYLENOL	0	0	0	1 (1.8)	1 (0.6)
COUGH SYRUP	0	0	0	1 (1.8)	1 (0.6)
CROMOGLICIC ACID	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DALTEPARIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DESITIN WITH ZINC OXIDE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DESLORATADINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DEXIBUPROFEN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DEXMETHYLPHENIDATE	0	0	0	1 (1.8)	1 (0.6)
DEXTROSE W/POTASSIUM CHLORIDE	0	0	0	1 (1.8)	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 17 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
DIFLUCORTOLONE VALERATE W/ISOCONAZOLE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DIGOXIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DIMENHYDRINATE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DIMETANE DX	0	0	0	1 (1.8)	1 (0.6)
DIMETAPP	0	0	0	1 (1.8)	1 (0.6)
DIMETAPP DM	0	0	0	1 (1.8)	1 (0.6)
DIPHENTANN-D	0	0	0	1 (1.8)	1 (0.6)
DIPROBASE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
DOCOSANOL	0	0	0	1 (1.8)	1 (0.6)
DUONASE	0	0	0	1 (1.8)	1 (0.6)
DUOVENT	1 (5.0)	0	1 (0.8)	0	1 (0.6)
ECHINACEA PURPUREA	0	0	0	1 (1.8)	1 (0.6)
EL-4	0	1 (1.0)	1 (0.8)	0	1 (0.6)
EPIPEVISONE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ERTAPENEM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ETHINYL ESTRADIOL W/NORGESTREL	0	0	0	1 (1.8)	1 (0.6)
ETHYL CHLORIDE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ETODOLAC	0	0	0	1 (1.8)	1 (0.6)
EUCERIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
EUGYNON	0	0	0	1 (1.8)	1 (0.6)
EUPEPTINA	0	1 (1.0)	1 (0.8)	0	1 (0.6)
EUPHRASIA OFFICINALIS	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 18 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
EXCEDRIN	0	0	0	1 (1.8)	1 (0.6)
EXCIPIAL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
FITOSTIMOLINE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
FLEET ENEMA	0	0	0	1 (1.8)	1 (0.6)
FLUCLOXACILLIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
FLUOCINOLONE ACETONIDE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
FLUORIDE	0	0	0	1 (1.8)	1 (0.6)
FLUOROMETHOLONE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
FOLIC ACID	0	0	0	1 (1.8)	1 (0.6)
FRUCTOSE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
GASTROGRAFIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
GAVISCON	0	1 (1.0)	1 (0.8)	0	1 (0.6)
GERBER SOOTHE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
GOLYTELY	0	1 (1.0)	1 (0.8)	0	1 (0.6)
HAEMOPHILUS INFLUENZAE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
HAMAMELIS VIRGINIANA	0	1 (1.0)	1 (0.8)	0	1 (0.6)
HEPARINOID	0	1 (1.0)	1 (0.8)	0	1 (0.6)
HERBAL EXTRACT NOS	0	0	0	1 (1.8)	1 (0.6)
HERBAL NOS W/MINERALS NOS/VITAMINS NOS	1 (5.0)	0	1 (0.8)	0	1 (0.6)
HOMATROPINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
HOMEOPATHIC PREPARATION	0	0	0	1 (1.8)	1 (0.6)
HUMAN PAPILLOMA VACCINE	0	0	0	1 (1.8)	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 19 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
HUMAN RED BLOOD CELLS	0	0	0	1 (1.8)	1 (0.6)
HYDROXYQUINOLINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
HYDROXYZINE	0	0	0	1 (1.8)	1 (0.6)
I.V. SOLUTION ADDITIVES	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ICHTHOPASTE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
IMMUNOGLOBULIN ANTIHEPATITIS B	0	1 (1.0)	1 (0.8)	0	1 (0.6)
INTRALIPID	0	1 (1.0)	1 (0.8)	0	1 (0.6)
IOTALAMIC ACID	0	1 (1.0)	1 (0.8)	0	1 (0.6)
IOVERSOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
IOXILAN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
IPRATROPIUM W/SALBUTAMOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ISOPROPANOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
JARRO DOPHILUS	0	0	0	1 (1.8)	1 (0.6)
JONOSTERIL	0	0	0	1 (1.8)	1 (0.6)
KETOCONAZOLE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
LACTINEX	0	1 (1.0)	1 (0.8)	0	1 (0.6)
LEVOBUPIVACAINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
LISINOPRIL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MAALOX PLUS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MACROGOL 4000	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MAGNESIUM	1 (5.0)	0	1 (0.8)	0	1 (0.6)
MAGNESIUM SULFATE	0	0	0	1 (1.8)	1 (0.6)
MANNITOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 20 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
MARCAIN-ADRENALIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MARCAINE WITH EPINEPHRINE	0	0	0	1 (1.8)	1 (0.6)
MEDIUM-CHAIN TRIGLYCERIDES	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MENADIONE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MENTHOL W/METHYL SALICYLATE	0	0	0	1 (1.8)	1 (0.6)
MEQUITAZINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MEROKEN NEW	0	1 (1.0)	1 (0.8)	0	1 (0.6)
METANIUM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
METHYLPHENIDATE	0	0	0	1 (1.8)	1 (0.6)
METOPIMAZINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
METRONIDAZOLE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MICAFUNGIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MICROKLIST	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MINERAL OIL EMULSION	0	0	0	1 (1.8)	1 (0.6)
MINERAL SUPPLEMENTS	0	0	0	1 (1.8)	1 (0.6)
MUCOLYTICS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MULTI DAY MULTIVITAMIN PLUS IRON	0	0	0	1 (1.8)	1 (0.6)
MULTIVITAMINS WITH FLUORIDE	0	0	0	1 (1.8)	1 (0.6)
MULTIVITAMINS WITH MINERALS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
MULTONIC	0	0	0	1 (1.8)	1 (0.6)
NAFCILLIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
NARINE	0	0	0	1 (1.8)	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 21 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
NATURES WAY PRIMADOPHILUS ORIGINAL	1 (5.0)	0	1 (0.8)	0	1 (0.6)
NEOSPORIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
NITROFURANTOIN	0	0	0	1 (1.8)	1 (0.6)
NORFLOXACIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
NORMOSOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
NUTRIENTS NOS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
OLOPATADINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
OMEGA-6 FATTY ACIDS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ORALPAEDON	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ORNITHINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
OSMOSAL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
OTHER ANTISEPTICS AND DISINFECTANTS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
OTHER EMOLLIENTS AND PROTECTIVES	1 (5.0)	0	1 (0.8)	0	1 (0.6)
OTHER NUTRIENTS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
OTHER VITAMIN PRODUCTS, COMBINATIONS	0	0	0	1 (1.8)	1 (0.6)
PAMIDRONIC ACID	0	0	0	1 (1.8)	1 (0.6)
PANCREATIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PANCRELIPASE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PAPAVERINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PARA-NOX	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 22 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
PARAFFIN SOFT	0	0	0	1 (1.8)	1 (0.6)
PARAFFIN, LIQUID	0	0	0	1 (1.8)	1 (0.6)
PEDIACARE COUGH-COLD	0	0	0	1 (1.8)	1 (0.6)
PEDITUS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PHENOL	0	0	0	1 (1.8)	1 (0.6)
PHENTERMINE	0	0	0	1 (1.8)	1 (0.6)
PIMECROLIMUS	0	0	0	1 (1.8)	1 (0.6)
PIPERACILLIN W/TAZOBACTAM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PIRITRAMIDE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
POLY VI SOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
POLYTRIM	0	0	0	1 (1.8)	1 (0.6)
POTASSIUM CITRATE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
POTASSIUM PERMANGANATE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
POTASSIUM PHOSPHATE MONOBASIC	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PRILOCAINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PRIMAXIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PRIORIX TETRA	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PROCATEROL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PROMETHAZINE	0	0	0	1 (1.8)	1 (0.6)
PROPRANOLOL	1 (5.0)	0	1 (0.8)	0	1 (0.6)
PROTEIN HYDROLYSATE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
PROTEINS NOS W/VITAMINS NOS	0	0	0	1 (1.8)	1 (0.6)
PSYLLIUM HYDROPHILIC MUCILLOID	0	0	0	1 (1.8)	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 23 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
RESPIRATORY SYSTEM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
RETINOL W/VITAMIN D NOS/WOOL FAT	1 (5.0)	0	1 (0.8)	0	1 (0.6)
RIFINAH	0	1 (1.0)	1 (0.8)	0	1 (0.6)
RINGER-LACTATE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ROCEPHIN IM.	0	1 (1.0)	1 (0.8)	0	1 (0.6)
SACCHAROMYCES BOULARDIL LYOPHYLIZED	0	0	0	1 (1.8)	1 (0.6)
SALACTOL	0	0	0	1 (1.8)	1 (0.6)
SALICYLIC ACID	0	0	0	1 (1.8)	1 (0.6)
SAPROPTERIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
SELENIUM SULFIDE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
SENSORCAINE W/EPINEPHRINE BITARTRATE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
SILVER	0	0	0	1 (1.8)	1 (0.6)
SODIUM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
SODIUM W/POTASSIUM PHOSPHATE	0	0	0	1 (1.8)	1 (0.6)
SOLPADEINE	0	0	0	1 (1.8)	1 (0.6)
SPIRONOLACTONE	1 (5.0)	0	1 (0.8)	0	1 (0.6)
STOMATOLOGICAL PREPARATIONS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
SULCONAZOLE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
SULFAMETHOXAZOLE	0	0	0	1 (1.8)	1 (0.6)
SUPRADYN	0	0	0	1 (1.8)	1 (0.6)
SUXAMETHONIUM	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 24 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
TECHNETIUM TC 99M SULFUR COLLOID	0	1 (1.0)	1 (0.8)	0	1 (0.6)
TERRA-CORTRIL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
TETANUS VACCINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
TETRYZOLINE	0	0	0	1 (1.8)	1 (0.6)
THEOPHYLLINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
THIAMYLAL	1 (5.0)	0	1 (0.8)	0	1 (0.6)
THIOCTIC ACID	0	0	0	1 (1.8)	1 (0.6)
TIPEPIDINE	0	1 (1.0)	1 (0.8)	0	1 (0.6)
TIXOCORTOL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
TOCOPHEROL	0	0	0	1 (1.8)	1 (0.6)
TOLTERODINE	0	0	0	1 (1.8)	1 (0.6)
TRANEXAMIC ACID	0	0	0	1 (1.8)	1 (0.6)
TRETINOIN	0	0	0	1 (1.8)	1 (0.6)
TRIAMINIC-DM	0	0	0	1 (1.8)	1 (0.6)
TRIGLYCERIDES	0	1 (1.0)	1 (0.8)	0	1 (0.6)
TUBERCULOSIS VACCINES	0	1 (1.0)	1 (0.8)	0	1 (0.6)
TUSSIN DM	0	1 (1.0)	1 (0.8)	0	1 (0.6)
UNSPECIFIED HERBAL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
UVESTEROL	0	1 (1.0)	1 (0.8)	0	1 (0.6)
VACCINES	0	1 (1.0)	1 (0.8)	0	1 (0.6)
VALISONE-G	0	1 (1.0)	1 (0.8)	0	1 (0.6)
VANICREAM	1 (5.0)	0	1 (0.8)	0	1 (0.6)
VICKS FORMULA 44M	0	0	0	1 (1.8)	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Subjects diagnosed with SMA: concomitant medications
Page 25 of 25

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
VICODIN	0	1 (1.0)	1 (0.8)	0	1 (0.6)
VIKOMINAS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
VIRAL VACCINES	1 (5.0)	0	1 (0.8)	0	1 (0.6)
VITAMIN B COMPLEX	0	0	0	1 (1.8)	1 (0.6)
VITAMIN C WITH ZINC	0	0	0	1 (1.8)	1 (0.6)
VITAMINS, OTHER COMBINATIONS	0	1 (1.0)	1 (0.8)	0	1 (0.6)
VITIS VINIFERA	0	0	0	1 (1.8)	1 (0.6)
WATER FOR INJECTION	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE: Numbers in parentheses are percentages.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 127　Incidence of Adverse Events in Subjects With SMA Treated With ISIS 396443

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 1 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	16 (80.0)	97 (97.0)	113 (94.2)	56 (100.0)	169 (96.0)
感染症および寄生虫症	13 (65.0)	84 (84.0)	97 (80.8)	44 (78.6)	141 (80.1)
上気道感染	8 (40.0)	36 (36.0)	44 (36.7)	27 (48.2)	71 (40.3)
鼻咽頭炎	4 (20.0)	21 (21.0)	25 (20.8)	16 (28.6)	41 (23.3)
肺炎	2 (10.0)	30 (30.0)	32 (26.7)	5 (8.9)	37 (21.0)
ウイルス感染	0	12 (12.0)	12 (10.0)	9 (16.1)	21 (11.9)
ライノウイルス感染	2 (10.0)	16 (16.0)	18 (15.0)	0	18 (10.2)
中耳炎	3 (15.0)	9 (9.0)	12 (10.0)	5 (8.9)	17 (9.7)
気道感染	0	14 (14.0)	14 (11.7)	1 (1.8)	15 (8.5)
ウイルス性上気道感染	0	10 (10.0)	10 (8.3)	5 (8.9)	15 (8.5)
ウイルス性肺炎	1 (5.0)	10 (10.0)	11 (9.2)	2 (3.6)	13 (7.4)
細気管支炎	1 (5.0)	11 (11.0)	12 (10.0)	0	12 (6.8)
インフルエンザ	3 (15.0)	6 (6.0)	9 (7.5)	3 (5.4)	12 (6.8)
尿路感染	1 (5.0)	7 (7.0)	8 (6.7)	4 (7.1)	12 (6.8)
ウイルス性胃腸炎	2 (10.0)	1 (1.0)	3 (2.5)	8 (14.3)	11 (6.3)
耳感染	0	6 (6.0)	6 (5.0)	4 (7.1)	10 (5.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 2 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
レンサ球菌性咽頭炎	1 (5.0)	1 (1.0)	2 (1.7)	8 (14.3)	10 (5.7)
結膜炎	0	6 (6.0)	6 (5.0)	3 (5.4)	9 (5.1)
胃腸炎	0	2 (2.0)	2 (1.7)	7 (12.5)	9 (5.1)
口腔カンジダ症	0	8 (8.0)	8 (6.7)	0	8 (4.5)
気管支炎	1 (5.0)	6 (6.0)	7 (5.8)	0	7 (4.0)
下気道感染	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
ＲＳウイルス細気管支炎	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
ウイルス性気道感染	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
鼻炎	2 (10.0)	3 (3.0)	5 (4.2)	1 (1.8)	6 (3.4)
ウイルス性気管支炎	0	5 (5.0)	5 (4.2)	0	5 (2.8)
限局性感染	0	1 (1.0)	1 (0.8)	3 (5.4)	4 (2.3)
細菌性肺炎	0	4 (4.0)	4 (3.3)	0	4 (2.3)
皮膚カンジダ	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
細菌性気管炎	0	3 (3.0)	3 (2.5)	0	3 (1.7)
皮膚真菌感染	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
手足口病	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
膿痂疹	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
ウイルス性下気道感染	0	3 (3.0)	3 (2.5)	0	3 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 3 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
シュードモナス感染	0	3 (3.0)	3 (2.5)	0	3 (1.7)
ＲＳウイルス感染	0	0	0	3 (5.4)	3 (1.7)
副鼻腔炎	0	0	0	3 (5.4)	3 (1.7)
アデノウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
細菌感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
カンジダ性おむつ皮疹	0	2 (2.0)	2 (1.7)	0	2 (1.1)
蜂巣炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
細菌性結膜炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
エンテロウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ウイルス性消化管感染	0	0	0	2 (3.6)	2 (1.1)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
モラクセラ感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
急性中耳炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
パラインフルエンザウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
モラクセラ菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
敗血症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ストーマ部膿瘍	0	2 (2.0)	2 (1.7)	0	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 4 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
アデノウイルス性上気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
細菌性疾患キャリアー	0	1 (1.0)	1 (0.8)	0	1 (0.6)
コロナウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性耳感染	1 (5.0)	0	1 (0.8)	0	1 (0.6)
感染性湿疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
蟯虫症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腸球菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
伝染性紅斑	0	1 (1.0)	1 (0.8)	0	1 (0.6)
大腸菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
眼感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性眼感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性眼感染	0	0	0	1 (1.8)	1 (0.6)
真菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性胃炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ロタウイルス胃腸炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ヘモフィルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
伝染性軟属腫	0	0	0	1 (1.8)	1 (0.6)
単核細胞症症候群	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 5 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
粘膜皮膚カンジダ症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
院内感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口腔真菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口腔ヘルペス	0	1 (1.0)	1 (0.8)	0	1 (0.6)
咽頭炎	0	0	0	1 (1.8)	1 (0.6)
インフルエンザ性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
パラインフルエンザウイルス性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺炎球菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
シュードモナス菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腎盂腎炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
細菌性気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ばら疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚細菌感染	0	0	0	1 (1.8)	1 (0.6)
皮膚感染	1 (5.0)	0	1 (0.8)	0	1 (0.6)
ブドウ球菌性菌血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌皮膚感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ部感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 6 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
レンサ球菌感染	1 (5.0)	0	1 (0.8)	0	1 (0.6)
扁桃炎	0	0	0	1 (1.8)	1 (0.6)
気管炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腟感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性扁桃炎	0	0	0	1 (1.8)	1 (0.6)
外陰腟真菌感染	0	0	0	1 (1.8)	1 (0.6)
菌血症	0	0	0	0	0
カンジダ感染	0	0	0	0	0
カンジダ性敗血症	0	0	0	0	0
麦粒腫	0	0	0	0	0
セラチア感染	0	0	0	0	0
全身性感染	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
呼吸器、胸郭および縦隔障害	6 (30.0)	79 (79.0)	85 (70.8)	25 (44.6)	110 (62.5)
呼吸窮迫	1 (5.0)	28 (28.0)	29 (24.2)	0	29 (16.5)
呼吸不全	0	26 (26.0)	26 (21.7)	1 (1.8)	27 (15.3)
無気肺	0	23 (23.0)	23 (19.2)	1 (1.8)	24 (13.6)
咳嗽	3 (15.0)	15 (15.0)	18 (15.0)	6 (10.7)	24 (13.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 7 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
鼻閉	3 (15.0)	15 (15.0)	18 (15.0)	3 (5.4)	21 (11.9)
鼻漏	3 (15.0)	8 (8.0)	11 (9.2)	6 (10.7)	17 (9.7)
急性呼吸不全	0	15 (15.0)	15 (12.5)	1 (1.8)	16 (9.1)
低酸素症	0	11 (11.0)	11 (9.2)	3 (5.4)	14 (8.0)
誤嚥性肺炎	0	12 (12.0)	12 (10.0)	0	12 (6.8)
呼吸困難	0	9 (9.0)	9 (7.5)	1 (1.8)	10 (5.7)
口腔咽頭痛	0	0	0	8 (14.3)	8 (4.5)
上気道うっ血	1 (5.0)	7 (7.0)	8 (6.7)	0	8 (4.5)
無呼吸	0	7 (7.0)	7 (5.8)	0	7 (4.0)
誤嚥	0	7 (7.0)	7 (5.8)	0	7 (4.0)
気管支分泌物貯留	0	7 (7.0)	7 (5.8)	0	7 (4.0)
慢性呼吸不全	0	6 (6.0)	6 (5.0)	0	6 (3.4)
呼吸停止	0	6 (6.0)	6 (5.0)	0	6 (3.4)
副鼻腔うっ血	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
上気道分泌増加	0	5 (5.0)	5 (4.2)	0	5 (2.8)
喘鳴	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
息詰まり	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
鼻出血	0	0	0	3 (5.4)	3 (1.7)
低換気	0	3 (3.0)	3 (2.5)	0	3 (1.7)
気胸	0	3 (3.0)	3 (2.5)	0	3 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 8 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
肺うっ血	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
呼吸障害	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
扁桃肥大	0	0	0	3 (5.4)	3 (1.7)
肺水腫	0	2 (2.0)	2 (1.7)	0	2 (1.1)
気道うっ血	0	2 (2.0)	2 (1.7)	0	2 (1.1)
拘束性肺疾患	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
アレルギー性鼻炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
呼吸補助筋の動員	0	2 (2.0)	2 (1.7)	0	2 (1.1)
急性呼吸窮迫症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
無呼吸発作	0	1 (1.0)	1 (0.8)	0	1 (0.6)
窒息	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管支閉塞	0	1 (1.0)	1 (0.8)	0	1 (0.6)
発声障害	0	0	0	1 (1.8)	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
減呼吸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管支分泌増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
喉頭肉芽腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
鼻汁変色	0	1 (1.0)	1 (0.8)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 9 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胸水	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺臓炎	0	0	0	1 (1.8)	1 (0.6)
湿性咳嗽	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸性アシドーシス	1 (5.0)	0	1 (0.8)	0	1 (0.6)
呼吸性アルカローシス	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低音性連続性ラ音	0	1 (1.0)	1 (0.8)	0	1 (0.6)
睡眠時無呼吸症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
変色痰	0	1 (1.0)	1 (0.8)	0	1 (0.6)
頻呼吸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乳幼児突発性危急事態	0	0	0	0	0
カタル	0	0	0	0	0
上気道の炎症	0	0	0	0	0
胃腸障害	8 (40.0)	71 (71.0)	79 (65.8)	26 (46.4)	105 (59.7)
便秘	2 (10.0)	37 (37.0)	39 (32.5)	7 (12.5)	46 (26.1)
嘔吐	0	22 (22.0)	22 (18.3)	12 (21.4)	34 (19.3)
下痢	1 (5.0)	16 (16.0)	17 (14.2)	2 (3.6)	19 (10.8)
胃食道逆流性疾患	2 (10.0)	16 (16.0)	18 (15.0)	1 (1.8)	19 (10.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 10 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
生歯	1 (5.0)	18 (18.0)	19 (15.8)	0	19 (10.8)
嚥下障害	1 (5.0)	9 (9.0)	10 (8.3)	0	10 (5.7)
悪心	0	0	0	10 (17.9)	10 (5.7)
放屁	2 (10.0)	6 (6.0)	8 (6.7)	1 (1.8)	9 (5.1)
流涎過多	0	8 (8.0)	8 (6.7)	0	8 (4.5)
腹部膨満	2 (10.0)	4 (4.0)	6 (5.0)	0	6 (3.4)
腹部不快感	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
アフタ性潰瘍	0	1 (1.0)	1 (0.8)	3 (5.4)	4 (2.3)
胃炎	0	4 (4.0)	4 (3.3)	0	4 (2.3)
腹痛	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
上腹部痛	0	0	0	2 (3.6)	2 (1.1)
血便排泄	0	2 (2.0)	2 (1.7)	0	2 (1.1)
口腔内痛	0	0	0	2 (3.6)	2 (1.1)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
口唇のひび割れ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
食中毒	0	0	0	1 (1.8)	1 (0.6)
排便回数増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃出血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃腸障害	0	0	0	1 (1.8)	1 (0.6)
消化管運動低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 11 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
吐血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
胃排出不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乳児仙痛	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乳児吐出	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口唇痛	0	0	0	1 (1.8)	1 (0.6)
口内炎	0	0	0	1 (1.8)	1 (0.6)
上部消化管出血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血性下痢	0	0	0	0	0
小腸炎	0	0	0	0	0
心窩部不快感	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動障害	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
レッチング	0	0	0	0	0
舌萎縮	0	0	0	0	0
一般・全身障害および投与部位の状態	6 (30.0)	65 (65.0)	71 (59.2)	31 (55.4)	102 (58.0)
発熱	5 (25.0)	59 (59.0)	64 (53.3)	16 (28.6)	80 (45.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 12 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
穿刺部位疼痛	0	0	0	10 (17.9)	10 (5.7)
疼痛	0	5 (5.0)	5 (4.2)	2 (3.6)	7 (4.0)
疲労	0	0	0	3 (5.4)	3 (1.7)
医療機器閉塞	0	2 (2.0)	2 (1.7)	0	2 (1.1)
不快感	0	2 (2.0)	2 (1.7)	0	2 (1.1)
低体温	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
末梢性浮腫	0	2 (2.0)	2 (1.7)	0	2 (1.1)
末梢腫脹	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
血管穿刺部位内出血	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
適用部位紅斑	1 (5.0)	0	1 (0.8)	0	1 (0.6)
カテーテル留置部位出血	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位炎症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位関連反応	0	0	0	1 (1.8)	1 (0.6)
胸部不快感	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
泣き	0	1 (1.0)	1 (0.8)	0	1 (0.6)
死亡	0	1 (1.0)	1 (0.8)	0	1 (0.6)
医療機器リーク	0	1 (1.0)	1 (0.8)	0	1 (0.6)
薬物不耐性	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 13 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
冷感	0	0	0	1 (1.8)	1 (0.6)
全身健康状態低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
重力性浮腫	0	0	0	1 (1.8)	1 (0.6)
注入部位内出血	1 (5.0)	0	1 (0.8)	0	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
ワクチン接種後の易刺激性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
倦怠感	0	1 (1.0)	1 (0.8)	0	1 (0.6)
医療機器合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
小結節	0	1 (1.0)	1 (0.8)	0	1 (0.6)
浮腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
穿刺部位反応	0	0	0	1 (1.8)	1 (0.6)
外科手術不成功	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腫脹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
適用部位発疹	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 14 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
傷害、中毒および処置合併症	3 (15.0)	30 (30.0)	33 (27.5)	40 (71.4)	73 (41.5)
腰椎穿刺後症候群	0	0	0	23 (41.1)	23 (13.1)
処置による疼痛	0	4 (4.0)	4 (3.3)	6 (10.7)	10 (5.7)
節足動物咬傷	1 (5.0)	4 (4.0)	5 (4.2)	3 (5.4)	8 (4.5)
裂傷	0	0	0	7 (12.5)	7 (4.0)
大腿骨骨折	0	3 (3.0)	3 (2.5)	3 (5.4)	6 (3.4)
挫傷	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
栄養補給チューブ合併症	0	4 (4.0)	4 (3.3)	0	4 (2.3)
関節脱臼	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
四肢損傷	0	0	0	3 (5.4)	3 (1.7)
ストーマ部紅斑	0	3 (3.0)	3 (2.5)	0	3 (1.7)
サンバーン	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
術後激越	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
転倒	1 (5.0)	0	1 (0.8)	1 (1.8)	2 (1.1)
関節損傷	0	0	0	2 (3.6)	2 (1.1)
処置後腫脹	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
処置による悪心	0	0	0	2 (3.6)	2 (1.1)
皮膚擦過傷	0	2 (2.0)	2 (1.7)	0	2 (1.1)
熱傷	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 15 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
隆起骨折	0	0	0	2 (3.6)	2 (1.1)
節足動物刺傷	0	0	0	1 (1.8)	1 (0.6)
麻酔からの覚醒遅延	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ダンピング症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
耳擦過傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
擦過傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
伝染病曝露	0	1 (1.0)	1 (0.8)	0	1 (0.6)
頭部損傷	0	0	0	1 (1.8)	1 (0.6)
靭帯捻挫	0	0	0	1 (1.8)	1 (0.6)
口唇損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
下肢骨折	0	0	0	1 (1.8)	1 (0.6)
半月板損傷	0	0	0	1 (1.8)	1 (0.6)
肉離れ	0	0	0	1 (1.8)	1 (0.6)
外傷性気胸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
処置後合併症	1 (5.0)	0	1 (0.8)	0	1 (0.6)
処置後不快感	1 (5.0)	0	1 (0.8)	0	1 (0.6)
術後イレウス	0	0	0	1 (1.8)	1 (0.6)
処置合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 16 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
軟部組織損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ部刺激感	0	1 (1.0)	1 (0.8)	0	1 (0.6)
硬膜下血腫	1 (5.0)	0	1 (0.8)	0	1 (0.6)
脛骨骨折	0	0	0	1 (1.8)	1 (0.6)
歯牙損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ワクチン接種合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管内挿管合併症	0	0	0	0	0
切開部位紅斑	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後出血	0	0	0	0	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
気管出血	0	0	0	0	0
気管損傷	0	0	0	0	0
気管閉塞	0	0	0	0	0
筋骨格系および結合組織障害	3 (15.0)	25 (25.0)	28 (23.3)	41 (73.2)	69 (39.2)
側弯症	0	11 (11.0)	11 (9.2)	15 (26.8)	26 (14.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 17 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
背部痛	0	1 (1.0)	1 (0.8)	23 (41.1)	24 (13.6)
関節拘縮	1 (5.0)	11 (11.0)	12 (10.0)	10 (17.9)	22 (12.5)
四肢痛	0	2 (2.0)	2 (1.7)	5 (8.9)	7 (4.0)
関節痛	0	0	0	5 (8.9)	5 (2.8)
脊柱後弯症	0	5 (5.0)	5 (4.2)	0	5 (2.8)
胸郭変形	0	4 (4.0)	4 (3.3)	0	4 (2.3)
筋肉痛	0	0	0	4 (7.1)	4 (2.3)
頚部痛	0	0	0	3 (5.4)	3 (1.7)
頭位性斜頭症	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
斜頚	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
後側弯症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
脊柱前弯症	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
筋緊張	0	0	0	2 (3.6)	2 (1.1)
筋力低下	2 (10.0)	0	2 (1.7)	0	2 (1.1)
骨盤変形	0	0	0	2 (3.6)	2 (1.1)
泉門閉鎖遅延	0	1 (1.0)	1 (0.8)	0	1 (0.6)
四肢拘縮	0	0	0	1 (1.8)	1 (0.6)
手変形	0	1 (1.0)	1 (0.8)	0	1 (0.6)
関節硬直	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脊柱変形	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 18 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
滑膜炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
体重支持困難	1 (5.0)	0	1 (0.8)	0	1 (0.6)
関節可動域低下	0	0	0	0	0
皮膚および皮下組織障害	9 (45.0)	37 (37.0)	46 (38.3)	17 (30.4)	63 (35.8)
発疹	1 (5.0)	14 (14.0)	15 (12.5)	1 (1.8)	16 (9.1)
おむつ皮膚炎	2 (10.0)	10 (10.0)	12 (10.0)	1 (1.8)	13 (7.4)
接触性皮膚炎	0	3 (3.0)	3 (2.5)	3 (5.4)	6 (3.4)
湿疹	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
皮膚炎	2 (10.0)	2 (2.0)	4 (3.3)	1 (1.8)	5 (2.8)
斑状出血	0	3 (3.0)	3 (2.5)	0	3 (1.7)
紅斑	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
過剰肉芽組織	0	3 (3.0)	3 (2.5)	0	3 (1.7)
汗疹	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
皮膚刺激	0	3 (3.0)	3 (2.5)	0	3 (1.7)
過角化	0	2 (2.0)	2 (1.7)	0	2 (1.1)
点状出血	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
蕁麻疹	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
ざ瘡	0	0	0	1 (1.8)	1 (0.6)
脱毛症	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 19 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
水疱	0	0	0	1 (1.8)	1 (0.6)
褥瘡性潰瘍	0	0	0	1 (1.8)	1 (0.6)
アレルギー性皮膚炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚乾燥	0	1 (1.0)	1 (0.8)	0	1 (0.6)
貨幣状湿疹	1 (5.0)	0	1 (0.8)	0	1 (0.6)
環状肉芽腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
間擦疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
毛孔性角化症	0	0	0	1 (1.8)	1 (0.6)
寝汗	0	0	0	1 (1.8)	1 (0.6)
そう痒症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
紅斑性皮疹	1 (5.0)	0	1 (0.8)	0	1 (0.6)
斑状皮疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脂漏性皮膚炎	1 (5.0)	0	1 (0.8)	0	1 (0.6)
皮膚色素脱失	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚病変	0	0	0	1 (1.8)	1 (0.6)
皮膚浮腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚潰瘍	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮下気腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 20 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
アトピー性皮膚炎	0	0	0	0	0
多汗症	0	0	0	0	0
神経系障害	3 (15.0)	18 (18.0)	21 (17.5)	30 (53.6)	51 (29.0)
頭痛	0	1 (1.0)	1 (0.8)	28 (50.0)	29 (16.5)
不随意性筋収縮	0	4 (4.0)	4 (3.3)	0	4 (2.3)
眼振	0	3 (3.0)	3 (2.5)	0	3 (1.7)
よだれ	0	2 (2.0)	2 (1.7)	0	2 (1.1)
感覚鈍麻	0	0	0	2 (3.6)	2 (1.1)
筋緊張低下	2 (10.0)	0	2 (1.7)	0	2 (1.1)
痙攣発作	0	2 (2.0)	2 (1.7)	0	2 (1.1)
失神	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
失声症	0	0	0	1 (1.8)	1 (0.6)
脳損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脳梗塞	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脳脊髄液漏	0	1 (1.0)	1 (0.8)	0	1 (0.6)
間代	0	1 (1.0)	1 (0.8)	0	1 (0.6)
味覚異常	0	0	0	1 (1.8)	1 (0.6)
失読症	0	0	0	1 (1.8)	1 (0.6)
反射亢進	1 (5.0)	0	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 21 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
低酸素性虚血性脳症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
言語障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
嗜眠	0	1 (1.0)	1 (0.8)	0	1 (0.6)
片頭痛	0	0	0	1 (1.8)	1 (0.6)
錯感覚	0	0	0	1 (1.8)	1 (0.6)
傾眠	0	1 (1.0)	1 (0.8)	0	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)
失神寸前の状態	0	0	0	0	0
臨床検査	3 (15.0)	28 (28.0)	31 (25.8)	8 (14.3)	39 (22.2)
酸素飽和度低下	1 (5.0)	12 (12.0)	13 (10.8)	0	13 (7.4)
体重減少	0	6 (6.0)	6 (5.0)	3 (5.4)	9 (5.1)
体温上昇	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
心拍数増加	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ヒトライノウイルス検査陽性	0	3 (3.0)	3 (2.5)	0	3 (1.7)
好中球数増加	0	3 (3.0)	3 (2.5)	0	3 (1.7)
白血球数増加	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
アラニンアミノトランスフェラーゼ増加	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
血中カリウム減少	0	2 (2.0)	2 (1.7)	0	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 22 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Ｃ－反応性蛋白増加	0	2 (2.0)	2 (1.7)	0	2 (1.1)
医学的観察	0	2 (2.0)	2 (1.7)	0	2 (1.1)
モラクセラ検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
シュードモナス検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ブドウ球菌検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
血中アルカリホスファターゼ増加	1 (5.0)	0	1 (0.8)	0	1 (0.6)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)
血中クロール減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中鉄減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中テストステロン減少	0	0	0	1 (1.8)	1 (0.6)
体温低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
骨密度減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸音異常	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ＣＳＦ白血球数増加	0	0	0	1 (1.8)	1 (0.6)
心電図ＳＴ－Ｔ部分異常	0	1 (1.0)	1 (0.8)	0	1 (0.6)
好酸球数増加	1 (5.0)	0	1 (0.8)	0	1 (0.6)
心拍数減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心拍数不整	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 23 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
炎症マーカー上昇	0	1 (1.0)	1 (0.8)	0	1 (0.6)
A型インフルエンザウイルス検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肝機能検査異常	0	1 (1.0)	1 (0.8)	0	1 (0.6)
リンパ球数増加	1 (5.0)	0	1 (0.8)	0	1 (0.6)
好中球百分率増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
整形外科検査	0	1 (1.0)	1 (0.8)	0	1 (0.6)
セラチア検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
レンサ球菌検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)
尿量減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ビタミンA減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
喀痰培養陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンD減少	0	0	0	0	0
心臓障害	2 (10.0)	24 (24.0)	26 (21.7)	3 (5.4)	29 (16.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 24 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
頻脈	2 (10.0)	9 (9.0)	11 (9.2)	1 (1.8)	12 (6.8)
徐脈	0	7 (7.0)	7 (5.8)	0	7 (4.0)
心肺停止	0	6 (6.0)	6 (5.0)	0	6 (3.4)
心停止	0	3 (3.0)	3 (2.5)	0	3 (1.7)
チアノーゼ	0	3 (3.0)	3 (2.5)	0	3 (1.7)
左室肥大	0	2 (2.0)	2 (1.7)	0	2 (1.1)
動悸	0	0	0	2 (3.6)	2 (1.1)
心室性頻脈	0	2 (2.0)	2 (1.7)	0	2 (1.1)
心筋症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
洞性頻脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
上室性頻脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
代謝および栄養障害	4 (20.0)	19 (19.0)	23 (19.2)	5 (8.9)	28 (15.9)
体重増加不良	1 (5.0)	6 (6.0)	7 (5.8)	0	7 (4.0)
成長障害	2 (10.0)	4 (4.0)	6 (5.0)	0	6 (3.4)
脱水	2 (10.0)	1 (1.0)	3 (2.5)	2 (3.6)	5 (2.8)
乳児および小児期早期の哺育障害	0	3 (3.0)	3 (2.5)	0	3 (1.7)
栄養補給不耐性	0	3 (3.0)	3 (2.5)	0	3 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 25 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
低ナトリウム血症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
過小食	0	2 (2.0)	2 (1.7)	0	2 (1.1)
食欲減退	0	0	0	1 (1.8)	1 (0.6)
食欲亢進	0	0	0	1 (1.8)	1 (0.6)
鉄欠乏	0	1 (1.0)	1 (0.8)	0	1 (0.6)
代謝性アルカローシス	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ビタミンD欠乏	0	0	0	1 (1.8)	1 (0.6)
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
免疫系障害	2 (10.0)	13 (13.0)	15 (12.5)	7 (12.5)	22 (12.5)
季節性アレルギー	1 (5.0)	6 (6.0)	7 (5.8)	3 (5.4)	10 (5.7)
薬物過敏症	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
過敏症	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.8)
食物アレルギー	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
精神障害	0	12 (12.0)	12 (10.0)	4 (7.1)	16 (9.1)
不安	0	5 (5.0)	5 (4.2)	0	5 (2.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 26 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
激越	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
易刺激性	0	3 (3.0)	3 (2.5)	0	3 (1.7)
注意欠陥多動性障害	0	0	0	1 (1.8)	1 (0.6)
息こらえ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
不快気分	0	0	0	1 (1.8)	1 (0.6)
不眠症	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.8)	0	1 (0.6)
睡眠時随伴症	0	0	0	1 (1.8)	1 (0.6)
落ち着きのなさ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
睡眠障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
チック	0	0	0	1 (1.8)	1 (0.6)
心因性嘔吐	0	0	0	1 (1.8)	1 (0.6)
血管障害	2 (10.0)	8 (8.0)	10 (8.3)	1 (1.8)	11 (6.3)
高血圧	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
蒼白	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
毛細血管脆弱	0	1 (1.0)	1 (0.8)	0	1 (0.6)
本態性高血圧症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低血圧	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 27 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ショック	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血栓症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血管炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
充血	0	0	0	0	0
血液およびリンパ系障害	2 (10.0)	6 (6.0)	8 (6.7)	1 (1.8)	9 (5.1)
貧血	0	3 (3.0)	3 (2.5)	0	3 (1.7)
好中球減少症	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
好酸球増加症	1 (5.0)	0	1 (0.8)	0	1 (0.6)
リンパ節症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血小板増加症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
骨髄障害	0	0	0	0	0
白血球増加症	0	0	0	0	0
眼障害	1 (5.0)	6 (6.0)	7 (5.8)	2 (3.6)	9 (5.1)
斜視	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
乱視	0	1 (1.0)	1 (0.8)	0	1 (0.6)
霰粒腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
後天性涙道狭窄	1 (5.0)	0	1 (0.8)	0	1 (0.6)
眼乾燥	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 28 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
眼運動障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.8)	0	1 (0.6)
遠視	0	0	0	1 (1.8)	1 (0.6)
近視	0	1 (1.0)	1 (0.8)	0	1 (0.6)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0
先天性、家族性および遺伝性障害	0	7 (7.0)	7 (5.8)	0	7 (4.0)
斜頭症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
斜指症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
先天性横隔膜ヘルニア	0	1 (1.0)	1 (0.8)	0	1 (0.6)
発育性股関節形成不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
貧血母斑	0	1 (1.0)	1 (0.8)	0	1 (0.6)
鳩胸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
停留精巣	0	0	0	0	0
包茎	0	0	0	0	0
耳および迷路障害	0	3 (3.0)	3 (2.5)	3 (5.4)	6 (3.4)
耳痛	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 29 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
耳の障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
耳垢分泌過多	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乗物酔い	0	0	0	1 (1.8)	1 (0.6)
鼓膜穿孔	0	0	0	1 (1.8)	1 (0.6)
耳出血	0	0	0	0	0
腎および尿路障害	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.8)
排尿困難	0	0	0	1 (1.8)	1 (0.6)
水腎症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.8)	0	1 (0.6)
膀胱尿管逆流	0	0	0	1 (1.8)	1 (0.6)
糖尿	0	0	0	0	0
生殖系および乳房障害	1 (5.0)	4 (4.0)	5 (4.2)	0	5 (2.8)
後天性包茎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
亀頭包皮炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
卵巣嚢胞	0	1 (1.0)	1 (0.8)	0	1 (0.6)
陰茎障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in subjects with SMA treated with ISIS 396443
Page 30 of 30

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
外陰腟発疹	1 (5.0)	0	1 (0.8)	0	1 (0.6)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
アクロコルドン	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血管の良性新生物	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脂漏性角化症	1 (5.0)	0	1 (0.8)	0	1 (0.6)
皮膚乳頭腫	0	0	0	1 (1.8)	1 (0.6)
肝胆道系障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肝腫大	0	1 (1.0)	1 (0.8)	0	1 (0.6)
妊娠、産褥および周産期の状態	1 (5.0)	0	1 (0.8)	0	1 (0.6)
臍肉芽腫	1 (5.0)	0	1 (0.8)	0	1 (0.6)
外科および内科処置	0	1 (1.0)	1 (0.8)	0	1 (0.6)
機械的換気	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 128　Frequency of Adverse Events in Subjects With SMA Treated With ISIS 396443

Frequency of Adverse Events in Subjects With SMA Treated With ISIS 396443
Page 1 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20	100	120	56	176
Number of events	141 (100.0)	1627 (100.0)	1768 (100.0)	682 (100.0)	2450 (100.0)
感染症および寄生虫症	47 (33.3)	444 (27.3)	491 (27.8)	190 (27.9)	681 (27.8)
上気道感染	13 (9.2)	63 (3.9)	76 (4.3)	53 (7.8)	129 (5.3)
鼻咽頭炎	6 (4.3)	34 (2.1)	40 (2.3)	23 (3.4)	63 (2.6)
肺炎	2 (1.4)	50 (3.1)	52 (2.9)	10 (1.5)	62 (2.5)
気道感染	0	33 (2.0)	33 (1.9)	1 (0.1)	34 (1.4)
ウイルス感染	0	15 (0.9)	15 (0.8)	11 (1.6)	26 (1.1)
中耳炎	5 (3.5)	11 (0.7)	16 (0.9)	6 (0.9)	22 (0.9)
ライノウイルス感染	2 (1.4)	20 (1.2)	22 (1.2)	0	22 (0.9)
ウイルス性上気道感染	0	17 (1.0)	17 (1.0)	5 (0.7)	22 (0.9)
尿路感染	3 (2.1)	10 (0.6)	13 (0.7)	6 (0.9)	19 (0.8)
耳感染	0	10 (0.6)	10 (0.6)	5 (0.7)	15 (0.6)
細気管支炎	1 (0.7)	13 (0.8)	14 (0.8)	0	14 (0.6)
ウイルス性肺炎	1 (0.7)	10 (0.6)	11 (0.6)	3 (0.4)	14 (0.6)
レンサ球菌性咽頭炎	1 (0.7)	1 (<0.1)	2 (0.1)	11 (1.6)	13 (0.5)
インフルエンザ	3 (2.1)	6 (0.4)	9 (0.5)	3 (0.4)	12 (0.5)
ウイルス性胃腸炎	2 (1.4)	1 (<0.1)	3 (0.2)	8 (1.2)	11 (0.4)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 2 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
鼻炎	3 (2.1)	7 (0.4)	10 (0.6)	1 (0.1)	11 (0.4)
結膜炎	0	6 (0.4)	6 (0.3)	4 (0.6)	10 (0.4)
胃腸炎	0	2 (0.1)	2 (0.1)	8 (1.2)	10 (0.4)
下気道感染	0	9 (0.6)	9 (0.5)	1 (0.1)	10 (0.4)
口腔カンジダ症	0	10 (0.6)	10 (0.6)	0	10 (0.4)
気管支炎	1 (0.7)	7 (0.4)	8 (0.5)	0	8 (0.3)
ウイルス性気管支炎	0	8 (0.5)	8 (0.5)	0	8 (0.3)
ウイルス性気道感染	0	7 (0.4)	7 (0.4)	1 (0.1)	8 (0.3)
ＲＳウイルス細気管支炎	0	5 (0.3)	5 (0.3)	1 (0.1)	6 (0.2)
細菌性気管炎	0	4 (0.2)	4 (0.2)	0	4 (0.2)
限局性感染	0	1 (<0.1)	1 (<0.1)	3 (0.4)	4 (0.2)
細菌性肺炎	0	4 (0.2)	4 (0.2)	0	4 (0.2)
皮膚カンジダ	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
ストーマ部膿瘍	0	4 (0.2)	4 (0.2)	0	4 (0.2)
細菌感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
エンテロウイルス感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
皮膚真菌感染	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
手足口病	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
膿痂疹	1 (0.7)	1 (<0.1)	2 (0.1)	1 (0.1)	3 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 3 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ウイルス性下気道感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
パラインフルエンザウイルス感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
モラクセラ菌性肺炎	0	3 (0.2)	3 (0.2)	0	3 (0.1)
シュードモナス感染	0	3 (0.2)	3 (0.2)	0	3 (0.1)
ＲＳウイルス感染	0	0	0	3 (0.4)	3 (0.1)
副鼻腔炎	0	0	0	3 (0.4)	3 (0.1)
アデノウイルス感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
カンジダ性おむつ皮疹	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
蜂巣炎	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
細菌性結膜炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
真菌感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
ウイルス性消化管感染	0	0	0	2 (0.3)	2 (<0.1)
肺感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
メタニューモウイルス感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
モラクセラ感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
口腔真菌感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
急性中耳炎	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
シュードモナス菌性肺炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 4 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ＲＳウイルス肺炎	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
敗血症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
ブドウ球菌皮膚感染	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
アデノウイルス性上気道感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
細菌性疾患キャリアー	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
コロナウイルス感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ブドウ球菌性耳感染	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
感染性湿疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
蟯虫症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
腸球菌感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
伝染性紅斑	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
大腸菌感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
眼感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ブドウ球菌性眼感染	0	0	0	1 (0.1)	1 (<0.1)
ウイルス性眼感染	0	0	0	1 (0.1)	1 (<0.1)
ウイルス性胃炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ロタウイルス胃腸炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ヘモフィルス感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
伝染性軟属腫	0	0	0	1 (0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 5 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
単核細胞症症候群	0	0	0	1 (0.1)	1 (<0.1)
粘膜皮膚カンジダ症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
院内感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
口腔ヘルペス	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
咽頭炎	0	0	0	1 (0.1)	1 (<0.1)
インフルエンザ性肺炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
パラインフルエンザウイルス性肺炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肺炎球菌性肺炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
腎盂腎炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
細菌性気道感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ばら疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚細菌感染	0	0	0	1 (0.1)	1 (<0.1)
皮膚感染	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
ブドウ球菌性菌血症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ブドウ球菌感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ブドウ球菌性敗血症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ストーマ部感染	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
レンサ球菌感染	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
扁桃炎	0	0	0	1 (0.1)	1 (<0.1)
気管炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 6 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
腟感染	0	0	0	1 (0.1)	1 (<0.1)
ウイルス性扁桃炎	0	0	0	1 (0.1)	1 (<0.1)
外陰腟真菌感染	0	0	0	1 (0.1)	1 (<0.1)
菌血症	0	0	0	0	0
カンジダ感染	0	0	0	0	0
カンジダ性敗血症	0	0	0	0	0
麦粒腫	0	0	0	0	0
セラチア感染	0	0	0	0	0
全身性感染	0	0	0	0	0
ウイルス性発疹	0	0	0	0	0
呼吸器、胸郭および縦隔障害	14 (9.9)	372 (22.9)	386 (21.8)	54 (7.9)	440 (18.0)
無気肺	0	54 (3.3)	54 (3.1)	3 (0.4)	57 (2.3)
呼吸窮迫	2 (1.4)	44 (2.7)	46 (2.6)	0	46 (1.9)
急性呼吸不全	0	39 (2.4)	39 (2.2)	1 (0.1)	40 (1.6)
咳嗽	3 (2.1)	21 (1.3)	24 (1.4)	7 (1.0)	31 (1.3)
呼吸不全	0	29 (1.8)	29 (1.6)	1 (0.1)	30 (1.2)
鼻閉	3 (2.1)	23 (1.4)	26 (1.5)	3 (0.4)	29 (1.2)
低酸素症	0	17 (1.0)	17 (1.0)	3 (0.4)	20 (0.8)
誤嚥性肺炎	0	18 (1.1)	18 (1.0)	0	18 (0.7)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 7 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
鼻漏	3 (2.1)	9 (0.6)	12 (0.7)	6 (0.9)	18 (0.7)
口腔咽頭痛	0	0	0	11 (1.6)	11 (0.4)
気管支分泌物貯留	0	10 (0.6)	10 (0.6)	0	10 (0.4)
呼吸困難	0	9 (0.6)	9 (0.5)	1 (0.1)	10 (0.4)
無呼吸	0	8 (0.5)	8 (0.5)	0	8 (0.3)
誤嚥	0	8 (0.5)	8 (0.5)	0	8 (0.3)
上気道分泌増加	0	8 (0.5)	8 (0.5)	0	8 (0.3)
呼吸停止	0	8 (0.5)	8 (0.5)	0	8 (0.3)
副鼻腔うっ血	0	6 (0.4)	6 (0.3)	2 (0.3)	8 (0.3)
上気道うっ血	1 (0.7)	7 (0.4)	8 (0.5)	0	8 (0.3)
慢性呼吸不全	0	7 (0.4)	7 (0.4)	0	7 (0.3)
鼻出血	0	0	0	6 (0.9)	6 (0.2)
喘鳴	0	4 (0.2)	4 (0.2)	2 (0.3)	6 (0.2)
気胸	0	4 (0.2)	4 (0.2)	0	4 (0.2)
息詰まり	1 (0.7)	2 (0.1)	3 (0.2)	0	3 (0.1)
低換気	0	3 (0.2)	3 (0.2)	0	3 (0.1)
肺うっ血	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
呼吸障害	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)
扁桃肥大	0	0	0	3 (0.4)	3 (0.1)
気管支閉塞	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
肺水腫	0	2 (0.1)	2 (0.1)	0	2 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 8 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
気道うっ血	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
拘束性肺疾患	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
アレルギー性鼻炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
呼吸補助筋の動員	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
急性呼吸窮迫症候群	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
無呼吸発作	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
窒息	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
発声障害	0	0	0	1 (0.1)	1 (<0.1)
高炭酸ガス血症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
減呼吸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気管支分泌増加	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
喉頭肉芽腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肺障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
鼻汁変色	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
閉塞性気道障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
胸水	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気縦隔症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肺臓炎	0	0	0	1 (0.1)	1 (<0.1)
湿性咳嗽	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
呼吸性アシドーシス	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
呼吸性アルカローシス	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 9 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
低音性連続性ラ音	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
睡眠時無呼吸症候群	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
変色痰	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
頻呼吸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気管障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
乳幼児突発性危急事態	0	0	0	0	0
カタル	0	0	0	0	0
上気道の炎症	0	0	0	0	0
胃腸障害	12 (8.5)	189 (11.6)	201 (11.4)	60 (8.8)	261 (10.7)
便秘	2 (1.4)	41 (2.5)	43 (2.4)	11 (1.6)	54 (2.2)
嘔吐	0	36 (2.2)	36 (2.0)	17 (2.5)	53 (2.2)
下痢	1 (0.7)	28 (1.7)	29 (1.6)	3 (0.4)	32 (1.3)
胃食道逆流性疾患	2 (1.4)	17 (1.0)	19 (1.1)	1 (0.1)	20 (0.8)
生歯	1 (0.7)	18 (1.1)	19 (1.1)	0	19 (0.8)
嚥下障害	1 (0.7)	12 (0.7)	13 (0.7)	0	13 (0.5)
悪心	0	0	0	11 (1.6)	11 (0.4)
放屁	2 (1.4)	6 (0.4)	8 (0.5)	1 (0.1)	9 (0.4)
流涎過多	0	8 (0.5)	8 (0.5)	0	8 (0.3)
腹部膨満	2 (1.4)	4 (0.2)	6 (0.3)	0	6 (0.2)
腹部不快感	1 (0.7)	2 (0.1)	3 (0.2)	1 (0.1)	4 (0.2)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 10 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
アフタ性潰瘍	0	1 (<0.1)	1 (<0.1)	3 (0.4)	4 (0.2)
胃炎	0	4 (0.2)	4 (0.2)	0	4 (0.2)
腹痛	0	1 (<0.1)	1 (<0.1)	2 (0.3)	3 (0.1)
上腹部痛	0	0	0	2 (0.3)	2 (<0.1)
血便排泄	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
口腔内痛	0	0	0	2 (0.3)	2 (<0.1)
腹部症状	0	0	0	1 (0.1)	1 (<0.1)
口唇のひび割れ	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
食中毒	0	0	0	1 (0.1)	1 (<0.1)
排便回数増加	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
胃出血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
胃腸障害	0	0	0	1 (0.1)	1 (<0.1)
消化管運動低下	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
吐血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
口の感覚鈍麻	0	0	0	1 (0.1)	1 (<0.1)
胃排出不全	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
乳児仙痛	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
乳児吐出	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
口唇痛	0	0	0	1 (0.1)	1 (<0.1)
口内炎	0	0	0	1 (0.1)	1 (<0.1)
上部消化管出血	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

vNOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 11 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血性下痢	0	0	0	0	0
小腸炎	0	0	0	0	0
心窩部不快感	0	0	0	0	0
胃腸出血	0	0	0	0	0
消化管運動障害	0	0	0	0	0
消化管刺激症状	0	0	0	0	0
レッチング	0	0	0	0	0
舌萎縮	0	0	0	0	0
一般・全身障害および投与部位の状態	16 (11.3)	183 (11.2)	199 (11.3)	55 (8.1)	254 (10.4)
発熱	14 (9.9)	151 (9.3)	165 (9.3)	23 (3.4)	188 (7.7)
穿刺部位疼痛	0	0	0	12 (1.8)	12 (0.5)
疼痛	0	5 (0.3)	5 (0.3)	3 (0.4)	8 (0.3)
医療機器閉塞	0	4 (0.2)	4 (0.2)	0	4 (0.2)
低体温	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
末梢性浮腫	0	4 (0.2)	4 (0.2)	0	4 (0.2)
疲労	0	0	0	3 (0.4)	3 (0.1)
不快感	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
末梢腫脹	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
血管穿刺部位内出血	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 12 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
適用部位紅斑	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
カテーテル留置部位出血	0	0	0	1 (0.1)	1 (<0.1)
カテーテル留置部位炎症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
カテーテル留置部位疼痛	0	0	0	1 (0.1)	1 (<0.1)
カテーテル留置部位関連反応	0	0	0	1 (0.1)	1 (<0.1)
胸部不快感	0	0	0	1 (0.1)	1 (<0.1)
悪寒	0	0	0	1 (0.1)	1 (<0.1)
泣き	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
死亡	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
医療機器リーク	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
薬物不耐性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
冷感	0	0	0	1 (0.1)	1 (<0.1)
全身健康状態低下	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
重力性浮腫	0	0	0	1 (0.1)	1 (<0.1)
注入部位内出血	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
注射部位出血	0	0	0	1 (0.1)	1 (<0.1)
注射部位疼痛	0	0	0	1 (0.1)	1 (<0.1)
ワクチン接種後の易刺激性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
倦怠感	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
医療機器合併症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 13 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
小結節	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
浮腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
穿刺部位反応	0	0	0	1 (0.1)	1 (<0.1)
外科手術不成功	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
腫脹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
適用部位発疹	0	0	0	0	0
医療機器機能不良	0	0	0	0	0
注入部位血管外漏出	0	0	0	0	0
注射部位血腫	0	0	0	0	0
血管穿刺部位反応	0	0	0	0	0
筋骨格系および結合組織障害	6 (4.3)	71 (4.4)	77 (4.4)	101 (14.8)	178 (7.3)
背部痛	0	1 (<0.1)	1 (<0.1)	45 (6.6)	46 (1.9)
関節拘縮	1 (0.7)	33 (2.0)	34 (1.9)	11 (1.6)	45 (1.8)
側弯症	0	13 (0.8)	13 (0.7)	17 (2.5)	30 (1.2)
四肢痛	0	3 (0.2)	3 (0.2)	7 (1.0)	10 (0.4)
関節痛	0	0	0	8 (1.2)	8 (0.3)
脊柱後弯症	0	5 (0.3)	5 (0.3)	0	5 (0.2)
胸郭変形	0	4 (0.2)	4 (0.2)	0	4 (0.2)
筋肉痛	0	0	0	4 (0.6)	4 (0.2)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 14 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
頚部痛	0	0	0	3 (0.4)	3 (0.1)
頭位性斜頭症	1 (0.7)	2 (0.1)	3 (0.2)	0	3 (0.1)
斜頚	1 (0.7)	2 (0.1)	3 (0.2)	0	3 (0.1)
後側弯症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
脊柱前弯症	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
筋緊張	0	0	0	2 (0.3)	2 (<0.1)
筋力低下	2 (1.4)	0	2 (0.1)	0	2 (<0.1)
骨盤変形	0	0	0	2 (0.3)	2 (<0.1)
泉門閉鎖遅延	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
四肢拘縮	0	0	0	1 (0.1)	1 (<0.1)
手変形	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
関節硬直	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脊柱変形	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
滑膜炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
体重支持困難	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
関節可動域低下	0	0	0	0	0
傷害、中毒および処置合併症	6 (4.3)	48 (3.0)	54 (3.1)	88 (12.9)	142 (5.8)
腰椎穿刺後症候群	0	0	0	33 (4.8)	33 (1.3)
処置による疼痛	0	4 (0.2)	4 (0.2)	10 (1.5)	14 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 15 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
節足動物咬傷	1 (0.7)	8 (0.5)	9 (0.5)	4 (0.6)	13 (0.5)
裂傷	0	0	0	7 (1.0)	7 (0.3)
大腿骨骨折	0	3 (0.2)	3 (0.2)	3 (0.4)	6 (0.2)
術後激越	0	1 (<0.1)	1 (<0.1)	3 (0.4)	4 (0.2)
挫傷	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
栄養補給チューブ合併症	0	4 (0.2)	4 (0.2)	0	4 (0.2)
関節脱臼	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)
四肢損傷	0	0	0	4 (0.6)	4 (0.2)
関節損傷	0	0	0	3 (0.4)	3 (0.1)
皮膚擦過傷	0	3 (0.2)	3 (0.2)	0	3 (0.1)
ストーマ部紅斑	0	3 (0.2)	3 (0.2)	0	3 (0.1)
サンバーン	0	1 (<0.1)	1 (<0.1)	2 (0.3)	3 (0.1)
耳擦過傷	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
転倒	1 (0.7)	0	1 (<0.1)	1 (0.1)	2 (<0.1)
処置後腫脹	1 (0.7)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
処置による悪心	0	0	0	2 (0.3)	2 (<0.1)
熱傷	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
隆起骨折	0	0	0	2 (0.3)	2 (<0.1)
節足動物刺傷	0	0	0	1 (0.1)	1 (<0.1)
麻酔からの覚醒遅延	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ダンピング症候群	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 16 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
擦過傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
伝染病曝露	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
頭部損傷	0	0	0	1 (0.1)	1 (<0.1)
靭帯捻挫	0	0	0	1 (0.1)	1 (<0.1)
口唇損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
下肢骨折	0	0	0	1 (0.1)	1 (<0.1)
半月板損傷	0	0	0	1 (0.1)	1 (<0.1)
肉離れ	0	0	0	1 (0.1)	1 (<0.1)
外傷性気胸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
処置後合併症	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
処置後不快感	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
術後イレウス	0	0	0	1 (0.1)	1 (<0.1)
処置合併症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
処置による頭痛	0	0	0	1 (0.1)	1 (<0.1)
処置部位反応	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
軟部組織損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ストーマ合併症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ストーマ部刺激感	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
硬膜下血腫	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
脛骨骨折	0	0	0	1 (0.1)	1 (<0.1)
歯牙損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 17 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ワクチン接種合併症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
気管内挿管合併症	0	0	0	0	0
切開部位紅斑	0	0	0	0	0
処置後挫傷	0	0	0	0	0
処置後出血	0	0	0	0	0
ストーマ部出血	0	0	0	0	0
ストーマ部炎症	0	0	0	0	0
気管出血	0	0	0	0	0
気管損傷	0	0	0	0	0
気管閉塞	0	0	0	0	0
皮膚および皮下組織障害	11 (7.8)	75 (4.6)	86 (4.9)	18 (2.6)	104 (4.2)
発疹	1 (0.7)	22 (1.4)	23 (1.3)	1 (0.1)	24 (1.0)
おむつ皮膚炎	2 (1.4)	11 (0.7)	13 (0.7)	1 (0.1)	14 (0.6)
皮膚炎	2 (1.4)	4 (0.2)	6 (0.3)	1 (0.1)	7 (0.3)
接触性皮膚炎	0	4 (0.2)	4 (0.2)	3 (0.4)	7 (0.3)
湿疹	0	4 (0.2)	4 (0.2)	2 (0.3)	6 (0.2)
斑状出血	0	3 (0.2)	3 (0.2)	0	3 (0.1)
紅斑	1 (0.7)	1 (<0.1)	2 (0.1)	1 (0.1)	3 (0.1)
過剰肉芽組織	0	3 (0.2)	3 (0.2)	0	3 (0.1)
汗疹	0	2 (0.1)	2 (0.1)	1 (0.1)	3 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 18 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
皮膚刺激	0	3 (0.2)	3 (0.2)	0	3 (0.1)
脱毛症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
水疱	0	0	0	2 (0.3)	2 (<0.1)
貨幣状湿疹	2 (1.4)	0	2 (0.1)	0	2 (<0.1)
過角化	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
点状出血	1 (0.7)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
蕁麻疹	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
ざ瘡	0	0	0	1 (0.1)	1 (<0.1)
褥瘡性潰瘍	0	0	0	1 (0.1)	1 (<0.1)
アレルギー性皮膚炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚乾燥	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
環状肉芽腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
間擦疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
毛孔性角化症	0	0	0	1 (0.1)	1 (<0.1)
寝汗	0	0	0	1 (0.1)	1 (<0.1)
そう痒症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
紅斑性皮疹	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
斑状皮疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
丘疹性皮疹	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脂漏性皮膚炎	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
皮膚色素脱失	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 19 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
皮膚障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚病変	0	0	0	1 (0.1)	1 (<0.1)
皮膚浮腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮膚潰瘍	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
皮下気腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
アトピー性皮膚炎	0	0	0	0	0
多汗症	0	0	0	0	0
臨床検査	8 (5.7)	78 (4.8)	86 (4.9)	9 (1.3)	95 (3.9)
酸素飽和度低下	1 (0.7)	18 (1.1)	19 (1.1)	0	19 (0.8)
体重減少	0	6 (0.4)	6 (0.3)	3 (0.4)	9 (0.4)
体温上昇	1 (0.7)	5 (0.3)	6 (0.3)	1 (0.1)	7 (0.3)
Ｃ－反応性蛋白増加	0	5 (0.3)	5 (0.3)	0	5 (0.2)
心拍数増加	0	4 (0.2)	4 (0.2)	1 (0.1)	5 (0.2)
好中球数増加	0	4 (0.2)	4 (0.2)	0	4 (0.2)
ヒトライノウイルス検査陽性	0	3 (0.2)	3 (0.2)	0	3 (0.1)
シュードモナス検査陽性	0	3 (0.2)	3 (0.2)	0	3 (0.1)
白血球数増加	1 (0.7)	2 (0.1)	3 (0.2)	0	3 (0.1)
アラニンアミノトランスフェラーゼ増加	1 (0.7)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (0.7)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
血中カリウム減少	0	2 (0.1)	2 (0.1)	0	2 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 20 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
医学的観察	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
モラクセラ検査陽性	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
ブドウ球菌検査陽性	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
血中アルカリホスファターゼ増加	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
血中重炭酸塩減少	0	0	0	1 (0.1)	1 (<0.1)
血中クロール減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血中鉄減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血中ナトリウム減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血中テストステロン減少	0	0	0	1 (0.1)	1 (<0.1)
体温低下	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
骨密度減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
呼吸音異常	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ＣＳＦ白血球数増加	0	0	0	1 (0.1)	1 (<0.1)
心電図ＳＴ－Ｔ部分異常	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
好酸球数増加	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
心拍数減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
心拍数不整	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
炎症マーカー上昇	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
Ａ型インフルエンザウイルス検査陽性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肝機能検査異常	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 21 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
リンパ球数増加	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
好中球百分率増加	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
整形外科検査	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
セラチア検査陽性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
レンサ球菌検査陽性	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
尿検査異常	0	0	0	1 (0.1)	1 (<0.1)
尿量減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ビタミンA減少	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ヘッドラグ異常	0	0	0	0	0
リンパ節触知	0	0	0	0	0
呼吸数増加	0	0	0	0	0
レスピロウイルス検査陽性	0	0	0	0	0
喀痰培養陽性	0	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0	0
ビタミンD減少	0	0	0	0	0
神経系障害	3 (2.1)	22 (1.4)	25 (1.4)	67 (9.8)	92 (3.8)
頭痛	0	1 (<0.1)	1 (<0.1)	54 (7.9)	55 (2.2)
不随意性筋収縮	0	4 (0.2)	4 (0.2)	0	4 (0.2)
片頭痛	0	0	0	3 (0.4)	3 (0.1)
眼振	0	3 (0.2)	3 (0.2)	0	3 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 22 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
錯感覚	0	0	0	3 (0.4)	3 (0.1)
痙攣発作	0	3 (0.2)	3 (0.2)	0	3 (0.1)
よだれ	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
感覚鈍麻	0	0	0	2 (0.3)	2 (<0.1)
筋緊張低下	2 (1.4)	0	2 (0.1)	0	2 (<0.1)
失神	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
失声症	0	0	0	1 (0.1)	1 (<0.1)
脳損傷	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脳梗塞	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脳脊髄液漏	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
間代	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
味覚異常	0	0	0	1 (0.1)	1 (<0.1)
失読症	0	0	0	1 (0.1)	1 (<0.1)
反射亢進	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
低酸素性虚血性脳症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
言語障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
嗜眠	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
傾眠	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
振戦	0	0	0	1 (0.1)	1 (<0.1)
失神寸前の状態	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 23 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
心臓障害	2 (1.4)	39 (2.4)	41 (2.3)	4 (0.6)	45 (1.8)
頻脈	2 (1.4)	11 (0.7)	13 (0.7)	1 (0.1)	14 (0.6)
徐脈	0	7 (0.4)	7 (0.4)	0	7 (0.3)
心肺停止	0	6 (0.4)	6 (0.3)	0	6 (0.2)
心停止	0	3 (0.2)	3 (0.2)	0	3 (0.1)
チアノーゼ	0	3 (0.2)	3 (0.2)	0	3 (0.1)
動悸	0	0	0	3 (0.4)	3 (0.1)
心室性頻脈	0	3 (0.2)	3 (0.2)	0	3 (0.1)
左室肥大	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
心筋症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
心膜気腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
洞性頻脈	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
上室性頻脈	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
代謝および栄養障害	6 (4.3)	31 (1.9)	37 (2.1)	5 (0.7)	42 (1.7)
体重増加不良	2 (1.4)	9 (0.6)	11 (0.6)	0	11 (0.4)
成長障害	2 (1.4)	4 (0.2)	6 (0.3)	0	6 (0.2)
乳児および小児期早期の哺育障害	0	6 (0.4)	6 (0.3)	0	6 (0.2)
脱水	2 (1.4)	1 (<0.1)	3 (0.2)	2 (0.3)	5 (0.2)
栄養補給不耐性	0	4 (0.2)	4 (0.2)	0	4 (0.2)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 24 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
低ナトリウム血症	0	3 (0.2)	3 (0.2)	0	3 (0.1)
過小食	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
食欲減退	0	0	0	1 (0.1)	1 (<0.1)
食欲亢進	0	0	0	1 (0.1)	1 (<0.1)
鉄欠乏	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
代謝性アルカローシス	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
ビタミンD欠乏	0	0	0	1 (0.1)	1 (<0.1)
食物不耐性	0	0	0	0	0
高血糖	0	0	0	0	0
低血糖	0	0	0	0	0
低カリウム血症	0	0	0	0	0
免疫系障害	2 (1.4)	13 (0.8)	15 (0.8)	10 (1.5)	25 (1.0)
季節性アレルギー	1 (0.7)	6 (0.4)	7 (0.4)	4 (0.6)	11 (0.4)
過敏症	0	2 (0.1)	2 (0.1)	5 (0.7)	7 (0.3)
薬物過敏症	0	4 (0.2)	4 (0.2)	1 (0.1)	5 (0.2)
食物アレルギー	1 (0.7)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
精神障害	0	16 (1.0)	16 (0.9)	8 (1.2)	24 (1.0)
不安	0	5 (0.3)	5 (0.3)	0	5 (0.2)
激越	0	2 (0.1)	2 (0.1)	2 (0.3)	4 (0.2)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 25 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
易刺激性	0	4 (0.2)	4 (0.2)	0	4 (0.2)
睡眠障害	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
注意欠陥多動性障害	0	0	0	1 (0.1)	1 (<0.1)
息こらえ	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
不快気分	0	0	0	1 (0.1)	1 (<0.1)
不眠症	0	0	0	1 (0.1)	1 (<0.1)
気分動揺	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
睡眠時随伴症	0	0	0	1 (0.1)	1 (<0.1)
落ち着きのなさ	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
チック	0	0	0	1 (0.1)	1 (<0.1)
心因性嘔吐	0	0	0	1 (0.1)	1 (<0.1)
血管障害	2 (1.4)	12 (0.7)	14 (0.8)	1 (0.1)	15 (0.6)
血栓症	0	4 (0.2)	4 (0.2)	0	4 (0.2)
高血圧	1 (0.7)	2 (0.1)	3 (0.2)	0	3 (0.1)
蒼白	1 (0.7)	1 (<0.1)	2 (0.1)	0	2 (<0.1)
血管炎	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
毛細血管脆弱	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
本態性高血圧症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
低血圧	0	0	0	1 (0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 26 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ショック	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
充血	0	0	0	0	0
眼障害	1 (0.7)	7 (0.4)	8 (0.5)	2 (0.3)	10 (0.4)
斜視	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
乱視	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
霰粒腫	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
後天性涙道狭窄	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
眼乾燥	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
眼運動障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
眼瞼下垂	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
遠視	0	0	0	1 (0.1)	1 (<0.1)
近視	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
弱視	0	0	0	0	0
流涙増加	0	0	0	0	0
血液およびリンパ系障害	2 (1.4)	6 (0.4)	8 (0.5)	1 (0.1)	9 (0.4)
貧血	0	3 (0.2)	3 (0.2)	0	3 (0.1)
好中球減少症	1 (0.7)	1 (<0.1)	2 (0.1)	1 (0.1)	3 (0.1)
好酸球増加症	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
リンパ節症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 27 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血小板増加症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
骨髄障害	0	0	0	0	0
白血球増加症	0	0	0	0	0
先天性、家族性および遺伝性障害	0	7 (0.4)	7 (0.4)	0	7 (0.3)
斜頭症	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
斜指症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
先天性横隔膜ヘルニア	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
発育性股関節形成不全	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
貧血母斑	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
鳩胸	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
停留精巣	0	0	0	0	0
包茎	0	0	0	0	0
耳および迷路障害	0	3 (0.2)	3 (0.2)	3 (0.4)	6 (0.2)
耳痛	0	1 (<0.1)	1 (<0.1)	1 (0.1)	2 (<0.1)
耳の障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
耳垢分泌過多	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
乗物酔い	0	0	0	1 (0.1)	1 (<0.1)
鼓膜穿孔	0	0	0	1 (0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 28 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
耳出血	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (0.7)	2 (0.1)	3 (0.2)	3 (0.4)	6 (0.2)
皮膚乳頭腫	0	0	0	3 (0.4)	3 (0.1)
アクロコルドン	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
血管の良性新生物	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
脂漏性角化症	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
腎および尿路障害	0	3 (0.2)	3 (0.2)	3 (0.4)	6 (0.2)
尿閉	0	2 (0.1)	2 (0.1)	0	2 (<0.1)
排尿困難	0	0	0	1 (0.1)	1 (<0.1)
水腎症	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
尿失禁	0	0	0	1 (0.1)	1 (<0.1)
膀胱尿管逆流	0	0	0	1 (0.1)	1 (<0.1)
糖尿	0	0	0	0	0
生殖系および乳房障害	1 (0.7)	4 (0.2)	5 (0.3)	0	5 (0.2)
後天性包茎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
亀頭包皮炎	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in subjects with SMA treated with ISIS 396443
Page 29 of 29

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
卵巣嚢胞	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
陰茎障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
外陰腟発疹	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
肝胆道系障害	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
肝腫大	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
妊娠、産褥および周産期の状態	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
臍肉芽腫	1 (0.7)	0	1 (<0.1)	0	1 (<0.1)
外科および内科処置	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)
機械的換気	0	1 (<0.1)	1 (<0.1)	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the all subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 129　Incidence of Adverse Events in Infants Diagnosed With SMA

Incidence of adverse events in infants diagnosed with SMA
Page 1 of 32

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	16 (80.0)	40 (97.6)	77 (96.3)	97 (97.0)	113 (94.2)
感染症および寄生虫症	13 (65.0)	31 (75.6)	65 (81.3)	84 (84.0)	97 (80.8)
上気道感染	8 (40.0)	9 (22.0)	24 (30.0)	36 (36.0)	44 (36.7)
肺炎	2 (10.0)	7 (17.1)	23 (28.8)	30 (30.0)	32 (26.7)
鼻咽頭炎	4 (20.0)	4 (9.8)	15 (18.8)	21 (21.0)	25 (20.8)
ライノウイルス感染	2 (10.0)	6 (14.6)	10 (12.5)	16 (16.0)	18 (15.0)
気道感染	0	2 (4.9)	9 (11.3)	14 (14.0)	14 (11.7)
ウイルス感染	0	3 (7.3)	8 (10.0)	12 (12.0)	12 (10.0)
細気管支炎	1 (5.0)	3 (7.3)	8 (10.0)	11 (11.0)	12 (10.0)
ウイルス性肺炎	1 (5.0)	2 (4.9)	7 (8.8)	10 (10.0)	11 (9.2)
ウイルス性上気道感染	0	7 (17.1)	8 (10.0)	10 (10.0)	10 (8.3)
中耳炎	3 (15.0)	2 (4.9)	3 (3.8)	9 (9.0)	12 (10.0)
口腔カンジダ症	0	3 (7.3)	7 (8.8)	8 (8.0)	8 (6.7)
尿路感染	1 (5.0)	0	7 (8.8)	7 (7.0)	8 (6.7)
気管支炎	1 (5.0)	1 (2.4)	6 (7.5)	6 (6.0)	7 (5.8)
結膜炎	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.0)
耳感染	0	1 (2.4)	5 (6.3)	6 (6.0)	6 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 2 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
インフルエンザ	3 (15.0)	0	5 (6.3)	6 (6.0)	9 (7.5)
ウイルス性気管支炎	0	0	5 (6.3)	5 (5.0)	5 (4.2)
下気道感染	0	2 (4.9)	4 (5.0)	5 (5.0)	5 (4.2)
ＲＳウイルス細気管支炎	0	3 (7.3)	4 (5.0)	5 (5.0)	5 (4.2)
ウイルス性気道感染	0	2 (4.9)	4 (5.0)	5 (5.0)	5 (4.2)
細菌性肺炎	0	3 (7.3)	3 (3.8)	4 (4.0)	4 (3.3)
細菌性気管炎	0	4 (9.8)	1 (1.3)	3 (3.0)	3 (2.5)
ウイルス性下気道感染	0	0	2 (2.5)	3 (3.0)	3 (2.5)
シュードモナス感染	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.5)
鼻炎	2 (10.0)	3 (7.3)	2 (2.5)	3 (3.0)	5 (4.2)
アデノウイルス感染	0	0	2 (2.5)	2 (2.0)	2 (1.7)
細菌感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
カンジダ性おむつ皮疹	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
細菌性結膜炎	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
エンテロウイルス感染	0	0	0	2 (2.0)	2 (1.7)
皮膚真菌感染	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
胃腸炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
手足口病	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 3 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
モラクセラ感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
パラインフルエンザウイルス感染	0	1 (2.4)	0	2 (2.0)	2 (1.7)
モラクセラ菌性肺炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
敗血症	0	0	2 (2.5)	2 (2.0)	2 (1.7)
皮膚カンジダ	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ストーマ部膿瘍	0	0	2 (2.5)	2 (2.0)	2 (1.7)
アデノウイルス性上気道感染	0	0	0	1 (1.0)	1 (0.8)
細菌性疾患キャリアー	0	1 (2.4)	0	1 (1.0)	1 (0.8)
蜂巣炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
コロナウイルス感染	0	2 (4.9)	0	1 (1.0)	1 (0.8)
感染性湿疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
蟯虫症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腸球菌感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
伝染性紅斑	0	0	0	1 (1.0)	1 (0.8)
大腸菌感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
眼感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
真菌感染	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
ウイルス性胃炎	0	0	0	1 (1.0)	1 (0.8)
ロタウイルス胃腸炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ウイルス性胃腸炎	2 (10.0)	2 (4.9)	1 (1.3)	1 (1.0)	3 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 4 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ヘモフィルス感染	0	0	0	1 (1.0)	1 (0.8)
膿痂疹	1 (5.0)	1 (2.4)	1 (1.3)	1 (1.0)	2 (1.7)
限局性感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
粘膜皮膚カンジダ症	0	0	0	1 (1.0)	1 (0.8)
院内感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
口腔真菌感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
口腔ヘルペス	0	0	1 (1.3)	1 (1.0)	1 (0.8)
急性中耳炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
レンサ球菌性咽頭炎	1 (5.0)	0	0	1 (1.0)	2 (1.7)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
パラインフルエンザウイルス性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
肺炎球菌性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
シュードモナス菌性肺炎	0	1 (2.4)	0	1 (1.0)	1 (0.8)
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腎盂腎炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
細菌性気道感染	0	1 (2.4)	0	1 (1.0)	1 (0.8)
ばら疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ブドウ球菌性菌血症	0	0	0	1 (1.0)	1 (0.8)
ブドウ球菌感染	0	2 (4.9)	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 5 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ブドウ球菌皮膚感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ部感染	0	3 (7.3)	1 (1.3)	1 (1.0)	1 (0.8)
気管炎	0	1 (2.4)	0	1 (1.0)	1 (0.8)
菌血症	0	1 (2.4)	0	0	0
カンジダ感染	0	3 (7.3)	0	0	0
カンジダ性敗血症	0	1 (2.4)	0	0	0
ブドウ球菌性耳感染	1 (5.0)	0	0	0	1 (0.8)
ウイルス性耳感染	0	0	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0
消化管感染	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0
麦粒腫	0	1 (2.4)	0	0	0
シラミ寄生	0	0	0	0	0
伝染性軟属腫	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0
外耳炎	0	0	0	0	0
咽頭炎	0	0	0	0	0
咽頭扁桃炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 6 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ＲＳウイルス感染	0	0	0	0	0
猩紅熱	0	0	0	0	0
セラチア感染	0	1 (2.4)	0	0	0
副鼻腔炎	0	1 (2.4)	0	0	0
皮膚細菌感染	0	0	0	0	0
皮膚感染	1 (5.0)	1 (2.4)	0	0	1 (0.8)
ストーマ部蜂巣炎	0	0	0	0	0
レンサ球菌感染	1 (5.0)	0	0	0	1 (0.8)
全身性感染	0	1 (2.4)	0	0	0
扁桃炎	0	0	0	0	0
歯膿瘍	0	0	0	0	0
腟感染	0	0	0	0	0
ウイルス性発疹	0	1 (2.4)	0	0	0
ウイルス性扁桃炎	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0
呼吸器、胸郭および縦隔障害	6 (30.0)	36 (87.8)	61 (76.3)	79 (79.0)	85 (70.8)
呼吸窮迫	1 (5.0)	12 (29.3)	21 (26.3)	28 (28.0)	29 (24.2)
呼吸不全	0	16 (39.0)	20 (25.0)	26 (26.0)	26 (21.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 7 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
無気肺	0	12 (29.3)	18 (22.5)	23 (23.0)	23 (19.2)
急性呼吸不全	0	10 (24.4)	11 (13.8)	15 (15.0)	15 (12.5)
咳嗽	3 (15.0)	8 (19.5)	9 (11.3)	15 (15.0)	18 (15.0)
鼻閉	3 (15.0)	5 (12.2)	8 (10.0)	15 (15.0)	18 (15.0)
誤嚥性肺炎	0	7 (17.1)	9 (11.3)	12 (12.0)	12 (10.0)
低酸素症	0	2 (4.9)	7 (8.8)	11 (11.0)	11 (9.2)
呼吸困難	0	6 (14.6)	7 (8.8)	9 (9.0)	9 (7.5)
鼻漏	3 (15.0)	3 (7.3)	6 (7.5)	8 (8.0)	11 (9.2)
無呼吸	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (5.8)
誤嚥	0	3 (7.3)	5 (6.3)	7 (7.0)	7 (5.8)
気管支分泌物貯留	0	7 (17.1)	4 (5.0)	7 (7.0)	7 (5.8)
上気道うっ血	1 (5.0)	1 (2.4)	6 (7.5)	7 (7.0)	8 (6.7)
慢性呼吸不全	0	0	2 (2.5)	6 (6.0)	6 (5.0)
呼吸停止	0	4 (9.8)	5 (6.3)	6 (6.0)	6 (5.0)
上気道分泌増加	0	1 (2.4)	1 (1.3)	5 (5.0)	5 (4.2)
副鼻腔うっ血	0	0	3 (3.8)	4 (4.0)	4 (3.3)
喘鳴	0	0	2 (2.5)	4 (4.0)	4 (3.3)
低換気	0	0	2 (2.5)	3 (3.0)	3 (2.5)
気胸	0	0	1 (1.3)	3 (3.0)	3 (2.5)
息詰まり	1 (5.0)	1 (2.4)	1 (1.3)	2 (2.0)	3 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 8 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
肺うっ血	0	0	0	2 (2.0)	2 (1.7)
肺水腫	0	0	0	2 (2.0)	2 (1.7)
呼吸障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
気道うっ血	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
アレルギー性鼻炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
呼吸補助筋の動員	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
急性呼吸窮迫症候群	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
無呼吸発作	0	0	0	1 (1.0)	1 (0.8)
窒息	0	0	0	1 (1.0)	1 (0.8)
気管支閉塞	0	0	1 (1.3)	1 (1.0)	1 (0.8)
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
減呼吸	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気管支分泌増加	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
喉頭肉芽腫	0	0	0	1 (1.0)	1 (0.8)
肺障害	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
鼻汁変色	0	0	0	1 (1.0)	1 (0.8)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
胸水	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気縦隔症	0	0	0	1 (1.0)	1 (0.8)
湿性咳嗽	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 9 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
呼吸性アルカローシス	0	0	1 (1.3)	1 (1.0)	1 (0.8)
拘束性肺疾患	0	0	0	1 (1.0)	1 (0.8)
低音性連続性ラ音	0	0	0	1 (1.0)	1 (0.8)
睡眠時無呼吸症候群	0	4 (9.8)	0	1 (1.0)	1 (0.8)
変色痰	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
頻呼吸	0	2 (4.9)	0	1 (1.0)	1 (0.8)
気管障害	0	0	0	1 (1.0)	1 (0.8)
アデノイド肥大	0	0	0	0	0
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
カタル	0	1 (2.4)	0	0	0
発声障害	0	0	0	0	0
鼻出血	0	0	0	0	0
口腔咽頭痛	0	1 (2.4)	0	0	0
肺臓炎	0	0	0	0	0
呼吸性アシドーシス	1 (5.0)	0	0	0	1 (0.8)
扁桃肥大	0	0	0	0	0
上気道の炎症	0	2 (4.9)	0	0	0
胃腸障害	8 (40.0)	26 (63.4)	53 (66.3)	71 (71.0)	79 (65.8)
便秘	2 (10.0)	9 (22.0)	28 (35.0)	37 (37.0)	39 (32.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 10 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
嘔吐	0	8 (19.5)	14 (17.5)	22 (22.0)	22 (18.3)
生歯	1 (5.0)	3 (7.3)	14 (17.5)	18 (18.0)	19 (15.8)
下痢	1 (5.0)	7 (17.1)	11 (13.8)	16 (16.0)	17 (14.2)
胃食道逆流性疾患	2 (10.0)	8 (19.5)	10 (12.5)	16 (16.0)	18 (15.0)
嚥下障害	1 (5.0)	9 (22.0)	9 (11.3)	9 (9.0)	10 (8.3)
流涎過多	0	2 (4.9)	6 (7.5)	8 (8.0)	8 (6.7)
放屁	2 (10.0)	1 (2.4)	4 (5.0)	6 (6.0)	8 (6.7)
腹部膨満	2 (10.0)	0	1 (1.3)	4 (4.0)	6 (5.0)
胃炎	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.3)
腹部不快感	1 (5.0)	0	2 (2.5)	2 (2.0)	3 (2.5)
血便排泄	0	0	2 (2.5)	2 (2.0)	2 (1.7)
腹痛	0	0	0	1 (1.0)	1 (0.8)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.8)
口唇のひび割れ	0	0	0	1 (1.0)	1 (0.8)
排便回数増加	0	0	0	1 (1.0)	1 (0.8)
胃出血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
消化管運動低下	0	0	0	1 (1.0)	1 (0.8)
吐血	0	0	0	1 (1.0)	1 (0.8)
胃排出不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
乳児仙痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 11 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
乳児吐出	0	0	1 (1.3)	1 (1.0)	1 (0.8)
上部消化管出血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
上腹部痛	0	2 (4.9)	0	0	0
腹部症状	0	0	0	0	0
齲歯	0	0	0	0	0
血性下痢	0	1 (2.4)	0	0	0
小腸炎	0	1 (2.4)	0	0	0
心窩部不快感	0	1 (2.4)	0	0	0
便失禁	0	0	0	0	0
食中毒	0	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	1 (2.4)	0	0	0
消化管運動障害	0	1 (2.4)	0	0	0
消化管刺激症状	0	1 (2.4)	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0
口腔内痛	0	0	0	0	0
レッチング	0	1 (2.4)	0	0	0
口内炎	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 12 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
舌萎縮	0	1 (2.4)	0	0	0
歯の脱落	0	0	0	0	0
歯痛	0	0	0	0	0
一般・全身障害および投与部位の状態	6 (30.0)	28 (68.3)	51 (63.8)	65 (65.0)	71 (59.2)
発熱	5 (25.0)	24 (58.5)	45 (56.3)	59 (59.0)	64 (53.3)
疼痛	0	2 (4.9)	1 (1.3)	5 (5.0)	5 (4.2)
医療機器閉塞	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
不快感	0	0	0	2 (2.0)	2 (1.7)
末梢性浮腫	0	0	0	2 (2.0)	2 (1.7)
カテーテル留置部位炎症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.8)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
医療機器リーク	0	0	0	1 (1.0)	1 (0.8)
薬物不耐性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
全身健康状態低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低体温	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ワクチン接種後の易刺激性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
倦怠感	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 13 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
医療機器合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
小結節	0	0	1 (1.3)	1 (1.0)	1 (0.8)
浮腫	0	3 (7.3)	0	1 (1.0)	1 (0.8)
末梢腫脹	0	0	0	1 (1.0)	1 (0.8)
外科手術不成功	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腫脹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管穿刺部位内出血	0	2 (4.9)	0	1 (1.0)	1 (0.8)
適用部位紅斑	1 (5.0)	0	0	0	1 (0.8)
適用部位発疹	0	1 (2.4)	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
胸痛	0	0	0	0	0
悪寒	0	0	0	0	0
医療機器機能不良	0	1 (2.4)	0	0	0
疲労	0	1 (2.4)	0	0	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
炎症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 14 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
注入部位内出血	1 (5.0)	1 (2.4)	0	0	1 (0.8)
注入部位血管外漏出	0	1 (2.4)	0	0	0
注射部位血腫	0	1 (2.4)	0	0	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
圧痛	0	0	0	0	0
血管穿刺部位反応	0	1 (2.4)	0	0	0
皮膚および皮下組織障害	9 (45.0)	15 (36.6)	23 (28.8)	37 (37.0)	46 (38.3)
発疹	1 (5.0)	4 (9.8)	9 (11.3)	14 (14.0)	15 (12.5)
おむつ皮膚炎	2 (10.0)	4 (9.8)	6 (7.5)	10 (10.0)	12 (10.0)
湿疹	0	2 (4.9)	1 (1.3)	4 (4.0)	4 (3.3)
接触性皮膚炎	0	3 (7.3)	2 (2.5)	3 (3.0)	3 (2.5)
斑状出血	0	0	2 (2.5)	3 (3.0)	3 (2.5)
過剰肉芽組織	0	0	0	3 (3.0)	3 (2.5)
皮膚刺激	0	0	0	3 (3.0)	3 (2.5)
皮膚炎	2 (10.0)	0	1 (1.3)	2 (2.0)	4 (3.3)
過角化	0	0	2 (2.5)	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 15 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
汗疹	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脱毛症	0	0	0	1 (1.0)	1 (0.8)
アレルギー性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
皮膚乾燥	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
紅斑	1 (5.0)	3 (7.3)	1 (1.3)	1 (1.0)	2 (1.7)
環状肉芽腫	0	0	1 (1.3)	1 (1.0)	1 (0.8)
間擦疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
点状出血	1 (5.0)	0	0	1 (1.0)	2 (1.7)
そう痒症	0	0	0	1 (1.0)	1 (0.8)
斑状皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
皮膚色素脱失	0	0	0	1 (1.0)	1 (0.8)
皮膚障害	0	0	0	1 (1.0)	1 (0.8)
皮膚浮腫	0	0	1 (1.3)	1 (1.0)	1 (0.8)
皮膚潰瘍	0	0	0	1 (1.0)	1 (0.8)
皮下気腫	0	0	0	1 (1.0)	1 (0.8)
蕁麻疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0
褥瘡性潰瘍	0	3 (7.3)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 16 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
アトピー性皮膚炎	0	2 (4.9)	0	0	0
貨幣状湿疹	1 (5.0)	0	0	0	1 (0.8)
皮下出血	0	0	0	0	0
多汗症	0	1 (2.4)	0	0	0
毛孔性角化症	0	1 (2.4)	0	0	0
寝汗	0	0	0	0	0
皮膚疼痛	0	0	0	0	0
紅斑性皮疹	1 (5.0)	1 (2.4)	0	0	1 (0.8)
毛孔性皮疹	0	0	0	0	0
痂皮	0	0	0	0	0
脂漏性皮膚炎	1 (5.0)	0	0	0	1 (0.8)
皮膚病変	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 17 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
傷害、中毒および処置合併症	3 (15.0)	10 (24.4)	19 (23.8)	30 (30.0)	33 (27.5)
節足動物咬傷	1 (5.0)	0	1 (1.3)	4 (4.0)	5 (4.2)
栄養補給チューブ合併症	0	3 (7.3)	2 (2.5)	4 (4.0)	4 (3.3)
処置による疼痛	0	0	2 (2.5)	4 (4.0)	4 (3.3)
大腿骨骨折	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
ストーマ部紅斑	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
挫傷	0	0	1 (1.3)	2 (2.0)	2 (1.7)
関節脱臼	0	0	0	2 (2.0)	2 (1.7)
皮膚擦過傷	0	0	0	2 (2.0)	2 (1.7)
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.8)
麻酔からの覚醒遅延	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ダンピング症候群	0	0	0	1 (1.0)	1 (0.8)
耳擦過傷	0	0	0	1 (1.0)	1 (0.8)
擦過傷	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
伝染病曝露	0	0	1 (1.3)	1 (1.0)	1 (0.8)
口唇損傷	0	0	0	1 (1.0)	1 (0.8)
外傷性気胸	0	0	0	1 (1.0)	1 (0.8)
処置後腫脹	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 18 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.8)
軟部組織損傷	0	0	0	1 (1.0)	1 (0.8)
ストーマ合併症	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ部刺激感	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
サンバーン	0	0	0	1 (1.0)	1 (0.8)
熱傷	0	0	0	1 (1.0)	1 (0.8)
歯牙損傷	0	0	0	1 (1.0)	1 (0.8)
ワクチン接種合併症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
麻酔による呼吸器合併症	0	0	0	0	0
節足動物刺傷	0	0	0	0	0
気管内挿管合併症	0	1 (2.4)	0	0	0
転倒	1 (5.0)	0	0	0	1 (0.8)
足骨折	0	0	0	0	0
体内異物	0	0	0	0	0
頭部損傷	0	1 (2.4)	0	0	0
上腕骨骨折	0	0	0	0	0
切開部位紅斑	0	1 (2.4)	0	0	0
関節損傷	0	0	0	0	0
裂傷	0	1 (2.4)	0	0	0
靭帯捻挫	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 19 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
四肢損傷	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
肉離れ	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
処置後合併症	1 (5.0)	0	0	0	1 (0.8)
処置後挫傷	0	1 (2.4)	0	0	0
処置後不快感	1 (5.0)	0	0	0	1 (0.8)
処置後出血	0	1 (2.4)	0	0	0
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
交通事故	0	0	0	0	0
ストーマ部出血	0	1 (2.4)	0	0	0
ストーマ部炎症	0	1 (2.4)	0	0	0
硬膜下血腫	1 (5.0)	0	0	0	1 (0.8)
脛骨骨折	0	0	0	0	0
隆起骨折	0	0	0	0	0
気管出血	0	1 (2.4)	0	0	0
気管損傷	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 20 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
気管閉塞	0	1 (2.4)	0	0	0
臨床検査	3 (15.0)	14 (34.1)	21 (26.3)	28 (28.0)	31 (25.8)
酸素飽和度低下	1 (5.0)	10 (24.4)	10 (12.5)	12 (12.0)	13 (10.8)
体重減少	0	1 (2.4)	4 (5.0)	6 (6.0)	6 (5.0)
ヒトライノウイルス検査陽性	0	0	1 (1.3)	3 (3.0)	3 (2.5)
好中球数増加	0	0	1 (1.3)	3 (3.0)	3 (2.5)
血中カリウム減少	0	0	2 (2.5)	2 (2.0)	2 (1.7)
体温上昇	1 (5.0)	1 (2.4)	2 (2.5)	2 (2.0)	3 (2.5)
Ｃ－反応性蛋白増加	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
心拍数増加	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
医学的観察	0	0	2 (2.5)	2 (2.0)	2 (1.7)
モラクセラ検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
シュードモナス検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
ブドウ球菌検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
白血球数増加	1 (5.0)	0	0	2 (2.0)	3 (2.5)
アラニンアミノトランスフェラーゼ増加	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中鉄減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 21 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
体温低下	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
骨密度減少	0	0	0	1 (1.0)	1 (0.8)
呼吸音異常	0	0	0	1 (1.0)	1 (0.8)
心電図ＳＴ－Ｔ部分異常	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
心拍数減少	0	1 (2.4)	0	1 (1.0)	1 (0.8)
心拍数不整	0	0	1 (1.3)	1 (1.0)	1 (0.8)
炎症マーカー上昇	0	0	1 (1.3)	1 (1.0)	1 (0.8)
Ａ型インフルエンザウイルス検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肝機能検査異常	0	0	1 (1.3)	1 (1.0)	1 (0.8)
好中球百分率増加	0	0	0	1 (1.0)	1 (0.8)
整形外科検査	0	0	1 (1.3)	1 (1.0)	1 (0.8)
セラチア検査陽性	0	0	0	1 (1.0)	1 (0.8)
レンサ球菌検査陽性	0	0	0	1 (1.0)	1 (0.8)
尿量減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ビタミンＡ減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中アルカリホスファターゼ増加	1 (5.0)	0	0	0	1 (0.8)
血中重炭酸塩減少	0	0	0	0	0
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 22 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
心雑音	0	0	0	0	0
機能性心雑音	0	0	0	0	0
好酸球数増加	1 (5.0)	0	0	0	1 (0.8)
ヘッドラグ異常	0	1 (2.4)	0	0	0
リンパ節触知	0	1 (2.4)	0	0	0
リンパ球数増加	1 (5.0)	0	0	0	1 (0.8)
呼吸数増加	0	1 (2.4)	0	0	0
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0
喀痰培養陽性	0	1 (2.4)	0	0	0
トランスアミナーゼ上昇	0	1 (2.4)	0	0	0
尿検査異常	0	0	0	0	0
ビタミンD減少	0	1 (2.4)	0	0	0
筋骨格系および結合組織障害	3 (15.0)	5 (12.2)	11 (13.8)	25 (25.0)	28 (23.3)
関節拘縮	1 (5.0)	2 (4.9)	3 (3.8)	11 (11.0)	12 (10.0)
側弯症	0	2 (4.9)	4 (5.0)	11 (11.0)	11 (9.2)
脊柱後弯症	0	1 (2.4)	1 (1.3)	5 (5.0)	5 (4.2)
胸郭変形	0	0	1 (1.3)	4 (4.0)	4 (3.3)
後側弯症	0	0	1 (1.3)	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 23 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
四肢痛	0	0	1 (1.3)	2 (2.0)	2 (1.7)
頭位性斜頭症	1 (5.0)	1 (2.4)	2 (2.5)	2 (2.0)	3 (2.5)
斜頚	1 (5.0)	0	0	2 (2.0)	3 (2.5)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
泉門閉鎖遅延	0	0	1 (1.3)	1 (1.0)	1 (0.8)
手変形	0	0	0	1 (1.0)	1 (0.8)
関節硬直	0	1 (2.4)	0	1 (1.0)	1 (0.8)
脊柱前弯症	0	0	0	1 (1.0)	1 (0.8)
脊柱変形	0	0	0	1 (1.0)	1 (0.8)
滑膜炎	0	0	0	1 (1.0)	1 (0.8)
関節痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
単径部痛	0	0	0	0	0
関節可動域低下	0	1 (2.4)	0	0	0
関節腫脹	0	0	0	0	0
筋緊張	0	1 (2.4)	0	0	0
筋力低下	2 (10.0)	1 (2.4)	0	0	2 (1.7)
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
骨盤変形	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 24 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
体重支持困難	1 (5.0)	0	0	0	1 (0.8)
心臓障害	2 (10.0)	13 (31.7)	18 (22.5)	24 (24.0)	26 (21.7)
頻脈	2 (10.0)	5 (12.2)	7 (8.8)	9 (9.0)	11 (9.2)
徐脈	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (5.8)
心肺停止	0	5 (12.2)	5 (6.3)	6 (6.0)	6 (5.0)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
チアノーゼ	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
左室肥大	0	0	2 (2.5)	2 (2.0)	2 (1.7)
心室性頻脈	0	0	1 (1.3)	2 (2.0)	2 (1.7)
心筋症	0	0	0	1 (1.0)	1 (0.8)
心膜気腫	0	0	0	1 (1.0)	1 (0.8)
洞性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.8)
上室性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.8)
動悸	0	0	0	0	0
代謝および栄養障害	4 (20.0)	13 (31.7)	14 (17.5)	19 (19.0)	23 (19.2)
体重増加不良	1 (5.0)	2 (4.9)	5 (6.3)	6 (6.0)	7 (5.8)
成長障害	2 (10.0)	2 (4.9)	3 (3.8)	4 (4.0)	6 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 25 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
乳児および小児期早期の哺育障害	0	3 (7.3)	3 (3.8)	3 (3.0)	3 (2.5)
栄養補給不耐性	0	0	3 (3.8)	3 (3.0)	3 (2.5)
低ナトリウム血症	0	0	0	2 (2.0)	2 (1.7)
過小食	0	0	0	2 (2.0)	2 (1.7)
脱水	2 (10.0)	2 (4.9)	1 (1.3)	1 (1.0)	3 (2.5)
鉄欠乏	0	0	1 (1.3)	1 (1.0)	1 (0.8)
代謝性アルカローシス	0	0	0	1 (1.0)	1 (0.8)
食欲減退	0	0	0	0	0
食物不耐性	0	1 (2.4)	0	0	0
高血糖	0	1 (2.4)	0	0	0
低血糖	0	2 (4.9)	0	0	0
低カリウム血症	0	3 (7.3)	0	0	0
食欲亢進	0	0	0	0	0
栄養障害	0	0	0	0	0
ビタミンD欠乏	0	1 (2.4)	0	0	0
神経系障害	3 (15.0)	2 (4.9)	9 (11.3)	18 (18.0)	21 (17.5)
不随意性筋収縮	0	0	1 (1.3)	4 (4.0)	4 (3.3)
眼振	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 26 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
よだれ	0	0	1 (1.3)	2 (2.0)	2 (1.7)
痙攣発作	0	0	1 (1.3)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)
脳梗塞	0	0	0	1 (1.0)	1 (0.8)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.8)
間代	0	0	1 (1.3)	1 (1.0)	1 (0.8)
頭痛	0	0	0	1 (1.0)	1 (0.8)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
言語障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
嗜眠	0	0	0	1 (1.0)	1 (0.8)
傾眠	0	0	1 (1.3)	1 (1.0)	1 (0.8)
失神	0	0	0	1 (1.0)	1 (0.8)
失声症	0	0	0	0	0
浮動性めまい	0	0	0	0	0
味覚異常	0	0	0	0	0
失読症	0	0	0	0	0
反射亢進	1 (5.0)	0	0	0	1 (0.8)
感覚鈍麻	0	0	0	0	0
筋緊張低下	2 (10.0)	0	0	0	2 (1.7)
片頭痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 27 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ミオクローヌス	0	0	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	1 (2.4)	0	0	0
振戦	0	0	0	0	0
免疫系障害	2 (10.0)	4 (9.8)	7 (8.8)	13 (13.0)	15 (12.5)
季節性アレルギー	1 (5.0)	2 (4.9)	3 (3.8)	6 (6.0)	7 (5.8)
薬物過敏症	0	1 (2.4)	2 (2.5)	4 (4.0)	4 (3.3)
過敏症	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
食物アレルギー	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
化学物質アレルギー	0	0	0	0	0
精神障害	0	5 (12.2)	9 (11.3)	12 (12.0)	12 (10.0)
不安	0	0	2 (2.5)	5 (5.0)	5 (4.2)
易刺激性	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
激越	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
息こらえ	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.8)
落ち着きのなさ	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
睡眠障害	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 28 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
注意欠陥多動性障害	0	0	0	0	0
不快気分	0	0	0	0	0
不眠症	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
チック	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
血管障害	2 (10.0)	1 (2.4)	5 (6.3)	8 (8.0)	10 (8.3)
高血圧	1 (5.0)	0	1 (1.3)	2 (2.0)	3 (2.5)
毛細血管脆弱	0	0	0	1 (1.0)	1 (0.8)
本態性高血圧症	0	0	0	1 (1.0)	1 (0.8)
蒼白	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血栓症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
充血	0	1 (2.4)	0	0	0
低血圧	0	0	0	0	0
先天性、家族性および遺伝性障害	0	4 (9.8)	4 (5.0)	7 (7.0)	7 (5.8)
斜頭症	0	0	0	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 29 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
斜指症	0	0	0	1 (1.0)	1 (0.8)
先天性横隔膜ヘルニア	0	0	1 (1.3)	1 (1.0)	1 (0.8)
発育性股関節形成不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
貧血母斑	0	0	1 (1.3)	1 (1.0)	1 (0.8)
鳩胸	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
停留精巣	0	1 (2.4)	0	0	0
包茎	0	1 (2.4)	0	0	0
血液およびリンパ系障害	2 (10.0)	3 (7.3)	1 (1.3)	6 (6.0)	8 (6.7)
貧血	0	1 (2.4)	1 (1.3)	3 (3.0)	3 (2.5)
リンパ節症	0	0	0	1 (1.0)	1 (0.8)
好中球減少症	1 (5.0)	0	0	1 (1.0)	2 (1.7)
血小板増加症	0	0	0	1 (1.0)	1 (0.8)
骨髄障害	0	1 (2.4)	0	0	0
好酸球増加症	1 (5.0)	0	0	0	1 (0.8)
白血球増加症	0	1 (2.4)	0	0	0
眼障害	1 (5.0)	3 (7.3)	4 (5.0)	6 (6.0)	7 (5.8)
乱視	0	0	0	1 (1.0)	1 (0.8)
霰粒腫	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 30 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
眼乾燥	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
眼運動障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.8)
近視	0	0	1 (1.3)	1 (1.0)	1 (0.8)
斜視	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
弱視	0	1 (2.4)	0	0	0
眼瞼痙攣	0	0	0	0	0
後天性涙道狭窄	1 (5.0)	0	0	0	1 (0.8)
遠視	0	0	0	0	0
流涙増加	0	1 (2.4)	0	0	0
生殖系および乳房障害	1 (5.0)	0	4 (5.0)	4 (4.0)	5 (4.2)
後天性包茎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
亀頭包皮炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
卵巣嚢胞	0	0	1 (1.3)	1 (1.0)	1 (0.8)
陰茎障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
会陰痛	0	0	0	0	0
外陰腟発疹	1 (5.0)	0	0	0	1 (0.8)
耳および迷路障害	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 31 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
耳の障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
耳痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
耳垢分泌過多	0	0	0	1 (1.0)	1 (0.8)
耳出血	0	1 (2.4)	0	0	0
乗物酔い	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.0)	0	0	2 (2.0)	3 (2.5)
アクロコルドン	0	0	0	1 (1.0)	1 (0.8)
血管の良性新生物	0	0	0	1 (1.0)	1 (0.8)
脂漏性角化症	1 (5.0)	0	0	0	1 (0.8)
皮膚乳頭腫	0	0	0	0	0
腎および尿路障害	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
水腎症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.8)
排尿困難	0	0	0	0	0
糖尿	0	1 (2.4)	0	0	0
尿失禁	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in infants diagnosed with SMA
Page 32 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
膀胱尿管逆流	0	0	0	0	0
肝胆道系障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肝腫大	0	0	1 (1.3)	1 (1.0)	1 (0.8)
外科および内科処置	0	0	1 (1.3)	1 (1.0)	1 (0.8)
機械的換気	0	0	1 (1.3)	1 (1.0)	1 (0.8)
内分泌障害	0	0	0	0	0
思春期早発症	0	0	0	0	0
妊娠、産褥および周産期の状態	1 (5.0)	0	0	0	1 (0.8)
臍肉芽腫	1 (5.0)	0	0	0	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

表 130　Frequency of Adverse Events in Infants Diagnosed With SMA

Frequency of adverse events in infants diagnosed with SMA
Page 1 of 32

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20	41	80	100	120
Number of events	141 (100.0)	612 (100.0)	1057 (100.0)	1627 (100.0)	1768 (100.0)
感染症および寄生虫症	47 (33.3)	132 (21.6)	303 (28.7)	444 (27.3)	491 (27.8)
上気道感染	13 (9.2)	12 (2.0)	40 (3.8)	63 (3.9)	76 (4.3)
肺炎	2 (1.4)	9 (1.5)	33 (3.1)	50 (3.1)	52 (2.9)
鼻咽頭炎	6 (4.3)	4 (0.7)	21 (2.0)	34 (2.1)	40 (2.3)
気道感染	0	4 (0.7)	18 (1.7)	33 (2.0)	33 (1.9)
ライノウイルス感染	2 (1.4)	9 (1.5)	13 (1.2)	20 (1.2)	22 (1.2)
ウイルス性上気道感染	0	7 (1.1)	15 (1.4)	17 (1.0)	17 (1.0)
ウイルス感染	0	4 (0.7)	10 (0.9)	15 (0.9)	15 (0.8)
細気管支炎	1 (0.7)	3 (0.5)	8 (0.8)	13 (0.8)	14 (0.8)
中耳炎	5 (3.5)	2 (0.3)	3 (0.3)	11 (0.7)	16 (0.9)
耳感染	0	1 (0.2)	8 (0.8)	10 (0.6)	10 (0.6)
口腔カンジダ症	0	4 (0.7)	9 (0.9)	10 (0.6)	10 (0.6)
ウイルス性肺炎	1 (0.7)	2 (0.3)	7 (0.7)	10 (0.6)	11 (0.6)
尿路感染	3 (2.1)	0	10 (0.9)	10 (0.6)	13 (0.7)
下気道感染	0	2 (0.3)	8 (0.8)	9 (0.6)	9 (0.5)
ウイルス性気管支炎	0	0	8 (0.8)	8 (0.5)	8 (0.5)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 2 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
気管支炎	1 (0.7)	1 (0.2)	7 (0.7)	7 (0.4)	8 (0.5)
ウイルス性気道感染	0	3 (0.5)	6 (0.6)	7 (0.4)	7 (0.4)
鼻炎	3 (2.1)	4 (0.7)	6 (0.6)	7 (0.4)	10 (0.6)
結膜炎	0	3 (0.5)	5 (0.5)	6 (0.4)	6 (0.3)
インフルエンザ	3 (2.1)	0	5 (0.5)	6 (0.4)	9 (0.5)
ＲＳウイルス細気管支炎	0	3 (0.5)	4 (0.4)	5 (0.3)	5 (0.3)
細菌性気管炎	0	9 (1.5)	2 (0.2)	4 (0.2)	4 (0.2)
細菌性肺炎	0	3 (0.5)	3 (0.3)	4 (0.2)	4 (0.2)
ストーマ部膿瘍	0	0	4 (0.4)	4 (0.2)	4 (0.2)
細菌感染	0	0	1 (<0.1)	3 (0.2)	3 (0.2)
エンテロウイルス感染	0	0	0	3 (0.2)	3 (0.2)
ウイルス性下気道感染	0	0	2 (0.2)	3 (0.2)	3 (0.2)
パラインフルエンザウイルス感染	0	1 (0.2)	0	3 (0.2)	3 (0.2)
モラクセラ菌性肺炎	0	0	2 (0.2)	3 (0.2)	3 (0.2)
シュードモナス感染	0	2 (0.3)	3 (0.3)	3 (0.2)	3 (0.2)
アデノウイルス感染	0	0	2 (0.2)	2 (0.1)	2 (0.1)
カンジダ性おむつ皮疹	0	1 (0.2)	1 (<0.1)	2 (0.1)	2 (0.1)
細菌性結膜炎	0	2 (0.3)	2 (0.2)	2 (0.1)	2 (0.1)
真菌感染	0	1 (0.2)	2 (0.2)	2 (0.1)	2 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 3 of 32

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
皮膚真菌感染	0	1 (0.2)	1 (<0.1)	2 (0.1)	2 (0.1)
胃腸炎	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
手足口病	0	1 (0.2)	1 (<0.1)	2 (0.1)	2 (0.1)
肺感染	0	0	2 (0.2)	2 (0.1)	2 (0.1)
メタニューモウイルス感染	0	0	0	2 (0.1)	2 (0.1)
モラクセラ感染	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
口腔真菌感染	0	0	2 (0.2)	2 (0.1)	2 (0.1)
シュードモナス菌性肺炎	0	1 (0.2)	0	2 (0.1)	2 (0.1)
敗血症	0	0	2 (0.2)	2 (0.1)	2 (0.1)
皮膚カンジダ	0	1 (0.2)	2 (0.2)	2 (0.1)	2 (0.1)
ブドウ球菌皮膚感染	0	0	2 (0.2)	2 (0.1)	2 (0.1)
アデノウイルス性上気道感染	0	0	0	1 (<0.1)	1 (<0.1)
細菌性疾患キャリアー	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
蜂巣炎	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
コロナウイルス感染	0	2 (0.3)	0	1 (<0.1)	1 (<0.1)
感染性湿疹	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
蟯虫症	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
腸球菌感染	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
伝染性紅斑	0	0	0	1 (<0.1)	1 (<0.1)
大腸菌感染	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 4 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
眼感染	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ウイルス性胃炎	0	0	0	1 (<0.1)	1 (<0.1)
ロタウイルス胃腸炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ウイルス性胃腸炎	2 (1.4)	2 (0.3)	1 (<0.1)	1 (<0.1)	3 (0.2)
ヘモフィルス感染	0	0	0	1 (<0.1)	1 (<0.1)
膿痂疹	1 (0.7)	1 (0.2)	1 (<0.1)	1 (<0.1)	2 (0.1)
限局性感染	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
粘膜皮膚カンジダ症	0	0	0	1 (<0.1)	1 (<0.1)
院内感染	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
口腔ヘルペス	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
急性中耳炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
レンサ球菌性咽頭炎	1 (0.7)	0	0	1 (<0.1)	2 (0.1)
インフルエンザ性肺炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
パラインフルエンザウイルス性肺炎	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
肺炎球菌性肺炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ＲＳウイルス肺炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
腎盂腎炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
細菌性気道感染	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
ばら疹	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ブドウ球菌性菌血症	0	0	0	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 5 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ブドウ球菌感染	0	2 (0.3)	0	1 (<0.1)	1 (<0.1)
ブドウ球菌性敗血症	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ストーマ部感染	0	4 (0.7)	1 (<0.1)	1 (<0.1)	1 (<0.1)
気管炎	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
菌血症	0	1 (0.2)	0	0	0
カンジダ感染	0	6 (1.0)	0	0	0
カンジダ性敗血症	0	1 (0.2)	0	0	0
ブドウ球菌性耳感染	1 (0.7)	0	0	0	1 (<0.1)
ウイルス性耳感染	0	0	0	0	0
ブドウ球菌性眼感染	0	0	0	0	0
ウイルス性眼感染	0	0	0	0	0
消化管感染	0	0	0	0	0
ウイルス性消化管感染	0	0	0	0	0
麦粒腫	0	2 (0.3)	0	0	0
シラミ寄生	0	0	0	0	0
伝染性軟属腫	0	0	0	0	0
単核細胞症症候群	0	0	0	0	0
外耳炎	0	0	0	0	0
咽頭炎	0	0	0	0	0
咽頭扁桃炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 6 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ＲＳウイルス感染	0	0	0	0	0
猩紅熱	0	0	0	0	0
セラチア感染	0	2 (0.3)	0	0	0
副鼻腔炎	0	1 (0.2)	0	0	0
皮膚細菌感染	0	0	0	0	0
皮膚感染	1 (0.7)	1 (0.2)	0	0	1 (<0.1)
ストーマ部蜂巣炎	0	0	0	0	0
レンサ球菌感染	1 (0.7)	0	0	0	1 (<0.1)
全身性感染	0	1 (0.2)	0	0	0
扁桃炎	0	0	0	0	0
歯膿瘍	0	0	0	0	0
腟感染	0	0	0	0	0
ウイルス性発疹	0	1 (0.2)	0	0	0
ウイルス性扁桃炎	0	0	0	0	0
外陰腟真菌感染	0	0	0	0	0
呼吸器、胸郭および縦隔障害	14 (9.9)	171 (27.9)	250 (23.7)	372 (22.9)	386 (21.8)
無気肺	0	19 (3.1)	45 (4.3)	54 (3.3)	54 (3.1)
呼吸窮迫	2 (1.4)	20 (3.3)	32 (3.0)	44 (2.7)	46 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 7 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
急性呼吸不全	0	13 (2.1)	29 (2.7)	39 (2.4)	39 (2.2)
呼吸不全	0	28 (4.6)	22 (2.1)	29 (1.8)	29 (1.6)
鼻閉	3 (2.1)	6 (1.0)	12 (1.1)	23 (1.4)	26 (1.5)
咳嗽	3 (2.1)	11 (1.8)	11 (1.0)	21 (1.3)	24 (1.4)
誤嚥性肺炎	0	8 (1.3)	14 (1.3)	18 (1.1)	18 (1.0)
低酸素症	0	4 (0.7)	9 (0.9)	17 (1.0)	17 (1.0)
気管支分泌物貯留	0	8 (1.3)	7 (0.7)	10 (0.6)	10 (0.6)
呼吸困難	0	7 (1.1)	7 (0.7)	9 (0.6)	9 (0.5)
鼻漏	3 (2.1)	3 (0.5)	7 (0.7)	9 (0.6)	12 (0.7)
無呼吸	0	10 (1.6)	4 (0.4)	8 (0.5)	8 (0.5)
誤嚥	0	3 (0.5)	6 (0.6)	8 (0.5)	8 (0.5)
上気道分泌増加	0	1 (0.2)	2 (0.2)	8 (0.5)	8 (0.5)
呼吸停止	0	5 (0.8)	7 (0.7)	8 (0.5)	8 (0.5)
慢性呼吸不全	0	0	3 (0.3)	7 (0.4)	7 (0.4)
上気道うっ血	1 (0.7)	1 (0.2)	6 (0.6)	7 (0.4)	8 (0.5)
副鼻腔うっ血	0	0	4 (0.4)	6 (0.4)	6 (0.3)
気胸	0	0	1 (<0.1)	4 (0.2)	4 (0.2)
喘鳴	0	0	2 (0.2)	4 (0.2)	4 (0.2)
低換気	0	0	2 (0.2)	3 (0.2)	3 (0.2)
気管支閉塞	0	0	2 (0.2)	2 (0.1)	2 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 8 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
息詰まり	1 (0.7)	2 (0.3)	1 (<0.1)	2 (0.1)	3 (0.2)
肺うっ血	0	0	0	2 (0.1)	2 (0.1)
肺水腫	0	0	0	2 (0.1)	2 (0.1)
呼吸障害	0	0	2 (0.2)	2 (0.1)	2 (0.1)
気道うっ血	0	3 (0.5)	2 (0.2)	2 (0.1)	2 (0.1)
アレルギー性鼻炎	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
呼吸補助筋の動員	0	1 (0.2)	1 (<0.1)	2 (0.1)	2 (0.1)
急性呼吸窮迫症候群	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
無呼吸発作	0	0	0	1 (<0.1)	1 (<0.1)
窒息	0	0	0	1 (<0.1)	1 (<0.1)
高炭酸ガス血症	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
減呼吸	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
気管支分泌増加	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
喉頭肉芽腫	0	0	0	1 (<0.1)	1 (<0.1)
肺障害	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
鼻汁変色	0	0	0	1 (<0.1)	1 (<0.1)
閉塞性気道障害	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
胸水	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
気縦隔症	0	0	0	1 (<0.1)	1 (<0.1)
湿性咳嗽	0	0	0	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 9 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
呼吸性アルカローシス	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
拘束性肺疾患	0	0	0	1 (<0.1)	1 (<0.1)
低音性連続性ラ音	0	0	0	1 (<0.1)	1 (<0.1)
睡眠時無呼吸症候群	0	4 (0.7)	0	1 (<0.1)	1 (<0.1)
変色痰	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
頻呼吸	0	3 (0.5)	0	1 (<0.1)	1 (<0.1)
気管障害	0	0	0	1 (<0.1)	1 (<0.1)
アデノイド肥大	0	0	0	0	0
乳幼児突発性危急事態	0	2 (0.3)	0	0	0
カタル	0	1 (0.2)	0	0	0
発声障害	0	0	0	0	0
鼻出血	0	0	0	0	0
口腔咽頭痛	0	1 (0.2)	0	0	0
肺臓炎	0	0	0	0	0
呼吸性アシドーシス	1 (0.7)	0	0	0	1 (<0.1)
扁桃肥大	0	0	0	0	0
上気道の炎症	0	3 (0.5)	0	0	0
胃腸障害	12 (8.5)	71 (11.6)	129 (12.2)	189 (11.6)	201 (11.4)
便秘	2 (1.4)	9 (1.5)	31 (2.9)	41 (2.5)	43 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 10 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
嘔吐	0	8 (1.3)	23 (2.2)	36 (2.2)	36 (2.0)
下痢	1 (0.7)	13 (2.1)	14 (1.3)	28 (1.7)	29 (1.6)
生歯	1 (0.7)	3 (0.5)	14 (1.3)	18 (1.1)	19 (1.1)
胃食道逆流性疾患	2 (1.4)	8 (1.3)	11 (1.0)	17 (1.0)	19 (1.1)
嚥下障害	1 (0.7)	12 (2.0)	12 (1.1)	12 (0.7)	13 (0.7)
流涎過多	0	2 (0.3)	6 (0.6)	8 (0.5)	8 (0.5)
放屁	2 (1.4)	1 (0.2)	4 (0.4)	6 (0.4)	8 (0.5)
腹部膨満	2 (1.4)	0	1 (<0.1)	4 (0.2)	6 (0.3)
胃炎	0	1 (0.2)	3 (0.3)	4 (0.2)	4 (0.2)
腹部不快感	1 (0.7)	0	2 (0.2)	2 (0.1)	3 (0.2)
血便排泄	0	0	2 (0.2)	2 (0.1)	2 (0.1)
腹痛	0	0	0	1 (<0.1)	1 (<0.1)
アフタ性潰瘍	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
口唇のひび割れ	0	0	0	1 (<0.1)	1 (<0.1)
排便回数増加	0	0	0	1 (<0.1)	1 (<0.1)
胃出血	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
消化管運動低下	0	0	0	1 (<0.1)	1 (<0.1)
吐血	0	0	0	1 (<0.1)	1 (<0.1)
胃排出不全	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
乳児仙痛	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 11 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
乳児吐出	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
上部消化管出血	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
上腹部痛	0	2 (0.3)	0	0	0
腹部症状	0	0	0	0	0
齲歯	0	0	0	0	0
血性下痢	0	1 (0.2)	0	0	0
小腸炎	0	1 (0.2)	0	0	0
心窩部不快感	0	2 (0.3)	0	0	0
便失禁	0	0	0	0	0
食中毒	0	0	0	0	0
胃腸障害	0	0	0	0	0
胃腸出血	0	3 (0.5)	0	0	0
消化管運動障害	0	1 (0.2)	0	0	0
消化管刺激症状	0	1 (0.2)	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0
口腔内痛	0	0	0	0	0
レッチング	0	1 (0.2)	0	0	0
口内炎	0	1 (0.2)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 12 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
舌萎縮	0	1 (0.2)	0	0	0
歯の脱落	0	0	0	0	0
歯痛	0	0	0	0	0
一般・全身障害および投与部位の状態	16 (11.3)	61 (10.0)	129 (12.2)	183 (11.2)	199 (11.3)
発熱	14 (9.9)	43 (7.0)	114 (10.8)	151 (9.3)	165 (9.3)
疼痛	0	3 (0.5)	1 (<0.1)	5 (0.3)	5 (0.3)
医療機器閉塞	0	1 (0.2)	1 (<0.1)	4 (0.2)	4 (0.2)
末梢性浮腫	0	0	0	4 (0.2)	4 (0.2)
不快感	0	0	0	2 (0.1)	2 (0.1)
低体温	0	0	2 (0.2)	2 (0.1)	2 (0.1)
カテーテル留置部位炎症	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
泣き	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
死亡	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
医療機器リーク	0	0	0	1 (<0.1)	1 (<0.1)
薬物不耐性	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
全身健康状態低下	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ワクチン接種後の易刺激性	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
倦怠感	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 13 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
医療機器合併症	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
小結節	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
浮腫	0	3 (0.5)	0	1 (<0.1)	1 (<0.1)
末梢腫脹	0	0	0	1 (<0.1)	1 (<0.1)
外科手術不成功	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
腫脹	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
血管穿刺部位内出血	0	2 (0.3)	0	1 (<0.1)	1 (<0.1)
適用部位紅斑	1 (0.7)	0	0	0	1 (<0.1)
適用部位発疹	0	1 (0.2)	0	0	0
カテーテル留置部位出血	0	0	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
カテーテル留置部位関連反応	0	0	0	0	0
胸部不快感	0	0	0	0	0
胸痛	0	0	0	0	0
悪寒	0	0	0	0	0
医療機器機能不良	0	1 (0.2)	0	0	0
疲労	0	1 (0.2)	0	0	0
冷感	0	0	0	0	0
重力性浮腫	0	0	0	0	0
炎症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 14 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
注入部位内出血	1 (0.7)	1 (0.2)	0	0	1 (<0.1)
注入部位血管外漏出	0	1 (0.2)	0	0	0
注射部位血腫	0	1 (0.2)	0	0	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
穿刺部位疼痛	0	0	0	0	0
穿刺部位反応	0	0	0	0	0
圧痛	0	0	0	0	0
血管穿刺部位反応	0	1 (0.2)	0	0	0
臨床検査	8 (5.7)	31 (5.1)	54 (5.1)	78 (4.8)	86 (4.9)
酸素飽和度低下	1 (0.7)	17 (2.8)	16 (1.5)	18 (1.1)	19 (1.1)
体重減少	0	1 (0.2)	4 (0.4)	6 (0.4)	6 (0.3)
体温上昇	1 (0.7)	1 (0.2)	5 (0.5)	5 (0.3)	6 (0.3)
Ｃ－反応性蛋白増加	0	1 (0.2)	5 (0.5)	5 (0.3)	5 (0.3)
心拍数増加	0	1 (0.2)	1 (<0.1)	4 (0.2)	4 (0.2)
好中球数増加	0	0	1 (<0.1)	4 (0.2)	4 (0.2)
ヒトライノウイルス検査陽性	0	0	1 (<0.1)	3 (0.2)	3 (0.2)
シュードモナス検査陽性	0	0	1 (<0.1)	3 (0.2)	3 (0.2)
血中カリウム減少	0	0	2 (0.2)	2 (0.1)	2 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 15 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
医学的観察	0	0	2 (0.2)	2 (0.1)	2 (0.1)
モラクセラ検査陽性	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
ブドウ球菌検査陽性	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
白血球数増加	1 (0.7)	0	0	2 (0.1)	3 (0.2)
アラニンアミノトランスフェラーゼ増加	1 (0.7)	0	1 (<0.1)	1 (<0.1)	2 (0.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (0.7)	0	1 (<0.1)	1 (<0.1)	2 (0.1)
血中クロール減少	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
血中鉄減少	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
血中ナトリウム減少	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
体温低下	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
骨密度減少	0	0	0	1 (<0.1)	1 (<0.1)
呼吸音異常	0	0	0	1 (<0.1)	1 (<0.1)
心電図ＳＴ－Ｔ部分異常	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
心拍数減少	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
心拍数不整	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
炎症マーカー上昇	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
Ａ型インフルエンザウイルス検査陽性	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
肝機能検査異常	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
好中球百分率増加	0	0	0	1 (<0.1)	1 (<0.1)
整形外科検査	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 16 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
セラチア検査陽性	0	0	0	1 (<0.1)	1 (<0.1)
レンサ球菌検査陽性	0	0	0	1 (<0.1)	1 (<0.1)
尿量減少	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ビタミンA減少	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
血中アルカリホスファターゼ増加	1 (0.7)	0	0	0	1 (<0.1)
血中重炭酸塩減少	0	0	0	0	0
血中テストステロン減少	0	0	0	0	0
ＣＳＦ白血球数増加	0	0	0	0	0
心雑音	0	0	0	0	0
機能性心雑音	0	0	0	0	0
好酸球数増加	1 (0.7)	0	0	0	1 (<0.1)
ヘッドラグ異常	0	1 (0.2)	0	0	0
リンパ節触知	0	1 (0.2)	0	0	0
リンパ球数増加	1 (0.7)	0	0	0	1 (<0.1)
呼吸数増加	0	1 (0.2)	0	0	0
レスピロウイルス検査陽性	0	1 (0.2)	0	0	0
喀痰培養陽性	0	1 (0.2)	0	0	0
トランスアミナーゼ上昇	0	1 (0.2)	0	0	0
尿検査異常	0	0	0	0	0
ビタミンD減少	0	1 (0.2)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 17 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
皮膚および皮下組織障害	11 (7.8)	27 (4.4)	39 (3.7)	75 (4.6)	86 (4.9)
発疹	1 (0.7)	5 (0.8)	12 (1.1)	22 (1.4)	23 (1.3)
おむつ皮膚炎	2 (1.4)	4 (0.7)	6 (0.6)	11 (0.7)	13 (0.7)
皮膚炎	2 (1.4)	0	2 (0.2)	4 (0.2)	6 (0.3)
接触性皮膚炎	0	3 (0.5)	3 (0.3)	4 (0.2)	4 (0.2)
湿疹	0	2 (0.3)	1 (<0.1)	4 (0.2)	4 (0.2)
斑状出血	0	0	2 (0.2)	3 (0.2)	3 (0.2)
過剰肉芽組織	0	0	0	3 (0.2)	3 (0.2)
皮膚刺激	0	0	0	3 (0.2)	3 (0.2)
脱毛症	0	0	0	2 (0.1)	2 (0.1)
過角化	0	0	2 (0.2)	2 (0.1)	2 (0.1)
汗疹	0	0	2 (0.2)	2 (0.1)	2 (0.1)
アレルギー性皮膚炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
皮膚乾燥	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
紅斑	1 (0.7)	3 (0.5)	1 (<0.1)	1 (<0.1)	2 (0.1)
環状肉芽腫	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
間擦疹	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
点状出血	1 (0.7)	0	0	1 (<0.1)	2 (0.1)
そう痒症	0	0	0	1 (<0.1)	1 (<0.1)
斑状皮疹	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 18 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
丘疹性皮疹	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
皮膚色素脱失	0	0	0	1 (<0.1)	1 (<0.1)
皮膚障害	0	0	0	1 (<0.1)	1 (<0.1)
皮膚浮腫	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
皮膚潰瘍	0	0	0	1 (<0.1)	1 (<0.1)
皮下気腫	0	0	0	1 (<0.1)	1 (<0.1)
蕁麻疹	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ざ瘡	0	0	0	0	0
水疱	0	0	0	0	0
褥瘡性潰瘍	0	3 (0.5)	0	0	0
アトピー性皮膚炎	0	3 (0.5)	0	0	0
貨幣状湿疹	2 (1.4)	0	0	0	2 (0.1)
皮下出血	0	0	0	0	0
多汗症	0	1 (0.2)	0	0	0
毛孔性角化症	0	1 (0.2)	0	0	0
寝汗	0	0	0	0	0
皮膚疼痛	0	0	0	0	0
紅斑性皮疹	1 (0.7)	1 (0.2)	0	0	1 (<0.1)
毛孔性皮疹	0	0	0	0	0
痂皮	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 19 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
脂漏性皮膚炎	1 (0.7)	0	0	0	1 (<0.1)
皮膚病変	0	0	0	0	0
筋骨格系および結合組織障害	6 (4.3)	12 (2.0)	22 (2.1)	71 (4.4)	77 (4.4)
関節拘縮	1 (0.7)	4 (0.7)	9 (0.9)	33 (2.0)	34 (1.9)
側弯症	0	2 (0.3)	5 (0.5)	13 (0.8)	13 (0.7)
脊柱後弯症	0	1 (0.2)	1 (<0.1)	5 (0.3)	5 (0.3)
胸郭変形	0	0	1 (<0.1)	4 (0.2)	4 (0.2)
四肢痛	0	0	1 (<0.1)	3 (0.2)	3 (0.2)
後側弯症	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
頭位性斜頭症	1 (0.7)	1 (0.2)	2 (0.2)	2 (0.1)	3 (0.2)
斜頚	1 (0.7)	0	0	2 (0.1)	3 (0.2)
背部痛	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
泉門閉鎖遅延	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
手変形	0	0	0	1 (<0.1)	1 (<0.1)
関節硬直	0	1 (0.2)	0	1 (<0.1)	1 (<0.1)
脊柱前弯症	0	0	0	1 (<0.1)	1 (<0.1)
脊柱変形	0	0	0	1 (<0.1)	1 (<0.1)
滑膜炎	0	0	0	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 20 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
関節痛	0	0	0	0	0
四肢拘縮	0	0	0	0	0
単径部痛	0	0	0	0	0
関節可動域低下	0	1 (0.2)	0	0	0
関節腫脹	0	0	0	0	0
筋緊張	0	1 (0.2)	0	0	0
筋力低下	2 (1.4)	1 (0.2)	0	0	2 (0.1)
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
骨盤変形	0	0	0	0	0
体重支持困難	1 (0.7)	0	0	0	1 (<0.1)
傷害、中毒および処置合併症	6 (4.3)	27 (4.4)	21 (2.0)	48 (3.0)	54 (3.1)
節足動物咬傷	1 (0.7)	0	1 (<0.1)	8 (0.5)	9 (0.5)
栄養補給チューブ合併症	0	4 (0.7)	2 (0.2)	4 (0.2)	4 (0.2)
処置による疼痛	0	0	2 (0.2)	4 (0.2)	4 (0.2)
大腿骨骨折	0	2 (0.3)	3 (0.3)	3 (0.2)	3 (0.2)
皮膚擦過傷	0	0	0	3 (0.2)	3 (0.2)
ストーマ部紅斑	0	2 (0.3)	2 (0.2)	3 (0.2)	3 (0.2)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 21 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
挫傷	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
耳擦過傷	0	0	0	2 (0.1)	2 (0.1)
関節脱臼	0	0	0	2 (0.1)	2 (0.1)
術後激越	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
麻酔からの覚醒遅延	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
ダンピング症候群	0	0	0	1 (<0.1)	1 (<0.1)
擦過傷	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
伝染病曝露	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
口唇損傷	0	0	0	1 (<0.1)	1 (<0.1)
外傷性気胸	0	0	0	1 (<0.1)	1 (<0.1)
処置後腫脹	1 (0.7)	0	1 (<0.1)	1 (<0.1)	2 (0.1)
処置合併症	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
処置部位反応	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
軟部組織損傷	0	0	0	1 (<0.1)	1 (<0.1)
ストーマ合併症	0	3 (0.5)	1 (<0.1)	1 (<0.1)	1 (<0.1)
ストーマ部刺激感	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
サンバーン	0	0	0	1 (<0.1)	1 (<0.1)
熱傷	0	0	0	1 (<0.1)	1 (<0.1)
歯牙損傷	0	0	0	1 (<0.1)	1 (<0.1)
ワクチン接種合併症	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 22 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
麻酔による呼吸器合併症	0	0	0	0	0
節足動物刺傷	0	0	0	0	0
気管内挿管合併症	0	1 (0.2)	0	0	0
転倒	1 (0.7)	0	0	0	1 (<0.1)
足骨折	0	0	0	0	0
体内異物	0	0	0	0	0
頭部損傷	0	1 (0.2)	0	0	0
上腕骨骨折	0	0	0	0	0
切開部位紅斑	0	1 (0.2)	0	0	0
関節損傷	0	0	0	0	0
裂傷	0	1 (0.2)	0	0	0
靭帯捻挫	0	0	0	0	0
四肢損傷	0	0	0	0	0
下肢骨折	0	0	0	0	0
半月板損傷	0	0	0	0	0
肉離れ	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
処置後合併症	1 (0.7)	0	0	0	1 (<0.1)
処置後挫傷	0	2 (0.3)	0	0	0
処置後不快感	1 (0.7)	0	0	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 23 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
処置後出血	0	1 (0.2)	0	0	0
術後イレウス	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
交通事故	0	0	0	0	0
ストーマ部出血	0	1 (0.2)	0	0	0
ストーマ部炎症	0	1 (0.2)	0	0	0
硬膜下血腫	1 (0.7)	0	0	0	1 (<0.1)
脛骨骨折	0	0	0	0	0
隆起骨折	0	0	0	0	0
気管出血	0	2 (0.3)	0	0	0
気管損傷	0	1 (0.2)	0	0	0
気管閉塞	0	1 (0.2)	0	0	0
心臓障害	2 (1.4)	27 (4.4)	28 (2.6)	39 (2.4)	41 (2.3)
頻脈	2 (1.4)	11 (1.8)	9 (0.9)	11 (0.7)	13 (0.7)
徐脈	0	4 (0.7)	4 (0.4)	7 (0.4)	7 (0.4)
心肺停止	0	6 (1.0)	5 (0.5)	6 (0.4)	6 (0.3)
心停止	0	2 (0.3)	2 (0.2)	3 (0.2)	3 (0.2)
チアノーゼ	0	4 (0.7)	2 (0.2)	3 (0.2)	3 (0.2)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 24 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
心室性頻脈	0	0	2 (0.2)	3 (0.2)	3 (0.2)
左室肥大	0	0	2 (0.2)	2 (0.1)	2 (0.1)
心筋症	0	0	0	1 (<0.1)	1 (<0.1)
心膜気腫	0	0	0	1 (<0.1)	1 (<0.1)
洞性頻脈	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
上室性頻脈	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
動悸	0	0	0	0	0
代謝および栄養障害	6 (4.3)	20 (3.3)	22 (2.1)	31 (1.9)	37 (2.1)
体重増加不良	2 (1.4)	4 (0.7)	7 (0.7)	9 (0.6)	11 (0.6)
乳児および小児期早期の哺育障害	0	4 (0.7)	6 (0.6)	6 (0.4)	6 (0.3)
成長障害	2 (1.4)	2 (0.3)	3 (0.3)	4 (0.2)	6 (0.3)
栄養補給不耐性	0	0	4 (0.4)	4 (0.2)	4 (0.2)
低ナトリウム血症	0	0	0	3 (0.2)	3 (0.2)
過小食	0	0	0	2 (0.1)	2 (0.1)
脱水	2 (1.4)	2 (0.3)	1 (<0.1)	1 (<0.1)	3 (0.2)
鉄欠乏	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
代謝性アルカローシス	0	0	0	1 (<0.1)	1 (<0.1)
食欲減退	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 25 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
食物不耐性	0	1 (0.2)	0	0	0
高血糖	0	1 (0.2)	0	0	0
低血糖	0	2 (0.3)	0	0	0
低カリウム血症	0	3 (0.5)	0	0	0
食欲亢進	0	0	0	0	0
栄養障害	0	0	0	0	0
ビタミンD欠乏	0	1 (0.2)	0	0	0
神経系障害	3 (2.1)	6 (1.0)	10 (0.9)	22 (1.4)	25 (1.4)
不随意性筋収縮	0	0	1 (<0.1)	4 (0.2)	4 (0.2)
眼振	0	1 (0.2)	2 (0.2)	3 (0.2)	3 (0.2)
痙攣発作	0	0	1 (<0.1)	3 (0.2)	3 (0.2)
よだれ	0	0	1 (<0.1)	2 (0.1)	2 (0.1)
脳損傷	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
脳梗塞	0	0	0	1 (<0.1)	1 (<0.1)
脳脊髄液漏	0	0	0	1 (<0.1)	1 (<0.1)
間代	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
頭痛	0	0	0	1 (<0.1)	1 (<0.1)
低酸素性虚血性脳症	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
言語障害	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 26 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
嗜眠	0	0	0	1 (<0.1)	1 (<0.1)
傾眠	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
失神	0	0	0	1 (<0.1)	1 (<0.1)
失声症	0	0	0	0	0
浮動性めまい	0	0	0	0	0
味覚異常	0	0	0	0	0
失読症	0	0	0	0	0
反射亢進	1 (0.7)	0	0	0	1 (<0.1)
感覚鈍麻	0	0	0	0	0
筋緊張低下	2 (1.4)	0	0	0	2 (0.1)
片頭痛	0	0	0	0	0
ミオクローヌス	0	0	0	0	0
錯感覚	0	0	0	0	0
失神寸前の状態	0	5 (0.8)	0	0	0
振戦	0	0	0	0	0
精神障害	0	7 (1.1)	13 (1.2)	16 (1.0)	16 (0.9)
不安	0	0	2 (0.2)	5 (0.3)	5 (0.3)
易刺激性	0	1 (0.2)	4 (0.4)	4 (0.2)	4 (0.2)
激越	0	3 (0.5)	2 (0.2)	2 (0.1)	2 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 27 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
睡眠障害	0	2 (0.3)	2 (0.2)	2 (0.1)	2 (0.1)
息こらえ	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
気分動揺	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
落ち着きのなさ	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
注意欠陥多動性障害	0	0	0	0	0
不快気分	0	0	0	0	0
不眠症	0	0	0	0	0
睡眠時随伴症	0	0	0	0	0
チック	0	0	0	0	0
心因性嘔吐	0	0	0	0	0
免疫系障害	2 (1.4)	5 (0.8)	7 (0.7)	13 (0.8)	15 (0.8)
季節性アレルギー	1 (0.7)	2 (0.3)	3 (0.3)	6 (0.4)	7 (0.4)
薬物過敏症	0	1 (0.2)	2 (0.2)	4 (0.2)	4 (0.2)
過敏症	0	2 (0.3)	1 (<0.1)	2 (0.1)	2 (0.1)
食物アレルギー	1 (0.7)	0	1 (<0.1)	1 (<0.1)	2 (0.1)
化学物質アレルギー	0	0	0	0	0
血管障害	2 (1.4)	1 (0.2)	9 (0.9)	12 (0.7)	14 (0.8)
血栓症	0	0	4 (0.4)	4 (0.2)	4 (0.2)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 28 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
高血圧	1 (0.7)	0	1 (<0.1)	2 (0.1)	3 (0.2)
血管炎	0	0	2 (0.2)	2 (0.1)	2 (0.1)
毛細血管脆弱	0	0	0	1 (<0.1)	1 (<0.1)
本態性高血圧症	0	0	0	1 (<0.1)	1 (<0.1)
蒼白	1 (0.7)	0	1 (<0.1)	1 (<0.1)	2 (0.1)
ショック	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
充血	0	1 (0.2)	0	0	0
低血圧	0	0	0	0	0
先天性、家族性および遺伝性障害	0	4 (0.7)	4 (0.4)	7 (0.4)	7 (0.4)
斜頭症	0	0	0	2 (0.1)	2 (0.1)
斜指症	0	0	0	1 (<0.1)	1 (<0.1)
先天性横隔膜ヘルニア	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
発育性股関節形成不全	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
貧血母斑	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
鳩胸	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
停留精巣	0	1 (0.2)	0	0	0
包茎	0	1 (0.2)	0	0	0
眼障害	1 (0.7)	4 (0.7)	5 (0.5)	7 (0.4)	8 (0.5)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
乱視	0	0	0	1 (<0.1)	1 (<0.1)
霰粒腫	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
眼乾燥	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
眼運動障害	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
眼瞼下垂	0	0	0	1 (<0.1)	1 (<0.1)
近視	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
斜視	0	1 (0.2)	1 (<0.1)	1 (<0.1)	1 (<0.1)
弱視	0	1 (0.2)	0	0	0
眼瞼痙攣	0	0	0	0	0
後天性涙道狭窄	1 (0.7)	0	0	0	1 (<0.1)
遠視	0	0	0	0	0
流涙増加	0	1 (0.2)	0	0	0
血液およびリンパ系障害	2 (1.4)	4 (0.7)	1 (<0.1)	6 (0.4)	8 (0.5)
貧血	0	1 (0.2)	1 (<0.1)	3 (0.2)	3 (0.2)
リンパ節症	0	0	0	1 (<0.1)	1 (<0.1)
好中球減少症	1 (0.7)	0	0	1 (<0.1)	2 (0.1)
血小板増加症	0	0	0	1 (<0.1)	1 (<0.1)
骨髄障害	0	1 (0.2)	0	0	0
好酸球増加症	1 (0.7)	0	0	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 30 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
白血球増加症	0	2 (0.3)	0	0	0
生殖系および乳房障害	1 (0.7)	0	4 (0.4)	4 (0.2)	5 (0.3)
後天性包茎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
亀頭包皮炎	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
卵巣嚢胞	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
陰茎障害	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
会陰痛	0	0	0	0	0
外陰腟発疹	1 (0.7)	0	0	0	1 (<0.1)
耳および迷路障害	0	1 (0.2)	2 (0.2)	3 (0.2)	3 (0.2)
耳の障害	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
耳痛	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
耳垢分泌過多	0	0	0	1 (<0.1)	1 (<0.1)
耳出血	0	1 (0.2)	0	0	0
乗物酔い	0	0	0	0	0
鼓膜穿孔	0	0	0	0	0
腎および尿路障害	0	1 (0.2)	3 (0.3)	3 (0.2)	3 (0.2)
尿閉	0	0	2 (0.2)	2 (0.1)	2 (0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 31 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
水腎症	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
排尿困難	0	0	0	0	0
糖尿	0	1 (0.2)	0	0	0
尿失禁	0	0	0	0	0
膀胱尿管逆流	0	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (0.7)	0	0	2 (0.1)	3 (0.2)
アクロコルドン	0	0	0	1 (<0.1)	1 (<0.1)
血管の良性新生物	0	0	0	1 (<0.1)	1 (<0.1)
脂漏性角化症	1 (0.7)	0	0	0	1 (<0.1)
皮膚乳頭腫	0	0	0	0	0
肝胆道系障害	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
肝腫大	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
外科および内科処置	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
機械的換気	0	0	1 (<0.1)	1 (<0.1)	1 (<0.1)
内分泌障害	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Frequency of adverse events in infants diagnosed with SMA
Page 32 of 32

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
思春期早発症	0	0	0	0	0
妊娠、産褥および周産期の状態	1 (0.7)	0	0	0	1 (<0.1)
臍肉芽腫	1 (0.7)	0	0	0	1 (<0.1)

NOTE 1: Numbers in parentheses are percentages.
2: To match the corresponding table of incidence, preferred terms are presented by decreasing incidence within each system organ class in the column symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 131　Incidence of Adverse Events by Preferred Term in Infants Diagnosed With SMA

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 1 of 23

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	16 (80.0)	40 (97.6)	77 (96.3)	97 (97.0)	113 (94.2)
発熱	5 (25.0)	24 (58.5)	45 (56.3)	59 (59.0)	64 (53.3)
便秘	2 (10.0)	9 (22.0)	28 (35.0)	37 (37.0)	39 (32.5)
上気道感染	8 (40.0)	9 (22.0)	24 (30.0)	36 (36.0)	44 (36.7)
肺炎	2 (10.0)	7 (17.1)	23 (28.8)	30 (30.0)	32 (26.7)
呼吸窮迫	1 (5.0)	12 (29.3)	21 (26.3)	28 (28.0)	29 (24.2)
呼吸不全	0	16 (39.0)	20 (25.0)	26 (26.0)	26 (21.7)
無気肺	0	12 (29.3)	18 (22.5)	23 (23.0)	23 (19.2)
嘔吐	0	8 (19.5)	14 (17.5)	22 (22.0)	22 (18.3)
鼻咽頭炎	4 (20.0)	4 (9.8)	15 (18.8)	21 (21.0)	25 (20.8)
生歯	1 (5.0)	3 (7.3)	14 (17.5)	18 (18.0)	19 (15.8)
下痢	1 (5.0)	7 (17.1)	11 (13.8)	16 (16.0)	17 (14.2)
胃食道逆流性疾患	2 (10.0)	8 (19.5)	10 (12.5)	16 (16.0)	18 (15.0)
ライノウイルス感染	2 (10.0)	6 (14.6)	10 (12.5)	16 (16.0)	18 (15.0)
急性呼吸不全	0	10 (24.4)	11 (13.8)	15 (15.0)	15 (12.5)
咳嗽	3 (15.0)	8 (19.5)	9 (11.3)	15 (15.0)	18 (15.0)
鼻閉	3 (15.0)	5 (12.2)	8 (10.0)	15 (15.0)	18 (15.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 2 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
発疹	1 (5.0)	4 (9.8)	9 (11.3)	14 (14.0)	15 (12.5)
気道感染	0	2 (4.9)	9 (11.3)	14 (14.0)	14 (11.7)
酸素飽和度低下	1 (5.0)	10 (24.4)	10 (12.5)	12 (12.0)	13 (10.8)
誤嚥性肺炎	0	7 (17.1)	9 (11.3)	12 (12.0)	12 (10.0)
ウイルス感染	0	3 (7.3)	8 (10.0)	12 (12.0)	12 (10.0)
細気管支炎	1 (5.0)	3 (7.3)	8 (10.0)	11 (11.0)	12 (10.0)
低酸素症	0	2 (4.9)	7 (8.8)	11 (11.0)	11 (9.2)
関節拘縮	1 (5.0)	2 (4.9)	3 (3.8)	11 (11.0)	12 (10.0)
側弯症	0	2 (4.9)	4 (5.0)	11 (11.0)	11 (9.2)
おむつ皮膚炎	2 (10.0)	4 (9.8)	6 (7.5)	10 (10.0)	12 (10.0)
ウイルス性肺炎	1 (5.0)	2 (4.9)	7 (8.8)	10 (10.0)	11 (9.2)
ウイルス性上気道感染	0	7 (17.1)	8 (10.0)	10 (10.0)	10 (8.3)
嚥下障害	1 (5.0)	9 (22.0)	9 (11.3)	9 (9.0)	10 (8.3)
呼吸困難	0	6 (14.6)	7 (8.8)	9 (9.0)	9 (7.5)
中耳炎	3 (15.0)	2 (4.9)	3 (3.8)	9 (9.0)	12 (10.0)
頻脈	2 (10.0)	5 (12.2)	7 (8.8)	9 (9.0)	11 (9.2)
口腔カンジダ症	0	3 (7.3)	7 (8.8)	8 (8.0)	8 (6.7)
鼻漏	3 (15.0)	3 (7.3)	6 (7.5)	8 (8.0)	11 (9.2)
流涎過多	0	2 (4.9)	6 (7.5)	8 (8.0)	8 (6.7)
無呼吸	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (5.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 3 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
誤嚥	0	3 (7.3)	5 (6.3)	7 (7.0)	7 (5.8)
徐脈	0	3 (7.3)	4 (5.0)	7 (7.0)	7 (5.8)
気管支分泌物貯留	0	7 (17.1)	4 (5.0)	7 (7.0)	7 (5.8)
上気道うっ血	1 (5.0)	1 (2.4)	6 (7.5)	7 (7.0)	8 (6.7)
尿路感染	1 (5.0)	0	7 (8.8)	7 (7.0)	8 (6.7)
気管支炎	1 (5.0)	1 (2.4)	6 (7.5)	6 (6.0)	7 (5.8)
心肺停止	0	5 (12.2)	5 (6.3)	6 (6.0)	6 (5.0)
慢性呼吸不全	0	0	2 (2.5)	6 (6.0)	6 (5.0)
結膜炎	0	3 (7.3)	5 (6.3)	6 (6.0)	6 (5.0)
耳感染	0	1 (2.4)	5 (6.3)	6 (6.0)	6 (5.0)
放屁	2 (10.0)	1 (2.4)	4 (5.0)	6 (6.0)	8 (6.7)
インフルエンザ	3 (15.0)	0	5 (6.3)	6 (6.0)	9 (7.5)
呼吸停止	0	4 (9.8)	5 (6.3)	6 (6.0)	6 (5.0)
季節性アレルギー	1 (5.0)	2 (4.9)	3 (3.8)	6 (6.0)	7 (5.8)
体重減少	0	1 (2.4)	4 (5.0)	6 (6.0)	6 (5.0)
体重増加不良	1 (5.0)	2 (4.9)	5 (6.3)	6 (6.0)	7 (5.8)
不安	0	0	2 (2.5)	5 (5.0)	5 (4.2)
ウイルス性気管支炎	0	0	5 (6.3)	5 (5.0)	5 (4.2)
上気道分泌増加	0	1 (2.4)	1 (1.3)	5 (5.0)	5 (4.2)
脊柱後弯症	0	1 (2.4)	1 (1.3)	5 (5.0)	5 (4.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
下気道感染	0	2 (4.9)	4 (5.0)	5 (5.0)	5 (4.2)
疼痛	0	2 (4.9)	1 (1.3)	5 (5.0)	5 (4.2)
ＲＳウイルス細気管支炎	0	3 (7.3)	4 (5.0)	5 (5.0)	5 (4.2)
ウイルス性気道感染	0	2 (4.9)	4 (5.0)	5 (5.0)	5 (4.2)
腹部膨満	2 (10.0)	0	1 (1.3)	4 (4.0)	6 (5.0)
節足動物咬傷	1 (5.0)	0	1 (1.3)	4 (4.0)	5 (4.2)
胸郭変形	0	0	1 (1.3)	4 (4.0)	4 (3.3)
薬物過敏症	0	1 (2.4)	2 (2.5)	4 (4.0)	4 (3.3)
湿疹	0	2 (4.9)	1 (1.3)	4 (4.0)	4 (3.3)
成長障害	2 (10.0)	2 (4.9)	3 (3.8)	4 (4.0)	6 (5.0)
栄養補給チューブ合併症	0	3 (7.3)	2 (2.5)	4 (4.0)	4 (3.3)
胃炎	0	1 (2.4)	3 (3.8)	4 (4.0)	4 (3.3)
不随意性筋収縮	0	0	1 (1.3)	4 (4.0)	4 (3.3)
細菌性肺炎	0	3 (7.3)	3 (3.8)	4 (4.0)	4 (3.3)
処置による疼痛	0	0	2 (2.5)	4 (4.0)	4 (3.3)
副鼻腔うっ血	0	0	3 (3.8)	4 (4.0)	4 (3.3)
喘鳴	0	0	2 (2.5)	4 (4.0)	4 (3.3)
貧血	0	1 (2.4)	1 (1.3)	3 (3.0)	3 (2.5)
細菌性気管炎	0	4 (9.8)	1 (1.3)	3 (3.0)	3 (2.5)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 5 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
チアノーゼ	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
接触性皮膚炎	0	3 (7.3)	2 (2.5)	3 (3.0)	3 (2.5)
斑状出血	0	0	2 (2.5)	3 (3.0)	3 (2.5)
過剰肉芽組織	0	0	0	3 (3.0)	3 (2.5)
乳児および小児期早期の哺育障害	0	3 (7.3)	3 (3.8)	3 (3.0)	3 (2.5)
栄養補給不耐性	0	0	3 (3.8)	3 (3.0)	3 (2.5)
大腿骨骨折	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
ヒトライノウイルス検査陽性	0	0	1 (1.3)	3 (3.0)	3 (2.5)
低換気	0	0	2 (2.5)	3 (3.0)	3 (2.5)
易刺激性	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
ウイルス性下気道感染	0	0	2 (2.5)	3 (3.0)	3 (2.5)
好中球数増加	0	0	1 (1.3)	3 (3.0)	3 (2.5)
眼振	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.5)
気胸	0	0	1 (1.3)	3 (3.0)	3 (2.5)
シュードモナス感染	0	2 (4.9)	3 (3.8)	3 (3.0)	3 (2.5)
鼻炎	2 (10.0)	3 (7.3)	2 (2.5)	3 (3.0)	5 (4.2)
皮膚刺激	0	0	0	3 (3.0)	3 (2.5)
ストーマ部紅斑	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
腹部不快感	1 (5.0)	0	2 (2.5)	2 (2.0)	3 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 6 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
アデノウイルス感染	0	0	2 (2.5)	2 (2.0)	2 (1.7)
激越	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
細菌感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
血中カリウム減少	0	0	2 (2.5)	2 (2.0)	2 (1.7)
体温上昇	1 (5.0)	1 (2.4)	2 (2.5)	2 (2.0)	3 (2.5)
Ｃ－反応性蛋白増加	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
カンジダ性おむつ皮疹	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
息詰まり	1 (5.0)	1 (2.4)	1 (1.3)	2 (2.0)	3 (2.5)
細菌性結膜炎	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
挫傷	0	0	1 (1.3)	2 (2.0)	2 (1.7)
皮膚炎	2 (10.0)	0	1 (1.3)	2 (2.0)	4 (3.3)
医療機器閉塞	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
不快感	0	0	0	2 (2.0)	2 (1.7)
よだれ	0	0	1 (1.3)	2 (2.0)	2 (1.7)
エンテロウイルス感染	0	0	0	2 (2.0)	2 (1.7)
皮膚真菌感染	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
胃腸炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
血便排泄	0	0	2 (2.5)	2 (2.0)	2 (1.7)
手足口病	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
心拍数増加	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 7 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
過角化	0	0	2 (2.5)	2 (2.0)	2 (1.7)
過敏症	0	2 (4.9)	1 (1.3)	2 (2.0)	2 (1.7)
高血圧	1 (5.0)	0	1 (1.3)	2 (2.0)	3 (2.5)
低ナトリウム血症	0	0	0	2 (2.0)	2 (1.7)
過小食	0	0	0	2 (2.0)	2 (1.7)
関節脱臼	0	0	0	2 (2.0)	2 (1.7)
後側弯症	0	0	1 (1.3)	2 (2.0)	2 (1.7)
左室肥大	0	0	2 (2.5)	2 (2.0)	2 (1.7)
医学的観察	0	0	2 (2.5)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)
汗疹	0	0	2 (2.5)	2 (2.0)	2 (1.7)
モラクセラ感染	0	0	1 (1.3)	2 (2.0)	2 (1.7)
モラクセラ検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
末梢性浮腫	0	0	0	2 (2.0)	2 (1.7)
四肢痛	0	0	1 (1.3)	2 (2.0)	2 (1.7)
パラインフルエンザウイルス感染	0	1 (2.4)	0	2 (2.0)	2 (1.7)
斜頭症	0	0	0	2 (2.0)	2 (1.7)
モラクセラ菌性肺炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
頭位性斜頭症	1 (5.0)	1 (2.4)	2 (2.5)	2 (2.0)	3 (2.5)
シュードモナス検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
肺うっ血	0	0	0	2 (2.0)	2 (1.7)
肺水腫	0	0	0	2 (2.0)	2 (1.7)
呼吸障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
気道うっ血	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
アレルギー性鼻炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
痙攣発作	0	0	1 (1.3)	2 (2.0)	2 (1.7)
敗血症	0	0	2 (2.5)	2 (2.0)	2 (1.7)
皮膚擦過傷	0	0	0	2 (2.0)	2 (1.7)
皮膚カンジダ	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
ブドウ球菌検査陽性	0	0	1 (1.3)	2 (2.0)	2 (1.7)
ストーマ部膿瘍	0	0	2 (2.5)	2 (2.0)	2 (1.7)
斜頚	1 (5.0)	0	0	2 (2.0)	3 (2.5)
呼吸補助筋の動員	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
心室性頻脈	0	0	1 (1.3)	2 (2.0)	2 (1.7)
白血球数増加	1 (5.0)	0	0	2 (2.0)	3 (2.5)
腹痛	0	0	0	1 (1.0)	1 (0.8)
後天性包茎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
アクロコルドン	0	0	0	1 (1.0)	1 (0.8)
急性呼吸窮迫症候群	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
アデノウイルス性上気道感染	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 9 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.8)
アラニンアミノトランスフェラーゼ増加	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
脱毛症	0	0	0	1 (1.0)	1 (0.8)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.8)
無呼吸発作	0	0	0	1 (1.0)	1 (0.8)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
窒息	0	0	0	1 (1.0)	1 (0.8)
乱視	0	0	0	1 (1.0)	1 (0.8)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
細菌性疾患キャリアー	0	1 (2.4)	0	1 (1.0)	1 (0.8)
亀頭包皮炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管の良性新生物	0	0	0	1 (1.0)	1 (0.8)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中鉄減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
体温低下	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
骨密度減少	0	0	0	1 (1.0)	1 (0.8)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)
息こらえ	0	0	1 (1.3)	1 (1.0)	1 (0.8)
呼吸音異常	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 10 of 23

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
気管支閉塞	0	0	1 (1.3)	1 (1.0)	1 (0.8)
毛細血管脆弱	0	0	0	1 (1.0)	1 (0.8)
心筋症	0	0	0	1 (1.0)	1 (0.8)
カテーテル留置部位炎症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
蜂巣炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
脳梗塞	0	0	0	1 (1.0)	1 (0.8)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.8)
霰粒腫	0	0	1 (1.3)	1 (1.0)	1 (0.8)
口唇のひび割れ	0	0	0	1 (1.0)	1 (0.8)
斜指症	0	0	0	1 (1.0)	1 (0.8)
間代	0	0	1 (1.3)	1 (1.0)	1 (0.8)
先天性横隔膜ヘルニア	0	0	1 (1.3)	1 (1.0)	1 (0.8)
コロナウイルス感染	0	2 (4.9)	0	1 (1.0)	1 (0.8)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.8)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
脱水	2 (10.0)	2 (4.9)	1 (1.3)	1 (1.0)	3 (2.5)
泉門閉鎖遅延	0	0	1 (1.3)	1 (1.0)	1 (0.8)
麻酔からの覚醒遅延	0	0	1 (1.3)	1 (1.0)	1 (0.8)
アレルギー性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
発育性股関節形成不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
医療機器リーク	0	0	0	1 (1.0)	1 (0.8)
薬物不耐性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
眼乾燥	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
皮膚乾燥	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
ダンピング症候群	0	0	0	1 (1.0)	1 (0.8)
耳擦過傷	0	0	0	1 (1.0)	1 (0.8)
耳の障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
耳痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
感染性湿疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
心電図ＳＴ－Ｔ部分異常	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
蟯虫症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腸球菌感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
紅斑	1 (5.0)	3 (7.3)	1 (1.3)	1 (1.0)	2 (1.7)
伝染性紅斑	0	0	0	1 (1.0)	1 (0.8)
大腸菌感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
本態性高血圧症	0	0	0	1 (1.0)	1 (0.8)
耳垢分泌過多	0	0	0	1 (1.0)	1 (0.8)
擦過傷	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
伝染病曝露	0	0	1 (1.3)	1 (1.0)	1 (0.8)
眼感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
眼運動障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.8)
食物アレルギー	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
排便回数増加	0	0	0	1 (1.0)	1 (0.8)
真菌感染	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
胃出血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ウイルス性胃炎	0	0	0	1 (1.0)	1 (0.8)
ロタウイルス胃腸炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ウイルス性胃腸炎	2 (10.0)	2 (4.9)	1 (1.3)	1 (1.0)	3 (2.5)
消化管運動低下	0	0	0	1 (1.0)	1 (0.8)
全身健康状態低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)
環状肉芽腫	0	0	1 (1.3)	1 (1.0)	1 (0.8)
吐血	0	0	0	1 (1.0)	1 (0.8)
ヘモフィルス感染	0	0	0	1 (1.0)	1 (0.8)
手変形	0	0	0	1 (1.0)	1 (0.8)
頭痛	0	0	0	1 (1.0)	1 (0.8)
心拍数減少	0	1 (2.4)	0	1 (1.0)	1 (0.8)
心拍数不整	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肝腫大	0	0	1 (1.3)	1 (1.0)	1 (0.8)
水腎症	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 13 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
減呼吸	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低体温	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
胃排出不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
膿痂疹	1 (5.0)	1 (2.4)	1 (1.3)	1 (1.0)	2 (1.7)
気管支分泌増加	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
乳児仙痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
乳児吐出	0	0	1 (1.3)	1 (1.0)	1 (0.8)
炎症マーカー上昇	0	0	1 (1.3)	1 (1.0)	1 (0.8)
A型インフルエンザウイルス検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
間擦疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
鉄欠乏	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ワクチン接種後の易刺激性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
関節硬直	0	1 (2.4)	0	1 (1.0)	1 (0.8)
言語障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
喉頭肉芽腫	0	0	0	1 (1.0)	1 (0.8)
嗜眠	0	0	0	1 (1.0)	1 (0.8)
口唇損傷	0	0	0	1 (1.0)	1 (0.8)
肝機能検査異常	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
限局性感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
脊柱前弯症	0	0	0	1 (1.0)	1 (0.8)
肺障害	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
リンパ節症	0	0	0	1 (1.0)	1 (0.8)
倦怠感	0	0	1 (1.3)	1 (1.0)	1 (0.8)
機械的換気	0	0	1 (1.3)	1 (1.0)	1 (0.8)
医療機器合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
代謝性アルカローシス	0	0	0	1 (1.0)	1 (0.8)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.8)
粘膜皮膚カンジダ症	0	0	0	1 (1.0)	1 (0.8)
近視	0	0	1 (1.3)	1 (1.0)	1 (0.8)
貧血母斑	0	0	1 (1.3)	1 (1.0)	1 (0.8)
鼻汁変色	0	0	0	1 (1.0)	1 (0.8)
好中球減少症	1 (5.0)	0	0	1 (1.0)	2 (1.7)
好中球百分率増加	0	0	0	1 (1.0)	1 (0.8)
小結節	0	0	1 (1.3)	1 (1.0)	1 (0.8)
院内感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
浮腫	0	3 (7.3)	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 15 of 23

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
口腔真菌感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
口腔ヘルペス	0	0	1 (1.3)	1 (1.0)	1 (0.8)
整形外科検査	0	0	1 (1.3)	1 (1.0)	1 (0.8)
急性中耳炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
卵巣嚢胞	0	0	1 (1.3)	1 (1.0)	1 (0.8)
蒼白	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
鳩胸	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
陰茎障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
末梢腫脹	0	0	0	1 (1.0)	1 (0.8)
点状出血	1 (5.0)	0	0	1 (1.0)	2 (1.7)
レンサ球菌性咽頭炎	1 (5.0)	0	0	1 (1.0)	2 (1.7)
胸水	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気縦隔症	0	0	0	1 (1.0)	1 (0.8)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
パラインフルエンザウイルス性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
肺炎球菌性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
シュードモナス菌性肺炎	0	1 (2.4)	0	1 (1.0)	1 (0.8)
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
心膜気腫	0	0	0	1 (1.0)	1 (0.8)
外傷性気胸	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 16 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
処置後腫脹	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.8)
湿性咳嗽	0	0	0	1 (1.0)	1 (0.8)
そう痒症	0	0	0	1 (1.0)	1 (0.8)
腎盂腎炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
斑状皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
呼吸性アルカローシス	0	0	1 (1.3)	1 (1.0)	1 (0.8)
細菌性気道感染	0	1 (2.4)	0	1 (1.0)	1 (0.8)
落ち着きのなさ	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
拘束性肺疾患	0	0	0	1 (1.0)	1 (0.8)
低音性連続性ラ音	0	0	0	1 (1.0)	1 (0.8)
ばら疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
セラチア検査陽性	0	0	0	1 (1.0)	1 (0.8)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.8)
洞性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.8)
皮膚色素脱失	0	0	0	1 (1.0)	1 (0.8)
皮膚障害	0	0	0	1 (1.0)	1 (0.8)
皮膚浮腫	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 17 of 23

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
皮膚潰瘍	0	0	0	1 (1.0)	1 (0.8)
睡眠時無呼吸症候群	0	4 (9.8)	0	1 (1.0)	1 (0.8)
睡眠障害	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
軟部組織損傷	0	0	0	1 (1.0)	1 (0.8)
傾眠	0	0	1 (1.3)	1 (1.0)	1 (0.8)
脊柱変形	0	0	0	1 (1.0)	1 (0.8)
変色痰	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
ブドウ球菌性菌血症	0	0	0	1 (1.0)	1 (0.8)
ブドウ球菌感染	0	2 (4.9)	0	1 (1.0)	1 (0.8)
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ブドウ球菌皮膚感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ合併症	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ部感染	0	3 (7.3)	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ部刺激感	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
斜視	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
レンサ球菌検査陽性	0	0	0	1 (1.0)	1 (0.8)
皮下気腫	0	0	0	1 (1.0)	1 (0.8)
サンバーン	0	0	0	1 (1.0)	1 (0.8)
上室性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.8)
外科手術不成功	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 18 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
腫脹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
失神	0	0	0	1 (1.0)	1 (0.8)
滑膜炎	0	0	0	1 (1.0)	1 (0.8)
頻呼吸	0	2 (4.9)	0	1 (1.0)	1 (0.8)
熱傷	0	0	0	1 (1.0)	1 (0.8)
血小板増加症	0	0	0	1 (1.0)	1 (0.8)
血栓症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
歯牙損傷	0	0	0	1 (1.0)	1 (0.8)
気管障害	0	0	0	1 (1.0)	1 (0.8)
気管炎	0	1 (2.4)	0	1 (1.0)	1 (0.8)
上部消化管出血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.8)
尿量減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
蕁麻疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ワクチン接種合併症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
血管炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管穿刺部位内出血	0	2 (4.9)	0	1 (1.0)	1 (0.8)
ビタミンA減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
上腹部痛	0	2 (4.9)	0	0	0
弱視	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 19 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
適用部位紅斑	1 (5.0)	0	0	0	1 (0.8)
適用部位発疹	0	1 (2.4)	0	0	0
菌血症	0	1 (2.4)	0	0	0
血中アルカリホスファターゼ増加	1 (5.0)	0	0	0	1 (0.8)
骨髄障害	0	1 (2.4)	0	0	0
カンジダ感染	0	3 (7.3)	0	0	0
カンジダ性敗血症	0	1 (2.4)	0	0	0
カタル	0	1 (2.4)	0	0	0
停留精巣	0	1 (2.4)	0	0	0
後天性涙道狭窄	1 (5.0)	0	0	0	1 (0.8)
褥瘡性潰瘍	0	3 (7.3)	0	0	0
アトピー性皮膚炎	0	2 (4.9)	0	0	0
医療機器機能不良	0	1 (2.4)	0	0	0
血性下痢	0	1 (2.4)	0	0	0
耳出血	0	1 (2.4)	0	0	0
ブドウ球菌性耳感染	1 (5.0)	0	0	0	1 (0.8)
貨幣状湿疹	1 (5.0)	0	0	0	1 (0.8)
気管内挿管合併症	0	1 (2.4)	0	0	0
小腸炎	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 20 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
好酸球数増加	1 (5.0)	0	0	0	1 (0.8)
好酸球増加症	1 (5.0)	0	0	0	1 (0.8)
心窩部不快感	0	1 (2.4)	0	0	0
転倒	1 (5.0)	0	0	0	1 (0.8)
疲労	0	1 (2.4)	0	0	0
食物不耐性	0	1 (2.4)	0	0	0
胃腸出血	0	1 (2.4)	0	0	0
消化管運動障害	0	1 (2.4)	0	0	0
消化管刺激症状	0	1 (2.4)	0	0	0
糖尿	0	1 (2.4)	0	0	0
頭部損傷	0	1 (2.4)	0	0	0
ヘッドラグ異常	0	1 (2.4)	0	0	0
麦粒腫	0	1 (2.4)	0	0	0
充血	0	1 (2.4)	0	0	0
高血糖	0	1 (2.4)	0	0	0
多汗症	0	1 (2.4)	0	0	0
反射亢進	1 (5.0)	0	0	0	1 (0.8)
低血糖	0	2 (4.9)	0	0	0
低カリウム血症	0	3 (7.3)	0	0	0
筋緊張低下	2 (10.0)	0	0	0	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 21 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
切開部位紅斑	0	1 (2.4)	0	0	0
注入部位内出血	1 (5.0)	1 (2.4)	0	0	1 (0.8)
注入部位血管外漏出	0	1 (2.4)	0	0	0
注射部位血腫	0	1 (2.4)	0	0	0
関節可動域低下	0	1 (2.4)	0	0	0
毛孔性角化症	0	1 (2.4)	0	0	0
裂傷	0	1 (2.4)	0	0	0
流涙増加	0	1 (2.4)	0	0	0
白血球増加症	0	1 (2.4)	0	0	0
リンパ節触知	0	1 (2.4)	0	0	0
リンパ球数増加	1 (5.0)	0	0	0	1 (0.8)
筋緊張	0	1 (2.4)	0	0	0
筋力低下	2 (10.0)	1 (2.4)	0	0	2 (1.7)
口腔咽頭痛	0	1 (2.4)	0	0	0
包茎	0	1 (2.4)	0	0	0
処置後合併症	1 (5.0)	0	0	0	1 (0.8)
処置後挫傷	0	1 (2.4)	0	0	0
処置後不快感	1 (5.0)	0	0	0	1 (0.8)
処置後出血	0	1 (2.4)	0	0	0
失神寸前の状態	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
紅斑性皮疹	1 (5.0)	1 (2.4)	0	0	1 (0.8)
呼吸性アシドーシス	1 (5.0)	0	0	0	1 (0.8)
呼吸数増加	0	1 (2.4)	0	0	0
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0
レッチング	0	1 (2.4)	0	0	0
脂漏性皮膚炎	1 (5.0)	0	0	0	1 (0.8)
脂漏性角化症	1 (5.0)	0	0	0	1 (0.8)
セラチア感染	0	1 (2.4)	0	0	0
副鼻腔炎	0	1 (2.4)	0	0	0
皮膚感染	1 (5.0)	1 (2.4)	0	0	1 (0.8)
喀痰培養陽性	0	1 (2.4)	0	0	0
ストーマ部出血	0	1 (2.4)	0	0	0
ストーマ部炎症	0	1 (2.4)	0	0	0
口内炎	0	1 (2.4)	0	0	0
レンサ球菌感染	1 (5.0)	0	0	0	1 (0.8)
硬膜下血腫	1 (5.0)	0	0	0	1 (0.8)
全身性感染	0	1 (2.4)	0	0	0
舌萎縮	0	1 (2.4)	0	0	0
気管出血	0	1 (2.4)	0	0	0
気管損傷	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in infants diagnosed with SMA
Page 23 of 23

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
気管閉塞	0	1 (2.4)	0	0	0
トランスアミナーゼ上昇	0	1 (2.4)	0	0	0
臍肉芽腫	1 (5.0)	0	0	0	1 (0.8)
上気道の炎症	0	2 (4.9)	0	0	0
血管穿刺部位反応	0	1 (2.4)	0	0	0
ウイルス性発疹	0	1 (2.4)	0	0	0
ビタミンD減少	0	1 (2.4)	0	0	0
ビタミンD欠乏	0	1 (2.4)	0	0	0
外陰腟発疹	1 (5.0)	0	0	0	1 (0.8)
体重支持困難	1 (5.0)	0	0	0	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) - controlled and uncontrolled studies: ISIS 396443.

表 132　Incidence of Adverse Events by Preferred Term in Subjects With SMA Treated With ISIS 396443

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 1 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	16 (80.0)	97 (97.0)	113 (94.2)	56 (100.0)	169 (96.0)
発熱	5 (25.0)	59 (59.0)	64 (53.3)	16 (28.6)	80 (45.5)
上気道感染	8 (40.0)	36 (36.0)	44 (36.7)	27 (48.2)	71 (40.3)
便秘	2 (10.0)	37 (37.0)	39 (32.5)	7 (12.5)	46 (26.1)
鼻咽頭炎	4 (20.0)	21 (21.0)	25 (20.8)	16 (28.6)	41 (23.3)
肺炎	2 (10.0)	30 (30.0)	32 (26.7)	5 (8.9)	37 (21.0)
嘔吐	0	22 (22.0)	22 (18.3)	12 (21.4)	34 (19.3)
頭痛	0	1 (1.0)	1 (0.8)	28 (50.0)	29 (16.5)
呼吸窮迫	1 (5.0)	28 (28.0)	29 (24.2)	0	29 (16.5)
呼吸不全	0	26 (26.0)	26 (21.7)	1 (1.8)	27 (15.3)
側弯症	0	11 (11.0)	11 (9.2)	15 (26.8)	26 (14.8)
無気肺	0	23 (23.0)	23 (19.2)	1 (1.8)	24 (13.6)
背部痛	0	1 (1.0)	1 (0.8)	23 (41.1)	24 (13.6)
咳嗽	3 (15.0)	15 (15.0)	18 (15.0)	6 (10.7)	24 (13.6)
腰椎穿刺後症候群	0	0	0	23 (41.1)	23 (13.1)
関節拘縮	1 (5.0)	11 (11.0)	12 (10.0)	10 (17.9)	22 (12.5)
鼻閉	3 (15.0)	15 (15.0)	18 (15.0)	3 (5.4)	21 (11.9)
ウイルス感染	0	12 (12.0)	12 (10.0)	9 (16.1)	21 (11.9)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 2 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
下痢	1 (5.0)	16 (16.0)	17 (14.2)	2 (3.6)	19 (10.8)
胃食道逆流性疾患	2 (10.0)	16 (16.0)	18 (15.0)	1 (1.8)	19 (10.8)
生歯	1 (5.0)	18 (18.0)	19 (15.8)	0	19 (10.8)
ライノウイルス感染	2 (10.0)	16 (16.0)	18 (15.0)	0	18 (10.2)
中耳炎	3 (15.0)	9 (9.0)	12 (10.0)	5 (8.9)	17 (9.7)
鼻漏	3 (15.0)	8 (8.0)	11 (9.2)	6 (10.7)	17 (9.7)
急性呼吸不全	0	15 (15.0)	15 (12.5)	1 (1.8)	16 (9.1)
発疹	1 (5.0)	14 (14.0)	15 (12.5)	1 (1.8)	16 (9.1)
気道感染	0	14 (14.0)	14 (11.7)	1 (1.8)	15 (8.5)
ウイルス性上気道感染	0	10 (10.0)	10 (8.3)	5 (8.9)	15 (8.5)
低酸素症	0	11 (11.0)	11 (9.2)	3 (5.4)	14 (8.0)
おむつ皮膚炎	2 (10.0)	10 (10.0)	12 (10.0)	1 (1.8)	13 (7.4)
酸素飽和度低下	1 (5.0)	12 (12.0)	13 (10.8)	0	13 (7.4)
ウイルス性肺炎	1 (5.0)	10 (10.0)	11 (9.2)	2 (3.6)	13 (7.4)
細気管支炎	1 (5.0)	11 (11.0)	12 (10.0)	0	12 (6.8)
インフルエンザ	3 (15.0)	6 (6.0)	9 (7.5)	3 (5.4)	12 (6.8)
誤嚥性肺炎	0	12 (12.0)	12 (10.0)	0	12 (6.8)
頻脈	2 (10.0)	9 (9.0)	11 (9.2)	1 (1.8)	12 (6.8)
尿路感染	1 (5.0)	7 (7.0)	8 (6.7)	4 (7.1)	12 (6.8)
ウイルス性胃腸炎	2 (10.0)	1 (1.0)	3 (2.5)	8 (14.3)	11 (6.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 3 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
嚥下障害	1 (5.0)	9 (9.0)	10 (8.3)	0	10 (5.7)
呼吸困難	0	9 (9.0)	9 (7.5)	1 (1.8)	10 (5.7)
耳感染	0	6 (6.0)	6 (5.0)	4 (7.1)	10 (5.7)
悪心	0	0	0	10 (17.9)	10 (5.7)
レンサ球菌性咽頭炎	1 (5.0)	1 (1.0)	2 (1.7)	8 (14.3)	10 (5.7)
処置による疼痛	0	4 (4.0)	4 (3.3)	6 (10.7)	10 (5.7)
穿刺部位疼痛	0	0	0	10 (17.9)	10 (5.7)
季節性アレルギー	1 (5.0)	6 (6.0)	7 (5.8)	3 (5.4)	10 (5.7)
結膜炎	0	6 (6.0)	6 (5.0)	3 (5.4)	9 (5.1)
放屁	2 (10.0)	6 (6.0)	8 (6.7)	1 (1.8)	9 (5.1)
胃腸炎	0	2 (2.0)	2 (1.7)	7 (12.5)	9 (5.1)
体重減少	0	6 (6.0)	6 (5.0)	3 (5.4)	9 (5.1)
節足動物咬傷	1 (5.0)	4 (4.0)	5 (4.2)	3 (5.4)	8 (4.5)
口腔カンジダ症	0	8 (8.0)	8 (6.7)	0	8 (4.5)
口腔咽頭痛	0	0	0	8 (14.3)	8 (4.5)
流涎過多	0	8 (8.0)	8 (6.7)	0	8 (4.5)
上気道うっ血	1 (5.0)	7 (7.0)	8 (6.7)	0	8 (4.5)
無呼吸	0	7 (7.0)	7 (5.8)	0	7 (4.0)
誤嚥	0	7 (7.0)	7 (5.8)	0	7 (4.0)
徐脈	0	7 (7.0)	7 (5.8)	0	7 (4.0)
気管支分泌物貯留	0	7 (7.0)	7 (5.8)	0	7 (4.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 4 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
気管支炎	1 (5.0)	6 (6.0)	7 (5.8)	0	7 (4.0)
裂傷	0	0	0	7 (12.5)	7 (4.0)
疼痛	0	5 (5.0)	5 (4.2)	2 (3.6)	7 (4.0)
四肢痛	0	2 (2.0)	2 (1.7)	5 (8.9)	7 (4.0)
体重増加不良	1 (5.0)	6 (6.0)	7 (5.8)	0	7 (4.0)
腹部膨満	2 (10.0)	4 (4.0)	6 (5.0)	0	6 (3.4)
心肺停止	0	6 (6.0)	6 (5.0)	0	6 (3.4)
慢性呼吸不全	0	6 (6.0)	6 (5.0)	0	6 (3.4)
接触性皮膚炎	0	3 (3.0)	3 (2.5)	3 (5.4)	6 (3.4)
湿疹	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
成長障害	2 (10.0)	4 (4.0)	6 (5.0)	0	6 (3.4)
大腿骨骨折	0	3 (3.0)	3 (2.5)	3 (5.4)	6 (3.4)
下気道感染	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
呼吸停止	0	6 (6.0)	6 (5.0)	0	6 (3.4)
ＲＳウイルス細気管支炎	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
ウイルス性気道感染	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
鼻炎	2 (10.0)	3 (3.0)	5 (4.2)	1 (1.8)	6 (3.4)
副鼻腔うっ血	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
不安	0	5 (5.0)	5 (4.2)	0	5 (2.8)
関節痛	0	0	0	5 (8.9)	5 (2.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 5 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ウイルス性気管支炎	0	5 (5.0)	5 (4.2)	0	5 (2.8)
脱水	2 (10.0)	1 (1.0)	3 (2.5)	2 (3.6)	5 (2.8)
皮膚炎	2 (10.0)	2 (2.0)	4 (3.3)	1 (1.8)	5 (2.8)
薬物過敏症	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
過敏症	0	2 (2.0)	2 (1.7)	3 (5.4)	5 (2.8)
上気道分泌増加	0	5 (5.0)	5 (4.2)	0	5 (2.8)
脊柱後弯症	0	5 (5.0)	5 (4.2)	0	5 (2.8)
喘鳴	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
腹部不快感	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
激越	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
アフタ性潰瘍	0	1 (1.0)	1 (0.8)	3 (5.4)	4 (2.3)
体温上昇	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
挫傷	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
胸郭変形	0	4 (4.0)	4 (3.3)	0	4 (2.3)
栄養補給チューブ合併症	0	4 (4.0)	4 (3.3)	0	4 (2.3)
胃炎	0	4 (4.0)	4 (3.3)	0	4 (2.3)
関節脱臼	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
限局性感染	0	1 (1.0)	1 (0.8)	3 (5.4)	4 (2.3)
不随意性筋収縮	0	4 (4.0)	4 (3.3)	0	4 (2.3)
筋肉痛	0	0	0	4 (7.1)	4 (2.3)
細菌性肺炎	0	4 (4.0)	4 (3.3)	0	4 (2.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 6 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
皮膚カンジダ	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
腹痛	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
貧血	0	3 (3.0)	3 (2.5)	0	3 (1.7)
細菌性気管炎	0	3 (3.0)	3 (2.5)	0	3 (1.7)
心停止	0	3 (3.0)	3 (2.5)	0	3 (1.7)
息詰まり	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
チアノーゼ	0	3 (3.0)	3 (2.5)	0	3 (1.7)
斑状出血	0	3 (3.0)	3 (2.5)	0	3 (1.7)
鼻出血	0	0	0	3 (5.4)	3 (1.7)
紅斑	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
過剰肉芽組織	0	3 (3.0)	3 (2.5)	0	3 (1.7)
疲労	0	0	0	3 (5.4)	3 (1.7)
乳児および小児期早期の哺育障害	0	3 (3.0)	3 (2.5)	0	3 (1.7)
栄養補給不耐性	0	3 (3.0)	3 (2.5)	0	3 (1.7)
皮膚真菌感染	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
手足口病	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
心拍数増加	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ヒトライノウイルス検査陽性	0	3 (3.0)	3 (2.5)	0	3 (1.7)
高血圧	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
低換気	0	3 (3.0)	3 (2.5)	0	3 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 7 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
膿痂疹	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
易刺激性	0	3 (3.0)	3 (2.5)	0	3 (1.7)
四肢損傷	0	0	0	3 (5.4)	3 (1.7)
ウイルス性下気道感染	0	3 (3.0)	3 (2.5)	0	3 (1.7)
汗疹	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
頚部痛	0	0	0	3 (5.4)	3 (1.7)
好中球減少症	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
好中球数増加	0	3 (3.0)	3 (2.5)	0	3 (1.7)
眼振	0	3 (3.0)	3 (2.5)	0	3 (1.7)
気胸	0	3 (3.0)	3 (2.5)	0	3 (1.7)
頭位性斜頭症	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
シュードモナス感染	0	3 (3.0)	3 (2.5)	0	3 (1.7)
肺うっ血	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
呼吸障害	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
ＲＳウイルス感染	0	0	0	3 (5.4)	3 (1.7)
副鼻腔炎	0	0	0	3 (5.4)	3 (1.7)
皮膚刺激	0	3 (3.0)	3 (2.5)	0	3 (1.7)
ストーマ部紅斑	0	3 (3.0)	3 (2.5)	0	3 (1.7)
サンバーン	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
扁桃肥大	0	0	0	3 (5.4)	3 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 8 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
斜頚	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
白血球数増加	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
上腹部痛	0	0	0	2 (3.6)	2 (1.1)
アデノウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
術後激越	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
アラニンアミノトランスフェラーゼ増加	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
細菌感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
血中カリウム減少	0	2 (2.0)	2 (1.7)	0	2 (1.1)
Ｃ－反応性蛋白増加	0	2 (2.0)	2 (1.7)	0	2 (1.1)
カンジダ性おむつ皮疹	0	2 (2.0)	2 (1.7)	0	2 (1.1)
蜂巣炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
細菌性結膜炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
医療機器閉塞	0	2 (2.0)	2 (1.7)	0	2 (1.1)
不快感	0	2 (2.0)	2 (1.7)	0	2 (1.1)
よだれ	0	2 (2.0)	2 (1.7)	0	2 (1.1)
耳痛	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
エンテロウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
転倒	1 (5.0)	0	1 (0.8)	1 (1.8)	2 (1.1)
食物アレルギー	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
ウイルス性消化管感染	0	0	0	2 (3.6)	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 9 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血便排泄	0	2 (2.0)	2 (1.7)	0	2 (1.1)
過角化	0	2 (2.0)	2 (1.7)	0	2 (1.1)
感覚鈍麻	0	0	0	2 (3.6)	2 (1.1)
低ナトリウム血症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
過小食	0	2 (2.0)	2 (1.7)	0	2 (1.1)
低体温	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
筋緊張低下	2 (10.0)	0	2 (1.7)	0	2 (1.1)
関節損傷	0	0	0	2 (3.6)	2 (1.1)
後側弯症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
左室肥大	0	2 (2.0)	2 (1.7)	0	2 (1.1)
脊柱前弯症	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
医学的観察	0	2 (2.0)	2 (1.7)	0	2 (1.1)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
モラクセラ感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
モラクセラ検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
筋緊張	0	0	0	2 (3.6)	2 (1.1)
筋力低下	2 (10.0)	0	2 (1.7)	0	2 (1.1)
末梢性浮腫	0	2 (2.0)	2 (1.7)	0	2 (1.1)
口腔内痛	0	0	0	2 (3.6)	2 (1.1)
急性中耳炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
蒼白	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 10 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
動悸	0	0	0	2 (3.6)	2 (1.1)
パラインフルエンザウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)
骨盤変形	0	0	0	2 (3.6)	2 (1.1)
末梢腫脹	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
点状出血	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
斜頭症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
モラクセラ菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
処置後腫脹	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
処置による悪心	0	0	0	2 (3.6)	2 (1.1)
シュードモナス検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
肺水腫	0	2 (2.0)	2 (1.7)	0	2 (1.1)
気道うっ血	0	2 (2.0)	2 (1.7)	0	2 (1.1)
拘束性肺疾患	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
アレルギー性鼻炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
痙攣発作	0	2 (2.0)	2 (1.7)	0	2 (1.1)
敗血症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
皮膚擦過傷	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ブドウ球菌検査陽性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
ストーマ部膿瘍	0	2 (2.0)	2 (1.7)	0	2 (1.1)
斜視	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 11 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
失神	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
熱傷	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
隆起骨折	0	0	0	2 (3.6)	2 (1.1)
蕁麻疹	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
呼吸補助筋の動員	0	2 (2.0)	2 (1.7)	0	2 (1.1)
心室性頻脈	0	2 (2.0)	2 (1.7)	0	2 (1.1)
血管穿刺部位内出血	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
ざ瘡	0	0	0	1 (1.8)	1 (0.6)
後天性包茎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
アクロコルドン	0	1 (1.0)	1 (0.8)	0	1 (0.6)
急性呼吸窮迫症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
アデノウイルス性上気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脱毛症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
失声症	0	0	0	1 (1.8)	1 (0.6)
無呼吸発作	0	1 (1.0)	1 (0.8)	0	1 (0.6)
適用部位紅斑	1 (5.0)	0	1 (0.8)	0	1 (0.6)
節足動物刺傷	0	0	0	1 (1.8)	1 (0.6)
窒息	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乱視	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 12 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
注意欠陥多動性障害	0	0	0	1 (1.8)	1 (0.6)
細菌性疾患キャリアー	0	1 (1.0)	1 (0.8)	0	1 (0.6)
亀頭包皮炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血管の良性新生物	0	1 (1.0)	1 (0.8)	0	1 (0.6)
水疱	0	0	0	1 (1.8)	1 (0.6)
血中アルカリホスファターゼ増加	1 (5.0)	0	1 (0.8)	0	1 (0.6)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)
血中クロール減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中鉄減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中テストステロン減少	0	0	0	1 (1.8)	1 (0.6)
体温低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
骨密度減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脳損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
息こらえ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸音異常	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管支閉塞	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ＣＳＦ白血球数増加	0	0	0	1 (1.8)	1 (0.6)
毛細血管脆弱	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心筋症	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 13 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
カテーテル留置部位出血	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位炎症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
カテーテル留置部位関連反応	0	0	0	1 (1.8)	1 (0.6)
脳梗塞	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脳脊髄液漏	0	1 (1.0)	1 (0.8)	0	1 (0.6)
霰粒腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口唇のひび割れ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胸部不快感	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
斜指症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
間代	0	1 (1.0)	1 (0.8)	0	1 (0.6)
先天性横隔膜ヘルニア	0	1 (1.0)	1 (0.8)	0	1 (0.6)
コロナウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
泣き	0	1 (1.0)	1 (0.8)	0	1 (0.6)
後天性涙道狭窄	1 (5.0)	0	1 (0.8)	0	1 (0.6)
死亡	0	1 (1.0)	1 (0.8)	0	1 (0.6)
食欲減退	0	0	0	1 (1.8)	1 (0.6)
褥瘡性潰瘍	0	0	0	1 (1.8)	1 (0.6)
泉門閉鎖遅延	0	1 (1.0)	1 (0.8)	0	1 (0.6)
麻酔からの覚醒遅延	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 14 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
アレルギー性皮膚炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
発育性股関節形成不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
医療機器リーク	0	1 (1.0)	1 (0.8)	0	1 (0.6)
薬物不耐性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
眼乾燥	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚乾燥	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ダンピング症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
味覚異常	0	0	0	1 (1.8)	1 (0.6)
失読症	0	0	0	1 (1.8)	1 (0.6)
発声障害	0	0	0	1 (1.8)	1 (0.6)
不快気分	0	0	0	1 (1.8)	1 (0.6)
排尿困難	0	0	0	1 (1.8)	1 (0.6)
耳擦過傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
耳の障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性耳感染	1 (5.0)	0	1 (0.8)	0	1 (0.6)
感染性湿疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
貨幣状湿疹	1 (5.0)	0	1 (0.8)	0	1 (0.6)
心電図ＳＴ－Ｔ部分異常	0	1 (1.0)	1 (0.8)	0	1 (0.6)
蟯虫症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腸球菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 15 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
好酸球数増加	1 (5.0)	0	1 (0.8)	0	1 (0.6)
好酸球増加症	1 (5.0)	0	1 (0.8)	0	1 (0.6)
伝染性紅斑	0	1 (1.0)	1 (0.8)	0	1 (0.6)
大腸菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
本態性高血圧症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
耳垢分泌過多	0	1 (1.0)	1 (0.8)	0	1 (0.6)
擦過傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
伝染病曝露	0	1 (1.0)	1 (0.8)	0	1 (0.6)
四肢拘縮	0	0	0	1 (1.8)	1 (0.6)
眼感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性眼感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性眼感染	0	0	0	1 (1.8)	1 (0.6)
眼運動障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.8)	0	1 (0.6)
冷感	0	0	0	1 (1.8)	1 (0.6)
食中毒	0	0	0	1 (1.8)	1 (0.6)
排便回数増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
真菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃出血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性胃炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ロタウイルス胃腸炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胃腸障害	0	0	0	1 (1.8)	1 (0.6)
消化管運動低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
全身健康状態低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
環状肉芽腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
重力性浮腫	0	0	0	1 (1.8)	1 (0.6)
吐血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ヘモフィルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
手変形	0	1 (1.0)	1 (0.8)	0	1 (0.6)
頭部損傷	0	0	0	1 (1.8)	1 (0.6)
心拍数減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心拍数不整	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肝腫大	0	1 (1.0)	1 (0.8)	0	1 (0.6)
水腎症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
遠視	0	0	0	1 (1.8)	1 (0.6)
反射亢進	1 (5.0)	0	1 (0.8)	0	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
減呼吸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低血圧	0	0	0	1 (1.8)	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃排出不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 17 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
食欲亢進	0	0	0	1 (1.8)	1 (0.6)
気管支分泌増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乳児仙痛	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乳児吐出	0	1 (1.0)	1 (0.8)	0	1 (0.6)
炎症マーカー上昇	0	1 (1.0)	1 (0.8)	0	1 (0.6)
A型インフルエンザウイルス検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
注入部位内出血	1 (5.0)	0	1 (0.8)	0	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
不眠症	0	0	0	1 (1.8)	1 (0.6)
間擦疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
鉄欠乏	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ワクチン接種後の易刺激性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
関節硬直	0	1 (1.0)	1 (0.8)	0	1 (0.6)
毛孔性角化症	0	0	0	1 (1.8)	1 (0.6)
言語障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
喉頭肉芽腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
嗜眠	0	1 (1.0)	1 (0.8)	0	1 (0.6)
靭帯捻挫	0	0	0	1 (1.8)	1 (0.6)
口唇損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口唇痛	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 18 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
肝機能検査異常	0	1 (1.0)	1 (0.8)	0	1 (0.6)
下肢骨折	0	0	0	1 (1.8)	1 (0.6)
肺障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
リンパ節症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
リンパ球数増加	1 (5.0)	0	1 (0.8)	0	1 (0.6)
倦怠感	0	1 (1.0)	1 (0.8)	0	1 (0.6)
機械的換気	0	1 (1.0)	1 (0.8)	0	1 (0.6)
医療機器合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
半月板損傷	0	0	0	1 (1.8)	1 (0.6)
代謝性アルカローシス	0	1 (1.0)	1 (0.8)	0	1 (0.6)
片頭痛	0	0	0	1 (1.8)	1 (0.6)
伝染性軟属腫	0	0	0	1 (1.8)	1 (0.6)
単核細胞症症候群	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乗物酔い	0	0	0	1 (1.8)	1 (0.6)
粘膜皮膚カンジダ症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肉離れ	0	0	0	1 (1.8)	1 (0.6)
近視	0	1 (1.0)	1 (0.8)	0	1 (0.6)
貧血母斑	0	1 (1.0)	1 (0.8)	0	1 (0.6)
鼻汁変色	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 19 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
好中球百分率増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
寝汗	0	0	0	1 (1.8)	1 (0.6)
小結節	0	1 (1.0)	1 (0.8)	0	1 (0.6)
院内感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
浮腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口腔真菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口腔ヘルペス	0	1 (1.0)	1 (0.8)	0	1 (0.6)
整形外科検査	0	1 (1.0)	1 (0.8)	0	1 (0.6)
卵巣嚢胞	0	1 (1.0)	1 (0.8)	0	1 (0.6)
錯感覚	0	0	0	1 (1.8)	1 (0.6)
睡眠時随伴症	0	0	0	1 (1.8)	1 (0.6)
鳩胸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
陰茎障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
咽頭炎	0	0	0	1 (1.8)	1 (0.6)
胸水	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
インフルエンザ性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
パラインフルエンザウイルス性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺炎球菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
シュードモナス菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 20 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
肺臓炎	0	0	0	1 (1.8)	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
外傷性気胸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
処置後合併症	1 (5.0)	0	1 (0.8)	0	1 (0.6)
処置後不快感	1 (5.0)	0	1 (0.8)	0	1 (0.6)
術後イレウス	0	0	0	1 (1.8)	1 (0.6)
処置合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.8)	0	1 (0.6)
湿性咳嗽	0	1 (1.0)	1 (0.8)	0	1 (0.6)
そう痒症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
穿刺部位反応	0	0	0	1 (1.8)	1 (0.6)
腎盂腎炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
紅斑性皮疹	1 (5.0)	0	1 (0.8)	0	1 (0.6)
斑状皮疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸性アシドーシス	1 (5.0)	0	1 (0.8)	0	1 (0.6)
呼吸性アルカローシス	0	1 (1.0)	1 (0.8)	0	1 (0.6)
細菌性気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
落ち着きのなさ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低音性連続性ラ音	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 21 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ばら疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脂漏性皮膚炎	1 (5.0)	0	1 (0.8)	0	1 (0.6)
脂漏性角化症	1 (5.0)	0	1 (0.8)	0	1 (0.6)
セラチア検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ショック	0	1 (1.0)	1 (0.8)	0	1 (0.6)
洞性頻脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚細菌感染	0	0	0	1 (1.8)	1 (0.6)
皮膚色素脱失	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚感染	1 (5.0)	0	1 (0.8)	0	1 (0.6)
皮膚病変	0	0	0	1 (1.8)	1 (0.6)
皮膚浮腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚乳頭腫	0	0	0	1 (1.8)	1 (0.6)
皮膚潰瘍	0	1 (1.0)	1 (0.8)	0	1 (0.6)
睡眠時無呼吸症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
睡眠障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
軟部組織損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
傾眠	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脊柱変形	0	1 (1.0)	1 (0.8)	0	1 (0.6)
変色痰	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性菌血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 22 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ブドウ球菌感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌皮膚感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ部感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ部刺激感	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口内炎	0	0	0	1 (1.8)	1 (0.6)
レンサ球菌感染	1 (5.0)	0	1 (0.8)	0	1 (0.6)
レンサ球菌検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮下気腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
硬膜下血腫	1 (5.0)	0	1 (0.8)	0	1 (0.6)
上室性頻脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
外科手術不成功	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腫脹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
頻呼吸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血小板増加症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血栓症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
脛骨骨折	0	0	0	1 (1.8)	1 (0.6)
チック	0	0	0	1 (1.8)	1 (0.6)
扁桃炎	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 23 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
歯牙損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)
鼓膜穿孔	0	0	0	1 (1.8)	1 (0.6)
臍肉芽腫	1 (5.0)	0	1 (0.8)	0	1 (0.6)
上部消化管出血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.8)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)
尿量減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ワクチン接種合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腟感染	0	0	0	1 (1.8)	1 (0.6)
血管炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
膀胱尿管逆流	0	0	0	1 (1.8)	1 (0.6)
ウイルス性扁桃炎	0	0	0	1 (1.8)	1 (0.6)
ビタミンA減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ビタミンD欠乏	0	0	0	1 (1.8)	1 (0.6)
心因性嘔吐	0	0	0	1 (1.8)	1 (0.6)
外陰腟真菌感染	0	0	0	1 (1.8)	1 (0.6)
外陰腟発疹	1 (5.0)	0	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events by preferred term in subjects with SMA treated with ISIS 396443
Page 24 of 24

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
体重支持困難	1 (5.0)	0	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each preferred term.
3: Preferred terms are presented by decreasing incidence in the all subjects treated column.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 133　Infantile-Onset Subjects Treated With ISIS 396443 in Controlled and Uncontrolled Studies: Incidence of Adverse Events by 90-Day Intervals

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events
by 90-day intervals
Page 1 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
Number of subjects dosed	100 (100.0)	90 (100.0)	75 (100.0)	57 (100.0)
Number of subjects with an event	92 (92.0)	79 (87.8)	65 (86.7)	40 (70.2)
呼吸器、胸郭および縦隔障害	61 (61.0)	39 (43.3)	36 (48.0)	21 (36.8)
呼吸不全	13 (13.0)	6 (6.7)	5 (6.7)	3 (5.3)
無気肺	11 (11.0)	7 (7.8)	7 (9.3)	5 (8.8)
呼吸窮迫	11 (11.0)	12 (13.3)	4 (5.3)	5 (8.8)
鼻閉	10 (10.0)	4 (4.4)	3 (4.0)	1 (1.8)
急性呼吸不全	8 (8.0)	6 (6.7)	10 (13.3)	4 (7.0)
無呼吸	5 (5.0)	1 (1.1)	1 (1.3)	0
咳嗽	5 (5.0)	3 (3.3)	5 (6.7)	2 (3.5)
低酸素症	5 (5.0)	3 (3.3)	4 (5.3)	0
誤嚥	4 (4.0)	2 (2.2)	1 (1.3)	0
呼吸困難	4 (4.0)	3 (3.3)	1 (1.3)	1 (1.8)
気管支分泌物貯留	3 (3.0)	3 (3.3)	2 (2.7)	1 (1.8)
低換気	3 (3.0)	0	0	0
誤嚥性肺炎	3 (3.0)	2 (2.2)	5 (6.7)	2 (3.5)
上気道うっ血	3 (3.0)	0	2 (2.7)	1 (1.8)
息詰まり	2 (2.0)	0	0	0
慢性呼吸不全	2 (2.0)	1 (1.1)	1 (1.3)	1 (1.8)
気胸	2 (2.0)	1 (1.1)	0	0
呼吸停止	2 (2.0)	0	2 (2.7)	2 (3.5)
呼吸障害	2 (2.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 2 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
Number of subjects dosed	43 (100.0)	15 (100.0)	15 (100.0)	11 (100.0)
Number of subjects with an event	27 (62.8)	12 (80.0)	9 (60.0)	7 (63.6)
呼吸器、胸郭および縦隔障害	7 (16.3)	5 (33.3)	4 (26.7)	3 (27.3)
呼吸不全	1 (2.3)	0	0	0
無気肺	2 (4.7)	1 (6.7)	1 (6.7)	1 (9.1)
呼吸窮迫	1 (2.3)	2 (13.3)	0	0
鼻閉	0	0	1 (6.7)	0
急性呼吸不全	1 (2.3)	1 (6.7)	0	0
無呼吸	0	0	0	0
咳嗽	2 (4.7)	0	1 (6.7)	0
低酸素症	0	0	0	0
誤嚥	0	0	0	0
呼吸困難	0	0	0	0
気管支分泌物貯留	0	0	0	0
低換気	0	0	0	0
誤嚥性肺炎	0	0	0	0
上気道うっ血	0	1 (6.7)	0	0
息詰まり	0	0	0	0
慢性呼吸不全	0	1 (6.7)	0	0
気胸	1 (2.3)	0	0	0
呼吸停止	0	0	0	0
呼吸障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 3 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
Number of subjects dosed	8 (100.0)	4 (100.0)	2 (100.0)	1 (100.0)
Number of subjects with an event	8 (100.0)	2 (50.0)	1 (50.0)	0
呼吸器、胸郭および縦隔障害	5 (62.5)	0	1 (50.0)	0
呼吸不全	0	0	0	0
無気肺	0	0	0	0
呼吸窮迫	1 (12.5)	0	0	0
鼻閉	1 (12.5)	0	0	0
急性呼吸不全	1 (12.5)	0	0	0
無呼吸	0	0	0	0
咳嗽	0	0	1 (50.0)	0
低酸素症	0	0	0	0
誤嚥	0	0	0	0
呼吸困難	0	0	0	0
気管支分泌物貯留	1 (12.5)	0	0	0
低換気	0	0	0	0
誤嚥性肺炎	0	0	0	0
上気道うっ血	0	0	0	0
息詰まり	0	0	0	0
慢性呼吸不全	0	0	0	0
気胸	0	0	0	0
呼吸停止	0	0	0	0
呼吸障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 4 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
鼻漏	2 (2.0)	2 (2.2)	3 (4.0)	1 (1.8)
呼吸補助筋の動員	2 (2.0)	0	0	0
上気道分泌増加	1 (1.0)	3 (3.3)	1 (1.3)	0
肺障害	1 (1.0)	0	0	0
閉塞性気道障害	1 (1.0)	0	0	0
胸水	1 (1.0)	0	0	0
呼吸性アルカローシス	1 (1.0)	0	0	0
気道うっ血	1 (1.0)	0	0	1 (1.8)
副鼻腔うっ血	1 (1.0)	1 (1.1)	1 (1.3)	0
睡眠時無呼吸症候群	1 (1.0)	0	0	0
頻呼吸	1 (1.0)	0	0	0
急性呼吸窮迫症候群	0	0	0	1 (1.8)
無呼吸発作	0	1 (1.1)	0	0
窒息	0	0	1 (1.3)	0
気管支閉塞	0	1 (1.1)	1 (1.3)	0
高炭酸ガス血症	0	0	1 (1.3)	0
減呼吸	0	0	0	1 (1.8)
気管支分泌増加	0	0	1 (1.3)	0
喉頭肉芽腫	0	0	0	0
鼻汁変色	0	0	0	0
気縦隔症	0	0	0	0
湿性咳嗽	0	0	0	0
肺うっ血	0	1 (1.1)	0	0
肺水腫	0	0	0	0
拘束性肺疾患	0	1 (1.1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 5 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
鼻漏	0	0	0	0
呼吸補助筋の動員	0	0	0	0
上気道分泌増加	0	1 (6.7)	1 (6.7)	0
肺障害	0	0	0	0
閉塞性気道障害	0	0	0	0
胸水	0	0	0	0
呼吸性アルカローシス	0	0	0	0
気道うっ血	0	0	0	0
副鼻腔うっ血	0	1 (6.7)	1 (6.7)	0
睡眠時無呼吸症候群	0	0	0	0
頻呼吸	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0
無呼吸発作	0	0	0	0
窒息	0	0	0	0
気管支閉塞	0	0	0	0
高炭酸ガス血症	0	0	0	0
減呼吸	0	0	0	0
気管支分泌増加	0	0	0	0
喉頭肉芽腫	1 (2.3)	0	0	0
鼻汁変色	0	1 (6.7)	0	0
気縦隔症	1 (2.3)	0	0	0
湿性咳嗽	0	0	0	0
肺うっ血	1 (2.3)	0	0	0
肺水腫	0	0	0	1 (9.1)
拘束性肺疾患	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 6 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
鼻漏	0	0	0	0
呼吸補助筋の動員	0	0	0	0
上気道分泌増加	1 (12.5)	0	0	0
肺障害	0	0	0	0
閉塞性気道障害	0	0	0	0
胸水	0	0	0	0
呼吸性アルカローシス	0	0	0	0
気道うっ血	0	0	0	0
副鼻腔うっ血	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0
頻呼吸	0	0	0	0
急性呼吸窮迫症候群	0	0	0	0
無呼吸発作	0	0	0	0
窒息	0	0	0	0
気管支閉塞	0	0	0	0
高炭酸ガス血症	0	0	0	0
減呼吸	0	0	0	0
気管支分泌増加	0	0	0	0
喉頭肉芽腫	0	0	0	0
鼻汁変色	0	0	0	0
気縦隔症	0	0	0	0
湿性咳嗽	1 (12.5)	0	0	0
肺うっ血	0	0	0	0
肺水腫	1 (12.5)	0	0	0
拘束性肺疾患	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 7 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
アレルギー性鼻炎	0	1 (1.1)	0	0
低音性連続性ラ音	0	0	0	0
変色痰	0	0	0	0
気管障害	0	0	0	0
喘鳴	0	1 (1.1)	2 (2.7)	1 (1.8)
感染症および寄生虫症	52 (52.0)	58 (64.4)	52 (69.3)	31 (54.4)
肺炎	11 (11.0)	12 (13.3)	5 (6.7)	8 (14.0)
鼻咽頭炎	9 (9.0)	5 (5.6)	9 (12.0)	3 (5.3)
ライノウイルス感染	9 (9.0)	2 (2.2)	3 (4.0)	3 (5.3)
上気道感染	8 (8.0)	15 (16.7)	13 (17.3)	8 (14.0)
細気管支炎	5 (5.0)	3 (3.3)	1 (1.3)	1 (1.8)
口腔カンジダ症	5 (5.0)	0	1 (1.3)	2 (3.5)
気道感染	5 (5.0)	6 (6.7)	5 (6.7)	4 (7.0)
ウイルス性上気道感染	5 (5.0)	6 (6.7)	1 (1.3)	2 (3.5)
気管支炎	4 (4.0)	0	1 (1.3)	1 (1.8)
ウイルス感染	4 (4.0)	4 (4.4)	2 (2.7)	1 (1.8)
ウイルス性肺炎	3 (3.0)	2 (2.2)	3 (4.0)	1 (1.8)
ウイルス性気道感染	3 (3.0)	2 (2.2)	0	1 (1.8)
カンジダ性おむつ皮疹	2 (2.0)	0	0	0
結膜炎	2 (2.0)	0	3 (4.0)	0
モラクセラ菌性肺炎	2 (2.0)	1 (1.1)	0	0
細菌性気管炎	1 (1.0)	1 (1.1)	0	0
ウイルス性気管支炎	1 (1.0)	1 (1.1)	4 (5.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 8 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
アレルギー性鼻炎	0	0	0	1 (9.1)
低音性連続性ラ音	0	0	1 (6.7)	0
変色痰	1 (2.3)	0	0	0
気管障害	0	1 (6.7)	0	0
喘鳴	0	0	0	0
感染症および寄生虫症	16 (37.2)	9 (60.0)	5 (33.3)	6 (54.5)
肺炎	2 (4.7)	0	0	1 (9.1)
鼻咽頭炎	1 (2.3)	2 (13.3)	1 (6.7)	0
ライノウイルス感染	2 (4.7)	0	0	0
上気道感染	4 (9.3)	1 (6.7)	2 (13.3)	1 (9.1)
細気管支炎	1 (2.3)	1 (6.7)	0	0
口腔カンジダ症	0	1 (6.7)	0	0
気道感染	0	3 (20.0)	1 (6.7)	1 (9.1)
ウイルス性上気道感染	0	0	0	0
気管支炎	1 (2.3)	0	0	0
ウイルス感染	1 (2.3)	1 (6.7)	1 (6.7)	0
ウイルス性肺炎	0	0	0	0
ウイルス性気道感染	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0
結膜炎	0	0	1 (6.7)	0
モラクセラ菌性肺炎	0	0	0	0
細菌性気管炎	0	0	0	0
ウイルス性気管支炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 9 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
アレルギー性鼻炎	0	0	0	0
低音性連続性ラ音	0	0	0	0
変色痰	0	0	0	0
気管障害	0	0	0	0
喘鳴	0	0	0	0
感染症および寄生虫症	4 (50.0)	2 (50.0)	0	0
肺炎	1 (12.5)	0	0	0
鼻咽頭炎	1 (12.5)	0	0	0
ライノウイルス感染	0	0	0	0
上気道感染	0	2 (50.0)	0	0
細気管支炎	0	0	0	0
口腔カンジダ症	0	0	0	0
気道感染	1 (12.5)	0	0	0
ウイルス性上気道感染	1 (12.5)	0	0	0
気管支炎	0	0	0	0
ウイルス感染	0	0	0	0
ウイルス性肺炎	1 (12.5)	0	0	0
ウイルス性気道感染	0	0	0	0
カンジダ性おむつ皮疹	0	0	0	0
結膜炎	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0
細菌性気管炎	1 (12.5)	0	0	0
ウイルス性気管支炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 10 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
細菌性結膜炎	1 (1.0)	0	1 (1.3)	0
耳感染	1 (1.0)	2 (2.2)	3 (4.0)	2 (3.5)
感染性湿疹	1 (1.0)	0	0	0
真菌感染	1 (1.0)	0	0	0
皮膚真菌感染	1 (1.0)	0	1 (1.3)	0
ウイルス性胃炎	1 (1.0)	0	0	0
膿痂疹	1 (1.0)	0	0	0
インフルエンザ	1 (1.0)	2 (2.2)	2 (2.7)	0
限局性感染	1 (1.0)	0	0	0
下気道感染	1 (1.0)	0	4 (5.3)	2 (3.5)
肺感染	1 (1.0)	0	1 (1.3)	0
メタニューモウイルス感染	1 (1.0)	1 (1.1)	0	0
レンサ球菌性咽頭炎	1 (1.0)	0	0	0
細菌性肺炎	1 (1.0)	0	2 (2.7)	1 (1.8)
パラインフルエンザウイルス性肺炎	1 (1.0)	0	0	0
ＲＳウイルス肺炎	1 (1.0)	0	0	0
ＲＳウイルス細気管支炎	1 (1.0)	2 (2.2)	2 (2.7)	0
鼻炎	1 (1.0)	1 (1.1)	1 (1.3)	0
敗血症	1 (1.0)	0	1 (1.3)	0
皮膚カンジダ	1 (1.0)	0	1 (1.3)	0
ストーマ部膿瘍	1 (1.0)	0	0	0
尿路感染	1 (1.0)	3 (3.3)	1 (1.3)	1 (1.8)
アデノウイルス性上気道感染	0	0	0	0
アデノウイルス感染	0	0	2 (2.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 11 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
細菌性結膜炎	0	0	0	0
耳感染	0	0	0	0
感染性湿疹	0	0	0	0
真菌感染	0	0	0	0
皮膚真菌感染	0	0	0	0
ウイルス性胃炎	0	0	0	0
膿痂疹	0	0	0	0
インフルエンザ	1 (2.3)	0	0	0
限局性感染	0	0	0	0
下気道感染	1 (2.3)	0	0	1 (9.1)
肺感染	0	0	0	0
メタニューモウイルス感染	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	0
細菌性肺炎	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0
鼻炎	1 (2.3)	0	1 (6.7)	0
敗血症	0	0	0	0
皮膚カンジダ	0	0	0	0
ストーマ部膿瘍	1 (2.3)	0	0	0
尿路感染	1 (2.3)	0	0	0
アデノウイルス性上気道感染	0	0	0	0
アデノウイルス感染	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 12 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
細菌性結膜炎	0	0	0	0
耳感染	0	0	0	0
感染性湿疹	0	0	0	0
真菌感染	0	0	0	0
皮膚真菌感染	0	0	0	0
ウイルス性胃炎	0	0	0	0
膿痂疹	0	0	0	0
インフルエンザ	0	0	0	0
限局性感染	0	0	0	0
下気道感染	0	0	0	0
肺感染	0	0	0	0
メタニューモウイルス感染	0	0	0	0
レンサ球菌性咽頭炎	0	0	0	0
細菌性肺炎	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	0
ＲＳウイルス肺炎	0	0	0	0
ＲＳウイルス細気管支炎	0	0	0	0
鼻炎	0	0	0	0
敗血症	0	0	0	0
皮膚カンジダ	0	0	0	0
ストーマ部膿瘍	0	0	0	0
尿路感染	0	0	0	0
アデノウイルス性上気道感染	1 (12.5)	0	0	0
アデノウイルス感染	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 13 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
細菌性疾患キャリアー	0	0	0	0
細菌感染	0	0	2 (2.7)	1 (1.8)
蜂巣炎	0	0	1 (1.3)	0
コロナウイルス感染	0	1 (1.1)	0	0
蟯虫症	0	1 (1.1)	0	0
腸球菌感染	0	0	1 (1.3)	0
エンテロウイルス感染	0	0	0	1 (1.8)
伝染性紅斑	0	0	0	0
大腸菌感染	0	1 (1.1)	0	0
眼感染	0	0	1 (1.3)	0
胃腸炎	0	1 (1.1)	1 (1.3)	0
ロタウイルス胃腸炎	0	1 (1.1)	0	0
ウイルス性胃腸炎	0	1 (1.1)	0	0
ヘモフィルス感染	0	0	0	1 (1.8)
手足口病	0	0	1 (1.3)	0
ウイルス性下気道感染	0	3 (3.3)	0	0
モラクセラ感染	0	1 (1.1)	0	0
粘膜皮膚カンジダ症	0	1 (1.1)	0	0
院内感染	0	0	1 (1.3)	0
口腔真菌感染	0	1 (1.1)	1 (1.3)	0
口腔ヘルペス	0	0	0	1 (1.8)
中耳炎	0	1 (1.1)	4 (5.3)	0
急性中耳炎	0	1 (1.1)	0	0
パラインフルエンザウイルス感染	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 14 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
細菌性疾患キャリアー	0	0	0	1 (9.1)
細菌感染	0	0	0	0
蜂巣炎	0	0	0	0
コロナウイルス感染	0	0	0	0
蟯虫症	0	0	0	0
腸球菌感染	0	0	0	0
エンテロウイルス感染	1 (2.3)	0	0	0
伝染性紅斑	0	0	0	1 (9.1)
大腸菌感染	0	0	0	0
眼感染	0	0	0	0
胃腸炎	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0
ウイルス性胃腸炎	0	0	0	0
ヘモフィルス感染	0	0	0	0
手足口病	0	0	1 (6.7)	0
ウイルス性下気道感染	0	0	0	0
モラクセラ感染	0	0	0	0
粘膜皮膚カンジダ症	0	0	0	0
院内感染	0	0	0	0
口腔真菌感染	0	0	0	0
口腔ヘルペス	0	0	0	0
中耳炎	3 (7.0)	1 (6.7)	0	1 (9.1)
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	1 (2.3)	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 15 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
細菌性疾患キャリアー	0	0	0	0
細菌感染	0	0	0	0
蜂巣炎	0	0	0	0
コロナウイルス感染	0	0	0	0
蟯虫症	0	0	0	0
腸球菌感染	0	0	0	0
エンテロウイルス感染	0	0	0	0
伝染性紅斑	0	0	0	0
大腸菌感染	0	0	0	0
眼感染	0	0	0	0
胃腸炎	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0
ウイルス性胃腸炎	0	0	0	0
ヘモフィルス感染	0	0	0	0
手足口病	0	0	0	0
ウイルス性下気道感染	0	0	0	0
モラクセラ感染	1 (12.5)	0	0	0
粘膜皮膚カンジダ症	0	0	0	0
院内感染	0	0	0	0
口腔真菌感染	0	0	0	0
口腔ヘルペス	0	0	0	0
中耳炎	0	0	0	0
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 16 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
インフルエンザ性肺炎	0	1 (1.1)	0	0
肺炎球菌性肺炎	0	0	0	1 (1.8)
シュードモナス菌性肺炎	0	0	0	0
シュードモナス感染	0	1 (1.1)	1 (1.3)	1 (1.8)
腎盂腎炎	0	0	1 (1.3)	0
細菌性気道感染	0	0	0	1 (1.8)
ばら疹	0	1 (1.1)	0	0
ブドウ球菌性菌血症	0	1 (1.1)	0	0
ブドウ球菌感染	0	0	0	0
ブドウ球菌性敗血症	0	0	1 (1.3)	0
ブドウ球菌皮膚感染	0	0	1 (1.3)	0
ストーマ部感染	0	0	0	1 (1.8)
気管炎	0	0	0	0
胃腸障害	47 (47.0)	38 (42.2)	21 (28.0)	13 (22.8)
便秘	17 (17.0)	13 (14.4)	8 (10.7)	1 (1.8)
胃食道逆流性疾患	9 (9.0)	3 (3.3)	1 (1.3)	1 (1.8)
生歯	9 (9.0)	5 (5.6)	3 (4.0)	0
嘔吐	9 (9.0)	9 (10.0)	2 (2.7)	5 (8.8)
下痢	5 (5.0)	6 (6.7)	2 (2.7)	6 (10.5)
嚥下障害	4 (4.0)	3 (3.3)	2 (2.7)	0
流涎過多	4 (4.0)	0	3 (4.0)	1 (1.8)
放屁	2 (2.0)	3 (3.3)	1 (1.3)	0
胃炎	2 (2.0)	0	0	1 (1.8)
腹部不快感	1 (1.0)	0	0	1 (1.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 17 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
インフルエンザ性肺炎	0	0	0	0
肺炎球菌性肺炎	0	0	0	0
シュードモナス菌性肺炎	1 (2.3)	0	0	0
シュードモナス感染	0	0	0	0
腎盂腎炎	0	0	0	0
細菌性気道感染	0	0	0	0
ばら疹	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0
ブドウ球菌感染	0	1 (6.7)	0	0
ブドウ球菌性敗血症	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0
ストーマ部感染	0	0	0	0
気管炎	1 (2.3)	0	0	0
胃腸障害	7 (16.3)	4 (26.7)	2 (13.3)	3 (27.3)
便秘	0	1 (6.7)	0	0
胃食道逆流性疾患	1 (2.3)	0	0	1 (9.1)
生歯	1 (2.3)	0	0	0
嘔吐	3 (7.0)	1 (6.7)	0	1 (9.1)
下痢	2 (4.7)	1 (6.7)	1 (6.7)	1 (9.1)
嚥下障害	0	0	0	0
流涎過多	0	0	0	0
放屁	0	0	0	0
胃炎	0	0	1 (6.7)	0
腹部不快感	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 18 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
インフルエンザ性肺炎	0	0	0	0
肺炎球菌性肺炎	0	0	0	0
シュードモナス菌性肺炎	0	0	0	0
シュードモナス感染	0	0	0	0
腎盂腎炎	0	0	0	0
細菌性気道感染	0	0	0	0
ばら疹	0	0	0	0
ブドウ球菌性菌血症	0	0	0	0
ブドウ球菌感染	0	0	0	0
ブドウ球菌性敗血症	0	0	0	0
ブドウ球菌皮膚感染	0	0	0	0
ストーマ部感染	0	0	0	0
気管炎	0	0	0	0
胃腸障害	2 (25.0)	1 (25.0)	0	0
便秘	0	0	0	0
胃食道逆流性疾患	0	0	0	0
生歯	0	0	0	0
嘔吐	1 (12.5)	0	0	0
下痢	2 (25.0)	1 (25.0)	0	0
嚥下障害	0	0	0	0
流涎過多	0	0	0	0
放屁	0	0	0	0
胃炎	0	0	0	0
腹部不快感	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 19 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
腹痛	1 (1.0)	0	0	0
アフタ性潰瘍	1 (1.0)	0	0	0
胃出血	1 (1.0)	0	0	0
血便排泄	1 (1.0)	1 (1.1)	0	0
乳児仙痛	1 (1.0)	0	0	0
腹部膨満	0	2 (2.2)	0	1 (1.8)
口唇のひび割れ	0	1 (1.1)	0	0
排便回数増加	0	0	0	0
消化管運動低下	0	0	0	1 (1.8)
吐血	0	0	0	0
胃排出不全	0	0	1 (1.3)	0
乳児吐出	0	1 (1.1)	0	0
上部消化管出血	0	0	1 (1.3)	0
一般・全身障害および投与部位の状態	40 (40.0)	26 (28.9)	24 (32.0)	18 (31.6)
発熱	30 (30.0)	25 (27.8)	23 (30.7)	17 (29.8)
疼痛	3 (3.0)	2 (2.2)	0	0
泣き	1 (1.0)	0	0	0
死亡	1 (1.0)	0	0	0
医療機器閉塞	1 (1.0)	1 (1.1)	1 (1.3)	0
不快感	1 (1.0)	0	0	1 (1.8)
全身健康状態低下	1 (1.0)	0	0	0
低体温	1 (1.0)	0	0	0
ワクチン接種後の易刺激性	1 (1.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 20 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
腹痛	0	0	0	0
アフタ性潰瘍	0	0	0	0
胃出血	0	0	0	0
血便排泄	0	0	0	0
乳児仙痛	0	0	0	0
腹部膨満	0	0	0	1 (9.1)
口唇のひび割れ	0	0	0	0
排便回数増加	0	1 (6.7)	0	0
消化管運動低下	0	0	0	0
吐血	1 (2.3)	0	0	0
胃排出不全	0	0	0	0
乳児吐出	0	0	0	0
上部消化管出血	0	0	0	0
一般・全身障害および投与部位の状態	10 (23.3)	3 (20.0)	0	2 (18.2)
発熱	10 (23.3)	2 (13.3)	0	2 (18.2)
疼痛	0	0	0	0
泣き	0	0	0	0
死亡	0	0	0	0
医療機器閉塞	0	0	0	0
不快感	0	0	0	0
全身健康状態低下	0	0	0	0
低体温	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 21 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
腹痛	0	0	0	0
アフタ性潰瘍	0	0	0	0
胃出血	0	0	0	0
血便排泄	0	0	0	0
乳児仙痛	0	0	0	0
腹部膨満	0	0	0	0
口唇のひび割れ	0	0	0	0
排便回数増加	0	0	0	0
消化管運動低下	0	0	0	0
吐血	0	0	0	0
胃排出不全	0	0	0	0
乳児吐出	0	0	0	0
上部消化管出血	0	0	0	0
一般・全身障害および投与部位の状態	3 (37.5)	0	0	0
発熱	2 (25.0)	0	0	0
疼痛	0	0	0	0
泣き	0	0	0	0
死亡	0	0	0	0
医療機器閉塞	0	0	0	0
不快感	0	0	0	0
全身健康状態低下	0	0	0	0
低体温	0	0	0	0
ワクチン接種後の易刺激性	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 22 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
倦怠感	1 (1.0)	0	0	0
小結節	1 (1.0)	0	0	0
浮腫	1 (1.0)	0	0	0
末梢腫脹	1 (1.0)	0	0	0
外科手術不成功	1 (1.0)	0	0	0
血管穿刺部位内出血	1 (1.0)	0	0	0
カテーテル留置部位炎症	0	0	0	1 (1.8)
医療機器リーク	0	1 (1.1)	0	0
薬物不耐性	0	1 (1.1)	0	0
医療機器合併症	0	0	0	0
末梢性浮腫	0	0	0	1 (1.8)
腫脹	0	0	0	1 (1.8)
皮膚および皮下組織障害	19 (19.0)	12 (13.3)	9 (12.0)	5 (8.8)
おむつ皮膚炎	4 (4.0)	1 (1.1)	1 (1.3)	2 (3.5)
発疹	4 (4.0)	3 (3.3)	6 (8.0)	0
湿疹	3 (3.0)	1 (1.1)	0	0
接触性皮膚炎	2 (2.0)	0	0	0
脱毛症	1 (1.0)	0	0	0
皮膚炎	1 (1.0)	1 (1.1)	0	0
斑状出血	1 (1.0)	0	0	1 (1.8)
紅斑	1 (1.0)	0	0	0
過剰肉芽組織	1 (1.0)	1 (1.1)	0	0
点状出血	1 (1.0)	0	0	0
斑状皮疹	1 (1.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 23 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
倦怠感	0	0	0	0
小結節	0	0	0	0
浮腫	0	0	0	0
末梢腫脹	0	0	0	0
外科手術不成功	0	0	0	0
血管穿刺部位内出血	0	0	0	0
カテーテル留置部位炎症	0	0	0	0
医療機器リーク	0	0	0	0
薬物不耐性	0	0	0	0
医療機器合併症	1 (2.3)	0	0	0
末梢性浮腫	0	1 (6.7)	0	0
腫脹	0	0	0	0
皮膚および皮下組織障害	6 (14.0)	3 (20.0)	2 (13.3)	3 (27.3)
おむつ皮膚炎	2 (4.7)	1 (6.7)	0	0
発疹	2 (4.7)	0	1 (6.7)	1 (9.1)
湿疹	0	0	0	0
接触性皮膚炎	0	0	0	1 (9.1)
脱毛症	0	0	0	0
皮膚炎	1 (2.3)	0	0	1 (9.1)
斑状出血	0	0	1 (6.7)	0
紅斑	0	0	0	0
過剰肉芽組織	0	1 (6.7)	0	0
点状出血	0	0	0	0
斑状皮疹	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 24 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
倦怠感	0	0	0	0
小結節	0	0	0	0
浮腫	0	0	0	0
末梢腫脹	0	0	0	0
外科手術不成功	0	0	0	0
血管穿刺部位内出血	0	0	0	0
カテーテル留置部位炎症	0	0	0	0
医療機器リーク	0	0	0	0
薬物不耐性	0	0	0	0
医療機器合併症	0	0	0	0
末梢性浮腫	1 (12.5)	0	0	0
腫脹	0	0	0	0
皮膚および皮下組織障害	2 (25.0)	0	0	0
おむつ皮膚炎	0	0	0	0
発疹	0	0	0	0
湿疹	0	0	0	0
接触性皮膚炎	0	0	0	0
脱毛症	0	0	0	0
皮膚炎	0	0	0	0
斑状出血	0	0	0	0
紅斑	0	0	0	0
過剰肉芽組織	0	0	0	0
点状出血	0	0	0	0
斑状皮疹	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 25 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
アレルギー性皮膚炎	0	0	1 (1.3)	0
皮膚乾燥	0	0	0	1 (1.8)
環状肉芽腫	0	1 (1.1)	0	0
過角化	0	1 (1.1)	0	1 (1.8)
間擦疹	0	1 (1.1)	0	0
汗疹	0	2 (2.2)	0	0
そう痒症	0	0	0	0
丘疹性皮疹	0	0	1 (1.3)	0
皮膚色素脱失	0	0	0	0
皮膚障害	0	0	0	0
皮膚刺激	0	1 (1.1)	0	0
皮膚浮腫	0	0	1 (1.3)	0
皮膚潰瘍	0	0	1 (1.3)	0
皮下気腫	0	1 (1.1)	0	0
蕁麻疹	0	1 (1.1)	0	0
傷害、中毒および処置合併症	15 (15.0)	8 (8.9)	4 (5.3)	7 (12.3)
処置による疼痛	3 (3.0)	0	1 (1.3)	0
ストーマ部紅斑	2 (2.0)	0	1 (1.3)	0
節足動物咬傷	1 (1.0)	3 (3.3)	0	1 (1.8)
麻酔からの覚醒遅延	1 (1.0)	0	0	0
擦過傷	1 (1.0)	0	0	0
栄養補給チューブ合併症	1 (1.0)	2 (2.2)	1 (1.3)	0
大腿骨骨折	1 (1.0)	0	0	2 (3.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 26 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
アレルギー性皮膚炎	0	0	0	0
皮膚乾燥	0	0	0	0
環状肉芽腫	0	0	0	0
過角化	0	0	0	0
間擦疹	0	0	0	0
汗疹	0	0	0	0
そう痒症	1 (2.3)	0	0	0
丘疹性皮疹	0	0	0	0
皮膚色素脱失	0	1 (6.7)	0	0
皮膚障害	1 (2.3)	0	0	0
皮膚刺激	0	0	0	0
皮膚浮腫	0	0	0	0
皮膚潰瘍	0	0	0	0
皮下気腫	0	0	0	0
蕁麻疹	0	0	0	0
傷害、中毒および処置合併症	3 (7.0)	1 (6.7)	2 (13.3)	0
処置による疼痛	0	0	0	0
ストーマ部紅斑	0	0	0	0
節足動物咬傷	2 (4.7)	0	0	0
麻酔からの覚醒遅延	0	0	0	0
擦過傷	0	0	0	0
栄養補給チューブ合併症	0	0	0	0
大腿骨骨折	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 27 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
アレルギー性皮膚炎	0	0	0	0
皮膚乾燥	0	0	0	0
環状肉芽腫	0	0	0	0
過角化	0	0	0	0
間擦疹	0	0	0	0
汗疹	0	0	0	0
そう痒症	0	0	0	0
丘疹性皮疹	0	0	0	0
皮膚色素脱失	0	0	0	0
皮膚障害	0	0	0	0
皮膚刺激	2 (25.0)	0	0	0
皮膚浮腫	0	0	0	0
皮膚潰瘍	0	0	0	0
皮下気腫	0	0	0	0
蕁麻疹	0	0	0	0
傷害、中毒および処置合併症	1 (12.5)	0	0	0
処置による疼痛	0	0	0	0
ストーマ部紅斑	0	0	0	0
節足動物咬傷	0	0	0	0
麻酔からの覚醒遅延	0	0	0	0
擦過傷	0	0	0	0
栄養補給チューブ合併症	0	0	0	0
大腿骨骨折	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 28 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
処置合併症	1 (1.0)	0	0	0
処置部位反応	1 (1.0)	0	0	0
皮膚擦過傷	1 (1.0)	0	0	0
ストーマ部刺激感	1 (1.0)	0	0	0
サンバーン	1 (1.0)	0	0	0
熱傷	1 (1.0)	0	0	0
ワクチン接種合併症	1 (1.0)	0	0	0
術後激越	0	0	0	1 (1.8)
挫傷	0	0	1 (1.3)	0
ダンピング症候群	0	1 (1.1)	0	0
耳擦過傷	0	0	0	0
伝染病曝露	0	0	0	1 (1.8)
関節脱臼	0	0	0	0
口唇損傷	0	0	0	1 (1.8)
外傷性気胸	0	1 (1.1)	0	0
処置後腫脹	0	0	0	1 (1.8)
軟部組織損傷	0	0	0	0
ストーマ合併症	0	1 (1.1)	0	0
歯牙損傷	0	0	0	1 (1.8)
心臓障害	14 (14.0)	11 (12.2)	1 (1.3)	2 (3.5)
頻脈	4 (4.0)	5 (5.6)	1 (1.3)	0
徐脈	3 (3.0)	2 (2.2)	0	0
心停止	3 (3.0)	0	0	0
心肺停止	2 (2.0)	3 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 29 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
処置合併症	0	0	0	0
処置部位反応	0	0	0	0
皮膚擦過傷	0	0	1 (6.7)	0
ストーマ部刺激感	0	0	0	0
サンバーン	0	0	0	0
熱傷	0	0	0	0
ワクチン接種合併症	0	0	0	0
術後激越	0	0	0	0
挫傷	0	0	1 (6.7)	0
ダンピング症候群	0	0	0	0
耳擦過傷	1 (2.3)	0	1 (6.7)	0
伝染病曝露	0	0	0	0
関節脱臼	1 (2.3)	1 (6.7)	0	0
口唇損傷	0	0	0	0
外傷性気胸	0	0	0	0
処置後腫脹	0	0	0	0
軟部組織損傷	0	0	0	0
ストーマ合併症	0	0	0	0
歯牙損傷	0	0	0	0
心臓障害	6 (14.0)	0	1 (6.7)	0
頻脈	1 (2.3)	0	0	0
徐脈	1 (2.3)	0	1 (6.7)	0
心停止	0	0	0	0
心肺停止	1 (2.3)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 30 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
処置合併症	0	0	0	0
処置部位反応	0	0	0	0
皮膚擦過傷	0	0	0	0
ストーマ部刺激感	0	0	0	0
サンバーン	0	0	0	0
熱傷	0	0	0	0
ワクチン接種合併症	0	0	0	0
術後激越	0	0	0	0
挫傷	0	0	0	0
ダンピング症候群	0	0	0	0
耳擦過傷	0	0	0	0
伝染病曝露	0	0	0	0
関節脱臼	0	0	0	0
口唇損傷	0	0	0	0
外傷性気胸	0	0	0	0
処置後腫脹	0	0	0	0
軟部組織損傷	1 (12.5)	0	0	0
ストーマ合併症	0	0	0	0
歯牙損傷	0	0	0	0
心臓障害	0	0	0	0
頻脈	0	0	0	0
徐脈	0	0	0	0
心停止	0	0	0	0
心肺停止	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 31 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
チアノーゼ	2 (2.0)	1 (1.1)	0	0
洞性頻脈	1 (1.0)	0	0	0
上室性頻脈	1 (1.0)	0	0	0
心室性頻脈	1 (1.0)	0	0	0
心筋症	0	0	0	0
左室肥大	0	0	0	2 (3.5)
心膜気腫	0	0	0	0
臨床検査	13 (13.0)	10 (11.1)	10 (13.3)	6 (10.5)
酸素飽和度低下	5 (5.0)	4 (4.4)	4 (5.3)	0
体重減少	2 (2.0)	1 (1.1)	1 (1.3)	0
血中鉄減少	1 (1.0)	0	0	0
血中カリウム減少	1 (1.0)	0	1 (1.3)	0
体温低下	1 (1.0)	0	0	0
体温上昇	1 (1.0)	0	1 (1.3)	1 (1.8)
心電図ＳＴ－Ｔ部分異常	1 (1.0)	0	0	0
心拍数不整	1 (1.0)	0	0	0
ヒトライノウイルス検査陽性	1 (1.0)	0	0	1 (1.8)
Ａ型インフルエンザウイルス検査陽性	1 (1.0)	0	0	0
医学的観察	1 (1.0)	0	1 (1.3)	0
モラクセラ検査陽性	1 (1.0)	0	0	0
シュードモナス検査陽性	1 (1.0)	0	0	0
ブドウ球菌検査陽性	1 (1.0)	0	0	1 (1.8)
尿量減少	1 (1.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 32 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
チアノーゼ	0	0	0	0
洞性頻脈	0	0	0	0
上室性頻脈	0	0	0	0
心室性頻脈	1 (2.3)	0	0	0
心筋症	1 (2.3)	0	0	0
左室肥大	0	0	0	0
心膜気腫	1 (2.3)	0	0	0
臨床検査	3 (7.0)	1 (6.7)	2 (13.3)	2 (18.2)
酸素飽和度低下	1 (2.3)	0	1 (6.7)	0
体重減少	1 (2.3)	0	0	1 (9.1)
血中鉄減少	0	0	0	0
血中カリウム減少	0	0	0	0
体温低下	0	0	0	0
体温上昇	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0
心拍数不整	0	0	0	0
ヒトライノウイルス検査陽性	0	0	1 (6.7)	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0
医学的観察	0	0	0	0
モラクセラ検査陽性	0	0	0	0
シュードモナス検査陽性	0	1 (6.7)	0	0
ブドウ球菌検査陽性	0	0	0	0
尿量減少	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 33 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
チアノーゼ	0	0	0	0
洞性頻脈	0	0	0	0
上室性頻脈	0	0	0	0
心室性頻脈	0	0	0	0
心筋症	0	0	0	0
左室肥大	0	0	0	0
心膜気腫	0	0	0	0
臨床検査	1 (12.5)	0	0	0
酸素飽和度低下	0	0	0	0
体重減少	0	0	0	0
血中鉄減少	0	0	0	0
血中カリウム減少	0	0	0	0
体温低下	0	0	0	0
体温上昇	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0
心拍数不整	0	0	0	0
ヒトライノウイルス検査陽性	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	0	0	0	0
医学的観察	0	0	0	0
モラクセラ検査陽性	1 (12.5)	0	0	0
シュードモナス検査陽性	1 (12.5)	0	0	0
ブドウ球菌検査陽性	0	0	0	0
尿量減少	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 34 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
アラニンアミノトランスフェラーゼ増加	0	0	1 (1.3)	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	1 (1.3)	0
血中クロール減少	0	0	1 (1.3)	0
血中ナトリウム減少	0	0	1 (1.3)	0
骨密度減少	0	0	0	0
呼吸音異常	0	1 (1.1)	0	0
Ｃ－反応性蛋白増加	0	2 (2.2)	1 (1.3)	1 (1.8)
心拍数減少	0	0	1 (1.3)	0
心拍数増加	0	1 (1.1)	1 (1.3)	0
炎症マーカー上昇	0	0	0	1 (1.8)
肝機能検査異常	0	0	0	0
好中球数増加	0	0	1 (1.3)	2 (3.5)
好中球百分率増加	0	0	0	1 (1.8)
整形外科検査	0	1 (1.1)	0	0
セラチア検査陽性	0	0	0	0
レンサ球菌検査陽性	0	0	0	0
ビタミンＡ減少	0	0	0	1 (1.8)
白血球数増加	0	0	1 (1.3)	1 (1.8)
代謝および栄養障害	11 (11.0)	6 (6.7)	4 (5.3)	1 (1.8)
体重増加不良	4 (4.0)	2 (2.2)	1 (1.3)	0
乳児および小児期早期の哺育障害	3 (3.0)	1 (1.1)	0	0
栄養補給不耐性	2 (2.0)	0	0	1 (1.8)
脱水	1 (1.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 35 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
アラニンアミノトランスフェラーゼ増加	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0
血中クロール減少	0	0	0	0
血中ナトリウム減少	0	0	0	0
骨密度減少	0	0	0	1 (9.1)
呼吸音異常	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0
心拍数減少	0	0	0	0
心拍数増加	0	1 (6.7)	1 (6.7)	0
炎症マーカー上昇	0	0	0	0
肝機能検査異常	1 (2.3)	0	0	0
好中球数増加	0	0	1 (6.7)	0
好中球百分率増加	0	0	0	0
整形外科検査	0	0	0	0
セラチア検査陽性	0	0	0	0
レンサ球菌検査陽性	0	1 (6.7)	0	0
ビタミンＡ減少	0	0	0	0
白血球数増加	0	0	0	0
代謝および栄養障害	0	0	0	0
体重増加不良	0	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0
栄養補給不耐性	0	0	0	0
脱水	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 36 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
アラニンアミノトランスフェラーゼ増加	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	0	0
血中クロール減少	0	0	0	0
血中ナトリウム減少	0	0	0	0
骨密度減少	0	0	0	0
呼吸音異常	0	0	0	0
Ｃ－反応性蛋白増加	0	0	0	0
心拍数減少	0	0	0	0
心拍数増加	0	0	0	0
炎症マーカー上昇	0	0	0	0
肝機能検査異常	0	0	0	0
好中球数増加	0	0	0	0
好中球百分率増加	0	0	0	0
整形外科検査	0	0	0	0
セラチア検査陽性	1 (12.5)	0	0	0
レンサ球菌検査陽性	0	0	0	0
ビタミンＡ減少	0	0	0	0
白血球数増加	0	0	0	0
代謝および栄養障害	1 (12.5)	0	0	0
体重増加不良	1 (12.5)	0	0	0
乳児および小児期早期の哺育障害	0	0	0	0
栄養補給不耐性	0	0	0	0
脱水	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 37 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
成長障害	1 (1.0)	2 (2.2)	1 (1.3)	0
過小食	1 (1.0)	1 (1.1)	0	0
代謝性アルカローシス	1 (1.0)	0	0	0
低ナトリウム血症	0	0	2 (2.7)	0
鉄欠乏	0	1 (1.1)	0	0
筋骨格系および結合組織障害	8 (8.0)	4 (4.4)	6 (8.0)	3 (5.3)
関節拘縮	3 (3.0)	3 (3.3)	2 (2.7)	2 (3.5)
側弯症	2 (2.0)	1 (1.1)	3 (4.0)	0
背部痛	1 (1.0)	0	0	0
胸郭変形	1 (1.0)	0	1 (1.3)	1 (1.8)
手変形	1 (1.0)	0	0	0
頭位性斜頭症	1 (1.0)	0	0	0
泉門閉鎖遅延	0	0	0	1 (1.8)
関節硬直	0	0	0	0
後側弯症	0	0	1 (1.3)	0
脊柱後弯症	0	1 (1.1)	1 (1.3)	1 (1.8)
脊柱前弯症	0	0	0	0
四肢痛	0	0	0	0
脊柱変形	0	0	0	0
滑膜炎	0	0	0	0
斜頚	0	0	1 (1.3)	0
神経系障害	8 (8.0)	6 (6.7)	1 (1.3)	1 (1.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 38 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
成長障害	0	0	0	0
過小食	0	0	0	0
代謝性アルカローシス	0	0	0	0
低ナトリウム血症	0	0	0	0
鉄欠乏	0	0	0	0
筋骨格系および結合組織障害	8 (18.6)	4 (26.7)	5 (33.3)	1 (9.1)
関節拘縮	3 (7.0)	1 (6.7)	2 (13.3)	0
側弯症	4 (9.3)	1 (6.7)	1 (6.7)	1 (9.1)
背部痛	0	0	0	0
胸郭変形	0	1 (6.7)	0	0
手変形	0	0	0	0
頭位性斜頭症	1 (2.3)	0	0	0
泉門閉鎖遅延	0	0	0	0
関節硬直	0	0	1 (6.7)	0
後側弯症	0	0	0	0
脊柱後弯症	0	0	1 (6.7)	0
脊柱前弯症	0	0	0	1 (9.1)
四肢痛	1 (2.3)	0	1 (6.7)	0
脊柱変形	0	1 (6.7)	0	0
滑膜炎	0	0	0	0
斜頚	1 (2.3)	0	0	0
神経系障害	2 (4.7)	1 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 39 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
成長障害	0	0	0	0
過小食	0	0	0	0
代謝性アルカローシス	0	0	0	0
低ナトリウム血症	0	0	0	0
鉄欠乏	0	0	0	0
筋骨格系および結合組織障害	3 (37.5)	1 (25.0)	0	0
関節拘縮	1 (12.5)	0	0	0
側弯症	0	0	0	0
背部痛	0	0	0	0
胸郭変形	0	0	0	0
手変形	0	0	0	0
頭位性斜頭症	0	0	0	0
泉門閉鎖遅延	0	0	0	0
関節硬直	0	0	0	0
後側弯症	1 (12.5)	0	0	0
脊柱後弯症	0	1 (25.0)	0	0
脊柱前弯症	0	0	0	0
四肢痛	1 (12.5)	0	0	0
脊柱変形	0	0	0	0
滑膜炎	1 (12.5)	0	0	0
斜頚	0	0	0	0
神経系障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 40 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
脳損傷	1 (1.0)	0	0	0
脳脊髄液漏	1 (1.0)	0	0	0
間代	1 (1.0)	0	0	0
よだれ	1 (1.0)	0	0	1 (1.8)
低酸素性虚血性脳症	1 (1.0)	0	0	0
不随意性筋収縮	1 (1.0)	2 (2.2)	0	0
眼振	1 (1.0)	2 (2.2)	0	0
痙攣発作	1 (1.0)	1 (1.1)	0	0
失神	1 (1.0)	0	0	0
脳梗塞	0	1 (1.1)	0	0
頭痛	0	0	0	0
言語障害	0	0	0	0
嗜眠	0	0	1 (1.3)	0
傾眠	0	1 (1.1)	0	0
精神障害	8 (8.0)	3 (3.3)	1 (1.3)	0
激越	2 (2.0)	0	0	0
不安	2 (2.0)	3 (3.3)	0	0
易刺激性	2 (2.0)	0	1 (1.3)	0
息こらえ	1 (1.0)	0	0	0
気分動揺	1 (1.0)	0	0	0
落ち着きのなさ	1 (1.0)	0	0	0
睡眠障害	0	1 (1.1)	0	0
眼障害	3 (3.0)	2 (2.2)	1 (1.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 41 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
脳損傷	0	0	0	0
脳脊髄液漏	0	0	0	0
間代	0	0	0	0
よだれ	0	0	0	0
低酸素性虚血性脳症	0	0	0	0
不随意性筋収縮	1 (2.3)	0	0	0
眼振	0	0	0	0
痙攣発作	0	0	0	0
失神	0	0	0	0
脳梗塞	0	0	0	0
頭痛	0	1 (6.7)	0	0
言語障害	1 (2.3)	0	0	0
嗜眠	0	0	0	0
傾眠	0	0	0	0
精神障害	0	0	0	0
激越	0	0	0	0
不安	0	0	0	0
易刺激性	0	0	0	0
息こらえ	0	0	0	0
気分動揺	0	0	0	0
落ち着きのなさ	0	0	0	0
睡眠障害	0	0	0	0
眼障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 42 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
脳損傷	0	0	0	0
脳脊髄液漏	0	0	0	0
間代	0	0	0	0
よだれ	0	0	0	0
低酸素性虚血性脳症	0	0	0	0
不随意性筋収縮	0	0	0	0
眼振	0	0	0	0
痙攣発作	0	0	0	0
失神	0	0	0	0
脳梗塞	0	0	0	0
頭痛	0	0	0	0
言語障害	0	0	0	0
嗜眠	0	0	0	0
傾眠	0	0	0	0
精神障害	0	0	0	0
激越	0	0	0	0
不安	0	0	0	0
易刺激性	0	0	0	0
息こらえ	0	0	0	0
気分動揺	0	0	0	0
落ち着きのなさ	0	0	0	0
睡眠障害	0	0	0	0
眼障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 43 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
乱視	1 (1.0)	0	0	0
眼乾燥	1 (1.0)	0	0	0
眼瞼下垂	1 (1.0)	0	0	0
霰粒腫	0	1 (1.1)	0	0
眼運動障害	0	1 (1.1)	0	0
近視	0	0	1 (1.3)	0
斜視	0	0	1 (1.3)	0
生殖系および乳房障害	3 (3.0)	0	1 (1.3)	0
後天性包茎	1 (1.0)	0	0	0
卵巣嚢胞	1 (1.0)	0	0	0
陰茎障害	1 (1.0)	0	0	0
亀頭包皮炎	0	0	1 (1.3)	0
血管障害	3 (3.0)	1 (1.1)	1 (1.3)	3 (5.3)
毛細血管脆弱	1 (1.0)	0	0	0
蒼白	1 (1.0)	0	0	0
ショック	1 (1.0)	0	0	0
本態性高血圧症	0	0	0	0
高血圧	0	1 (1.1)	0	1 (1.8)
血栓症	0	0	1 (1.3)	1 (1.8)
血管炎	0	0	0	1 (1.8)
血液およびリンパ系障害	2 (2.0)	1 (1.1)	3 (4.0)	0
貧血	1 (1.0)	0	2 (2.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 44 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
乱視	0	0	0	0
眼乾燥	0	0	0	0
眼瞼下垂	0	0	0	0
霰粒腫	0	0	0	0
眼運動障害	0	0	0	0
近視	0	0	0	0
斜視	0	0	0	0
生殖系および乳房障害	0	0	0	0
後天性包茎	0	0	0	0
卵巣嚢胞	0	0	0	0
陰茎障害	0	0	0	0
亀頭包皮炎	0	0	0	0
血管障害	1 (2.3)	0	0	0
毛細血管脆弱	0	0	0	0
蒼白	0	0	0	0
ショック	0	0	0	0
本態性高血圧症	1 (2.3)	0	0	0
高血圧	0	0	0	0
血栓症	0	0	0	0
血管炎	0	0	0	0
血液およびリンパ系障害	0	0	0	0
貧血	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 45 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
乱視	0	0	0	0
眼乾燥	0	0	0	0
眼瞼下垂	0	0	0	0
霰粒腫	0	0	0	0
眼運動障害	0	0	0	0
近視	0	0	0	0
斜視	0	0	0	0
生殖系および乳房障害	0	0	0	0
後天性包茎	0	0	0	0
卵巣嚢胞	0	0	0	0
陰茎障害	0	0	0	0
亀頭包皮炎	0	0	0	0
血管障害	0	0	0	0
毛細血管脆弱	0	0	0	0
蒼白	0	0	0	0
ショック	0	0	0	0
本態性高血圧症	0	0	0	0
高血圧	0	0	0	0
血栓症	0	0	0	0
血管炎	0	0	0	0
血液およびリンパ系障害	0	0	0	0
貧血	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 46 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
好中球減少症	1 (1.0)	0	0	0
リンパ節症	0	0	1 (1.3)	0
血小板増加症	0	1 (1.1)	0	0
先天性、家族性および遺伝性障害	2 (2.0)	1 (1.1)	1 (1.3)	2 (3.5)
先天性横隔膜ヘルニア	1 (1.0)	0	0	0
鳩胸	1 (1.0)	0	0	0
斜指症	0	0	0	0
発育性股関節形成不全	0	0	0	1 (1.8)
貧血母斑	0	0	0	1 (1.8)
斜頭症	0	1 (1.1)	1 (1.3)	0
免疫系障害	2 (2.0)	2 (2.2)	2 (2.7)	2 (3.5)
薬物過敏症	1 (1.0)	0	1 (1.3)	0
過敏症	1 (1.0)	0	0	0
食物アレルギー	0	0	1 (1.3)	0
季節性アレルギー	0	2 (2.2)	0	2 (3.5)
腎および尿路障害	2 (2.0)	0	0	0
水腎症	1 (1.0)	0	0	0
尿閉	1 (1.0)	0	0	0
肝胆道系障害	1 (1.0)	0	0	0
肝腫大	1 (1.0)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 47 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
好中球減少症	0	0	0	0
リンパ節症	0	0	0	0
血小板増加症	0	0	0	0
先天性、家族性および遺伝性障害	1 (2.3)	0	0	0
先天性横隔膜ヘルニア	0	0	0	0
鳩胸	0	0	0	0
斜指症	1 (2.3)	0	0	0
発育性股関節形成不全	0	0	0	0
貧血母斑	0	0	0	0
斜頭症	0	0	0	0
免疫系障害	1 (2.3)	2 (13.3)	2 (13.3)	0
薬物過敏症	0	2 (13.3)	0	0
過敏症	0	0	1 (6.7)	0
食物アレルギー	0	0	0	0
季節性アレルギー	1 (2.3)	0	1 (6.7)	0
腎および尿路障害	0	0	0	0
水腎症	0	0	0	0
尿閉	0	0	0	0
肝胆道系障害	0	0	0	0
肝腫大	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 48 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
好中球減少症	0	0	0	0
リンパ節症	0	0	0	0
血小板増加症	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0
先天性横隔膜ヘルニア	0	0	0	0
鳩胸	0	0	0	0
斜指症	0	0	0	0
発育性股関節形成不全	0	0	0	0
貧血母斑	0	0	0	0
斜頭症	0	0	0	0
免疫系障害	0	0	0	0
薬物過敏症	0	0	0	0
過敏症	0	0	0	0
食物アレルギー	0	0	0	0
季節性アレルギー	0	0	0	0
腎および尿路障害	0	0	0	0
水腎症	0	0	0	0
尿閉	0	0	0	0
肝胆道系障害	0	0	0	0
肝腫大	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 49 of 51

	Days 1-90	Days 91-180	Days 181-270	Days 271-360
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.0)	0	0	0
血管の良性新生物	1 (1.0)	0	0	0
アクロコルドン	0	0	0	0
外科および内科処置	1 (1.0)	0	0	0
機械的換気	1 (1.0)	0	0	0
耳および迷路障害	0	1 (1.1)	1 (1.3)	0
耳の障害	0	1 (1.1)	0	0
耳痛	0	0	1 (1.3)	0
耳垢分泌過多	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 50 of 51

	Days 361-450	Days 451-540	Days 541-630	Days 631-720
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (2.3)	0	0	0
血管の良性新生物	0	0	0	0
アクロコルドン	1 (2.3)	0	0	0
外科および内科処置	0	0	0	0
機械的換気	0	0	0	0
耳および迷路障害	1 (2.3)	0	0	0
耳の障害	0	0	0	0
耳痛	0	0	0	0
耳垢分泌過多	1 (2.3)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by 90-day intervals
Page 51 of 51

	Days 721-810	Days 811-900	Days 901-990	Days 991-1080
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0
血管の良性新生物	0	0	0	0
アクロコルドン	0	0	0	0
外科および内科処置	0	0	0	0
機械的換気	0	0	0	0
耳および迷路障害	0	0	0	0
耳の障害	0	0	0	0
耳痛	0	0	0	0
耳垢分泌過多	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

表 134 Presymptomatic Infants: Incidence of Adverse Events by 90-Day Intervals

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 1 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
Number of subjects dosed	20 (100.0)	18 (100.0)	16 (100.0)	11 (100.0)	9 (100.0)
Number of subjects with an event	14 (70.0)	11 (61.1)	9 (56.3)	7 (63.6)	8 (88.9)
感染症および寄生虫症	8 (40.0)	5 (27.8)	6 (37.5)	3 (27.3)	6 (66.7)
鼻咽頭炎	2 (10.0)	2 (11.1)	0	0	0
上気道感染	2 (10.0)	1 (5.6)	5 (31.3)	2 (18.2)	1 (11.1)
気管支炎	1 (5.0)	0	0	0	0
インフルエンザ	1 (5.0)	2 (11.1)	0	0	0
肺炎	1 (5.0)	0	0	0	1 (11.1)
ウイルス性肺炎	1 (5.0)	0	0	0	0
尿路感染	1 (5.0)	0	0	0	0
細気管支炎	0	0	1 (6.3)	0	0
ブドウ球菌性耳感染	0	0	0	0	1 (11.1)
ウイルス性胃腸炎	0	1 (5.6)	1 (6.3)	0	0
膿痂疹	0	1 (5.6)	0	0	0
中耳炎	0	0	1 (6.3)	1 (9.1)	2 (22.2)
レンサ球菌性咽頭炎	0	0	0	0	1 (11.1)
鼻炎	0	0	0	1 (9.1)	2 (22.2)
ライノウイルス感染	0	0	1 (6.3)	0	1 (11.1)
皮膚感染	0	0	0	1 (9.1)	0
レンサ球菌感染	0	0	0	0	1 (11.1)
皮膚および皮下組織障害	5 (25.0)	4 (22.2)	1 (6.3)	0	1 (11.1)
皮膚炎	2 (10.0)	0	0	0	0
おむつ皮膚炎	1 (5.0)	1 (5.6)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 2 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
点状出血	1 (5.0)	0	0	0	0
脂漏性皮膚炎	1 (5.0)	0	0	0	0
貨幣状湿疹	0	1 (5.6)	1 (6.3)	0	0
紅斑	0	1 (5.6)	0	0	0
発疹	0	1 (5.6)	0	0	0
紅斑性皮疹	0	0	0	0	1 (11.1)
胃腸障害	4 (20.0)	1 (5.6)	2 (12.5)	1 (9.1)	1 (11.1)
腹部膨満	2 (10.0)	0	0	0	0
放屁	2 (10.0)	0	0	0	0
胃食道逆流性疾患	2 (10.0)	0	0	0	0
腹部不快感	1 (5.0)	0	0	0	0
便秘	0	0	1 (6.3)	1 (9.1)	0
下痢	0	0	0	0	1 (11.1)
嚥下障害	0	1 (5.6)	0	0	0
生歯	0	0	1 (6.3)	0	0
一般・全身障害および投与部位の状態	4 (20.0)	1 (5.6)	3 (18.8)	2 (18.2)	3 (33.3)
発熱	3 (15.0)	1 (5.6)	3 (18.8)	2 (18.2)	3 (33.3)
注入部位内出血	1 (5.0)	0	0	0	0
適用部位紅斑	0	0	1 (6.3)	0	0
筋骨格系および結合組織障害	3 (15.0)	1 (5.6)	1 (6.3)	0	0
筋力低下	2 (10.0)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 3 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
斜頚	1 (5.0)	0	0	0	0
体重支持困難	1 (5.0)	0	0	0	0
関節拘縮	0	0	1 (6.3)	0	0
頭位性斜頭症	0	1 (5.6)	0	0	0
神経系障害	3 (15.0)	0	0	0	0
筋緊張低下	2 (10.0)	0	0	0	0
反射亢進	1 (5.0)	0	0	0	0
心臓障害	2 (10.0)	0	0	0	0
頻脈	2 (10.0)	0	0	0	0
傷害、中毒および処置合併症	2 (10.0)	1 (5.6)	0	1 (9.1)	1 (11.1)
処置後合併症	1 (5.0)	0	0	0	0
処置後不快感	1 (5.0)	0	0	0	0
硬膜下血腫	1 (5.0)	0	0	0	0
節足動物咬傷	0	0	0	0	1 (11.1)
転倒	0	1 (5.6)	0	0	0
処置後腫脹	0	0	0	1 (9.1)	0
代謝および栄養障害	2 (10.0)	1 (5.6)	0	0	2 (22.2)
脱水	1 (5.0)	0	0	0	1 (11.1)
体重増加不良	1 (5.0)	1 (5.6)	0	0	0
成長障害	0	1 (5.6)	0	0	1 (11.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 4 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
呼吸器、胸郭および縦隔障害	2 (10.0)	1 (5.6)	2 (12.5)	2 (18.2)	2 (22.2)
鼻閉	1 (5.0)	1 (5.6)	1 (6.3)	0	0
呼吸性アシドーシス	1 (5.0)	0	0	0	0
呼吸窮迫	1 (5.0)	0	0	0	1 (11.1)
息詰まり	0	0	0	1 (9.1)	0
咳嗽	0	0	1 (6.3)	1 (9.1)	1 (11.1)
鼻漏	0	0	1 (6.3)	1 (9.1)	1 (11.1)
上気道うっ血	0	0	0	1 (9.1)	0
血管障害	2 (10.0)	0	0	0	0
高血圧	1 (5.0)	0	0	0	0
蒼白	1 (5.0)	0	0	0	0
血液およびリンパ系障害	1 (5.0)	0	0	1 (9.1)	0
好中球減少症	1 (5.0)	0	0	0	0
好酸球増加症	0	0	0	1 (9.1)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.0)	0	0	0	0
脂漏性角化症	1 (5.0)	0	0	0	0
妊娠、産褥および周産期の状態	1 (5.0)	0	0	0	0
臍肉芽腫	1 (5.0)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants: incidence of adverse events by 90-day intervals
Page 5 of 5

	Days 1-90	Days 91-180	Days 181-270	Days 271-360	Days 361-450
眼障害	0	1 (5.6)	0	0	0
後天性涙道狭窄	0	1 (5.6)	0	0	0
免疫系障害	0	0	1 (6.3)	1 (9.1)	0
食物アレルギー	0	0	0	1 (9.1)	0
季節性アレルギー	0	0	1 (6.3)	0	0
臨床検査	0	0	1 (6.3)	1 (9.1)	3 (33.3)
アラニンアミノトランスフェラーゼ増加	0	0	1 (6.3)	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0	1 (6.3)	0	0
血中アルカリホスファターゼ増加	0	0	0	0	1 (11.1)
体温上昇	0	0	0	0	1 (11.1)
好酸球数増加	0	0	0	1 (9.1)	0
リンパ球数増加	0	0	0	1 (9.1)	0
酸素飽和度低下	0	0	0	0	1 (11.1)
白血球数増加	0	0	0	1 (9.1)	0
生殖系および乳房障害	0	1 (5.6)	0	0	0
外陰腟発疹	0	1 (5.6)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 135　Incidence of Adverse Events in the 24 Hours Following Dosing in Infants Diagnosed With SMA

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 1 of 9

		Symptomaic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	PreSymptomaic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	9 (45.0)	16 (39.0)	44 (55.0)	53 (53.0)	62 (51.7)
呼吸器、胸郭および縦隔障害	2 (10.0)	4 (9.8)	14 (17.5)	15 (15.0)	17 (14.2)
無気肺	0	0	3 (3.8)	3 (3.0)	3 (2.5)
低酸素症	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
呼吸窮迫	0	0	1 (1.3)	2 (2.0)	2 (1.7)
急性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
息詰まり	0	0	1 (1.3)	1 (1.0)	1 (0.8)
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低換気	0	0	1 (1.3)	1 (1.0)	1 (0.8)
鼻閉	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
誤嚥性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
上気道うっ血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気管支分泌物貯留	0	1 (2.4)	0	0	0
咳嗽	0	1 (2.4)	0	0	0
発声障害	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 2 of 9

		Symptomaic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	PreSymptomaic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
鼻出血	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
呼吸性アシドーシス	1 (5.0)	0	0	0	1 (0.8)
拘束性肺疾患	0	0	0	0	0
変色痰	0	1 (2.4)	0	0	0
感染症および寄生虫症	2 (10.0)	0	11 (13.8)	13 (13.0)	15 (12.5)
鼻咽頭炎	0	0	3 (3.8)	3 (3.0)	3 (2.5)
肺炎	0	0	3 (3.8)	3 (3.0)	3 (2.5)
上気道感染	1 (5.0)	0	1 (1.3)	2 (2.0)	3 (2.5)
膿痂疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
口腔カンジダ症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
中耳炎	0	0	0	1 (1.0)	1 (0.8)
鼻炎	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
ライノウイルス感染	0	0	0	1 (1.0)	1 (0.8)
尿路感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
真菌感染	0	0	0	0	0
胃腸炎	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA

		Symptomaic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	PreSymptomaic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
胃腸障害	2 (10.0)	3 (7.3)	10 (12.5)	12 (12.0)	14 (11.7)
嘔吐	0	0	3 (3.8)	5 (5.0)	5 (4.2)
便秘	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
嚥下障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
胃食道逆流性疾患	1 (5.0)	1 (2.4)	1 (1.3)	2 (2.0)	3 (2.5)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.8)
流涎過多	0	0	1 (1.3)	1 (1.0)	1 (0.8)
生歯	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腹部膨満	1 (5.0)	0	0	0	1 (0.8)
腹痛	0	0	0	0	0
上腹部痛	0	0	0	0	0
腹部症状	0	0	0	0	0
下痢	0	1 (2.4)	0	0	0
便失禁	0	0	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0
口内炎	0	1 (2.4)	0	0	0
歯の脱落	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 4 of 9

		Symptomaic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	PreSymptomaic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
一般・全身障害および投与部位の状態	1 (5.0)	6 (14.6)	6 (7.5)	8 (8.0)	9 (7.5)
発熱	1 (5.0)	3 (7.3)	5 (6.3)	6 (6.0)	7 (5.8)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管穿刺部位内出血	0	0	0	1 (1.0)	1 (0.8)
適用部位発疹	0	1 (2.4)	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
胸痛	0	0	0	0	0
悪寒	0	0	0	0	0
疲労	0	0	0	0	0
冷感	0	0	0	0	0
注射部位血腫	0	1 (2.4)	0	0	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
疼痛	0	2 (4.9)	0	0	0
穿刺部位疼痛	0	0	0	0	0
傷害、中毒および処置合併症	1 (5.0)	0	7 (8.8)	8 (8.0)	9 (7.5)
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 5 of 9

	Presymptomatic: ISIS 396443	Symptomaic (infantile-onset) Controlled study (CS3B) Control	Controlled study (CS3B) ISIS 396443	Controlled and uncontrolled studies : ISIS 396443	PreSymptomaic and symptomatic: ISIS 396443
節足動物咬傷	0	0	0	1 (1.0)	1 (0.8)
挫傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)
大腿骨骨折	0	0	1 (1.3)	1 (1.0)	1 (0.8)
処置後腫脹	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置による疼痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ部刺激感	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腰椎穿刺後症候群	0	0	0	0	0
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
臨床検査	1 (5.0)	4 (9.8)	6 (7.5)	6 (6.0)	7 (5.8)
酸素飽和度低下	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中カリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
体温上昇	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
Ｃ－反応性蛋白増加	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ブドウ球菌検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中重炭酸塩減少	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 6 of 9

		Symptomaic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	PreSymptomaic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
呼吸数増加	0	1 (2.4)	0	0	0
尿検査異常	0	0	0	0	0
体重減少	0	1 (2.4)	0	0	0
皮膚および皮下組織障害	3 (15.0)	2 (4.9)	4 (5.0)	5 (5.0)	8 (6.7)
脱毛症	0	0	0	1 (1.0)	1 (0.8)
接触性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
斑状出血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
点状出血	1 (5.0)	0	0	1 (1.0)	2 (1.7)
発疹	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
皮膚炎	2 (10.0)	0	0	0	2 (1.7)
紅斑	0	0	0	0	0
多汗症	0	1 (2.4)	0	0	0
汗疹	0	0	0	0	0
寝汗	0	0	0	0	0
心臓障害	2 (10.0)	5 (12.2)	4 (5.0)	4 (4.0)	6 (5.0)
頻脈	2 (10.0)	3 (7.3)	3 (3.8)	3 (3.0)	5 (4.2)
徐脈	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 7 of 9

	Presymptomatic: ISIS 396443	Symptomaic (infantile-onset) Controlled study (CS3B) Control	Controlled study (CS3B) ISIS 396443	Controlled and uncontrolled studies : ISIS 396443	PreSymptomaic and symptomatic: ISIS 396443
心室性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.8)
チアノーゼ	0	1 (2.4)	0	0	0
精神障害	0	0	4 (5.0)	4 (4.0)	4 (3.3)
易刺激性	0	0	2 (2.5)	2 (2.0)	2 (1.7)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.8)
落ち着きのなさ	0	0	1 (1.3)	1 (1.0)	1 (0.8)
激越	0	0	0	0	0
不眠症	0	0	0	0	0
筋骨格系および結合組織障害	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
四肢痛	0	0	0	1 (1.0)	1 (0.8)
側弯症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
滑膜炎	0	0	0	1 (1.0)	1 (0.8)
関節痛	0	0	0	0	0
関節拘縮	0	1 (2.4)	0	0	0
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 8 of 9

	Presymptomatic: ISIS 396443	Symptomaic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	PreSymptomaic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
骨盤変形	0	0	0	0	0
神経系障害	1 (5.0)	0	1 (1.3)	3 (3.0)	4 (3.3)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.8)
頭痛	0	0	0	1 (1.0)	1 (0.8)
眼振	0	0	1 (1.3)	1 (1.0)	1 (0.8)
反射亢進	1 (5.0)	0	0	0	1 (0.8)
不随意性筋収縮	0	0	0	0	0
振戦	0	0	0	0	0
代謝および栄養障害	1 (5.0)	0	1 (1.3)	2 (2.0)	3 (2.5)
過小食	0	0	0	1 (1.0)	1 (0.8)
体重増加不良	0	0	1 (1.3)	1 (1.0)	1 (0.8)
脱水	0	0	0	0	0
成長障害	1 (5.0)	0	0	0	1 (0.8)
栄養障害	0	0	0	0	0
眼障害	0	0	0	1 (1.0)	1 (0.8)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in infants diagnosed with SMA
Page 9 of 9

		Symptomaic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	PreSymptomaic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
腎および尿路障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.8)
尿失禁	0	0	0	0	0
血液およびリンパ系障害	1 (5.0)	0	0	0	1 (0.8)
好中球減少症	1 (5.0)	0	0	0	1 (0.8)
免疫系障害	0	1 (2.4)	0	0	0
化学物質アレルギー	0	0	0	0	0
薬物過敏症	0	0	0	0	0
過敏症	0	1 (2.4)	0	0	0
季節性アレルギー	0	0	0	0	0
血管障害	1 (5.0)	0	0	0	1 (0.8)
低血圧	0	0	0	0	0
蒼白	1 (5.0)	0	0	0	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomaic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 136　Incidence of Adverse Events in the 72 Hours Following Dosing in Infants Diagnosed With SMA

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 1 of 11

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	10 (50.0)	24 (58.5)	51 (63.8)	67 (67.0)	77 (64.2)
感染症および寄生虫症	2 (10.0)	4 (9.8)	20 (25.0)	24 (24.0)	26 (21.7)
肺炎	0	1 (2.4)	5 (6.3)	5 (5.0)	5 (4.2)
上気道感染	1 (5.0)	1 (2.4)	4 (5.0)	5 (5.0)	6 (5.0)
鼻咽頭炎	0	0	3 (3.8)	4 (4.0)	4 (3.3)
口腔カンジダ症	0	0	2 (2.5)	2 (2.0)	2 (1.7)
ウイルス性気管支炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
結膜炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ウイルス性胃炎	0	0	0	1 (1.0)	1 (0.8)
膿痂疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
中耳炎	0	1 (2.4)	0	1 (1.0)	1 (0.8)
気道感染	0	0	0	1 (1.0)	1 (0.8)
ウイルス性気道感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
鼻炎	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
ライノウイルス感染	0	0	0	1 (1.0)	1 (0.8)
尿路感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 2 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ウイルス性上気道感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
細菌性気管炎	0	1 (2.4)	0	0	0
真菌感染	0	0	0	0	0
胃腸炎	0	0	0	0	0
インフルエンザ	0	0	0	0	0
副鼻腔炎	0	0	0	0	0
ウイルス感染	0	0	0	0	0
呼吸器、胸郭および縦隔障害	2 (10.0)	10 (24.4)	18 (22.5)	21 (21.0)	23 (19.2)
無気肺	0	0	5 (6.3)	5 (5.0)	5 (4.2)
急性呼吸不全	0	0	3 (3.8)	4 (4.0)	4 (3.3)
低酸素症	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
呼吸不全	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)
呼吸窮迫	1 (5.0)	0	1 (1.3)	2 (2.0)	3 (2.5)
無呼吸	0	1 (2.4)	0	1 (1.0)	1 (0.8)
息詰まり	0	0	1 (1.3)	1 (1.0)	1 (0.8)
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
咳嗽	0	4 (9.8)	0	1 (1.0)	1 (0.8)
低換気	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 3 of 11

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
鼻閉	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
誤嚥性肺炎	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
上気道うっ血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
乳幼児突発性危急事態	0	1 (2.4)	0	0	0
気管支分泌物貯留	0	2 (4.9)	0	0	0
カタル	0	0	0	0	0
発声障害	0	0	0	0	0
鼻出血	0	0	0	0	0
口腔咽頭痛	0	0	0	0	0
呼吸性アシドーシス	1 (5.0)	0	0	0	1 (0.8)
拘束性肺疾患	0	0	0	0	0
鼻漏	0	1 (2.4)	0	0	0
睡眠時無呼吸症候群	0	1 (2.4)	0	0	0
変色痰	0	1 (2.4)	0	0	0
胃腸障害	2 (10.0)	5 (12.2)	14 (17.5)	18 (18.0)	20 (16.7)
嘔吐	0	0	4 (5.0)	6 (6.0)	6 (5.0)
便秘	0	1 (2.4)	4 (5.0)	4 (4.0)	4 (3.3)
胃食道逆流性疾患	1 (5.0)	2 (4.9)	2 (2.5)	3 (3.0)	4 (3.3)
嚥下障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 4 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
生歯	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
腹痛	0	0	0	1 (1.0)	1 (0.8)
アフタ性潰瘍	0	0	1 (1.3)	1 (1.0)	1 (0.8)
流涎過多	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腹部膨満	2 (10.0)	0	0	0	2 (1.7)
上腹部痛	0	0	0	0	0
腹部症状	0	0	0	0	0
下痢	0	1 (2.4)	0	0	0
便失禁	0	0	0	0	0
食中毒	0	0	0	0	0
口の感覚鈍麻	0	0	0	0	0
口唇痛	0	0	0	0	0
悪心	0	0	0	0	0
口内炎	0	1 (2.4)	0	0	0
歯の脱落	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (5.0)	9 (22.0)	9 (11.3)	12 (12.0)	13 (10.8)
発熱	1 (5.0)	4 (9.8)	7 (8.8)	9 (9.0)	10 (8.3)
泣き	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 5 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
小結節	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管穿刺部位内出血	0	1 (2.4)	0	1 (1.0)	1 (0.8)
適用部位発疹	0	1 (2.4)	0	0	0
カテーテル留置部位疼痛	0	0	0	0	0
胸痛	0	0	0	0	0
悪寒	0	0	0	0	0
死亡	0	1 (2.4)	0	0	0
疲労	0	0	0	0	0
冷感	0	0	0	0	0
注射部位血腫	0	1 (2.4)	0	0	0
注射部位出血	0	0	0	0	0
注射部位疼痛	0	0	0	0	0
疼痛	0	2 (4.9)	0	0	0
穿刺部位疼痛	0	0	0	0	0
傷害、中毒および処置合併症	2 (10.0)	2 (4.9)	7 (8.8)	10 (10.0)	12 (10.0)
術後激越	0	0	1 (1.3)	1 (1.0)	1 (0.8)
節足動物咬傷	0	0	0	1 (1.0)	1 (0.8)
挫傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 6 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
ダンピング症候群	0	0	0	1 (1.0)	1 (0.8)
大腿骨骨折	0	0	1 (1.3)	1 (1.0)	1 (0.8)
処置後腫脹	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
処置による疼痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
処置部位反応	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ストーマ部刺激感	0	0	1 (1.3)	1 (1.0)	1 (0.8)
サンバーン	0	0	0	1 (1.0)	1 (0.8)
栄養補給チューブ合併症	0	1 (2.4)	0	0	0
頭部損傷	0	1 (2.4)	0	0	0
裂傷	0	0	0	0	0
腰椎穿刺後症候群	0	0	0	0	0
処置後不快感	1 (5.0)	0	0	0	1 (0.8)
処置による頭痛	0	0	0	0	0
処置による悪心	0	0	0	0	0
臨床検査	1 (5.0)	4 (9.8)	7 (8.8)	8 (8.0)	9 (7.5)
酸素飽和度低下	0	2 (4.9)	2 (2.5)	2 (2.0)	2 (1.7)
血中クロール減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中カリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中ナトリウム減少	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 7 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
体温低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)
体温上昇	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
Ｃ－反応性蛋白増加	0	0	1 (1.3)	1 (1.0)	1 (0.8)
心拍数増加	0	0	0	1 (1.0)	1 (0.8)
ブドウ球菌検査陽性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血中重炭酸塩減少	0	0	0	0	0
呼吸数増加	0	1 (2.4)	0	0	0
尿検査異常	0	0	0	0	0
体重減少	0	1 (2.4)	0	0	0
皮膚および皮下組織障害	4 (20.0)	2 (4.9)	5 (6.3)	7 (7.0)	11 (9.2)
脱毛症	0	0	0	1 (1.0)	1 (0.8)
接触性皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
おむつ皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
斑状出血	0	0	1 (1.3)	1 (1.0)	1 (0.8)
湿疹	0	0	0	1 (1.0)	1 (0.8)
点状出血	1 (5.0)	0	0	1 (1.0)	2 (1.7)
発疹	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
丘疹性皮疹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
皮膚炎	2 (10.0)	0	0	0	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 8 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
貨幣状湿疹	1 (5.0)	0	0	0	1 (0.8)
紅斑	0	0	0	0	0
多汗症	0	1 (2.4)	0	0	0
汗疹	0	0	0	0	0
寝汗	0	0	0	0	0
皮膚疼痛	0	0	0	0	0
心臓障害	2 (10.0)	5 (12.2)	5 (6.3)	5 (5.0)	7 (5.8)
頻脈	2 (10.0)	3 (7.3)	3 (3.8)	3 (3.0)	5 (4.2)
徐脈	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
チアノーゼ	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
心室性頻脈	0	0	1 (1.3)	1 (1.0)	1 (0.8)
代謝および栄養障害	1 (5.0)	2 (4.9)	3 (3.8)	4 (4.0)	5 (4.2)
乳児および小児期早期の哺育障害	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
栄養補給不耐性	0	0	1 (1.3)	1 (1.0)	1 (0.8)
過小食	0	0	0	1 (1.0)	1 (0.8)
体重増加不良	0	0	1 (1.3)	1 (1.0)	1 (0.8)
食欲減退	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 9 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
脱水	0	1 (2.4)	0	0	0
成長障害	1 (5.0)	1 (2.4)	0	0	1 (0.8)
栄養障害	0	0	0	0	0
精神障害	0	0	4 (5.0)	4 (4.0)	4 (3.3)
易刺激性	0	0	2 (2.5)	2 (2.0)	2 (1.7)
気分動揺	0	0	1 (1.3)	1 (1.0)	1 (0.8)
落ち着きのなさ	0	0	1 (1.3)	1 (1.0)	1 (0.8)
激越	0	0	0	0	0
不眠症	0	0	0	0	0
筋骨格系および結合組織障害	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
背部痛	0	0	1 (1.3)	1 (1.0)	1 (0.8)
四肢痛	0	0	0	1 (1.0)	1 (0.8)
側弯症	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
滑膜炎	0	0	0	1 (1.0)	1 (0.8)
関節痛	0	0	0	0	0
関節拘縮	0	1 (2.4)	0	0	0
筋力低下	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 10 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
筋肉痛	0	0	0	0	0
頚部痛	0	0	0	0	0
骨盤変形	0	0	0	0	0
神経系障害	1 (5.0)	0	1 (1.3)	3 (3.0)	4 (3.3)
脳脊髄液漏	0	0	0	1 (1.0)	1 (0.8)
頭痛	0	0	0	1 (1.0)	1 (0.8)
眼振	0	0	1 (1.3)	1 (1.0)	1 (0.8)
失声症	0	0	0	0	0
反射亢進	1 (5.0)	0	0	0	1 (0.8)
不随意性筋収縮	0	0	0	0	0
錯感覚	0	0	0	0	0
振戦	0	0	0	0	0
眼障害	0	0	1 (1.3)	2 (2.0)	2 (1.7)
眼乾燥	0	0	1 (1.3)	1 (1.0)	1 (0.8)
眼瞼下垂	0	0	0	1 (1.0)	1 (0.8)
腎および尿路障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
尿閉	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in infants diagnosed with SMA
Page 11 of 11

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
尿失禁	0	0	0	0	0
血液およびリンパ系障害	1 (5.0)	0	0	0	1 (0.8)
好中球減少症	1 (5.0)	0	0	0	1 (0.8)
耳および迷路障害	0	0	0	0	0
乗物酔い	0	0	0	0	0
免疫系障害	0	1 (2.4)	0	0	0
化学物質アレルギー	0	0	0	0	0
薬物過敏症	0	0	0	0	0
過敏症	0	1 (2.4)	0	0	0
季節性アレルギー	0	0	0	0	0
血管障害	1 (5.0)	0	0	0	1 (0.8)
低血圧	0	0	0	0	0
蒼白	1 (5.0)	0	0	0	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 137　Incidence of Adverse Events in the 24 Hours Following Dosing in Subjects With SMA

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 1 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	9 (45.0)	53 (53.0)	62 (51.7)	41 (73.2)	103 (58.5)
傷害、中毒および処置合併症	1 (5.0)	8 (8.0)	9 (7.5)	16 (28.6)	25 (14.2)
腰椎穿刺後症候群	0	0	0	12 (21.4)	12 (6.8)
術後激越	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
処置後腫脹	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
処置による悪心	0	0	0	2 (3.6)	2 (1.1)
処置による疼痛	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
節足動物咬傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
挫傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
大腿骨骨折	0	1 (1.0)	1 (0.8)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ部刺激感	0	1 (1.0)	1 (0.8)	0	1 (0.6)
筋骨格系および結合組織障害	0	3 (3.0)	3 (2.5)	22 (39.3)	25 (14.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 2 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
背部痛	0	1 (1.0)	1 (0.8)	16 (28.6)	17 (9.7)
側弯症	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
筋肉痛	0	0	0	2 (3.6)	2 (1.1)
関節痛	0	0	0	1 (1.8)	1 (0.6)
頚部痛	0	0	0	1 (1.8)	1 (0.6)
四肢痛	0	1 (1.0)	1 (0.8)	0	1 (0.6)
骨盤変形	0	0	0	1 (1.8)	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
関節拘縮	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 3 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
胃腸障害	2 (10.0)	12 (12.0)	14 (11.7)	10 (17.9)	24 (13.6)
嘔吐	0	5 (5.0)	5 (4.2)	4 (7.1)	9 (5.1)
便秘	0	2 (2.0)	2 (1.7)	2 (3.6)	4 (2.3)
胃食道逆流性疾患	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
アフタ性潰瘍	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
嚥下障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
悪心	0	0	0	2 (3.6)	2 (1.1)
腹部膨満	1 (5.0)	0	1 (0.8)	0	1 (0.6)
腹痛	0	0	0	1 (1.8)	1 (0.6)
上腹部痛	0	0	0	1 (1.8)	1 (0.6)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
口唇痛	0	0	0	1 (1.8)	1 (0.6)
流涎過多	0	1 (1.0)	1 (0.8)	0	1 (0.6)
生歯	0	1 (1.0)	1 (0.8)	0	1 (0.6)
下痢	0	0	0	0	0
口内炎	0	0	0	0	0
呼吸器、胸郭および縦隔障害	2 (10.0)	15 (15.0)	17 (14.2)	5 (8.9)	22 (12.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
無気肺	0	3 (3.0)	3 (2.5)	0	3 (1.7)
低酸素症	0	3 (3.0)	3 (2.5)	0	3 (1.7)
口腔咽頭痛	0	0	0	3 (5.4)	3 (1.7)
鼻閉	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
呼吸窮迫	0	2 (2.0)	2 (1.7)	0	2 (1.1)
急性呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
息詰まり	0	1 (1.0)	1 (0.8)	0	1 (0.6)
慢性呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
鼻出血	0	0	0	1 (1.8)	1 (0.6)
低換気	0	1 (1.0)	1 (0.8)	0	1 (0.6)
誤嚥性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸性アシドーシス	1 (5.0)	0	1 (0.8)	0	1 (0.6)
呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
拘束性肺疾患	0	0	0	1 (1.8)	1 (0.6)
上気道うっ血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管支分泌物貯留	0	0	0	0	0
咳嗽	0	0	0	0	0
変色痰	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 5 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
一般・全身障害および投与部位の状態	1 (5.0)	8 (8.0)	9 (7.5)	12 (21.4)	21 (11.9)
発熱	1 (5.0)	6 (6.0)	7 (5.8)	3 (5.4)	10 (5.7)
穿刺部位疼痛	0	0	0	7 (12.5)	7 (4.0)
血管穿刺部位内出血	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
泣き	0	1 (1.0)	1 (0.8)	0	1 (0.6)
疲労	0	0	0	1 (1.8)	1 (0.6)
冷感	0	0	0	1 (1.8)	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
適用部位発疹	0	0	0	0	0
注射部位血腫	0	0	0	0	0
疼痛	0	0	0	0	0
神経系障害	1 (5.0)	3 (3.0)	4 (3.3)	13 (23.2)	17 (9.7)
頭痛	0	1 (1.0)	1 (0.8)	12 (21.4)	13 (7.4)
脳脊髄液漏	0	1 (1.0)	1 (0.8)	0	1 (0.6)
反射亢進	1 (5.0)	0	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 6 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
眼振	0	1 (1.0)	1 (0.8)	0	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)
感染症および寄生虫症	2 (10.0)	13 (13.0)	15 (12.5)	1 (1.8)	16 (9.1)
鼻咽頭炎	0	3 (3.0)	3 (2.5)	0	3 (1.7)
肺炎	0	3 (3.0)	3 (2.5)	0	3 (1.7)
上気道感染	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
鼻炎	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
胃腸炎	0	0	0	1 (1.8)	1 (0.6)
膿痂疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
口腔カンジダ症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
中耳炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ライノウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
尿路感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
臨床検査	1 (5.0)	6 (6.0)	7 (5.8)	3 (5.4)	10 (5.7)
体温上昇	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
酸素飽和度低下	0	2 (2.0)	2 (1.7)	0	2 (1.1)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 7 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
血中クロール減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中カリウム減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
Ｃ－反応性蛋白増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)
呼吸数増加	0	0	0	0	0
体重減少	0	0	0	0	0
皮膚および皮下組織障害	3 (15.0)	5 (5.0)	8 (6.7)	1 (1.8)	9 (5.1)
皮膚炎	2 (10.0)	0	2 (1.7)	0	2 (1.1)
点状出血	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
脱毛症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
接触性皮膚炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
斑状出血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
汗疹	0	0	0	1 (1.8)	1 (0.6)
発疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
多汗症	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
心臓障害	2 (10.0)	4 (4.0)	6 (5.0)	1 (1.8)	7 (4.0)
頻脈	2 (10.0)	3 (3.0)	5 (4.2)	1 (1.8)	6 (3.4)
徐脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心室性頻脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
チアノーゼ	0	0	0	0	0
精神障害	0	4 (4.0)	4 (3.3)	1 (1.8)	5 (2.8)
易刺激性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
激越	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.8)	0	1 (0.6)
落ち着きのなさ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
代謝および栄養障害	1 (5.0)	2 (2.0)	3 (2.5)	1 (1.8)	4 (2.3)
脱水	0	0	0	1 (1.8)	1 (0.6)
成長障害	1 (5.0)	0	1 (0.8)	0	1 (0.6)
過小食	0	1 (1.0)	1 (0.8)	0	1 (0.6)
体重増加不良	0	1 (1.0)	1 (0.8)	0	1 (0.6)
免疫系障害	0	0	0	3 (5.4)	3 (1.7)
薬物過敏症	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 24 hours following dosing in subjects with SMA
Page 9 of 9

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
過敏症	0	0	0	1 (1.8)	1 (0.6)
季節性アレルギー	0	0	0	1 (1.8)	1 (0.6)
腎および尿路障害	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血管障害	1 (5.0)	0	1 (0.8)	1 (1.8)	2 (1.1)
低血圧	0	0	0	1 (1.8)	1 (0.6)
蒼白	1 (5.0)	0	1 (0.8)	0	1 (0.6)
血液およびリンパ系障害	1 (5.0)	0	1 (0.8)	0	1 (0.6)
好中球減少症	1 (5.0)	0	1 (0.8)	0	1 (0.6)
眼障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 138　Incidence of Adverse Events in the 72 Hours Following Dosing in Subjects With SMA

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 1 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	10 (50.0)	67 (67.0)	77 (64.2)	46 (82.1)	123 (69.9)
傷害、中毒および処置合併症	2 (10.0)	10 (10.0)	12 (10.0)	23 (41.1)	35 (19.9)
腰椎穿刺後症候群	0	0	0	19 (33.9)	19 (10.8)
処置による疼痛	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
術後激越	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
処置後腫脹	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
処置による悪心	0	0	0	2 (3.6)	2 (1.1)
節足動物咬傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
挫傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ダンピング症候群	0	1 (1.0)	1 (0.8)	0	1 (0.6)
大腿骨骨折	0	1 (1.0)	1 (0.8)	0	1 (0.6)
処置後不快感	1 (5.0)	0	1 (0.8)	0	1 (0.6)
処置による頭痛	0	0	0	1 (1.8)	1 (0.6)
処置部位反応	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ストーマ部刺激感	0	1 (1.0)	1 (0.8)	0	1 (0.6)
サンバーン	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
栄養補給チューブ合併症	0	0	0	0	0
頭部損傷	0	0	0	0	0
胃腸障害	2 (10.0)	18 (18.0)	20 (16.7)	14 (25.0)	34 (19.3)
嘔吐	0	6 (6.0)	6 (5.0)	9 (16.1)	15 (8.5)
便秘	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
悪心	0	0	0	6 (10.7)	6 (3.4)
胃食道逆流性疾患	1 (5.0)	3 (3.0)	4 (3.3)	0	4 (2.3)
腹部膨満	2 (10.0)	0	2 (1.7)	0	2 (1.1)
腹痛	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
アフタ性潰瘍	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
嚥下障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
生歯	0	2 (2.0)	2 (1.7)	0	2 (1.1)
上腹部痛	0	0	0	1 (1.8)	1 (0.6)
腹部症状	0	0	0	1 (1.8)	1 (0.6)
食中毒	0	0	0	1 (1.8)	1 (0.6)
口の感覚鈍麻	0	0	0	1 (1.8)	1 (0.6)
口唇痛	0	0	0	1 (1.8)	1 (0.6)
流涎過多	0	1 (1.0)	1 (0.8)	0	1 (0.6)
下痢	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 3 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
口内炎	0	0	0	0	0
感染症および寄生虫症	2 (10.0)	24 (24.0)	26 (21.7)	4 (7.1)	30 (17.0)
上気道感染	1 (5.0)	5 (5.0)	6 (5.0)	1 (1.8)	7 (4.0)
肺炎	0	5 (5.0)	5 (4.2)	0	5 (2.8)
鼻咽頭炎	0	4 (4.0)	4 (3.3)	0	4 (2.3)
口腔カンジダ症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
鼻炎	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
ウイルス性気管支炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
結膜炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性胃炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃腸炎	0	0	0	1 (1.8)	1 (0.6)
膿痂疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
中耳炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ライノウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
副鼻腔炎	0	0	0	1 (1.8)	1 (0.6)
尿路感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 4 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
ウイルス感染	0	0	0	1 (1.8)	1 (0.6)
ウイルス性上気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
細菌性気管炎	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (5.0)	12 (12.0)	13 (10.8)	15 (26.8)	28 (15.9)
発熱	1 (5.0)	9 (9.0)	10 (8.3)	3 (5.4)	13 (7.4)
穿刺部位疼痛	0	0	0	9 (16.1)	9 (5.1)
疲労	0	0	0	2 (3.6)	2 (1.1)
血管穿刺部位内出血	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
カテーテル留置部位疼痛	0	0	0	1 (1.8)	1 (0.6)
悪寒	0	0	0	1 (1.8)	1 (0.6)
泣き	0	1 (1.0)	1 (0.8)	0	1 (0.6)
冷感	0	0	0	1 (1.8)	1 (0.6)
注射部位出血	0	0	0	1 (1.8)	1 (0.6)
注射部位疼痛	0	0	0	1 (1.8)	1 (0.6)
小結節	0	1 (1.0)	1 (0.8)	0	1 (0.6)
疼痛	0	0	0	1 (1.8)	1 (0.6)
適用部位発疹	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 5 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
死亡	0	0	0	0	0
注射部位血腫	0	0	0	0	0
呼吸器、胸郭および縦隔障害	2 (10.0)	21 (21.0)	23 (19.2)	5 (8.9)	28 (15.9)
無気肺	0	5 (5.0)	5 (4.2)	0	5 (2.8)
急性呼吸不全	0	4 (4.0)	4 (3.3)	0	4 (2.3)
低酸素症	0	3 (3.0)	3 (2.5)	0	3 (1.7)
口腔咽頭痛	0	0	0	3 (5.4)	3 (1.7)
呼吸窮迫	1 (5.0)	2 (2.0)	3 (2.5)	0	3 (1.7)
呼吸不全	0	3 (3.0)	3 (2.5)	0	3 (1.7)
咳嗽	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
鼻閉	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
無呼吸	0	1 (1.0)	1 (0.8)	0	1 (0.6)
息詰まり	0	1 (1.0)	1 (0.8)	0	1 (0.6)
慢性呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
鼻出血	0	0	0	1 (1.8)	1 (0.6)
低換気	0	1 (1.0)	1 (0.8)	0	1 (0.6)
誤嚥性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸性アシドーシス	1 (5.0)	0	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 6 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
拘束性肺疾患	0	0	0	1 (1.8)	1 (0.6)
上気道うっ血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
乳幼児突発性危急事態	0	0	0	0	0
気管支分泌物貯留	0	0	0	0	0
鼻漏	0	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	0
変色痰	0	0	0	0	0
筋骨格系および結合組織障害	0	3 (3.0)	3 (2.5)	24 (42.9)	27 (15.3)
背部痛	0	1 (1.0)	1 (0.8)	19 (33.9)	20 (11.4)
側弯症	0	1 (1.0)	1 (0.8)	2 (3.6)	3 (1.7)
筋肉痛	0	0	0	2 (3.6)	2 (1.1)
頚部痛	0	0	0	2 (3.6)	2 (1.1)
関節痛	0	0	0	1 (1.8)	1 (0.6)
四肢痛	0	1 (1.0)	1 (0.8)	0	1 (0.6)
骨盤変形	0	0	0	1 (1.8)	1 (0.6)
滑膜炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
関節拘縮	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 7 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
神経系障害	1 (5.0)	3 (3.0)	4 (3.3)	18 (32.1)	22 (12.5)
頭痛	0	1 (1.0)	1 (0.8)	17 (30.4)	18 (10.2)
失声症	0	0	0	1 (1.8)	1 (0.6)
脳脊髄液漏	0	1 (1.0)	1 (0.8)	0	1 (0.6)
反射亢進	1 (5.0)	0	1 (0.8)	0	1 (0.6)
眼振	0	1 (1.0)	1 (0.8)	0	1 (0.6)
錯感覚	0	0	0	1 (1.8)	1 (0.6)
振戦	0	0	0	1 (1.8)	1 (0.6)
皮膚および皮下組織障害	4 (20.0)	7 (7.0)	11 (9.2)	3 (5.4)	14 (8.0)
皮膚炎	2 (10.0)	0	2 (1.7)	0	2 (1.1)
接触性皮膚炎	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
点状出血	1 (5.0)	1 (1.0)	2 (1.7)	0	2 (1.1)
脱毛症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
おむつ皮膚炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
斑状出血	0	1 (1.0)	1 (0.8)	0	1 (0.6)
湿疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
貨幣状湿疹	1 (5.0)	0	1 (0.8)	0	1 (0.6)
汗疹	0	0	0	1 (1.8)	1 (0.6)
寝汗	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 8 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
発疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
丘疹性皮疹	0	1 (1.0)	1 (0.8)	0	1 (0.6)
多汗症	0	0	0	0	0
臨床検査	1 (5.0)	8 (8.0)	9 (7.5)	4 (7.1)	13 (7.4)
体温上昇	1 (5.0)	1 (1.0)	2 (1.7)	1 (1.8)	3 (1.7)
心拍数増加	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
酸素飽和度低下	0	2 (2.0)	2 (1.7)	0	2 (1.1)
血中重炭酸塩減少	0	0	0	1 (1.8)	1 (0.6)
血中クロール減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中カリウム減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血中ナトリウム減少	0	1 (1.0)	1 (0.8)	0	1 (0.6)
体温低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
Ｃ－反応性蛋白増加	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌検査陽性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
尿検査異常	0	0	0	1 (1.8)	1 (0.6)
呼吸数増加	0	0	0	0	0
体重減少	0	0	0	0	0
心臓障害	2 (10.0)	5 (5.0)	7 (5.8)	1 (1.8)	8 (4.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 9 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
頻脈	2 (10.0)	3 (3.0)	5 (4.2)	1 (1.8)	6 (3.4)
徐脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
チアノーゼ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心室性頻脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
代謝および栄養障害	1 (5.0)	4 (4.0)	5 (4.2)	2 (3.6)	7 (4.0)
食欲減退	0	0	0	1 (1.8)	1 (0.6)
脱水	0	0	0	1 (1.8)	1 (0.6)
成長障害	1 (5.0)	0	1 (0.8)	0	1 (0.6)
乳児および小児期早期の哺育障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
栄養補給不耐性	0	1 (1.0)	1 (0.8)	0	1 (0.6)
過小食	0	1 (1.0)	1 (0.8)	0	1 (0.6)
体重増加不良	0	1 (1.0)	1 (0.8)	0	1 (0.6)
精神障害	0	4 (4.0)	4 (3.3)	2 (3.6)	6 (3.4)
易刺激性	0	2 (2.0)	2 (1.7)	0	2 (1.1)
激越	0	0	0	1 (1.8)	1 (0.6)
不眠症	0	0	0	1 (1.8)	1 (0.6)
気分動揺	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 10 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
落ち着きのなさ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
免疫系障害	0	0	0	3 (5.4)	3 (1.7)
薬物過敏症	0	0	0	1 (1.8)	1 (0.6)
過敏症	0	0	0	1 (1.8)	1 (0.6)
季節性アレルギー	0	0	0	1 (1.8)	1 (0.6)
眼障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
眼乾燥	0	1 (1.0)	1 (0.8)	0	1 (0.6)
眼瞼下垂	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腎および尿路障害	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
尿失禁	0	0	0	1 (1.8)	1 (0.6)
尿閉	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血管障害	1 (5.0)	0	1 (0.8)	1 (1.8)	2 (1.1)
低血圧	0	0	0	1 (1.8)	1 (0.6)
蒼白	1 (5.0)	0	1 (0.8)	0	1 (0.6)
血液およびリンパ系障害	1 (5.0)	0	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events in the 72 hours following dosing in subjects with SMA
Page 11 of 11

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
好中球減少症	1 (5.0)	0	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 139 Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B: Incidence of Adverse Events by Severity - Treatment Group: ISIS 396443

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 1 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					80 (100)
Number of subjects with an event	7 (8.8)	25 (31.3)	45 (56.3)	0	77 (96.3)
感染症および寄生虫症	9 (11.3)	28 (35.0)	28 (35.0)	0	65 (81.3)
上気道感染	10 (12.5)	9 (11.3)	5 (6.3)	0	24 (30.0)
肺炎	2 (2.5)	11 (13.8)	10 (12.5)	0	23 (28.8)
鼻咽頭炎	10 (12.5)	5 (6.3)	0	0	15 (18.8)
ライノウイルス感染	0	6 (7.5)	4 (5.0)	0	10 (12.5)
気道感染	2 (2.5)	4 (5.0)	3 (3.8)	0	9 (11.3)
細気管支炎	4 (5.0)	0	4 (5.0)	0	8 (10.0)
ウイルス感染	2 (2.5)	6 (7.5)	0	0	8 (10.0)
ウイルス性上気道感染	1 (1.3)	6 (7.5)	1 (1.3)	0	8 (10.0)
口腔カンジダ症	6 (7.5)	1 (1.3)	0	0	7 (8.8)
ウイルス性肺炎	0	5 (6.3)	2 (2.5)	0	7 (8.8)
尿路感染	3 (3.8)	4 (5.0)	0	0	7 (8.8)
気管支炎	3 (3.8)	2 (2.5)	1 (1.3)	0	6 (7.5)
ウイルス性気管支炎	2 (2.5)	0	3 (3.8)	0	5 (6.3)
結膜炎	4 (5.0)	1 (1.3)	0	0	5 (6.3)
耳感染	2 (2.5)	3 (3.8)	0	0	5 (6.3)
インフルエンザ	1 (1.3)	4 (5.0)	0	0	5 (6.3)
下気道感染	0	2 (2.5)	2 (2.5)	0	4 (5.0)
ＲＳウイルス細気管支炎	0	1 (1.3)	3 (3.8)	0	4 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 2 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
ウイルス性気道感染	3 (3.8)	1 (1.3)	0	0	4 (5.0)
中耳炎	3 (3.8)	0	0	0	3 (3.8)
細菌性肺炎	0	1 (1.3)	2 (2.5)	0	3 (3.8)
シュードモナス感染	2 (2.5)	1 (1.3)	0	0	3 (3.8)
アデノウイルス感染	0	2 (2.5)	0	0	2 (2.5)
細菌性結膜炎	1 (1.3)	1 (1.3)	0	0	2 (2.5)
ウイルス性下気道感染	0	2 (2.5)	0	0	2 (2.5)
鼻炎	2 (2.5)	0	0	0	2 (2.5)
敗血症	0	0	2 (2.5)	0	2 (2.5)
皮膚カンジダ	1 (1.3)	1 (1.3)	0	0	2 (2.5)
ストーマ部膿瘍	1 (1.3)	1 (1.3)	0	0	2 (2.5)
細菌感染	1 (1.3)	0	0	0	1 (1.3)
細菌性気管炎	0	0	1 (1.3)	0	1 (1.3)
カンジダ性おむつ皮疹	1 (1.3)	0	0	0	1 (1.3)
蜂巣炎	1 (1.3)	0	0	0	1 (1.3)
感染性湿疹	1 (1.3)	0	0	0	1 (1.3)
蟯虫症	1 (1.3)	0	0	0	1 (1.3)
腸球菌感染	1 (1.3)	0	0	0	1 (1.3)
大腸菌感染	1 (1.3)	0	0	0	1 (1.3)
眼感染	1 (1.3)	0	0	0	1 (1.3)
真菌感染	0	1 (1.3)	0	0	1 (1.3)
皮膚真菌感染	1 (1.3)	0	0	0	1 (1.3)
胃腸炎	0	1 (1.3)	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 3 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
ロタウイルス胃腸炎	0	1 (1.3)	0	0	1 (1.3)
ウイルス性胃腸炎	0	1 (1.3)	0	0	1 (1.3)
手足口病	1 (1.3)	0	0	0	1 (1.3)
膿痂疹	1 (1.3)	0	0	0	1 (1.3)
限局性感染	1 (1.3)	0	0	0	1 (1.3)
肺感染	0	0	1 (1.3)	0	1 (1.3)
モラクセラ感染	0	0	1 (1.3)	0	1 (1.3)
院内感染	1 (1.3)	0	0	0	1 (1.3)
口腔真菌感染	1 (1.3)	0	0	0	1 (1.3)
口腔ヘルペス	1 (1.3)	0	0	0	1 (1.3)
急性中耳炎	0	1 (1.3)	0	0	1 (1.3)
インフルエンザ性肺炎	0	0	1 (1.3)	0	1 (1.3)
モラクセラ菌性肺炎	0	0	1 (1.3)	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	1 (1.3)	0	0	1 (1.3)
肺炎球菌性肺炎	0	0	1 (1.3)	0	1 (1.3)
ＲＳウイルス肺炎	0	0	1 (1.3)	0	1 (1.3)
腎盂腎炎	0	1 (1.3)	0	0	1 (1.3)
ばら疹	1 (1.3)	0	0	0	1 (1.3)
ブドウ球菌性敗血症	0	0	1 (1.3)	0	1 (1.3)
ブドウ球菌皮膚感染	0	1 (1.3)	0	0	1 (1.3)
ストーマ部感染	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 4 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
呼吸器、胸郭および縦隔障害	11 (13.8)	11 (13.8)	39 (48.8)	0	61 (76.3)
呼吸窮迫	1 (1.3)	8 (10.0)	12 (15.0)	0	21 (26.3)
呼吸不全	1 (1.3)	5 (6.3)	14 (17.5)	0	20 (25.0)
無気肺	3 (3.8)	9 (11.3)	6 (7.5)	0	18 (22.5)
急性呼吸不全	0	0	11 (13.8)	0	11 (13.8)
咳嗽	5 (6.3)	4 (5.0)	0	0	9 (11.3)
誤嚥性肺炎	1 (1.3)	5 (6.3)	3 (3.8)	0	9 (11.3)
鼻閉	8 (10.0)	0	0	0	8 (10.0)
呼吸困難	4 (5.0)	1 (1.3)	2 (2.5)	0	7 (8.8)
低酸素症	2 (2.5)	2 (2.5)	3 (3.8)	0	7 (8.8)
鼻漏	5 (6.3)	1 (1.3)	0	0	6 (7.5)
上気道うっ血	6 (7.5)	0	0	0	6 (7.5)
誤嚥	1 (1.3)	2 (2.5)	2 (2.5)	0	5 (6.3)
呼吸停止	0	1 (1.3)	4 (5.0)	0	5 (6.3)
無呼吸	0	3 (3.8)	1 (1.3)	0	4 (5.0)
気管支分泌物貯留	1 (1.3)	2 (2.5)	1 (1.3)	0	4 (5.0)
副鼻腔うっ血	3 (3.8)	0	0	0	3 (3.8)
慢性呼吸不全	0	1 (1.3)	1 (1.3)	0	2 (2.5)
低換気	0	1 (1.3)	1 (1.3)	0	2 (2.5)
呼吸障害	0	1 (1.3)	1 (1.3)	0	2 (2.5)
気道うっ血	1 (1.3)	1 (1.3)	0	0	2 (2.5)
喘鳴	2 (2.5)	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 5 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
急性呼吸窮迫症候群	0	1 (1.3)	0	0	1 (1.3)
気管支閉塞	1 (1.3)	0	0	0	1 (1.3)
息詰まり	1 (1.3)	0	0	0	1 (1.3)
高炭酸ガス血症	0	0	1 (1.3)	0	1 (1.3)
減呼吸	0	1 (1.3)	0	0	1 (1.3)
気管支分泌増加	0	1 (1.3)	0	0	1 (1.3)
上気道分泌増加	0	1 (1.3)	0	0	1 (1.3)
肺障害	0	0	1 (1.3)	0	1 (1.3)
閉塞性気道障害	0	0	1 (1.3)	0	1 (1.3)
胸水	0	1 (1.3)	0	0	1 (1.3)
気胸	0	0	1 (1.3)	0	1 (1.3)
呼吸性アルカローシス	0	1 (1.3)	0	0	1 (1.3)
アレルギー性鼻炎	1 (1.3)	0	0	0	1 (1.3)
変色痰	0	1 (1.3)	0	0	1 (1.3)
呼吸補助筋の動員	1 (1.3)	0	0	0	1 (1.3)
胃腸障害	34 (42.5)	14 (17.5)	5 (6.3)	0	53 (66.3)
便秘	25 (31.3)	3 (3.8)	0	0	28 (35.0)
生歯	9 (11.3)	5 (6.3)	0	0	14 (17.5)
嘔吐	11 (13.8)	3 (3.8)	0	0	14 (17.5)
下痢	8 (10.0)	3 (3.8)	0	0	11 (13.8)
胃食道逆流性疾患	8 (10.0)	2 (2.5)	0	0	10 (12.5)
嚥下障害	3 (3.8)	2 (2.5)	4 (5.0)	0	9 (11.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 6 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
流涎過多	4 (5.0)	2 (2.5)	0	0	6 (7.5)
放屁	3 (3.8)	1 (1.3)	0	0	4 (5.0)
胃炎	2 (2.5)	0	1 (1.3)	0	3 (3.8)
腹部不快感	2 (2.5)	0	0	0	2 (2.5)
血便排泄	2 (2.5)	0	0	0	2 (2.5)
腹部膨満	1 (1.3)	0	0	0	1 (1.3)
アフタ性潰瘍	1 (1.3)	0	0	0	1 (1.3)
胃出血	0	1 (1.3)	0	0	1 (1.3)
胃排出不全	1 (1.3)	0	0	0	1 (1.3)
乳児仙痛	1 (1.3)	0	0	0	1 (1.3)
乳児吐出	1 (1.3)	0	0	0	1 (1.3)
上部消化管出血	1 (1.3)	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	25 (31.3)	22 (27.5)	4 (5.0)	0	51 (63.8)
発熱	24 (30.0)	19 (23.8)	2 (2.5)	0	45 (56.3)
カテーテル留置部位炎症	1 (1.3)	0	0	0	1 (1.3)
泣き	1 (1.3)	0	0	0	1 (1.3)
死亡	0	0	1 (1.3)	0	1 (1.3)
医療機器閉塞	1 (1.3)	0	0	0	1 (1.3)
薬物不耐性	1 (1.3)	0	0	0	1 (1.3)
全身健康状態低下	0	0	1 (1.3)	0	1 (1.3)
低体温	0	1 (1.3)	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 7 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
ワクチン接種後の易刺激性	1 (1.3)	0	0	0	1 (1.3)
倦怠感	0	1 (1.3)	0	0	1 (1.3)
医療機器合併症	1 (1.3)	0	0	0	1 (1.3)
小結節	1 (1.3)	0	0	0	1 (1.3)
疼痛	0	1 (1.3)	0	0	1 (1.3)
外科手術不成功	0	0	1 (1.3)	0	1 (1.3)
腫脹	1 (1.3)	0	0	0	1 (1.3)
皮膚および皮下組織障害	20 (25.0)	2 (2.5)	1 (1.3)	0	23 (28.8)
発疹	8 (10.0)	1 (1.3)	0	0	9 (11.3)
おむつ皮膚炎	4 (5.0)	1 (1.3)	1 (1.3)	0	6 (7.5)
接触性皮膚炎	2 (2.5)	0	0	0	2 (2.5)
斑状出血	2 (2.5)	0	0	0	2 (2.5)
過角化	2 (2.5)	0	0	0	2 (2.5)
汗疹	2 (2.5)	0	0	0	2 (2.5)
皮膚炎	1 (1.3)	0	0	0	1 (1.3)
アレルギー性皮膚炎	1 (1.3)	0	0	0	1 (1.3)
皮膚乾燥	1 (1.3)	0	0	0	1 (1.3)
湿疹	1 (1.3)	0	0	0	1 (1.3)
紅斑	1 (1.3)	0	0	0	1 (1.3)
環状肉芽腫	1 (1.3)	0	0	0	1 (1.3)
間擦疹	1 (1.3)	0	0	0	1 (1.3)
斑状皮疹	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 8 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
丘疹性皮疹	1 (1.3)	0	0	0	1 (1.3)
皮膚浮腫	1 (1.3)	0	0	0	1 (1.3)
蕁麻疹	1 (1.3)	0	0	0	1 (1.3)
臨床検査	11 (13.8)	9 (11.3)	1 (1.3)	0	21 (26.3)
酸素飽和度低下	2 (2.5)	7 (8.8)	1 (1.3)	0	10 (12.5)
体重減少	3 (3.8)	1 (1.3)	0	0	4 (5.0)
血中カリウム減少	1 (1.3)	1 (1.3)	0	0	2 (2.5)
体温上昇	2 (2.5)	0	0	0	2 (2.5)
Ｃ－反応性蛋白増加	0	2 (2.5)	0	0	2 (2.5)
医学的観察	2 (2.5)	0	0	0	2 (2.5)
アラニンアミノトランスフェラーゼ増加	0	1 (1.3)	0	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.3)	0	0	0	1 (1.3)
血中クロール減少	0	1 (1.3)	0	0	1 (1.3)
血中鉄減少	1 (1.3)	0	0	0	1 (1.3)
血中ナトリウム減少	0	1 (1.3)	0	0	1 (1.3)
体温低下	1 (1.3)	0	0	0	1 (1.3)
心電図ＳＴ－Ｔ部分異常	0	1 (1.3)	0	0	1 (1.3)
心拍数増加	1 (1.3)	0	0	0	1 (1.3)
心拍数不整	1 (1.3)	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	1 (1.3)	0	0	0	1 (1.3)
炎症マーカー上昇	1 (1.3)	0	0	0	1 (1.3)
Ａ型インフルエンザウイルス検査陽性	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 9 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
肝機能検査異常	0	1 (1.3)	0	0	1 (1.3)
モラクセラ検査陽性	1 (1.3)	0	0	0	1 (1.3)
好中球数増加	0	1 (1.3)	0	0	1 (1.3)
整形外科検査	1 (1.3)	0	0	0	1 (1.3)
シュードモナス検査陽性	1 (1.3)	0	0	0	1 (1.3)
ブドウ球菌検査陽性	1 (1.3)	0	0	0	1 (1.3)
尿量減少	1 (1.3)	0	0	0	1 (1.3)
ビタミンＡ減少	1 (1.3)	0	0	0	1 (1.3)
傷害、中毒および処置合併症	12 (15.0)	6 (7.5)	1 (1.3)	0	19 (23.8)
大腿骨骨折	1 (1.3)	2 (2.5)	0	0	3 (3.8)
栄養補給チューブ合併症	1 (1.3)	0	1 (1.3)	0	2 (2.5)
処置による疼痛	1 (1.3)	1 (1.3)	0	0	2 (2.5)
ストーマ部紅斑	2 (2.5)	0	0	0	2 (2.5)
術後激越	1 (1.3)	0	0	0	1 (1.3)
節足動物咬傷	0	1 (1.3)	0	0	1 (1.3)
挫傷	1 (1.3)	0	0	0	1 (1.3)
麻酔からの覚醒遅延	0	1 (1.3)	0	0	1 (1.3)
擦過傷	0	1 (1.3)	0	0	1 (1.3)
伝染病曝露	1 (1.3)	0	0	0	1 (1.3)
処置後腫脹	1 (1.3)	0	0	0	1 (1.3)
処置合併症	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 10 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
処置部位反応	1 (1.3)	0	0	0	1 (1.3)
ストーマ合併症	1 (1.3)	0	0	0	1 (1.3)
ストーマ部刺激感	1 (1.3)	0	0	0	1 (1.3)
ワクチン接種合併症	1 (1.3)	0	0	0	1 (1.3)
心臓障害	4 (5.0)	7 (8.8)	7 (8.8)	0	18 (22.5)
頻脈	3 (3.8)	4 (5.0)	0	0	7 (8.8)
心肺停止	0	0	5 (6.3)	0	5 (6.3)
徐脈	2 (2.5)	2 (2.5)	0	0	4 (5.0)
心停止	0	0	2 (2.5)	0	2 (2.5)
チアノーゼ	1 (1.3)	1 (1.3)	0	0	2 (2.5)
左室肥大	2 (2.5)	0	0	0	2 (2.5)
洞性頻脈	0	1 (1.3)	0	0	1 (1.3)
上室性頻脈	1 (1.3)	0	0	0	1 (1.3)
心室性頻脈	0	1 (1.3)	0	0	1 (1.3)
代謝および栄養障害	6 (7.5)	7 (8.8)	1 (1.3)	0	14 (17.5)
体重増加不良	2 (2.5)	2 (2.5)	1 (1.3)	0	5 (6.3)
成長障害	3 (3.8)	0	0	0	3 (3.8)
乳児および小児期早期の哺育障害	0	3 (3.8)	0	0	3 (3.8)
栄養補給不耐性	1 (1.3)	2 (2.5)	0	0	3 (3.8)
脱水	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 11 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
鉄欠乏	1 (1.3)	0	0	0	1 (1.3)
筋骨格系および結合組織障害	7 (8.8)	3 (3.8)	1 (1.3)	0	11 (13.8)
側弯症	3 (3.8)	1 (1.3)	0	0	4 (5.0)
関節拘縮	1 (1.3)	2 (2.5)	0	0	3 (3.8)
頭位性斜頭症	2 (2.5)	0	0	0	2 (2.5)
背部痛	1 (1.3)	0	0	0	1 (1.3)
胸郭変形	0	0	1 (1.3)	0	1 (1.3)
泉門閉鎖遅延	1 (1.3)	0	0	0	1 (1.3)
後側弯症	0	1 (1.3)	0	0	1 (1.3)
脊柱後弯症	0	1 (1.3)	0	0	1 (1.3)
四肢痛	1 (1.3)	0	0	0	1 (1.3)
神経系障害	6 (7.5)	1 (1.3)	2 (2.5)	0	9 (11.3)
眼振	2 (2.5)	0	0	0	2 (2.5)
脳損傷	0	0	1 (1.3)	0	1 (1.3)
間代	1 (1.3)	0	0	0	1 (1.3)
よだれ	1 (1.3)	0	0	0	1 (1.3)
低酸素性虚血性脳症	0	0	1 (1.3)	0	1 (1.3)
言語障害	0	1 (1.3)	0	0	1 (1.3)
不随意性筋収縮	1 (1.3)	0	0	0	1 (1.3)
痙攣発作	0	0	1 (1.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 12 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
傾眠	1 (1.3)	0	0	0	1 (1.3)
精神障害	8 (10.0)	1 (1.3)	0	0	9 (11.3)
易刺激性	3 (3.8)	0	0	0	3 (3.8)
激越	2 (2.5)	0	0	0	2 (2.5)
不安	1 (1.3)	1 (1.3)	0	0	2 (2.5)
息こらえ	1 (1.3)	0	0	0	1 (1.3)
気分動揺	1 (1.3)	0	0	0	1 (1.3)
落ち着きのなさ	1 (1.3)	0	0	0	1 (1.3)
睡眠障害	1 (1.3)	0	0	0	1 (1.3)
免疫系障害	6 (7.5)	0	1 (1.3)	0	7 (8.8)
季節性アレルギー	3 (3.8)	0	0	0	3 (3.8)
薬物過敏症	1 (1.3)	0	1 (1.3)	0	2 (2.5)
食物アレルギー	1 (1.3)	0	0	0	1 (1.3)
過敏症	1 (1.3)	0	0	0	1 (1.3)
血管障害	2 (2.5)	0	3 (3.8)	0	5 (6.3)
高血圧	0	0	1 (1.3)	0	1 (1.3)
蒼白	1 (1.3)	0	0	0	1 (1.3)
ショック	0	0	1 (1.3)	0	1 (1.3)
血栓症	0	0	1 (1.3)	0	1 (1.3)
血管炎	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 13 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
先天性、家族性および遺伝性障害	2 (2.5)	2 (2.5)	0	0	4 (5.0)
先天性横隔膜ヘルニア	0	1 (1.3)	0	0	1 (1.3)
発育性股関節形成不全	0	1 (1.3)	0	0	1 (1.3)
貧血母斑	1 (1.3)	0	0	0	1 (1.3)
鳩胸	1 (1.3)	0	0	0	1 (1.3)
眼障害	4 (5.0)	0	0	0	4 (5.0)
霰粒腫	1 (1.3)	0	0	0	1 (1.3)
眼乾燥	1 (1.3)	0	0	0	1 (1.3)
眼運動障害	1 (1.3)	0	0	0	1 (1.3)
近視	1 (1.3)	0	0	0	1 (1.3)
斜視	1 (1.3)	0	0	0	1 (1.3)
生殖系および乳房障害	3 (3.8)	1 (1.3)	0	0	4 (5.0)
後天性包茎	0	1 (1.3)	0	0	1 (1.3)
亀頭包皮炎	1 (1.3)	0	0	0	1 (1.3)
卵巣嚢胞	1 (1.3)	0	0	0	1 (1.3)
陰茎障害	1 (1.3)	0	0	0	1 (1.3)
耳および迷路障害	1 (1.3)	1 (1.3)	0	0	2 (2.5)
耳の障害	0	1 (1.3)	0	0	1 (1.3)
耳痛	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: ISIS 396443
Page 14 of 14

	Severity				Total
	Mild	Moderate	Severe	Unknown	
腎および尿路障害	1 (1.3)	1 (1.3)	0	0	2 (2.5)
水腎症	1 (1.3)	0	0	0	1 (1.3)
尿閉	0	1 (1.3)	0	0	1 (1.3)
血液およびリンパ系障害	0	1 (1.3)	0	0	1 (1.3)
貧血	0	1 (1.3)	0	0	1 (1.3)
肝胆道系障害	1 (1.3)	0	0	0	1 (1.3)
肝腫大	1 (1.3)	0	0	0	1 (1.3)
外科および内科処置	0	0	1 (1.3)	0	1 (1.3)
機械的換気	0	0	1 (1.3)	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 140　Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B: Incidence of Adverse Events by Severity - Treatment Group: Control

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control
Page 1 of 11

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					41 (100)
Number of subjects with an event	1 (2.4)	6 (14.6)	33 (80.5)	0	40 (97.6)
呼吸器、胸郭および縦隔障害	4 (9.8)	3 (7.3)	29 (70.7)	0	36 (87.8)
呼吸不全	0	1 (2.4)	15 (36.6)	0	16 (39.0)
無気肺	2 (4.9)	6 (14.6)	4 (9.8)	0	12 (29.3)
呼吸窮迫	1 (2.4)	3 (7.3)	8 (19.5)	0	12 (29.3)
急性呼吸不全	1 (2.4)	0	9 (22.0)	0	10 (24.4)
咳嗽	7 (17.1)	1 (2.4)	0	0	8 (19.5)
気管支分泌物貯留	0	2 (4.9)	5 (12.2)	0	7 (17.1)
誤嚥性肺炎	0	5 (12.2)	2 (4.9)	0	7 (17.1)
呼吸困難	1 (2.4)	4 (9.8)	1 (2.4)	0	6 (14.6)
鼻閉	4 (9.8)	1 (2.4)	0	0	5 (12.2)
呼吸停止	0	1 (2.4)	3 (7.3)	0	4 (9.8)
睡眠時無呼吸症候群	1 (2.4)	2 (4.9)	1 (2.4)	0	4 (9.8)
無呼吸	0	1 (2.4)	2 (4.9)	0	3 (7.3)
誤嚥	1 (2.4)	1 (2.4)	1 (2.4)	0	3 (7.3)
気道うっ血	3 (7.3)	0	0	0	3 (7.3)
鼻漏	3 (7.3)	0	0	0	3 (7.3)
乳幼児突発性危急事態	0	0	2 (4.9)	0	2 (4.9)
低酸素症	0	1 (2.4)	1 (2.4)	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control

	Severity				Total
	Mild	Moderate	Severe	Unknown	
頻呼吸	2 (4.9)	0	0	0	2 (4.9)
上気道の炎症	2 (4.9)	0	0	0	2 (4.9)
急性呼吸窮迫症候群	0	0	1 (2.4)	0	1 (2.4)
カタル	0	1 (2.4)	0	0	1 (2.4)
息詰まり	0	1 (2.4)	0	0	1 (2.4)
気管支分泌増加	0	1 (2.4)	0	0	1 (2.4)
上気道分泌増加	1 (2.4)	0	0	0	1 (2.4)
肺障害	0	1 (2.4)	0	0	1 (2.4)
口腔咽頭痛	1 (2.4)	0	0	0	1 (2.4)
変色痰	1 (2.4)	0	0	0	1 (2.4)
上気道うっ血	0	1 (2.4)	0	0	1 (2.4)
呼吸補助筋の動員	1 (2.4)	0	0	0	1 (2.4)
感染症および寄生虫症	9 (22.0)	5 (12.2)	17 (41.5)	0	31 (75.6)
上気道感染	4 (9.8)	5 (12.2)	0	0	9 (22.0)
肺炎	1 (2.4)	1 (2.4)	5 (12.2)	0	7 (17.1)
ウイルス性上気道感染	1 (2.4)	1 (2.4)	5 (12.2)	0	7 (17.1)
ライノウイルス感染	2 (4.9)	1 (2.4)	3 (7.3)	0	6 (14.6)
細菌性気管炎	2 (4.9)	1 (2.4)	1 (2.4)	0	4 (9.8)
鼻咽頭炎	3 (7.3)	1 (2.4)	0	0	4 (9.8)
細気管支炎	1 (2.4)	1 (2.4)	1 (2.4)	0	3 (7.3)
カンジダ感染	2 (4.9)	1 (2.4)	0	0	3 (7.3)
結膜炎	3 (7.3)	0	0	0	3 (7.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control
Page 3 of 11

	Severity				Total
	Mild	Moderate	Severe	Unknown	
口腔カンジダ症	3 (7.3)	0	0	0	3 (7.3)
細菌性肺炎	0	2 (4.9)	1 (2.4)	0	3 (7.3)
ＲＳウイルス細気管支炎	0	0	3 (7.3)	0	3 (7.3)
鼻炎	3 (7.3)	0	0	0	3 (7.3)
ストーマ部感染	2 (4.9)	1 (2.4)	0	0	3 (7.3)
ウイルス感染	2 (4.9)	0	1 (2.4)	0	3 (7.3)
コロナウイルス感染	0	1 (2.4)	1 (2.4)	0	2 (4.9)
ウイルス性胃腸炎	2 (4.9)	0	0	0	2 (4.9)
下気道感染	2 (4.9)	0	0	0	2 (4.9)
中耳炎	1 (2.4)	1 (2.4)	0	0	2 (4.9)
ウイルス性肺炎	0	0	2 (4.9)	0	2 (4.9)
シュードモナス感染	1 (2.4)	1 (2.4)	0	0	2 (4.9)
気道感染	1 (2.4)	0	1 (2.4)	0	2 (4.9)
ウイルス性気道感染	0	1 (2.4)	1 (2.4)	0	2 (4.9)
ブドウ球菌感染	2 (4.9)	0	0	0	2 (4.9)
菌血症	1 (2.4)	0	0	0	1 (2.4)
細菌性疾患キャリアー	0	1 (2.4)	0	0	1 (2.4)
気管支炎	1 (2.4)	0	0	0	1 (2.4)
カンジダ性おむつ皮疹	1 (2.4)	0	0	0	1 (2.4)
カンジダ性敗血症	0	0	1 (2.4)	0	1 (2.4)
蜂巣炎	1 (2.4)	0	0	0	1 (2.4)
細菌性結膜炎	1 (2.4)	0	0	0	1 (2.4)
耳感染	1 (2.4)	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control

	Severity				Total
	Mild	Moderate	Severe	Unknown	
真菌感染	1 (2.4)	0	0	0	1 (2.4)
皮膚真菌感染	1 (2.4)	0	0	0	1 (2.4)
手足口病	1 (2.4)	0	0	0	1 (2.4)
麦粒腫	1 (2.4)	0	0	0	1 (2.4)
膿痂疹	1 (2.4)	0	0	0	1 (2.4)
パラインフルエンザウイルス感染	0	1 (2.4)	0	0	1 (2.4)
パラインフルエンザウイルス性肺炎	0	0	1 (2.4)	0	1 (2.4)
シュードモナス菌性肺炎	0	0	1 (2.4)	0	1 (2.4)
細菌性気道感染	0	1 (2.4)	0	0	1 (2.4)
セラチア感染	0	1 (2.4)	0	0	1 (2.4)
副鼻腔炎	1 (2.4)	0	0	0	1 (2.4)
皮膚カンジダ	1 (2.4)	0	0	0	1 (2.4)
皮膚感染	1 (2.4)	0	0	0	1 (2.4)
全身性感染	0	1 (2.4)	0	0	1 (2.4)
気管炎	0	1 (2.4)	0	0	1 (2.4)
ウイルス性発疹	1 (2.4)	0	0	0	1 (2.4)
一般・全身障害および投与部位の状態	16 (39.0)	11 (26.8)	1 (2.4)	0	28 (68.3)
発熱	16 (39.0)	8 (19.5)	0	0	24 (58.5)
浮腫	1 (2.4)	2 (4.9)	0	0	3 (7.3)
疼痛	2 (4.9)	0	0	0	2 (4.9)
血管穿刺部位内出血	2 (4.9)	0	0	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control

	Severity				Total
	Mild	Moderate	Severe	Unknown	
適用部位発疹	1 (2.4)	0	0	0	1 (2.4)
カテーテル留置部位炎症	1 (2.4)	0	0	0	1 (2.4)
死亡	0	0	1 (2.4)	0	1 (2.4)
医療機器機能不良	1 (2.4)	0	0	0	1 (2.4)
医療機器閉塞	1 (2.4)	0	0	0	1 (2.4)
疲労	1 (2.4)	0	0	0	1 (2.4)
注入部位内出血	0	1 (2.4)	0	0	1 (2.4)
注入部位血管外漏出	1 (2.4)	0	0	0	1 (2.4)
注射部位血腫	1 (2.4)	0	0	0	1 (2.4)
血管穿刺部位反応	0	1 (2.4)	0	0	1 (2.4)
胃腸障害	15 (36.6)	6 (14.6)	5 (12.2)	0	26 (63.4)
便秘	8 (19.5)	1 (2.4)	0	0	9 (22.0)
嚥下障害	2 (4.9)	3 (7.3)	4 (9.8)	0	9 (22.0)
胃食道逆流性疾患	6 (14.6)	2 (4.9)	0	0	8 (19.5)
嘔吐	6 (14.6)	1 (2.4)	1 (2.4)	0	8 (19.5)
下痢	6 (14.6)	1 (2.4)	0	0	7 (17.1)
生歯	2 (4.9)	1 (2.4)	0	0	3 (7.3)
上腹部痛	2 (4.9)	0	0	0	2 (4.9)
流涎過多	1 (2.4)	0	1 (2.4)	0	2 (4.9)
血性下痢	1 (2.4)	0	0	0	1 (2.4)
小腸炎	0	1 (2.4)	0	0	1 (2.4)
心窩部不快感	0	1 (2.4)	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control

	Severity				Total
	Mild	Moderate	Severe	Unknown	
放屁	1 (2.4)	0	0	0	1 (2.4)
胃炎	1 (2.4)	0	0	0	1 (2.4)
胃腸出血	0	1 (2.4)	0	0	1 (2.4)
消化管運動障害	1 (2.4)	0	0	0	1 (2.4)
消化管刺激症状	0	1 (2.4)	0	0	1 (2.4)
レッチング	1 (2.4)	0	0	0	1 (2.4)
口内炎	1 (2.4)	0	0	0	1 (2.4)
舌萎縮	1 (2.4)	0	0	0	1 (2.4)
皮膚および皮下組織障害	12 (29.3)	3 (7.3)	0	0	15 (36.6)
おむつ皮膚炎	3 (7.3)	1 (2.4)	0	0	4 (9.8)
発疹	4 (9.8)	0	0	0	4 (9.8)
褥瘡性潰瘍	1 (2.4)	2 (4.9)	0	0	3 (7.3)
接触性皮膚炎	3 (7.3)	0	0	0	3 (7.3)
紅斑	3 (7.3)	0	0	0	3 (7.3)
アトピー性皮膚炎	2 (4.9)	0	0	0	2 (4.9)
湿疹	1 (2.4)	1 (2.4)	0	0	2 (4.9)
皮膚乾燥	1 (2.4)	0	0	0	1 (2.4)
多汗症	1 (2.4)	0	0	0	1 (2.4)
毛孔性角化症	1 (2.4)	0	0	0	1 (2.4)
紅斑性皮疹	1 (2.4)	0	0	0	1 (2.4)
臨床検査	4 (9.8)	6 (14.6)	4 (9.8)	0	14 (34.1)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control
Page 7 of 11

	Severity				Total
	Mild	Moderate	Severe	Unknown	
酸素飽和度低下	3 (7.3)	4 (9.8)	3 (7.3)	0	10 (24.4)
体温低下	1 (2.4)	0	0	0	1 (2.4)
体温上昇	1 (2.4)	0	0	0	1 (2.4)
Ｃ－反応性蛋白増加	0	1 (2.4)	0	0	1 (2.4)
心電図ＳＴ－Ｔ部分異常	1 (2.4)	0	0	0	1 (2.4)
ヘッドラグ異常	1 (2.4)	0	0	0	1 (2.4)
心拍数減少	0	0	1 (2.4)	0	1 (2.4)
心拍数増加	1 (2.4)	0	0	0	1 (2.4)
リンパ節触知	1 (2.4)	0	0	0	1 (2.4)
呼吸数増加	1 (2.4)	0	0	0	1 (2.4)
レスピロウイルス検査陽性	0	0	1 (2.4)	0	1 (2.4)
喀痰培養陽性	0	1 (2.4)	0	0	1 (2.4)
トランスアミナーゼ上昇	1 (2.4)	0	0	0	1 (2.4)
ビタミンＤ減少	1 (2.4)	0	0	0	1 (2.4)
体重減少	1 (2.4)	0	0	0	1 (2.4)
心臓障害	4 (9.8)	2 (4.9)	7 (17.1)	0	13 (31.7)
心肺停止	0	0	5 (12.2)	0	5 (12.2)
頻脈	4 (9.8)	1 (2.4)	0	0	5 (12.2)
徐脈	1 (2.4)	2 (4.9)	0	0	3 (7.3)
心停止	0	0	2 (4.9)	0	2 (4.9)
チアノーゼ	0	1 (2.4)	1 (2.4)	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control
Page 8 of 11

	Severity				Total
	Mild	Moderate	Severe	Unknown	
代謝および栄養障害	6 (14.6)	6 (14.6)	1 (2.4)	0	13 (31.7)
乳児および小児期早期の哺育障害	1 (2.4)	2 (4.9)	0	0	3 (7.3)
低カリウム血症	0	3 (7.3)	0	0	3 (7.3)
脱水	1 (2.4)	1 (2.4)	0	0	2 (4.9)
成長障害	1 (2.4)	1 (2.4)	0	0	2 (4.9)
低血糖	1 (2.4)	1 (2.4)	0	0	2 (4.9)
体重増加不良	1 (2.4)	0	1 (2.4)	0	2 (4.9)
食物不耐性	1 (2.4)	0	0	0	1 (2.4)
高血糖	1 (2.4)	0	0	0	1 (2.4)
ビタミンD欠乏	1 (2.4)	0	0	0	1 (2.4)
傷害、中毒および処置合併症	7 (17.1)	1 (2.4)	2 (4.9)	0	10 (24.4)
栄養補給チューブ合併症	3 (7.3)	0	0	0	3 (7.3)
ストーマ合併症	2 (4.9)	0	0	0	2 (4.9)
ストーマ部紅斑	2 (4.9)	0	0	0	2 (4.9)
気管内挿管合併症	0	1 (2.4)	0	0	1 (2.4)
擦過傷	1 (2.4)	0	0	0	1 (2.4)
大腿骨骨折	0	0	1 (2.4)	0	1 (2.4)
頭部損傷	1 (2.4)	0	0	0	1 (2.4)
切開部位紅斑	1 (2.4)	0	0	0	1 (2.4)
裂傷	1 (2.4)	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control

	Severity				Total
	Mild	Moderate	Severe	Unknown	
処置後挫傷	1 (2.4)	0	0	0	1 (2.4)
処置後出血	1 (2.4)	0	0	0	1 (2.4)
ストーマ部出血	1 (2.4)	0	0	0	1 (2.4)
ストーマ部炎症	1 (2.4)	0	0	0	1 (2.4)
ストーマ部刺激感	1 (2.4)	0	0	0	1 (2.4)
気管出血	0	0	1 (2.4)	0	1 (2.4)
気管損傷	1 (2.4)	0	0	0	1 (2.4)
気管閉塞	0	0	1 (2.4)	0	1 (2.4)
ワクチン接種合併症	1 (2.4)	0	0	0	1 (2.4)
筋骨格系および結合組織障害	2 (4.9)	3 (7.3)	0	0	5 (12.2)
関節拘縮	0	2 (4.9)	0	0	2 (4.9)
側弯症	2 (4.9)	0	0	0	2 (4.9)
関節可動域低下	1 (2.4)	0	0	0	1 (2.4)
関節硬直	1 (2.4)	0	0	0	1 (2.4)
脊柱後弯症	1 (2.4)	0	0	0	1 (2.4)
筋緊張	1 (2.4)	0	0	0	1 (2.4)
筋力低下	0	1 (2.4)	0	0	1 (2.4)
頭位性斜頭症	0	1 (2.4)	0	0	1 (2.4)
精神障害	2 (4.9)	3 (7.3)	0	0	5 (12.2)
激越	1 (2.4)	1 (2.4)	0	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control

	Severity				Total
	Mild	Moderate	Severe	Unknown	
睡眠障害	1 (2.4)	1 (2.4)	0	0	2 (4.9)
易刺激性	1 (2.4)	0	0	0	1 (2.4)
落ち着きのなさ	0	1 (2.4)	0	0	1 (2.4)
先天性、家族性および遺伝性障害	4 (9.8)	0	0	0	4 (9.8)
停留精巣	1 (2.4)	0	0	0	1 (2.4)
発育性股関節形成不全	1 (2.4)	0	0	0	1 (2.4)
鳩胸	1 (2.4)	0	0	0	1 (2.4)
包茎	1 (2.4)	0	0	0	1 (2.4)
免疫系障害	4 (9.8)	0	0	0	4 (9.8)
過敏症	2 (4.9)	0	0	0	2 (4.9)
季節性アレルギー	2 (4.9)	0	0	0	2 (4.9)
薬物過敏症	1 (2.4)	0	0	0	1 (2.4)
血液およびリンパ系障害	2 (4.9)	1 (2.4)	0	0	3 (7.3)
貧血	1 (2.4)	0	0	0	1 (2.4)
骨髄障害	0	1 (2.4)	0	0	1 (2.4)
白血球増加症	1 (2.4)	0	0	0	1 (2.4)
眼障害	3 (7.3)	0	0	0	3 (7.3)
弱視	1 (2.4)	0	0	0	1 (2.4)
眼乾燥	1 (2.4)	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by severity
Treatment group: Control

	Severity				Total
	Mild	Moderate	Severe	Unknown	
流涙増加	1 (2.4)	0	0	0	1 (2.4)
斜視	1 (2.4)	0	0	0	1 (2.4)
神経系障害	1 (2.4)	1 (2.4)	0	0	2 (4.9)
眼振	1 (2.4)	0	0	0	1 (2.4)
失神寸前の状態	0	1 (2.4)	0	0	1 (2.4)
耳および迷路障害	1 (2.4)	0	0	0	1 (2.4)
耳出血	1 (2.4)	0	0	0	1 (2.4)
腎および尿路障害	1 (2.4)	0	0	0	1 (2.4)
糖尿	1 (2.4)	0	0	0	1 (2.4)
血管障害	1 (2.4)	0	0	0	1 (2.4)
充血	1 (2.4)	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 141 Presymptomatic Infants Diagnosed With SMA: Incidence of Adverse Events by Severity

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 1 of 6

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					20 (100)
Number of subjects with an event	5 (25.0)	9 (45.0)	2 (10.0)	0	16 (80.0)
感染症および寄生虫症	6 (30.0)	5 (25.0)	2 (10.0)	0	13 (65.0)
上気道感染	5 (25.0)	3 (15.0)	0	0	8 (40.0)
鼻咽頭炎	4 (20.0)	0	0	0	4 (20.0)
インフルエンザ	1 (5.0)	2 (10.0)	0	0	3 (15.0)
中耳炎	1 (5.0)	2 (10.0)	0	0	3 (15.0)
ウイルス性胃腸炎	2 (10.0)	0	0	0	2 (10.0)
肺炎	0	1 (5.0)	1 (5.0)	0	2 (10.0)
鼻炎	2 (10.0)	0	0	0	2 (10.0)
ライノウイルス感染	0	1 (5.0)	1 (5.0)	0	2 (10.0)
細気管支炎	0	1 (5.0)	0	0	1 (5.0)
気管支炎	0	1 (5.0)	0	0	1 (5.0)
ブドウ球菌性耳感染	1 (5.0)	0	0	0	1 (5.0)
膿痂疹	0	1 (5.0)	0	0	1 (5.0)
レンサ球菌性咽頭炎	1 (5.0)	0	0	0	1 (5.0)
ウイルス性肺炎	1 (5.0)	0	0	0	1 (5.0)
皮膚感染	1 (5.0)	0	0	0	1 (5.0)
レンサ球菌感染	1 (5.0)	0	0	0	1 (5.0)
尿路感染	0	1 (5.0)	0	0	1 (5.0)
皮膚および皮下組織障害	7 (35.0)	2 (10.0)	0	0	9 (45.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 2 of 6

	Severity				Total
	Mild	Moderate	Severe	Unknown	
皮膚炎	2 (10.0)	0	0	0	2 (10.0)
おむつ皮膚炎	1 (5.0)	1 (5.0)	0	0	2 (10.0)
貨幣状湿疹	1 (5.0)	0	0	0	1 (5.0)
紅斑	1 (5.0)	0	0	0	1 (5.0)
点状出血	1 (5.0)	0	0	0	1 (5.0)
発疹	1 (5.0)	0	0	0	1 (5.0)
紅斑性皮疹	1 (5.0)	0	0	0	1 (5.0)
脂漏性皮膚炎	0	1 (5.0)	0	0	1 (5.0)
胃腸障害	6 (30.0)	2 (10.0)	0	0	8 (40.0)
腹部膨満	2 (10.0)	0	0	0	2 (10.0)
便秘	1 (5.0)	1 (5.0)	0	0	2 (10.0)
放屁	2 (10.0)	0	0	0	2 (10.0)
胃食道逆流性疾患	2 (10.0)	0	0	0	2 (10.0)
腹部不快感	1 (5.0)	0	0	0	1 (5.0)
下痢	1 (5.0)	0	0	0	1 (5.0)
嚥下障害	1 (5.0)	0	0	0	1 (5.0)
生歯	0	1 (5.0)	0	0	1 (5.0)
一般・全身障害および投与部位の状態	3 (15.0)	3 (15.0)	0	0	6 (30.0)
発熱	2 (10.0)	3 (15.0)	0	0	5 (25.0)
適用部位紅斑	1 (5.0)	0	0	0	1 (5.0)
注入部位内出血	1 (5.0)	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 3 of 6

	Severity				Total
	Mild	Moderate	Severe	Unknown	
呼吸器、胸郭および縦隔障害	4 (20.0)	1 (5.0)	1 (5.0)	0	6 (30.0)
咳嗽	3 (15.0)	0	0	0	3 (15.0)
鼻閉	3 (15.0)	0	0	0	3 (15.0)
鼻漏	3 (15.0)	0	0	0	3 (15.0)
息詰まり	0	1 (5.0)	0	0	1 (5.0)
呼吸性アシドーシス	1 (5.0)	0	0	0	1 (5.0)
呼吸窮迫	0	0	1 (5.0)	0	1 (5.0)
上気道うっ血	1 (5.0)	0	0	0	1 (5.0)
代謝および栄養障害	2 (10.0)	2 (10.0)	0	0	4 (20.0)
脱水	1 (5.0)	1 (5.0)	0	0	2 (10.0)
成長障害	1 (5.0)	1 (5.0)	0	0	2 (10.0)
体重増加不良	1 (5.0)	0	0	0	1 (5.0)
傷害、中毒および処置合併症	2 (10.0)	1 (5.0)	0	0	3 (15.0)
節足動物咬傷	1 (5.0)	0	0	0	1 (5.0)
転倒	1 (5.0)	0	0	0	1 (5.0)
処置後合併症	1 (5.0)	0	0	0	1 (5.0)
処置後不快感	1 (5.0)	0	0	0	1 (5.0)
処置後腫脹	1 (5.0)	0	0	0	1 (5.0)
硬膜下血腫	0	1 (5.0)	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 4 of 6

	Severity				Total
	Mild	Moderate	Severe	Unknown	
臨床検査	2 (10.0)	1 (5.0)	0	0	3 (15.0)
アラニンアミノトランスフェラーゼ増加	1 (5.0)	0	0	0	1 (5.0)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.0)	0	0	0	1 (5.0)
血中アルカリホスファターゼ増加	0	1 (5.0)	0	0	1 (5.0)
体温上昇	1 (5.0)	0	0	0	1 (5.0)
好酸球数増加	1 (5.0)	0	0	0	1 (5.0)
リンパ球数増加	1 (5.0)	0	0	0	1 (5.0)
酸素飽和度低下	1 (5.0)	0	0	0	1 (5.0)
白血球数増加	1 (5.0)	0	0	0	1 (5.0)
筋骨格系および結合組織障害	2 (10.0)	1 (5.0)	0	0	3 (15.0)
筋力低下	2 (10.0)	0	0	0	2 (10.0)
関節拘縮	1 (5.0)	0	0	0	1 (5.0)
頭位性斜頭症	1 (5.0)	0	0	0	1 (5.0)
斜頚	0	1 (5.0)	0	0	1 (5.0)
体重支持困難	1 (5.0)	0	0	0	1 (5.0)
神経系障害	3 (15.0)	0	0	0	3 (15.0)
筋緊張低下	2 (10.0)	0	0	0	2 (10.0)
反射亢進	1 (5.0)	0	0	0	1 (5.0)
血液およびリンパ系障害	1 (5.0)	1 (5.0)	0	0	2 (10.0)
好酸球増加症	1 (5.0)	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 5 of 6

	Severity				Total
	Mild	Moderate	Severe	Unknown	
好中球減少症	0	1 (5.0)	0	0	1 (5.0)
心臓障害	2 (10.0)	0	0	0	2 (10.0)
頻脈	2 (10.0)	0	0	0	2 (10.0)
免疫系障害	1 (5.0)	1 (5.0)	0	0	2 (10.0)
食物アレルギー	1 (5.0)	0	0	0	1 (5.0)
季節性アレルギー	0	1 (5.0)	0	0	1 (5.0)
血管障害	1 (5.0)	1 (5.0)	0	0	2 (10.0)
高血圧	0	1 (5.0)	0	0	1 (5.0)
蒼白	1 (5.0)	0	0	0	1 (5.0)
眼障害	1 (5.0)	0	0	0	1 (5.0)
後天性涙道狭窄	1 (5.0)	0	0	0	1 (5.0)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.0)	0	0	0	1 (5.0)
脂漏性角化症	1 (5.0)	0	0	0	1 (5.0)
妊娠、産褥および周産期の状態	1 (5.0)	0	0	0	1 (5.0)
臍肉芽腫	1 (5.0)	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA: incidence of adverse events by severity
Page 6 of 6

	Severity				Total
	Mild	Moderate	Severe	Unknown	
生殖系および乳房障害	1 (5.0)	0	0	0	1 (5.0)
外陰腟発疹	1 (5.0)	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 42　Later-Onset Subjects:Incidence of Adverse Events by Severity

Later-onset subjects: incidence of adverse events by severity
Page 1 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
Number of subjects dosed					56 (100.0)
Number of subjects with an event	15 (26.8)	35 (62.5)	6 (10.7)	0	56 (100.0)
感染症および寄生虫症	20 (35.7)	22 (39.3)	2 (3.6)	0	44 (78.6)
上気道感染	20 (35.7)	7 (12.5)	0	0	27 (48.2)
鼻咽頭炎	13 (23.2)	3 (5.4)	0	0	16 (28.6)
ウイルス感染	6 (10.7)	3 (5.4)	0	0	9 (16.1)
ウイルス性胃腸炎	6 (10.7)	2 (3.6)	0	0	8 (14.3)
レンサ球菌性咽頭炎	5 (8.9)	3 (5.4)	0	0	8 (14.3)
胃腸炎	2 (3.6)	5 (8.9)	0	0	7 (12.5)
中耳炎	5 (8.9)	0	0	0	5 (8.9)
肺炎	2 (3.6)	2 (3.6)	1 (1.8)	0	5 (8.9)
ウイルス性上気道感染	3 (5.4)	2 (3.6)	0	0	5 (8.9)
耳感染	4 (7.1)	0	0	0	4 (7.1)
尿路感染	2 (3.6)	2 (3.6)	0	0	4 (7.1)
結膜炎	3 (5.4)	0	0	0	3 (5.4)
インフルエンザ	2 (3.6)	1 (1.8)	0	0	3 (5.4)
限局性感染	3 (5.4)	0	0	0	3 (5.4)
ＲＳウイルス感染	0	3 (5.4)	0	0	3 (5.4)
副鼻腔炎	3 (5.4)	0	0	0	3 (5.4)
ウイルス性消化管感染	2 (3.6)	0	0	0	2 (3.6)
ウイルス性肺炎	0	0	2 (3.6)	0	2 (3.6)
皮膚カンジダ	2 (3.6)	0	0	0	2 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 2 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
蜂巣炎	0	1 (1.8)	0	0	1 (1.8)
ブドウ球菌性眼感染	1 (1.8)	0	0	0	1 (1.8)
ウイルス性眼感染	1 (1.8)	0	0	0	1 (1.8)
皮膚真菌感染	1 (1.8)	0	0	0	1 (1.8)
手足口病	1 (1.8)	0	0	0	1 (1.8)
膿痂疹	1 (1.8)	0	0	0	1 (1.8)
下気道感染	0	0	1 (1.8)	0	1 (1.8)
伝染性軟属腫	1 (1.8)	0	0	0	1 (1.8)
単核細胞症症候群	1 (1.8)	0	0	0	1 (1.8)
急性中耳炎	1 (1.8)	0	0	0	1 (1.8)
咽頭炎	1 (1.8)	0	0	0	1 (1.8)
ＲＳウイルス肺炎	0	1 (1.8)	0	0	1 (1.8)
ＲＳウイルス細気管支炎	0	0	1 (1.8)	0	1 (1.8)
気道感染	0	1 (1.8)	0	0	1 (1.8)
ウイルス性気道感染	0	1 (1.8)	0	0	1 (1.8)
鼻炎	1 (1.8)	0	0	0	1 (1.8)
皮膚細菌感染	1 (1.8)	0	0	0	1 (1.8)
扁桃炎	1 (1.8)	0	0	0	1 (1.8)
膣感染	0	1 (1.8)	0	0	1 (1.8)
ウイルス性扁桃炎	1 (1.8)	0	0	0	1 (1.8)
外陰膣真菌感染	1 (1.8)	0	0	0	1 (1.8)
筋骨格系および結合組織障害	26 (46.4)	14 (25.0)	1 (1.8)	0	41 (73.2)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 3 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
背部痛	15 (26.8)	8 (14.3)	0	0	23 (41.1)
側弯症	10 (17.9)	5 (8.9)	0	0	15 (26.8)
関節拘縮	9 (16.1)	1 (1.8)	0	0	10 (17.9)
関節痛	3 (5.4)	2 (3.6)	0	0	5 (8.9)
四肢痛	2 (3.6)	3 (5.4)	0	0	5 (8.9)
筋肉痛	3 (5.4)	0	1 (1.8)	0	4 (7.1)
頚部痛	3 (5.4)	0	0	0	3 (5.4)
筋緊張	2 (3.6)	0	0	0	2 (3.6)
骨盤変形	2 (3.6)	0	0	0	2 (3.6)
四肢拘縮	1 (1.8)	0	0	0	1 (1.8)
脊柱前弯症	1 (1.8)	0	0	0	1 (1.8)
傷害、中毒および処置合併症	22 (39.3)	17 (30.4)	1 (1.8)	0	40 (71.4)
腰椎穿刺後症候群	15 (26.8)	7 (12.5)	1 (1.8)	0	23 (41.1)
裂傷	6 (10.7)	1 (1.8)	0	0	7 (12.5)
処置による疼痛	3 (5.4)	3 (5.4)	0	0	6 (10.7)
節足動物咬傷	3 (5.4)	0	0	0	3 (5.4)
大腿骨骨折	0	3 (5.4)	0	0	3 (5.4)
四肢損傷	2 (3.6)	1 (1.8)	0	0	3 (5.4)
挫傷	1 (1.8)	1 (1.8)	0	0	2 (3.6)
関節脱臼	1 (1.8)	1 (1.8)	0	0	2 (3.6)
関節損傷	1 (1.8)	1 (1.8)	0	0	2 (3.6)
処置による悪心	2 (3.6)	0	0	0	2 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 4 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
サンバーン	2 (3.6)	0	0	0	2 (3.6)
隆起骨折	0	2 (3.6)	0	0	2 (3.6)
術後激越	0	1 (1.8)	0	0	1 (1.8)
節足動物刺傷	1 (1.8)	0	0	0	1 (1.8)
転倒	1 (1.8)	0	0	0	1 (1.8)
頭部損傷	0	1 (1.8)	0	0	1 (1.8)
靭帯捻挫	1 (1.8)	0	0	0	1 (1.8)
下肢骨折	0	1 (1.8)	0	0	1 (1.8)
半月板損傷	0	1 (1.8)	0	0	1 (1.8)
肉離れ	1 (1.8)	0	0	0	1 (1.8)
術後イレウス	0	1 (1.8)	0	0	1 (1.8)
処置による頭痛	1 (1.8)	0	0	0	1 (1.8)
熱傷	1 (1.8)	0	0	0	1 (1.8)
脛骨骨折	1 (1.8)	0	0	0	1 (1.8)
一般・全身障害および投与部位の状態	25 (44.6)	5 (8.9)	1 (1.8)	0	31 (55.4)
発熱	13 (23.2)	3 (5.4)	0	0	16 (28.6)
穿刺部位疼痛	9 (16.1)	0	1 (1.8)	0	10 (17.9)
疲労	2 (3.6)	1 (1.8)	0	0	3 (5.4)
疼痛	1 (1.8)	1 (1.8)	0	0	2 (3.6)
カテーテル留置部位出血	1 (1.8)	0	0	0	1 (1.8)
カテーテル留置部位疼痛	1 (1.8)	0	0	0	1 (1.8)
カテーテル留置部位関連反応	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 5 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
胸部不快感	1 (1.8)	0	0	0	1 (1.8)
悪寒	1 (1.8)	0	0	0	1 (1.8)
冷感	1 (1.8)	0	0	0	1 (1.8)
重力性浮腫	1 (1.8)	0	0	0	1 (1.8)
低体温	1 (1.8)	0	0	0	1 (1.8)
注射部位出血	1 (1.8)	0	0	0	1 (1.8)
注射部位疼痛	1 (1.8)	0	0	0	1 (1.8)
末梢腫脹	1 (1.8)	0	0	0	1 (1.8)
穿刺部位反応	1 (1.8)	0	0	0	1 (1.8)
血管穿刺部位内出血	1 (1.8)	0	0	0	1 (1.8)
神経系障害	20 (35.7)	9 (16.1)	1 (1.8)	0	30 (53.6)
頭痛	20 (35.7)	8 (14.3)	0	0	28 (50.0)
感覚鈍麻	2 (3.6)	0	0	0	2 (3.6)
失声症	1 (1.8)	0	0	0	1 (1.8)
味覚異常	1 (1.8)	0	0	0	1 (1.8)
失読症	0	1 (1.8)	0	0	1 (1.8)
片頭痛	0	0	1 (1.8)	0	1 (1.8)
錯感覚	1 (1.8)	0	0	0	1 (1.8)
失神	1 (1.8)	0	0	0	1 (1.8)
振戦	1 (1.8)	0	0	0	1 (1.8)
胃腸障害	20 (35.7)	6 (10.7)	0	0	26 (46.4)
嘔吐	11 (19.6)	1 (1.8)	0	0	12 (21.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 6 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
悪心	8 (14.3)	2 (3.6)	0	0	10 (17.9)
便秘	5 (8.9)	2 (3.6)	0	0	7 (12.5)
アフタ性潰瘍	3 (5.4)	0	0	0	3 (5.4)
腹痛	2 (3.6)	0	0	0	2 (3.6)
上腹部痛	2 (3.6)	0	0	0	2 (3.6)
下痢	2 (3.6)	0	0	0	2 (3.6)
口腔内痛	1 (1.8)	1 (1.8)	0	0	2 (3.6)
腹部不快感	0	1 (1.8)	0	0	1 (1.8)
腹部症状	0	1 (1.8)	0	0	1 (1.8)
放屁	1 (1.8)	0	0	0	1 (1.8)
食中毒	0	1 (1.8)	0	0	1 (1.8)
胃腸障害	1 (1.8)	0	0	0	1 (1.8)
胃食道逆流性疾患	1 (1.8)	0	0	0	1 (1.8)
口の感覚鈍麻	1 (1.8)	0	0	0	1 (1.8)
口唇痛	1 (1.8)	0	0	0	1 (1.8)
口内炎	1 (1.8)	0	0	0	1 (1.8)
呼吸器、胸郭および縦隔障害	20 (35.7)	3 (5.4)	2 (3.6)	0	25 (44.6)
口腔咽頭痛	8 (14.3)	0	0	0	8 (14.3)
咳嗽	5 (8.9)	1 (1.8)	0	0	6 (10.7)
鼻漏	6 (10.7)	0	0	0	6 (10.7)
鼻出血	2 (3.6)	1 (1.8)	0	0	3 (5.4)
低酸素症	0	2 (3.6)	1 (1.8)	0	3 (5.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 7 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
鼻閉	3 (5.4)	0	0	0	3 (5.4)
扁桃肥大	3 (5.4)	0	0	0	3 (5.4)
副鼻腔うっ血	2 (3.6)	0	0	0	2 (3.6)
急性呼吸不全	0	1 (1.8)	0	0	1 (1.8)
無気肺	0	0	1 (1.8)	0	1 (1.8)
発声障害	1 (1.8)	0	0	0	1 (1.8)
呼吸困難	0	0	1 (1.8)	0	1 (1.8)
肺臓炎	0	1 (1.8)	0	0	1 (1.8)
肺うっ血	1 (1.8)	0	0	0	1 (1.8)
呼吸障害	0	1 (1.8)	0	0	1 (1.8)
呼吸不全	0	0	1 (1.8)	0	1 (1.8)
拘束性肺疾患	0	1 (1.8)	0	0	1 (1.8)
喘鳴	0	1 (1.8)	0	0	1 (1.8)
皮膚および皮下組織障害	17 (30.4)	0	0	0	17 (30.4)
接触性皮膚炎	3 (5.4)	0	0	0	3 (5.4)
湿疹	2 (3.6)	0	0	0	2 (3.6)
ざ瘡	1 (1.8)	0	0	0	1 (1.8)
水疱	1 (1.8)	0	0	0	1 (1.8)
褥瘡性潰瘍	1 (1.8)	0	0	0	1 (1.8)
皮膚炎	1 (1.8)	0	0	0	1 (1.8)
おむつ皮膚炎	1 (1.8)	0	0	0	1 (1.8)
紅斑	1 (1.8)	0	0	0	1 (1.8)
毛孔性角化症	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 8 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
汗疹	1 (1.8)	0	0	0	1 (1.8)
寝汗	1 (1.8)	0	0	0	1 (1.8)
発疹	1 (1.8)	0	0	0	1 (1.8)
皮膚病変	1 (1.8)	0	0	0	1 (1.8)
蕁麻疹	1 (1.8)	0	0	0	1 (1.8)
臨床検査	7 (12.5)	1 (1.8)	0	0	8 (14.3)
体重減少	2 (3.6)	1 (1.8)	0	0	3 (5.4)
血中重炭酸塩減少	1 (1.8)	0	0	0	1 (1.8)
血中テストステロン減少	1 (1.8)	0	0	0	1 (1.8)
体温上昇	1 (1.8)	0	0	0	1 (1.8)
ＣＳＦ白血球数増加	1 (1.8)	0	0	0	1 (1.8)
心拍数増加	1 (1.8)	0	0	0	1 (1.8)
尿検査異常	1 (1.8)	0	0	0	1 (1.8)
免疫系障害	6 (10.7)	0	1 (1.8)	0	7 (12.5)
過敏症	3 (5.4)	0	0	0	3 (5.4)
季節性アレルギー	3 (5.4)	0	0	0	3 (5.4)
薬物過敏症	0	0	1 (1.8)	0	1 (1.8)
代謝および栄養障害	4 (7.1)	1 (1.8)	0	0	5 (8.9)
脱水	1 (1.8)	1 (1.8)	0	0	2 (3.6)
食欲減退	1 (1.8)	0	0	0	1 (1.8)
食欲亢進	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 9 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
ビタミンD欠乏	1 (1.8)	0	0	0	1 (1.8)
精神障害	2 (3.6)	2 (3.6)	0	0	4 (7.1)
激越	1 (1.8)	1 (1.8)	0	0	2 (3.6)
注意欠陥多動性障害	0	1 (1.8)	0	0	1 (1.8)
不快気分	1 (1.8)	0	0	0	1 (1.8)
不眠症	0	1 (1.8)	0	0	1 (1.8)
睡眠時随伴症	0	1 (1.8)	0	0	1 (1.8)
チック	1 (1.8)	0	0	0	1 (1.8)
心因性嘔吐	1 (1.8)	0	0	0	1 (1.8)
心臓障害	3 (5.4)	0	0	0	3 (5.4)
動悸	2 (3.6)	0	0	0	2 (3.6)
頻脈	1 (1.8)	0	0	0	1 (1.8)
耳および迷路障害	3 (5.4)	0	0	0	3 (5.4)
耳痛	1 (1.8)	0	0	0	1 (1.8)
乗物酔い	1 (1.8)	0	0	0	1 (1.8)
鼓膜穿孔	1 (1.8)	0	0	0	1 (1.8)
腎および尿路障害	1 (1.8)	2 (3.6)	0	0	3 (5.4)
排尿困難	0	1 (1.8)	0	0	1 (1.8)
尿失禁	1 (1.8)	0	0	0	1 (1.8)
膀胱尿管逆流	0	1 (1.8)	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by severity
Page 10 of 10

	Severity				Total
	Mild	Moderate	Severe	Unknown	
眼障害	2 (3.6)	0	0	0	2 (3.6)
遠視	1 (1.8)	0	0	0	1 (1.8)
斜視	1 (1.8)	0	0	0	1 (1.8)
血液およびリンパ系障害	1 (1.8)	0	0	0	1 (1.8)
好中球減少症	1 (1.8)	0	0	0	1 (1.8)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	1 (1.8)	0	0	1 (1.8)
皮膚乳頭腫	0	1 (1.8)	0	0	1 (1.8)
血管障害	0	1 (1.8)	0	0	1 (1.8)
低血圧	0	1 (1.8)	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the greatest severity.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 143　Incidence of Severe Adverse Events in Infants Diagnosed With SMA

Incidence of severe adverse events in infants diagnosed with SMA
Page 1 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	2 (10.0)	33 (80.5)	45 (56.3)	54 (54.0)	56 (46.7)
呼吸器、胸郭および縦隔障害	1 (5.0)	29 (70.7)	39 (48.8)	48 (48.0)	49 (40.8)
呼吸不全	0	15 (36.6)	14 (17.5)	18 (18.0)	18 (15.0)
呼吸窮迫	1 (5.0)	8 (19.5)	12 (15.0)	14 (14.0)	15 (12.5)
急性呼吸不全	0	9 (22.0)	11 (13.8)	13 (13.0)	13 (10.8)
無気肺	0	4 (9.8)	6 (7.5)	7 (7.0)	7 (5.8)
低酸素症	0	1 (2.4)	3 (3.8)	5 (5.0)	5 (4.2)
誤嚥性肺炎	0	2 (4.9)	3 (3.8)	4 (4.0)	4 (3.3)
呼吸停止	0	3 (7.3)	4 (5.0)	4 (4.0)	4 (3.3)
無呼吸	0	2 (4.9)	1 (1.3)	3 (3.0)	3 (2.5)
誤嚥	0	1 (2.4)	2 (2.5)	3 (3.0)	3 (2.5)
呼吸困難	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
低換気	0	0	1 (1.3)	2 (2.0)	2 (1.7)
気胸	0	0	1 (1.3)	2 (2.0)	2 (1.7)
窒息	0	0	0	1 (1.0)	1 (0.8)
気管支分泌物貯留	0	5 (12.2)	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 2 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
慢性呼吸不全	0	0	1 (1.3)	1 (1.0)	1 (0.8)
高炭酸ガス血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肺障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
閉塞性気道障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
気縦隔症	0	0	0	1 (1.0)	1 (0.8)
呼吸障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
急性呼吸窮迫症候群	0	1 (2.4)	0	0	0
乳幼児突発性危急事態	0	2 (4.9)	0	0	0
睡眠時無呼吸症候群	0	1 (2.4)	0	0	0
感染症および寄生虫症	2 (10.0)	17 (41.5)	28 (35.0)	34 (34.0)	36 (30.0)
肺炎	1 (5.0)	5 (12.2)	10 (12.5)	13 (13.0)	14 (11.7)
細気管支炎	0	1 (2.4)	4 (5.0)	5 (5.0)	5 (4.2)
ライノウイルス感染	1 (5.0)	3 (7.3)	4 (5.0)	5 (5.0)	6 (5.0)
上気道感染	0	0	5 (6.3)	5 (5.0)	5 (4.2)
ウイルス性気管支炎	0	0	3 (3.8)	3 (3.0)	3 (2.5)
ウイルス性肺炎	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
ＲＳウイルス細気管支炎	0	3 (7.3)	3 (3.8)	3 (3.0)	3 (2.5)
気道感染	0	1 (2.4)	3 (3.8)	3 (3.0)	3 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 3 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
細菌性気管炎	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
下気道感染	0	0	2 (2.5)	2 (2.0)	2 (1.7)
メタニューモウイルス感染	0	0	0	2 (2.0)	2 (1.7)
細菌性肺炎	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
モラクセラ菌性肺炎	0	0	1 (1.3)	2 (2.0)	2 (1.7)
敗血症	0	0	2 (2.5)	2 (2.0)	2 (1.7)
気管支炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
コロナウイルス感染	0	1 (2.4)	0	1 (1.0)	1 (0.8)
エンテロウイルス感染	0	0	0	1 (1.0)	1 (0.8)
ウイルス性下気道感染	0	0	0	1 (1.0)	1 (0.8)
肺感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
モラクセラ感染	0	0	1 (1.3)	1 (1.0)	1 (0.8)
インフルエンザ性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
肺炎球菌性肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ＲＳウイルス肺炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ウイルス性気道感染	0	1 (2.4)	0	1 (1.0)	1 (0.8)
ブドウ球菌性菌血症	0	0	0	1 (1.0)	1 (0.8)
ブドウ球菌性敗血症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ウイルス性上気道感染	0	5 (12.2)	1 (1.3)	1 (1.0)	1 (0.8)
カンジダ性敗血症	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 4 of 7

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
パラインフルエンザウイルス性肺炎	0	1 (2.4)	0	0	0
シュードモナス菌性肺炎	0	1 (2.4)	0	0	0
ウイルス感染	0	1 (2.4)	0	0	0
心臓障害	0	7 (17.1)	7 (8.8)	10 (10.0)	10 (8.3)
心肺停止	0	5 (12.2)	5 (6.3)	6 (6.0)	6 (5.0)
心停止	0	2 (4.9)	2 (2.5)	3 (3.0)	3 (2.5)
徐脈	0	0	0	1 (1.0)	1 (0.8)
チアノーゼ	0	1 (2.4)	0	1 (1.0)	1 (0.8)
心膜気腫	0	0	0	1 (1.0)	1 (0.8)
胃腸障害	0	5 (12.2)	5 (6.3)	6 (6.0)	6 (5.0)
嚥下障害	0	4 (9.8)	4 (5.0)	4 (4.0)	4 (3.3)
胃炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
嘔吐	0	1 (2.4)	0	1 (1.0)	1 (0.8)
流涎過多	0	1 (2.4)	0	0	0
一般・全身障害および投与部位の状態	0	1 (2.4)	4 (5.0)	5 (5.0)	5 (4.2)
発熱	0	0	2 (2.5)	2 (2.0)	2 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 5 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
全身健康状態低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)
疼痛	0	0	0	1 (1.0)	1 (0.8)
外科手術不成功	0	0	1 (1.3)	1 (1.0)	1 (0.8)
神経系障害	0	0	2 (2.5)	3 (3.0)	3 (2.5)
痙攣発作	0	0	1 (1.3)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管障害	0	0	3 (3.8)	3 (3.0)	3 (2.5)
高血圧	0	0	1 (1.3)	1 (1.0)	1 (0.8)
ショック	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血栓症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
代謝および栄養障害	0	1 (2.4)	1 (1.3)	2 (2.0)	2 (1.7)
低ナトリウム血症	0	0	0	1 (1.0)	1 (0.8)
体重増加不良	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 6 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
筋骨格系および結合組織障害	0	0	1 (1.3)	2 (2.0)	2 (1.7)
胸郭変形	0	0	1 (1.3)	1 (1.0)	1 (0.8)
関節拘縮	0	0	0	1 (1.0)	1 (0.8)
免疫系障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
薬物過敏症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
傷害、中毒および処置合併症	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
栄養補給チューブ合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
大腿骨骨折	0	1 (2.4)	0	0	0
気管出血	0	1 (2.4)	0	0	0
気管閉塞	0	1 (2.4)	0	0	0
臨床検査	0	4 (9.8)	1 (1.3)	1 (1.0)	1 (0.8)
酸素飽和度低下	0	3 (7.3)	1 (1.3)	1 (1.0)	1 (0.8)
心拍数減少	0	1 (2.4)	0	0	0
レスピロウイルス検査陽性	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in infants diagnosed with SMA
Page 7 of 7

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
精神障害	0	0	0	1 (1.0)	1 (0.8)
不安	0	0	0	1 (1.0)	1 (0.8)
皮膚および皮下組織障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
おむつ皮膚炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
外科および内科処置	0	0	1 (1.3)	1 (1.0)	1 (0.8)
機械的換気	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 144 Incidence of Severe Adverse Events in Subjects With SMA Treated With ISIS 396443

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 1 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	2 (10.0)	54 (54.0)	56 (46.7)	6 (10.7)	62 (35.2)
呼吸器、胸郭および縦隔障害	1 (5.0)	48 (48.0)	49 (40.8)	2 (3.6)	51 (29.0)
呼吸不全	0	18 (18.0)	18 (15.0)	1 (1.8)	19 (10.8)
呼吸窮迫	1 (5.0)	14 (14.0)	15 (12.5)	0	15 (8.5)
急性呼吸不全	0	13 (13.0)	13 (10.8)	0	13 (7.4)
無気肺	0	7 (7.0)	7 (5.8)	1 (1.8)	8 (4.5)
低酸素症	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
誤嚥性肺炎	0	4 (4.0)	4 (3.3)	0	4 (2.3)
呼吸停止	0	4 (4.0)	4 (3.3)	0	4 (2.3)
無呼吸	0	3 (3.0)	3 (2.5)	0	3 (1.7)
誤嚥	0	3 (3.0)	3 (2.5)	0	3 (1.7)
呼吸困難	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
低換気	0	2 (2.0)	2 (1.7)	0	2 (1.1)
気胸	0	2 (2.0)	2 (1.7)	0	2 (1.1)
窒息	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気管支分泌物貯留	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 2 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
慢性呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
高炭酸ガス血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
閉塞性気道障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
気縦隔症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
感染症および寄生虫症	2 (10.0)	34 (34.0)	36 (30.0)	2 (3.6)	38 (21.6)
肺炎	1 (5.0)	13 (13.0)	14 (11.7)	1 (1.8)	15 (8.5)
ライノウイルス感染	1 (5.0)	5 (5.0)	6 (5.0)	0	6 (3.4)
細気管支炎	0	5 (5.0)	5 (4.2)	0	5 (2.8)
ウイルス性肺炎	0	3 (3.0)	3 (2.5)	2 (3.6)	5 (2.8)
上気道感染	0	5 (5.0)	5 (4.2)	0	5 (2.8)
ＲＳウイルス細気管支炎	0	3 (3.0)	3 (2.5)	1 (1.8)	4 (2.3)
ウイルス性気管支炎	0	3 (3.0)	3 (2.5)	0	3 (1.7)
下気道感染	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
気道感染	0	3 (3.0)	3 (2.5)	0	3 (1.7)
細菌性気管炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
メタニューモウイルス感染	0	2 (2.0)	2 (1.7)	0	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 3 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
細菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
モラクセラ菌性肺炎	0	2 (2.0)	2 (1.7)	0	2 (1.1)
敗血症	0	2 (2.0)	2 (1.7)	0	2 (1.1)
気管支炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
コロナウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
エンテロウイルス感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性下気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
モラクセラ感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
インフルエンザ性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
肺炎球菌性肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ＲＳウイルス肺炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性菌血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ブドウ球菌性敗血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性上気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 4 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
心臓障害	0	10 (10.0)	10 (8.3)	0	10 (5.7)
心肺停止	0	6 (6.0)	6 (5.0)	0	6 (3.4)
心停止	0	3 (3.0)	3 (2.5)	0	3 (1.7)
徐脈	0	1 (1.0)	1 (0.8)	0	1 (0.6)
チアノーゼ	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心膜気腫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
胃腸障害	0	6 (6.0)	6 (5.0)	0	6 (3.4)
嚥下障害	0	4 (4.0)	4 (3.3)	0	4 (2.3)
胃炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)
嘔吐	0	1 (1.0)	1 (0.8)	0	1 (0.6)
一般・全身障害および投与部位の状態	0	5 (5.0)	5 (4.2)	1 (1.8)	6 (3.4)
発熱	0	2 (2.0)	2 (1.7)	0	2 (1.1)
死亡	0	1 (1.0)	1 (0.8)	0	1 (0.6)
全身健康状態低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
疼痛	0	1 (1.0)	1 (0.8)	0	1 (0.6)
穿刺部位疼痛	0	0	0	1 (1.8)	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 5 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
外科手術不成功	0	1 (1.0)	1 (0.8)	0	1 (0.6)
神経系障害	0	3 (3.0)	3 (2.5)	1 (1.8)	4 (2.3)
痙攣発作	0	2 (2.0)	2 (1.7)	0	2 (1.1)
脳損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
片頭痛	0	0	0	1 (1.8)	1 (0.6)
筋骨格系および結合組織障害	0	2 (2.0)	2 (1.7)	1 (1.8)	3 (1.7)
胸郭変形	0	1 (1.0)	1 (0.8)	0	1 (0.6)
関節拘縮	0	1 (1.0)	1 (0.8)	0	1 (0.6)
筋肉痛	0	0	0	1 (1.8)	1 (0.6)
血管障害	0	3 (3.0)	3 (2.5)	0	3 (1.7)
高血圧	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ショック	0	1 (1.0)	1 (0.8)	0	1 (0.6)
血栓症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
免疫系障害	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 6 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
薬物過敏症	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
傷害、中毒および処置合併症	0	1 (1.0)	1 (0.8)	1 (1.8)	2 (1.1)
栄養補給チューブ合併症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
腰椎穿刺後症候群	0	0	0	1 (1.8)	1 (0.6)
代謝および栄養障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
低ナトリウム血症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
体重増加不良	0	1 (1.0)	1 (0.8)	0	1 (0.6)
臨床検査	0	1 (1.0)	1 (0.8)	0	1 (0.6)
酸素飽和度低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)
精神障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
不安	0	1 (1.0)	1 (0.8)	0	1 (0.6)
皮膚および皮下組織障害	0	1 (1.0)	1 (0.8)	0	1 (0.6)
おむつ皮膚炎	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of severe adverse events in subjects with SMA treated with ISIS 396443
Page 7 of 7

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
外科および内科処置	0	1 (1.0)	1 (0.8)	0	1 (0.6)
機械的換気	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 145 Incidence of Potentially Drug-Related Adverse Events in Infants Diagnosed With SMA

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 1 of 5

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	3 (15.0)	6 (14.6)	9 (11.3)	11 (11.0)	14 (11.7)
一般・全身障害および投与部位の状態	1 (5.0)	3 (7.3)	2 (2.5)	2 (2.0)	3 (2.5)
発熱	1 (5.0)	2 (4.9)	2 (2.5)	2 (2.0)	3 (2.5)
疼痛	0	1 (2.4)	0	0	0
臨床検査	1 (5.0)	0	2 (2.5)	2 (2.0)	3 (2.5)
体温低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)
体温上昇	0	0	1 (1.3)	1 (1.0)	1 (0.8)
アラニンアミノトランスフェラーゼ増加	1 (5.0)	0	0	0	1 (0.8)
アスパラギン酸アミノトランスフェラーゼ増加	1 (5.0)	0	0	0	1 (0.8)
ＣＳＦ白血球数増加	0	0	0	0	0
好酸球数増加	1 (5.0)	0	0	0	1 (0.8)
心拍数増加	0	0	0	0	0
リンパ球数増加	1 (5.0)	0	0	0	1 (0.8)
白血球数増加	1 (5.0)	0	0	0	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 2 of 5

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
血液およびリンパ系障害	0	0	0	1 (1.0)	1 (0.8)
好中球減少症	0	0	0	1 (1.0)	1 (0.8)
心臓障害	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
頻脈	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
動悸	0	0	0	0	0
先天性、家族性および遺伝性障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
貧血母斑	0	0	1 (1.3)	1 (1.0)	1 (0.8)
胃腸障害	0	2 (4.9)	0	1 (1.0)	1 (0.8)
嘔吐	0	1 (2.4)	0	1 (1.0)	1 (0.8)
下痢	0	1 (2.4)	0	0	0
感染症および寄生虫症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
蜂巣炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
歯膿瘍	0	0	0	0	0
ウイルス感染	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 3 of 5

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
傷害、中毒および処置合併症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
処置後腫脹	0	0	1 (1.3)	1 (1.0)	1 (0.8)
腰椎穿刺後症候群	0	0	0	0	0
処置による悪心	0	0	0	0	0
神経系障害	1 (5.0)	0	1 (1.3)	1 (1.0)	2 (1.7)
眼振	0	0	1 (1.3)	1 (1.0)	1 (0.8)
頭痛	0	0	0	0	0
反射亢進	1 (5.0)	0	0	0	1 (0.8)
錯感覚	0	0	0	0	0
血管障害	0	0	1 (1.3)	1 (1.0)	1 (0.8)
血管炎	0	0	1 (1.3)	1 (1.0)	1 (0.8)
代謝および栄養障害	0	0	0	0	0
食欲亢進	0	0	0	0	0
筋骨格系および結合組織障害	1 (5.0)	0	0	0	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 4 of 5

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
背部痛	0	0	0	0	0
筋力低下	1 (5.0)	0	0	0	1 (0.8)
体重支持困難	1 (5.0)	0	0	0	1 (0.8)
精神障害	0	0	0	0	0
不眠症	0	0	0	0	0
腎および尿路障害	0	0	0	0	0
尿失禁	0	0	0	0	0
呼吸器、胸郭および縦隔障害	0	0	0	0	0
カタル	0	0	0	0	0
咳嗽	0	0	0	0	0
発声障害	0	0	0	0	0
鼻出血	0	0	0	0	0
皮膚および皮下組織障害	0	1 (2.4)	0	0	0
寝汗	0	0	0	0	0
皮膚疼痛	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of potentially drug-related adverse events in infants diagnosed with SMA
Page 5 of 5

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
		Control	ISIS 396443		
発疹	0	1 (2.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 146　Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B: Incidence of Adverse Events by Relationship to Study Drug - Treatment Group: ISIS 396443

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 1 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
Number of subjects dosed						80 (100.0)
Number of subjects with an event	42 (52.5)	26 (32.5)	9 (11.3)	0	0	77 (96.3)
感染症および寄生虫症	53 (66.3)	11 (13.8)	1 (1.3)	0	0	65 (81.3)
上気道感染	21 (26.3)	3 (3.8)	0	0	0	24 (30.0)
肺炎	20 (25.0)	3 (3.8)	0	0	0	23 (28.8)
鼻咽頭炎	14 (17.5)	1 (1.3)	0	0	0	15 (18.8)
ライノウイルス感染	10 (12.5)	0	0	0	0	10 (12.5)
気道感染	9 (11.3)	0	0	0	0	9 (11.3)
細気管支炎	8 (10.0)	0	0	0	0	8 (10.0)
ウイルス感染	7 (8.8)	1 (1.3)	0	0	0	8 (10.0)
ウイルス性上気道感染	8 (10.0)	0	0	0	0	8 (10.0)
口腔カンジダ症	7 (8.8)	0	0	0	0	7 (8.8)
ウイルス性肺炎	7 (8.8)	0	0	0	0	7 (8.8)
尿路感染	4 (5.0)	3 (3.8)	0	0	0	7 (8.8)
気管支炎	6 (7.5)	0	0	0	0	6 (7.5)
ウイルス性気管支炎	5 (6.3)	0	0	0	0	5 (6.3)
結膜炎	4 (5.0)	1 (1.3)	0	0	0	5 (6.3)
耳感染	5 (6.3)	0	0	0	0	5 (6.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 2 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
インフルエンザ	5 (6.3)	0	0	0	0	5 (6.3)
下気道感染	4 (5.0)	0	0	0	0	4 (5.0)
ＲＳウイルス細気管支炎	4 (5.0)	0	0	0	0	4 (5.0)
ウイルス性気道感染	4 (5.0)	0	0	0	0	4 (5.0)
中耳炎	3 (3.8)	0	0	0	0	3 (3.8)
細菌性肺炎	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
シュードモナス感染	3 (3.8)	0	0	0	0	3 (3.8)
アデノウイルス感染	2 (2.5)	0	0	0	0	2 (2.5)
細菌性結膜炎	2 (2.5)	0	0	0	0	2 (2.5)
ウイルス性下気道感染	2 (2.5)	0	0	0	0	2 (2.5)
鼻炎	2 (2.5)	0	0	0	0	2 (2.5)
敗血症	2 (2.5)	0	0	0	0	2 (2.5)
皮膚カンジダ	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
ストーマ部膿瘍	2 (2.5)	0	0	0	0	2 (2.5)
細菌感染	1 (1.3)	0	0	0	0	1 (1.3)
細菌性気管炎	1 (1.3)	0	0	0	0	1 (1.3)
カンジダ性おむつ皮疹	1 (1.3)	0	0	0	0	1 (1.3)
蜂巣炎	0	0	1 (1.3)	0	0	1 (1.3)
感染性湿疹	0	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
蟯虫症	0	1 (1.3)	0	0	0	1 (1.3)
腸球菌感染	1 (1.3)	0	0	0	0	1 (1.3)
大腸菌感染	1 (1.3)	0	0	0	0	1 (1.3)
眼感染	1 (1.3)	0	0	0	0	1 (1.3)
真菌感染	0	1 (1.3)	0	0	0	1 (1.3)
皮膚真菌感染	1 (1.3)	0	0	0	0	1 (1.3)
胃腸炎	1 (1.3)	0	0	0	0	1 (1.3)
ロタウイルス胃腸炎	1 (1.3)	0	0	0	0	1 (1.3)
ウイルス性胃腸炎	1 (1.3)	0	0	0	0	1 (1.3)
手足口病	1 (1.3)	0	0	0	0	1 (1.3)
膿痂疹	1 (1.3)	0	0	0	0	1 (1.3)
限局性感染	1 (1.3)	0	0	0	0	1 (1.3)
肺感染	0	1 (1.3)	0	0	0	1 (1.3)
モラクセラ感染	1 (1.3)	0	0	0	0	1 (1.3)
院内感染	1 (1.3)	0	0	0	0	1 (1.3)
口腔真菌感染	1 (1.3)	0	0	0	0	1 (1.3)
口腔ヘルペス	1 (1.3)	0	0	0	0	1 (1.3)
急性中耳炎	1 (1.3)	0	0	0	0	1 (1.3)
インフルエンザ性肺炎	1 (1.3)	0	0	0	0	1 (1.3)
モラクセラ菌性肺炎	1 (1.3)	0	0	0	0	1 (1.3)
パラインフルエンザウイルス性肺炎	0	1 (1.3)	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 4 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
肺炎球菌性肺炎	1 (1.3)	0	0	0	0	1 (1.3)
ＲＳウイルス肺炎	1 (1.3)	0	0	0	0	1 (1.3)
腎盂腎炎	0	1 (1.3)	0	0	0	1 (1.3)
ばら疹	1 (1.3)	0	0	0	0	1 (1.3)
ブドウ球菌性敗血症	1 (1.3)	0	0	0	0	1 (1.3)
ブドウ球菌皮膚感染	1 (1.3)	0	0	0	0	1 (1.3)
ストーマ部感染	1 (1.3)	0	0	0	0	1 (1.3)
呼吸器、胸郭および縦隔障害	51 (63.8)	10 (12.5)	0	0	0	61 (76.3)
呼吸窮迫	20 (25.0)	1 (1.3)	0	0	0	21 (26.3)
呼吸不全	18 (22.5)	2 (2.5)	0	0	0	20 (25.0)
無気肺	15 (18.8)	3 (3.8)	0	0	0	18 (22.5)
急性呼吸不全	9 (11.3)	2 (2.5)	0	0	0	11 (13.8)
咳嗽	8 (10.0)	1 (1.3)	0	0	0	9 (11.3)
誤嚥性肺炎	8 (10.0)	1 (1.3)	0	0	0	9 (11.3)
鼻閉	7 (8.8)	1 (1.3)	0	0	0	8 (10.0)
呼吸困難	6 (7.5)	1 (1.3)	0	0	0	7 (8.8)
低酸素症	5 (6.3)	2 (2.5)	0	0	0	7 (8.8)
鼻漏	6 (7.5)	0	0	0	0	6 (7.5)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 5 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
上気道うっ血	6 (7.5)	0	0	0	0	6 (7.5)
誤嚥	5 (6.3)	0	0	0	0	5 (6.3)
呼吸停止	4 (5.0)	1 (1.3)	0	0	0	5 (6.3)
無呼吸	4 (5.0)	0	0	0	0	4 (5.0)
気管支分泌物貯留	4 (5.0)	0	0	0	0	4 (5.0)
副鼻腔うっ血	3 (3.8)	0	0	0	0	3 (3.8)
慢性呼吸不全	2 (2.5)	0	0	0	0	2 (2.5)
低換気	2 (2.5)	0	0	0	0	2 (2.5)
呼吸障害	2 (2.5)	0	0	0	0	2 (2.5)
気道うっ血	2 (2.5)	0	0	0	0	2 (2.5)
喘鳴	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
急性呼吸窮迫症候群	1 (1.3)	0	0	0	0	1 (1.3)
気管支閉塞	1 (1.3)	0	0	0	0	1 (1.3)
息詰まり	1 (1.3)	0	0	0	0	1 (1.3)
高炭酸ガス血症	1 (1.3)	0	0	0	0	1 (1.3)
減呼吸	1 (1.3)	0	0	0	0	1 (1.3)
気管支分泌増加	1 (1.3)	0	0	0	0	1 (1.3)
上気道分泌増加	1 (1.3)	0	0	0	0	1 (1.3)
肺障害	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 6 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
閉塞性気道障害	1 (1.3)	0	0	0	0	1 (1.3)
胸水	1 (1.3)	0	0	0	0	1 (1.3)
気胸	1 (1.3)	0	0	0	0	1 (1.3)
呼吸性アルカローシス	1 (1.3)	0	0	0	0	1 (1.3)
アレルギー性鼻炎	1 (1.3)	0	0	0	0	1 (1.3)
変色痰	1 (1.3)	0	0	0	0	1 (1.3)
呼吸補助筋の動員	1 (1.3)	0	0	0	0	1 (1.3)
胃腸障害	43 (53.8)	10 (12.5)	0	0	0	53 (66.3)
便秘	26 (32.5)	2 (2.5)	0	0	0	28 (35.0)
生歯	14 (17.5)	0	0	0	0	14 (17.5)
嘔吐	13 (16.3)	1 (1.3)	0	0	0	14 (17.5)
下痢	10 (12.5)	1 (1.3)	0	0	0	11 (13.8)
胃食道逆流性疾患	9 (11.3)	1 (1.3)	0	0	0	10 (12.5)
嚥下障害	7 (8.8)	2 (2.5)	0	0	0	9 (11.3)
流涎過多	5 (6.3)	1 (1.3)	0	0	0	6 (7.5)
放屁	4 (5.0)	0	0	0	0	4 (5.0)
胃炎	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
腹部不快感	2 (2.5)	0	0	0	0	2 (2.5)
血便排泄	2 (2.5)	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 7 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
腹部膨満	0	1 (1.3)	0	0	0	1 (1.3)
アフタ性潰瘍	1 (1.3)	0	0	0	0	1 (1.3)
胃出血	1 (1.3)	0	0	0	0	1 (1.3)
胃排出不全	1 (1.3)	0	0	0	0	1 (1.3)
乳児仙痛	1 (1.3)	0	0	0	0	1 (1.3)
乳児吐出	1 (1.3)	0	0	0	0	1 (1.3)
上部消化管出血	1 (1.3)	0	0	0	0	1 (1.3)
一般・全身障害および投与部位の状態	42 (52.5)	7 (8.8)	2 (2.5)	0	0	51 (63.8)
発熱	37 (46.3)	6 (7.5)	2 (2.5)	0	0	45 (56.3)
カテーテル留置部位炎症	1 (1.3)	0	0	0	0	1 (1.3)
泣き	0	1 (1.3)	0	0	0	1 (1.3)
死亡	1 (1.3)	0	0	0	0	1 (1.3)
医療機器閉塞	1 (1.3)	0	0	0	0	1 (1.3)
薬物不耐性	1 (1.3)	0	0	0	0	1 (1.3)
全身健康状態低下	1 (1.3)	0	0	0	0	1 (1.3)
低体温	1 (1.3)	0	0	0	0	1 (1.3)
ワクチン接種後の易刺激性	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 8 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
倦怠感	1 (1.3)	0	0	0	0	1 (1.3)
医療機器合併症	1 (1.3)	0	0	0	0	1 (1.3)
小結節	1 (1.3)	0	0	0	0	1 (1.3)
疼痛	1 (1.3)	0	0	0	0	1 (1.3)
外科手術不成功	1 (1.3)	0	0	0	0	1 (1.3)
腫脹	1 (1.3)	0	0	0	0	1 (1.3)
皮膚および皮下組織障害	17 (21.3)	6 (7.5)	0	0	0	23 (28.8)
発疹	5 (6.3)	4 (5.0)	0	0	0	9 (11.3)
おむつ皮膚炎	6 (7.5)	0	0	0	0	6 (7.5)
接触性皮膚炎	2 (2.5)	0	0	0	0	2 (2.5)
斑状出血	2 (2.5)	0	0	0	0	2 (2.5)
過角化	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
汗疹	2 (2.5)	0	0	0	0	2 (2.5)
皮膚炎	1 (1.3)	0	0	0	0	1 (1.3)
アレルギー性皮膚炎	1 (1.3)	0	0	0	0	1 (1.3)
皮膚乾燥	1 (1.3)	0	0	0	0	1 (1.3)
湿疹	0	1 (1.3)	0	0	0	1 (1.3)
紅斑	0	1 (1.3)	0	0	0	1 (1.3)
環状肉芽腫	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 9 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
間擦疹	1 (1.3)	0	0	0	0	1 (1.3)
斑状皮疹	1 (1.3)	0	0	0	0	1 (1.3)
丘疹性皮疹	1 (1.3)	0	0	0	0	1 (1.3)
皮膚浮腫	0	1 (1.3)	0	0	0	1 (1.3)
蕁麻疹	1 (1.3)	0	0	0	0	1 (1.3)
臨床検査	14 (17.5)	5 (6.3)	2 (2.5)	0	0	21 (26.3)
酸素飽和度低下	7 (8.8)	3 (3.8)	0	0	0	10 (12.5)
体重減少	4 (5.0)	0	0	0	0	4 (5.0)
血中カリウム減少	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
体温上昇	1 (1.3)	0	1 (1.3)	0	0	2 (2.5)
Ｃ－反応性蛋白増加	2 (2.5)	0	0	0	0	2 (2.5)
医学的観察	2 (2.5)	0	0	0	0	2 (2.5)
アラニンアミノトランスフェラーゼ増加	1 (1.3)	0	0	0	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.3)	0	0	0	0	1 (1.3)
血中クロール減少	1 (1.3)	0	0	0	0	1 (1.3)
血中鉄減少	1 (1.3)	0	0	0	0	1 (1.3)
血中ナトリウム減少	1 (1.3)	0	0	0	0	1 (1.3)
体温低下	0	0	1 (1.3)	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 10 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
心電図ＳＴ－Ｔ部分異常	1 (1.3)	0	0	0	0	1 (1.3)
心拍数増加	1 (1.3)	0	0	0	0	1 (1.3)
心拍数不整	0	1 (1.3)	0	0	0	1 (1.3)
ヒトライノウイルス検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
炎症マーカー上昇	1 (1.3)	0	0	0	0	1 (1.3)
Ａ型インフルエンザウイルス検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
肝機能検査異常	1 (1.3)	0	0	0	0	1 (1.3)
モラクセラ検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
好中球数増加	1 (1.3)	0	0	0	0	1 (1.3)
整形外科検査	1 (1.3)	0	0	0	0	1 (1.3)
シュードモナス検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
ブドウ球菌検査陽性	1 (1.3)	0	0	0	0	1 (1.3)
尿量減少	0	1 (1.3)	0	0	0	1 (1.3)
ビタミンＡ減少	1 (1.3)	0	0	0	0	1 (1.3)
傷害、中毒および処置合併症	16 (20.0)	2 (2.5)	1 (1.3)	0	0	19 (23.8)
大腿骨骨折	3 (3.8)	0	0	0	0	3 (3.8)
栄養補給チューブ合併症	2 (2.5)	0	0	0	0	2 (2.5)
処置による疼痛	2 (2.5)	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 11 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
ストーマ部紅斑	2 (2.5)	0	0	0	0	2 (2.5)
術後激越	0	1 (1.3)	0	0	0	1 (1.3)
節足動物咬傷	1 (1.3)	0	0	0	0	1 (1.3)
挫傷	0	1 (1.3)	0	0	0	1 (1.3)
麻酔からの覚醒遅延	1 (1.3)	0	0	0	0	1 (1.3)
擦過傷	1 (1.3)	0	0	0	0	1 (1.3)
伝染病曝露	1 (1.3)	0	0	0	0	1 (1.3)
処置後腫脹	0	0	1 (1.3)	0	0	1 (1.3)
処置合併症	1 (1.3)	0	0	0	0	1 (1.3)
処置部位反応	1 (1.3)	0	0	0	0	1 (1.3)
ストーマ合併症	1 (1.3)	0	0	0	0	1 (1.3)
ストーマ部刺激感	1 (1.3)	0	0	0	0	1 (1.3)
ワクチン接種合併症	1 (1.3)	0	0	0	0	1 (1.3)
心臓障害	12 (15.0)	5 (6.3)	1 (1.3)	0	0	18 (22.5)
頻脈	4 (5.0)	2 (2.5)	1 (1.3)	0	0	7 (8.8)
心肺停止	4 (5.0)	1 (1.3)	0	0	0	5 (6.3)
徐脈	3 (3.8)	1 (1.3)	0	0	0	4 (5.0)
心停止	2 (2.5)	0	0	0	0	2 (2.5)
チアノーゼ	2 (2.5)	0	0	0	0	2 (2.5)
左室肥大	2 (2.5)	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 12 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
洞性頻脈	0	1 (1.3)	0	0	0	1 (1.3)
上室性頻脈	0	1 (1.3)	0	0	0	1 (1.3)
心室性頻脈	0	1 (1.3)	0	0	0	1 (1.3)
代謝および栄養障害	12 (15.0)	2 (2.5)	0	0	0	14 (17.5)
体重増加不良	4 (5.0)	1 (1.3)	0	0	0	5 (6.3)
成長障害	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
乳児および小児期早期の哺育障害	3 (3.8)	0	0	0	0	3 (3.8)
栄養補給不耐性	3 (3.8)	0	0	0	0	3 (3.8)
脱水	1 (1.3)	0	0	0	0	1 (1.3)
鉄欠乏	1 (1.3)	0	0	0	0	1 (1.3)
筋骨格系および結合組織障害	11 (13.8)	0	0	0	0	11 (13.8)
側弯症	4 (5.0)	0	0	0	0	4 (5.0)
関節拘縮	3 (3.8)	0	0	0	0	3 (3.8)
頭位性斜頭症	2 (2.5)	0	0	0	0	2 (2.5)
背部痛	1 (1.3)	0	0	0	0	1 (1.3)
胸郭変形	1 (1.3)	0	0	0	0	1 (1.3)
泉門閉鎖遅延	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 13 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
後側弯症	1 (1.3)	0	0	0	0	1 (1.3)
脊柱後弯症	1 (1.3)	0	0	0	0	1 (1.3)
四肢痛	1 (1.3)	0	0	0	0	1 (1.3)
神経系障害	7 (8.8)	1 (1.3)	1 (1.3)	0	0	9 (11.3)
眼振	1 (1.3)	0	1 (1.3)	0	0	2 (2.5)
脳損傷	1 (1.3)	0	0	0	0	1 (1.3)
間代	0	1 (1.3)	0	0	0	1 (1.3)
よだれ	1 (1.3)	0	0	0	0	1 (1.3)
低酸素性虚血性脳症	1 (1.3)	0	0	0	0	1 (1.3)
言語障害	1 (1.3)	0	0	0	0	1 (1.3)
不随意性筋収縮	1 (1.3)	0	0	0	0	1 (1.3)
痙攣発作	1 (1.3)	0	0	0	0	1 (1.3)
傾眠	1 (1.3)	0	0	0	0	1 (1.3)
精神障害	6 (7.5)	3 (3.8)	0	0	0	9 (11.3)
易刺激性	2 (2.5)	1 (1.3)	0	0	0	3 (3.8)
激越	0	2 (2.5)	0	0	0	2 (2.5)
不安	2 (2.5)	0	0	0	0	2 (2.5)
息こらえ	1 (1.3)	0	0	0	0	1 (1.3)
気分動揺	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 14 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
落ち着きのなさ	1 (1.3)	0	0	0	0	1 (1.3)
睡眠障害	1 (1.3)	0	0	0	0	1 (1.3)
免疫系障害	7 (8.8)	0	0	0	0	7 (8.8)
季節性アレルギー	3 (3.8)	0	0	0	0	3 (3.8)
薬物過敏症	2 (2.5)	0	0	0	0	2 (2.5)
食物アレルギー	1 (1.3)	0	0	0	0	1 (1.3)
過敏症	1 (1.3)	0	0	0	0	1 (1.3)
血管障害	3 (3.8)	1 (1.3)	1 (1.3)	0	0	5 (6.3)
高血圧	0	1 (1.3)	0	0	0	1 (1.3)
蒼白	1 (1.3)	0	0	0	0	1 (1.3)
ショック	1 (1.3)	0	0	0	0	1 (1.3)
血栓症	1 (1.3)	0	0	0	0	1 (1.3)
血管炎	0	0	1 (1.3)	0	0	1 (1.3)
先天性、家族性および遺伝性障害	2 (2.5)	1 (1.3)	1 (1.3)	0	0	4 (5.0)
先天性横隔膜ヘルニア	1 (1.3)	0	0	0	0	1 (1.3)
発育性股関節形成不全	0	1 (1.3)	0	0	0	1 (1.3)
貧血母斑	0	0	1 (1.3)	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
鳩胸	1 (1.3)	0	0	0	0	1 (1.3)
眼障害	4 (5.0)	0	0	0	0	4 (5.0)
霰粒腫	1 (1.3)	0	0	0	0	1 (1.3)
眼乾燥	1 (1.3)	0	0	0	0	1 (1.3)
眼運動障害	1 (1.3)	0	0	0	0	1 (1.3)
近視	1 (1.3)	0	0	0	0	1 (1.3)
斜視	1 (1.3)	0	0	0	0	1 (1.3)
生殖系および乳房障害	4 (5.0)	0	0	0	0	4 (5.0)
後天性包茎	1 (1.3)	0	0	0	0	1 (1.3)
亀頭包皮炎	1 (1.3)	0	0	0	0	1 (1.3)
卵巣嚢胞	1 (1.3)	0	0	0	0	1 (1.3)
陰茎障害	1 (1.3)	0	0	0	0	1 (1.3)
耳および迷路障害	1 (1.3)	1 (1.3)	0	0	0	2 (2.5)
耳の障害	0	1 (1.3)	0	0	0	1 (1.3)
耳痛	1 (1.3)	0	0	0	0	1 (1.3)
腎および尿路障害	2 (2.5)	0	0	0	0	2 (2.5)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: ISIS 396443
Page 16 of 16

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
水腎症	1 (1.3)	0	0	0	0	1 (1.3)
尿閉	1 (1.3)	0	0	0	0	1 (1.3)
血液およびリンパ系障害	1 (1.3)	0	0	0	0	1 (1.3)
貧血	1 (1.3)	0	0	0	0	1 (1.3)
肝胆道系障害	1 (1.3)	0	0	0	0	1 (1.3)
肝腫大	1 (1.3)	0	0	0	0	1 (1.3)
外科および内科処置	1 (1.3)	0	0	0	0	1 (1.3)
機械的換気	1 (1.3)	0	0	0	0	1 (1.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 147　Infantile-Onset Subjects in Controlled Study ISIS 396443-CS3B: Incidence of Adverse Events by Relationship to Study Drug - Treatment Group: Control

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 1 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
Number of subjects dosed						41 (100.0)
Number of subjects with an event	25 (61.0)	9 (22.0)	6 (14.6)	0	0	40 (97.6)
呼吸器、胸郭および縦隔障害	29 (70.7)	7 (17.1)	0	0	0	36 (87.8)
呼吸不全	14 (34.1)	2 (4.9)	0	0	0	16 (39.0)
無気肺	11 (26.8)	1 (2.4)	0	0	0	12 (29.3)
呼吸窮迫	11 (26.8)	1 (2.4)	0	0	0	12 (29.3)
急性呼吸不全	9 (22.0)	1 (2.4)	0	0	0	10 (24.4)
咳嗽	7 (17.1)	1 (2.4)	0	0	0	8 (19.5)
気管支分泌物貯留	5 (12.2)	2 (4.9)	0	0	0	7 (17.1)
誤嚥性肺炎	7 (17.1)	0	0	0	0	7 (17.1)
呼吸困難	4 (9.8)	2 (4.9)	0	0	0	6 (14.6)
鼻閉	5 (12.2)	0	0	0	0	5 (12.2)
呼吸停止	2 (4.9)	2 (4.9)	0	0	0	4 (9.8)
睡眠時無呼吸症候群	4 (9.8)	0	0	0	0	4 (9.8)
無呼吸	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
誤嚥	3 (7.3)	0	0	0	0	3 (7.3)
気道うっ血	3 (7.3)	0	0	0	0	3 (7.3)
鼻漏	3 (7.3)	0	0	0	0	3 (7.3)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 2 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
乳幼児突発性危急事態	2 (4.9)	0	0	0	0	2 (4.9)
低酸素症	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
頻呼吸	2 (4.9)	0	0	0	0	2 (4.9)
上気道の炎症	2 (4.9)	0	0	0	0	2 (4.9)
急性呼吸窮迫症候群	1 (2.4)	0	0	0	0	1 (2.4)
カタル	0	1 (2.4)	0	0	0	1 (2.4)
息詰まり	1 (2.4)	0	0	0	0	1 (2.4)
気管支分泌増加	1 (2.4)	0	0	0	0	1 (2.4)
上気道分泌増加	1 (2.4)	0	0	0	0	1 (2.4)
肺障害	1 (2.4)	0	0	0	0	1 (2.4)
口腔咽頭痛	1 (2.4)	0	0	0	0	1 (2.4)
変色痰	0	1 (2.4)	0	0	0	1 (2.4)
上気道うっ血	1 (2.4)	0	0	0	0	1 (2.4)
呼吸補助筋の動員	0	1 (2.4)	0	0	0	1 (2.4)
感染症および寄生虫症	26 (63.4)	5 (12.2)	0	0	0	31 (75.6)
上気道感染	8 (19.5)	1 (2.4)	0	0	0	9 (22.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 3 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
肺炎	6 (14.6)	1 (2.4)	0	0	0	7 (17.1)
ウイルス性上気道感染	7 (17.1)	0	0	0	0	7 (17.1)
ライノウイルス感染	6 (14.6)	0	0	0	0	6 (14.6)
細菌性気管炎	4 (9.8)	0	0	0	0	4 (9.8)
鼻咽頭炎	3 (7.3)	1 (2.4)	0	0	0	4 (9.8)
細気管支炎	3 (7.3)	0	0	0	0	3 (7.3)
カンジダ感染	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
結膜炎	3 (7.3)	0	0	0	0	3 (7.3)
口腔カンジダ症	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
細菌性肺炎	3 (7.3)	0	0	0	0	3 (7.3)
ＲＳウイルス細気管支炎	3 (7.3)	0	0	0	0	3 (7.3)
鼻炎	3 (7.3)	0	0	0	0	3 (7.3)
ストーマ部感染	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
ウイルス感染	3 (7.3)	0	0	0	0	3 (7.3)
コロナウイルス感染	2 (4.9)	0	0	0	0	2 (4.9)
ウイルス性胃腸炎	2 (4.9)	0	0	0	0	2 (4.9)
下気道感染	2 (4.9)	0	0	0	0	2 (4.9)
中耳炎	2 (4.9)	0	0	0	0	2 (4.9)
ウイルス性肺炎	2 (4.9)	0	0	0	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 4 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
シュードモナス感染	2 (4.9)	0	0	0	0	2 (4.9)
気道感染	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
ウイルス性気道感染	2 (4.9)	0	0	0	0	2 (4.9)
ブドウ球菌感染	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
菌血症	1 (2.4)	0	0	0	0	1 (2.4)
細菌性疾患キャリアー	1 (2.4)	0	0	0	0	1 (2.4)
気管支炎	1 (2.4)	0	0	0	0	1 (2.4)
カンジダ性おむつ皮疹	1 (2.4)	0	0	0	0	1 (2.4)
カンジダ性敗血症	1 (2.4)	0	0	0	0	1 (2.4)
蜂巣炎	1 (2.4)	0	0	0	0	1 (2.4)
細菌性結膜炎	1 (2.4)	0	0	0	0	1 (2.4)
耳感染	1 (2.4)	0	0	0	0	1 (2.4)
真菌感染	1 (2.4)	0	0	0	0	1 (2.4)
皮膚真菌感染	1 (2.4)	0	0	0	0	1 (2.4)
手足口病	1 (2.4)	0	0	0	0	1 (2.4)
麦粒腫	1 (2.4)	0	0	0	0	1 (2.4)
膿痂疹	1 (2.4)	0	0	0	0	1 (2.4)
パラインフルエンザウイルス感染	1 (2.4)	0	0	0	0	1 (2.4)
パラインフルエンザウイルス性肺炎	1 (2.4)	0	0	0	0	1 (2.4)
シュードモナス菌性肺炎	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 5 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
細菌性気道感染	1 (2.4)	0	0	0	0	1 (2.4)
セラチア感染	1 (2.4)	0	0	0	0	1 (2.4)
副鼻腔炎	1 (2.4)	0	0	0	0	1 (2.4)
皮膚カンジダ	0	1 (2.4)	0	0	0	1 (2.4)
皮膚感染	0	1 (2.4)	0	0	0	1 (2.4)
全身性感染	0	1 (2.4)	0	0	0	1 (2.4)
気管炎	1 (2.4)	0	0	0	0	1 (2.4)
ウイルス性発疹	1 (2.4)	0	0	0	0	1 (2.4)
一般・全身障害および投与部位の状態	20 (48.8)	5 (12.2)	3 (7.3)	0	0	28 (68.3)
発熱	18 (43.9)	4 (9.8)	2 (4.9)	0	0	24 (58.5)
浮腫	3 (7.3)	0	0	0	0	3 (7.3)
疼痛	1 (2.4)	0	1 (2.4)	0	0	2 (4.9)
血管穿刺部位内出血	2 (4.9)	0	0	0	0	2 (4.9)
適用部位発疹	1 (2.4)	0	0	0	0	1 (2.4)
カテーテル留置部位炎症	1 (2.4)	0	0	0	0	1 (2.4)
死亡	1 (2.4)	0	0	0	0	1 (2.4)
医療機器機能不良	1 (2.4)	0	0	0	0	1 (2.4)
医療機器閉塞	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 6 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
疲労	0	1 (2.4)	0	0	0	1 (2.4)
注入部位内出血	1 (2.4)	0	0	0	0	1 (2.4)
注入部位血管外漏出	1 (2.4)	0	0	0	0	1 (2.4)
注射部位血腫	1 (2.4)	0	0	0	0	1 (2.4)
血管穿刺部位反応	0	1 (2.4)	0	0	0	1 (2.4)
胃腸障害	21 (51.2)	3 (7.3)	2 (4.9)	0	0	26 (63.4)
便秘	8 (19.5)	1 (2.4)	0	0	0	9 (22.0)
嚥下障害	8 (19.5)	1 (2.4)	0	0	0	9 (22.0)
胃食道逆流性疾患	8 (19.5)	0	0	0	0	8 (19.5)
嘔吐	6 (14.6)	1 (2.4)	1 (2.4)	0	0	8 (19.5)
下痢	5 (12.2)	1 (2.4)	1 (2.4)	0	0	7 (17.1)
生歯	3 (7.3)	0	0	0	0	3 (7.3)
上腹部痛	2 (4.9)	0	0	0	0	2 (4.9)
流涎過多	2 (4.9)	0	0	0	0	2 (4.9)
血性下痢	1 (2.4)	0	0	0	0	1 (2.4)
小腸炎	1 (2.4)	0	0	0	0	1 (2.4)
心窩部不快感	0	1 (2.4)	0	0	0	1 (2.4)
放屁	0	1 (2.4)	0	0	0	1 (2.4)
胃炎	1 (2.4)	0	0	0	0	1 (2.4)
胃腸出血	0	1 (2.4)	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 7 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
消化管運動障害	1 (2.4)	0	0	0	0	1 (2.4)
消化管刺激症状	0	1 (2.4)	0	0	0	1 (2.4)
レッチング	1 (2.4)	0	0	0	0	1 (2.4)
口内炎	1 (2.4)	0	0	0	0	1 (2.4)
舌萎縮	1 (2.4)	0	0	0	0	1 (2.4)
皮膚および皮下組織障害	13 (31.7)	1 (2.4)	1 (2.4)	0	0	15 (36.6)
おむつ皮膚炎	4 (9.8)	0	0	0	0	4 (9.8)
発疹	3 (7.3)	0	1 (2.4)	0	0	4 (9.8)
褥瘡性潰瘍	3 (7.3)	0	0	0	0	3 (7.3)
接触性皮膚炎	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
紅斑	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
アトピー性皮膚炎	2 (4.9)	0	0	0	0	2 (4.9)
湿疹	2 (4.9)	0	0	0	0	2 (4.9)
皮膚乾燥	1 (2.4)	0	0	0	0	1 (2.4)
多汗症	1 (2.4)	0	0	0	0	1 (2.4)
毛孔性角化症	1 (2.4)	0	0	0	0	1 (2.4)
紅斑性皮疹	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 8 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
臨床検査	12 (29.3)	2 (4.9)	0	0	0	14 (34.1)
酸素飽和度低下	8 (19.5)	2 (4.9)	0	0	0	10 (24.4)
体温低下	1 (2.4)	0	0	0	0	1 (2.4)
体温上昇	0	1 (2.4)	0	0	0	1 (2.4)
Ｃ－反応性蛋白増加	1 (2.4)	0	0	0	0	1 (2.4)
心電図ＳＴ－Ｔ部分異常	1 (2.4)	0	0	0	0	1 (2.4)
ヘッドラグ異常	1 (2.4)	0	0	0	0	1 (2.4)
心拍数減少	0	1 (2.4)	0	0	0	1 (2.4)
心拍数増加	1 (2.4)	0	0	0	0	1 (2.4)
リンパ節触知	1 (2.4)	0	0	0	0	1 (2.4)
呼吸数増加	0	1 (2.4)	0	0	0	1 (2.4)
レスピロウイルス検査陽性	1 (2.4)	0	0	0	0	1 (2.4)
喀痰培養陽性	1 (2.4)	0	0	0	0	1 (2.4)
トランスアミナーゼ上昇	1 (2.4)	0	0	0	0	1 (2.4)
ビタミンＤ減少	1 (2.4)	0	0	0	0	1 (2.4)
体重減少	1 (2.4)	0	0	0	0	1 (2.4)
心臓障害	10 (24.4)	3 (7.3)	0	0	0	13 (31.7)
心肺停止	3 (7.3)	2 (4.9)	0	0	0	5 (12.2)
頻脈	5 (12.2)	0	0	0	0	5 (12.2)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
徐脈	3 (7.3)	0	0	0	0	3 (7.3)
心停止	2 (4.9)	0	0	0	0	2 (4.9)
チアノーゼ	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
代謝および栄養障害	11 (26.8)	2 (4.9)	0	0	0	13 (31.7)
乳児および小児期早期の哺育障害	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
低カリウム血症	3 (7.3)	0	0	0	0	3 (7.3)
脱水	2 (4.9)	0	0	0	0	2 (4.9)
成長障害	2 (4.9)	0	0	0	0	2 (4.9)
低血糖	2 (4.9)	0	0	0	0	2 (4.9)
体重増加不良	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
食物不耐性	0	1 (2.4)	0	0	0	1 (2.4)
高血糖	1 (2.4)	0	0	0	0	1 (2.4)
ビタミンD欠乏	1 (2.4)	0	0	0	0	1 (2.4)
傷害、中毒および処置合併症	9 (22.0)	1 (2.4)	0	0	0	10 (24.4)
栄養補給チューブ合併症	3 (7.3)	0	0	0	0	3 (7.3)
ストーマ合併症	2 (4.9)	0	0	0	0	2 (4.9)
ストーマ部紅斑	2 (4.9)	0	0	0	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 10 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
気管内挿管合併症	1 (2.4)	0	0	0	0	1 (2.4)
擦過傷	0	1 (2.4)	0	0	0	1 (2.4)
大腿骨骨折	1 (2.4)	0	0	0	0	1 (2.4)
頭部損傷	1 (2.4)	0	0	0	0	1 (2.4)
切開部位紅斑	0	1 (2.4)	0	0	0	1 (2.4)
裂傷	1 (2.4)	0	0	0	0	1 (2.4)
処置後挫傷	1 (2.4)	0	0	0	0	1 (2.4)
処置後出血	0	1 (2.4)	0	0	0	1 (2.4)
ストーマ部出血	1 (2.4)	0	0	0	0	1 (2.4)
ストーマ部炎症	1 (2.4)	0	0	0	0	1 (2.4)
ストーマ部刺激感	1 (2.4)	0	0	0	0	1 (2.4)
気管出血	0	1 (2.4)	0	0	0	1 (2.4)
気管損傷	1 (2.4)	0	0	0	0	1 (2.4)
気管閉塞	0	1 (2.4)	0	0	0	1 (2.4)
ワクチン接種合併症	1 (2.4)	0	0	0	0	1 (2.4)
筋骨格系および結合組織障害	5 (12.2)	0	0	0	0	5 (12.2)
関節拘縮	2 (4.9)	0	0	0	0	2 (4.9)
側弯症	2 (4.9)	0	0	0	0	2 (4.9)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 11 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
関節可動域低下	1 (2.4)	0	0	0	0	1 (2.4)
関節硬直	1 (2.4)	0	0	0	0	1 (2.4)
脊柱後弯症	1 (2.4)	0	0	0	0	1 (2.4)
筋緊張	1 (2.4)	0	0	0	0	1 (2.4)
筋力低下	1 (2.4)	0	0	0	0	1 (2.4)
頭位性斜頭症	1 (2.4)	0	0	0	0	1 (2.4)
精神障害	4 (9.8)	1 (2.4)	0	0	0	5 (12.2)
激越	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
睡眠障害	2 (4.9)	0	0	0	0	2 (4.9)
易刺激性	1 (2.4)	0	0	0	0	1 (2.4)
落ち着きのなさ	1 (2.4)	0	0	0	0	1 (2.4)
先天性、家族性および遺伝性障害	4 (9.8)	0	0	0	0	4 (9.8)
停留精巣	1 (2.4)	0	0	0	0	1 (2.4)
発育性股関節形成不全	1 (2.4)	0	0	0	0	1 (2.4)
鳩胸	1 (2.4)	0	0	0	0	1 (2.4)
包茎	1 (2.4)	0	0	0	0	1 (2.4)
免疫系障害	4 (9.8)	0	0	0	0	4 (9.8)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
過敏症	2 (4.9)	0	0	0	0	2 (4.9)
季節性アレルギー	2 (4.9)	0	0	0	0	2 (4.9)
薬物過敏症	1 (2.4)	0	0	0	0	1 (2.4)
血液およびリンパ系障害	2 (4.9)	1 (2.4)	0	0	0	3 (7.3)
貧血	1 (2.4)	0	0	0	0	1 (2.4)
骨髄障害	1 (2.4)	0	0	0	0	1 (2.4)
白血球増加症	0	1 (2.4)	0	0	0	1 (2.4)
眼障害	1 (2.4)	2 (4.9)	0	0	0	3 (7.3)
弱視	1 (2.4)	0	0	0	0	1 (2.4)
眼乾燥	0	1 (2.4)	0	0	0	1 (2.4)
流涙増加	1 (2.4)	0	0	0	0	1 (2.4)
斜視	0	1 (2.4)	0	0	0	1 (2.4)
神経系障害	1 (2.4)	1 (2.4)	0	0	0	2 (4.9)
眼振	1 (2.4)	0	0	0	0	1 (2.4)
失神寸前の状態	0	1 (2.4)	0	0	0	1 (2.4)
耳および迷路障害	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by relationship to study drug
Treatment group: Control
Page 13 of 13

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
耳出血	1 (2.4)	0	0	0	0	1 (2.4)
腎および尿路障害	1 (2.4)	0	0	0	0	1 (2.4)
糖尿	1 (2.4)	0	0	0	0	1 (2.4)
血管障害	1 (2.4)	0	0	0	0	1 (2.4)
充血	1 (2.4)	0	0	0	0	1 (2.4)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 148 Presymptomatic Infants Diagnosed With SMA: Incidence of Adverse Events by Relationship to Study Drug

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 1 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
Number of subjects dosed						20 (100.0)
Number of subjects with an event	10 (50.0)	3 (15.0)	3 (15.0)	0	0	16 (80.0)
感染症および寄生虫症	11 (55.0)	2 (10.0)	0	0	0	13 (65.0)
上気道感染	8 (40.0)	0	0	0	0	8 (40.0)
鼻咽頭炎	4 (20.0)	0	0	0	0	4 (20.0)
インフルエンザ	3 (15.0)	0	0	0	0	3 (15.0)
中耳炎	3 (15.0)	0	0	0	0	3 (15.0)
ウイルス性胃腸炎	2 (10.0)	0	0	0	0	2 (10.0)
肺炎	2 (10.0)	0	0	0	0	2 (10.0)
鼻炎	2 (10.0)	0	0	0	0	2 (10.0)
ライノウイルス感染	2 (10.0)	0	0	0	0	2 (10.0)
細気管支炎	1 (5.0)	0	0	0	0	1 (5.0)
気管支炎	1 (5.0)	0	0	0	0	1 (5.0)
ブドウ球菌性耳感染	1 (5.0)	0	0	0	0	1 (5.0)
膿痂疹	1 (5.0)	0	0	0	0	1 (5.0)
レンサ球菌性咽頭炎	1 (5.0)	0	0	0	0	1 (5.0)
ウイルス性肺炎	0	1 (5.0)	0	0	0	1 (5.0)
皮膚感染	1 (5.0)	0	0	0	0	1 (5.0)
レンサ球菌感染	1 (5.0)	0	0	0	0	1 (5.0)
尿路感染	0	1 (5.0)	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 2 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
皮膚および皮下組織障害	9 (45.0)	0	0	0	0	9 (45.0)
皮膚炎	2 (10.0)	0	0	0	0	2 (10.0)
おむつ皮膚炎	2 (10.0)	0	0	0	0	2 (10.0)
貨幣状湿疹	1 (5.0)	0	0	0	0	1 (5.0)
紅斑	1 (5.0)	0	0	0	0	1 (5.0)
点状出血	1 (5.0)	0	0	0	0	1 (5.0)
発疹	1 (5.0)	0	0	0	0	1 (5.0)
紅斑性皮疹	1 (5.0)	0	0	0	0	1 (5.0)
脂漏性皮膚炎	1 (5.0)	0	0	0	0	1 (5.0)
胃腸障害	8 (40.0)	0	0	0	0	8 (40.0)
腹部膨満	2 (10.0)	0	0	0	0	2 (10.0)
便秘	2 (10.0)	0	0	0	0	2 (10.0)
放屁	2 (10.0)	0	0	0	0	2 (10.0)
胃食道逆流性疾患	2 (10.0)	0	0	0	0	2 (10.0)
腹部不快感	1 (5.0)	0	0	0	0	1 (5.0)
下痢	1 (5.0)	0	0	0	0	1 (5.0)
嚥下障害	1 (5.0)	0	0	0	0	1 (5.0)
生歯	1 (5.0)	0	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 3 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
一般・全身障害および投与部位の状態	5 (25.0)	0	1 (5.0)	0	0	6 (30.0)
発熱	4 (20.0)	0	1 (5.0)	0	0	5 (25.0)
適用部位紅斑	1 (5.0)	0	0	0	0	1 (5.0)
注入部位内出血	1 (5.0)	0	0	0	0	1 (5.0)
呼吸器、胸郭および縦隔障害	6 (30.0)	0	0	0	0	6 (30.0)
咳嗽	3 (15.0)	0	0	0	0	3 (15.0)
鼻閉	3 (15.0)	0	0	0	0	3 (15.0)
鼻漏	3 (15.0)	0	0	0	0	3 (15.0)
息詰まり	1 (5.0)	0	0	0	0	1 (5.0)
呼吸性アシドーシス	1 (5.0)	0	0	0	0	1 (5.0)
呼吸窮迫	1 (5.0)	0	0	0	0	1 (5.0)
上気道うっ血	1 (5.0)	0	0	0	0	1 (5.0)
代謝および栄養障害	4 (20.0)	0	0	0	0	4 (20.0)
脱水	2 (10.0)	0	0	0	0	2 (10.0)
成長障害	2 (10.0)	0	0	0	0	2 (10.0)
体重増加不良	1 (5.0)	0	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 4 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
傷害、中毒および処置合併症	2 (10.0)	1 (5.0)	0	0	0	3 (15.0)
節足動物咬傷	1 (5.0)	0	0	0	0	1 (5.0)
転倒	1 (5.0)	0	0	0	0	1 (5.0)
処置後合併症	1 (5.0)	0	0	0	0	1 (5.0)
処置後不快感	0	1 (5.0)	0	0	0	1 (5.0)
処置後腫脹	1 (5.0)	0	0	0	0	1 (5.0)
硬膜下血腫	1 (5.0)	0	0	0	0	1 (5.0)
臨床検査	2 (10.0)	0	1 (5.0)	0	0	3 (15.0)
アラニンアミノトランスフェラーゼ増加	0	0	1 (5.0)	0	0	1 (5.0)
アスパラギン酸アミノトランスフェラーゼ増加	0	0	1 (5.0)	0	0	1 (5.0)
血中アルカリホスファターゼ増加	1 (5.0)	0	0	0	0	1 (5.0)
体温上昇	1 (5.0)	0	0	0	0	1 (5.0)
好酸球数増加	0	0	1 (5.0)	0	0	1 (5.0)
リンパ球数増加	0	0	1 (5.0)	0	0	1 (5.0)
酸素飽和度低下	1 (5.0)	0	0	0	0	1 (5.0)
白血球数増加	0	0	1 (5.0)	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 5 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
筋骨格系および結合組織障害	2 (10.0)	0	1 (5.0)	0	0	3 (15.0)
筋力低下	1 (5.0)	0	1 (5.0)	0	0	2 (10.0)
関節拘縮	1 (5.0)	0	0	0	0	1 (5.0)
頭位性斜頭症	1 (5.0)	0	0	0	0	1 (5.0)
斜頚	1 (5.0)	0	0	0	0	1 (5.0)
体重支持困難	0	0	1 (5.0)	0	0	1 (5.0)
神経系障害	1 (5.0)	1 (5.0)	1 (5.0)	0	0	3 (15.0)
筋緊張低下	1 (5.0)	1 (5.0)	0	0	0	2 (10.0)
反射亢進	0	0	1 (5.0)	0	0	1 (5.0)
血液およびリンパ系障害	1 (5.0)	1 (5.0)	0	0	0	2 (10.0)
好酸球増加症	0	1 (5.0)	0	0	0	1 (5.0)
好中球減少症	1 (5.0)	0	0	0	0	1 (5.0)
心臓障害	0	1 (5.0)	1 (5.0)	0	0	2 (10.0)
頻脈	0	1 (5.0)	1 (5.0)	0	0	2 (10.0)
免疫系障害	2 (10.0)	0	0	0	0	2 (10.0)
食物アレルギー	1 (5.0)	0	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Presymptomatic infants diagnosed with SMA:
incidence of adverse events by relationship to study drug
Page 6 of 6

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
季節性アレルギー	1 (5.0)	0	0	0	0	1 (5.0)
血管障害	2 (10.0)	0	0	0	0	2 (10.0)
高血圧	1 (5.0)	0	0	0	0	1 (5.0)
蒼白	1 (5.0)	0	0	0	0	1 (5.0)
眼障害	1 (5.0)	0	0	0	0	1 (5.0)
後天性涙道狭窄	1 (5.0)	0	0	0	0	1 (5.0)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (5.0)	0	0	0	0	1 (5.0)
脂漏性角化症	1 (5.0)	0	0	0	0	1 (5.0)
妊娠、産褥および周産期の状態	1 (5.0)	0	0	0	0	1 (5.0)
臍肉芽腫	1 (5.0)	0	0	0	0	1 (5.0)
生殖系および乳房障害	1 (5.0)	0	0	0	0	1 (5.0)
外陰腟発疹	1 (5.0)	0	0	0	0	1 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: In the total column, a subject was counted only once within each system organ class/preferred term. Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 49　Later-Onset Subjects:Incidence of Adverse Events by Relationship to Study Drug

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 1 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
Number of subjects dosed						56 (100.0)
Number of subjects with an event	20 (35.7)	30 (53.6)	6 (10.7)	0	0	56 (100.0)
感染症および寄生虫症	39 (69.6)	5 (8.9)	0	0	0	44 (78.6)
上気道感染	25 (44.6)	2 (3.6)	0	0	0	27 (48.2)
鼻咽頭炎	14 (25.0)	2 (3.6)	0	0	0	16 (28.6)
ウイルス感染	9 (16.1)	0	0	0	0	9 (16.1)
ウイルス性胃腸炎	8 (14.3)	0	0	0	0	8 (14.3)
レンサ球菌性咽頭炎	8 (14.3)	0	0	0	0	8 (14.3)
胃腸炎	6 (10.7)	1 (1.8)	0	0	0	7 (12.5)
中耳炎	5 (8.9)	0	0	0	0	5 (8.9)
肺炎	5 (8.9)	0	0	0	0	5 (8.9)
ウイルス性上気道感染	5 (8.9)	0	0	0	0	5 (8.9)
耳感染	3 (5.4)	1 (1.8)	0	0	0	4 (7.1)
尿路感染	4 (7.1)	0	0	0	0	4 (7.1)
結膜炎	3 (5.4)	0	0	0	0	3 (5.4)
インフルエンザ	3 (5.4)	0	0	0	0	3 (5.4)
限局性感染	3 (5.4)	0	0	0	0	3 (5.4)
ＲＳウイルス感染	3 (5.4)	0	0	0	0	3 (5.4)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 2 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
副鼻腔炎	3 (5.4)	0	0	0	0	3 (5.4)
ウイルス性消化管感染	2 (3.6)	0	0	0	0	2 (3.6)
ウイルス性肺炎	2 (3.6)	0	0	0	0	2 (3.6)
皮膚カンジダ	2 (3.6)	0	0	0	0	2 (3.6)
蜂巣炎	1 (1.8)	0	0	0	0	1 (1.8)
ブドウ球菌性眼感染	1 (1.8)	0	0	0	0	1 (1.8)
ウイルス性眼感染	1 (1.8)	0	0	0	0	1 (1.8)
皮膚真菌感染	1 (1.8)	0	0	0	0	1 (1.8)
手足口病	1 (1.8)	0	0	0	0	1 (1.8)
膿痂疹	1 (1.8)	0	0	0	0	1 (1.8)
下気道感染	1 (1.8)	0	0	0	0	1 (1.8)
伝染性軟属腫	1 (1.8)	0	0	0	0	1 (1.8)
単核細胞症症候群	1 (1.8)	0	0	0	0	1 (1.8)
急性中耳炎	1 (1.8)	0	0	0	0	1 (1.8)
咽頭炎	1 (1.8)	0	0	0	0	1 (1.8)
ＲＳウイルス肺炎	1 (1.8)	0	0	0	0	1 (1.8)
ＲＳウイルス細気管支炎	1 (1.8)	0	0	0	0	1 (1.8)
気道感染	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 3 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
ウイルス性気道感染	1 (1.8)	0	0	0	0	1 (1.8)
鼻炎	1 (1.8)	0	0	0	0	1 (1.8)
皮膚細菌感染	1 (1.8)	0	0	0	0	1 (1.8)
扁桃炎	1 (1.8)	0	0	0	0	1 (1.8)
膣感染	1 (1.8)	0	0	0	0	1 (1.8)
ウイルス性扁桃炎	1 (1.8)	0	0	0	0	1 (1.8)
外陰膣真菌感染	1 (1.8)	0	0	0	0	1 (1.8)
筋骨格系および結合組織障害	32 (57.1)	9 (16.1)	0	0	0	41 (73.2)
背部痛	15 (26.8)	8 (14.3)	0	0	0	23 (41.1)
側弯症	15 (26.8)	0	0	0	0	15 (26.8)
関節拘縮	10 (17.9)	0	0	0	0	10 (17.9)
関節痛	4 (7.1)	1 (1.8)	0	0	0	5 (8.9)
四肢痛	5 (8.9)	0	0	0	0	5 (8.9)
筋肉痛	3 (5.4)	1 (1.8)	0	0	0	4 (7.1)
頚部痛	3 (5.4)	0	0	0	0	3 (5.4)
筋緊張	2 (3.6)	0	0	0	0	2 (3.6)
骨盤変形	2 (3.6)	0	0	0	0	2 (3.6)
四肢拘縮	1 (1.8)	0	0	0	0	1 (1.8)
脊柱前弯症	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 4 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
傷害、中毒および処置合併症	28 (50.0)	11 (19.6)	1 (1.8)	0	0	40 (71.4)
腰椎穿刺後症候群	12 (21.4)	10 (17.9)	1 (1.8)	0	0	23 (41.1)
裂傷	7 (12.5)	0	0	0	0	7 (12.5)
処置による疼痛	6 (10.7)	0	0	0	0	6 (10.7)
節足動物咬傷	3 (5.4)	0	0	0	0	3 (5.4)
大腿骨骨折	3 (5.4)	0	0	0	0	3 (5.4)
四肢損傷	3 (5.4)	0	0	0	0	3 (5.4)
挫傷	2 (3.6)	0	0	0	0	2 (3.6)
関節脱臼	2 (3.6)	0	0	0	0	2 (3.6)
関節損傷	2 (3.6)	0	0	0	0	2 (3.6)
処置による悪心	2 (3.6)	0	0	0	0	2 (3.6)
サンバーン	2 (3.6)	0	0	0	0	2 (3.6)
隆起骨折	2 (3.6)	0	0	0	0	2 (3.6)
術後激越	0	1 (1.8)	0	0	0	1 (1.8)
節足動物刺傷	1 (1.8)	0	0	0	0	1 (1.8)
転倒	1 (1.8)	0	0	0	0	1 (1.8)
頭部損傷	1 (1.8)	0	0	0	0	1 (1.8)
靭帯捻挫	1 (1.8)	0	0	0	0	1 (1.8)
下肢骨折	1 (1.8)	0	0	0	0	1 (1.8)
半月板損傷	1 (1.8)	0	0	0	0	1 (1.8)
肉離れ	1 (1.8)	0	0	0	0	1 (1.8)
術後イレウス	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 5 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
処置による頭痛	1 (1.8)	0	0	0	0	1 (1.8)
熱傷	1 (1.8)	0	0	0	0	1 (1.8)
脛骨骨折	1 (1.8)	0	0	0	0	1 (1.8)
一般・全身障害および投与部位の状態	21 (37.5)	10 (17.9)	0	0	0	31 (55.4)
発熱	11 (19.6)	5 (8.9)	0	0	0	16 (28.6)
穿刺部位疼痛	7 (12.5)	3 (5.4)	0	0	0	10 (17.9)
疲労	1 (1.8)	2 (3.6)	0	0	0	3 (5.4)
疼痛	2 (3.6)	0	0	0	0	2 (3.6)
カテーテル留置部位出血	1 (1.8)	0	0	0	0	1 (1.8)
カテーテル留置部位疼痛	1 (1.8)	0	0	0	0	1 (1.8)
カテーテル留置部位関連反応	1 (1.8)	0	0	0	0	1 (1.8)
胸部不快感	1 (1.8)	0	0	0	0	1 (1.8)
悪寒	0	1 (1.8)	0	0	0	1 (1.8)
冷感	0	1 (1.8)	0	0	0	1 (1.8)
重力性浮腫	1 (1.8)	0	0	0	0	1 (1.8)
低体温	0	1 (1.8)	0	0	0	1 (1.8)
注射部位出血	1 (1.8)	0	0	0	0	1 (1.8)
注射部位疼痛	1 (1.8)	0	0	0	0	1 (1.8)
末梢腫脹	1 (1.8)	0	0	0	0	1 (1.8)
穿刺部位反応	1 (1.8)	0	0	0	0	1 (1.8)
血管穿刺部位内出血	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 6 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
神経系障害	18 (32.1)	10 (17.9)	2 (3.6)	0	0	30 (53.6)
頭痛	16 (28.6)	10 (17.9)	2 (3.6)	0	0	28 (50.0)
感覚鈍麻	1 (1.8)	1 (1.8)	0	0	0	2 (3.6)
失声症	1 (1.8)	0	0	0	0	1 (1.8)
味覚異常	0	1 (1.8)	0	0	0	1 (1.8)
失読症	1 (1.8)	0	0	0	0	1 (1.8)
片頭痛	1 (1.8)	0	0	0	0	1 (1.8)
錯感覚	0	0	1 (1.8)	0	0	1 (1.8)
失神	1 (1.8)	0	0	0	0	1 (1.8)
振戦	1 (1.8)	0	0	0	0	1 (1.8)
胃腸障害	19 (33.9)	7 (12.5)	0	0	0	26 (46.4)
嘔吐	7 (12.5)	5 (8.9)	0	0	0	12 (21.4)
悪心	7 (12.5)	3 (5.4)	0	0	0	10 (17.9)
便秘	7 (12.5)	0	0	0	0	7 (12.5)
アフタ性潰瘍	3 (5.4)	0	0	0	0	3 (5.4)
腹痛	2 (3.6)	0	0	0	0	2 (3.6)
上腹部痛	2 (3.6)	0	0	0	0	2 (3.6)
下痢	2 (3.6)	0	0	0	0	2 (3.6)
口腔内痛	2 (3.6)	0	0	0	0	2 (3.6)
腹部不快感	1 (1.8)	0	0	0	0	1 (1.8)
腹部症状	1 (1.8)	0	0	0	0	1 (1.8)
放屁	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 7 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
食中毒	1 (1.8)	0	0	0	0	1 (1.8)
胃腸障害	1 (1.8)	0	0	0	0	1 (1.8)
胃食道逆流性疾患	1 (1.8)	0	0	0	0	1 (1.8)
口の感覚鈍麻	0	1 (1.8)	0	0	0	1 (1.8)
口唇痛	1 (1.8)	0	0	0	0	1 (1.8)
口内炎	0	1 (1.8)	0	0	0	1 (1.8)
呼吸器、胸郭および縦隔障害	23 (41.1)	2 (3.6)	0	0	0	25 (44.6)
口腔咽頭痛	7 (12.5)	1 (1.8)	0	0	0	8 (14.3)
咳嗽	6 (10.7)	0	0	0	0	6 (10.7)
鼻漏	6 (10.7)	0	0	0	0	6 (10.7)
鼻出血	2 (3.6)	1 (1.8)	0	0	0	3 (5.4)
低酸素症	3 (5.4)	0	0	0	0	3 (5.4)
鼻閉	3 (5.4)	0	0	0	0	3 (5.4)
扁桃肥大	3 (5.4)	0	0	0	0	3 (5.4)
副鼻腔うっ血	2 (3.6)	0	0	0	0	2 (3.6)
急性呼吸不全	1 (1.8)	0	0	0	0	1 (1.8)
無気肺	1 (1.8)	0	0	0	0	1 (1.8)
発声障害	1 (1.8)	0	0	0	0	1 (1.8)
呼吸困難	1 (1.8)	0	0	0	0	1 (1.8)
肺臓炎	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 8 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
肺うっ血	1 (1.8)	0	0	0	0	1 (1.8)
呼吸障害	1 (1.8)	0	0	0	0	1 (1.8)
呼吸不全	1 (1.8)	0	0	0	0	1 (1.8)
拘束性肺疾患	1 (1.8)	0	0	0	0	1 (1.8)
喘鳴	1 (1.8)	0	0	0	0	1 (1.8)
皮膚および皮下組織障害	14 (25.0)	3 (5.4)	0	0	0	17 (30.4)
接触性皮膚炎	3 (5.4)	0	0	0	0	3 (5.4)
湿疹	2 (3.6)	0	0	0	0	2 (3.6)
ざ瘡	1 (1.8)	0	0	0	0	1 (1.8)
水疱	1 (1.8)	0	0	0	0	1 (1.8)
褥瘡性潰瘍	1 (1.8)	0	0	0	0	1 (1.8)
皮膚炎	1 (1.8)	0	0	0	0	1 (1.8)
おむつ皮膚炎	1 (1.8)	0	0	0	0	1 (1.8)
紅斑	1 (1.8)	0	0	0	0	1 (1.8)
毛孔性角化症	1 (1.8)	0	0	0	0	1 (1.8)
汗疹	1 (1.8)	0	0	0	0	1 (1.8)
寝汗	0	1 (1.8)	0	0	0	1 (1.8)
発疹	1 (1.8)	0	0	0	0	1 (1.8)
皮膚病変	0	1 (1.8)	0	0	0	1 (1.8)
蕁麻疹	0	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 9 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
臨床検査	2 (3.6)	4 (7.1)	2 (3.6)	0	0	8 (14.3)
体重減少	1 (1.8)	2 (3.6)	0	0	0	3 (5.4)
血中重炭酸塩減少	1 (1.8)	0	0	0	0	1 (1.8)
血中テストステロン減少	1 (1.8)	0	0	0	0	1 (1.8)
体温上昇	0	1 (1.8)	0	0	0	1 (1.8)
ＣＳＦ白血球数増加	0	0	1 (1.8)	0	0	1 (1.8)
心拍数増加	0	0	1 (1.8)	0	0	1 (1.8)
尿検査異常	0	1 (1.8)	0	0	0	1 (1.8)
免疫系障害	6 (10.7)	1 (1.8)	0	0	0	7 (12.5)
過敏症	3 (5.4)	0	0	0	0	3 (5.4)
季節性アレルギー	3 (5.4)	0	0	0	0	3 (5.4)
薬物過敏症	0	1 (1.8)	0	0	0	1 (1.8)
代謝および栄養障害	2 (3.6)	3 (5.4)	0	0	0	5 (8.9)
脱水	1 (1.8)	1 (1.8)	0	0	0	2 (3.6)
食欲減退	0	1 (1.8)	0	0	0	1 (1.8)
食欲亢進	1 (1.8)	0	0	0	0	1 (1.8)
ビタミンＤ欠乏	0	1 (1.8)	0	0	0	1 (1.8)
精神障害	1 (1.8)	3 (5.4)	0	0	0	4 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 10 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
激越	1 (1.8)	1 (1.8)	0	0	0	2 (3.6)
注意欠陥多動性障害	1 (1.8)	0	0	0	0	1 (1.8)
不快気分	1 (1.8)	0	0	0	0	1 (1.8)
不眠症	0	1 (1.8)	0	0	0	1 (1.8)
睡眠時随伴症	0	1 (1.8)	0	0	0	1 (1.8)
チック	1 (1.8)	0	0	0	0	1 (1.8)
心因性嘔吐	1 (1.8)	0	0	0	0	1 (1.8)
心臓障害	2 (3.6)	0	1 (1.8)	0	0	3 (5.4)
動悸	1 (1.8)	0	1 (1.8)	0	0	2 (3.6)
頻脈	1 (1.8)	0	0	0	0	1 (1.8)
耳および迷路障害	3 (5.4)	0	0	0	0	3 (5.4)
耳痛	1 (1.8)	0	0	0	0	1 (1.8)
乗物酔い	1 (1.8)	0	0	0	0	1 (1.8)
鼓膜穿孔	1 (1.8)	0	0	0	0	1 (1.8)
腎および尿路障害	2 (3.6)	1 (1.8)	0	0	0	3 (5.4)
排尿困難	1 (1.8)	0	0	0	0	1 (1.8)
尿失禁	0	1 (1.8)	0	0	0	1 (1.8)
膀胱尿管逆流	1 (1.8)	0	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by relationship to study drug
Page 11 of 11

	Relationship to study drug					Total
	Not related	Unlikely/ Remote	Possibly	Related	Unknown	
眼障害	2 (3.6)	0	0	0	0	2 (3.6)
遠視	1 (1.8)	0	0	0	0	1 (1.8)
斜視	1 (1.8)	0	0	0	0	1 (1.8)
血液およびリンパ系障害障害	1 (1.8)	0	0	0	0	1 (1.8)
好中球減少症	1 (1.8)	0	0	0	0	1 (1.8)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.8)	0	0	0	0	1 (1.8)
皮膚乳頭腫	1 (1.8)	0	0	0	0	1 (1.8)
血管障害	0	1 (1.8)	0	0	0	1 (1.8)
低血圧	0	1 (1.8)	0	0	0	1 (1.8)

NOTE 1:Numbers in parentheses are percentages.
2:In the total column, a subject was counted only once within each system organ class/preferred term.Within each system organ class and preferred term, a subject was counted only once under the strongest relationship.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 150 Incidence of Events With a Fatal Outcome in Infants Diagnosed With SMA

Incidence of events with a fatal outcome in infants diagnosed with SMA
Page 1 of 2

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	0	16 (39.0)	13 (16.3)	17 (17.0)	17 (14.2)
呼吸器、胸郭および縦隔障害	0	12 (29.3)	7 (8.8)	10 (10.0)	10 (8.3)
呼吸不全	0	8 (19.5)	4 (5.0)	6 (6.0)	6 (5.0)
急性呼吸不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
窒息	0	0	0	1 (1.0)	1 (0.8)
呼吸停止	0	0	1 (1.3)	1 (1.0)	1 (0.8)
呼吸窮迫	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
誤嚥	0	1 (2.4)	0	0	0
心臓障害	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
心肺停止	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
一般・全身障害および投与部位の状態	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
全身健康状態低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of events with a fatal outcome in infants diagnosed with SMA
Page 2 of 2

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)			
	Presymptomatic: ISIS 396443	Control	ISIS 396443	Controlled and uncontrolled studies : ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
神経系障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
感染症および寄生虫症	0	0	0	1 (1.0)	1 (0.8)
ウイルス性下気道感染	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]7

表 151 Incidence of Events With a Fatal Outcome in Subjects With SMA

Incidence of events with a fatal outcome in subjects with SMA
Page 1 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	0	17 (17.0)	17 (14.2)	0	17 (9.7)
呼吸器、胸郭および縦隔障害	0	10 (10.0)	10 (8.3)	0	10 (5.7)
呼吸不全	0	6 (6.0)	6 (5.0)	0	6 (3.4)
急性呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
窒息	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸停止	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸窮迫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心臓障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
心肺停止	0	2 (2.0)	2 (1.7)	0	2 (1.1)
一般・全身障害および投与部位の状態	0	2 (2.0)	2 (1.7)	0	2 (1.1)
死亡	0	1 (1.0)	1 (0.8)	0	1 (0.6)
全身健康状態低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of events with a fatal outcome in subjects with SMA
Page 2 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
神経系障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
脳損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
感染症および寄生虫症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性下気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 152　Incidence of Potentially Drug-Related Serious Adverse Events in Infants Diagnosed With SMA

Incidence of potentially drug-related serious adverse events in infants diagnosed with SMA

No Potentially Drug-Related Serious Adverse Events Reported

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

表 153 Incidence of Adverse Events That Led to Discontinuation of Study Drug in Infants Diagnosed With SMA

Incidence of adverse events that led to discontinuation of study drug in infants diagnosed with SMA
Page 1 of 2

		Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
	Presymptomatic: ISIS 396443	Control	ISIS 396443	ISIS 396443	ISIS 396443
Number of subjects dosed	20 (100.0)	41 (100.0)	80 (100.0)	100 (100.0)	120 (100.0)
Number of subjects with an event	0	16 (39.0)	13 (16.3)	16 (16.0)	16 (13.3)
呼吸器、胸郭および縦隔障害	0	12 (29.3)	7 (8.8)	9 (9.0)	9 (7.5)
呼吸不全	0	8 (19.5)	4 (5.0)	6 (6.0)	6 (5.0)
急性呼吸不全	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
呼吸停止	0	0	1 (1.3)	1 (1.0)	1 (0.8)
呼吸窮迫	0	2 (4.9)	1 (1.3)	1 (1.0)	1 (0.8)
誤嚥	0	1 (2.4)	0	0	0
心臓障害	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
心肺停止	0	3 (7.3)	2 (2.5)	2 (2.0)	2 (1.7)
一般・全身障害および投与部位の状態	0	1 (2.4)	2 (2.5)	2 (2.0)	2 (1.7)
死亡	0	1 (2.4)	1 (1.3)	1 (1.0)	1 (0.8)
全身健康状態低下	0	0	1 (1.3)	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events that led to discontinuation of study drug in infants diagnosed with SMA
Page 2 of 2

	Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
		Controlled study (CS3B)		Controlled and uncontrolled studies :	Presymptomatic and symptomatic:
		Control	ISIS 396443	ISIS 396443	ISIS 396443
神経系障害	0	0	2 (2.5)	2 (2.0)	2 (1.7)
脳損傷	0	0	1 (1.3)	1 (1.0)	1 (0.8)
低酸素性虚血性脳症	0	0	1 (1.3)	1 (1.0)	1 (0.8)
感染症および寄生虫症	0	0	0	1 (1.0)	1 (0.8)
ウイルス性下気道感染	0	0	0	1 (1.0)	1 (0.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the column Symptomatic (infantile-onset) controlled and uncontrolled studies: ISIS 396443

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 154 Incidence of Adverse Events That Led to Discontinuation of Study Drug in Subjects With SMA

Incidence of adverse events that led to discontinuation of study drug in subjects with SMA
Page 1 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
Number of subjects dosed	20 (100.0)	100 (100.0)	120 (100.0)	56 (100.0)	176 (100.0)
Number of subjects with an event	0	16 (16.0)	16 (13.3)	0	16 (9.1)
呼吸器、胸郭および縦隔障害	0	9 (9.0)	9 (7.5)	0	9 (5.1)
呼吸不全	0	6 (6.0)	6 (5.0)	0	6 (3.4)
急性呼吸不全	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸停止	0	1 (1.0)	1 (0.8)	0	1 (0.6)
呼吸窮迫	0	1 (1.0)	1 (0.8)	0	1 (0.6)
心臓障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
心肺停止	0	2 (2.0)	2 (1.7)	0	2 (1.1)
一般・全身障害および投与部位の状態	0	2 (2.0)	2 (1.7)	0	2 (1.1)
死亡	0	1 (1.0)	1 (0.8)	0	1 (0.6)
全身健康状態低下	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

Incidence of adverse events that led to discontinuation of study drug in subjects with SMA
Page 2 of 2

	Infants diagnosed with SMA				
	Presymptomatic	Symptomatic (infantile-onset): controlled and uncontrolled studies	Presymptomatic and symptomatic	Later-onset SMA	All subjects treated
神経系障害	0	2 (2.0)	2 (1.7)	0	2 (1.1)
脳損傷	0	1 (1.0)	1 (0.8)	0	1 (0.6)
低酸素性虚血性脳症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
感染症および寄生虫症	0	1 (1.0)	1 (0.8)	0	1 (0.6)
ウイルス性下気道感染	0	1 (1.0)	1 (0.8)	0	1 (0.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class in the All subjects treated column

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 155　Infantile-Onset Subjects Treated With ISIS 396443 in Controlled and Uncontrolled Studies: Shifts From Baseline to Maximum Post-Baseline Urinalysis Laboratory Values

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 1 of 12

URINALYSIS:Specific Gravity

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	85	1	10
High/positive	0	0	0
Unknown	4	0	0

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

URINALYSIS:pH

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	81	4	10
High/positive	1	0	0
Unknown	4	0	0

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 3 of 12

URINALYSIS:Protein

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	49	28	10
High/positive	3	6	0
Unknown	2	2	0

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

URINALYSIS:Glucose

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	84	1	10
High/positive	0	1	0
Unknown	4	0	0

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

URINALYSIS:Ketones

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	67	15	10
High/positive	1	3	0
Unknown	4	0	0

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 6 of 12

URINALYSIS:Bilirubin

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	81	0	10
High/positive	0	0	0
Unknown	9	0	0

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 7 of 12

URINALYSIS:Occult Blood

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	75	3	11
High/positive	4	1	0
Unknown	4	1	1

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 8 of 12

URINALYSIS:Erythrocytes

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	18	2	8
High/positive	0	2	0
Unknown	29	1	40

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 9 of 12

URINALYSIS:Leukocytes

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	32	9	12
High/positive	5	5	0
Unknown	25	4	8

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 10 of 12

URINALYSIS:Epithelial Cells

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	4	1	2
High/positive	2	3	0
Unknown	1	1	86

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

Page 11 of 12

URINALYSIS:Bacteria

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	3	4	0
High/positive	0	7	13
Unknown	2	21	50

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:

shifts from baseline to maximum post-baseline urinalysis laboratory values

URINALYSIS:Casts

	Maximum post-baseline value		
Baseline	Negative	High/positive	Unknown
Negative	3	0	2
High/positive	0	0	0
Unknown	5	1	89

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 156　Summary of Shifts From Baseline for Hematology in Infants Diagnosed With SMA

Summary of shifts from baseline for hematology in infants diagnosed with SMA
Page 1 of 3

		Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
			Control	ISIS 396443		
Leukocytes	Low	2/ 17 (12)	3/ 33 (9)	4/ 69 (6)	6/ 88 (7)	8/105 (8)
	High	2/ 18 (11)	7/ 34 (21)	15/ 69 (22)	23/ 86 (27)	25/104 (24)
Neutrophils	Low	2/ 5 (40)	2/ 31 (6)	8/ 67 (12)	11/ 80 (14)	13/ 85 (15)
	High	0/ 5	3/ 32 (9)	6/ 71 (8)	14/ 90 (16)	14/ 95 (15)
Neutrophils/Leukocytes	Low	4/ 4 (100)	6/ 8 (75)	9/ 11 (82)	16/ 23 (70)	20/ 27 (74)
	High	0/ 4	1/ 34 (3)	2/ 72 (3)	6/ 87 (7)	6/ 91 (7)
Lymphocytes	Low	0/ 19	0/ 33	1/ 72 (1)	5/ 92 (5)	5/111 (5)
	High	10/ 19 (53)	11/ 30 (37)	32/ 70 (46)	36/ 84 (43)	46/103 (45)
Lymphocytes/Leukocytes	Low	0/ 19	1/ 34 (3)	2/ 72 (3)	5/ 86 (6)	5/105 (5)
	High	7/ 7 (100)	6/ 8 (75)	9/ 10 (90)	17/ 22 (77)	24/ 29 (83)
Monocytes	Low	12/ 19 (63)	6/ 26 (23)	13/ 40 (33)	14/ 60 (23)	26/ 79 (33)
	High	1/ 17 (6)	0/ 33	2/ 72 (3)	9/ 82 (11)	10/ 99 (10)

NOTE 1: Entries are number low (or high)/number at risk (percentage). Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
2: Shift to low includes normal to low, high to low, and unknown to low.
3: Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Summary of shifts from baseline for hematology in infants diagnosed with SMA
Page 2 of 3

		Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
			Control	ISIS 396443	ISIS 396443	ISIS 396443
Monocytes/Leukocytes	Low	9/ 18 (50)	4/ 29 (14)	9/ 56 (16)	10/ 71 (14)	19/ 89 (21)
	High	2/ 16 (13)	2/ 32 (6)	7/ 72 (10)	14/ 84 (17)	16/100 (16)
Eosinophils	Low	0/ 19	0/ 33	1/ 72 (1)	6/ 92 (7)	6/111 (5)
	High	14/ 15 (93)	12/ 18 (67)	17/ 29 (59)	22/ 38 (58)	36/ 53 (68)
Eosinophils/Leukocytes	Low	0/ 19	0/ 34	1/ 72 (1)	6/ 86 (7)	6/105 (6)
	High	10/ 13 (77)	13/ 27 (48)	25/ 41 (61)	28/ 54 (52)	38/ 67 (57)
Basophils	Low	0/ 19	1/ 33 (3)	0/ 72	4/ 87 (5)	4/106 (4)
	High	2/ 19 (11)	2/ 33 (6)	2/ 71 (3)	6/ 86 (7)	8/105 (8)
Basophils/Leukocytes	Low	0/ 19	1/ 33 (3)	0/ 71	4/ 81 (5)	4/100 (4)
	High	4/ 19 (21)	7/ 33 (21)	9/ 71 (13)	10/ 85 (12)	14/104 (13)
Erythrocytes	Low	2/ 18 (11)	2/ 34 (6)	2/ 71 (3)	4/ 91 (4)	6/109 (6)
	High	6/ 18 (33)	1/ 27 (4)	9/ 52 (17)	16/ 72 (22)	22/ 90 (24)

NOTE 1: Entries are number low (or high)/number at risk (percentage). Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
2: Shift to low includes normal to low, high to low, and unknown to low.
3: Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Summary of shifts from baseline for hematology in infants diagnosed with SMA
Page 3 of 3

		Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies:	Presymptomatic and symptomatic:
			Control	ISIS 396443	ISIS 396443	ISIS 396443
Ery. Mean Corpuscular Volume (fL)	Low	1/ 5 (20)	1/ 5 (20)	1/ 9 (11)	3/ 25 (12)	4/ 30 (13)
	High	0/ 5	0/ 5	0/ 9	3/ 29 (10)	3/ 34 (9)
Ery. Mean Corpuscular Hemoglobin	Low	1/ 5 (20)	1/ 5 (20)	1/ 8 (13)	5/ 24 (21)	6/ 29 (21)
	High	0/ 5	0/ 5	2/ 9 (22)	2/ 28 (7)	2/ 33 (6)
Ery. Mean Corpuscular HGB Concentration	Low	0/ 4	1/ 5 (20)	0/ 8	9/ 26 (35)	9/ 30 (30)
	High	0/ 4	0/ 5	0/ 9	2/ 27 (7)	2/ 31 (6)
Hemoglobin	Low	3/ 17 (18)	5/ 34 (15)	9/ 68 (13)	15/ 86 (17)	18/103 (17)
	High	0/ 18	7/ 34 (21)	10/ 71 (14)	18/ 91 (20)	18/109 (17)
Hematocrit	Low	4/ 16 (25)	7/ 33 (21)	11/ 68 (16)	15/ 86 (17)	19/102 (19)
	High	2/ 18 (11)	7/ 34 (21)	7/ 71 (10)	17/ 91 (19)	19/109 (17)
Platelets	Low	3/ 19 (16)	0/ 33	9/ 70 (13)	11/ 90 (12)	14/109 (13)
	High	13/ 17 (76)	6/ 15 (40)	9/ 35 (26)	16/ 50 (32)	29/ 67 (43)

NOTE 1: Entries are number low (or high)/number at risk (percentage). Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
2: Shift to low includes normal to low, high to low, and unknown to low.
3: Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 157　Summary of Shifts From Baseline for Blood Chemistry in Infants Diagnosed With SMA

Summary of shifts from baseline for blood chemistry in infants diagnosed with SMA
Page 1 of 3

		Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
			Control	ISIS 396443		
Liver function						
Aspartate Aminotransferase (U/L)	High	2/ 17 (12)	1/ 31 (3)	5/ 70 (7)	7/ 86 (8)	9/103 (9)
Alanine Aminotransferase (U/L)	High	5/ 17 (29)	4/ 31 (13)	10/ 69 (14)	12/ 87 (14)	17/104 (16)
Alkaline Phosphatase (U/L)	High	3/ 18 (17)	0/ 32	3/ 72 (4)	4/ 88 (5)	7/106 (7)
Direct Bilirubin (umol/L)	High	0/ 17	0/ 30	0/ 68	5/ 81 (6)	5/ 98 (5)
Indirect Bilirubin (umol/L)	High	1/ 10 (10)	0/ 28	0/ 68	0/ 75	1/ 85 (1)
Kidney function						
Blood Urea Nitrogen (mmol/L)	High	0/ 19	0/ 34	1/ 73 (1)	1/ 92 (1)	1/111 (<1)
Creatinine (umol/L)	High	0/ 19	0/ 34	0/ 73	0/ 93	0/112
Cystatin C (mg/L)	High	0/ 3	1/ 33 (3)	1/ 73 (1)	1/ 76 (1)	1/ 79 (1)

NOTE 1: Entries are number low (or high)/number at risk (percentage). Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
2: Shift to low includes normal to low, high to low, and unknown to low.
3: Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Summary of shifts from baseline for blood chemistry in infants diagnosed with SMA
Page 2 of 3

		Presymptomatic: ISIS 396443	Symptomatic (infantile-onset): Controlled study (CS3B) Control	Symptomatic (infantile-onset): Controlled study (CS3B) ISIS 396443	Symptomatic (infantile-onset): Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
Electrolytes						
Sodium (mmol/L)	Low	0/ 17	0/ 34	1/ 73 (1)	5/ 90 (6)	5/107 (5)
	High	0/ 19	0/ 34	0/ 73	2/ 93 (2)	2/112 (2)
Potassium (mmol/L)	Low	0/ 19	4/ 34 (12)	4/ 72 (6)	7/ 92 (8)	7/111 (6)
	High	3/ 14 (21)	1/ 34 (3)	6/ 71 (8)	10/ 91 (11)	13/105 (12)
Chloride (mmol/L)	Low	0/ 19	1/ 34 (3)	5/ 73 (7)	8/ 93 (9)	8/112 (7)
	High	0/ 19	0/ 34	1/ 72 (1)	3/ 91 (3)	3/110 (3)
Bicarbonate (mmol/L)	Low	2/ 2 (100)	0/ 1	2/ 3 (67)	7/ 22 (32)	9/ 24 (38)
	High	0/ 2	0/ 1	0/ 3	2/ 23 (9)	2/ 25 (8)
Other						
Protein (g/L)	Low	6/ 15 (40)	0/ 32	2/ 69 (3)	3/ 85 (4)	9/100 (9)
	High	1/ 19 (5)	4/ 34 (12)	17/ 71 (24)	24/ 91 (26)	25/110 (23)
Albumin (g/L)	Low	0/ 19	0/ 34	0/ 73	1/ 93 (1)	1/112 (<1)
	High	4/ 18 (22)	1/ 34 (3)	2/ 71 (3)	6/ 91 (7)	10/109 (9)
Calcium (mmol/L)	Low	4/ 19 (21)	0/ 34	7/ 72 (10)	7/ 92 (8)	11/111 (10)
	High	3/ 14 (21)	1/ 30 (3)	4/ 63 (6)	12/ 79 (15)	15/ 93 (16)
Phosphate (mmol/L)	Low	0/ 19	0/ 33	0/ 73	0/ 93	0/112
	High	2/ 18 (11)	3/ 33 (9)	5/ 73 (7)	7/ 89 (8)	9/107 (8)

NOTE 1: Entries are number low (or high)/number at risk (percentage). Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
2: Shift to low includes normal to low, high to low, and unknown to low.
3: Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Summary of shifts from baseline for blood chemistry in infants diagnosed with SMA
Page 3 of 3

		Presymptomatic: ISIS 396443	Symptomatic (infantile-onset)			
			Controlled study (CS3B)		Controlled and uncontrolled studies: ISIS 396443	Presymptomatic and symptomatic: ISIS 396443
			Control	ISIS 396443		
Continued..						
Glucose	Low	0/ 18	2/ 33 (6)	3/ 72 (4)	5/ 92 (5)	5/110 (5)
	High	8/ 15 (53)	12/ 27 (44)	27/ 52 (52)	29/ 70 (41)	37/ 85 (44)
Creatine Kinase (U/L)	Low	0/ 19	0/ 33	0/ 72	2/ 92 (2)	2/111 (2)
	High	9/ 12 (75)	5/ 18 (28)	16/ 34 (47)	19/ 44 (43)	28/ 56 (50)

NOTE 1: Entries are number low (or high)/number at risk (percentage). Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
2: Shift to low includes normal to low, high to low, and unknown to low.
3: Shift to high includes normal to high, low to high, and unknown to high.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 58　Summary of Shifts From Baseline for CSF Safety Parameters in Subjects With Later-Onset SMA

Summary of shifts from baseline for CSF safety parameters in subjects with later-onset SMA

		Later-onset SMA
Erythrocytes (/cubic mm)	Low	0/ 43
	High	17/ 33 (52)
Leukocytes (/cubic mm)	Low	0/ 52
	High	9/ 51 (18)
Glucose (mmol/L)	Low	7/ 43 (16)
	High	2/ 51 (4)
Protein (g/L)	Low	4/ 40 (10)
	High	9/ 53 (17)

NOTE:Entries are number low (or high)/number at risk (percentage).Number at risk for shift to low (or high) is the number of subjects whose baseline value was not low (or high) and who had at least one post-baseline value. Numbers in parentheses are percentages based on the number at risk.
a) Shift to low includes normal to low, high to low, and unknown to low.
b) Shift to high includes normal to high, low to high, and unknown to high.

SOURCE:[redacted]20[redacted]　DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 159 Summary of Shifts in ECG Results in Infantile-Onset SMA

Summary of shifts in ECG results in infantile-onset SMA

	Controlled study (CS3B)		Controlled and uncontrolled studies:
	Control	ISIS 396443	ISIS 396443
Number of subjects dosed	41	80	100
Shift to abnormal, not clinically significant (a)	5/34 (14.7)	17/65 (26.2)	21/81 (25.9)
Shift to abnormal, clinically significant (b)	0/34	8/65 (12.3)	10/81 (12.3)

NOTE: Entries are number with a shift/number at risk (percentage). Number at risk is the number of subjects whose baseline value was not abnormal and who had at least one post-baseline value.
(a) Shift to 'abnormal, not clinically significant' includes 'unknown' or 'normal' to 'abnormal, not clinically significant'.
(b) Shift to 'abnormal, clinically significant' includes 'unknown' or 'normal' to 'abnormal, clinically significant'.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 60　Summary of Shifts in ECG Results in Later-Onset SMA

Summary of shifts in ECG results in later-onset SMA

	Later-onset SMA
Number of subjects dosed	56
Shift to abnormal, not clinically significant (a)	30/45 (67)
Shift to abnormal, clinically significant (b)	0/45

NOTE:Entries are number with a shift/number at risk (percentage).Number at risk is the number of subjects whose baseline value was not abnormal and who had at least one post-baseline value.
(a) Shift to 'abnormal, not clinically significant' includes 'unknown' or 'normal' to 'abnormal, not clinically significant'.
(b) Shift to 'abnormal, clinically significant' includes 'unknown' or 'normal' to 'abnormal, clinically significant'.

SOURCE:[redacted]
DATE:[redacted]

表 161 Incidence of Outliers in ECGs Based on Fridericia Corrected QT Interval

Incidence of outliers in ECGs based on Fridericia corrected QT interval

	Infantile-onset SMA				
	Controlled study (CS3B)		Controlled and uncontrolled studies:	Later-onset	All treated subjects
	Control	ISIS 396443	ISIS 396443	SMA	with SMA
Number of subjects dosed	41	80	100	56	176
Number of subjects with:					
(i) any post-baseline ECG	41 (100.0)	80 (100.0)	100 (100.0)	56 (100.0)	156 (100.0)
Post-baseline corrected QTcF (msec)					
>450	13 (31.7)	24 (30.0)	32 (32.0)	20 (35.7)	52 (33.3)
>480	2 (4.9)	7 (8.8)	9 (9.0)	2 (3.6)	11 (7.1)
>500	0	3 (3.8)	3 (3.0)	2 (3.6)	5 (3.2)
(ii) a baseline and any post-baseline ECG	41 (100.0)	80 (100.0)	100 (100.0)	55 (100.0)	155 (100.0)
Increase from baseline in QTcF (msec)					
>30	12 (29.3)	17 (21.3)	24 (24.0)	18 (32.7)	42 (27.1)
>60	4 (9.8)	5 (6.3)	6 (6.0)	0	6 (3.9)
>500 msec post-baseline and >60 msec increase from baseline	0	2 (2.5)	2 (2.0)	0	2 (1.3)

Abbreviation: QTcF=Fridericia-corrected QT interval

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 62　Subject Listing of Neurological Tests Performed That Were Not Secondary to SMA With Their Findings

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 1 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1775-3003	CRANIAL NERVES - VISION	-15	Screening	01MAY2012	ABNORMAL	Corrective lenses for astigmatism
396443-CS1 /1775-3004	GENERAL - SPEECH/LANGUAGE	467	Day 8-10	13SEP2013	ABNORMAL	IMMATURE ARTICULATION
	SENSATION - DIP REGION - DISTAL INTERPHALANGEAL JOINT OF THE HAND - LEFT - TEMPERATURE SENSATION	548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT
	SENSATION - DIP REGION - DISTAL INTERPHALANGEAL JOINT OF THE HAND - RIGHT - TEMPERATURE SENSATION	548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT
	SENSATION - FIRST METATARSAL BONE - FOOT DIGIT 1 - LEFT - TEMPERATURE SENSATION	443	Screening-10	20AUG2013	ABSENT	UNKNOWN
		460	Day 1-10/ PRE-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 4 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 6 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT

SOURCE: [redacted]20[redacted]　　DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 2 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1775-3004	SENSATION - FIRST METATARSAL BONE - FOOT DIGIT 1 - RIGHT - TEMPERATURE SENSATION	443	Screening-10	20AUG2013	ABSENT	UNKNOWN
		460	Day 1-10/ PRE-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 4 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		460	Day 1-10/ 6 HOUR POST-DOSE	06SEP2013	ABSENT	UNKNOWN
		548	Day 85-10	03DEC2013	ABSENT	UNKNOWN CAUSE; NOT CLINICALLY SIGNIFICANT
	SENSATION - FOOT DIGIT 1 - LEFT - TEMPERATURE SENSATION	29	Day 29	02JUL2012	ABSENT	Maybe lost interest
	SENSATION - FOOT DIGIT 1 - RIGHT - TEMPERATURE SENSATION	29	Day 29	02JUL2012	ABSENT	Maybe lost interest
396443-CS1 /1775-4002	CRANIAL NERVES - FACIAL MOTION	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015	ABNORMAL	MINIMAL EYE CLOSURE WEAKNESS BILATERALLY.
	GENERAL - APPEARANCE/FACIAL/MOTOR EXPR	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015		MINIMAL EYE CLOSURE WEAKNESS BILATERALLY.
	GENERAL - MENTAL STATUS	400	Day 1-10/ 4 HOUR POST-DOSE	14AUG2013	ABNORMAL	DUE TO SEDATION

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 3 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1775-4002	GENERAL - SPEECH/LANGUAGE	400	Day 1-10/ 4 HOUR POST-DOSE	14AUG2013	ABNORMAL	DUE TO SEDATION
	REFLEXES - ANKLE - LEFT - REFLEX	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015	0	
	REFLEXES - ANKLE - RIGHT - REFLEX	1017	Day 351-12/ 4 HOUR POST-DOSE	23APR2015	0	
		1017	Day 351-12/ 6 HOUR POST-DOSE	23APR2015	0	
396443-CS1 /1776-1004	GENERAL - MENTAL STATUS	1275	Day 533-12	20JUL2015	ABNORMAL	ANXIOUS PER PROCEDURE
396443-CS1 /1776-2002	CRANIAL NERVES - HEARING	726	Screening-12	07MAR2014	ABNORMAL	MILDLY DECREASED BILATERAL TO TUNING FORK
	GENERAL - MENTAL STATUS	1464	Day 715-12	14MAR2016	ABNORMAL	SAD AND TEARFUL
396443-CS1 /1778-4009	PLANTAR RESPONSE - TOE - LEFT - REFLEX	-6	Screening	10AUG2012	ABNORMAL	extensor plantar response
		1	Day 1/ PRE-DOSE	16AUG2012	ABNORMAL	extensor plantar response
		1	Day 1/ 4 HOUR POST-DOSE	16AUG2012	ABNORMAL	extensor plantar response

SOURCE:[redacted]20[redacted] DATE:[redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 4 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1778-4009	PLANTAR RESPONSE - TOE - LEFT - REFLEX	1	Day 1/ 6 HOUR POST-DOSE	16AUG2012	ABNORMAL	extensor plantar response
		2	Day 2	17AUG2012	ABNORMAL	Babinski
		9	Day 8	24AUG2012	ABNORMAL	extensor plantar response
		29	Day 29	13SEP2012	ABNORMAL	extensor plantar response
		85	Day 85	08NOV2012	ABNORMAL	Extensor plantar response
396443-CS1 /1780-1003	MOTOR SYSTEM - DORSIFLEXION - FOOT - RIGHT - MUSCLE TONE	328	Day 36-2	10DEC2012	ABNORMAL	SPLINTING DUE TO PLANTAR WART
396443-CS1 /1780-1005	GENERAL - SPEECH/LANGUAGE	-2	Screening	23JAN2012	ABNORMAL	Some articulation problems and speech delay, NCS (See medical history item #2)
		1	Day 1/ PRE-DOSE	25JAN2012	ABNORMAL	articulation/ speech abnormal, NCS, no change from baseline
		1	Day 1/ 4 HOUR POST-DOSE	25JAN2012	ABNORMAL	NCS, no change from baseline- articulation dificulties
		1	Day 1/ 6 HOUR POST-DOSE	25JAN2012	ABNORMAL	No change from baseline
		2	Day 2	26JAN2012	ABNORMAL	No change from baseline
		8	Day 8	01FEB2012	ABNORMAL	No change from baseline
		29	Day 29	22FEB2012	ABNORMAL	articulation disorder, NCS, no change from baseline
		422	Screening-2	21MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 5 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1780-1005	GENERAL - SPEECH/LANGUAGE	427	Day 1-2/ PRE-DOSE	26MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		427	Day 1-2/ 4 HOUR POST-DOSE	26MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		427	Day 1-2/ 6 HOUR POST-DOSE	26MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		428	Day 2-2	27MAR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		434	Day 8-2	02APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		455	Day 29-2/ PRE-DOSE	23APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		455	Day 29-2/ 4 HOUR POST-DOSE	23APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		455	Day 29-2/ 6 HOUR POST-DOSE	23APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		461	Day 36-2	29APR2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		511	Day 85-2/ PRE-DOSE	18JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		511	Day 85-2/ 4 HOUR POST-DOSE	18JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		511	Day 85-2/ 6 HOUR POST-DOSE	18JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		517	Day 92-2	24JUN2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER
		601	Day 169-2	16SEP2013	ABNORMAL	DEVELOPMENTAL ARTICULATION AND LANGUAGE DISORDER: IMPROVED

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 6 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1780-1005	GENERAL - SPEECH/LANGUAGE	680	Day 253-2	04DEC2013	ABNORMAL	ARTICULATION AND LANGUAGE DISORDER UNCHANGED
		812	Screening-12	15APR2014	ABNORMAL	ARTICULATION ABNORMAL-MILD
		818	Day 1-12	21APR2014	ABNORMAL	ARTICULATION ABNORMAL -MILD
		818	Day 1-12/ 4 HOUR POST-DOSE	21APR2014	ABNORMAL	ARTICULATION ABNORMAL-MILD
		818	Day 1-12/ 6 HOUR POST-DOSE	21APR2014	ABNORMAL	ARTICULATION ABNORMAL-MILD
		825	Day 8-12	28APR2014	ABNORMAL	ARTICULATION
		903	Day 85-12	15JUL2014	ABNORMAL	ARTICULATION--MILD.
		987	Day 169-12	07OCT2014	ABNORMAL	ARTICULATIONS ABOUT MILD
		987	Day 169-12/ 4 HOUR POST-DOSE	07OCT2014	ABNORMAL	ARTICULATION ABOUT MILD
		987	Day 169-12/ 6 HOUR POST-DOSE	07OCT2014	ABNORMAL	MILD ARTICULATION
		1084	Day 260-12	12JAN2015	ABNORMAL	ARTICULATIONS ABOUT MILD
		1175	Day 351-12	13APR2015	ABNORMAL	MILD ARTICULATION
		1175	Day 351-12/ 4 HOUR POST-DOSE	13APR2015	ABNORMAL	ARTICULATION ABOUT MILD
		1175	Day 351-12/ 6 HOUR POST-DOSE	13APR2015	ABNORMAL	ARTICULATION ABOUT MILD
		1269	Day 442-12	16JUL2015	ABNORMAL	ARTICULATION
		1344	Day 533-12	29SEP2015	ABNORMAL	MILD ARTICULATION
		1344	Day 533-12/ 4 HOUR POST-DOSE	29SEP2015	ABNORMAL	MILD ARTICULATION
		1344	Day 533-12/ 6 HOUR POST-DOSE	29SEP2015	ABNORMAL	MILD ARTICULATION
		1444	Day 624-12	07JAN2016	ABNORMAL	MILD ARTICULATION
		1533	Day 715-12	05APR2016	ABNORMAL	MILD ARTICULATION

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 7 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS1 /1780-4006	REFLEXES - ANKLE - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - ANKLE - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BICEPS - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BICEPS - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BRACHIORADIALIS - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - BRACHIORADIALIS - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - KNEE - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - KNEE - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - TRICEPS - LEFT - REFLEX	1148	Day 533-12	15SEP2015	0	
	REFLEXES - TRICEPS - RIGHT - REFLEX	1148	Day 533-12	15SEP2015	0	
396443-CS2 /1775-3204	CRANIAL NERVES - EYE MOVEMENT	260	Day 253-2	15JAN2014	ABNORMAL	VERY SLLIGHT STRABISIMUS ON RIGHT OTHERWISE NORMAL

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 8 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2 /1778-1208	CRANIAL NERVES - VISION	-8	Screening-2	27NOV2012	ABNORMAL	MYOPIA, WEARS CONTACT LENSES
		1	Day 1-2/ PRE-DOSE	05DEC2012	ABNORMAL	MYOPIA
		1	Day 1-2/ 4 HOUR POST-DOSE	05DEC2012	ABNORMAL	MYOPIA
		1	Day 1-2/ 6 HOUR POST-DOSE	05DEC2012	ABNORMAL	MYOPIA
		2	Day 2-2	06DEC2012	ABNORMAL	MYOPIA
		8	Day 8-2	12DEC2012	ABNORMAL	MYOPIA - WEARS CONTACT LENSES
		29	Day 29-2/ PRE-DOSE	02JAN2013	ABNORMAL	MYOPIA
		29	Day 29-2/ 4 HOUR POST-DOSE	02JAN2013	ABNORMAL	MYOPIA
		29	Day 29-2/ 6 HOUR POST-DOSE	02JAN2013	ABNORMAL	MYOPIA
		35	Day 36-2	08JAN2013	ABNORMAL	MYOPIA
		86	Day 85-2/ PRE-DOSE	28FEB2013	ABNORMAL	MYOPIA.WEARING GLASSES.
		86	Day 85-2/ 4 HOUR POST-DOSE	28FEB2013	ABNORMAL	MYOPIA, WEARS GLASSES
		86	Day 85-2/ 6 HOUR POST-DOSE	28FEB2013	ABNORMAL	MYOPIA, WEARS GLASSES
		92	Day 92-2	06MAR2013	ABNORMAL	MYOPIA, WEARS GLASSES
		170	Day 169-2	23MAY2013	ABNORMAL	MYOPIA
		251	Day 253-2	12AUG2013	ABNORMAL	MYOPIA

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 9 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2 /1778-2206	PLANTAR RESPONSE - TOE - LEFT - REFLEX	30	Day 29-2/ PRE-DOSE	10APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
		30	Day 29-2/ 4 HOUR POST-DOSE	10APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
		30	Day 29-2/ 6 HOUR POST-DOSE	10APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
		37	Day 36-2	17APR2013	ABNORMAL	EXTENSOR PLANTAR RESPONSE
396443-CS2 /1778-3207	CRANIAL NERVES - VISION	-9	Screening-2	14MAY2013	ABNORMAL	MYOPIA
		1	Day 1-2/ PRE-DOSE	23MAY2013	ABNORMAL	MYOPIA
		1	Day 1-2/ 4 HOUR POST-DOSE	23MAY2013	ABNORMAL	MYOPIA
		1	Day 1-2/ 6 HOUR POST-DOSE	23MAY2013	ABNORMAL	MYOPIA
		2	Day 2-2	24MAY2013	ABNORMAL	MYOPIA
		7	Day 8-2	29MAY2013	ABNORMAL	MYOPIA
		36	Day 36-2	27JUN2013	ABNORMAL	MYOPIA
		79	Day 85-2/ PRE-DOSE	09AUG2013	ABNORMAL	MYOPIA
		79	Day 85-2/ 4 HOUR POST-DOSE	09AUG2013	ABNORMAL	MYOPIA
		79	Day 85-2/ 6 HOUR POST-DOSE	09AUG2013	ABNORMAL	MYOPIA
		85	Day 92-2	15AUG2013	ABNORMAL	MYOPIA
		168	Day 169-2	06NOV2013	ABNORMAL	MYOPIA
		253	Day 253-2	30JAN2014	ABNORMAL	MYOPIA

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 10 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2 /1780-1201	MOTOR SYSTEM - DORSIFLEXION - FOOT - LEFT - MUSCLE TONE	2	Day 2-2	17OCT2012	ABNORMAL	SECONDARY TO IV PLACEMENT AND REMOVAL.ANXIOUS, WOULD NOT COOPERATE.
396443-CS2 /1780-3205	GENERAL - SPEECH/LANGUAGE	-5	Screening-2	08MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		1	Day 1-2/ PRE-DOSE	13MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		1	Day 1-2/ 4 HOUR POST-DOSE	13MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		1	Day 1-2/ 6 HOUR POST-DOSE	13MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		2	Day 2-2	14MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		9	Day 8-2	21MAY2013	ABNORMAL	ARTICULATION ABNORMALITIES
		37	Day 36-2	18JUN2013	ABNORMAL	ARTICULATION ABNORMALITIES
		86	Day 85-2/ PRE-DOSE	06AUG2013	ABNORMAL	ARTICULATION ABNORMALITIES
		86	Day 85-2/ 4 HOUR POST-DOSE	06AUG2013	ABNORMAL	ARTICULATION ABNORMALITIES
		86	Day 85-2/ 6 HOUR POST-DOSE	06AUG2013	ABNORMAL	ARTICULATION ABNORMALITIES
		92	Day 92-2	12AUG2013	ABNORMAL	IMPROVED SPEECH ARTICULATION FROM BASELINE
		166	Day 169-2	25OCT2013	ABNORMAL	ARTICULATION ABNORMALITIES
		256	Day 253-2	23JAN2014	ABNORMAL	ARTICULATION ABNORMALITIES
		337	Screening-12	14APR2014	ABNORMAL	ARTICULATION
		341	Day 1-12	18APR2014	ABNORMAL	ARTICULATION

SOURCE: [redacted]20[redacted] DATE: [redacted]20[redacted]

Subject Listing of Neurological Tests Performed that were not Secondary to SMA with Their Findings
Page 11 of 11

Unique Subject ID	Neurological Exam	Day	Visit/ Time Point	Visit Date	Abnormility Finding	Abnormility Finding Description
396443-CS2	GENERAL - SPEECH/LANGUAGE /1780-3205	341	Day 1-12/ 4 HOUR POST-DOSE	18APR2014	ABNORMAL	ARTICULATION
		341	Day 1-12/ 6 HOUR POST-DOSE	18APR2014	ABNORMAL	ARTICULATION
		347	Day 8-12	24APR2014	ABNORMAL	ARTICULATION
		428	Day 85-12	14JUL2014	ABNORMAL	ARTICULATION
		690	Day 351-12	02APR2015	ABNORMAL	ARTICULATION
		690	Day 351-12/ 4 HOUR POST-DOSE	02APR2015	ABNORMAL	ARTICULATION
		690	Day 351-12/ 6 HOUR POST-DOSE	02APR2015	ABNORMAL	ARTICULATION
		787	Day 442-12	08JUL2015	ABNORMAL	ARTICULATION
		877	Day 533-12	06OCT2015	ABNORMAL	ARTICULATION
		877	Day 533-12/ 4 HOUR POST-DOSE	06OCT2015	ABNORMAL	ARTICULATION
		877	Day 533-12/ 6 HOUR POST-DOSE	06OCT2015	ABNORMAL	ARTICULATION
		968	Day 624-12	05JAN2016	ABNORMAL	ARTICULATION
		1059	Day 715-12	05APR2016	ABNORMAL	ARTICULATION

SOURCE: [redacted] DATE: [redacted]
[redacted]

表 163 Infantile-Onset Subjects Treated With ISIS 396443 in Controlled and Uncontrolled Studies: Incidence of Adverse Events by Age at First Dose

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 1 of 17

	<90 days of age	>=90 days of age
Number of subjects dosed	10 (100.0)	90 (100.0)
Number of subjects with an event	10 (100.0)	87 (96.7)
感染症および寄生虫症	8 (80.0)	76 (84.4)
上気道感染	2 (20.0)	34 (37.8)
肺炎	3 (30.0)	27 (30.0)
鼻咽頭炎	3 (30.0)	18 (20.0)
ライノウイルス感染	1 (10.0)	15 (16.7)
気道感染	2 (20.0)	12 (13.3)
ウイルス感染	1 (10.0)	11 (12.2)
細気管支炎	1 (10.0)	10 (11.1)
ウイルス性上気道感染	0	10 (11.1)
ウイルス性肺炎	1 (10.0)	9 (10.0)
口腔カンジダ症	0	8 (8.9)
中耳炎	2 (20.0)	7 (7.8)
気管支炎	0	6 (6.7)
インフルエンザ	0	6 (6.7)
尿路感染	1 (10.0)	6 (6.7)
結膜炎	1 (10.0)	5 (5.6)
耳感染	1 (10.0)	5 (5.6)
ＲＳウイルス細気管支炎	0	5 (5.6)
ウイルス性気道感染	0	5 (5.6)
ウイルス性気管支炎	1 (10.0)	4 (4.4)
下気道感染	1 (10.0)	4 (4.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 2 of 17

	<90 days of age	>=90 days of age
細菌性肺炎	0	4 (4.4)
シュードモナス感染	0	3 (3.3)
アデノウイルス感染	0	2 (2.2)
細菌感染	0	2 (2.2)
細菌性気管炎	1 (10.0)	2 (2.2)
カンジダ性おむつ皮疹	0	2 (2.2)
細菌性結膜炎	0	2 (2.2)
エンテロウイルス感染	0	2 (2.2)
皮膚真菌感染	0	2 (2.2)
胃腸炎	0	2 (2.2)
ウイルス性下気道感染	1 (10.0)	2 (2.2)
メタニューモウイルス感染	0	2 (2.2)
パラインフルエンザウイルス感染	0	2 (2.2)
モラクセラ菌性肺炎	0	2 (2.2)
鼻炎	1 (10.0)	2 (2.2)
敗血症	0	2 (2.2)
皮膚カンジダ	0	2 (2.2)
ストーマ部膿瘍	0	2 (2.2)
細菌性疾患キャリアー	0	1 (1.1)
蜂巣炎	0	1 (1.1)
感染性湿疹	0	1 (1.1)
蟯虫症	0	1 (1.1)
腸球菌感染	0	1 (1.1)
伝染性紅斑	0	1 (1.1)
大腸菌感染	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 3 of 17

	<90 days of age	>=90 days of age
眼感染	0	1 (1.1)
真菌感染	0	1 (1.1)
ウイルス性胃炎	0	1 (1.1)
ロタウイルス胃腸炎	0	1 (1.1)
ウイルス性胃腸炎	0	1 (1.1)
ヘモフィルス感染	0	1 (1.1)
手足口病	1 (10.0)	1 (1.1)
膿痂疹	0	1 (1.1)
限局性感染	0	1 (1.1)
肺感染	0	1 (1.1)
モラクセラ感染	1 (10.0)	1 (1.1)
粘膜皮膚カンジダ症	0	1 (1.1)
院内感染	0	1 (1.1)
口腔真菌感染	0	1 (1.1)
口腔ヘルペス	0	1 (1.1)
急性中耳炎	0	1 (1.1)
レンサ球菌性咽頭炎	0	1 (1.1)
インフルエンザ性肺炎	0	1 (1.1)
パラインフルエンザウイルス性肺炎	0	1 (1.1)
肺炎球菌性肺炎	0	1 (1.1)
シュードモナス菌性肺炎	0	1 (1.1)
ＲＳウイルス肺炎	0	1 (1.1)
腎盂腎炎	0	1 (1.1)
細菌性気道感染	0	1 (1.1)
ばら疹	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose

	<90 days of age	>=90 days of age
ブドウ球菌感染	0	1 (1.1)
ブドウ球菌性敗血症	0	1 (1.1)
ブドウ球菌皮膚感染	0	1 (1.1)
ストーマ部感染	0	1 (1.1)
気管炎	0	1 (1.1)
アデノウイルス性上気道感染	1 (10.0)	0
コロナウイルス感染	1 (10.0)	0
ブドウ球菌性菌血症	1 (10.0)	0
呼吸器、胸郭および縦隔障害	7 (70.0)	72 (80.0)
呼吸窮迫	2 (20.0)	26 (28.9)
呼吸不全	3 (30.0)	23 (25.6)
無気肺	1 (10.0)	22 (24.4)
急性呼吸不全	1 (10.0)	14 (15.6)
咳嗽	2 (20.0)	13 (14.4)
鼻閉	2 (20.0)	13 (14.4)
誤嚥性肺炎	0	12 (13.3)
低酸素症	1 (10.0)	10 (11.1)
呼吸困難	0	9 (10.0)
鼻漏	0	8 (8.9)
気管支分泌物貯留	0	7 (7.8)
上気道うっ血	0	7 (7.8)
呼吸停止	0	6 (6.7)
無呼吸	2 (20.0)	5 (5.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 5 of 17

	<90 days of age	>=90 days of age
誤嚥	2 (20.0)	5 (5.6)
慢性呼吸不全	1 (10.0)	5 (5.6)
上気道分泌増加	1 (10.0)	4 (4.4)
低換気	0	3 (3.3)
気胸	0	3 (3.3)
副鼻腔うっ血	1 (10.0)	3 (3.3)
喘鳴	1 (10.0)	3 (3.3)
息詰まり	0	2 (2.2)
肺うっ血	0	2 (2.2)
呼吸障害	0	2 (2.2)
気道うっ血	0	2 (2.2)
アレルギー性鼻炎	0	2 (2.2)
急性呼吸窮迫症候群	0	1 (1.1)
無呼吸発作	0	1 (1.1)
窒息	0	1 (1.1)
気管支閉塞	0	1 (1.1)
高炭酸ガス血症	0	1 (1.1)
減呼吸	0	1 (1.1)
気管支分泌増加	0	1 (1.1)
喉頭肉芽腫	0	1 (1.1)
肺障害	0	1 (1.1)
鼻汁変色	0	1 (1.1)
閉塞性気道障害	0	1 (1.1)
胸水	0	1 (1.1)
湿性咳嗽	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 6 of 17

	<90 days of age	>=90 days of age
肺水腫	1 (10.0)	1 (1.1)
呼吸性アルカローシス	0	1 (1.1)
拘束性肺疾患	0	1 (1.1)
睡眠時無呼吸症候群	0	1 (1.1)
変色痰	0	1 (1.1)
頻呼吸	0	1 (1.1)
気管障害	0	1 (1.1)
呼吸補助筋の動員	1 (10.0)	1 (1.1)
気縦隔症	1 (10.0)	0
低音性連続性ラ音	1 (10.0)	0
胃腸障害	8 (80.0)	63 (70.0)
便秘	6 (60.0)	31 (34.4)
嘔吐	3 (30.0)	19 (21.1)
生歯	1 (10.0)	17 (18.9)
下痢	1 (10.0)	15 (16.7)
胃食道逆流性疾患	2 (20.0)	14 (15.6)
嚥下障害	1 (10.0)	8 (8.9)
流涎過多	1 (10.0)	7 (7.8)
腹部膨満	0	4 (4.4)
放屁	2 (20.0)	4 (4.4)
胃炎	0	4 (4.4)
腹部不快感	0	2 (2.2)
アフタ性潰瘍	0	1 (1.1)
口唇のひび割れ	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 7 of 17

	<90 days of age	>=90 days of age
排便回数増加	0	1 (1.1)
胃出血	0	1 (1.1)
消化管運動低下	0	1 (1.1)
吐血	0	1 (1.1)
血便排泄	1 (10.0)	1 (1.1)
胃排出不全	0	1 (1.1)
乳児仙痛	0	1 (1.1)
乳児吐出	0	1 (1.1)
上部消化管出血	0	1 (1.1)
腹痛	1 (10.0)	0
一般・全身障害および投与部位の状態	5 (50.0)	60 (66.7)
発熱	5 (50.0)	54 (60.0)
疼痛	1 (10.0)	4 (4.4)
末梢性浮腫	0	2 (2.2)
カテーテル留置部位炎症	0	1 (1.1)
泣き	0	1 (1.1)
死亡	0	1 (1.1)
医療機器閉塞	1 (10.0)	1 (1.1)
不快感	1 (10.0)	1 (1.1)
薬物不耐性	0	1 (1.1)
全身健康状態低下	0	1 (1.1)
低体温	0	1 (1.1)
ワクチン接種後の易刺激性	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 8 of 17

	<90 days of age	>=90 days of age
倦怠感	0	1 (1.1)
医療機器合併症	0	1 (1.1)
小結節	0	1 (1.1)
浮腫	0	1 (1.1)
末梢腫脹	0	1 (1.1)
外科手術不成功	0	1 (1.1)
腫脹	0	1 (1.1)
医療機器リーク	1 (10.0)	0
血管穿刺部位内出血	1 (10.0)	0
皮膚および皮下組織障害	5 (50.0)	32 (35.6)
発疹	2 (20.0)	12 (13.3)
おむつ皮膚炎	2 (20.0)	8 (8.9)
湿疹	1 (10.0)	3 (3.3)
皮膚刺激	0	3 (3.3)
接触性皮膚炎	1 (10.0)	2 (2.2)
斑状出血	1 (10.0)	2 (2.2)
過剰肉芽組織	1 (10.0)	2 (2.2)
過角化	0	2 (2.2)
汗疹	0	2 (2.2)
脱毛症	0	1 (1.1)
皮膚炎	1 (10.0)	1 (1.1)
アレルギー性皮膚炎	0	1 (1.1)
皮膚乾燥	0	1 (1.1)
紅斑	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 9 of 17

	<90 days of age	>=90 days of age
環状肉芽腫	0	1 (1.1)
間擦疹	0	1 (1.1)
点状出血	0	1 (1.1)
そう痒症	0	1 (1.1)
斑状皮疹	0	1 (1.1)
丘疹性皮疹	0	1 (1.1)
皮膚色素脱失	0	1 (1.1)
皮膚障害	0	1 (1.1)
皮膚浮腫	0	1 (1.1)
皮膚潰瘍	0	1 (1.1)
蕁麻疹	0	1 (1.1)
皮下気腫	1 (10.0)	0
傷害、中毒および処置合併症	3 (30.0)	27 (30.0)
節足動物咬傷	0	4 (4.4)
処置による疼痛	0	4 (4.4)
栄養補給チューブ合併症	1 (10.0)	3 (3.3)
大腿骨骨折	0	3 (3.3)
ストーマ部紅斑	0	3 (3.3)
挫傷	0	2 (2.2)
術後激越	0	1 (1.1)
麻酔からの覚醒遅延	0	1 (1.1)
ダンピング症候群	0	1 (1.1)
伝染病曝露	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 10 of 17

	<90 days of age	>=90 days of age
関節脱臼	1 (10.0)	1 (1.1)
口唇損傷	0	1 (1.1)
処置後腫脹	0	1 (1.1)
処置合併症	0	1 (1.1)
皮膚擦過傷	1 (10.0)	1 (1.1)
軟部組織損傷	0	1 (1.1)
ストーマ合併症	0	1 (1.1)
ストーマ部刺激感	0	1 (1.1)
サンバーン	0	1 (1.1)
熱傷	0	1 (1.1)
歯牙損傷	0	1 (1.1)
ワクチン接種合併症	0	1 (1.1)
耳擦過傷	1 (10.0)	0
擦過傷	1 (10.0)	0
外傷性気胸	1 (10.0)	0
処置部位反応	1 (10.0)	0
臨床検査	1 (10.0)	27 (30.0)
酸素飽和度低下	0	12 (13.3)
体重減少	0	6 (6.7)
ヒトライノウイルス検査陽性	0	3 (3.3)
血中カリウム減少	0	2 (2.2)
体温上昇	0	2 (2.2)
Ｃ－反応性蛋白増加	0	2 (2.2)
心拍数増加	0	2 (2.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 11 of 17

	<90 days of age	>=90 days of age
医学的観察	0	2 (2.2)
モラクセラ検査陽性	0	2 (2.2)
好中球数増加	1 (10.0)	2 (2.2)
シュードモナス検査陽性	0	2 (2.2)
ブドウ球菌検査陽性	0	2 (2.2)
アラニンアミノトランスフェラーゼ増加	0	1 (1.1)
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (1.1)
血中クロール減少	0	1 (1.1)
血中鉄減少	0	1 (1.1)
血中ナトリウム減少	0	1 (1.1)
体温低下	0	1 (1.1)
呼吸音異常	0	1 (1.1)
心電図ＳＴ－Ｔ部分異常	0	1 (1.1)
心拍数減少	0	1 (1.1)
心拍数不整	0	1 (1.1)
炎症マーカー上昇	0	1 (1.1)
Ａ型インフルエンザウイルス検査陽性	0	1 (1.1)
肝機能検査異常	0	1 (1.1)
好中球百分率増加	0	1 (1.1)
整形外科検査	0	1 (1.1)
セラチア検査陽性	0	1 (1.1)
レンサ球菌検査陽性	0	1 (1.1)
尿量減少	0	1 (1.1)
ビタミンＡ減少	0	1 (1.1)
白血球数増加	1 (10.0)	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 12 of 17

	<90 days of age	>=90 days of age
骨密度減少	1 (10.0)	0
心臓障害	2 (20.0)	22 (24.4)
頻脈	0	9 (10.0)
徐脈	1 (10.0)	6 (6.7)
心肺停止	0	6 (6.7)
心停止	0	3 (3.3)
チアノーゼ	0	3 (3.3)
左室肥大	0	2 (2.2)
心室性頻脈	0	2 (2.2)
洞性頻脈	0	1 (1.1)
上室性頻脈	0	1 (1.1)
心筋症	1 (10.0)	0
心膜気腫	1 (10.0)	0
筋骨格系および結合組織障害	4 (40.0)	21 (23.3)
側弯症	1 (10.0)	10 (11.1)
関節拘縮	2 (20.0)	9 (10.0)
脊柱後弯症	1 (10.0)	4 (4.4)
胸郭変形	1 (10.0)	3 (3.3)
後側弯症	0	2 (2.2)
頭位性斜頭症	0	2 (2.2)
斜頚	0	2 (2.2)
背部痛	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 13 of 17

	<90 days of age	>=90 days of age
泉門閉鎖遅延	0	1 (1.1)
手変形	0	1 (1.1)
関節硬直	0	1 (1.1)
四肢痛	1 (10.0)	1 (1.1)
脊柱変形	0	1 (1.1)
滑膜炎	0	1 (1.1)
脊柱前弯症	1 (10.0)	0
代謝および栄養障害	2 (20.0)	17 (18.9)
体重増加不良	0	6 (6.7)
成長障害	1 (10.0)	3 (3.3)
乳児および小児期早期の哺育障害	0	3 (3.3)
栄養補給不耐性	0	3 (3.3)
過小食	0	2 (2.2)
脱水	0	1 (1.1)
低ナトリウム血症	1 (10.0)	1 (1.1)
鉄欠乏	0	1 (1.1)
代謝性アルカローシス	0	1 (1.1)
神経系障害	4 (40.0)	14 (15.6)
眼振	0	3 (3.3)
よだれ	0	2 (2.2)
不随意性筋収縮	2 (20.0)	2 (2.2)
脳損傷	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 14 of 17

	<90 days of age	>=90 days of age
脳脊髄液漏	0	1 (1.1)
間代	0	1 (1.1)
頭痛	0	1 (1.1)
言語障害	0	1 (1.1)
嗜眠	0	1 (1.1)
痙攣発作	1 (10.0)	1 (1.1)
傾眠	0	1 (1.1)
失神	0	1 (1.1)
脳梗塞	1 (10.0)	0
低酸素性虚血性脳症	1 (10.0)	0
精神障害	1 (10.0)	11 (12.2)
不安	1 (10.0)	4 (4.4)
易刺激性	0	3 (3.3)
激越	0	2 (2.2)
息こらえ	0	1 (1.1)
気分動揺	0	1 (1.1)
落ち着きのなさ	0	1 (1.1)
睡眠障害	0	1 (1.1)
免疫系障害	3 (30.0)	10 (11.1)
季節性アレルギー	1 (10.0)	5 (5.6)
薬物過敏症	1 (10.0)	3 (3.3)
過敏症	0	2 (2.2)
食物アレルギー	1 (10.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 15 of 17

	<90 days of age	>=90 days of age
血管障害	1 (10.0)	7 (7.8)
毛細血管脆弱	0	1 (1.1)
本態性高血圧症	0	1 (1.1)
高血圧	1 (10.0)	1 (1.1)
蒼白	0	1 (1.1)
ショック	0	1 (1.1)
血栓症	0	1 (1.1)
血管炎	0	1 (1.1)
眼障害	0	6 (6.7)
乱視	0	1 (1.1)
霰粒腫	0	1 (1.1)
眼乾燥	0	1 (1.1)
眼運動障害	0	1 (1.1)
眼瞼下垂	0	1 (1.1)
近視	0	1 (1.1)
斜視	0	1 (1.1)
先天性、家族性および遺伝性障害	2 (20.0)	5 (5.6)
先天性横隔膜ヘルニア	0	1 (1.1)
発育性股関節形成不全	0	1 (1.1)
貧血母斑	0	1 (1.1)
鳩胸	0	1 (1.1)
斜頭症	1 (10.0)	1 (1.1)
斜指症	1 (10.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 16 of 17

	<90 days of age	>=90 days of age
血液およびリンパ系障害	2 (20.0)	4 (4.4)
貧血	0	3 (3.3)
リンパ節症	0	1 (1.1)
好中球減少症	1 (10.0)	0
血小板増加症	1 (10.0)	0
生殖系および乳房障害	0	4 (4.4)
後天性包茎	0	1 (1.1)
亀頭包皮炎	0	1 (1.1)
卵巣嚢胞	0	1 (1.1)
陰茎障害	0	1 (1.1)
耳および迷路障害	0	3 (3.3)
耳の障害	0	1 (1.1)
耳痛	0	1 (1.1)
耳垢分泌過多	0	1 (1.1)
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	0	2 (2.2)
アクロコルドン	0	1 (1.1)
血管の良性新生物	0	1 (1.1)
腎および尿路障害	1 (10.0)	1 (1.1)
尿閉	0	1 (1.1)
水腎症	1 (10.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by age at first dose
Page 17 of 17

	<90 days of age	>=90 days of age
外科および内科処置	0	1 (1.1)
機械的換気	0	1 (1.1)
肝胆道系障害	1 (10.0)	0
肝腫大	1 (10.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 164　Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443: Incidence of Adverse Events by Age at First Dose

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 1 of 18

	<90 days of age	>=90 days of age
Number of subjects dosed	30 (100.0)	90 (100.0)
Number of subjects with an event	26 (86.7)	87 (96.7)
感染症および寄生虫症	21 (70.0)	76 (84.4)
上気道感染	10 (33.3)	34 (37.8)
肺炎	5 (16.7)	27 (30.0)
鼻咽頭炎	7 (23.3)	18 (20.0)
ライノウイルス感染	3 (10.0)	15 (16.7)
気道感染	2 (6.7)	12 (13.3)
ウイルス感染	1 (3.3)	11 (12.2)
細気管支炎	2 (6.7)	10 (11.1)
ウイルス性上気道感染	0	10 (11.1)
ウイルス性肺炎	2 (6.7)	9 (10.0)
口腔カンジダ症	0	8 (8.9)
中耳炎	5 (16.7)	7 (7.8)
気管支炎	1 (3.3)	6 (6.7)
インフルエンザ	3 (10.0)	6 (6.7)
尿路感染	2 (6.7)	6 (6.7)
結膜炎	1 (3.3)	5 (5.6)
耳感染	1 (3.3)	5 (5.6)
ＲＳウイルス細気管支炎	0	5 (5.6)
ウイルス性気道感染	0	5 (5.6)
ウイルス性気管支炎	1 (3.3)	4 (4.4)
下気道感染	1 (3.3)	4 (4.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 2 of 18

	<90 days of age	>=90 days of age
細菌性肺炎	0	4 (4.4)
シュードモナス感染	0	3 (3.3)
アデノウイルス感染	0	2 (2.2)
細菌感染	0	2 (2.2)
細菌性気管炎	1 (3.3)	2 (2.2)
カンジダ性おむつ皮疹	0	2 (2.2)
細菌性結膜炎	0	2 (2.2)
エンテロウイルス感染	0	2 (2.2)
皮膚真菌感染	0	2 (2.2)
胃腸炎	0	2 (2.2)
ウイルス性下気道感染	1 (3.3)	2 (2.2)
メタニューモウイルス感染	0	2 (2.2)
パラインフルエンザウイルス感染	0	2 (2.2)
モラクセラ菌性肺炎	0	2 (2.2)
鼻炎	3 (10.0)	2 (2.2)
敗血症	0	2 (2.2)
皮膚カンジダ	0	2 (2.2)
ストーマ部膿瘍	0	2 (2.2)
細菌性疾患キャリアー	0	1 (1.1)
蜂巣炎	0	1 (1.1)
感染性湿疹	0	1 (1.1)
蟯虫症	0	1 (1.1)
腸球菌感染	0	1 (1.1)
伝染性紅斑	0	1 (1.1)
大腸菌感染	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 3 of 18

	<90 days of age	>=90 days of age
眼感染	0	1 (1.1)
真菌感染	0	1 (1.1)
ウイルス性胃炎	0	1 (1.1)
ロタウイルス胃腸炎	0	1 (1.1)
ウイルス性胃腸炎	2 (6.7)	1 (1.1)
ヘモフィルス感染	0	1 (1.1)
手足口病	1 (3.3)	1 (1.1)
膿痂疹	1 (3.3)	1 (1.1)
限局性感染	0	1 (1.1)
肺感染	0	1 (1.1)
モラクセラ感染	1 (3.3)	1 (1.1)
粘膜皮膚カンジダ症	0	1 (1.1)
院内感染	0	1 (1.1)
口腔真菌感染	0	1 (1.1)
口腔ヘルペス	0	1 (1.1)
急性中耳炎	0	1 (1.1)
レンサ球菌性咽頭炎	1 (3.3)	1 (1.1)
インフルエンザ性肺炎	0	1 (1.1)
パラインフルエンザウイルス性肺炎	0	1 (1.1)
肺炎球菌性肺炎	0	1 (1.1)
シュードモナス菌性肺炎	0	1 (1.1)
ＲＳウイルス肺炎	0	1 (1.1)
腎盂腎炎	0	1 (1.1)
細菌性気道感染	0	1 (1.1)
ばら疹	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 4 of 18

	<90 days of age	>=90 days of age
ブドウ球菌感染	0	1 (1.1)
ブドウ球菌性敗血症	0	1 (1.1)
ブドウ球菌皮膚感染	0	1 (1.1)
ストーマ部感染	0	1 (1.1)
気管炎	0	1 (1.1)
アデノウイルス性上気道感染	1 (3.3)	0
コロナウイルス感染	1 (3.3)	0
ブドウ球菌性耳感染	1 (3.3)	0
皮膚感染	1 (3.3)	0
ブドウ球菌性菌血症	1 (3.3)	0
レンサ球菌感染	1 (3.3)	0
呼吸器、胸郭および縦隔障害	13 (43.3)	72 (80.0)
呼吸窮迫	3 (10.0)	26 (28.9)
呼吸不全	3 (10.0)	23 (25.6)
無気肺	1 (3.3)	22 (24.4)
急性呼吸不全	1 (3.3)	14 (15.6)
咳嗽	5 (16.7)	13 (14.4)
鼻閉	5 (16.7)	13 (14.4)
誤嚥性肺炎	0	12 (13.3)
低酸素症	1 (3.3)	10 (11.1)
呼吸困難	0	9 (10.0)
鼻漏	3 (10.0)	8 (8.9)
気管支分泌物貯留	0	7 (7.8)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 5 of 18

	<90 days of age	>=90 days of age
上気道うっ血	1 (3.3)	7 (7.8)
呼吸停止	0	6 (6.7)
無呼吸	2 (6.7)	5 (5.6)
誤嚥	2 (6.7)	5 (5.6)
慢性呼吸不全	1 (3.3)	5 (5.6)
上気道分泌増加	1 (3.3)	4 (4.4)
低換気	0	3 (3.3)
気胸	0	3 (3.3)
副鼻腔うっ血	1 (3.3)	3 (3.3)
喘鳴	1 (3.3)	3 (3.3)
息詰まり	1 (3.3)	2 (2.2)
肺うっ血	0	2 (2.2)
呼吸障害	0	2 (2.2)
気道うっ血	0	2 (2.2)
アレルギー性鼻炎	0	2 (2.2)
急性呼吸窮迫症候群	0	1 (1.1)
無呼吸発作	0	1 (1.1)
窒息	0	1 (1.1)
気管支閉塞	0	1 (1.1)
高炭酸ガス血症	0	1 (1.1)
減呼吸	0	1 (1.1)
気管支分泌増加	0	1 (1.1)
喉頭肉芽腫	0	1 (1.1)
肺障害	0	1 (1.1)
鼻汁変色	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 6 of 18

	<90 days of age	>=90 days of age
閉塞性気道障害	0	1 (1.1)
胸水	0	1 (1.1)
湿性咳嗽	0	1 (1.1)
肺水腫	1 (3.3)	1 (1.1)
呼吸性アルカローシス	0	1 (1.1)
拘束性肺疾患	0	1 (1.1)
睡眠時無呼吸症候群	0	1 (1.1)
変色痰	0	1 (1.1)
頻呼吸	0	1 (1.1)
気管障害	0	1 (1.1)
呼吸補助筋の動員	1 (3.3)	1 (1.1)
気縦隔症	1 (3.3)	0
呼吸性アシドーシス	1 (3.3)	0
低音性連続性ラ音	1 (3.3)	0
胃腸障害	16 (53.3)	63 (70.0)
便秘	8 (26.7)	31 (34.4)
嘔吐	3 (10.0)	19 (21.1)
生歯	2 (6.7)	17 (18.9)
下痢	2 (6.7)	15 (16.7)
胃食道逆流性疾患	4 (13.3)	14 (15.6)
嚥下障害	2 (6.7)	8 (8.9)
流涎過多	1 (3.3)	7 (7.8)
腹部膨満	2 (6.7)	4 (4.4)
放屁	4 (13.3)	4 (4.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 7 of 18

	<90 days of age	>=90 days of age
胃炎	0	4 (4.4)
腹部不快感	1 (3.3)	2 (2.2)
アフタ性潰瘍	0	1 (1.1)
口唇のひび割れ	0	1 (1.1)
排便回数増加	0	1 (1.1)
胃出血	0	1 (1.1)
消化管運動低下	0	1 (1.1)
吐血	0	1 (1.1)
血便排泄	1 (3.3)	1 (1.1)
胃排出不全	0	1 (1.1)
乳児仙痛	0	1 (1.1)
乳児吐出	0	1 (1.1)
上部消化管出血	0	1 (1.1)
腹痛	1 (3.3)	0
一般・全身障害および投与部位の状態	11 (36.7)	60 (66.7)
発熱	10 (33.3)	54 (60.0)
疼痛	1 (3.3)	4 (4.4)
末梢性浮腫	0	2 (2.2)
カテーテル留置部位炎症	0	1 (1.1)
泣き	0	1 (1.1)
死亡	0	1 (1.1)
医療機器閉塞	1 (3.3)	1 (1.1)
不快感	1 (3.3)	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 8 of 18

	<90 days of age	>=90 days of age
薬物不耐性	0	1 (1.1)
全身健康状態低下	0	1 (1.1)
低体温	0	1 (1.1)
ワクチン接種後の易刺激性	0	1 (1.1)
倦怠感	0	1 (1.1)
医療機器合併症	0	1 (1.1)
小結節	0	1 (1.1)
浮腫	0	1 (1.1)
末梢腫脹	0	1 (1.1)
外科手術不成功	0	1 (1.1)
腫脹	0	1 (1.1)
適用部位紅斑	1 (3.3)	0
医療機器リーク	1 (3.3)	0
注入部位内出血	1 (3.3)	0
血管穿刺部位内出血	1 (3.3)	0
皮膚および皮下組織障害	14 (46.7)	32 (35.6)
発疹	3 (10.0)	12 (13.3)
おむつ皮膚炎	4 (13.3)	8 (8.9)
湿疹	1 (3.3)	3 (3.3)
皮膚刺激	0	3 (3.3)
接触性皮膚炎	1 (3.3)	2 (2.2)
斑状出血	1 (3.3)	2 (2.2)
過剰肉芽組織	1 (3.3)	2 (2.2)
過角化	0	2 (2.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 9 of 18

	<90 days of age	>=90 days of age
汗疹	0	2 (2.2)
脱毛症	0	1 (1.1)
皮膚炎	3 (10.0)	1 (1.1)
アレルギー性皮膚炎	0	1 (1.1)
皮膚乾燥	0	1 (1.1)
紅斑	1 (3.3)	1 (1.1)
環状肉芽腫	0	1 (1.1)
間擦疹	0	1 (1.1)
点状出血	1 (3.3)	1 (1.1)
そう痒症	0	1 (1.1)
斑状皮疹	0	1 (1.1)
丘疹性皮疹	0	1 (1.1)
皮膚色素脱失	0	1 (1.1)
皮膚障害	0	1 (1.1)
皮膚浮腫	0	1 (1.1)
皮膚潰瘍	0	1 (1.1)
蕁麻疹	0	1 (1.1)
貨幣状湿疹	1 (3.3)	0
紅斑性皮疹	1 (3.3)	0
脂漏性皮膚炎	1 (3.3)	0
皮下気腫	1 (3.3)	0
傷害、中毒および処置合併症	6 (20.0)	27 (30.0)
節足動物咬傷	1 (3.3)	4 (4.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 10 of 18

	<90 days of age	>=90 days of age
処置による疼痛	0	4 (4.4)
栄養補給チューブ合併症	1 (3.3)	3 (3.3)
大腿骨骨折	0	3 (3.3)
ストーマ部紅斑	0	3 (3.3)
挫傷	0	2 (2.2)
術後激越	0	1 (1.1)
麻酔からの覚醒遅延	0	1 (1.1)
ダンピング症候群	0	1 (1.1)
伝染病曝露	0	1 (1.1)
関節脱臼	1 (3.3)	1 (1.1)
口唇損傷	0	1 (1.1)
処置後腫脹	1 (3.3)	1 (1.1)
処置合併症	0	1 (1.1)
皮膚擦過傷	1 (3.3)	1 (1.1)
軟部組織損傷	0	1 (1.1)
ストーマ合併症	0	1 (1.1)
ストーマ部刺激感	0	1 (1.1)
サンバーン	0	1 (1.1)
熱傷	0	1 (1.1)
歯牙損傷	0	1 (1.1)
ワクチン接種合併症	0	1 (1.1)
耳擦過傷	1 (3.3)	0
擦過傷	1 (3.3)	0
転倒	1 (3.3)	0
外傷性気胸	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 11 of 18

	<90 days of age	>=90 days of age
処置後合併症	1 (3.3)	0
処置後不快感	1 (3.3)	0
処置部位反応	1 (3.3)	0
硬膜下血腫	1 (3.3)	0
臨床検査	4 (13.3)	27 (30.0)
酸素飽和度低下	1 (3.3)	12 (13.3)
体重減少	0	6 (6.7)
ヒトライノウイルス検査陽性	0	3 (3.3)
血中カリウム減少	0	2 (2.2)
体温上昇	1 (3.3)	2 (2.2)
Ｃ－反応性蛋白増加	0	2 (2.2)
心拍数増加	0	2 (2.2)
医学的観察	0	2 (2.2)
モラクセラ検査陽性	0	2 (2.2)
好中球数増加	1 (3.3)	2 (2.2)
シュードモナス検査陽性	0	2 (2.2)
ブドウ球菌検査陽性	0	2 (2.2)
アラニンアミノトランスフェラーゼ増加	1 (3.3)	1 (1.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (3.3)	1 (1.1)
血中クロール減少	0	1 (1.1)
血中鉄減少	0	1 (1.1)
血中ナトリウム減少	0	1 (1.1)
体温低下	0	1 (1.1)
呼吸音異常	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 12 of 18

	<90 days of age	>=90 days of age
心電図ＳＴ－Ｔ部分異常	0	1 (1.1)
心拍数減少	0	1 (1.1)
心拍数不整	0	1 (1.1)
炎症マーカー上昇	0	1 (1.1)
Ａ型インフルエンザウイルス検査陽性	0	1 (1.1)
肝機能検査異常	0	1 (1.1)
好中球百分率増加	0	1 (1.1)
整形外科検査	0	1 (1.1)
セラチア検査陽性	0	1 (1.1)
レンサ球菌検査陽性	0	1 (1.1)
尿量減少	0	1 (1.1)
ビタミンＡ減少	0	1 (1.1)
白血球数増加	2 (6.7)	1 (1.1)
血中アルカリホスファターゼ増加	1 (3.3)	0
骨密度減少	1 (3.3)	0
好酸球数増加	1 (3.3)	0
リンパ球数増加	1 (3.3)	0
心臓障害	4 (13.3)	22 (24.4)
頻脈	2 (6.7)	9 (10.0)
徐脈	1 (3.3)	6 (6.7)
心肺停止	0	6 (6.7)
心停止	0	3 (3.3)
チアノーゼ	0	3 (3.3)
左室肥大	0	2 (2.2)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 13 of 18

	<90 days of age	>=90 days of age
心室性頻脈	0	2 (2.2)
洞性頻脈	0	1 (1.1)
上室性頻脈	0	1 (1.1)
心筋症	1 (3.3)	0
心膜気腫	1 (3.3)	0
筋骨格系および結合組織障害	7 (23.3)	21 (23.3)
側弯症	1 (3.3)	10 (11.1)
関節拘縮	3 (10.0)	9 (10.0)
脊柱後弯症	1 (3.3)	4 (4.4)
胸郭変形	1 (3.3)	3 (3.3)
後側弯症	0	2 (2.2)
頭位性斜頭症	1 (3.3)	2 (2.2)
斜頚	1 (3.3)	2 (2.2)
背部痛	0	1 (1.1)
泉門閉鎖遅延	0	1 (1.1)
手変形	0	1 (1.1)
関節硬直	0	1 (1.1)
四肢痛	1 (3.3)	1 (1.1)
脊柱変形	0	1 (1.1)
滑膜炎	0	1 (1.1)
脊柱前弯症	1 (3.3)	0
筋力低下	2 (6.7)	0
体重支持困難	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 14 of 18

	<90 days of age	>=90 days of age
代謝および栄養障害	6 (20.0)	17 (18.9)
体重増加不良	1 (3.3)	6 (6.7)
成長障害	3 (10.0)	3 (3.3)
乳児および小児期早期の哺育障害	0	3 (3.3)
栄養補給不耐性	0	3 (3.3)
過小食	0	2 (2.2)
脱水	2 (6.7)	1 (1.1)
低ナトリウム血症	1 (3.3)	1 (1.1)
鉄欠乏	0	1 (1.1)
代謝性アルカローシス	0	1 (1.1)
神経系障害	7 (23.3)	14 (15.6)
眼振	0	3 (3.3)
よだれ	0	2 (2.2)
不随意性筋収縮	2 (6.7)	2 (2.2)
脳損傷	0	1 (1.1)
脳脊髄液漏	0	1 (1.1)
間代	0	1 (1.1)
頭痛	0	1 (1.1)
言語障害	0	1 (1.1)
嗜眠	0	1 (1.1)
痙攣発作	1 (3.3)	1 (1.1)
傾眠	0	1 (1.1)
失神	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 15 of 18

	<90 days of age	>=90 days of age
脳梗塞	1 (3.3)	0
反射亢進	1 (3.3)	0
筋緊張低下	2 (6.7)	0
低酸素性虚血性脳症	1 (3.3)	0
精神障害	1 (3.3)	11 (12.2)
不安	1 (3.3)	4 (4.4)
易刺激性	0	3 (3.3)
激越	0	2 (2.2)
息こらえ	0	1 (1.1)
気分動揺	0	1 (1.1)
落ち着きのなさ	0	1 (1.1)
睡眠障害	0	1 (1.1)
免疫系障害	5 (16.7)	10 (11.1)
季節性アレルギー	2 (6.7)	5 (5.6)
薬物過敏症	1 (3.3)	3 (3.3)
過敏症	0	2 (2.2)
食物アレルギー	2 (6.7)	0
血管障害	3 (10.0)	7 (7.8)
毛細血管脆弱	0	1 (1.1)
本態性高血圧症	0	1 (1.1)
高血圧	2 (6.7)	1 (1.1)
蒼白	1 (3.3)	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 16 of 18

	<90 days of age	>=90 days of age
ショック	0	1 (1.1)
血栓症	0	1 (1.1)
血管炎	0	1 (1.1)
眼障害	1 (3.3)	6 (6.7)
乱視	0	1 (1.1)
霰粒腫	0	1 (1.1)
眼乾燥	0	1 (1.1)
眼運動障害	0	1 (1.1)
眼瞼下垂	0	1 (1.1)
近視	0	1 (1.1)
斜視	0	1 (1.1)
後天性涙道狭窄	1 (3.3)	0
先天性、家族性および遺伝性障害	2 (6.7)	5 (5.6)
先天性横隔膜ヘルニア	0	1 (1.1)
発育性股関節形成不全	0	1 (1.1)
貧血母斑	0	1 (1.1)
鳩胸	0	1 (1.1)
斜頭症	1 (3.3)	1 (1.1)
斜指症	1 (3.3)	0
血液およびリンパ系障害	4 (13.3)	4 (4.4)
貧血	0	3 (3.3)
リンパ節症	0	1 (1.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 17 of 18

	<90 days of age	>=90 days of age
好酸球増加症	1 (3.3)	0
好中球減少症	2 (6.7)	0
血小板増加症	1 (3.3)	0
生殖系および乳房障害	1 (3.3)	4 (4.4)
後天性包茎	0	1 (1.1)
亀頭包皮炎	0	1 (1.1)
卵巣嚢胞	0	1 (1.1)
陰茎障害	0	1 (1.1)
外陰腟発疹	1 (3.3)	0
耳および迷路障害	0	3 (3.3)
耳の障害	0	1 (1.1)
耳痛	0	1 (1.1)
耳垢分泌過多	0	1 (1.1)
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	1 (3.3)	2 (2.2)
アクロコルドン	0	1 (1.1)
血管の良性新生物	0	1 (1.1)
脂漏性角化症	1 (3.3)	0
腎および尿路障害	1 (3.3)	1 (1.1)
尿閉	0	1 (1.1)
水腎症	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by age at first dose
Page 18 of 18

	<90 days of age	>=90 days of age
外科および内科処置	0	1 (1.1)
機械的換気	0	1 (1.1)
肝胆道系障害	1 (3.3)	0
肝腫大	1 (3.3)	0
妊娠、産褥および周産期の状態	1 (3.3)	0
臍肉芽腫	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 65　Later-Onset Subjects:Incidence of Adverse Events by Age at First Dose

Later-onset subjects: incidence of adverse events by age at first dose
Page 1 of 9

	<6 years of age	>=6 years of age
Number of subjects dosed	28 (100.0)	28 (100.0)
Number of subjects with an event	28 (100.0)	28 (100.0)
傷害、中毒および処置合併症	18 (64.3)	22 (78.6)
腰椎穿刺後症候群	6 (21.4)	17 (60.7)
処置による疼痛	1 (3.6)	5 (17.9)
裂傷	5 (17.9)	2 (7.1)
節足動物咬傷	2 (7.1)	1 (3.6)
節足動物刺傷	0	1 (3.6)
挫傷	1 (3.6)	1 (3.6)
大腿骨骨折	2 (7.1)	1 (3.6)
頭部損傷	0	1 (3.6)
関節損傷	1 (3.6)	1 (3.6)
靭帯捻挫	0	1 (3.6)
四肢損傷	2 (7.1)	1 (3.6)
半月板損傷	0	1 (3.6)
肉離れ	0	1 (3.6)
術後イレウス	0	1 (3.6)
処置による頭痛	0	1 (3.6)
処置による悪心	1 (3.6)	1 (3.6)
サンバーン	1 (3.6)	1 (3.6)
脛骨骨折	0	1 (3.6)
隆起骨折	1 (3.6)	1 (3.6)
術後激越	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 2 of 9

	<6 years of age	>=6 years of age
転倒	1 (3.6)	0
関節脱臼	2 (7.1)	0
下肢骨折	1 (3.6)	0
熱傷	1 (3.6)	0
感染症および寄生虫症	23 (82.1)	21 (75.0)
上気道感染	14 (50.0)	13 (46.4)
鼻咽頭炎	7 (25.0)	9 (32.1)
胃腸炎	2 (7.1)	5 (17.9)
レンサ球菌性咽頭炎	3 (10.7)	5 (17.9)
限局性感染	0	3 (10.7)
副鼻腔炎	0	3 (10.7)
尿路感染	1 (3.6)	3 (10.7)
ウイルス性胃腸炎	6 (21.4)	2 (7.1)
インフルエンザ	1 (3.6)	2 (7.1)
中耳炎	3 (10.7)	2 (7.1)
肺炎	3 (10.7)	2 (7.1)
ウイルス感染	7 (25.0)	2 (7.1)
ウイルス性上気道感染	3 (10.7)	2 (7.1)
蜂巣炎	0	1 (3.6)
結膜炎	2 (7.1)	1 (3.6)
ブドウ球菌性眼感染	0	1 (3.6)
皮膚真菌感染	0	1 (3.6)
ウイルス性消化管感染	1 (3.6)	1 (3.6)
膿痂疹	0	1 (3.6)
急性中耳炎	0	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 3 of 9

	<6 years of age	>=6 years of age
ＲＳウイルス感染	2 (7.1)	1 (3.6)
皮膚カンジダ	1 (3.6)	1 (3.6)
扁桃炎	0	1 (3.6)
外陰膣真菌感染	0	1 (3.6)
耳感染	4 (14.3)	0
ウイルス性眼感染	1 (3.6)	0
手足口病	1 (3.6)	0
下気道感染	1 (3.6)	0
伝染性軟属腫	1 (3.6)	0
単核細胞症症候群	1 (3.6)	0
咽頭炎	1 (3.6)	0
ＲＳウイルス肺炎	1 (3.6)	0
ウイルス性肺炎	2 (7.1)	0
ＲＳウイルス細気管支炎	1 (3.6)	0
気道感染	1 (3.6)	0
ウイルス性気道感染	1 (3.6)	0
鼻炎	1 (3.6)	0
皮膚細菌感染	1 (3.6)	0
膣感染	1 (3.6)	0
ウイルス性扁桃炎	1 (3.6)	0
筋骨格系および結合組織障害	21 (75.0)	20 (71.4)
背部痛	8 (28.6)	15 (53.6)
側弯症	6 (21.4)	9 (32.1)
四肢痛	2 (7.1)	3 (10.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 4 of 9

	<6 years of age	>=6 years of age
関節痛	3 (10.7)	2 (7.1)
関節拘縮	8 (28.6)	2 (7.1)
頚部痛	1 (3.6)	2 (7.1)
脊柱前弯症	0	1 (3.6)
筋肉痛	3 (10.7)	1 (3.6)
骨盤変形	1 (3.6)	1 (3.6)
四肢拘縮	1 (3.6)	0
筋緊張	2 (7.1)	0
神経系障害	10 (35.7)	20 (71.4)
頭痛	9 (32.1)	19 (67.9)
感覚鈍麻	0	2 (7.1)
失声症	0	1 (3.6)
失読症	0	1 (3.6)
片頭痛	0	1 (3.6)
錯感覚	0	1 (3.6)
失神	0	1 (3.6)
味覚異常	1 (3.6)	0
振戦	1 (3.6)	0
一般・全身障害および投与部位の状態	16 (57.1)	15 (53.6)
穿刺部位疼痛	3 (10.7)	7 (25.0)
発熱	12 (42.9)	4 (14.3)
疲労	1 (3.6)	2 (7.1)
疼痛	0	2 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 5 of 9

	<6 years of age	>=6 years of age
カテーテル留置部位出血	0	1 (3.6)
カテーテル留置部位疼痛	0	1 (3.6)
胸部不快感	0	1 (3.6)
悪寒	0	1 (3.6)
重力性浮腫	0	1 (3.6)
注射部位疼痛	0	1 (3.6)
末梢腫脹	0	1 (3.6)
穿刺部位反応	0	1 (3.6)
血管穿刺部位内出血	0	1 (3.6)
カテーテル留置部位関連反応	1 (3.6)	0
冷感	1 (3.6)	0
低体温	1 (3.6)	0
注射部位出血	1 (3.6)	0
胃腸障害	15 (53.6)	11 (39.3)
悪心	6 (21.4)	4 (14.3)
嘔吐	8 (28.6)	4 (14.3)
腹痛	0	2 (7.1)
アフタ性潰瘍	1 (3.6)	2 (7.1)
口腔内痛	0	2 (7.1)
腹部不快感	0	1 (3.6)
腹部症状	0	1 (3.6)
食中毒	0	1 (3.6)
胃腸障害	0	1 (3.6)
胃食道逆流性疾患	0	1 (3.6)
口の感覚鈍麻	0	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 6 of 9

	<6 years of age	>=6 years of age
上腹部痛	2 (7.1)	0
便秘	7 (25.0)	0
下痢	2 (7.1)	0
放屁	1 (3.6)	0
口唇痛	1 (3.6)	0
口内炎	1 (3.6)	0
呼吸器、胸郭および縦隔障害	14 (50.0)	11 (39.3)
口腔咽頭痛	2 (7.1)	6 (21.4)
咳嗽	3 (10.7)	3 (10.7)
副鼻腔うっ血	0	2 (7.1)
鼻出血	2 (7.1)	1 (3.6)
鼻閉	2 (7.1)	1 (3.6)
肺うっ血	0	1 (3.6)
鼻漏	5 (17.9)	1 (3.6)
扁桃肥大	2 (7.1)	1 (3.6)
急性呼吸不全	1 (3.6)	0
無気肺	1 (3.6)	0
発声障害	1 (3.6)	0
呼吸困難	1 (3.6)	0
低酸素症	3 (10.7)	0
肺臓炎	1 (3.6)	0
呼吸障害	1 (3.6)	0
呼吸不全	1 (3.6)	0
拘束性肺疾患	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 7 of 9

	<6 years of age	>=6 years of age
喘鳴	1 (3.6)	0
皮膚および皮下組織障害	11 (39.3)	6 (21.4)
湿疹	0	2 (7.1)
ざ瘡	0	1 (3.6)
皮膚炎	0	1 (3.6)
接触性皮膚炎	2 (7.1)	1 (3.6)
毛孔性角化症	0	1 (3.6)
水疱	1 (3.6)	0
褥瘡性潰瘍	1 (3.6)	0
おむつ皮膚炎	1 (3.6)	0
紅斑	1 (3.6)	0
汗疹	1 (3.6)	0
寝汗	1 (3.6)	0
発疹	1 (3.6)	0
皮膚病変	1 (3.6)	0
蕁麻疹	1 (3.6)	0
免疫系障害	2 (7.1)	5 (17.9)
過敏症	0	3 (10.7)
薬物過敏症	0	1 (3.6)
季節性アレルギー	2 (7.1)	1 (3.6)
臨床検査	3 (10.7)	5 (17.9)
体重減少	1 (3.6)	2 (7.1)
血中重炭酸塩減少	0	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 8 of 9

	<6 years of age	>=6 years of age
血中テストステロン減少	0	1 (3.6)
ＣＳＦ白血球数増加	0	1 (3.6)
心拍数増加	0	1 (3.6)
体温上昇	1 (3.6)	0
尿検査異常	1 (3.6)	0
精神障害	0	4 (14.3)
激越	0	2 (7.1)
注意欠陥多動性障害	0	1 (3.6)
不快気分	0	1 (3.6)
不眠症	0	1 (3.6)
睡眠時随伴症	0	1 (3.6)
チック	0	1 (3.6)
心因性嘔吐	0	1 (3.6)
代謝および栄養障害	3 (10.7)	2 (7.1)
食欲減退	0	1 (3.6)
ビタミンＤ欠乏	0	1 (3.6)
脱水	2 (7.1)	0
食欲亢進	1 (3.6)	0
血液およびリンパ系障害	0	1 (3.6)
好中球減少症	0	1 (3.6)
心臓障害	2 (7.1)	1 (3.6)
動悸	1 (3.6)	1 (3.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by age at first dose
Page 9 of 9

	<6 years of age	>=6 years of age
頻脈	1 (3.6)	0
眼障害	1 (3.6)	1 (3.6)
遠視	0	1 (3.6)
斜視	1 (3.6)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	1 (3.6)
皮膚乳頭腫	0	1 (3.6)
腎および尿路障害	2 (7.1)	1 (3.6)
膀胱尿管逆流	0	1 (3.6)
排尿困難	1 (3.6)	0
尿失禁	1 (3.6)	0
耳および迷路障害	3 (10.7)	0
耳痛	1 (3.6)	0
乗物酔い	1 (3.6)	0
鼓膜穿孔	1 (3.6)	0
血管障害	1 (3.6)	0
低血圧	1 (3.6)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 166 Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443: Incidence of Adverse Events by Sex

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 1 of 18

	Male	Female
Number of subjects dosed	60 (100.0)	60 (100.0)
Number of subjects with an event	56 (93.3)	57 (95.0)
感染症および寄生虫症	47 (78.3)	50 (83.3)
上気道感染	22 (36.7)	22 (36.7)
鼻咽頭炎	15 (25.0)	10 (16.7)
肺炎	13 (21.7)	19 (31.7)
ライノウイルス感染	11 (18.3)	7 (11.7)
中耳炎	8 (13.3)	4 (6.7)
細気管支炎	7 (11.7)	5 (8.3)
気道感染	6 (10.0)	8 (13.3)
ウイルス感染	6 (10.0)	6 (10.0)
ウイルス性肺炎	5 (8.3)	6 (10.0)
気管支炎	4 (6.7)	3 (5.0)
ウイルス性上気道感染	4 (6.7)	6 (10.0)
ウイルス性気管支炎	3 (5.0)	2 (3.3)
下気道感染	3 (5.0)	2 (3.3)
口腔カンジダ症	3 (5.0)	5 (8.3)
ウイルス性気道感染	3 (5.0)	2 (3.3)
鼻炎	3 (5.0)	2 (3.3)
細菌性気管炎	2 (3.3)	1 (1.7)
結膜炎	2 (3.3)	4 (6.7)
耳感染	2 (3.3)	4 (6.7)
ウイルス性胃腸炎	2 (3.3)	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 2 of 18

	Male	Female
インフルエンザ	2 (3.3)	7 (11.7)
ウイルス性下気道感染	2 (3.3)	1 (1.7)
レンサ球菌性咽頭炎	2 (3.3)	0
シュードモナス感染	2 (3.3)	1 (1.7)
ＲＳウイルス細気管支炎	2 (3.3)	3 (5.0)
敗血症	2 (3.3)	0
皮膚カンジダ	2 (3.3)	0
尿路感染	2 (3.3)	6 (10.0)
アデノウイルス性上気道感染	1 (1.7)	0
アデノウイルス感染	1 (1.7)	1 (1.7)
カンジダ性おむつ皮疹	1 (1.7)	1 (1.7)
コロナウイルス感染	1 (1.7)	0
ブドウ球菌性耳感染	1 (1.7)	0
感染性湿疹	1 (1.7)	0
眼感染	1 (1.7)	0
真菌感染	1 (1.7)	0
ウイルス性胃炎	1 (1.7)	0
手足口病	1 (1.7)	1 (1.7)
膿痂疹	1 (1.7)	1 (1.7)
限局性感染	1 (1.7)	0
メタニューモウイルス感染	1 (1.7)	1 (1.7)
モラクセラ感染	1 (1.7)	1 (1.7)
口腔ヘルペス	1 (1.7)	0
急性中耳炎	1 (1.7)	0
パラインフルエンザウイルス感染	1 (1.7)	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 3 of 18

	Male	Female
細菌性肺炎	1 (1.7)	3 (5.0)
モラクセラ菌性肺炎	1 (1.7)	1 (1.7)
ＲＳウイルス肺炎	1 (1.7)	0
腎盂腎炎	1 (1.7)	0
細菌性気道感染	1 (1.7)	0
ばら疹	1 (1.7)	0
皮膚感染	1 (1.7)	0
ブドウ球菌性菌血症	1 (1.7)	0
ブドウ球菌皮膚感染	1 (1.7)	0
ストーマ部感染	1 (1.7)	0
レンサ球菌感染	1 (1.7)	0
細菌性疾患キャリアー	0	1 (1.7)
細菌感染	0	2 (3.3)
蜂巣炎	0	1 (1.7)
細菌性結膜炎	0	2 (3.3)
蟯虫症	0	1 (1.7)
腸球菌感染	0	1 (1.7)
エンテロウイルス感染	0	2 (3.3)
伝染性紅斑	0	1 (1.7)
大腸菌感染	0	1 (1.7)
皮膚真菌感染	0	2 (3.3)
胃腸炎	0	2 (3.3)
ロタウイルス胃腸炎	0	1 (1.7)
ヘモフィルス感染	0	1 (1.7)
肺感染	0	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex

	Male	Female
粘膜皮膚カンジダ症	0	1 (1.7)
院内感染	0	1 (1.7)
口腔真菌感染	0	1 (1.7)
インフルエンザ性肺炎	0	1 (1.7)
パラインフルエンザウイルス性肺炎	0	1 (1.7)
肺炎球菌性肺炎	0	1 (1.7)
シュードモナス菌性肺炎	0	1 (1.7)
ブドウ球菌感染	0	1 (1.7)
ブドウ球菌性敗血症	0	1 (1.7)
ストーマ部膿瘍	0	2 (3.3)
気管炎	0	1 (1.7)
呼吸器、胸郭および縦隔障害	44 (73.3)	41 (68.3)
呼吸窮迫	14 (23.3)	15 (25.0)
呼吸不全	14 (23.3)	12 (20.0)
咳嗽	10 (16.7)	8 (13.3)
急性呼吸不全	8 (13.3)	7 (11.7)
鼻閉	8 (13.3)	10 (16.7)
無気肺	7 (11.7)	16 (26.7)
低酸素症	6 (10.0)	5 (8.3)
無呼吸	5 (8.3)	2 (3.3)
上気道うっ血	5 (8.3)	3 (5.0)
気管支分泌物貯留	4 (6.7)	3 (5.0)
呼吸困難	4 (6.7)	5 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 5 of 18

	Male	Female
呼吸停止	4 (6.7)	2 (3.3)
鼻漏	4 (6.7)	7 (11.7)
誤嚥	3 (5.0)	4 (6.7)
慢性呼吸不全	2 (3.3)	4 (6.7)
低換気	2 (3.3)	1 (1.7)
上気道分泌増加	2 (3.3)	3 (5.0)
誤嚥性肺炎	2 (3.3)	10 (16.7)
気道うっ血	2 (3.3)	0
副鼻腔うっ血	2 (3.3)	2 (3.3)
無呼吸発作	1 (1.7)	0
窒息	1 (1.7)	0
息詰まり	1 (1.7)	2 (3.3)
鼻汁変色	1 (1.7)	0
閉塞性気道障害	1 (1.7)	0
気縦隔症	1 (1.7)	0
肺うっ血	1 (1.7)	1 (1.7)
肺水腫	1 (1.7)	1 (1.7)
呼吸性アルカローシス	1 (1.7)	0
呼吸障害	1 (1.7)	1 (1.7)
アレルギー性鼻炎	1 (1.7)	1 (1.7)
低音性連続性ラ音	1 (1.7)	0
変色痰	1 (1.7)	0
呼吸補助筋の動員	1 (1.7)	1 (1.7)
喘鳴	1 (1.7)	3 (5.0)
急性呼吸窮迫症候群	0	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 6 of 18

	Male	Female
気管支閉塞	0	1 (1.7)
高炭酸ガス血症	0	1 (1.7)
減呼吸	0	1 (1.7)
気管支分泌増加	0	1 (1.7)
喉頭肉芽腫	0	1 (1.7)
肺障害	0	1 (1.7)
胸水	0	1 (1.7)
気胸	0	3 (5.0)
湿性咳嗽	0	1 (1.7)
呼吸性アシドーシス	0	1 (1.7)
拘束性肺疾患	0	1 (1.7)
睡眠時無呼吸症候群	0	1 (1.7)
頻呼吸	0	1 (1.7)
気管障害	0	1 (1.7)
胃腸障害	40 (66.7)	39 (65.0)
便秘	19 (31.7)	20 (33.3)
生歯	11 (18.3)	8 (13.3)
嘔吐	10 (16.7)	12 (20.0)
胃食道逆流性疾患	9 (15.0)	9 (15.0)
下痢	8 (13.3)	9 (15.0)
嚥下障害	5 (8.3)	5 (8.3)
流涎過多	5 (8.3)	3 (5.0)
放屁	4 (6.7)	4 (6.7)
腹部不快感	2 (3.3)	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 7 of 18

	Male	Female
腹部膨満	2 (3.3)	4 (6.7)
腹痛	1 (1.7)	0
胃炎	1 (1.7)	3 (5.0)
消化管運動低下	1 (1.7)	0
胃排出不全	1 (1.7)	0
乳児仙痛	1 (1.7)	0
乳児吐出	1 (1.7)	0
アフタ性潰瘍	0	1 (1.7)
口唇のひび割れ	0	1 (1.7)
排便回数増加	0	1 (1.7)
胃出血	0	1 (1.7)
吐血	0	1 (1.7)
血便排泄	0	2 (3.3)
上部消化管出血	0	1 (1.7)
一般・全身障害および投与部位の状態	36 (60.0)	35 (58.3)
発熱	31 (51.7)	33 (55.0)
疼痛	4 (6.7)	1 (1.7)
医療機器閉塞	2 (3.3)	0
不快感	2 (3.3)	0
末梢性浮腫	2 (3.3)	0
適用部位紅斑	1 (1.7)	0
医療機器リーク	1 (1.7)	0
薬物不耐性	1 (1.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex

	Male	Female
全身健康状態低下	1 (1.7)	0
注入部位内出血	1 (1.7)	0
倦怠感	1 (1.7)	0
浮腫	1 (1.7)	0
血管穿刺部位内出血	1 (1.7)	0
カテーテル留置部位炎症	0	1 (1.7)
泣き	0	1 (1.7)
死亡	0	1 (1.7)
低体温	0	1 (1.7)
ワクチン接種後の易刺激性	0	1 (1.7)
医療機器合併症	0	1 (1.7)
小結節	0	1 (1.7)
末梢腫脹	0	1 (1.7)
外科手術不成功	0	1 (1.7)
腫脹	0	1 (1.7)
皮膚および皮下組織障害	24 (40.0)	22 (36.7)
発疹	8 (13.3)	7 (11.7)
おむつ皮膚炎	6 (10.0)	6 (10.0)
湿疹	4 (6.7)	0
皮膚炎	3 (5.0)	1 (1.7)
斑状出血	2 (3.3)	1 (1.7)
紅斑	2 (3.3)	0
汗疹	2 (3.3)	0
アレルギー性皮膚炎	1 (1.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 9 of 18

	Male	Female
接触性皮膚炎	1 (1.7)	2 (3.3)
皮膚乾燥	1 (1.7)	0
過剰肉芽組織	1 (1.7)	2 (3.3)
紅斑性皮疹	1 (1.7)	0
斑状皮疹	1 (1.7)	0
丘疹性皮疹	1 (1.7)	0
皮膚色素脱失	1 (1.7)	0
皮膚刺激	1 (1.7)	2 (3.3)
皮膚浮腫	1 (1.7)	0
皮下気腫	1 (1.7)	0
脱毛症	0	1 (1.7)
貨幣状湿疹	0	1 (1.7)
環状肉芽腫	0	1 (1.7)
過角化	0	2 (3.3)
間擦疹	0	1 (1.7)
点状出血	0	2 (3.3)
そう痒症	0	1 (1.7)
脂漏性皮膚炎	0	1 (1.7)
皮膚障害	0	1 (1.7)
皮膚潰瘍	0	1 (1.7)
蕁麻疹	0	1 (1.7)
傷害、中毒および処置合併症	19 (31.7)	14 (23.3)
節足動物咬傷	5 (8.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 10 of 18

	Male	Female
栄養補給チューブ合併症	3 (5.0)	1 (1.7)
関節脱臼	2 (3.3)	0
処置後腫脹	2 (3.3)	0
皮膚擦過傷	2 (3.3)	0
ストーマ部紅斑	2 (3.3)	1 (1.7)
挫傷	1 (1.7)	1 (1.7)
ダンピング症候群	1 (1.7)	0
耳擦過傷	1 (1.7)	0
擦過傷	1 (1.7)	0
伝染病曝露	1 (1.7)	0
転倒	1 (1.7)	0
大腿骨骨折	1 (1.7)	2 (3.3)
口唇損傷	1 (1.7)	0
外傷性気胸	1 (1.7)	0
処置後不快感	1 (1.7)	0
処置による疼痛	1 (1.7)	3 (5.0)
処置部位反応	1 (1.7)	0
ストーマ部刺激感	1 (1.7)	0
硬膜下血腫	1 (1.7)	0
サンバーン	1 (1.7)	0
熱傷	1 (1.7)	0
歯牙損傷	1 (1.7)	0
術後激越	0	1 (1.7)
麻酔からの覚醒遅延	0	1 (1.7)
処置後合併症	0	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex

	Male	Female
処置合併症	0	1 (1.7)
軟部組織損傷	0	1 (1.7)
ストーマ合併症	0	1 (1.7)
ワクチン接種合併症	0	1 (1.7)
臨床検査	16 (26.7)	15 (25.0)
酸素飽和度低下	6 (10.0)	7 (11.7)
体重減少	4 (6.7)	2 (3.3)
白血球数増加	3 (5.0)	0
アラニンアミノトランスフェラーゼ増加	2 (3.3)	0
アスパラギン酸アミノトランスフェラーゼ増加	2 (3.3)	0
血中カリウム減少	2 (3.3)	0
好中球数増加	2 (3.3)	1 (1.7)
血中アルカリホスファターゼ増加	1 (1.7)	0
血中クロール減少	1 (1.7)	0
血中ナトリウム減少	1 (1.7)	0
体温低下	1 (1.7)	0
体温上昇	1 (1.7)	2 (3.3)
骨密度減少	1 (1.7)	0
Ｃ－反応性蛋白増加	1 (1.7)	1 (1.7)
心電図ＳＴ－Ｔ部分異常	1 (1.7)	0
好酸球数増加	1 (1.7)	0
心拍数増加	1 (1.7)	1 (1.7)
ヒトライノウイルス検査陽性	1 (1.7)	2 (3.3)
Ａ型インフルエンザウイルス検査陽性	1 (1.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 12 of 18

	Male	Female
肝機能検査異常	1 (1.7)	0
リンパ球数増加	1 (1.7)	0
医学的観察	1 (1.7)	1 (1.7)
好中球百分率増加	1 (1.7)	0
整形外科検査	1 (1.7)	0
シュードモナス検査陽性	1 (1.7)	1 (1.7)
ブドウ球菌検査陽性	1 (1.7)	1 (1.7)
尿量減少	1 (1.7)	0
ビタミンA減少	1 (1.7)	0
血中鉄減少	0	1 (1.7)
呼吸音異常	0	1 (1.7)
心拍数減少	0	1 (1.7)
心拍数不整	0	1 (1.7)
炎症マーカー上昇	0	1 (1.7)
モラクセラ検査陽性	0	2 (3.3)
セラチア検査陽性	0	1 (1.7)
レンサ球菌検査陽性	0	1 (1.7)
心臓障害	14 (23.3)	12 (20.0)
頻脈	6 (10.0)	5 (8.3)
徐脈	5 (8.3)	2 (3.3)
心停止	3 (5.0)	0
心肺停止	2 (3.3)	4 (6.7)
心筋症	1 (1.7)	0
左室肥大	1 (1.7)	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 13 of 18

	Male	Female
心膜気腫	1 (1.7)	0
チアノーゼ	0	3 (5.0)
洞性頻脈	0	1 (1.7)
上室性頻脈	0	1 (1.7)
心室性頻脈	0	2 (3.3)
筋骨格系および結合組織障害	13 (21.7)	15 (25.0)
関節拘縮	8 (13.3)	4 (6.7)
脊柱後弯症	4 (6.7)	1 (1.7)
側弯症	4 (6.7)	7 (11.7)
斜頚	2 (3.3)	1 (1.7)
胸郭変形	1 (1.7)	3 (5.0)
脊柱前弯症	1 (1.7)	0
筋力低下	1 (1.7)	1 (1.7)
四肢痛	1 (1.7)	1 (1.7)
頭位性斜頭症	1 (1.7)	2 (3.3)
脊柱変形	1 (1.7)	0
滑膜炎	1 (1.7)	0
体重支持困難	1 (1.7)	0
背部痛	0	1 (1.7)
泉門閉鎖遅延	0	1 (1.7)
手変形	0	1 (1.7)
関節硬直	0	1 (1.7)
後側弯症	0	2 (3.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 14 of 18

	Male	Female
神経系障害	11 (18.3)	10 (16.7)
筋緊張低下	2 (3.3)	0
不随意性筋収縮	2 (3.3)	2 (3.3)
脳梗塞	1 (1.7)	0
間代	1 (1.7)	0
よだれ	1 (1.7)	1 (1.7)
頭痛	1 (1.7)	0
低酸素性虚血性脳症	1 (1.7)	0
言語障害	1 (1.7)	0
眼振	1 (1.7)	2 (3.3)
痙攣発作	1 (1.7)	1 (1.7)
脳損傷	0	1 (1.7)
脳脊髄液漏	0	1 (1.7)
反射亢進	0	1 (1.7)
嗜眠	0	1 (1.7)
傾眠	0	1 (1.7)
失神	0	1 (1.7)
代謝および栄養障害	10 (16.7)	13 (21.7)
体重増加不良	5 (8.3)	2 (3.3)
成長障害	4 (6.7)	2 (3.3)
乳児および小児期早期の哺育障害	1 (1.7)	2 (3.3)
低ナトリウム血症	1 (1.7)	1 (1.7)
脱水	0	3 (5.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 15 of 18

	Male	Female
栄養補給不耐性	0	3 (5.0)
過小食	0	2 (3.3)
鉄欠乏	0	1 (1.7)
代謝性アルカローシス	0	1 (1.7)
精神障害	6 (10.0)	6 (10.0)
不安	4 (6.7)	1 (1.7)
息こらえ	1 (1.7)	0
易刺激性	1 (1.7)	2 (3.3)
落ち着きのなさ	1 (1.7)	0
睡眠障害	1 (1.7)	0
激越	0	2 (3.3)
気分動揺	0	1 (1.7)
血液およびリンパ系障害	5 (8.3)	3 (5.0)
貧血	2 (3.3)	1 (1.7)
リンパ節症	1 (1.7)	0
好中球減少症	1 (1.7)	1 (1.7)
血小板増加症	1 (1.7)	0
好酸球増加症	0	1 (1.7)
先天性、家族性および遺伝性障害	5 (8.3)	2 (3.3)
斜指症	1 (1.7)	0
先天性横隔膜ヘルニア	1 (1.7)	0
貧血母斑	1 (1.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 16 of 18

	Male	Female
鳩胸	1 (1.7)	0
斜頭症	1 (1.7)	1 (1.7)
発育性股関節形成不全	0	1 (1.7)
免疫系障害	5 (8.3)	10 (16.7)
季節性アレルギー	2 (3.3)	5 (8.3)
薬物過敏症	1 (1.7)	3 (5.0)
食物アレルギー	1 (1.7)	1 (1.7)
過敏症	1 (1.7)	1 (1.7)
眼障害	4 (6.7)	3 (5.0)
霰粒腫	1 (1.7)	0
後天性涙道狭窄	1 (1.7)	0
眼乾燥	1 (1.7)	0
眼瞼下垂	1 (1.7)	0
乱視	0	1 (1.7)
眼運動障害	0	1 (1.7)
近視	0	1 (1.7)
斜視	0	1 (1.7)
血管障害	4 (6.7)	6 (10.0)
高血圧	1 (1.7)	2 (3.3)
蒼白	1 (1.7)	1 (1.7)
血栓症	1 (1.7)	0
血管炎	1 (1.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 17 of 18

	Male	Female
毛細血管脆弱	0	1 (1.7)
本態性高血圧症	0	1 (1.7)
ショック	0	1 (1.7)
生殖系および乳房障害	3 (5.0)	2 (3.3)
後天性包茎	1 (1.7)	0
亀頭包皮炎	1 (1.7)	0
陰茎障害	1 (1.7)	0
卵巣嚢胞	0	1 (1.7)
外陰腟発疹	0	1 (1.7)
耳および迷路障害	2 (3.3)	1 (1.7)
耳の障害	1 (1.7)	0
耳痛	1 (1.7)	0
耳垢分泌過多	0	1 (1.7)
腎および尿路障害	2 (3.3)	0
水腎症	1 (1.7)	0
尿閉	1 (1.7)	0
肝胆道系障害	1 (1.7)	0
肝腫大	1 (1.7)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.7)	2 (3.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by sex
Page 18 of 18

	Male	Female
脂漏性角化症	1 (1.7)	0
アクロコルドン	0	1 (1.7)
血管の良性新生物	0	1 (1.7)
外科および内科処置	1 (1.7)	0
機械的換気	1 (1.7)	0
妊娠、産褥および周産期の状態	0	1 (1.7)
臍肉芽腫	0	1 (1.7)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 67　Later-Onset Subjects:Incidence of Adverse Events by Sex

Later-onset subjects: incidence of adverse events by sex
Page 1 of 9

	Male	Female
Number of subjects dosed	26 (100.0)	30 (100.0)
Number of subjects with an event	26 (100.0)	30 (100.0)
感染症および寄生虫症	22 (84.6)	22 (73.3)
上気道感染	11 (42.3)	16 (53.3)
鼻咽頭炎	6 (23.1)	10 (33.3)
レンサ球菌性咽頭炎	5 (19.2)	3 (10.0)
胃腸炎	4 (15.4)	3 (10.0)
耳感染	3 (11.5)	1 (3.3)
ウイルス性胃腸炎	3 (11.5)	5 (16.7)
副鼻腔炎	3 (11.5)	0
結膜炎	2 (7.7)	1 (3.3)
肺炎	2 (7.7)	3 (10.0)
ブドウ球菌性眼感染	1 (3.8)	0
ウイルス性眼感染	1 (3.8)	0
ウイルス性消化管感染	1 (3.8)	1 (3.3)
膿痂疹	1 (3.8)	0
インフルエンザ	1 (3.8)	2 (6.7)
伝染性軟属腫	1 (3.8)	0
中耳炎	1 (3.8)	4 (13.3)
ＲＳウイルス肺炎	1 (3.8)	0
ウイルス性肺炎	1 (3.8)	1 (3.3)
ＲＳウイルス細気管支炎	1 (3.8)	0
皮膚細菌感染	1 (3.8)	0
皮膚カンジダ	1 (3.8)	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 2 of 9

	Male	Female
尿路感染	1 (3.8)	3 (10.0)
ウイルス感染	1 (3.8)	8 (26.7)
ウイルス性上気道感染	1 (3.8)	4 (13.3)
蜂巣炎	0	1 (3.3)
皮膚真菌感染	0	1 (3.3)
手足口病	0	1 (3.3)
限局性感染	0	3 (10.0)
下気道感染	0	1 (3.3)
単核細胞症症候群	0	1 (3.3)
急性中耳炎	0	1 (3.3)
咽頭炎	0	1 (3.3)
ＲＳウイルス感染	0	3 (10.0)
気道感染	0	1 (3.3)
ウイルス性気道感染	0	1 (3.3)
鼻炎	0	1 (3.3)
扁桃炎	0	1 (3.3)
膣感染	0	1 (3.3)
ウイルス性扁桃炎	0	1 (3.3)
外陰膣真菌感染	0	1 (3.3)
傷害、中毒および処置合併症	17 (65.4)	23 (76.7)
腰椎穿刺後症候群	9 (34.6)	14 (46.7)
裂傷	3 (11.5)	4 (13.3)
大腿骨骨折	2 (7.7)	1 (3.3)
処置による疼痛	2 (7.7)	4 (13.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 3 of 9

	Male	Female
節足動物咬傷	1 (3.8)	2 (6.7)
関節損傷	1 (3.8)	1 (3.3)
靭帯捻挫	1 (3.8)	0
下肢骨折	1 (3.8)	0
術後イレウス	1 (3.8)	0
処置による頭痛	1 (3.8)	0
処置による悪心	1 (3.8)	1 (3.3)
熱傷	1 (3.8)	0
隆起骨折	1 (3.8)	1 (3.3)
術後激越	0	1 (3.3)
節足動物刺傷	0	1 (3.3)
挫傷	0	2 (6.7)
転倒	0	1 (3.3)
頭部損傷	0	1 (3.3)
関節脱臼	0	2 (6.7)
四肢損傷	0	3 (10.0)
半月板損傷	0	1 (3.3)
肉離れ	0	1 (3.3)
サンバーン	0	2 (6.7)
脛骨骨折	0	1 (3.3)
筋骨格系および結合組織障害	17 (65.4)	24 (80.0)
背部痛	9 (34.6)	14 (46.7)
側弯症	8 (30.8)	7 (23.3)
関節拘縮	4 (15.4)	6 (20.0)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 4 of 9

	Male	Female
筋肉痛	2 (7.7)	2 (6.7)
関節痛	1 (3.8)	4 (13.3)
脊柱前弯症	1 (3.8)	0
筋緊張	1 (3.8)	1 (3.3)
四肢拘縮	0	1 (3.3)
頚部痛	0	3 (10.0)
四肢痛	0	5 (16.7)
骨盤変形	0	2 (6.7)
一般・全身障害および投与部位の状態	16 (61.5)	15 (50.0)
発熱	10 (38.5)	6 (20.0)
穿刺部位疼痛	5 (19.2)	5 (16.7)
胸部不快感	1 (3.8)	0
疲労	1 (3.8)	2 (6.7)
冷感	1 (3.8)	0
低体温	1 (3.8)	0
注射部位出血	1 (3.8)	0
注射部位疼痛	1 (3.8)	0
疼痛	1 (3.8)	1 (3.3)
穿刺部位反応	1 (3.8)	0
カテーテル留置部位出血	0	1 (3.3)
カテーテル留置部位疼痛	0	1 (3.3)
カテーテル留置部位関連反応	0	1 (3.3)
悪寒	0	1 (3.3)
重力性浮腫	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 5 of 9

	Male	Female
末梢腫脹	0	1 (3.3)
血管穿刺部位内出血	0	1 (3.3)
神経系障害	16 (61.5)	14 (46.7)
頭痛	15 (57.7)	13 (43.3)
味覚異常	1 (3.8)	0
片頭痛	1 (3.8)	0
失神	1 (3.8)	0
振戦	1 (3.8)	0
失声症	0	1 (3.3)
失読症	0	1 (3.3)
感覚鈍麻	0	2 (6.7)
錯感覚	0	1 (3.3)
呼吸器、胸郭および縦隔障害	12 (46.2)	13 (43.3)
口腔咽頭痛	5 (19.2)	3 (10.0)
咳嗽	3 (11.5)	3 (10.0)
鼻漏	3 (11.5)	3 (10.0)
急性呼吸不全	1 (3.8)	0
無気肺	1 (3.8)	0
呼吸困難	1 (3.8)	0
鼻出血	1 (3.8)	2 (6.7)
低酸素症	1 (3.8)	2 (6.7)
鼻閉	1 (3.8)	2 (6.7)
肺うっ血	1 (3.8)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 6 of 9

	Male	Female
呼吸障害	1 (3.8)	0
呼吸不全	1 (3.8)	0
扁桃肥大	1 (3.8)	2 (6.7)
発声障害	0	1 (3.3)
肺臓炎	0	1 (3.3)
拘束性肺疾患	0	1 (3.3)
副鼻腔うっ血	0	2 (6.7)
喘鳴	0	1 (3.3)
胃腸障害	10 (38.5)	16 (53.3)
便秘	6 (23.1)	1 (3.3)
嘔吐	6 (23.1)	6 (20.0)
悪心	5 (19.2)	5 (16.7)
アフタ性潰瘍	1 (3.8)	2 (6.7)
下痢	1 (3.8)	1 (3.3)
口唇痛	1 (3.8)	0
口内炎	1 (3.8)	0
腹部不快感	0	1 (3.3)
腹痛	0	2 (6.7)
上腹部痛	0	2 (6.7)
腹部症状	0	1 (3.3)
放屁	0	1 (3.3)
食中毒	0	1 (3.3)
胃腸障害	0	1 (3.3)
胃食道逆流性疾患	0	1 (3.3)
口の感覚鈍麻	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 7 of 9

	Male	Female
口腔内痛	0	2 (6.7)
皮膚および皮下組織障害	7 (26.9)	10 (33.3)
皮膚炎	1 (3.8)	0
接触性皮膚炎	1 (3.8)	2 (6.7)
おむつ皮膚炎	1 (3.8)	0
湿疹	1 (3.8)	1 (3.3)
紅斑	1 (3.8)	0
毛孔性角化症	1 (3.8)	0
皮膚病変	1 (3.8)	0
ざ瘡	0	1 (3.3)
水疱	0	1 (3.3)
褥瘡性潰瘍	0	1 (3.3)
汗疹	0	1 (3.3)
寝汗	0	1 (3.3)
発疹	0	1 (3.3)
蕁麻疹	0	1 (3.3)
臨床検査	5 (19.2)	3 (10.0)
体重減少	3 (11.5)	0
血中テストステロン減少	1 (3.8)	0
ＣＳＦ白血球数増加	1 (3.8)	0
心拍数増加	1 (3.8)	0
血中重炭酸塩減少	0	1 (3.3)
体温上昇	0	1 (3.3)
尿検査異常	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 8 of 9

	Male	Female
免疫系障害	4 (15.4)	3 (10.0)
季節性アレルギー	2 (7.7)	1 (3.3)
薬物過敏症	1 (3.8)	0
過敏症	1 (3.8)	2 (6.7)
腎および尿路障害	2 (7.7)	1 (3.3)
尿失禁	1 (3.8)	0
膀胱尿管逆流	1 (3.8)	0
排尿困難	0	1 (3.3)
血液およびリンパ系障害	1 (3.8)	0
好中球減少症	1 (3.8)	0
耳および迷路障害	1 (3.8)	2 (6.7)
乗物酔い	1 (3.8)	0
耳痛	0	1 (3.3)
鼓膜穿孔	0	1 (3.3)
眼障害	1 (3.8)	1 (3.3)
斜視	1 (3.8)	0
遠視	0	1 (3.3)
代謝および栄養障害	1 (3.8)	4 (13.3)
食欲亢進	1 (3.8)	0
食欲減退	0	1 (3.3)
脱水	0	2 (6.7)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by sex
Page 9 of 9

	Male	Female
ビタミンD欠乏	0	1 (3.3)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (3.8)	0
皮膚乳頭腫	1 (3.8)	0
精神障害	1 (3.8)	3 (10.0)
激越	1 (3.8)	1 (3.3)
睡眠時随伴症	1 (3.8)	0
注意欠陥多動性障害	0	1 (3.3)
不快気分	0	1 (3.3)
不眠症	0	1 (3.3)
チック	0	1 (3.3)
心因性嘔吐	0	1 (3.3)
心臓障害	0	3 (10.0)
動悸	0	2 (6.7)
頻脈	0	1 (3.3)
血管障害	0	1 (3.3)
低血圧	0	1 (3.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 168　Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443: Incidence of Adverse Events by Race

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 1 of 18

	White	Non-white
Number of subjects dosed	94 (100.0)	19 (100.0)
Number of subjects with an event	89 (94.7)	19 (100.0)
感染症および寄生虫症	76 (80.9)	17 (89.5)
上気道感染	37 (39.4)	7 (36.8)
肺炎	25 (26.6)	5 (26.3)
鼻咽頭炎	17 (18.1)	7 (36.8)
ライノウイルス感染	14 (14.9)	4 (21.1)
気道感染	12 (12.8)	2 (10.5)
ウイルス性上気道感染	10 (10.6)	0
細気管支炎	9 (9.6)	3 (15.8)
ウイルス感染	9 (9.6)	3 (15.8)
中耳炎	8 (8.5)	4 (21.1)
口腔カンジダ症	7 (7.4)	1 (5.3)
ウイルス性肺炎	7 (7.4)	4 (21.1)
尿路感染	7 (7.4)	1 (5.3)
気管支炎	6 (6.4)	0
ウイルス性気管支炎	5 (5.3)	0
結膜炎	5 (5.3)	1 (5.3)
ＲＳウイルス細気管支炎	5 (5.3)	0
耳感染	4 (4.3)	2 (10.5)
インフルエンザ	4 (4.3)	2 (10.5)
細菌性肺炎	4 (4.3)	0
ウイルス性胃腸炎	3 (3.2)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 2 of 18

	White	Non-white
下気道感染	3 (3.2)	2 (10.5)
ウイルス性気道感染	3 (3.2)	2 (10.5)
鼻炎	3 (3.2)	0
アデノウイルス感染	2 (2.1)	0
カンジダ性おむつ皮疹	2 (2.1)	0
細菌性結膜炎	2 (2.1)	0
胃腸炎	2 (2.1)	0
手足口病	2 (2.1)	0
膿痂疹	2 (2.1)	0
ウイルス性下気道感染	2 (2.1)	1 (5.3)
メタニューモウイルス感染	2 (2.1)	0
レンサ球菌性咽頭炎	2 (2.1)	0
モラクセラ菌性肺炎	2 (2.1)	0
シュードモナス感染	2 (2.1)	1 (5.3)
皮膚カンジダ	2 (2.1)	0
ストーマ部膿瘍	2 (2.1)	0
細菌性疾患キャリアー	1 (1.1)	0
細菌感染	1 (1.1)	1 (5.3)
細菌性気管炎	1 (1.1)	2 (10.5)
蜂巣炎	1 (1.1)	0
ブドウ球菌性耳感染	1 (1.1)	0
蟯虫症	1 (1.1)	0
腸球菌感染	1 (1.1)	0
エンテロウイルス感染	1 (1.1)	1 (5.3)
眼感染	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 3 of 18

	White	Non-white
真菌感染	1 (1.1)	0
皮膚真菌感染	1 (1.1)	1 (5.3)
ウイルス性胃炎	1 (1.1)	0
ロタウイルス胃腸炎	1 (1.1)	0
肺感染	1 (1.1)	0
粘膜皮膚カンジダ症	1 (1.1)	0
院内感染	1 (1.1)	0
口腔真菌感染	1 (1.1)	0
口腔ヘルペス	1 (1.1)	0
急性中耳炎	1 (1.1)	0
パラインフルエンザウイルス感染	1 (1.1)	1 (5.3)
パラインフルエンザウイルス性肺炎	1 (1.1)	0
肺炎球菌性肺炎	1 (1.1)	0
ＲＳウイルス肺炎	1 (1.1)	0
腎盂腎炎	1 (1.1)	0
細菌性気道感染	1 (1.1)	0
ばら疹	1 (1.1)	0
敗血症	1 (1.1)	1 (5.3)
皮膚感染	1 (1.1)	0
ブドウ球菌感染	1 (1.1)	0
ブドウ球菌性敗血症	1 (1.1)	0
ブドウ球菌皮膚感染	1 (1.1)	0
ストーマ部感染	1 (1.1)	0
レンサ球菌感染	1 (1.1)	0
気管炎	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race

	White	Non-white
アデノウイルス性上気道感染	0	1 (5.3)
コロナウイルス感染	0	1 (5.3)
感染性湿疹	0	1 (5.3)
伝染性紅斑	0	1 (5.3)
大腸菌感染	0	1 (5.3)
ヘモフィルス感染	0	1 (5.3)
限局性感染	0	1 (5.3)
モラクセラ感染	0	2 (10.5)
インフルエンザ性肺炎	0	1 (5.3)
シュードモナス菌性肺炎	0	1 (5.3)
ブドウ球菌性菌血症	0	1 (5.3)
呼吸器、胸郭および縦隔障害	70 (74.5)	13 (68.4)
呼吸窮迫	23 (24.5)	6 (31.6)
無気肺	21 (22.3)	2 (10.5)
呼吸不全	21 (22.3)	5 (26.3)
鼻閉	17 (18.1)	1 (5.3)
咳嗽	16 (17.0)	1 (5.3)
急性呼吸不全	13 (13.8)	2 (10.5)
誤嚥性肺炎	11 (11.7)	1 (5.3)
低酸素症	10 (10.6)	1 (5.3)
鼻漏	9 (9.6)	2 (10.5)
上気道うっ血	8 (8.5)	0
無呼吸	6 (6.4)	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 5 of 18

	White	Non-white
誤嚥	6 (6.4)	1 (5.3)
気管支分泌物貯留	6 (6.4)	1 (5.3)
慢性呼吸不全	5 (5.3)	1 (5.3)
呼吸困難	5 (5.3)	4 (21.1)
上気道分泌増加	4 (4.3)	1 (5.3)
呼吸停止	4 (4.3)	2 (10.5)
低換気	3 (3.2)	0
副鼻腔うっ血	3 (3.2)	1 (5.3)
喘鳴	3 (3.2)	1 (5.3)
気胸	2 (2.1)	1 (5.3)
肺うっ血	2 (2.1)	0
アレルギー性鼻炎	2 (2.1)	0
呼吸補助筋の動員	2 (2.1)	0
急性呼吸窮迫症候群	1 (1.1)	0
無呼吸発作	1 (1.1)	0
窒息	1 (1.1)	0
気管支閉塞	1 (1.1)	0
息詰まり	1 (1.1)	1 (5.3)
高炭酸ガス血症	1 (1.1)	0
減呼吸	1 (1.1)	0
喉頭肉芽腫	1 (1.1)	0
肺障害	1 (1.1)	0
鼻汁変色	1 (1.1)	0
閉塞性気道障害	1 (1.1)	0
胸水	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 6 of 18

	White	Non-white
湿性咳嗽	1 (1.1)	0
肺水腫	1 (1.1)	1 (5.3)
呼吸障害	1 (1.1)	1 (5.3)
気道うっ血	1 (1.1)	1 (5.3)
拘束性肺疾患	1 (1.1)	0
低音性連続性ラ音	1 (1.1)	0
睡眠時無呼吸症候群	1 (1.1)	0
変色痰	1 (1.1)	0
気管障害	1 (1.1)	0
気管支分泌増加	0	1 (5.3)
気縦隔症	0	1 (5.3)
呼吸性アルカローシス	0	1 (5.3)
頻呼吸	0	1 (5.3)
胃腸障害	67 (71.3)	11 (57.9)
便秘	32 (34.0)	6 (31.6)
生歯	18 (19.1)	1 (5.3)
嘔吐	16 (17.0)	6 (31.6)
下痢	15 (16.0)	2 (10.5)
胃食道逆流性疾患	15 (16.0)	3 (15.8)
嚥下障害	9 (9.6)	1 (5.3)
放屁	8 (8.5)	0
流涎過多	8 (8.5)	0
腹部膨満	4 (4.3)	2 (10.5)
腹部不快感	3 (3.2)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 7 of 18

	White	Non-white
胃炎	3 (3.2)	1 (5.3)
血便排泄	2 (2.1)	0
腹痛	1 (1.1)	0
アフタ性潰瘍	1 (1.1)	0
口唇のひび割れ	1 (1.1)	0
胃出血	1 (1.1)	0
消化管運動低下	1 (1.1)	0
胃排出不全	1 (1.1)	0
乳児仙痛	1 (1.1)	0
乳児吐出	1 (1.1)	0
上部消化管出血	1 (1.1)	0
排便回数増加	0	1 (5.3)
吐血	0	1 (5.3)
一般・全身障害および投与部位の状態	60 (63.8)	10 (52.6)
発熱	53 (56.4)	10 (52.6)
疼痛	5 (5.3)	0
不快感	2 (2.1)	0
末梢性浮腫	2 (2.1)	0
適用部位紅斑	1 (1.1)	0
カテーテル留置部位炎症	1 (1.1)	0
泣き	1 (1.1)	0
死亡	1 (1.1)	0
医療機器閉塞	1 (1.1)	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 8 of 18

	White	Non-white
薬物不耐性	1 (1.1)	0
全身健康状態低下	1 (1.1)	0
低体温	1 (1.1)	0
注入部位内出血	1 (1.1)	0
倦怠感	1 (1.1)	0
医療機器合併症	1 (1.1)	0
小結節	1 (1.1)	0
浮腫	1 (1.1)	0
外科手術不成功	1 (1.1)	0
腫脹	1 (1.1)	0
血管穿刺部位内出血	1 (1.1)	0
医療機器リーク	0	1 (5.3)
ワクチン接種後の易刺激性	0	1 (5.3)
末梢腫脹	0	1 (5.3)
皮膚および皮下組織障害	35 (37.2)	7 (36.8)
発疹	13 (13.8)	1 (5.3)
おむつ皮膚炎	11 (11.7)	1 (5.3)
斑状出血	3 (3.2)	0
皮膚刺激	3 (3.2)	0
接触性皮膚炎	2 (2.1)	1 (5.3)
湿疹	2 (2.1)	2 (10.5)
過剰肉芽組織	2 (2.1)	1 (5.3)
過角化	2 (2.1)	0
皮膚炎	1 (1.1)	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race

	White	Non-white
皮膚乾燥	1 (1.1)	0
貨幣状湿疹	1 (1.1)	0
紅斑	1 (1.1)	1 (5.3)
環状肉芽腫	1 (1.1)	0
間擦疹	1 (1.1)	0
汗疹	1 (1.1)	1 (5.3)
そう痒症	1 (1.1)	0
斑状皮疹	1 (1.1)	0
丘疹性皮疹	1 (1.1)	0
脂漏性皮膚炎	1 (1.1)	0
皮膚色素脱失	1 (1.1)	0
皮膚浮腫	1 (1.1)	0
皮膚潰瘍	1 (1.1)	0
蕁麻疹	1 (1.1)	0
脱毛症	0	1 (5.3)
アレルギー性皮膚炎	0	1 (5.3)
点状出血	0	1 (5.3)
紅斑性皮疹	0	1 (5.3)
皮膚障害	0	1 (5.3)
皮下気腫	0	1 (5.3)
臨床検査	28 (29.8)	3 (15.8)
酸素飽和度低下	11 (11.7)	2 (10.5)
体重減少	6 (6.4)	0
ヒトライノウイルス検査陽性	3 (3.2)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race

	White	Non-white
好中球数増加	3 (3.2)	0
白血球数増加	3 (3.2)	0
アラニンアミノトランスフェラーゼ増加	2 (2.1)	0
アスパラギン酸アミノトランスフェラーゼ増加	2 (2.1)	0
血中カリウム減少	2 (2.1)	0
体温上昇	2 (2.1)	1 (5.3)
Ｃ－反応性蛋白増加	2 (2.1)	0
心拍数増加	2 (2.1)	0
医学的観察	2 (2.1)	0
モラクセラ検査陽性	2 (2.1)	0
シュードモナス検査陽性	2 (2.1)	0
血中アルカリホスファターゼ増加	1 (1.1)	0
血中クロール減少	1 (1.1)	0
血中鉄減少	1 (1.1)	0
血中ナトリウム減少	1 (1.1)	0
体温低下	1 (1.1)	0
骨密度減少	1 (1.1)	0
呼吸音異常	1 (1.1)	0
心電図ＳＴ－Ｔ部分異常	1 (1.1)	0
好酸球数増加	1 (1.1)	0
心拍数不整	1 (1.1)	0
炎症マーカー上昇	1 (1.1)	0
Ａ型インフルエンザウイルス検査陽性	1 (1.1)	0
肝機能検査異常	1 (1.1)	0
リンパ球数増加	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 11 of 18

	White	Non-white
好中球百分率増加	1 (1.1)	0
整形外科検査	1 (1.1)	0
セラチア検査陽性	1 (1.1)	0
ブドウ球菌検査陽性	1 (1.1)	1 (5.3)
レンサ球菌検査陽性	1 (1.1)	0
尿量減少	1 (1.1)	0
ビタミンA減少	1 (1.1)	0
心拍数減少	0	1 (5.3)
傷害、中毒および処置合併症	27 (28.7)	6 (31.6)
節足動物咬傷	5 (5.3)	0
処置による疼痛	4 (4.3)	0
栄養補給チューブ合併症	3 (3.2)	1 (5.3)
大腿骨骨折	3 (3.2)	0
処置後腫脹	2 (2.1)	0
皮膚擦過傷	2 (2.1)	0
ストーマ部紅斑	2 (2.1)	1 (5.3)
術後激越	1 (1.1)	0
挫傷	1 (1.1)	1 (5.3)
ダンピング症候群	1 (1.1)	0
耳擦過傷	1 (1.1)	0
擦過傷	1 (1.1)	0
転倒	1 (1.1)	0
関節脱臼	1 (1.1)	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 12 of 18

	White	Non-white
口唇損傷	1 (1.1)	0
処置後合併症	1 (1.1)	0
処置後不快感	1 (1.1)	0
処置合併症	1 (1.1)	0
処置部位反応	1 (1.1)	0
ストーマ合併症	1 (1.1)	0
ストーマ部刺激感	1 (1.1)	0
硬膜下血腫	1 (1.1)	0
サンバーン	1 (1.1)	0
熱傷	1 (1.1)	0
歯牙損傷	1 (1.1)	0
ワクチン接種合併症	1 (1.1)	0
麻酔からの覚醒遅延	0	1 (5.3)
伝染病曝露	0	1 (5.3)
外傷性気胸	0	1 (5.3)
軟部組織損傷	0	1 (5.3)
心臓障害	24 (25.5)	2 (10.5)
頻脈	10 (10.6)	1 (5.3)
徐脈	6 (6.4)	1 (5.3)
心肺停止	6 (6.4)	0
心停止	3 (3.2)	0
チアノーゼ	3 (3.2)	0
左室肥大	2 (2.1)	0
心筋症	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 13 of 18

	White	Non-white
洞性頻脈	1 (1.1)	0
上室性頻脈	1 (1.1)	0
心室性頻脈	1 (1.1)	1 (5.3)
心膜気腫	0	1 (5.3)
筋骨格系および結合組織障害	24 (25.5)	3 (15.8)
関節拘縮	12 (12.8)	0
側弯症	9 (9.6)	2 (10.5)
胸郭変形	4 (4.3)	0
脊柱後弯症	4 (4.3)	1 (5.3)
頭位性斜頭症	3 (3.2)	0
斜頚	3 (3.2)	0
後側弯症	2 (2.1)	0
四肢痛	2 (2.1)	0
背部痛	1 (1.1)	0
泉門閉鎖遅延	1 (1.1)	0
手変形	1 (1.1)	0
筋力低下	1 (1.1)	0
脊柱変形	1 (1.1)	0
滑膜炎	1 (1.1)	0
体重支持困難	1 (1.1)	0
関節硬直	0	1 (5.3)
脊柱前弯症	0	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 14 of 18

	White	Non-white
代謝および栄養障害	17 (18.1)	5 (26.3)
体重増加不良	7 (7.4)	0
成長障害	3 (3.2)	2 (10.5)
乳児および小児期早期の哺育障害	3 (3.2)	0
栄養補給不耐性	3 (3.2)	0
脱水	2 (2.1)	1 (5.3)
低ナトリウム血症	1 (1.1)	1 (5.3)
過小食	1 (1.1)	1 (5.3)
鉄欠乏	1 (1.1)	0
代謝性アルカローシス	1 (1.1)	0
神経系障害	17 (18.1)	3 (15.8)
不随意性筋収縮	4 (4.3)	0
よだれ	2 (2.1)	0
眼振	2 (2.1)	1 (5.3)
脳損傷	1 (1.1)	0
間代	1 (1.1)	0
頭痛	1 (1.1)	0
反射亢進	1 (1.1)	0
筋緊張低下	1 (1.1)	0
低酸素性虚血性脳症	1 (1.1)	0
言語障害	1 (1.1)	0
嗜眠	1 (1.1)	0
痙攣発作	1 (1.1)	1 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 15 of 18

	White	Non-white
傾眠	1 (1.1)	0
失神	1 (1.1)	0
脳梗塞	0	1 (5.3)
脳脊髄液漏	0	1 (5.3)
免疫系障害	11 (11.7)	4 (21.1)
季節性アレルギー	6 (6.4)	1 (5.3)
薬物過敏症	3 (3.2)	1 (5.3)
食物アレルギー	2 (2.1)	0
過敏症	0	2 (10.5)
精神障害	11 (11.7)	1 (5.3)
不安	5 (5.3)	0
激越	2 (2.1)	0
易刺激性	2 (2.1)	1 (5.3)
息こらえ	1 (1.1)	0
気分動揺	1 (1.1)	0
落ち着きのなさ	1 (1.1)	0
睡眠障害	1 (1.1)	0
血管障害	7 (7.4)	2 (10.5)
高血圧	2 (2.1)	1 (5.3)
毛細血管脆弱	1 (1.1)	0
蒼白	1 (1.1)	0
ショック	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 16 of 18

	White	Non-white
血栓症	1 (1.1)	0
血管炎	1 (1.1)	0
本態性高血圧症	0	1 (5.3)
先天性、家族性および遺伝性障害	6 (6.4)	1 (5.3)
斜頭症	2 (2.1)	0
先天性横隔膜ヘルニア	1 (1.1)	0
発育性股関節形成不全	1 (1.1)	0
貧血母斑	1 (1.1)	0
鳩胸	1 (1.1)	0
斜指症	0	1 (5.3)
眼障害	6 (6.4)	1 (5.3)
霰粒腫	1 (1.1)	0
後天性涙道狭窄	1 (1.1)	0
眼乾燥	1 (1.1)	0
眼運動障害	1 (1.1)	0
眼瞼下垂	1 (1.1)	0
近視	1 (1.1)	0
斜視	1 (1.1)	0
乱視	0	1 (5.3)
血液およびリンパ系障害	5 (5.3)	2 (10.5)
貧血	2 (2.1)	1 (5.3)
好酸球増加症	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 17 of 18

	White	Non-white
リンパ節症	1 (1.1)	0
好中球減少症	1 (1.1)	0
血小板増加症	0	1 (5.3)
生殖系および乳房障害	4 (4.3)	1 (5.3)
後天性包茎	1 (1.1)	0
亀頭包皮炎	1 (1.1)	0
卵巣嚢胞	1 (1.1)	0
陰茎障害	1 (1.1)	0
外陰腟発疹	0	1 (5.3)
耳および迷路障害	2 (2.1)	1 (5.3)
耳の障害	1 (1.1)	0
耳痛	1 (1.1)	0
耳垢分泌過多	0	1 (5.3)
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	2 (2.1)	1 (5.3)
アクロコルドン	1 (1.1)	0
脂漏性角化症	1 (1.1)	0
血管の良性新生物	0	1 (5.3)
肝胆道系障害	1 (1.1)	0
肝腫大	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by race
Page 18 of 18

	White	Non-white
妊娠、産褥および周産期の状態	1 (1.1)	0
臍肉芽腫	1 (1.1)	0
腎および尿路障害	1 (1.1)	1 (5.3)
水腎症	1 (1.1)	0
尿閉	0	1 (5.3)
外科および内科処置	1 (1.1)	0
機械的換気	1 (1.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 69　Later-Onset Subjects:Incidence of Adverse Events by Race

Later-onset subjects: incidence of adverse events by race
Page 1 of 9

	White	Non-white
Number of subjects dosed	49 (100.0)	7 (100.0)
Number of subjects with an event	49 (100.0)	7 (100.0)
感染症および寄生虫症	39 (79.6)	5 (71.4)
上気道感染	24 (49.0)	3 (42.9)
鼻咽頭炎	15 (30.6)	1 (14.3)
レンサ球菌性咽頭炎	8 (16.3)	0
ウイルス感染	8 (16.3)	1 (14.3)
ウイルス性胃腸炎	7 (14.3)	1 (14.3)
胃腸炎	6 (12.2)	1 (14.3)
中耳炎	5 (10.2)	0
肺炎	5 (10.2)	0
ウイルス性上気道感染	5 (10.2)	0
耳感染	4 (8.2)	0
結膜炎	3 (6.1)	0
インフルエンザ	3 (6.1)	0
限局性感染	3 (6.1)	0
尿路感染	3 (6.1)	1 (14.3)
ウイルス性消化管感染	2 (4.1)	0
ウイルス性肺炎	2 (4.1)	0
ＲＳウイルス感染	2 (4.1)	1 (14.3)
副鼻腔炎	2 (4.1)	1 (14.3)
皮膚カンジダ	2 (4.1)	0
蜂巣炎	1 (2.0)	0
ブドウ球菌性眼感染	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 2 of 9

	White	Non-white
ウイルス性眼感染	1 (2.0)	0
皮膚真菌感染	1 (2.0)	0
手足口病	1 (2.0)	0
膿痂疹	1 (2.0)	0
下気道感染	1 (2.0)	0
伝染性軟属腫	1 (2.0)	0
単核細胞症症候群	1 (2.0)	0
急性中耳炎	1 (2.0)	0
咽頭炎	1 (2.0)	0
ＲＳウイルス肺炎	1 (2.0)	0
ＲＳウイルス細気管支炎	1 (2.0)	0
気道感染	1 (2.0)	0
ウイルス性気道感染	1 (2.0)	0
鼻炎	1 (2.0)	0
皮膚細菌感染	1 (2.0)	0
扁桃炎	1 (2.0)	0
膣感染	1 (2.0)	0
ウイルス性扁桃炎	1 (2.0)	0
外陰膣真菌感染	1 (2.0)	0
傷害、中毒および処置合併症	37 (75.5)	3 (42.9)
腰椎穿刺後症候群	21 (42.9)	2 (28.6)
裂傷	7 (14.3)	0
処置による疼痛	5 (10.2)	1 (14.3)
大腿骨骨折	3 (6.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 3 of 9

	White	Non-white
四肢損傷	3 (6.1)	0
節足動物咬傷	2 (4.1)	1 (14.3)
関節脱臼	2 (4.1)	0
関節損傷	2 (4.1)	0
処置による悪心	2 (4.1)	0
サンバーン	2 (4.1)	0
術後激越	1 (2.0)	0
節足動物刺傷	1 (2.0)	0
挫傷	1 (2.0)	1 (14.3)
転倒	1 (2.0)	0
靭帯捻挫	1 (2.0)	0
下肢骨折	1 (2.0)	0
半月板損傷	1 (2.0)	0
肉離れ	1 (2.0)	0
術後イレウス	1 (2.0)	0
処置による頭痛	1 (2.0)	0
脛骨骨折	1 (2.0)	0
隆起骨折	1 (2.0)	1 (14.3)
頭部損傷	0	1 (14.3)
熱傷	0	1 (14.3)
筋骨格系および結合組織障害	37 (75.5)	4 (57.1)
背部痛	20 (40.8)	3 (42.9)
側弯症	13 (26.5)	2 (28.6)
関節拘縮	10 (20.4)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 4 of 9

	White	Non-white
四肢痛	5 (10.2)	0
関節痛	4 (8.2)	1 (14.3)
筋肉痛	4 (8.2)	0
頚部痛	3 (6.1)	0
筋緊張	2 (4.1)	0
四肢拘縮	1 (2.0)	0
骨盤変形	1 (2.0)	1 (14.3)
脊柱前弯症	0	1 (14.3)
一般・全身障害および投与部位の状態	27 (55.1)	4 (57.1)
発熱	15 (30.6)	1 (14.3)
穿刺部位疼痛	8 (16.3)	2 (28.6)
疲労	3 (6.1)	0
カテーテル留置部位出血	1 (2.0)	0
カテーテル留置部位疼痛	1 (2.0)	0
カテーテル留置部位関連反応	1 (2.0)	0
胸部不快感	1 (2.0)	0
悪寒	1 (2.0)	0
冷感	1 (2.0)	0
低体温	1 (2.0)	0
注射部位出血	1 (2.0)	0
注射部位疼痛	1 (2.0)	0
疼痛	1 (2.0)	1 (14.3)
末梢腫脹	1 (2.0)	0
穿刺部位反応	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 5 of 9

	White	Non-white
血管穿刺部位内出血	1 (2.0)	0
重力性浮腫	0	1 (14.3)
神経系障害	25 (51.0)	5 (71.4)
頭痛	23 (46.9)	5 (71.4)
味覚異常	1 (2.0)	0
失読症	1 (2.0)	0
感覚鈍麻	1 (2.0)	1 (14.3)
片頭痛	1 (2.0)	0
失神	1 (2.0)	0
振戦	1 (2.0)	0
失声症	0	1 (14.3)
錯感覚	0	1 (14.3)
胃腸障害	24 (49.0)	2 (28.6)
嘔吐	12 (24.5)	0
悪心	9 (18.4)	1 (14.3)
便秘	7 (14.3)	0
腹痛	2 (4.1)	0
上腹部痛	2 (4.1)	0
下痢	2 (4.1)	0
腹部不快感	1 (2.0)	0
腹部症状	1 (2.0)	0
アフタ性潰瘍	1 (2.0)	2 (28.6)
放屁	1 (2.0)	0
食中毒	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 6 of 9

	White	Non-white
胃腸障害	1 (2.0)	0
胃食道逆流性疾患	1 (2.0)	0
口の感覚鈍麻	1 (2.0)	0
口唇痛	1 (2.0)	0
口腔内痛	1 (2.0)	1 (14.3)
口内炎	1 (2.0)	0
呼吸器、胸郭および縦隔障害	21 (42.9)	4 (57.1)
口腔咽頭痛	6 (12.2)	2 (28.6)
鼻漏	6 (12.2)	0
咳嗽	5 (10.2)	1 (14.3)
鼻出血	3 (6.1)	0
低酸素症	3 (6.1)	0
鼻閉	3 (6.1)	0
副鼻腔うっ血	2 (4.1)	0
急性呼吸不全	1 (2.0)	0
無気肺	1 (2.0)	0
発声障害	1 (2.0)	0
呼吸困難	1 (2.0)	0
肺臓炎	1 (2.0)	0
肺うっ血	1 (2.0)	0
呼吸障害	1 (2.0)	0
呼吸不全	1 (2.0)	0
拘束性肺疾患	1 (2.0)	0
扁桃肥大	1 (2.0)	2 (28.6)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 7 of 9

	White	Non-white
喘鳴	1 (2.0)	0
皮膚および皮下組織障害	15 (30.6)	2 (28.6)
接触性皮膚炎	3 (6.1)	0
湿疹	2 (4.1)	0
水疱	1 (2.0)	0
褥瘡性潰瘍	1 (2.0)	0
皮膚炎	1 (2.0)	0
おむつ皮膚炎	1 (2.0)	0
紅斑	1 (2.0)	0
毛孔性角化症	1 (2.0)	0
汗疹	1 (2.0)	0
寝汗	1 (2.0)	0
発疹	1 (2.0)	0
蕁麻疹	1 (2.0)	0
ざ瘡	0	1 (14.3)
皮膚病変	0	1 (14.3)
免疫系障害	7 (14.3)	0
過敏症	3 (6.1)	0
季節性アレルギー	3 (6.1)	0
薬物過敏症	1 (2.0)	0
臨床検査	7 (14.3)	1 (14.3)
体重減少	2 (4.1)	1 (14.3)
血中重炭酸塩減少	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 8 of 9

	White	Non-white
血中テストステロン減少	1 (2.0)	0
体温上昇	1 (2.0)	0
ＣＳＦ白血球数増加	1 (2.0)	0
心拍数増加	1 (2.0)	0
尿検査異常	1 (2.0)	0
代謝および栄養障害	4 (8.2)	1 (14.3)
脱水	2 (4.1)	0
食欲減退	1 (2.0)	0
食欲亢進	1 (2.0)	0
ビタミンＤ欠乏	0	1 (14.3)
耳および迷路障害	3 (6.1)	0
耳痛	1 (2.0)	0
乗物酔い	1 (2.0)	0
鼓膜穿孔	1 (2.0)	0
精神障害	3 (6.1)	1 (14.3)
激越	2 (4.1)	0
注意欠陥多動性障害	1 (2.0)	0
不快気分	1 (2.0)	0
不眠症	1 (2.0)	0
睡眠時随伴症	1 (2.0)	0
チック	1 (2.0)	0
心因性嘔吐	0	1 (14.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by race
Page 9 of 9

	White	Non-white
心臓障害	2 (4.1)	1 (14.3)
動悸	2 (4.1)	0
頻脈	0	1 (14.3)
腎および尿路障害	2 (4.1)	1 (14.3)
排尿困難	1 (2.0)	0
尿失禁	1 (2.0)	0
膀胱尿管逆流	0	1 (14.3)
血液およびリンパ系障害	1 (2.0)	0
好中球減少症	1 (2.0)	0
眼障害	1 (2.0)	1 (14.3)
遠視	1 (2.0)	0
斜視	0	1 (14.3)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (2.0)	0
皮膚乳頭腫	1 (2.0)	0
血管障害	1 (2.0)	0
低血圧	1 (2.0)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]
##[redacted]##

表 170 Infants Diagnosed With SMA (Presymptomatic and Infantile-Onset) Treated With ISIS 396443: Incidence of Adverse Events by Weight Quartiles

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 1 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
Number of subjects dosed	29 (100.0)	31 (100.0)	28 (100.0)	32 (100.0)
Number of subjects with an event	25 (86.2)	31 (100.0)	27 (96.4)	30 (93.8)
感染症および寄生虫症	21 (72.4)	27 (87.1)	24 (85.7)	25 (78.1)
上気道感染	10 (34.5)	9 (29.0)	11 (39.3)	14 (43.8)
鼻咽頭炎	5 (17.2)	10 (32.3)	4 (14.3)	6 (18.8)
肺炎	5 (17.2)	10 (32.3)	8 (28.6)	9 (28.1)
気管支炎	3 (10.3)	0	2 (7.1)	2 (6.3)
インフルエンザ	3 (10.3)	5 (16.1)	1 (3.6)	0
中耳炎	3 (10.3)	3 (9.7)	2 (7.1)	4 (12.5)
気道感染	3 (10.3)	1 (3.2)	5 (17.9)	5 (15.6)
ウイルス感染	3 (10.3)	5 (16.1)	2 (7.1)	2 (6.3)
ウイルス性気管支炎	2 (6.9)	0	2 (7.1)	1 (3.1)
ウイルス性胃腸炎	2 (6.9)	0	0	1 (3.1)
鼻炎	2 (6.9)	1 (3.2)	1 (3.6)	1 (3.1)
ライノウイルス感染	2 (6.9)	4 (12.9)	8 (28.6)	4 (12.5)
細気管支炎	1 (3.4)	4 (12.9)	4 (14.3)	3 (9.4)
結膜炎	1 (3.4)	1 (3.2)	2 (7.1)	2 (6.3)
ブドウ球菌性耳感染	1 (3.4)	0	0	0
大腸菌感染	1 (3.4)	0	0	0
ロタウイルス胃腸炎	1 (3.4)	0	0	0
手足口病	1 (3.4)	1 (3.2)	0	0
膿痂疹	1 (3.4)	1 (3.2)	0	0
ウイルス性下気道感染	1 (3.4)	0	2 (7.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 2 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
口腔カンジダ症	1 (3.4)	2 (6.5)	4 (14.3)	1 (3.1)
レンサ球菌性咽頭炎	1 (3.4)	0	0	1 (3.1)
ウイルス性肺炎	1 (3.4)	1 (3.2)	3 (10.7)	6 (18.8)
シュードモナス感染	1 (3.4)	0	1 (3.6)	1 (3.1)
皮膚感染	1 (3.4)	0	0	0
レンサ球菌感染	1 (3.4)	0	0	0
尿路感染	1 (3.4)	5 (16.1)	2 (7.1)	0
ウイルス性上気道感染	1 (3.4)	2 (6.5)	5 (17.9)	2 (6.3)
アデノウイルス性上気道感染	0	1 (3.2)	0	0
アデノウイルス感染	0	0	2 (7.1)	0
細菌性疾患キャリアー	0	0	1 (3.6)	0
細菌感染	0	2 (6.5)	0	0
細菌性気管炎	0	1 (3.2)	1 (3.6)	1 (3.1)
カンジダ性おむつ皮疹	0	0	1 (3.6)	1 (3.1)
蜂巣炎	0	0	0	1 (3.1)
細菌性結膜炎	0	1 (3.2)	0	1 (3.1)
コロナウイルス感染	0	1 (3.2)	0	0
耳感染	0	2 (6.5)	1 (3.6)	3 (9.4)
感染性湿疹	0	0	1 (3.6)	0
蟯虫症	0	1 (3.2)	0	0
腸球菌感染	0	0	1 (3.6)	0
エンテロウイルス感染	0	1 (3.2)	1 (3.6)	0
伝染性紅斑	0	1 (3.2)	0	0
眼感染	0	0	0	1 (3.1)
真菌感染	0	1 (3.2)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 3 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
皮膚真菌感染	0	1 (3.2)	0	1 (3.1)
ウイルス性胃炎	0	0	1 (3.6)	0
胃腸炎	0	0	1 (3.6)	1 (3.1)
ヘモフィルス感染	0	1 (3.2)	0	0
限局性感染	0	0	1 (3.6)	0
下気道感染	0	2 (6.5)	2 (7.1)	1 (3.1)
肺感染	0	1 (3.2)	0	0
メタニューモウイルス感染	0	0	1 (3.6)	1 (3.1)
モラクセラ感染	0	2 (6.5)	0	0
粘膜皮膚カンジダ症	0	0	1 (3.6)	0
院内感染	0	0	1 (3.6)	0
口腔真菌感染	0	0	0	1 (3.1)
口腔ヘルペス	0	1 (3.2)	0	0
急性中耳炎	0	0	0	1 (3.1)
パラインフルエンザウイルス感染	0	1 (3.2)	0	1 (3.1)
細菌性肺炎	0	1 (3.2)	1 (3.6)	2 (6.3)
インフルエンザ性肺炎	0	0	1 (3.6)	0
モラクセラ菌性肺炎	0	0	1 (3.6)	1 (3.1)
パラインフルエンザウイルス性肺炎	0	0	0	1 (3.1)
肺炎球菌性肺炎	0	1 (3.2)	0	0
シュードモナス菌性肺炎	0	0	0	1 (3.1)
ＲＳウイルス肺炎	0	0	0	1 (3.1)
腎盂腎炎	0	1 (3.2)	0	0
ＲＳウイルス細気管支炎	0	2 (6.5)	1 (3.6)	2 (6.3)
細菌性気道感染	0	0	1 (3.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 4 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
ウイルス性気道感染	0	2 (6.5)	3 (10.7)	0
ばら疹	0	0	1 (3.6)	0
敗血症	0	0	1 (3.6)	1 (3.1)
皮膚カンジダ	0	0	2 (7.1)	0
ブドウ球菌性菌血症	0	1 (3.2)	0	0
ブドウ球菌感染	0	0	1 (3.6)	0
ブドウ球菌性敗血症	0	0	0	1 (3.1)
ブドウ球菌皮膚感染	0	1 (3.2)	0	0
ストーマ部膿瘍	0	0	2 (7.1)	0
ストーマ部感染	0	0	0	1 (3.1)
気管炎	0	0	1 (3.6)	0
胃腸障害	15 (51.7)	18 (58.1)	23 (82.1)	23 (71.9)
便秘	6 (20.7)	11 (35.5)	11 (39.3)	11 (34.4)
放屁	4 (13.8)	1 (3.2)	0	3 (9.4)
胃食道逆流性疾患	3 (10.3)	4 (12.9)	8 (28.6)	3 (9.4)
生歯	3 (10.3)	2 (6.5)	4 (14.3)	10 (31.3)
嘔吐	3 (10.3)	6 (19.4)	9 (32.1)	4 (12.5)
腹部膨満	2 (6.9)	0	1 (3.6)	3 (9.4)
下痢	2 (6.9)	4 (12.9)	6 (21.4)	5 (15.6)
嚥下障害	2 (6.9)	2 (6.5)	3 (10.7)	3 (9.4)
胃炎	2 (6.9)	0	1 (3.6)	1 (3.1)
腹部不快感	1 (3.4)	0	0	2 (6.3)
腹痛	1 (3.4)	0	0	0
血便排泄	1 (3.4)	0	1 (3.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 5 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
アフタ性潰瘍	0	0	1 (3.6)	0
口唇のひび割れ	0	0	1 (3.6)	0
排便回数増加	0	1 (3.2)	0	0
胃出血	0	0	1 (3.6)	0
消化管運動低下	0	0	0	1 (3.1)
吐血	0	0	0	1 (3.1)
胃排出不全	0	0	0	1 (3.1)
乳児仙痛	0	0	1 (3.6)	0
乳児吐出	0	0	1 (3.6)	0
流涎過多	0	4 (12.9)	3 (10.7)	1 (3.1)
上部消化管出血	0	0	1 (3.6)	0
呼吸器、胸郭および縦隔障害	13 (44.8)	24 (77.4)	23 (82.1)	25 (78.1)
咳嗽	4 (13.8)	3 (9.7)	5 (17.9)	6 (18.8)
呼吸窮迫	4 (13.8)	9 (29.0)	10 (35.7)	6 (18.8)
鼻漏	4 (13.8)	2 (6.5)	2 (7.1)	3 (9.4)
鼻閉	3 (10.3)	4 (12.9)	6 (21.4)	5 (15.6)
無気肺	2 (6.9)	7 (22.6)	9 (32.1)	5 (15.6)
呼吸不全	2 (6.9)	5 (16.1)	9 (32.1)	10 (31.3)
誤嚥	1 (3.4)	5 (16.1)	1 (3.6)	0
気管支閉塞	1 (3.4)	0	0	0
息詰まり	1 (3.4)	1 (3.2)	1 (3.6)	0
低換気	1 (3.4)	0	1 (3.6)	1 (3.1)
上気道分泌増加	1 (3.4)	1 (3.2)	3 (10.7)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 6 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
肺障害	1 (3.4)	0	0	0
誤嚥性肺炎	1 (3.4)	2 (6.5)	7 (25.0)	2 (6.3)
呼吸性アシドーシス	1 (3.4)	0	0	0
副鼻腔うっ血	1 (3.4)	1 (3.2)	1 (3.6)	1 (3.1)
上気道うっ血	1 (3.4)	3 (9.7)	2 (7.1)	2 (6.3)
呼吸補助筋の動員	1 (3.4)	1 (3.2)	0	0
急性呼吸窮迫症候群	0	0	1 (3.6)	0
急性呼吸不全	0	4 (12.9)	5 (17.9)	6 (18.8)
無呼吸	0	3 (9.7)	4 (14.3)	0
無呼吸発作	0	0	1 (3.6)	0
窒息	0	1 (3.2)	0	0
気管支分泌物貯留	0	1 (3.2)	3 (10.7)	3 (9.4)
慢性呼吸不全	0	1 (3.2)	3 (10.7)	2 (6.3)
呼吸困難	0	3 (9.7)	2 (7.1)	4 (12.5)
高炭酸ガス血症	0	1 (3.2)	0	0
減呼吸	0	0	1 (3.6)	0
低酸素症	0	3 (9.7)	4 (14.3)	4 (12.5)
気管支分泌増加	0	1 (3.2)	0	0
喉頭肉芽腫	0	0	1 (3.6)	0
鼻汁変色	0	0	0	1 (3.1)
閉塞性気道障害	0	0	0	1 (3.1)
胸水	0	0	1 (3.6)	0
気縦隔症	0	1 (3.2)	0	0
気胸	0	2 (6.5)	1 (3.6)	0
湿性咳嗽	0	0	0	1 (3.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 7 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
肺うっ血	0	0	1 (3.6)	1 (3.1)
肺水腫	0	1 (3.2)	1 (3.6)	0
呼吸性アルカローシス	0	0	0	1 (3.1)
呼吸停止	0	2 (6.5)	2 (7.1)	2 (6.3)
呼吸障害	0	0	1 (3.6)	1 (3.1)
気道うっ血	0	0	1 (3.6)	1 (3.1)
拘束性肺疾患	0	0	1 (3.6)	0
アレルギー性鼻炎	0	0	0	2 (6.3)
低音性連続性ラ音	0	1 (3.2)	0	0
睡眠時無呼吸症候群	0	0	1 (3.6)	0
変色痰	0	0	1 (3.6)	0
頻呼吸	0	1 (3.2)	0	0
気管障害	0	0	1 (3.6)	0
喘鳴	0	2 (6.5)	2 (7.1)	0
皮膚および皮下組織障害	13 (44.8)	11 (35.5)	11 (39.3)	11 (34.4)
おむつ皮膚炎	5 (17.2)	1 (3.2)	3 (10.7)	3 (9.4)
皮膚炎	2 (6.9)	1 (3.2)	1 (3.6)	0
発疹	2 (6.9)	3 (9.7)	3 (10.7)	7 (21.9)
接触性皮膚炎	1 (3.4)	0	1 (3.6)	1 (3.1)
貨幣状湿疹	1 (3.4)	0	0	0
紅斑	1 (3.4)	1 (3.2)	0	0
点状出血	1 (3.4)	1 (3.2)	0	0
紅斑性皮疹	1 (3.4)	0	0	0
脂漏性皮膚炎	1 (3.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 8 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
脱毛症	0	1 (3.2)	0	0
アレルギー性皮膚炎	0	1 (3.2)	0	0
皮膚乾燥	0	0	0	1 (3.1)
斑状出血	0	1 (3.2)	1 (3.6)	1 (3.1)
湿疹	0	2 (6.5)	1 (3.6)	1 (3.1)
過剰肉芽組織	0	2 (6.5)	1 (3.6)	0
環状肉芽腫	0	1 (3.2)	0	0
過角化	0	0	1 (3.6)	1 (3.1)
間擦疹	0	1 (3.2)	0	0
汗疹	0	0	2 (7.1)	0
そう痒症	0	0	0	1 (3.1)
斑状皮疹	0	0	0	1 (3.1)
丘疹性皮疹	0	1 (3.2)	0	0
皮膚色素脱失	0	0	0	1 (3.1)
皮膚障害	0	0	0	1 (3.1)
皮膚刺激	0	0	2 (7.1)	1 (3.1)
皮膚浮腫	0	0	0	1 (3.1)
皮膚潰瘍	0	0	0	1 (3.1)
皮下気腫	0	1 (3.2)	0	0
蕁麻疹	0	0	0	1 (3.1)
一般・全身障害および投与部位の状態	12 (41.4)	19 (61.3)	18 (64.3)	22 (68.8)
発熱	11 (37.9)	16 (51.6)	17 (60.7)	20 (62.5)
適用部位紅斑	1 (3.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 9 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
不快感	1 (3.4)	0	0	1 (3.1)
注入部位内出血	1 (3.4)	0	0	0
疼痛	1 (3.4)	0	1 (3.6)	3 (9.4)
外科手術不成功	1 (3.4)	0	0	0
血管穿刺部位内出血	1 (3.4)	0	0	0
カテーテル留置部位炎症	0	0	1 (3.6)	0
泣き	0	0	0	1 (3.1)
死亡	0	1 (3.2)	0	0
医療機器リーク	0	1 (3.2)	0	0
医療機器閉塞	0	1 (3.2)	0	1 (3.1)
薬物不耐性	0	0	1 (3.6)	0
全身健康状態低下	0	1 (3.2)	0	0
低体温	0	0	1 (3.6)	0
ワクチン接種後の易刺激性	0	1 (3.2)	0	0
倦怠感	0	1 (3.2)	0	0
医療機器合併症	0	1 (3.2)	0	0
小結節	0	0	1 (3.6)	0
浮腫	0	0	0	1 (3.1)
末梢性浮腫	0	0	0	2 (6.3)
末梢腫脹	0	0	0	1 (3.1)
腫脹	0	0	1 (3.6)	0
代謝および栄養障害	6 (20.7)	8 (25.8)	7 (25.0)	2 (6.3)
脱水	2 (6.9)	1 (3.2)	0	0
成長障害	2 (6.9)	2 (6.5)	2 (7.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 10 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
体重増加不良	2 (6.9)	3 (9.7)	1 (3.6)	1 (3.1)
乳児および小児期早期の哺育障害	1 (3.4)	1 (3.2)	1 (3.6)	0
鉄欠乏	1 (3.4)	0	0	0
栄養補給不耐性	0	1 (3.2)	2 (7.1)	0
低ナトリウム血症	0	1 (3.2)	1 (3.6)	0
過小食	0	0	1 (3.6)	1 (3.1)
代謝性アルカローシス	0	0	1 (3.6)	0
筋骨格系および結合組織障害	6 (20.7)	8 (25.8)	8 (28.6)	6 (18.8)
関節拘縮	2 (6.9)	3 (9.7)	4 (14.3)	3 (9.4)
筋力低下	2 (6.9)	0	0	0
頭位性斜頭症	2 (6.9)	0	0	1 (3.1)
胸郭変形	1 (3.4)	1 (3.2)	2 (7.1)	0
四肢痛	1 (3.4)	0	0	1 (3.1)
側弯症	1 (3.4)	5 (16.1)	3 (10.7)	2 (6.3)
斜頚	1 (3.4)	1 (3.2)	0	1 (3.1)
体重支持困難	1 (3.4)	0	0	0
背部痛	0	0	1 (3.6)	0
泉門閉鎖遅延	0	0	1 (3.6)	0
手変形	0	0	1 (3.6)	0
関節硬直	0	1 (3.2)	0	0
後側弯症	0	0	2 (7.1)	0
脊柱後弯症	0	4 (12.9)	0	1 (3.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 11 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
脊柱前弯症	0	1 (3.2)	0	0
脊柱変形	0	0	0	1 (3.1)
滑膜炎	0	0	0	1 (3.1)
傷害、中毒および処置合併症	5 (17.2)	7 (22.6)	12 (42.9)	9 (28.1)
節足動物咬傷	1 (3.4)	1 (3.2)	0	3 (9.4)
擦過傷	1 (3.4)	0	0	0
転倒	1 (3.4)	0	0	0
処置後合併症	1 (3.4)	0	0	0
処置後不快感	1 (3.4)	0	0	0
処置後腫脹	1 (3.4)	0	0	1 (3.1)
処置合併症	1 (3.4)	0	0	0
処置部位反応	1 (3.4)	0	0	0
硬膜下血腫	1 (3.4)	0	0	0
術後激越	0	0	0	1 (3.1)
挫傷	0	0	1 (3.6)	1 (3.1)
麻酔からの覚醒遅延	0	1 (3.2)	0	0
ダンピング症候群	0	0	1 (3.6)	0
耳擦過傷	0	1 (3.2)	0	0
伝染病曝露	0	0	0	1 (3.1)
栄養補給チューブ合併症	0	1 (3.2)	3 (10.7)	0
大腿骨骨折	0	0	3 (10.7)	0
関節脱臼	0	1 (3.2)	0	1 (3.1)
口唇損傷	0	0	0	1 (3.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 12 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
外傷性気胸	0	1 (3.2)	0	0
処置による疼痛	0	2 (6.5)	2 (7.1)	0
皮膚擦過傷	0	1 (3.2)	0	1 (3.1)
軟部組織損傷	0	0	0	1 (3.1)
ストーマ合併症	0	1 (3.2)	0	0
ストーマ部紅斑	0	1 (3.2)	0	2 (6.3)
ストーマ部刺激感	0	0	1 (3.6)	0
サンバーン	0	1 (3.2)	0	0
熱傷	0	1 (3.2)	0	0
歯牙損傷	0	0	0	1 (3.1)
ワクチン接種合併症	0	0	1 (3.6)	0
臨床検査	5 (17.2)	9 (29.0)	9 (32.1)	8 (25.0)
酸素飽和度低下	2 (6.9)	3 (9.7)	5 (17.9)	3 (9.4)
アラニンアミノトランスフェラーゼ増加	1 (3.4)	0	0	1 (3.1)
アスパラギン酸アミノトランスフェラーゼ増加	1 (3.4)	0	0	1 (3.1)
血中アルカリホスファターゼ増加	1 (3.4)	0	0	0
血中鉄減少	1 (3.4)	0	0	0
体温上昇	1 (3.4)	2 (6.5)	0	0
Ｃ－反応性蛋白増加	1 (3.4)	0	0	1 (3.1)
好酸球数増加	1 (3.4)	0	0	0
ヒトライノウイルス検査陽性	1 (3.4)	0	1 (3.6)	1 (3.1)
リンパ球数増加	1 (3.4)	0	0	0
モラクセラ検査陽性	1 (3.4)	0	1 (3.6)	0
白血球数増加	1 (3.4)	1 (3.2)	0	1 (3.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 13 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
血中クロール減少	0	0	0	1 (3.1)
血中カリウム減少	0	1 (3.2)	0	1 (3.1)
血中ナトリウム減少	0	0	0	1 (3.1)
体温低下	0	0	1 (3.6)	0
骨密度減少	0	1 (3.2)	0	0
呼吸音異常	0	0	1 (3.6)	0
心電図ＳＴ－Ｔ部分異常	0	0	1 (3.6)	0
心拍数減少	0	1 (3.2)	0	0
心拍数増加	0	0	2 (7.1)	0
心拍数不整	0	0	0	1 (3.1)
炎症マーカー上昇	0	0	1 (3.6)	0
Ａ型インフルエンザウイルス検査陽性	0	0	1 (3.6)	0
肝機能検査異常	0	0	1 (3.6)	0
医学的観察	0	1 (3.2)	1 (3.6)	0
好中球数増加	0	1 (3.2)	1 (3.6)	1 (3.1)
好中球百分率増加	0	0	0	1 (3.1)
整形外科検査	0	0	1 (3.6)	0
シュードモナス検査陽性	0	0	1 (3.6)	1 (3.1)
セラチア検査陽性	0	0	1 (3.6)	0
ブドウ球菌検査陽性	0	1 (3.2)	1 (3.6)	0
レンサ球菌検査陽性	0	0	1 (3.6)	0
尿量減少	0	1 (3.2)	0	0
ビタミンＡ減少	0	0	1 (3.6)	0
体重減少	0	1 (3.2)	2 (7.1)	3 (9.4)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 14 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
神経系障害	5 (17.2)	6 (19.4)	6 (21.4)	4 (12.5)
筋緊張低下	2 (6.9)	0	0	0
反射亢進	1 (3.4)	0	0	0
不随意性筋収縮	1 (3.4)	1 (3.2)	1 (3.6)	1 (3.1)
傾眠	1 (3.4)	0	0	0
脳損傷	0	0	1 (3.6)	0
脳梗塞	0	1 (3.2)	0	0
脳脊髄液漏	0	1 (3.2)	0	0
間代	0	1 (3.2)	0	0
よだれ	0	0	1 (3.6)	1 (3.1)
頭痛	0	0	0	1 (3.1)
低酸素性虚血性脳症	0	1 (3.2)	0	0
言語障害	0	0	1 (3.6)	0
嗜眠	0	0	1 (3.6)	0
眼振	0	1 (3.2)	1 (3.6)	1 (3.1)
痙攣発作	0	1 (3.2)	1 (3.6)	0
失神	0	0	1 (3.6)	0
血管障害	4 (13.8)	3 (9.7)	2 (7.1)	1 (3.1)
高血圧	2 (6.9)	1 (3.2)	0	0
蒼白	2 (6.9)	0	0	0
毛細血管脆弱	0	1 (3.2)	0	0
本態性高血圧症	0	0	0	1 (3.1)
ショック	0	0	1 (3.6)	0
血栓症	0	0	1 (3.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 15 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
血管炎	0	1 (3.2)	0	0
血液およびリンパ系障害	3 (10.3)	1 (3.2)	0	4 (12.5)
好中球減少症	2 (6.9)	0	0	0
好酸球増加症	1 (3.4)	0	0	0
貧血	0	0	0	3 (9.4)
リンパ節症	0	0	0	1 (3.1)
血小板増加症	0	1 (3.2)	0	0
心臓障害	3 (10.3)	9 (29.0)	9 (32.1)	5 (15.6)
頻脈	3 (10.3)	2 (6.5)	3 (10.7)	3 (9.4)
徐脈	0	2 (6.5)	3 (10.7)	2 (6.3)
心停止	0	1 (3.2)	1 (3.6)	1 (3.1)
心肺停止	0	1 (3.2)	5 (17.9)	0
心筋症	0	1 (3.2)	0	0
チアノーゼ	0	1 (3.2)	2 (7.1)	0
左室肥大	0	2 (6.5)	0	0
心膜気腫	0	1 (3.2)	0	0
洞性頻脈	0	1 (3.2)	0	0
上室性頻脈	0	1 (3.2)	0	0
心室性頻脈	0	0	1 (3.6)	1 (3.1)
免疫系障害	3 (10.3)	6 (19.4)	4 (14.3)	2 (6.3)
食物アレルギー	2 (6.9)	0	0	0
季節性アレルギー	1 (3.4)	3 (9.7)	2 (7.1)	1 (3.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 16 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
薬物過敏症	0	2 (6.5)	2 (7.1)	0
過敏症	0	1 (3.2)	0	1 (3.1)
先天性、家族性および遺伝性障害	1 (3.4)	2 (6.5)	3 (10.7)	1 (3.1)
斜頭症	1 (3.4)	0	0	1 (3.1)
斜指症	0	1 (3.2)	0	0
先天性横隔膜ヘルニア	0	0	1 (3.6)	0
発育性股関節形成不全	0	0	1 (3.6)	0
貧血母斑	0	1 (3.2)	0	0
鳩胸	0	0	1 (3.6)	0
眼障害	1 (3.4)	2 (6.5)	1 (3.6)	3 (9.4)
後天性涙道狭窄	1 (3.4)	0	0	0
乱視	0	0	0	1 (3.1)
霰粒腫	0	0	1 (3.6)	0
眼乾燥	0	1 (3.2)	0	0
眼運動障害	0	1 (3.2)	0	0
眼瞼下垂	0	0	0	1 (3.1)
近視	0	0	0	1 (3.1)
斜視	0	0	0	1 (3.1)
肝胆道系障害	1 (3.4)	0	0	0
肝腫大	1 (3.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 17 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (3.4)	0	0	2 (6.3)
脂漏性角化症	1 (3.4)	0	0	0
アクロコルドン	0	0	0	1 (3.1)
血管の良性新生物	0	0	0	1 (3.1)
妊娠、産褥および周産期の状態	1 (3.4)	0	0	0
臍肉芽腫	1 (3.4)	0	0	0
精神障害	1 (3.4)	4 (12.9)	3 (10.7)	4 (12.5)
不安	1 (3.4)	0	2 (7.1)	2 (6.3)
激越	0	1 (3.2)	1 (3.6)	0
息こらえ	0	0	0	1 (3.1)
易刺激性	0	2 (6.5)	0	1 (3.1)
気分動揺	0	1 (3.2)	0	0
落ち着きのなさ	0	0	0	1 (3.1)
睡眠障害	0	0	1 (3.6)	0
腎および尿路障害	1 (3.4)	0	0	1 (3.1)
水腎症	1 (3.4)	0	0	0
尿閉	0	0	0	1 (3.1)
生殖系および乳房障害	1 (3.4)	1 (3.2)	2 (7.1)	1 (3.1)
外陰腟発疹	1 (3.4)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by weight quartiles
Page 18 of 18

	<5.28 kg	5.28-<6.305 kg	6.305-<7 kg	>=7 kg
後天性包茎	0	0	1 (3.6)	0
亀頭包皮炎	0	1 (3.2)	0	0
卵巣嚢胞	0	0	1 (3.6)	0
陰茎障害	0	0	0	1 (3.1)
耳および迷路障害	0	1 (3.2)	1 (3.6)	1 (3.1)
耳の障害	0	1 (3.2)	0	0
耳痛	0	0	1 (3.6)	0
耳垢分泌過多	0	0	0	1 (3.1)
外科および内科処置	0	0	1 (3.6)	0
機械的換気	0	0	1 (3.6)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 71　Later-Onset Subjects:Incidence of Adverse Events by Weight Quartiles

Later-onset subjects: incidence of adverse events by weight quartiles
Page 1 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
Number of subjects dosed	14 (100.0)	14 (100.0)	14 (100.0)	14 (100.0)
Number of subjects with an event	14 (100.0)	14 (100.0)	14 (100.0)	14 (100.0)
感染症および寄生虫症	12 (85.7)	12 (85.7)	10 (71.4)	10 (71.4)
上気道感染	8 (57.1)	7 (50.0)	7 (50.0)	5 (35.7)
ウイルス感染	4 (28.6)	3 (21.4)	2 (14.3)	0
ウイルス性胃腸炎	3 (21.4)	2 (14.3)	3 (21.4)	0
鼻咽頭炎	3 (21.4)	4 (28.6)	3 (21.4)	6 (42.9)
耳感染	2 (14.3)	2 (14.3)	0	0
胃腸炎	2 (14.3)	1 (7.1)	2 (14.3)	2 (14.3)
中耳炎	2 (14.3)	1 (7.1)	1 (7.1)	1 (7.1)
レンサ球菌性咽頭炎	2 (14.3)	1 (7.1)	3 (21.4)	2 (14.3)
肺炎	2 (14.3)	1 (7.1)	1 (7.1)	1 (7.1)
ウイルス性肺炎	2 (14.3)	0	0	0
ＲＳウイルス感染	2 (14.3)	0	1 (7.1)	0
ウイルス性上気道感染	2 (14.3)	1 (7.1)	1 (7.1)	1 (7.1)
結膜炎	1 (7.1)	1 (7.1)	1 (7.1)	0
ウイルス性眼感染	1 (7.1)	0	0	0
手足口病	1 (7.1)	0	0	0
インフルエンザ	1 (7.1)	0	2 (14.3)	0
下気道感染	1 (7.1)	0	0	0
単核細胞症症候群	1 (7.1)	0	0	0
ＲＳウイルス肺炎	1 (7.1)	0	0	0
ＲＳウイルス細気管支炎	1 (7.1)	0	0	0
ウイルス性気道感染	1 (7.1)	0	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted]　DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 2 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
皮膚細菌感染	1 (7.1)	0	0	0
尿路感染	1 (7.1)	1 (7.1)	1 (7.1)	1 (7.1)
膣感染	1 (7.1)	0	0	0
ウイルス性扁桃炎	1 (7.1)	0	0	0
蜂巣炎	0	0	0	1 (7.1)
ブドウ球菌性眼感染	0	0	0	1 (7.1)
皮膚真菌感染	0	0	0	1 (7.1)
ウイルス性消化管感染	0	1 (7.1)	1 (7.1)	0
膿痂疹	0	0	0	1 (7.1)
限局性感染	0	0	1 (7.1)	2 (14.3)
伝染性軟属腫	0	1 (7.1)	0	0
急性中耳炎	0	0	1 (7.1)	0
咽頭炎	0	1 (7.1)	0	0
気道感染	0	1 (7.1)	0	0
鼻炎	0	1 (7.1)	0	0
副鼻腔炎	0	1 (7.1)	0	2 (14.3)
皮膚カンジダ	0	1 (7.1)	1 (7.1)	0
扁桃炎	0	0	1 (7.1)	0
外陰膣真菌感染	0	0	1 (7.1)	0
筋骨格系および結合組織障害	12 (85.7)	9 (64.3)	10 (71.4)	10 (71.4)
側弯症	6 (42.9)	1 (7.1)	5 (35.7)	3 (21.4)
背部痛	4 (28.6)	3 (21.4)	8 (57.1)	8 (57.1)
関節拘縮	4 (28.6)	4 (28.6)	1 (7.1)	1 (7.1)
筋肉痛	2 (14.3)	1 (7.1)	0	1 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 3 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
四肢痛	2 (14.3)	0	3 (21.4)	0
関節痛	1 (7.1)	1 (7.1)	2 (14.3)	1 (7.1)
筋緊張	1 (7.1)	1 (7.1)	0	0
頚部痛	1 (7.1)	0	2 (14.3)	0
四肢拘縮	0	1 (7.1)	0	0
脊柱前弯症	0	1 (7.1)	0	0
骨盤変形	0	1 (7.1)	1 (7.1)	0
呼吸器、胸郭および縦隔障害	10 (71.4)	6 (42.9)	6 (42.9)	3 (21.4)
鼻漏	3 (21.4)	2 (14.3)	1 (7.1)	0
咳嗽	2 (14.3)	1 (7.1)	2 (14.3)	1 (7.1)
鼻出血	2 (14.3)	0	1 (7.1)	0
低酸素症	2 (14.3)	1 (7.1)	0	0
扁桃肥大	2 (14.3)	1 (7.1)	0	0
急性呼吸不全	1 (7.1)	0	0	0
無気肺	1 (7.1)	0	0	0
発声障害	1 (7.1)	0	0	0
呼吸困難	1 (7.1)	0	0	0
鼻閉	1 (7.1)	1 (7.1)	1 (7.1)	0
肺臓炎	1 (7.1)	0	0	0
呼吸障害	1 (7.1)	0	0	0
呼吸不全	1 (7.1)	0	0	0
拘束性肺疾患	1 (7.1)	0	0	0
喘鳴	1 (7.1)	0	0	0
口腔咽頭痛	0	3 (21.4)	3 (21.4)	2 (14.3)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 4 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
肺うっ血	0	0	1 (7.1)	0
副鼻腔うっ血	0	0	2 (14.3)	0
傷害、中毒および処置合併症	9 (64.3)	8 (57.1)	9 (64.3)	14 (100.0)
裂傷	4 (28.6)	1 (7.1)	0	2 (14.3)
節足動物咬傷	2 (14.3)	0	1 (7.1)	0
大腿骨骨折	2 (14.3)	0	1 (7.1)	0
転倒	1 (7.1)	0	0	0
関節脱臼	1 (7.1)	1 (7.1)	0	0
四肢損傷	1 (7.1)	0	1 (7.1)	1 (7.1)
腰椎穿刺後症候群	1 (7.1)	5 (35.7)	5 (35.7)	12 (85.7)
処置による疼痛	1 (7.1)	0	4 (28.6)	1 (7.1)
熱傷	1 (7.1)	0	0	0
術後激越	0	1 (7.1)	0	0
節足動物刺傷	0	0	1 (7.1)	0
挫傷	0	1 (7.1)	0	1 (7.1)
頭部損傷	0	0	0	1 (7.1)
関節損傷	0	0	1 (7.1)	1 (7.1)
靭帯捻挫	0	0	1 (7.1)	0
下肢骨折	0	1 (7.1)	0	0
半月板損傷	0	0	0	1 (7.1)
肉離れ	0	0	1 (7.1)	0
術後イレウス	0	0	1 (7.1)	0
処置による頭痛	0	0	0	1 (7.1)
処置による悪心	0	1 (7.1)	0	1 (7.1)

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 5 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
サンバーン	0	1 (7.1)	0	1 (7.1)
脛骨骨折	0	0	1 (7.1)	0
隆起骨折	0	1 (7.1)	1 (7.1)	0
一般・全身障害および投与部位の状態	7 (50.0)	10 (71.4)	8 (57.1)	6 (42.9)
発熱	7 (50.0)	6 (42.9)	2 (14.3)	1 (7.1)
低体温	1 (7.1)	0	0	0
注射部位出血	1 (7.1)	0	0	0
カテーテル留置部位出血	0	0	1 (7.1)	0
カテーテル留置部位疼痛	0	0	1 (7.1)	0
カテーテル留置部位関連反応	0	1 (7.1)	0	0
胸部不快感	0	0	1 (7.1)	0
悪寒	0	0	1 (7.1)	0
疲労	0	1 (7.1)	0	2 (14.3)
冷感	0	1 (7.1)	0	0
重力性浮腫	0	0	1 (7.1)	0
注射部位疼痛	0	0	0	1 (7.1)
疼痛	0	0	2 (14.3)	0
末梢腫脹	0	0	1 (7.1)	0
穿刺部位疼痛	0	3 (21.4)	4 (28.6)	3 (21.4)
穿刺部位反応	0	0	1 (7.1)	0
血管穿刺部位内出血	0	0	1 (7.1)	0
胃腸障害	6 (42.9)	9 (64.3)	7 (50.0)	4 (28.6)
便秘	3 (21.4)	4 (28.6)	0	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 6 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
悪心	2 (14.3)	4 (28.6)	1 (7.1)	3 (21.4)
嘔吐	2 (14.3)	6 (42.9)	3 (21.4)	1 (7.1)
上腹部痛	1 (7.1)	0	1 (7.1)	0
下痢	1 (7.1)	1 (7.1)	0	0
腹部不快感	0	0	0	1 (7.1)
腹痛	0	0	2 (14.3)	0
腹部症状	0	0	0	1 (7.1)
アフタ性潰瘍	0	2 (14.3)	1 (7.1)	0
放屁	0	0	1 (7.1)	0
食中毒	0	0	0	1 (7.1)
胃腸障害	0	0	1 (7.1)	0
胃食道逆流性疾患	0	0	0	1 (7.1)
口の感覚鈍麻	0	0	0	1 (7.1)
口唇痛	0	1 (7.1)	0	0
口腔内痛	0	0	1 (7.1)	1 (7.1)
口内炎	0	1 (7.1)	0	0
神経系障害	5 (35.7)	7 (50.0)	8 (57.1)	10 (71.4)
頭痛	4 (28.6)	7 (50.0)	7 (50.0)	10 (71.4)
振戦	1 (7.1)	0	0	0
失声症	0	0	1 (7.1)	0
味覚異常	0	1 (7.1)	0	0
失読症	0	0	1 (7.1)	0
感覚鈍麻	0	0	1 (7.1)	1 (7.1)
片頭痛	0	0	0	1 (7.1)
錯感覚	0	0	1 (7.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 7 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
失神	0	0	0	1 (7.1)
皮膚および皮下組織障害	4 (28.6)	6 (42.9)	2 (14.3)	5 (35.7)
接触性皮膚炎	1 (7.1)	1 (7.1)	0	1 (7.1)
汗疹	1 (7.1)	0	0	0
発疹	1 (7.1)	0	0	0
皮膚病変	1 (7.1)	0	0	0
ざ瘡	0	0	0	1 (7.1)
水疱	0	1 (7.1)	0	0
褥瘡性潰瘍	0	1 (7.1)	0	0
皮膚炎	0	0	1 (7.1)	0
おむつ皮膚炎	0	1 (7.1)	0	0
湿疹	0	0	0	2 (14.3)
紅斑	0	1 (7.1)	0	0
毛孔性角化症	0	0	0	1 (7.1)
寝汗	0	1 (7.1)	0	0
蕁麻疹	0	0	1 (7.1)	0
心臓障害	1 (7.1)	1 (7.1)	1 (7.1)	0
頻脈	1 (7.1)	0	0	0
動悸	0	1 (7.1)	1 (7.1)	0
眼障害	1 (7.1)	0	1 (7.1)	0
斜視	1 (7.1)	0	0	0
遠視	0	0	1 (7.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 8 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
代謝および栄養障害	1 (7.1)	2 (14.3)	1 (7.1)	1 (7.1)
食欲亢進	1 (7.1)	0	0	0
食欲減退	0	0	1 (7.1)	0
脱水	0	2 (14.3)	0	0
ビタミンD欠乏	0	0	0	1 (7.1)
腎および尿路障害	1 (7.1)	2 (14.3)	0	0
排尿困難	1 (7.1)	0	0	0
尿失禁	0	1 (7.1)	0	0
膀胱尿管逆流	0	1 (7.1)	0	0
血管障害	1 (7.1)	0	0	0
低血圧	1 (7.1)	0	0	0
血液およびリンパ系障害	0	0	1 (7.1)	0
好中球減少症	0	0	1 (7.1)	0
耳および迷路障害	0	3 (21.4)	0	0
耳痛	0	1 (7.1)	0	0
乗物酔い	0	1 (7.1)	0	0
鼓膜穿孔	0	1 (7.1)	0	0
免疫系障害	0	1 (7.1)	4 (28.6)	2 (14.3)
薬物過敏症	0	0	1 (7.1)	0
過敏症	0	0	1 (7.1)	2 (14.3)
季節性アレルギー	0	1 (7.1)	2 (14.3)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: incidence of adverse events by weight quartiles
Page 9 of 9

	<13.4 kg	13.4-<19.1 kg	19.1-<32.8 kg	>=32.8 kg
臨床検査	0	3 (21.4)	3 (21.4)	2 (14.3)
血中重炭酸塩減少	0	0	1 (7.1)	0
血中テストステロン減少	0	0	0	1 (7.1)
体温上昇	0	0	1 (7.1)	0
ＣＳＦ白血球数増加	0	0	1 (7.1)	0
心拍数増加	0	0	0	1 (7.1)
尿検査異常	0	1 (7.1)	0	0
体重減少	0	2 (14.3)	0	1 (7.1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (7.1)	0
皮膚乳頭腫	0	0	1 (7.1)	0
精神障害	0	0	3 (21.4)	1 (7.1)
激越	0	0	1 (7.1)	1 (7.1)
注意欠陥多動性障害	0	0	1 (7.1)	0
不快気分	0	0	0	1 (7.1)
不眠症	0	0	1 (7.1)	0
睡眠時随伴症	0	0	1 (7.1)	0
チック	0	0	1 (7.1)	0
心因性嘔吐	0	0	1 (7.1)	0

NOTE 1:Numbers in parentheses are percentages.
2:A subject was counted only once within each system organ class and preferred term.
3:Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 172　Presymptomatic Infants: Incidence of Adverse Events by Geographic Region

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 1 of 5

	North America	Europe	Asia-Pacific
Number of subjects dosed	13 (100.0)	3 (100.0)	4 (100.0)
Number of subjects with an event	11 (84.6)	3 (100.0)	2 (50.0)
感染症および寄生虫症	9 (69.2)	3 (100.0)	1 (25.0)
上気道感染	8 (61.5)	0	0
鼻咽頭炎	3 (23.1)	1 (33.3)	0
中耳炎	3 (23.1)	0	0
ウイルス性胃腸炎	2 (15.4)	0	0
ライノウイルス感染	2 (15.4)	0	0
細気管支炎	1 (7.7)	0	0
ブドウ球菌性耳感染	1 (7.7)	0	0
膿痂疹	1 (7.7)	0	0
レンサ球菌性咽頭炎	1 (7.7)	0	0
ウイルス性肺炎	1 (7.7)	0	0
皮膚感染	1 (7.7)	0	0
レンサ球菌感染	1 (7.7)	0	0
尿路感染	1 (7.7)	0	0
気管支炎	0	1 (33.3)	0
インフルエンザ	0	2 (66.7)	1 (25.0)
肺炎	0	2 (66.7)	0
鼻炎	0	2 (66.7)	0
胃腸障害	7 (53.8)	1 (33.3)	0
腹部膨満	2 (15.4)	0	0
放屁	2 (15.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 2 of 5

	North America	Europe	Asia-Pacific
胃食道逆流性疾患	2 (15.4)	0	0
腹部不快感	1 (7.7)	0	0
便秘	1 (7.7)	1 (33.3)	0
下痢	1 (7.7)	0	0
嚥下障害	1 (7.7)	0	0
生歯	1 (7.7)	0	0
一般・全身障害および投与部位の状態	5 (38.5)	0	1 (25.0)
発熱	4 (30.8)	0	1 (25.0)
適用部位紅斑	1 (7.7)	0	0
注入部位内出血	1 (7.7)	0	0
皮膚および皮下組織障害	5 (38.5)	3 (100.0)	1 (25.0)
おむつ皮膚炎	2 (15.4)	0	0
貨幣状湿疹	1 (7.7)	0	0
紅斑	1 (7.7)	0	0
紅斑性皮疹	1 (7.7)	0	0
脂漏性皮膚炎	1 (7.7)	0	0
皮膚炎	0	2 (66.7)	0
点状出血	0	1 (33.3)	0
発疹	0	0	1 (25.0)
呼吸器、胸郭および縦隔障害	4 (30.8)	2 (66.7)	0
鼻閉	3 (23.1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 3 of 5

	North America	Europe	Asia-Pacific
鼻漏	3 (23.1)	0	0
咳嗽	2 (15.4)	1 (33.3)	0
呼吸窮迫	1 (7.7)	0	0
上気道うっ血	1 (7.7)	0	0
息詰まり	0	1 (33.3)	0
呼吸性アシドーシス	0	1 (33.3)	0
傷害、中毒および処置合併症	3 (23.1)	0	0
節足動物咬傷	1 (7.7)	0	0
転倒	1 (7.7)	0	0
処置後合併症	1 (7.7)	0	0
処置後不快感	1 (7.7)	0	0
処置後腫脹	1 (7.7)	0	0
硬膜下血腫	1 (7.7)	0	0
臨床検査	3 (23.1)	0	0
アラニンアミノトランスフェラーゼ増加	1 (7.7)	0	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (7.7)	0	0
血中アルカリホスファターゼ増加	1 (7.7)	0	0
体温上昇	1 (7.7)	0	0
好酸球数増加	1 (7.7)	0	0
リンパ球数増加	1 (7.7)	0	0
酸素飽和度低下	1 (7.7)	0	0
白血球数増加	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 4 of 5

	North America	Europe	Asia-Pacific
代謝および栄養障害	3 (23.1)	1 (33.3)	0
脱水	2 (15.4)	0	0
成長障害	1 (7.7)	1 (33.3)	0
体重増加不良	1 (7.7)	0	0
心臓障害	2 (15.4)	0	0
頻脈	2 (15.4)	0	0
免疫系障害	2 (15.4)	0	0
食物アレルギー	1 (7.7)	0	0
季節性アレルギー	1 (7.7)	0	0
筋骨格系および結合組織障害	2 (15.4)	1 (33.3)	0
関節拘縮	1 (7.7)	0	0
筋力低下	1 (7.7)	1 (33.3)	0
頭位性斜頭症	1 (7.7)	0	0
斜頚	1 (7.7)	0	0
体重支持困難	1 (7.7)	0	0
神経系障害	2 (15.4)	0	1 (25.0)
反射亢進	1 (7.7)	0	0
筋緊張低下	1 (7.7)	0	1 (25.0)
血液およびリンパ系障害	1 (7.7)	1 (33.3)	0
好酸球増加症	1 (7.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Pre-symptomatic infants: incidence of adverse events by geographic region
Page 5 of 5

	North America	Europe	Asia-Pacific
好中球減少症	0	1 (33.3)	0
眼障害	1 (7.7)	0	0
後天性涙道狭窄	1 (7.7)	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (7.7)	0	0
脂漏性角化症	1 (7.7)	0	0
妊娠、産褥および周産期の状態	1 (7.7)	0	0
臍肉芽腫	1 (7.7)	0	0
生殖系および乳房障害	1 (7.7)	0	0
外陰腟発疹	1 (7.7)	0	0
血管障害	1 (7.7)	1 (33.3)	0
高血圧	1 (7.7)	0	0
蒼白	0	1 (33.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 173　Infantile-onset subjects in controlled study ISIS 396443-CS3B: incidence of adverse events by geographic region

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 1 of 36

	North America	
	Control	ISIS 396443
Number of subjects dosed	22 (100.0)	38 (100.0)
Number of subjects with an event	22 (100.0)	38 (100.0)
呼吸器、胸郭および縦隔障害	21 (95.5)	35 (92.1)
呼吸窮迫	10 (45.5)	12 (31.6)
急性呼吸不全	8 (36.4)	11 (28.9)
呼吸不全	7 (31.8)	11 (28.9)
無気肺	9 (40.9)	9 (23.7)
鼻閉	5 (22.7)	8 (21.1)
咳嗽	7 (31.8)	7 (18.4)
低酸素症	2 (9.1)	7 (18.4)
誤嚥性肺炎	5 (22.7)	6 (15.8)
誤嚥	3 (13.6)	5 (13.2)
上気道うっ血	1 (4.5)	5 (13.2)
呼吸困難	5 (22.7)	3 (7.9)
鼻漏	3 (13.6)	3 (7.9)
副鼻腔うっ血	0	3 (7.9)
無呼吸	2 (9.1)	2 (5.3)
気管支分泌物貯留	4 (18.2)	2 (5.3)
慢性呼吸不全	0	2 (5.3)
低換気	0	2 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 2 of 36

	North America	
	Control	ISIS 396443
急性呼吸窮迫症候群	0	1 (2.6)
高炭酸ガス血症	0	1 (2.6)
減呼吸	0	1 (2.6)
上気道分泌増加	1 (4.5)	1 (2.6)
胸水	0	1 (2.6)
気胸	0	1 (2.6)
呼吸性アルカローシス	0	1 (2.6)
呼吸停止	4 (18.2)	1 (2.6)
気道うっ血	2 (9.1)	1 (2.6)
アレルギー性鼻炎	0	1 (2.6)
変色痰	0	1 (2.6)
呼吸補助筋の動員	1 (4.5)	1 (2.6)
喘鳴	0	1 (2.6)
乳幼児突発性危急事態	2 (9.1)	0
気管支閉塞	0	0
カタル	0	0
息詰まり	1 (4.5)	0
気管支分泌増加	1 (4.5)	0
肺障害	0	0
閉塞性気道障害	0	0
口腔咽頭痛	0	0
呼吸障害	0	0
睡眠時無呼吸症候群	4 (18.2)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 3 of 36

	North America	
	Control	ISIS 396443
頻呼吸	2 (9.1)	0
上気道の炎症	0	0
感染症および寄生虫症	20 (90.9)	34 (89.5)
上気道感染	5 (22.7)	20 (52.6)
肺炎	4 (18.2)	11 (28.9)
ウイルス性上気道感染	7 (31.8)	8 (21.1)
ライノウイルス感染	5 (22.7)	7 (18.4)
鼻咽頭炎	4 (18.2)	6 (15.8)
ウイルス性肺炎	2 (9.1)	6 (15.8)
細気管支炎	2 (9.1)	4 (10.5)
口腔カンジダ症	1 (4.5)	4 (10.5)
尿路感染	0	4 (10.5)
耳感染	1 (4.5)	3 (7.9)
細菌性肺炎	3 (13.6)	3 (7.9)
ＲＳウイルス細気管支炎	3 (13.6)	3 (7.9)
ウイルス感染	3 (13.6)	3 (7.9)
アデノウイルス感染	0	2 (5.3)
ウイルス性気管支炎	0	2 (5.3)
結膜炎	2 (9.1)	2 (5.3)
細菌性結膜炎	1 (4.5)	2 (5.3)
インフルエンザ	0	2 (5.3)
中耳炎	2 (9.1)	2 (5.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 4 of 36

	North America	
	Control	ISIS 396443
ウイルス性気道感染	1 (4.5)	2 (5.3)
皮膚カンジダ	0	2 (5.3)
ストーマ部膿瘍	0	2 (5.3)
細菌感染	0	1 (2.6)
細菌性気管炎	4 (18.2)	1 (2.6)
気管支炎	0	1 (2.6)
蜂巣炎	1 (4.5)	1 (2.6)
眼感染	0	1 (2.6)
皮膚真菌感染	1 (4.5)	1 (2.6)
ウイルス性胃腸炎	2 (9.1)	1 (2.6)
下気道感染	1 (4.5)	1 (2.6)
ウイルス性下気道感染	0	1 (2.6)
モラクセラ感染	0	1 (2.6)
院内感染	0	1 (2.6)
急性中耳炎	0	1 (2.6)
インフルエンザ性肺炎	0	1 (2.6)
モラクセラ菌性肺炎	0	1 (2.6)
肺炎球菌性肺炎	0	1 (2.6)
シュードモナス感染	1 (4.5)	1 (2.6)
気道感染	0	1 (2.6)
敗血症	0	1 (2.6)
ブドウ球菌性敗血症	0	1 (2.6)
菌血症	1 (4.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 5 of 36

	North America	
	Control	ISIS 396443
細菌性疾患キャリアー	1 (4.5)	0
カンジダ感染	2 (9.1)	0
カンジダ性おむつ皮疹	1 (4.5)	0
カンジダ性敗血症	0	0
コロナウイルス感染	2 (9.1)	0
感染性湿疹	0	0
蟯虫症	0	0
腸球菌感染	0	0
大腸菌感染	0	0
真菌感染	0	0
胃腸炎	0	0
ロタウイルス胃腸炎	0	0
手足口病	1 (4.5)	0
麦粒腫	1 (4.5)	0
膿痂疹	1 (4.5)	0
限局性感染	0	0
肺感染	0	0
口腔真菌感染	0	0
口腔ヘルペス	0	0
パラインフルエンザウイルス感染	1 (4.5)	0
パラインフルエンザウイルス性肺炎	1 (4.5)	0
シュードモナス菌性肺炎	0	0
ＲＳウイルス肺炎	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region

	North America	
	Control	ISIS 396443
腎盂腎炎	0	0
細菌性気道感染	1 (4.5)	0
鼻炎	0	0
ばら疹	0	0
セラチア感染	1 (4.5)	0
副鼻腔炎	1 (4.5)	0
皮膚感染	1 (4.5)	0
ブドウ球菌感染	1 (4.5)	0
ブドウ球菌皮膚感染	0	0
ストーマ部感染	3 (13.6)	0
全身性感染	0	0
気管炎	1 (4.5)	0
ウイルス性発疹	1 (4.5)	0
胃腸障害	16 (72.7)	32 (84.2)
便秘	5 (22.7)	17 (44.7)
嚥下障害	7 (31.8)	9 (23.7)
下痢	6 (27.3)	8 (21.1)
生歯	2 (9.1)	8 (21.1)
嘔吐	6 (27.3)	8 (21.1)
胃食道逆流性疾患	4 (18.2)	7 (18.4)
流涎過多	0	6 (15.8)
放屁	1 (4.5)	4 (10.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 7 of 36

	North America	
	Control	ISIS 396443
胃炎	1 (4.5)	2 (5.3)
血便排泄	0	2 (5.3)
腹部膨満	0	1 (2.6)
胃出血	0	1 (2.6)
乳児仙痛	0	1 (2.6)
乳児吐出	0	1 (2.6)
上部消化管出血	0	1 (2.6)
腹部不快感	0	0
上腹部痛	1 (4.5)	0
アフタ性潰瘍	0	0
血性下痢	1 (4.5)	0
小腸炎	0	0
心窩部不快感	0	0
胃腸出血	0	0
消化管運動障害	1 (4.5)	0
消化管刺激症状	0	0
胃排出不全	0	0
レッチング	1 (4.5)	0
口内炎	0	0
舌萎縮	1 (4.5)	0
一般・全身障害および投与部位の状態	15 (68.2)	27 (71.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 8 of 36

	North America	
	Control	ISIS 396443
発熱	13 (59.1)	25 (65.8)
カテーテル留置部位炎症	1 (4.5)	1 (2.6)
泣き	0	1 (2.6)
薬物不耐性	0	1 (2.6)
低体温	0	1 (2.6)
医療機器合併症	0	1 (2.6)
小結節	0	1 (2.6)
疼痛	0	1 (2.6)
外科手術不成功	0	1 (2.6)
腫脹	0	1 (2.6)
適用部位発疹	1 (4.5)	0
死亡	1 (4.5)	0
医療機器機能不良	1 (4.5)	0
医療機器閉塞	1 (4.5)	0
疲労	0	0
全身健康状態低下	0	0
注入部位内出血	1 (4.5)	0
注入部位血管外漏出	1 (4.5)	0
注射部位血腫	0	0
ワクチン接種後の易刺激性	0	0
倦怠感	0	0
浮腫	2 (9.1)	0
血管穿刺部位内出血	2 (9.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 9 of 36

	North America	
	Control	ISIS 396443
血管穿刺部位反応	0	0
皮膚および皮下組織障害	13 (59.1)	19 (50.0)
発疹	3 (13.6)	8 (21.1)
おむつ皮膚炎	4 (18.2)	5 (13.2)
接触性皮膚炎	3 (13.6)	2 (5.3)
斑状出血	0	2 (5.3)
過角化	0	2 (5.3)
皮膚炎	0	1 (2.6)
アレルギー性皮膚炎	0	1 (2.6)
紅斑	2 (9.1)	1 (2.6)
環状肉芽腫	0	1 (2.6)
汗疹	0	1 (2.6)
斑状皮疹	0	1 (2.6)
丘疹性皮疹	0	1 (2.6)
皮膚浮腫	0	1 (2.6)
蕁麻疹	0	1 (2.6)
褥瘡性潰瘍	3 (13.6)	0
アトピー性皮膚炎	2 (9.1)	0
皮膚乾燥	1 (4.5)	0
湿疹	2 (9.1)	0
多汗症	1 (4.5)	0
間擦疹	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 10 of 36

	North America	
	Control	ISIS 396443
毛孔性角化症	1 (4.5)	0
紅斑性皮疹	1 (4.5)	0
傷害、中毒および処置合併症	7 (31.8)	14 (36.8)
大腿骨骨折	1 (4.5)	3 (7.9)
処置による疼痛	0	2 (5.3)
ストーマ部紅斑	1 (4.5)	2 (5.3)
術後激越	0	1 (2.6)
節足動物咬傷	0	1 (2.6)
挫傷	0	1 (2.6)
擦過傷	0	1 (2.6)
栄養補給チューブ合併症	3 (13.6)	1 (2.6)
処置後腫脹	0	1 (2.6)
処置部位反応	0	1 (2.6)
ストーマ合併症	2 (9.1)	1 (2.6)
ストーマ部刺激感	1 (4.5)	1 (2.6)
麻酔からの覚醒遅延	0	0
気管内挿管合併症	1 (4.5)	0
伝染病曝露	0	0
頭部損傷	0	0
切開部位紅斑	0	0
裂傷	1 (4.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 11 of 36

	North America	
	Control	ISIS 396443
処置後挫傷	1 (4.5)	0
処置後出血	0	0
処置合併症	0	0
ストーマ部出血	1 (4.5)	0
ストーマ部炎症	1 (4.5)	0
気管出血	0	0
気管損傷	1 (4.5)	0
気管閉塞	0	0
ワクチン接種合併症	1 (4.5)	0
心臓障害	11 (50.0)	11 (28.9)
頻脈	4 (18.2)	5 (13.2)
徐脈	3 (13.6)	3 (7.9)
心肺停止	4 (18.2)	3 (7.9)
チアノーゼ	2 (9.1)	2 (5.3)
左室肥大	0	2 (5.3)
心停止	2 (9.1)	1 (2.6)
上室性頻脈	0	1 (2.6)
洞性頻脈	0	0
心室性頻脈	0	0
臨床検査	10 (45.5)	9 (23.7)
酸素飽和度低下	7 (31.8)	8 (21.1)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 12 of 36

	North America	
	Control	ISIS 396443
体温低下	1 (4.5)	1 (2.6)
心電図ＳＴ－Ｔ部分異常	1 (4.5)	1 (2.6)
心拍数増加	1 (4.5)	1 (2.6)
心拍数不整	0	1 (2.6)
炎症マーカー上昇	0	1 (2.6)
Ａ型インフルエンザウイルス検査陽性	0	1 (2.6)
肝機能検査異常	0	1 (2.6)
好中球数増加	0	1 (2.6)
整形外科検査	0	1 (2.6)
ブドウ球菌検査陽性	0	1 (2.6)
ビタミンＡ減少	0	1 (2.6)
アラニンアミノトランスフェラーゼ増加	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	0
血中クロール減少	0	0
血中鉄減少	0	0
血中カリウム減少	0	0
血中ナトリウム減少	0	0
体温上昇	0	0
Ｃ－反応性蛋白増加	0	0
ヘッドラグ異常	0	0
心拍数減少	0	0
ヒトライノウイルス検査陽性	0	0
リンパ節触知	1 (4.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 13 of 36

	North America	
	Control	ISIS 396443
医学的観察	0	0
モラクセラ検査陽性	0	0
シュードモナス検査陽性	0	0
呼吸数増加	0	0
レスピロウイルス検査陽性	1 (4.5)	0
喀痰培養陽性	1 (4.5)	0
トランスアミナーゼ上昇	1 (4.5)	0
尿量減少	0	0
ビタミンD減少	1 (4.5)	0
体重減少	0	0
筋骨格系および結合組織障害	5 (22.7)	9 (23.7)
側弯症	2 (9.1)	3 (7.9)
関節拘縮	2 (9.1)	2 (5.3)
背部痛	0	1 (2.6)
胸郭変形	0	1 (2.6)
泉門閉鎖遅延	0	1 (2.6)
後側弯症	0	1 (2.6)
脊柱後弯症	1 (4.5)	1 (2.6)
四肢痛	0	1 (2.6)
頭位性斜頭症	1 (4.5)	1 (2.6)
関節可動域低下	1 (4.5)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 14 of 36

	North America	
	Control	ISIS 396443
関節硬直	1 (4.5)	0
筋緊張	1 (4.5)	0
筋力低下	1 (4.5)	0
代謝および栄養障害	9 (40.9)	7 (18.4)
成長障害	2 (9.1)	2 (5.3)
栄養補給不耐性	0	2 (5.3)
脱水	2 (9.1)	1 (2.6)
乳児および小児期早期の哺育障害	0	1 (2.6)
鉄欠乏	0	1 (2.6)
体重増加不良	1 (4.5)	1 (2.6)
食物不耐性	0	0
高血糖	1 (4.5)	0
低血糖	2 (9.1)	0
低カリウム血症	3 (13.6)	0
ビタミンD欠乏	1 (4.5)	0
神経系障害	1 (4.5)	7 (18.4)
眼振	0	2 (5.3)
脳損傷	0	1 (2.6)
よだれ	0	1 (2.6)
低酸素性虚血性脳症	0	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 15 of 36

	North America	
	Control	ISIS 396443
言語障害	0	1 (2.6)
痙攣発作	0	1 (2.6)
傾眠	0	1 (2.6)
間代	0	0
不随意性筋収縮	0	0
失神寸前の状態	1 (4.5)	0
精神障害	2 (9.1)	6 (15.8)
激越	1 (4.5)	2 (5.3)
易刺激性	1 (4.5)	2 (5.3)
不安	0	1 (2.6)
息こらえ	0	1 (2.6)
落ち着きのなさ	0	1 (2.6)
気分動揺	0	0
睡眠障害	1 (4.5)	0
免疫系障害	4 (18.2)	5 (13.2)
薬物過敏症	1 (4.5)	2 (5.3)
季節性アレルギー	2 (9.1)	2 (5.3)
食物アレルギー	0	1 (2.6)
過敏症	2 (9.1)	0
眼障害	1 (4.5)	4 (10.5)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 16 of 36

	North America	
	Control	ISIS 396443
霰粒腫	0	1 (2.6)
眼乾燥	0	1 (2.6)
眼運動障害	0	1 (2.6)
近視	0	1 (2.6)
斜視	0	1 (2.6)
弱視	0	0
流涙増加	1 (4.5)	0
先天性、家族性および遺伝性障害	4 (18.2)	3 (7.9)
先天性横隔膜ヘルニア	0	1 (2.6)
発育性股関節形成不全	1 (4.5)	1 (2.6)
鳩胸	1 (4.5)	1 (2.6)
停留精巣	1 (4.5)	0
貧血母斑	0	0
包茎	1 (4.5)	0
耳および迷路障害	1 (4.5)	2 (5.3)
耳の障害	0	1 (2.6)
耳痛	0	1 (2.6)
耳出血	1 (4.5)	0
腎および尿路障害	1 (4.5)	2 (5.3)
水腎症	0	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 17 of 36

	North America	
	Control	ISIS 396443
尿閉	0	1 (2.6)
糖尿	1 (4.5)	0
生殖系および乳房障害	0	2 (5.3)
後天性包茎	0	1 (2.6)
陰茎障害	0	1 (2.6)
亀頭包皮炎	0	0
卵巣嚢胞	0	0
血管障害	0	2 (5.3)
高血圧	0	1 (2.6)
ショック	0	1 (2.6)
充血	0	0
蒼白	0	0
血栓症	0	0
血管炎	0	0
血液およびリンパ系障害	2 (9.1)	1 (2.6)
貧血	1 (4.5)	1 (2.6)
骨髄障害	0	0
白血球増加症	1 (4.5)	0
肝胆道系障害	0	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 18 of 36

	North America	
	Control	ISIS 396443
肝腫大	0	1 (2.6)
外科および内科処置	0	1 (2.6)
機械的換気	0	1 (2.6)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 19 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
Number of subjects dosed	17 (100.0)	30 (100.0)	2 (100.0)	12 (100.0)
Number of subjects with an event	16 (94.1)	27 (90.0)	2 (100.0)	12 (100.0)
感染症および寄生虫症	11 (64.7)	22 (73.3)	0	9 (75.0)
気道感染	2 (11.8)	8 (26.7)	0	0
鼻咽頭炎	0	7 (23.3)	0	2 (16.7)
肺炎	3 (17.6)	7 (23.3)	0	5 (41.7)
気管支炎	1 (5.9)	5 (16.7)	0	0
ウイルス感染	0	5 (16.7)	0	0
ウイルス性気管支炎	0	3 (10.0)	0	0
口腔カンジダ症	2 (11.8)	3 (10.0)	0	0
ライノウイルス感染	1 (5.9)	3 (10.0)	0	0
細気管支炎	1 (5.9)	2 (6.7)	0	2 (16.7)
耳感染	0	2 (6.7)	0	0
下気道感染	1 (5.9)	2 (6.7)	0	1 (8.3)
シュードモナス感染	1 (5.9)	2 (6.7)	0	0
ウイルス性気道感染	1 (5.9)	2 (6.7)	0	0
鼻炎	3 (17.6)	2 (6.7)	0	0
カンジダ性おむつ皮疹	0	1 (3.3)	0	0
結膜炎	1 (5.9)	1 (3.3)	0	2 (16.7)
大腸菌感染	0	1 (3.3)	0	0
真菌感染	1 (5.9)	1 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 20 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
ロタウイルス胃腸炎	0	1 (3.3)	0	0
手足口病	0	1 (3.3)	0	0
膿痂疹	0	1 (3.3)	0	0
インフルエンザ	0	1 (3.3)	0	2 (16.7)
限局性感染	0	1 (3.3)	0	0
ウイルス性下気道感染	0	1 (3.3)	0	0
口腔真菌感染	0	1 (3.3)	0	0
口腔ヘルペス	0	1 (3.3)	0	0
中耳炎	0	1 (3.3)	0	0
ＲＳウイルス肺炎	0	1 (3.3)	0	0
ウイルス性肺炎	0	1 (3.3)	0	0
腎盂腎炎	0	1 (3.3)	0	0
ＲＳウイルス細気管支炎	0	1 (3.3)	0	0
ばら疹	0	1 (3.3)	0	0
敗血症	0	1 (3.3)	0	0
ブドウ球菌皮膚感染	0	1 (3.3)	0	0
ストーマ部感染	0	1 (3.3)	0	0
上気道感染	4 (23.5)	1 (3.3)	0	3 (25.0)
尿路感染	0	1 (3.3)	0	2 (16.7)
アデノウイルス感染	0	0	0	0
菌血症	0	0	0	0
細菌性疾患キャリアー	0	0	0	0
細菌感染	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 21 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
細菌性気管炎	0	0	0	0
カンジダ感染	1 (5.9)	0	0	0
カンジダ性敗血症	1 (5.9)	0	0	0
蜂巣炎	0	0	0	0
細菌性結膜炎	0	0	0	0
コロナウイルス感染	0	0	0	0
感染性湿疹	0	0	0	1 (8.3)
蟯虫症	0	0	0	1 (8.3)
腸球菌感染	0	0	0	1 (8.3)
眼感染	0	0	0	0
皮膚真菌感染	0	0	0	0
胃腸炎	0	0	0	1 (8.3)
ウイルス性胃腸炎	0	0	0	0
麦粒腫	0	0	0	0
肺感染	0	0	0	1 (8.3)
モラクセラ感染	0	0	0	0
院内感染	0	0	0	0
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0
細菌性肺炎	0	0	0	0
インフルエンザ性肺炎	0	0	0	0
モラクセラ菌性肺炎	0	0	0	0
パラインフルエンザウイルス性肺炎	0	0	0	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 22 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
肺炎球菌性肺炎	0	0	0	0
シュードモナス菌性肺炎	1 (5.9)	0	0	0
細菌性気道感染	0	0	0	0
セラチア感染	0	0	0	0
副鼻腔炎	0	0	0	0
皮膚カンジダ	1 (5.9)	0	0	0
皮膚感染	0	0	0	0
ブドウ球菌感染	1 (5.9)	0	0	0
ブドウ球菌性敗血症	0	0	0	0
ストーマ部膿瘍	0	0	0	0
全身性感染	1 (5.9)	0	0	0
気管炎	0	0	0	0
ウイルス性発疹	0	0	0	0
ウイルス性上気道感染	0	0	0	0
呼吸器、胸郭および縦隔障害	14 (82.4)	22 (73.3)	1 (50.0)	4 (33.3)
呼吸不全	8 (47.1)	9 (30.0)	1 (50.0)	0
無気肺	3 (17.6)	8 (26.7)	0	1 (8.3)
呼吸窮迫	2 (11.8)	8 (26.7)	0	1 (8.3)
呼吸停止	0	4 (13.3)	0	0
誤嚥性肺炎	2 (11.8)	3 (10.0)	0	0
無呼吸	1 (5.9)	2 (6.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
気管支分泌物貯留	3 (17.6)	2 (6.7)	0	0
咳嗽	1 (5.9)	2 (6.7)	0	0
呼吸障害	0	2 (6.7)	0	0
鼻漏	0	2 (6.7)	0	1 (8.3)
気管支閉塞	0	1 (3.3)	0	0
息詰まり	0	1 (3.3)	0	0
呼吸困難	1 (5.9)	1 (3.3)	0	3 (25.0)
気管支分泌増加	0	1 (3.3)	0	0
肺障害	1 (5.9)	1 (3.3)	0	0
閉塞性気道障害	0	1 (3.3)	0	0
気道うっ血	1 (5.9)	1 (3.3)	0	0
上気道うっ血	0	1 (3.3)	0	0
急性呼吸窮迫症候群	1 (5.9)	0	0	0
急性呼吸不全	2 (11.8)	0	0	0
乳幼児突発性危急事態	0	0	0	0
誤嚥	0	0	0	0
カタル	1 (5.9)	0	0	0
慢性呼吸不全	0	0	0	0
高炭酸ガス血症	0	0	0	0
減呼吸	0	0	0	0
低換気	0	0	0	0
低酸素症	0	0	0	0
上気道分泌増加	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 24 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
鼻閉	0	0	0	0
口腔咽頭痛	1 (5.9)	0	0	0
胸水	0	0	0	0
気胸	0	0	0	0
呼吸性アルカローシス	0	0	0	0
アレルギー性鼻炎	0	0	0	0
副鼻腔うっ血	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0
変色痰	1 (5.9)	0	0	0
頻呼吸	0	0	0	0
上気道の炎症	2 (11.8)	0	0	0
呼吸補助筋の動員	0	0	0	0
喘鳴	0	0	0	1 (8.3)
一般・全身障害および投与部位の状態	12 (70.6)	20 (66.7)	1 (50.0)	4 (33.3)
発熱	10 (58.8)	16 (53.3)	1 (50.0)	4 (33.3)
死亡	0	1 (3.3)	0	0
医療機器閉塞	0	1 (3.3)	0	0
全身健康状態低下	0	1 (3.3)	0	0
ワクチン接種後の易刺激性	0	1 (3.3)	0	0
倦怠感	0	1 (3.3)	0	0
適用部位発疹	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 25 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
カテーテル留置部位炎症	0	0	0	0
泣き	0	0	0	0
医療機器機能不良	0	0	0	0
薬物不耐性	0	0	0	0
疲労	1 (5.9)	0	0	0
低体温	0	0	0	0
注入部位内出血	0	0	0	0
注入部位血管外漏出	0	0	0	0
注射部位血腫	1 (5.9)	0	0	0
医療機器合併症	0	0	0	0
小結節	0	0	0	0
浮腫	0	0	1 (50.0)	0
疼痛	2 (11.8)	0	0	0
外科手術不成功	0	0	0	0
腫脹	0	0	0	0
血管穿刺部位内出血	0	0	0	0
血管穿刺部位反応	1 (5.9)	0	0	0
胃腸障害	9 (52.9)	14 (46.7)	1 (50.0)	7 (58.3)
便秘	4 (23.5)	6 (20.0)	0	5 (41.7)
嘔吐	2 (11.8)	5 (16.7)	0	1 (8.3)
胃食道逆流性疾患	3 (17.6)	3 (10.0)	1 (50.0)	0
生歯	1 (5.9)	3 (10.0)	0	3 (25.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 26 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
腹部不快感	0	2 (6.7)	0	0
下痢	1 (5.9)	2 (6.7)	0	1 (8.3)
胃炎	0	1 (3.3)	0	0
胃排出不全	0	1 (3.3)	0	0
腹部膨満	0	0	0	0
上腹部痛	1 (5.9)	0	0	0
アフタ性潰瘍	0	0	0	1 (8.3)
血性下痢	0	0	0	0
嚥下障害	2 (11.8)	0	0	0
小腸炎	1 (5.9)	0	0	0
心窩部不快感	1 (5.9)	0	0	0
放屁	0	0	0	0
胃出血	0	0	0	0
胃腸出血	1 (5.9)	0	0	0
消化管運動障害	0	0	0	0
消化管刺激症状	1 (5.9)	0	0	0
血便排泄	0	0	0	0
乳児仙痛	0	0	0	0
乳児吐出	0	0	0	0
レッチング	0	0	0	0
流涎過多	2 (11.8)	0	0	0
口内炎	1 (5.9)	0	0	0
舌萎縮	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 27 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
上部消化管出血	0	0	0	0
臨床検査	4 (23.5)	11 (36.7)	0	1 (8.3)
体重減少	1 (5.9)	4 (13.3)	0	0
血中カリウム減少	0	2 (6.7)	0	0
体温上昇	1 (5.9)	2 (6.7)	0	0
Ｃ－反応性蛋白増加	1 (5.9)	2 (6.7)	0	0
医学的観察	0	2 (6.7)	0	0
アラニンアミノトランスフェラーゼ増加	0	1 (3.3)	0	0
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (3.3)	0	0
血中クロール減少	0	1 (3.3)	0	0
血中鉄減少	0	1 (3.3)	0	0
血中ナトリウム減少	0	1 (3.3)	0	0
ヒトライノウイルス検査陽性	0	1 (3.3)	0	0
モラクセラ検査陽性	0	1 (3.3)	0	0
酸素飽和度低下	3 (17.6)	1 (3.3)	0	1 (8.3)
シュードモナス検査陽性	0	1 (3.3)	0	0
尿量減少	0	1 (3.3)	0	0
体温低下	0	0	0	0
心電図ＳＴ－Ｔ部分異常	0	0	0	0
ヘッドラグ異常	1 (5.9)	0	0	0
心拍数減少	1 (5.9)	0	0	0
心拍数増加	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 28 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
心拍数不整	0	0	0	0
炎症マーカー上昇	0	0	0	0
A型インフルエンザウイルス検査陽性	0	0	0	0
肝機能検査異常	0	0	0	0
リンパ節触知	0	0	0	0
好中球数増加	0	0	0	0
整形外科検査	0	0	0	0
呼吸数増加	1 (5.9)	0	0	0
レスピロウイルス検査陽性	0	0	0	0
喀痰培養陽性	0	0	0	0
ブドウ球菌検査陽性	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0
ビタミンA減少	0	0	0	0
ビタミンD減少	0	0	0	0
代謝および栄養障害	4 (23.5)	6 (20.0)	0	1 (8.3)
体重増加不良	1 (5.9)	4 (13.3)	0	0
乳児および小児期早期の哺育障害	3 (17.6)	2 (6.7)	0	0
栄養補給不耐性	0	1 (3.3)	0	0
脱水	0	0	0	0
成長障害	0	0	0	1 (8.3)
食物不耐性	1 (5.9)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 29 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
高血糖	0	0	0	0
低血糖	0	0	0	0
低カリウム血症	0	0	0	0
鉄欠乏	0	0	0	0
ビタミンD欠乏	0	0	0	0
心臓障害	2 (11.8)	5 (16.7)	0	2 (16.7)
心肺停止	1 (5.9)	2 (6.7)	0	0
頻脈	1 (5.9)	2 (6.7)	0	0
徐脈	0	1 (3.3)	0	0
心停止	0	1 (3.3)	0	0
チアノーゼ	0	0	0	0
左室肥大	0	0	0	0
洞性頻脈	0	0	0	1 (8.3)
上室性頻脈	0	0	0	0
心室性頻脈	0	0	0	1 (8.3)
傷害、中毒および処置合併症	2 (11.8)	5 (16.7)	1 (50.0)	0
麻酔からの覚醒遅延	0	1 (3.3)	0	0
伝染病曝露	0	1 (3.3)	0	0
栄養補給チューブ合併症	0	1 (3.3)	0	0
処置合併症	0	1 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 30 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
ワクチン接種合併症	0	1 (3.3)	0	0
術後激越	0	0	0	0
節足動物咬傷	0	0	0	0
挫傷	0	0	0	0
気管内挿管合併症	0	0	0	0
擦過傷	1 (5.9)	0	0	0
大腿骨骨折	0	0	0	0
頭部損傷	1 (5.9)	0	0	0
切開部位紅斑	1 (5.9)	0	0	0
裂傷	0	0	0	0
処置後挫傷	0	0	0	0
処置後出血	1 (5.9)	0	0	0
処置後腫脹	0	0	0	0
処置による疼痛	0	0	0	0
処置部位反応	0	0	0	0
ストーマ合併症	0	0	0	0
ストーマ部紅斑	0	0	1 (50.0)	0
ストーマ部出血	0	0	0	0
ストーマ部炎症	0	0	0	0
ストーマ部刺激感	0	0	0	0
気管出血	1 (5.9)	0	0	0
気管損傷	0	0	0	0
気管閉塞	1 (5.9)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 31 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
血管障害	1 (5.9)	3 (10.0)	0	0
蒼白	0	1 (3.3)	0	0
血栓症	0	1 (3.3)	0	0
血管炎	0	1 (3.3)	0	0
充血	1 (5.9)	0	0	0
高血圧	0	0	0	0
ショック	0	0	0	0
免疫系障害	0	2 (6.7)	0	0
過敏症	0	1 (3.3)	0	0
季節性アレルギー	0	1 (3.3)	0	0
薬物過敏症	0	0	0	0
食物アレルギー	0	0	0	0
筋骨格系および結合組織障害	0	2 (6.7)	0	0
関節拘縮	0	1 (3.3)	0	0
頭位性斜頭症	0	1 (3.3)	0	0
側弯症	0	1 (3.3)	0	0
背部痛	0	0	0	0
胸郭変形	0	0	0	0
泉門閉鎖遅延	0	0	0	0
関節可動域低下	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 32 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
関節硬直	0	0	0	0
後側弯症	0	0	0	0
脊柱後弯症	0	0	0	0
筋緊張	0	0	0	0
筋力低下	0	0	0	0
四肢痛	0	0	0	0
神経系障害	0	2 (6.7)	1 (50.0)	0
間代	0	1 (3.3)	0	0
不随意性筋収縮	0	1 (3.3)	0	0
脳損傷	0	0	0	0
よだれ	0	0	0	0
低酸素性虚血性脳症	0	0	0	0
言語障害	0	0	0	0
眼振	0	0	1 (50.0)	0
失神寸前の状態	0	0	0	0
痙攣発作	0	0	0	0
傾眠	0	0	0	0
精神障害	3 (17.6)	2 (6.7)	0	1 (8.3)
不安	0	1 (3.3)	0	0
易刺激性	0	1 (3.3)	0	0
睡眠障害	1 (5.9)	1 (3.3)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 33 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
激越	1 (5.9)	0	0	0
息こらえ	0	0	0	0
気分動揺	0	0	0	1 (8.3)
落ち着きのなさ	1 (5.9)	0	0	0
生殖系および乳房障害	0	2 (6.7)	0	0
亀頭包皮炎	0	1 (3.3)	0	0
卵巣嚢胞	0	1 (3.3)	0	0
後天性包茎	0	0	0	0
陰茎障害	0	0	0	0
皮膚および皮下組織障害	1 (5.9)	2 (6.7)	1 (50.0)	2 (16.7)
おむつ皮膚炎	0	1 (3.3)	0	0
皮膚乾燥	0	1 (3.3)	0	0
褥瘡性潰瘍	0	0	0	0
皮膚炎	0	0	0	0
アレルギー性皮膚炎	0	0	0	0
アトピー性皮膚炎	0	0	0	0
接触性皮膚炎	0	0	0	0
斑状出血	0	0	0	0
湿疹	0	0	0	1 (8.3)
紅斑	0	0	1 (50.0)	0
環状肉芽腫	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 34 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
多汗症	0	0	0	0
過角化	0	0	0	0
間擦疹	0	0	0	1 (8.3)
毛孔性角化症	0	0	0	0
汗疹	0	0	0	1 (8.3)
発疹	1 (5.9)	0	0	1 (8.3)
紅斑性皮疹	0	0	0	0
斑状皮疹	0	0	0	0
丘疹性皮疹	0	0	0	0
皮膚浮腫	0	0	0	0
蕁麻疹	0	0	0	0
先天性、家族性および遺伝性障害	0	1 (3.3)	0	0
貧血母斑	0	1 (3.3)	0	0
先天性横隔膜ヘルニア	0	0	0	0
停留精巣	0	0	0	0
発育性股関節形成不全	0	0	0	0
鳩胸	0	0	0	0
包茎	0	0	0	0
血液およびリンパ系障害	1 (5.9)	0	0	0
貧血	0	0	0	0
骨髄障害	1 (5.9)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 35 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
白血球増加症	0	0	0	0
耳および迷路障害	0	0	0	0
耳の障害	0	0	0	0
耳出血	0	0	0	0
耳痛	0	0	0	0
眼障害	1 (5.9)	0	1 (50.0)	0
弱視	0	0	1 (50.0)	0
霰粒腫	0	0	0	0
眼乾燥	1 (5.9)	0	0	0
眼運動障害	0	0	0	0
流涙増加	0	0	0	0
近視	0	0	0	0
斜視	0	0	1 (50.0)	0
肝胆道系障害	0	0	0	0
肝腫大	0	0	0	0
腎および尿路障害	0	0	0	0
糖尿	0	0	0	0
水腎症	0	0	0	0
尿閉	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects in controlled study ISIS 396443-CS3B:
incidence of adverse events by geographic region
Page 36 of 36

	Europe		Asia-Pacific	
	Control	ISIS 396443	Control	ISIS 396443
外科および内科処置	0	0	0	0
機械的換気	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 174 Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies: incidence of adverse events by geographic region

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 1 of 17

	North America	Europe	Asia-Pacific
Number of subjects dosed	58 (100.0)	30 (100.0)	12 (100.0)
Number of subjects with an event	58 (100.0)	27 (90.0)	12 (100.0)
感染症および寄生虫症	53 (91.4)	22 (73.3)	9 (75.0)
上気道感染	32 (55.2)	1 (3.3)	3 (25.0)
肺炎	18 (31.0)	7 (23.3)	5 (41.7)
ライノウイルス感染	13 (22.4)	3 (10.0)	0
鼻咽頭炎	12 (20.7)	7 (23.3)	2 (16.7)
ウイルス性上気道感染	10 (17.2)	0	0
ウイルス性肺炎	9 (15.5)	1 (3.3)	0
中耳炎	8 (13.8)	1 (3.3)	0
細気管支炎	7 (12.1)	2 (6.7)	2 (16.7)
ウイルス感染	7 (12.1)	5 (16.7)	0
気道感染	6 (10.3)	8 (26.7)	0
口腔カンジダ症	5 (8.6)	3 (10.0)	0
耳感染	4 (6.9)	2 (6.7)	0
細菌性肺炎	4 (6.9)	0	0
ＲＳウイルス細気管支炎	4 (6.9)	1 (3.3)	0
尿路感染	4 (6.9)	1 (3.3)	2 (16.7)
細菌性気管炎	3 (5.2)	0	0
結膜炎	3 (5.2)	1 (3.3)	2 (16.7)
インフルエンザ	3 (5.2)	1 (3.3)	2 (16.7)
ウイルス性気道感染	3 (5.2)	2 (6.7)	0
アデノウイルス感染	2 (3.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 2 of 17

	North America	Europe	Asia-Pacific
細菌感染	2 (3.4)	0	0
ウイルス性気管支炎	2 (3.4)	3 (10.0)	0
細菌性結膜炎	2 (3.4)	0	0
エンテロウイルス感染	2 (3.4)	0	0
皮膚真菌感染	2 (3.4)	0	0
下気道感染	2 (3.4)	2 (6.7)	1 (8.3)
ウイルス性下気道感染	2 (3.4)	1 (3.3)	0
メタニューモウイルス感染	2 (3.4)	0	0
モラクセラ感染	2 (3.4)	0	0
パラインフルエンザウイルス感染	2 (3.4)	0	0
モラクセラ菌性肺炎	2 (3.4)	0	0
皮膚カンジダ	2 (3.4)	0	0
ストーマ部膿瘍	2 (3.4)	0	0
アデノウイルス性上気道感染	1 (1.7)	0	0
細菌性疾患キャリアー	1 (1.7)	0	0
気管支炎	1 (1.7)	5 (16.7)	0
カンジダ性おむつ皮疹	1 (1.7)	1 (3.3)	0
蜂巣炎	1 (1.7)	0	0
コロナウイルス感染	1 (1.7)	0	0
伝染性紅斑	1 (1.7)	0	0
眼感染	1 (1.7)	0	0
ウイルス性胃炎	1 (1.7)	0	0
胃腸炎	1 (1.7)	0	1 (8.3)
ウイルス性胃腸炎	1 (1.7)	0	0
ヘモフィルス感染	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 3 of 17

	North America	Europe	Asia-Pacific
手足口病	1 (1.7)	1 (3.3)	0
粘膜皮膚カンジダ症	1 (1.7)	0	0
院内感染	1 (1.7)	0	0
急性中耳炎	1 (1.7)	0	0
レンサ球菌性咽頭炎	1 (1.7)	0	0
インフルエンザ性肺炎	1 (1.7)	0	0
肺炎球菌性肺炎	1 (1.7)	0	0
シュードモナス菌性肺炎	1 (1.7)	0	0
シュードモナス感染	1 (1.7)	2 (6.7)	0
細菌性気道感染	1 (1.7)	0	0
鼻炎	1 (1.7)	2 (6.7)	0
敗血症	1 (1.7)	1 (3.3)	0
ブドウ球菌性菌血症	1 (1.7)	0	0
ブドウ球菌感染	1 (1.7)	0	0
ブドウ球菌性敗血症	1 (1.7)	0	0
気管炎	1 (1.7)	0	0
感染性湿疹	0	0	1 (8.3)
蟯虫症	0	0	1 (8.3)
腸球菌感染	0	0	1 (8.3)
大腸菌感染	0	1 (3.3)	0
真菌感染	0	1 (3.3)	0
ロタウイルス胃腸炎	0	1 (3.3)	0
膿痂疹	0	1 (3.3)	0
限局性感染	0	1 (3.3)	0
肺感染	0	0	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 4 of 17

	North America	Europe	Asia-Pacific
口腔真菌感染	0	1 (3.3)	0
口腔ヘルペス	0	1 (3.3)	0
パラインフルエンザウイルス性肺炎	0	0	1 (8.3)
ＲＳウイルス肺炎	0	1 (3.3)	0
腎盂腎炎	0	1 (3.3)	0
ばら疹	0	1 (3.3)	0
ブドウ球菌皮膚感染	0	1 (3.3)	0
ストーマ部感染	0	1 (3.3)	0
呼吸器、胸郭および縦隔障害	53 (91.4)	22 (73.3)	4 (33.3)
呼吸窮迫	19 (32.8)	8 (26.7)	1 (8.3)
呼吸不全	17 (29.3)	9 (30.0)	0
急性呼吸不全	15 (25.9)	0	0
鼻閉	15 (25.9)	0	0
無気肺	14 (24.1)	8 (26.7)	1 (8.3)
咳嗽	13 (22.4)	2 (6.7)	0
低酸素症	11 (19.0)	0	0
誤嚥性肺炎	9 (15.5)	3 (10.0)	0
誤嚥	7 (12.1)	0	0
慢性呼吸不全	6 (10.3)	0	0
上気道うっ血	6 (10.3)	1 (3.3)	0
無呼吸	5 (8.6)	2 (6.7)	0
気管支分泌物貯留	5 (8.6)	2 (6.7)	0
呼吸困難	5 (8.6)	1 (3.3)	3 (25.0)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 5 of 17

	North America	Europe	Asia-Pacific
上気道分泌増加	5 (8.6)	0	0
鼻漏	5 (8.6)	2 (6.7)	1 (8.3)
副鼻腔うっ血	4 (6.9)	0	0
低換気	3 (5.2)	0	0
気胸	3 (5.2)	0	0
喘鳴	3 (5.2)	0	1 (8.3)
肺うっ血	2 (3.4)	0	0
肺水腫	2 (3.4)	0	0
呼吸停止	2 (3.4)	4 (13.3)	0
アレルギー性鼻炎	2 (3.4)	0	0
呼吸補助筋の動員	2 (3.4)	0	0
急性呼吸窮迫症候群	1 (1.7)	0	0
無呼吸発作	1 (1.7)	0	0
窒息	1 (1.7)	0	0
息詰まり	1 (1.7)	1 (3.3)	0
高炭酸ガス血症	1 (1.7)	0	0
減呼吸	1 (1.7)	0	0
喉頭肉芽腫	1 (1.7)	0	0
鼻汁変色	1 (1.7)	0	0
胸水	1 (1.7)	0	0
気縦隔症	1 (1.7)	0	0
湿性咳嗽	1 (1.7)	0	0
呼吸性アルカローシス	1 (1.7)	0	0
気道うっ血	1 (1.7)	1 (3.3)	0
拘束性肺疾患	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 6 of 17

	North America	Europe	Asia-Pacific
低音性連続性ラ音	1 (1.7)	0	0
睡眠時無呼吸症候群	1 (1.7)	0	0
変色痰	1 (1.7)	0	0
頻呼吸	1 (1.7)	0	0
気管障害	1 (1.7)	0	0
気管支閉塞	0	1 (3.3)	0
気管支分泌増加	0	1 (3.3)	0
肺障害	0	1 (3.3)	0
閉塞性気道障害	0	1 (3.3)	0
呼吸障害	0	2 (6.7)	0
胃腸障害	50 (86.2)	14 (46.7)	7 (58.3)
便秘	26 (44.8)	6 (20.0)	5 (41.7)
嘔吐	16 (27.6)	5 (16.7)	1 (8.3)
下痢	13 (22.4)	2 (6.7)	1 (8.3)
胃食道逆流性疾患	13 (22.4)	3 (10.0)	0
生歯	12 (20.7)	3 (10.0)	3 (25.0)
嚥下障害	9 (15.5)	0	0
流涎過多	8 (13.8)	0	0
放屁	6 (10.3)	0	0
腹部膨満	4 (6.9)	0	0
胃炎	3 (5.2)	1 (3.3)	0
血便排泄	2 (3.4)	0	0
腹痛	1 (1.7)	0	0
口唇のひび割れ	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 7 of 17

	North America	Europe	Asia-Pacific
排便回数増加	1 (1.7)	0	0
胃出血	1 (1.7)	0	0
消化管運動低下	1 (1.7)	0	0
吐血	1 (1.7)	0	0
乳児仙痛	1 (1.7)	0	0
乳児吐出	1 (1.7)	0	0
上部消化管出血	1 (1.7)	0	0
腹部不快感	0	2 (6.7)	0
アフタ性潰瘍	0	0	1 (8.3)
胃排出不全	0	1 (3.3)	0
一般・全身障害および投与部位の状態	41 (70.7)	20 (66.7)	4 (33.3)
発熱	39 (67.2)	16 (53.3)	4 (33.3)
疼痛	5 (8.6)	0	0
不快感	2 (3.4)	0	0
末梢性浮腫	2 (3.4)	0	0
カテーテル留置部位炎症	1 (1.7)	0	0
泣き	1 (1.7)	0	0
医療機器リーク	1 (1.7)	0	0
医療機器閉塞	1 (1.7)	1 (3.3)	0
薬物不耐性	1 (1.7)	0	0
低体温	1 (1.7)	0	0
医療機器合併症	1 (1.7)	0	0
小結節	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 8 of 17

	North America	Europe	Asia-Pacific
浮腫	1 (1.7)	0	0
末梢腫脹	1 (1.7)	0	0
外科手術不成功	1 (1.7)	0	0
腫脹	1 (1.7)	0	0
血管穿刺部位内出血	1 (1.7)	0	0
死亡	0	1 (3.3)	0
全身健康状態低下	0	1 (3.3)	0
ワクチン接種後の易刺激性	0	1 (3.3)	0
倦怠感	0	1 (3.3)	0
皮膚および皮下組織障害	33 (56.9)	2 (6.7)	2 (16.7)
発疹	13 (22.4)	0	1 (8.3)
おむつ皮膚炎	9 (15.5)	1 (3.3)	0
接触性皮膚炎	3 (5.2)	0	0
斑状出血	3 (5.2)	0	0
湿疹	3 (5.2)	0	1 (8.3)
過剰肉芽組織	3 (5.2)	0	0
皮膚刺激	3 (5.2)	0	0
皮膚炎	2 (3.4)	0	0
過角化	2 (3.4)	0	0
脱毛症	1 (1.7)	0	0
アレルギー性皮膚炎	1 (1.7)	0	0
紅斑	1 (1.7)	0	0
環状肉芽腫	1 (1.7)	0	0
汗疹	1 (1.7)	0	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 9 of 17

	North America	Europe	Asia-Pacific
点状出血	1 (1.7)	0	0
そう痒症	1 (1.7)	0	0
斑状皮疹	1 (1.7)	0	0
丘疹性皮疹	1 (1.7)	0	0
皮膚色素脱失	1 (1.7)	0	0
皮膚障害	1 (1.7)	0	0
皮膚浮腫	1 (1.7)	0	0
皮膚潰瘍	1 (1.7)	0	0
皮下気腫	1 (1.7)	0	0
蕁麻疹	1 (1.7)	0	0
皮膚乾燥	0	1 (3.3)	0
間擦疹	0	0	1 (8.3)
傷害、中毒および処置合併症	25 (43.1)	5 (16.7)	0
節足動物咬傷	4 (6.9)	0	0
処置による疼痛	4 (6.9)	0	0
栄養補給チューブ合併症	3 (5.2)	1 (3.3)	0
大腿骨骨折	3 (5.2)	0	0
ストーマ部紅斑	3 (5.2)	0	0
挫傷	2 (3.4)	0	0
関節脱臼	2 (3.4)	0	0
皮膚擦過傷	2 (3.4)	0	0
術後激越	1 (1.7)	0	0
ダンピング症候群	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 10 of 17

	North America	Europe	Asia-Pacific
耳擦過傷	1 (1.7)	0	0
擦過傷	1 (1.7)	0	0
口唇損傷	1 (1.7)	0	0
外傷性気胸	1 (1.7)	0	0
処置後腫脹	1 (1.7)	0	0
処置部位反応	1 (1.7)	0	0
軟部組織損傷	1 (1.7)	0	0
ストーマ合併症	1 (1.7)	0	0
ストーマ部刺激感	1 (1.7)	0	0
サンバーン	1 (1.7)	0	0
熱傷	1 (1.7)	0	0
歯牙損傷	1 (1.7)	0	0
麻酔からの覚醒遅延	0	1 (3.3)	0
伝染病曝露	0	1 (3.3)	0
処置合併症	0	1 (3.3)	0
ワクチン接種合併症	0	1 (3.3)	0
筋骨格系および結合組織障害	23 (39.7)	2 (6.7)	0
関節拘縮	10 (17.2)	1 (3.3)	0
側弯症	10 (17.2)	1 (3.3)	0
脊柱後弯症	5 (8.6)	0	0
胸郭変形	4 (6.9)	0	0
後側弯症	2 (3.4)	0	0
四肢痛	2 (3.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 11 of 17

	North America	Europe	Asia-Pacific
斜頚	2 (3.4)	0	0
背部痛	1 (1.7)	0	0
泉門閉鎖遅延	1 (1.7)	0	0
手変形	1 (1.7)	0	0
関節硬直	1 (1.7)	0	0
脊柱前弯症	1 (1.7)	0	0
頭位性斜頭症	1 (1.7)	1 (3.3)	0
脊柱変形	1 (1.7)	0	0
滑膜炎	1 (1.7)	0	0
心臓障害	17 (29.3)	5 (16.7)	2 (16.7)
頻脈	7 (12.1)	2 (6.7)	0
徐脈	6 (10.3)	1 (3.3)	0
心肺停止	4 (6.9)	2 (6.7)	0
チアノーゼ	3 (5.2)	0	0
心停止	2 (3.4)	1 (3.3)	0
左室肥大	2 (3.4)	0	0
心筋症	1 (1.7)	0	0
心膜気腫	1 (1.7)	0	0
上室性頻脈	1 (1.7)	0	0
心室性頻脈	1 (1.7)	0	1 (8.3)
洞性頻脈	0	0	1 (8.3)
臨床検査	16 (27.6)	11 (36.7)	1 (8.3)
酸素飽和度低下	10 (17.2)	1 (3.3)	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 12 of 17

	North America	Europe	Asia-Pacific
好中球数増加	3 (5.2)	0	0
心拍数増加	2 (3.4)	0	0
ヒトライノウイルス検査陽性	2 (3.4)	1 (3.3)	0
ブドウ球菌検査陽性	2 (3.4)	0	0
体重減少	2 (3.4)	4 (13.3)	0
白血球数増加	2 (3.4)	0	0
体温低下	1 (1.7)	0	0
骨密度減少	1 (1.7)	0	0
呼吸音異常	1 (1.7)	0	0
心電図ＳＴ－Ｔ部分異常	1 (1.7)	0	0
心拍数減少	1 (1.7)	0	0
心拍数不整	1 (1.7)	0	0
炎症マーカー上昇	1 (1.7)	0	0
Ａ型インフルエンザウイルス検査陽性	1 (1.7)	0	0
肝機能検査異常	1 (1.7)	0	0
モラクセラ検査陽性	1 (1.7)	1 (3.3)	0
好中球百分率増加	1 (1.7)	0	0
整形外科検査	1 (1.7)	0	0
シュードモナス検査陽性	1 (1.7)	1 (3.3)	0
セラチア検査陽性	1 (1.7)	0	0
レンサ球菌検査陽性	1 (1.7)	0	0
ビタミンＡ減少	1 (1.7)	0	0
アラニンアミノトランスフェラーゼ増加	0	1 (3.3)	0
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (3.3)	0
血中クロール減少	0	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 13 of 17

	North America	Europe	Asia-Pacific
血中鉄減少	0	1 (3.3)	0
血中カリウム減少	0	2 (6.7)	0
血中ナトリウム減少	0	1 (3.3)	0
体温上昇	0	2 (6.7)	0
Ｃ－反応性蛋白増加	0	2 (6.7)	0
医学的観察	0	2 (6.7)	0
尿量減少	0	1 (3.3)	0
神経系障害	16 (27.6)	2 (6.7)	0
不随意性筋収縮	3 (5.2)	1 (3.3)	0
眼振	3 (5.2)	0	0
よだれ	2 (3.4)	0	0
痙攣発作	2 (3.4)	0	0
脳損傷	1 (1.7)	0	0
脳梗塞	1 (1.7)	0	0
脳脊髄液漏	1 (1.7)	0	0
頭痛	1 (1.7)	0	0
低酸素性虚血性脳症	1 (1.7)	0	0
言語障害	1 (1.7)	0	0
嗜眠	1 (1.7)	0	0
傾眠	1 (1.7)	0	0
失神	1 (1.7)	0	0
間代	0	1 (3.3)	0
代謝および栄養障害	12 (20.7)	6 (20.0)	1 (8.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 14 of 17

	North America	Europe	Asia-Pacific
成長障害	3 (5.2)	0	1 (8.3)
栄養補給不耐性	2 (3.4)	1 (3.3)	0
低ナトリウム血症	2 (3.4)	0	0
過小食	2 (3.4)	0	0
体重増加不良	2 (3.4)	4 (13.3)	0
脱水	1 (1.7)	0	0
乳児および小児期早期の哺育障害	1 (1.7)	2 (6.7)	0
鉄欠乏	1 (1.7)	0	0
代謝性アルカローシス	1 (1.7)	0	0
免疫系障害	11 (19.0)	2 (6.7)	0
季節性アレルギー	5 (8.6)	1 (3.3)	0
薬物過敏症	4 (6.9)	0	0
食物アレルギー	1 (1.7)	0	0
過敏症	1 (1.7)	1 (3.3)	0
精神障害	9 (15.5)	2 (6.7)	1 (8.3)
不安	4 (6.9)	1 (3.3)	0
激越	2 (3.4)	0	0
易刺激性	2 (3.4)	1 (3.3)	0
息こらえ	1 (1.7)	0	0
落ち着きのなさ	1 (1.7)	0	0
気分動揺	0	0	1 (8.3)
睡眠障害	0	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 15 of 17

	North America	Europe	Asia-Pacific
血液およびリンパ系障害	6 (10.3)	0	0
貧血	3 (5.2)	0	0
リンパ節症	1 (1.7)	0	0
好中球減少症	1 (1.7)	0	0
血小板増加症	1 (1.7)	0	0
先天性、家族性および遺伝性障害	6 (10.3)	1 (3.3)	0
斜頭症	2 (3.4)	0	0
斜指症	1 (1.7)	0	0
先天性横隔膜ヘルニア	1 (1.7)	0	0
発育性股関節形成不全	1 (1.7)	0	0
鳩胸	1 (1.7)	0	0
貧血母斑	0	1 (3.3)	0
眼障害	6 (10.3)	0	0
乱視	1 (1.7)	0	0
霰粒腫	1 (1.7)	0	0
眼乾燥	1 (1.7)	0	0
眼運動障害	1 (1.7)	0	0
眼瞼下垂	1 (1.7)	0	0
近視	1 (1.7)	0	0
斜視	1 (1.7)	0	0
血管障害	5 (8.6)	3 (10.0)	0
高血圧	2 (3.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 16 of 17

	North America	Europe	Asia-Pacific
毛細血管脆弱	1 (1.7)	0	0
本態性高血圧症	1 (1.7)	0	0
ショック	1 (1.7)	0	0
蒼白	0	1 (3.3)	0
血栓症	0	1 (3.3)	0
血管炎	0	1 (3.3)	0
耳および迷路障害	3 (5.2)	0	0
耳の障害	1 (1.7)	0	0
耳痛	1 (1.7)	0	0
耳垢分泌過多	1 (1.7)	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	2 (3.4)	0	0
アクロコルドン	1 (1.7)	0	0
血管の良性新生物	1 (1.7)	0	0
腎および尿路障害	2 (3.4)	0	0
水腎症	1 (1.7)	0	0
尿閉	1 (1.7)	0	0
生殖系および乳房障害	2 (3.4)	2 (6.7)	0
後天性包茎	1 (1.7)	0	0
陰茎障害	1 (1.7)	0	0
亀頭包皮炎	0	1 (3.3)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infantile-onset subjects treated with ISIS 396443 in controlled and uncontrolled studies:
incidence of adverse events by geographic region
Page 17 of 17

	North America	Europe	Asia-Pacific
卵巣嚢胞	0	1 (3.3)	0
肝胆道系障害	1 (1.7)	0	0
肝腫大	1 (1.7)	0	0
外科および内科処置	1 (1.7)	0	0
機械的換気	1 (1.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 175 Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443: incidence of adverse events by geographic region

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 1 of 18

	North America	Europe	Asia-Pacific
Number of subjects dosed	71 (100.0)	33 (100.0)	16 (100.0)
Number of subjects with an event	69 (97.2)	30 (90.9)	14 (87.5)
感染症および寄生虫症	62 (87.3)	25 (75.8)	10 (62.5)
上気道感染	40 (56.3)	1 (3.0)	3 (18.8)
肺炎	18 (25.4)	9 (27.3)	5 (31.3)
鼻咽頭炎	15 (21.1)	8 (24.2)	2 (12.5)
ライノウイルス感染	15 (21.1)	3 (9.1)	0
中耳炎	11 (15.5)	1 (3.0)	0
ウイルス性肺炎	10 (14.1)	1 (3.0)	0
ウイルス性上気道感染	10 (14.1)	0	0
細気管支炎	8 (11.3)	2 (6.1)	2 (12.5)
ウイルス感染	7 (9.9)	5 (15.2)	0
気道感染	6 (8.5)	8 (24.2)	0
口腔カンジダ症	5 (7.0)	3 (9.1)	0
尿路感染	5 (7.0)	1 (3.0)	2 (12.5)
耳感染	4 (5.6)	2 (6.1)	0
細菌性肺炎	4 (5.6)	0	0
ＲＳウイルス細気管支炎	4 (5.6)	1 (3.0)	0
細菌性気管炎	3 (4.2)	0	0
結膜炎	3 (4.2)	1 (3.0)	2 (12.5)
ウイルス性胃腸炎	3 (4.2)	0	0
インフルエンザ	3 (4.2)	3 (9.1)	3 (18.8)
ウイルス性気道感染	3 (4.2)	2 (6.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 2 of 18

	North America	Europe	Asia-Pacific
アデノウイルス感染	2 (2.8)	0	0
細菌感染	2 (2.8)	0	0
ウイルス性気管支炎	2 (2.8)	3 (9.1)	0
細菌性結膜炎	2 (2.8)	0	0
エンテロウイルス感染	2 (2.8)	0	0
皮膚真菌感染	2 (2.8)	0	0
下気道感染	2 (2.8)	2 (6.1)	1 (6.3)
ウイルス性下気道感染	2 (2.8)	1 (3.0)	0
メタニューモウイルス感染	2 (2.8)	0	0
モラクセラ感染	2 (2.8)	0	0
パラインフルエンザウイルス感染	2 (2.8)	0	0
レンサ球菌性咽頭炎	2 (2.8)	0	0
モラクセラ菌性肺炎	2 (2.8)	0	0
皮膚カンジダ	2 (2.8)	0	0
ストーマ部膿瘍	2 (2.8)	0	0
アデノウイルス性上気道感染	1 (1.4)	0	0
細菌性疾患キャリアー	1 (1.4)	0	0
気管支炎	1 (1.4)	6 (18.2)	0
カンジダ性おむつ皮疹	1 (1.4)	1 (3.0)	0
蜂巣炎	1 (1.4)	0	0
コロナウイルス感染	1 (1.4)	0	0
ブドウ球菌性耳感染	1 (1.4)	0	0
伝染性紅斑	1 (1.4)	0	0
眼感染	1 (1.4)	0	0
ウイルス性胃炎	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 3 of 18

	North America	Europe	Asia-Pacific
胃腸炎	1 (1.4)	0	1 (6.3)
ヘモフィルス感染	1 (1.4)	0	0
手足口病	1 (1.4)	1 (3.0)	0
膿痂疹	1 (1.4)	1 (3.0)	0
粘膜皮膚カンジダ症	1 (1.4)	0	0
院内感染	1 (1.4)	0	0
急性中耳炎	1 (1.4)	0	0
インフルエンザ性肺炎	1 (1.4)	0	0
肺炎球菌性肺炎	1 (1.4)	0	0
シュードモナス菌性肺炎	1 (1.4)	0	0
シュードモナス感染	1 (1.4)	2 (6.1)	0
細菌性気道感染	1 (1.4)	0	0
鼻炎	1 (1.4)	4 (12.1)	0
敗血症	1 (1.4)	1 (3.0)	0
皮膚感染	1 (1.4)	0	0
ブドウ球菌性菌血症	1 (1.4)	0	0
ブドウ球菌感染	1 (1.4)	0	0
ブドウ球菌性敗血症	1 (1.4)	0	0
レンサ球菌感染	1 (1.4)	0	0
気管炎	1 (1.4)	0	0
感染性湿疹	0	0	1 (6.3)
蟯虫症	0	0	1 (6.3)
腸球菌感染	0	0	1 (6.3)
大腸菌感染	0	1 (3.0)	0
真菌感染	0	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 4 of 18

	North America	Europe	Asia-Pacific
ロタウイルス胃腸炎	0	1 (3.0)	0
限局性感染	0	1 (3.0)	0
肺感染	0	0	1 (6.3)
口腔真菌感染	0	1 (3.0)	0
口腔ヘルペス	0	1 (3.0)	0
パラインフルエンザウイルス性肺炎	0	0	1 (6.3)
ＲＳウイルス肺炎	0	1 (3.0)	0
腎盂腎炎	0	1 (3.0)	0
ばら疹	0	1 (3.0)	0
ブドウ球菌皮膚感染	0	1 (3.0)	0
ストーマ部感染	0	1 (3.0)	0
胃腸障害	57 (80.3)	15 (45.5)	7 (43.8)
便秘	27 (38.0)	7 (21.2)	5 (31.3)
嘔吐	16 (22.5)	5 (15.2)	1 (6.3)
胃食道逆流性疾患	15 (21.1)	3 (9.1)	0
下痢	14 (19.7)	2 (6.1)	1 (6.3)
生歯	13 (18.3)	3 (9.1)	3 (18.8)
嚥下障害	10 (14.1)	0	0
放屁	8 (11.3)	0	0
流涎過多	8 (11.3)	0	0
腹部膨満	6 (8.5)	0	0
胃炎	3 (4.2)	1 (3.0)	0
血便排泄	2 (2.8)	0	0
腹部不快感	1 (1.4)	2 (6.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 5 of 18

	North America	Europe	Asia-Pacific
腹痛	1 (1.4)	0	0
口唇のひび割れ	1 (1.4)	0	0
排便回数増加	1 (1.4)	0	0
胃出血	1 (1.4)	0	0
消化管運動低下	1 (1.4)	0	0
吐血	1 (1.4)	0	0
乳児仙痛	1 (1.4)	0	0
乳児吐出	1 (1.4)	0	0
上部消化管出血	1 (1.4)	0	0
アフタ性潰瘍	0	0	1 (6.3)
胃排出不全	0	1 (3.0)	0
呼吸器、胸郭および縦隔障害	57 (80.3)	24 (72.7)	4 (25.0)
呼吸窮迫	20 (28.2)	8 (24.2)	1 (6.3)
鼻閉	18 (25.4)	0	0
呼吸不全	17 (23.9)	9 (27.3)	0
急性呼吸不全	15 (21.1)	0	0
咳嗽	15 (21.1)	3 (9.1)	0
無気肺	14 (19.7)	8 (24.2)	1 (6.3)
低酸素症	11 (15.5)	0	0
誤嚥性肺炎	9 (12.7)	3 (9.1)	0
鼻漏	8 (11.3)	2 (6.1)	1 (6.3)
誤嚥	7 (9.9)	0	0
上気道うっ血	7 (9.9)	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 6 of 18

	North America	Europe	Asia-Pacific
慢性呼吸不全	6 (8.5)	0	0
無呼吸	5 (7.0)	2 (6.1)	0
気管支分泌物貯留	5 (7.0)	2 (6.1)	0
呼吸困難	5 (7.0)	1 (3.0)	3 (18.8)
上気道分泌増加	5 (7.0)	0	0
副鼻腔うっ血	4 (5.6)	0	0
低換気	3 (4.2)	0	0
気胸	3 (4.2)	0	0
喘鳴	3 (4.2)	0	1 (6.3)
肺うっ血	2 (2.8)	0	0
肺水腫	2 (2.8)	0	0
呼吸停止	2 (2.8)	4 (12.1)	0
アレルギー性鼻炎	2 (2.8)	0	0
呼吸補助筋の動員	2 (2.8)	0	0
急性呼吸窮迫症候群	1 (1.4)	0	0
無呼吸発作	1 (1.4)	0	0
窒息	1 (1.4)	0	0
息詰まり	1 (1.4)	2 (6.1)	0
高炭酸ガス血症	1 (1.4)	0	0
減呼吸	1 (1.4)	0	0
喉頭肉芽腫	1 (1.4)	0	0
鼻汁変色	1 (1.4)	0	0
胸水	1 (1.4)	0	0
気縦隔症	1 (1.4)	0	0
湿性咳嗽	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 7 of 18

	North America	Europe	Asia-Pacific
呼吸性アルカローシス	1 (1.4)	0	0
気道うっ血	1 (1.4)	1 (3.0)	0
拘束性肺疾患	1 (1.4)	0	0
低音性連続性ラ音	1 (1.4)	0	0
睡眠時無呼吸症候群	1 (1.4)	0	0
変色痰	1 (1.4)	0	0
頻呼吸	1 (1.4)	0	0
気管障害	1 (1.4)	0	0
気管支閉塞	0	1 (3.0)	0
気管支分泌増加	0	1 (3.0)	0
肺障害	0	1 (3.0)	0
閉塞性気道障害	0	1 (3.0)	0
呼吸性アシドーシス	0	1 (3.0)	0
呼吸障害	0	2 (6.1)	0
一般・全身障害および投与部位の状態	46 (64.8)	20 (60.6)	5 (31.3)
発熱	43 (60.6)	16 (48.5)	5 (31.3)
疼痛	5 (7.0)	0	0
不快感	2 (2.8)	0	0
末梢性浮腫	2 (2.8)	0	0
適用部位紅斑	1 (1.4)	0	0
カテーテル留置部位炎症	1 (1.4)	0	0
泣き	1 (1.4)	0	0
医療機器リーク	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 8 of 18

	North America	Europe	Asia-Pacific
医療機器閉塞	1 (1.4)	1 (3.0)	0
薬物不耐性	1 (1.4)	0	0
低体温	1 (1.4)	0	0
注入部位内出血	1 (1.4)	0	0
医療機器合併症	1 (1.4)	0	0
小結節	1 (1.4)	0	0
浮腫	1 (1.4)	0	0
末梢腫脹	1 (1.4)	0	0
外科手術不成功	1 (1.4)	0	0
腫脹	1 (1.4)	0	0
血管穿刺部位内出血	1 (1.4)	0	0
死亡	0	1 (3.0)	0
全身健康状態低下	0	1 (3.0)	0
ワクチン接種後の易刺激性	0	1 (3.0)	0
倦怠感	0	1 (3.0)	0
皮膚および皮下組織障害	38 (53.5)	5 (15.2)	3 (18.8)
発疹	13 (18.3)	0	2 (12.5)
おむつ皮膚炎	11 (15.5)	1 (3.0)	0
接触性皮膚炎	3 (4.2)	0	0
斑状出血	3 (4.2)	0	0
湿疹	3 (4.2)	0	1 (6.3)
過剰肉芽組織	3 (4.2)	0	0
皮膚刺激	3 (4.2)	0	0
皮膚炎	2 (2.8)	2 (6.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 9 of 18

	North America	Europe	Asia-Pacific
紅斑	2 (2.8)	0	0
過角化	2 (2.8)	0	0
脱毛症	1 (1.4)	0	0
アレルギー性皮膚炎	1 (1.4)	0	0
貨幣状湿疹	1 (1.4)	0	0
環状肉芽腫	1 (1.4)	0	0
汗疹	1 (1.4)	0	1 (6.3)
点状出血	1 (1.4)	1 (3.0)	0
そう痒症	1 (1.4)	0	0
紅斑性皮疹	1 (1.4)	0	0
斑状皮疹	1 (1.4)	0	0
丘疹性皮疹	1 (1.4)	0	0
脂漏性皮膚炎	1 (1.4)	0	0
皮膚色素脱失	1 (1.4)	0	0
皮膚障害	1 (1.4)	0	0
皮膚浮腫	1 (1.4)	0	0
皮膚潰瘍	1 (1.4)	0	0
皮下気腫	1 (1.4)	0	0
蕁麻疹	1 (1.4)	0	0
皮膚乾燥	0	1 (3.0)	0
間擦疹	0	0	1 (6.3)
傷害、中毒および処置合併症	28 (39.4)	5 (15.2)	0
節足動物咬傷	5 (7.0)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 10 of 18

	North America	Europe	Asia-Pacific
処置による疼痛	4 (5.6)	0	0
栄養補給チューブ合併症	3 (4.2)	1 (3.0)	0
大腿骨骨折	3 (4.2)	0	0
ストーマ部紅斑	3 (4.2)	0	0
挫傷	2 (2.8)	0	0
関節脱臼	2 (2.8)	0	0
処置後腫脹	2 (2.8)	0	0
皮膚擦過傷	2 (2.8)	0	0
術後激越	1 (1.4)	0	0
ダンピング症候群	1 (1.4)	0	0
耳擦過傷	1 (1.4)	0	0
擦過傷	1 (1.4)	0	0
転倒	1 (1.4)	0	0
口唇損傷	1 (1.4)	0	0
外傷性気胸	1 (1.4)	0	0
処置後合併症	1 (1.4)	0	0
処置後不快感	1 (1.4)	0	0
処置部位反応	1 (1.4)	0	0
軟部組織損傷	1 (1.4)	0	0
ストーマ合併症	1 (1.4)	0	0
ストーマ部刺激感	1 (1.4)	0	0
硬膜下血腫	1 (1.4)	0	0
サンバーン	1 (1.4)	0	0
熱傷	1 (1.4)	0	0
歯牙損傷	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 11 of 18

	North America	Europe	Asia-Pacific
麻酔からの覚醒遅延	0	1 (3.0)	0
伝染病曝露	0	1 (3.0)	0
処置合併症	0	1 (3.0)	0
ワクチン接種合併症	0	1 (3.0)	0
筋骨格系および結合組織障害	25 (35.2)	3 (9.1)	0
関節拘縮	11 (15.5)	1 (3.0)	0
側弯症	10 (14.1)	1 (3.0)	0
脊柱後弯症	5 (7.0)	0	0
胸郭変形	4 (5.6)	0	0
斜頚	3 (4.2)	0	0
後側弯症	2 (2.8)	0	0
四肢痛	2 (2.8)	0	0
頭位性斜頭症	2 (2.8)	1 (3.0)	0
背部痛	1 (1.4)	0	0
泉門閉鎖遅延	1 (1.4)	0	0
手変形	1 (1.4)	0	0
関節硬直	1 (1.4)	0	0
脊柱前弯症	1 (1.4)	0	0
筋力低下	1 (1.4)	1 (3.0)	0
脊柱変形	1 (1.4)	0	0
滑膜炎	1 (1.4)	0	0
体重支持困難	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 12 of 18

	North America	Europe	Asia-Pacific
心臓障害	19 (26.8)	5 (15.2)	2 (12.5)
頻脈	9 (12.7)	2 (6.1)	0
徐脈	6 (8.5)	1 (3.0)	0
心肺停止	4 (5.6)	2 (6.1)	0
チアノーゼ	3 (4.2)	0	0
心停止	2 (2.8)	1 (3.0)	0
左室肥大	2 (2.8)	0	0
心筋症	1 (1.4)	0	0
心膜気腫	1 (1.4)	0	0
上室性頻脈	1 (1.4)	0	0
心室性頻脈	1 (1.4)	0	1 (6.3)
洞性頻脈	0	0	1 (6.3)
臨床検査	19 (26.8)	11 (33.3)	1 (6.3)
酸素飽和度低下	11 (15.5)	1 (3.0)	1 (6.3)
好中球数増加	3 (4.2)	0	0
白血球数増加	3 (4.2)	0	0
心拍数増加	2 (2.8)	0	0
ヒトライノウイルス検査陽性	2 (2.8)	1 (3.0)	0
ブドウ球菌検査陽性	2 (2.8)	0	0
体重減少	2 (2.8)	4 (12.1)	0
アラニンアミノトランスフェラーゼ増加	1 (1.4)	1 (3.0)	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.4)	1 (3.0)	0
血中アルカリホスファターゼ増加	1 (1.4)	0	0
体温低下	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 13 of 18

	North America	Europe	Asia-Pacific
体温上昇	1 (1.4)	2 (6.1)	0
骨密度減少	1 (1.4)	0	0
呼吸音異常	1 (1.4)	0	0
心電図ＳＴ－Ｔ部分異常	1 (1.4)	0	0
好酸球数増加	1 (1.4)	0	0
心拍数減少	1 (1.4)	0	0
心拍数不整	1 (1.4)	0	0
炎症マーカー上昇	1 (1.4)	0	0
Ａ型インフルエンザウイルス検査陽性	1 (1.4)	0	0
肝機能検査異常	1 (1.4)	0	0
リンパ球数増加	1 (1.4)	0	0
モラクセラ検査陽性	1 (1.4)	1 (3.0)	0
好中球百分率増加	1 (1.4)	0	0
整形外科検査	1 (1.4)	0	0
シュードモナス検査陽性	1 (1.4)	1 (3.0)	0
セラチア検査陽性	1 (1.4)	0	0
レンサ球菌検査陽性	1 (1.4)	0	0
ビタミンＡ減少	1 (1.4)	0	0
血中クロール減少	0	1 (3.0)	0
血中鉄減少	0	1 (3.0)	0
血中カリウム減少	0	2 (6.1)	0
血中ナトリウム減少	0	1 (3.0)	0
Ｃ－反応性蛋白増加	0	2 (6.1)	0
医学的観察	0	2 (6.1)	0
尿量減少	0	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 14 of 18

	North America	Europe	Asia-Pacific
神経系障害	18 (25.4)	2 (6.1)	1 (6.3)
不随意性筋収縮	3 (4.2)	1 (3.0)	0
眼振	3 (4.2)	0	0
よだれ	2 (2.8)	0	0
痙攣発作	2 (2.8)	0	0
脳損傷	1 (1.4)	0	0
脳梗塞	1 (1.4)	0	0
脳脊髄液漏	1 (1.4)	0	0
頭痛	1 (1.4)	0	0
反射亢進	1 (1.4)	0	0
筋緊張低下	1 (1.4)	0	1 (6.3)
低酸素性虚血性脳症	1 (1.4)	0	0
言語障害	1 (1.4)	0	0
嗜眠	1 (1.4)	0	0
傾眠	1 (1.4)	0	0
失神	1 (1.4)	0	0
間代	0	1 (3.0)	0
代謝および栄養障害	15 (21.1)	7 (21.2)	1 (6.3)
成長障害	4 (5.6)	1 (3.0)	1 (6.3)
脱水	3 (4.2)	0	0
体重増加不良	3 (4.2)	4 (12.1)	0
栄養補給不耐性	2 (2.8)	1 (3.0)	0
低ナトリウム血症	2 (2.8)	0	0
過小食	2 (2.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 15 of 18

	North America	Europe	Asia-Pacific
乳児および小児期早期の哺育障害	1 (1.4)	2 (6.1)	0
鉄欠乏	1 (1.4)	0	0
代謝性アルカローシス	1 (1.4)	0	0
免疫系障害	13 (18.3)	2 (6.1)	0
季節性アレルギー	6 (8.5)	1 (3.0)	0
薬物過敏症	4 (5.6)	0	0
食物アレルギー	2 (2.8)	0	0
過敏症	1 (1.4)	1 (3.0)	0
精神障害	9 (12.7)	2 (6.1)	1 (6.3)
不安	4 (5.6)	1 (3.0)	0
激越	2 (2.8)	0	0
易刺激性	2 (2.8)	1 (3.0)	0
息こらえ	1 (1.4)	0	0
落ち着きのなさ	1 (1.4)	0	0
気分動揺	0	0	1 (6.3)
睡眠障害	0	1 (3.0)	0
血液およびリンパ系障害	7 (9.9)	1 (3.0)	0
貧血	3 (4.2)	0	0
好酸球増加症	1 (1.4)	0	0
リンパ節症	1 (1.4)	0	0
好中球減少症	1 (1.4)	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 16 of 18

	North America	Europe	Asia-Pacific
血小板増加症	1 (1.4)	0	0
眼障害	7 (9.9)	0	0
乱視	1 (1.4)	0	0
霰粒腫	1 (1.4)	0	0
後天性涙道狭窄	1 (1.4)	0	0
眼乾燥	1 (1.4)	0	0
眼運動障害	1 (1.4)	0	0
眼瞼下垂	1 (1.4)	0	0
近視	1 (1.4)	0	0
斜視	1 (1.4)	0	0
先天性、家族性および遺伝性障害	6 (8.5)	1 (3.0)	0
斜頭症	2 (2.8)	0	0
斜指症	1 (1.4)	0	0
先天性横隔膜ヘルニア	1 (1.4)	0	0
発育性股関節形成不全	1 (1.4)	0	0
鳩胸	1 (1.4)	0	0
貧血母斑	0	1 (3.0)	0
血管障害	6 (8.5)	4 (12.1)	0
高血圧	3 (4.2)	0	0
毛細血管脆弱	1 (1.4)	0	0
本態性高血圧症	1 (1.4)	0	0
ショック	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 17 of 18

	North America	Europe	Asia-Pacific
蒼白	0	2 (6.1)	0
血栓症	0	1 (3.0)	0
血管炎	0	1 (3.0)	0
耳および迷路障害	3 (4.2)	0	0
耳の障害	1 (1.4)	0	0
耳痛	1 (1.4)	0	0
耳垢分泌過多	1 (1.4)	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	3 (4.2)	0	0
アクロコルドン	1 (1.4)	0	0
血管の良性新生物	1 (1.4)	0	0
脂漏性角化症	1 (1.4)	0	0
生殖系および乳房障害	3 (4.2)	2 (6.1)	0
後天性包茎	1 (1.4)	0	0
陰茎障害	1 (1.4)	0	0
外陰腟発疹	1 (1.4)	0	0
亀頭包皮炎	0	1 (3.0)	0
卵巣嚢胞	0	1 (3.0)	0
腎および尿路障害	2 (2.8)	0	0
水腎症	1 (1.4)	0	0
尿閉	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Infants diagnosed with SMA (presymptomatic and infantile-onset) treated with ISIS 396443:
incidence of adverse events by geographic region
Page 18 of 18

	North America	Europe	Asia-Pacific
肝胆道系障害	1 (1.4)	0	0
肝腫大	1 (1.4)	0	0
妊娠、産褥および周産期の状態	1 (1.4)	0	0
臍肉芽腫	1 (1.4)	0	0
外科および内科処置	1 (1.4)	0	0
機械的換気	1 (1.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 76　Later-onset subjects: incidence of adverse events by geographic region

Later-onset subjects: incidence of adverse events by geographic region
Page 1 of 9

	North America	Europe	Asia-Pacific
Number of subjects dosed	56 (100.0)	0	0
Number of subjects with an event	56 (100.0)	0	0
感染症および寄生虫症	44 (78.6)	0	0
上気道感染	27 (48.2)	0	0
鼻咽頭炎	16 (28.6)	0	0
ウイルス感染	9 (16.1)	0	0
ウイルス性胃腸炎	8 (14.3)	0	0
レンサ球菌性咽頭炎	8 (14.3)	0	0
胃腸炎	7 (12.5)	0	0
中耳炎	5 (8.9)	0	0
肺炎	5 (8.9)	0	0
ウイルス性上気道感染	5 (8.9)	0	0
耳感染	4 (7.1)	0	0
尿路感染	4 (7.1)	0	0
結膜炎	3 (5.4)	0	0
インフルエンザ	3 (5.4)	0	0
限局性感染	3 (5.4)	0	0
ＲＳウイルス感染	3 (5.4)	0	0
副鼻腔炎	3 (5.4)	0	0
ウイルス性消化管感染	2 (3.6)	0	0
ウイルス性肺炎	2 (3.6)	0	0
皮膚カンジダ	2 (3.6)	0	0
蜂巣炎	1 (1.8)	0	0
ブドウ球菌性眼感染	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 2 of 9

	North America	Europe	Asia-Pacific
ウイルス性眼感染	1 (1.8)	0	0
皮膚真菌感染	1 (1.8)	0	0
手足口病	1 (1.8)	0	0
膿痂疹	1 (1.8)	0	0
下気道感染	1 (1.8)	0	0
伝染性軟属腫	1 (1.8)	0	0
単核細胞症症候群	1 (1.8)	0	0
急性中耳炎	1 (1.8)	0	0
咽頭炎	1 (1.8)	0	0
ＲＳウイルス肺炎	1 (1.8)	0	0
ＲＳウイルス細気管支炎	1 (1.8)	0	0
気道感染	1 (1.8)	0	0
ウイルス性気道感染	1 (1.8)	0	0
鼻炎	1 (1.8)	0	0
皮膚細菌感染	1 (1.8)	0	0
扁桃炎	1 (1.8)	0	0
腟感染	1 (1.8)	0	0
ウイルス性扁桃炎	1 (1.8)	0	0
外陰腟真菌感染	1 (1.8)	0	0
筋骨格系および結合組織障害	41 (73.2)	0	0
背部痛	23 (41.1)	0	0
側弯症	15 (26.8)	0	0
関節拘縮	10 (17.9)	0	0
関節痛	5 (8.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 3 of 9

	North America	Europe	Asia-Pacific
四肢痛	5 (8.9)	0	0
筋肉痛	4 (7.1)	0	0
頚部痛	3 (5.4)	0	0
筋緊張	2 (3.6)	0	0
骨盤変形	2 (3.6)	0	0
四肢拘縮	1 (1.8)	0	0
脊柱前弯症	1 (1.8)	0	0
傷害、中毒および処置合併症	40 (71.4)	0	0
腰椎穿刺後症候群	23 (41.1)	0	0
裂傷	7 (12.5)	0	0
処置による疼痛	6 (10.7)	0	0
節足動物咬傷	3 (5.4)	0	0
大腿骨骨折	3 (5.4)	0	0
四肢損傷	3 (5.4)	0	0
挫傷	2 (3.6)	0	0
関節脱臼	2 (3.6)	0	0
関節損傷	2 (3.6)	0	0
処置による悪心	2 (3.6)	0	0
サンバーン	2 (3.6)	0	0
隆起骨折	2 (3.6)	0	0
術後激越	1 (1.8)	0	0
節足動物刺傷	1 (1.8)	0	0
転倒	1 (1.8)	0	0
頭部損傷	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 4 of 9

	North America	Europe	Asia-Pacific
靭帯捻挫	1 (1.8)	0	0
下肢骨折	1 (1.8)	0	0
半月板損傷	1 (1.8)	0	0
肉離れ	1 (1.8)	0	0
術後イレウス	1 (1.8)	0	0
処置による頭痛	1 (1.8)	0	0
熱傷	1 (1.8)	0	0
脛骨骨折	1 (1.8)	0	0
一般・全身障害および投与部位の状態	31 (55.4)	0	0
発熱	16 (28.6)	0	0
穿刺部位疼痛	10 (17.9)	0	0
疲労	3 (5.4)	0	0
疼痛	2 (3.6)	0	0
カテーテル留置部位出血	1 (1.8)	0	0
カテーテル留置部位疼痛	1 (1.8)	0	0
カテーテル留置部位関連反応	1 (1.8)	0	0
胸部不快感	1 (1.8)	0	0
悪寒	1 (1.8)	0	0
冷感	1 (1.8)	0	0
重力性浮腫	1 (1.8)	0	0
低体温	1 (1.8)	0	0
注射部位出血	1 (1.8)	0	0
注射部位疼痛	1 (1.8)	0	0
末梢腫脹	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 5 of 9

	North America	Europe	Asia-Pacific
穿刺部位反応	1 (1.8)	0	0
血管穿刺部位内出血	1 (1.8)	0	0
神経系障害	30 (53.6)	0	0
頭痛	28 (50.0)	0	0
感覚鈍麻	2 (3.6)	0	0
失声症	1 (1.8)	0	0
味覚異常	1 (1.8)	0	0
失読症	1 (1.8)	0	0
片頭痛	1 (1.8)	0	0
錯感覚	1 (1.8)	0	0
失神	1 (1.8)	0	0
振戦	1 (1.8)	0	0
胃腸障害	26 (46.4)	0	0
嘔吐	12 (21.4)	0	0
悪心	10 (17.9)	0	0
便秘	7 (12.5)	0	0
アフタ性潰瘍	3 (5.4)	0	0
腹痛	2 (3.6)	0	0
上腹部痛	2 (3.6)	0	0
下痢	2 (3.6)	0	0
口腔内痛	2 (3.6)	0	0
腹部不快感	1 (1.8)	0	0
腹部症状	1 (1.8)	0	0
放屁	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 6 of 9

	North America	Europe	Asia-Pacific
食中毒	1 (1.8)	0	0
胃腸障害	1 (1.8)	0	0
胃食道逆流性疾患	1 (1.8)	0	0
口の感覚鈍麻	1 (1.8)	0	0
口唇痛	1 (1.8)	0	0
口内炎	1 (1.8)	0	0
呼吸器、胸郭および縦隔障害	25 (44.6)	0	0
口腔咽頭痛	8 (14.3)	0	0
咳嗽	6 (10.7)	0	0
鼻漏	6 (10.7)	0	0
鼻出血	3 (5.4)	0	0
低酸素症	3 (5.4)	0	0
鼻閉	3 (5.4)	0	0
扁桃肥大	3 (5.4)	0	0
副鼻腔うっ血	2 (3.6)	0	0
急性呼吸不全	1 (1.8)	0	0
無気肺	1 (1.8)	0	0
発声障害	1 (1.8)	0	0
呼吸困難	1 (1.8)	0	0
肺臓炎	1 (1.8)	0	0
肺うっ血	1 (1.8)	0	0
呼吸障害	1 (1.8)	0	0
呼吸不全	1 (1.8)	0	0
拘束性肺疾患	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 7 of 9

	North America	Europe	Asia-Pacific
喘鳴	1 (1.8)	0	0
皮膚および皮下組織障害	17 (30.4)	0	0
接触性皮膚炎	3 (5.4)	0	0
湿疹	2 (3.6)	0	0
ざ瘡	1 (1.8)	0	0
水疱	1 (1.8)	0	0
褥瘡性潰瘍	1 (1.8)	0	0
皮膚炎	1 (1.8)	0	0
おむつ皮膚炎	1 (1.8)	0	0
紅斑	1 (1.8)	0	0
毛孔性角化症	1 (1.8)	0	0
汗疹	1 (1.8)	0	0
寝汗	1 (1.8)	0	0
発疹	1 (1.8)	0	0
皮膚病変	1 (1.8)	0	0
蕁麻疹	1 (1.8)	0	0
臨床検査	8 (14.3)	0	0
体重減少	3 (5.4)	0	0
血中重炭酸塩減少	1 (1.8)	0	0
血中テストステロン減少	1 (1.8)	0	0
体温上昇	1 (1.8)	0	0
ＣＳＦ白血球数増加	1 (1.8)	0	0
心拍数増加	1 (1.8)	0	0
尿検査異常	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 8 of 9

	North America	Europe	Asia-Pacific
免疫系障害	7 (12.5)	0	0
過敏症	3 (5.4)	0	0
季節性アレルギー	3 (5.4)	0	0
薬物過敏症	1 (1.8)	0	0
代謝および栄養障害	5 (8.9)	0	0
脱水	2 (3.6)	0	0
食欲減退	1 (1.8)	0	0
食欲亢進	1 (1.8)	0	0
ビタミンD欠乏	1 (1.8)	0	0
精神障害	4 (7.1)	0	0
激越	2 (3.6)	0	0
注意欠陥多動性障害	1 (1.8)	0	0
不快気分	1 (1.8)	0	0
不眠症	1 (1.8)	0	0
睡眠時随伴症	1 (1.8)	0	0
チック	1 (1.8)	0	0
心因性嘔吐	1 (1.8)	0	0
心臓障害	3 (5.4)	0	0
動悸	2 (3.6)	0	0
頻脈	1 (1.8)	0	0
耳および迷路障害	3 (5.4)	0	0
耳痛	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

Later-onset subjects: incidence of adverse events by geographic region
Page 9 of 9

	North America	Europe	Asia-Pacific
乗物酔い	1 (1.8)	0	0
鼓膜穿孔	1 (1.8)	0	0
腎および尿路障害	3 (5.4)	0	0
排尿困難	1 (1.8)	0	0
尿失禁	1 (1.8)	0	0
膀胱尿管逆流	1 (1.8)	0	0
眼障害	2 (3.6)	0	0
遠視	1 (1.8)	0	0
斜視	1 (1.8)	0	0
血液およびリンパ系障害	1 (1.8)	0	0
好中球減少症	1 (1.8)	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.8)	0	0
皮膚乳頭腫	1 (1.8)	0	0
血管障害	1 (1.8)	0	0
低血圧	1 (1.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 177　All Subjects Treated With ISIS 396443: Incidence of Adverse Events by Geographic Region

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 1 of 21

	North America	Europe	Asia-Pacific
Number of subjects dosed	127 (100.0)	33 (100.0)	16 (100.0)
Number of subjects with an event	125 (98.4)	30 (90.9)	14 (87.5)
感染症および寄生虫症	106 (83.5)	25 (75.8)	10 (62.5)
上気道感染	67 (52.8)	1 (3.0)	3 (18.8)
鼻咽頭炎	31 (24.4)	8 (24.2)	2 (12.5)
肺炎	23 (18.1)	9 (27.3)	5 (31.3)
中耳炎	16 (12.6)	1 (3.0)	0
ウイルス感染	16 (12.6)	5 (15.2)	0
ライノウイルス感染	15 (11.8)	3 (9.1)	0
ウイルス性上気道感染	15 (11.8)	0	0
ウイルス性肺炎	12 (9.4)	1 (3.0)	0
ウイルス性胃腸炎	11 (8.7)	0	0
レンサ球菌性咽頭炎	10 (7.9)	0	0
尿路感染	9 (7.1)	1 (3.0)	2 (12.5)
細気管支炎	8 (6.3)	2 (6.1)	2 (12.5)
耳感染	8 (6.3)	2 (6.1)	0
胃腸炎	8 (6.3)	0	1 (6.3)
気道感染	7 (5.5)	8 (24.2)	0
結膜炎	6 (4.7)	1 (3.0)	2 (12.5)
インフルエンザ	6 (4.7)	3 (9.1)	3 (18.8)
口腔カンジダ症	5 (3.9)	3 (9.1)	0
ＲＳウイルス細気管支炎	5 (3.9)	1 (3.0)	0
細菌性肺炎	4 (3.1)	0	0
ウイルス性気道感染	4 (3.1)	2 (6.1)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted]　　DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 2 of 21

	North America	Europe	Asia-Pacific
皮膚カンジダ	4 (3.1)	0	0
細菌性気管炎	3 (2.4)	0	0
皮膚真菌感染	3 (2.4)	0	0
限局性感染	3 (2.4)	1 (3.0)	0
下気道感染	3 (2.4)	2 (6.1)	1 (6.3)
ＲＳウイルス感染	3 (2.4)	0	0
副鼻腔炎	3 (2.4)	0	0
アデノウイルス感染	2 (1.6)	0	0
細菌感染	2 (1.6)	0	0
ウイルス性気管支炎	2 (1.6)	3 (9.1)	0
蜂巣炎	2 (1.6)	0	0
細菌性結膜炎	2 (1.6)	0	0
エンテロウイルス感染	2 (1.6)	0	0
ウイルス性消化管感染	2 (1.6)	0	0
手足口病	2 (1.6)	1 (3.0)	0
膿痂疹	2 (1.6)	1 (3.0)	0
ウイルス性下気道感染	2 (1.6)	1 (3.0)	0
メタニューモウイルス感染	2 (1.6)	0	0
モラクセラ感染	2 (1.6)	0	0
急性中耳炎	2 (1.6)	0	0
パラインフルエンザウイルス感染	2 (1.6)	0	0
モラクセラ菌性肺炎	2 (1.6)	0	0
鼻炎	2 (1.6)	4 (12.1)	0
ストーマ部膿瘍	2 (1.6)	0	0
アデノウイルス性上気道感染	1 (0.8)	0	0
細菌性疾患キャリアー	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 3 of 21

	North America	Europe	Asia-Pacific
気管支炎	1 (0.8)	6 (18.2)	0
カンジダ性おむつ皮疹	1 (0.8)	1 (3.0)	0
コロナウイルス感染	1 (0.8)	0	0
ブドウ球菌性耳感染	1 (0.8)	0	0
伝染性紅斑	1 (0.8)	0	0
眼感染	1 (0.8)	0	0
ブドウ球菌性眼感染	1 (0.8)	0	0
ウイルス性眼感染	1 (0.8)	0	0
ウイルス性胃炎	1 (0.8)	0	0
ヘモフィルス感染	1 (0.8)	0	0
伝染性軟属腫	1 (0.8)	0	0
単核細胞症症候群	1 (0.8)	0	0
粘膜皮膚カンジダ症	1 (0.8)	0	0
院内感染	1 (0.8)	0	0
咽頭炎	1 (0.8)	0	0
インフルエンザ性肺炎	1 (0.8)	0	0
肺炎球菌性肺炎	1 (0.8)	0	0
シュードモナス菌性肺炎	1 (0.8)	0	0
ＲＳウイルス肺炎	1 (0.8)	1 (3.0)	0
シュードモナス感染	1 (0.8)	2 (6.1)	0
細菌性気道感染	1 (0.8)	0	0
敗血症	1 (0.8)	1 (3.0)	0
皮膚細菌感染	1 (0.8)	0	0
皮膚感染	1 (0.8)	0	0
ブドウ球菌性菌血症	1 (0.8)	0	0
ブドウ球菌感染	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 4 of 21

	North America	Europe	Asia-Pacific
ブドウ球菌性敗血症	1 (0.8)	0	0
レンサ球菌感染	1 (0.8)	0	0
扁桃炎	1 (0.8)	0	0
気管炎	1 (0.8)	0	0
腟感染	1 (0.8)	0	0
ウイルス性扁桃炎	1 (0.8)	0	0
外陰腟真菌感染	1 (0.8)	0	0
感染性湿疹	0	0	1 (6.3)
蟯虫症	0	0	1 (6.3)
腸球菌感染	0	0	1 (6.3)
大腸菌感染	0	1 (3.0)	0
真菌感染	0	1 (3.0)	0
ロタウイルス胃腸炎	0	1 (3.0)	0
肺感染	0	0	1 (6.3)
口腔真菌感染	0	1 (3.0)	0
口腔ヘルペス	0	1 (3.0)	0
パラインフルエンザウイルス性肺炎	0	0	1 (6.3)
腎盂腎炎	0	1 (3.0)	0
ばら疹	0	1 (3.0)	0
ブドウ球菌皮膚感染	0	1 (3.0)	0
ストーマ部感染	0	1 (3.0)	0
胃腸障害	83 (65.4)	15 (45.5)	7 (43.8)
便秘	34 (26.8)	7 (21.2)	5 (31.3)
嘔吐	28 (22.0)	5 (15.2)	1 (6.3)
下痢	16 (12.6)	2 (6.1)	1 (6.3)

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 5 of 21

	North America	Europe	Asia-Pacific
胃食道逆流性疾患	16 (12.6)	3 (9.1)	0
生歯	13 (10.2)	3 (9.1)	3 (18.8)
嚥下障害	10 (7.9)	0	0
悪心	10 (7.9)	0	0
放屁	9 (7.1)	0	0
流涎過多	8 (6.3)	0	0
腹部膨満	6 (4.7)	0	0
腹痛	3 (2.4)	0	0
アフタ性潰瘍	3 (2.4)	0	1 (6.3)
胃炎	3 (2.4)	1 (3.0)	0
腹部不快感	2 (1.6)	2 (6.1)	0
上腹部痛	2 (1.6)	0	0
血便排泄	2 (1.6)	0	0
口腔内痛	2 (1.6)	0	0
腹部症状	1 (0.8)	0	0
口唇のひび割れ	1 (0.8)	0	0
食中毒	1 (0.8)	0	0
排便回数増加	1 (0.8)	0	0
胃出血	1 (0.8)	0	0
胃腸障害	1 (0.8)	0	0
消化管運動低下	1 (0.8)	0	0
吐血	1 (0.8)	0	0
口の感覚鈍麻	1 (0.8)	0	0
乳児仙痛	1 (0.8)	0	0
乳児吐出	1 (0.8)	0	0
口唇痛	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 6 of 21

	North America	Europe	Asia-Pacific
口内炎	1 (0.8)	0	0
上部消化管出血	1 (0.8)	0	0
胃排出不全	0	1 (3.0)	0
呼吸器、胸郭および縦隔障害	82 (64.6)	24 (72.7)	4 (25.0)
咳嗽	21 (16.5)	3 (9.1)	0
鼻閉	21 (16.5)	0	0
呼吸窮迫	20 (15.7)	8 (24.2)	1 (6.3)
呼吸不全	18 (14.2)	9 (27.3)	0
急性呼吸不全	16 (12.6)	0	0
無気肺	15 (11.8)	8 (24.2)	1 (6.3)
低酸素症	14 (11.0)	0	0
鼻漏	14 (11.0)	2 (6.1)	1 (6.3)
誤嚥性肺炎	9 (7.1)	3 (9.1)	0
口腔咽頭痛	8 (6.3)	0	0
誤嚥	7 (5.5)	0	0
上気道うっ血	7 (5.5)	1 (3.0)	0
慢性呼吸不全	6 (4.7)	0	0
呼吸困難	6 (4.7)	1 (3.0)	3 (18.8)
副鼻腔うっ血	6 (4.7)	0	0
無呼吸	5 (3.9)	2 (6.1)	0
気管支分泌物貯留	5 (3.9)	2 (6.1)	0
上気道分泌増加	5 (3.9)	0	0
喘鳴	4 (3.1)	0	1 (6.3)
鼻出血	3 (2.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 7 of 21

	North America	Europe	Asia-Pacific
低換気	3 (2.4)	0	0
気胸	3 (2.4)	0	0
肺うっ血	3 (2.4)	0	0
扁桃肥大	3 (2.4)	0	0
肺水腫	2 (1.6)	0	0
呼吸停止	2 (1.6)	4 (12.1)	0
拘束性肺疾患	2 (1.6)	0	0
アレルギー性鼻炎	2 (1.6)	0	0
呼吸補助筋の動員	2 (1.6)	0	0
急性呼吸窮迫症候群	1 (0.8)	0	0
無呼吸発作	1 (0.8)	0	0
窒息	1 (0.8)	0	0
息詰まり	1 (0.8)	2 (6.1)	0
発声障害	1 (0.8)	0	0
高炭酸ガス血症	1 (0.8)	0	0
減呼吸	1 (0.8)	0	0
喉頭肉芽腫	1 (0.8)	0	0
鼻汁変色	1 (0.8)	0	0
胸水	1 (0.8)	0	0
気縦隔症	1 (0.8)	0	0
肺臓炎	1 (0.8)	0	0
湿性咳嗽	1 (0.8)	0	0
呼吸性アルカローシス	1 (0.8)	0	0
呼吸障害	1 (0.8)	2 (6.1)	0
気道うっ血	1 (0.8)	1 (3.0)	0
低音性連続性ラ音	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 8 of 21

	North America	Europe	Asia-Pacific
睡眠時無呼吸症候群	1 (0.8)	0	0
変色痰	1 (0.8)	0	0
頻呼吸	1 (0.8)	0	0
気管障害	1 (0.8)	0	0
気管支閉塞	0	1 (3.0)	0
気管支分泌増加	0	1 (3.0)	0
肺障害	0	1 (3.0)	0
閉塞性気道障害	0	1 (3.0)	0
呼吸性アシドーシス	0	1 (3.0)	0
一般・全身障害および投与部位の状態	77 (60.6)	20 (60.6)	5 (31.3)
発熱	59 (46.5)	16 (48.5)	5 (31.3)
穿刺部位疼痛	10 (7.9)	0	0
疼痛	7 (5.5)	0	0
疲労	3 (2.4)	0	0
不快感	2 (1.6)	0	0
低体温	2 (1.6)	0	0
末梢性浮腫	2 (1.6)	0	0
末梢腫脹	2 (1.6)	0	0
血管穿刺部位内出血	2 (1.6)	0	0
適用部位紅斑	1 (0.8)	0	0
カテーテル留置部位出血	1 (0.8)	0	0
カテーテル留置部位炎症	1 (0.8)	0	0
カテーテル留置部位疼痛	1 (0.8)	0	0
カテーテル留置部位関連反応	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 9 of 21

	North America	Europe	Asia-Pacific
胸部不快感	1 (0.8)	0	0
悪寒	1 (0.8)	0	0
泣き	1 (0.8)	0	0
医療機器リーク	1 (0.8)	0	0
医療機器閉塞	1 (0.8)	1 (3.0)	0
薬物不耐性	1 (0.8)	0	0
冷感	1 (0.8)	0	0
重力性浮腫	1 (0.8)	0	0
注入部位内出血	1 (0.8)	0	0
注射部位出血	1 (0.8)	0	0
注射部位疼痛	1 (0.8)	0	0
医療機器合併症	1 (0.8)	0	0
小結節	1 (0.8)	0	0
浮腫	1 (0.8)	0	0
穿刺部位反応	1 (0.8)	0	0
外科手術不成功	1 (0.8)	0	0
腫脹	1 (0.8)	0	0
死亡	0	1 (3.0)	0
全身健康状態低下	0	1 (3.0)	0
ワクチン接種後の易刺激性	0	1 (3.0)	0
倦怠感	0	1 (3.0)	0
傷害、中毒および処置合併症	68 (53.5)	5 (15.2)	0
腰椎穿刺後症候群	23 (18.1)	0	0
処置による疼痛	10 (7.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 10 of 21

	North America	Europe	Asia-Pacific
節足動物咬傷	8 (6.3)	0	0
裂傷	7 (5.5)	0	0
大腿骨骨折	6 (4.7)	0	0
挫傷	4 (3.1)	0	0
関節脱臼	4 (3.1)	0	0
栄養補給チューブ合併症	3 (2.4)	1 (3.0)	0
四肢損傷	3 (2.4)	0	0
ストーマ部紅斑	3 (2.4)	0	0
サンバーン	3 (2.4)	0	0
術後激越	2 (1.6)	0	0
転倒	2 (1.6)	0	0
関節損傷	2 (1.6)	0	0
処置後腫脹	2 (1.6)	0	0
処置による悪心	2 (1.6)	0	0
皮膚擦過傷	2 (1.6)	0	0
熱傷	2 (1.6)	0	0
隆起骨折	2 (1.6)	0	0
節足動物刺傷	1 (0.8)	0	0
ダンピング症候群	1 (0.8)	0	0
耳擦過傷	1 (0.8)	0	0
擦過傷	1 (0.8)	0	0
頭部損傷	1 (0.8)	0	0
靭帯捻挫	1 (0.8)	0	0
口唇損傷	1 (0.8)	0	0
下肢骨折	1 (0.8)	0	0
半月板損傷	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 11 of 21

	North America	Europe	Asia-Pacific
肉離れ	1 (0.8)	0	0
外傷性気胸	1 (0.8)	0	0
処置後合併症	1 (0.8)	0	0
処置後不快感	1 (0.8)	0	0
術後イレウス	1 (0.8)	0	0
処置による頭痛	1 (0.8)	0	0
処置部位反応	1 (0.8)	0	0
軟部組織損傷	1 (0.8)	0	0
ストーマ合併症	1 (0.8)	0	0
ストーマ部刺激感	1 (0.8)	0	0
硬膜下血腫	1 (0.8)	0	0
脛骨骨折	1 (0.8)	0	0
歯牙損傷	1 (0.8)	0	0
麻酔からの覚醒遅延	0	1 (3.0)	0
伝染病曝露	0	1 (3.0)	0
処置合併症	0	1 (3.0)	0
ワクチン接種合併症	0	1 (3.0)	0
筋骨格系および結合組織障害	66 (52.0)	3 (9.1)	0
側弯症	25 (19.7)	1 (3.0)	0
背部痛	24 (18.9)	0	0
関節拘縮	21 (16.5)	1 (3.0)	0
四肢痛	7 (5.5)	0	0
関節痛	5 (3.9)	0	0
脊柱後弯症	5 (3.9)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 12 of 21

	North America	Europe	Asia-Pacific
胸郭変形	4 (3.1)	0	0
筋肉痛	4 (3.1)	0	0
頚部痛	3 (2.4)	0	0
斜頚	3 (2.4)	0	0
後側弯症	2 (1.6)	0	0
脊柱前弯症	2 (1.6)	0	0
筋緊張	2 (1.6)	0	0
骨盤変形	2 (1.6)	0	0
頭位性斜頭症	2 (1.6)	1 (3.0)	0
泉門閉鎖遅延	1 (0.8)	0	0
四肢拘縮	1 (0.8)	0	0
手変形	1 (0.8)	0	0
関節硬直	1 (0.8)	0	0
筋力低下	1 (0.8)	1 (3.0)	0
脊柱変形	1 (0.8)	0	0
滑膜炎	1 (0.8)	0	0
体重支持困難	1 (0.8)	0	0
皮膚および皮下組織障害	55 (43.3)	5 (15.2)	3 (18.8)
発疹	14 (11.0)	0	2 (12.5)
おむつ皮膚炎	12 (9.4)	1 (3.0)	0
接触性皮膚炎	6 (4.7)	0	0
湿疹	5 (3.9)	0	1 (6.3)
皮膚炎	3 (2.4)	2 (6.1)	0
斑状出血	3 (2.4)	0	0
紅斑	3 (2.4)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 13 of 21

	North America	Europe	Asia-Pacific
過剰肉芽組織	3 (2.4)	0	0
皮膚刺激	3 (2.4)	0	0
過角化	2 (1.6)	0	0
汗疹	2 (1.6)	0	1 (6.3)
蕁麻疹	2 (1.6)	0	0
ざ瘡	1 (0.8)	0	0
脱毛症	1 (0.8)	0	0
水疱	1 (0.8)	0	0
褥瘡性潰瘍	1 (0.8)	0	0
アレルギー性皮膚炎	1 (0.8)	0	0
貨幣状湿疹	1 (0.8)	0	0
環状肉芽腫	1 (0.8)	0	0
毛孔性角化症	1 (0.8)	0	0
寝汗	1 (0.8)	0	0
点状出血	1 (0.8)	1 (3.0)	0
そう痒症	1 (0.8)	0	0
紅斑性皮疹	1 (0.8)	0	0
斑状皮疹	1 (0.8)	0	0
丘疹性皮疹	1 (0.8)	0	0
脂漏性皮膚炎	1 (0.8)	0	0
皮膚色素脱失	1 (0.8)	0	0
皮膚障害	1 (0.8)	0	0
皮膚病変	1 (0.8)	0	0
皮膚浮腫	1 (0.8)	0	0
皮膚潰瘍	1 (0.8)	0	0
皮下気腫	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 14 of 21

	North America	Europe	Asia-Pacific
皮膚乾燥	0	1 (3.0)	0
間擦疹	0	0	1 (6.3)
神経系障害	48 (37.8)	2 (6.1)	1 (6.3)
頭痛	29 (22.8)	0	0
不随意性筋収縮	3 (2.4)	1 (3.0)	0
眼振	3 (2.4)	0	0
よだれ	2 (1.6)	0	0
感覚鈍麻	2 (1.6)	0	0
痙攣発作	2 (1.6)	0	0
失神	2 (1.6)	0	0
失声症	1 (0.8)	0	0
脳損傷	1 (0.8)	0	0
脳梗塞	1 (0.8)	0	0
脳脊髄液漏	1 (0.8)	0	0
味覚異常	1 (0.8)	0	0
失読症	1 (0.8)	0	0
反射亢進	1 (0.8)	0	0
筋緊張低下	1 (0.8)	0	1 (6.3)
低酸素性虚血性脳症	1 (0.8)	0	0
言語障害	1 (0.8)	0	0
嗜眠	1 (0.8)	0	0
片頭痛	1 (0.8)	0	0
錯感覚	1 (0.8)	0	0
傾眠	1 (0.8)	0	0
振戦	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 15 of 21

	North America	Europe	Asia-Pacific
間代	0	1 (3.0)	0
臨床検査	27 (21.3)	11 (33.3)	1 (6.3)
酸素飽和度低下	11 (8.7)	1 (3.0)	1 (6.3)
体重減少	5 (3.9)	4 (12.1)	0
心拍数増加	3 (2.4)	0	0
好中球数増加	3 (2.4)	0	0
白血球数増加	3 (2.4)	0	0
体温上昇	2 (1.6)	2 (6.1)	0
ヒトライノウイルス検査陽性	2 (1.6)	1 (3.0)	0
ブドウ球菌検査陽性	2 (1.6)	0	0
アラニンアミノトランスフェラーゼ増加	1 (0.8)	1 (3.0)	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (0.8)	1 (3.0)	0
血中アルカリホスファターゼ増加	1 (0.8)	0	0
血中重炭酸塩減少	1 (0.8)	0	0
血中テストステロン減少	1 (0.8)	0	0
体温低下	1 (0.8)	0	0
骨密度減少	1 (0.8)	0	0
呼吸音異常	1 (0.8)	0	0
ＣＳＦ白血球数増加	1 (0.8)	0	0
心電図ＳＴ－Ｔ部分異常	1 (0.8)	0	0
好酸球数増加	1 (0.8)	0	0
心拍数減少	1 (0.8)	0	0
心拍数不整	1 (0.8)	0	0
炎症マーカー上昇	1 (0.8)	0	0
Ａ型インフルエンザウイルス検査陽性	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 16 of 21

	North America	Europe	Asia-Pacific
肝機能検査異常	1 (0.8)	0	0
リンパ球数増加	1 (0.8)	0	0
モラクセラ検査陽性	1 (0.8)	1 (3.0)	0
好中球百分率増加	1 (0.8)	0	0
整形外科検査	1 (0.8)	0	0
シュードモナス検査陽性	1 (0.8)	1 (3.0)	0
セラチア検査陽性	1 (0.8)	0	0
レンサ球菌検査陽性	1 (0.8)	0	0
尿検査異常	1 (0.8)	0	0
ビタミンA減少	1 (0.8)	0	0
血中クロール減少	0	1 (3.0)	0
血中鉄減少	0	1 (3.0)	0
血中カリウム減少	0	2 (6.1)	0
血中ナトリウム減少	0	1 (3.0)	0
C－反応性蛋白増加	0	2 (6.1)	0
医学的観察	0	2 (6.1)	0
尿量減少	0	1 (3.0)	0
心臓障害	22 (17.3)	5 (15.2)	2 (12.5)
頻脈	10 (7.9)	2 (6.1)	0
徐脈	6 (4.7)	1 (3.0)	0
心肺停止	4 (3.1)	2 (6.1)	0
チアノーゼ	3 (2.4)	0	0
心停止	2 (1.6)	1 (3.0)	0
左室肥大	2 (1.6)	0	0
動悸	2 (1.6)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 17 of 21

	North America	Europe	Asia-Pacific
心筋症	1 (0.8)	0	0
心膜気腫	1 (0.8)	0	0
上室性頻脈	1 (0.8)	0	0
心室性頻脈	1 (0.8)	0	1 (6.3)
洞性頻脈	0	0	1 (6.3)
免疫系障害	20 (15.7)	2 (6.1)	0
季節性アレルギー	9 (7.1)	1 (3.0)	0
薬物過敏症	5 (3.9)	0	0
過敏症	4 (3.1)	1 (3.0)	0
食物アレルギー	2 (1.6)	0	0
代謝および栄養障害	20 (15.7)	7 (21.2)	1 (6.3)
脱水	5 (3.9)	0	0
成長障害	4 (3.1)	1 (3.0)	1 (6.3)
体重増加不良	3 (2.4)	4 (12.1)	0
栄養補給不耐性	2 (1.6)	1 (3.0)	0
低ナトリウム血症	2 (1.6)	0	0
過小食	2 (1.6)	0	0
食欲減退	1 (0.8)	0	0
乳児および小児期早期の哺育障害	1 (0.8)	2 (6.1)	0
食欲亢進	1 (0.8)	0	0
鉄欠乏	1 (0.8)	0	0
代謝性アルカローシス	1 (0.8)	0	0
ビタミンD欠乏	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 18 of 21

	North America	Europe	Asia-Pacific
精神障害	13 (10.2)	2 (6.1)	1 (6.3)
激越	4 (3.1)	0	0
不安	4 (3.1)	1 (3.0)	0
易刺激性	2 (1.6)	1 (3.0)	0
注意欠陥多動性障害	1 (0.8)	0	0
息こらえ	1 (0.8)	0	0
不快気分	1 (0.8)	0	0
不眠症	1 (0.8)	0	0
睡眠時随伴症	1 (0.8)	0	0
落ち着きのなさ	1 (0.8)	0	0
チック	1 (0.8)	0	0
心因性嘔吐	1 (0.8)	0	0
気分動揺	0	0	1 (6.3)
睡眠障害	0	1 (3.0)	0
眼障害	9 (7.1)	0	0
斜視	2 (1.6)	0	0
乱視	1 (0.8)	0	0
霰粒腫	1 (0.8)	0	0
後天性涙道狭窄	1 (0.8)	0	0
眼乾燥	1 (0.8)	0	0
眼運動障害	1 (0.8)	0	0
眼瞼下垂	1 (0.8)	0	0
遠視	1 (0.8)	0	0
近視	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 19 of 21

	North America	Europe	Asia-Pacific
血液およびリンパ系障害	8 (6.3)	1 (3.0)	0
貧血	3 (2.4)	0	0
好中球減少症	2 (1.6)	1 (3.0)	0
好酸球増加症	1 (0.8)	0	0
リンパ節症	1 (0.8)	0	0
血小板増加症	1 (0.8)	0	0
血管障害	7 (5.5)	4 (12.1)	0
高血圧	3 (2.4)	0	0
毛細血管脆弱	1 (0.8)	0	0
本態性高血圧症	1 (0.8)	0	0
低血圧	1 (0.8)	0	0
ショック	1 (0.8)	0	0
蒼白	0	2 (6.1)	0
血栓症	0	1 (3.0)	0
血管炎	0	1 (3.0)	0
先天性、家族性および遺伝性障害	6 (4.7)	1 (3.0)	0
斜頭症	2 (1.6)	0	0
斜指症	1 (0.8)	0	0
先天性横隔膜ヘルニア	1 (0.8)	0	0
発育性股関節形成不全	1 (0.8)	0	0
鳩胸	1 (0.8)	0	0
貧血母斑	0	1 (3.0)	0
耳および迷路障害	6 (4.7)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 20 of 21

	North America	Europe	Asia-Pacific
耳痛	2 (1.6)	0	0
耳の障害	1 (0.8)	0	0
耳垢分泌過多	1 (0.8)	0	0
乗物酔い	1 (0.8)	0	0
鼓膜穿孔	1 (0.8)	0	0
腎および尿路障害	5 (3.9)	0	0
排尿困難	1 (0.8)	0	0
水腎症	1 (0.8)	0	0
尿失禁	1 (0.8)	0	0
尿閉	1 (0.8)	0	0
膀胱尿管逆流	1 (0.8)	0	0
良性、悪性および詳細不明の新生物 (嚢胞およびポリープを含む)	4 (3.1)	0	0
アクロコルドン	1 (0.8)	0	0
血管の良性新生物	1 (0.8)	0	0
脂漏性角化症	1 (0.8)	0	0
皮膚乳頭腫	1 (0.8)	0	0
生殖系および乳房障害	3 (2.4)	2 (6.1)	0
後天性包茎	1 (0.8)	0	0
陰茎障害	1 (0.8)	0	0
外陰腟発疹	1 (0.8)	0	0
亀頭包皮炎	0	1 (3.0)	0
卵巣嚢胞	0	1 (3.0)	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

All subjects treated with ISIS 396443: incidence of adverse events by geographic region
Page 21 of 21

	North America	Europe	Asia-Pacific
肝胆道系障害	1 (0.8)	0	0
肝腫大	1 (0.8)	0	0
妊娠、産褥および周産期の状態	1 (0.8)	0	0
臍肉芽腫	1 (0.8)	0	0
外科および内科処置	1 (0.8)	0	0
機械的換気	1 (0.8)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: A subject was counted only once within each system organ class and preferred term.
3: Preferred terms are presented by decreasing incidence within each system organ class.

SOURCE: [redacted] DATE: [redacted]20[redacted]

表 78　Later-Onset Subjects:Listing of Serious Adverse Events

Later-onset subjects: listing of serious adverse events
Page 1 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1202	396443-CS2	321	321	PSEUDO ALLERGIC REACTION PRESUMABLY TO OPIOID (FENTANYL)	薬物過敏症	SEVERE	UNLIKELY

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted]　　DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 2 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1204	396443-CS2	533	536	PNEUMONIA	肺炎	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 3 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1407	396443-CS12	817	819	HUMAN METAPNEUMOVIRUS PNEUMONITIS	ウイルス性肺炎	SEVERE	NOT RELATED
	396443-CS12	897	898	RESPIRATORY DISTRESS (SHORTNESS OF BREATH)	呼吸困難	SEVERE	NOT RELATED
	396443-CS12	1018	1043	PNEUMONIA	肺炎	SEVERE	NOT RELATED
	396443-CS12	1018	1043	RESPIRATORY FAILURE	呼吸不全	SEVERE	NOT RELATED
	396443-CS12	1018	1043	RSV BRONCHIOLITIS	ＲＳウイルス細気管支炎	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 4 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1412	396443-CS12	812	813	EARLY GASTROENTERITIS	胃腸炎	MODERATE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 5 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1416	396443-CS12	494	498	POST LP HEADACHE	腰椎穿刺後症候群	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 6 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1417	396443-CS12	1017	1020	LOWER RESPIRATORY TRACT INFECTION	下気道感染	SEVERE	NOT RELATED
	396443-CS12	1017	1020	VIRAL PNEUMONIA	ウイルス性肺炎	SEVERE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 7 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
1445	396443-CS12	664	675	ACUTE RESPIRATORY FAILURE WITH HYPOXIA	急性呼吸不全	MODERATE	NOT RELATED
	396443-CS12	664	675	RSV PNEUMONIA	ＲＳウイルス肺炎	MODERATE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]

Later-onset subjects: listing of serious adverse events
Page 8 of 8

Subject number	Study Identifier	Study day		Adverse event		Severity (c)	Relationship to study drug(c)
		Onset (a)	Res	Investigator term(b)	Preferred term (MedDRA)		
4207	396443-CS2	4	7	POST-LUMBAR PUNCTURE HEADACHE	腰椎穿刺後症候群	MODERATE	NOT RELATED

NOTE:(a) #=Adverse Event with onset prior to dosing.
(b) *=Adverse Event caused subject to discontinue study drug, **=Adverse Event caused subject to discontinue the study, ***=Adverse Event caused subject to discontinue both study drug and study.
(c) Investigator assessment.
Abbreviations:NR=Not resolved; Res=Resolution.

SOURCE:[redacted] DATE:[redacted]20[redacted]
##[redacted]20[redacted]##

表 79　　Later-Onset Subjects:Listing of Adverse Events That Led to Discontinuation of Study Drug

Later-onset subjects: listing of adverse events that led to discontinuation of study drug

No Adverse Events Reported That Led To Discontinuation Of Study Drug

SOURCE:[redacted]　　DATE:[redacted]
##[redacted]20[redacted]##

表 80　All Subjects Treated With ISIS 396443:Listing of Adverse Events That Led to Discontinuation of Study Drug

All subjects treated with ISIS 396443: listing of adverse events that led to discontinuation of study drug
Page 1 of 2

Subject number	Day of onset	Day of resolution	Date of last dose	Adverse event		Severity (b)	Relationship to study drug(b)
				Investigator term(a)	Preferred term (MedDRA)		
2302	150	163	18MAR2014	RESPIRATORY FAILURE*	呼吸不全	SEVERE	UNLIKELY
2304	40	62	07JAN2014	RESPIRATORY FAILURE*	呼吸不全	SEVERE	NOT RELATED
2311	113	120	08JUL2014	LOWER RESPIRATORY TRACT INFECTION VIRAL*	ウイルス性下気道感染	SEVERE	NOT RELATED
1776-5041	4	6	04MAY2015	RESPIRATORY FAILURE*	呼吸不全	SEVERE	NOT RELATED
1780-5032	54	60	12FEB2016	HYPOXIC BRAIN INJURY*	脳損傷	SEVERE	NOT RELATED
2000-5109	213	214	31JUL2015	ACUTE ON CHRONIC RESPIRATORY FAILURE*	急性呼吸不全	SEVERE	NOT RELATED
2000-5145	33	35	30NOV2014	HYPOXIC-ISCHEMIC ENCEPHALOPATHY*	低酸素性虚血性脳症	SEVERE	NOT RELATED
2000-5418	113	113	12JAN2015	RESPIRATORY FAILURE*	呼吸不全	SEVERE	NOT RELATED
2003-5363	122	122	25DEC2015	CARDIO RESPIRATORY ARREST*	心肺停止	SEVERE	UNLIKELY
2006-5059	79	80	16APR2016	RESPIRATORY FAILURE FOLLOWING PARTIAL PNEUMONIA*	呼吸不全	SEVERE	NOT RELATED

NOTE:(a) *=Adverse Event was serious
(b) Investigator assessment.

SOURCE:[redacted]　　DATE:[redacted]20[redacted]

All subjects treated with ISIS 396443: listing of adverse events that led to discontinuation of study drug
Page 2 of 2

Subject number	Day of onset	Day of resolution	Date of last dose	Adverse event: Investigator term(a)	Adverse event: Preferred term (MedDRA)	Severity (b)	Relationship to study drug(b)
2006-5223	192	192	05DEC2015	RESPIRATORY ARREST DUE TO LOWER RESPIRATORY TRACT INFECTION*	呼吸停止	SEVERE	NOT RELATED
2008-5403	84	84	20MAY2015	CARDIO RESPIRATORY ARREST*	心肺停止	SEVERE	NOT RELATED
2010-5219	36	44	23APR2015	RESPIRATORY INSUFFICIENCY*	呼吸不全	SEVERE	NOT RELATED
2037-5009	142	143	11NOV2015	RESPIRATORY DISNESS*	呼吸窮迫	SEVERE	NOT RELATED
2037-5167	82	82	12SEP2015	DEATH DURING ASLEEP*	死亡	SEVERE	NOT RELATED

NOTE:(a) *=Adverse Event was serious
(b) Investigator assessment.

SOURCE:[redacted] DATE:[redacted]
##[redacted]20[redacted]##